data_6mnt_residue ############################ # Computer software used # ############################ save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 6mnt _Structure_validation_residue.Date_analyzed 2019-02-15 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 38.2 p . . . . . 0 N--CA 1.452 -0.327 0 CA-C-O 121.136 0.494 . . . . 0.0 110.286 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 228' ' ' LEU . . . . . 0.429 ' HB3' ' HB2' ' A' ' 259' ' ' ALA . 73.0 mt -107.62 100.72 10.1 Favored 'General case' 0 N--CA 1.445 -0.692 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 -178.325 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 229' ' ' THR . . . . . 0.496 ' O ' HG22 ' A' ' 230' ' ' VAL . 76.1 p -126.39 172.19 10.36 Favored 'General case' 0 C--N 1.325 -0.459 0 C-N-CA 119.924 -0.71 . . . . 0.0 110.41 -178.621 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 230' ' ' VAL . . . . . 0.75 HG23 HG11 ' A' ' 257' ' ' VAL . 61.5 t -143.96 136.36 23.21 Favored 'Isoleucine or valine' 0 C--O 1.24 0.565 0 CA-C-O 120.779 0.324 . . . . 0.0 110.845 -178.176 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 29.7 m -97.28 160.16 14.5 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.125 177.201 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 92.52 161.58 36.57 Favored Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.462 -0.875 . . . . 0.0 111.177 -177.281 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 233' ' ' GLN . . . . . 0.593 ' HG2' ' HA ' ' A' ' 328' ' ' GLU . 83.4 mt-30 -118.16 102.85 50.38 Favored Pre-proline 0 C--N 1.319 -0.723 0 CA-C-N 117.081 0.44 . . . . 0.0 111.739 -177.354 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -75.86 123.75 7.61 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 121.468 1.445 . . . . 0.0 110.444 171.829 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 20.3 pt-20 -166.19 127.1 1.76 Allowed 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.605 -178.584 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 236' ' ' HIS . . . . . 0.48 ' C ' ' HD3' ' A' ' 237' ' ' LYS . 92.1 m-70 -141.04 143.36 34.35 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.219 174.794 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 237' ' ' LYS . . . . . 0.48 ' HD3' ' C ' ' A' ' 236' ' ' HIS . 13.7 mmtm . . . . . 0 C--N 1.313 -1.018 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.207 -172.62 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 252' ' ' GLN . . . . . 0.538 ' HA ' ' O ' ' A' ' 302' ' ' ILE . 25.2 mt-30 . . . . . 0 N--CA 1.468 0.474 0 N-CA-C 114.13 1.159 . . . . 0.0 114.13 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 174.72 109.47 0.24 Allowed Glycine 0 N--CA 1.446 -0.648 0 CA-C-N 114.338 -1.301 . . . . 0.0 109.933 -177.145 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 41.5 p -95.44 125.09 39.81 Favored 'General case' 0 C--N 1.324 -0.522 0 O-C-N 122.32 -0.517 . . . . 0.0 111.706 -171.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . 0.584 ' HB ' ' CG1' ' A' ' 230' ' ' VAL . 20.5 pt -124.37 145.18 31.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.901 -176.181 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 256' ' ' THR . . . . . 0.614 ' O ' HG12 ' A' ' 230' ' ' VAL . 31.0 m -99.56 106.05 17.99 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 174.232 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.75 HG11 HG23 ' A' ' 230' ' ' VAL . 32.8 m -88.13 141.57 14.13 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.595 0 C-N-CA 119.27 -0.972 . . . . 0.0 113.607 -165.04 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 36.4 m -94.23 10.3 34.57 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 113.404 -1.725 . . . . 0.0 109.275 169.593 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 259' ' ' ALA . . . . . 0.429 ' HB2' ' HB3' ' A' ' 228' ' ' LEU . . . -126.76 145.58 50.56 Favored 'General case' 0 CA--C 1.518 -0.256 0 N-CA-C 113.037 0.755 . . . . 0.0 113.037 -167.209 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 62.5 m 57.94 -68.51 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.558 0 CA-C-N 113.822 -1.535 . . . . 0.0 114.919 167.354 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 107.49 51.39 0.76 Allowed Glycine 0 N--CA 1.449 -0.466 0 N-CA-C 109.861 -1.296 . . . . 0.0 109.861 -167.408 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 262' ' ' LEU . . . . . . . . . . . . . 92.4 mt -65.0 163.93 13.71 Favored 'General case' 0 C--O 1.235 0.332 0 N-CA-C 113.709 1.003 . . . . 0.0 113.709 -168.021 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 73.0 mt-30 -135.23 -179.42 5.62 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 113.694 -1.594 . . . . 0.0 108.042 173.425 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 264' ' ' VAL . . . . . 0.418 ' HA ' ' CG1' ' A' ' 292' ' ' VAL . 38.5 t -73.76 127.81 35.84 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 C-N-CA 120.679 -0.408 . . . . 0.0 111.062 -179.79 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . 0.567 ' H ' ' HB ' ' A' ' 292' ' ' VAL . . . 121.49 8.05 7.88 Favored Glycine 0 C--N 1.335 0.486 0 C-N-CA 120.363 -0.922 . . . . 0.0 114.395 175.246 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 65.6 m-20 -90.71 164.93 13.95 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 117.831 0.816 . . . . 0.0 111.517 178.511 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 267' ' ' ALA . . . . . 0.75 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -139.9 126.0 19.84 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.199 -0.909 . . . . 0.0 109.052 174.536 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 268' ' ' PHE . . . . . . . . . . . . . 4.7 p90 -147.6 166.74 26.47 Favored 'General case' 0 C--N 1.327 -0.413 0 C-N-CA 119.74 -0.784 . . . . 0.0 111.829 -173.353 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 269' ' ' THR . . . . . 0.46 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 44.2 p -117.73 139.82 50.53 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.853 176.09 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 270' ' ' ILE . . . . . 0.533 HG12 HG12 ' A' ' 332' ' ' ILE . 59.6 mt -106.71 144.37 15.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 120.668 0.27 . . . . 0.0 110.964 -177.425 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -67.83 119.51 12.64 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.442 -179.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 106.04 -22.69 30.91 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 121.098 -0.572 . . . . 0.0 112.386 178.615 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . 0.557 HG12 ' HB3' ' A' ' 288' ' ' GLN . 36.5 t -87.02 101.44 11.16 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-O 121.046 0.45 . . . . 0.0 110.286 178.756 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 274' ' ' ASN . . . . . 0.521 ' HB3' ' HA2' ' A' ' 285' ' ' GLY . 3.6 m120 -110.01 129.6 55.65 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.272 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 51.0 p -73.01 160.47 32.03 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.588 0.709 . . . . 0.0 112.148 -178.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 276' ' ' VAL . . . . . 0.551 ' O ' ' HD2' ' A' ' 277' ' ' HIS . 22.8 m -127.9 -176.67 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 CA-C-N 114.748 -1.115 . . . . 0.0 110.432 -178.561 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 277' ' ' HIS . . . . . 0.652 ' HB3' ' HA ' ' A' ' 281' ' ' LYS . 0.7 OUTLIER 29.84 51.21 0.08 Allowed 'General case' 0 N--CA 1.473 0.69 0 O-C-N 124.826 1.328 . . . . 0.0 113.624 177.89 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 4.1 tp-100 -74.84 -43.15 56.1 Favored 'General case' 0 N--CA 1.439 -1.018 0 N-CA-C 108.488 -0.931 . . . . 0.0 108.488 171.248 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 279' ' ' ILE . . . . . 0.424 ' O ' ' HB2' ' A' ' 282' ' ' ASP . 26.5 mm -117.32 75.08 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.278 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.269 177.464 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 58.3 p 51.4 81.93 0.07 Allowed 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 123.665 0.786 . . . . 0.0 112.642 -178.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 281' ' ' LYS . . . . . 0.652 ' HA ' ' HB3' ' A' ' 277' ' ' HIS . 1.0 OUTLIER 56.96 27.63 13.47 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-N 115.42 -0.809 . . . . 0.0 112.011 -179.555 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 282' ' ' ASP . . . . . 0.424 ' HB2' ' O ' ' A' ' 279' ' ' ILE . 57.3 t0 -90.1 128.55 36.34 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.947 -0.57 . . . . 0.0 109.677 177.323 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 44.7 p -101.18 114.94 29.36 Favored 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 76.0 p -116.19 -11.35 11.34 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.649 -0.705 . . . . 0.0 112.145 -167.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 285' ' ' GLY . . . . . 0.521 ' HA2' ' HB3' ' A' ' 274' ' ' ASN . . . 76.83 10.83 85.9 Favored Glycine 0 CA--C 1.517 0.196 0 C-N-CA 120.814 -0.707 . . . . 0.0 113.267 177.249 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 83.2 mt-30 -71.81 131.09 86.14 Favored Pre-proline 0 C--N 1.327 -0.39 0 CA-C-N 116.824 0.312 . . . . 0.0 110.596 179.616 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 287' ' ' PRO . . . . . 0.46 ' HB2' ' HB ' ' A' ' 269' ' ' THR . 15.8 Cg_endo -59.3 131.32 40.3 Favored 'Trans proline' 0 C--N 1.343 0.254 0 C-N-CA 122.699 2.266 . . . . 0.0 112.292 -178.646 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 288' ' ' GLN . . . . . 0.557 ' HB3' HG12 ' A' ' 273' ' ' VAL . 69.2 tp60 -78.3 132.16 37.35 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.847 -178.528 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 46.9 t -92.13 136.3 24.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.356 179.345 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 290' ' ' PHE . . . . . 0.75 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 55.7 m-85 -117.16 150.67 38.33 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.806 -177.081 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 21.2 mmt85 -108.02 157.69 18.02 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.797 -0.638 . . . . 0.0 109.835 172.252 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . 0.567 ' HB ' ' H ' ' A' ' 265' ' ' GLY . 52.2 t -102.6 128.77 55.07 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.03 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.509 177.406 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 293' ' ' LEU . . . . . 0.637 HD21 ' N ' ' A' ' 293' ' ' LEU . 2.8 mm? -103.99 -37.05 7.53 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.108 -178.578 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 294' ' ' ALA . . . . . 0.416 ' HA ' HG22 ' A' ' 264' ' ' VAL . . . -156.96 141.54 16.75 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.562 -0.29 . . . . 0.0 111.009 -178.819 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 46.3 t -131.64 129.01 61.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.052 0.453 . . . . 0.0 110.122 176.176 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 56.5 p -122.3 88.81 3.0 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.793 -0.64 . . . . 0.0 109.897 178.295 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 75.42 -124.3 7.56 Favored Glycine 0 N--CA 1.446 -0.671 0 C-N-CA 119.932 -1.128 . . . . 0.0 110.552 -171.425 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 41.7 p -99.72 26.37 6.3 Favored 'General case' 0 C--N 1.319 -0.745 0 O-C-N 122.142 -0.622 . . . . 0.0 110.87 173.505 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 54.1 m -107.95 106.3 16.49 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 176.009 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . 0.437 HG13 HG23 ' A' ' 302' ' ' ILE . 42.0 t -104.44 124.87 59.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.952 -175.001 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 47.3 m -94.89 109.67 21.64 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 176.149 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 302' ' ' ILE . . . . . 0.538 ' O ' ' HA ' ' A' ' 252' ' ' GLN . 28.8 pt -111.25 160.93 10.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-O 121.459 0.647 . . . . 0.0 112.343 -173.412 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 303' ' ' SER . . . . . 0.475 ' HA ' ' C ' ' A' ' 304' ' ' PRO . 34.6 t -167.24 155.9 9.09 Favored Pre-proline 0 C--N 1.32 -0.713 0 N-CA-C 105.964 -1.865 . . . . 0.0 105.964 178.331 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 304' ' ' PRO . . . . . 0.475 ' C ' ' HA ' ' A' ' 303' ' ' SER . 65.2 Cg_exo -56.46 151.54 27.16 Favored 'Cis proline' 0 N--CA 1.473 0.291 0 CA-C-N 121.23 1.475 . . . . 0.0 114.642 1.715 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 305' ' ' LYS . . . . . 0.53 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -67.34 169.01 9.56 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 114.085 -1.416 . . . . 0.0 111.763 -179.04 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 306' ' ' ILE . . . . . 0.4 HG21 HD11 ' A' ' 306' ' ' ILE . 62.6 mt -108.59 114.09 45.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.85 -178.154 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 307' ' ' LEU . . . . . 0.525 ' O ' ' HB2' ' A' ' 320' ' ' ALA . 94.0 mt -125.94 118.45 23.97 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-N 116.753 -0.203 . . . . 0.0 111.021 -179.72 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 308' ' ' PRO . . . . . 0.727 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 9.9 Cg_exo -74.18 122.31 7.49 Favored 'Trans proline' 0 CA--C 1.534 0.493 0 C-N-CA 123.519 2.813 . . . . 0.0 113.742 -178.557 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . 0.481 ' O ' ' HD2' ' A' ' 317' ' ' ARG . 48.1 t -80.58 -19.44 11.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 121.189 0.518 . . . . 0.0 110.48 176.014 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 59.5 mm-40 -92.77 -5.32 51.42 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.904 0.383 . . . . 0.0 110.834 179.206 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.535 ' HB2' ' HB2' ' A' ' 308' ' ' PRO . 5.5 m120 -132.5 -129.98 0.18 Allowed 'General case' 0 CA--C 1.532 0.285 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.26 -178.531 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 312' ' ' THR . . . . . 0.501 ' OG1' ' HD2' ' A' ' 308' ' ' PRO . 59.6 m 60.84 -78.61 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.281 0 C-N-CA 124.28 1.032 . . . . 0.0 112.121 177.655 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 38.3 t70 -176.68 150.29 0.82 Allowed 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 -177.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 46.7 t -53.18 -37.61 28.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 120.748 0.309 . . . . 0.0 111.53 -179.516 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -84.91 -36.3 21.55 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 112.377 0.51 . . . . 0.0 112.377 -178.314 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 316' ' ' SER . . . . . 0.529 ' HA ' ' CZ ' ' A' ' 319' ' ' TYR . 67.9 m -93.53 -12.68 29.06 Favored 'General case' 0 C--N 1.327 -0.398 0 N-CA-C 113.364 0.875 . . . . 0.0 113.364 -172.346 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 317' ' ' ARG . . . . . 0.508 ' HG2' ' HD3' ' A' ' 318' ' ' PRO . 33.6 ptt85 -75.44 -34.4 1.59 Allowed Pre-proline 0 CA--C 1.548 0.882 0 N-CA-C 113.171 0.804 . . . . 0.0 113.171 -179.47 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 318' ' ' PRO . . . . . 0.508 ' HD3' ' HG2' ' A' ' 317' ' ' ARG . 33.9 Cg_exo -60.36 -26.79 83.53 Favored 'Trans proline' 0 C--N 1.371 1.718 0 C-N-CA 121.702 1.602 . . . . 0.0 113.17 -177.785 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 319' ' ' TYR . . . . . 0.529 ' CZ ' ' HA ' ' A' ' 316' ' ' SER . 2.7 p90 -106.82 30.0 6.5 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.076 0.465 . . . . 0.0 111.312 177.863 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . 0.525 ' HB2' ' O ' ' A' ' 307' ' ' LEU . . . -89.87 162.68 15.34 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.404 -0.817 . . . . 0.0 109.838 173.628 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 19.4 p30 -100.71 -19.18 16.16 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 113.788 1.032 . . . . 0.0 113.788 -171.457 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 322' ' ' VAL . . . . . 0.419 ' O ' HG21 ' A' ' 309' ' ' VAL . 35.6 m -136.77 161.08 36.78 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.401 0 CA-C-N 118.073 0.397 . . . . 0.0 111.155 -179.969 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 54.5 m-20 -60.91 -41.03 95.34 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 111.849 0.314 . . . . 0.0 111.849 -178.781 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 324' ' ' ALA . . . . . 0.727 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -157.09 166.24 33.82 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.398 -0.364 . . . . 0.0 111.77 -175.346 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 24.5 pttm -106.31 108.93 62.67 Favored Pre-proline 0 C--N 1.327 -0.411 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 169.016 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 326' ' ' PRO . . . . . 0.438 ' HG2' HG21 ' A' ' 273' ' ' VAL . 41.3 Cg_exo -65.0 167.24 16.39 Favored 'Trans proline' 0 C--N 1.343 0.244 0 C-N-CA 122.581 2.187 . . . . 0.0 113.107 -170.543 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -62.85 143.53 57.51 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 115.753 -0.658 . . . . 0.0 109.767 175.089 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 328' ' ' GLU . . . . . 0.593 ' HA ' ' HG2' ' A' ' 233' ' ' GLN . 15.6 pt-20 44.86 -135.25 0.65 Allowed 'General case' 0 N--CA 1.468 0.449 0 O-C-N 124.227 0.955 . . . . 0.0 110.941 -174.132 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 329' ' ' SER . . . . . 0.605 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 53.3 m -111.7 -31.63 6.91 Favored 'General case' 0 C--N 1.321 -0.636 0 C-N-CA 120.743 -0.383 . . . . 0.0 110.535 178.317 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 330' ' ' ALA . . . . . 0.506 ' HB2' ' O ' ' A' ' 329' ' ' SER . . . 78.6 -167.42 0.04 OUTLIER 'General case' 0 N--CA 1.475 0.824 0 O-C-N 124.111 0.882 . . . . 0.0 112.902 174.634 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -83.85 152.91 24.32 Favored 'General case' 0 CA--C 1.52 -0.182 0 CA-C-N 115.361 -0.836 . . . . 0.0 111.193 -176.179 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 332' ' ' ILE . . . . . 0.533 HG12 HG12 ' A' ' 270' ' ' ILE . 48.7 mt -126.58 145.0 34.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 121.202 0.525 . . . . 0.0 112.034 -176.56 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.436 ' N ' HG23 ' A' ' 332' ' ' ILE . 87.8 m -111.22 97.57 6.88 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.459 -0.792 . . . . 0.0 109.103 173.486 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 334' ' ' ILE . . . . . 0.479 HG23 HD13 ' A' ' 334' ' ' ILE . 30.2 mm -79.11 132.27 32.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -171.705 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 335' ' ' LEU . . . . . 0.534 ' N ' HD12 ' A' ' 335' ' ' LEU . 8.4 mp -119.79 151.59 38.57 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.412 -0.813 . . . . 0.0 109.818 170.468 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 75.0 m-80 -110.3 9.95 23.62 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.293 174.193 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 38.8 ttpt . . . . . 0 C--O 1.244 0.788 0 CA-C-O 118.493 -0.765 . . . . 0.0 110.181 179.295 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 35.7 t . . . . . 0 C--O 1.235 0.305 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 228' ' ' LEU . . . . . 0.572 HD12 ' HB2' ' A' ' 259' ' ' ALA . 80.3 mt -103.61 146.9 27.88 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.352 -0.84 . . . . 0.0 109.548 -175.523 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 229' ' ' THR . . . . . 0.517 HG22 ' HA ' ' A' ' 331' ' ' ALA . 40.9 p -126.43 178.77 5.65 Favored 'General case' 0 C--N 1.323 -0.547 0 C-N-CA 119.729 -0.788 . . . . 0.0 111.042 -179.835 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 230' ' ' VAL . . . . . 0.815 HG22 HD12 ' A' ' 332' ' ' ILE . 58.1 t -146.28 137.15 18.6 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 -179.599 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 70.8 m -111.18 155.41 22.95 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.944 0.402 . . . . 0.0 110.854 178.188 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 86.03 169.63 46.14 Favored Glycine 0 N--CA 1.449 -0.499 0 N-CA-C 110.76 -0.936 . . . . 0.0 110.76 -172.471 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 233' ' ' GLN . . . . . 0.416 ' HA ' ' HD3' ' A' ' 234' ' ' PRO . 86.1 mt-30 -117.54 145.56 36.54 Favored Pre-proline 0 C--N 1.323 -0.572 0 CA-C-N 117.626 0.713 . . . . 0.0 111.482 179.761 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 234' ' ' PRO . . . . . 0.416 ' HD3' ' HA ' ' A' ' 233' ' ' GLN . 3.8 Cg_exo -71.94 172.29 14.91 Favored 'Trans proline' 0 N--CA 1.462 -0.374 0 C-N-CA 122.751 2.301 . . . . 0.0 111.55 176.249 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 55.7 mp0 -96.89 151.19 19.92 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.174 0.512 . . . . 0.0 110.911 -179.063 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 236' ' ' HIS . . . . . 0.574 ' CE1' ' HE2' ' A' ' 325' ' ' LYS . 17.1 p-80 -140.48 125.73 18.7 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.33 -0.85 . . . . 0.0 108.9 174.338 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 237' ' ' LYS . . . . . 0.556 ' HD3' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.326 -0.414 0 N-CA-C 111.76 0.282 . . . . 0.0 111.76 -176.385 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 252' ' ' GLN . . . . . 0.462 ' HA ' ' O ' ' A' ' 302' ' ' ILE . 26.2 mt-30 . . . . . 0 N--CA 1.47 0.562 0 N-CA-C 114.894 1.442 . . . . 0.0 114.894 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . 0.54 ' O ' HG12 ' A' ' 302' ' ' ILE . . . 179.96 110.43 0.28 Allowed Glycine 0 N--CA 1.451 -0.349 0 CA-C-N 113.738 -1.574 . . . . 0.0 110.588 178.581 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 41.6 p -97.12 126.49 42.32 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 117.378 0.589 . . . . 0.0 111.406 -174.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . 0.451 ' CD1' HG12 ' A' ' 230' ' ' VAL . 12.7 pt -132.18 157.79 43.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.62 -176.406 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 256' ' ' THR . . . . . 0.406 ' O ' HG13 ' A' ' 230' ' ' VAL . 32.7 m -98.98 107.57 20.04 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 175.06 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.54 HG23 HD13 ' A' ' 262' ' ' LEU . 29.8 m -89.79 143.31 11.45 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.575 0 C-N-CA 119.556 -0.858 . . . . 0.0 113.012 -168.206 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 258' ' ' SER . . . . . 0.411 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 37.2 m -91.04 9.32 31.3 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 114.023 -1.444 . . . . 0.0 108.893 169.789 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 259' ' ' ALA . . . . . 0.572 ' HB2' HD12 ' A' ' 228' ' ' LEU . . . -84.78 161.56 19.93 Favored 'General case' 0 N--CA 1.448 -0.525 0 CA-C-N 115.119 -0.946 . . . . 0.0 109.502 -177.624 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 34.3 t -126.63 130.77 51.11 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 120.639 0.257 . . . . 0.0 110.61 -178.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 75.87 43.79 21.51 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.963 -0.637 . . . . 0.0 113.328 177.179 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 262' ' ' LEU . . . . . 0.54 HD13 HG23 ' A' ' 257' ' ' VAL . 79.3 mt -89.99 142.92 27.24 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 117.17 0.485 . . . . 0.0 110.478 175.757 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 73.0 mt-30 -133.84 171.43 14.17 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.51 176.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 264' ' ' VAL . . . . . 0.564 HG23 ' HA ' ' A' ' 294' ' ' ALA . 44.0 t -76.58 142.05 14.87 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 N-CA-C 110.195 -0.298 . . . . 0.0 110.195 179.1 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 94.87 -4.9 68.77 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.5 -0.857 . . . . 0.0 113.257 177.255 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 266' ' ' ASP . . . . . 0.494 ' O ' ' HA ' ' A' ' 291' ' ' ARG . 48.7 m-20 -78.88 158.03 28.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 117.172 0.486 . . . . 0.0 110.837 178.287 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 267' ' ' ALA . . . . . 0.647 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -122.72 147.67 46.21 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.974 -176.658 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 268' ' ' PHE . . . . . 0.834 ' HA ' HD22 ' A' ' 335' ' ' LEU . 3.6 p90 -164.04 173.28 12.73 Favored 'General case' 0 C--N 1.33 -0.259 0 C-N-CA 120.056 -0.657 . . . . 0.0 111.895 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 54.1 p -121.58 129.98 53.21 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.345 176.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 270' ' ' ILE . . . . . 0.815 HG12 HG13 ' A' ' 332' ' ' ILE . 62.6 mt -98.35 134.4 37.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.72 -178.839 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -76.07 118.47 18.85 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.828 179.206 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 109.62 -21.44 25.84 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.629 -0.796 . . . . 0.0 111.938 -178.778 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 40.9 t -104.35 102.12 13.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 N-CA-C 109.557 -0.535 . . . . 0.0 109.557 175.293 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 4.1 m120 -104.44 151.57 23.37 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 -179.481 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 275' ' ' SER . . . . . 0.977 ' HB3' ' HB3' ' A' ' 288' ' ' GLN . 23.2 p -88.17 157.53 18.79 Favored 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 112.13 0.419 . . . . 0.0 112.13 -178.079 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 18.8 m -125.98 162.76 28.88 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.605 0 CA-C-N 115.332 -0.849 . . . . 0.0 109.959 172.744 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 277' ' ' HIS . . . . . 0.451 ' HD2' HG22 ' A' ' 284' ' ' THR . 88.8 m-70 -130.04 91.29 3.1 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 175.526 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 4.1 tp-100 -80.64 -23.42 39.71 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.361 -172.112 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 2.1 mp -64.99 -41.56 92.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 121.069 0.461 . . . . 0.0 109.884 177.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 280' ' ' THR . . . . . 0.44 ' HG1' ' HB2' ' A' ' 282' ' ' ASP . 77.8 p -87.45 -16.44 34.8 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.316 174.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 5.6 tmtm? 59.49 53.65 5.03 Favored 'General case' 0 CA--C 1.531 0.216 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 -176.086 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 282' ' ' ASP . . . . . 0.44 ' HB2' ' HG1' ' A' ' 280' ' ' THR . 9.8 t70 -110.91 142.26 43.23 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.336 -0.847 . . . . 0.0 109.401 -175.256 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 36.0 p -102.28 106.19 16.96 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 178.295 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 284' ' ' THR . . . . . 0.451 HG22 ' HD2' ' A' ' 277' ' ' HIS . 82.5 p -110.13 -53.47 2.67 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.655 -0.702 . . . . 0.0 111.406 -171.628 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 66.13 31.48 79.41 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 121.001 -0.618 . . . . 0.0 111.966 -179.364 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 11.2 mm100 -106.11 142.15 24.25 Favored Pre-proline 0 C--N 1.326 -0.451 0 CA-C-N 116.026 -0.087 . . . . 0.0 110.772 -177.311 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 287' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_exo -59.3 127.82 25.32 Favored 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 122.648 2.232 . . . . 0.0 111.671 178.161 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 288' ' ' GLN . . . . . 0.977 ' HB3' ' HB3' ' A' ' 275' ' ' SER . 15.9 pt20 -93.55 159.18 15.34 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.984 -178.163 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 45.6 t -88.53 126.26 41.76 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 CA-C-N 115.446 -0.797 . . . . 0.0 110.002 175.246 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 290' ' ' PHE . . . . . 0.647 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 4.1 m-85 -99.67 169.21 9.43 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 178.762 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 291' ' ' ARG . . . . . 0.494 ' HA ' ' O ' ' A' ' 266' ' ' ASP . 12.5 ttp-105 -144.14 127.47 16.79 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-O 121.808 0.813 . . . . 0.0 110.947 172.417 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 57.5 t -65.84 139.91 20.48 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.979 0 CA-C-N 114.044 -1.434 . . . . 0.0 112.175 -176.347 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 293' ' ' LEU . . . . . . . . . . . . . 89.4 mt -105.56 -32.69 8.37 Favored 'General case' 0 CA--C 1.529 0.157 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.193 177.035 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 294' ' ' ALA . . . . . 0.564 ' HA ' HG23 ' A' ' 264' ' ' VAL . . . -158.6 144.94 17.1 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-O 120.463 0.173 . . . . 0.0 111.15 -179.18 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 57.4 t -136.34 126.8 41.33 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 176.836 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 47.0 t -157.54 112.54 2.73 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.897 -178.56 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 57.6 49.76 70.93 Favored Glycine 0 C--N 1.333 0.376 0 C-N-CA 121.148 -0.548 . . . . 0.0 112.469 178.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 66.8 p 55.4 10.3 0.46 Allowed 'General case' 0 N--CA 1.473 0.675 0 C-N-CA 124.201 1.0 . . . . 0.0 112.89 -175.722 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 42.6 m -97.81 106.02 18.26 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 173.351 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . 0.633 HG13 HG21 ' A' ' 302' ' ' ILE . 53.1 t -109.86 127.02 67.03 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.51 -170.494 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 301' ' ' THR . . . . . 0.457 ' HB ' ' HB1' ' A' ' 294' ' ' ALA . 57.3 m -90.54 113.89 25.98 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 172.655 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 302' ' ' ILE . . . . . 0.633 HG21 HG13 ' A' ' 300' ' ' VAL . 31.0 pt -110.4 174.76 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-O 121.643 0.735 . . . . 0.0 111.727 -173.321 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 303' ' ' SER . . . . . 0.51 ' OG ' ' HA ' ' A' ' 304' ' ' PRO . 31.8 t -163.1 156.67 16.98 Favored Pre-proline 0 C--N 1.317 -0.811 0 N-CA-C 105.759 -1.941 . . . . 0.0 105.759 178.732 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 304' ' ' PRO . . . . . 0.51 ' HA ' ' OG ' ' A' ' 303' ' ' SER . 24.9 Cg_exo -66.33 -179.42 12.34 Favored 'Cis proline' 0 N--CA 1.474 0.339 0 CA-C-N 121.004 1.394 . . . . 0.0 113.906 1.404 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 305' ' ' LYS . . . . . 0.483 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -77.48 160.98 28.29 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.317 -0.856 . . . . 0.0 112.254 -175.264 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 306' ' ' ILE . . . . . . . . . . . . . 2.2 mp -94.05 109.91 22.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.18 179.03 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 307' ' ' LEU . . . . . 0.417 HD12 ' O ' ' A' ' 319' ' ' TYR . 96.0 mt -141.51 99.39 6.36 Favored Pre-proline 0 CA--C 1.516 -0.361 0 CA-C-O 120.455 0.169 . . . . 0.0 111.052 178.411 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 308' ' ' PRO . . . . . 0.751 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 22.6 Cg_exo -69.43 148.19 66.63 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 123.077 2.518 . . . . 0.0 113.297 -177.354 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . 0.409 ' O ' HG13 ' A' ' 309' ' ' VAL . 45.5 t -93.7 -23.98 5.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 170.452 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -76.05 34.37 0.13 Allowed 'General case' 0 CA--C 1.532 0.272 0 CA-C-N 115.375 -0.83 . . . . 0.0 112.726 -177.3 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 77.3 m-20 -99.07 162.87 12.83 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 174.77 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 61.5 m -78.43 -32.81 48.77 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 176.615 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -65.31 119.57 11.18 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.781 179.699 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 60.1 t -68.39 -35.43 70.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.767 -0.651 . . . . 0.0 111.16 -178.657 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . 0.419 ' O ' ' HD2' ' A' ' 318' ' ' PRO . . . -65.07 -17.9 64.85 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 112.157 0.428 . . . . 0.0 112.157 -178.787 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 316' ' ' SER . . . . . 0.585 ' HA ' ' CZ ' ' A' ' 319' ' ' TYR . 52.4 m -78.92 -17.21 55.89 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 111.812 0.301 . . . . 0.0 111.812 -179.313 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 317' ' ' ARG . . . . . 0.424 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 70.0 mtm180 -74.4 -46.88 5.86 Favored Pre-proline 0 CA--C 1.539 0.542 0 N-CA-C 112.928 0.714 . . . . 0.0 112.928 -176.569 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 318' ' ' PRO . . . . . 0.424 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 75.9 Cg_exo -54.85 -38.48 92.32 Favored 'Trans proline' 0 C--N 1.358 1.033 0 C-N-CA 122.126 1.884 . . . . 0.0 113.685 -175.78 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 319' ' ' TYR . . . . . 0.585 ' CZ ' ' HA ' ' A' ' 316' ' ' SER . 2.1 p90 -98.72 7.58 45.92 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 120.76 -0.376 . . . . 0.0 111.937 -178.536 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . 0.401 ' HB2' ' O ' ' A' ' 317' ' ' ARG . . . -60.43 156.02 16.93 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-O 121.122 0.487 . . . . 0.0 111.834 -177.28 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 321' ' ' ASN . . . . . 0.456 ' HB2' ' HE2' ' A' ' 305' ' ' LYS . 46.7 t30 -132.59 -27.61 1.71 Allowed 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.952 -179.04 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 322' ' ' VAL . . . . . . . . . . . . . 28.7 m -131.59 166.95 27.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.759 -179.733 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -68.43 -48.05 65.61 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.612 -0.267 . . . . 0.0 111.154 177.832 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 324' ' ' ALA . . . . . 0.751 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -164.63 177.35 8.12 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.988 -0.551 . . . . 0.0 111.59 -176.132 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 325' ' ' LYS . . . . . 0.574 ' HE2' ' CE1' ' A' ' 236' ' ' HIS . 21.9 pttp -118.61 119.52 32.64 Favored Pre-proline 0 C--N 1.325 -0.462 0 CA-C-N 115.346 -0.843 . . . . 0.0 109.692 172.529 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_endo -79.23 169.13 19.4 Favored 'Trans proline' 0 C--O 1.233 0.243 0 C-N-CA 122.962 2.441 . . . . 0.0 112.901 -176.171 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -67.57 129.15 39.02 Favored 'General case' 0 C--O 1.238 0.455 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 175.643 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 57.0 mm-40 65.48 -156.17 0.28 Allowed 'General case' 0 N--CA 1.463 0.216 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 -172.089 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 329' ' ' SER . . . . . 0.627 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 69.3 m -112.5 -12.27 13.5 Favored 'General case' 0 C--N 1.322 -0.606 0 C-N-CA 120.544 -0.462 . . . . 0.0 110.869 176.785 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 330' ' ' ALA . . . . . 0.442 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 70.24 -154.01 0.12 Allowed 'General case' 0 N--CA 1.469 0.502 0 N-CA-C 113.209 0.818 . . . . 0.0 113.209 172.408 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 331' ' ' ALA . . . . . 0.517 ' HA ' HG22 ' A' ' 229' ' ' THR . . . -93.09 137.61 32.28 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.75 -177.801 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 332' ' ' ILE . . . . . 0.815 HD12 HG22 ' A' ' 230' ' ' VAL . 1.9 mp -116.33 144.27 24.41 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.113 -178.685 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.401 ' N ' HG23 ' A' ' 332' ' ' ILE . 40.8 m -109.87 106.29 15.81 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.609 -0.515 . . . . 0.0 109.609 179.728 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 334' ' ' ILE . . . . . 0.506 HG13 HD13 ' A' ' 228' ' ' LEU . 19.5 mm -81.39 133.55 29.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 N-CA-C 113.755 1.02 . . . . 0.0 113.755 -172.208 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 335' ' ' LEU . . . . . 0.834 HD22 ' HA ' ' A' ' 268' ' ' PHE . 1.6 pt? -148.02 -147.62 0.23 Allowed 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 113.61 -1.632 . . . . 0.0 108.344 169.071 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -163.38 -39.97 0.03 OUTLIER 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 108.393 -0.965 . . . . 0.0 108.393 177.801 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 62.4 tttp . . . . . 0 C--O 1.243 0.716 0 CA-C-N 114.55 -1.204 . . . . 0.0 109.5 174.82 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 26.2 t . . . . . 0 N--CA 1.452 -0.326 0 N-CA-C 109.527 -0.545 . . . . 0.0 109.527 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 228' ' ' LEU . . . . . 0.518 ' HB3' ' HA ' ' A' ' 259' ' ' ALA . 83.8 mt -108.37 140.79 41.16 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 109.689 -0.486 . . . . 0.0 109.689 179.293 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 229' ' ' THR . . . . . 0.496 ' O ' HG23 ' A' ' 230' ' ' VAL . 70.8 p -124.27 177.12 6.02 Favored 'General case' 0 C--N 1.325 -0.464 0 C-N-CA 119.957 -0.697 . . . . 0.0 110.978 -178.506 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 230' ' ' VAL . . . . . 0.733 HG22 HD13 ' A' ' 332' ' ' ILE . 61.3 t -146.61 146.84 18.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.014 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 41.3 t -132.08 133.85 44.82 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.822 0.344 . . . . 0.0 110.402 178.755 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 104.21 73.28 0.92 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.41 -0.9 . . . . 0.0 112.929 177.625 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 13.8 mm-40 -66.86 133.0 93.93 Favored Pre-proline 0 C--N 1.33 -0.248 0 CA-C-O 120.84 0.353 . . . . 0.0 111.377 176.546 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 234' ' ' PRO . . . . . 0.568 ' HB2' ' HE1' ' A' ' 236' ' ' HIS . 56.9 Cg_endo -69.97 138.38 37.03 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 122.373 2.049 . . . . 0.0 111.515 176.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -97.88 126.41 43.25 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 121.391 0.615 . . . . 0.0 111.532 -176.261 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 236' ' ' HIS . . . . . 0.568 ' HE1' ' HB2' ' A' ' 234' ' ' PRO . 24.2 m80 -130.41 133.83 46.66 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.404 -0.817 . . . . 0.0 109.562 -178.548 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 237' ' ' LYS . . . . . 0.78 ' HA ' HG22 ' A' ' 312' ' ' THR . 6.8 mptt . . . . . 0 C--N 1.327 -0.379 0 C-N-CA 120.556 -0.458 . . . . 0.0 110.551 178.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 20.4 mt-30 . . . . . 0 N--CA 1.468 0.461 0 CA-C-O 121.519 0.676 . . . . 0.0 112.42 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . 0.449 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -172.65 95.71 0.11 Allowed Glycine 0 N--CA 1.447 -0.631 0 CA-C-N 115.429 -0.805 . . . . 0.0 111.178 179.099 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 59.9 p -95.39 116.98 29.53 Favored 'General case' 0 C--N 1.323 -0.561 0 O-C-N 122.48 -0.424 . . . . 0.0 110.914 -175.113 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . 0.472 HG22 ' HD3' ' A' ' 234' ' ' PRO . 21.2 pt -128.78 148.39 33.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.831 -177.618 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 59.8 m -101.27 107.26 18.58 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 174.096 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.748 HG22 HD11 ' A' ' 262' ' ' LEU . 32.8 m -90.73 143.65 10.77 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.728 0 N-CA-C 112.975 0.731 . . . . 0.0 112.975 -168.649 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 35.3 t -91.44 8.04 38.23 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 114.112 -1.404 . . . . 0.0 107.963 167.165 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 259' ' ' ALA . . . . . 0.518 ' HA ' ' HB3' ' A' ' 228' ' ' LEU . . . -85.64 158.12 20.16 Favored 'General case' 0 N--CA 1.448 -0.565 0 CA-C-N 114.926 -1.034 . . . . 0.0 109.626 -178.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 34.1 t -131.94 137.31 47.9 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 116.577 -0.283 . . . . 0.0 110.325 -179.217 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 90.27 39.28 6.07 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.6 -0.809 . . . . 0.0 112.571 -179.437 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 262' ' ' LEU . . . . . 0.748 HD11 HG22 ' A' ' 257' ' ' VAL . 60.2 mt -101.46 139.81 36.6 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.711 0.291 . . . . 0.0 110.877 179.788 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 68.5 mt-30 -142.2 167.72 21.45 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.82 -0.627 . . . . 0.0 109.436 179.298 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 264' ' ' VAL . . . . . 0.492 HG23 ' HA ' ' A' ' 294' ' ' ALA . 48.7 t -70.83 132.87 32.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 C-N-CA 120.772 -0.371 . . . . 0.0 110.161 177.834 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 105.58 8.63 34.72 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.548 -0.834 . . . . 0.0 112.401 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 59.7 m-20 -88.64 162.48 16.31 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.988 0.423 . . . . 0.0 110.861 179.045 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 267' ' ' ALA . . . . . 0.687 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -139.34 123.12 17.57 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.487 -0.779 . . . . 0.0 109.475 179.75 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 268' ' ' PHE . . . . . 0.448 ' CD1' HG23 ' A' ' 332' ' ' ILE . 3.5 p90 -142.15 173.66 11.32 Favored 'General case' 0 C--N 1.32 -0.676 0 C-N-CA 120.114 -0.634 . . . . 0.0 111.465 -174.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 269' ' ' THR . . . . . 0.535 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 63.8 p -118.89 132.37 56.1 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.53 178.115 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 270' ' ' ILE . . . . . 0.68 HG12 HG13 ' A' ' 332' ' ' ILE . 50.6 mt -100.61 134.02 41.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.57 179.625 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -72.72 143.47 48.01 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.956 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 85.78 -21.55 14.54 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.189 -177.522 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 53.5 t -105.69 102.46 13.9 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-O 120.983 0.42 . . . . 0.0 110.799 -179.593 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 4.0 m120 -100.72 154.94 18.19 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.22 -0.659 . . . . 0.0 109.22 174.702 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 6.7 t -83.7 179.98 7.46 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.912 0.387 . . . . 0.0 109.96 -177.853 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 34.2 m -131.92 153.11 38.0 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.712 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.236 172.775 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 26.4 m80 -136.94 137.08 39.17 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.091 179.236 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 8.5 tt0 -67.99 -31.67 71.53 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.916 0.389 . . . . 0.0 110.315 177.196 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 279' ' ' ILE . . . . . 0.452 HD12 HG23 ' A' ' 279' ' ' ILE . 72.3 mt -66.54 -50.36 67.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.861 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 71.5 p -85.42 -5.08 59.33 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 111.674 0.25 . . . . 0.0 111.674 -178.615 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 281' ' ' LYS . . . . . 0.514 ' HB3' ' NZ ' ' A' ' 281' ' ' LYS . 0.0 OUTLIER 70.94 52.97 0.27 Allowed 'General case' 0 CA--C 1.535 0.403 0 CA-C-O 121.742 0.782 . . . . 0.0 109.161 179.479 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 56.6 m-20 62.26 10.51 3.87 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 114.732 -1.122 . . . . 0.0 113.95 173.485 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 59.9 p -107.09 107.97 19.22 Favored 'General case' 0 C--N 1.314 -0.956 0 CA-C-O 121.041 0.448 . . . . 0.0 110.589 175.605 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 59.8 p -125.76 -52.37 1.57 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.061 -175.385 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 76.42 10.61 85.58 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.732 -0.747 . . . . 0.0 111.267 -173.363 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 93.4 mm-40 -111.11 130.42 22.99 Favored Pre-proline 0 C--N 1.326 -0.445 0 N-CA-C 110.322 -0.251 . . . . 0.0 110.322 -177.609 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 287' ' ' PRO . . . . . 0.535 ' HB2' ' HB ' ' A' ' 269' ' ' THR . 27.3 Cg_exo -60.76 142.05 96.63 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.627 2.218 . . . . 0.0 111.696 177.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 4.1 tp60 -68.18 145.05 54.69 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 120.877 0.37 . . . . 0.0 110.711 -179.637 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 47.6 t -99.73 121.77 50.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.492 176.631 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 290' ' ' PHE . . . . . 0.687 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 7.3 m-85 -103.31 156.17 17.92 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.028 0.442 . . . . 0.0 111.775 -174.02 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 36.3 mmt180 -122.31 121.18 36.14 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.112 -0.949 . . . . 0.0 109.408 174.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 61.7 t -78.51 135.51 25.84 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.89 -174.476 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 293' ' ' LEU . . . . . . . . . . . . . 6.6 mp -106.95 -33.8 7.4 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.674 179.034 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 294' ' ' ALA . . . . . 0.492 ' HA ' HG23 ' A' ' 264' ' ' VAL . . . -155.54 146.7 22.59 Favored 'General case' 0 N--CA 1.463 0.19 0 N-CA-C 111.677 0.251 . . . . 0.0 111.677 -177.365 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 61.6 t -137.66 126.37 33.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.086 -0.506 . . . . 0.0 109.74 177.169 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 40.3 t -156.69 109.69 2.59 Favored 'General case' 0 C--N 1.326 -0.418 0 C-N-CA 121.139 -0.224 . . . . 0.0 110.944 -177.638 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 59.81 48.57 85.41 Favored Glycine 0 C--N 1.333 0.373 0 C-N-CA 121.077 -0.583 . . . . 0.0 112.488 179.447 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 298' ' ' THR . . . . . 0.409 ' O ' HG21 ' A' ' 257' ' ' VAL . 60.5 p 55.71 10.93 0.58 Allowed 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 124.342 1.057 . . . . 0.0 112.728 -176.361 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 58.3 m -99.92 106.47 18.29 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 173.024 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . 0.486 HG13 HG21 ' A' ' 302' ' ' ILE . 40.2 t -108.9 132.03 58.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.35 -169.519 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 51.6 m -100.87 111.35 23.54 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 175.422 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 302' ' ' ILE . . . . . 0.486 HG21 HG13 ' A' ' 300' ' ' VAL . 27.7 pt -121.64 164.6 18.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-O 121.284 0.564 . . . . 0.0 112.027 -174.262 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 303' ' ' SER . . . . . 0.463 ' HB3' ' HA ' ' A' ' 304' ' ' PRO . 53.1 m -135.29 165.28 37.58 Favored Pre-proline 0 C--N 1.313 -0.984 0 N-CA-C 106.325 -1.732 . . . . 0.0 106.325 168.775 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 304' ' ' PRO . . . . . 0.463 ' HA ' ' HB3' ' A' ' 303' ' ' SER . 17.4 Cg_exo -70.38 176.52 34.05 Favored 'Cis proline' 0 N--CA 1.472 0.243 0 CA-C-N 120.816 1.327 . . . . 0.0 113.71 0.923 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 305' ' ' LYS . . . . . 0.711 ' HG2' ' HG ' ' A' ' 307' ' ' LEU . 0.1 OUTLIER -73.86 152.69 40.15 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 114.986 -1.007 . . . . 0.0 111.284 -178.501 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 306' ' ' ILE . . . . . 0.456 HG22 HD12 ' A' ' 306' ' ' ILE . 46.4 mm -94.66 85.29 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.634 -178.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 307' ' ' LEU . . . . . 0.711 ' HG ' ' HG2' ' A' ' 305' ' ' LYS . 66.9 mt -106.12 110.32 63.89 Favored Pre-proline 0 C--N 1.325 -0.462 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 178.109 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 308' ' ' PRO . . . . . 0.468 ' CG ' ' HB2' ' A' ' 311' ' ' ASN . 65.1 Cg_endo -80.9 148.66 17.49 Favored 'Trans proline' 0 N--CA 1.463 -0.275 0 C-N-CA 122.548 2.166 . . . . 0.0 113.609 -172.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . 0.515 HG23 ' O ' ' A' ' 322' ' ' VAL . 47.0 t -87.65 -43.09 15.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.829 175.252 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 65.4 mm-40 -91.51 6.47 45.47 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 112.437 0.532 . . . . 0.0 112.437 -176.287 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.468 ' HB2' ' CG ' ' A' ' 308' ' ' PRO . 5.9 m120 -130.0 173.33 10.82 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 110.231 -0.285 . . . . 0.0 110.231 178.597 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 312' ' ' THR . . . . . 0.78 HG22 ' HA ' ' A' ' 237' ' ' LYS . 23.7 m 60.07 31.03 20.43 Favored 'General case' 0 CA--C 1.539 0.543 0 CA-C-O 121.758 0.79 . . . . 0.0 110.656 176.887 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 44.5 m-20 63.87 -177.71 0.16 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 114.883 -1.053 . . . . 0.0 112.208 177.106 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 314' ' ' VAL . . . . . 0.445 HG12 ' O ' ' A' ' 314' ' ' VAL . 50.0 t -68.31 -24.66 30.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.426 -176.441 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -60.63 -23.73 64.98 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 111.976 0.362 . . . . 0.0 111.976 -179.859 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 31.2 t -86.89 -22.02 25.97 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.31 -177.845 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 317' ' ' ARG . . . . . 0.614 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 83.3 mtt-85 -56.6 -53.68 61.8 Favored Pre-proline 0 CA--C 1.541 0.605 0 N-CA-C 113.499 0.926 . . . . 0.0 113.499 -177.525 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 318' ' ' PRO . . . . . 0.614 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 44.1 Cg_exo -61.97 -35.39 77.32 Favored 'Trans proline' 0 C--N 1.356 0.931 0 C-N-CA 122.018 1.812 . . . . 0.0 113.677 -174.587 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 7.4 m-85 -105.62 21.67 16.83 Favored 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 121.152 -0.219 . . . . 0.0 111.089 -179.065 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -65.79 160.0 24.03 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.096 0.474 . . . . 0.0 111.685 -177.39 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 20.6 t-20 -123.58 -33.19 3.25 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.85 -0.613 . . . . 0.0 109.956 177.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 322' ' ' VAL . . . . . 0.515 ' O ' HG23 ' A' ' 309' ' ' VAL . 35.4 m -135.42 163.76 34.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.345 177.308 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 63.6 m-20 -55.89 -41.28 74.21 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 112.684 0.624 . . . . 0.0 112.684 -176.407 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 324' ' ' ALA . . . . . 0.435 ' HA ' ' CB ' ' A' ' 308' ' ' PRO . . . -169.49 167.49 9.82 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.876 0.369 . . . . 0.0 111.746 -173.759 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 325' ' ' LYS . . . . . 0.487 ' HZ3' ' HB2' ' A' ' 325' ' ' LYS . 0.0 OUTLIER -108.7 106.25 58.42 Favored Pre-proline 0 C--N 1.325 -0.49 0 CA-C-N 114.968 -1.014 . . . . 0.0 109.26 168.732 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 76.0 Cg_endo -85.21 168.47 10.32 Favored 'Trans proline' 0 C--O 1.234 0.276 0 C-N-CA 122.8 2.333 . . . . 0.0 112.769 -173.472 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -69.6 121.86 17.94 Favored 'General case' 0 C--O 1.235 0.327 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 176.588 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 328' ' ' GLU . . . . . 0.448 ' HA ' ' OE2' ' A' ' 328' ' ' GLU . 43.6 mm-40 64.16 164.24 0.13 Allowed 'General case' 0 C--O 1.234 0.243 0 O-C-N 123.891 0.744 . . . . 0.0 111.417 -175.288 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 329' ' ' SER . . . . . 0.588 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 22.2 m -86.49 -14.49 42.95 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.35 -174.306 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 330' ' ' ALA . . . . . 0.484 ' HB2' ' O ' ' A' ' 329' ' ' SER . . . 71.26 -154.43 0.1 Allowed 'General case' 0 N--CA 1.467 0.403 0 CA-C-O 121.332 0.586 . . . . 0.0 112.287 175.532 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 331' ' ' ALA . . . . . 0.462 ' C ' HD11 ' A' ' 332' ' ' ILE . . . -90.04 125.79 35.53 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.147 -0.933 . . . . 0.0 110.168 179.35 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 332' ' ' ILE . . . . . 0.733 HD13 HG22 ' A' ' 230' ' ' VAL . 1.7 mp -106.35 144.72 15.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.31 -178.917 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.591 ' N ' HG21 ' A' ' 332' ' ' ILE . 88.5 m -109.97 103.02 11.72 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.069 -0.514 . . . . 0.0 109.711 -178.171 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 334' ' ' ILE . . . . . 0.56 HD11 HG22 ' A' ' 332' ' ' ILE . 37.9 mm -83.1 129.3 37.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 115.57 -0.741 . . . . 0.0 112.42 -171.209 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 335' ' ' LEU . . . . . 0.477 ' N ' HD12 ' A' ' 335' ' ' LEU . 6.8 mp -123.67 153.04 41.36 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.264 -0.88 . . . . 0.0 109.823 172.644 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 22.9 p30 -110.9 5.02 20.19 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 170.442 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 23.1 tptm . . . . . 0 C--O 1.245 0.82 0 CA-C-N 114.541 -1.209 . . . . 0.0 110.99 -179.412 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 31.5 t . . . . . 0 CA--C 1.531 0.243 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 228' ' ' LEU . . . . . 0.643 ' HB3' ' HB2' ' A' ' 259' ' ' ALA . 85.1 mt -96.46 130.93 43.5 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 109.511 -0.552 . . . . 0.0 109.511 175.728 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 229' ' ' THR . . . . . 0.488 ' O ' HG21 ' A' ' 230' ' ' VAL . 41.3 p -129.63 179.54 5.77 Favored 'General case' 0 C--N 1.325 -0.465 0 C-N-CA 120.296 -0.562 . . . . 0.0 110.986 -178.631 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 230' ' ' VAL . . . . . 0.797 ' HB ' ' HB3' ' A' ' 329' ' ' SER . 89.5 t -146.18 130.85 11.58 Favored 'Isoleucine or valine' 0 C--O 1.24 0.571 0 CA-C-O 120.601 0.239 . . . . 0.0 111.549 -177.2 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 18.7 m -97.29 97.84 9.49 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.194 -0.912 . . . . 0.0 109.733 172.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 163.02 134.74 1.69 Allowed Glycine 0 C--O 1.226 -0.344 0 C-N-CA 120.719 -0.753 . . . . 0.0 111.72 -177.429 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 11.0 mm100 -61.62 144.73 92.44 Favored Pre-proline 0 C--N 1.328 -0.369 0 N-CA-C 112.688 0.625 . . . . 0.0 112.688 -174.516 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -70.7 175.22 9.18 Favored 'Trans proline' 0 C--N 1.348 0.521 0 C-N-CA 123.381 2.721 . . . . 0.0 111.793 175.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 235' ' ' GLU . . . . . 0.461 ' O ' ' HB ' ' A' ' 306' ' ' ILE . 87.6 mt-10 -94.3 138.11 32.67 Favored 'General case' 0 C--O 1.211 -0.962 0 C-N-CA 120.833 -0.347 . . . . 0.0 111.688 -176.524 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 236' ' ' HIS . . . . . 0.417 ' HB3' ' O ' ' A' ' 306' ' ' ILE . 25.5 p-80 -169.04 126.82 0.99 Allowed 'General case' 0 C--N 1.307 -1.256 0 CA-C-N 115.097 -0.956 . . . . 0.0 109.366 166.975 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 237' ' ' LYS . . . . . 0.548 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.327 -0.377 0 C-N-CA 120.32 -0.552 . . . . 0.0 110.473 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 17.2 mt-30 . . . . . 0 C--O 1.237 0.413 0 CA-C-O 121.769 0.795 . . . . 0.0 112.83 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . 0.423 ' O ' ' HA ' ' A' ' 301' ' ' THR . . . -160.86 145.33 10.89 Favored Glycine 0 N--CA 1.449 -0.467 0 CA-C-N 115.007 -0.997 . . . . 0.0 111.94 177.714 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 254' ' ' THR . . . . . 0.458 HG21 ' OG1' ' A' ' 301' ' ' THR . 34.1 p -95.32 117.99 31.28 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.843 0.354 . . . . 0.0 111.13 -179.797 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . 0.467 HG23 HD13 ' A' ' 255' ' ' ILE . 24.7 pt -114.75 142.84 26.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.08 0.467 . . . . 0.0 111.494 -178.724 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 58.1 m -92.49 109.63 21.03 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 176.354 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.611 HG13 HG22 ' A' ' 230' ' ' VAL . 33.9 m -90.21 143.78 10.48 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.703 0 C-N-CA 119.646 -0.821 . . . . 0.0 113.004 -168.351 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 24.0 t -91.59 9.07 33.7 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 114.051 -1.432 . . . . 0.0 108.192 168.883 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 259' ' ' ALA . . . . . 0.643 ' HB2' ' HB3' ' A' ' 228' ' ' LEU . . . -99.05 169.8 9.16 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-N 114.774 -1.103 . . . . 0.0 109.484 -178.592 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 33.8 t -142.57 155.28 44.97 Favored 'General case' 0 C--N 1.324 -0.54 0 C-N-CA 120.828 -0.349 . . . . 0.0 110.733 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 74.34 42.8 33.54 Favored Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.47 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 262' ' ' LEU . . . . . 0.451 HD11 HG23 ' A' ' 257' ' ' VAL . 64.5 mt -102.39 140.02 37.21 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 110.17 -0.308 . . . . 0.0 110.17 179.37 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 81.5 mt-30 -135.24 169.45 17.44 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.479 -0.328 . . . . 0.0 110.206 179.822 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 264' ' ' VAL . . . . . 0.445 HG22 ' HA ' ' A' ' 294' ' ' ALA . 45.5 t -77.77 136.26 24.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.594 179.63 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 92.13 7.65 63.81 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.442 -0.885 . . . . 0.0 112.292 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 266' ' ' ASP . . . . . 0.509 ' HB2' HG22 ' A' ' 292' ' ' VAL . 72.8 m-20 -81.73 160.47 23.63 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.232 0.539 . . . . 0.0 110.133 176.785 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 267' ' ' ALA . . . . . 0.529 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -126.84 145.37 50.67 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 115.332 -0.849 . . . . 0.0 108.822 178.952 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 268' ' ' PHE . . . . . 0.788 ' HA ' HD22 ' A' ' 335' ' ' LEU . 4.6 p90 -162.53 170.66 18.27 Favored 'General case' 0 C--N 1.32 -0.713 0 C-N-CA 119.971 -0.692 . . . . 0.0 111.452 -177.124 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 269' ' ' THR . . . . . 0.464 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 72.7 p -121.85 150.84 41.35 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.009 178.499 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 270' ' ' ILE . . . . . 0.828 HG23 HG23 ' A' ' 273' ' ' VAL . 54.4 mt -115.51 138.33 46.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 120.864 0.364 . . . . 0.0 111.622 -177.396 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 271' ' ' ALA . . . . . 0.498 ' N ' HG22 ' A' ' 270' ' ' ILE . . . -66.12 117.58 8.64 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 115.571 -0.74 . . . . 0.0 111.062 178.353 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 104.46 -23.05 32.66 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.932 -0.651 . . . . 0.0 112.182 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . 0.828 HG23 HG23 ' A' ' 270' ' ' ILE . 91.0 t -88.36 112.39 23.74 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-O 120.71 0.291 . . . . 0.0 110.491 175.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 72.9 m-80 -129.54 143.58 50.89 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.663 -178.071 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 52.3 p -70.86 164.75 24.68 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.152 0.501 . . . . 0.0 111.699 -177.7 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 29.3 m -112.58 179.48 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-N 115.652 -0.704 . . . . 0.0 112.469 -176.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 19.2 p-80 -46.19 106.92 0.09 Allowed 'General case' 0 C--O 1.235 0.304 0 CA-C-N 114.631 -1.168 . . . . 0.0 111.817 176.772 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 278' ' ' GLN . . . . . 0.494 ' H ' ' HB2' ' A' ' 282' ' ' ASP . 8.4 tt0 -83.94 -51.29 7.27 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.19 -176.467 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 3.2 mp -105.59 -66.81 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.828 0.347 . . . . 0.0 110.78 -178.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 21.3 p -139.58 86.46 2.11 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.61 -177.545 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt 59.56 29.57 19.14 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.759 -0.655 . . . . 0.0 112.044 177.108 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 282' ' ' ASP . . . . . 0.494 ' HB2' ' H ' ' A' ' 278' ' ' GLN . 1.7 m-20 -58.05 101.48 0.08 Allowed 'General case' 0 N--CA 1.468 0.43 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.68 -179.535 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 45.1 p -105.88 105.65 15.78 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.159 175.117 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 65.7 p -127.6 -35.0 2.17 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.589 -174.449 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 82.23 26.18 48.97 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.306 -177.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 70.7 mt-30 -79.71 121.13 82.09 Favored Pre-proline 0 C--N 1.329 -0.295 0 O-C-N 122.891 -0.182 . . . . 0.0 110.667 -179.658 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 287' ' ' PRO . . . . . 0.464 ' HB2' ' HB ' ' A' ' 269' ' ' THR . 26.4 Cg_exo -60.33 126.75 20.89 Favored 'Trans proline' 0 C--O 1.234 0.296 0 C-N-CA 122.518 2.145 . . . . 0.0 111.408 177.451 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 4.4 tm0? -74.49 136.54 42.23 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 -175.062 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 44.5 t -86.91 124.54 40.57 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-O 121.038 0.447 . . . . 0.0 111.524 -172.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 290' ' ' PHE . . . . . 0.637 ' HD1' ' HD2' ' A' ' 304' ' ' PRO . 60.6 m-85 -98.5 168.44 10.19 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.31 -174.694 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 27.8 mmm180 -125.12 148.42 48.57 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.224 -0.898 . . . . 0.0 109.736 178.463 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . 0.509 HG22 ' HB2' ' A' ' 266' ' ' ASP . 47.9 t -100.92 136.75 31.08 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-N 116.607 -0.27 . . . . 0.0 111.098 179.628 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 293' ' ' LEU . . . . . 0.601 HD11 ' N ' ' A' ' 293' ' ' LEU . 5.5 mp -103.95 -39.94 6.4 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.128 -178.868 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 294' ' ' ALA . . . . . 0.445 ' HA ' HG22 ' A' ' 264' ' ' VAL . . . -156.9 139.61 15.09 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.646 0.26 . . . . 0.0 111.473 -178.493 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 60.6 t -131.21 125.56 57.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-N 116.104 -0.498 . . . . 0.0 109.688 175.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 33.9 t -157.29 111.37 2.64 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.583 -0.281 . . . . 0.0 110.758 -178.018 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 60.58 50.82 63.39 Favored Glycine 0 C--N 1.333 0.372 0 C-N-CA 121.087 -0.578 . . . . 0.0 112.615 179.787 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 45.9 p 50.6 23.71 1.42 Allowed 'General case' 0 N--CA 1.47 0.552 0 C-N-CA 123.477 0.711 . . . . 0.0 112.434 -176.395 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 43.7 m -113.21 106.58 14.8 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 174.072 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 39.4 t -112.99 131.63 64.06 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 115.944 -0.571 . . . . 0.0 111.557 -168.633 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 301' ' ' THR . . . . . 0.458 ' OG1' HG21 ' A' ' 254' ' ' THR . 91.6 m -96.7 110.62 23.03 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 108.725 -0.842 . . . . 0.0 108.725 172.299 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 302' ' ' ILE . . . . . 0.462 ' O ' ' HB2' ' A' ' 303' ' ' SER . 2.5 pp -111.75 -172.54 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 N-CA-C 112.12 0.415 . . . . 0.0 112.12 -175.134 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 303' ' ' SER . . . . . 0.659 ' OG ' ' HA ' ' A' ' 304' ' ' PRO . 14.8 t 169.95 161.16 0.2 Allowed Pre-proline 0 C--O 1.221 -0.397 0 N-CA-C 106.224 -1.769 . . . . 0.0 106.224 -175.563 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 304' ' ' PRO . . . . . 0.659 ' HA ' ' OG ' ' A' ' 303' ' ' SER . 9.4 Cg_exo -72.94 -172.66 9.87 Favored 'Cis proline' 0 C--N 1.348 0.522 0 CA-C-N 121.384 1.53 . . . . 0.0 113.506 0.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 305' ' ' LYS . . . . . 0.625 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -84.3 176.3 8.82 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 114.751 -1.113 . . . . 0.0 112.644 -175.382 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 306' ' ' ILE . . . . . 0.461 ' HB ' ' O ' ' A' ' 235' ' ' GLU . 50.8 mm -119.46 86.2 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 114.485 -1.234 . . . . 0.0 109.878 -174.017 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 307' ' ' LEU . . . . . 0.58 HD12 ' HD1' ' A' ' 319' ' ' TYR . 83.9 mt -108.84 101.59 44.69 Favored Pre-proline 0 C--N 1.321 -0.633 0 C-N-CA 120.918 -0.313 . . . . 0.0 111.652 -173.618 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 308' ' ' PRO . . . . . 0.733 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 17.9 Cg_exo -69.92 148.44 64.01 Favored 'Trans proline' 0 C--O 1.233 0.232 0 C-N-CA 123.197 2.598 . . . . 0.0 113.336 -177.019 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 44.2 t -93.16 -21.36 6.11 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.529 -0.76 . . . . 0.0 109.44 173.1 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 53.5 mt-10 -74.62 13.65 0.59 Allowed 'General case' 0 CA--C 1.531 0.223 0 N-CA-C 112.797 0.665 . . . . 0.0 112.797 -178.448 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 77.8 m-20 -82.25 -24.66 34.66 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 120.846 -0.341 . . . . 0.0 110.92 177.468 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 312' ' ' THR . . . . . 0.418 ' O ' HG22 ' A' ' 312' ' ' THR . 58.2 m 72.01 -13.64 0.58 Allowed 'General case' 0 CA--C 1.541 0.634 0 O-C-N 123.743 0.652 . . . . 0.0 112.233 178.159 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -74.13 152.98 39.75 Favored 'General case' 0 C--N 1.331 -0.21 0 O-C-N 121.905 -0.497 . . . . 0.0 110.803 178.347 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 30.8 t -79.35 -19.33 12.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.306 -0.861 . . . . 0.0 111.485 -173.259 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -78.49 -36.88 44.47 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 113.019 0.748 . . . . 0.0 113.019 -174.096 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 16.2 m -88.18 -35.03 17.6 Favored 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -172.657 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 317' ' ' ARG . . . . . 0.424 ' N ' ' CD ' ' A' ' 318' ' ' PRO . 16.9 ptm180 -62.12 -33.05 11.03 Favored Pre-proline 0 CA--C 1.546 0.801 0 N-CA-C 114.516 1.302 . . . . 0.0 114.516 -175.263 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 318' ' ' PRO . . . . . 0.424 ' CD ' ' N ' ' A' ' 317' ' ' ARG . 35.2 Cg_exo -54.86 -38.87 92.26 Favored 'Trans proline' 0 C--N 1.368 1.587 0 C-N-CA 121.587 1.525 . . . . 0.0 112.795 178.874 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 319' ' ' TYR . . . . . 0.58 ' HD1' HD12 ' A' ' 307' ' ' LEU . 2.2 p90 -122.83 32.73 5.63 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 120.504 -0.479 . . . . 0.0 111.83 -179.251 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -63.34 157.15 23.73 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.605 178.171 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 46.2 t30 -128.49 -36.86 1.85 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.068 -0.514 . . . . 0.0 111.49 -177.662 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 322' ' ' VAL . . . . . . . . . . . . . 34.8 m -131.86 175.62 10.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 120.711 0.291 . . . . 0.0 111.217 -178.847 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 54.7 m-20 -78.62 -44.12 24.71 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.536 -0.302 . . . . 0.0 111.569 -177.272 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 324' ' ' ALA . . . . . 0.733 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -144.55 166.48 25.04 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.458 -175.589 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 325' ' ' LYS . . . . . 0.404 ' HA ' ' HD3' ' A' ' 326' ' ' PRO . 24.1 pttm -115.12 113.89 43.65 Favored Pre-proline 0 C--N 1.327 -0.383 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.729 175.153 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 326' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 325' ' ' LYS . 8.6 Cg_exo -72.92 167.84 26.24 Favored 'Trans proline' 0 C--O 1.233 0.236 0 C-N-CA 122.867 2.378 . . . . 0.0 112.167 -178.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -76.76 128.33 34.44 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 175.084 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 51.0 mt-10 64.96 -167.83 0.21 Allowed 'General case' 0 N--CA 1.466 0.333 0 O-C-N 123.5 0.5 . . . . 0.0 110.463 -176.191 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 329' ' ' SER . . . . . 0.797 ' HB3' ' HB ' ' A' ' 230' ' ' VAL . 42.6 t -90.88 -12.19 36.95 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 177.265 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 63.03 -160.36 0.31 Allowed 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 113.033 0.753 . . . . 0.0 113.033 171.261 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -76.36 127.96 33.9 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 115.182 -0.917 . . . . 0.0 110.676 -178.018 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 332' ' ' ILE . . . . . 0.562 HG12 HG12 ' A' ' 270' ' ' ILE . 50.0 mt -113.61 144.61 20.88 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.962 -177.432 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 95.7 m -115.63 106.09 13.51 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.675 176.824 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 334' ' ' ILE . . . . . 0.406 HG23 ' N ' ' A' ' 335' ' ' LEU . 41.2 mm -83.62 138.02 19.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.753 -0.658 . . . . 0.0 112.379 -170.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 335' ' ' LEU . . . . . 0.788 HD22 ' HA ' ' A' ' 268' ' ' PHE . 1.3 pt? -145.16 -159.14 0.96 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 114.978 -1.01 . . . . 0.0 108.814 171.184 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -152.36 48.36 0.76 Allowed 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.837 0.351 . . . . 0.0 111.592 179.709 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 337' ' ' LYS . . . . . 0.47 ' HB2' ' NZ ' ' A' ' 337' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.246 0.911 0 CA-C-O 118.827 -0.606 . . . . 0.0 110.515 178.908 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 24.8 m . . . . . 0 N--CA 1.453 -0.304 0 CA-C-O 121.111 0.482 . . . . 0.0 109.952 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 228' ' ' LEU . . . . . 0.718 ' HB3' ' HB1' ' A' ' 259' ' ' ALA . 83.7 mt -110.59 113.88 26.85 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 174.678 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 229' ' ' THR . . . . . 0.669 ' O ' HG21 ' A' ' 230' ' ' VAL . 41.6 p -120.71 177.68 4.98 Favored 'General case' 0 C--N 1.32 -0.676 0 C-N-CA 119.926 -0.709 . . . . 0.0 110.617 -177.856 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 230' ' ' VAL . . . . . 0.717 HG23 HD13 ' A' ' 332' ' ' ILE . 89.7 t -150.88 134.78 8.23 Favored 'Isoleucine or valine' 0 C--O 1.239 0.548 0 CA-C-O 120.826 0.346 . . . . 0.0 110.898 -178.365 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 44.3 t -97.98 153.01 18.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.027 175.674 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . 0.558 ' O ' ' HD3' ' A' ' 234' ' ' PRO . . . 108.42 127.21 5.54 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.449 -0.882 . . . . 0.0 111.489 -178.467 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 233' ' ' GLN . . . . . 0.723 ' HG2' ' H ' ' A' ' 328' ' ' GLU . 64.2 mt-30 -95.27 102.38 9.5 Favored Pre-proline 0 C--N 1.324 -0.507 0 CA-C-N 116.53 0.165 . . . . 0.0 110.56 -177.553 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 234' ' ' PRO . . . . . 0.558 ' HD3' ' O ' ' A' ' 232' ' ' GLY . 74.4 Cg_endo -96.78 125.65 0.26 Allowed 'Trans proline' 0 N--CA 1.45 -1.076 0 C-N-CA 122.294 1.996 . . . . 0.0 112.388 -178.195 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 235' ' ' GLU . . . . . 0.911 ' HA ' ' HE3' ' A' ' 325' ' ' LYS . 24.2 pt-20 -105.72 147.67 28.3 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 173.377 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 236' ' ' HIS . . . . . 0.709 ' HB2' ' H ' ' A' ' 306' ' ' ILE . 39.4 m170 -134.62 130.57 36.64 Favored 'General case' 0 CA--C 1.503 -0.85 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 -178.94 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 237' ' ' LYS . . . . . 0.619 ' HA ' ' HE3' ' A' ' 237' ' ' LYS . 7.5 mmmt . . . . . 0 C--N 1.315 -0.9 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 -178.815 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 252' ' ' GLN . . . . . 0.55 ' HA ' ' CD2' ' A' ' 236' ' ' HIS . 23.4 mt-30 . . . . . 0 N--CA 1.468 0.441 0 CA-C-O 120.723 0.297 . . . . 0.0 111.2 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 157.4 -168.7 34.24 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 119.242 -1.456 . . . . 0.0 113.358 -179.691 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 254' ' ' THR . . . . . 0.551 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 67.2 p -99.53 149.92 22.74 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.911 0.386 . . . . 0.0 111.378 -177.671 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . 0.403 ' O ' ' HA ' ' A' ' 299' ' ' THR . 18.8 pt -125.32 152.94 32.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.959 178.243 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 39.2 m -96.2 105.65 17.74 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.028 -0.731 . . . . 0.0 109.028 177.126 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.601 HG13 HG13 ' A' ' 230' ' ' VAL . 22.7 m -89.93 143.19 11.7 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.681 0 CA-C-O 121.725 0.774 . . . . 0.0 112.73 -169.251 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 50.3 m -93.15 8.63 39.34 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 114.219 -1.355 . . . . 0.0 109.129 170.358 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 259' ' ' ALA . . . . . 0.718 ' HB1' ' HB3' ' A' ' 228' ' ' LEU . . . -99.1 174.76 6.17 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.209 -175.098 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 64.7 p -141.88 149.88 40.83 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.889 0.376 . . . . 0.0 110.981 178.43 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 87.59 32.22 13.91 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.823 -0.704 . . . . 0.0 112.992 179.373 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 262' ' ' LEU . . . . . 0.566 HD11 ' HB2' ' A' ' 259' ' ' ALA . 3.2 mp -97.68 135.53 39.34 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-N 116.995 0.398 . . . . 0.0 110.226 178.894 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -134.04 171.85 13.63 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 177.315 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 38.4 t -78.78 136.65 23.4 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 C-N-CA 120.593 -0.443 . . . . 0.0 109.951 176.658 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 95.61 15.25 44.05 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.538 -0.839 . . . . 0.0 112.141 -179.152 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 266' ' ' ASP . . . . . 0.458 ' HB2' HG21 ' A' ' 292' ' ' VAL . 64.0 m-20 -88.79 166.07 14.27 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.164 0.507 . . . . 0.0 110.779 178.507 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 267' ' ' ALA . . . . . 0.629 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -140.61 122.7 15.68 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.39 -0.823 . . . . 0.0 109.437 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 268' ' ' PHE . . . . . . . . . . . . . 4.6 p90 -142.68 174.11 10.94 Favored 'General case' 0 C--N 1.323 -0.579 0 C-N-CA 119.752 -0.779 . . . . 0.0 111.718 -172.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 269' ' ' THR . . . . . 0.451 HG22 ' HB2' ' A' ' 287' ' ' PRO . 81.9 p -122.18 148.51 44.85 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.179 177.498 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 270' ' ' ILE . . . . . 0.705 HD11 ' HE1' ' A' ' 290' ' ' PHE . 26.6 mt -113.62 137.53 46.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.212 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -61.47 130.53 46.48 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.343 179.881 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 272' ' ' GLY . . . . . 0.517 ' HA3' ' HG2' ' A' ' 326' ' ' PRO . . . 91.91 -23.12 27.86 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 121.189 -0.529 . . . . 0.0 112.113 -178.878 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 59.7 t -95.94 103.14 14.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-O 120.96 0.409 . . . . 0.0 110.285 177.222 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 274' ' ' ASN . . . . . 0.564 ' HA ' ' HA ' ' A' ' 287' ' ' PRO . 70.0 m-80 -119.81 149.6 41.8 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.212 -178.306 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 77.7 p -81.45 162.25 23.37 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.387 0.613 . . . . 0.0 111.474 -176.813 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 29.8 m -112.14 -179.27 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-N 114.968 -1.014 . . . . 0.0 110.939 179.63 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 277' ' ' HIS . . . . . 0.531 ' CD2' ' HD2' ' A' ' 281' ' ' LYS . 26.7 p-80 -43.15 115.53 0.77 Allowed 'General case' 0 C--N 1.331 -0.213 0 O-C-N 124.331 1.02 . . . . 0.0 111.732 177.66 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 71.2 tp60 -83.57 -38.65 21.38 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.731 -178.059 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 279' ' ' ILE . . . . . 0.406 HD11 ' N ' ' A' ' 279' ' ' ILE . 2.9 mp -107.25 -80.85 0.32 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.431 0 C-N-CA 120.892 -0.323 . . . . 0.0 111.577 -176.969 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 35.7 p -127.48 70.74 1.32 Allowed 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 112.787 0.662 . . . . 0.0 112.787 -172.35 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 281' ' ' LYS . . . . . 0.531 ' HD2' ' CD2' ' A' ' 277' ' ' HIS . 14.6 mmmm 53.79 35.45 21.52 Favored 'General case' 0 N--CA 1.47 0.534 0 CA-C-O 121.203 0.525 . . . . 0.0 110.801 178.397 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 52.8 m-20 -69.44 174.04 5.28 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.264 -0.88 . . . . 0.0 111.595 -177.539 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 73.8 p -104.47 109.98 22.07 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.209 178.156 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 67.8 p -116.1 -76.69 0.57 Allowed 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.167 -174.001 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 70.29 7.74 60.85 Favored Glycine 0 C--N 1.329 0.156 0 C-N-CA 121.028 -0.605 . . . . 0.0 113.289 176.577 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 286' ' ' GLN . . . . . 0.404 ' HA ' ' HD3' ' A' ' 287' ' ' PRO . 96.1 mm-40 -93.29 142.43 25.27 Favored Pre-proline 0 C--N 1.324 -0.511 0 N-CA-C 110.314 -0.254 . . . . 0.0 110.314 -179.1 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 287' ' ' PRO . . . . . 0.564 ' HA ' ' HA ' ' A' ' 274' ' ' ASN . 48.2 Cg_exo -56.76 140.78 91.86 Favored 'Trans proline' 0 CA--C 1.529 0.266 0 C-N-CA 122.737 2.291 . . . . 0.0 112.601 -178.549 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 69.5 tp60 -78.22 140.88 38.91 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.006 -178.77 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 42.2 t -92.48 131.25 40.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.706 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 290' ' ' PHE . . . . . 0.705 ' HE1' HD11 ' A' ' 270' ' ' ILE . 8.2 m-30 -106.89 170.31 8.02 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 116.295 -0.412 . . . . 0.0 111.075 -175.939 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 26.2 mmm180 -118.28 145.02 45.37 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.995 0.426 . . . . 0.0 110.578 176.645 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . 0.462 HG12 HG11 ' A' ' 300' ' ' VAL . 59.6 t -101.02 130.42 50.44 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.589 177.716 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 293' ' ' LEU . . . . . 0.577 HD23 ' HB3' ' A' ' 303' ' ' SER . 2.3 mm? -106.1 -29.53 9.83 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.023 -176.504 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 294' ' ' ALA . . . . . 0.443 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -161.89 140.67 9.46 Favored 'General case' 0 C--N 1.331 -0.197 0 C-N-CA 121.013 -0.275 . . . . 0.0 111.442 -178.141 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 58.7 t -135.78 121.08 28.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 176.496 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 62.3 m -150.76 105.61 3.3 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.06 -179.515 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 64.52 57.52 12.66 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.142 179.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 65.5 p 49.42 25.9 1.48 Allowed 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 123.468 0.707 . . . . 0.0 112.448 -176.218 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 299' ' ' THR . . . . . 0.403 ' HA ' ' O ' ' A' ' 255' ' ' ILE . 70.8 m -115.59 111.66 21.0 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 177.166 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . 0.551 ' O ' ' HA ' ' A' ' 254' ' ' THR . 47.4 t -114.4 126.87 72.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.81 -170.817 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 66.3 m -81.55 115.65 20.95 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 172.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 302' ' ' ILE . . . . . 0.412 HG13 ' CE1' ' A' ' 236' ' ' HIS . 28.3 pt -112.82 148.84 15.54 Favored 'Isoleucine or valine' 0 C--O 1.24 0.594 0 N-CA-C 113.395 0.887 . . . . 0.0 113.395 -171.119 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 303' ' ' SER . . . . . 0.735 ' OG ' ' HA ' ' A' ' 304' ' ' PRO . 36.1 t -163.59 163.63 16.08 Favored Pre-proline 0 CA--C 1.537 0.458 0 N-CA-C 106.807 -1.553 . . . . 0.0 106.807 -178.314 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 304' ' ' PRO . . . . . 0.735 ' HA ' ' OG ' ' A' ' 303' ' ' SER . 1.0 OUTLIER -83.49 -151.55 0.68 Allowed 'Cis proline' 0 C--N 1.349 0.588 0 CA-C-N 120.752 1.304 . . . . 0.0 112.694 0.565 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 305' ' ' LYS . . . . . 0.536 ' HA ' ' HB3' ' A' ' 236' ' ' HIS . 0.0 OUTLIER -71.52 144.85 49.47 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.346 0.593 . . . . 0.0 111.046 -177.838 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 306' ' ' ILE . . . . . 0.709 ' H ' ' HB2' ' A' ' 236' ' ' HIS . 52.5 mt -108.44 76.64 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-N 115.513 -0.767 . . . . 0.0 109.135 176.6 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 307' ' ' LEU . . . . . 0.649 ' HB2' ' HA ' ' A' ' 320' ' ' ALA . 91.0 mt -98.83 120.23 59.21 Favored Pre-proline 0 C--N 1.322 -0.617 0 CA-C-N 115.505 -0.771 . . . . 0.0 112.261 -172.688 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 308' ' ' PRO . . . . . 0.752 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 15.8 Cg_exo -68.71 147.12 68.86 Favored 'Trans proline' 0 N--CA 1.462 -0.381 0 C-N-CA 123.309 2.673 . . . . 0.0 111.995 175.469 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . 0.418 ' O ' HG11 ' A' ' 309' ' ' VAL . 35.1 t -93.88 -16.09 7.68 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 N-CA-C 108.018 -1.105 . . . . 0.0 108.018 170.305 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 51.5 mm-40 -96.02 34.06 1.61 Allowed 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 115.218 -0.901 . . . . 0.0 112.422 -177.782 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 25.5 p30 -111.67 -177.18 3.12 Favored 'General case' 0 N--CA 1.464 0.241 0 C-N-CA 120.711 -0.396 . . . . 0.0 110.811 175.523 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 26.2 m -91.07 -20.13 22.4 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.923 -177.334 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 313' ' ' ASP . . . . . 0.546 ' O ' ' HG3' ' A' ' 317' ' ' ARG . 1.3 m-20 -63.58 104.03 0.6 Allowed 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.997 -178.063 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 314' ' ' VAL . . . . . 0.438 ' O ' HG11 ' A' ' 314' ' ' VAL . 48.9 t -64.34 -22.95 32.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.119 177.412 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -85.3 -20.87 29.36 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 111.955 0.354 . . . . 0.0 111.955 -179.747 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 67.6 m -94.24 -36.26 12.09 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 112.151 0.426 . . . . 0.0 112.151 -177.162 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 317' ' ' ARG . . . . . 0.546 ' HG3' ' O ' ' A' ' 313' ' ' ASP . 81.5 mtp180 -54.43 -46.88 98.95 Favored Pre-proline 0 CA--C 1.544 0.748 0 N-CA-C 113.228 0.825 . . . . 0.0 113.228 -177.71 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 318' ' ' PRO . . . . . 0.535 ' HD2' ' N ' ' A' ' 317' ' ' ARG . 11.9 Cg_endo -59.45 -38.46 83.41 Favored 'Trans proline' 0 C--N 1.359 1.115 0 C-N-CA 122.075 1.85 . . . . 0.0 112.807 -178.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 38.4 m-85 -97.75 15.34 23.96 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.651 -177.579 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . 0.649 ' HA ' ' HB2' ' A' ' 307' ' ' LEU . . . -82.18 153.51 25.95 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.723 -0.672 . . . . 0.0 111.001 -178.333 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -136.51 -0.18 2.43 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.988 179.756 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 322' ' ' VAL . . . . . . . . . . . . . 33.1 m -134.21 164.7 33.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 175.574 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -74.63 -33.64 62.61 Favored 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 120.807 -0.357 . . . . 0.0 110.61 -179.385 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 324' ' ' ALA . . . . . 0.752 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -173.22 172.56 3.8 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.402 -0.817 . . . . 0.0 111.282 -175.243 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 325' ' ' LYS . . . . . 0.911 ' HE3' ' HA ' ' A' ' 235' ' ' GLU . 10.7 ptmm? -131.84 106.73 13.99 Favored Pre-proline 0 C--N 1.326 -0.441 0 CA-C-N 115.285 -0.87 . . . . 0.0 110.768 172.616 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 326' ' ' PRO . . . . . 0.517 ' HG2' ' HA3' ' A' ' 272' ' ' GLY . 16.4 Cg_exo -67.39 170.56 13.26 Favored 'Trans proline' 0 C--O 1.233 0.234 0 C-N-CA 123.507 2.804 . . . . 0.0 112.065 178.433 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -58.63 163.85 3.02 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.807 -178.718 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 328' ' ' GLU . . . . . 0.723 ' H ' ' HG2' ' A' ' 233' ' ' GLN . 1.1 pm0 39.26 -153.28 0.01 OUTLIER 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 124.385 1.074 . . . . 0.0 112.748 -175.064 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 329' ' ' SER . . . . . 0.701 ' O ' HG22 ' A' ' 270' ' ' ILE . 48.8 m -112.59 -14.33 13.2 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.859 -176.861 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 61.15 -161.51 0.29 Allowed 'General case' 0 N--CA 1.469 0.525 0 N-CA-C 113.5 0.926 . . . . 0.0 113.5 171.38 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -78.04 138.46 38.8 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-N 114.975 -1.011 . . . . 0.0 110.551 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 332' ' ' ILE . . . . . 0.717 HD13 HG23 ' A' ' 230' ' ' VAL . 54.0 mt -122.8 145.14 30.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-O 121.151 0.5 . . . . 0.0 111.473 -176.182 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 89.8 m -106.23 97.44 7.24 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.82 177.437 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 334' ' ' ILE . . . . . 0.466 HG23 HD12 ' A' ' 334' ' ' ILE . 30.5 mm -86.84 117.6 31.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.376 -0.375 . . . . 0.0 112.002 -174.804 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 335' ' ' LEU . . . . . 0.409 HD21 ' O ' ' A' ' 267' ' ' ALA . 1.8 pt? -141.68 134.84 29.2 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.609 -0.723 . . . . 0.0 109.57 173.279 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -106.19 83.29 1.87 Allowed 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -177.768 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 25.4 pttm . . . . . 0 C--O 1.243 0.74 0 CA-C-O 118.578 -0.725 . . . . 0.0 110.158 -179.894 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 36.5 t . . . . . 0 N--CA 1.445 -0.678 0 CA-C-O 121.005 0.431 . . . . 0.0 110.407 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 228' ' ' LEU . . . . . 0.677 ' HB3' ' HB3' ' A' ' 259' ' ' ALA . 84.5 mt -69.42 134.31 48.82 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.383 -0.826 . . . . 0.0 109.477 176.421 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 229' ' ' THR . . . . . 0.408 ' OG1' ' HB3' ' A' ' 258' ' ' SER . 41.4 p -131.18 179.38 6.04 Favored 'General case' 0 C--N 1.326 -0.432 0 C-N-CA 119.904 -0.719 . . . . 0.0 112.174 -175.082 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 230' ' ' VAL . . . . . 0.644 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 53.3 t -122.26 127.81 75.3 Favored 'Isoleucine or valine' 0 C--O 1.238 0.472 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.039 178.482 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 35.7 m -105.86 115.75 30.77 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.317 178.186 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 134.92 170.17 12.11 Favored Glycine 0 N--CA 1.443 -0.851 0 C-N-CA 120.211 -0.995 . . . . 0.0 111.86 -178.499 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 233' ' ' GLN . . . . . 0.415 ' OE1' ' HA ' ' A' ' 327' ' ' ALA . 87.9 mm-40 -113.5 107.96 52.62 Favored Pre-proline 0 C--N 1.321 -0.637 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 -178.473 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 234' ' ' PRO . . . . . 0.648 ' O ' ' HD3' ' A' ' 325' ' ' LYS . 6.3 Cg_exo -74.88 125.74 9.59 Favored 'Trans proline' 0 N--CA 1.454 -0.812 0 C-N-CA 122.072 1.848 . . . . 0.0 111.007 178.073 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 70.0 mm-40 -124.15 149.92 45.73 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.731 178.36 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 78.9 t60 -161.04 130.54 4.81 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-N 115.778 -0.647 . . . . 0.0 110.235 172.39 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 237' ' ' LYS . . . . . 0.597 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.316 -0.862 0 CA-C-N 114.918 -1.037 . . . . 0.0 108.67 177.166 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 252' ' ' GLN . . . . . 0.649 ' HB3' ' O ' ' A' ' 302' ' ' ILE . 2.9 mm100 . . . . . 0 N--CA 1.452 -0.361 0 N-CA-C 110.311 -0.255 . . . . 0.0 110.311 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -85.3 135.34 13.37 Favored Glycine 0 N--CA 1.448 -0.504 0 C-N-CA 120.317 -0.944 . . . . 0.0 111.848 177.564 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 67.8 p -107.36 118.12 35.89 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.02 0.438 . . . . 0.0 110.162 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . 0.509 HG23 ' HG3' ' A' ' 234' ' ' PRO . 24.2 pt -119.39 146.05 24.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.73 -174.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 92.4 m -97.16 115.81 28.23 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 172.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.501 HG21 HD13 ' A' ' 262' ' ' LEU . 32.8 m -92.08 143.19 11.85 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.974 0 C-N-CA 119.388 -0.925 . . . . 0.0 112.697 -170.94 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 258' ' ' SER . . . . . 0.408 ' HB3' ' OG1' ' A' ' 229' ' ' THR . 23.1 t -90.72 9.92 28.01 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 114.005 -1.452 . . . . 0.0 107.968 169.671 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 259' ' ' ALA . . . . . 0.677 ' HB3' ' HB3' ' A' ' 228' ' ' LEU . . . -93.38 -179.27 5.0 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 114.862 -1.063 . . . . 0.0 110.262 -177.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 32.2 t -152.8 150.92 29.86 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 176.433 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 84.98 22.74 51.84 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.42 -178.649 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 262' ' ' LEU . . . . . 0.501 HD13 HG21 ' A' ' 257' ' ' VAL . 78.6 mt -90.08 140.51 29.58 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.683 0.278 . . . . 0.0 110.439 179.439 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 2.6 mm100 -137.55 168.71 19.12 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.58 -178.28 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 264' ' ' VAL . . . . . 0.503 HG22 ' HA ' ' A' ' 294' ' ' ALA . 45.6 t -74.81 138.58 20.74 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-O 120.743 0.306 . . . . 0.0 110.312 177.645 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 91.37 0.57 73.14 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.685 178.316 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 55.1 m-20 -81.32 165.32 21.49 Favored 'General case' 0 CA--C 1.514 -0.419 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 176.385 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 267' ' ' ALA . . . . . 0.826 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -130.7 148.65 52.51 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 176.869 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 268' ' ' PHE . . . . . 0.498 ' HA ' HD22 ' A' ' 335' ' ' LEU . 3.3 p90 -164.88 168.78 17.32 Favored 'General case' 0 C--N 1.321 -0.649 0 C-N-CA 120.176 -0.61 . . . . 0.0 111.3 -179.216 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 269' ' ' THR . . . . . 0.569 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 63.3 p -113.49 149.5 34.22 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.037 175.55 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 270' ' ' ILE . . . . . 0.47 HG23 HD13 ' A' ' 270' ' ' ILE . 59.4 mt -121.53 129.92 75.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 178.186 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -61.29 139.13 58.22 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.242 0.544 . . . . 0.0 112.242 -173.038 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 88.17 -24.95 9.69 Favored Glycine 0 C--O 1.231 -0.074 0 CA-C-N 115.778 -0.646 . . . . 0.0 112.678 179.199 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 38.2 t -97.21 101.49 12.31 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 174.288 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 274' ' ' ASN . . . . . 1.044 ' HA ' ' HA ' ' A' ' 287' ' ' PRO . 3.6 m120 -94.46 169.11 10.44 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.316 -179.084 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 275' ' ' SER . . . . . 0.409 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 8.3 t -104.72 179.79 4.17 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 107.876 -1.157 . . . . 0.0 107.876 171.555 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 32.7 m -126.28 149.15 31.0 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.07 0 C-N-CA 120.472 -0.491 . . . . 0.0 111.196 173.421 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 277' ' ' HIS . . . . . 0.408 ' CD2' ' HB2' ' A' ' 282' ' ' ASP . 90.6 m-70 -78.08 117.2 19.15 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.065 -0.516 . . . . 0.0 109.621 175.169 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 39.4 tt0 -62.91 -35.25 79.44 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.906 -173.137 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 60.7 mt -60.09 -69.41 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 112.295 0.48 . . . . 0.0 112.295 -173.57 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 46.4 p -114.52 17.22 17.45 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 112.424 0.527 . . . . 0.0 112.424 -174.426 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 2.8 tmtp? 60.04 53.02 4.79 Favored 'General case' 0 CA--C 1.535 0.397 0 CA-C-O 121.328 0.585 . . . . 0.0 109.527 177.688 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 282' ' ' ASP . . . . . 0.408 ' HB2' ' CD2' ' A' ' 277' ' ' HIS . 58.5 m-20 -94.27 129.98 40.71 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.892 0.377 . . . . 0.0 111.007 -178.804 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.505 HG21 ' OD1' ' A' ' 323' ' ' ASP . 76.1 p -107.2 107.43 18.38 Favored 'General case' 0 C--N 1.321 -0.656 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 173.842 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 47.0 p -118.68 7.27 11.65 Favored 'General case' 0 C--N 1.322 -0.587 0 C-N-CA 120.737 -0.385 . . . . 0.0 111.999 -172.217 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 85.58 26.65 34.91 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.403 -0.903 . . . . 0.0 112.646 176.386 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 286' ' ' GLN . . . . . 0.406 ' HA ' ' HD3' ' A' ' 287' ' ' PRO . 84.7 mt-30 -105.03 117.17 59.28 Favored Pre-proline 0 C--N 1.324 -0.535 0 N-CA-C 110.328 -0.249 . . . . 0.0 110.328 178.616 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 287' ' ' PRO . . . . . 1.044 ' HA ' ' HA ' ' A' ' 274' ' ' ASN . 39.5 Cg_exo -61.7 167.36 10.21 Favored 'Trans proline' 0 C--O 1.233 0.274 0 C-N-CA 123.222 2.615 . . . . 0.0 113.559 -175.67 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 62.9 tp60 -88.05 136.45 32.96 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.278 -0.874 . . . . 0.0 110.564 178.165 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 289' ' ' VAL . . . . . 0.423 HG13 ' HB3' ' A' ' 267' ' ' ALA . 43.8 t -94.47 123.24 46.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.069 -0.514 . . . . 0.0 109.888 177.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 290' ' ' PHE . . . . . 0.826 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 60.1 m-85 -104.07 133.56 48.81 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 112.082 0.401 . . . . 0.0 112.082 -173.396 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 40.2 mmm-85 -94.91 119.59 33.71 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-O 121.5 0.667 . . . . 0.0 109.414 167.761 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . 0.56 HG12 ' CG2' ' A' ' 295' ' ' VAL . 54.9 t -71.37 140.91 17.45 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 CA-C-N 114.705 -1.134 . . . . 0.0 112.409 -174.905 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 293' ' ' LEU . . . . . 0.61 HD11 ' N ' ' A' ' 293' ' ' LEU . 3.9 mp -102.34 -30.89 10.79 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.41 175.604 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 294' ' ' ALA . . . . . 0.503 ' HA ' HG22 ' A' ' 264' ' ' VAL . . . -158.02 138.85 13.07 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.558 -177.394 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 295' ' ' VAL . . . . . 0.56 ' CG2' HG12 ' A' ' 292' ' ' VAL . 59.4 t -133.84 97.67 2.35 Favored 'Isoleucine or valine' 0 C--O 1.236 0.358 0 CA-C-N 115.851 -0.613 . . . . 0.0 109.378 173.826 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 30.5 m -133.98 114.57 13.38 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.848 -176.064 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 60.96 51.04 61.07 Favored Glycine 0 C--N 1.329 0.179 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.336 -179.515 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 70.4 p 52.32 19.5 1.14 Allowed 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 123.635 0.774 . . . . 0.0 112.654 -176.267 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 32.8 m -109.45 108.95 19.64 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 177.174 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . 0.421 ' HA ' ' O ' ' A' ' 294' ' ' ALA . 43.7 t -112.04 126.96 69.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.54 -170.931 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 301' ' ' THR . . . . . 0.443 ' CG2' ' HB2' ' A' ' 252' ' ' GLN . 69.1 m -98.29 117.92 33.77 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 174.259 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 302' ' ' ILE . . . . . 0.678 ' O ' HD11 ' A' ' 302' ' ' ILE . 2.4 pp -116.18 149.82 18.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 N-CA-C 114.116 1.154 . . . . 0.0 114.116 -171.033 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 303' ' ' SER . . . . . 0.588 ' OG ' HD12 ' A' ' 293' ' ' LEU . 86.1 p -140.64 162.62 48.05 Favored Pre-proline 0 C--O 1.216 -0.682 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 173.185 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 304' ' ' PRO . . . . . 0.541 ' O ' ' HA ' ' A' ' 303' ' ' SER . 17.6 Cg_endo -55.83 174.39 3.55 Favored 'Cis proline' 0 N--CA 1.477 0.554 0 CA-C-N 121.479 1.564 . . . . 0.0 113.825 0.038 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 305' ' ' LYS . . . . . 0.462 ' HD2' ' N ' ' A' ' 305' ' ' LYS . 0.4 OUTLIER -65.3 158.42 26.42 Favored 'General case' 0 CA--C 1.511 -0.553 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.38 179.502 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 306' ' ' ILE . . . . . 0.424 HG22 ' HB3' ' A' ' 325' ' ' LYS . 43.3 mt -101.62 73.02 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -0.987 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.779 178.453 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 307' ' ' LEU . . . . . 0.496 ' HB2' ' HA ' ' A' ' 320' ' ' ALA . 91.7 mt -107.11 112.14 63.2 Favored Pre-proline 0 C--N 1.324 -0.543 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.216 -176.262 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 308' ' ' PRO . . . . . 0.561 ' HA ' ' O ' ' A' ' 322' ' ' VAL . 11.3 Cg_exo -69.79 146.35 59.74 Favored 'Trans proline' 0 N--CA 1.462 -0.324 0 C-N-CA 122.708 2.272 . . . . 0.0 111.034 177.708 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . 0.693 HG21 ' HB2' ' A' ' 320' ' ' ALA . 20.0 t -83.41 -21.32 8.85 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 CA-C-O 121.282 0.563 . . . . 0.0 110.39 -177.694 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -76.24 -6.95 53.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.58 -0.736 . . . . 0.0 112.28 -175.994 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -75.46 153.94 37.31 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.143 0.497 . . . . 0.0 111.749 -177.005 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 53.1 m -96.88 -7.58 33.06 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.835 -0.62 . . . . 0.0 109.402 178.24 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 313' ' ' ASP . . . . . 0.463 ' HB3' ' HB2' ' A' ' 316' ' ' SER . 9.8 t70 -54.25 119.0 4.54 Favored 'General case' 0 C--O 1.232 0.153 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.507 179.868 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 46.7 t -56.57 -49.61 76.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.41 -0.814 . . . . 0.0 112.679 -173.071 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -81.82 -19.73 40.5 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 112.352 0.501 . . . . 0.0 112.352 -174.668 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 316' ' ' SER . . . . . 0.463 ' HB2' ' HB3' ' A' ' 313' ' ' ASP . 49.2 m -91.81 -25.26 19.09 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 112.283 0.475 . . . . 0.0 112.283 -175.742 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 317' ' ' ARG . . . . . 0.473 ' CG ' ' HD3' ' A' ' 318' ' ' PRO . 1.6 ptm85 -71.62 -35.79 4.04 Favored Pre-proline 0 CA--C 1.545 0.771 0 N-CA-C 114.293 1.22 . . . . 0.0 114.293 -175.902 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 318' ' ' PRO . . . . . 0.473 ' HD3' ' CG ' ' A' ' 317' ' ' ARG . 24.2 Cg_exo -65.89 -38.92 21.33 Favored 'Trans proline' 0 C--N 1.362 1.268 0 CA-C-N 121.132 1.44 . . . . 0.0 112.476 -177.463 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 3.9 m-85 -95.94 17.37 15.5 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.075 -179.719 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . 0.693 ' HB2' HG21 ' A' ' 309' ' ' VAL . . . -64.67 134.34 54.07 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.523 177.805 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 15.2 p-10 -144.11 1.44 1.11 Allowed 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -174.023 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 322' ' ' VAL . . . . . 0.561 ' O ' ' HA ' ' A' ' 308' ' ' PRO . 29.4 m -133.93 161.45 40.92 Favored 'Isoleucine or valine' 0 C--O 1.234 0.266 0 CA-C-O 121.288 0.566 . . . . 0.0 112.262 -177.82 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 323' ' ' ASP . . . . . 0.672 ' HB2' ' HB2' ' A' ' 274' ' ' ASN . 57.2 m-20 -93.24 77.59 4.54 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.865 174.958 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 324' ' ' ALA . . . . . . . . . . . . . . . 72.37 163.85 0.28 Allowed 'General case' 0 N--CA 1.471 0.621 0 N-CA-C 113.387 0.884 . . . . 0.0 113.387 175.12 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 325' ' ' LYS . . . . . 0.648 ' HD3' ' O ' ' A' ' 234' ' ' PRO . 9.9 ptpp? -119.15 105.93 43.93 Favored Pre-proline 0 C--N 1.325 -0.459 0 CA-C-N 114.485 -1.234 . . . . 0.0 108.715 166.902 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 326' ' ' PRO . . . . . 0.412 ' HD3' ' HA ' ' A' ' 325' ' ' LYS . 3.8 Cg_exo -84.17 167.21 12.43 Favored 'Trans proline' 0 C--O 1.234 0.299 0 C-N-CA 122.657 2.238 . . . . 0.0 112.992 -171.363 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 327' ' ' ALA . . . . . 0.415 ' HA ' ' OE1' ' A' ' 233' ' ' GLN . . . -72.82 134.85 45.07 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 115.605 -0.725 . . . . 0.0 109.689 174.136 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 70.1 mm-40 71.3 111.18 0.06 Allowed 'General case' 0 N--CA 1.464 0.256 0 O-C-N 124.089 0.868 . . . . 0.0 110.432 -173.243 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 329' ' ' SER . . . . . 0.644 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 58.2 m -63.36 -41.28 98.83 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.603 -176.561 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 330' ' ' ALA . . . . . 0.547 ' HB1' ' O ' ' A' ' 329' ' ' SER . . . 79.35 -160.66 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.762 0 N-CA-C 112.828 0.677 . . . . 0.0 112.828 174.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 331' ' ' ALA . . . . . 0.424 ' H ' ' HB3' ' A' ' 330' ' ' ALA . . . -68.43 157.73 35.21 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-N 115.091 -0.958 . . . . 0.0 113.562 -170.405 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 332' ' ' ILE . . . . . 0.578 HD12 ' HB2' ' A' ' 259' ' ' ALA . 17.5 mt -119.16 146.11 24.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.075 -0.966 . . . . 0.0 110.223 179.555 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.528 ' HB ' ' OG1' ' A' ' 269' ' ' THR . 59.5 m -127.18 111.67 14.24 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 175.544 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 46.9 mm -83.87 134.93 25.85 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.359 0 N-CA-C 113.295 0.85 . . . . 0.0 113.295 -171.538 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 335' ' ' LEU . . . . . 0.5 ' O ' ' HB1' ' A' ' 267' ' ' ALA . 1.8 pt? -158.45 130.36 6.75 Favored 'General case' 0 C--O 1.222 -0.366 0 CA-C-N 115.083 -0.962 . . . . 0.0 109.906 170.562 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -102.65 2.74 36.34 Favored 'General case' 0 C--N 1.318 -0.801 0 O-C-N 122.011 -0.43 . . . . 0.0 111.144 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 40.1 ttmt . . . . . 0 C--O 1.244 0.773 0 CA-C-O 118.279 -0.867 . . . . 0.0 110.246 -178.388 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 35.4 m . . . . . 0 C--O 1.236 0.363 0 CA-C-O 120.904 0.383 . . . . 0.0 111.015 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 228' ' ' LEU . . . . . 0.54 ' H ' ' CD2' ' A' ' 228' ' ' LEU . 1.9 mm? -60.39 150.56 30.49 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.252 -179.665 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 229' ' ' THR . . . . . 0.599 ' O ' HG23 ' A' ' 230' ' ' VAL . 53.6 p -129.96 176.18 8.26 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 119.787 -0.765 . . . . 0.0 111.1 -179.773 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 230' ' ' VAL . . . . . 0.803 HG22 HD11 ' A' ' 332' ' ' ILE . 64.9 t -148.69 138.87 16.56 Favored 'Isoleucine or valine' 0 C--O 1.238 0.478 0 CA-C-O 120.789 0.328 . . . . 0.0 110.926 -177.128 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 47.1 t -122.72 97.39 5.43 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.419 -0.809 . . . . 0.0 109.101 173.284 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . -126.22 -151.8 7.96 Favored Glycine 0 N--CA 1.445 -0.762 0 C-N-CA 119.951 -1.119 . . . . 0.0 113.102 -175.036 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 233' ' ' GLN . . . . . 0.761 ' HB3' ' HD2' ' A' ' 234' ' ' PRO . 80.3 mt-30 -70.58 169.61 13.53 Favored Pre-proline 0 C--N 1.325 -0.468 0 CA-C-N 115.212 -0.494 . . . . 0.0 110.991 -178.609 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 234' ' ' PRO . . . . . 0.761 ' HD2' ' HB3' ' A' ' 233' ' ' GLN . 18.7 Cg_endo -57.53 175.08 0.43 Allowed 'Trans proline' 0 C--N 1.354 0.833 0 C-N-CA 123.404 2.736 . . . . 0.0 112.833 177.777 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 235' ' ' GLU . . . . . 0.442 ' HB2' ' HD2' ' A' ' 325' ' ' LYS . 25.1 mp0 -91.86 155.18 18.39 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 108.96 -0.756 . . . . 0.0 108.96 -177.052 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 65.6 m-70 -108.5 148.76 29.76 Favored 'General case' 0 C--N 1.323 -0.581 0 C-N-CA 120.521 -0.472 . . . . 0.0 111.177 -171.511 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 237' ' ' LYS . . . . . 0.49 ' HA ' HD23 ' A' ' 307' ' ' LEU . 0.0 OUTLIER . . . . . 0 C--N 1.324 -0.527 0 CA-C-N 115.5 -0.773 . . . . 0.0 108.957 -178.38 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 19.2 mt-30 . . . . . 0 N--CA 1.471 0.614 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . 0.585 ' O ' ' HA ' ' A' ' 301' ' ' THR . . . 133.29 -146.45 18.36 Favored Glycine 0 N--CA 1.445 -0.76 0 C-N-CA 118.576 -1.773 . . . . 0.0 114.223 174.314 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 51.4 p -93.98 130.1 40.21 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.036 -0.582 . . . . 0.0 112.443 -170.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . 0.693 HD13 HG11 ' A' ' 230' ' ' VAL . 2.3 pp -129.79 163.4 35.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.902 177.432 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 256' ' ' THR . . . . . 0.579 ' O ' HG12 ' A' ' 230' ' ' VAL . 31.3 m -100.47 116.38 32.28 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 -178.51 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.434 HG12 HG23 ' A' ' 300' ' ' VAL . 31.8 m -90.78 142.56 12.77 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.573 0 C-N-CA 120.192 -0.603 . . . . 0.0 112.593 -176.098 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 36.8 t -91.94 9.03 34.74 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 114.495 -1.23 . . . . 0.0 108.379 167.575 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 259' ' ' ALA . . . . . 0.748 ' HB3' HD12 ' A' ' 262' ' ' LEU . . . -91.07 171.54 9.19 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.138 -0.937 . . . . 0.0 109.748 -178.023 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 34.5 t -143.65 132.02 22.11 Favored 'General case' 0 C--N 1.324 -0.504 0 C-N-CA 120.991 -0.283 . . . . 0.0 110.857 179.508 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 99.24 25.49 9.43 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.682 -0.771 . . . . 0.0 113.083 177.705 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 262' ' ' LEU . . . . . 0.748 HD12 ' HB3' ' A' ' 259' ' ' ALA . 3.4 mp -87.79 146.26 25.71 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 117.034 0.417 . . . . 0.0 110.195 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 83.6 mt-30 -141.04 169.16 18.13 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.105 -0.498 . . . . 0.0 109.768 177.404 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 264' ' ' VAL . . . . . 0.461 ' CG2' ' HA ' ' A' ' 294' ' ' ALA . 31.8 t -77.86 139.69 18.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 C-N-CA 121.032 -0.267 . . . . 0.0 110.594 -179.677 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 91.71 3.35 68.71 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.13 179.462 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 70.5 m-20 -80.46 166.78 20.89 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.295 0.569 . . . . 0.0 111.039 179.145 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 267' ' ' ALA . . . . . 0.685 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -125.84 144.11 50.79 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 114.802 -1.09 . . . . 0.0 108.551 175.22 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 268' ' ' PHE . . . . . 0.578 ' CD1' HG22 ' A' ' 332' ' ' ILE . 0.0 OUTLIER -163.45 163.82 24.72 Favored 'General case' 0 C--N 1.313 -1.002 0 C-N-CA 120.125 -0.63 . . . . 0.0 110.167 -179.955 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 269' ' ' THR . . . . . 0.445 HG22 ' HB2' ' A' ' 287' ' ' PRO . 63.3 p -125.89 137.99 53.77 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 120.822 0.344 . . . . 0.0 110.934 -175.397 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 270' ' ' ILE . . . . . 0.659 HG12 HG12 ' A' ' 332' ' ' ILE . 60.5 mt -95.89 138.63 20.89 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.806 -179.316 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -62.23 125.52 24.18 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.97 179.577 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 94.4 -21.57 41.93 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.125 -178.62 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . 0.583 HG13 ' HB3' ' A' ' 288' ' ' GLN . 57.0 t -90.73 101.4 12.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.282 0.563 . . . . 0.0 110.106 177.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -115.91 134.32 55.11 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 178.791 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 35.6 p -70.8 152.81 43.36 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.258 0.552 . . . . 0.0 111.97 -179.125 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 276' ' ' VAL . . . . . 0.432 HG22 ' HG3' ' A' ' 278' ' ' GLN . 33.8 m -114.7 156.07 15.75 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-N 115.221 -0.899 . . . . 0.0 110.157 174.588 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 21.7 m80 -116.6 71.27 0.78 Allowed 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 177.473 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 278' ' ' GLN . . . . . 0.432 ' HG3' HG22 ' A' ' 276' ' ' VAL . 26.8 mt-30 -70.58 -9.62 57.27 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 112.17 0.433 . . . . 0.0 112.17 -175.239 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 2.0 mp -67.67 -49.08 73.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 176.024 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 70.1 p -90.93 -12.75 35.11 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.117 0.484 . . . . 0.0 109.925 174.288 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 26.5 tptp 68.28 50.8 0.73 Allowed 'General case' 0 CA--C 1.531 0.237 0 CA-C-N 114.902 -1.045 . . . . 0.0 110.342 -177.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -118.34 142.15 47.8 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.889 177.553 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 62.8 p -107.43 109.93 21.77 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.48 174.745 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 68.0 p -114.33 -12.19 12.45 Favored 'General case' 0 C--N 1.32 -0.691 0 C-N-CA 120.721 -0.392 . . . . 0.0 111.999 -171.429 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 64.16 31.46 80.91 Favored Glycine 0 CA--C 1.518 0.252 0 C-N-CA 120.964 -0.636 . . . . 0.0 113.313 175.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 98.1 mm-40 -89.14 122.46 68.71 Favored Pre-proline 0 C--N 1.327 -0.37 0 CA-C-N 116.941 0.37 . . . . 0.0 110.197 178.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 287' ' ' PRO . . . . . 0.445 ' HB2' HG22 ' A' ' 269' ' ' THR . 86.1 Cg_exo -48.29 131.08 22.1 Favored 'Trans proline' 0 C--N 1.346 0.42 0 C-N-CA 123.033 2.489 . . . . 0.0 112.989 -177.695 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 288' ' ' GLN . . . . . 0.583 ' HB3' HG13 ' A' ' 273' ' ' VAL . 67.1 tp60 -70.1 127.28 32.28 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.868 -178.867 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 65.7 t -91.73 131.74 38.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 116.042 -0.527 . . . . 0.0 110.578 178.47 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 290' ' ' PHE . . . . . 0.685 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 57.8 m-85 -113.5 154.5 26.96 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.72 -178.272 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 291' ' ' ARG . . . . . 0.476 ' HG3' HH11 ' A' ' 291' ' ' ARG . 0.1 OUTLIER -114.5 121.58 43.96 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.15 0.5 . . . . 0.0 110.196 172.812 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 56.9 t -70.39 136.46 25.99 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-N 115.037 -0.983 . . . . 0.0 111.889 -175.291 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 293' ' ' LEU . . . . . 0.498 HD13 ' HB2' ' A' ' 303' ' ' SER . 5.5 mp -96.22 -35.69 11.19 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.91 -0.587 . . . . 0.0 111.085 179.048 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 294' ' ' ALA . . . . . 0.556 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -163.63 140.8 7.21 Favored 'General case' 0 C--N 1.332 -0.184 0 C-N-CA 121.058 -0.257 . . . . 0.0 111.641 -179.579 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 59.9 t -134.77 103.37 4.48 Favored 'Isoleucine or valine' 0 C--O 1.235 0.303 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.784 175.191 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 51.0 m -143.81 114.64 7.73 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.559 -179.013 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 67.05 48.43 59.99 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.276 -178.551 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 77.9 p 51.5 21.53 1.28 Allowed 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 123.608 0.763 . . . . 0.0 112.106 -176.198 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 37.0 m -110.04 105.9 15.2 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 177.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . 0.609 HG12 HG23 ' A' ' 302' ' ' ILE . 48.9 t -108.52 128.09 64.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.4 -172.119 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 301' ' ' THR . . . . . 0.585 ' HA ' ' O ' ' A' ' 253' ' ' GLY . 54.1 m -86.75 115.82 24.44 Favored 'General case' 0 N--CA 1.451 -0.423 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 173.631 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 302' ' ' ILE . . . . . 0.61 HD12 ' O ' ' A' ' 302' ' ' ILE . 2.4 pp -111.74 151.04 13.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 N-CA-C 113.527 0.936 . . . . 0.0 113.527 -171.05 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 303' ' ' SER . . . . . 0.547 ' HB3' ' HA ' ' A' ' 304' ' ' PRO . 64.9 m -166.99 166.5 8.48 Favored Pre-proline 0 C--N 1.322 -0.595 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 179.326 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 304' ' ' PRO . . . . . 0.547 ' HA ' ' HB3' ' A' ' 303' ' ' SER . 4.3 Cg_exo -77.62 -113.81 0.0 OUTLIER 'Cis proline' 0 C--N 1.347 0.48 0 CA-C-N 120.907 1.36 . . . . 0.0 113.438 0.516 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 305' ' ' LYS . . . . . 0.498 ' HB3' ' HG ' ' A' ' 307' ' ' LEU . 31.2 mmtp -93.04 155.74 17.32 Favored 'General case' 0 CA--C 1.515 -0.385 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.354 -171.473 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 306' ' ' ILE . . . . . . . . . . . . . 3.1 mp -131.09 74.18 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.641 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 167.283 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 307' ' ' LEU . . . . . 0.498 ' HG ' ' HB3' ' A' ' 305' ' ' LYS . 73.7 mt -112.67 113.91 50.08 Favored Pre-proline 0 C--N 1.328 -0.366 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.183 -171.092 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 308' ' ' PRO . . . . . 0.727 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 37.8 Cg_exo -66.91 148.62 82.43 Favored 'Trans proline' 0 N--CA 1.472 0.254 0 C-N-CA 123.378 2.719 . . . . 0.0 113.924 -175.137 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . 0.498 ' O ' HG13 ' A' ' 309' ' ' VAL . 46.0 t -94.06 -7.92 9.99 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.362 0 CA-C-N 115.421 -0.809 . . . . 0.0 109.303 171.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 310' ' ' GLU . . . . . 0.414 ' HG2' ' O ' ' A' ' 323' ' ' ASP . 65.3 mm-40 -77.17 11.83 1.7 Allowed 'General case' 0 CA--C 1.531 0.248 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.928 179.076 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.52 ' OD1' ' HB2' ' A' ' 308' ' ' PRO . 4.6 m120 -80.41 158.69 25.89 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.888 0.375 . . . . 0.0 110.669 178.472 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 31.5 m -107.74 -13.28 15.06 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.168 0.508 . . . . 0.0 110.494 -176.027 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 11.8 p-10 -87.58 156.25 19.59 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 121.091 0.472 . . . . 0.0 111.172 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 314' ' ' VAL . . . . . 0.414 ' O ' HG11 ' A' ' 314' ' ' VAL . 49.1 t -81.79 -24.06 9.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 115.707 -0.678 . . . . 0.0 111.112 -178.295 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -61.9 -42.72 99.42 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 111.913 0.338 . . . . 0.0 111.913 -178.114 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 26.3 t -82.1 -10.31 59.24 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.609 -0.268 . . . . 0.0 111.293 -176.431 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 317' ' ' ARG . . . . . 0.628 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 36.8 mmt180 -58.37 -54.5 55.24 Favored Pre-proline 0 N--CA 1.468 0.464 0 N-CA-C 113.554 0.946 . . . . 0.0 113.554 -179.704 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 318' ' ' PRO . . . . . 0.628 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 24.5 Cg_exo -68.21 -19.19 44.81 Favored 'Trans proline' 0 C--N 1.353 0.78 0 C-N-CA 122.017 1.811 . . . . 0.0 113.232 -175.178 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 319' ' ' TYR . . . . . 0.445 ' O ' HD11 ' A' ' 307' ' ' LEU . 55.4 m-85 -102.16 -18.37 15.57 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 111.965 0.357 . . . . 0.0 111.965 -174.245 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -55.64 126.49 25.61 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.795 0.331 . . . . 0.0 111.244 -178.666 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 15.3 p-10 -126.51 -4.94 6.54 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.288 -177.631 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 322' ' ' VAL . . . . . 0.496 ' O ' HG22 ' A' ' 309' ' ' VAL . 29.9 m -136.35 156.43 36.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.637 0.256 . . . . 0.0 110.885 178.511 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 323' ' ' ASP . . . . . 0.414 ' O ' ' HG2' ' A' ' 310' ' ' GLU . 71.9 m-20 -52.93 -50.97 62.93 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.889 -178.065 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 324' ' ' ALA . . . . . 0.727 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -163.05 -179.94 7.07 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.006 0.431 . . . . 0.0 111.135 -177.066 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 325' ' ' LYS . . . . . 0.442 ' HD2' ' HB2' ' A' ' 235' ' ' GLU . 22.0 pttp -105.84 137.43 19.34 Favored Pre-proline 0 C--N 1.325 -0.481 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.122 176.575 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -86.35 167.46 9.05 Favored 'Trans proline' 0 N--CA 1.454 -0.809 0 C-N-CA 122.712 2.275 . . . . 0.0 112.306 -179.411 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -75.6 138.34 41.37 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 175.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 62.64 -132.42 0.51 Allowed 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 -174.021 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 329' ' ' SER . . . . . 0.485 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 48.6 m -111.49 -17.34 13.1 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 171.185 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 74.47 -173.67 0.13 Allowed 'General case' 0 N--CA 1.474 0.759 0 N-CA-C 113.65 0.981 . . . . 0.0 113.65 170.887 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 331' ' ' ALA . . . . . 0.431 ' HA ' ' O ' ' A' ' 228' ' ' LEU . . . -80.76 146.75 30.84 Favored 'General case' 0 CA--C 1.518 -0.264 0 CA-C-N 114.997 -1.001 . . . . 0.0 111.171 -176.604 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 332' ' ' ILE . . . . . 0.803 HD11 HG22 ' A' ' 230' ' ' VAL . 47.5 mt -128.45 147.18 33.0 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-O 120.956 0.408 . . . . 0.0 111.528 -176.938 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 88.1 m -116.71 112.96 21.94 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.857 -179.591 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 334' ' ' ILE . . . . . 0.402 HD12 HG23 ' A' ' 334' ' ' ILE . 38.4 mm -79.56 131.87 33.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 113.044 0.757 . . . . 0.0 113.044 -171.482 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 335' ' ' LEU . . . . . . . . . . . . . 9.6 mp -115.92 168.61 9.91 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 114.562 -1.199 . . . . 0.0 109.643 171.5 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -116.82 3.96 12.95 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.473 176.69 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 337' ' ' LYS . . . . . 0.457 ' O ' ' HB2' ' A' ' 267' ' ' ALA . 14.8 ptmm? . . . . . 0 C--O 1.246 0.889 0 CA-C-O 118.611 -0.709 . . . . 0.0 111.687 -176.415 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 51.1 m . . . . . 0 N--CA 1.453 -0.281 0 CA-C-O 121.057 0.456 . . . . 0.0 110.506 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 228' ' ' LEU . . . . . 0.66 HD13 ' HB1' ' A' ' 259' ' ' ALA . 89.9 mt -70.28 147.27 49.89 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 175.148 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 229' ' ' THR . . . . . 0.536 ' O ' HG21 ' A' ' 230' ' ' VAL . 63.8 p -126.29 171.65 10.77 Favored 'General case' 0 C--N 1.324 -0.54 0 C-N-CA 119.163 -1.015 . . . . 0.0 111.334 -176.919 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 230' ' ' VAL . . . . . 0.629 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 48.0 t -147.1 141.08 20.0 Favored 'Isoleucine or valine' 0 C--O 1.24 0.577 0 CA-C-O 120.657 0.265 . . . . 0.0 110.754 -177.662 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 30.6 t -106.48 148.84 27.7 Favored 'General case' 0 C--O 1.237 0.428 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.985 176.634 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 124.8 157.15 9.61 Favored Glycine 0 N--CA 1.449 -0.486 0 N-CA-C 110.944 -0.862 . . . . 0.0 110.944 -176.712 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 233' ' ' GLN . . . . . 0.538 ' NE2' ' HA ' ' A' ' 328' ' ' GLU . 96.6 mm-40 -110.01 101.48 47.52 Favored Pre-proline 0 C--N 1.324 -0.534 0 CA-C-N 117.419 0.609 . . . . 0.0 111.305 -177.819 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -91.83 126.36 0.92 Allowed 'Trans proline' 0 N--CA 1.448 -1.159 0 C-N-CA 122.806 2.337 . . . . 0.0 111.756 177.605 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -132.54 149.36 52.33 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.525 -0.307 . . . . 0.0 110.214 177.027 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 236' ' ' HIS . . . . . 0.724 ' CD2' ' HA ' ' A' ' 305' ' ' LYS . 29.3 m80 -136.55 136.11 39.02 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.182 -179.532 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 237' ' ' LYS . . . . . 0.536 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.324 -0.531 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.024 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 21.3 mt-30 . . . . . 0 N--CA 1.468 0.473 0 CA-C-O 120.951 0.405 . . . . 0.0 110.693 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 136.0 -160.86 24.75 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 119.031 -1.557 . . . . 0.0 113.613 176.125 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 254' ' ' THR . . . . . 0.471 ' HB ' ' CG2' ' A' ' 299' ' ' THR . 66.0 p -94.63 135.73 35.75 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-O 121.331 0.586 . . . . 0.0 111.88 -175.307 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . 0.552 HD13 HG13 ' A' ' 230' ' ' VAL . 14.6 pt -121.77 156.42 26.04 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-N 115.535 -0.757 . . . . 0.0 110.179 177.151 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 256' ' ' THR . . . . . 0.403 ' O ' HG11 ' A' ' 230' ' ' VAL . 28.3 m -94.66 111.26 23.04 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 -179.755 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.553 HG11 HG13 ' A' ' 230' ' ' VAL . 23.1 m -93.45 144.54 9.28 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.76 0 CA-C-O 121.642 0.734 . . . . 0.0 112.717 -170.213 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 35.4 t -91.19 9.65 30.29 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 114.088 -1.415 . . . . 0.0 108.049 167.857 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 259' ' ' ALA . . . . . 0.66 ' HB1' HD13 ' A' ' 228' ' ' LEU . . . -87.08 163.72 16.85 Favored 'General case' 0 N--CA 1.45 -0.427 0 CA-C-N 115.004 -0.998 . . . . 0.0 109.66 -177.826 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 37.5 t -144.13 143.99 31.37 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 120.683 0.278 . . . . 0.0 110.384 -179.726 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 80.94 36.75 21.11 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.649 179.625 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 262' ' ' LEU . . . . . 0.428 HD11 ' HB2' ' A' ' 259' ' ' ALA . 66.4 mt -98.83 150.8 21.51 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.941 0.401 . . . . 0.0 110.432 179.52 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 73.4 mt-30 -142.26 164.73 29.37 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.241 176.29 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 39.9 t -74.83 139.28 19.42 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 177.856 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 96.43 -1.91 62.55 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.42 -0.895 . . . . 0.0 113.504 177.737 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 39.7 m-20 -80.09 155.75 27.37 Favored 'General case' 0 CA--C 1.516 -0.353 0 CA-C-N 117.177 0.488 . . . . 0.0 111.053 177.094 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 267' ' ' ALA . . . . . 0.624 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -112.97 152.83 28.93 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.433 -0.803 . . . . 0.0 109.316 178.164 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 268' ' ' PHE . . . . . 0.605 ' CD2' HG22 ' A' ' 332' ' ' ILE . 7.9 p90 -164.84 172.36 13.02 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-O 121.189 0.518 . . . . 0.0 112.156 -175.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 74.4 p -127.84 149.89 50.08 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 114.758 -1.11 . . . . 0.0 108.789 173.131 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 270' ' ' ILE . . . . . 0.636 HG12 HG12 ' A' ' 332' ' ' ILE . 61.1 mt -118.6 136.94 54.18 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.674 0 CA-C-O 120.66 0.267 . . . . 0.0 110.478 -179.194 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -60.41 123.1 16.28 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.936 -0.575 . . . . 0.0 111.766 -176.581 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 100.43 -22.48 39.74 Favored Glycine 0 N--CA 1.451 -0.311 0 CA-C-N 115.915 -0.584 . . . . 0.0 112.223 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 41.8 t -95.03 109.96 23.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 120.803 0.335 . . . . 0.0 110.294 177.818 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 69.6 m-80 -129.48 160.39 33.32 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 179.204 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 275' ' ' SER . . . . . 0.455 ' O ' HG11 ' A' ' 276' ' ' VAL . 35.7 p -85.22 -171.68 3.75 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 111.966 0.358 . . . . 0.0 111.966 -176.359 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 276' ' ' VAL . . . . . 0.49 HG23 ' O ' ' A' ' 321' ' ' ASN . 29.6 m -145.98 173.24 3.36 Favored 'Isoleucine or valine' 0 C--O 1.232 0.176 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.098 178.79 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 39.5 m80 -118.82 127.13 53.24 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.328 -0.396 . . . . 0.0 109.988 171.629 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 83.6 mt-30 -79.32 -23.42 43.5 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 173.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 2.5 mp -63.27 -51.1 75.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.362 179.349 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 70.9 p -100.04 -15.09 18.36 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.022 -0.536 . . . . 0.0 111.799 -176.057 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 34.5 mmtp 65.25 30.13 11.4 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 123.037 0.535 . . . . 0.0 111.429 -177.186 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 67.0 m-20 -105.83 151.55 24.36 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.072 176.084 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 72.6 p -96.21 92.3 6.32 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.3 0.571 . . . . 0.0 110.412 176.569 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 284' ' ' THR . . . . . 0.446 ' C ' ' H ' ' A' ' 286' ' ' GLN . 47.5 p -141.48 -112.14 0.13 Allowed 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.884 -179.082 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 63.65 -8.62 0.32 Allowed Glycine 0 CA--C 1.522 0.491 0 N-CA-C 114.529 0.572 . . . . 0.0 114.529 174.543 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 286' ' ' GLN . . . . . 0.543 ' HB3' ' HD2' ' A' ' 287' ' ' PRO . 2.0 mp0 67.45 167.72 0.12 Allowed Pre-proline 0 CA--C 1.537 0.453 0 C-N-CA 123.416 0.687 . . . . 0.0 111.045 -177.885 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 287' ' ' PRO . . . . . 0.543 ' HD2' ' HB3' ' A' ' 286' ' ' GLN . 81.3 Cg_exo -47.72 133.66 21.94 Favored 'Trans proline' 0 C--N 1.353 0.8 0 C-N-CA 122.821 2.347 . . . . 0.0 113.77 -172.658 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 71.2 tp60 -69.23 136.61 52.23 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.711 -178.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 48.8 t -94.89 134.13 33.34 Favored 'Isoleucine or valine' 0 C--O 1.236 0.376 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.543 179.586 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 290' ' ' PHE . . . . . 0.624 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 33.4 m-85 -116.81 168.74 9.95 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.443 -176.817 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 291' ' ' ARG . . . . . 0.444 ' O ' HD21 ' A' ' 293' ' ' LEU . 42.5 mmm-85 -131.08 125.46 33.23 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 173.819 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 47.3 t -65.16 134.78 29.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.701 -177.243 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 293' ' ' LEU . . . . . 0.859 HD22 ' HB2' ' A' ' 303' ' ' SER . 2.5 mm? -96.19 -38.72 10.02 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.101 179.397 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 294' ' ' ALA . . . . . 0.482 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -159.69 142.11 13.58 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 121.088 -0.245 . . . . 0.0 111.452 -178.382 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 77.8 t -136.16 112.11 12.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.288 -0.415 . . . . 0.0 109.938 175.436 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 37.4 t -150.03 120.42 7.37 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.337 -179.367 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 58.19 51.11 60.39 Favored Glycine 0 C--N 1.33 0.195 0 C-N-CA 121.086 -0.578 . . . . 0.0 112.386 -179.24 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 73.6 p 48.54 27.85 1.57 Allowed 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 123.536 0.734 . . . . 0.0 112.112 -176.526 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 299' ' ' THR . . . . . 0.471 ' CG2' ' HB ' ' A' ' 254' ' ' THR . 65.3 m -119.66 115.26 23.58 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 176.706 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . 0.482 ' HA ' ' O ' ' A' ' 294' ' ' ALA . 59.7 t -113.79 130.93 67.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.587 -171.69 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 57.0 m -80.62 116.19 20.52 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 172.266 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 302' ' ' ILE . . . . . 0.557 ' O ' HD11 ' A' ' 302' ' ' ILE . 2.5 pp -111.36 140.79 29.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-O 122.264 1.03 . . . . 0.0 113.715 -171.463 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 303' ' ' SER . . . . . 0.859 ' HB2' HD22 ' A' ' 293' ' ' LEU . 49.4 m -165.02 170.98 5.8 Favored Pre-proline 0 C--N 1.325 -0.493 0 N-CA-C 105.829 -1.915 . . . . 0.0 105.829 -178.913 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 304' ' ' PRO . . . . . 0.563 ' HA ' ' HB3' ' A' ' 303' ' ' SER . 5.1 Cg_exo -74.98 -135.57 0.14 OUTLIER 'Cis proline' 0 C--N 1.351 0.664 0 CA-C-N 121.49 1.568 . . . . 0.0 113.578 0.646 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 305' ' ' LYS . . . . . 0.724 ' HA ' ' CD2' ' A' ' 236' ' ' HIS . 0.0 OUTLIER -90.68 144.41 25.77 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.47 -0.786 . . . . 0.0 112.088 -173.303 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 306' ' ' ILE . . . . . 0.586 ' H ' ' CG ' ' A' ' 236' ' ' HIS . 47.3 mm -116.0 86.93 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 114.824 -1.08 . . . . 0.0 108.611 175.121 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 307' ' ' LEU . . . . . 0.582 HD13 ' O ' ' A' ' 319' ' ' TYR . 58.7 mt -102.29 101.04 17.28 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.196 -173.599 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 308' ' ' PRO . . . . . 0.706 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 32.3 Cg_exo -65.56 134.07 36.87 Favored 'Trans proline' 0 C--N 1.343 0.253 0 C-N-CA 123.14 2.56 . . . . 0.0 113.76 -173.678 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . 0.548 HG23 ' O ' ' A' ' 322' ' ' VAL . 60.4 t -80.59 -28.56 11.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 169.291 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 -79.38 36.03 0.29 Allowed 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 115.279 -0.873 . . . . 0.0 111.186 176.511 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 22.6 p30 -83.7 -175.34 5.77 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.971 0.415 . . . . 0.0 111.137 -176.678 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 85.6 m -123.38 -28.58 3.93 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.407 177.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 57.5 m-20 -74.45 132.93 42.36 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.074 -178.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 43.8 t -62.7 -33.05 57.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.982 179.078 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -70.37 -20.45 62.96 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.749 179.752 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 316' ' ' SER . . . . . 0.531 ' HA ' ' CZ ' ' A' ' 319' ' ' TYR . 50.4 m -88.25 -7.02 57.44 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 111.936 0.347 . . . . 0.0 111.936 -176.897 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 317' ' ' ARG . . . . . 0.606 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 38.6 mmt180 -63.67 -51.38 66.36 Favored Pre-proline 0 CA--C 1.539 0.528 0 N-CA-C 112.598 0.592 . . . . 0.0 112.598 -179.005 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 318' ' ' PRO . . . . . 0.606 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 26.8 Cg_exo -68.78 -39.55 8.46 Favored 'Trans proline' 0 C--N 1.356 0.964 0 C-N-CA 121.9 1.733 . . . . 0.0 114.441 -172.055 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 319' ' ' TYR . . . . . 0.582 ' O ' HD13 ' A' ' 307' ' ' LEU . 1.8 p90 -88.47 -6.77 57.43 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 113.004 0.742 . . . . 0.0 113.004 -171.598 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . 0.418 ' HB1' HG21 ' A' ' 309' ' ' VAL . . . -52.99 135.51 36.72 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 111.634 0.235 . . . . 0.0 111.634 -178.799 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 321' ' ' ASN . . . . . 0.49 ' O ' HG23 ' A' ' 276' ' ' VAL . 14.4 p-10 -132.05 -11.25 3.34 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 116.639 -0.255 . . . . 0.0 111.444 -178.187 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 322' ' ' VAL . . . . . 0.548 ' O ' HG23 ' A' ' 309' ' ' VAL . 33.6 m -131.96 166.52 28.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 N-CA-C 110.488 -0.19 . . . . 0.0 110.488 178.855 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -51.84 -66.35 0.4 Allowed 'General case' 0 N--CA 1.465 0.293 0 CA-C-O 121.252 0.548 . . . . 0.0 111.266 178.372 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 324' ' ' ALA . . . . . 0.706 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -167.24 -179.29 4.46 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.584 -177.09 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 325' ' ' LYS . . . . . 0.44 ' HA ' ' HD3' ' A' ' 326' ' ' PRO . 21.5 pttp -109.65 112.34 58.65 Favored Pre-proline 0 N--CA 1.447 -0.624 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 170.342 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 326' ' ' PRO . . . . . 0.44 ' HD3' ' HA ' ' A' ' 325' ' ' LYS . 25.4 Cg_exo -66.49 168.87 15.32 Favored 'Trans proline' 0 C--O 1.234 0.287 0 C-N-CA 122.704 2.269 . . . . 0.0 112.044 -175.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -58.48 146.29 35.82 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 116.009 -0.541 . . . . 0.0 109.787 176.531 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 328' ' ' GLU . . . . . 0.538 ' HA ' ' NE2' ' A' ' 233' ' ' GLN . 16.0 pt-20 48.01 -145.13 0.34 Allowed 'General case' 0 N--CA 1.474 0.759 0 O-C-N 124.09 0.869 . . . . 0.0 110.995 -173.47 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 329' ' ' SER . . . . . 0.629 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 49.2 m -104.66 -19.38 13.98 Favored 'General case' 0 C--N 1.322 -0.602 0 C-N-CA 120.608 -0.437 . . . . 0.0 110.52 -179.448 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 330' ' ' ALA . . . . . 0.463 ' HB1' ' O ' ' A' ' 329' ' ' SER . . . 73.79 -167.54 0.11 Allowed 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 113.427 0.899 . . . . 0.0 113.427 171.371 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 331' ' ' ALA . . . . . 0.422 ' HA ' ' O ' ' A' ' 228' ' ' LEU . . . -87.26 144.0 27.01 Favored 'General case' 0 C--O 1.232 0.15 0 CA-C-N 115.153 -0.93 . . . . 0.0 111.611 -175.018 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 332' ' ' ILE . . . . . 0.636 HG12 HG12 ' A' ' 270' ' ' ILE . 50.1 mt -120.7 145.33 27.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.74 -178.861 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 61.3 m -130.98 106.07 8.16 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 110.121 -0.326 . . . . 0.0 110.121 178.396 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 49.0 mm -78.85 138.12 20.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.022 -0.536 . . . . 0.0 112.191 -174.109 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 335' ' ' LEU . . . . . 0.435 HD23 ' HA ' ' A' ' 268' ' ' PHE . 1.8 pt? -157.55 135.94 11.18 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.289 -0.869 . . . . 0.0 109.327 173.712 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -85.21 2.69 42.67 Favored 'General case' 0 C--N 1.325 -0.499 0 C-N-CA 120.841 -0.344 . . . . 0.0 111.283 -178.958 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 337' ' ' LYS . . . . . 0.472 ' C ' ' HD3' ' A' ' 337' ' ' LYS . 9.8 tmtt? . . . . . 0 C--O 1.245 0.862 0 CA-C-O 118.056 -0.973 . . . . 0.0 108.381 177.673 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 49.6 m . . . . . 0 C--O 1.231 0.083 0 CA-C-O 120.638 0.256 . . . . 0.0 111.333 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 228' ' ' LEU . . . . . 0.433 HD23 ' HA ' ' A' ' 259' ' ' ALA . 81.9 mt -102.35 142.8 32.98 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.292 -178.182 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 229' ' ' THR . . . . . 0.553 ' O ' HG21 ' A' ' 230' ' ' VAL . 35.4 p -120.63 171.37 8.62 Favored 'General case' 0 C--N 1.325 -0.467 0 C-N-CA 119.866 -0.733 . . . . 0.0 110.589 177.372 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 230' ' ' VAL . . . . . 0.553 HG21 ' O ' ' A' ' 229' ' ' THR . 72.4 t -146.69 130.62 10.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 120.916 0.389 . . . . 0.0 110.376 -179.597 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 231' ' ' SER . . . . . 0.506 ' O ' ' HB ' ' A' ' 255' ' ' ILE . 37.4 m -96.02 164.32 12.75 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.821 177.481 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 101.41 142.02 12.38 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.2 -1.0 . . . . 0.0 111.961 -179.283 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 64.0 mt-30 -100.02 107.81 48.76 Favored Pre-proline 0 C--N 1.322 -0.606 0 O-C-N 123.073 -0.075 . . . . 0.0 111.03 -176.461 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 234' ' ' PRO . . . . . 0.579 ' HB2' HG13 ' A' ' 306' ' ' ILE . 29.0 Cg_endo -61.56 127.62 22.29 Favored 'Trans proline' 0 C--N 1.348 0.511 0 C-N-CA 122.173 1.916 . . . . 0.0 110.718 176.174 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 235' ' ' GLU . . . . . 0.571 ' OE1' ' HE2' ' A' ' 237' ' ' LYS . 0.3 OUTLIER -116.79 -178.34 3.41 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 113.418 0.896 . . . . 0.0 113.418 -170.995 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 55.4 t60 -167.5 135.61 2.47 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 114.632 -1.167 . . . . 0.0 110.915 -173.803 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 237' ' ' LYS . . . . . 0.571 ' HE2' ' OE1' ' A' ' 235' ' ' GLU . 0.0 OUTLIER . . . . . 0 C--N 1.323 -0.571 0 CA-C-N 114.979 -1.009 . . . . 0.0 111.762 173.072 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 252' ' ' GLN . . . . . 0.434 ' HA ' HE21 ' A' ' 252' ' ' GLN . 2.8 mm100 . . . . . 0 N--CA 1.451 -0.378 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -85.41 138.5 16.5 Favored Glycine 0 N--CA 1.447 -0.579 0 C-N-CA 120.327 -0.94 . . . . 0.0 112.338 -179.144 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 66.9 p -121.89 116.51 24.53 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 176.728 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . 0.506 ' HB ' ' O ' ' A' ' 231' ' ' SER . 0.2 OUTLIER -129.69 158.95 42.18 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 121.038 0.447 . . . . 0.0 111.399 -176.493 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 18.5 m -96.82 116.64 29.5 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 177.681 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.813 HG22 HD13 ' A' ' 262' ' ' LEU . 32.8 m -88.82 143.3 11.46 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.739 0 C-N-CA 119.709 -0.796 . . . . 0.0 112.349 -170.98 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 258' ' ' SER . . . . . 0.453 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 25.1 m -92.79 9.44 35.17 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 114.341 -1.3 . . . . 0.0 109.33 172.809 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 259' ' ' ALA . . . . . 0.433 ' HA ' HD23 ' A' ' 228' ' ' LEU . . . -83.05 179.9 7.62 Favored 'General case' 0 N--CA 1.452 -0.338 0 CA-C-N 115.417 -0.811 . . . . 0.0 108.942 179.659 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 22.9 t -140.98 127.34 19.82 Favored 'General case' 0 C--N 1.32 -0.693 0 C-N-CA 120.23 -0.588 . . . . 0.0 111.348 -177.484 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 78.8 50.9 5.72 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.891 -0.671 . . . . 0.0 113.276 176.207 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 262' ' ' LEU . . . . . 0.813 HD13 HG22 ' A' ' 257' ' ' VAL . 64.8 mt -95.1 160.13 14.7 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 117.147 0.474 . . . . 0.0 110.559 178.08 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 66.0 mt-30 -142.9 165.23 27.93 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 -179.311 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 27.1 t -79.58 124.14 37.38 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 C-N-CA 120.409 -0.516 . . . . 0.0 109.701 175.531 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . 0.545 ' H ' ' HB ' ' A' ' 292' ' ' VAL . . . 116.0 14.39 7.88 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.316 -0.945 . . . . 0.0 112.835 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 57.1 m-20 -90.51 165.83 13.56 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.186 0.517 . . . . 0.0 111.044 176.346 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 267' ' ' ALA . . . . . 0.563 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -130.59 143.92 51.07 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 175.094 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 268' ' ' PHE . . . . . 0.446 ' CD1' HG21 ' A' ' 332' ' ' ILE . 7.8 p90 -159.5 168.71 25.53 Favored 'General case' 0 C--N 1.323 -0.582 0 C-N-CA 118.958 -1.097 . . . . 0.0 112.644 -173.547 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 269' ' ' THR . . . . . 0.505 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 43.7 p -116.72 144.08 44.87 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.063 -0.971 . . . . 0.0 109.704 175.683 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 270' ' ' ILE . . . . . 0.969 HG12 HG13 ' A' ' 332' ' ' ILE . 57.2 mt -112.0 127.91 68.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 116.563 -0.29 . . . . 0.0 110.469 -178.73 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -65.15 120.04 11.96 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.077 0.465 . . . . 0.0 111.227 -179.478 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 102.7 -23.93 32.37 Favored Glycine 0 N--CA 1.452 -0.28 0 CA-C-N 115.887 -0.597 . . . . 0.0 112.315 179.278 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . 0.46 HG21 ' HG2' ' A' ' 326' ' ' PRO . 39.0 t -96.34 102.48 13.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 174.574 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 274' ' ' ASN . . . . . 0.743 ' HB2' ' HB2' ' A' ' 323' ' ' ASP . 4.2 m120 -91.99 169.63 10.5 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.275 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 8.3 t -109.74 162.48 14.42 Favored 'General case' 0 CA--C 1.507 -0.704 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 178.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 13.0 m -122.52 178.84 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.067 0 CA-C-N 115.24 -0.891 . . . . 0.0 109.372 166.402 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 277' ' ' HIS . . . . . 0.575 ' HE1' HG22 ' A' ' 284' ' ' THR . 22.3 m80 -100.5 133.21 45.27 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 178.922 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 2.3 mp0 -72.29 -10.22 59.5 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.79 0.329 . . . . 0.0 111.401 -178.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 279' ' ' ILE . . . . . 0.649 HD11 ' N ' ' A' ' 279' ' ' ILE . 2.0 mp -102.43 -57.48 4.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 120.729 0.3 . . . . 0.0 110.946 -178.312 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 60.9 p -101.13 -6.21 24.63 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 112.663 0.616 . . . . 0.0 112.663 -174.226 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 13.9 mmmm 57.54 29.35 16.98 Favored 'General case' 0 N--CA 1.47 0.574 0 N-CA-C 111.591 0.219 . . . . 0.0 111.591 -178.499 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -77.78 139.61 39.36 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.265 -176.489 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 70.3 p -108.2 118.8 37.71 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.862 -0.608 . . . . 0.0 109.806 179.486 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 284' ' ' THR . . . . . 0.575 HG22 ' HE1' ' A' ' 277' ' ' HIS . 72.0 p -115.2 -14.36 11.73 Favored 'General case' 0 C--N 1.315 -0.894 0 C-N-CA 120.67 -0.412 . . . . 0.0 111.798 -172.408 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 88.17 5.13 76.94 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.521 -0.847 . . . . 0.0 112.388 179.709 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 286' ' ' GLN . . . . . 0.445 ' HA ' ' HD3' ' A' ' 287' ' ' PRO . 71.0 mt-30 -92.18 138.53 24.37 Favored Pre-proline 0 C--N 1.327 -0.382 0 N-CA-C 110.23 -0.285 . . . . 0.0 110.23 178.677 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 287' ' ' PRO . . . . . 0.609 ' HA ' ' HA ' ' A' ' 274' ' ' ASN . 21.7 Cg_exo -65.58 152.7 81.01 Favored 'Trans proline' 0 C--O 1.233 0.236 0 C-N-CA 122.615 2.21 . . . . 0.0 112.445 -179.031 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 3.9 tp-100 -81.54 150.72 28.08 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.542 177.626 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 62.1 t -94.86 125.04 47.58 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.401 0 CA-C-N 116.096 -0.502 . . . . 0.0 109.657 176.441 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 290' ' ' PHE . . . . . 0.742 ' HD1' ' HD2' ' A' ' 304' ' ' PRO . 69.9 m-85 -106.58 168.42 9.18 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.085 -174.072 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 27.1 tpt180 -132.8 120.89 22.18 Favored 'General case' 0 N--CA 1.448 -0.539 0 CA-C-O 121.222 0.534 . . . . 0.0 109.573 179.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . 0.545 ' HB ' ' H ' ' A' ' 265' ' ' GLY . 57.7 t -65.99 132.42 31.56 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.919 -177.037 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 293' ' ' LEU . . . . . . . . . . . . . 88.5 mt -101.42 -44.55 5.59 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.475 178.332 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 294' ' ' ALA . . . . . 0.448 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -150.05 139.11 21.1 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.592 0.234 . . . . 0.0 111.334 -175.123 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 62.0 t -134.11 117.75 26.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.126 176.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 60.6 m -157.01 120.14 4.09 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.471 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 62.32 40.37 98.94 Favored Glycine 0 C--N 1.331 0.305 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.003 -177.539 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 82.1 p 53.35 20.78 2.07 Favored 'General case' 0 N--CA 1.469 0.519 0 C-N-CA 123.939 0.896 . . . . 0.0 112.27 -174.721 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 60.3 m -103.18 107.7 18.62 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 174.493 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . 0.448 ' HA ' ' O ' ' A' ' 294' ' ' ALA . 47.2 t -104.09 128.03 57.81 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.36 -173.247 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 42.0 m -90.48 117.36 29.12 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 172.559 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 302' ' ' ILE . . . . . 0.428 HG21 HG13 ' A' ' 300' ' ' VAL . 29.1 pt -110.74 140.74 28.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 N-CA-C 112.83 0.678 . . . . 0.0 112.83 -169.269 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 303' ' ' SER . . . . . 0.45 ' HA ' ' C ' ' A' ' 304' ' ' PRO . 48.2 t -130.35 151.39 78.45 Favored Pre-proline 0 C--N 1.323 -0.55 0 CA-C-N 114.104 -1.407 . . . . 0.0 107.207 172.715 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 304' ' ' PRO . . . . . 0.742 ' HD2' ' HD1' ' A' ' 290' ' ' PHE . 34.3 Cg_exo -63.04 179.14 8.44 Favored 'Cis proline' 0 N--CA 1.473 0.308 0 CA-C-N 120.163 1.094 . . . . 0.0 113.09 0.781 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 305' ' ' LYS . . . . . 0.578 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -87.86 148.74 24.5 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.24 177.643 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 306' ' ' ILE . . . . . 0.579 HG13 ' HB2' ' A' ' 234' ' ' PRO . 43.7 mm -65.75 98.66 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.663 -175.075 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 307' ' ' LEU . . . . . 0.491 ' O ' HG21 ' A' ' 322' ' ' VAL . 72.6 mt -119.25 95.57 49.39 Favored Pre-proline 0 C--N 1.325 -0.498 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 -179.506 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 308' ' ' PRO . . . . . 0.642 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 6.2 Cg_exo -77.67 169.6 20.58 Favored 'Trans proline' 0 N--CA 1.463 -0.32 0 C-N-CA 123.121 2.547 . . . . 0.0 112.635 -176.8 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . 0.615 ' HA ' ' HB2' ' A' ' 320' ' ' ALA . 39.2 t -93.56 -30.72 4.41 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-O 121.251 0.548 . . . . 0.0 109.683 177.343 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 42.5 mp0 -86.64 35.68 0.68 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.133 -0.94 . . . . 0.0 112.254 -173.833 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 79.1 m-20 -74.33 158.81 33.33 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.301 0.572 . . . . 0.0 111.845 -178.644 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 28.9 m -90.44 -36.63 14.46 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.129 -0.941 . . . . 0.0 110.22 179.266 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 313' ' ' ASP . . . . . 0.419 ' HB2' ' HB3' ' A' ' 316' ' ' SER . 1.6 m-20 -67.98 133.31 48.86 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.32 179.406 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 39.3 t -60.45 -52.23 63.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.172 -177.768 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -68.46 -17.82 64.28 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.852 -178.234 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 316' ' ' SER . . . . . 0.419 ' HB3' ' HB2' ' A' ' 313' ' ' ASP . 39.1 t -84.07 -11.02 57.36 Favored 'General case' 0 C--N 1.323 -0.546 0 C-N-CA 120.973 -0.291 . . . . 0.0 111.357 -178.376 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 317' ' ' ARG . . . . . 0.527 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 81.0 mtm180 -73.65 -49.2 6.46 Favored Pre-proline 0 CA--C 1.536 0.432 0 N-CA-C 112.506 0.558 . . . . 0.0 112.506 -179.082 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 318' ' ' PRO . . . . . 0.527 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 42.3 Cg_exo -61.07 -25.87 81.99 Favored 'Trans proline' 0 C--N 1.361 1.197 0 C-N-CA 122.17 1.914 . . . . 0.0 113.218 -176.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 46.6 m-85 -91.41 27.67 1.9 Allowed 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.473 -0.331 . . . . 0.0 111.313 -177.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . 0.615 ' HB2' ' HA ' ' A' ' 309' ' ' VAL . . . -77.72 127.55 32.61 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.073 179.297 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 75.5 m-80 -130.47 -9.24 4.13 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 111.859 0.318 . . . . 0.0 111.859 179.216 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 322' ' ' VAL . . . . . 0.491 HG21 ' O ' ' A' ' 307' ' ' LEU . 33.1 m -138.5 156.93 30.18 Favored 'Isoleucine or valine' 0 C--O 1.233 0.215 0 CA-C-O 120.944 0.402 . . . . 0.0 111.094 177.691 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 323' ' ' ASP . . . . . 0.743 ' HB2' ' HB2' ' A' ' 274' ' ' ASN . 2.1 m-20 -86.66 86.84 7.35 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.417 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 324' ' ' ALA . . . . . 0.642 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . 77.06 151.0 0.12 Allowed 'General case' 0 N--CA 1.473 0.685 0 CA-C-N 114.66 -1.154 . . . . 0.0 113.791 171.502 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 325' ' ' LYS . . . . . 0.495 ' HB3' HG23 ' A' ' 306' ' ' ILE . 55.5 pttt -98.71 105.95 33.88 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 114.435 -1.257 . . . . 0.0 109.287 168.525 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 326' ' ' PRO . . . . . 0.46 ' HG2' HG21 ' A' ' 273' ' ' VAL . 5.8 Cg_exo -85.99 169.27 8.99 Favored 'Trans proline' 0 C--O 1.235 0.367 0 C-N-CA 123.483 2.788 . . . . 0.0 113.195 -171.837 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -59.52 127.51 32.41 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.626 177.633 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 24.5 pt-20 44.65 -158.07 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.66 0 O-C-N 124.402 1.064 . . . . 0.0 112.034 -176.363 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 329' ' ' SER . . . . . 0.41 ' O ' ' HB3' ' A' ' 330' ' ' ALA . 54.6 m -102.9 -31.16 10.39 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 112.204 0.446 . . . . 0.0 112.204 -173.643 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 330' ' ' ALA . . . . . 0.41 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 71.95 -152.25 0.08 Allowed 'General case' 0 N--CA 1.471 0.59 0 CA-C-O 121.037 0.446 . . . . 0.0 111.534 178.359 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -85.47 116.34 23.73 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.248 -178.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 332' ' ' ILE . . . . . 0.969 HG13 HG12 ' A' ' 270' ' ' ILE . 1.7 mp -101.84 140.85 19.38 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 115.826 -0.624 . . . . 0.0 109.537 176.293 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 73.4 m -110.11 103.32 12.03 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 110.206 -0.294 . . . . 0.0 110.206 -176.624 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 334' ' ' ILE . . . . . 0.492 HG13 HD22 ' A' ' 262' ' ' LEU . 34.6 mm -85.89 125.87 40.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 N-CA-C 112.588 0.588 . . . . 0.0 112.588 -174.155 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 335' ' ' LEU . . . . . 0.408 HD12 ' O ' ' A' ' 267' ' ' ALA . 0.0 OUTLIER -139.41 172.43 12.82 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.3 -0.864 . . . . 0.0 109.804 171.259 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 50.9 t30 -136.87 59.11 1.7 Allowed 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 178.552 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 62.3 tttp . . . . . 0 C--O 1.244 0.768 0 CA-C-O 118.173 -0.918 . . . . 0.0 110.457 -176.106 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 68.3 m . . . . . 0 C--O 1.235 0.299 0 CA-C-O 121.254 0.55 . . . . 0.0 110.854 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 228' ' ' LEU . . . . . 0.728 ' O ' ' HA ' ' A' ' 331' ' ' ALA . 5.3 mp -67.91 119.32 12.39 Favored 'General case' 0 N--CA 1.433 -1.316 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.821 179.463 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 229' ' ' THR . . . . . 0.451 ' OG1' ' HB3' ' A' ' 258' ' ' SER . 22.3 p -128.08 178.68 6.04 Favored 'General case' 0 C--N 1.324 -0.533 0 C-N-CA 120.513 -0.475 . . . . 0.0 111.07 178.644 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 230' ' ' VAL . . . . . 0.737 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 98.3 t -144.82 130.72 14.64 Favored 'Isoleucine or valine' 0 C--O 1.235 0.303 0 CA-C-O 120.578 0.228 . . . . 0.0 111.078 -177.218 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 38.9 t -101.1 112.28 24.71 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.538 -0.755 . . . . 0.0 109.484 172.438 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . 0.809 ' H ' ' HG3' ' A' ' 328' ' ' GLU . . . 141.69 125.51 2.08 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.788 -0.72 . . . . 0.0 111.71 -176.319 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 233' ' ' GLN . . . . . 0.794 ' HG2' ' H ' ' A' ' 328' ' ' GLU . 21.8 mt-30 -83.5 123.33 76.75 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-N 116.49 0.145 . . . . 0.0 111.063 -177.12 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -92.71 126.26 0.71 Allowed 'Trans proline' 0 N--CA 1.451 -0.986 0 C-N-CA 122.643 2.228 . . . . 0.0 111.978 177.517 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -157.0 158.36 36.4 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.865 0.364 . . . . 0.0 110.748 177.569 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 236' ' ' HIS . . . . . 0.417 ' ND1' ' H ' ' A' ' 306' ' ' ILE . 25.5 m80 -136.07 146.19 46.78 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.322 0.582 . . . . 0.0 111.85 177.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 237' ' ' LYS . . . . . 0.629 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.325 -0.48 0 N-CA-C 107.664 -1.235 . . . . 0.0 107.664 178.149 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 252' ' ' GLN . . . . . 0.428 ' HB2' HG21 ' A' ' 301' ' ' THR . 2.7 mm100 . . . . . 0 N--CA 1.453 -0.286 0 N-CA-C 110.219 -0.289 . . . . 0.0 110.219 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . 0.444 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -87.65 121.07 5.74 Favored Glycine 0 N--CA 1.447 -0.616 0 C-N-CA 120.4 -0.905 . . . . 0.0 111.88 179.269 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 52.3 p -105.1 117.35 33.79 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 178.33 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . 0.475 HD11 ' C ' ' A' ' 255' ' ' ILE . 2.1 pp -131.46 165.13 32.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -175.121 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 32.6 m -102.53 113.95 27.74 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 179.2 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.426 HG23 HD12 ' A' ' 262' ' ' LEU . 30.6 m -90.61 143.89 10.27 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.718 0 CA-C-O 121.48 0.657 . . . . 0.0 112.589 -174.907 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 258' ' ' SER . . . . . 0.451 ' HB3' ' OG1' ' A' ' 229' ' ' THR . 25.8 t -92.06 7.31 42.91 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 113.911 -1.495 . . . . 0.0 108.146 167.514 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 259' ' ' ALA . . . . . 0.654 ' HB2' ' HB3' ' A' ' 228' ' ' LEU . . . -86.48 172.57 10.24 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 115.128 -0.942 . . . . 0.0 109.713 -178.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 50.2 m -145.65 148.63 33.28 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.833 0.349 . . . . 0.0 111.043 -179.328 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 81.14 15.9 75.81 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.992 -0.623 . . . . 0.0 113.184 178.236 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 262' ' ' LEU . . . . . 0.426 HD12 HG23 ' A' ' 257' ' ' VAL . 70.7 mt -76.31 145.73 39.36 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.971 0.385 . . . . 0.0 110.351 179.234 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 85.0 mt-30 -140.8 164.75 29.39 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.092 -0.504 . . . . 0.0 109.911 -179.126 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 45.7 t -76.24 122.87 31.34 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.257 177.489 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 113.43 -3.07 25.02 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.44 -0.886 . . . . 0.0 112.795 179.085 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 266' ' ' ASP . . . . . 0.473 ' HA ' ' OD1' ' A' ' 336' ' ' ASN . 58.6 m-20 -81.58 151.76 27.53 Favored 'General case' 0 CA--C 1.513 -0.475 0 CA-C-O 120.82 0.343 . . . . 0.0 110.296 177.074 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 267' ' ' ALA . . . . . 0.581 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -114.47 149.35 36.46 Favored 'General case' 0 N--CA 1.443 -0.806 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 173.792 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 268' ' ' PHE . . . . . 0.663 ' HA ' HD23 ' A' ' 335' ' ' LEU . 4.1 p90 -163.95 172.36 14.03 Favored 'General case' 0 C--N 1.318 -0.782 0 C-N-CA 119.632 -0.827 . . . . 0.0 111.699 -177.13 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 74.9 p -118.12 127.36 53.7 Favored 'General case' 0 N--CA 1.443 -0.801 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.337 177.688 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 270' ' ' ILE . . . . . 0.602 HG22 ' O ' ' A' ' 329' ' ' SER . 25.8 mm -95.23 129.92 44.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 CA-C-N 115.3 -0.863 . . . . 0.0 110.454 -178.27 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -66.47 129.57 40.3 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 121.007 0.432 . . . . 0.0 111.133 -178.518 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 92.98 -22.87 31.94 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 121.032 -0.604 . . . . 0.0 112.065 -178.036 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . 0.726 HG21 ' HG2' ' A' ' 326' ' ' PRO . 45.8 t -101.14 117.79 46.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 121.195 0.521 . . . . 0.0 110.294 176.491 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -130.67 142.19 50.43 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.701 -178.556 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 4.8 t -81.87 172.45 13.3 Favored 'General case' 0 CA--C 1.512 -0.518 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 -177.047 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 29.9 m -130.5 178.43 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.835 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.713 173.29 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 86.2 m-70 -109.68 86.39 2.29 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 173.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 278' ' ' GLN . . . . . 0.414 ' HB3' ' O ' ' A' ' 320' ' ' ALA . 23.7 pt20 -72.35 -14.85 61.83 Favored 'General case' 0 N--CA 1.464 0.261 0 N-CA-C 111.964 0.357 . . . . 0.0 111.964 -173.45 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 2.4 mp -73.15 -52.11 23.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 121.126 0.489 . . . . 0.0 110.038 -179.538 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 42.9 p -97.95 -3.14 38.98 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.505 -178.799 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 64.85 54.57 1.31 Allowed 'General case' 0 N--CA 1.466 0.35 0 CA-C-O 121.547 0.689 . . . . 0.0 110.012 178.466 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 58.9 m-20 -115.43 130.78 57.0 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.033 0.444 . . . . 0.0 110.817 177.824 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 65.7 p -106.32 117.8 34.97 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.246 176.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 70.4 p -123.44 -23.19 4.87 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.809 -171.602 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 75.19 31.73 56.97 Favored Glycine 0 N--CA 1.453 -0.186 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.817 177.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 3.0 mm100 -89.77 131.27 40.11 Favored Pre-proline 0 C--N 1.327 -0.375 0 N-CA-C 110.359 -0.237 . . . . 0.0 110.359 179.7 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 287' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_exo -50.21 128.22 22.05 Favored 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 122.78 2.32 . . . . 0.0 112.546 -178.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 50.1 tt0 -74.56 148.03 41.22 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.668 -176.381 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 52.7 t -94.48 117.97 39.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.459 -0.791 . . . . 0.0 109.639 175.384 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 290' ' ' PHE . . . . . 0.712 ' HA ' ' HD3' ' A' ' 304' ' ' PRO . 5.0 m-85 -99.06 170.13 8.92 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.014 0.435 . . . . 0.0 111.604 -175.799 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 21.1 tpp180 -140.03 123.74 17.33 Favored 'General case' 0 N--CA 1.446 -0.668 0 CA-C-N 115.533 -0.758 . . . . 0.0 109.358 177.011 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 44.0 t -81.42 136.62 22.74 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.591 -176.211 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 293' ' ' LEU . . . . . 0.457 ' HA ' HD13 ' A' ' 293' ' ' LEU . 2.2 mm? -108.0 -30.51 8.41 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.164 178.299 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 294' ' ' ALA . . . . . . . . . . . . . . . -156.12 136.92 13.43 Favored 'General case' 0 C--N 1.331 -0.201 0 C-N-CA 121.06 -0.256 . . . . 0.0 111.603 -177.508 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 60.6 t -132.49 117.86 33.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.034 -0.53 . . . . 0.0 109.641 175.063 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 34.9 t -157.52 119.52 3.75 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.519 -177.404 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 58.85 44.24 96.11 Favored Glycine 0 C--N 1.333 0.383 0 C-N-CA 121.163 -0.541 . . . . 0.0 112.318 -179.029 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 51.4 p 50.51 24.06 1.49 Allowed 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 123.703 0.801 . . . . 0.0 112.583 -175.343 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 41.0 m -111.12 112.78 24.82 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 108.388 -0.968 . . . . 0.0 108.388 173.61 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . 0.703 HG12 HG23 ' A' ' 302' ' ' ILE . 39.0 t -111.91 132.29 60.93 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.731 -169.216 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 301' ' ' THR . . . . . 0.428 HG21 ' HB2' ' A' ' 252' ' ' GLN . 88.0 m -91.92 109.35 20.69 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 172.554 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 302' ' ' ILE . . . . . 0.703 HG23 HG12 ' A' ' 300' ' ' VAL . 29.1 pt -111.33 150.87 13.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 N-CA-C 113.099 0.777 . . . . 0.0 113.099 -170.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 303' ' ' SER . . . . . 0.497 ' HB2' ' HA ' ' A' ' 304' ' ' PRO . 85.8 p -135.06 166.39 29.51 Favored Pre-proline 0 C--N 1.322 -0.597 0 N-CA-C 106.52 -1.659 . . . . 0.0 106.52 170.063 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 304' ' ' PRO . . . . . 0.712 ' HD3' ' HA ' ' A' ' 290' ' ' PHE . 14.7 Cg_exo -70.45 -167.58 4.14 Favored 'Cis proline' 0 CA--C 1.53 0.28 0 CA-C-N 120.75 1.303 . . . . 0.0 113.282 0.57 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 305' ' ' LYS . . . . . 0.503 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -81.31 162.84 23.3 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.736 179.803 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 306' ' ' ILE . . . . . 0.417 ' H ' ' ND1' ' A' ' 236' ' ' HIS . 43.5 mm -111.55 84.3 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-O 120.831 0.348 . . . . 0.0 110.525 -177.373 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 307' ' ' LEU . . . . . . . . . . . . . 85.0 mt -108.35 103.49 50.91 Favored Pre-proline 0 C--N 1.327 -0.371 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.434 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 308' ' ' PRO . . . . . 0.745 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 13.5 Cg_exo -76.94 156.09 34.36 Favored 'Trans proline' 0 N--CA 1.465 -0.184 0 C-N-CA 122.611 2.207 . . . . 0.0 113.848 -171.472 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 46.7 t -78.89 -16.22 13.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 N-CA-C 108.18 -1.044 . . . . 0.0 108.18 168.069 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 67.0 mm-40 -83.61 7.05 18.54 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 114.805 -1.088 . . . . 0.0 110.885 175.033 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -68.74 128.24 35.94 Favored 'General case' 0 C--O 1.233 0.232 0 CA-C-O 120.764 0.316 . . . . 0.0 110.167 -176.59 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 61.7 m -75.89 -34.3 59.97 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.562 -175.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 313' ' ' ASP . . . . . 0.586 ' O ' ' HG3' ' A' ' 317' ' ' ARG . 28.0 t70 -68.85 114.32 7.06 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.976 0.417 . . . . 0.0 110.491 177.584 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 314' ' ' VAL . . . . . 0.651 ' HA ' ' HD3' ' A' ' 317' ' ' ARG . 41.5 t -63.86 -20.23 26.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.634 -0.712 . . . . 0.0 111.652 -175.836 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -75.09 -34.13 61.71 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.545 0.212 . . . . 0.0 111.468 178.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 316' ' ' SER . . . . . 0.404 ' HA ' ' CE1' ' A' ' 319' ' ' TYR . 34.2 t -89.4 -6.78 56.27 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.619 0.247 . . . . 0.0 111.359 -177.158 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 317' ' ' ARG . . . . . 0.651 ' HD3' ' HA ' ' A' ' 314' ' ' VAL . 56.8 mtp85 -69.68 -47.03 25.35 Favored Pre-proline 0 CA--C 1.541 0.609 0 N-CA-C 113.302 0.852 . . . . 0.0 113.302 -179.495 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 318' ' ' PRO . . . . . 0.434 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 87.2 Cg_exo -52.2 -38.49 71.67 Favored 'Trans proline' 0 C--N 1.361 1.224 0 C-N-CA 122.444 2.096 . . . . 0.0 113.796 -174.536 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 319' ' ' TYR . . . . . 0.404 ' CE1' ' HA ' ' A' ' 316' ' ' SER . 1.5 p90 -109.17 39.13 2.12 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 112.077 0.399 . . . . 0.0 112.077 -178.35 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . 0.414 ' O ' ' HB3' ' A' ' 278' ' ' GLN . . . -71.99 135.66 46.48 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.896 174.219 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 16.0 p-10 -119.01 -2.41 10.8 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 120.82 -0.352 . . . . 0.0 111.485 -176.703 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 322' ' ' VAL . . . . . . . . . . . . . 30.8 m -135.11 163.17 36.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 N-CA-C 110.34 -0.244 . . . . 0.0 110.34 175.112 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 56.7 m-20 -72.37 -38.18 68.6 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 111.657 0.243 . . . . 0.0 111.657 -178.677 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 324' ' ' ALA . . . . . 0.745 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -159.84 162.29 34.67 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.694 -171.867 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 325' ' ' LYS . . . . . 0.477 ' HA ' ' HD3' ' A' ' 326' ' ' PRO . 54.2 pttt -105.21 106.41 55.64 Favored Pre-proline 0 C--N 1.324 -0.501 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.279 169.424 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 326' ' ' PRO . . . . . 0.726 ' HG2' HG21 ' A' ' 273' ' ' VAL . 5.9 Cg_exo -86.49 166.83 9.03 Favored 'Trans proline' 0 C--O 1.233 0.256 0 C-N-CA 122.946 2.431 . . . . 0.0 113.566 -170.4 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 327' ' ' ALA . . . . . 0.509 ' HA ' ' HG2' ' A' ' 233' ' ' GLN . . . -81.69 122.02 27.11 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.235 -0.893 . . . . 0.0 109.444 172.032 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 328' ' ' GLU . . . . . 0.809 ' HG3' ' H ' ' A' ' 232' ' ' GLY . 53.6 mp0 60.48 175.42 0.1 Allowed 'General case' 0 N--CA 1.465 0.323 0 O-C-N 123.608 0.568 . . . . 0.0 111.084 -173.666 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 329' ' ' SER . . . . . 0.737 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 37.7 m -106.47 -15.46 14.8 Favored 'General case' 0 C--N 1.324 -0.532 0 C-N-CA 120.33 -0.548 . . . . 0.0 111.085 -177.347 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 330' ' ' ALA . . . . . 0.477 ' O ' HD13 ' A' ' 332' ' ' ILE . . . 62.95 -152.8 0.34 Allowed 'General case' 0 N--CA 1.465 0.312 0 CA-C-O 120.852 0.358 . . . . 0.0 111.857 175.094 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 331' ' ' ALA . . . . . 0.728 ' HA ' ' O ' ' A' ' 228' ' ' LEU . . . -68.5 139.78 55.67 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.56 -0.745 . . . . 0.0 112.203 -175.153 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 332' ' ' ILE . . . . . 0.477 HD13 ' O ' ' A' ' 330' ' ' ALA . 2.2 mp -111.7 144.59 19.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.279 179.379 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 84.8 m -121.07 105.71 10.88 Favored 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 175.522 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 334' ' ' ILE . . . . . 0.402 HD12 HG22 ' A' ' 334' ' ' ILE . 39.8 mm -79.95 127.73 39.07 Favored 'Isoleucine or valine' 0 C--O 1.235 0.3 0 N-CA-C 112.432 0.53 . . . . 0.0 112.432 -175.831 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 335' ' ' LEU . . . . . 0.663 HD23 ' HA ' ' A' ' 268' ' ' PHE . 1.8 pt? -148.91 132.46 16.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.58 174.036 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 336' ' ' ASN . . . . . 0.473 ' OD1' ' HA ' ' A' ' 266' ' ' ASP . 72.3 m-80 -109.0 77.38 1.06 Allowed 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.386 176.454 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 22.0 pttp . . . . . 0 C--O 1.243 0.743 0 O-C-N 124.589 1.18 . . . . 0.0 112.179 -179.078 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 39.6 t . . . . . 0 C--O 1.232 0.173 0 CA-C-O 121.133 0.492 . . . . 0.0 110.565 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 228' ' ' LEU . . . . . 0.591 ' HB3' ' CB ' ' A' ' 259' ' ' ALA . 80.9 mt -82.26 138.95 34.48 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.884 178.61 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 229' ' ' THR . . . . . 0.463 ' O ' HG22 ' A' ' 230' ' ' VAL . 70.8 p -126.63 178.25 6.02 Favored 'General case' 0 C--N 1.325 -0.478 0 C-N-CA 120.104 -0.638 . . . . 0.0 110.752 -179.043 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 230' ' ' VAL . . . . . 0.612 HG21 HG13 ' A' ' 332' ' ' ILE . 84.1 t -143.42 150.21 17.64 Favored 'Isoleucine or valine' 0 C--O 1.239 0.544 0 N-CA-C 110.356 -0.239 . . . . 0.0 110.356 -178.574 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 33.1 t -126.08 129.1 48.44 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.298 178.597 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . 0.569 ' O ' HG21 ' A' ' 255' ' ' ILE . . . 110.2 109.95 3.23 Favored Glycine 0 C--O 1.228 -0.277 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.852 178.258 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 233' ' ' GLN . . . . . 0.576 ' HG3' ' O ' ' A' ' 326' ' ' PRO . 14.3 mm-40 -111.43 101.41 50.66 Favored Pre-proline 0 C--N 1.324 -0.505 0 O-C-N 122.807 -0.231 . . . . 0.0 111.135 178.989 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 234' ' ' PRO . . . . . 0.469 ' O ' ' HE2' ' A' ' 325' ' ' LYS . 7.0 Cg_exo -70.25 126.13 12.64 Favored 'Trans proline' 0 N--CA 1.459 -0.513 0 C-N-CA 122.247 1.964 . . . . 0.0 110.855 176.202 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 235' ' ' GLU . . . . . 0.402 ' HA ' ' CD ' ' A' ' 325' ' ' LYS . 13.0 pt-20 -97.41 124.42 41.59 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 121.634 0.731 . . . . 0.0 111.502 -177.639 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 26.1 m80 -122.2 147.51 46.09 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.49 179.745 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 237' ' ' LYS . . . . . 0.428 ' H ' ' HD2' ' A' ' 237' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.317 -0.837 0 CA-C-N 115.137 -0.938 . . . . 0.0 109.214 -178.912 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 252' ' ' GLN . . . . . 0.51 ' HG3' HD13 ' A' ' 293' ' ' LEU . 3.0 mm100 . . . . . 0 N--CA 1.451 -0.421 0 CA-C-O 120.515 0.198 . . . . 0.0 110.561 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -106.23 138.52 14.4 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.186 -1.007 . . . . 0.0 112.942 -176.166 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 254' ' ' THR . . . . . 0.484 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 75.6 p -111.0 117.98 34.81 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 176.595 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . 0.58 HG13 HG13 ' A' ' 230' ' ' VAL . 0.2 OUTLIER -123.09 163.91 21.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 120.733 0.302 . . . . 0.0 111.269 -176.058 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 85.7 m -100.93 112.61 25.09 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 172.327 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.529 HG21 HD11 ' A' ' 262' ' ' LEU . 35.2 m -90.01 144.97 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.783 0 CA-C-O 121.663 0.744 . . . . 0.0 112.663 -169.764 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 258' ' ' SER . . . . . 0.431 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 23.2 m -90.31 7.7 37.1 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 114.376 -1.284 . . . . 0.0 108.637 171.283 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 259' ' ' ALA . . . . . 0.591 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -96.19 159.53 14.91 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-N 114.89 -1.05 . . . . 0.0 110.162 -177.509 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 45.8 p -127.97 154.14 45.93 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.362 -179.129 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 73.83 20.25 79.75 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 121.113 -0.565 . . . . 0.0 113.377 178.117 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 262' ' ' LEU . . . . . 0.529 HD11 HG21 ' A' ' 257' ' ' VAL . 77.5 mt -78.32 142.82 37.47 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 117.11 0.455 . . . . 0.0 110.606 179.347 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 81.6 mt-30 -141.3 174.5 10.48 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.975 -0.557 . . . . 0.0 109.866 -179.894 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 44.1 t -78.72 132.95 31.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 N-CA-C 110.098 -0.334 . . . . 0.0 110.098 176.332 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 102.89 4.4 48.42 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.378 -0.915 . . . . 0.0 112.61 179.071 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -86.05 153.8 21.87 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.871 0.367 . . . . 0.0 110.185 177.181 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 267' ' ' ALA . . . . . 0.53 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -125.08 142.48 51.46 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 177.985 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 268' ' ' PHE . . . . . . . . . . . . . 3.8 p90 -160.13 169.85 22.46 Favored 'General case' 0 C--N 1.323 -0.562 0 C-N-CA 120.097 -0.641 . . . . 0.0 111.572 -176.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 269' ' ' THR . . . . . 0.438 ' HB ' ' HB3' ' A' ' 287' ' ' PRO . 67.4 p -119.08 145.88 45.55 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.526 175.872 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 270' ' ' ILE . . . . . 0.534 HG12 HD12 ' A' ' 332' ' ' ILE . 57.9 mt -111.51 131.97 61.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.696 -177.265 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -66.08 120.13 12.62 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.372 -178.531 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 272' ' ' GLY . . . . . 0.499 ' HA3' ' HG3' ' A' ' 326' ' ' PRO . . . 101.3 -22.32 39.52 Favored Glycine 0 C--O 1.23 -0.1 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.102 -179.673 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . 0.477 HG22 HG21 ' A' ' 270' ' ' ILE . 52.2 t -103.16 102.68 13.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 176.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 7.1 m120 -119.62 156.66 29.98 Favored 'General case' 0 C--N 1.323 -0.583 0 C-N-CA 120.1 -0.64 . . . . 0.0 111.235 -173.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 59.0 p -75.8 166.81 22.98 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.301 0.572 . . . . 0.0 112.41 -173.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 34.3 m -123.96 153.66 30.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 114.909 -1.041 . . . . 0.0 109.851 174.261 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 53.1 m170 -110.35 91.51 3.68 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 179.345 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 16.9 pt20 -79.44 -11.36 59.91 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.92 -0.582 . . . . 0.0 112.435 -172.077 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 2.2 mp -76.42 -55.92 9.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-O 120.935 0.398 . . . . 0.0 109.962 179.003 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 45.6 p -96.12 -1.4 48.65 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.618 -178.865 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 281' ' ' LYS . . . . . 0.441 ' HB3' ' HZ2' ' A' ' 281' ' ' LYS . 3.8 mmmp? 52.74 52.37 14.13 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.06 -177.793 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 52.1 t0 -111.64 146.92 36.59 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.04 -177.464 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 36.4 p -107.1 110.6 22.75 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.938 0.399 . . . . 0.0 110.391 176.576 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 78.3 p -119.05 -26.45 5.96 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.702 -176.755 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 71.35 31.92 65.56 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.925 176.711 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 95.2 mm-40 -82.72 133.18 49.66 Favored Pre-proline 0 C--N 1.325 -0.49 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 179.232 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 287' ' ' PRO . . . . . 0.438 ' HB3' ' HB ' ' A' ' 269' ' ' THR . 82.2 Cg_exo -49.47 133.26 31.18 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.902 2.402 . . . . 0.0 112.851 -177.453 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 3.3 tm0? -83.65 134.89 34.76 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 -176.804 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 40.3 t -98.39 125.23 51.77 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-O 120.986 0.422 . . . . 0.0 110.776 -176.0 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 290' ' ' PHE . . . . . 0.53 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 6.0 m-85 -98.29 165.65 11.77 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.138 0.495 . . . . 0.0 112.181 -173.782 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 40.2 mmt-85 -129.46 120.35 25.31 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 114.889 -1.051 . . . . 0.0 108.763 174.014 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 58.3 t -77.98 135.78 25.5 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.913 0 CA-C-N 116.306 -0.406 . . . . 0.0 112.059 -174.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 293' ' ' LEU . . . . . 0.51 HD13 ' HG3' ' A' ' 252' ' ' GLN . 72.2 mt -102.49 -37.81 7.83 Favored 'General case' 0 N--CA 1.462 0.152 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.674 177.382 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 294' ' ' ALA . . . . . . . . . . . . . . . -151.51 139.91 20.48 Favored 'General case' 0 C--N 1.328 -0.339 0 C-N-CA 120.999 -0.28 . . . . 0.0 111.55 -175.139 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 58.0 t -137.71 110.21 7.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.987 -0.551 . . . . 0.0 109.614 175.339 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 296' ' ' SER . . . . . 0.4 ' O ' ' HB ' ' A' ' 299' ' ' THR . 58.9 p -139.85 104.06 4.79 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.163 -175.672 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 61.16 56.79 21.8 Favored Glycine 0 C--N 1.331 0.266 0 C-N-CA 120.979 -0.629 . . . . 0.0 112.406 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 66.4 p 53.21 17.24 0.95 Allowed 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 123.98 0.912 . . . . 0.0 112.519 -176.12 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 299' ' ' THR . . . . . 0.4 ' HB ' ' O ' ' A' ' 296' ' ' SER . 89.5 m -105.54 108.1 19.44 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 174.115 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . 0.741 HG13 HG22 ' A' ' 302' ' ' ILE . 45.2 t -111.05 135.04 51.43 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.35 -172.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 60.4 m -99.85 114.02 26.93 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 173.129 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 302' ' ' ILE . . . . . 0.741 HG22 HG13 ' A' ' 300' ' ' VAL . 27.2 pt -110.66 137.11 44.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 N-CA-C 113.094 0.775 . . . . 0.0 113.094 -168.801 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 303' ' ' SER . . . . . . . . . . . . . 50.3 m -119.49 157.59 51.28 Favored Pre-proline 0 C--N 1.32 -0.716 0 CA-C-N 114.029 -1.441 . . . . 0.0 107.641 170.569 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 304' ' ' PRO . . . . . 0.492 ' HD3' ' HA ' ' A' ' 290' ' ' PHE . 2.7 Cg_exo -75.23 -172.48 10.88 Favored 'Cis proline' 0 N--CA 1.462 -0.335 0 C-N-CA 124.368 -1.097 . . . . 0.0 111.716 -0.077 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 305' ' ' LYS . . . . . 0.435 ' HD2' ' O ' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -80.89 145.35 31.36 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.271 0.558 . . . . 0.0 111.804 179.462 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 306' ' ' ILE . . . . . 0.417 HG22 ' HE3' ' A' ' 325' ' ' LYS . 2.9 mp -99.86 100.5 10.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.41 -172.783 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 307' ' ' LEU . . . . . 0.468 ' HA ' ' HD3' ' A' ' 308' ' ' PRO . 82.9 mt -117.14 119.74 34.49 Favored Pre-proline 0 CA--C 1.516 -0.363 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.413 179.766 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 308' ' ' PRO . . . . . 0.791 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 7.1 Cg_exo -80.19 139.66 13.45 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 123.183 2.589 . . . . 0.0 113.406 -176.065 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . 0.467 HG22 ' HB3' ' A' ' 320' ' ' ALA . 45.3 t -82.04 -30.16 9.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 167.284 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 89.1 mt-10 -84.73 25.79 0.88 Allowed 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 115.006 -0.997 . . . . 0.0 111.169 177.553 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.707 ' HB2' ' HB2' ' A' ' 308' ' ' PRO . 24.5 t-20 -87.74 141.63 28.45 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 179.638 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 38.0 m -60.3 -28.53 68.18 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.198 -178.019 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 32.7 t70 -79.14 113.46 17.28 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.001 0.429 . . . . 0.0 110.195 177.107 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 314' ' ' VAL . . . . . 0.469 ' O ' ' HD3' ' A' ' 318' ' ' PRO . 40.4 t -69.04 -19.86 24.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.965 -177.543 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -75.03 -17.89 60.42 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 112.218 0.451 . . . . 0.0 112.218 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 59.4 m -96.7 -22.03 17.24 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 112.43 0.53 . . . . 0.0 112.43 -176.394 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 317' ' ' ARG . . . . . 0.415 ' N ' ' CD ' ' A' ' 318' ' ' PRO . 15.9 ptp180 -74.5 -31.65 1.25 Allowed Pre-proline 0 CA--C 1.549 0.92 0 N-CA-C 114.901 1.445 . . . . 0.0 114.901 -175.584 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 318' ' ' PRO . . . . . 0.469 ' HD3' ' O ' ' A' ' 314' ' ' VAL . 33.6 Cg_exo -62.09 -39.09 51.92 Favored 'Trans proline' 0 C--N 1.365 1.412 0 CA-C-N 121.486 1.566 . . . . 0.0 112.68 -178.009 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 54.7 m-85 -112.02 41.33 1.98 Allowed 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.543 -179.731 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . 0.467 ' HB3' HG22 ' A' ' 309' ' ' VAL . . . -78.63 159.87 27.84 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.967 179.699 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 47.2 t30 -111.83 -25.29 9.53 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.76 -178.744 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 322' ' ' VAL . . . . . . . . . . . . . 33.0 m -134.46 172.68 15.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.766 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 53.1 m-20 -67.15 -49.69 63.89 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.557 176.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 324' ' ' ALA . . . . . 0.791 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -173.08 179.64 2.2 Favored 'General case' 0 CA--C 1.518 -0.281 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.555 -177.166 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 325' ' ' LYS . . . . . 0.469 ' HE2' ' O ' ' A' ' 234' ' ' PRO . 8.7 ptpp? -126.83 106.96 22.61 Favored Pre-proline 0 C--N 1.326 -0.414 0 CA-C-N 115.324 -0.853 . . . . 0.0 109.805 171.525 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 326' ' ' PRO . . . . . 0.576 ' O ' ' HG3' ' A' ' 233' ' ' GLN . 67.1 Cg_endo -78.92 167.14 22.52 Favored 'Trans proline' 0 C--N 1.34 0.124 0 C-N-CA 122.535 2.156 . . . . 0.0 112.49 -175.878 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -63.03 129.63 41.18 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.122 176.81 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 47.1 mt-10 73.01 142.72 0.06 Allowed 'General case' 0 N--CA 1.469 0.493 0 O-C-N 123.977 0.798 . . . . 0.0 110.561 -174.564 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 329' ' ' SER . . . . . 0.534 ' O ' ' HB1' ' A' ' 330' ' ' ALA . 17.6 m -77.31 -22.29 52.17 Favored 'General case' 0 C--N 1.323 -0.55 0 C-N-CA 120.865 -0.334 . . . . 0.0 111.383 -174.652 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 330' ' ' ALA . . . . . 0.534 ' HB1' ' O ' ' A' ' 329' ' ' SER . . . 74.15 -162.6 0.08 Allowed 'General case' 0 N--CA 1.47 0.546 0 O-C-N 123.716 0.635 . . . . 0.0 112.686 174.251 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -81.34 145.93 30.61 Favored 'General case' 0 CA--C 1.517 -0.29 0 CA-C-N 115.318 -0.856 . . . . 0.0 110.943 -178.042 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 332' ' ' ILE . . . . . 0.612 HG13 HG21 ' A' ' 230' ' ' VAL . 29.4 mm -115.47 144.55 22.81 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.245 -177.304 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 75.5 m -109.05 96.65 6.46 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 110.094 -0.336 . . . . 0.0 110.094 179.118 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 334' ' ' ILE . . . . . 0.46 HG23 HD12 ' A' ' 334' ' ' ILE . 45.7 mm -81.71 130.61 35.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 N-CA-C 111.912 0.338 . . . . 0.0 111.912 -175.329 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 335' ' ' LEU . . . . . . . . . . . . . 1.9 pt? -156.58 132.43 9.62 Favored 'General case' 0 C--O 1.234 0.244 0 CA-C-O 121.388 0.613 . . . . 0.0 110.982 174.671 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 76.1 m-20 -94.69 52.63 1.53 Allowed 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.451 176.713 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 55.8 tptt . . . . . 0 C--O 1.246 0.897 0 CA-C-O 118.124 -0.941 . . . . 0.0 109.525 -179.807 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 48.3 m . . . . . 0 C--O 1.233 0.184 0 CA-C-O 121.284 0.564 . . . . 0.0 109.629 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 228' ' ' LEU . . . . . 0.458 ' HB3' ' CB ' ' A' ' 259' ' ' ALA . 90.5 mt -128.12 141.3 51.53 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.289 -0.869 . . . . 0.0 109.09 176.766 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 38.3 p -130.94 -179.2 5.18 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 120.578 -0.449 . . . . 0.0 111.339 -177.005 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 230' ' ' VAL . . . . . 0.58 ' HB ' ' CB ' ' A' ' 329' ' ' SER . 40.7 t -140.0 140.01 36.19 Favored 'Isoleucine or valine' 0 C--O 1.239 0.528 0 CA-C-O 120.557 0.218 . . . . 0.0 110.772 -178.651 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 32.1 m -99.24 138.92 35.65 Favored 'General case' 0 C--O 1.234 0.277 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.29 176.004 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 127.73 166.23 12.03 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.51 -0.853 . . . . 0.0 111.959 179.202 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 81.3 mt-30 -117.12 102.03 52.89 Favored Pre-proline 0 C--N 1.324 -0.539 0 CA-C-N 116.782 0.291 . . . . 0.0 111.073 -179.557 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -76.35 126.82 9.36 Favored 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 122.716 2.277 . . . . 0.0 111.155 177.015 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -158.55 141.22 14.44 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.175 -178.739 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 92.8 m-70 -146.72 138.24 24.39 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.495 -177.266 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 237' ' ' LYS . . . . . 0.541 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 6.2 mptt . . . . . 0 C--N 1.323 -0.548 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 252' ' ' GLN . . . . . 0.534 ' HB3' ' O ' ' A' ' 302' ' ' ILE . 2.6 mm100 . . . . . 0 N--CA 1.45 -0.434 0 CA-C-O 120.695 0.284 . . . . 0.0 110.878 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -110.28 147.81 17.43 Favored Glycine 0 N--CA 1.447 -0.581 0 C-N-CA 119.842 -1.171 . . . . 0.0 113.019 -176.612 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 70.1 p -118.93 117.73 29.62 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 176.838 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . 0.42 HG23 HD13 ' A' ' 255' ' ' ILE . 0.2 OUTLIER -128.66 165.64 27.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-O 120.951 0.405 . . . . 0.0 111.128 -176.253 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 40.5 m -99.61 116.87 32.74 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 178.273 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . . . . . . . . . 34.1 m -90.44 144.39 9.22 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.774 0 CA-C-O 121.47 0.653 . . . . 0.0 112.494 -172.378 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 258' ' ' SER . . . . . 0.414 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 40.3 m -90.61 8.48 33.99 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 114.359 -1.291 . . . . 0.0 108.721 170.355 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 259' ' ' ALA . . . . . 0.458 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -91.4 163.69 14.1 Favored 'General case' 0 N--CA 1.449 -0.518 0 CA-C-N 114.994 -1.003 . . . . 0.0 109.453 -179.012 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 50.6 m -129.8 149.33 51.59 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 120.762 0.315 . . . . 0.0 111.386 -177.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 68.73 37.53 84.53 Favored Glycine 0 N--CA 1.451 -0.355 0 CA-C-N 115.786 -0.643 . . . . 0.0 113.534 176.453 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 262' ' ' LEU . . . . . . . . . . . . . 60.4 mt -92.45 150.74 20.6 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 117.364 0.582 . . . . 0.0 109.835 176.794 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 84.7 mt-30 -144.41 170.26 16.36 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.113 -0.494 . . . . 0.0 109.675 -179.619 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 50.3 t -78.25 141.89 14.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.844 -179.457 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 94.13 -2.07 68.28 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.701 -0.761 . . . . 0.0 113.206 177.288 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 44.8 m-20 -81.04 155.46 26.33 Favored 'General case' 0 CA--C 1.515 -0.386 0 CA-C-O 121.251 0.548 . . . . 0.0 111.202 178.129 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 267' ' ' ALA . . . . . 0.694 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -116.16 146.97 41.86 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.222 -0.899 . . . . 0.0 109.13 178.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 268' ' ' PHE . . . . . 0.576 ' CD2' HG22 ' A' ' 332' ' ' ILE . 6.6 p90 -164.17 162.06 22.55 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 120.4 -0.52 . . . . 0.0 111.93 -174.935 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 269' ' ' THR . . . . . 0.469 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 71.1 p -115.23 147.74 39.98 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 115.016 -0.993 . . . . 0.0 109.137 173.422 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 270' ' ' ILE . . . . . 0.482 HG23 HD11 ' A' ' 270' ' ' ILE . 54.1 mt -123.13 138.07 54.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-O 120.61 0.243 . . . . 0.0 110.516 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -63.58 125.2 23.47 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.872 -175.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 103.64 -22.6 35.24 Favored Glycine 0 N--CA 1.449 -0.471 0 CA-C-N 115.73 -0.668 . . . . 0.0 112.207 178.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . 0.516 HG13 HG13 ' A' ' 322' ' ' VAL . 39.5 t -95.11 102.31 13.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-O 120.946 0.403 . . . . 0.0 110.058 178.204 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -110.52 135.76 50.69 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.231 -179.892 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 32.5 p -77.94 156.23 30.38 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.229 0.538 . . . . 0.0 112.078 -177.428 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 32.9 m -113.48 160.3 13.04 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.65 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.478 174.845 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 35.7 m80 -132.19 79.86 1.88 Allowed 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.903 177.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 2.5 tp-100 -53.22 -29.55 32.92 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.585 -0.28 . . . . 0.0 111.296 -176.115 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 50.1 mm -63.6 -48.42 86.88 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.352 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.616 178.914 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 75.2 p -97.81 7.14 46.89 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-O 120.762 0.315 . . . . 0.0 111.5 -177.39 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 281' ' ' LYS . . . . . 0.416 ' O ' ' HG3' ' A' ' 281' ' ' LYS . 52.9 tptt 71.59 50.18 0.27 Allowed 'General case' 0 CA--C 1.536 0.408 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.947 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 2.4 p30 29.62 50.41 0.07 Allowed 'General case' 0 N--CA 1.474 0.741 0 N-CA-C 115.801 1.778 . . . . 0.0 115.801 171.471 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.418 ' O ' HG21 ' A' ' 284' ' ' THR . 62.1 p -107.1 88.65 2.78 Favored 'General case' 0 C--N 1.322 -0.612 0 C-N-CA 119.744 -0.782 . . . . 0.0 110.335 167.935 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 284' ' ' THR . . . . . 0.418 HG21 ' O ' ' A' ' 283' ' ' THR . 35.5 p -145.62 -70.36 0.27 Allowed 'General case' 0 C--N 1.319 -0.761 0 CA-C-N 115.499 -0.773 . . . . 0.0 111.339 -177.79 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 89.09 32.3 10.86 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.013 -178.526 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 12.0 mm100 -100.94 127.8 31.24 Favored Pre-proline 0 C--N 1.326 -0.422 0 O-C-N 122.894 -0.18 . . . . 0.0 110.926 -177.244 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 287' ' ' PRO . . . . . 0.469 ' HB2' ' HB ' ' A' ' 269' ' ' THR . 24.2 Cg_exo -58.17 129.84 34.98 Favored 'Trans proline' 0 C--O 1.236 0.406 0 C-N-CA 122.42 2.08 . . . . 0.0 110.734 173.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 40.4 tt0 -72.87 142.06 47.93 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.963 0.411 . . . . 0.0 111.124 -173.773 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 47.7 t -90.6 134.82 28.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 115.465 -0.789 . . . . 0.0 109.931 177.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 290' ' ' PHE . . . . . 0.694 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 45.5 m-85 -111.48 163.06 14.44 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.471 -177.449 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 43.2 mmm-85 -125.25 121.22 33.44 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 173.436 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 47.2 t -66.03 132.16 31.64 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-N 115.597 -0.729 . . . . 0.0 111.591 -175.604 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 293' ' ' LEU . . . . . . . . . . . . . 93.9 mt -93.68 -41.64 9.59 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.906 -0.588 . . . . 0.0 111.562 177.381 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 294' ' ' ALA . . . . . 0.406 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -157.26 142.69 17.3 Favored 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 120.896 -0.322 . . . . 0.0 111.316 -176.601 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 61.2 t -133.92 116.54 23.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 109.238 -0.653 . . . . 0.0 109.238 174.466 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 52.5 p -140.73 92.29 2.49 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.061 -175.741 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 66.84 63.73 3.69 Favored Glycine 0 N--CA 1.453 -0.181 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.222 -179.411 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 76.6 p 51.0 23.21 1.4 Allowed 'General case' 0 N--CA 1.47 0.557 0 C-N-CA 123.614 0.766 . . . . 0.0 112.579 -177.651 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 44.2 m -116.59 113.38 22.64 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 175.361 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . 0.61 HG13 HG23 ' A' ' 302' ' ' ILE . 45.5 t -113.49 130.5 67.4 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.541 -171.325 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 38.3 m -91.16 116.72 29.04 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 108.072 -1.085 . . . . 0.0 108.072 171.484 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 302' ' ' ILE . . . . . 0.61 HG23 HG13 ' A' ' 300' ' ' VAL . 31.0 pt -110.68 137.3 43.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 N-CA-C 112.812 0.671 . . . . 0.0 112.812 -169.047 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 303' ' ' SER . . . . . . . . . . . . . 81.7 p -137.67 153.52 74.15 Favored Pre-proline 0 C--N 1.325 -0.496 0 CA-C-N 114.645 -1.161 . . . . 0.0 108.547 173.889 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 304' ' ' PRO . . . . . 0.513 ' HD2' ' HD1' ' A' ' 290' ' ' PHE . 5.9 Cg_exo -73.67 -173.07 10.83 Favored 'Cis proline' 0 N--CA 1.463 -0.296 0 C-N-CA 124.005 -1.248 . . . . 0.0 112.01 -0.005 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 305' ' ' LYS . . . . . 0.537 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -85.75 170.2 12.69 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 120.873 0.368 . . . . 0.0 110.874 -177.841 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 306' ' ' ILE . . . . . . . . . . . . . 60.3 mt -112.09 93.6 2.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.59 -176.389 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 307' ' ' LEU . . . . . 0.447 ' HA ' HD23 ' A' ' 307' ' ' LEU . 94.4 mt -108.23 104.97 55.58 Favored Pre-proline 0 C--N 1.326 -0.441 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.691 -179.54 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 308' ' ' PRO . . . . . 0.716 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 6.3 Cg_exo -75.96 138.6 20.97 Favored 'Trans proline' 0 N--CA 1.461 -0.422 0 C-N-CA 122.982 2.455 . . . . 0.0 112.467 -177.324 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . 0.439 HG23 ' O ' ' A' ' 322' ' ' VAL . 46.8 t -65.74 -25.59 36.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 121.189 0.518 . . . . 0.0 109.683 174.674 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 310' ' ' GLU . . . . . 0.448 ' HA ' ' OE1' ' A' ' 310' ' ' GLU . 4.8 mm-40 -80.92 33.67 0.33 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.752 -0.658 . . . . 0.0 112.169 177.192 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 21.4 p30 -85.29 -8.08 58.68 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.964 -0.107 . . . . 0.0 111.178 -179.644 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 71.1 m 74.91 -46.61 0.6 Allowed 'General case' 0 N--CA 1.471 0.613 0 C-N-CA 123.457 0.703 . . . . 0.0 112.283 178.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 42.8 m-20 -57.47 115.46 2.75 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-O 121.211 0.529 . . . . 0.0 111.116 -179.073 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 23.3 t -61.55 -33.6 57.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.449 -176.379 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -75.79 -22.14 56.68 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 111.752 0.278 . . . . 0.0 111.752 179.626 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 65.5 m -87.12 -20.66 26.76 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 111.777 0.288 . . . . 0.0 111.777 -178.857 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 317' ' ' ARG . . . . . 0.488 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 75.0 mtp180 -56.04 -48.9 95.82 Favored Pre-proline 0 CA--C 1.539 0.525 0 N-CA-C 113.034 0.754 . . . . 0.0 113.034 -179.282 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 318' ' ' PRO . . . . . 0.488 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 52.0 Cg_exo -58.57 -16.18 28.81 Favored 'Trans proline' 0 C--N 1.36 1.137 0 C-N-CA 122.213 1.942 . . . . 0.0 113.988 -176.758 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 8.8 m-85 -106.69 1.28 24.93 Favored 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 121.116 -0.234 . . . . 0.0 111.568 -179.657 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -66.08 139.03 58.15 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.811 0.339 . . . . 0.0 111.02 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 14.8 p-10 -124.07 -9.5 7.66 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.379 -179.466 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 322' ' ' VAL . . . . . 0.516 HG13 HG13 ' A' ' 273' ' ' VAL . 32.3 m -132.92 163.97 36.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 175.537 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 54.6 m-20 -81.05 -22.16 39.5 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 111.885 0.328 . . . . 0.0 111.885 -177.755 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 324' ' ' ALA . . . . . 0.716 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -171.1 154.66 4.14 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.045 -172.573 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 23.8 pttm -101.31 114.4 65.73 Favored Pre-proline 0 C--N 1.325 -0.488 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 169.314 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -72.57 167.64 26.55 Favored 'Trans proline' 0 C--O 1.235 0.346 0 C-N-CA 122.622 2.215 . . . . 0.0 113.306 -172.47 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -66.62 136.8 56.13 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-N 115.804 -0.634 . . . . 0.0 109.885 175.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 47.1 -155.27 0.05 Allowed 'General case' 0 N--CA 1.471 0.594 0 O-C-N 124.446 1.091 . . . . 0.0 111.19 -173.7 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 329' ' ' SER . . . . . 0.58 ' CB ' ' HB ' ' A' ' 230' ' ' VAL . 53.1 m -98.66 -38.92 8.93 Favored 'General case' 0 C--N 1.322 -0.609 0 C-N-CA 120.548 -0.461 . . . . 0.0 111.024 -177.052 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 330' ' ' ALA . . . . . 0.502 ' HB2' ' O ' ' A' ' 329' ' ' SER . . . 79.39 -164.39 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.923 0 N-CA-C 112.869 0.692 . . . . 0.0 112.869 174.34 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -84.49 149.17 26.12 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 115.507 -0.77 . . . . 0.0 112.429 -172.066 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 332' ' ' ILE . . . . . 0.576 HG22 ' CD2' ' A' ' 268' ' ' PHE . 38.3 mt -111.08 145.78 16.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.663 -0.699 . . . . 0.0 111.16 178.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 95.7 m -120.67 97.2 5.44 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 172.693 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 40.3 mm -79.18 128.96 38.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 N-CA-C 111.92 0.341 . . . . 0.0 111.92 -175.617 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 335' ' ' LEU . . . . . . . . . . . . . 1.5 pt? -152.9 130.74 11.68 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.407 0.622 . . . . 0.0 110.593 174.431 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 23.4 p30 -90.8 5.47 48.24 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.287 -177.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 337' ' ' LYS . . . . . 0.604 ' HZ3' ' HB3' ' A' ' 337' ' ' LYS . 8.0 mtpm? . . . . . 0 C--O 1.245 0.828 0 CA-C-O 118.186 -0.911 . . . . 0.0 110.758 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 42.9 m . . . . . 0 N--CA 1.453 -0.311 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 228' ' ' LEU . . . . . 0.684 ' HB3' ' HB3' ' A' ' 259' ' ' ALA . 87.9 mt -127.1 136.07 51.63 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 172.287 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 229' ' ' THR . . . . . 0.518 ' O ' HG21 ' A' ' 230' ' ' VAL . 40.5 p -122.16 172.17 8.46 Favored 'General case' 0 C--N 1.325 -0.462 0 C-N-CA 119.502 -0.879 . . . . 0.0 110.811 -179.72 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 230' ' ' VAL . . . . . 0.833 HG23 HD11 ' A' ' 332' ' ' ILE . 48.3 t -145.82 146.02 19.72 Favored 'Isoleucine or valine' 0 C--O 1.239 0.537 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.328 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 231' ' ' SER . . . . . 0.435 ' HA ' ' OE1' ' A' ' 328' ' ' GLU . 33.3 t -118.79 127.21 53.32 Favored 'General case' 0 N--CA 1.452 -0.328 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.017 -178.975 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . 0.532 ' O ' ' HD3' ' A' ' 234' ' ' PRO . . . 149.13 160.43 9.13 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.072 179.182 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 14.6 mm-40 -99.34 100.98 11.54 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 116.769 0.285 . . . . 0.0 111.628 -179.069 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 234' ' ' PRO . . . . . 0.532 ' HD3' ' O ' ' A' ' 232' ' ' GLY . 3.2 Cg_endo -84.01 126.44 3.85 Favored 'Trans proline' 0 N--CA 1.455 -0.762 0 C-N-CA 122.711 2.274 . . . . 0.0 111.434 176.352 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 235' ' ' GLU . . . . . 0.441 ' HB3' ' HE2' ' A' ' 237' ' ' LYS . 98.4 mt-10 -126.54 126.79 44.27 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.315 0.578 . . . . 0.0 111.387 -178.7 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 236' ' ' HIS . . . . . 0.505 ' C ' ' HD3' ' A' ' 237' ' ' LYS . 27.8 m80 -139.73 130.3 25.7 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.192 -0.913 . . . . 0.0 109.204 176.358 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 237' ' ' LYS . . . . . 0.619 ' HD3' ' N ' ' A' ' 237' ' ' LYS . 0.1 OUTLIER . . . . . 0 C--N 1.324 -0.54 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.054 -176.126 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 252' ' ' GLN . . . . . 0.404 ' HA ' HE21 ' A' ' 252' ' ' GLN . 2.5 mm100 . . . . . 0 N--CA 1.454 -0.254 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . 0.476 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -97.4 124.08 8.02 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.216 -0.992 . . . . 0.0 111.881 177.553 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 254' ' ' THR . . . . . 0.445 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 76.8 p -115.52 116.13 27.65 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 178.613 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . 0.445 HG23 HD11 ' A' ' 255' ' ' ILE . 0.2 OUTLIER -135.64 167.13 25.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.628 -175.747 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 86.9 m -92.5 123.34 35.73 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.2 178.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.596 HG13 HG12 ' A' ' 230' ' ' VAL . 33.1 m -91.0 144.94 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.66 0 N-CA-C 113.029 0.751 . . . . 0.0 113.029 -173.106 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 258' ' ' SER . . . . . 0.489 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 29.1 m -91.07 10.33 27.22 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 114.113 -1.403 . . . . 0.0 108.866 169.915 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 259' ' ' ALA . . . . . 0.684 ' HB3' ' HB3' ' A' ' 228' ' ' LEU . . . -98.02 176.97 5.57 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.181 -0.918 . . . . 0.0 109.926 -175.19 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 37.2 t -143.77 146.6 33.24 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 110.191 -0.3 . . . . 0.0 110.191 179.067 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 70.98 45.31 51.89 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.996 -0.621 . . . . 0.0 112.906 179.143 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 262' ' ' LEU . . . . . . . . . . . . . 64.0 mt -99.47 144.25 28.79 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 177.101 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 84.2 mt-30 -139.88 160.94 38.78 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 110.287 -0.264 . . . . 0.0 110.287 -178.735 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 44.0 t -69.36 136.2 26.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.177 177.527 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 96.03 -1.28 62.93 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.561 -0.828 . . . . 0.0 112.94 178.616 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 266' ' ' ASP . . . . . 0.422 ' O ' ' HA ' ' A' ' 291' ' ' ARG . 65.7 m-20 -78.99 164.21 24.58 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.926 0.394 . . . . 0.0 110.537 177.281 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 267' ' ' ALA . . . . . 0.64 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -123.84 154.38 39.71 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.73 -179.183 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 268' ' ' PHE . . . . . 0.686 ' CD2' HG23 ' A' ' 332' ' ' ILE . 9.4 p90 -164.16 171.19 15.37 Favored 'General case' 0 N--CA 1.449 -0.519 0 C-N-CA 120.297 -0.561 . . . . 0.0 112.217 -179.169 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 69.3 p -129.97 126.11 37.01 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 114.86 -1.064 . . . . 0.0 109.329 175.571 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 270' ' ' ILE . . . . . 0.969 HG12 HG13 ' A' ' 332' ' ' ILE . 60.0 mt -96.74 136.09 28.69 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 116.504 -0.316 . . . . 0.0 110.826 -176.554 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -64.96 128.22 34.86 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.873 -176.395 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 100.98 -23.68 34.72 Favored Glycine 0 N--CA 1.452 -0.26 0 CA-C-N 115.64 -0.709 . . . . 0.0 112.653 177.409 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . 0.421 HG23 ' HG3' ' A' ' 326' ' ' PRO . 31.8 t -102.99 102.33 13.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 120.898 0.38 . . . . 0.0 111.025 179.784 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -113.95 166.35 11.69 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 174.248 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 275' ' ' SER . . . . . 0.447 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 36.5 p -83.72 179.39 7.6 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 112.314 0.487 . . . . 0.0 112.314 -176.443 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 35.7 m -141.46 159.72 22.05 Favored 'Isoleucine or valine' 0 C--O 1.232 0.174 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.743 -177.163 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 80.9 m-70 -118.13 99.58 6.97 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 173.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 10.8 mm100 -73.61 -24.03 59.98 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 111.863 0.32 . . . . 0.0 111.863 -175.206 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 50.7 mm -67.07 -49.27 74.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.764 0.316 . . . . 0.0 111.334 -177.719 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 40.8 p -101.62 -0.14 35.26 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.509 -0.314 . . . . 0.0 111.343 -179.123 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 3.9 tmtp? 60.18 53.6 4.4 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-O 121.903 0.859 . . . . 0.0 109.588 179.725 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 64.8 t0 -117.78 115.91 25.95 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.372 -0.831 . . . . 0.0 109.144 179.08 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 59.2 p -93.96 86.03 4.92 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.918 0.866 . . . . 0.0 111.014 -178.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 284' ' ' THR . . . . . 0.45 ' C ' ' H ' ' A' ' 286' ' ' GLN . 40.0 p -148.63 -88.84 0.08 Allowed 'General case' 0 C--N 1.313 -1.015 0 CA-C-N 114.218 -1.356 . . . . 0.0 109.562 179.282 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 285' ' ' GLY . . . . . 0.534 ' O ' ' HB2' ' A' ' 286' ' ' GLN . . . 68.31 -17.33 0.45 Allowed Glycine 0 C--N 1.333 0.411 0 N-CA-C 114.627 0.611 . . . . 0.0 114.627 173.423 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 286' ' ' GLN . . . . . 0.534 ' HB2' ' O ' ' A' ' 285' ' ' GLY . 72.2 mt-30 76.49 164.45 0.13 Allowed Pre-proline 0 C--O 1.235 0.314 0 C-N-CA 123.519 0.728 . . . . 0.0 110.314 -174.671 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 287' ' ' PRO . . . . . . . . . . . . . 78.2 Cg_exo -51.65 128.26 25.58 Favored 'Trans proline' 0 C--N 1.351 0.665 0 C-N-CA 122.641 2.228 . . . . 0.0 112.71 -175.902 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 3.8 tm0? -74.38 135.79 42.45 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 -178.029 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 42.5 t -93.83 121.43 44.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.862 0.363 . . . . 0.0 110.896 -175.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 290' ' ' PHE . . . . . 0.64 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 3.9 m-85 -98.79 160.04 14.54 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.343 -178.517 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 291' ' ' ARG . . . . . 0.424 ' HD2' ' O ' ' A' ' 290' ' ' PHE . 45.2 mmm-85 -131.29 136.97 48.61 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.122 0.487 . . . . 0.0 110.155 175.66 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 46.3 t -83.67 139.86 17.04 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.223 -177.68 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 293' ' ' LEU . . . . . 0.522 HD12 ' HB3' ' A' ' 303' ' ' SER . 86.6 mt -111.71 -26.4 9.01 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.69 178.914 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 294' ' ' ALA . . . . . 0.485 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -156.35 139.76 15.79 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 120.718 -0.393 . . . . 0.0 111.624 179.496 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 64.8 t -137.52 109.58 6.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 115.825 -0.625 . . . . 0.0 109.521 173.778 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 47.6 t -151.4 116.37 5.23 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.51 -177.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 63.2 44.11 97.58 Favored Glycine 0 C--N 1.331 0.282 0 C-N-CA 120.847 -0.692 . . . . 0.0 111.942 -179.202 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 81.0 p 54.76 16.22 1.34 Allowed 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 123.88 0.872 . . . . 0.0 112.332 -175.401 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 35.8 m -101.07 116.06 31.94 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 174.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . 0.569 HG11 HG22 ' A' ' 302' ' ' ILE . 71.8 t -114.64 131.59 66.31 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-O 121.09 0.471 . . . . 0.0 111.867 -172.167 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 301' ' ' THR . . . . . 0.412 ' HB ' ' HB1' ' A' ' 294' ' ' ALA . 51.1 m -93.01 115.99 28.64 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.255 -0.884 . . . . 0.0 108.65 174.056 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 302' ' ' ILE . . . . . 0.569 HG22 HG11 ' A' ' 300' ' ' VAL . 30.4 pt -110.66 139.68 33.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-O 121.722 0.772 . . . . 0.0 112.771 -170.693 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 303' ' ' SER . . . . . 0.595 ' HA ' ' O ' ' A' ' 304' ' ' PRO . 82.5 p -138.41 169.02 13.74 Favored Pre-proline 0 C--N 1.323 -0.547 0 CA-C-N 114.404 -1.271 . . . . 0.0 107.759 177.082 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 304' ' ' PRO . . . . . 0.595 ' O ' ' HA ' ' A' ' 303' ' ' SER . 9.7 Cg_exo -73.01 -133.29 0.09 OUTLIER 'Cis proline' 0 C--N 1.348 0.516 0 CA-C-N 120.776 1.313 . . . . 0.0 112.527 0.251 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 305' ' ' LYS . . . . . 0.894 ' HD3' ' HG ' ' A' ' 307' ' ' LEU . 0.0 OUTLIER -102.07 145.1 29.8 Favored 'General case' 0 N--CA 1.448 -0.574 0 CA-C-O 121.453 0.644 . . . . 0.0 111.333 177.871 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 306' ' ' ILE . . . . . 0.787 HG21 ' HD3' ' A' ' 326' ' ' PRO . 2.7 mp -113.04 85.46 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.049 -177.076 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 307' ' ' LEU . . . . . 0.894 ' HG ' ' HD3' ' A' ' 305' ' ' LYS . 55.7 mt -96.77 116.5 66.12 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.704 -174.66 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 308' ' ' PRO . . . . . 0.67 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 68.7 Cg_endo -79.75 140.52 14.73 Favored 'Trans proline' 0 C--O 1.235 0.36 0 C-N-CA 122.95 2.433 . . . . 0.0 113.899 -174.191 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . 0.561 HG21 ' CB ' ' A' ' 320' ' ' ALA . 15.9 t -93.89 -27.92 4.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.821 174.702 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 62.4 mm-40 -82.21 33.49 0.4 Allowed 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.847 -177.73 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.458 ' OD1' ' HB2' ' A' ' 308' ' ' PRO . 5.5 m120 -126.23 168.95 13.38 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.967 177.955 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 27.3 m -80.64 -18.02 49.42 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.898 -176.427 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 50.7 m-20 -57.19 114.67 2.26 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-O 120.989 0.423 . . . . 0.0 111.387 -179.443 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 38.8 t -74.25 -31.44 29.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.579 -179.694 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -70.06 -30.03 67.18 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.428 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 34.0 t -75.76 -28.9 58.63 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.799 -178.767 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 317' ' ' ARG . . . . . 0.774 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 21.7 mmt85 -51.34 -57.38 14.38 Favored Pre-proline 0 CA--C 1.542 0.672 0 N-CA-C 113.882 1.067 . . . . 0.0 113.882 -176.539 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 318' ' ' PRO . . . . . 0.774 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 22.8 Cg_exo -70.79 -21.49 28.63 Favored 'Trans proline' 0 C--N 1.355 0.893 0 C-N-CA 121.958 1.772 . . . . 0.0 113.522 -173.412 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 319' ' ' TYR . . . . . 0.556 ' O ' HD13 ' A' ' 307' ' ' LEU . 0.9 OUTLIER -108.69 2.78 22.11 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.368 0.604 . . . . 0.0 109.598 -175.855 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . 0.643 ' HA ' ' HB2' ' A' ' 307' ' ' LEU . . . -62.36 138.62 58.47 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.318 -178.757 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 321' ' ' ASN . . . . . 0.401 ' O ' ' HA ' ' A' ' 275' ' ' SER . 16.0 p-10 -128.67 -3.46 5.33 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.007 -179.864 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 322' ' ' VAL . . . . . 0.529 ' O ' HG23 ' A' ' 309' ' ' VAL . 35.7 m -140.66 166.7 18.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.595 -0.275 . . . . 0.0 110.66 -179.836 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 53.8 m-20 -60.81 -49.23 78.3 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.072 0.463 . . . . 0.0 110.872 179.304 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 324' ' ' ALA . . . . . 0.67 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -157.53 170.65 21.93 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.575 -176.028 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 25.0 pttm -83.1 151.36 63.21 Favored Pre-proline 0 C--N 1.328 -0.359 0 N-CA-C 108.104 -1.072 . . . . 0.0 108.104 170.382 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 326' ' ' PRO . . . . . 0.787 ' HD3' HG21 ' A' ' 306' ' ' ILE . 20.6 Cg_exo -68.02 126.25 14.23 Favored 'Trans proline' 0 N--CA 1.461 -0.405 0 C-N-CA 121.731 1.621 . . . . 0.0 112.886 -174.702 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -83.36 117.3 22.92 Favored 'General case' 0 CA--C 1.511 -0.533 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 167.187 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 328' ' ' GLU . . . . . 0.435 ' OE1' ' HA ' ' A' ' 231' ' ' SER . 31.2 tp10 63.95 168.08 0.16 Allowed 'General case' 0 CA--C 1.539 0.554 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 -165.166 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 329' ' ' SER . . . . . 0.575 ' HB2' ' O ' ' A' ' 230' ' ' VAL . 49.3 m -81.09 -22.19 39.38 Favored 'General case' 0 C--N 1.316 -0.882 0 O-C-N 120.775 -1.203 . . . . 0.0 110.678 -176.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 330' ' ' ALA . . . . . 0.409 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 73.5 -160.09 0.09 Allowed 'General case' 0 N--CA 1.473 0.692 0 O-C-N 123.855 0.722 . . . . 0.0 112.872 170.944 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -95.51 129.33 42.72 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.254 -0.885 . . . . 0.0 110.041 179.379 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 332' ' ' ILE . . . . . 0.969 HG13 HG12 ' A' ' 270' ' ' ILE . 1.8 mp -111.16 145.49 17.36 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.442 -175.606 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.41 ' N ' HG21 ' A' ' 332' ' ' ILE . 47.5 m -118.69 97.65 5.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.021 -178.557 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 42.7 mm -80.02 136.46 23.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 N-CA-C 112.959 0.726 . . . . 0.0 112.959 -172.675 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 335' ' ' LEU . . . . . 0.624 HD23 ' N ' ' A' ' 335' ' ' LEU . 1.6 pt? -151.21 -173.82 4.62 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 114.69 -1.141 . . . . 0.0 108.737 172.646 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 76.4 m-20 -111.63 -14.05 13.7 Favored 'General case' 0 C--N 1.325 -0.499 0 O-C-N 122.079 -0.388 . . . . 0.0 111.704 -177.135 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 337' ' ' LYS . . . . . 0.625 ' HZ2' ' HB2' ' A' ' 337' ' ' LYS . 9.8 mtmp? . . . . . 0 C--O 1.244 0.792 0 CA-C-O 118.557 -0.735 . . . . 0.0 110.931 -177.163 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 40.8 p . . . . . 0 C--O 1.232 0.147 0 CA-C-O 120.488 0.185 . . . . 0.0 111.118 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 228' ' ' LEU . . . . . 0.402 ' HB3' ' CB ' ' A' ' 259' ' ' ALA . 83.8 mt -104.46 126.15 51.29 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 174.778 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 68.4 p -129.35 177.94 6.81 Favored 'General case' 0 C--N 1.32 -0.692 0 C-N-CA 120.06 -0.656 . . . . 0.0 111.147 -177.059 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 230' ' ' VAL . . . . . 0.734 HG22 HG13 ' A' ' 332' ' ' ILE . 64.6 t -140.48 142.57 30.72 Favored 'Isoleucine or valine' 0 C--O 1.238 0.474 0 CA-C-O 120.774 0.321 . . . . 0.0 110.309 -179.427 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 43.3 m -109.33 138.17 46.1 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.481 178.627 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 162.39 -170.15 37.9 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.896 -0.669 . . . . 0.0 111.747 -179.728 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 83.6 mt-30 -99.88 116.26 64.86 Favored Pre-proline 0 C--N 1.325 -0.486 0 CA-C-N 116.716 0.258 . . . . 0.0 110.927 179.45 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -69.17 127.6 15.31 Favored 'Trans proline' 0 C--O 1.236 0.412 0 C-N-CA 122.113 1.876 . . . . 0.0 110.971 175.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 235' ' ' GLU . . . . . 0.548 ' O ' ' HB ' ' A' ' 306' ' ' ILE . 0.3 OUTLIER -125.78 -176.92 3.75 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-O 121.661 0.744 . . . . 0.0 111.63 -174.395 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 22.3 p-80 -156.13 133.13 10.54 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 178.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 237' ' ' LYS . . . . . 0.782 ' HD3' ' HA ' ' A' ' 305' ' ' LYS . 8.9 mptt . . . . . 0 C--N 1.32 -0.682 0 C-N-CA 119.439 -0.904 . . . . 0.0 111.69 -172.194 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 252' ' ' GLN . . . . . 0.446 ' CG ' ' HE2' ' A' ' 237' ' ' LYS . 21.6 mt-30 . . . . . 0 N--CA 1.471 0.624 0 CA-C-O 121.382 0.61 . . . . 0.0 111.645 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . 0.54 ' O ' ' HA ' ' A' ' 301' ' ' THR . . . 126.33 -152.22 18.22 Favored Glycine 0 N--CA 1.446 -0.661 0 C-N-CA 119.141 -1.504 . . . . 0.0 113.401 172.812 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 254' ' ' THR . . . . . 0.448 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 58.4 p -94.21 135.49 35.53 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.13 0.49 . . . . 0.0 111.621 -174.908 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . 0.532 HD12 ' HB ' ' A' ' 300' ' ' VAL . 2.1 pp -132.39 169.07 22.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 115.446 -0.797 . . . . 0.0 111.223 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 83.8 m -105.15 126.25 51.88 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.015 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.646 HG21 HD12 ' A' ' 262' ' ' LEU . 33.5 m -100.81 145.42 11.21 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.643 0 N-CA-C 112.529 0.566 . . . . 0.0 112.529 -174.839 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 52.8 m -91.36 7.26 41.89 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 114.694 -1.139 . . . . 0.0 109.132 167.682 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 259' ' ' ALA . . . . . 0.402 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -95.78 170.09 9.56 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-N 115.492 -0.777 . . . . 0.0 110.13 -177.683 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 51.3 p -137.29 153.29 50.34 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.798 0.333 . . . . 0.0 111.45 -178.708 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 72.37 48.79 22.76 Favored Glycine 0 N--CA 1.452 -0.248 0 CA-C-N 115.929 -0.578 . . . . 0.0 112.847 178.342 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 262' ' ' LEU . . . . . 0.646 HD12 HG21 ' A' ' 257' ' ' VAL . 61.7 mt -102.31 144.28 31.01 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.971 0.415 . . . . 0.0 111.08 -178.873 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 72.1 mt-30 -137.78 172.45 12.94 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.69 -0.687 . . . . 0.0 109.547 176.059 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 264' ' ' VAL . . . . . 0.618 HG22 ' HA ' ' A' ' 294' ' ' ALA . 44.5 t -79.04 136.28 24.07 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 174.909 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 95.67 -0.76 63.26 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.5 -0.857 . . . . 0.0 112.586 179.33 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 266' ' ' ASP . . . . . 0.42 ' HB2' HG23 ' A' ' 292' ' ' VAL . 65.3 m-20 -65.17 152.26 44.05 Favored 'General case' 0 CA--C 1.517 -0.315 0 CA-C-O 121.11 0.481 . . . . 0.0 110.751 178.343 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 267' ' ' ALA . . . . . 0.698 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -124.14 122.76 38.71 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.353 -0.839 . . . . 0.0 109.415 179.544 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 268' ' ' PHE . . . . . . . . . . . . . 5.4 p90 -144.56 169.07 18.68 Favored 'General case' 0 C--N 1.319 -0.741 0 C-N-CA 120.016 -0.673 . . . . 0.0 111.784 -172.816 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 269' ' ' THR . . . . . 0.477 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 42.9 p -119.97 148.81 43.08 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.559 -0.746 . . . . 0.0 109.966 176.615 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 270' ' ' ILE . . . . . 0.642 HG12 HD11 ' A' ' 332' ' ' ILE . 58.5 mt -114.09 138.85 42.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 116.559 -0.291 . . . . 0.0 110.668 -177.226 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -67.99 117.04 9.33 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.948 179.082 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 109.4 -22.49 24.49 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.782 -0.723 . . . . 0.0 111.95 -179.14 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . 0.427 ' O ' ' HA ' ' A' ' 287' ' ' PRO . 50.4 t -96.35 101.27 12.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 175.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 72.5 m-80 -124.44 131.79 53.5 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.494 -177.594 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 54.5 p -64.03 163.99 11.35 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.524 0.678 . . . . 0.0 112.508 -176.488 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 276' ' ' VAL . . . . . 0.47 HG21 ' O ' ' A' ' 321' ' ' ASN . 21.5 m -126.81 149.94 32.26 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.623 0 CA-C-N 114.901 -1.045 . . . . 0.0 109.276 176.029 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 58.7 m170 -103.53 120.87 41.71 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 120.756 0.312 . . . . 0.0 110.738 -175.191 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 3.1 mm100 -82.17 -29.2 31.67 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.764 -177.723 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 2.0 mp -72.12 -52.64 23.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.436 -179.017 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 58.0 p -89.38 -13.06 38.62 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.772 -178.356 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 31.7 mmmt 58.84 45.26 15.64 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.55 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 44.1 t0 -132.8 155.25 49.27 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 110.157 -0.312 . . . . 0.0 110.157 -179.571 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 59.9 p -107.77 113.38 26.59 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 175.072 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 80.6 p -110.93 6.77 21.38 Favored 'General case' 0 C--N 1.32 -0.699 0 C-N-CA 120.285 -0.566 . . . . 0.0 112.077 -170.318 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 66.77 31.6 78.82 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.594 -0.813 . . . . 0.0 113.363 174.414 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 10.6 mm100 -95.89 109.1 44.74 Favored Pre-proline 0 C--N 1.328 -0.338 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 177.817 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 287' ' ' PRO . . . . . 0.477 ' HB2' ' HB ' ' A' ' 269' ' ' THR . 51.5 Cg_exo -58.35 139.34 90.21 Favored 'Trans proline' 0 C--N 1.343 0.288 0 C-N-CA 122.598 2.199 . . . . 0.0 112.888 -176.107 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 40.8 tt0 -77.4 148.37 35.55 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.179 -179.637 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 59.7 t -94.25 137.4 23.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.085 178.063 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 290' ' ' PHE . . . . . 0.698 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 51.7 m-85 -118.34 167.83 11.18 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.758 -176.525 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 37.4 mmt180 -128.66 130.96 47.95 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.77 177.653 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . 0.42 HG23 ' HB2' ' A' ' 266' ' ' ASP . 57.7 t -79.65 139.97 17.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.497 -0.774 . . . . 0.0 111.359 -179.054 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 293' ' ' LEU . . . . . 0.656 HD13 ' HB2' ' A' ' 303' ' ' SER . 6.9 mp -102.25 -31.66 10.44 Favored 'General case' 0 C--N 1.334 -0.089 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.844 179.738 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 294' ' ' ALA . . . . . 0.618 ' HA ' HG22 ' A' ' 264' ' ' VAL . . . -158.55 144.31 16.75 Favored 'General case' 0 N--CA 1.465 0.284 0 C-N-CA 120.664 -0.415 . . . . 0.0 111.763 179.523 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 62.5 t -139.28 112.48 6.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.85 176.085 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 54.2 p -132.67 95.41 3.59 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.368 -0.378 . . . . 0.0 111.114 -178.413 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 65.43 57.78 10.75 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.02 -178.789 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 67.0 p 51.19 22.37 1.31 Allowed 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 123.501 0.72 . . . . 0.0 112.552 -176.174 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 299' ' ' THR . . . . . 0.423 ' HA ' ' O ' ' A' ' 255' ' ' ILE . 91.7 m -112.29 109.55 19.27 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 174.014 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . 0.628 HG12 HG21 ' A' ' 302' ' ' ILE . 47.3 t -107.0 134.1 49.69 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-N 115.704 -0.68 . . . . 0.0 112.02 -168.39 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 301' ' ' THR . . . . . 0.54 ' HA ' ' O ' ' A' ' 253' ' ' GLY . 91.5 m -85.22 114.92 22.68 Favored 'General case' 0 C--O 1.237 0.403 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 169.746 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 302' ' ' ILE . . . . . 0.628 HG21 HG12 ' A' ' 300' ' ' VAL . 30.6 pt -110.7 138.6 38.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 N-CA-C 113.655 0.983 . . . . 0.0 113.655 -167.805 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 303' ' ' SER . . . . . 0.656 ' HB2' HD13 ' A' ' 293' ' ' LEU . 68.7 m -153.87 169.39 10.01 Favored Pre-proline 0 C--N 1.323 -0.557 0 CA-C-N 112.859 -1.973 . . . . 0.0 105.89 175.047 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 304' ' ' PRO . . . . . 0.587 ' HA ' ' HB3' ' A' ' 303' ' ' SER . 22.7 Cg_endo -93.38 -119.83 0.0 OUTLIER 'Cis proline' 0 N--CA 1.455 -0.742 0 CA-C-N 121.02 1.4 . . . . 0.0 113.592 0.822 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 305' ' ' LYS . . . . . 0.782 ' HA ' ' HD3' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -98.41 144.29 27.94 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.081 -0.509 . . . . 0.0 112.357 -172.324 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 306' ' ' ILE . . . . . 0.578 HD12 ' N ' ' A' ' 306' ' ' ILE . 2.2 mp -104.4 127.35 58.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 170.699 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 307' ' ' LEU . . . . . 0.445 ' O ' HG22 ' A' ' 322' ' ' VAL . 59.0 mt -129.09 98.28 24.17 Favored Pre-proline 0 C--N 1.323 -0.548 0 C-N-CA 120.676 -0.41 . . . . 0.0 110.519 -172.779 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 308' ' ' PRO . . . . . 0.554 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 12.7 Cg_exo -74.17 131.34 15.21 Favored 'Trans proline' 0 C--N 1.343 0.252 0 C-N-CA 122.802 2.335 . . . . 0.0 113.495 -175.19 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . 0.795 HG22 ' HB2' ' A' ' 320' ' ' ALA . 61.9 t -87.05 -37.57 11.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.563 173.897 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 63.1 mm-40 -81.08 32.69 0.33 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.859 -0.609 . . . . 0.0 111.484 179.814 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.526 HD22 ' HB3' ' A' ' 317' ' ' ARG . 0.0 OUTLIER -85.38 157.05 20.62 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.945 0.403 . . . . 0.0 111.248 179.16 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 36.4 m -92.15 -18.28 23.73 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.839 178.244 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -76.42 121.49 23.13 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.612 -179.746 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 40.7 t -75.76 -20.19 15.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.129 -177.457 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -80.59 -21.96 41.14 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.739 0.304 . . . . 0.0 111.512 178.582 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 36.0 t -96.3 -23.3 16.73 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.559 -0.291 . . . . 0.0 111.456 -176.138 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 317' ' ' ARG . . . . . 0.526 ' HB3' HD22 ' A' ' 311' ' ' ASN . 2.1 ptp180 -62.23 -34.03 14.07 Favored Pre-proline 0 CA--C 1.548 0.901 0 N-CA-C 113.807 1.04 . . . . 0.0 113.807 -178.886 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 318' ' ' PRO . . . . . 0.42 ' HD3' ' CG ' ' A' ' 317' ' ' ARG . 26.1 Cg_exo -63.13 -18.14 63.57 Favored 'Trans proline' 0 C--N 1.367 1.521 0 CA-C-N 121.263 1.487 . . . . 0.0 112.113 178.266 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 319' ' ' TYR . . . . . 0.428 ' O ' HD12 ' A' ' 307' ' ' LEU . 48.5 m-85 -103.35 -3.2 25.87 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.028 -177.803 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . 0.795 ' HB2' HG22 ' A' ' 309' ' ' VAL . . . -54.06 144.77 18.49 Favored 'General case' 0 C--N 1.33 -0.246 0 N-CA-C 112.144 0.424 . . . . 0.0 112.144 -178.128 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 321' ' ' ASN . . . . . 0.47 ' O ' HG21 ' A' ' 276' ' ' VAL . 48.9 t30 -148.05 -18.61 0.35 Allowed 'General case' 0 CA--C 1.532 0.278 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.472 -178.281 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 322' ' ' VAL . . . . . 0.513 ' O ' HG21 ' A' ' 309' ' ' VAL . 35.1 m -137.43 160.96 34.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 N-CA-C 110.234 -0.284 . . . . 0.0 110.234 177.654 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 71.8 m-20 -41.9 -69.24 0.14 Allowed 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 112.588 0.588 . . . . 0.0 112.588 -177.364 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 324' ' ' ALA . . . . . 0.554 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -165.7 -176.08 3.74 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.962 0.411 . . . . 0.0 111.496 -175.595 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 325' ' ' LYS . . . . . 0.508 ' HG2' HG22 ' A' ' 306' ' ' ILE . 34.4 mtmm -88.02 138.97 30.71 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.592 174.362 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 326' ' ' PRO . . . . . 0.67 ' HB2' ' HB1' ' A' ' 330' ' ' ALA . 43.1 Cg_endo -86.01 167.34 9.57 Favored 'Trans proline' 0 N--CA 1.455 -0.759 0 C-N-CA 122.551 2.167 . . . . 0.0 112.145 178.61 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -70.47 122.98 20.69 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 177.83 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 52.8 mt-10 62.39 -121.04 0.66 Allowed 'General case' 0 N--CA 1.463 0.184 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 -172.328 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 329' ' ' SER . . . . . 0.611 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 33.9 m -111.94 -14.25 13.52 Favored 'General case' 0 C--N 1.322 -0.603 0 C-N-CA 120.535 -0.466 . . . . 0.0 110.118 172.813 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 330' ' ' ALA . . . . . 0.67 ' HB1' ' HB2' ' A' ' 326' ' ' PRO . . . 73.9 -169.19 0.11 Allowed 'General case' 0 N--CA 1.474 0.755 0 O-C-N 124.214 0.946 . . . . 0.0 113.37 172.467 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -80.08 141.54 35.72 Favored 'General case' 0 CA--C 1.517 -0.304 0 CA-C-N 115.101 -0.954 . . . . 0.0 110.611 -179.065 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 332' ' ' ILE . . . . . 0.734 HG13 HG22 ' A' ' 230' ' ' VAL . 16.1 mm -120.68 144.11 30.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.405 -175.503 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 82.3 m -114.04 97.13 6.18 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 175.007 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 334' ' ' ILE . . . . . 0.402 HD11 HG21 ' A' ' 334' ' ' ILE . 38.5 mm -81.65 125.34 39.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 115.999 -0.546 . . . . 0.0 112.339 -172.045 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 335' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -122.73 163.22 20.56 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.187 170.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 20.9 t-20 -94.04 -14.74 25.5 Favored 'General case' 0 C--N 1.319 -0.76 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 171.659 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 26.7 tptp . . . . . 0 C--O 1.244 0.799 0 CA-C-N 114.613 -1.176 . . . . 0.0 111.257 174.431 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 26.5 m . . . . . 0 N--CA 1.442 -0.858 0 CA-C-O 121.314 0.578 . . . . 0.0 110.959 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 228' ' ' LEU . . . . . 0.522 HD23 ' HA ' ' A' ' 259' ' ' ALA . 55.2 mt -94.08 129.55 40.57 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.598 -178.6 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 229' ' ' THR . . . . . 0.513 ' O ' HG22 ' A' ' 230' ' ' VAL . 60.6 p -126.97 179.53 5.36 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 120.275 -0.57 . . . . 0.0 111.281 -176.18 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 230' ' ' VAL . . . . . 0.652 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 75.3 t -146.39 138.8 19.79 Favored 'Isoleucine or valine' 0 C--O 1.237 0.409 0 CA-C-O 120.735 0.302 . . . . 0.0 110.708 -179.359 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 49.4 m -137.99 165.37 26.73 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.746 178.686 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 116.12 -108.84 1.89 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 119.913 -1.137 . . . . 0.0 113.995 172.041 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 11.0 mm-40 -62.49 155.36 68.43 Favored Pre-proline 0 C--N 1.328 -0.354 0 N-CA-C 112.761 0.652 . . . . 0.0 112.761 -173.225 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -63.9 175.56 2.98 Favored 'Trans proline' 0 C--N 1.349 0.573 0 C-N-CA 123.611 2.874 . . . . 0.0 112.661 178.161 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 52.1 mm-40 -92.51 -176.79 4.4 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.695 -176.02 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 37.9 m-70 -113.82 143.75 44.14 Favored 'General case' 0 C--N 1.321 -0.658 0 C-N-CA 119.842 -0.743 . . . . 0.0 112.199 -165.33 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 237' ' ' LYS . . . . . 0.612 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.325 -0.484 0 CA-C-N 115.338 -0.847 . . . . 0.0 109.892 -176.11 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 2.6 mm100 . . . . . 0 N--CA 1.467 0.381 0 CA-C-O 120.897 0.38 . . . . 0.0 111.055 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . 0.552 ' O ' ' HA ' ' A' ' 301' ' ' THR . . . 119.05 -153.11 17.03 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 119.25 -1.453 . . . . 0.0 113.752 176.435 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 254' ' ' THR . . . . . 0.545 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 77.8 p -94.78 148.97 21.74 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.219 0.533 . . . . 0.0 112.243 -172.644 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . 0.536 HD11 HG23 ' A' ' 302' ' ' ILE . 22.6 pt -130.65 161.26 40.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.395 -0.82 . . . . 0.0 110.416 177.71 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 93.6 m -94.76 106.19 18.16 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 174.533 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.503 HG21 HD13 ' A' ' 262' ' ' LEU . 34.3 m -93.21 141.46 14.68 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.914 0 C-N-CA 119.565 -0.854 . . . . 0.0 112.329 -174.693 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 53.8 m -93.0 8.91 37.96 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 114.016 -1.447 . . . . 0.0 109.239 169.684 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 259' ' ' ALA . . . . . 0.522 ' HA ' HD23 ' A' ' 228' ' ' LEU . . . -81.17 166.37 20.7 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.861 -177.641 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 42.6 m -124.93 108.26 11.7 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 111.988 0.366 . . . . 0.0 111.988 -174.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 92.71 50.14 2.57 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.617 -0.801 . . . . 0.0 113.429 173.316 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 262' ' ' LEU . . . . . 0.503 HD13 HG21 ' A' ' 257' ' ' VAL . 3.2 mp -86.94 143.59 27.32 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.891 0.346 . . . . 0.0 110.319 179.563 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 68.6 mt-30 -131.12 168.84 16.77 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.605 177.876 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 38.6 t -79.22 128.49 38.5 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 C-N-CA 120.8 -0.36 . . . . 0.0 110.338 178.184 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . 0.53 ' H ' ' HB ' ' A' ' 292' ' ' VAL . . . 102.41 8.67 43.2 Favored Glycine 0 N--CA 1.448 -0.532 0 C-N-CA 120.393 -0.908 . . . . 0.0 113.017 177.605 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -76.94 160.93 28.79 Favored 'General case' 0 CA--C 1.515 -0.373 0 CA-C-O 121.047 0.451 . . . . 0.0 110.579 176.424 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 267' ' ' ALA . . . . . 0.63 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -131.68 131.88 43.48 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 177.851 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 268' ' ' PHE . . . . . . . . . . . . . 3.6 p90 -152.33 169.31 22.83 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 119.468 -0.893 . . . . 0.0 111.76 -172.787 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 269' ' ' THR . . . . . 0.872 HG21 ' HB2' ' A' ' 287' ' ' PRO . 71.1 p -119.61 163.05 17.93 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.235 177.477 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 270' ' ' ILE . . . . . 0.585 HG12 HG12 ' A' ' 332' ' ' ILE . 56.7 mt -124.24 140.46 47.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 C-N-CA 120.815 -0.354 . . . . 0.0 111.432 -178.257 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -62.5 113.17 2.8 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.131 179.655 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 103.51 -21.68 38.31 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 121.083 -0.579 . . . . 0.0 112.031 -178.106 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 51.1 t -101.1 103.77 15.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-O 121.089 0.471 . . . . 0.0 110.77 178.87 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 71.9 m-80 -122.67 156.35 34.52 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.165 -0.471 . . . . 0.0 109.967 179.234 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 53.8 p -71.95 173.83 7.83 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.14 0.495 . . . . 0.0 111.819 -175.842 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 27.1 m -112.02 -178.45 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.674 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 277' ' ' HIS . . . . . 0.401 ' CB ' ' HA ' ' A' ' 281' ' ' LYS . 9.9 m-70 -54.51 93.26 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.023 -0.99 . . . . 0.0 110.965 -173.932 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -81.99 -28.2 32.75 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.981 0.42 . . . . 0.0 109.878 -175.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 279' ' ' ILE . . . . . 0.443 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.6 mp -82.18 -104.31 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.405 0 CA-C-N 116.083 -0.508 . . . . 0.0 109.817 -179.028 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 41.0 p -128.94 76.07 1.69 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.633 0.254 . . . . 0.0 110.676 179.173 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 281' ' ' LYS . . . . . 0.401 ' HA ' ' CB ' ' A' ' 277' ' ' HIS . 34.4 mmtp 54.64 31.5 15.32 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.437 -174.559 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 36.3 t70 -87.32 138.44 31.48 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.647 -176.712 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 54.4 p -95.5 120.33 35.57 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.126 -178.593 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 81.5 p -128.93 -45.43 1.28 Allowed 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.276 -171.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 79.62 28.01 52.76 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.701 -0.761 . . . . 0.0 111.967 -178.58 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 25.5 mt-30 -76.05 134.62 71.05 Favored Pre-proline 0 C--N 1.328 -0.366 0 N-CA-C 110.214 -0.291 . . . . 0.0 110.214 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 287' ' ' PRO . . . . . 0.872 ' HB2' HG21 ' A' ' 269' ' ' THR . 26.3 Cg_exo -64.67 134.19 39.85 Favored 'Trans proline' 0 CA--C 1.53 0.308 0 C-N-CA 122.546 2.164 . . . . 0.0 112.098 -177.9 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 69.7 tp60 -76.65 129.14 35.97 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.578 -178.503 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 25.7 t -97.01 137.61 24.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.831 -178.357 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 290' ' ' PHE . . . . . 0.652 ' HD1' ' HD2' ' A' ' 304' ' ' PRO . 55.0 m-85 -115.58 169.43 9.19 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.046 -178.836 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 9.8 tpt180 -131.06 142.56 50.3 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.167 0.508 . . . . 0.0 110.047 -179.154 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . 0.53 ' HB ' ' H ' ' A' ' 265' ' ' GLY . 55.8 t -92.49 130.57 41.4 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.877 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.683 179.693 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 293' ' ' LEU . . . . . 0.55 HD23 ' N ' ' A' ' 293' ' ' LEU . 2.9 mm? -105.71 -24.34 12.54 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.448 -0.342 . . . . 0.0 111.402 -178.355 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 294' ' ' ALA . . . . . . . . . . . . . . . -164.24 145.39 8.43 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.465 0.174 . . . . 0.0 110.982 179.688 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 45.5 t -135.07 138.28 49.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 175.575 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 36.9 t -139.44 87.31 2.18 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 177.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 73.41 -128.22 11.31 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.118 -1.039 . . . . 0.0 110.544 -169.483 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 31.1 p -102.35 29.34 5.25 Favored 'General case' 0 C--N 1.315 -0.898 0 O-C-N 122.155 -0.615 . . . . 0.0 110.506 172.63 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 63.5 m -112.07 105.42 13.79 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 174.033 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . 0.545 ' O ' ' HA ' ' A' ' 254' ' ' THR . 44.3 t -114.24 130.46 68.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 N-CA-C 112.259 0.466 . . . . 0.0 112.259 -168.797 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 301' ' ' THR . . . . . 0.552 ' HA ' ' O ' ' A' ' 253' ' ' GLY . 51.4 m -84.46 113.63 21.34 Favored 'General case' 0 C--O 1.237 0.402 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.219 173.342 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 302' ' ' ILE . . . . . 0.536 HG23 HD11 ' A' ' 255' ' ' ILE . 38.9 pt -116.39 157.13 17.4 Favored 'Isoleucine or valine' 0 C--O 1.24 0.599 0 CA-C-O 121.85 0.833 . . . . 0.0 112.897 -174.602 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 303' ' ' SER . . . . . 0.477 ' HB3' ' HA ' ' A' ' 304' ' ' PRO . 48.8 m -159.64 163.21 23.58 Favored Pre-proline 0 C--N 1.326 -0.435 0 CA-C-N 113.381 -1.736 . . . . 0.0 106.522 175.012 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 304' ' ' PRO . . . . . 0.652 ' HD2' ' HD1' ' A' ' 290' ' ' PHE . 5.1 Cg_exo -78.63 -134.23 0.14 OUTLIER 'Cis proline' 0 CA--C 1.534 0.518 0 CA-C-N 120.504 1.216 . . . . 0.0 113.047 0.85 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 305' ' ' LYS . . . . . 0.473 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -113.16 156.42 23.25 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.333 0.587 . . . . 0.0 112.375 -176.841 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 306' ' ' ILE . . . . . 0.73 HG23 HG22 ' A' ' 322' ' ' VAL . 2.6 mp -104.34 98.53 6.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.25 -0.886 . . . . 0.0 109.491 179.168 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 307' ' ' LEU . . . . . 0.513 HD12 ' O ' ' A' ' 319' ' ' TYR . 76.3 mt -107.52 100.19 32.83 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.517 -0.31 . . . . 0.0 111.188 -175.007 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 308' ' ' PRO . . . . . 0.738 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 32.4 Cg_exo -66.94 138.22 47.42 Favored 'Trans proline' 0 N--CA 1.474 0.346 0 C-N-CA 123.622 2.881 . . . . 0.0 114.588 -173.757 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . 0.556 HG21 ' O ' ' A' ' 322' ' ' VAL . 50.8 t -76.74 -29.9 18.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.051 -0.977 . . . . 0.0 108.771 167.772 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -79.2 30.03 0.22 Allowed 'General case' 0 C--O 1.234 0.289 0 CA-C-N 115.292 -0.867 . . . . 0.0 112.045 179.437 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.409 ' H ' ' C ' ' A' ' 309' ' ' VAL . 74.3 m-80 71.05 154.69 0.14 Allowed 'General case' 0 N--CA 1.469 0.481 0 N-CA-C 113.647 0.98 . . . . 0.0 113.647 173.692 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 312' ' ' THR . . . . . 0.537 ' OG1' ' HG2' ' A' ' 308' ' ' PRO . 44.4 m -168.18 -44.09 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 113.675 -1.602 . . . . 0.0 107.824 173.169 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 39.2 t70 -146.52 167.86 22.64 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 114.246 -1.343 . . . . 0.0 108.59 176.339 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 47.2 t -60.34 -38.26 77.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-O 120.787 0.327 . . . . 0.0 111.104 178.381 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -77.38 -17.83 57.86 Favored 'General case' 0 N--CA 1.463 0.212 0 N-CA-C 111.967 0.358 . . . . 0.0 111.967 -179.844 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 34.7 t -71.51 -25.02 62.08 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.579 -0.282 . . . . 0.0 111.447 -176.765 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 317' ' ' ARG . . . . . 0.755 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 54.2 mtp85 -69.71 -57.96 6.09 Favored Pre-proline 0 CA--C 1.536 0.426 0 N-CA-C 112.257 0.466 . . . . 0.0 112.257 -178.691 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 318' ' ' PRO . . . . . 0.755 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 36.8 Cg_exo -63.69 -35.23 59.27 Favored 'Trans proline' 0 C--N 1.357 0.975 0 C-N-CA 122.051 1.834 . . . . 0.0 112.684 -176.779 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 319' ' ' TYR . . . . . 0.513 ' O ' HD12 ' A' ' 307' ' ' LEU . 6.4 m-85 -99.43 32.11 2.9 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.022 -179.23 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -55.55 127.68 30.92 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.893 178.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 47.9 t30 -120.99 -28.25 4.82 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.185 -176.654 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 322' ' ' VAL . . . . . 0.73 HG22 HG23 ' A' ' 306' ' ' ILE . 27.2 m -135.42 168.51 22.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.582 -0.281 . . . . 0.0 110.624 179.223 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 65.6 m-20 -52.83 -59.98 3.83 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 121.015 0.436 . . . . 0.0 110.769 176.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 324' ' ' ALA . . . . . 0.738 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -171.79 171.94 5.04 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.427 179.668 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 325' ' ' LYS . . . . . 0.543 ' HB3' HG21 ' A' ' 306' ' ' ILE . 21.7 pttp -112.46 117.95 46.27 Favored Pre-proline 0 C--N 1.326 -0.444 0 CA-C-O 121.251 0.548 . . . . 0.0 110.145 172.807 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -72.21 169.33 21.78 Favored 'Trans proline' 0 C--N 1.34 0.103 0 C-N-CA 123.284 2.656 . . . . 0.0 111.884 -177.408 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -63.42 122.27 15.83 Favored 'General case' 0 C--O 1.236 0.372 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 177.607 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 56.0 mt-10 67.79 165.33 0.23 Allowed 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.327 -171.519 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 329' ' ' SER . . . . . 0.652 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 49.0 m -66.65 -14.78 62.89 Favored 'General case' 0 C--N 1.326 -0.423 0 C-N-CA 120.999 -0.28 . . . . 0.0 111.746 -175.673 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 68.17 -162.36 0.2 Allowed 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 113.261 0.837 . . . . 0.0 113.261 171.097 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 331' ' ' ALA . . . . . 0.442 ' HA ' ' HA ' ' A' ' 229' ' ' THR . . . -82.98 150.49 26.35 Favored 'General case' 0 CA--C 1.519 -0.249 0 CA-C-N 115.333 -0.849 . . . . 0.0 111.122 -177.001 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 332' ' ' ILE . . . . . 0.585 HG12 HG12 ' A' ' 270' ' ' ILE . 42.6 mt -122.91 145.23 30.09 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.054 -178.559 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.442 ' HB ' ' OG1' ' A' ' 269' ' ' THR . 31.9 m -111.53 106.77 15.73 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 175.238 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 34.9 mm -83.78 121.67 36.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 112.889 0.7 . . . . 0.0 112.889 -170.203 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 335' ' ' LEU . . . . . 0.489 HD22 ' N ' ' A' ' 335' ' ' LEU . 3.0 mm? -111.62 -168.57 1.33 Allowed 'General case' 0 C--O 1.236 0.394 0 CA-C-N 115.094 -0.957 . . . . 0.0 109.672 171.491 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 74.4 m-80 -116.78 -15.1 10.74 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.806 -0.633 . . . . 0.0 110.989 176.557 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 23.2 pttm . . . . . 0 C--O 1.244 0.779 0 CA-C-O 118.546 -0.74 . . . . 0.0 111.288 -177.619 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 41.1 m . . . . . 0 C--O 1.234 0.264 0 CA-C-O 120.919 0.39 . . . . 0.0 111.525 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 228' ' ' LEU . . . . . 0.511 ' HB3' ' HB3' ' A' ' 259' ' ' ALA . 69.7 mt -89.3 125.12 34.98 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 109.711 -0.478 . . . . 0.0 109.711 177.658 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 229' ' ' THR . . . . . 0.597 ' O ' HG23 ' A' ' 230' ' ' VAL . 58.4 p -124.27 175.35 7.12 Favored 'General case' 0 C--N 1.323 -0.573 0 C-N-CA 119.891 -0.724 . . . . 0.0 110.32 179.12 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 230' ' ' VAL . . . . . 0.837 HG22 HD11 ' A' ' 332' ' ' ILE . 89.0 t -148.63 141.82 18.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-O 120.76 0.314 . . . . 0.0 110.654 -177.614 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 49.0 m -92.38 129.13 38.41 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.905 -0.589 . . . . 0.0 109.619 174.142 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . -86.5 118.52 4.91 Favored Glycine 0 N--CA 1.444 -0.829 0 C-N-CA 120.264 -0.97 . . . . 0.0 113.322 -175.622 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 233' ' ' GLN . . . . . 0.941 ' HB3' ' HD2' ' A' ' 234' ' ' PRO . 75.7 mt-30 -80.2 178.97 2.05 Favored Pre-proline 0 C--N 1.328 -0.358 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 169.641 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 234' ' ' PRO . . . . . 0.941 ' HD2' ' HB3' ' A' ' 233' ' ' GLN . 72.9 Cg_exo -32.22 127.53 0.1 OUTLIER 'Trans proline' 0 C--N 1.366 1.463 0 C-N-CA 123.633 2.888 . . . . 0.0 113.861 -176.782 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 235' ' ' GLU . . . . . 0.7 ' OE1' ' HE3' ' A' ' 325' ' ' LYS . 46.1 mt-10 -95.58 -178.78 4.52 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.589 -175.727 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 236' ' ' HIS . . . . . 0.6 ' C ' ' HD3' ' A' ' 237' ' ' LYS . 91.7 m-70 -135.68 143.55 45.5 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 122.559 1.171 . . . . 0.0 113.549 -166.309 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 237' ' ' LYS . . . . . 0.6 ' HD3' ' C ' ' A' ' 236' ' ' HIS . 0.0 OUTLIER . . . . . 0 C--N 1.314 -0.942 0 CA-C-N 112.531 -2.122 . . . . 0.0 107.729 -179.71 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 252' ' ' GLN . . . . . 0.432 ' HA ' HE21 ' A' ' 252' ' ' GLN . 2.4 mm100 . . . . . 0 N--CA 1.454 -0.231 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . 0.5 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -105.81 122.25 7.06 Favored Glycine 0 N--CA 1.443 -0.883 0 C-N-CA 120.282 -0.961 . . . . 0.0 112.088 177.437 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 254' ' ' THR . . . . . 0.498 ' O ' ' HB2' ' A' ' 233' ' ' GLN . 48.3 p -106.33 116.79 32.54 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 109.16 -0.682 . . . . 0.0 109.16 176.439 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . 0.53 HD12 HG12 ' A' ' 230' ' ' VAL . 2.1 pp -125.49 165.63 22.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 N-CA-C 112.868 0.692 . . . . 0.0 112.868 -173.074 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 256' ' ' THR . . . . . 0.466 ' O ' HG13 ' A' ' 230' ' ' VAL . 25.7 m -105.98 117.51 34.23 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 178.649 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.723 HG13 HG21 ' A' ' 230' ' ' VAL . 33.7 m -90.22 143.0 12.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 C-N-CA 119.71 -0.796 . . . . 0.0 112.757 -171.932 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 37.0 m -92.35 9.83 32.41 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 114.076 -1.42 . . . . 0.0 108.791 168.519 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 259' ' ' ALA . . . . . 0.511 ' HB3' ' HB3' ' A' ' 228' ' ' LEU . . . -101.1 168.3 9.68 Favored 'General case' 0 N--CA 1.454 -0.268 0 CA-C-N 115.049 -0.978 . . . . 0.0 109.371 -176.842 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 49.5 m -132.86 163.18 29.69 Favored 'General case' 0 C--N 1.324 -0.529 0 C-N-CA 120.806 -0.358 . . . . 0.0 111.502 -178.487 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 64.29 50.11 61.89 Favored Glycine 0 N--CA 1.452 -0.247 0 CA-C-N 115.729 -0.669 . . . . 0.0 113.128 177.047 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 262' ' ' LEU . . . . . . . . . . . . . 53.4 mt -101.76 159.68 15.12 Favored 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 120.652 -0.419 . . . . 0.0 110.543 179.73 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 73.4 mt-30 -143.35 165.14 28.33 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.988 -0.551 . . . . 0.0 109.812 179.744 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 41.2 t -79.86 134.47 27.49 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 N-CA-C 109.411 -0.588 . . . . 0.0 109.411 173.621 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . 0.458 ' H ' ' HB ' ' A' ' 292' ' ' VAL . . . 95.47 15.81 42.36 Favored Glycine 0 N--CA 1.446 -0.656 0 C-N-CA 120.284 -0.96 . . . . 0.0 112.729 178.918 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 40.7 m-20 -87.82 165.78 15.06 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.956 0.407 . . . . 0.0 110.689 174.784 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 267' ' ' ALA . . . . . 0.727 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -135.8 123.28 22.08 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.541 -0.754 . . . . 0.0 109.503 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 268' ' ' PHE . . . . . 0.463 ' HA ' HD23 ' A' ' 335' ' ' LEU . 5.9 p90 -141.16 175.03 9.97 Favored 'General case' 0 C--N 1.32 -0.704 0 C-N-CA 120.123 -0.631 . . . . 0.0 111.497 -172.554 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 269' ' ' THR . . . . . 0.417 ' OG1' ' HB ' ' A' ' 333' ' ' THR . 64.3 p -118.32 154.22 32.7 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.748 176.542 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 270' ' ' ILE . . . . . 0.912 HG12 HG13 ' A' ' 332' ' ' ILE . 60.1 mt -124.58 141.28 45.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 120.761 0.315 . . . . 0.0 110.78 -178.068 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -76.03 125.49 29.22 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.903 178.472 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 96.58 -21.83 43.54 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.087 -178.749 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . 0.57 HG23 HG21 ' A' ' 270' ' ' ILE . 48.5 t -100.42 103.25 14.54 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 121.059 0.457 . . . . 0.0 110.054 176.976 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 274' ' ' ASN . . . . . 0.51 ' O ' ' HB ' ' A' ' 322' ' ' VAL . 70.8 m-80 -121.01 137.84 54.45 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 -179.756 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 275' ' ' SER . . . . . 0.66 ' HB3' ' HB2' ' A' ' 288' ' ' GLN . 60.3 p -73.01 174.48 7.8 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.006 0.431 . . . . 0.0 111.511 -175.124 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 276' ' ' VAL . . . . . 0.707 HG13 HG22 ' A' ' 309' ' ' VAL . 33.3 m -110.05 178.69 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.284 -179.421 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 277' ' ' HIS . . . . . 0.833 ' HB2' ' HA ' ' A' ' 281' ' ' LYS . 7.7 p80 -36.84 88.73 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.675 0 O-C-N 124.561 1.163 . . . . 0.0 113.985 -177.271 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 39.7 tt0 -84.64 -36.46 21.96 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.518 -178.173 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 2.6 mp -80.94 -84.33 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.305 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.398 -172.788 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 32.6 p -127.69 45.79 2.67 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 111.597 0.221 . . . . 0.0 111.597 -174.686 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 281' ' ' LYS . . . . . 0.833 ' HA ' ' HB2' ' A' ' 277' ' ' HIS . 3.3 tmtp? 56.68 46.3 20.43 Favored 'General case' 0 CA--C 1.533 0.312 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 -176.792 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 49.2 p-10 -104.75 -162.01 0.86 Allowed 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 114.79 -1.095 . . . . 0.0 110.885 -175.085 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 76.1 p -105.97 124.45 49.59 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 178.749 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 81.2 p -127.28 -75.86 0.57 Allowed 'General case' 0 C--N 1.321 -0.643 0 C-N-CA 120.429 -0.508 . . . . 0.0 111.159 -174.26 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 67.09 31.24 77.22 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.898 -0.668 . . . . 0.0 112.002 -179.306 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 95.2 mm-40 -105.35 145.27 30.47 Favored Pre-proline 0 C--N 1.329 -0.311 0 N-CA-C 110.467 -0.197 . . . . 0.0 110.467 -178.142 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 287' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -55.22 137.5 77.06 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.805 2.336 . . . . 0.0 112.267 -179.813 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 288' ' ' GLN . . . . . 0.66 ' HB2' ' HB3' ' A' ' 275' ' ' SER . 52.0 tt0 -88.37 155.48 19.67 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.895 -176.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 59.0 t -89.84 113.34 25.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.349 178.638 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 290' ' ' PHE . . . . . 0.727 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 54.1 m-85 -100.52 131.12 46.6 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.46 -177.331 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 9.8 tpt180 -106.87 120.53 42.29 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.535 0.683 . . . . 0.0 109.877 178.368 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . 0.458 ' HB ' ' H ' ' A' ' 265' ' ' GLY . 57.6 t -67.66 140.01 19.94 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.954 0 CA-C-N 114.656 -1.157 . . . . 0.0 112.531 -176.198 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 293' ' ' LEU . . . . . 0.55 HD13 ' OG ' ' A' ' 303' ' ' SER . 4.4 mp -104.69 -30.94 9.62 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.739 175.534 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 294' ' ' ALA . . . . . 0.462 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -159.71 144.8 15.37 Favored 'General case' 0 C--N 1.333 -0.126 0 CA-C-O 120.534 0.207 . . . . 0.0 111.532 -176.358 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 70.7 t -138.09 100.23 1.68 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 175.589 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 35.8 m -138.49 113.5 9.27 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.439 -0.346 . . . . 0.0 111.085 -175.457 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 63.17 48.49 79.22 Favored Glycine 0 C--N 1.331 0.252 0 C-N-CA 120.834 -0.698 . . . . 0.0 111.922 -178.716 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 71.3 p 51.08 24.33 1.87 Allowed 'General case' 0 N--CA 1.469 0.5 0 C-N-CA 123.77 0.828 . . . . 0.0 112.229 -174.742 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 299' ' ' THR . . . . . 0.476 ' HA ' ' O ' ' A' ' 255' ' ' ILE . 29.0 m -111.48 111.18 22.02 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 176.304 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . 0.565 HG12 HG22 ' A' ' 302' ' ' ILE . 44.7 t -111.02 129.08 66.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.587 -172.445 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 93.5 m -90.97 116.08 28.49 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 172.298 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 302' ' ' ILE . . . . . 0.565 HG22 HG12 ' A' ' 300' ' ' VAL . 29.2 pt -113.26 142.8 24.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 N-CA-C 112.917 0.71 . . . . 0.0 112.917 -171.57 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 303' ' ' SER . . . . . 0.55 ' OG ' HD13 ' A' ' 293' ' ' LEU . 89.5 p -137.71 142.13 35.56 Favored Pre-proline 0 C--N 1.322 -0.599 0 N-CA-C 106.95 -1.5 . . . . 0.0 106.95 169.906 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 304' ' ' PRO . . . . . 0.505 ' HD2' ' HD1' ' A' ' 290' ' ' PHE . 25.2 Cg_exo -66.83 -179.48 13.45 Favored 'Cis proline' 0 C--N 1.331 -0.377 0 CA-C-N 119.913 1.005 . . . . 0.0 112.88 0.868 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 305' ' ' LYS . . . . . 0.512 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -112.87 145.93 39.8 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-O 121.102 0.477 . . . . 0.0 111.543 -179.259 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 306' ' ' ILE . . . . . 0.402 HD11 ' N ' ' A' ' 306' ' ' ILE . 2.2 mp -72.11 106.11 2.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.262 -0.881 . . . . 0.0 111.058 -175.958 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 307' ' ' LEU . . . . . 0.407 HD11 ' O ' ' A' ' 319' ' ' TYR . 86.7 mt -124.68 108.08 28.82 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.116 -0.493 . . . . 0.0 109.853 178.32 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 308' ' ' PRO . . . . . 0.684 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 23.8 Cg_exo -72.89 136.92 26.0 Favored 'Trans proline' 0 N--CA 1.476 0.452 0 C-N-CA 123.006 2.471 . . . . 0.0 114.423 -170.849 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . 0.707 HG22 HG13 ' A' ' 276' ' ' VAL . 47.5 t -91.14 -23.53 5.87 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.186 0 CA-C-N 115.283 -0.871 . . . . 0.0 109.549 171.675 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 310' ' ' GLU . . . . . 0.492 ' OE1' ' HB1' ' A' ' 324' ' ' ALA . 50.2 mt-10 -80.9 8.53 8.11 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.182 -179.537 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 22.6 t-20 -74.99 137.36 41.5 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 178.399 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 68.6 m -60.67 -35.98 77.6 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 111.608 0.225 . . . . 0.0 111.608 -174.671 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 39.7 m-20 -61.38 126.76 28.52 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-O 121.167 0.508 . . . . 0.0 111.247 179.89 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 57.9 t -69.86 -28.26 36.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.493 -177.466 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -72.03 -17.92 61.99 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 111.997 0.369 . . . . 0.0 111.997 -179.828 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 35.1 t -76.82 -40.52 47.62 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 121.223 -0.191 . . . . 0.0 111.21 -177.41 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 317' ' ' ARG . . . . . 0.456 ' N ' ' HD2' ' A' ' 318' ' ' PRO . 65.9 mtt85 -54.44 -53.24 61.82 Favored Pre-proline 0 CA--C 1.54 0.584 0 N-CA-C 113.652 0.982 . . . . 0.0 113.652 -176.276 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 318' ' ' PRO . . . . . 0.456 ' HD2' ' N ' ' A' ' 317' ' ' ARG . 9.9 Cg_endo -56.36 -23.93 49.21 Favored 'Trans proline' 0 C--N 1.357 0.989 0 C-N-CA 122.468 2.112 . . . . 0.0 113.282 -176.86 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 319' ' ' TYR . . . . . 0.407 ' O ' HD11 ' A' ' 307' ' ' LEU . 53.9 m-85 -115.23 12.38 16.48 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.703 -177.4 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -78.1 161.04 27.69 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.35 -178.306 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 29.2 t-20 -122.42 -44.51 2.25 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.734 -175.416 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 322' ' ' VAL . . . . . 0.51 ' HB ' ' O ' ' A' ' 274' ' ' ASN . 34.7 m -124.95 179.0 3.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.793 -177.884 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 74.9 m-20 -62.3 -60.09 4.07 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.81 -178.736 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 324' ' ' ALA . . . . . 0.684 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -151.27 172.51 15.75 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 112.785 0.661 . . . . 0.0 112.785 -174.27 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 325' ' ' LYS . . . . . 0.7 ' HE3' ' OE1' ' A' ' 235' ' ' GLU . 14.9 ptmt -99.06 126.41 38.29 Favored Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 114.252 -1.34 . . . . 0.0 110.152 170.818 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 326' ' ' PRO . . . . . 0.552 ' HG3' HG21 ' A' ' 273' ' ' VAL . 90.8 Cg_endo -86.21 168.23 9.03 Favored 'Trans proline' 0 N--CA 1.461 -0.403 0 C-N-CA 122.963 2.442 . . . . 0.0 111.857 -179.757 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -69.8 122.71 19.75 Favored 'General case' 0 C--O 1.236 0.385 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 174.448 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 62.2 mm-40 58.22 -140.79 0.75 Allowed 'General case' 0 CA--C 1.528 0.115 0 O-C-N 123.53 0.519 . . . . 0.0 109.647 -172.822 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 329' ' ' SER . . . . . 0.623 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 48.7 m -112.86 -14.12 13.1 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 120.44 -0.504 . . . . 0.0 111.076 176.615 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 67.33 -151.02 0.18 Allowed 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 112.402 0.519 . . . . 0.0 112.402 175.329 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -89.86 127.4 35.99 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.945 -178.293 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 332' ' ' ILE . . . . . 0.912 HG13 HG12 ' A' ' 270' ' ' ILE . 1.7 mp -110.96 140.12 31.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.432 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.417 ' HB ' ' OG1' ' A' ' 269' ' ' THR . 50.8 m -103.43 99.0 8.81 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.147 -0.479 . . . . 0.0 109.739 -178.944 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 22.6 mm -84.27 127.67 39.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 N-CA-C 113.934 1.087 . . . . 0.0 113.934 -171.405 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 335' ' ' LEU . . . . . 0.463 HD23 ' HA ' ' A' ' 268' ' ' PHE . 1.6 pt? -153.36 -172.85 4.37 Favored 'General case' 0 N--CA 1.447 -0.576 0 CA-C-N 114.024 -1.444 . . . . 0.0 107.65 168.816 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 20.6 t-20 -121.35 -23.92 5.57 Favored 'General case' 0 C--N 1.321 -0.649 0 C-N-CA 120.363 -0.535 . . . . 0.0 110.583 -178.599 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 68.1 mttm . . . . . 0 C--O 1.245 0.818 0 CA-C-O 118.097 -0.954 . . . . 0.0 111.399 179.071 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 54.7 p . . . . . 0 C--O 1.233 0.232 0 CA-C-O 121.349 0.595 . . . . 0.0 110.051 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 228' ' ' LEU . . . . . 0.557 HD11 ' HB2' ' A' ' 259' ' ' ALA . 91.1 mt -108.52 146.77 32.71 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.116 -0.947 . . . . 0.0 108.871 177.028 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 229' ' ' THR . . . . . 0.529 ' O ' HG23 ' A' ' 230' ' ' VAL . 77.7 p -130.56 179.6 5.84 Favored 'General case' 0 C--N 1.325 -0.477 0 C-N-CA 119.973 -0.691 . . . . 0.0 110.675 -179.013 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 230' ' ' VAL . . . . . 0.859 HG22 HG13 ' A' ' 332' ' ' ILE . 91.3 t -146.51 136.71 17.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 120.91 0.386 . . . . 0.0 110.592 178.902 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 33.7 t -107.04 146.42 31.17 Favored 'General case' 0 N--CA 1.45 -0.465 0 CA-C-N 116.039 -0.528 . . . . 0.0 109.604 176.498 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . 0.481 ' O ' ' HD3' ' A' ' 234' ' ' PRO . . . 124.4 149.18 7.6 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.396 -0.906 . . . . 0.0 111.592 -176.817 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 66.5 mt-30 -98.6 103.82 20.88 Favored Pre-proline 0 C--N 1.323 -0.568 0 CA-C-N 116.72 0.26 . . . . 0.0 111.117 -176.583 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 234' ' ' PRO . . . . . 0.481 ' HD3' ' O ' ' A' ' 232' ' ' GLY . 4.8 Cg_exo -74.96 125.49 9.38 Favored 'Trans proline' 0 N--CA 1.457 -0.626 0 C-N-CA 122.259 1.972 . . . . 0.0 111.077 177.676 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -131.93 141.07 49.22 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.609 -179.14 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 236' ' ' HIS . . . . . 0.48 ' HE1' ' HA ' ' A' ' 252' ' ' GLN . 87.2 m-70 -141.48 149.04 40.41 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.681 -0.69 . . . . 0.0 109.947 178.207 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 237' ' ' LYS . . . . . 0.648 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.32 -0.685 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.498 -175.349 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 252' ' ' GLN . . . . . 0.48 ' HA ' ' HE1' ' A' ' 236' ' ' HIS . 2.7 mm100 . . . . . 0 N--CA 1.449 -0.481 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . 0.458 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -113.76 121.92 5.61 Favored Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.126 -1.035 . . . . 0.0 112.305 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 254' ' ' THR . . . . . 0.446 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 65.7 p -104.16 116.71 32.67 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 177.418 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 17.0 pt -123.84 147.38 28.27 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.981 -173.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 85.6 m -95.71 110.92 22.98 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 174.449 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.421 HG22 ' O ' ' A' ' 257' ' ' VAL . 34.0 m -89.8 143.14 11.82 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.723 0 C-N-CA 119.93 -0.708 . . . . 0.0 112.833 -168.137 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 34.4 t -91.91 7.39 42.29 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 114.454 -1.248 . . . . 0.0 108.667 169.77 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 259' ' ' ALA . . . . . 0.828 ' HB3' HD23 ' A' ' 262' ' ' LEU . . . -88.25 175.08 7.83 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-N 115.473 -0.785 . . . . 0.0 109.243 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 32.5 t -134.67 130.19 35.95 Favored 'General case' 0 C--N 1.323 -0.547 0 C-N-CA 120.465 -0.494 . . . . 0.0 111.57 -177.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 97.5 16.76 33.29 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.856 -0.688 . . . . 0.0 113.951 174.081 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 262' ' ' LEU . . . . . 0.828 HD23 ' HB3' ' A' ' 259' ' ' ALA . 2.0 mm? -65.7 128.92 37.91 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-N 117.344 0.572 . . . . 0.0 110.859 -178.841 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -128.83 175.39 8.67 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 176.335 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 43.4 t -78.64 131.2 34.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 174.325 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 100.15 9.19 48.92 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.627 -0.797 . . . . 0.0 112.699 -179.557 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -86.12 165.45 16.58 Favored 'General case' 0 CA--C 1.511 -0.521 0 CA-C-O 121.12 0.486 . . . . 0.0 110.147 175.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 267' ' ' ALA . . . . . 0.68 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -140.27 145.68 37.6 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.471 -179.575 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 268' ' ' PHE . . . . . 0.583 ' HA ' HD23 ' A' ' 335' ' ' LEU . 4.6 p90 -159.73 166.04 31.28 Favored 'General case' 0 C--N 1.319 -0.744 0 C-N-CA 120.127 -0.629 . . . . 0.0 111.328 -178.603 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 71.8 p -119.34 126.76 52.19 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.861 -0.608 . . . . 0.0 109.968 177.776 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 270' ' ' ILE . . . . . 0.636 HG12 HD12 ' A' ' 332' ' ' ILE . 46.6 mt -88.89 135.98 24.5 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.912 -177.49 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -65.31 122.16 16.5 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.23 -179.772 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 99.08 -23.86 34.64 Favored Glycine 0 N--CA 1.452 -0.256 0 CA-C-N 115.996 -0.547 . . . . 0.0 112.241 -179.392 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 49.0 t -94.22 108.42 20.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 121.152 0.501 . . . . 0.0 110.37 176.528 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 274' ' ' ASN . . . . . 0.41 ' HB2' ' OD1' ' A' ' 323' ' ' ASP . 63.7 m-80 -123.9 159.99 28.47 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 116.004 -0.544 . . . . 0.0 109.602 -179.398 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 53.1 p -92.04 164.68 13.52 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-O 121.124 0.487 . . . . 0.0 111.327 -179.048 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 30.0 m -125.9 167.46 20.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.544 178.518 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 28.9 m80 -126.0 92.07 3.51 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.595 -0.275 . . . . 0.0 110.72 178.69 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 84.1 mt-30 -72.59 -14.13 61.54 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.769 0.319 . . . . 0.0 111.081 179.184 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 279' ' ' ILE . . . . . 0.469 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.2 mp -77.05 -59.95 2.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 116.539 -0.3 . . . . 0.0 110.319 -178.475 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 51.4 p -85.36 -10.02 56.85 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.454 -179.878 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 31.9 mmmt 58.35 43.81 19.39 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.7 -178.29 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -112.34 154.49 25.64 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.1 -178.357 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 49.8 p -105.96 123.01 47.3 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 176.731 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 284' ' ' THR . . . . . 0.459 ' HB ' ' HG3' ' A' ' 286' ' ' GLN . 82.0 p -124.53 -37.28 2.52 Favored 'General case' 0 C--N 1.317 -0.814 0 C-N-CA 120.487 -0.485 . . . . 0.0 111.508 -172.06 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 70.45 29.49 69.92 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.601 -0.809 . . . . 0.0 111.809 -177.394 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 286' ' ' GLN . . . . . 0.459 ' HG3' ' HB ' ' A' ' 284' ' ' THR . 24.4 mt-30 -76.25 113.87 32.43 Favored Pre-proline 0 C--N 1.33 -0.243 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.826 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 287' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_exo -51.65 126.55 19.97 Favored 'Trans proline' 0 C--O 1.232 0.224 0 C-N-CA 122.42 2.08 . . . . 0.0 111.928 -179.112 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -77.23 130.06 36.74 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 -175.018 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 57.6 t -90.01 130.74 38.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.006 -176.108 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 290' ' ' PHE . . . . . 0.68 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 4.6 m-85 -98.79 151.18 21.07 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.05 -178.062 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 291' ' ' ARG . . . . . 0.484 ' HD2' ' C ' ' A' ' 290' ' ' PHE . 1.0 OUTLIER -113.18 130.09 56.32 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 174.172 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . 0.462 HG12 HG13 ' A' ' 300' ' ' VAL . 47.9 t -92.49 129.51 42.96 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.231 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.923 -177.625 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 293' ' ' LEU . . . . . 0.525 HD23 ' N ' ' A' ' 293' ' ' LEU . 3.1 mm? -114.6 -20.7 10.6 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.684 -179.251 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 294' ' ' ALA . . . . . . . . . . . . . . . -148.92 136.61 20.49 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.641 -0.424 . . . . 0.0 111.914 -179.303 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 295' ' ' VAL . . . . . 0.452 HG11 ' O ' ' A' ' 262' ' ' LEU . 80.4 t -142.7 123.0 10.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.681 -0.691 . . . . 0.0 109.79 175.515 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 36.2 t -154.09 108.66 3.06 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.58 -0.282 . . . . 0.0 110.742 179.158 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 63.57 54.8 29.21 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 121.031 -0.604 . . . . 0.0 112.189 -179.296 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 58.4 p 52.28 21.89 1.82 Allowed 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 123.725 0.81 . . . . 0.0 112.754 -176.764 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 45.8 m -107.64 117.83 35.13 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 173.911 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . 0.607 HG11 HG22 ' A' ' 302' ' ' ILE . 48.1 t -117.08 129.96 72.78 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.299 -172.041 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 45.1 m -98.21 116.75 31.09 Favored 'General case' 0 C--O 1.236 0.381 0 N-CA-C 108.744 -0.835 . . . . 0.0 108.744 174.718 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 302' ' ' ILE . . . . . 0.607 HG22 HG11 ' A' ' 300' ' ' VAL . 29.2 pt -111.81 146.17 17.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 113.373 0.879 . . . . 0.0 113.373 -168.627 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 303' ' ' SER . . . . . 0.519 ' HB3' ' HA ' ' A' ' 304' ' ' PRO . 47.4 m -132.25 166.24 30.15 Favored Pre-proline 0 C--N 1.32 -0.698 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 171.899 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 304' ' ' PRO . . . . . 0.519 ' HA ' ' HB3' ' A' ' 303' ' ' SER . 6.0 Cg_exo -79.67 -142.71 0.24 Allowed 'Cis proline' 0 CA--C 1.531 0.327 0 CA-C-N 120.72 1.293 . . . . 0.0 112.636 0.291 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 305' ' ' LYS . . . . . 0.456 ' HD2' ' O ' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -97.51 147.6 24.08 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.389 0.614 . . . . 0.0 112.152 178.784 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 306' ' ' ILE . . . . . 0.589 HG23 HG22 ' A' ' 322' ' ' VAL . 1.9 mp -119.83 110.35 28.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 115.043 -0.98 . . . . 0.0 110.131 -176.534 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 307' ' ' LEU . . . . . 0.423 ' HA ' ' HD3' ' A' ' 308' ' ' PRO . 88.6 mt -126.32 115.08 23.48 Favored Pre-proline 0 C--N 1.332 -0.183 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.221 -177.697 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 308' ' ' PRO . . . . . 0.767 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 35.3 Cg_exo -67.31 147.81 78.83 Favored 'Trans proline' 0 N--CA 1.474 0.339 0 C-N-CA 123.762 2.975 . . . . 0.0 114.714 -173.521 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . 0.635 HG23 ' HB3' ' A' ' 320' ' ' ALA . 26.2 t -93.34 -17.81 7.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 114.866 -1.061 . . . . 0.0 108.607 167.654 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 59.4 mm-40 -76.9 -6.71 53.57 Favored 'General case' 0 C--O 1.233 0.199 0 CA-C-N 115.23 -0.895 . . . . 0.0 112.117 -178.157 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 4.1 m120 -85.62 151.47 23.87 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.917 0.389 . . . . 0.0 111.101 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 30.9 m -93.28 -1.16 56.37 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.579 0.704 . . . . 0.0 109.125 175.347 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 313' ' ' ASP . . . . . 0.638 ' O ' ' HG3' ' A' ' 317' ' ' ARG . 59.7 t0 -58.0 117.57 4.47 Favored 'General case' 0 C--N 1.333 -0.116 0 CA-C-N 115.328 -0.851 . . . . 0.0 110.781 -179.292 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 49.0 t -53.54 -33.8 22.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.835 -0.62 . . . . 0.0 112.172 -178.446 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -85.18 -29.81 24.43 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 112.183 0.438 . . . . 0.0 112.183 -178.017 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 316' ' ' SER . . . . . 0.533 ' HB3' ' HB3' ' A' ' 313' ' ' ASP . 33.5 t -82.03 -27.74 32.88 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 111.759 0.281 . . . . 0.0 111.759 -175.133 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 317' ' ' ARG . . . . . 0.638 ' HG3' ' O ' ' A' ' 313' ' ' ASP . 49.8 mtp85 -63.98 -52.87 53.24 Favored Pre-proline 0 CA--C 1.539 0.548 0 N-CA-C 112.935 0.717 . . . . 0.0 112.935 -176.478 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 318' ' ' PRO . . . . . 0.596 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 22.1 Cg_exo -67.82 -28.93 35.95 Favored 'Trans proline' 0 C--N 1.357 0.991 0 C-N-CA 121.979 1.786 . . . . 0.0 112.871 -177.005 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 319' ' ' TYR . . . . . 0.41 ' O ' HD13 ' A' ' 307' ' ' LEU . 5.1 m-85 -98.42 12.84 33.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.017 -179.005 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . 0.635 ' HB3' HG23 ' A' ' 309' ' ' VAL . . . -59.76 144.27 48.76 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.539 -178.666 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 17.5 p30 -142.98 -12.17 0.75 Allowed 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.53 -177.434 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 322' ' ' VAL . . . . . 0.589 HG22 HG23 ' A' ' 306' ' ' ILE . 35.0 m -139.15 178.65 3.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.404 177.658 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 323' ' ' ASP . . . . . 0.41 ' OD1' ' HB2' ' A' ' 274' ' ' ASN . 51.6 m-20 -64.01 -62.58 1.54 Allowed 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.978 176.87 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 324' ' ' ALA . . . . . 0.767 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -162.94 173.75 13.24 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 116.143 -0.481 . . . . 0.0 112.094 -175.44 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 22.0 pttp -119.28 106.97 42.04 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 115.218 -0.901 . . . . 0.0 109.457 172.277 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -86.29 167.52 9.13 Favored 'Trans proline' 0 C--O 1.235 0.367 0 C-N-CA 122.624 2.216 . . . . 0.0 113.507 -172.204 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 327' ' ' ALA . . . . . 0.429 ' O ' ' HB2' ' A' ' 328' ' ' GLU . . . -79.48 132.79 36.44 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 170.155 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 328' ' ' GLU . . . . . 0.429 ' HB2' ' O ' ' A' ' 327' ' ' ALA . 62.1 mm-40 73.27 166.25 0.3 Allowed 'General case' 0 N--CA 1.467 0.387 0 O-C-N 123.566 0.542 . . . . 0.0 109.576 -170.589 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 329' ' ' SER . . . . . 0.647 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 53.9 m -104.44 -10.53 17.64 Favored 'General case' 0 C--N 1.319 -0.731 0 C-N-CA 120.349 -0.54 . . . . 0.0 111.803 -174.265 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 330' ' ' ALA . . . . . 0.419 ' HB1' ' H ' ' A' ' 331' ' ' ALA . . . 67.62 -161.22 0.22 Allowed 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 113.022 0.749 . . . . 0.0 113.022 172.459 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 331' ' ' ALA . . . . . 0.419 ' H ' ' HB1' ' A' ' 330' ' ' ALA . . . -75.33 142.72 43.15 Favored 'General case' 0 CA--C 1.518 -0.275 0 CA-C-N 115.117 -0.947 . . . . 0.0 110.475 179.414 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 332' ' ' ILE . . . . . 0.859 HG13 HG22 ' A' ' 230' ' ' VAL . 24.8 mm -120.62 144.46 29.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.753 -175.783 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 33.8 m -111.27 97.63 6.92 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 178.404 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 39.5 mm -81.57 131.54 33.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 112.769 0.655 . . . . 0.0 112.769 -173.247 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 335' ' ' LEU . . . . . 0.583 HD23 ' HA ' ' A' ' 268' ' ' PHE . 1.7 pt? -152.03 -167.16 2.69 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 114.685 -1.143 . . . . 0.0 108.723 173.118 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 15.9 p-10 -110.88 -25.41 9.87 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 109.635 -0.505 . . . . 0.0 109.635 176.014 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 27.1 tptp . . . . . 0 C--O 1.247 0.925 0 O-C-N 124.397 1.061 . . . . 0.0 111.407 177.506 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 61.1 p . . . . . 0 N--CA 1.453 -0.32 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 228' ' ' LEU . . . . . 0.569 ' HB3' ' CB ' ' A' ' 259' ' ' ALA . 53.4 mt -111.15 127.1 55.47 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.491 -173.31 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 229' ' ' THR . . . . . 0.499 ' HA ' ' HA ' ' A' ' 331' ' ' ALA . 64.3 p -129.91 -178.83 4.88 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 120.694 -0.402 . . . . 0.0 111.22 -178.822 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 230' ' ' VAL . . . . . 0.731 ' O ' ' HB2' ' A' ' 329' ' ' SER . 34.9 t -134.17 151.59 32.61 Favored 'Isoleucine or valine' 0 C--O 1.24 0.594 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 -179.43 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 41.7 t -126.89 125.37 41.48 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.23 175.383 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 87.61 91.75 1.02 Allowed Glycine 0 CA--C 1.52 0.382 0 C-N-CA 120.888 -0.673 . . . . 0.0 113.97 176.15 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 233' ' ' GLN . . . . . 0.559 ' HG2' ' OG ' ' A' ' 329' ' ' SER . 94.8 mm-40 -97.86 117.01 65.66 Favored Pre-proline 0 CA--C 1.519 -0.242 0 O-C-N 122.821 -0.223 . . . . 0.0 110.623 171.843 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 234' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 233' ' ' GLN . 11.8 Cg_exo -67.09 172.93 9.18 Favored 'Trans proline' 0 N--CA 1.462 -0.353 0 C-N-CA 122.685 2.257 . . . . 0.0 111.741 176.565 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 235' ' ' GLU . . . . . 0.413 ' HG3' ' HE2' ' A' ' 237' ' ' LYS . 9.7 pt-20 -96.42 146.91 24.36 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.013 178.058 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 236' ' ' HIS . . . . . 0.615 ' C ' ' HD2' ' A' ' 237' ' ' LYS . 28.6 m80 -126.07 129.78 49.81 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.088 0.471 . . . . 0.0 111.01 -173.953 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 237' ' ' LYS . . . . . 0.615 ' HD2' ' C ' ' A' ' 236' ' ' HIS . 2.8 mptp? . . . . . 0 C--N 1.323 -0.546 0 CA-C-N 115.441 -0.799 . . . . 0.0 110.0 -179.114 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 252' ' ' GLN . . . . . 0.525 ' HA ' HE21 ' A' ' 252' ' ' GLN . 2.2 mm100 . . . . . 0 N--CA 1.447 -0.591 0 N-CA-C 110.043 -0.354 . . . . 0.0 110.043 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . 0.452 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -154.47 172.58 32.98 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 119.667 -1.254 . . . . 0.0 113.032 -178.965 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 254' ' ' THR . . . . . 0.532 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 47.0 p -119.38 128.81 54.41 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 177.822 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . 0.472 HD12 HG13 ' A' ' 230' ' ' VAL . 26.6 pt -114.66 149.73 16.83 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.357 -175.659 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 40.8 m -98.4 110.47 23.05 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 177.223 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . . . . . . . . . 35.0 m -92.41 144.99 8.15 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.859 0 CA-C-O 121.631 0.729 . . . . 0.0 112.697 -171.123 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 41.1 m -90.3 7.75 36.83 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 114.046 -1.434 . . . . 0.0 108.41 168.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 259' ' ' ALA . . . . . 0.569 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -91.06 162.04 14.86 Favored 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 115.117 -0.947 . . . . 0.0 110.468 -177.497 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 48.7 m -137.82 138.91 39.64 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.122 -0.49 . . . . 0.0 109.814 177.36 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 94.55 34.26 6.4 Favored Glycine 0 N--CA 1.447 -0.586 0 C-N-CA 120.444 -0.884 . . . . 0.0 112.233 -178.42 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 262' ' ' LEU . . . . . 0.423 ' O ' HG11 ' A' ' 295' ' ' VAL . 67.5 mt -102.37 143.39 32.18 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 178.361 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 3.0 mm100 -142.78 175.32 9.91 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 178.116 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 49.0 t -78.17 132.48 32.37 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.202 177.698 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 103.77 8.24 40.24 Favored Glycine 0 N--CA 1.453 -0.211 0 C-N-CA 120.569 -0.824 . . . . 0.0 112.775 179.406 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -89.05 157.56 18.3 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.915 0.388 . . . . 0.0 110.066 176.838 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 267' ' ' ALA . . . . . 0.588 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -131.23 121.94 25.68 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 178.883 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 268' ' ' PHE . . . . . . . . . . . . . 4.6 p90 -145.14 164.57 30.87 Favored 'General case' 0 C--N 1.32 -0.706 0 C-N-CA 119.4 -0.92 . . . . 0.0 111.988 -173.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 75.7 p -117.64 129.6 55.85 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.531 -0.759 . . . . 0.0 109.76 176.191 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 270' ' ' ILE . . . . . 0.444 HG21 HD13 ' A' ' 270' ' ' ILE . 66.0 mt -97.54 141.52 15.75 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.766 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 179.838 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -63.98 132.84 51.87 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.032 0.444 . . . . 0.0 111.438 -176.577 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 98.68 -22.35 41.37 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.992 -0.623 . . . . 0.0 112.158 -178.56 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . 0.683 HG21 ' HG2' ' A' ' 326' ' ' PRO . 45.2 t -77.95 103.44 5.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 120.665 0.269 . . . . 0.0 110.459 178.476 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 274' ' ' ASN . . . . . 0.405 ' O ' ' HB ' ' A' ' 322' ' ' VAL . 3.3 m120 -96.72 136.97 36.51 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 108.79 -0.819 . . . . 0.0 108.79 174.842 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 8.1 t -99.48 165.58 11.57 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.773 0.321 . . . . 0.0 110.399 -176.219 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 19.0 m -128.76 155.49 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.014 0 CA-C-N 115.092 -0.958 . . . . 0.0 109.987 167.271 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 277' ' ' HIS . . . . . 0.615 ' HB2' ' HB3' ' A' ' 282' ' ' ASP . 29.3 m80 -100.41 89.74 4.06 Favored 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 108.547 -0.909 . . . . 0.0 108.547 175.148 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 5.3 tm0? -59.78 -47.54 85.3 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.091 -172.139 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 279' ' ' ILE . . . . . 0.41 HD13 HG22 ' A' ' 279' ' ' ILE . 59.2 mt -56.44 -48.15 80.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 N-CA-C 111.942 0.349 . . . . 0.0 111.942 -177.166 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 40.6 p -94.97 -3.71 48.0 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 112.414 0.524 . . . . 0.0 112.414 -176.3 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 4.0 tppp? 59.22 53.2 5.52 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 121.285 0.564 . . . . 0.0 110.256 -178.337 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 282' ' ' ASP . . . . . 0.615 ' HB3' ' HB2' ' A' ' 277' ' ' HIS . 37.2 t70 -120.13 116.37 25.52 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.299 -175.416 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 67.8 p -107.16 118.17 35.99 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.3 178.83 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 67.5 p -129.05 -15.98 4.14 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 112.063 0.394 . . . . 0.0 112.063 -174.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 87.23 -3.09 86.89 Favored Glycine 0 N--CA 1.453 -0.179 0 C-N-CA 120.61 -0.805 . . . . 0.0 112.724 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 286' ' ' GLN . . . . . 0.448 ' HA ' ' HD3' ' A' ' 287' ' ' PRO . 82.9 mt-30 -64.76 137.92 97.3 Favored Pre-proline 0 C--N 1.33 -0.27 0 N-CA-C 110.425 -0.213 . . . . 0.0 110.425 179.006 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 287' ' ' PRO . . . . . 0.577 ' HA ' ' O ' ' A' ' 273' ' ' VAL . 32.8 Cg_exo -62.52 149.37 91.23 Favored 'Trans proline' 0 CA--C 1.529 0.257 0 C-N-CA 122.633 2.222 . . . . 0.0 113.448 -174.558 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 288' ' ' GLN . . . . . 0.526 ' HA ' HE21 ' A' ' 288' ' ' GLN . 1.9 tp-100 -87.06 136.82 32.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.075 176.989 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 38.8 t -94.55 130.15 43.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.901 -0.591 . . . . 0.0 109.645 177.592 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 290' ' ' PHE . . . . . 0.588 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 53.6 m-85 -99.97 165.52 11.5 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.926 0.393 . . . . 0.0 111.772 -175.145 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 30.3 mmt-85 -119.76 127.98 53.32 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 174.075 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 57.7 t -86.6 130.74 36.26 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.886 0 CA-C-O 120.785 0.326 . . . . 0.0 111.583 -175.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 293' ' ' LEU . . . . . 0.502 HD23 ' HB2' ' A' ' 303' ' ' SER . 3.1 mm? -103.58 -34.88 8.5 Favored 'General case' 0 C--N 1.333 -0.112 0 CA-C-N 115.945 -0.571 . . . . 0.0 111.297 178.503 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 294' ' ' ALA . . . . . 0.508 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -154.22 140.1 18.19 Favored 'General case' 0 CA--C 1.518 -0.252 0 C-N-CA 120.648 -0.421 . . . . 0.0 111.593 -179.149 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 295' ' ' VAL . . . . . 0.423 HG11 ' O ' ' A' ' 262' ' ' LEU . 96.9 t -135.73 100.09 2.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.705 175.016 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 50.5 m -141.77 118.29 10.92 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.845 -176.33 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 63.93 46.5 91.36 Favored Glycine 0 C--N 1.33 0.236 0 C-N-CA 121.147 -0.549 . . . . 0.0 112.144 -178.018 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 72.2 p 51.0 23.54 1.53 Allowed 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 123.701 0.8 . . . . 0.0 112.221 -175.739 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 299' ' ' THR . . . . . 0.441 ' HA ' ' O ' ' A' ' 255' ' ' ILE . 50.7 m -114.0 118.47 34.22 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 176.609 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . 0.547 HG11 HG21 ' A' ' 302' ' ' ILE . 43.6 t -110.18 128.39 66.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.412 -172.515 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 59.3 m -83.97 114.14 21.49 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 108.091 -1.078 . . . . 0.0 108.091 171.568 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 302' ' ' ILE . . . . . 0.547 HG21 HG11 ' A' ' 300' ' ' VAL . 31.0 pt -111.01 144.76 18.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 N-CA-C 113.279 0.844 . . . . 0.0 113.279 -167.059 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 303' ' ' SER . . . . . 0.513 ' HA ' ' O ' ' A' ' 304' ' ' PRO . 50.4 m -149.6 157.7 38.43 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-N 114.041 -1.436 . . . . 0.0 107.409 173.018 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 304' ' ' PRO . . . . . 0.513 ' O ' ' HA ' ' A' ' 303' ' ' SER . 15.7 Cg_exo -69.27 -162.21 1.72 Allowed 'Cis proline' 0 CA--C 1.531 0.34 0 CA-C-N 120.151 1.09 . . . . 0.0 112.811 0.742 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 305' ' ' LYS . . . . . 0.577 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -95.27 142.38 27.75 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.401 0.619 . . . . 0.0 111.964 -178.124 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 306' ' ' ILE . . . . . 0.484 ' N ' HD13 ' A' ' 306' ' ' ILE . 2.0 mp -86.35 84.92 2.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.079 -0.964 . . . . 0.0 109.939 -178.397 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 307' ' ' LEU . . . . . . . . . . . . . 96.8 mt -112.38 102.45 54.17 Favored Pre-proline 0 C--N 1.324 -0.501 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.579 -178.757 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 308' ' ' PRO . . . . . 0.626 ' HD2' HD21 ' A' ' 311' ' ' ASN . 12.4 Cg_exo -75.5 150.29 35.86 Favored 'Trans proline' 0 N--CA 1.462 -0.334 0 C-N-CA 122.898 2.399 . . . . 0.0 113.004 -174.398 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . 0.726 HG21 ' HB2' ' A' ' 320' ' ' ALA . 42.5 t -72.26 -27.3 26.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 108.647 -0.872 . . . . 0.0 108.647 170.305 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 54.7 mm-40 -92.21 32.68 1.14 Allowed 'General case' 0 N--CA 1.453 -0.285 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.805 176.3 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.626 HD21 ' HD2' ' A' ' 308' ' ' PRO . 26.0 t-20 -71.98 -31.93 66.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.378 -178.336 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 312' ' ' THR . . . . . 0.47 ' HB ' ' O ' ' A' ' 311' ' ' ASN . 84.9 m 83.34 -25.43 0.14 Allowed 'General case' 0 N--CA 1.469 0.491 0 O-C-N 124.088 0.867 . . . . 0.0 111.116 -178.837 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 65.8 m-20 -81.89 122.9 28.33 Favored 'General case' 0 C--O 1.233 0.216 0 C-N-CA 120.522 -0.471 . . . . 0.0 109.96 172.571 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 38.8 t -59.35 -39.38 78.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 115.188 -0.914 . . . . 0.0 112.229 -173.092 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -66.22 -25.27 66.83 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 112.229 0.455 . . . . 0.0 112.229 -177.332 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 42.4 t -86.54 -12.59 48.32 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 111.773 0.286 . . . . 0.0 111.773 -177.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 317' ' ' ARG . . . . . 0.554 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 51.8 mtp85 -62.8 -50.61 76.78 Favored Pre-proline 0 CA--C 1.538 0.492 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 -178.503 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 318' ' ' PRO . . . . . 0.554 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 39.2 Cg_exo -63.32 -26.05 71.48 Favored 'Trans proline' 0 C--N 1.356 0.936 0 C-N-CA 121.903 1.735 . . . . 0.0 112.788 -177.755 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 6.0 m-85 -93.23 19.99 7.47 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.335 -179.409 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . 0.726 ' HB2' HG21 ' A' ' 309' ' ' VAL . . . -59.49 131.02 49.68 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 112.31 0.485 . . . . 0.0 112.31 -175.799 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 76.3 m-20 -128.15 -18.38 4.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.507 -0.77 . . . . 0.0 110.255 175.052 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 322' ' ' VAL . . . . . 0.489 ' O ' ' HA ' ' A' ' 308' ' ' PRO . 33.8 m -138.7 176.75 5.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.107 -179.576 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -98.74 -18.97 17.73 Favored 'General case' 0 C--N 1.327 -0.385 0 C-N-CA 121.002 -0.279 . . . . 0.0 111.123 -179.773 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 324' ' ' ALA . . . . . 0.461 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -168.62 156.67 8.1 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.98 -173.117 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 325' ' ' LYS . . . . . 0.411 ' HA ' ' HD3' ' A' ' 326' ' ' PRO . 35.4 mtmm -87.02 120.87 71.71 Favored Pre-proline 0 N--CA 1.453 -0.294 0 N-CA-C 107.618 -1.252 . . . . 0.0 107.618 165.442 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 326' ' ' PRO . . . . . 0.683 ' HG2' HG21 ' A' ' 273' ' ' VAL . 51.1 Cg_exo -61.14 162.81 18.53 Favored 'Trans proline' 0 C--O 1.233 0.274 0 C-N-CA 122.525 2.15 . . . . 0.0 113.612 -171.372 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -73.45 132.35 42.84 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 108.593 -0.891 . . . . 0.0 108.593 170.896 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 9.0 pm0 42.38 -137.46 0.25 Allowed 'General case' 0 N--CA 1.47 0.565 0 O-C-N 124.132 0.895 . . . . 0.0 110.338 -169.757 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 329' ' ' SER . . . . . 0.731 ' HB2' ' O ' ' A' ' 230' ' ' VAL . 38.1 m -113.98 -44.87 3.11 Favored 'General case' 0 C--N 1.322 -0.622 0 C-N-CA 119.797 -0.761 . . . . 0.0 111.604 176.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 330' ' ' ALA . . . . . 0.461 ' HB2' ' O ' ' A' ' 329' ' ' SER . . . 78.54 -166.66 0.04 OUTLIER 'General case' 0 N--CA 1.474 0.771 0 O-C-N 123.813 0.696 . . . . 0.0 112.52 176.169 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 331' ' ' ALA . . . . . 0.499 ' HA ' ' HA ' ' A' ' 229' ' ' THR . . . -84.95 157.92 20.67 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.755 -0.657 . . . . 0.0 112.386 -173.764 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 332' ' ' ILE . . . . . 0.501 HG23 HD12 ' A' ' 332' ' ' ILE . 29.1 mt -110.0 144.97 17.15 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.232 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.083 -179.223 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 54.4 m -111.45 98.46 7.48 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 172.35 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 334' ' ' ILE . . . . . 0.477 HD11 HG22 ' A' ' 334' ' ' ILE . 32.2 mm -84.96 134.79 26.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 N-CA-C 113.247 0.832 . . . . 0.0 113.247 -171.074 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 335' ' ' LEU . . . . . 0.409 HD21 ' O ' ' A' ' 267' ' ' ALA . 1.9 pt? -164.39 -166.16 1.07 Allowed 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 115.074 -0.966 . . . . 0.0 109.62 172.418 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 74.3 m-80 -143.84 21.39 1.8 Allowed 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 175.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 68.2 mttm . . . . . 0 C--O 1.242 0.66 0 CA-C-N 115.196 -0.911 . . . . 0.0 110.84 -174.371 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 51.8 m . . . . . 0 C--O 1.234 0.285 0 CA-C-O 121.051 0.453 . . . . 0.0 111.906 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 228' ' ' LEU . . . . . 0.537 HD13 ' HB1' ' A' ' 259' ' ' ALA . 88.8 mt -68.77 144.77 54.24 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.317 173.891 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 229' ' ' THR . . . . . 0.414 ' O ' HG23 ' A' ' 230' ' ' VAL . 40.7 p -132.29 179.32 6.18 Favored 'General case' 0 C--N 1.326 -0.441 0 C-N-CA 120.262 -0.575 . . . . 0.0 111.137 -176.998 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 230' ' ' VAL . . . . . 0.757 HG21 HG13 ' A' ' 257' ' ' VAL . 72.1 t -143.22 145.87 22.15 Favored 'Isoleucine or valine' 0 C--O 1.239 0.532 0 CA-C-O 120.775 0.322 . . . . 0.0 110.373 -179.446 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 46.2 t -131.74 97.58 4.24 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 115.234 -0.894 . . . . 0.0 109.181 173.818 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . -142.15 -157.53 7.19 Favored Glycine 0 N--CA 1.447 -0.6 0 C-N-CA 120.184 -1.008 . . . . 0.0 112.639 -176.008 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 83.5 mt-30 -86.1 159.98 52.95 Favored Pre-proline 0 C--N 1.323 -0.571 0 N-CA-C 110.396 -0.224 . . . . 0.0 110.396 179.775 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo -64.51 174.66 4.15 Favored 'Trans proline' 0 C--N 1.35 0.619 0 C-N-CA 122.875 2.383 . . . . 0.0 111.418 176.357 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 235' ' ' GLU . . . . . 0.553 ' HA ' ' OE1' ' A' ' 235' ' ' GLU . 3.9 mm-40 -91.9 167.54 12.05 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 113.461 0.911 . . . . 0.0 113.461 -174.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 236' ' ' HIS . . . . . 0.504 ' CE1' ' HA2' ' A' ' 253' ' ' GLY . 23.2 m80 -111.63 143.21 42.89 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 113.266 -1.788 . . . . 0.0 111.432 -165.239 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 237' ' ' LYS . . . . . 0.46 ' HD3' ' C ' ' A' ' 236' ' ' HIS . 18.7 mmtp . . . . . 0 C--N 1.317 -0.833 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.793 -173.461 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 252' ' ' GLN . . . . . 0.484 ' HB3' ' O ' ' A' ' 302' ' ' ILE . 3.0 mm100 . . . . . 0 CA--C 1.527 0.095 0 CA-C-O 120.503 0.192 . . . . 0.0 110.729 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . 0.504 ' HA2' ' CE1' ' A' ' 236' ' ' HIS . . . -95.5 152.22 20.29 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.184 177.877 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 52.1 p -129.5 116.96 19.73 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.758 0.314 . . . . 0.0 110.588 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . 0.404 ' HB ' ' CG1' ' A' ' 230' ' ' VAL . 18.0 pt -125.94 149.92 31.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 N-CA-C 112.25 0.463 . . . . 0.0 112.25 -175.798 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 256' ' ' THR . . . . . 0.499 ' O ' HG13 ' A' ' 230' ' ' VAL . 91.5 m -98.86 113.35 25.43 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 175.124 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.757 HG13 HG21 ' A' ' 230' ' ' VAL . 34.8 m -90.12 143.26 11.56 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.669 0 N-CA-C 113.38 0.881 . . . . 0.0 113.38 -167.009 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 37.4 t -92.73 7.94 41.44 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 113.795 -1.548 . . . . 0.0 108.523 168.163 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 259' ' ' ALA . . . . . 0.537 ' HB1' HD13 ' A' ' 228' ' ' LEU . . . -84.77 165.78 17.51 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-N 115.616 -0.72 . . . . 0.0 109.822 -177.344 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 49.4 m -123.47 142.0 51.44 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 120.814 0.34 . . . . 0.0 111.443 -178.005 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 67.3 50.65 43.27 Favored Glycine 0 N--CA 1.452 -0.25 0 CA-C-N 115.812 -0.631 . . . . 0.0 113.58 175.317 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 262' ' ' LEU . . . . . 0.711 HD12 HG22 ' A' ' 257' ' ' VAL . 77.7 mt -99.64 145.83 27.15 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 117.086 0.443 . . . . 0.0 110.842 178.034 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 83.6 mt-30 -142.94 171.75 13.63 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.928 178.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 264' ' ' VAL . . . . . 0.441 HG12 ' O ' ' A' ' 292' ' ' VAL . 50.8 t -77.16 133.32 31.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 176.731 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . 0.466 ' O ' ' HE3' ' A' ' 337' ' ' LYS . . . 107.62 -7.83 36.76 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.44 -0.886 . . . . 0.0 112.619 -179.372 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 266' ' ' ASP . . . . . 0.568 ' HB2' HG22 ' A' ' 292' ' ' VAL . 63.4 m-20 -69.28 155.63 40.09 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-O 121.069 0.462 . . . . 0.0 110.567 178.262 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 267' ' ' ALA . . . . . 0.601 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -130.2 129.69 43.72 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.45 -0.795 . . . . 0.0 108.884 177.442 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 268' ' ' PHE . . . . . . . . . . . . . 3.2 p90 -151.38 175.63 12.06 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 119.97 -0.692 . . . . 0.0 111.466 -175.456 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 269' ' ' THR . . . . . 0.652 HG23 ' HB2' ' A' ' 287' ' ' PRO . 82.7 p -126.14 147.19 49.67 Favored 'General case' 0 C--N 1.32 -0.674 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 176.571 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 270' ' ' ILE . . . . . 0.429 HG23 HD13 ' A' ' 270' ' ' ILE . 47.1 mm -103.65 138.26 28.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 N-CA-C 110.236 -0.283 . . . . 0.0 110.236 179.381 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -63.34 135.4 56.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.442 -178.608 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 89.41 -23.19 20.02 Favored Glycine 0 CA--C 1.517 0.198 0 CA-C-N 115.92 -0.582 . . . . 0.0 112.712 179.755 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 42.5 t -86.09 130.24 36.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 120.925 0.393 . . . . 0.0 110.879 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 72.3 m-80 -135.24 142.08 45.91 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.329 179.671 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 65.2 p -84.04 165.81 18.25 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.252 0.549 . . . . 0.0 111.746 -178.279 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 35.4 m -113.64 175.82 2.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 115.315 -0.857 . . . . 0.0 110.668 179.432 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 277' ' ' HIS . . . . . 0.418 ' HB3' ' HA ' ' A' ' 281' ' ' LYS . 5.8 p80 22.04 77.75 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.866 0 O-C-N 124.822 1.326 . . . . 0.0 113.866 179.304 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 278' ' ' GLN . . . . . 0.417 ' HG3' HD12 ' A' ' 279' ' ' ILE . 2.7 tp-100 -62.03 -50.52 71.7 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.177 -179.055 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 279' ' ' ILE . . . . . 0.519 ' H ' ' HB3' ' A' ' 282' ' ' ASP . 2.5 mp -104.43 -77.44 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 174.814 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 35.9 p -141.11 92.61 2.5 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 177.477 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 281' ' ' LYS . . . . . 0.418 ' HA ' ' HB3' ' A' ' 277' ' ' HIS . 31.7 mmmt 59.82 26.99 16.23 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.058 -0.973 . . . . 0.0 110.503 -172.6 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 282' ' ' ASP . . . . . 0.519 ' HB3' ' H ' ' A' ' 279' ' ' ILE . 37.3 t70 -81.01 117.38 21.56 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.338 -0.846 . . . . 0.0 109.858 178.605 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 41.1 p -105.52 105.78 15.97 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.991 0.424 . . . . 0.0 110.931 -176.502 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 52.9 p -129.18 -7.58 4.82 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.183 -177.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 67.82 32.6 78.06 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.601 -0.809 . . . . 0.0 113.368 176.249 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 286' ' ' GLN . . . . . 0.4 ' HA ' ' HD3' ' A' ' 287' ' ' PRO . 11.7 mm100 -72.09 135.89 82.32 Favored Pre-proline 0 C--N 1.325 -0.479 0 CA-C-N 117.06 0.43 . . . . 0.0 110.2 179.106 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 287' ' ' PRO . . . . . 0.652 ' HB2' HG23 ' A' ' 269' ' ' THR . 41.0 Cg_exo -57.0 135.0 68.21 Favored 'Trans proline' 0 C--O 1.235 0.333 0 C-N-CA 122.465 2.11 . . . . 0.0 111.958 -178.778 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 2.5 tm0? -75.08 128.93 36.67 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 -177.294 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 46.4 t -94.19 123.83 46.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.935 0.398 . . . . 0.0 110.512 -177.621 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 290' ' ' PHE . . . . . 0.601 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 4.6 m-85 -97.28 168.6 10.32 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.818 -177.214 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 11.9 tpt180 -139.37 121.16 15.41 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 177.355 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . 0.568 HG22 ' HB2' ' A' ' 266' ' ' ASP . 60.7 t -75.61 134.25 29.58 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.913 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.868 -172.824 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 293' ' ' LEU . . . . . 0.5 ' N ' HD13 ' A' ' 293' ' ' LEU . 7.0 mp -104.38 -35.2 8.02 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.628 178.388 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 294' ' ' ALA . . . . . 0.527 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -149.75 137.95 20.51 Favored 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 120.667 -0.413 . . . . 0.0 111.641 -176.545 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 66.5 t -136.03 109.63 9.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.555 174.79 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 50.4 m -151.48 117.02 5.38 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.544 -177.279 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 61.21 46.97 93.4 Favored Glycine 0 C--N 1.33 0.218 0 C-N-CA 120.804 -0.712 . . . . 0.0 111.79 -177.83 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 76.3 p 51.78 19.79 1.01 Allowed 'General case' 0 N--CA 1.471 0.587 0 C-N-CA 123.76 0.824 . . . . 0.0 112.427 -175.169 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 54.3 m -105.22 116.68 32.35 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 176.756 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . 0.578 HG12 HG23 ' A' ' 302' ' ' ILE . 49.0 t -114.21 125.77 71.58 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.288 -172.753 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 53.9 m -87.77 115.76 25.44 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 172.78 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 302' ' ' ILE . . . . . 0.578 HG23 HG12 ' A' ' 300' ' ' VAL . 28.6 pt -110.81 147.81 14.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-O 121.867 0.842 . . . . 0.0 113.156 -169.012 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 303' ' ' SER . . . . . 0.499 ' HB3' HD11 ' A' ' 293' ' ' LEU . 48.2 t -151.23 148.82 23.27 Favored Pre-proline 0 C--N 1.317 -0.812 0 CA-C-N 113.808 -1.542 . . . . 0.0 106.911 174.487 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 304' ' ' PRO . . . . . 0.492 ' C ' ' HA ' ' A' ' 303' ' ' SER . 32.2 Cg_exo -64.31 152.71 74.16 Favored 'Cis proline' 0 C--N 1.332 -0.302 0 C-N-CA 124.252 -1.145 . . . . 0.0 113.299 0.969 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 305' ' ' LYS . . . . . 0.584 ' HE3' HD13 ' A' ' 307' ' ' LEU . 0.0 OUTLIER -82.04 148.81 28.41 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-N 114.888 -1.051 . . . . 0.0 110.184 173.761 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 306' ' ' ILE . . . . . 0.828 HG22 ' HA ' ' A' ' 325' ' ' LYS . 42.5 mm -84.23 117.85 30.47 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 N-CA-C 113.02 0.748 . . . . 0.0 113.02 -167.626 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 307' ' ' LEU . . . . . 0.613 HD12 ' O ' ' A' ' 319' ' ' TYR . 82.1 mt -121.46 100.0 44.94 Favored Pre-proline 0 C--N 1.331 -0.199 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.782 177.314 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 308' ' ' PRO . . . . . 0.708 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 16.0 Cg_exo -72.74 134.48 22.06 Favored 'Trans proline' 0 C--O 1.232 0.218 0 C-N-CA 123.19 2.593 . . . . 0.0 113.611 -176.271 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . 0.652 ' HA ' ' HB2' ' A' ' 316' ' ' SER . 46.4 t -72.18 -34.66 50.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.356 0.598 . . . . 0.0 109.409 171.345 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 87.8 mt-10 -77.07 36.27 0.17 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.288 -0.869 . . . . 0.0 111.939 179.777 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 20.3 t-20 -122.3 56.71 1.1 Allowed 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 -178.751 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 312' ' ' THR . . . . . 0.653 ' HB ' HG21 ' A' ' 314' ' ' VAL . 30.0 m 60.35 17.43 7.12 Favored 'General case' 0 CA--C 1.539 0.553 0 CA-C-O 121.716 0.77 . . . . 0.0 109.411 -171.762 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 37.1 t70 69.53 -2.58 1.88 Allowed 'General case' 0 CA--C 1.537 0.466 0 CA-C-N 114.728 -1.124 . . . . 0.0 111.233 -177.369 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 314' ' ' VAL . . . . . 0.653 HG21 ' HB ' ' A' ' 312' ' ' THR . 57.6 t -57.44 -45.59 85.67 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 N-CA-C 112.723 0.638 . . . . 0.0 112.723 -177.759 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . 0.515 ' HB3' ' O ' ' A' ' 308' ' ' PRO . . . -74.44 -17.54 60.77 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.021 0.439 . . . . 0.0 110.899 -179.714 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 316' ' ' SER . . . . . 0.652 ' HB2' ' HA ' ' A' ' 309' ' ' VAL . 44.3 t -81.36 -18.72 44.64 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.552 177.126 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 317' ' ' ARG . . . . . 0.688 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 37.3 mmm-85 -61.1 -55.84 40.34 Favored Pre-proline 0 CA--C 1.536 0.42 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.635 -176.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 318' ' ' PRO . . . . . 0.688 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 11.8 Cg_exo -71.98 -41.13 2.18 Favored 'Trans proline' 0 C--N 1.357 1.003 0 C-N-CA 121.565 1.51 . . . . 0.0 112.588 -178.516 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 319' ' ' TYR . . . . . 0.613 ' O ' HD12 ' A' ' 307' ' ' LEU . 1.0 OUTLIER 177.35 96.67 0.01 OUTLIER 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.103 177.653 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . 0.597 ' HB3' ' HA ' ' A' ' 316' ' ' SER . . . -69.68 138.51 53.02 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.077 176.899 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 19.6 p30 -129.23 -27.9 2.41 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.479 -0.328 . . . . 0.0 111.57 176.833 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 322' ' ' VAL . . . . . 0.434 ' O ' HG22 ' A' ' 309' ' ' VAL . 35.1 m -138.31 179.49 3.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.703 0.287 . . . . 0.0 110.596 177.758 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 -90.38 -32.72 16.33 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.502 177.776 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 324' ' ' ALA . . . . . 0.708 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -149.2 159.51 44.19 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.638 -0.255 . . . . 0.0 111.478 -175.351 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 325' ' ' LYS . . . . . 0.828 ' HA ' HG22 ' A' ' 306' ' ' ILE . 64.3 pttt -79.94 146.9 64.79 Favored Pre-proline 0 N--CA 1.452 -0.335 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 171.413 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -57.33 129.81 36.02 Favored 'Trans proline' 0 N--CA 1.462 -0.365 0 C-N-CA 122.253 1.969 . . . . 0.0 111.873 -178.299 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -75.13 121.79 22.61 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 174.285 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER 61.95 -135.95 0.52 Allowed 'General case' 0 C--N 1.332 -0.158 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 -167.474 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 329' ' ' SER . . . . . 0.712 ' HB2' ' O ' ' A' ' 230' ' ' VAL . 50.5 m -113.95 -41.45 3.55 Favored 'General case' 0 C--N 1.32 -0.711 0 C-N-CA 120.16 -0.616 . . . . 0.0 109.871 169.67 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 79.77 -171.04 0.04 OUTLIER 'General case' 0 N--CA 1.479 1.008 0 O-C-N 124.129 0.893 . . . . 0.0 113.394 170.819 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -83.77 157.22 22.17 Favored 'General case' 0 C--O 1.233 0.213 0 CA-C-N 115.176 -0.92 . . . . 0.0 111.107 -176.823 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 332' ' ' ILE . . . . . 0.42 HG21 HD12 ' A' ' 270' ' ' ILE . 1.5 mp -126.37 146.37 32.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.474 -174.854 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.446 ' HB ' ' OG1' ' A' ' 269' ' ' THR . 88.6 m -110.66 99.16 8.16 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.998 -0.742 . . . . 0.0 108.998 173.251 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 334' ' ' ILE . . . . . 0.573 HD12 HD21 ' A' ' 262' ' ' LEU . 37.8 mm -81.58 125.7 39.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -171.238 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 335' ' ' LEU . . . . . 0.429 ' HB2' ' O ' ' A' ' 267' ' ' ALA . 8.2 mp -113.07 167.3 10.64 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.074 -0.966 . . . . 0.0 109.958 172.167 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 74.0 m-80 -124.33 6.57 8.4 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 115.315 -0.857 . . . . 0.0 109.271 174.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 337' ' ' LYS . . . . . 0.466 ' HE3' ' O ' ' A' ' 265' ' ' GLY . 21.5 pttp . . . . . 0 C--O 1.244 0.798 0 O-C-N 124.656 1.223 . . . . 0.0 112.565 -179.418 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 29.0 t . . . . . 0 N--CA 1.457 -0.114 0 CA-C-O 121.559 0.695 . . . . 0.0 109.499 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 228' ' ' LEU . . . . . 0.581 HD13 ' HB1' ' A' ' 259' ' ' ALA . 89.8 mt -99.77 146.79 26.17 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.274 -0.875 . . . . 0.0 109.237 178.533 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 229' ' ' THR . . . . . 0.533 ' O ' HG21 ' A' ' 230' ' ' VAL . 72.5 p -128.93 178.75 6.16 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 119.835 -0.746 . . . . 0.0 111.075 -177.89 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 230' ' ' VAL . . . . . 0.775 HG23 HD13 ' A' ' 332' ' ' ILE . 75.7 t -147.15 127.68 5.39 Favored 'Isoleucine or valine' 0 C--O 1.237 0.434 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.482 -178.918 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 34.1 t -92.53 145.18 24.64 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.012 176.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 115.46 141.64 7.44 Favored Glycine 0 N--CA 1.444 -0.773 0 C-N-CA 120.619 -0.801 . . . . 0.0 111.647 -179.097 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 233' ' ' GLN . . . . . 0.817 ' HG3' ' H ' ' A' ' 328' ' ' GLU . 15.0 mp0 -101.75 103.69 30.16 Favored Pre-proline 0 C--N 1.321 -0.638 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 -177.739 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -85.3 122.47 2.47 Favored 'Trans proline' 0 N--CA 1.45 -1.084 0 C-N-CA 121.485 1.457 . . . . 0.0 111.751 179.64 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 235' ' ' GLU . . . . . 0.464 ' HG2' ' HB3' ' A' ' 325' ' ' LYS . 54.2 mt-10 -154.07 120.05 5.32 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.328 178.787 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 63.3 t-80 -138.64 146.77 42.08 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 174.474 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 237' ' ' LYS . . . . . 0.653 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 5.8 mptt . . . . . 0 C--N 1.326 -0.415 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.765 -169.484 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 4.7 mp0 . . . . . 0 N--CA 1.444 -0.749 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . 0.588 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -80.75 93.08 1.46 Allowed Glycine 0 N--CA 1.446 -0.643 0 C-N-CA 120.312 -0.947 . . . . 0.0 112.23 177.748 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 72.7 p -94.5 116.33 28.66 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.022 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . 0.65 HD11 HG11 ' A' ' 230' ' ' VAL . 2.1 pp -136.24 171.53 16.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 N-CA-C 113.012 0.745 . . . . 0.0 113.012 -173.121 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 256' ' ' THR . . . . . 0.406 ' O ' HG12 ' A' ' 230' ' ' VAL . 64.9 m -111.65 117.89 34.15 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 177.505 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.501 HG11 HD11 ' A' ' 255' ' ' ILE . 34.9 m -90.9 144.7 8.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 N-CA-C 113.838 1.051 . . . . 0.0 113.838 -169.101 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 39.2 t -92.22 8.42 38.2 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 113.772 -1.558 . . . . 0.0 108.339 166.188 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 259' ' ' ALA . . . . . 0.581 ' HB1' HD13 ' A' ' 228' ' ' LEU . . . -92.85 166.13 12.57 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.274 -0.876 . . . . 0.0 109.908 -177.52 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 32.4 t -139.17 137.09 35.75 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.77 0.319 . . . . 0.0 110.158 178.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 97.26 29.4 7.96 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.199 -177.821 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 262' ' ' LEU . . . . . 0.695 HD22 HD13 ' A' ' 334' ' ' ILE . 79.2 mt -101.63 126.78 48.52 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.107 0.479 . . . . 0.0 111.16 -179.617 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 97.0 mm-40 -134.11 -178.92 5.25 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.257 -0.883 . . . . 0.0 108.873 177.359 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 41.0 t -77.81 131.12 35.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 176.653 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 106.41 9.01 32.16 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.305 -0.95 . . . . 0.0 113.195 179.021 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -88.88 163.32 15.68 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.994 0.426 . . . . 0.0 110.31 176.57 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 267' ' ' ALA . . . . . 0.698 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -135.38 146.52 48.42 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.474 -0.784 . . . . 0.0 109.023 177.917 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 268' ' ' PHE . . . . . . . . . . . . . 2.7 p90 -163.87 175.48 10.38 Favored 'General case' 0 C--N 1.325 -0.489 0 C-N-CA 120.054 -0.658 . . . . 0.0 111.709 -177.841 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 73.9 p -125.41 144.69 50.4 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.471 -0.786 . . . . 0.0 109.131 173.808 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 270' ' ' ILE . . . . . 0.484 HG23 HD13 ' A' ' 270' ' ' ILE . 58.7 mt -103.14 141.66 18.57 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 C-N-CA 121.127 -0.229 . . . . 0.0 110.968 -176.752 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -67.38 125.79 27.23 Favored 'General case' 0 C--O 1.232 0.133 0 CA-C-O 120.869 0.366 . . . . 0.0 110.947 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 91.82 -22.24 32.23 Favored Glycine 0 N--CA 1.453 -0.189 0 C-N-CA 121.058 -0.591 . . . . 0.0 112.194 -178.262 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . 0.515 HG22 ' HG3' ' A' ' 326' ' ' PRO . 48.9 t -94.58 102.55 13.73 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-O 121.33 0.586 . . . . 0.0 110.743 178.346 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 274' ' ' ASN . . . . . 0.695 ' HA ' ' HA ' ' A' ' 287' ' ' PRO . 70.7 m-80 -110.17 150.83 28.08 Favored 'General case' 0 C--N 1.318 -0.801 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 174.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 275' ' ' SER . . . . . 0.483 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 7.6 t -85.35 -169.58 2.71 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 120.301 -0.559 . . . . 0.0 110.092 -174.98 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 27.3 m -113.27 177.46 1.66 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 CA-C-N 115.612 -0.722 . . . . 0.0 112.054 179.553 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 277' ' ' HIS . . . . . 0.788 ' CG ' ' HA ' ' A' ' 281' ' ' LYS . 3.4 p80 -57.03 119.69 6.73 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 113.893 -1.503 . . . . 0.0 111.838 173.695 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -81.94 -49.52 10.21 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.987 -177.867 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 279' ' ' ILE . . . . . 0.438 ' CD1' ' H ' ' A' ' 279' ' ' ILE . 2.7 mp -68.18 -93.74 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.401 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.163 -174.759 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 36.2 p -137.98 68.24 1.4 Allowed 'General case' 0 C--O 1.235 0.307 0 CA-C-O 120.637 0.256 . . . . 0.0 111.393 -174.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 281' ' ' LYS . . . . . 0.788 ' HA ' ' CG ' ' A' ' 277' ' ' HIS . 0.0 OUTLIER 56.59 32.33 20.74 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.675 -177.016 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 282' ' ' ASP . . . . . 0.563 ' O ' ' HB3' ' A' ' 277' ' ' HIS . 1.6 m-20 -74.86 -177.03 3.11 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.645 176.134 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 68.9 p -106.57 108.07 19.39 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 120.76 0.314 . . . . 0.0 110.211 178.258 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 74.8 p -117.07 -58.29 2.08 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.681 -175.314 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 64.24 30.85 78.97 Favored Glycine 0 C--O 1.23 -0.124 0 C-N-CA 121.064 -0.589 . . . . 0.0 113.347 174.633 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 2.9 mm100 -101.12 129.69 26.58 Favored Pre-proline 0 C--N 1.323 -0.584 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 179.259 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 287' ' ' PRO . . . . . 0.695 ' HA ' ' HA ' ' A' ' 274' ' ' ASN . 48.3 Cg_exo -56.16 138.15 82.02 Favored 'Trans proline' 0 C--N 1.344 0.329 0 C-N-CA 122.563 2.175 . . . . 0.0 112.159 -179.356 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 288' ' ' GLN . . . . . 0.449 ' HA ' HE21 ' A' ' 288' ' ' GLN . 2.2 tp-100 -64.81 139.9 58.81 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.78 -179.069 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 52.8 t -97.42 124.0 50.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 176.205 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 290' ' ' PHE . . . . . 0.698 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 6.2 m-85 -98.87 151.44 20.85 Favored 'General case' 0 C--N 1.323 -0.559 0 C-N-CA 120.884 -0.326 . . . . 0.0 110.876 -174.578 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 37.2 mmt180 -116.97 118.86 33.59 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.691 -0.686 . . . . 0.0 109.34 174.187 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 48.9 t -75.56 127.52 37.05 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.954 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.874 -178.517 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 293' ' ' LEU . . . . . . . . . . . . . 84.8 mt -110.84 -19.48 12.81 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.928 -176.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 294' ' ' ALA . . . . . . . . . . . . . . . -155.72 138.3 15.05 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 111.85 0.315 . . . . 0.0 111.85 -178.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 60.5 t -138.14 132.59 42.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 175.039 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 41.5 t -157.95 110.61 2.38 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.677 -0.238 . . . . 0.0 110.97 -176.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 60.76 46.03 95.29 Favored Glycine 0 C--N 1.33 0.25 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.028 179.798 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 75.6 p 53.91 17.9 1.47 Allowed 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 123.887 0.875 . . . . 0.0 112.647 -175.845 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 52.9 m -102.77 109.55 21.18 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 108.015 -1.106 . . . . 0.0 108.015 171.171 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . 0.709 HG12 HG21 ' A' ' 302' ' ' ILE . 39.9 t -104.56 134.69 45.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.715 -169.124 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 94.3 m -96.99 109.31 22.08 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.352 -0.84 . . . . 0.0 108.997 172.626 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 302' ' ' ILE . . . . . 0.709 HG21 HG12 ' A' ' 300' ' ' VAL . 30.2 pt -110.66 138.06 40.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-O 121.648 0.737 . . . . 0.0 111.922 -175.37 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 303' ' ' SER . . . . . . . . . . . . . 50.5 m -129.54 150.95 77.1 Favored Pre-proline 0 C--N 1.317 -0.846 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 173.162 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 304' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_exo -68.22 176.54 27.47 Favored 'Cis proline' 0 C--N 1.333 -0.282 0 C-N-CA 124.637 -0.985 . . . . 0.0 112.892 1.015 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 305' ' ' LYS . . . . . 0.569 ' HE2' ' CD1' ' A' ' 307' ' ' LEU . 0.0 OUTLIER -94.04 166.81 11.96 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.492 178.583 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 306' ' ' ILE . . . . . 0.461 HD12 HG23 ' A' ' 306' ' ' ILE . 42.6 mm -87.47 96.3 5.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.366 -174.144 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 307' ' ' LEU . . . . . 0.569 ' CD1' ' HE2' ' A' ' 305' ' ' LYS . 84.2 mt -106.82 110.32 63.6 Favored Pre-proline 0 C--N 1.33 -0.28 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 175.859 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 308' ' ' PRO . . . . . 0.615 ' HG3' ' HE3' ' A' ' 325' ' ' LYS . 79.1 Cg_endo -82.69 157.8 16.24 Favored 'Trans proline' 0 C--O 1.231 0.143 0 C-N-CA 122.512 2.141 . . . . 0.0 114.364 -172.12 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 39.6 t -81.76 -11.17 12.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 114.958 -1.019 . . . . 0.0 108.467 168.782 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 4.6 mm-40 -70.54 -7.03 40.77 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.19 -0.914 . . . . 0.0 110.219 176.618 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 23.8 t-20 -64.07 118.29 8.3 Favored 'General case' 0 N--CA 1.451 -0.391 0 CA-C-N 115.605 -0.725 . . . . 0.0 109.45 -179.141 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 19.5 m -86.3 -17.19 35.25 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.36 -171.441 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 313' ' ' ASP . . . . . 0.573 ' O ' ' HG3' ' A' ' 317' ' ' ARG . 9.8 t70 -71.83 118.58 14.86 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 178.438 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 41.2 t -59.08 -36.4 62.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.054 -0.521 . . . . 0.0 112.273 -173.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -73.87 -25.36 60.0 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.502 0.191 . . . . 0.0 111.38 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 32.6 t -94.55 -6.22 44.16 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.693 -0.23 . . . . 0.0 111.096 -179.007 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 317' ' ' ARG . . . . . 0.573 ' HG3' ' O ' ' A' ' 313' ' ' ASP . 76.4 mtp180 -59.52 -49.6 91.39 Favored Pre-proline 0 N--CA 1.468 0.464 0 N-CA-C 112.392 0.516 . . . . 0.0 112.392 177.837 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 318' ' ' PRO . . . . . 0.499 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 54.3 Cg_exo -56.5 -24.4 52.86 Favored 'Trans proline' 0 C--N 1.359 1.118 0 C-N-CA 122.477 2.118 . . . . 0.0 112.756 -179.803 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 319' ' ' TYR . . . . . 0.521 ' O ' HD11 ' A' ' 307' ' ' LEU . 11.6 m-30 -77.08 -6.19 51.84 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.369 -0.832 . . . . 0.0 111.495 -175.68 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -54.85 130.28 40.51 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-O 120.976 0.417 . . . . 0.0 111.723 -177.662 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 26.7 t-20 -110.71 -37.88 5.31 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.663 -0.699 . . . . 0.0 109.554 179.294 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 322' ' ' VAL . . . . . 0.483 ' HA ' ' HA ' ' A' ' 275' ' ' SER . 34.4 m -130.74 170.28 19.86 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 115.267 -0.879 . . . . 0.0 110.16 179.083 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 73.2 m-20 -62.11 -44.14 97.31 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 112.386 0.513 . . . . 0.0 112.386 -177.782 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 324' ' ' ALA . . . . . 0.444 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -156.56 168.41 27.47 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 112.666 0.617 . . . . 0.0 112.666 -172.493 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 325' ' ' LYS . . . . . 0.615 ' HE3' ' HG3' ' A' ' 308' ' ' PRO . 9.9 mtmp? -102.05 106.45 47.87 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 114.816 -1.084 . . . . 0.0 108.531 167.582 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 326' ' ' PRO . . . . . 0.515 ' HG3' HG22 ' A' ' 273' ' ' VAL . 74.3 Cg_endo -80.24 162.51 22.77 Favored 'Trans proline' 0 N--CA 1.459 -0.506 0 C-N-CA 122.018 1.812 . . . . 0.0 112.58 -175.59 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -80.03 122.55 26.88 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 174.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 328' ' ' GLU . . . . . 0.817 ' H ' ' HG3' ' A' ' 233' ' ' GLN . 85.0 tt0 71.89 162.81 0.26 Allowed 'General case' 0 CA--C 1.532 0.251 0 O-C-N 124.093 0.87 . . . . 0.0 109.672 -176.006 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 329' ' ' SER . . . . . 0.614 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 50.6 m -85.34 -14.57 46.02 Favored 'General case' 0 C--N 1.323 -0.554 0 C-N-CA 120.913 -0.315 . . . . 0.0 110.861 -177.375 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 330' ' ' ALA . . . . . 0.449 ' H ' ' HG2' ' A' ' 328' ' ' GLU . . . 63.5 -160.36 0.3 Allowed 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 121.381 0.61 . . . . 0.0 112.611 173.015 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 331' ' ' ALA . . . . . 0.414 ' HA ' ' HA ' ' A' ' 229' ' ' THR . . . -82.03 148.14 28.79 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.292 -0.867 . . . . 0.0 110.131 178.253 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 332' ' ' ILE . . . . . 0.775 HD13 HG23 ' A' ' 230' ' ' VAL . 43.4 mt -124.24 144.63 33.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-O 121.169 0.509 . . . . 0.0 111.304 -178.148 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 29.6 m -104.21 97.7 7.62 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.494 -0.775 . . . . 0.0 109.217 179.611 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 334' ' ' ILE . . . . . 0.695 HD13 HD22 ' A' ' 262' ' ' LEU . 36.4 mm -78.55 127.91 38.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 112.858 0.688 . . . . 0.0 112.858 -170.772 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 335' ' ' LEU . . . . . 0.507 ' N ' HD12 ' A' ' 335' ' ' LEU . 8.2 mp -109.15 176.13 5.2 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 114.871 -1.059 . . . . 0.0 110.122 171.541 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 23.0 p30 -131.61 9.57 4.67 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 115.321 -0.854 . . . . 0.0 109.628 173.526 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 337' ' ' LYS . . . . . 0.526 ' NZ ' ' HB3' ' A' ' 337' ' ' LYS . 8.1 mtpm? . . . . . 0 C--O 1.244 0.794 0 CA-C-O 118.552 -0.737 . . . . 0.0 110.891 178.745 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 65.9 p . . . . . 0 N--CA 1.453 -0.313 0 CA-C-O 121.329 0.585 . . . . 0.0 109.812 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 228' ' ' LEU . . . . . 0.733 ' HB3' ' HB3' ' A' ' 259' ' ' ALA . 83.4 mt -98.01 126.82 43.6 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-N 115.614 -0.721 . . . . 0.0 109.761 -179.548 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 229' ' ' THR . . . . . 0.568 ' O ' HG23 ' A' ' 230' ' ' VAL . 55.5 p -124.73 179.24 5.07 Favored 'General case' 0 C--N 1.322 -0.625 0 C-N-CA 120.458 -0.497 . . . . 0.0 110.3 -179.611 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 230' ' ' VAL . . . . . 0.66 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 63.5 t -147.63 146.92 17.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 120.602 0.239 . . . . 0.0 110.672 -178.234 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 231' ' ' SER . . . . . 0.501 ' HA ' ' HB3' ' A' ' 328' ' ' GLU . 48.9 m -132.11 96.62 3.94 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 173.386 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . 0.421 ' HA3' ' HA ' ' A' ' 255' ' ' ILE . . . -122.5 -163.05 11.74 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 119.854 -1.165 . . . . 0.0 113.693 -172.889 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 233' ' ' GLN . . . . . 0.587 ' HB3' ' HD2' ' A' ' 234' ' ' PRO . 94.6 mm-40 -85.49 163.63 43.76 Favored Pre-proline 0 C--N 1.327 -0.397 0 CA-C-N 115.615 -0.293 . . . . 0.0 110.541 -178.833 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 234' ' ' PRO . . . . . 0.587 ' HD2' ' HB3' ' A' ' 233' ' ' GLN . 9.5 Cg_endo -55.37 134.3 63.1 Favored 'Trans proline' 0 C--N 1.35 0.646 0 C-N-CA 122.871 2.38 . . . . 0.0 113.442 -176.51 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 235' ' ' GLU . . . . . 0.554 ' HB2' ' CE ' ' A' ' 325' ' ' LYS . 57.7 mt-10 -97.18 124.79 41.34 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 114.982 -1.008 . . . . 0.0 108.452 177.903 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 6.3 p80 -174.1 172.81 3.27 Favored 'General case' 0 CA--C 1.521 -0.152 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 -175.145 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 237' ' ' LYS . . . . . 0.764 ' HB3' ' HG3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER . . . . . 0 CA--C 1.529 0.172 0 CA-C-O 121.546 0.688 . . . . 0.0 110.881 165.649 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 252' ' ' GLN . . . . . 0.47 ' HA ' HE21 ' A' ' 252' ' ' GLN . 2.5 mm100 . . . . . 0 N--CA 1.471 0.606 0 CA-C-O 122.039 0.923 . . . . 0.0 113.425 . . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -172.11 113.33 0.48 Allowed Glycine 0 N--CA 1.448 -0.555 0 CA-C-N 114.723 -1.126 . . . . 0.0 110.644 178.418 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 74.1 p -95.52 117.47 30.47 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 117.399 0.599 . . . . 0.0 110.771 -175.152 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . 0.499 ' HB ' ' CG1' ' A' ' 230' ' ' VAL . 22.7 pt -120.81 132.59 69.93 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-O 121.239 0.542 . . . . 0.0 111.97 -175.447 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 60.7 m -88.34 110.55 20.86 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 173.874 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.658 HG12 HG21 ' A' ' 230' ' ' VAL . 33.2 m -90.1 143.06 11.98 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.84 0 C-N-CA 119.341 -0.943 . . . . 0.0 112.798 -167.89 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 25.0 m -91.61 9.23 33.09 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 113.852 -1.522 . . . . 0.0 108.301 169.915 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 259' ' ' ALA . . . . . 0.733 ' HB3' ' HB3' ' A' ' 228' ' ' LEU . . . -100.5 178.19 4.8 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 114.725 -1.125 . . . . 0.0 109.55 -177.314 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 42.0 t -145.03 151.38 38.46 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.782 0.325 . . . . 0.0 110.79 179.113 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 84.52 15.87 67.57 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.982 -0.628 . . . . 0.0 112.876 178.544 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 262' ' ' LEU . . . . . 0.423 ' O ' HG11 ' A' ' 295' ' ' VAL . 63.4 mt -85.38 129.92 34.7 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.678 0.275 . . . . 0.0 110.703 -179.11 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 14.4 mm-40 -139.95 173.04 11.92 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.726 178.93 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 264' ' ' VAL . . . . . 0.442 HG13 ' O ' ' A' ' 292' ' ' VAL . 36.1 t -67.63 137.89 23.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 C-N-CA 121.001 -0.279 . . . . 0.0 110.34 -179.852 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 101.93 4.7 51.24 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.541 -0.837 . . . . 0.0 112.962 177.648 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 68.4 m-20 -85.84 137.7 32.58 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.257 0.551 . . . . 0.0 110.143 177.193 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 267' ' ' ALA . . . . . 0.603 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -119.85 122.98 42.52 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.262 -0.881 . . . . 0.0 108.741 178.07 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 268' ' ' PHE . . . . . 0.504 ' HB3' ' HA ' ' A' ' 334' ' ' ILE . 7.8 p90 -142.3 168.31 20.05 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.097 -0.641 . . . . 0.0 112.309 -169.893 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 76.0 p -115.4 162.77 16.68 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 114.859 -1.064 . . . . 0.0 108.486 170.89 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 270' ' ' ILE . . . . . 0.508 HG23 HD12 ' A' ' 270' ' ' ILE . 59.5 mt -126.05 141.96 44.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.693 -178.5 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -66.36 112.51 4.06 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.97 179.439 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 272' ' ' GLY . . . . . 0.432 ' HA3' ' HG3' ' A' ' 326' ' ' PRO . . . 104.21 -9.43 50.04 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.642 -0.789 . . . . 0.0 112.467 179.947 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . 0.486 HG21 ' HB ' ' A' ' 270' ' ' ILE . 58.3 t -102.15 102.95 14.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.884 0.373 . . . . 0.0 110.17 178.796 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 6.9 m120 -126.76 116.38 20.83 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.058 -177.352 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 275' ' ' SER . . . . . 0.474 ' HB3' ' HB2' ' A' ' 288' ' ' GLN . 29.2 p -72.72 161.78 30.32 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 113.24 0.83 . . . . 0.0 113.24 -172.401 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 19.4 m -118.21 178.6 2.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 114.644 -1.162 . . . . 0.0 110.165 178.436 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 85.1 m-70 -112.23 105.08 13.31 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 171.548 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 4.9 mp0 -74.18 -35.88 64.01 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.645 -0.252 . . . . 0.0 111.329 -173.445 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 2.1 mp -67.9 -55.94 14.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.983 -176.007 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 75.9 p -88.33 -3.81 58.78 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 111.782 0.289 . . . . 0.0 111.782 -177.64 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 28.0 tptp 58.81 53.1 6.04 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 121.441 0.638 . . . . 0.0 110.23 179.391 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -117.03 136.75 52.72 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.605 -176.93 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 66.8 p -107.63 127.53 53.74 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.149 -179.943 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 70.7 p -134.49 -30.75 1.11 Allowed 'General case' 0 C--N 1.321 -0.645 0 CA-C-O 120.774 0.321 . . . . 0.0 111.424 -176.709 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 79.39 32.48 38.25 Favored Glycine 0 N--CA 1.448 -0.536 0 C-N-CA 120.408 -0.901 . . . . 0.0 112.666 178.214 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 71.3 mt-30 -85.0 124.43 72.39 Favored Pre-proline 0 C--N 1.326 -0.415 0 CA-C-N 116.903 0.352 . . . . 0.0 110.489 179.973 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 287' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_exo -59.53 126.0 19.44 Favored 'Trans proline' 0 C--N 1.345 0.395 0 C-N-CA 122.281 1.988 . . . . 0.0 111.285 178.272 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 288' ' ' GLN . . . . . 0.474 ' HB2' ' HB3' ' A' ' 275' ' ' SER . 50.6 tt0 -80.4 150.55 29.76 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.045 0.45 . . . . 0.0 111.589 -175.212 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 50.0 t -99.16 127.35 51.93 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 CA-C-N 115.327 -0.851 . . . . 0.0 110.221 179.278 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 290' ' ' PHE . . . . . 0.603 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 4.0 m-85 -101.2 168.7 9.4 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.562 -0.29 . . . . 0.0 111.025 -176.771 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 21.6 mmt85 -126.49 120.78 30.55 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.264 0.554 . . . . 0.0 110.745 174.418 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . 0.442 ' O ' HG13 ' A' ' 264' ' ' VAL . 59.5 t -78.24 128.56 38.23 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.829 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.313 176.035 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 293' ' ' LEU . . . . . . . . . . . . . 83.5 mt -109.0 -30.09 8.25 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 111.986 0.365 . . . . 0.0 111.986 -177.762 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 294' ' ' ALA . . . . . . . . . . . . . . . -152.44 139.94 19.65 Favored 'General case' 0 C--N 1.329 -0.296 0 C-N-CA 121.171 -0.212 . . . . 0.0 111.334 179.717 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 295' ' ' VAL . . . . . 0.423 HG11 ' O ' ' A' ' 262' ' ' LEU . 55.3 t -133.48 128.52 54.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 175.118 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 27.2 m -145.64 97.13 2.93 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.917 -176.316 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 57.45 61.03 7.94 Favored Glycine 0 C--N 1.33 0.224 0 C-N-CA 121.009 -0.615 . . . . 0.0 112.531 178.814 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 81.8 p 56.71 5.4 0.21 Allowed 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 124.395 1.078 . . . . 0.0 113.253 -177.17 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 97.4 m -97.88 106.31 18.6 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 171.623 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . 0.539 HG13 HG23 ' A' ' 302' ' ' ILE . 38.8 t -109.26 120.93 61.48 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.797 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.193 -170.883 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 52.6 m -89.66 105.7 17.98 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 174.526 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 302' ' ' ILE . . . . . 0.539 HG23 HG13 ' A' ' 300' ' ' VAL . 2.4 pp -111.72 179.13 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 121.893 0.854 . . . . 0.0 112.861 -174.898 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 303' ' ' SER . . . . . 0.442 ' HA ' ' O ' ' A' ' 304' ' ' PRO . 67.5 p -160.0 157.47 25.43 Favored Pre-proline 0 C--N 1.314 -0.961 0 CA-C-N 113.668 -1.606 . . . . 0.0 106.678 174.714 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 304' ' ' PRO . . . . . 0.442 ' O ' ' HA ' ' A' ' 303' ' ' SER . 3.8 Cg_exo -78.26 -141.67 0.2 Allowed 'Cis proline' 0 CA--C 1.536 0.605 0 CA-C-N 119.84 0.979 . . . . 0.0 112.993 1.057 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 305' ' ' LYS . . . . . 0.764 ' HG3' ' HB3' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -130.4 171.02 13.42 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.014 -178.545 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 306' ' ' ILE . . . . . 0.585 HG21 HG23 ' A' ' 322' ' ' VAL . 47.2 mm -132.36 129.35 59.38 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.619 0 C-N-CA 119.242 -0.983 . . . . 0.0 113.57 -164.765 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 307' ' ' LEU . . . . . 0.668 HD13 ' HA ' ' A' ' 316' ' ' SER . 88.0 mt -134.39 125.44 17.75 Favored Pre-proline 0 CA--C 1.514 -0.435 0 CA-C-O 120.883 0.373 . . . . 0.0 111.459 170.287 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 308' ' ' PRO . . . . . 0.976 ' HG2' ' HB2' ' A' ' 311' ' ' ASN . 66.8 Cg_endo -84.24 157.71 13.0 Favored 'Trans proline' 0 N--CA 1.455 -0.782 0 C-N-CA 122.89 2.394 . . . . 0.0 112.711 179.041 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 44.5 t -80.79 -18.93 11.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-O 121.587 0.708 . . . . 0.0 109.126 172.104 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 54.7 mt-10 -94.62 34.91 1.27 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.475 -0.784 . . . . 0.0 111.141 177.613 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.976 ' HB2' ' HG2' ' A' ' 308' ' ' PRO . 19.6 t-20 -103.18 142.09 34.75 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -178.443 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 26.3 m -83.27 -7.46 59.59 Favored 'General case' 0 CA--C 1.54 0.587 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.447 -175.05 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 313' ' ' ASP . . . . . 0.411 ' O ' ' HG3' ' A' ' 317' ' ' ARG . 62.9 m-20 -79.62 140.11 37.23 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.684 0.278 . . . . 0.0 110.821 177.818 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 46.1 t -64.4 -45.63 95.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.655 -177.964 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -75.54 -22.42 57.07 Favored 'General case' 0 N--CA 1.464 0.262 0 N-CA-C 111.999 0.37 . . . . 0.0 111.999 -176.204 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 316' ' ' SER . . . . . 0.668 ' HA ' HD13 ' A' ' 307' ' ' LEU . 46.1 t -73.14 -21.52 60.7 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.533 -0.303 . . . . 0.0 111.771 -178.16 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 317' ' ' ARG . . . . . 0.674 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 73.0 mtp180 -74.24 -54.76 3.19 Favored Pre-proline 0 CA--C 1.536 0.434 0 N-CA-C 112.23 0.456 . . . . 0.0 112.23 -176.25 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 318' ' ' PRO . . . . . 0.674 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 16.8 Cg_exo -68.79 -38.66 9.81 Favored 'Trans proline' 0 C--N 1.354 0.848 0 C-N-CA 121.978 1.785 . . . . 0.0 112.268 -178.852 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 319' ' ' TYR . . . . . 0.522 ' O ' HD11 ' A' ' 307' ' ' LEU . 3.2 m-85 -90.11 30.43 1.09 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.089 0.471 . . . . 0.0 110.576 -179.903 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -65.9 159.41 25.6 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.679 -0.692 . . . . 0.0 111.059 179.454 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -142.43 -26.28 0.63 Allowed 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.866 -178.551 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 322' ' ' VAL . . . . . 0.585 HG23 HG21 ' A' ' 306' ' ' ILE . 33.8 m -132.93 174.13 13.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.402 179.458 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -85.4 -12.76 51.28 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 112.068 0.395 . . . . 0.0 112.068 -179.05 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 324' ' ' ALA . . . . . 0.587 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -178.73 163.42 1.45 Allowed 'General case' 0 N--CA 1.469 0.485 0 CA-C-O 120.737 0.304 . . . . 0.0 111.619 -176.313 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 325' ' ' LYS . . . . . 0.622 ' HZ1' ' HB3' ' A' ' 325' ' ' LYS . 6.7 mtpm? -120.56 134.13 24.15 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.731 172.974 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 326' ' ' PRO . . . . . 0.648 ' HB2' ' HB3' ' A' ' 330' ' ' ALA . 3.4 Cg_exo -78.26 167.81 22.6 Favored 'Trans proline' 0 N--CA 1.459 -0.549 0 C-N-CA 122.803 2.335 . . . . 0.0 111.578 177.101 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -65.18 137.15 57.43 Favored 'General case' 0 C--O 1.235 0.334 0 N-CA-C 110.129 -0.323 . . . . 0.0 110.129 177.886 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 328' ' ' GLU . . . . . 0.501 ' HB3' ' HA ' ' A' ' 231' ' ' SER . 55.2 mm-40 59.74 -128.41 1.12 Allowed 'General case' 0 C--O 1.232 0.164 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 -174.163 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 329' ' ' SER . . . . . 0.66 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 42.0 m -111.83 -10.55 14.01 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.548 -0.296 . . . . 0.0 110.204 175.339 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 330' ' ' ALA . . . . . 0.648 ' HB3' ' HB2' ' A' ' 326' ' ' PRO . . . 73.21 -166.39 0.11 Allowed 'General case' 0 N--CA 1.474 0.757 0 N-CA-C 113.56 0.948 . . . . 0.0 113.56 173.824 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -83.16 143.69 30.33 Favored 'General case' 0 CA--C 1.519 -0.223 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.56 -178.852 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 332' ' ' ILE . . . . . 0.495 HG13 HG22 ' A' ' 230' ' ' VAL . 23.1 mm -113.32 145.17 19.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.562 -171.875 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 29.7 m -118.98 96.59 5.3 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 174.314 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 334' ' ' ILE . . . . . 0.504 ' HA ' ' HB3' ' A' ' 268' ' ' PHE . 35.7 mm -83.15 130.07 36.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 N-CA-C 112.636 0.606 . . . . 0.0 112.636 -172.968 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 335' ' ' LEU . . . . . 0.447 ' HB2' ' O ' ' A' ' 267' ' ' ALA . 7.3 mp -112.52 160.95 17.3 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.23 -0.896 . . . . 0.0 110.089 171.962 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 72.8 m-80 -112.22 -0.29 15.56 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.261 -0.882 . . . . 0.0 109.209 174.132 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 27.9 mtpp . . . . . 0 C--O 1.245 0.845 0 O-C-N 124.191 0.932 . . . . 0.0 111.2 -178.281 . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 43.6 t . . . . . 0 C--O 1.234 0.273 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 228' ' ' LEU . . . . . 0.527 ' HB3' ' HB2' ' A' ' 259' ' ' ALA . 91.7 mt -130.11 125.18 34.49 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 172.461 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 229' ' ' THR . . . . . 0.582 ' O ' HG21 ' A' ' 230' ' ' VAL . 37.6 p -117.87 175.19 5.78 Favored 'General case' 0 C--N 1.32 -0.674 0 C-N-CA 119.483 -0.887 . . . . 0.0 111.214 -177.087 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 230' ' ' VAL . . . . . 0.922 HG23 HD12 ' A' ' 332' ' ' ILE . 60.6 t -148.61 141.44 18.4 Favored 'Isoleucine or valine' 0 C--O 1.24 0.56 0 CA-C-O 120.905 0.383 . . . . 0.0 110.788 -176.448 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 50.0 m -109.98 117.74 34.59 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.907 175.123 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 177.61 169.0 38.1 Favored Glycine 0 N--CA 1.447 -0.578 0 N-CA-C 111.087 -0.805 . . . . 0.0 111.087 -177.903 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 72.2 mt-30 -111.75 101.51 51.43 Favored Pre-proline 0 C--N 1.323 -0.57 0 CA-C-N 117.148 0.474 . . . . 0.0 111.62 -177.86 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_endo -83.62 125.99 3.95 Favored 'Trans proline' 0 N--CA 1.453 -0.864 0 C-N-CA 122.986 2.457 . . . . 0.0 110.331 173.932 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 56.0 mm-40 -120.63 163.55 17.86 Favored 'General case' 0 C--N 1.321 -0.674 0 C-N-CA 120.576 -0.45 . . . . 0.0 111.831 -172.572 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 236' ' ' HIS . . . . . 0.533 ' HB3' ' O ' ' A' ' 306' ' ' ILE . 19.3 p-80 -108.76 145.89 34.43 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.339 172.433 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 237' ' ' LYS . . . . . 0.507 ' HZ3' ' NE2' ' A' ' 252' ' ' GLN . 0.0 OUTLIER . . . . . 0 C--N 1.32 -0.679 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.569 178.099 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 252' ' ' GLN . . . . . 0.507 ' NE2' ' HZ3' ' A' ' 237' ' ' LYS . 53.8 mt-30 . . . . . 0 N--CA 1.471 0.583 0 CA-C-O 121.391 0.615 . . . . 0.0 110.959 . . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . 0.9 ' O ' ' HA ' ' A' ' 301' ' ' THR . . . 100.35 -23.76 34.62 Favored Glycine 0 N--CA 1.438 -1.203 0 C-N-CA 120.068 -1.063 . . . . 0.0 112.74 -179.248 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 60.0 p -135.81 118.79 16.36 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 118.01 0.905 . . . . 0.0 112.724 -176.676 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . 0.766 HD11 ' HB ' ' A' ' 300' ' ' VAL . 2.1 pp -144.83 170.79 6.75 Favored 'Isoleucine or valine' 0 C--O 1.234 0.283 0 CA-C-O 121.032 0.444 . . . . 0.0 112.001 172.445 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 75.2 m -115.62 114.35 24.79 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.344 177.057 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.513 HG22 ' O ' ' A' ' 298' ' ' THR . 34.9 m -90.86 145.21 7.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 N-CA-C 113.004 0.742 . . . . 0.0 113.004 -173.114 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 30.9 m -91.35 8.83 34.22 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 114.077 -1.42 . . . . 0.0 108.502 166.818 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 259' ' ' ALA . . . . . 0.527 ' HB2' ' HB3' ' A' ' 228' ' ' LEU . . . -88.25 175.65 7.58 Favored 'General case' 0 N--CA 1.452 -0.364 0 CA-C-N 115.115 -0.948 . . . . 0.0 109.402 -177.899 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 27.4 p -140.61 117.22 10.88 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 112.356 0.502 . . . . 0.0 112.356 -177.412 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 78.91 50.04 6.12 Favored Glycine 0 N--CA 1.45 -0.392 0 CA-C-N 115.596 -0.729 . . . . 0.0 113.391 175.632 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 262' ' ' LEU . . . . . . . . . . . . . 77.6 mt -85.06 146.53 27.12 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 117.346 0.573 . . . . 0.0 110.268 176.837 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 98.9 mm-40 -123.77 163.25 21.54 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.551 -178.757 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 264' ' ' VAL . . . . . 0.638 HG21 ' HA ' ' A' ' 294' ' ' ALA . 20.2 t -79.48 145.1 9.86 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.215 177.626 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 86.4 10.07 74.67 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.623 -0.799 . . . . 0.0 112.186 177.832 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -88.5 159.59 17.88 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.147 0.499 . . . . 0.0 110.482 177.208 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 267' ' ' ALA . . . . . 0.532 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -121.82 151.48 40.57 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 115.334 -0.848 . . . . 0.0 108.869 178.238 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 268' ' ' PHE . . . . . 0.49 ' HA ' HD22 ' A' ' 335' ' ' LEU . 4.1 p90 -164.27 168.75 18.4 Favored 'General case' 0 C--N 1.318 -0.761 0 C-N-CA 119.777 -0.769 . . . . 0.0 111.648 -178.029 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 269' ' ' THR . . . . . 0.502 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 73.3 p -122.85 141.83 51.44 Favored 'General case' 0 N--CA 1.442 -0.848 0 CA-C-N 115.438 -0.801 . . . . 0.0 109.621 177.078 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 270' ' ' ILE . . . . . 0.706 HG12 HG12 ' A' ' 332' ' ' ILE . 61.6 mt -105.49 139.18 27.43 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.57 -178.525 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -61.22 125.86 25.28 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.695 179.512 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 93.51 -22.45 35.31 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.473 -178.811 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . 0.492 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 42.4 t -96.5 114.59 33.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 O-C-N 122.573 -0.369 . . . . 0.0 110.296 177.504 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 72.3 m-80 -129.2 160.87 31.55 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.304 -179.223 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 68.9 p -86.37 169.61 12.76 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.239 0.542 . . . . 0.0 111.803 -174.883 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 276' ' ' VAL . . . . . 0.407 ' O ' ' HG2' ' A' ' 278' ' ' GLN . 27.3 m -112.03 -178.07 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 115.499 -0.773 . . . . 0.0 111.152 -178.47 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 277' ' ' HIS . . . . . 0.519 ' HB3' ' HA ' ' A' ' 281' ' ' LYS . 5.0 m80 -66.16 80.97 0.08 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.703 -0.681 . . . . 0.0 110.392 -175.33 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 278' ' ' GLN . . . . . 0.458 HE21 ' HA ' ' A' ' 278' ' ' GLN . 2.4 mm100 -80.32 -32.99 37.86 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 111.72 0.267 . . . . 0.0 111.72 -174.418 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 2.4 mp -69.89 -89.48 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.375 0 CA-C-O 120.831 0.348 . . . . 0.0 110.533 -174.641 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 35.5 p -133.69 60.03 1.72 Allowed 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.076 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 281' ' ' LYS . . . . . 0.519 ' HA ' ' HB3' ' A' ' 277' ' ' HIS . 31.4 mmmt 54.52 41.13 32.14 Favored 'General case' 0 CA--C 1.522 -0.122 0 CA-C-N 115.562 -0.745 . . . . 0.0 109.208 -170.874 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 282' ' ' ASP . . . . . 0.464 ' N ' ' HB3' ' A' ' 277' ' ' HIS . 9.3 t70 -92.33 137.84 32.03 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 114.445 -1.252 . . . . 0.0 110.484 -175.15 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 46.2 p -85.44 105.1 15.82 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.185 -178.387 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 73.1 p -110.72 -41.62 4.24 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.915 -171.804 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 63.64 28.31 72.34 Favored Glycine 0 C--N 1.33 0.24 0 C-N-CA 120.877 -0.677 . . . . 0.0 112.498 177.222 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 84.6 mt-30 -94.5 145.7 30.15 Favored Pre-proline 0 C--N 1.323 -0.547 0 CA-C-O 120.419 0.152 . . . . 0.0 110.647 -176.792 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 287' ' ' PRO . . . . . 0.502 ' HB2' ' HB ' ' A' ' 269' ' ' THR . 27.5 Cg_endo -62.2 143.77 94.75 Favored 'Trans proline' 0 CA--C 1.53 0.31 0 C-N-CA 122.445 2.097 . . . . 0.0 112.029 178.589 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 288' ' ' GLN . . . . . 0.414 ' HB3' HG13 ' A' ' 273' ' ' VAL . 70.8 tp60 -76.3 128.43 34.86 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.872 0.367 . . . . 0.0 110.945 -177.486 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 45.6 t -93.74 133.18 35.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.059 179.17 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 290' ' ' PHE . . . . . 0.532 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 60.9 m-85 -113.5 168.81 9.44 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.826 -176.996 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 291' ' ' ARG . . . . . 0.42 ' O ' HD13 ' A' ' 293' ' ' LEU . 35.8 mmt180 -126.74 120.38 29.25 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 177.765 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 56.4 t -67.18 125.59 24.96 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.227 -179.755 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 293' ' ' LEU . . . . . 0.682 HD11 ' HB2' ' A' ' 303' ' ' SER . 5.2 mp -85.07 -38.44 19.13 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.841 179.865 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 294' ' ' ALA . . . . . 0.638 ' HA ' HG21 ' A' ' 264' ' ' VAL . . . -167.13 155.48 9.73 Favored 'General case' 0 C--O 1.225 -0.21 0 CA-C-N 116.681 -0.236 . . . . 0.0 110.94 179.059 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 295' ' ' VAL . . . . . 0.607 HG11 HG22 ' A' ' 300' ' ' VAL . 61.7 t -140.49 124.74 18.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 175.384 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 32.4 m -139.73 89.54 2.33 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 120.76 0.314 . . . . 0.0 110.835 -177.189 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . 0.471 ' C ' ' H ' ' A' ' 299' ' ' THR . . . 63.95 65.76 2.87 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.487 179.434 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 298' ' ' THR . . . . . 0.513 ' O ' HG22 ' A' ' 257' ' ' VAL . 81.0 p 63.06 -25.18 0.06 Allowed 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 124.994 1.317 . . . . 0.0 113.683 -178.774 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 299' ' ' THR . . . . . 0.471 ' H ' ' C ' ' A' ' 297' ' ' GLY . 75.3 m -77.43 108.9 10.91 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 174.333 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . 0.766 ' HB ' HD11 ' A' ' 255' ' ' ILE . 48.8 t -106.08 134.42 47.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.025 -173.017 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 301' ' ' THR . . . . . 0.9 ' HA ' ' O ' ' A' ' 253' ' ' GLY . 97.1 m -78.02 105.37 9.19 Favored 'General case' 0 N--CA 1.446 -0.632 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 173.009 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 302' ' ' ILE . . . . . 0.672 HD13 ' O ' ' A' ' 302' ' ' ILE . 2.6 pp -111.24 141.35 26.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 122.179 0.99 . . . . 0.0 113.671 -170.989 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 303' ' ' SER . . . . . 0.682 ' HB2' HD11 ' A' ' 293' ' ' LEU . 57.2 m -167.48 169.55 5.56 Favored Pre-proline 0 C--N 1.317 -0.826 0 N-CA-C 105.342 -2.096 . . . . 0.0 105.342 179.02 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 304' ' ' PRO . . . . . 0.556 ' HA ' ' HB3' ' A' ' 303' ' ' SER . 2.7 Cg_endo -82.65 -157.28 1.35 Allowed 'Cis proline' 0 C--N 1.347 0.458 0 CA-C-N 121.571 1.597 . . . . 0.0 113.473 0.278 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 305' ' ' LYS . . . . . 0.782 ' HD3' ' HG ' ' A' ' 307' ' ' LEU . 0.0 OUTLIER -83.51 163.34 20.51 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.27 -0.877 . . . . 0.0 112.884 -176.069 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 306' ' ' ILE . . . . . 0.533 ' O ' ' HB3' ' A' ' 236' ' ' HIS . 2.7 mp -114.02 94.32 3.06 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.793 -176.761 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 307' ' ' LEU . . . . . 0.782 ' HG ' ' HD3' ' A' ' 305' ' ' LYS . 86.0 mt -108.81 107.24 59.9 Favored Pre-proline 0 C--N 1.327 -0.392 0 C-N-CA 120.81 -0.356 . . . . 0.0 111.606 -177.768 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 308' ' ' PRO . . . . . 0.761 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 23.0 Cg_exo -69.85 145.39 56.5 Favored 'Trans proline' 0 C--N 1.343 0.253 0 C-N-CA 123.505 2.804 . . . . 0.0 113.467 -178.038 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . 0.513 HG22 ' HB3' ' A' ' 320' ' ' ALA . 40.3 t -93.69 -25.6 4.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 169.35 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 54.7 mm-40 -79.83 -0.36 34.32 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.113 -0.949 . . . . 0.0 112.144 -177.602 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -80.85 163.34 23.48 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-O 121.004 0.431 . . . . 0.0 111.174 -179.091 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 50.2 m -92.32 -15.87 26.79 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.362 -179.029 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 313' ' ' ASP . . . . . 0.553 ' O ' ' HG3' ' A' ' 317' ' ' ARG . 62.9 t0 -64.26 104.05 0.71 Allowed 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.065 178.93 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 314' ' ' VAL . . . . . 0.404 ' O ' ' HD3' ' A' ' 318' ' ' PRO . 48.5 t -63.63 -30.84 50.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.683 -176.012 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -70.44 -25.17 63.07 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 111.718 0.266 . . . . 0.0 111.718 179.984 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 32.4 t -95.09 -8.28 37.02 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.604 0.24 . . . . 0.0 111.211 -178.115 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 317' ' ' ARG . . . . . 0.553 ' HG3' ' O ' ' A' ' 313' ' ' ASP . 54.4 mtp85 -67.43 -49.96 39.85 Favored Pre-proline 0 CA--C 1.54 0.564 0 N-CA-C 112.938 0.718 . . . . 0.0 112.938 -179.26 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 318' ' ' PRO . . . . . 0.504 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 37.1 Cg_exo -63.41 -31.98 71.95 Favored 'Trans proline' 0 C--N 1.357 1.016 0 C-N-CA 121.951 1.768 . . . . 0.0 112.679 -178.51 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 48.8 m-85 -84.13 -14.95 48.97 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.511 -178.214 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . 0.513 ' HB3' HG22 ' A' ' 309' ' ' VAL . . . -49.7 135.29 19.17 Favored 'General case' 0 N--CA 1.464 0.254 0 N-CA-C 112.71 0.633 . . . . 0.0 112.71 -174.097 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 16.1 p-10 -128.38 -10.36 5.18 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.939 178.964 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 322' ' ' VAL . . . . . 0.409 ' O ' HG21 ' A' ' 309' ' ' VAL . 33.7 m -132.27 167.29 26.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 N-CA-C 109.986 -0.375 . . . . 0.0 109.986 177.017 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -67.2 -51.89 47.95 Favored 'General case' 0 C--N 1.326 -0.434 0 C-N-CA 121.026 -0.27 . . . . 0.0 111.702 -177.93 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 324' ' ' ALA . . . . . 0.761 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -162.47 -178.04 6.02 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.044 0.449 . . . . 0.0 111.779 -176.388 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 14.5 ptmm? -112.56 132.07 22.37 Favored Pre-proline 0 C--N 1.327 -0.384 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.314 176.949 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -86.15 168.44 9.04 Favored 'Trans proline' 0 N--CA 1.456 -0.71 0 C-N-CA 122.921 2.414 . . . . 0.0 112.412 179.51 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -72.83 123.77 24.05 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.053 -0.522 . . . . 0.0 109.718 175.202 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 66.6 mm-40 65.6 -161.43 0.26 Allowed 'General case' 0 N--CA 1.465 0.307 0 O-C-N 123.574 0.546 . . . . 0.0 110.424 -174.97 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 329' ' ' SER . . . . . 0.522 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 43.0 m -91.16 -13.48 32.88 Favored 'General case' 0 C--N 1.323 -0.578 0 C-N-CA 120.825 -0.35 . . . . 0.0 110.347 178.174 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 330' ' ' ALA . . . . . 0.428 ' HB2' ' H ' ' A' ' 331' ' ' ALA . . . 64.5 -161.55 0.28 Allowed 'General case' 0 N--CA 1.467 0.425 0 CA-C-N 115.412 -0.813 . . . . 0.0 113.128 171.323 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 331' ' ' ALA . . . . . 0.428 ' H ' ' HB2' ' A' ' 330' ' ' ALA . . . -86.71 136.72 32.91 Favored 'General case' 0 CA--C 1.517 -0.323 0 CA-C-N 115.09 -0.959 . . . . 0.0 110.577 -179.983 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 332' ' ' ILE . . . . . 0.922 HD12 HG23 ' A' ' 230' ' ' VAL . 45.8 mt -116.12 144.42 23.83 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.847 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.822 -178.735 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 78.1 m -116.26 99.24 7.07 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.156 -178.016 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 334' ' ' ILE . . . . . 0.469 HD12 HG22 ' A' ' 334' ' ' ILE . 38.3 mm -75.99 131.12 35.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.43 -174.992 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 335' ' ' LEU . . . . . 0.49 HD22 ' HA ' ' A' ' 268' ' ' PHE . 2.0 pt? -148.61 133.68 18.23 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.217 173.68 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 5.6 m120 -78.16 70.93 4.59 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.223 178.406 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 59.4 tttp . . . . . 0 C--O 1.243 0.738 0 CA-C-O 118.315 -0.85 . . . . 0.0 110.713 -174.989 . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 54.0 m . . . . . 0 N--CA 1.465 0.322 0 CA-C-O 120.791 0.329 . . . . 0.0 111.304 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 228' ' ' LEU . . . . . 0.732 HD13 ' HB1' ' A' ' 259' ' ' ALA . 85.3 mt -131.5 158.9 39.66 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.982 -0.553 . . . . 0.0 109.845 -177.288 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 229' ' ' THR . . . . . 0.555 ' HA ' ' HA ' ' A' ' 331' ' ' ALA . 37.9 p -132.76 178.87 6.53 Favored 'General case' 0 C--N 1.33 -0.274 0 C-N-CA 120.324 -0.55 . . . . 0.0 111.186 177.851 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 230' ' ' VAL . . . . . 0.57 HG23 HD12 ' A' ' 332' ' ' ILE . 58.7 t -147.47 123.94 2.92 Favored 'Isoleucine or valine' 0 C--O 1.235 0.336 0 CA-C-N 116.654 -0.248 . . . . 0.0 110.921 -179.165 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 49.8 m -109.14 97.68 7.25 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.107 -0.497 . . . . 0.0 109.86 174.446 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . 0.903 ' HA3' ' HB ' ' A' ' 255' ' ' ILE . . . -133.94 -152.14 6.65 Favored Glycine 0 N--CA 1.443 -0.859 0 C-N-CA 119.743 -1.218 . . . . 0.0 113.163 -176.735 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 233' ' ' GLN . . . . . 0.49 ' HB3' ' HD2' ' A' ' 234' ' ' PRO . 11.7 mm100 -72.34 171.45 9.7 Favored Pre-proline 0 C--N 1.324 -0.521 0 CA-C-N 115.2 -0.5 . . . . 0.0 110.988 -179.172 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 234' ' ' PRO . . . . . 0.49 ' HD2' ' HB3' ' A' ' 233' ' ' GLN . 41.7 Cg_exo -56.74 176.29 0.23 Allowed 'Trans proline' 0 C--N 1.356 0.923 0 C-N-CA 123.346 2.697 . . . . 0.0 112.741 177.801 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 235' ' ' GLU . . . . . 0.717 ' HG3' ' HD2' ' A' ' 325' ' ' LYS . 2.6 pm0 -91.38 -176.74 4.64 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.031 0.444 . . . . 0.0 111.102 -174.467 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 236' ' ' HIS . . . . . 0.43 ' CE1' ' HB2' ' A' ' 305' ' ' LYS . 18.9 t-80 -100.87 147.6 25.93 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.509 -0.769 . . . . 0.0 111.702 -171.135 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 237' ' ' LYS . . . . . 0.502 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.327 -0.409 0 CA-C-N 114.735 -1.12 . . . . 0.0 109.914 179.066 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 252' ' ' GLN . . . . . 0.444 ' OE1' ' HA ' ' A' ' 305' ' ' LYS . 2.2 mm100 . . . . . 0 N--CA 1.472 0.659 0 CA-C-O 120.888 0.375 . . . . 0.0 110.566 . . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 101.91 -148.55 17.79 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 119.587 -1.292 . . . . 0.0 113.984 174.778 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 254' ' ' THR . . . . . 0.606 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 71.0 p -101.49 148.66 24.93 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 112.65 0.611 . . . . 0.0 112.65 -171.674 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . 0.903 ' HB ' ' HA3' ' A' ' 232' ' ' GLY . 0.2 OUTLIER -138.01 172.96 13.48 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.243 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.288 173.632 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 256' ' ' THR . . . . . 0.488 ' O ' HG13 ' A' ' 230' ' ' VAL . 58.2 m -100.54 125.81 46.93 Favored 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 109.406 -0.59 . . . . 0.0 109.406 176.729 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.62 HG21 HD13 ' A' ' 262' ' ' LEU . 34.0 m -98.73 143.37 13.28 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.828 0 C-N-CA 119.65 -0.82 . . . . 0.0 112.483 -174.541 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 258' ' ' SER . . . . . 0.405 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 38.8 t -91.56 8.48 36.4 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 114.443 -1.253 . . . . 0.0 108.405 169.505 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 259' ' ' ALA . . . . . 0.732 ' HB1' HD13 ' A' ' 228' ' ' LEU . . . -91.32 169.3 10.92 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-N 115.021 -0.99 . . . . 0.0 110.018 -177.442 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 37.9 t -136.95 148.57 47.04 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 110.194 -0.298 . . . . 0.0 110.194 -179.751 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 71.27 39.6 61.98 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.977 -0.63 . . . . 0.0 113.083 178.108 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 262' ' ' LEU . . . . . 0.62 HD13 HG21 ' A' ' 257' ' ' VAL . 77.6 mt -97.64 142.31 29.6 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.944 0.372 . . . . 0.0 110.395 178.348 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 71.6 mt-30 -143.72 179.96 6.83 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 176.284 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 264' ' ' VAL . . . . . 0.574 HG22 ' HA ' ' A' ' 294' ' ' ALA . 34.0 t -79.31 140.43 16.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 N-CA-C 109.897 -0.408 . . . . 0.0 109.897 176.201 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 93.52 4.72 63.82 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.526 -0.845 . . . . 0.0 112.453 178.797 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 266' ' ' ASP . . . . . 0.43 ' HB2' HG23 ' A' ' 292' ' ' VAL . 1.1 m-20 -78.89 152.81 30.97 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.083 0.468 . . . . 0.0 110.072 176.578 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 267' ' ' ALA . . . . . 0.699 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -126.96 121.67 32.36 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 178.696 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 268' ' ' PHE . . . . . 0.568 ' CD1' HG21 ' A' ' 332' ' ' ILE . 0.0 OUTLIER -148.04 171.53 15.68 Favored 'General case' 0 C--N 1.318 -0.791 0 C-N-CA 120.218 -0.593 . . . . 0.0 111.026 -172.071 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 269' ' ' THR . . . . . 0.551 ' OG1' ' HB ' ' A' ' 333' ' ' THR . 72.6 p -123.82 156.39 36.23 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 110.2 -0.296 . . . . 0.0 110.2 -179.379 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 270' ' ' ILE . . . . . 0.551 HG12 HG12 ' A' ' 332' ' ' ILE . 60.9 mt -115.02 139.36 41.68 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 120.794 0.33 . . . . 0.0 111.144 -179.332 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -65.82 112.64 3.84 Favored 'General case' 0 C--O 1.231 0.125 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.037 -179.903 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 109.22 -21.85 26.04 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.021 -179.14 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . 0.587 ' O ' ' HA ' ' A' ' 287' ' ' PRO . 47.1 t -93.11 102.67 13.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.885 0.374 . . . . 0.0 110.93 178.722 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 3.8 m120 -103.76 150.98 23.57 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 173.504 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 275' ' ' SER . . . . . 0.438 ' HB2' ' HB2' ' A' ' 288' ' ' GLN . 6.0 t -88.76 -177.96 5.66 Favored 'General case' 0 C--N 1.325 -0.473 0 C-N-CA 120.332 -0.547 . . . . 0.0 110.231 -176.496 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 35.0 m -112.25 -179.01 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.917 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.171 172.887 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 6.3 p80 -39.74 111.66 0.21 Allowed 'General case' 0 CA--C 1.533 0.298 0 O-C-N 123.972 0.795 . . . . 0.0 112.568 -179.882 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 80.7 mt-30 -80.16 -42.38 23.55 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.475 -176.439 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 279' ' ' ILE . . . . . 0.571 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.7 mp -110.21 -76.16 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.175 177.858 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 21.7 p -142.11 90.78 2.28 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-O 121.124 0.487 . . . . 0.0 111.661 -178.418 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 74.8 mmtt 61.05 23.98 14.12 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 115.145 -0.934 . . . . 0.0 112.463 175.584 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 11.2 p-10 -86.46 81.64 8.24 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.615 0.721 . . . . 0.0 110.867 176.769 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 37.2 p -102.34 106.9 17.76 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.854 177.753 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 73.1 p -114.67 2.16 14.4 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.835 -0.62 . . . . 0.0 112.174 -170.081 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 71.02 31.29 66.88 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.515 -0.85 . . . . 0.0 112.652 177.859 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 26.2 mt-30 -102.11 142.54 24.79 Favored Pre-proline 0 C--N 1.325 -0.467 0 O-C-N 122.682 -0.305 . . . . 0.0 111.155 179.503 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 287' ' ' PRO . . . . . 0.587 ' HA ' ' O ' ' A' ' 273' ' ' VAL . 39.0 Cg_exo -59.1 136.95 76.46 Favored 'Trans proline' 0 C--N 1.343 0.276 0 C-N-CA 122.988 2.459 . . . . 0.0 112.106 177.89 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 288' ' ' GLN . . . . . 0.438 ' HB2' ' HB2' ' A' ' 275' ' ' SER . 41.5 tt0 -79.52 142.92 35.34 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.827 0.346 . . . . 0.0 111.013 -178.008 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 289' ' ' VAL . . . . . 0.473 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 42.7 t -90.81 126.68 43.54 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.295 179.496 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 290' ' ' PHE . . . . . 0.699 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 33.3 m-85 -110.42 158.76 18.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.677 -0.238 . . . . 0.0 110.583 -176.323 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 291' ' ' ARG . . . . . 0.522 ' HD2' ' C ' ' A' ' 290' ' ' PHE . 9.0 mpt_? -115.88 131.06 57.05 Favored 'General case' 0 CA--C 1.516 -0.357 0 CA-C-O 121.48 0.657 . . . . 0.0 110.74 173.606 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . 0.43 HG23 ' HB2' ' A' ' 266' ' ' ASP . 40.9 t -82.86 140.0 16.97 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 CA-C-N 114.722 -1.126 . . . . 0.0 111.402 -176.354 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 293' ' ' LEU . . . . . 0.45 ' CD2' ' HB2' ' A' ' 303' ' ' SER . 3.3 mm? -103.79 -32.38 9.36 Favored 'General case' 0 C--N 1.334 -0.08 0 N-CA-C 112.353 0.501 . . . . 0.0 112.353 -177.684 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 294' ' ' ALA . . . . . 0.574 ' HA ' HG22 ' A' ' 264' ' ' VAL . . . -157.83 139.27 13.67 Favored 'General case' 0 N--CA 1.464 0.241 0 C-N-CA 120.715 -0.394 . . . . 0.0 111.798 -178.245 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 295' ' ' VAL . . . . . 0.419 HG11 ' O ' ' A' ' 262' ' ' LEU . 73.0 t -141.39 111.99 3.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.457 177.612 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 50.2 m -140.38 114.63 9.19 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.584 -0.28 . . . . 0.0 110.707 178.542 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 59.53 54.59 36.44 Favored Glycine 0 C--N 1.33 0.25 0 C-N-CA 121.146 -0.549 . . . . 0.0 112.891 179.172 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 82.8 p 53.08 21.09 1.97 Allowed 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 123.61 0.764 . . . . 0.0 112.302 -177.1 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 58.6 m -111.45 105.89 14.63 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 176.358 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . 0.606 ' O ' ' HA ' ' A' ' 254' ' ' THR . 55.2 t -105.32 131.62 54.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 115.954 -0.567 . . . . 0.0 111.547 -171.881 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 28.5 m -89.1 114.49 25.75 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 108.277 -1.009 . . . . 0.0 108.277 173.454 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 302' ' ' ILE . . . . . 0.481 ' O ' HD11 ' A' ' 302' ' ' ILE . 2.5 pp -110.58 149.07 13.6 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 N-CA-C 113.676 0.991 . . . . 0.0 113.676 -170.558 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 303' ' ' SER . . . . . 0.511 ' HB3' ' HA ' ' A' ' 304' ' ' PRO . 60.3 m -166.21 165.87 9.97 Favored Pre-proline 0 C--N 1.325 -0.487 0 N-CA-C 105.952 -1.87 . . . . 0.0 105.952 -179.724 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 304' ' ' PRO . . . . . 0.511 ' HA ' ' HB3' ' A' ' 303' ' ' SER . 5.8 Cg_exo -79.41 -146.44 0.37 Allowed 'Cis proline' 0 C--N 1.345 0.362 0 CA-C-N 120.996 1.391 . . . . 0.0 113.579 0.64 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 305' ' ' LYS . . . . . 0.542 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -84.11 146.71 27.75 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.478 -0.783 . . . . 0.0 111.739 -176.173 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 306' ' ' ILE . . . . . 0.458 ' N ' HD13 ' A' ' 306' ' ' ILE . 2.9 mp -115.26 113.73 44.35 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.199 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.92 179.227 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 307' ' ' LEU . . . . . . . . . . . . . 95.5 mt -133.97 107.37 11.54 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-O 120.563 0.22 . . . . 0.0 111.308 -179.309 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 308' ' ' PRO . . . . . 0.668 ' HG2' ' HB2' ' A' ' 311' ' ' ASN . 45.3 Cg_endo -74.51 148.0 37.03 Favored 'Trans proline' 0 C--O 1.233 0.232 0 C-N-CA 122.796 2.331 . . . . 0.0 113.573 -176.631 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . 0.418 HG23 ' O ' ' A' ' 322' ' ' VAL . 46.5 t -73.58 -34.26 41.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.059 173.0 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -86.35 34.35 0.63 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.371 -0.832 . . . . 0.0 111.143 178.468 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.668 ' HB2' ' HG2' ' A' ' 308' ' ' PRO . 25.7 t-20 -81.32 -34.2 32.04 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -178.287 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 41.8 m 73.91 -11.27 0.98 Allowed 'General case' 0 CA--C 1.539 0.529 0 CA-C-N 115.328 -0.851 . . . . 0.0 111.679 178.662 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 313' ' ' ASP . . . . . 0.495 ' HB3' ' HG ' ' A' ' 316' ' ' SER . 31.1 t70 -79.67 117.42 20.57 Favored 'General case' 0 C--N 1.329 -0.286 0 O-C-N 121.951 -0.468 . . . . 0.0 110.27 175.119 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 314' ' ' VAL . . . . . 0.427 HG11 ' O ' ' A' ' 314' ' ' VAL . 26.5 t -59.32 -20.4 18.07 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.473 0 CA-C-N 115.781 -0.645 . . . . 0.0 112.268 -174.706 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -84.89 -38.41 19.45 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 111.949 0.352 . . . . 0.0 111.949 -179.364 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 316' ' ' SER . . . . . 0.495 ' HG ' ' HB3' ' A' ' 313' ' ' ASP . 38.3 p -97.93 -28.83 13.64 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 113.511 0.93 . . . . 0.0 113.511 -172.33 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 317' ' ' ARG . . . . . 0.616 ' N ' ' HD2' ' A' ' 318' ' ' PRO . 16.1 ptm180 -66.18 -35.76 11.37 Favored Pre-proline 0 CA--C 1.547 0.86 0 N-CA-C 113.656 0.984 . . . . 0.0 113.656 -176.182 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 318' ' ' PRO . . . . . 0.616 ' HD2' ' N ' ' A' ' 317' ' ' ARG . 12.8 Cg_endo -58.38 -34.13 98.42 Favored 'Trans proline' 0 C--N 1.366 1.468 0 C-N-CA 121.666 1.577 . . . . 0.0 112.512 -179.861 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 51.0 m-85 -101.02 36.8 1.88 Allowed 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.6 -178.085 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -67.86 139.64 56.53 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.485 -178.183 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 321' ' ' ASN . . . . . 0.405 ' OD1' HG11 ' A' ' 322' ' ' VAL . 20.5 p30 -121.78 -14.66 8.07 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.516 178.012 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 322' ' ' VAL . . . . . 0.458 HG23 HG23 ' A' ' 306' ' ' ILE . 34.1 m -133.59 166.74 28.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 115.618 -0.719 . . . . 0.0 109.195 173.458 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 65.0 m-20 -82.7 -27.53 31.16 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 112.164 0.431 . . . . 0.0 112.164 -176.375 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 324' ' ' ALA . . . . . 0.517 ' CA ' ' HB3' ' A' ' 308' ' ' PRO . . . -160.58 158.21 28.66 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.973 0.416 . . . . 0.0 111.716 -175.209 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 325' ' ' LYS . . . . . 0.717 ' HD2' ' HG3' ' A' ' 235' ' ' GLU . 21.5 pttp -114.01 127.26 27.01 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 115.714 -0.676 . . . . 0.0 110.157 177.318 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -86.08 167.84 9.32 Favored 'Trans proline' 0 N--CA 1.457 -0.651 0 C-N-CA 122.814 2.343 . . . . 0.0 112.758 -178.213 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -71.71 124.4 24.69 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.471 178.927 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 61.69 -118.44 0.68 Allowed 'General case' 0 N--CA 1.464 0.239 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.323 -175.578 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 329' ' ' SER . . . . . 0.568 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 32.6 m -112.18 -33.94 6.08 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.59 -0.277 . . . . 0.0 111.309 179.863 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 76.24 -165.99 0.06 Allowed 'General case' 0 N--CA 1.474 0.725 0 O-C-N 123.844 0.715 . . . . 0.0 112.432 177.429 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 331' ' ' ALA . . . . . 0.555 ' HA ' ' HA ' ' A' ' 229' ' ' THR . . . -82.88 153.92 24.87 Favored 'General case' 0 CA--C 1.519 -0.236 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.899 -177.226 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 332' ' ' ILE . . . . . 0.57 HD12 HG23 ' A' ' 230' ' ' VAL . 44.4 mt -128.49 144.85 36.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 121.233 0.54 . . . . 0.0 111.762 -177.616 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.551 ' HB ' ' OG1' ' A' ' 269' ' ' THR . 94.7 m -108.63 118.75 37.59 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.291 -0.868 . . . . 0.0 109.207 175.23 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 31.9 mm -97.26 132.33 42.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 N-CA-C 113.761 1.023 . . . . 0.0 113.761 -168.025 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 335' ' ' LEU . . . . . 0.575 HD22 ' N ' ' A' ' 335' ' ' LEU . 1.5 pt? -150.78 -162.32 1.53 Allowed 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 113.977 -1.465 . . . . 0.0 108.129 167.993 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 14.9 p-10 -159.34 35.49 0.2 Allowed 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 120.949 0.404 . . . . 0.0 110.212 178.055 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 88.4 tttt . . . . . 0 C--O 1.245 0.83 0 CA-C-N 115.023 -0.99 . . . . 0.0 110.722 -179.433 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 20.3 m . . . . . 0 C--O 1.231 0.131 0 N-CA-C 110.018 -0.364 . . . . 0.0 110.018 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 228' ' ' LEU . . . . . 0.52 HD22 ' HA ' ' A' ' 259' ' ' ALA . 87.7 mt -69.49 136.98 52.17 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.509 176.936 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 229' ' ' THR . . . . . 0.543 ' O ' HG21 ' A' ' 230' ' ' VAL . 61.3 p -125.22 173.99 8.41 Favored 'General case' 0 C--N 1.325 -0.49 0 C-N-CA 119.721 -0.792 . . . . 0.0 110.374 179.766 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 230' ' ' VAL . . . . . 0.614 HG23 HD12 ' A' ' 332' ' ' ILE . 94.5 t -146.06 139.8 20.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-O 120.873 0.368 . . . . 0.0 110.549 -178.801 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 231' ' ' SER . . . . . 0.61 ' HA ' ' OE1' ' A' ' 328' ' ' GLU . 45.8 t -106.04 150.75 25.45 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-N 115.485 -0.779 . . . . 0.0 110.64 178.145 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . 0.424 ' O ' HG23 ' A' ' 255' ' ' ILE . . . 79.32 92.67 0.36 Allowed Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.409 178.408 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 233' ' ' GLN . . . . . 0.445 ' O ' ' HG3' ' A' ' 235' ' ' GLU . 82.8 mt-30 -42.74 135.37 2.75 Favored Pre-proline 0 N--CA 1.47 0.531 0 N-CA-C 112.595 0.591 . . . . 0.0 112.595 -177.997 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -62.97 127.94 21.69 Favored 'Trans proline' 0 C--N 1.349 0.59 0 C-N-CA 122.521 2.147 . . . . 0.0 111.18 175.018 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 235' ' ' GLU . . . . . 0.445 ' HG3' ' O ' ' A' ' 233' ' ' GLN . 49.0 mt-10 -113.64 117.46 31.65 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 112.281 0.475 . . . . 0.0 112.281 -170.419 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 236' ' ' HIS . . . . . 0.532 ' CD2' ' HB2' ' A' ' 305' ' ' LYS . 27.6 t60 -138.32 130.92 29.25 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.507 172.984 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 237' ' ' LYS . . . . . 0.545 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.322 -0.608 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.527 -179.624 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 40.7 mt-30 . . . . . 0 N--CA 1.466 0.351 0 CA-C-O 121.414 0.626 . . . . 0.0 111.515 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . 0.423 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -169.1 105.87 0.23 Allowed Glycine 0 N--CA 1.444 -0.799 0 CA-C-N 115.352 -0.84 . . . . 0.0 111.309 177.391 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 62.8 p -93.47 116.15 28.68 Favored 'General case' 0 C--N 1.324 -0.515 0 C-N-CA 120.579 -0.448 . . . . 0.0 110.006 -177.993 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . 0.424 HG23 ' O ' ' A' ' 232' ' ' GLY . 19.0 pt -129.27 157.18 42.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.807 -0.633 . . . . 0.0 112.01 -172.162 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 28.8 m -96.3 109.66 22.12 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 174.606 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.478 HG13 HG22 ' A' ' 230' ' ' VAL . 33.6 m -89.94 142.37 13.01 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 C-N-CA 119.429 -0.908 . . . . 0.0 112.235 -173.022 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 31.6 m -93.2 9.53 35.68 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 114.377 -1.283 . . . . 0.0 109.44 171.974 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 259' ' ' ALA . . . . . 0.52 ' HA ' HD22 ' A' ' 228' ' ' LEU . . . -80.97 -177.37 6.39 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.189 -175.709 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 50.9 m -125.07 118.92 27.24 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 112.232 0.456 . . . . 0.0 112.232 -175.522 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 59.49 51.35 59.59 Favored Glycine 0 C--N 1.331 0.284 0 CA-C-N 115.656 -0.702 . . . . 0.0 114.127 172.19 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 262' ' ' LEU . . . . . . . . . . . . . 67.9 mt -77.96 160.13 28.39 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 117.453 0.626 . . . . 0.0 110.559 177.753 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 85.7 mt-30 -141.74 167.09 22.96 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.453 179.864 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 264' ' ' VAL . . . . . 0.441 HG22 ' HA ' ' A' ' 294' ' ' ALA . 44.0 t -78.67 141.47 15.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.496 178.32 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 93.55 1.2 66.36 Favored Glycine 0 N--CA 1.453 -0.229 0 C-N-CA 120.535 -0.84 . . . . 0.0 112.757 177.174 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 266' ' ' ASP . . . . . 0.439 ' HB3' ' CG2' ' A' ' 334' ' ' ILE . 1.3 m-20 -81.09 164.82 22.14 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.032 0.444 . . . . 0.0 110.585 178.243 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 267' ' ' ALA . . . . . 0.53 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -124.37 146.77 48.65 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.796 -178.086 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 268' ' ' PHE . . . . . 0.674 ' HB3' ' HA ' ' A' ' 334' ' ' ILE . 11.1 p90 -164.09 177.88 8.09 Favored 'General case' 0 C--N 1.322 -0.629 0 C-N-CA 120.152 -0.619 . . . . 0.0 112.405 -176.177 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 269' ' ' THR . . . . . 0.492 HG21 ' HB2' ' A' ' 287' ' ' PRO . 43.2 p -134.03 156.55 48.02 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 114.646 -1.161 . . . . 0.0 109.002 173.138 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 270' ' ' ILE . . . . . 0.934 HG12 HG13 ' A' ' 332' ' ' ILE . 77.6 mt -119.15 141.78 37.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-O 120.569 0.223 . . . . 0.0 110.682 -177.524 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -70.16 128.7 37.2 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.768 0.318 . . . . 0.0 110.973 178.112 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 90.56 -23.3 23.12 Favored Glycine 0 N--CA 1.453 -0.172 0 C-N-CA 121.267 -0.492 . . . . 0.0 112.023 -177.822 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . 0.452 ' HB ' ' HB ' ' A' ' 270' ' ' ILE . 57.2 t -94.58 103.23 14.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 175.043 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 274' ' ' ASN . . . . . 0.446 ' HB3' ' O ' ' A' ' 285' ' ' GLY . 8.1 m120 -125.03 129.43 50.27 Favored 'General case' 0 C--N 1.316 -0.865 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 -179.613 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 275' ' ' SER . . . . . 0.523 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 48.8 m -84.18 173.52 10.97 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.751 0.786 . . . . 0.0 112.974 -167.031 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 276' ' ' VAL . . . . . 0.622 HG11 HG23 ' A' ' 283' ' ' THR . 18.5 m -122.95 166.87 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 CA-C-N 114.676 -1.147 . . . . 0.0 109.327 176.41 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 277' ' ' HIS . . . . . 0.499 ' O ' ' HA ' ' A' ' 281' ' ' LYS . 33.6 m80 -88.16 123.89 33.26 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 177.853 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 10.5 mm100 -80.29 -17.16 52.94 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.086 -176.614 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 46.7 mm -70.31 -65.19 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.736 -179.531 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 64.6 p -108.05 11.58 27.6 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.506 -0.316 . . . . 0.0 111.851 -177.323 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 281' ' ' LYS . . . . . 0.499 ' HA ' ' O ' ' A' ' 277' ' ' HIS . 12.7 mptt 55.41 47.47 21.12 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-O 121.122 0.487 . . . . 0.0 111.192 -177.489 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 282' ' ' ASP . . . . . 0.477 ' HB3' ' HB2' ' A' ' 277' ' ' HIS . 7.3 t70 -79.91 108.96 13.9 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.619 176.971 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.622 HG23 HG11 ' A' ' 276' ' ' VAL . 64.4 p -102.97 98.22 8.22 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.591 -178.142 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 31.1 p -140.55 10.8 2.28 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.613 -0.721 . . . . 0.0 111.763 -177.737 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 285' ' ' GLY . . . . . 0.446 ' O ' ' HB3' ' A' ' 274' ' ' ASN . . . 75.66 33.57 51.49 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.177 -1.011 . . . . 0.0 113.26 175.651 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 286' ' ' GLN . . . . . 0.464 ' O ' ' HB2' ' A' ' 275' ' ' SER . 11.6 mm100 -91.27 111.77 50.52 Favored Pre-proline 0 C--N 1.325 -0.469 0 CA-C-N 117.006 0.403 . . . . 0.0 110.782 -179.636 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 287' ' ' PRO . . . . . 0.492 ' HB2' HG21 ' A' ' 269' ' ' THR . 14.7 Cg_endo -59.59 134.26 56.8 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.916 2.41 . . . . 0.0 113.155 -177.057 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 5.4 tm0? -110.13 152.31 26.18 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 176.806 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 289' ' ' VAL . . . . . 0.463 ' CG1' ' HB3' ' A' ' 267' ' ' ALA . 53.8 t -68.18 134.03 30.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 CA-C-O 120.924 0.392 . . . . 0.0 111.988 -171.806 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 290' ' ' PHE . . . . . 0.8 ' HA ' ' HD3' ' A' ' 304' ' ' PRO . 4.5 m-85 -97.88 159.48 14.9 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.75 178.051 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 20.3 mmt85 -131.45 125.63 33.0 Favored 'General case' 0 N--CA 1.453 -0.316 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.622 -179.02 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 53.2 t -76.01 135.34 27.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.161 179.318 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 293' ' ' LEU . . . . . 0.473 ' CD1' ' HG ' ' A' ' 303' ' ' SER . 85.4 mt -99.49 -43.0 6.69 Favored 'General case' 0 C--N 1.333 -0.13 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.502 179.769 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 294' ' ' ALA . . . . . 0.449 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -154.34 144.23 21.77 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.496 -0.32 . . . . 0.0 111.183 -175.52 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 59.0 t -135.91 113.3 14.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.714 176.87 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 45.6 t -157.33 125.02 5.34 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.55 -177.738 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 61.26 43.7 99.04 Favored Glycine 0 C--N 1.331 0.25 0 C-N-CA 120.987 -0.625 . . . . 0.0 111.773 -177.93 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 67.1 p 50.82 23.02 1.27 Allowed 'General case' 0 N--CA 1.471 0.604 0 C-N-CA 123.709 0.804 . . . . 0.0 112.23 -175.052 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 59.6 m -111.9 116.96 31.48 Favored 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 176.852 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . 0.455 HG23 HG11 ' A' ' 257' ' ' VAL . 61.5 t -113.1 126.67 70.54 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.176 -173.15 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 54.5 m -91.24 116.2 28.63 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 173.987 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 302' ' ' ILE . . . . . 0.423 HG12 ' O ' ' A' ' 253' ' ' GLY . 29.5 pt -111.5 158.78 11.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 N-CA-C 113.234 0.828 . . . . 0.0 113.234 -170.013 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 303' ' ' SER . . . . . 0.512 ' HB3' ' HA ' ' A' ' 304' ' ' PRO . 72.1 m -144.47 166.16 19.97 Favored Pre-proline 0 C--N 1.323 -0.584 0 CA-C-N 113.631 -1.622 . . . . 0.0 107.05 172.521 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 304' ' ' PRO . . . . . 0.8 ' HD3' ' HA ' ' A' ' 290' ' ' PHE . 10.5 Cg_exo -72.7 -169.8 6.86 Favored 'Cis proline' 0 C--N 1.346 0.423 0 CA-C-N 120.719 1.293 . . . . 0.0 113.484 0.605 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 305' ' ' LYS . . . . . 0.532 ' HB2' ' CD2' ' A' ' 236' ' ' HIS . 0.0 OUTLIER -78.18 147.73 34.37 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.471 -0.786 . . . . 0.0 111.333 -177.774 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 306' ' ' ILE . . . . . 0.641 HD12 ' HE2' ' A' ' 290' ' ' PHE . 51.1 mm -114.07 110.71 33.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.718 -174.244 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 307' ' ' LEU . . . . . 0.455 ' HG ' ' CD2' ' A' ' 236' ' ' HIS . 90.7 mt -134.04 123.06 16.66 Favored Pre-proline 0 N--CA 1.465 0.28 0 CA-C-N 116.62 -0.264 . . . . 0.0 111.46 175.776 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 308' ' ' PRO . . . . . 0.739 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 32.7 Cg_exo -67.68 148.92 78.7 Favored 'Trans proline' 0 C--O 1.233 0.236 0 C-N-CA 123.705 2.937 . . . . 0.0 114.284 -176.333 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . 0.447 HG12 ' O ' ' A' ' 309' ' ' VAL . 45.2 t -94.14 -13.79 8.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.132 -0.94 . . . . 0.0 109.055 168.988 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 53.1 mt-10 -78.51 35.79 0.24 Allowed 'General case' 0 CA--C 1.533 0.317 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.959 177.225 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.768 ' HA ' ' HD3' ' A' ' 317' ' ' ARG . 15.5 p30 40.74 66.23 0.67 Allowed 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 114.258 1.207 . . . . 0.0 114.258 173.733 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 85.0 m -81.35 -41.55 21.84 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.753 -0.658 . . . . 0.0 109.657 170.118 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 59.0 t0 -137.83 146.05 43.0 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 175.541 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 61.3 t -62.02 -43.36 97.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 O-C-N 123.191 0.307 . . . . 0.0 111.078 178.858 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -69.96 -19.88 63.34 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.005 0.431 . . . . 0.0 111.094 178.58 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 316' ' ' SER . . . . . 0.439 ' HG ' ' HB3' ' A' ' 307' ' ' LEU . 35.0 t -78.74 -15.24 58.69 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.502 179.804 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 317' ' ' ARG . . . . . 0.768 ' HD3' ' HA ' ' A' ' 311' ' ' ASN . 2.4 mmm180 -74.52 -51.87 4.04 Favored Pre-proline 0 CA--C 1.536 0.437 0 N-CA-C 112.883 0.697 . . . . 0.0 112.883 -177.709 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 318' ' ' PRO . . . . . 0.578 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 23.5 Cg_exo -64.95 -18.95 63.69 Favored 'Trans proline' 0 C--N 1.355 0.874 0 C-N-CA 121.844 1.696 . . . . 0.0 112.388 -178.407 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 319' ' ' TYR . . . . . 0.407 ' O ' HD11 ' A' ' 307' ' ' LEU . 3.7 m-85 -113.52 22.08 14.49 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.284 -179.499 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -59.68 142.29 53.32 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.226 -177.408 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 50.3 t30 -135.2 -21.57 1.6 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.942 -178.917 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 322' ' ' VAL . . . . . 0.523 ' HA ' ' HA ' ' A' ' 275' ' ' SER . 34.7 m -140.53 172.04 12.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.141 178.658 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 51.1 m-20 -65.94 -44.76 84.09 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.647 -0.251 . . . . 0.0 111.427 179.203 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 324' ' ' ALA . . . . . 0.739 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -174.97 -178.86 1.29 Allowed 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 112.358 0.503 . . . . 0.0 112.358 -177.229 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 36.5 mtmm -108.01 116.72 56.59 Favored Pre-proline 0 N--CA 1.452 -0.364 0 CA-C-N 114.51 -1.223 . . . . 0.0 108.404 168.261 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -71.64 167.09 27.45 Favored 'Trans proline' 0 C--O 1.233 0.236 0 C-N-CA 122.411 2.074 . . . . 0.0 112.22 -177.905 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -67.58 121.58 16.17 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 175.541 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 328' ' ' GLU . . . . . 0.61 ' OE1' ' HA ' ' A' ' 231' ' ' SER . 31.2 tp10 67.53 164.4 0.21 Allowed 'General case' 0 CA--C 1.537 0.45 0 O-C-N 123.986 0.804 . . . . 0.0 109.562 -174.204 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 329' ' ' SER . . . . . 0.486 ' HB2' ' O ' ' A' ' 230' ' ' VAL . 53.5 m -71.21 -29.65 65.41 Favored 'General case' 0 C--N 1.327 -0.403 0 O-C-N 121.65 -0.656 . . . . 0.0 110.875 -177.838 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 74.86 -153.11 0.04 OUTLIER 'General case' 0 N--CA 1.469 0.514 0 O-C-N 123.971 0.794 . . . . 0.0 112.499 173.342 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -87.22 116.61 25.42 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.149 -0.932 . . . . 0.0 111.167 -176.816 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 332' ' ' ILE . . . . . 0.934 HG13 HG12 ' A' ' 270' ' ' ILE . 1.8 mp -107.67 139.92 27.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 177.556 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.419 ' N ' HG22 ' A' ' 332' ' ' ILE . 61.6 m -129.68 103.89 7.11 Favored 'General case' 0 C--N 1.327 -0.392 0 C-N-CA 120.853 -0.339 . . . . 0.0 111.306 -174.624 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 334' ' ' ILE . . . . . 0.674 ' HA ' ' HB3' ' A' ' 268' ' ' PHE . 3.1 mp -90.73 134.98 27.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.491 -177.161 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 335' ' ' LEU . . . . . 0.447 HD21 ' O ' ' A' ' 267' ' ' ALA . 1.6 pt? -116.73 136.35 53.03 Favored 'General case' 0 N--CA 1.441 -0.897 0 N-CA-C 107.721 -1.215 . . . . 0.0 107.721 166.366 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 15.4 p-10 -75.46 47.56 0.39 Allowed 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.141 0.496 . . . . 0.0 110.822 -177.277 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 337' ' ' LYS . . . . . 0.618 ' HZ2' ' HB2' ' A' ' 337' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.243 0.722 0 CA-C-O 118.364 -0.827 . . . . 0.0 110.603 179.442 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 26.9 m . . . . . 0 N--CA 1.454 -0.268 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 228' ' ' LEU . . . . . 0.401 HD11 ' CG1' ' A' ' 334' ' ' ILE . 72.9 mt -91.54 87.94 6.58 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 -178.836 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 229' ' ' THR . . . . . 0.462 ' O ' HG22 ' A' ' 230' ' ' VAL . 22.7 p -113.76 173.43 6.43 Favored 'General case' 0 C--N 1.316 -0.865 0 C-N-CA 119.739 -0.784 . . . . 0.0 110.386 -177.953 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 230' ' ' VAL . . . . . 0.632 HG21 HD11 ' A' ' 332' ' ' ILE . 78.9 t -142.75 133.12 23.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-O 121.023 0.439 . . . . 0.0 110.785 -176.542 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 39.5 t -108.31 100.28 9.59 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-N 115.339 -0.846 . . . . 0.0 109.482 175.725 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . -173.27 166.77 39.32 Favored Glycine 0 N--CA 1.444 -0.786 0 N-CA-C 111.391 -0.684 . . . . 0.0 111.391 -178.35 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 12.9 mm-40 -107.49 102.03 42.34 Favored Pre-proline 0 C--N 1.321 -0.659 0 CA-C-N 116.706 0.253 . . . . 0.0 110.72 -179.866 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 234' ' ' PRO . . . . . 0.585 ' HB2' HD13 ' A' ' 306' ' ' ILE . 33.7 Cg_endo -98.11 127.14 0.22 Allowed 'Trans proline' 0 N--CA 1.451 -1.002 0 C-N-CA 123.034 2.489 . . . . 0.0 112.227 -178.479 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -160.28 -177.39 6.22 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.709 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 33.4 t-80 -159.14 132.98 7.47 Favored 'General case' 0 CA--C 1.517 -0.297 0 CA-C-O 121.605 0.716 . . . . 0.0 111.941 176.38 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 237' ' ' LYS . . . . . 0.607 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.322 -0.608 0 CA-C-N 114.67 -1.15 . . . . 0.0 110.012 178.203 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 3.1 mm100 . . . . . 0 N--CA 1.463 0.176 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 253' ' ' GLY . . . . . 0.44 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -128.19 116.06 2.22 Favored Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 118.941 -1.6 . . . . 0.0 113.423 -174.275 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 254' ' ' THR . . . . . 0.47 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 80.9 p -109.41 115.45 29.98 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 170.605 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 255' ' ' ILE . . . . . 0.595 HD11 HG11 ' A' ' 230' ' ' VAL . 2.0 pp -131.52 164.85 33.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 N-CA-C 112.733 0.642 . . . . 0.0 112.733 -172.79 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 256' ' ' THR . . . . . 0.413 ' O ' HG12 ' A' ' 230' ' ' VAL . 28.9 m -102.17 118.29 36.59 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 178.789 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 257' ' ' VAL . . . . . 0.402 ' O ' HG23 ' A' ' 257' ' ' VAL . 35.0 m -90.4 142.91 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.728 0 C-N-CA 119.768 -0.773 . . . . 0.0 112.762 -172.17 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 32.1 t -91.96 9.56 32.6 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 113.772 -1.558 . . . . 0.0 108.317 168.679 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 259' ' ' ALA . . . . . . . . . . . . . . . -92.19 160.94 14.93 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-N 115.303 -0.862 . . . . 0.0 109.184 179.588 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 34.9 t -118.22 131.06 56.4 Favored 'General case' 0 C--N 1.322 -0.627 0 C-N-CA 120.779 -0.368 . . . . 0.0 111.491 -175.794 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 69.96 51.05 25.71 Favored Glycine 0 N--CA 1.449 -0.445 0 CA-C-N 115.607 -0.724 . . . . 0.0 113.655 173.656 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 262' ' ' LEU . . . . . . . . . . . . . 62.6 mt -91.23 151.55 20.88 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 117.044 0.422 . . . . 0.0 110.161 176.63 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 82.5 mt-30 -137.42 168.22 20.08 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.026 0.441 . . . . 0.0 110.883 -178.427 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 264' ' ' VAL . . . . . 0.521 HG11 ' O ' ' A' ' 292' ' ' VAL . 57.6 t -78.23 123.74 35.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.971 176.915 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . 0.438 ' H ' ' HB ' ' A' ' 292' ' ' VAL . . . 114.15 6.98 19.81 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.51 -0.852 . . . . 0.0 112.808 -179.978 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 61.7 m-20 -89.7 166.02 13.84 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.157 0.503 . . . . 0.0 110.611 176.205 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 267' ' ' ALA . . . . . 0.684 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -129.61 153.3 48.21 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.287 -0.87 . . . . 0.0 109.008 177.676 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 268' ' ' PHE . . . . . 0.648 ' HD2' HG23 ' A' ' 332' ' ' ILE . 9.9 p90 -164.0 165.73 22.21 Favored 'General case' 0 C--N 1.32 -0.675 0 C-N-CA 119.701 -0.8 . . . . 0.0 112.498 -176.887 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 269' ' ' THR . . . . . 0.52 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 66.4 p -115.45 149.51 37.94 Favored 'General case' 0 N--CA 1.444 -0.763 0 CA-C-N 114.624 -1.171 . . . . 0.0 109.224 173.302 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 270' ' ' ILE . . . . . 0.968 HG12 HG13 ' A' ' 332' ' ' ILE . 60.5 mt -121.46 131.47 72.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 N-CA-C 110.416 -0.216 . . . . 0.0 110.416 -179.26 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -62.24 132.91 54.26 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.124 -179.499 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 91.47 -21.72 33.94 Favored Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.182 -178.08 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 273' ' ' VAL . . . . . 0.653 HG23 HD12 ' A' ' 306' ' ' ILE . 31.0 t -105.38 104.36 16.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 C-N-CA 122.402 0.281 . . . . 0.0 110.367 -179.483 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 274' ' ' ASN . . . . . 0.473 ' HA ' ' HA ' ' A' ' 287' ' ' PRO . 7.3 m120 -126.11 144.42 50.74 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.509 -0.476 . . . . 0.0 111.408 -175.429 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 275' ' ' SER . . . . . 0.47 ' HB3' ' OE1' ' A' ' 288' ' ' GLN . 29.5 p -63.77 160.98 16.09 Favored 'General case' 0 CA--C 1.515 -0.377 0 CA-C-N 115.826 -0.624 . . . . 0.0 112.494 -179.377 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 33.8 m -119.36 149.94 21.85 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.663 0 CA-C-N 114.916 -1.038 . . . . 0.0 110.618 176.246 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 87.9 m-70 -109.73 71.62 0.77 Allowed 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 173.323 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 -74.42 -9.62 58.77 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.379 -0.828 . . . . 0.0 112.136 -173.459 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 279' ' ' ILE . . . . . 0.416 HD11 HG23 ' A' ' 279' ' ' ILE . 47.1 mm -92.4 -56.6 5.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 120.732 0.301 . . . . 0.0 110.761 -179.676 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 280' ' ' THR . . . . . 0.413 ' HG1' ' CG ' ' A' ' 282' ' ' ASP . 73.0 p -86.48 -14.42 43.2 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.321 -178.716 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 281' ' ' LYS . . . . . 0.434 ' HZ3' ' HB3' ' A' ' 281' ' ' LYS . 3.1 mmmp? 62.27 48.47 4.8 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.994 -178.231 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 282' ' ' ASP . . . . . 0.413 ' CG ' ' HG1' ' A' ' 280' ' ' THR . 52.6 m-20 -92.28 122.92 35.21 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.285 176.943 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 60.9 p -89.35 102.68 15.35 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.052 0.453 . . . . 0.0 110.054 176.616 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 68.5 p -130.91 -40.22 1.19 Allowed 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.837 -0.619 . . . . 0.0 111.242 -174.972 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 73.07 32.36 60.66 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 120.518 -0.848 . . . . 0.0 112.254 -179.624 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 73.6 mt-30 -76.19 140.41 69.48 Favored Pre-proline 0 C--O 1.223 -0.321 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.603 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 287' ' ' PRO . . . . . 0.52 ' HB2' ' HB ' ' A' ' 269' ' ' THR . 36.2 Cg_endo -69.78 150.57 68.26 Favored 'Trans proline' 0 CA--C 1.529 0.255 0 C-N-CA 122.057 1.838 . . . . 0.0 112.566 -177.163 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 288' ' ' GLN . . . . . 0.47 ' OE1' ' HB3' ' A' ' 275' ' ' SER . 5.5 mm100 -78.34 149.28 33.47 Favored 'General case' 0 CA--C 1.514 -0.422 0 CA-C-O 121.186 0.517 . . . . 0.0 112.2 176.929 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 49.7 t -104.61 112.7 39.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 114.877 -1.056 . . . . 0.0 109.37 175.569 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 290' ' ' PHE . . . . . 0.684 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 53.9 m-85 -98.85 160.23 14.41 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.384 -175.584 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 32.7 mmt180 -118.02 150.54 39.12 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 178.588 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 292' ' ' VAL . . . . . 0.521 ' O ' HG11 ' A' ' 264' ' ' VAL . 52.5 t -100.25 122.92 52.76 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.913 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.57 -177.87 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 293' ' ' LEU . . . . . 0.575 HD21 ' N ' ' A' ' 293' ' ' LEU . 3.4 mm? -104.41 -24.1 13.1 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.465 -0.334 . . . . 0.0 111.674 -177.332 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 294' ' ' ALA . . . . . 0.493 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -154.4 136.59 14.79 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 120.762 -0.375 . . . . 0.0 111.638 179.898 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 58.0 t -135.51 120.1 27.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 175.104 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 31.2 t -157.41 111.69 2.65 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.604 -178.331 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 63.34 50.2 64.43 Favored Glycine 0 C--N 1.33 0.229 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.059 -178.315 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 72.2 p 50.82 23.38 1.4 Allowed 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 123.445 0.698 . . . . 0.0 112.524 -175.576 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 299' ' ' THR . . . . . 0.453 ' HA ' ' O ' ' A' ' 255' ' ' ILE . 40.6 m -111.75 116.87 31.43 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 176.148 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . 0.557 HG13 HG22 ' A' ' 302' ' ' ILE . 59.1 t -113.69 133.91 58.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.619 -172.34 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 43.5 m -96.82 120.61 37.46 Favored 'General case' 0 C--O 1.235 0.32 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 172.548 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 302' ' ' ILE . . . . . 0.557 HG22 HG13 ' A' ' 300' ' ' VAL . 27.7 pt -111.26 143.72 20.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-O 121.626 0.727 . . . . 0.0 112.811 -169.725 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 303' ' ' SER . . . . . 0.455 ' HB3' ' CD2' ' A' ' 293' ' ' LEU . 46.8 t -156.29 129.11 4.26 Favored Pre-proline 0 C--N 1.323 -0.578 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 173.24 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 304' ' ' PRO . . . . . 0.616 ' HD2' ' HA ' ' A' ' 290' ' ' PHE . 34.8 Cg_exo -63.0 -176.05 4.24 Favored 'Cis proline' 0 N--CA 1.477 0.505 0 CA-C-N 119.912 1.004 . . . . 0.0 114.324 1.807 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 305' ' ' LYS . . . . . 0.658 ' HE2' HD13 ' A' ' 307' ' ' LEU . 0.0 OUTLIER -136.57 -175.52 4.04 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.938 -176.205 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 306' ' ' ILE . . . . . 0.653 HD12 HG23 ' A' ' 273' ' ' VAL . 41.8 mt -94.29 99.97 10.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.946 -173.525 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 307' ' ' LEU . . . . . 0.658 HD13 ' HE2' ' A' ' 305' ' ' LYS . 2.7 mp -114.43 105.55 53.63 Favored Pre-proline 0 C--N 1.33 -0.277 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 175.729 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 308' ' ' PRO . . . . . 0.727 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 24.1 Cg_exo -68.92 127.66 15.61 Favored 'Trans proline' 0 CA--C 1.53 0.286 0 C-N-CA 122.955 2.437 . . . . 0.0 113.394 -176.07 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . 0.475 HG23 ' HB1' ' A' ' 320' ' ' ALA . 76.9 t -84.27 -37.14 12.6 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.088 174.966 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -75.29 -6.65 50.93 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.256 179.243 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.481 ' HB2' ' HB2' ' A' ' 308' ' ' PRO . 69.7 m-80 -136.87 -158.69 0.88 Allowed 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.262 -0.427 . . . . 0.0 109.996 -176.633 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 16.5 m 71.23 -73.16 0.1 Allowed 'General case' 0 C--O 1.234 0.275 0 C-N-CA 123.755 0.822 . . . . 0.0 110.903 177.005 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 51.0 t0 -176.44 159.81 2.0 Allowed 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 177.253 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 61.7 t -64.45 -39.73 86.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-O 120.908 0.385 . . . . 0.0 110.55 176.038 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -72.5 -18.87 61.62 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.637 178.732 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 50.3 m -83.86 -25.86 29.92 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.535 -0.302 . . . . 0.0 111.177 -179.221 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 317' ' ' ARG . . . . . 0.659 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 74.1 mtm180 -49.14 -52.57 46.88 Favored Pre-proline 0 CA--C 1.539 0.52 0 N-CA-C 112.641 0.608 . . . . 0.0 112.641 -178.574 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 318' ' ' PRO . . . . . 0.659 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 51.8 Cg_exo -59.74 -13.97 24.56 Favored 'Trans proline' 0 C--N 1.36 1.14 0 C-N-CA 122.53 2.154 . . . . 0.0 113.833 -177.232 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 44.9 m-85 -110.75 -0.55 17.0 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.99 0.424 . . . . 0.0 110.77 -179.282 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 320' ' ' ALA . . . . . 0.647 ' HB3' ' O ' ' A' ' 307' ' ' LEU . . . -90.5 159.85 16.3 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.155 -178.899 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 321' ' ' ASN . . . . . 0.427 ' O ' ' HA ' ' A' ' 275' ' ' SER . 0.1 OUTLIER -130.68 -0.69 4.33 Favored 'General case' 0 N--CA 1.464 0.255 0 N-CA-C 112.75 0.648 . . . . 0.0 112.75 -178.977 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 322' ' ' VAL . . . . . 0.537 HG11 HG11 ' A' ' 273' ' ' VAL . 32.8 m -136.11 162.08 36.71 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.258 0 N-CA-C 110.097 -0.334 . . . . 0.0 110.097 176.988 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 51.6 m-20 -72.92 -39.82 65.97 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 111.731 0.271 . . . . 0.0 111.731 -176.376 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 324' ' ' ALA . . . . . 0.727 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -155.5 174.61 15.02 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 112.149 0.426 . . . . 0.0 112.149 -173.353 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 24.6 pttm -119.12 107.44 41.73 Favored Pre-proline 0 N--CA 1.454 -0.233 0 CA-C-N 115.472 -0.785 . . . . 0.0 110.031 170.923 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 55.0 Cg_endo -74.04 167.82 26.28 Favored 'Trans proline' 0 C--O 1.233 0.232 0 C-N-CA 122.695 2.263 . . . . 0.0 112.562 -176.525 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -71.6 123.81 23.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.875 -179.289 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 54.8 mt-10 66.36 -170.14 0.2 Allowed 'General case' 0 N--CA 1.465 0.32 0 O-C-N 123.674 0.609 . . . . 0.0 111.004 -175.998 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 329' ' ' SER . . . . . 0.552 ' HB2' ' O ' ' A' ' 230' ' ' VAL . 50.9 m -94.29 -27.81 15.93 Favored 'General case' 0 C--N 1.325 -0.467 0 C-N-CA 120.727 -0.389 . . . . 0.0 111.995 -174.458 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 75.62 -151.32 0.03 OUTLIER 'General case' 0 N--CA 1.478 0.95 0 N-CA-C 113.273 0.842 . . . . 0.0 113.273 173.023 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 331' ' ' ALA . . . . . 0.407 ' C ' HD12 ' A' ' 332' ' ' ILE . . . -92.98 120.64 33.49 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 114.741 -1.118 . . . . 0.0 110.818 -177.735 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 332' ' ' ILE . . . . . 0.968 HG13 HG12 ' A' ' 270' ' ' ILE . 1.7 mp -106.54 145.87 13.73 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 115.682 -0.69 . . . . 0.0 111.221 -176.903 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.415 ' N ' HG21 ' A' ' 332' ' ' ILE . 44.1 m -118.29 95.33 4.83 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.0 -178.077 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 334' ' ' ILE . . . . . 0.528 ' HA ' ' HB3' ' A' ' 268' ' ' PHE . 39.8 mm -78.34 133.48 30.18 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-O 120.949 0.404 . . . . 0.0 111.35 -176.276 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 335' ' ' LEU . . . . . 0.603 HD13 ' H ' ' A' ' 337' ' ' LYS . 1.8 pp -152.44 -172.65 4.3 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.429 177.875 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -124.96 44.23 2.84 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.776 0.322 . . . . 0.0 110.844 -178.925 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 337' ' ' LYS . . . . . 0.603 ' H ' HD13 ' A' ' 335' ' ' LEU . 60.8 tttm . . . . . 0 C--O 1.245 0.836 0 CA-C-O 118.635 -0.698 . . . . 0.0 110.509 -178.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.86 0 N-CA-C 112.545 -0.222 . . . . 0.0 112.545 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 64.3 p -125.2 168.6 13.23 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 122.704 -0.292 . . . . 0.0 110.631 178.725 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 73.8 p -70.18 161.06 30.96 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.613 178.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 23.3 pt-20 -112.73 29.37 8.01 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-O 121.192 0.52 . . . . 0.0 111.0 178.473 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 38.2 p -89.36 81.76 6.58 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.286 176.642 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 228' ' ' LEU . . . . . 0.429 ' HB3' ' HB2' ' A' ' 259' ' ' ALA . 73.0 mt -107.62 100.72 10.1 Favored 'General case' 0 N--CA 1.445 -0.692 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 -178.325 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 229' ' ' THR . . . . . 0.496 ' O ' HG22 ' A' ' 230' ' ' VAL . 76.1 p -126.39 172.19 10.36 Favored 'General case' 0 C--N 1.325 -0.459 0 C-N-CA 119.924 -0.71 . . . . 0.0 110.41 -178.621 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . 0.75 HG23 HG11 ' A' ' 257' ' ' VAL . 61.5 t -143.96 136.36 23.21 Favored 'Isoleucine or valine' 0 C--O 1.24 0.565 0 CA-C-O 120.779 0.324 . . . . 0.0 110.845 -178.176 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 29.7 m -97.28 160.16 14.5 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.125 177.201 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 92.52 161.58 36.57 Favored Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.462 -0.875 . . . . 0.0 111.177 -177.281 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 233' ' ' GLN . . . . . 0.593 ' HG2' ' HA ' ' A' ' 328' ' ' GLU . 83.4 mt-30 -118.16 102.85 50.38 Favored Pre-proline 0 C--N 1.319 -0.723 0 CA-C-N 117.081 0.44 . . . . 0.0 111.739 -177.354 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -75.86 123.75 7.61 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 121.468 1.445 . . . . 0.0 110.444 171.829 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 20.3 pt-20 -166.19 127.1 1.76 Allowed 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.605 -178.584 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 236' ' ' HIS . . . . . 0.48 ' C ' ' HD3' ' A' ' 237' ' ' LYS . 92.1 m-70 -141.04 143.36 34.35 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.219 174.794 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 237' ' ' LYS . . . . . 0.48 ' HD3' ' C ' ' A' ' 236' ' ' HIS . 13.7 mmtm -106.1 159.12 16.31 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.207 -172.62 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 238' ' ' VAL . . . . . . . . . . . . . 51.7 t -67.33 111.73 2.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 177.31 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 239' ' ' GLU . . . . . 0.426 ' HB2' ' HB ' ' A' ' 248' ' ' VAL . 53.6 mt-10 -85.87 135.12 33.83 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.56 -176.539 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 240' ' ' ALA . . . . . 0.566 ' O ' ' HA ' ' A' ' 247' ' ' PRO . . . -67.63 -53.29 29.22 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.025 177.75 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 241' ' ' LYS . . . . . 0.513 ' HD2' ' O ' ' A' ' 241' ' ' LYS . 0.0 OUTLIER -146.25 154.58 41.89 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.38 178.024 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -98.5 -158.02 0.64 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.609 -179.607 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 34.1 t -62.78 -30.5 71.51 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.326 -177.211 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -82.84 -14.27 54.64 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-O 121.191 0.519 . . . . 0.0 109.8 178.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 84.7 26.96 36.56 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.536 -0.84 . . . . 0.0 112.421 177.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 246' ' ' MET . . . . . 0.451 ' O ' ' HA ' ' A' ' 241' ' ' LYS . 24.3 ptt? -112.74 152.8 45.05 Favored Pre-proline 0 C--N 1.324 -0.529 0 N-CA-C 110.335 -0.246 . . . . 0.0 110.335 178.895 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 247' ' ' PRO . . . . . 0.566 ' HA ' ' O ' ' A' ' 240' ' ' ALA . 71.0 Cg_exo -53.2 135.89 60.78 Favored 'Trans proline' 0 C--N 1.351 0.67 0 C-N-CA 122.948 2.432 . . . . 0.0 112.537 -177.996 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . 0.426 ' HB ' ' HB2' ' A' ' 239' ' ' GLU . 42.1 t -120.1 133.78 65.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 N-CA-C 112.065 0.395 . . . . 0.0 112.065 -174.57 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -103.44 95.27 5.96 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 167.41 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 250' ' ' ASN . . . . . 0.472 HD22 HD22 ' A' ' 307' ' ' LEU . 15.6 p-10 -59.59 154.15 18.23 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.272 -172.122 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . 0.583 ' HG3' ' HG3' ' A' ' 252' ' ' GLN . 22.2 ptt-85 -143.65 -178.97 6.16 Favored 'General case' 0 C--N 1.326 -0.438 0 C-N-CA 120.936 -0.305 . . . . 0.0 111.45 -177.137 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 252' ' ' GLN . . . . . 0.583 ' HG3' ' HG3' ' A' ' 251' ' ' ARG . 25.2 mt-30 62.12 178.19 0.13 Allowed 'General case' 0 N--CA 1.468 0.474 0 N-CA-C 114.13 1.159 . . . . 0.0 114.13 170.86 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 174.72 109.47 0.24 Allowed Glycine 0 N--CA 1.446 -0.648 0 CA-C-N 114.338 -1.301 . . . . 0.0 109.933 -177.145 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 41.5 p -95.44 125.09 39.81 Favored 'General case' 0 C--N 1.324 -0.522 0 O-C-N 122.32 -0.517 . . . . 0.0 111.706 -171.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . 0.584 ' HB ' ' CG1' ' A' ' 230' ' ' VAL . 20.5 pt -124.37 145.18 31.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.901 -176.181 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 256' ' ' THR . . . . . 0.614 ' O ' HG12 ' A' ' 230' ' ' VAL . 31.0 m -99.56 106.05 17.99 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 174.232 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.75 HG11 HG23 ' A' ' 230' ' ' VAL . 32.8 m -88.13 141.57 14.13 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.595 0 C-N-CA 119.27 -0.972 . . . . 0.0 113.607 -165.04 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 36.4 m -94.23 10.3 34.57 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 113.404 -1.725 . . . . 0.0 109.275 169.593 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 259' ' ' ALA . . . . . 0.429 ' HB2' ' HB3' ' A' ' 228' ' ' LEU . . . -126.76 145.58 50.56 Favored 'General case' 0 CA--C 1.518 -0.256 0 N-CA-C 113.037 0.755 . . . . 0.0 113.037 -167.209 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 62.5 m 57.94 -68.51 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.558 0 CA-C-N 113.822 -1.535 . . . . 0.0 114.919 167.354 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 107.49 51.39 0.76 Allowed Glycine 0 N--CA 1.449 -0.466 0 N-CA-C 109.861 -1.296 . . . . 0.0 109.861 -167.408 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 262' ' ' LEU . . . . . . . . . . . . . 92.4 mt -65.0 163.93 13.71 Favored 'General case' 0 C--O 1.235 0.332 0 N-CA-C 113.709 1.003 . . . . 0.0 113.709 -168.021 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 73.0 mt-30 -135.23 -179.42 5.62 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 113.694 -1.594 . . . . 0.0 108.042 173.425 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 264' ' ' VAL . . . . . 0.418 ' HA ' ' CG1' ' A' ' 292' ' ' VAL . 38.5 t -73.76 127.81 35.84 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 C-N-CA 120.679 -0.408 . . . . 0.0 111.062 -179.79 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . 0.567 ' H ' ' HB ' ' A' ' 292' ' ' VAL . . . 121.49 8.05 7.88 Favored Glycine 0 C--N 1.335 0.486 0 C-N-CA 120.363 -0.922 . . . . 0.0 114.395 175.246 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 65.6 m-20 -90.71 164.93 13.95 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 117.831 0.816 . . . . 0.0 111.517 178.511 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 267' ' ' ALA . . . . . 0.75 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -139.9 126.0 19.84 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.199 -0.909 . . . . 0.0 109.052 174.536 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 268' ' ' PHE . . . . . . . . . . . . . 4.7 p90 -147.6 166.74 26.47 Favored 'General case' 0 C--N 1.327 -0.413 0 C-N-CA 119.74 -0.784 . . . . 0.0 111.829 -173.353 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 269' ' ' THR . . . . . 0.46 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 44.2 p -117.73 139.82 50.53 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.853 176.09 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 270' ' ' ILE . . . . . 0.533 HG12 HG12 ' A' ' 332' ' ' ILE . 59.6 mt -106.71 144.37 15.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 120.668 0.27 . . . . 0.0 110.964 -177.425 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -67.83 119.51 12.64 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.442 -179.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 106.04 -22.69 30.91 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 121.098 -0.572 . . . . 0.0 112.386 178.615 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . 0.557 HG12 ' HB3' ' A' ' 288' ' ' GLN . 36.5 t -87.02 101.44 11.16 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-O 121.046 0.45 . . . . 0.0 110.286 178.756 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 274' ' ' ASN . . . . . 0.521 ' HB3' ' HA2' ' A' ' 285' ' ' GLY . 3.6 m120 -110.01 129.6 55.65 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.272 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 51.0 p -73.01 160.47 32.03 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.588 0.709 . . . . 0.0 112.148 -178.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 276' ' ' VAL . . . . . 0.551 ' O ' ' HD2' ' A' ' 277' ' ' HIS . 22.8 m -127.9 -176.67 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 CA-C-N 114.748 -1.115 . . . . 0.0 110.432 -178.561 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 277' ' ' HIS . . . . . 0.652 ' HB3' ' HA ' ' A' ' 281' ' ' LYS . 0.7 OUTLIER 29.84 51.21 0.08 Allowed 'General case' 0 N--CA 1.473 0.69 0 O-C-N 124.826 1.328 . . . . 0.0 113.624 177.89 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 4.1 tp-100 -74.84 -43.15 56.1 Favored 'General case' 0 N--CA 1.439 -1.018 0 N-CA-C 108.488 -0.931 . . . . 0.0 108.488 171.248 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 279' ' ' ILE . . . . . 0.424 ' O ' ' HB2' ' A' ' 282' ' ' ASP . 26.5 mm -117.32 75.08 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.278 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.269 177.464 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 58.3 p 51.4 81.93 0.07 Allowed 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 123.665 0.786 . . . . 0.0 112.642 -178.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 281' ' ' LYS . . . . . 0.652 ' HA ' ' HB3' ' A' ' 277' ' ' HIS . 1.0 OUTLIER 56.96 27.63 13.47 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-N 115.42 -0.809 . . . . 0.0 112.011 -179.555 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 282' ' ' ASP . . . . . 0.424 ' HB2' ' O ' ' A' ' 279' ' ' ILE . 57.3 t0 -90.1 128.55 36.34 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.947 -0.57 . . . . 0.0 109.677 177.323 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 44.7 p -101.18 114.94 29.36 Favored 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 76.0 p -116.19 -11.35 11.34 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.649 -0.705 . . . . 0.0 112.145 -167.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 285' ' ' GLY . . . . . 0.521 ' HA2' ' HB3' ' A' ' 274' ' ' ASN . . . 76.83 10.83 85.9 Favored Glycine 0 CA--C 1.517 0.196 0 C-N-CA 120.814 -0.707 . . . . 0.0 113.267 177.249 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 83.2 mt-30 -71.81 131.09 86.14 Favored Pre-proline 0 C--N 1.327 -0.39 0 CA-C-N 116.824 0.312 . . . . 0.0 110.596 179.616 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 287' ' ' PRO . . . . . 0.46 ' HB2' ' HB ' ' A' ' 269' ' ' THR . 15.8 Cg_endo -59.3 131.32 40.3 Favored 'Trans proline' 0 C--N 1.343 0.254 0 C-N-CA 122.699 2.266 . . . . 0.0 112.292 -178.646 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 288' ' ' GLN . . . . . 0.557 ' HB3' HG12 ' A' ' 273' ' ' VAL . 69.2 tp60 -78.3 132.16 37.35 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.847 -178.528 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 46.9 t -92.13 136.3 24.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.356 179.345 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 290' ' ' PHE . . . . . 0.75 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 55.7 m-85 -117.16 150.67 38.33 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.806 -177.081 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 21.2 mmt85 -108.02 157.69 18.02 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.797 -0.638 . . . . 0.0 109.835 172.252 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . 0.567 ' HB ' ' H ' ' A' ' 265' ' ' GLY . 52.2 t -102.6 128.77 55.07 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.03 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.509 177.406 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 293' ' ' LEU . . . . . 0.637 HD21 ' N ' ' A' ' 293' ' ' LEU . 2.8 mm? -103.99 -37.05 7.53 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.108 -178.578 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 294' ' ' ALA . . . . . 0.416 ' HA ' HG22 ' A' ' 264' ' ' VAL . . . -156.96 141.54 16.75 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.562 -0.29 . . . . 0.0 111.009 -178.819 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 46.3 t -131.64 129.01 61.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.052 0.453 . . . . 0.0 110.122 176.176 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 56.5 p -122.3 88.81 3.0 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.793 -0.64 . . . . 0.0 109.897 178.295 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 75.42 -124.3 7.56 Favored Glycine 0 N--CA 1.446 -0.671 0 C-N-CA 119.932 -1.128 . . . . 0.0 110.552 -171.425 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 41.7 p -99.72 26.37 6.3 Favored 'General case' 0 C--N 1.319 -0.745 0 O-C-N 122.142 -0.622 . . . . 0.0 110.87 173.505 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 54.1 m -107.95 106.3 16.49 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 176.009 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . 0.437 HG13 HG23 ' A' ' 302' ' ' ILE . 42.0 t -104.44 124.87 59.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.952 -175.001 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 47.3 m -94.89 109.67 21.64 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 176.149 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 302' ' ' ILE . . . . . 0.538 ' O ' ' HA ' ' A' ' 252' ' ' GLN . 28.8 pt -111.25 160.93 10.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-O 121.459 0.647 . . . . 0.0 112.343 -173.412 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 303' ' ' SER . . . . . 0.475 ' HA ' ' C ' ' A' ' 304' ' ' PRO . 34.6 t -167.24 155.9 9.09 Favored Pre-proline 0 C--N 1.32 -0.713 0 N-CA-C 105.964 -1.865 . . . . 0.0 105.964 178.331 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 304' ' ' PRO . . . . . 0.475 ' C ' ' HA ' ' A' ' 303' ' ' SER . 65.2 Cg_exo -56.46 151.54 27.16 Favored 'Cis proline' 0 N--CA 1.473 0.291 0 CA-C-N 121.23 1.475 . . . . 0.0 114.642 1.715 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 305' ' ' LYS . . . . . 0.53 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -67.34 169.01 9.56 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 114.085 -1.416 . . . . 0.0 111.763 -179.04 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 306' ' ' ILE . . . . . 0.4 HG21 HD11 ' A' ' 306' ' ' ILE . 62.6 mt -108.59 114.09 45.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.85 -178.154 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 307' ' ' LEU . . . . . 0.525 ' O ' ' HB2' ' A' ' 320' ' ' ALA . 94.0 mt -125.94 118.45 23.97 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-N 116.753 -0.203 . . . . 0.0 111.021 -179.72 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 308' ' ' PRO . . . . . 0.727 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 9.9 Cg_exo -74.18 122.31 7.49 Favored 'Trans proline' 0 CA--C 1.534 0.493 0 C-N-CA 123.519 2.813 . . . . 0.0 113.742 -178.557 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . 0.481 ' O ' ' HD2' ' A' ' 317' ' ' ARG . 48.1 t -80.58 -19.44 11.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 121.189 0.518 . . . . 0.0 110.48 176.014 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 59.5 mm-40 -92.77 -5.32 51.42 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.904 0.383 . . . . 0.0 110.834 179.206 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.535 ' HB2' ' HB2' ' A' ' 308' ' ' PRO . 5.5 m120 -132.5 -129.98 0.18 Allowed 'General case' 0 CA--C 1.532 0.285 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.26 -178.531 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 312' ' ' THR . . . . . 0.501 ' OG1' ' HD2' ' A' ' 308' ' ' PRO . 59.6 m 60.84 -78.61 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.281 0 C-N-CA 124.28 1.032 . . . . 0.0 112.121 177.655 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 38.3 t70 -176.68 150.29 0.82 Allowed 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 -177.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 46.7 t -53.18 -37.61 28.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 120.748 0.309 . . . . 0.0 111.53 -179.516 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -84.91 -36.3 21.55 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 112.377 0.51 . . . . 0.0 112.377 -178.314 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 316' ' ' SER . . . . . 0.529 ' HA ' ' CZ ' ' A' ' 319' ' ' TYR . 67.9 m -93.53 -12.68 29.06 Favored 'General case' 0 C--N 1.327 -0.398 0 N-CA-C 113.364 0.875 . . . . 0.0 113.364 -172.346 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 317' ' ' ARG . . . . . 0.508 ' HG2' ' HD3' ' A' ' 318' ' ' PRO . 33.6 ptt85 -75.44 -34.4 1.59 Allowed Pre-proline 0 CA--C 1.548 0.882 0 N-CA-C 113.171 0.804 . . . . 0.0 113.171 -179.47 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 318' ' ' PRO . . . . . 0.508 ' HD3' ' HG2' ' A' ' 317' ' ' ARG . 33.9 Cg_exo -60.36 -26.79 83.53 Favored 'Trans proline' 0 C--N 1.371 1.718 0 C-N-CA 121.702 1.602 . . . . 0.0 113.17 -177.785 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 319' ' ' TYR . . . . . 0.529 ' CZ ' ' HA ' ' A' ' 316' ' ' SER . 2.7 p90 -106.82 30.0 6.5 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.076 0.465 . . . . 0.0 111.312 177.863 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . 0.525 ' HB2' ' O ' ' A' ' 307' ' ' LEU . . . -89.87 162.68 15.34 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.404 -0.817 . . . . 0.0 109.838 173.628 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 19.4 p30 -100.71 -19.18 16.16 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 113.788 1.032 . . . . 0.0 113.788 -171.457 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 322' ' ' VAL . . . . . 0.419 ' O ' HG21 ' A' ' 309' ' ' VAL . 35.6 m -136.77 161.08 36.78 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.401 0 CA-C-N 118.073 0.397 . . . . 0.0 111.155 -179.969 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 54.5 m-20 -60.91 -41.03 95.34 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 111.849 0.314 . . . . 0.0 111.849 -178.781 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 324' ' ' ALA . . . . . 0.727 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -157.09 166.24 33.82 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.398 -0.364 . . . . 0.0 111.77 -175.346 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 24.5 pttm -106.31 108.93 62.67 Favored Pre-proline 0 C--N 1.327 -0.411 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 169.016 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 326' ' ' PRO . . . . . 0.438 ' HG2' HG21 ' A' ' 273' ' ' VAL . 41.3 Cg_exo -65.0 167.24 16.39 Favored 'Trans proline' 0 C--N 1.343 0.244 0 C-N-CA 122.581 2.187 . . . . 0.0 113.107 -170.543 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -62.85 143.53 57.51 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 115.753 -0.658 . . . . 0.0 109.767 175.089 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 328' ' ' GLU . . . . . 0.593 ' HA ' ' HG2' ' A' ' 233' ' ' GLN . 15.6 pt-20 44.86 -135.25 0.65 Allowed 'General case' 0 N--CA 1.468 0.449 0 O-C-N 124.227 0.955 . . . . 0.0 110.941 -174.132 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 329' ' ' SER . . . . . 0.605 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 53.3 m -111.7 -31.63 6.91 Favored 'General case' 0 C--N 1.321 -0.636 0 C-N-CA 120.743 -0.383 . . . . 0.0 110.535 178.317 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 330' ' ' ALA . . . . . 0.506 ' HB2' ' O ' ' A' ' 329' ' ' SER . . . 78.6 -167.42 0.04 OUTLIER 'General case' 0 N--CA 1.475 0.824 0 O-C-N 124.111 0.882 . . . . 0.0 112.902 174.634 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -83.85 152.91 24.32 Favored 'General case' 0 CA--C 1.52 -0.182 0 CA-C-N 115.361 -0.836 . . . . 0.0 111.193 -176.179 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 332' ' ' ILE . . . . . 0.533 HG12 HG12 ' A' ' 270' ' ' ILE . 48.7 mt -126.58 145.0 34.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 121.202 0.525 . . . . 0.0 112.034 -176.56 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.436 ' N ' HG23 ' A' ' 332' ' ' ILE . 87.8 m -111.22 97.57 6.88 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.459 -0.792 . . . . 0.0 109.103 173.486 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 334' ' ' ILE . . . . . 0.479 HG23 HD13 ' A' ' 334' ' ' ILE . 30.2 mm -79.11 132.27 32.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -171.705 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 335' ' ' LEU . . . . . 0.534 ' N ' HD12 ' A' ' 335' ' ' LEU . 8.4 mp -119.79 151.59 38.57 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.412 -0.813 . . . . 0.0 109.818 170.468 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 75.0 m-80 -110.3 9.95 23.62 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.293 174.193 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 38.8 ttpt . . . . . 0 C--O 1.244 0.788 0 CA-C-O 118.493 -0.765 . . . . 0.0 110.181 179.295 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.776 0 N-CA-C 112.056 -0.418 . . . . 0.0 112.056 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 75.0 p 44.29 42.34 5.12 Favored 'General case' 0 N--CA 1.47 0.547 0 C-N-CA 123.67 0.788 . . . . 0.0 112.509 179.23 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 65.8 p -90.85 -176.2 4.6 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.367 178.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 226' ' ' GLU . . . . . 0.475 ' CD ' ' H ' ' A' ' 226' ' ' GLU . 0.7 OUTLIER -86.46 57.64 4.61 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.323 0.582 . . . . 0.0 110.224 176.252 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 35.7 t -77.54 80.54 4.02 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.237 177.616 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 228' ' ' LEU . . . . . 0.572 HD12 ' HB2' ' A' ' 259' ' ' ALA . 80.3 mt -103.61 146.9 27.88 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.352 -0.84 . . . . 0.0 109.548 -175.523 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 229' ' ' THR . . . . . 0.517 HG22 ' HA ' ' A' ' 331' ' ' ALA . 40.9 p -126.43 178.77 5.65 Favored 'General case' 0 C--N 1.323 -0.547 0 C-N-CA 119.729 -0.788 . . . . 0.0 111.042 -179.835 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . 0.815 HG22 HD12 ' A' ' 332' ' ' ILE . 58.1 t -146.28 137.15 18.6 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 -179.599 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 70.8 m -111.18 155.41 22.95 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.944 0.402 . . . . 0.0 110.854 178.188 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 86.03 169.63 46.14 Favored Glycine 0 N--CA 1.449 -0.499 0 N-CA-C 110.76 -0.936 . . . . 0.0 110.76 -172.471 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 233' ' ' GLN . . . . . 0.416 ' HA ' ' HD3' ' A' ' 234' ' ' PRO . 86.1 mt-30 -117.54 145.56 36.54 Favored Pre-proline 0 C--N 1.323 -0.572 0 CA-C-N 117.626 0.713 . . . . 0.0 111.482 179.761 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 234' ' ' PRO . . . . . 0.416 ' HD3' ' HA ' ' A' ' 233' ' ' GLN . 3.8 Cg_exo -71.94 172.29 14.91 Favored 'Trans proline' 0 N--CA 1.462 -0.374 0 C-N-CA 122.751 2.301 . . . . 0.0 111.55 176.249 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 55.7 mp0 -96.89 151.19 19.92 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.174 0.512 . . . . 0.0 110.911 -179.063 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 236' ' ' HIS . . . . . 0.574 ' CE1' ' HE2' ' A' ' 325' ' ' LYS . 17.1 p-80 -140.48 125.73 18.7 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.33 -0.85 . . . . 0.0 108.9 174.338 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 237' ' ' LYS . . . . . 0.556 ' HD3' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -169.56 140.05 2.16 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 111.76 0.282 . . . . 0.0 111.76 -176.385 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 238' ' ' VAL . . . . . 0.455 ' CG2' HD22 ' A' ' 250' ' ' ASN . 24.8 t -89.94 111.16 22.8 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.364 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 169.777 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 239' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -116.26 124.76 50.99 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-O 121.074 0.464 . . . . 0.0 111.168 -174.106 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 240' ' ' ALA . . . . . . . . . . . . . . . -66.65 -40.92 88.89 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.568 -177.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 241' ' ' LYS . . . . . 0.552 ' HD2' ' O ' ' A' ' 241' ' ' LYS . 0.6 OUTLIER -145.0 149.82 35.81 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.24 178.876 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 54.4 p-10 -102.0 -156.4 0.56 Allowed 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.369 -179.561 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 43.1 t -63.46 -21.34 66.25 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.218 178.046 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -87.25 -15.27 38.63 Favored 'General case' 0 CA--C 1.533 0.322 0 CA-C-O 121.308 0.575 . . . . 0.0 109.718 178.273 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . 0.547 ' HA2' ' HB2' ' A' ' 241' ' ' LYS . . . 72.36 26.66 71.43 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.892 -0.67 . . . . 0.0 112.848 176.586 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 246' ' ' MET . . . . . 0.555 ' O ' HG23 ' A' ' 248' ' ' VAL . 0.0 OUTLIER -111.76 165.95 11.85 Favored Pre-proline 0 C--N 1.325 -0.496 0 N-CA-C 110.326 -0.25 . . . . 0.0 110.326 179.496 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 247' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_exo -58.81 121.09 9.37 Favored 'Trans proline' 0 C--N 1.352 0.725 0 C-N-CA 122.402 2.068 . . . . 0.0 112.172 -176.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . 0.614 HG13 ' N ' ' A' ' 249' ' ' ASP . 61.4 t -119.22 152.32 21.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 120.87 0.366 . . . . 0.0 111.73 -174.823 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 249' ' ' ASP . . . . . 0.614 ' N ' HG13 ' A' ' 248' ' ' VAL . 8.0 t70 -120.53 144.46 48.04 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 170.664 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 250' ' ' ASN . . . . . 0.455 HD22 ' CG2' ' A' ' 238' ' ' VAL . 4.6 m120 -37.66 121.6 0.9 Allowed 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 123.423 0.689 . . . . 0.0 112.253 -175.291 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . 0.583 ' HG3' ' HG3' ' A' ' 252' ' ' GLN . 17.5 ptt-85 -150.31 171.64 16.65 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 120.869 -0.332 . . . . 0.0 111.364 -179.231 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 252' ' ' GLN . . . . . 0.583 ' HG3' ' HG3' ' A' ' 251' ' ' ARG . 26.2 mt-30 61.24 168.97 0.1 Allowed 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 114.894 1.442 . . . . 0.0 114.894 169.737 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . 0.54 ' O ' HG12 ' A' ' 302' ' ' ILE . . . 179.96 110.43 0.28 Allowed Glycine 0 N--CA 1.451 -0.349 0 CA-C-N 113.738 -1.574 . . . . 0.0 110.588 178.581 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 41.6 p -97.12 126.49 42.32 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 117.378 0.589 . . . . 0.0 111.406 -174.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . 0.451 ' CD1' HG12 ' A' ' 230' ' ' VAL . 12.7 pt -132.18 157.79 43.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.62 -176.406 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 256' ' ' THR . . . . . 0.406 ' O ' HG13 ' A' ' 230' ' ' VAL . 32.7 m -98.98 107.57 20.04 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 175.06 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.54 HG23 HD13 ' A' ' 262' ' ' LEU . 29.8 m -89.79 143.31 11.45 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.575 0 C-N-CA 119.556 -0.858 . . . . 0.0 113.012 -168.206 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 258' ' ' SER . . . . . 0.411 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 37.2 m -91.04 9.32 31.3 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 114.023 -1.444 . . . . 0.0 108.893 169.789 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 259' ' ' ALA . . . . . 0.572 ' HB2' HD12 ' A' ' 228' ' ' LEU . . . -84.78 161.56 19.93 Favored 'General case' 0 N--CA 1.448 -0.525 0 CA-C-N 115.119 -0.946 . . . . 0.0 109.502 -177.624 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 34.3 t -126.63 130.77 51.11 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 120.639 0.257 . . . . 0.0 110.61 -178.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 75.87 43.79 21.51 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.963 -0.637 . . . . 0.0 113.328 177.179 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 262' ' ' LEU . . . . . 0.54 HD13 HG23 ' A' ' 257' ' ' VAL . 79.3 mt -89.99 142.92 27.24 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 117.17 0.485 . . . . 0.0 110.478 175.757 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 73.0 mt-30 -133.84 171.43 14.17 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.51 176.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 264' ' ' VAL . . . . . 0.564 HG23 ' HA ' ' A' ' 294' ' ' ALA . 44.0 t -76.58 142.05 14.87 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 N-CA-C 110.195 -0.298 . . . . 0.0 110.195 179.1 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 94.87 -4.9 68.77 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.5 -0.857 . . . . 0.0 113.257 177.255 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 266' ' ' ASP . . . . . 0.494 ' O ' ' HA ' ' A' ' 291' ' ' ARG . 48.7 m-20 -78.88 158.03 28.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 117.172 0.486 . . . . 0.0 110.837 178.287 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 267' ' ' ALA . . . . . 0.647 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -122.72 147.67 46.21 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.974 -176.658 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 268' ' ' PHE . . . . . 0.834 ' HA ' HD22 ' A' ' 335' ' ' LEU . 3.6 p90 -164.04 173.28 12.73 Favored 'General case' 0 C--N 1.33 -0.259 0 C-N-CA 120.056 -0.657 . . . . 0.0 111.895 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 54.1 p -121.58 129.98 53.21 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.345 176.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 270' ' ' ILE . . . . . 0.815 HG12 HG13 ' A' ' 332' ' ' ILE . 62.6 mt -98.35 134.4 37.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.72 -178.839 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -76.07 118.47 18.85 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.828 179.206 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 109.62 -21.44 25.84 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.629 -0.796 . . . . 0.0 111.938 -178.778 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 40.9 t -104.35 102.12 13.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 N-CA-C 109.557 -0.535 . . . . 0.0 109.557 175.293 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 4.1 m120 -104.44 151.57 23.37 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 -179.481 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 275' ' ' SER . . . . . 0.977 ' HB3' ' HB3' ' A' ' 288' ' ' GLN . 23.2 p -88.17 157.53 18.79 Favored 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 112.13 0.419 . . . . 0.0 112.13 -178.079 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 18.8 m -125.98 162.76 28.88 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.605 0 CA-C-N 115.332 -0.849 . . . . 0.0 109.959 172.744 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 277' ' ' HIS . . . . . 0.451 ' HD2' HG22 ' A' ' 284' ' ' THR . 88.8 m-70 -130.04 91.29 3.1 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 175.526 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 4.1 tp-100 -80.64 -23.42 39.71 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.361 -172.112 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 2.1 mp -64.99 -41.56 92.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 121.069 0.461 . . . . 0.0 109.884 177.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 280' ' ' THR . . . . . 0.44 ' HG1' ' HB2' ' A' ' 282' ' ' ASP . 77.8 p -87.45 -16.44 34.8 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.316 174.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 5.6 tmtm? 59.49 53.65 5.03 Favored 'General case' 0 CA--C 1.531 0.216 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 -176.086 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 282' ' ' ASP . . . . . 0.44 ' HB2' ' HG1' ' A' ' 280' ' ' THR . 9.8 t70 -110.91 142.26 43.23 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.336 -0.847 . . . . 0.0 109.401 -175.256 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 36.0 p -102.28 106.19 16.96 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 178.295 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 284' ' ' THR . . . . . 0.451 HG22 ' HD2' ' A' ' 277' ' ' HIS . 82.5 p -110.13 -53.47 2.67 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.655 -0.702 . . . . 0.0 111.406 -171.628 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 66.13 31.48 79.41 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 121.001 -0.618 . . . . 0.0 111.966 -179.364 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 11.2 mm100 -106.11 142.15 24.25 Favored Pre-proline 0 C--N 1.326 -0.451 0 CA-C-N 116.026 -0.087 . . . . 0.0 110.772 -177.311 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 287' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_exo -59.3 127.82 25.32 Favored 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 122.648 2.232 . . . . 0.0 111.671 178.161 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 288' ' ' GLN . . . . . 0.977 ' HB3' ' HB3' ' A' ' 275' ' ' SER . 15.9 pt20 -93.55 159.18 15.34 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.984 -178.163 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 45.6 t -88.53 126.26 41.76 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 CA-C-N 115.446 -0.797 . . . . 0.0 110.002 175.246 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 290' ' ' PHE . . . . . 0.647 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 4.1 m-85 -99.67 169.21 9.43 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 178.762 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 291' ' ' ARG . . . . . 0.494 ' HA ' ' O ' ' A' ' 266' ' ' ASP . 12.5 ttp-105 -144.14 127.47 16.79 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-O 121.808 0.813 . . . . 0.0 110.947 172.417 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 57.5 t -65.84 139.91 20.48 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.979 0 CA-C-N 114.044 -1.434 . . . . 0.0 112.175 -176.347 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 293' ' ' LEU . . . . . . . . . . . . . 89.4 mt -105.56 -32.69 8.37 Favored 'General case' 0 CA--C 1.529 0.157 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.193 177.035 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 294' ' ' ALA . . . . . 0.564 ' HA ' HG23 ' A' ' 264' ' ' VAL . . . -158.6 144.94 17.1 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-O 120.463 0.173 . . . . 0.0 111.15 -179.18 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 57.4 t -136.34 126.8 41.33 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 176.836 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 47.0 t -157.54 112.54 2.73 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.897 -178.56 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 57.6 49.76 70.93 Favored Glycine 0 C--N 1.333 0.376 0 C-N-CA 121.148 -0.548 . . . . 0.0 112.469 178.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 66.8 p 55.4 10.3 0.46 Allowed 'General case' 0 N--CA 1.473 0.675 0 C-N-CA 124.201 1.0 . . . . 0.0 112.89 -175.722 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 42.6 m -97.81 106.02 18.26 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 173.351 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . 0.633 HG13 HG21 ' A' ' 302' ' ' ILE . 53.1 t -109.86 127.02 67.03 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.51 -170.494 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 301' ' ' THR . . . . . 0.457 ' HB ' ' HB1' ' A' ' 294' ' ' ALA . 57.3 m -90.54 113.89 25.98 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 172.655 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 302' ' ' ILE . . . . . 0.633 HG21 HG13 ' A' ' 300' ' ' VAL . 31.0 pt -110.4 174.76 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-O 121.643 0.735 . . . . 0.0 111.727 -173.321 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 303' ' ' SER . . . . . 0.51 ' OG ' ' HA ' ' A' ' 304' ' ' PRO . 31.8 t -163.1 156.67 16.98 Favored Pre-proline 0 C--N 1.317 -0.811 0 N-CA-C 105.759 -1.941 . . . . 0.0 105.759 178.732 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 304' ' ' PRO . . . . . 0.51 ' HA ' ' OG ' ' A' ' 303' ' ' SER . 24.9 Cg_exo -66.33 -179.42 12.34 Favored 'Cis proline' 0 N--CA 1.474 0.339 0 CA-C-N 121.004 1.394 . . . . 0.0 113.906 1.404 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 305' ' ' LYS . . . . . 0.483 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -77.48 160.98 28.29 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.317 -0.856 . . . . 0.0 112.254 -175.264 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 306' ' ' ILE . . . . . . . . . . . . . 2.2 mp -94.05 109.91 22.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.18 179.03 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 307' ' ' LEU . . . . . 0.417 HD12 ' O ' ' A' ' 319' ' ' TYR . 96.0 mt -141.51 99.39 6.36 Favored Pre-proline 0 CA--C 1.516 -0.361 0 CA-C-O 120.455 0.169 . . . . 0.0 111.052 178.411 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 308' ' ' PRO . . . . . 0.751 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 22.6 Cg_exo -69.43 148.19 66.63 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 123.077 2.518 . . . . 0.0 113.297 -177.354 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . 0.409 ' O ' HG13 ' A' ' 309' ' ' VAL . 45.5 t -93.7 -23.98 5.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 170.452 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -76.05 34.37 0.13 Allowed 'General case' 0 CA--C 1.532 0.272 0 CA-C-N 115.375 -0.83 . . . . 0.0 112.726 -177.3 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 77.3 m-20 -99.07 162.87 12.83 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 174.77 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 61.5 m -78.43 -32.81 48.77 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 176.615 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -65.31 119.57 11.18 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.781 179.699 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 60.1 t -68.39 -35.43 70.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.767 -0.651 . . . . 0.0 111.16 -178.657 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . 0.419 ' O ' ' HD2' ' A' ' 318' ' ' PRO . . . -65.07 -17.9 64.85 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 112.157 0.428 . . . . 0.0 112.157 -178.787 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 316' ' ' SER . . . . . 0.585 ' HA ' ' CZ ' ' A' ' 319' ' ' TYR . 52.4 m -78.92 -17.21 55.89 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 111.812 0.301 . . . . 0.0 111.812 -179.313 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 317' ' ' ARG . . . . . 0.424 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 70.0 mtm180 -74.4 -46.88 5.86 Favored Pre-proline 0 CA--C 1.539 0.542 0 N-CA-C 112.928 0.714 . . . . 0.0 112.928 -176.569 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 318' ' ' PRO . . . . . 0.424 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 75.9 Cg_exo -54.85 -38.48 92.32 Favored 'Trans proline' 0 C--N 1.358 1.033 0 C-N-CA 122.126 1.884 . . . . 0.0 113.685 -175.78 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 319' ' ' TYR . . . . . 0.585 ' CZ ' ' HA ' ' A' ' 316' ' ' SER . 2.1 p90 -98.72 7.58 45.92 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 120.76 -0.376 . . . . 0.0 111.937 -178.536 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . 0.401 ' HB2' ' O ' ' A' ' 317' ' ' ARG . . . -60.43 156.02 16.93 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-O 121.122 0.487 . . . . 0.0 111.834 -177.28 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 321' ' ' ASN . . . . . 0.456 ' HB2' ' HE2' ' A' ' 305' ' ' LYS . 46.7 t30 -132.59 -27.61 1.71 Allowed 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.952 -179.04 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 322' ' ' VAL . . . . . . . . . . . . . 28.7 m -131.59 166.95 27.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.759 -179.733 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -68.43 -48.05 65.61 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.612 -0.267 . . . . 0.0 111.154 177.832 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 324' ' ' ALA . . . . . 0.751 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -164.63 177.35 8.12 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.988 -0.551 . . . . 0.0 111.59 -176.132 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 325' ' ' LYS . . . . . 0.574 ' HE2' ' CE1' ' A' ' 236' ' ' HIS . 21.9 pttp -118.61 119.52 32.64 Favored Pre-proline 0 C--N 1.325 -0.462 0 CA-C-N 115.346 -0.843 . . . . 0.0 109.692 172.529 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_endo -79.23 169.13 19.4 Favored 'Trans proline' 0 C--O 1.233 0.243 0 C-N-CA 122.962 2.441 . . . . 0.0 112.901 -176.171 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -67.57 129.15 39.02 Favored 'General case' 0 C--O 1.238 0.455 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 175.643 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 57.0 mm-40 65.48 -156.17 0.28 Allowed 'General case' 0 N--CA 1.463 0.216 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 -172.089 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 329' ' ' SER . . . . . 0.627 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 69.3 m -112.5 -12.27 13.5 Favored 'General case' 0 C--N 1.322 -0.606 0 C-N-CA 120.544 -0.462 . . . . 0.0 110.869 176.785 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 330' ' ' ALA . . . . . 0.442 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 70.24 -154.01 0.12 Allowed 'General case' 0 N--CA 1.469 0.502 0 N-CA-C 113.209 0.818 . . . . 0.0 113.209 172.408 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 331' ' ' ALA . . . . . 0.517 ' HA ' HG22 ' A' ' 229' ' ' THR . . . -93.09 137.61 32.28 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.75 -177.801 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 332' ' ' ILE . . . . . 0.815 HD12 HG22 ' A' ' 230' ' ' VAL . 1.9 mp -116.33 144.27 24.41 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.113 -178.685 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.401 ' N ' HG23 ' A' ' 332' ' ' ILE . 40.8 m -109.87 106.29 15.81 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.609 -0.515 . . . . 0.0 109.609 179.728 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 334' ' ' ILE . . . . . 0.506 HG13 HD13 ' A' ' 228' ' ' LEU . 19.5 mm -81.39 133.55 29.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 N-CA-C 113.755 1.02 . . . . 0.0 113.755 -172.208 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 335' ' ' LEU . . . . . 0.834 HD22 ' HA ' ' A' ' 268' ' ' PHE . 1.6 pt? -148.02 -147.62 0.23 Allowed 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 113.61 -1.632 . . . . 0.0 108.344 169.071 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -163.38 -39.97 0.03 OUTLIER 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 108.393 -0.965 . . . . 0.0 108.393 177.801 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 62.4 tttp . . . . . 0 C--O 1.243 0.716 0 CA-C-N 114.55 -1.204 . . . . 0.0 109.5 174.82 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.809 0 N-CA-C 111.966 -0.454 . . . . 0.0 111.966 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 51.0 m -82.87 -24.6 33.15 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.81 0.338 . . . . 0.0 111.038 -177.452 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 66.2 p -106.46 164.69 11.84 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.505 178.098 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 9.0 mp0 -92.73 58.61 3.1 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.021 0.438 . . . . 0.0 109.902 178.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 26.2 t -91.8 -147.75 0.22 Allowed 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.527 -178.139 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 228' ' ' LEU . . . . . 0.518 ' HB3' ' HA ' ' A' ' 259' ' ' ALA . 83.8 mt -108.37 140.79 41.16 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 109.689 -0.486 . . . . 0.0 109.689 179.293 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 229' ' ' THR . . . . . 0.496 ' O ' HG23 ' A' ' 230' ' ' VAL . 70.8 p -124.27 177.12 6.02 Favored 'General case' 0 C--N 1.325 -0.464 0 C-N-CA 119.957 -0.697 . . . . 0.0 110.978 -178.506 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . 0.733 HG22 HD13 ' A' ' 332' ' ' ILE . 61.3 t -146.61 146.84 18.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.014 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 41.3 t -132.08 133.85 44.82 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.822 0.344 . . . . 0.0 110.402 178.755 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 104.21 73.28 0.92 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.41 -0.9 . . . . 0.0 112.929 177.625 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 13.8 mm-40 -66.86 133.0 93.93 Favored Pre-proline 0 C--N 1.33 -0.248 0 CA-C-O 120.84 0.353 . . . . 0.0 111.377 176.546 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 234' ' ' PRO . . . . . 0.568 ' HB2' ' HE1' ' A' ' 236' ' ' HIS . 56.9 Cg_endo -69.97 138.38 37.03 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 122.373 2.049 . . . . 0.0 111.515 176.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -97.88 126.41 43.25 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 121.391 0.615 . . . . 0.0 111.532 -176.261 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 236' ' ' HIS . . . . . 0.568 ' HE1' ' HB2' ' A' ' 234' ' ' PRO . 24.2 m80 -130.41 133.83 46.66 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.404 -0.817 . . . . 0.0 109.562 -178.548 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 237' ' ' LYS . . . . . 0.78 ' HA ' HG22 ' A' ' 312' ' ' THR . 6.8 mptt -120.06 128.02 53.11 Favored 'General case' 0 C--N 1.327 -0.379 0 C-N-CA 120.556 -0.458 . . . . 0.0 110.551 178.923 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 238' ' ' VAL . . . . . 0.777 ' HB ' ' HA ' ' A' ' 316' ' ' SER . 47.4 t -101.9 126.28 55.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.675 178.401 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 239' ' ' GLU . . . . . . . . . . . . . 72.1 mt-10 -126.04 154.78 42.52 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 172.338 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 240' ' ' ALA . . . . . . . . . . . . . . . -57.9 -46.89 84.25 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.728 0.299 . . . . 0.0 111.144 -176.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 241' ' ' LYS . . . . . 0.69 ' HB2' ' HA2' ' A' ' 245' ' ' GLY . 0.0 OUTLIER -145.62 164.48 31.57 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.228 179.089 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 242' ' ' ASP . . . . . 0.456 ' OD1' ' HG2' ' A' ' 246' ' ' MET . 9.4 p-10 -105.28 -158.31 0.65 Allowed 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 109.692 -0.484 . . . . 0.0 109.692 179.12 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 46.6 t -60.18 -36.61 78.0 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.767 175.294 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -87.68 -14.12 40.74 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.632 -0.258 . . . . 0.0 111.652 -179.479 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . 0.69 ' HA2' ' HB2' ' A' ' 241' ' ' LYS . . . 94.42 26.04 14.64 Favored Glycine 0 CA--C 1.519 0.322 0 C-N-CA 120.517 -0.849 . . . . 0.0 114.064 174.335 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 246' ' ' MET . . . . . 0.456 ' HG2' ' OD1' ' A' ' 242' ' ' ASP . 22.8 ptp -113.54 155.96 44.09 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 117.532 0.666 . . . . 0.0 110.596 176.944 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 247' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_exo -57.6 125.42 18.7 Favored 'Trans proline' 0 C--N 1.35 0.624 0 C-N-CA 122.61 2.207 . . . . 0.0 112.245 -179.331 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 41.5 t -80.38 113.35 19.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.219 -177.197 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 61.5 t0 -122.68 113.93 19.89 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 176.506 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 250' ' ' ASN . . . . . . . . . . . . . 6.5 m120 -75.27 -39.33 59.88 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.567 -0.288 . . . . 0.0 111.191 -177.039 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . 0.887 ' HA ' ' HB3' ' A' ' 305' ' ' LYS . 81.8 mtm180 60.75 -173.97 0.12 Allowed 'General case' 0 N--CA 1.466 0.337 0 N-CA-C 112.362 0.504 . . . . 0.0 112.362 -175.652 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 20.4 mt-30 60.45 178.41 0.1 Allowed 'General case' 0 N--CA 1.468 0.461 0 CA-C-N 114.843 -1.072 . . . . 0.0 112.42 177.02 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . 0.449 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -172.65 95.71 0.11 Allowed Glycine 0 N--CA 1.447 -0.631 0 CA-C-N 115.429 -0.805 . . . . 0.0 111.178 179.099 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 59.9 p -95.39 116.98 29.53 Favored 'General case' 0 C--N 1.323 -0.561 0 O-C-N 122.48 -0.424 . . . . 0.0 110.914 -175.113 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . 0.472 HG22 ' HD3' ' A' ' 234' ' ' PRO . 21.2 pt -128.78 148.39 33.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.831 -177.618 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 59.8 m -101.27 107.26 18.58 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 174.096 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.748 HG22 HD11 ' A' ' 262' ' ' LEU . 32.8 m -90.73 143.65 10.77 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.728 0 N-CA-C 112.975 0.731 . . . . 0.0 112.975 -168.649 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 35.3 t -91.44 8.04 38.23 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 114.112 -1.404 . . . . 0.0 107.963 167.165 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 259' ' ' ALA . . . . . 0.518 ' HA ' ' HB3' ' A' ' 228' ' ' LEU . . . -85.64 158.12 20.16 Favored 'General case' 0 N--CA 1.448 -0.565 0 CA-C-N 114.926 -1.034 . . . . 0.0 109.626 -178.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 34.1 t -131.94 137.31 47.9 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 116.577 -0.283 . . . . 0.0 110.325 -179.217 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 90.27 39.28 6.07 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.6 -0.809 . . . . 0.0 112.571 -179.437 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 262' ' ' LEU . . . . . 0.748 HD11 HG22 ' A' ' 257' ' ' VAL . 60.2 mt -101.46 139.81 36.6 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.711 0.291 . . . . 0.0 110.877 179.788 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 68.5 mt-30 -142.2 167.72 21.45 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.82 -0.627 . . . . 0.0 109.436 179.298 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 264' ' ' VAL . . . . . 0.492 HG23 ' HA ' ' A' ' 294' ' ' ALA . 48.7 t -70.83 132.87 32.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 C-N-CA 120.772 -0.371 . . . . 0.0 110.161 177.834 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 105.58 8.63 34.72 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.548 -0.834 . . . . 0.0 112.401 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 59.7 m-20 -88.64 162.48 16.31 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.988 0.423 . . . . 0.0 110.861 179.045 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 267' ' ' ALA . . . . . 0.687 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -139.34 123.12 17.57 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.487 -0.779 . . . . 0.0 109.475 179.75 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 268' ' ' PHE . . . . . 0.448 ' CD1' HG23 ' A' ' 332' ' ' ILE . 3.5 p90 -142.15 173.66 11.32 Favored 'General case' 0 C--N 1.32 -0.676 0 C-N-CA 120.114 -0.634 . . . . 0.0 111.465 -174.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 269' ' ' THR . . . . . 0.535 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 63.8 p -118.89 132.37 56.1 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.53 178.115 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 270' ' ' ILE . . . . . 0.68 HG12 HG13 ' A' ' 332' ' ' ILE . 50.6 mt -100.61 134.02 41.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.57 179.625 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -72.72 143.47 48.01 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.956 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 85.78 -21.55 14.54 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.189 -177.522 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 53.5 t -105.69 102.46 13.9 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-O 120.983 0.42 . . . . 0.0 110.799 -179.593 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 4.0 m120 -100.72 154.94 18.19 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.22 -0.659 . . . . 0.0 109.22 174.702 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 6.7 t -83.7 179.98 7.46 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.912 0.387 . . . . 0.0 109.96 -177.853 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 34.2 m -131.92 153.11 38.0 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.712 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.236 172.775 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 26.4 m80 -136.94 137.08 39.17 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.091 179.236 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 8.5 tt0 -67.99 -31.67 71.53 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.916 0.389 . . . . 0.0 110.315 177.196 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 279' ' ' ILE . . . . . 0.452 HD12 HG23 ' A' ' 279' ' ' ILE . 72.3 mt -66.54 -50.36 67.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.861 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 71.5 p -85.42 -5.08 59.33 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 111.674 0.25 . . . . 0.0 111.674 -178.615 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 281' ' ' LYS . . . . . 0.514 ' HB3' ' NZ ' ' A' ' 281' ' ' LYS . 0.0 OUTLIER 70.94 52.97 0.27 Allowed 'General case' 0 CA--C 1.535 0.403 0 CA-C-O 121.742 0.782 . . . . 0.0 109.161 179.479 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 56.6 m-20 62.26 10.51 3.87 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 114.732 -1.122 . . . . 0.0 113.95 173.485 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 59.9 p -107.09 107.97 19.22 Favored 'General case' 0 C--N 1.314 -0.956 0 CA-C-O 121.041 0.448 . . . . 0.0 110.589 175.605 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 59.8 p -125.76 -52.37 1.57 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.061 -175.385 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 76.42 10.61 85.58 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.732 -0.747 . . . . 0.0 111.267 -173.363 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 93.4 mm-40 -111.11 130.42 22.99 Favored Pre-proline 0 C--N 1.326 -0.445 0 N-CA-C 110.322 -0.251 . . . . 0.0 110.322 -177.609 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 287' ' ' PRO . . . . . 0.535 ' HB2' ' HB ' ' A' ' 269' ' ' THR . 27.3 Cg_exo -60.76 142.05 96.63 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.627 2.218 . . . . 0.0 111.696 177.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 4.1 tp60 -68.18 145.05 54.69 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 120.877 0.37 . . . . 0.0 110.711 -179.637 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 47.6 t -99.73 121.77 50.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.492 176.631 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 290' ' ' PHE . . . . . 0.687 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 7.3 m-85 -103.31 156.17 17.92 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.028 0.442 . . . . 0.0 111.775 -174.02 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 36.3 mmt180 -122.31 121.18 36.14 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.112 -0.949 . . . . 0.0 109.408 174.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 61.7 t -78.51 135.51 25.84 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.89 -174.476 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 293' ' ' LEU . . . . . . . . . . . . . 6.6 mp -106.95 -33.8 7.4 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.674 179.034 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 294' ' ' ALA . . . . . 0.492 ' HA ' HG23 ' A' ' 264' ' ' VAL . . . -155.54 146.7 22.59 Favored 'General case' 0 N--CA 1.463 0.19 0 N-CA-C 111.677 0.251 . . . . 0.0 111.677 -177.365 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 61.6 t -137.66 126.37 33.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.086 -0.506 . . . . 0.0 109.74 177.169 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 40.3 t -156.69 109.69 2.59 Favored 'General case' 0 C--N 1.326 -0.418 0 C-N-CA 121.139 -0.224 . . . . 0.0 110.944 -177.638 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 59.81 48.57 85.41 Favored Glycine 0 C--N 1.333 0.373 0 C-N-CA 121.077 -0.583 . . . . 0.0 112.488 179.447 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 298' ' ' THR . . . . . 0.409 ' O ' HG21 ' A' ' 257' ' ' VAL . 60.5 p 55.71 10.93 0.58 Allowed 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 124.342 1.057 . . . . 0.0 112.728 -176.361 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 58.3 m -99.92 106.47 18.29 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 173.024 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . 0.486 HG13 HG21 ' A' ' 302' ' ' ILE . 40.2 t -108.9 132.03 58.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.35 -169.519 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 51.6 m -100.87 111.35 23.54 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 175.422 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 302' ' ' ILE . . . . . 0.486 HG21 HG13 ' A' ' 300' ' ' VAL . 27.7 pt -121.64 164.6 18.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-O 121.284 0.564 . . . . 0.0 112.027 -174.262 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 303' ' ' SER . . . . . 0.463 ' HB3' ' HA ' ' A' ' 304' ' ' PRO . 53.1 m -135.29 165.28 37.58 Favored Pre-proline 0 C--N 1.313 -0.984 0 N-CA-C 106.325 -1.732 . . . . 0.0 106.325 168.775 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 304' ' ' PRO . . . . . 0.463 ' HA ' ' HB3' ' A' ' 303' ' ' SER . 17.4 Cg_exo -70.38 176.52 34.05 Favored 'Cis proline' 0 N--CA 1.472 0.243 0 CA-C-N 120.816 1.327 . . . . 0.0 113.71 0.923 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 305' ' ' LYS . . . . . 0.887 ' HB3' ' HA ' ' A' ' 251' ' ' ARG . 0.1 OUTLIER -73.86 152.69 40.15 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 114.986 -1.007 . . . . 0.0 111.284 -178.501 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 306' ' ' ILE . . . . . 0.456 HG22 HD12 ' A' ' 306' ' ' ILE . 46.4 mm -94.66 85.29 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.634 -178.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 307' ' ' LEU . . . . . 0.711 ' HG ' ' HG2' ' A' ' 305' ' ' LYS . 66.9 mt -106.12 110.32 63.89 Favored Pre-proline 0 C--N 1.325 -0.462 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 178.109 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 308' ' ' PRO . . . . . 0.468 ' CG ' ' HB2' ' A' ' 311' ' ' ASN . 65.1 Cg_endo -80.9 148.66 17.49 Favored 'Trans proline' 0 N--CA 1.463 -0.275 0 C-N-CA 122.548 2.166 . . . . 0.0 113.609 -172.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . 0.515 HG23 ' O ' ' A' ' 322' ' ' VAL . 47.0 t -87.65 -43.09 15.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.829 175.252 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 65.4 mm-40 -91.51 6.47 45.47 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 112.437 0.532 . . . . 0.0 112.437 -176.287 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.468 ' HB2' ' CG ' ' A' ' 308' ' ' PRO . 5.9 m120 -130.0 173.33 10.82 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 110.231 -0.285 . . . . 0.0 110.231 178.597 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 312' ' ' THR . . . . . 0.78 HG22 ' HA ' ' A' ' 237' ' ' LYS . 23.7 m 60.07 31.03 20.43 Favored 'General case' 0 CA--C 1.539 0.543 0 CA-C-O 121.758 0.79 . . . . 0.0 110.656 176.887 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 44.5 m-20 63.87 -177.71 0.16 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 114.883 -1.053 . . . . 0.0 112.208 177.106 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 314' ' ' VAL . . . . . 0.445 HG12 ' O ' ' A' ' 314' ' ' VAL . 50.0 t -68.31 -24.66 30.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.426 -176.441 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -60.63 -23.73 64.98 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 111.976 0.362 . . . . 0.0 111.976 -179.859 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 316' ' ' SER . . . . . 0.777 ' HA ' ' HB ' ' A' ' 238' ' ' VAL . 31.2 t -86.89 -22.02 25.97 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.31 -177.845 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 317' ' ' ARG . . . . . 0.614 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 83.3 mtt-85 -56.6 -53.68 61.8 Favored Pre-proline 0 CA--C 1.541 0.605 0 N-CA-C 113.499 0.926 . . . . 0.0 113.499 -177.525 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 318' ' ' PRO . . . . . 0.614 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 44.1 Cg_exo -61.97 -35.39 77.32 Favored 'Trans proline' 0 C--N 1.356 0.931 0 C-N-CA 122.018 1.812 . . . . 0.0 113.677 -174.587 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 7.4 m-85 -105.62 21.67 16.83 Favored 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 121.152 -0.219 . . . . 0.0 111.089 -179.065 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -65.79 160.0 24.03 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.096 0.474 . . . . 0.0 111.685 -177.39 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 20.6 t-20 -123.58 -33.19 3.25 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.85 -0.613 . . . . 0.0 109.956 177.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 322' ' ' VAL . . . . . 0.515 ' O ' HG23 ' A' ' 309' ' ' VAL . 35.4 m -135.42 163.76 34.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.345 177.308 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 63.6 m-20 -55.89 -41.28 74.21 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 112.684 0.624 . . . . 0.0 112.684 -176.407 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 324' ' ' ALA . . . . . 0.435 ' HA ' ' CB ' ' A' ' 308' ' ' PRO . . . -169.49 167.49 9.82 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.876 0.369 . . . . 0.0 111.746 -173.759 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 325' ' ' LYS . . . . . 0.487 ' HZ3' ' HB2' ' A' ' 325' ' ' LYS . 0.0 OUTLIER -108.7 106.25 58.42 Favored Pre-proline 0 C--N 1.325 -0.49 0 CA-C-N 114.968 -1.014 . . . . 0.0 109.26 168.732 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 76.0 Cg_endo -85.21 168.47 10.32 Favored 'Trans proline' 0 C--O 1.234 0.276 0 C-N-CA 122.8 2.333 . . . . 0.0 112.769 -173.472 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -69.6 121.86 17.94 Favored 'General case' 0 C--O 1.235 0.327 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 176.588 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 328' ' ' GLU . . . . . 0.448 ' HA ' ' OE2' ' A' ' 328' ' ' GLU . 43.6 mm-40 64.16 164.24 0.13 Allowed 'General case' 0 C--O 1.234 0.243 0 O-C-N 123.891 0.744 . . . . 0.0 111.417 -175.288 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 329' ' ' SER . . . . . 0.588 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 22.2 m -86.49 -14.49 42.95 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.35 -174.306 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 330' ' ' ALA . . . . . 0.484 ' HB2' ' O ' ' A' ' 329' ' ' SER . . . 71.26 -154.43 0.1 Allowed 'General case' 0 N--CA 1.467 0.403 0 CA-C-O 121.332 0.586 . . . . 0.0 112.287 175.532 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 331' ' ' ALA . . . . . 0.462 ' C ' HD11 ' A' ' 332' ' ' ILE . . . -90.04 125.79 35.53 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.147 -0.933 . . . . 0.0 110.168 179.35 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 332' ' ' ILE . . . . . 0.733 HD13 HG22 ' A' ' 230' ' ' VAL . 1.7 mp -106.35 144.72 15.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.31 -178.917 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.591 ' N ' HG21 ' A' ' 332' ' ' ILE . 88.5 m -109.97 103.02 11.72 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.069 -0.514 . . . . 0.0 109.711 -178.171 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 334' ' ' ILE . . . . . 0.56 HD11 HG22 ' A' ' 332' ' ' ILE . 37.9 mm -83.1 129.3 37.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 115.57 -0.741 . . . . 0.0 112.42 -171.209 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 335' ' ' LEU . . . . . 0.477 ' N ' HD12 ' A' ' 335' ' ' LEU . 6.8 mp -123.67 153.04 41.36 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.264 -0.88 . . . . 0.0 109.823 172.644 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 22.9 p30 -110.9 5.02 20.19 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 170.442 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 23.1 tptm . . . . . 0 C--O 1.245 0.82 0 CA-C-N 114.541 -1.209 . . . . 0.0 110.99 -179.412 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.842 0 N-CA-C 112.093 -0.403 . . . . 0.0 112.093 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 46.5 t -84.56 -73.66 0.42 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.784 0.326 . . . . 0.0 110.596 179.397 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 35.1 p -128.82 -88.96 0.52 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.676 178.37 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 41.1 tp10 58.42 82.79 0.13 Allowed 'General case' 0 C--O 1.234 0.268 0 C-N-CA 122.991 0.516 . . . . 0.0 110.749 178.277 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 31.5 t -168.6 -129.83 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 -179.733 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 228' ' ' LEU . . . . . 0.643 ' HB3' ' HB2' ' A' ' 259' ' ' ALA . 85.1 mt -96.46 130.93 43.5 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 109.511 -0.552 . . . . 0.0 109.511 175.728 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 229' ' ' THR . . . . . 0.488 ' O ' HG21 ' A' ' 230' ' ' VAL . 41.3 p -129.63 179.54 5.77 Favored 'General case' 0 C--N 1.325 -0.465 0 C-N-CA 120.296 -0.562 . . . . 0.0 110.986 -178.631 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . 0.797 ' HB ' ' HB3' ' A' ' 329' ' ' SER . 89.5 t -146.18 130.85 11.58 Favored 'Isoleucine or valine' 0 C--O 1.24 0.571 0 CA-C-O 120.601 0.239 . . . . 0.0 111.549 -177.2 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 18.7 m -97.29 97.84 9.49 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.194 -0.912 . . . . 0.0 109.733 172.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 163.02 134.74 1.69 Allowed Glycine 0 C--O 1.226 -0.344 0 C-N-CA 120.719 -0.753 . . . . 0.0 111.72 -177.429 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 11.0 mm100 -61.62 144.73 92.44 Favored Pre-proline 0 C--N 1.328 -0.369 0 N-CA-C 112.688 0.625 . . . . 0.0 112.688 -174.516 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -70.7 175.22 9.18 Favored 'Trans proline' 0 C--N 1.348 0.521 0 C-N-CA 123.381 2.721 . . . . 0.0 111.793 175.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 235' ' ' GLU . . . . . 0.461 ' O ' ' HB ' ' A' ' 306' ' ' ILE . 87.6 mt-10 -94.3 138.11 32.67 Favored 'General case' 0 C--O 1.211 -0.962 0 C-N-CA 120.833 -0.347 . . . . 0.0 111.688 -176.524 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 236' ' ' HIS . . . . . 0.417 ' HB3' ' O ' ' A' ' 306' ' ' ILE . 25.5 p-80 -169.04 126.82 0.99 Allowed 'General case' 0 C--N 1.307 -1.256 0 CA-C-N 115.097 -0.956 . . . . 0.0 109.366 166.975 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 237' ' ' LYS . . . . . 0.548 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -138.44 122.37 17.78 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.32 -0.552 . . . . 0.0 110.473 -179.987 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 238' ' ' VAL . . . . . . . . . . . . . 62.0 t -107.35 111.05 34.07 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 C-N-CA 120.484 -0.486 . . . . 0.0 110.023 169.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 239' ' ' GLU . . . . . 0.485 ' O ' ' HA ' ' A' ' 247' ' ' PRO . 54.3 mt-10 -125.82 116.38 21.48 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.01 178.078 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 240' ' ' ALA . . . . . 0.472 ' C ' ' HD2' ' A' ' 241' ' ' LYS . . . -74.83 -51.35 14.22 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.641 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 241' ' ' LYS . . . . . 0.472 ' HD2' ' C ' ' A' ' 240' ' ' ALA . 1.0 OUTLIER -115.83 127.33 54.97 Favored 'General case' 0 CA--C 1.515 -0.384 0 CA-C-O 121.233 0.54 . . . . 0.0 110.696 173.451 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 9.8 p-10 -106.06 -156.45 0.58 Allowed 'General case' 0 C--N 1.315 -0.901 0 CA-C-N 114.912 -1.04 . . . . 0.0 108.665 172.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 51.0 m -56.84 -36.04 69.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.51 -0.314 . . . . 0.0 111.047 174.588 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 6.0 m120 -96.74 -14.07 22.26 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.475 -0.329 . . . . 0.0 111.751 -178.488 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 85.61 20.87 55.49 Favored Glycine 0 CA--C 1.519 0.282 0 C-N-CA 120.685 -0.769 . . . . 0.0 113.433 177.201 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 246' ' ' MET . . . . . 0.42 ' HA ' ' HD3' ' A' ' 247' ' ' PRO . 94.6 mmm -114.09 133.03 22.43 Favored Pre-proline 0 C--N 1.326 -0.418 0 CA-C-N 116.964 0.382 . . . . 0.0 110.207 177.156 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 247' ' ' PRO . . . . . 0.485 ' HA ' ' O ' ' A' ' 239' ' ' GLU . 24.4 Cg_exo -64.9 116.68 3.96 Favored 'Trans proline' 0 C--N 1.349 0.573 0 C-N-CA 121.738 1.625 . . . . 0.0 112.175 -177.591 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 46.2 t -147.51 148.93 15.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.674 178.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 249' ' ' ASP . . . . . 0.577 ' OD2' HD22 ' A' ' 307' ' ' LEU . 8.5 t70 -89.21 123.96 33.92 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 170.779 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 250' ' ' ASN . . . . . . . . . . . . . 22.1 p30 -80.83 -11.73 59.55 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 112.167 0.432 . . . . 0.0 112.167 -173.369 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . 0.544 ' HB3' ' HD2' ' A' ' 305' ' ' LYS . 36.8 ptt85 44.55 -164.07 0.01 OUTLIER 'General case' 0 N--CA 1.475 0.808 0 C-N-CA 124.592 1.157 . . . . 0.0 113.456 179.368 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 252' ' ' GLN . . . . . 0.472 ' HG3' ' HG3' ' A' ' 251' ' ' ARG . 17.2 mt-30 65.12 132.65 0.02 OUTLIER 'General case' 0 C--O 1.237 0.413 0 C-N-CA 123.995 0.918 . . . . 0.0 112.83 -178.028 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . 0.423 ' O ' ' HA ' ' A' ' 301' ' ' THR . . . -160.86 145.33 10.89 Favored Glycine 0 N--CA 1.449 -0.467 0 CA-C-N 115.007 -0.997 . . . . 0.0 111.94 177.714 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 254' ' ' THR . . . . . 0.458 HG21 ' OG1' ' A' ' 301' ' ' THR . 34.1 p -95.32 117.99 31.28 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.843 0.354 . . . . 0.0 111.13 -179.797 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . 0.467 HG23 HD13 ' A' ' 255' ' ' ILE . 24.7 pt -114.75 142.84 26.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.08 0.467 . . . . 0.0 111.494 -178.724 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 58.1 m -92.49 109.63 21.03 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 176.354 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.611 HG13 HG22 ' A' ' 230' ' ' VAL . 33.9 m -90.21 143.78 10.48 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.703 0 C-N-CA 119.646 -0.821 . . . . 0.0 113.004 -168.351 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 24.0 t -91.59 9.07 33.7 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 114.051 -1.432 . . . . 0.0 108.192 168.883 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 259' ' ' ALA . . . . . 0.643 ' HB2' ' HB3' ' A' ' 228' ' ' LEU . . . -99.05 169.8 9.16 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-N 114.774 -1.103 . . . . 0.0 109.484 -178.592 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 33.8 t -142.57 155.28 44.97 Favored 'General case' 0 C--N 1.324 -0.54 0 C-N-CA 120.828 -0.349 . . . . 0.0 110.733 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 74.34 42.8 33.54 Favored Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.47 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 262' ' ' LEU . . . . . 0.451 HD11 HG23 ' A' ' 257' ' ' VAL . 64.5 mt -102.39 140.02 37.21 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 110.17 -0.308 . . . . 0.0 110.17 179.37 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 81.5 mt-30 -135.24 169.45 17.44 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.479 -0.328 . . . . 0.0 110.206 179.822 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 264' ' ' VAL . . . . . 0.445 HG22 ' HA ' ' A' ' 294' ' ' ALA . 45.5 t -77.77 136.26 24.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.594 179.63 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 92.13 7.65 63.81 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.442 -0.885 . . . . 0.0 112.292 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 266' ' ' ASP . . . . . 0.509 ' HB2' HG22 ' A' ' 292' ' ' VAL . 72.8 m-20 -81.73 160.47 23.63 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.232 0.539 . . . . 0.0 110.133 176.785 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 267' ' ' ALA . . . . . 0.529 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -126.84 145.37 50.67 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 115.332 -0.849 . . . . 0.0 108.822 178.952 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 268' ' ' PHE . . . . . 0.788 ' HA ' HD22 ' A' ' 335' ' ' LEU . 4.6 p90 -162.53 170.66 18.27 Favored 'General case' 0 C--N 1.32 -0.713 0 C-N-CA 119.971 -0.692 . . . . 0.0 111.452 -177.124 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 269' ' ' THR . . . . . 0.464 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 72.7 p -121.85 150.84 41.35 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.009 178.499 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 270' ' ' ILE . . . . . 0.828 HG23 HG23 ' A' ' 273' ' ' VAL . 54.4 mt -115.51 138.33 46.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 120.864 0.364 . . . . 0.0 111.622 -177.396 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 271' ' ' ALA . . . . . 0.498 ' N ' HG22 ' A' ' 270' ' ' ILE . . . -66.12 117.58 8.64 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 115.571 -0.74 . . . . 0.0 111.062 178.353 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 104.46 -23.05 32.66 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.932 -0.651 . . . . 0.0 112.182 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . 0.828 HG23 HG23 ' A' ' 270' ' ' ILE . 91.0 t -88.36 112.39 23.74 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-O 120.71 0.291 . . . . 0.0 110.491 175.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 72.9 m-80 -129.54 143.58 50.89 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.663 -178.071 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 52.3 p -70.86 164.75 24.68 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.152 0.501 . . . . 0.0 111.699 -177.7 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 29.3 m -112.58 179.48 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-N 115.652 -0.704 . . . . 0.0 112.469 -176.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 19.2 p-80 -46.19 106.92 0.09 Allowed 'General case' 0 C--O 1.235 0.304 0 CA-C-N 114.631 -1.168 . . . . 0.0 111.817 176.772 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 278' ' ' GLN . . . . . 0.494 ' H ' ' HB2' ' A' ' 282' ' ' ASP . 8.4 tt0 -83.94 -51.29 7.27 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.19 -176.467 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 3.2 mp -105.59 -66.81 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.828 0.347 . . . . 0.0 110.78 -178.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 21.3 p -139.58 86.46 2.11 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.61 -177.545 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt 59.56 29.57 19.14 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.759 -0.655 . . . . 0.0 112.044 177.108 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 282' ' ' ASP . . . . . 0.494 ' HB2' ' H ' ' A' ' 278' ' ' GLN . 1.7 m-20 -58.05 101.48 0.08 Allowed 'General case' 0 N--CA 1.468 0.43 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.68 -179.535 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 45.1 p -105.88 105.65 15.78 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.159 175.117 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 65.7 p -127.6 -35.0 2.17 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.589 -174.449 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 82.23 26.18 48.97 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.306 -177.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 70.7 mt-30 -79.71 121.13 82.09 Favored Pre-proline 0 C--N 1.329 -0.295 0 O-C-N 122.891 -0.182 . . . . 0.0 110.667 -179.658 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 287' ' ' PRO . . . . . 0.464 ' HB2' ' HB ' ' A' ' 269' ' ' THR . 26.4 Cg_exo -60.33 126.75 20.89 Favored 'Trans proline' 0 C--O 1.234 0.296 0 C-N-CA 122.518 2.145 . . . . 0.0 111.408 177.451 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 4.4 tm0? -74.49 136.54 42.23 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 -175.062 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 44.5 t -86.91 124.54 40.57 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-O 121.038 0.447 . . . . 0.0 111.524 -172.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 290' ' ' PHE . . . . . 0.637 ' HD1' ' HD2' ' A' ' 304' ' ' PRO . 60.6 m-85 -98.5 168.44 10.19 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.31 -174.694 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 27.8 mmm180 -125.12 148.42 48.57 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.224 -0.898 . . . . 0.0 109.736 178.463 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . 0.509 HG22 ' HB2' ' A' ' 266' ' ' ASP . 47.9 t -100.92 136.75 31.08 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-N 116.607 -0.27 . . . . 0.0 111.098 179.628 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 293' ' ' LEU . . . . . 0.601 HD11 ' N ' ' A' ' 293' ' ' LEU . 5.5 mp -103.95 -39.94 6.4 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.128 -178.868 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 294' ' ' ALA . . . . . 0.445 ' HA ' HG22 ' A' ' 264' ' ' VAL . . . -156.9 139.61 15.09 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.646 0.26 . . . . 0.0 111.473 -178.493 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 60.6 t -131.21 125.56 57.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-N 116.104 -0.498 . . . . 0.0 109.688 175.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 33.9 t -157.29 111.37 2.64 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.583 -0.281 . . . . 0.0 110.758 -178.018 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 60.58 50.82 63.39 Favored Glycine 0 C--N 1.333 0.372 0 C-N-CA 121.087 -0.578 . . . . 0.0 112.615 179.787 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 45.9 p 50.6 23.71 1.42 Allowed 'General case' 0 N--CA 1.47 0.552 0 C-N-CA 123.477 0.711 . . . . 0.0 112.434 -176.395 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 43.7 m -113.21 106.58 14.8 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 174.072 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 39.4 t -112.99 131.63 64.06 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 115.944 -0.571 . . . . 0.0 111.557 -168.633 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 301' ' ' THR . . . . . 0.458 ' OG1' HG21 ' A' ' 254' ' ' THR . 91.6 m -96.7 110.62 23.03 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 108.725 -0.842 . . . . 0.0 108.725 172.299 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 302' ' ' ILE . . . . . 0.462 ' O ' ' HB2' ' A' ' 303' ' ' SER . 2.5 pp -111.75 -172.54 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 N-CA-C 112.12 0.415 . . . . 0.0 112.12 -175.134 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 303' ' ' SER . . . . . 0.659 ' OG ' ' HA ' ' A' ' 304' ' ' PRO . 14.8 t 169.95 161.16 0.2 Allowed Pre-proline 0 C--O 1.221 -0.397 0 N-CA-C 106.224 -1.769 . . . . 0.0 106.224 -175.563 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 304' ' ' PRO . . . . . 0.659 ' HA ' ' OG ' ' A' ' 303' ' ' SER . 9.4 Cg_exo -72.94 -172.66 9.87 Favored 'Cis proline' 0 C--N 1.348 0.522 0 CA-C-N 121.384 1.53 . . . . 0.0 113.506 0.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 305' ' ' LYS . . . . . 0.625 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -84.3 176.3 8.82 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 114.751 -1.113 . . . . 0.0 112.644 -175.382 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 306' ' ' ILE . . . . . 0.461 ' HB ' ' O ' ' A' ' 235' ' ' GLU . 50.8 mm -119.46 86.2 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 114.485 -1.234 . . . . 0.0 109.878 -174.017 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 307' ' ' LEU . . . . . 0.58 HD12 ' HD1' ' A' ' 319' ' ' TYR . 83.9 mt -108.84 101.59 44.69 Favored Pre-proline 0 C--N 1.321 -0.633 0 C-N-CA 120.918 -0.313 . . . . 0.0 111.652 -173.618 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 308' ' ' PRO . . . . . 0.733 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 17.9 Cg_exo -69.92 148.44 64.01 Favored 'Trans proline' 0 C--O 1.233 0.232 0 C-N-CA 123.197 2.598 . . . . 0.0 113.336 -177.019 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 44.2 t -93.16 -21.36 6.11 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.529 -0.76 . . . . 0.0 109.44 173.1 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 53.5 mt-10 -74.62 13.65 0.59 Allowed 'General case' 0 CA--C 1.531 0.223 0 N-CA-C 112.797 0.665 . . . . 0.0 112.797 -178.448 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 77.8 m-20 -82.25 -24.66 34.66 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 120.846 -0.341 . . . . 0.0 110.92 177.468 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 312' ' ' THR . . . . . 0.418 ' O ' HG22 ' A' ' 312' ' ' THR . 58.2 m 72.01 -13.64 0.58 Allowed 'General case' 0 CA--C 1.541 0.634 0 O-C-N 123.743 0.652 . . . . 0.0 112.233 178.159 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -74.13 152.98 39.75 Favored 'General case' 0 C--N 1.331 -0.21 0 O-C-N 121.905 -0.497 . . . . 0.0 110.803 178.347 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 30.8 t -79.35 -19.33 12.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.306 -0.861 . . . . 0.0 111.485 -173.259 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -78.49 -36.88 44.47 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 113.019 0.748 . . . . 0.0 113.019 -174.096 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 16.2 m -88.18 -35.03 17.6 Favored 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -172.657 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 317' ' ' ARG . . . . . 0.424 ' N ' ' CD ' ' A' ' 318' ' ' PRO . 16.9 ptm180 -62.12 -33.05 11.03 Favored Pre-proline 0 CA--C 1.546 0.801 0 N-CA-C 114.516 1.302 . . . . 0.0 114.516 -175.263 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 318' ' ' PRO . . . . . 0.424 ' CD ' ' N ' ' A' ' 317' ' ' ARG . 35.2 Cg_exo -54.86 -38.87 92.26 Favored 'Trans proline' 0 C--N 1.368 1.587 0 C-N-CA 121.587 1.525 . . . . 0.0 112.795 178.874 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 319' ' ' TYR . . . . . 0.58 ' HD1' HD12 ' A' ' 307' ' ' LEU . 2.2 p90 -122.83 32.73 5.63 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 120.504 -0.479 . . . . 0.0 111.83 -179.251 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -63.34 157.15 23.73 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.605 178.171 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 46.2 t30 -128.49 -36.86 1.85 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.068 -0.514 . . . . 0.0 111.49 -177.662 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 322' ' ' VAL . . . . . . . . . . . . . 34.8 m -131.86 175.62 10.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 120.711 0.291 . . . . 0.0 111.217 -178.847 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 54.7 m-20 -78.62 -44.12 24.71 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.536 -0.302 . . . . 0.0 111.569 -177.272 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 324' ' ' ALA . . . . . 0.733 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -144.55 166.48 25.04 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.458 -175.589 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 325' ' ' LYS . . . . . 0.404 ' HA ' ' HD3' ' A' ' 326' ' ' PRO . 24.1 pttm -115.12 113.89 43.65 Favored Pre-proline 0 C--N 1.327 -0.383 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.729 175.153 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 326' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 325' ' ' LYS . 8.6 Cg_exo -72.92 167.84 26.24 Favored 'Trans proline' 0 C--O 1.233 0.236 0 C-N-CA 122.867 2.378 . . . . 0.0 112.167 -178.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -76.76 128.33 34.44 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 175.084 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 51.0 mt-10 64.96 -167.83 0.21 Allowed 'General case' 0 N--CA 1.466 0.333 0 O-C-N 123.5 0.5 . . . . 0.0 110.463 -176.191 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 329' ' ' SER . . . . . 0.797 ' HB3' ' HB ' ' A' ' 230' ' ' VAL . 42.6 t -90.88 -12.19 36.95 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 177.265 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 63.03 -160.36 0.31 Allowed 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 113.033 0.753 . . . . 0.0 113.033 171.261 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -76.36 127.96 33.9 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 115.182 -0.917 . . . . 0.0 110.676 -178.018 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 332' ' ' ILE . . . . . 0.562 HG12 HG12 ' A' ' 270' ' ' ILE . 50.0 mt -113.61 144.61 20.88 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.962 -177.432 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 95.7 m -115.63 106.09 13.51 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.675 176.824 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 334' ' ' ILE . . . . . 0.406 HG23 ' N ' ' A' ' 335' ' ' LEU . 41.2 mm -83.62 138.02 19.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.753 -0.658 . . . . 0.0 112.379 -170.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 335' ' ' LEU . . . . . 0.788 HD22 ' HA ' ' A' ' 268' ' ' PHE . 1.3 pt? -145.16 -159.14 0.96 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 114.978 -1.01 . . . . 0.0 108.814 171.184 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -152.36 48.36 0.76 Allowed 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.837 0.351 . . . . 0.0 111.592 179.709 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 337' ' ' LYS . . . . . 0.47 ' HB2' ' NZ ' ' A' ' 337' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.246 0.911 0 CA-C-O 118.827 -0.606 . . . . 0.0 110.515 178.908 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.952 0 N-CA-C 112.282 -0.327 . . . . 0.0 112.282 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 50.6 m -86.34 68.86 10.36 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.801 0.334 . . . . 0.0 111.164 179.661 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 36.8 p -102.0 -124.69 0.19 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.394 -0.367 . . . . 0.0 110.456 177.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 37.2 tt0 -86.95 37.71 0.77 Allowed 'General case' 0 C--O 1.236 0.365 0 CA-C-O 121.921 0.867 . . . . 0.0 109.698 177.256 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 24.8 m -86.76 -37.17 18.12 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.474 -0.785 . . . . 0.0 109.952 179.196 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 228' ' ' LEU . . . . . 0.718 ' HB3' ' HB1' ' A' ' 259' ' ' ALA . 83.7 mt -110.59 113.88 26.85 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 174.678 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 229' ' ' THR . . . . . 0.669 ' O ' HG21 ' A' ' 230' ' ' VAL . 41.6 p -120.71 177.68 4.98 Favored 'General case' 0 C--N 1.32 -0.676 0 C-N-CA 119.926 -0.709 . . . . 0.0 110.617 -177.856 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . 0.717 HG23 HD13 ' A' ' 332' ' ' ILE . 89.7 t -150.88 134.78 8.23 Favored 'Isoleucine or valine' 0 C--O 1.239 0.548 0 CA-C-O 120.826 0.346 . . . . 0.0 110.898 -178.365 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 44.3 t -97.98 153.01 18.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.027 175.674 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . 0.558 ' O ' ' HD3' ' A' ' 234' ' ' PRO . . . 108.42 127.21 5.54 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.449 -0.882 . . . . 0.0 111.489 -178.467 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 233' ' ' GLN . . . . . 0.723 ' HG2' ' H ' ' A' ' 328' ' ' GLU . 64.2 mt-30 -95.27 102.38 9.5 Favored Pre-proline 0 C--N 1.324 -0.507 0 CA-C-N 116.53 0.165 . . . . 0.0 110.56 -177.553 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 234' ' ' PRO . . . . . 0.558 ' HD3' ' O ' ' A' ' 232' ' ' GLY . 74.4 Cg_endo -96.78 125.65 0.26 Allowed 'Trans proline' 0 N--CA 1.45 -1.076 0 C-N-CA 122.294 1.996 . . . . 0.0 112.388 -178.195 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 235' ' ' GLU . . . . . 0.911 ' HA ' ' HE3' ' A' ' 325' ' ' LYS . 24.2 pt-20 -105.72 147.67 28.3 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 173.377 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 236' ' ' HIS . . . . . 0.709 ' HB2' ' H ' ' A' ' 306' ' ' ILE . 39.4 m170 -134.62 130.57 36.64 Favored 'General case' 0 CA--C 1.503 -0.85 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 -178.94 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 237' ' ' LYS . . . . . 0.719 ' HG2' ' HB2' ' A' ' 251' ' ' ARG . 7.5 mmmt -105.24 175.56 5.45 Favored 'General case' 0 C--N 1.315 -0.9 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 -178.815 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 238' ' ' VAL . . . . . 0.65 ' HB ' HG12 ' A' ' 248' ' ' VAL . 43.5 t -48.56 144.82 1.08 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.338 0 O-C-N 123.601 0.563 . . . . 0.0 111.145 -178.072 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 239' ' ' GLU . . . . . 0.594 ' HA ' HD21 ' A' ' 250' ' ' ASN . 7.8 pt-20 -59.85 166.26 2.75 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 115.723 -0.671 . . . . 0.0 112.545 -176.81 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 240' ' ' ALA . . . . . 0.424 ' O ' ' HA ' ' A' ' 247' ' ' PRO . . . -44.05 -44.03 7.18 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-N 115.365 -0.834 . . . . 0.0 113.048 -173.06 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 241' ' ' LYS . . . . . 0.534 ' O ' ' HD3' ' A' ' 241' ' ' LYS . 0.0 OUTLIER -146.26 144.98 30.21 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.835 0.35 . . . . 0.0 111.081 178.677 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 57.0 p30 -89.49 -158.38 0.51 Allowed 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.971 -177.366 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 58.6 m -76.99 -15.59 59.59 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.489 -0.323 . . . . 0.0 111.586 -179.112 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 21.1 t-20 -95.81 -15.48 22.49 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.214 0.531 . . . . 0.0 110.164 -179.807 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 94.74 16.61 41.54 Favored Glycine 0 N--CA 1.448 -0.555 0 C-N-CA 120.635 -0.793 . . . . 0.0 111.905 179.495 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 246' ' ' MET . . . . . 0.407 ' HA ' ' HD3' ' A' ' 247' ' ' PRO . 80.7 mtp -83.3 122.2 77.16 Favored Pre-proline 0 C--N 1.326 -0.441 0 CA-C-O 120.604 0.24 . . . . 0.0 110.384 178.75 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 247' ' ' PRO . . . . . 0.424 ' HA ' ' O ' ' A' ' 240' ' ' ALA . 14.0 Cg_exo -69.73 121.15 7.85 Favored 'Trans proline' 0 N--CA 1.461 -0.406 0 C-N-CA 122.583 2.189 . . . . 0.0 112.152 -179.029 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . 0.65 HG12 ' HB ' ' A' ' 238' ' ' VAL . 41.2 t -109.36 146.53 14.74 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 176.615 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -70.83 93.22 0.95 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.068 0.461 . . . . 0.0 110.195 -178.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 250' ' ' ASN . . . . . 0.594 HD21 ' HA ' ' A' ' 239' ' ' GLU . 21.1 t-20 -73.5 133.31 43.59 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.311 -176.807 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . 0.719 ' HB2' ' HG2' ' A' ' 237' ' ' LYS . 27.0 tpt85 -94.67 -98.14 0.16 Allowed 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.815 -178.049 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 252' ' ' GLN . . . . . 0.55 ' HA ' ' CD2' ' A' ' 236' ' ' HIS . 23.4 mt-30 60.5 179.33 0.1 Allowed 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 122.453 0.301 . . . . 0.0 111.2 -178.539 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 157.4 -168.7 34.24 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 119.242 -1.456 . . . . 0.0 113.358 -179.691 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 254' ' ' THR . . . . . 0.551 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 67.2 p -99.53 149.92 22.74 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.911 0.386 . . . . 0.0 111.378 -177.671 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . 0.403 ' O ' ' HA ' ' A' ' 299' ' ' THR . 18.8 pt -125.32 152.94 32.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.959 178.243 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 39.2 m -96.2 105.65 17.74 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.028 -0.731 . . . . 0.0 109.028 177.126 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.601 HG13 HG13 ' A' ' 230' ' ' VAL . 22.7 m -89.93 143.19 11.7 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.681 0 CA-C-O 121.725 0.774 . . . . 0.0 112.73 -169.251 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 50.3 m -93.15 8.63 39.34 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 114.219 -1.355 . . . . 0.0 109.129 170.358 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 259' ' ' ALA . . . . . 0.718 ' HB1' ' HB3' ' A' ' 228' ' ' LEU . . . -99.1 174.76 6.17 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.209 -175.098 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 64.7 p -141.88 149.88 40.83 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.889 0.376 . . . . 0.0 110.981 178.43 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 87.59 32.22 13.91 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.823 -0.704 . . . . 0.0 112.992 179.373 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 262' ' ' LEU . . . . . 0.566 HD11 ' HB2' ' A' ' 259' ' ' ALA . 3.2 mp -97.68 135.53 39.34 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-N 116.995 0.398 . . . . 0.0 110.226 178.894 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -134.04 171.85 13.63 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 177.315 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 38.4 t -78.78 136.65 23.4 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 C-N-CA 120.593 -0.443 . . . . 0.0 109.951 176.658 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 95.61 15.25 44.05 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.538 -0.839 . . . . 0.0 112.141 -179.152 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 266' ' ' ASP . . . . . 0.458 ' HB2' HG21 ' A' ' 292' ' ' VAL . 64.0 m-20 -88.79 166.07 14.27 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.164 0.507 . . . . 0.0 110.779 178.507 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 267' ' ' ALA . . . . . 0.629 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -140.61 122.7 15.68 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.39 -0.823 . . . . 0.0 109.437 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 268' ' ' PHE . . . . . . . . . . . . . 4.6 p90 -142.68 174.11 10.94 Favored 'General case' 0 C--N 1.323 -0.579 0 C-N-CA 119.752 -0.779 . . . . 0.0 111.718 -172.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 269' ' ' THR . . . . . 0.451 HG22 ' HB2' ' A' ' 287' ' ' PRO . 81.9 p -122.18 148.51 44.85 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.179 177.498 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 270' ' ' ILE . . . . . 0.705 HD11 ' HE1' ' A' ' 290' ' ' PHE . 26.6 mt -113.62 137.53 46.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.212 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -61.47 130.53 46.48 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.343 179.881 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 272' ' ' GLY . . . . . 0.517 ' HA3' ' HG2' ' A' ' 326' ' ' PRO . . . 91.91 -23.12 27.86 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 121.189 -0.529 . . . . 0.0 112.113 -178.878 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 59.7 t -95.94 103.14 14.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-O 120.96 0.409 . . . . 0.0 110.285 177.222 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 274' ' ' ASN . . . . . 0.564 ' HA ' ' HA ' ' A' ' 287' ' ' PRO . 70.0 m-80 -119.81 149.6 41.8 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.212 -178.306 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 77.7 p -81.45 162.25 23.37 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.387 0.613 . . . . 0.0 111.474 -176.813 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 29.8 m -112.14 -179.27 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-N 114.968 -1.014 . . . . 0.0 110.939 179.63 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 277' ' ' HIS . . . . . 0.531 ' CD2' ' HD2' ' A' ' 281' ' ' LYS . 26.7 p-80 -43.15 115.53 0.77 Allowed 'General case' 0 C--N 1.331 -0.213 0 O-C-N 124.331 1.02 . . . . 0.0 111.732 177.66 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 71.2 tp60 -83.57 -38.65 21.38 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.731 -178.059 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 279' ' ' ILE . . . . . 0.406 HD11 ' N ' ' A' ' 279' ' ' ILE . 2.9 mp -107.25 -80.85 0.32 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.431 0 C-N-CA 120.892 -0.323 . . . . 0.0 111.577 -176.969 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 35.7 p -127.48 70.74 1.32 Allowed 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 112.787 0.662 . . . . 0.0 112.787 -172.35 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 281' ' ' LYS . . . . . 0.531 ' HD2' ' CD2' ' A' ' 277' ' ' HIS . 14.6 mmmm 53.79 35.45 21.52 Favored 'General case' 0 N--CA 1.47 0.534 0 CA-C-O 121.203 0.525 . . . . 0.0 110.801 178.397 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 52.8 m-20 -69.44 174.04 5.28 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.264 -0.88 . . . . 0.0 111.595 -177.539 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 73.8 p -104.47 109.98 22.07 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.209 178.156 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 67.8 p -116.1 -76.69 0.57 Allowed 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.167 -174.001 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 70.29 7.74 60.85 Favored Glycine 0 C--N 1.329 0.156 0 C-N-CA 121.028 -0.605 . . . . 0.0 113.289 176.577 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 286' ' ' GLN . . . . . 0.404 ' HA ' ' HD3' ' A' ' 287' ' ' PRO . 96.1 mm-40 -93.29 142.43 25.27 Favored Pre-proline 0 C--N 1.324 -0.511 0 N-CA-C 110.314 -0.254 . . . . 0.0 110.314 -179.1 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 287' ' ' PRO . . . . . 0.564 ' HA ' ' HA ' ' A' ' 274' ' ' ASN . 48.2 Cg_exo -56.76 140.78 91.86 Favored 'Trans proline' 0 CA--C 1.529 0.266 0 C-N-CA 122.737 2.291 . . . . 0.0 112.601 -178.549 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 69.5 tp60 -78.22 140.88 38.91 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.006 -178.77 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 42.2 t -92.48 131.25 40.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.706 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 290' ' ' PHE . . . . . 0.705 ' HE1' HD11 ' A' ' 270' ' ' ILE . 8.2 m-30 -106.89 170.31 8.02 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 116.295 -0.412 . . . . 0.0 111.075 -175.939 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 26.2 mmm180 -118.28 145.02 45.37 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.995 0.426 . . . . 0.0 110.578 176.645 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . 0.462 HG12 HG11 ' A' ' 300' ' ' VAL . 59.6 t -101.02 130.42 50.44 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.589 177.716 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 293' ' ' LEU . . . . . 0.577 HD23 ' HB3' ' A' ' 303' ' ' SER . 2.3 mm? -106.1 -29.53 9.83 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.023 -176.504 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 294' ' ' ALA . . . . . 0.443 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -161.89 140.67 9.46 Favored 'General case' 0 C--N 1.331 -0.197 0 C-N-CA 121.013 -0.275 . . . . 0.0 111.442 -178.141 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 58.7 t -135.78 121.08 28.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 176.496 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 62.3 m -150.76 105.61 3.3 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.06 -179.515 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 64.52 57.52 12.66 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.142 179.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 65.5 p 49.42 25.9 1.48 Allowed 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 123.468 0.707 . . . . 0.0 112.448 -176.218 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 299' ' ' THR . . . . . 0.403 ' HA ' ' O ' ' A' ' 255' ' ' ILE . 70.8 m -115.59 111.66 21.0 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 177.166 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . 0.551 ' O ' ' HA ' ' A' ' 254' ' ' THR . 47.4 t -114.4 126.87 72.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.81 -170.817 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 66.3 m -81.55 115.65 20.95 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 172.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 302' ' ' ILE . . . . . 0.412 HG13 ' CE1' ' A' ' 236' ' ' HIS . 28.3 pt -112.82 148.84 15.54 Favored 'Isoleucine or valine' 0 C--O 1.24 0.594 0 N-CA-C 113.395 0.887 . . . . 0.0 113.395 -171.119 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 303' ' ' SER . . . . . 0.735 ' OG ' ' HA ' ' A' ' 304' ' ' PRO . 36.1 t -163.59 163.63 16.08 Favored Pre-proline 0 CA--C 1.537 0.458 0 N-CA-C 106.807 -1.553 . . . . 0.0 106.807 -178.314 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 304' ' ' PRO . . . . . 0.735 ' HA ' ' OG ' ' A' ' 303' ' ' SER . 1.0 OUTLIER -83.49 -151.55 0.68 Allowed 'Cis proline' 0 C--N 1.349 0.588 0 CA-C-N 120.752 1.304 . . . . 0.0 112.694 0.565 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 305' ' ' LYS . . . . . 0.536 ' HA ' ' HB3' ' A' ' 236' ' ' HIS . 0.0 OUTLIER -71.52 144.85 49.47 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.346 0.593 . . . . 0.0 111.046 -177.838 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 306' ' ' ILE . . . . . 0.709 ' H ' ' HB2' ' A' ' 236' ' ' HIS . 52.5 mt -108.44 76.64 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-N 115.513 -0.767 . . . . 0.0 109.135 176.6 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 307' ' ' LEU . . . . . 0.649 ' HB2' ' HA ' ' A' ' 320' ' ' ALA . 91.0 mt -98.83 120.23 59.21 Favored Pre-proline 0 C--N 1.322 -0.617 0 CA-C-N 115.505 -0.771 . . . . 0.0 112.261 -172.688 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 308' ' ' PRO . . . . . 0.752 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 15.8 Cg_exo -68.71 147.12 68.86 Favored 'Trans proline' 0 N--CA 1.462 -0.381 0 C-N-CA 123.309 2.673 . . . . 0.0 111.995 175.469 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . 0.418 ' O ' HG11 ' A' ' 309' ' ' VAL . 35.1 t -93.88 -16.09 7.68 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 N-CA-C 108.018 -1.105 . . . . 0.0 108.018 170.305 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 51.5 mm-40 -96.02 34.06 1.61 Allowed 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 115.218 -0.901 . . . . 0.0 112.422 -177.782 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 25.5 p30 -111.67 -177.18 3.12 Favored 'General case' 0 N--CA 1.464 0.241 0 C-N-CA 120.711 -0.396 . . . . 0.0 110.811 175.523 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 26.2 m -91.07 -20.13 22.4 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.923 -177.334 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 313' ' ' ASP . . . . . 0.546 ' O ' ' HG3' ' A' ' 317' ' ' ARG . 1.3 m-20 -63.58 104.03 0.6 Allowed 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.997 -178.063 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 314' ' ' VAL . . . . . 0.438 ' O ' HG11 ' A' ' 314' ' ' VAL . 48.9 t -64.34 -22.95 32.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.119 177.412 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -85.3 -20.87 29.36 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 111.955 0.354 . . . . 0.0 111.955 -179.747 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 67.6 m -94.24 -36.26 12.09 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 112.151 0.426 . . . . 0.0 112.151 -177.162 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 317' ' ' ARG . . . . . 0.546 ' HG3' ' O ' ' A' ' 313' ' ' ASP . 81.5 mtp180 -54.43 -46.88 98.95 Favored Pre-proline 0 CA--C 1.544 0.748 0 N-CA-C 113.228 0.825 . . . . 0.0 113.228 -177.71 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 318' ' ' PRO . . . . . 0.535 ' HD2' ' N ' ' A' ' 317' ' ' ARG . 11.9 Cg_endo -59.45 -38.46 83.41 Favored 'Trans proline' 0 C--N 1.359 1.115 0 C-N-CA 122.075 1.85 . . . . 0.0 112.807 -178.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 38.4 m-85 -97.75 15.34 23.96 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.651 -177.579 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . 0.649 ' HA ' ' HB2' ' A' ' 307' ' ' LEU . . . -82.18 153.51 25.95 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.723 -0.672 . . . . 0.0 111.001 -178.333 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -136.51 -0.18 2.43 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.988 179.756 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 322' ' ' VAL . . . . . . . . . . . . . 33.1 m -134.21 164.7 33.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 175.574 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -74.63 -33.64 62.61 Favored 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 120.807 -0.357 . . . . 0.0 110.61 -179.385 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 324' ' ' ALA . . . . . 0.752 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -173.22 172.56 3.8 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.402 -0.817 . . . . 0.0 111.282 -175.243 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 325' ' ' LYS . . . . . 0.911 ' HE3' ' HA ' ' A' ' 235' ' ' GLU . 10.7 ptmm? -131.84 106.73 13.99 Favored Pre-proline 0 C--N 1.326 -0.441 0 CA-C-N 115.285 -0.87 . . . . 0.0 110.768 172.616 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 326' ' ' PRO . . . . . 0.517 ' HG2' ' HA3' ' A' ' 272' ' ' GLY . 16.4 Cg_exo -67.39 170.56 13.26 Favored 'Trans proline' 0 C--O 1.233 0.234 0 C-N-CA 123.507 2.804 . . . . 0.0 112.065 178.433 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -58.63 163.85 3.02 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.807 -178.718 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 328' ' ' GLU . . . . . 0.723 ' H ' ' HG2' ' A' ' 233' ' ' GLN . 1.1 pm0 39.26 -153.28 0.01 OUTLIER 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 124.385 1.074 . . . . 0.0 112.748 -175.064 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 329' ' ' SER . . . . . 0.701 ' O ' HG22 ' A' ' 270' ' ' ILE . 48.8 m -112.59 -14.33 13.2 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.859 -176.861 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 61.15 -161.51 0.29 Allowed 'General case' 0 N--CA 1.469 0.525 0 N-CA-C 113.5 0.926 . . . . 0.0 113.5 171.38 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -78.04 138.46 38.8 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-N 114.975 -1.011 . . . . 0.0 110.551 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 332' ' ' ILE . . . . . 0.717 HD13 HG23 ' A' ' 230' ' ' VAL . 54.0 mt -122.8 145.14 30.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-O 121.151 0.5 . . . . 0.0 111.473 -176.182 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 89.8 m -106.23 97.44 7.24 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.82 177.437 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 334' ' ' ILE . . . . . 0.466 HG23 HD12 ' A' ' 334' ' ' ILE . 30.5 mm -86.84 117.6 31.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.376 -0.375 . . . . 0.0 112.002 -174.804 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 335' ' ' LEU . . . . . 0.409 HD21 ' O ' ' A' ' 267' ' ' ALA . 1.8 pt? -141.68 134.84 29.2 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.609 -0.723 . . . . 0.0 109.57 173.279 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -106.19 83.29 1.87 Allowed 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -177.768 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 25.4 pttm . . . . . 0 C--O 1.243 0.74 0 CA-C-O 118.578 -0.725 . . . . 0.0 110.158 -179.894 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.769 0 N-CA-C 112.019 -0.432 . . . . 0.0 112.019 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 34.0 t -85.39 -62.03 1.63 Allowed 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 110.318 -0.253 . . . . 0.0 110.318 -178.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 75.1 p 48.28 -140.39 0.64 Allowed 'General case' 0 N--CA 1.466 0.33 0 C-N-CA 123.358 0.663 . . . . 0.0 111.695 179.701 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 35.74 60.25 0.79 Allowed 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 124.101 0.96 . . . . 0.0 112.289 -178.539 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 36.5 t -95.04 121.67 36.9 Favored 'General case' 0 N--CA 1.445 -0.678 0 CA-C-N 115.659 -0.701 . . . . 0.0 110.407 -177.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 228' ' ' LEU . . . . . 0.677 ' HB3' ' HB3' ' A' ' 259' ' ' ALA . 84.5 mt -69.42 134.31 48.82 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.383 -0.826 . . . . 0.0 109.477 176.421 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 229' ' ' THR . . . . . 0.408 ' OG1' ' HB3' ' A' ' 258' ' ' SER . 41.4 p -131.18 179.38 6.04 Favored 'General case' 0 C--N 1.326 -0.432 0 C-N-CA 119.904 -0.719 . . . . 0.0 112.174 -175.082 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . 0.644 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 53.3 t -122.26 127.81 75.3 Favored 'Isoleucine or valine' 0 C--O 1.238 0.472 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.039 178.482 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 35.7 m -105.86 115.75 30.77 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.317 178.186 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 134.92 170.17 12.11 Favored Glycine 0 N--CA 1.443 -0.851 0 C-N-CA 120.211 -0.995 . . . . 0.0 111.86 -178.499 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 233' ' ' GLN . . . . . 0.415 ' OE1' ' HA ' ' A' ' 327' ' ' ALA . 87.9 mm-40 -113.5 107.96 52.62 Favored Pre-proline 0 C--N 1.321 -0.637 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 -178.473 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 234' ' ' PRO . . . . . 0.648 ' O ' ' HD3' ' A' ' 325' ' ' LYS . 6.3 Cg_exo -74.88 125.74 9.59 Favored 'Trans proline' 0 N--CA 1.454 -0.812 0 C-N-CA 122.072 1.848 . . . . 0.0 111.007 178.073 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 70.0 mm-40 -124.15 149.92 45.73 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.731 178.36 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 78.9 t60 -161.04 130.54 4.81 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-N 115.778 -0.647 . . . . 0.0 110.235 172.39 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 237' ' ' LYS . . . . . 0.597 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -130.39 132.49 45.8 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 114.918 -1.037 . . . . 0.0 108.67 177.166 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 238' ' ' VAL . . . . . 0.593 HG23 HD21 ' A' ' 307' ' ' LEU . 41.4 t -103.63 123.76 57.46 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 C-N-CA 120.115 -0.634 . . . . 0.0 110.767 178.82 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 239' ' ' GLU . . . . . . . . . . . . . 22.7 pt-20 -138.65 143.11 39.08 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 115.649 -0.705 . . . . 0.0 109.442 173.7 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 240' ' ' ALA . . . . . 0.747 ' O ' ' HA ' ' A' ' 247' ' ' PRO . . . -76.62 -91.55 0.03 OUTLIER 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 -178.889 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 241' ' ' LYS . . . . . 0.592 ' O ' ' HD3' ' A' ' 241' ' ' LYS . 0.0 OUTLIER -119.84 144.26 47.45 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.136 175.512 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -101.31 -157.85 0.63 Allowed 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.855 -178.63 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 29.0 p -59.5 -26.38 65.25 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 113.047 0.758 . . . . 0.0 113.047 -177.379 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 48.8 t30 -88.85 -14.61 36.5 Favored 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 120.706 -0.398 . . . . 0.0 110.678 179.389 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . 0.469 ' HA2' ' HE2' ' A' ' 241' ' ' LYS . . . 93.98 3.78 63.64 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.402 -0.904 . . . . 0.0 114.822 170.37 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 246' ' ' MET . . . . . . . . . . . . . 51.8 mtm -95.59 138.35 21.83 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 118.405 1.102 . . . . 0.0 111.258 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 247' ' ' PRO . . . . . 0.747 ' HA ' ' O ' ' A' ' 240' ' ' ALA . 4.7 Cg_exo -76.98 120.32 5.4 Favored 'Trans proline' 0 C--N 1.347 0.479 0 C-N-CA 122.905 2.403 . . . . 0.0 111.389 176.537 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 48.0 t -135.81 109.96 10.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-O 121.035 0.445 . . . . 0.0 110.487 -179.424 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 32.4 t70 -99.53 141.77 31.89 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 174.459 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 250' ' ' ASN . . . . . . . . . . . . . 73.8 m-80 -83.0 37.74 0.56 Allowed 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.812 -0.176 . . . . 0.0 111.356 -178.722 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . 0.775 ' HG3' ' H ' ' A' ' 252' ' ' GLN . 38.1 ptt180 38.08 -108.05 0.06 Allowed 'General case' 0 N--CA 1.473 0.693 0 O-C-N 124.318 1.012 . . . . 0.0 113.038 178.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 252' ' ' GLN . . . . . 0.775 ' H ' ' HG3' ' A' ' 251' ' ' ARG . 2.9 mm100 -127.3 175.21 8.35 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 110.311 -0.255 . . . . 0.0 110.311 -176.88 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -85.3 135.34 13.37 Favored Glycine 0 N--CA 1.448 -0.504 0 C-N-CA 120.317 -0.944 . . . . 0.0 111.848 177.564 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 67.8 p -107.36 118.12 35.89 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.02 0.438 . . . . 0.0 110.162 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . 0.509 HG23 ' HG3' ' A' ' 234' ' ' PRO . 24.2 pt -119.39 146.05 24.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.73 -174.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 92.4 m -97.16 115.81 28.23 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 172.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.501 HG21 HD13 ' A' ' 262' ' ' LEU . 32.8 m -92.08 143.19 11.85 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.974 0 C-N-CA 119.388 -0.925 . . . . 0.0 112.697 -170.94 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 258' ' ' SER . . . . . 0.408 ' HB3' ' OG1' ' A' ' 229' ' ' THR . 23.1 t -90.72 9.92 28.01 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 114.005 -1.452 . . . . 0.0 107.968 169.671 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 259' ' ' ALA . . . . . 0.677 ' HB3' ' HB3' ' A' ' 228' ' ' LEU . . . -93.38 -179.27 5.0 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 114.862 -1.063 . . . . 0.0 110.262 -177.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 32.2 t -152.8 150.92 29.86 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 176.433 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 84.98 22.74 51.84 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.42 -178.649 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 262' ' ' LEU . . . . . 0.501 HD13 HG21 ' A' ' 257' ' ' VAL . 78.6 mt -90.08 140.51 29.58 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.683 0.278 . . . . 0.0 110.439 179.439 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 2.6 mm100 -137.55 168.71 19.12 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.58 -178.28 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 264' ' ' VAL . . . . . 0.503 HG22 ' HA ' ' A' ' 294' ' ' ALA . 45.6 t -74.81 138.58 20.74 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-O 120.743 0.306 . . . . 0.0 110.312 177.645 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 91.37 0.57 73.14 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.685 178.316 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 55.1 m-20 -81.32 165.32 21.49 Favored 'General case' 0 CA--C 1.514 -0.419 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 176.385 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 267' ' ' ALA . . . . . 0.826 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -130.7 148.65 52.51 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 176.869 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 268' ' ' PHE . . . . . 0.498 ' HA ' HD22 ' A' ' 335' ' ' LEU . 3.3 p90 -164.88 168.78 17.32 Favored 'General case' 0 C--N 1.321 -0.649 0 C-N-CA 120.176 -0.61 . . . . 0.0 111.3 -179.216 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 269' ' ' THR . . . . . 0.569 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 63.3 p -113.49 149.5 34.22 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.037 175.55 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 270' ' ' ILE . . . . . 0.47 HG23 HD13 ' A' ' 270' ' ' ILE . 59.4 mt -121.53 129.92 75.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 178.186 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -61.29 139.13 58.22 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.242 0.544 . . . . 0.0 112.242 -173.038 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 88.17 -24.95 9.69 Favored Glycine 0 C--O 1.231 -0.074 0 CA-C-N 115.778 -0.646 . . . . 0.0 112.678 179.199 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 38.2 t -97.21 101.49 12.31 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 174.288 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 274' ' ' ASN . . . . . 1.044 ' HA ' ' HA ' ' A' ' 287' ' ' PRO . 3.6 m120 -94.46 169.11 10.44 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.316 -179.084 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 275' ' ' SER . . . . . 0.409 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 8.3 t -104.72 179.79 4.17 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 107.876 -1.157 . . . . 0.0 107.876 171.555 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 32.7 m -126.28 149.15 31.0 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.07 0 C-N-CA 120.472 -0.491 . . . . 0.0 111.196 173.421 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 277' ' ' HIS . . . . . 0.408 ' CD2' ' HB2' ' A' ' 282' ' ' ASP . 90.6 m-70 -78.08 117.2 19.15 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.065 -0.516 . . . . 0.0 109.621 175.169 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 39.4 tt0 -62.91 -35.25 79.44 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.906 -173.137 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 60.7 mt -60.09 -69.41 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 112.295 0.48 . . . . 0.0 112.295 -173.57 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 46.4 p -114.52 17.22 17.45 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 112.424 0.527 . . . . 0.0 112.424 -174.426 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 2.8 tmtp? 60.04 53.02 4.79 Favored 'General case' 0 CA--C 1.535 0.397 0 CA-C-O 121.328 0.585 . . . . 0.0 109.527 177.688 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 282' ' ' ASP . . . . . 0.408 ' HB2' ' CD2' ' A' ' 277' ' ' HIS . 58.5 m-20 -94.27 129.98 40.71 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.892 0.377 . . . . 0.0 111.007 -178.804 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.505 HG21 ' OD1' ' A' ' 323' ' ' ASP . 76.1 p -107.2 107.43 18.38 Favored 'General case' 0 C--N 1.321 -0.656 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 173.842 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 47.0 p -118.68 7.27 11.65 Favored 'General case' 0 C--N 1.322 -0.587 0 C-N-CA 120.737 -0.385 . . . . 0.0 111.999 -172.217 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 85.58 26.65 34.91 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.403 -0.903 . . . . 0.0 112.646 176.386 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 286' ' ' GLN . . . . . 0.406 ' HA ' ' HD3' ' A' ' 287' ' ' PRO . 84.7 mt-30 -105.03 117.17 59.28 Favored Pre-proline 0 C--N 1.324 -0.535 0 N-CA-C 110.328 -0.249 . . . . 0.0 110.328 178.616 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 287' ' ' PRO . . . . . 1.044 ' HA ' ' HA ' ' A' ' 274' ' ' ASN . 39.5 Cg_exo -61.7 167.36 10.21 Favored 'Trans proline' 0 C--O 1.233 0.274 0 C-N-CA 123.222 2.615 . . . . 0.0 113.559 -175.67 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 62.9 tp60 -88.05 136.45 32.96 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.278 -0.874 . . . . 0.0 110.564 178.165 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 289' ' ' VAL . . . . . 0.423 HG13 ' HB3' ' A' ' 267' ' ' ALA . 43.8 t -94.47 123.24 46.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.069 -0.514 . . . . 0.0 109.888 177.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 290' ' ' PHE . . . . . 0.826 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 60.1 m-85 -104.07 133.56 48.81 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 112.082 0.401 . . . . 0.0 112.082 -173.396 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 40.2 mmm-85 -94.91 119.59 33.71 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-O 121.5 0.667 . . . . 0.0 109.414 167.761 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . 0.56 HG12 ' CG2' ' A' ' 295' ' ' VAL . 54.9 t -71.37 140.91 17.45 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 CA-C-N 114.705 -1.134 . . . . 0.0 112.409 -174.905 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 293' ' ' LEU . . . . . 0.61 HD11 ' N ' ' A' ' 293' ' ' LEU . 3.9 mp -102.34 -30.89 10.79 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.41 175.604 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 294' ' ' ALA . . . . . 0.503 ' HA ' HG22 ' A' ' 264' ' ' VAL . . . -158.02 138.85 13.07 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.558 -177.394 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . 0.56 ' CG2' HG12 ' A' ' 292' ' ' VAL . 59.4 t -133.84 97.67 2.35 Favored 'Isoleucine or valine' 0 C--O 1.236 0.358 0 CA-C-N 115.851 -0.613 . . . . 0.0 109.378 173.826 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 30.5 m -133.98 114.57 13.38 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.848 -176.064 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 60.96 51.04 61.07 Favored Glycine 0 C--N 1.329 0.179 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.336 -179.515 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 70.4 p 52.32 19.5 1.14 Allowed 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 123.635 0.774 . . . . 0.0 112.654 -176.267 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 32.8 m -109.45 108.95 19.64 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 177.174 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . 0.421 ' HA ' ' O ' ' A' ' 294' ' ' ALA . 43.7 t -112.04 126.96 69.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.54 -170.931 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 301' ' ' THR . . . . . 0.443 ' CG2' ' HB2' ' A' ' 252' ' ' GLN . 69.1 m -98.29 117.92 33.77 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 174.259 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 302' ' ' ILE . . . . . 0.678 ' O ' HD11 ' A' ' 302' ' ' ILE . 2.4 pp -116.18 149.82 18.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 N-CA-C 114.116 1.154 . . . . 0.0 114.116 -171.033 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 303' ' ' SER . . . . . 0.588 ' OG ' HD12 ' A' ' 293' ' ' LEU . 86.1 p -140.64 162.62 48.05 Favored Pre-proline 0 C--O 1.216 -0.682 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 173.185 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 304' ' ' PRO . . . . . 0.541 ' O ' ' HA ' ' A' ' 303' ' ' SER . 17.6 Cg_endo -55.83 174.39 3.55 Favored 'Cis proline' 0 N--CA 1.477 0.554 0 CA-C-N 121.479 1.564 . . . . 0.0 113.825 0.038 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 305' ' ' LYS . . . . . 0.462 ' HD2' ' N ' ' A' ' 305' ' ' LYS . 0.4 OUTLIER -65.3 158.42 26.42 Favored 'General case' 0 CA--C 1.511 -0.553 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.38 179.502 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 306' ' ' ILE . . . . . 0.424 HG22 ' HB3' ' A' ' 325' ' ' LYS . 43.3 mt -101.62 73.02 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -0.987 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.779 178.453 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 307' ' ' LEU . . . . . 0.593 HD21 HG23 ' A' ' 238' ' ' VAL . 91.7 mt -107.11 112.14 63.2 Favored Pre-proline 0 C--N 1.324 -0.543 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.216 -176.262 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 308' ' ' PRO . . . . . 0.561 ' HA ' ' O ' ' A' ' 322' ' ' VAL . 11.3 Cg_exo -69.79 146.35 59.74 Favored 'Trans proline' 0 N--CA 1.462 -0.324 0 C-N-CA 122.708 2.272 . . . . 0.0 111.034 177.708 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . 0.693 HG21 ' HB2' ' A' ' 320' ' ' ALA . 20.0 t -83.41 -21.32 8.85 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 CA-C-O 121.282 0.563 . . . . 0.0 110.39 -177.694 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -76.24 -6.95 53.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.58 -0.736 . . . . 0.0 112.28 -175.994 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -75.46 153.94 37.31 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.143 0.497 . . . . 0.0 111.749 -177.005 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 53.1 m -96.88 -7.58 33.06 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.835 -0.62 . . . . 0.0 109.402 178.24 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 313' ' ' ASP . . . . . 0.463 ' HB3' ' HB2' ' A' ' 316' ' ' SER . 9.8 t70 -54.25 119.0 4.54 Favored 'General case' 0 C--O 1.232 0.153 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.507 179.868 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 46.7 t -56.57 -49.61 76.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.41 -0.814 . . . . 0.0 112.679 -173.071 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -81.82 -19.73 40.5 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 112.352 0.501 . . . . 0.0 112.352 -174.668 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 316' ' ' SER . . . . . 0.463 ' HB2' ' HB3' ' A' ' 313' ' ' ASP . 49.2 m -91.81 -25.26 19.09 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 112.283 0.475 . . . . 0.0 112.283 -175.742 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 317' ' ' ARG . . . . . 0.473 ' CG ' ' HD3' ' A' ' 318' ' ' PRO . 1.6 ptm85 -71.62 -35.79 4.04 Favored Pre-proline 0 CA--C 1.545 0.771 0 N-CA-C 114.293 1.22 . . . . 0.0 114.293 -175.902 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 318' ' ' PRO . . . . . 0.473 ' HD3' ' CG ' ' A' ' 317' ' ' ARG . 24.2 Cg_exo -65.89 -38.92 21.33 Favored 'Trans proline' 0 C--N 1.362 1.268 0 CA-C-N 121.132 1.44 . . . . 0.0 112.476 -177.463 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 3.9 m-85 -95.94 17.37 15.5 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.075 -179.719 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . 0.693 ' HB2' HG21 ' A' ' 309' ' ' VAL . . . -64.67 134.34 54.07 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.523 177.805 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 15.2 p-10 -144.11 1.44 1.11 Allowed 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -174.023 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 322' ' ' VAL . . . . . 0.561 ' O ' ' HA ' ' A' ' 308' ' ' PRO . 29.4 m -133.93 161.45 40.92 Favored 'Isoleucine or valine' 0 C--O 1.234 0.266 0 CA-C-O 121.288 0.566 . . . . 0.0 112.262 -177.82 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 323' ' ' ASP . . . . . 0.672 ' HB2' ' HB2' ' A' ' 274' ' ' ASN . 57.2 m-20 -93.24 77.59 4.54 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.865 174.958 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 324' ' ' ALA . . . . . . . . . . . . . . . 72.37 163.85 0.28 Allowed 'General case' 0 N--CA 1.471 0.621 0 N-CA-C 113.387 0.884 . . . . 0.0 113.387 175.12 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 325' ' ' LYS . . . . . 0.648 ' HD3' ' O ' ' A' ' 234' ' ' PRO . 9.9 ptpp? -119.15 105.93 43.93 Favored Pre-proline 0 C--N 1.325 -0.459 0 CA-C-N 114.485 -1.234 . . . . 0.0 108.715 166.902 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 326' ' ' PRO . . . . . 0.412 ' HD3' ' HA ' ' A' ' 325' ' ' LYS . 3.8 Cg_exo -84.17 167.21 12.43 Favored 'Trans proline' 0 C--O 1.234 0.299 0 C-N-CA 122.657 2.238 . . . . 0.0 112.992 -171.363 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 327' ' ' ALA . . . . . 0.415 ' HA ' ' OE1' ' A' ' 233' ' ' GLN . . . -72.82 134.85 45.07 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 115.605 -0.725 . . . . 0.0 109.689 174.136 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 70.1 mm-40 71.3 111.18 0.06 Allowed 'General case' 0 N--CA 1.464 0.256 0 O-C-N 124.089 0.868 . . . . 0.0 110.432 -173.243 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 329' ' ' SER . . . . . 0.644 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 58.2 m -63.36 -41.28 98.83 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.603 -176.561 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 330' ' ' ALA . . . . . 0.547 ' HB1' ' O ' ' A' ' 329' ' ' SER . . . 79.35 -160.66 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.762 0 N-CA-C 112.828 0.677 . . . . 0.0 112.828 174.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 331' ' ' ALA . . . . . 0.424 ' H ' ' HB3' ' A' ' 330' ' ' ALA . . . -68.43 157.73 35.21 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-N 115.091 -0.958 . . . . 0.0 113.562 -170.405 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 332' ' ' ILE . . . . . 0.578 HD12 ' HB2' ' A' ' 259' ' ' ALA . 17.5 mt -119.16 146.11 24.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.075 -0.966 . . . . 0.0 110.223 179.555 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.528 ' HB ' ' OG1' ' A' ' 269' ' ' THR . 59.5 m -127.18 111.67 14.24 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 175.544 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 46.9 mm -83.87 134.93 25.85 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.359 0 N-CA-C 113.295 0.85 . . . . 0.0 113.295 -171.538 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 335' ' ' LEU . . . . . 0.5 ' O ' ' HB1' ' A' ' 267' ' ' ALA . 1.8 pt? -158.45 130.36 6.75 Favored 'General case' 0 C--O 1.222 -0.366 0 CA-C-N 115.083 -0.962 . . . . 0.0 109.906 170.562 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -102.65 2.74 36.34 Favored 'General case' 0 C--N 1.318 -0.801 0 O-C-N 122.011 -0.43 . . . . 0.0 111.144 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 40.1 ttmt . . . . . 0 C--O 1.244 0.773 0 CA-C-O 118.279 -0.867 . . . . 0.0 110.246 -178.388 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.776 0 N-CA-C 112.277 -0.329 . . . . 0.0 112.277 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 33.9 t 65.33 -131.89 0.25 Allowed 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 122.574 0.35 . . . . 0.0 110.073 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 225' ' ' THR . . . . . 0.469 ' HB ' HD13 ' A' ' 228' ' ' LEU . 50.1 p -83.15 162.41 21.29 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-O 120.905 0.383 . . . . 0.0 110.653 179.736 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -152.83 86.24 1.25 Allowed 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.197 179.487 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 35.4 m 62.46 77.52 0.33 Allowed 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.015 179.235 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 228' ' ' LEU . . . . . 0.54 ' H ' ' CD2' ' A' ' 228' ' ' LEU . 1.9 mm? -60.39 150.56 30.49 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.252 -179.665 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 229' ' ' THR . . . . . 0.599 ' O ' HG23 ' A' ' 230' ' ' VAL . 53.6 p -129.96 176.18 8.26 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 119.787 -0.765 . . . . 0.0 111.1 -179.773 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . 0.803 HG22 HD11 ' A' ' 332' ' ' ILE . 64.9 t -148.69 138.87 16.56 Favored 'Isoleucine or valine' 0 C--O 1.238 0.478 0 CA-C-O 120.789 0.328 . . . . 0.0 110.926 -177.128 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 47.1 t -122.72 97.39 5.43 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.419 -0.809 . . . . 0.0 109.101 173.284 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . -126.22 -151.8 7.96 Favored Glycine 0 N--CA 1.445 -0.762 0 C-N-CA 119.951 -1.119 . . . . 0.0 113.102 -175.036 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 233' ' ' GLN . . . . . 0.761 ' HB3' ' HD2' ' A' ' 234' ' ' PRO . 80.3 mt-30 -70.58 169.61 13.53 Favored Pre-proline 0 C--N 1.325 -0.468 0 CA-C-N 115.212 -0.494 . . . . 0.0 110.991 -178.609 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 234' ' ' PRO . . . . . 0.761 ' HD2' ' HB3' ' A' ' 233' ' ' GLN . 18.7 Cg_endo -57.53 175.08 0.43 Allowed 'Trans proline' 0 C--N 1.354 0.833 0 C-N-CA 123.404 2.736 . . . . 0.0 112.833 177.777 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 235' ' ' GLU . . . . . 0.442 ' HB2' ' HD2' ' A' ' 325' ' ' LYS . 25.1 mp0 -91.86 155.18 18.39 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 108.96 -0.756 . . . . 0.0 108.96 -177.052 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 236' ' ' HIS . . . . . 0.613 ' CE1' ' HB3' ' A' ' 251' ' ' ARG . 65.6 m-70 -108.5 148.76 29.76 Favored 'General case' 0 C--N 1.323 -0.581 0 C-N-CA 120.521 -0.472 . . . . 0.0 111.177 -171.511 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 237' ' ' LYS . . . . . 0.49 ' HA ' HD23 ' A' ' 307' ' ' LEU . 0.0 OUTLIER -160.23 161.92 33.6 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.5 -0.773 . . . . 0.0 108.957 -178.38 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 238' ' ' VAL . . . . . 0.462 ' HB ' ' HA ' ' A' ' 316' ' ' SER . 45.8 t -103.43 120.82 53.97 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 C-N-CA 120.874 -0.331 . . . . 0.0 110.46 179.728 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 239' ' ' GLU . . . . . 0.503 ' HB2' HG22 ' A' ' 248' ' ' VAL . 53.7 mt-10 -120.71 154.17 35.95 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.049 176.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 240' ' ' ALA . . . . . . . . . . . . . . . -62.6 -40.02 95.6 Favored 'General case' 0 C--N 1.328 -0.344 0 O-C-N 123.369 0.418 . . . . 0.0 110.944 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 241' ' ' LYS . . . . . 0.601 ' O ' ' HD3' ' A' ' 241' ' ' LYS . 0.0 OUTLIER -149.54 143.29 25.51 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.433 0.635 . . . . 0.0 112.07 178.723 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 56.3 p-10 -106.38 -156.56 0.58 Allowed 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.258 179.449 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 47.1 t -58.71 -33.59 70.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.176 178.421 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 51.0 t30 -91.04 -13.83 32.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.875 0.369 . . . . 0.0 111.129 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . 0.496 ' HA2' ' HB2' ' A' ' 241' ' ' LYS . . . 95.5 22.14 22.46 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.622 -0.799 . . . . 0.0 112.571 178.975 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 246' ' ' MET . . . . . . . . . . . . . 83.8 mtp -113.44 151.5 44.49 Favored Pre-proline 0 C--N 1.325 -0.464 0 O-C-N 122.952 -0.146 . . . . 0.0 110.706 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 247' ' ' PRO . . . . . 0.449 ' HA ' ' O ' ' A' ' 239' ' ' GLU . 26.0 Cg_exo -58.9 130.06 34.94 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.277 1.985 . . . . 0.0 111.0 175.352 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . 0.503 HG22 ' HB2' ' A' ' 239' ' ' GLU . 48.5 t -70.21 118.17 14.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-O 121.179 0.514 . . . . 0.0 110.591 -175.077 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 27.2 t70 -79.35 144.21 34.41 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.557 -179.337 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 250' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -62.27 101.15 0.21 Allowed 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 178.117 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . 0.613 ' HB3' ' CE1' ' A' ' 236' ' ' HIS . 0.6 OUTLIER -67.08 -68.47 0.37 Allowed 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.469 -0.787 . . . . 0.0 112.141 -169.742 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 19.2 mt-30 62.84 178.89 0.14 Allowed 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 -176.769 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . 0.585 ' O ' ' HA ' ' A' ' 301' ' ' THR . . . 133.29 -146.45 18.36 Favored Glycine 0 N--CA 1.445 -0.76 0 C-N-CA 118.576 -1.773 . . . . 0.0 114.223 174.314 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 51.4 p -93.98 130.1 40.21 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.036 -0.582 . . . . 0.0 112.443 -170.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . 0.693 HD13 HG11 ' A' ' 230' ' ' VAL . 2.3 pp -129.79 163.4 35.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.902 177.432 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 256' ' ' THR . . . . . 0.579 ' O ' HG12 ' A' ' 230' ' ' VAL . 31.3 m -100.47 116.38 32.28 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 -178.51 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.434 HG12 HG23 ' A' ' 300' ' ' VAL . 31.8 m -90.78 142.56 12.77 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.573 0 C-N-CA 120.192 -0.603 . . . . 0.0 112.593 -176.098 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 36.8 t -91.94 9.03 34.74 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 114.495 -1.23 . . . . 0.0 108.379 167.575 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 259' ' ' ALA . . . . . 0.748 ' HB3' HD12 ' A' ' 262' ' ' LEU . . . -91.07 171.54 9.19 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.138 -0.937 . . . . 0.0 109.748 -178.023 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 34.5 t -143.65 132.02 22.11 Favored 'General case' 0 C--N 1.324 -0.504 0 C-N-CA 120.991 -0.283 . . . . 0.0 110.857 179.508 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 99.24 25.49 9.43 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.682 -0.771 . . . . 0.0 113.083 177.705 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 262' ' ' LEU . . . . . 0.748 HD12 ' HB3' ' A' ' 259' ' ' ALA . 3.4 mp -87.79 146.26 25.71 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 117.034 0.417 . . . . 0.0 110.195 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 83.6 mt-30 -141.04 169.16 18.13 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.105 -0.498 . . . . 0.0 109.768 177.404 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 264' ' ' VAL . . . . . 0.461 ' CG2' ' HA ' ' A' ' 294' ' ' ALA . 31.8 t -77.86 139.69 18.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 C-N-CA 121.032 -0.267 . . . . 0.0 110.594 -179.677 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 91.71 3.35 68.71 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.13 179.462 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 70.5 m-20 -80.46 166.78 20.89 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.295 0.569 . . . . 0.0 111.039 179.145 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 267' ' ' ALA . . . . . 0.685 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -125.84 144.11 50.79 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 114.802 -1.09 . . . . 0.0 108.551 175.22 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 268' ' ' PHE . . . . . 0.578 ' CD1' HG22 ' A' ' 332' ' ' ILE . 0.0 OUTLIER -163.45 163.82 24.72 Favored 'General case' 0 C--N 1.313 -1.002 0 C-N-CA 120.125 -0.63 . . . . 0.0 110.167 -179.955 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 269' ' ' THR . . . . . 0.445 HG22 ' HB2' ' A' ' 287' ' ' PRO . 63.3 p -125.89 137.99 53.77 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 120.822 0.344 . . . . 0.0 110.934 -175.397 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 270' ' ' ILE . . . . . 0.659 HG12 HG12 ' A' ' 332' ' ' ILE . 60.5 mt -95.89 138.63 20.89 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.806 -179.316 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -62.23 125.52 24.18 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.97 179.577 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 94.4 -21.57 41.93 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.125 -178.62 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . 0.583 HG13 ' HB3' ' A' ' 288' ' ' GLN . 57.0 t -90.73 101.4 12.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.282 0.563 . . . . 0.0 110.106 177.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -115.91 134.32 55.11 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 178.791 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 35.6 p -70.8 152.81 43.36 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.258 0.552 . . . . 0.0 111.97 -179.125 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 276' ' ' VAL . . . . . 0.432 HG22 ' HG3' ' A' ' 278' ' ' GLN . 33.8 m -114.7 156.07 15.75 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-N 115.221 -0.899 . . . . 0.0 110.157 174.588 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 21.7 m80 -116.6 71.27 0.78 Allowed 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 177.473 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 278' ' ' GLN . . . . . 0.432 ' HG3' HG22 ' A' ' 276' ' ' VAL . 26.8 mt-30 -70.58 -9.62 57.27 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 112.17 0.433 . . . . 0.0 112.17 -175.239 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 2.0 mp -67.67 -49.08 73.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 176.024 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 70.1 p -90.93 -12.75 35.11 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.117 0.484 . . . . 0.0 109.925 174.288 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 26.5 tptp 68.28 50.8 0.73 Allowed 'General case' 0 CA--C 1.531 0.237 0 CA-C-N 114.902 -1.045 . . . . 0.0 110.342 -177.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -118.34 142.15 47.8 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.889 177.553 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 62.8 p -107.43 109.93 21.77 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.48 174.745 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 68.0 p -114.33 -12.19 12.45 Favored 'General case' 0 C--N 1.32 -0.691 0 C-N-CA 120.721 -0.392 . . . . 0.0 111.999 -171.429 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 64.16 31.46 80.91 Favored Glycine 0 CA--C 1.518 0.252 0 C-N-CA 120.964 -0.636 . . . . 0.0 113.313 175.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 98.1 mm-40 -89.14 122.46 68.71 Favored Pre-proline 0 C--N 1.327 -0.37 0 CA-C-N 116.941 0.37 . . . . 0.0 110.197 178.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 287' ' ' PRO . . . . . 0.445 ' HB2' HG22 ' A' ' 269' ' ' THR . 86.1 Cg_exo -48.29 131.08 22.1 Favored 'Trans proline' 0 C--N 1.346 0.42 0 C-N-CA 123.033 2.489 . . . . 0.0 112.989 -177.695 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 288' ' ' GLN . . . . . 0.583 ' HB3' HG13 ' A' ' 273' ' ' VAL . 67.1 tp60 -70.1 127.28 32.28 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.868 -178.867 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 65.7 t -91.73 131.74 38.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 116.042 -0.527 . . . . 0.0 110.578 178.47 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 290' ' ' PHE . . . . . 0.685 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 57.8 m-85 -113.5 154.5 26.96 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.72 -178.272 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 291' ' ' ARG . . . . . 0.476 ' HG3' HH11 ' A' ' 291' ' ' ARG . 0.1 OUTLIER -114.5 121.58 43.96 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.15 0.5 . . . . 0.0 110.196 172.812 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 56.9 t -70.39 136.46 25.99 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-N 115.037 -0.983 . . . . 0.0 111.889 -175.291 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 293' ' ' LEU . . . . . 0.498 HD13 ' HB2' ' A' ' 303' ' ' SER . 5.5 mp -96.22 -35.69 11.19 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.91 -0.587 . . . . 0.0 111.085 179.048 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 294' ' ' ALA . . . . . 0.556 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -163.63 140.8 7.21 Favored 'General case' 0 C--N 1.332 -0.184 0 C-N-CA 121.058 -0.257 . . . . 0.0 111.641 -179.579 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 59.9 t -134.77 103.37 4.48 Favored 'Isoleucine or valine' 0 C--O 1.235 0.303 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.784 175.191 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 51.0 m -143.81 114.64 7.73 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.559 -179.013 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 67.05 48.43 59.99 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.276 -178.551 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 77.9 p 51.5 21.53 1.28 Allowed 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 123.608 0.763 . . . . 0.0 112.106 -176.198 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 37.0 m -110.04 105.9 15.2 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 177.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . 0.609 HG12 HG23 ' A' ' 302' ' ' ILE . 48.9 t -108.52 128.09 64.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.4 -172.119 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 301' ' ' THR . . . . . 0.585 ' HA ' ' O ' ' A' ' 253' ' ' GLY . 54.1 m -86.75 115.82 24.44 Favored 'General case' 0 N--CA 1.451 -0.423 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 173.631 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 302' ' ' ILE . . . . . 0.61 HD12 ' O ' ' A' ' 302' ' ' ILE . 2.4 pp -111.74 151.04 13.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 N-CA-C 113.527 0.936 . . . . 0.0 113.527 -171.05 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 303' ' ' SER . . . . . 0.547 ' HB3' ' HA ' ' A' ' 304' ' ' PRO . 64.9 m -166.99 166.5 8.48 Favored Pre-proline 0 C--N 1.322 -0.595 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 179.326 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 304' ' ' PRO . . . . . 0.547 ' HA ' ' HB3' ' A' ' 303' ' ' SER . 4.3 Cg_exo -77.62 -113.81 0.0 OUTLIER 'Cis proline' 0 C--N 1.347 0.48 0 CA-C-N 120.907 1.36 . . . . 0.0 113.438 0.516 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 305' ' ' LYS . . . . . 0.498 ' HB3' ' HG ' ' A' ' 307' ' ' LEU . 31.2 mmtp -93.04 155.74 17.32 Favored 'General case' 0 CA--C 1.515 -0.385 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.354 -171.473 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 306' ' ' ILE . . . . . . . . . . . . . 3.1 mp -131.09 74.18 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.641 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 167.283 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 307' ' ' LEU . . . . . 0.498 ' HG ' ' HB3' ' A' ' 305' ' ' LYS . 73.7 mt -112.67 113.91 50.08 Favored Pre-proline 0 C--N 1.328 -0.366 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.183 -171.092 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 308' ' ' PRO . . . . . 0.727 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 37.8 Cg_exo -66.91 148.62 82.43 Favored 'Trans proline' 0 N--CA 1.472 0.254 0 C-N-CA 123.378 2.719 . . . . 0.0 113.924 -175.137 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . 0.498 ' O ' HG13 ' A' ' 309' ' ' VAL . 46.0 t -94.06 -7.92 9.99 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.362 0 CA-C-N 115.421 -0.809 . . . . 0.0 109.303 171.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 310' ' ' GLU . . . . . 0.414 ' HG2' ' O ' ' A' ' 323' ' ' ASP . 65.3 mm-40 -77.17 11.83 1.7 Allowed 'General case' 0 CA--C 1.531 0.248 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.928 179.076 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.52 ' OD1' ' HB2' ' A' ' 308' ' ' PRO . 4.6 m120 -80.41 158.69 25.89 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.888 0.375 . . . . 0.0 110.669 178.472 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 31.5 m -107.74 -13.28 15.06 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.168 0.508 . . . . 0.0 110.494 -176.027 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 11.8 p-10 -87.58 156.25 19.59 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 121.091 0.472 . . . . 0.0 111.172 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 314' ' ' VAL . . . . . 0.414 ' O ' HG11 ' A' ' 314' ' ' VAL . 49.1 t -81.79 -24.06 9.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 115.707 -0.678 . . . . 0.0 111.112 -178.295 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -61.9 -42.72 99.42 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 111.913 0.338 . . . . 0.0 111.913 -178.114 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 316' ' ' SER . . . . . 0.462 ' HA ' ' HB ' ' A' ' 238' ' ' VAL . 26.3 t -82.1 -10.31 59.24 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.609 -0.268 . . . . 0.0 111.293 -176.431 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 317' ' ' ARG . . . . . 0.628 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 36.8 mmt180 -58.37 -54.5 55.24 Favored Pre-proline 0 N--CA 1.468 0.464 0 N-CA-C 113.554 0.946 . . . . 0.0 113.554 -179.704 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 318' ' ' PRO . . . . . 0.628 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 24.5 Cg_exo -68.21 -19.19 44.81 Favored 'Trans proline' 0 C--N 1.353 0.78 0 C-N-CA 122.017 1.811 . . . . 0.0 113.232 -175.178 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 319' ' ' TYR . . . . . 0.445 ' O ' HD11 ' A' ' 307' ' ' LEU . 55.4 m-85 -102.16 -18.37 15.57 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 111.965 0.357 . . . . 0.0 111.965 -174.245 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -55.64 126.49 25.61 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.795 0.331 . . . . 0.0 111.244 -178.666 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 15.3 p-10 -126.51 -4.94 6.54 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.288 -177.631 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 322' ' ' VAL . . . . . 0.496 ' O ' HG22 ' A' ' 309' ' ' VAL . 29.9 m -136.35 156.43 36.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.637 0.256 . . . . 0.0 110.885 178.511 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 323' ' ' ASP . . . . . 0.414 ' O ' ' HG2' ' A' ' 310' ' ' GLU . 71.9 m-20 -52.93 -50.97 62.93 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.889 -178.065 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 324' ' ' ALA . . . . . 0.727 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -163.05 -179.94 7.07 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.006 0.431 . . . . 0.0 111.135 -177.066 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 325' ' ' LYS . . . . . 0.442 ' HD2' ' HB2' ' A' ' 235' ' ' GLU . 22.0 pttp -105.84 137.43 19.34 Favored Pre-proline 0 C--N 1.325 -0.481 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.122 176.575 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -86.35 167.46 9.05 Favored 'Trans proline' 0 N--CA 1.454 -0.809 0 C-N-CA 122.712 2.275 . . . . 0.0 112.306 -179.411 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -75.6 138.34 41.37 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 175.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 62.64 -132.42 0.51 Allowed 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 -174.021 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 329' ' ' SER . . . . . 0.485 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 48.6 m -111.49 -17.34 13.1 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 171.185 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 74.47 -173.67 0.13 Allowed 'General case' 0 N--CA 1.474 0.759 0 N-CA-C 113.65 0.981 . . . . 0.0 113.65 170.887 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 331' ' ' ALA . . . . . 0.431 ' HA ' ' O ' ' A' ' 228' ' ' LEU . . . -80.76 146.75 30.84 Favored 'General case' 0 CA--C 1.518 -0.264 0 CA-C-N 114.997 -1.001 . . . . 0.0 111.171 -176.604 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 332' ' ' ILE . . . . . 0.803 HD11 HG22 ' A' ' 230' ' ' VAL . 47.5 mt -128.45 147.18 33.0 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-O 120.956 0.408 . . . . 0.0 111.528 -176.938 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 88.1 m -116.71 112.96 21.94 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.857 -179.591 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 334' ' ' ILE . . . . . 0.402 HD12 HG23 ' A' ' 334' ' ' ILE . 38.4 mm -79.56 131.87 33.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 113.044 0.757 . . . . 0.0 113.044 -171.482 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 335' ' ' LEU . . . . . . . . . . . . . 9.6 mp -115.92 168.61 9.91 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 114.562 -1.199 . . . . 0.0 109.643 171.5 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -116.82 3.96 12.95 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.473 176.69 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 337' ' ' LYS . . . . . 0.457 ' O ' ' HB2' ' A' ' 267' ' ' ALA . 14.8 ptmm? . . . . . 0 C--O 1.246 0.889 0 CA-C-O 118.611 -0.709 . . . . 0.0 111.687 -176.415 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.848 0 N-CA-C 112.467 -0.253 . . . . 0.0 112.467 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 50.4 m -104.63 -116.04 0.23 Allowed 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 177.734 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 50.3 m -68.32 -42.56 79.2 Favored 'General case' 0 C--O 1.234 0.239 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 175.722 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 50.8 mm-40 56.53 39.25 29.99 Favored 'General case' 0 C--N 1.333 -0.116 0 CA-C-N 115.053 -0.976 . . . . 0.0 110.954 178.442 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 51.1 m -119.92 49.5 1.39 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.506 -179.236 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 228' ' ' LEU . . . . . 0.66 HD13 ' HB1' ' A' ' 259' ' ' ALA . 89.9 mt -70.28 147.27 49.89 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 175.148 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 229' ' ' THR . . . . . 0.536 ' O ' HG21 ' A' ' 230' ' ' VAL . 63.8 p -126.29 171.65 10.77 Favored 'General case' 0 C--N 1.324 -0.54 0 C-N-CA 119.163 -1.015 . . . . 0.0 111.334 -176.919 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . 0.629 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 48.0 t -147.1 141.08 20.0 Favored 'Isoleucine or valine' 0 C--O 1.24 0.577 0 CA-C-O 120.657 0.265 . . . . 0.0 110.754 -177.662 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 30.6 t -106.48 148.84 27.7 Favored 'General case' 0 C--O 1.237 0.428 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.985 176.634 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 124.8 157.15 9.61 Favored Glycine 0 N--CA 1.449 -0.486 0 N-CA-C 110.944 -0.862 . . . . 0.0 110.944 -176.712 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 233' ' ' GLN . . . . . 0.538 ' NE2' ' HA ' ' A' ' 328' ' ' GLU . 96.6 mm-40 -110.01 101.48 47.52 Favored Pre-proline 0 C--N 1.324 -0.534 0 CA-C-N 117.419 0.609 . . . . 0.0 111.305 -177.819 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -91.83 126.36 0.92 Allowed 'Trans proline' 0 N--CA 1.448 -1.159 0 C-N-CA 122.806 2.337 . . . . 0.0 111.756 177.605 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 235' ' ' GLU . . . . . 0.588 ' O ' ' HB3' ' A' ' 251' ' ' ARG . 11.0 pt-20 -132.54 149.36 52.33 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.525 -0.307 . . . . 0.0 110.214 177.027 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 236' ' ' HIS . . . . . 0.724 ' CD2' ' HA ' ' A' ' 305' ' ' LYS . 29.3 m80 -136.55 136.11 39.02 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.182 -179.532 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 237' ' ' LYS . . . . . 0.536 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -155.16 128.09 8.14 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.024 -179.968 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 238' ' ' VAL . . . . . 0.695 HG21 HD12 ' A' ' 307' ' ' LEU . 46.4 t -84.94 147.74 5.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.597 -0.274 . . . . 0.0 110.671 -176.465 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 239' ' ' GLU . . . . . 1.01 ' HA ' ' HB ' ' A' ' 248' ' ' VAL . 7.7 pt-20 -52.85 116.87 2.56 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.869 -0.605 . . . . 0.0 112.499 179.678 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 240' ' ' ALA . . . . . . . . . . . . . . . -81.73 -56.38 4.03 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 174.284 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 241' ' ' LYS . . . . . 0.467 ' HZ1' ' HB3' ' A' ' 241' ' ' LYS . 0.2 OUTLIER -97.98 177.43 5.43 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.195 -0.912 . . . . 0.0 108.996 175.484 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 11.9 p-10 -105.88 -161.47 0.8 Allowed 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 120.852 0.358 . . . . 0.0 110.077 176.379 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 25.1 p -71.5 2.27 5.28 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 112.336 0.495 . . . . 0.0 112.336 178.498 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 49.8 t30 -79.27 -15.14 58.45 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.96 0.41 . . . . 0.0 110.763 178.388 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . 0.433 ' O ' ' HE3' ' A' ' 246' ' ' MET . . . -156.88 -77.68 0.02 OUTLIER Glycine 0 N--CA 1.445 -0.738 0 C-N-CA 120.177 -1.011 . . . . 0.0 112.651 -179.449 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 246' ' ' MET . . . . . 0.604 ' CE ' ' HA ' ' A' ' 246' ' ' MET . 1.6 mmt -112.29 118.06 46.41 Favored Pre-proline 0 C--N 1.326 -0.445 0 CA-C-O 120.967 0.413 . . . . 0.0 111.836 -178.769 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 247' ' ' PRO . . . . . 0.465 ' HD3' ' HA ' ' A' ' 246' ' ' MET . 11.4 Cg_endo -86.64 120.48 1.74 Allowed 'Trans proline' 0 N--CA 1.45 -1.035 0 C-N-CA 123.336 2.69 . . . . 0.0 111.584 174.051 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . 1.01 ' HB ' ' HA ' ' A' ' 239' ' ' GLU . 32.5 t -119.82 120.19 62.54 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 C-N-CA 120.656 -0.418 . . . . 0.0 110.074 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 36.7 t70 -118.31 146.1 44.59 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.604 -0.271 . . . . 0.0 110.66 -176.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 250' ' ' ASN . . . . . 0.481 ' HA ' ' H ' ' A' ' 237' ' ' LYS . 73.6 m-80 -61.39 -0.28 0.37 Allowed 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 113.11 0.782 . . . . 0.0 113.11 -176.844 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . 0.588 ' HB3' ' O ' ' A' ' 235' ' ' GLU . 36.0 tpt85 66.31 -93.12 0.03 OUTLIER 'General case' 0 N--CA 1.453 -0.31 0 C-N-CA 123.083 0.553 . . . . 0.0 110.506 179.394 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 21.3 mt-30 59.49 179.08 0.08 Allowed 'General case' 0 N--CA 1.468 0.473 0 CA-C-O 120.951 0.405 . . . . 0.0 110.693 179.223 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 136.0 -160.86 24.75 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 119.031 -1.557 . . . . 0.0 113.613 176.125 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 254' ' ' THR . . . . . 0.471 ' HB ' ' CG2' ' A' ' 299' ' ' THR . 66.0 p -94.63 135.73 35.75 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-O 121.331 0.586 . . . . 0.0 111.88 -175.307 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . 0.552 HD13 HG13 ' A' ' 230' ' ' VAL . 14.6 pt -121.77 156.42 26.04 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-N 115.535 -0.757 . . . . 0.0 110.179 177.151 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 256' ' ' THR . . . . . 0.403 ' O ' HG11 ' A' ' 230' ' ' VAL . 28.3 m -94.66 111.26 23.04 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 -179.755 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.553 HG11 HG13 ' A' ' 230' ' ' VAL . 23.1 m -93.45 144.54 9.28 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.76 0 CA-C-O 121.642 0.734 . . . . 0.0 112.717 -170.213 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 35.4 t -91.19 9.65 30.29 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 114.088 -1.415 . . . . 0.0 108.049 167.857 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 259' ' ' ALA . . . . . 0.66 ' HB1' HD13 ' A' ' 228' ' ' LEU . . . -87.08 163.72 16.85 Favored 'General case' 0 N--CA 1.45 -0.427 0 CA-C-N 115.004 -0.998 . . . . 0.0 109.66 -177.826 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 37.5 t -144.13 143.99 31.37 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 120.683 0.278 . . . . 0.0 110.384 -179.726 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 80.94 36.75 21.11 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.649 179.625 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 262' ' ' LEU . . . . . 0.428 HD11 ' HB2' ' A' ' 259' ' ' ALA . 66.4 mt -98.83 150.8 21.51 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.941 0.401 . . . . 0.0 110.432 179.52 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 73.4 mt-30 -142.26 164.73 29.37 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.241 176.29 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 39.9 t -74.83 139.28 19.42 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 177.856 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 96.43 -1.91 62.55 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.42 -0.895 . . . . 0.0 113.504 177.737 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 39.7 m-20 -80.09 155.75 27.37 Favored 'General case' 0 CA--C 1.516 -0.353 0 CA-C-N 117.177 0.488 . . . . 0.0 111.053 177.094 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 267' ' ' ALA . . . . . 0.624 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -112.97 152.83 28.93 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.433 -0.803 . . . . 0.0 109.316 178.164 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 268' ' ' PHE . . . . . 0.605 ' CD2' HG22 ' A' ' 332' ' ' ILE . 7.9 p90 -164.84 172.36 13.02 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-O 121.189 0.518 . . . . 0.0 112.156 -175.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 74.4 p -127.84 149.89 50.08 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 114.758 -1.11 . . . . 0.0 108.789 173.131 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 270' ' ' ILE . . . . . 0.636 HG12 HG12 ' A' ' 332' ' ' ILE . 61.1 mt -118.6 136.94 54.18 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.674 0 CA-C-O 120.66 0.267 . . . . 0.0 110.478 -179.194 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -60.41 123.1 16.28 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.936 -0.575 . . . . 0.0 111.766 -176.581 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 100.43 -22.48 39.74 Favored Glycine 0 N--CA 1.451 -0.311 0 CA-C-N 115.915 -0.584 . . . . 0.0 112.223 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 41.8 t -95.03 109.96 23.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 120.803 0.335 . . . . 0.0 110.294 177.818 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 69.6 m-80 -129.48 160.39 33.32 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 179.204 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 275' ' ' SER . . . . . 0.455 ' O ' HG11 ' A' ' 276' ' ' VAL . 35.7 p -85.22 -171.68 3.75 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 111.966 0.358 . . . . 0.0 111.966 -176.359 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 276' ' ' VAL . . . . . 0.49 HG23 ' O ' ' A' ' 321' ' ' ASN . 29.6 m -145.98 173.24 3.36 Favored 'Isoleucine or valine' 0 C--O 1.232 0.176 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.098 178.79 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 39.5 m80 -118.82 127.13 53.24 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.328 -0.396 . . . . 0.0 109.988 171.629 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 83.6 mt-30 -79.32 -23.42 43.5 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 173.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 2.5 mp -63.27 -51.1 75.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.362 179.349 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 70.9 p -100.04 -15.09 18.36 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.022 -0.536 . . . . 0.0 111.799 -176.057 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 34.5 mmtp 65.25 30.13 11.4 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 123.037 0.535 . . . . 0.0 111.429 -177.186 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 67.0 m-20 -105.83 151.55 24.36 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.072 176.084 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 72.6 p -96.21 92.3 6.32 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.3 0.571 . . . . 0.0 110.412 176.569 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 284' ' ' THR . . . . . 0.446 ' C ' ' H ' ' A' ' 286' ' ' GLN . 47.5 p -141.48 -112.14 0.13 Allowed 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.884 -179.082 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 63.65 -8.62 0.32 Allowed Glycine 0 CA--C 1.522 0.491 0 N-CA-C 114.529 0.572 . . . . 0.0 114.529 174.543 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 286' ' ' GLN . . . . . 0.543 ' HB3' ' HD2' ' A' ' 287' ' ' PRO . 2.0 mp0 67.45 167.72 0.12 Allowed Pre-proline 0 CA--C 1.537 0.453 0 C-N-CA 123.416 0.687 . . . . 0.0 111.045 -177.885 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 287' ' ' PRO . . . . . 0.543 ' HD2' ' HB3' ' A' ' 286' ' ' GLN . 81.3 Cg_exo -47.72 133.66 21.94 Favored 'Trans proline' 0 C--N 1.353 0.8 0 C-N-CA 122.821 2.347 . . . . 0.0 113.77 -172.658 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 71.2 tp60 -69.23 136.61 52.23 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.711 -178.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 48.8 t -94.89 134.13 33.34 Favored 'Isoleucine or valine' 0 C--O 1.236 0.376 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.543 179.586 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 290' ' ' PHE . . . . . 0.624 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 33.4 m-85 -116.81 168.74 9.95 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.443 -176.817 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 291' ' ' ARG . . . . . 0.444 ' O ' HD21 ' A' ' 293' ' ' LEU . 42.5 mmm-85 -131.08 125.46 33.23 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 173.819 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 47.3 t -65.16 134.78 29.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.701 -177.243 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 293' ' ' LEU . . . . . 0.859 HD22 ' HB2' ' A' ' 303' ' ' SER . 2.5 mm? -96.19 -38.72 10.02 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.101 179.397 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 294' ' ' ALA . . . . . 0.482 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -159.69 142.11 13.58 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 121.088 -0.245 . . . . 0.0 111.452 -178.382 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 77.8 t -136.16 112.11 12.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.288 -0.415 . . . . 0.0 109.938 175.436 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 37.4 t -150.03 120.42 7.37 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.337 -179.367 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 58.19 51.11 60.39 Favored Glycine 0 C--N 1.33 0.195 0 C-N-CA 121.086 -0.578 . . . . 0.0 112.386 -179.24 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 73.6 p 48.54 27.85 1.57 Allowed 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 123.536 0.734 . . . . 0.0 112.112 -176.526 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 299' ' ' THR . . . . . 0.471 ' CG2' ' HB ' ' A' ' 254' ' ' THR . 65.3 m -119.66 115.26 23.58 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 176.706 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . 0.482 ' HA ' ' O ' ' A' ' 294' ' ' ALA . 59.7 t -113.79 130.93 67.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.587 -171.69 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 57.0 m -80.62 116.19 20.52 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 172.266 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 302' ' ' ILE . . . . . 0.557 ' O ' HD11 ' A' ' 302' ' ' ILE . 2.5 pp -111.36 140.79 29.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-O 122.264 1.03 . . . . 0.0 113.715 -171.463 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 303' ' ' SER . . . . . 0.859 ' HB2' HD22 ' A' ' 293' ' ' LEU . 49.4 m -165.02 170.98 5.8 Favored Pre-proline 0 C--N 1.325 -0.493 0 N-CA-C 105.829 -1.915 . . . . 0.0 105.829 -178.913 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 304' ' ' PRO . . . . . 0.563 ' HA ' ' HB3' ' A' ' 303' ' ' SER . 5.1 Cg_exo -74.98 -135.57 0.14 OUTLIER 'Cis proline' 0 C--N 1.351 0.664 0 CA-C-N 121.49 1.568 . . . . 0.0 113.578 0.646 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 305' ' ' LYS . . . . . 0.724 ' HA ' ' CD2' ' A' ' 236' ' ' HIS . 0.0 OUTLIER -90.68 144.41 25.77 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.47 -0.786 . . . . 0.0 112.088 -173.303 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 306' ' ' ILE . . . . . 0.586 ' H ' ' CG ' ' A' ' 236' ' ' HIS . 47.3 mm -116.0 86.93 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 114.824 -1.08 . . . . 0.0 108.611 175.121 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 307' ' ' LEU . . . . . 0.695 HD12 HG21 ' A' ' 238' ' ' VAL . 58.7 mt -102.29 101.04 17.28 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.196 -173.599 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 308' ' ' PRO . . . . . 0.706 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 32.3 Cg_exo -65.56 134.07 36.87 Favored 'Trans proline' 0 C--N 1.343 0.253 0 C-N-CA 123.14 2.56 . . . . 0.0 113.76 -173.678 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . 0.548 HG23 ' O ' ' A' ' 322' ' ' VAL . 60.4 t -80.59 -28.56 11.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 169.291 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 -79.38 36.03 0.29 Allowed 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 115.279 -0.873 . . . . 0.0 111.186 176.511 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 22.6 p30 -83.7 -175.34 5.77 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.971 0.415 . . . . 0.0 111.137 -176.678 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 85.6 m -123.38 -28.58 3.93 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.407 177.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 57.5 m-20 -74.45 132.93 42.36 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.074 -178.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 43.8 t -62.7 -33.05 57.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.982 179.078 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -70.37 -20.45 62.96 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.749 179.752 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 316' ' ' SER . . . . . 0.531 ' HA ' ' CZ ' ' A' ' 319' ' ' TYR . 50.4 m -88.25 -7.02 57.44 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 111.936 0.347 . . . . 0.0 111.936 -176.897 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 317' ' ' ARG . . . . . 0.606 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 38.6 mmt180 -63.67 -51.38 66.36 Favored Pre-proline 0 CA--C 1.539 0.528 0 N-CA-C 112.598 0.592 . . . . 0.0 112.598 -179.005 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 318' ' ' PRO . . . . . 0.606 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 26.8 Cg_exo -68.78 -39.55 8.46 Favored 'Trans proline' 0 C--N 1.356 0.964 0 C-N-CA 121.9 1.733 . . . . 0.0 114.441 -172.055 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 319' ' ' TYR . . . . . 0.582 ' O ' HD13 ' A' ' 307' ' ' LEU . 1.8 p90 -88.47 -6.77 57.43 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 113.004 0.742 . . . . 0.0 113.004 -171.598 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . 0.418 ' HB1' HG21 ' A' ' 309' ' ' VAL . . . -52.99 135.51 36.72 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 111.634 0.235 . . . . 0.0 111.634 -178.799 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 321' ' ' ASN . . . . . 0.49 ' O ' HG23 ' A' ' 276' ' ' VAL . 14.4 p-10 -132.05 -11.25 3.34 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 116.639 -0.255 . . . . 0.0 111.444 -178.187 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 322' ' ' VAL . . . . . 0.548 ' O ' HG23 ' A' ' 309' ' ' VAL . 33.6 m -131.96 166.52 28.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 N-CA-C 110.488 -0.19 . . . . 0.0 110.488 178.855 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -51.84 -66.35 0.4 Allowed 'General case' 0 N--CA 1.465 0.293 0 CA-C-O 121.252 0.548 . . . . 0.0 111.266 178.372 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 324' ' ' ALA . . . . . 0.706 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -167.24 -179.29 4.46 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.584 -177.09 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 325' ' ' LYS . . . . . 0.44 ' HA ' ' HD3' ' A' ' 326' ' ' PRO . 21.5 pttp -109.65 112.34 58.65 Favored Pre-proline 0 N--CA 1.447 -0.624 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 170.342 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 326' ' ' PRO . . . . . 0.44 ' HD3' ' HA ' ' A' ' 325' ' ' LYS . 25.4 Cg_exo -66.49 168.87 15.32 Favored 'Trans proline' 0 C--O 1.234 0.287 0 C-N-CA 122.704 2.269 . . . . 0.0 112.044 -175.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -58.48 146.29 35.82 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 116.009 -0.541 . . . . 0.0 109.787 176.531 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 328' ' ' GLU . . . . . 0.538 ' HA ' ' NE2' ' A' ' 233' ' ' GLN . 16.0 pt-20 48.01 -145.13 0.34 Allowed 'General case' 0 N--CA 1.474 0.759 0 O-C-N 124.09 0.869 . . . . 0.0 110.995 -173.47 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 329' ' ' SER . . . . . 0.629 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 49.2 m -104.66 -19.38 13.98 Favored 'General case' 0 C--N 1.322 -0.602 0 C-N-CA 120.608 -0.437 . . . . 0.0 110.52 -179.448 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 330' ' ' ALA . . . . . 0.463 ' HB1' ' O ' ' A' ' 329' ' ' SER . . . 73.79 -167.54 0.11 Allowed 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 113.427 0.899 . . . . 0.0 113.427 171.371 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 331' ' ' ALA . . . . . 0.422 ' HA ' ' O ' ' A' ' 228' ' ' LEU . . . -87.26 144.0 27.01 Favored 'General case' 0 C--O 1.232 0.15 0 CA-C-N 115.153 -0.93 . . . . 0.0 111.611 -175.018 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 332' ' ' ILE . . . . . 0.636 HG12 HG12 ' A' ' 270' ' ' ILE . 50.1 mt -120.7 145.33 27.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.74 -178.861 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 61.3 m -130.98 106.07 8.16 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 110.121 -0.326 . . . . 0.0 110.121 178.396 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 49.0 mm -78.85 138.12 20.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.022 -0.536 . . . . 0.0 112.191 -174.109 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 335' ' ' LEU . . . . . 0.435 HD23 ' HA ' ' A' ' 268' ' ' PHE . 1.8 pt? -157.55 135.94 11.18 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.289 -0.869 . . . . 0.0 109.327 173.712 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -85.21 2.69 42.67 Favored 'General case' 0 C--N 1.325 -0.499 0 C-N-CA 120.841 -0.344 . . . . 0.0 111.283 -178.958 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 337' ' ' LYS . . . . . 0.472 ' C ' ' HD3' ' A' ' 337' ' ' LYS . 9.8 tmtt? . . . . . 0 C--O 1.245 0.862 0 CA-C-O 118.056 -0.973 . . . . 0.0 108.381 177.673 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.791 0 N-CA-C 112.226 -0.35 . . . . 0.0 112.226 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 44.4 m -98.23 168.05 10.48 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.505 0.153 . . . . 0.0 110.983 -178.549 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 47.0 m 66.56 -74.93 0.06 Allowed 'General case' 0 N--CA 1.466 0.348 0 O-C-N 123.912 0.757 . . . . 0.0 111.77 177.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 226' ' ' GLU . . . . . 0.416 ' HB2' ' HB1' ' A' ' 331' ' ' ALA . 47.6 mt-10 62.5 61.84 1.19 Allowed 'General case' 0 CA--C 1.531 0.25 0 C-N-CA 122.591 0.356 . . . . 0.0 110.659 179.723 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 49.6 m 72.19 -98.34 0.03 OUTLIER 'General case' 0 C--O 1.231 0.083 0 CA-C-N 115.39 -0.823 . . . . 0.0 111.333 -178.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 228' ' ' LEU . . . . . 0.433 HD23 ' HA ' ' A' ' 259' ' ' ALA . 81.9 mt -102.35 142.8 32.98 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.292 -178.182 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 229' ' ' THR . . . . . 0.553 ' O ' HG21 ' A' ' 230' ' ' VAL . 35.4 p -120.63 171.37 8.62 Favored 'General case' 0 C--N 1.325 -0.467 0 C-N-CA 119.866 -0.733 . . . . 0.0 110.589 177.372 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . 0.553 HG21 ' O ' ' A' ' 229' ' ' THR . 72.4 t -146.69 130.62 10.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 120.916 0.389 . . . . 0.0 110.376 -179.597 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 231' ' ' SER . . . . . 0.506 ' O ' ' HB ' ' A' ' 255' ' ' ILE . 37.4 m -96.02 164.32 12.75 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.821 177.481 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 101.41 142.02 12.38 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.2 -1.0 . . . . 0.0 111.961 -179.283 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 64.0 mt-30 -100.02 107.81 48.76 Favored Pre-proline 0 C--N 1.322 -0.606 0 O-C-N 123.073 -0.075 . . . . 0.0 111.03 -176.461 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 234' ' ' PRO . . . . . 0.579 ' HB2' HG13 ' A' ' 306' ' ' ILE . 29.0 Cg_endo -61.56 127.62 22.29 Favored 'Trans proline' 0 C--N 1.348 0.511 0 C-N-CA 122.173 1.916 . . . . 0.0 110.718 176.174 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 235' ' ' GLU . . . . . 0.571 ' OE1' ' HE2' ' A' ' 237' ' ' LYS . 0.3 OUTLIER -116.79 -178.34 3.41 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 113.418 0.896 . . . . 0.0 113.418 -170.995 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 55.4 t60 -167.5 135.61 2.47 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 114.632 -1.167 . . . . 0.0 110.915 -173.803 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 237' ' ' LYS . . . . . 0.571 ' HE2' ' OE1' ' A' ' 235' ' ' GLU . 0.0 OUTLIER -168.14 130.81 1.5 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 114.979 -1.009 . . . . 0.0 111.762 173.072 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 238' ' ' VAL . . . . . 0.421 HG21 ' OD1' ' A' ' 250' ' ' ASN . 46.2 t -97.08 112.11 28.41 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-N 115.117 -0.947 . . . . 0.0 108.981 174.125 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 239' ' ' GLU . . . . . 0.833 ' HG3' ' HB ' ' A' ' 248' ' ' VAL . 10.9 pt-20 -115.31 125.84 53.75 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 121.283 0.563 . . . . 0.0 111.414 -175.901 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 240' ' ' ALA . . . . . 0.601 ' O ' ' HA ' ' A' ' 247' ' ' PRO . . . -66.04 -35.68 81.2 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.461 -0.79 . . . . 0.0 111.289 -176.484 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 241' ' ' LYS . . . . . 0.544 ' O ' ' HD3' ' A' ' 241' ' ' LYS . 0.0 OUTLIER -147.98 146.1 28.81 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.117 0.484 . . . . 0.0 111.925 179.711 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 12.5 p-10 -98.3 -158.24 0.66 Allowed 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.194 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 56.2 p -69.95 -14.88 62.92 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.412 -0.358 . . . . 0.0 111.62 178.167 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 49.5 t30 -99.21 -13.49 19.7 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.017 0.437 . . . . 0.0 110.352 178.223 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 89.35 23.39 34.41 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.691 -0.766 . . . . 0.0 113.157 175.298 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 246' ' ' MET . . . . . 0.415 ' O ' ' HA ' ' A' ' 241' ' ' LYS . 26.6 mmt -112.61 154.12 44.79 Favored Pre-proline 0 C--N 1.325 -0.475 0 CA-C-N 116.948 0.374 . . . . 0.0 110.487 178.58 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 247' ' ' PRO . . . . . 0.601 ' HA ' ' O ' ' A' ' 240' ' ' ALA . 31.6 Cg_exo -57.09 140.55 92.99 Favored 'Trans proline' 0 C--N 1.348 0.519 0 C-N-CA 122.7 2.267 . . . . 0.0 112.053 178.132 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . 0.833 ' HB ' ' HG3' ' A' ' 239' ' ' GLU . 41.8 t -125.81 126.43 70.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.856 0.36 . . . . 0.0 111.026 -178.248 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 31.1 t70 -89.14 143.92 26.49 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 175.1 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 250' ' ' ASN . . . . . 0.421 ' OD1' HG21 ' A' ' 238' ' ' VAL . 74.6 m-80 -41.13 124.13 2.18 Favored 'General case' 0 N--CA 1.469 0.498 0 O-C-N 124.007 0.817 . . . . 0.0 112.215 -177.052 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . 0.679 ' HG3' ' H ' ' A' ' 252' ' ' GLN . 16.6 tpp180 -77.36 -178.6 5.25 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 109.522 -0.548 . . . . 0.0 109.522 -177.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 252' ' ' GLN . . . . . 0.679 ' H ' ' HG3' ' A' ' 251' ' ' ARG . 2.8 mm100 -100.2 157.11 16.82 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 178.347 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -85.41 138.5 16.5 Favored Glycine 0 N--CA 1.447 -0.579 0 C-N-CA 120.327 -0.94 . . . . 0.0 112.338 -179.144 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 66.9 p -121.89 116.51 24.53 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 176.728 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . 0.506 ' HB ' ' O ' ' A' ' 231' ' ' SER . 0.2 OUTLIER -129.69 158.95 42.18 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 121.038 0.447 . . . . 0.0 111.399 -176.493 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 18.5 m -96.82 116.64 29.5 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 177.681 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.813 HG22 HD13 ' A' ' 262' ' ' LEU . 32.8 m -88.82 143.3 11.46 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.739 0 C-N-CA 119.709 -0.796 . . . . 0.0 112.349 -170.98 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 258' ' ' SER . . . . . 0.453 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 25.1 m -92.79 9.44 35.17 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 114.341 -1.3 . . . . 0.0 109.33 172.809 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 259' ' ' ALA . . . . . 0.433 ' HA ' HD23 ' A' ' 228' ' ' LEU . . . -83.05 179.9 7.62 Favored 'General case' 0 N--CA 1.452 -0.338 0 CA-C-N 115.417 -0.811 . . . . 0.0 108.942 179.659 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 22.9 t -140.98 127.34 19.82 Favored 'General case' 0 C--N 1.32 -0.693 0 C-N-CA 120.23 -0.588 . . . . 0.0 111.348 -177.484 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 78.8 50.9 5.72 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.891 -0.671 . . . . 0.0 113.276 176.207 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 262' ' ' LEU . . . . . 0.813 HD13 HG22 ' A' ' 257' ' ' VAL . 64.8 mt -95.1 160.13 14.7 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 117.147 0.474 . . . . 0.0 110.559 178.08 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 66.0 mt-30 -142.9 165.23 27.93 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 -179.311 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 27.1 t -79.58 124.14 37.38 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 C-N-CA 120.409 -0.516 . . . . 0.0 109.701 175.531 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . 0.545 ' H ' ' HB ' ' A' ' 292' ' ' VAL . . . 116.0 14.39 7.88 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.316 -0.945 . . . . 0.0 112.835 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 57.1 m-20 -90.51 165.83 13.56 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.186 0.517 . . . . 0.0 111.044 176.346 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 267' ' ' ALA . . . . . 0.563 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -130.59 143.92 51.07 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 175.094 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 268' ' ' PHE . . . . . 0.446 ' CD1' HG21 ' A' ' 332' ' ' ILE . 7.8 p90 -159.5 168.71 25.53 Favored 'General case' 0 C--N 1.323 -0.582 0 C-N-CA 118.958 -1.097 . . . . 0.0 112.644 -173.547 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 269' ' ' THR . . . . . 0.505 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 43.7 p -116.72 144.08 44.87 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.063 -0.971 . . . . 0.0 109.704 175.683 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 270' ' ' ILE . . . . . 0.969 HG12 HG13 ' A' ' 332' ' ' ILE . 57.2 mt -112.0 127.91 68.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 116.563 -0.29 . . . . 0.0 110.469 -178.73 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -65.15 120.04 11.96 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.077 0.465 . . . . 0.0 111.227 -179.478 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 102.7 -23.93 32.37 Favored Glycine 0 N--CA 1.452 -0.28 0 CA-C-N 115.887 -0.597 . . . . 0.0 112.315 179.278 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . 0.46 HG21 ' HG2' ' A' ' 326' ' ' PRO . 39.0 t -96.34 102.48 13.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 174.574 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 274' ' ' ASN . . . . . 0.743 ' HB2' ' HB2' ' A' ' 323' ' ' ASP . 4.2 m120 -91.99 169.63 10.5 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.275 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 8.3 t -109.74 162.48 14.42 Favored 'General case' 0 CA--C 1.507 -0.704 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 178.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 13.0 m -122.52 178.84 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.067 0 CA-C-N 115.24 -0.891 . . . . 0.0 109.372 166.402 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 277' ' ' HIS . . . . . 0.575 ' HE1' HG22 ' A' ' 284' ' ' THR . 22.3 m80 -100.5 133.21 45.27 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 178.922 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 2.3 mp0 -72.29 -10.22 59.5 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.79 0.329 . . . . 0.0 111.401 -178.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 279' ' ' ILE . . . . . 0.649 HD11 ' N ' ' A' ' 279' ' ' ILE . 2.0 mp -102.43 -57.48 4.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 120.729 0.3 . . . . 0.0 110.946 -178.312 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 60.9 p -101.13 -6.21 24.63 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 112.663 0.616 . . . . 0.0 112.663 -174.226 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 13.9 mmmm 57.54 29.35 16.98 Favored 'General case' 0 N--CA 1.47 0.574 0 N-CA-C 111.591 0.219 . . . . 0.0 111.591 -178.499 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -77.78 139.61 39.36 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.265 -176.489 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 70.3 p -108.2 118.8 37.71 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.862 -0.608 . . . . 0.0 109.806 179.486 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 284' ' ' THR . . . . . 0.575 HG22 ' HE1' ' A' ' 277' ' ' HIS . 72.0 p -115.2 -14.36 11.73 Favored 'General case' 0 C--N 1.315 -0.894 0 C-N-CA 120.67 -0.412 . . . . 0.0 111.798 -172.408 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 88.17 5.13 76.94 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.521 -0.847 . . . . 0.0 112.388 179.709 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 286' ' ' GLN . . . . . 0.445 ' HA ' ' HD3' ' A' ' 287' ' ' PRO . 71.0 mt-30 -92.18 138.53 24.37 Favored Pre-proline 0 C--N 1.327 -0.382 0 N-CA-C 110.23 -0.285 . . . . 0.0 110.23 178.677 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 287' ' ' PRO . . . . . 0.609 ' HA ' ' HA ' ' A' ' 274' ' ' ASN . 21.7 Cg_exo -65.58 152.7 81.01 Favored 'Trans proline' 0 C--O 1.233 0.236 0 C-N-CA 122.615 2.21 . . . . 0.0 112.445 -179.031 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 3.9 tp-100 -81.54 150.72 28.08 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.542 177.626 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 62.1 t -94.86 125.04 47.58 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.401 0 CA-C-N 116.096 -0.502 . . . . 0.0 109.657 176.441 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 290' ' ' PHE . . . . . 0.742 ' HD1' ' HD2' ' A' ' 304' ' ' PRO . 69.9 m-85 -106.58 168.42 9.18 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.085 -174.072 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 27.1 tpt180 -132.8 120.89 22.18 Favored 'General case' 0 N--CA 1.448 -0.539 0 CA-C-O 121.222 0.534 . . . . 0.0 109.573 179.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . 0.545 ' HB ' ' H ' ' A' ' 265' ' ' GLY . 57.7 t -65.99 132.42 31.56 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.919 -177.037 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 293' ' ' LEU . . . . . . . . . . . . . 88.5 mt -101.42 -44.55 5.59 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.475 178.332 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 294' ' ' ALA . . . . . 0.448 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -150.05 139.11 21.1 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.592 0.234 . . . . 0.0 111.334 -175.123 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 62.0 t -134.11 117.75 26.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.126 176.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 60.6 m -157.01 120.14 4.09 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.471 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 62.32 40.37 98.94 Favored Glycine 0 C--N 1.331 0.305 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.003 -177.539 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 82.1 p 53.35 20.78 2.07 Favored 'General case' 0 N--CA 1.469 0.519 0 C-N-CA 123.939 0.896 . . . . 0.0 112.27 -174.721 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 60.3 m -103.18 107.7 18.62 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 174.493 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . 0.448 ' HA ' ' O ' ' A' ' 294' ' ' ALA . 47.2 t -104.09 128.03 57.81 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.36 -173.247 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 42.0 m -90.48 117.36 29.12 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 172.559 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 302' ' ' ILE . . . . . 0.428 HG21 HG13 ' A' ' 300' ' ' VAL . 29.1 pt -110.74 140.74 28.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 N-CA-C 112.83 0.678 . . . . 0.0 112.83 -169.269 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 303' ' ' SER . . . . . 0.45 ' HA ' ' C ' ' A' ' 304' ' ' PRO . 48.2 t -130.35 151.39 78.45 Favored Pre-proline 0 C--N 1.323 -0.55 0 CA-C-N 114.104 -1.407 . . . . 0.0 107.207 172.715 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 304' ' ' PRO . . . . . 0.742 ' HD2' ' HD1' ' A' ' 290' ' ' PHE . 34.3 Cg_exo -63.04 179.14 8.44 Favored 'Cis proline' 0 N--CA 1.473 0.308 0 CA-C-N 120.163 1.094 . . . . 0.0 113.09 0.781 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 305' ' ' LYS . . . . . 0.578 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -87.86 148.74 24.5 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.24 177.643 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 306' ' ' ILE . . . . . 0.579 HG13 ' HB2' ' A' ' 234' ' ' PRO . 43.7 mm -65.75 98.66 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.663 -175.075 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 307' ' ' LEU . . . . . 0.491 ' O ' HG21 ' A' ' 322' ' ' VAL . 72.6 mt -119.25 95.57 49.39 Favored Pre-proline 0 C--N 1.325 -0.498 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 -179.506 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 308' ' ' PRO . . . . . 0.642 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 6.2 Cg_exo -77.67 169.6 20.58 Favored 'Trans proline' 0 N--CA 1.463 -0.32 0 C-N-CA 123.121 2.547 . . . . 0.0 112.635 -176.8 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . 0.615 ' HA ' ' HB2' ' A' ' 320' ' ' ALA . 39.2 t -93.56 -30.72 4.41 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-O 121.251 0.548 . . . . 0.0 109.683 177.343 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 42.5 mp0 -86.64 35.68 0.68 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.133 -0.94 . . . . 0.0 112.254 -173.833 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 79.1 m-20 -74.33 158.81 33.33 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.301 0.572 . . . . 0.0 111.845 -178.644 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 28.9 m -90.44 -36.63 14.46 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.129 -0.941 . . . . 0.0 110.22 179.266 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 313' ' ' ASP . . . . . 0.419 ' HB2' ' HB3' ' A' ' 316' ' ' SER . 1.6 m-20 -67.98 133.31 48.86 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.32 179.406 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 39.3 t -60.45 -52.23 63.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.172 -177.768 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -68.46 -17.82 64.28 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.852 -178.234 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 316' ' ' SER . . . . . 0.419 ' HB3' ' HB2' ' A' ' 313' ' ' ASP . 39.1 t -84.07 -11.02 57.36 Favored 'General case' 0 C--N 1.323 -0.546 0 C-N-CA 120.973 -0.291 . . . . 0.0 111.357 -178.376 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 317' ' ' ARG . . . . . 0.527 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 81.0 mtm180 -73.65 -49.2 6.46 Favored Pre-proline 0 CA--C 1.536 0.432 0 N-CA-C 112.506 0.558 . . . . 0.0 112.506 -179.082 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 318' ' ' PRO . . . . . 0.527 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 42.3 Cg_exo -61.07 -25.87 81.99 Favored 'Trans proline' 0 C--N 1.361 1.197 0 C-N-CA 122.17 1.914 . . . . 0.0 113.218 -176.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 46.6 m-85 -91.41 27.67 1.9 Allowed 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.473 -0.331 . . . . 0.0 111.313 -177.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . 0.615 ' HB2' ' HA ' ' A' ' 309' ' ' VAL . . . -77.72 127.55 32.61 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.073 179.297 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 75.5 m-80 -130.47 -9.24 4.13 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 111.859 0.318 . . . . 0.0 111.859 179.216 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 322' ' ' VAL . . . . . 0.491 HG21 ' O ' ' A' ' 307' ' ' LEU . 33.1 m -138.5 156.93 30.18 Favored 'Isoleucine or valine' 0 C--O 1.233 0.215 0 CA-C-O 120.944 0.402 . . . . 0.0 111.094 177.691 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 323' ' ' ASP . . . . . 0.743 ' HB2' ' HB2' ' A' ' 274' ' ' ASN . 2.1 m-20 -86.66 86.84 7.35 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.417 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 324' ' ' ALA . . . . . 0.642 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . 77.06 151.0 0.12 Allowed 'General case' 0 N--CA 1.473 0.685 0 CA-C-N 114.66 -1.154 . . . . 0.0 113.791 171.502 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 325' ' ' LYS . . . . . 0.495 ' HB3' HG23 ' A' ' 306' ' ' ILE . 55.5 pttt -98.71 105.95 33.88 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 114.435 -1.257 . . . . 0.0 109.287 168.525 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 326' ' ' PRO . . . . . 0.46 ' HG2' HG21 ' A' ' 273' ' ' VAL . 5.8 Cg_exo -85.99 169.27 8.99 Favored 'Trans proline' 0 C--O 1.235 0.367 0 C-N-CA 123.483 2.788 . . . . 0.0 113.195 -171.837 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -59.52 127.51 32.41 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.626 177.633 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 24.5 pt-20 44.65 -158.07 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.66 0 O-C-N 124.402 1.064 . . . . 0.0 112.034 -176.363 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 329' ' ' SER . . . . . 0.41 ' O ' ' HB3' ' A' ' 330' ' ' ALA . 54.6 m -102.9 -31.16 10.39 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 112.204 0.446 . . . . 0.0 112.204 -173.643 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 330' ' ' ALA . . . . . 0.41 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 71.95 -152.25 0.08 Allowed 'General case' 0 N--CA 1.471 0.59 0 CA-C-O 121.037 0.446 . . . . 0.0 111.534 178.359 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 331' ' ' ALA . . . . . 0.416 ' HB1' ' HB2' ' A' ' 226' ' ' GLU . . . -85.47 116.34 23.73 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.248 -178.85 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 332' ' ' ILE . . . . . 0.969 HG13 HG12 ' A' ' 270' ' ' ILE . 1.7 mp -101.84 140.85 19.38 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 115.826 -0.624 . . . . 0.0 109.537 176.293 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 73.4 m -110.11 103.32 12.03 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 110.206 -0.294 . . . . 0.0 110.206 -176.624 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 334' ' ' ILE . . . . . 0.492 HG13 HD22 ' A' ' 262' ' ' LEU . 34.6 mm -85.89 125.87 40.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 N-CA-C 112.588 0.588 . . . . 0.0 112.588 -174.155 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 335' ' ' LEU . . . . . 0.408 HD12 ' O ' ' A' ' 267' ' ' ALA . 0.0 OUTLIER -139.41 172.43 12.82 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.3 -0.864 . . . . 0.0 109.804 171.259 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 50.9 t30 -136.87 59.11 1.7 Allowed 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 178.552 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 62.3 tttp . . . . . 0 C--O 1.244 0.768 0 CA-C-O 118.173 -0.918 . . . . 0.0 110.457 -176.106 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.727 0 N-CA-C 112.162 -0.375 . . . . 0.0 112.162 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 61.9 p -91.29 106.55 18.59 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.78 0.324 . . . . 0.0 110.772 179.351 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 71.7 p -110.9 161.4 15.87 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 120.976 0.417 . . . . 0.0 110.701 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 10.3 pm0 -102.98 32.27 3.8 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.9 -176.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 68.3 m 54.49 71.5 0.52 Allowed 'General case' 0 C--O 1.235 0.299 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.854 -178.239 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 228' ' ' LEU . . . . . 0.728 ' O ' ' HA ' ' A' ' 331' ' ' ALA . 5.3 mp -67.91 119.32 12.39 Favored 'General case' 0 N--CA 1.433 -1.316 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.821 179.463 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 229' ' ' THR . . . . . 0.451 ' OG1' ' HB3' ' A' ' 258' ' ' SER . 22.3 p -128.08 178.68 6.04 Favored 'General case' 0 C--N 1.324 -0.533 0 C-N-CA 120.513 -0.475 . . . . 0.0 111.07 178.644 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . 0.737 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 98.3 t -144.82 130.72 14.64 Favored 'Isoleucine or valine' 0 C--O 1.235 0.303 0 CA-C-O 120.578 0.228 . . . . 0.0 111.078 -177.218 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 38.9 t -101.1 112.28 24.71 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.538 -0.755 . . . . 0.0 109.484 172.438 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . 0.809 ' H ' ' HG3' ' A' ' 328' ' ' GLU . . . 141.69 125.51 2.08 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.788 -0.72 . . . . 0.0 111.71 -176.319 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 233' ' ' GLN . . . . . 0.794 ' HG2' ' H ' ' A' ' 328' ' ' GLU . 21.8 mt-30 -83.5 123.33 76.75 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-N 116.49 0.145 . . . . 0.0 111.063 -177.12 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -92.71 126.26 0.71 Allowed 'Trans proline' 0 N--CA 1.451 -0.986 0 C-N-CA 122.643 2.228 . . . . 0.0 111.978 177.517 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -157.0 158.36 36.4 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.865 0.364 . . . . 0.0 110.748 177.569 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 236' ' ' HIS . . . . . 0.615 ' HA ' HD22 ' A' ' 250' ' ' ASN . 25.5 m80 -136.07 146.19 46.78 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.322 0.582 . . . . 0.0 111.85 177.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 237' ' ' LYS . . . . . 0.629 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -132.15 129.1 39.38 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 107.664 -1.235 . . . . 0.0 107.664 178.149 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 238' ' ' VAL . . . . . 0.413 ' CG1' ' HH ' ' A' ' 319' ' ' TYR . 44.5 t -103.78 110.93 31.57 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 C-N-CA 119.908 -0.717 . . . . 0.0 110.819 -179.578 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 239' ' ' GLU . . . . . 0.807 ' HB2' ' HB ' ' A' ' 248' ' ' VAL . 0.6 OUTLIER -65.59 129.54 40.13 Favored 'General case' 0 N--CA 1.448 -0.565 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 174.272 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 240' ' ' ALA . . . . . . . . . . . . . . . -58.68 -38.6 78.56 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-O 120.77 0.319 . . . . 0.0 110.732 -178.563 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 241' ' ' LYS . . . . . 0.862 ' HB2' ' HA2' ' A' ' 245' ' ' GLY . 0.4 OUTLIER -154.96 149.66 26.53 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.665 177.481 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 242' ' ' ASP . . . . . 0.643 ' HB3' ' CG2' ' A' ' 248' ' ' VAL . 53.7 p-10 -106.12 -156.29 0.57 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.816 -0.629 . . . . 0.0 109.619 175.466 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 41.2 t -60.6 -27.96 68.14 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.885 177.75 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 5.7 m120 -93.97 -13.74 26.7 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.57 -0.286 . . . . 0.0 111.576 178.592 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . 0.862 ' HA2' ' HB2' ' A' ' 241' ' ' LYS . . . 87.48 28.23 25.18 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.663 -0.779 . . . . 0.0 113.342 179.089 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 246' ' ' MET . . . . . . . . . . . . . 21.5 ptp -113.68 156.29 43.79 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 117.035 0.418 . . . . 0.0 110.861 178.028 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 247' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_exo -63.13 121.78 9.76 Favored 'Trans proline' 0 C--N 1.349 0.601 0 C-N-CA 122.834 2.356 . . . . 0.0 112.144 -179.827 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . 0.807 ' HB ' ' HB2' ' A' ' 239' ' ' GLU . 41.0 t -101.76 126.5 55.69 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.474 -176.68 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 249' ' ' ASP . . . . . 0.45 ' OD2' ' HD2' ' A' ' 236' ' ' HIS . 60.1 t0 -106.28 140.04 39.85 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 170.417 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 250' ' ' ASN . . . . . 0.615 HD22 ' HA ' ' A' ' 236' ' ' HIS . 21.7 p30 -78.7 48.38 0.8 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.928 0.394 . . . . 0.0 111.646 -177.007 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . 0.477 ' HG3' ' H ' ' A' ' 252' ' ' GLN . 18.2 tpt85 61.39 -135.04 0.6 Allowed 'General case' 0 N--CA 1.452 -0.373 0 CA-C-N 115.569 -0.741 . . . . 0.0 109.258 176.246 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 252' ' ' GLN . . . . . 0.477 ' H ' ' HG3' ' A' ' 251' ' ' ARG . 2.7 mm100 -112.21 169.99 8.48 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 121.91 -0.493 . . . . 0.0 110.219 177.231 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . 0.444 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -87.65 121.07 5.74 Favored Glycine 0 N--CA 1.447 -0.616 0 C-N-CA 120.4 -0.905 . . . . 0.0 111.88 179.269 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 52.3 p -105.1 117.35 33.79 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 178.33 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . 0.475 HD11 ' C ' ' A' ' 255' ' ' ILE . 2.1 pp -131.46 165.13 32.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -175.121 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 32.6 m -102.53 113.95 27.74 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 179.2 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.426 HG23 HD12 ' A' ' 262' ' ' LEU . 30.6 m -90.61 143.89 10.27 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.718 0 CA-C-O 121.48 0.657 . . . . 0.0 112.589 -174.907 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 258' ' ' SER . . . . . 0.451 ' HB3' ' OG1' ' A' ' 229' ' ' THR . 25.8 t -92.06 7.31 42.91 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 113.911 -1.495 . . . . 0.0 108.146 167.514 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 259' ' ' ALA . . . . . 0.654 ' HB2' ' HB3' ' A' ' 228' ' ' LEU . . . -86.48 172.57 10.24 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 115.128 -0.942 . . . . 0.0 109.713 -178.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 50.2 m -145.65 148.63 33.28 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.833 0.349 . . . . 0.0 111.043 -179.328 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 81.14 15.9 75.81 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.992 -0.623 . . . . 0.0 113.184 178.236 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 262' ' ' LEU . . . . . 0.426 HD12 HG23 ' A' ' 257' ' ' VAL . 70.7 mt -76.31 145.73 39.36 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.971 0.385 . . . . 0.0 110.351 179.234 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 85.0 mt-30 -140.8 164.75 29.39 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.092 -0.504 . . . . 0.0 109.911 -179.126 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 45.7 t -76.24 122.87 31.34 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.257 177.489 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 113.43 -3.07 25.02 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.44 -0.886 . . . . 0.0 112.795 179.085 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 266' ' ' ASP . . . . . 0.473 ' HA ' ' OD1' ' A' ' 336' ' ' ASN . 58.6 m-20 -81.58 151.76 27.53 Favored 'General case' 0 CA--C 1.513 -0.475 0 CA-C-O 120.82 0.343 . . . . 0.0 110.296 177.074 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 267' ' ' ALA . . . . . 0.581 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -114.47 149.35 36.46 Favored 'General case' 0 N--CA 1.443 -0.806 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 173.792 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 268' ' ' PHE . . . . . 0.663 ' HA ' HD23 ' A' ' 335' ' ' LEU . 4.1 p90 -163.95 172.36 14.03 Favored 'General case' 0 C--N 1.318 -0.782 0 C-N-CA 119.632 -0.827 . . . . 0.0 111.699 -177.13 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 74.9 p -118.12 127.36 53.7 Favored 'General case' 0 N--CA 1.443 -0.801 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.337 177.688 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 270' ' ' ILE . . . . . 0.602 HG22 ' O ' ' A' ' 329' ' ' SER . 25.8 mm -95.23 129.92 44.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 CA-C-N 115.3 -0.863 . . . . 0.0 110.454 -178.27 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -66.47 129.57 40.3 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 121.007 0.432 . . . . 0.0 111.133 -178.518 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 92.98 -22.87 31.94 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 121.032 -0.604 . . . . 0.0 112.065 -178.036 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . 0.726 HG21 ' HG2' ' A' ' 326' ' ' PRO . 45.8 t -101.14 117.79 46.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 121.195 0.521 . . . . 0.0 110.294 176.491 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -130.67 142.19 50.43 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.701 -178.556 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 4.8 t -81.87 172.45 13.3 Favored 'General case' 0 CA--C 1.512 -0.518 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 -177.047 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 29.9 m -130.5 178.43 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.835 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.713 173.29 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 86.2 m-70 -109.68 86.39 2.29 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 173.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 278' ' ' GLN . . . . . 0.414 ' HB3' ' O ' ' A' ' 320' ' ' ALA . 23.7 pt20 -72.35 -14.85 61.83 Favored 'General case' 0 N--CA 1.464 0.261 0 N-CA-C 111.964 0.357 . . . . 0.0 111.964 -173.45 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 2.4 mp -73.15 -52.11 23.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 121.126 0.489 . . . . 0.0 110.038 -179.538 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 42.9 p -97.95 -3.14 38.98 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.505 -178.799 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 64.85 54.57 1.31 Allowed 'General case' 0 N--CA 1.466 0.35 0 CA-C-O 121.547 0.689 . . . . 0.0 110.012 178.466 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 58.9 m-20 -115.43 130.78 57.0 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.033 0.444 . . . . 0.0 110.817 177.824 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 65.7 p -106.32 117.8 34.97 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.246 176.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 70.4 p -123.44 -23.19 4.87 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.809 -171.602 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 75.19 31.73 56.97 Favored Glycine 0 N--CA 1.453 -0.186 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.817 177.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 3.0 mm100 -89.77 131.27 40.11 Favored Pre-proline 0 C--N 1.327 -0.375 0 N-CA-C 110.359 -0.237 . . . . 0.0 110.359 179.7 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 287' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_exo -50.21 128.22 22.05 Favored 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 122.78 2.32 . . . . 0.0 112.546 -178.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 50.1 tt0 -74.56 148.03 41.22 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.668 -176.381 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 52.7 t -94.48 117.97 39.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.459 -0.791 . . . . 0.0 109.639 175.384 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 290' ' ' PHE . . . . . 0.712 ' HA ' ' HD3' ' A' ' 304' ' ' PRO . 5.0 m-85 -99.06 170.13 8.92 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.014 0.435 . . . . 0.0 111.604 -175.799 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 21.1 tpp180 -140.03 123.74 17.33 Favored 'General case' 0 N--CA 1.446 -0.668 0 CA-C-N 115.533 -0.758 . . . . 0.0 109.358 177.011 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 44.0 t -81.42 136.62 22.74 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.591 -176.211 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 293' ' ' LEU . . . . . 0.457 ' HA ' HD13 ' A' ' 293' ' ' LEU . 2.2 mm? -108.0 -30.51 8.41 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.164 178.299 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 294' ' ' ALA . . . . . . . . . . . . . . . -156.12 136.92 13.43 Favored 'General case' 0 C--N 1.331 -0.201 0 C-N-CA 121.06 -0.256 . . . . 0.0 111.603 -177.508 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 60.6 t -132.49 117.86 33.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.034 -0.53 . . . . 0.0 109.641 175.063 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 34.9 t -157.52 119.52 3.75 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.519 -177.404 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 58.85 44.24 96.11 Favored Glycine 0 C--N 1.333 0.383 0 C-N-CA 121.163 -0.541 . . . . 0.0 112.318 -179.029 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 51.4 p 50.51 24.06 1.49 Allowed 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 123.703 0.801 . . . . 0.0 112.583 -175.343 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 41.0 m -111.12 112.78 24.82 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 108.388 -0.968 . . . . 0.0 108.388 173.61 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . 0.703 HG12 HG23 ' A' ' 302' ' ' ILE . 39.0 t -111.91 132.29 60.93 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.731 -169.216 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 301' ' ' THR . . . . . 0.428 HG21 ' HB2' ' A' ' 252' ' ' GLN . 88.0 m -91.92 109.35 20.69 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 172.554 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 302' ' ' ILE . . . . . 0.703 HG23 HG12 ' A' ' 300' ' ' VAL . 29.1 pt -111.33 150.87 13.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 N-CA-C 113.099 0.777 . . . . 0.0 113.099 -170.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 303' ' ' SER . . . . . 0.497 ' HB2' ' HA ' ' A' ' 304' ' ' PRO . 85.8 p -135.06 166.39 29.51 Favored Pre-proline 0 C--N 1.322 -0.597 0 N-CA-C 106.52 -1.659 . . . . 0.0 106.52 170.063 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 304' ' ' PRO . . . . . 0.712 ' HD3' ' HA ' ' A' ' 290' ' ' PHE . 14.7 Cg_exo -70.45 -167.58 4.14 Favored 'Cis proline' 0 CA--C 1.53 0.28 0 CA-C-N 120.75 1.303 . . . . 0.0 113.282 0.57 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 305' ' ' LYS . . . . . 0.503 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -81.31 162.84 23.3 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.736 179.803 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 306' ' ' ILE . . . . . 0.417 ' H ' ' ND1' ' A' ' 236' ' ' HIS . 43.5 mm -111.55 84.3 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-O 120.831 0.348 . . . . 0.0 110.525 -177.373 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 307' ' ' LEU . . . . . . . . . . . . . 85.0 mt -108.35 103.49 50.91 Favored Pre-proline 0 C--N 1.327 -0.371 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.434 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 308' ' ' PRO . . . . . 0.745 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 13.5 Cg_exo -76.94 156.09 34.36 Favored 'Trans proline' 0 N--CA 1.465 -0.184 0 C-N-CA 122.611 2.207 . . . . 0.0 113.848 -171.472 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 46.7 t -78.89 -16.22 13.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 N-CA-C 108.18 -1.044 . . . . 0.0 108.18 168.069 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 67.0 mm-40 -83.61 7.05 18.54 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 114.805 -1.088 . . . . 0.0 110.885 175.033 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -68.74 128.24 35.94 Favored 'General case' 0 C--O 1.233 0.232 0 CA-C-O 120.764 0.316 . . . . 0.0 110.167 -176.59 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 61.7 m -75.89 -34.3 59.97 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.562 -175.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 313' ' ' ASP . . . . . 0.586 ' O ' ' HG3' ' A' ' 317' ' ' ARG . 28.0 t70 -68.85 114.32 7.06 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.976 0.417 . . . . 0.0 110.491 177.584 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 314' ' ' VAL . . . . . 0.651 ' HA ' ' HD3' ' A' ' 317' ' ' ARG . 41.5 t -63.86 -20.23 26.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.634 -0.712 . . . . 0.0 111.652 -175.836 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -75.09 -34.13 61.71 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.545 0.212 . . . . 0.0 111.468 178.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 316' ' ' SER . . . . . 0.404 ' HA ' ' CE1' ' A' ' 319' ' ' TYR . 34.2 t -89.4 -6.78 56.27 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.619 0.247 . . . . 0.0 111.359 -177.158 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 317' ' ' ARG . . . . . 0.651 ' HD3' ' HA ' ' A' ' 314' ' ' VAL . 56.8 mtp85 -69.68 -47.03 25.35 Favored Pre-proline 0 CA--C 1.541 0.609 0 N-CA-C 113.302 0.852 . . . . 0.0 113.302 -179.495 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 318' ' ' PRO . . . . . 0.434 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 87.2 Cg_exo -52.2 -38.49 71.67 Favored 'Trans proline' 0 C--N 1.361 1.224 0 C-N-CA 122.444 2.096 . . . . 0.0 113.796 -174.536 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 319' ' ' TYR . . . . . 0.413 ' HH ' ' CG1' ' A' ' 238' ' ' VAL . 1.5 p90 -109.17 39.13 2.12 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 112.077 0.399 . . . . 0.0 112.077 -178.35 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . 0.414 ' O ' ' HB3' ' A' ' 278' ' ' GLN . . . -71.99 135.66 46.48 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.896 174.219 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 16.0 p-10 -119.01 -2.41 10.8 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 120.82 -0.352 . . . . 0.0 111.485 -176.703 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 322' ' ' VAL . . . . . . . . . . . . . 30.8 m -135.11 163.17 36.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 N-CA-C 110.34 -0.244 . . . . 0.0 110.34 175.112 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 56.7 m-20 -72.37 -38.18 68.6 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 111.657 0.243 . . . . 0.0 111.657 -178.677 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 324' ' ' ALA . . . . . 0.745 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -159.84 162.29 34.67 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.694 -171.867 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 325' ' ' LYS . . . . . 0.477 ' HA ' ' HD3' ' A' ' 326' ' ' PRO . 54.2 pttt -105.21 106.41 55.64 Favored Pre-proline 0 C--N 1.324 -0.501 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.279 169.424 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 326' ' ' PRO . . . . . 0.726 ' HG2' HG21 ' A' ' 273' ' ' VAL . 5.9 Cg_exo -86.49 166.83 9.03 Favored 'Trans proline' 0 C--O 1.233 0.256 0 C-N-CA 122.946 2.431 . . . . 0.0 113.566 -170.4 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 327' ' ' ALA . . . . . 0.509 ' HA ' ' HG2' ' A' ' 233' ' ' GLN . . . -81.69 122.02 27.11 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.235 -0.893 . . . . 0.0 109.444 172.032 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 328' ' ' GLU . . . . . 0.809 ' HG3' ' H ' ' A' ' 232' ' ' GLY . 53.6 mp0 60.48 175.42 0.1 Allowed 'General case' 0 N--CA 1.465 0.323 0 O-C-N 123.608 0.568 . . . . 0.0 111.084 -173.666 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 329' ' ' SER . . . . . 0.737 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 37.7 m -106.47 -15.46 14.8 Favored 'General case' 0 C--N 1.324 -0.532 0 C-N-CA 120.33 -0.548 . . . . 0.0 111.085 -177.347 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 330' ' ' ALA . . . . . 0.477 ' O ' HD13 ' A' ' 332' ' ' ILE . . . 62.95 -152.8 0.34 Allowed 'General case' 0 N--CA 1.465 0.312 0 CA-C-O 120.852 0.358 . . . . 0.0 111.857 175.094 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 331' ' ' ALA . . . . . 0.728 ' HA ' ' O ' ' A' ' 228' ' ' LEU . . . -68.5 139.78 55.67 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.56 -0.745 . . . . 0.0 112.203 -175.153 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 332' ' ' ILE . . . . . 0.477 HD13 ' O ' ' A' ' 330' ' ' ALA . 2.2 mp -111.7 144.59 19.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.279 179.379 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 84.8 m -121.07 105.71 10.88 Favored 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 175.522 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 334' ' ' ILE . . . . . 0.402 HD12 HG22 ' A' ' 334' ' ' ILE . 39.8 mm -79.95 127.73 39.07 Favored 'Isoleucine or valine' 0 C--O 1.235 0.3 0 N-CA-C 112.432 0.53 . . . . 0.0 112.432 -175.831 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 335' ' ' LEU . . . . . 0.663 HD23 ' HA ' ' A' ' 268' ' ' PHE . 1.8 pt? -148.91 132.46 16.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.58 174.036 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 336' ' ' ASN . . . . . 0.473 ' OD1' ' HA ' ' A' ' 266' ' ' ASP . 72.3 m-80 -109.0 77.38 1.06 Allowed 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.386 176.454 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 22.0 pttp . . . . . 0 C--O 1.243 0.743 0 O-C-N 124.589 1.18 . . . . 0.0 112.179 -179.078 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.784 0 N-CA-C 112.221 -0.351 . . . . 0.0 112.221 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 41.5 m -72.23 127.42 32.5 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.67 0.271 . . . . 0.0 110.451 179.789 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 225' ' ' THR . . . . . 0.428 ' O ' ' HA ' ' A' ' 333' ' ' THR . 48.3 p -110.98 -118.58 0.29 Allowed 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.617 -179.653 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 226' ' ' GLU . . . . . 0.506 ' HA ' ' O ' ' A' ' 332' ' ' ILE . 42.1 mt-10 -122.35 31.61 6.08 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.182 0.515 . . . . 0.0 110.004 178.399 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 39.6 t -75.62 -30.92 59.68 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.565 -177.659 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 228' ' ' LEU . . . . . 0.591 ' HB3' ' CB ' ' A' ' 259' ' ' ALA . 80.9 mt -82.26 138.95 34.48 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.884 178.61 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 229' ' ' THR . . . . . 0.463 ' O ' HG22 ' A' ' 230' ' ' VAL . 70.8 p -126.63 178.25 6.02 Favored 'General case' 0 C--N 1.325 -0.478 0 C-N-CA 120.104 -0.638 . . . . 0.0 110.752 -179.043 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . 0.612 HG21 HG13 ' A' ' 332' ' ' ILE . 84.1 t -143.42 150.21 17.64 Favored 'Isoleucine or valine' 0 C--O 1.239 0.544 0 N-CA-C 110.356 -0.239 . . . . 0.0 110.356 -178.574 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 33.1 t -126.08 129.1 48.44 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.298 178.597 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . 0.569 ' O ' HG21 ' A' ' 255' ' ' ILE . . . 110.2 109.95 3.23 Favored Glycine 0 C--O 1.228 -0.277 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.852 178.258 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 233' ' ' GLN . . . . . 0.576 ' HG3' ' O ' ' A' ' 326' ' ' PRO . 14.3 mm-40 -111.43 101.41 50.66 Favored Pre-proline 0 C--N 1.324 -0.505 0 O-C-N 122.807 -0.231 . . . . 0.0 111.135 178.989 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 234' ' ' PRO . . . . . 0.469 ' O ' ' HE2' ' A' ' 325' ' ' LYS . 7.0 Cg_exo -70.25 126.13 12.64 Favored 'Trans proline' 0 N--CA 1.459 -0.513 0 C-N-CA 122.247 1.964 . . . . 0.0 110.855 176.202 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 235' ' ' GLU . . . . . 0.402 ' HA ' ' CD ' ' A' ' 325' ' ' LYS . 13.0 pt-20 -97.41 124.42 41.59 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 121.634 0.731 . . . . 0.0 111.502 -177.639 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 236' ' ' HIS . . . . . 0.641 ' HB3' HD21 ' A' ' 250' ' ' ASN . 26.1 m80 -122.2 147.51 46.09 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.49 179.745 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 237' ' ' LYS . . . . . 0.428 ' H ' ' HD2' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -145.63 158.5 43.84 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 115.137 -0.938 . . . . 0.0 109.214 -178.912 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 238' ' ' VAL . . . . . 0.437 HG23 ' OD1' ' A' ' 250' ' ' ASN . 30.0 t -100.73 111.67 31.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 C-N-CA 120.306 -0.558 . . . . 0.0 111.097 -174.686 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 239' ' ' GLU . . . . . 0.535 ' HG2' HG21 ' A' ' 248' ' ' VAL . 8.3 pm0 -105.42 167.71 9.57 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.969 -0.56 . . . . 0.0 109.989 174.335 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 240' ' ' ALA . . . . . . . . . . . . . . . -73.52 -60.49 2.22 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.872 0.368 . . . . 0.0 111.02 -178.229 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 241' ' ' LYS . . . . . 0.67 ' HB2' ' HA2' ' A' ' 245' ' ' GLY . 0.0 OUTLIER -121.98 147.37 46.14 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.435 179.842 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -100.78 -160.0 0.77 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.128 -0.487 . . . . 0.0 109.801 -179.122 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 37.8 t -59.54 -30.15 68.41 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.267 178.546 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 5.8 m120 -98.72 1.49 46.16 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 111.836 0.31 . . . . 0.0 111.836 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . 0.67 ' HA2' ' HB2' ' A' ' 241' ' ' LYS . . . 69.0 38.99 85.27 Favored Glycine 0 N--CA 1.455 -0.092 0 C-N-CA 120.621 -0.799 . . . . 0.0 113.006 177.054 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 246' ' ' MET . . . . . . . . . . . . . 24.9 mmt -112.19 157.58 39.46 Favored Pre-proline 0 C--N 1.323 -0.565 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 178.021 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 247' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_exo -59.09 119.69 7.09 Favored 'Trans proline' 0 C--N 1.348 0.535 0 C-N-CA 121.803 1.669 . . . . 0.0 110.516 177.065 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . 0.535 HG21 ' HG2' ' A' ' 239' ' ' GLU . 59.7 t -79.66 113.41 18.99 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 N-CA-C 112.562 0.579 . . . . 0.0 112.562 -170.805 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -108.8 115.87 30.91 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 114.64 -1.164 . . . . 0.0 108.08 169.357 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 250' ' ' ASN . . . . . 0.641 HD21 ' HB3' ' A' ' 236' ' ' HIS . 6.7 m120 -57.38 138.28 55.13 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 112.547 0.573 . . . . 0.0 112.547 -170.115 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -80.19 -177.04 5.89 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.188 -0.914 . . . . 0.0 111.123 173.44 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 252' ' ' GLN . . . . . 0.51 ' HG3' HD13 ' A' ' 293' ' ' LEU . 3.0 mm100 -94.88 172.23 8.28 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.561 -176.786 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -106.23 138.52 14.4 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.186 -1.007 . . . . 0.0 112.942 -176.166 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 254' ' ' THR . . . . . 0.484 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 75.6 p -111.0 117.98 34.81 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 176.595 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . 0.58 HG13 HG13 ' A' ' 230' ' ' VAL . 0.2 OUTLIER -123.09 163.91 21.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 120.733 0.302 . . . . 0.0 111.269 -176.058 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 85.7 m -100.93 112.61 25.09 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 172.327 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.529 HG21 HD11 ' A' ' 262' ' ' LEU . 35.2 m -90.01 144.97 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.783 0 CA-C-O 121.663 0.744 . . . . 0.0 112.663 -169.764 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 258' ' ' SER . . . . . 0.431 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 23.2 m -90.31 7.7 37.1 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 114.376 -1.284 . . . . 0.0 108.637 171.283 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 259' ' ' ALA . . . . . 0.591 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -96.19 159.53 14.91 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-N 114.89 -1.05 . . . . 0.0 110.162 -177.509 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 45.8 p -127.97 154.14 45.93 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.362 -179.129 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 73.83 20.25 79.75 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 121.113 -0.565 . . . . 0.0 113.377 178.117 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 262' ' ' LEU . . . . . 0.529 HD11 HG21 ' A' ' 257' ' ' VAL . 77.5 mt -78.32 142.82 37.47 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 117.11 0.455 . . . . 0.0 110.606 179.347 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 81.6 mt-30 -141.3 174.5 10.48 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.975 -0.557 . . . . 0.0 109.866 -179.894 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 44.1 t -78.72 132.95 31.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 N-CA-C 110.098 -0.334 . . . . 0.0 110.098 176.332 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 102.89 4.4 48.42 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.378 -0.915 . . . . 0.0 112.61 179.071 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -86.05 153.8 21.87 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.871 0.367 . . . . 0.0 110.185 177.181 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 267' ' ' ALA . . . . . 0.53 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -125.08 142.48 51.46 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 177.985 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 268' ' ' PHE . . . . . . . . . . . . . 3.8 p90 -160.13 169.85 22.46 Favored 'General case' 0 C--N 1.323 -0.562 0 C-N-CA 120.097 -0.641 . . . . 0.0 111.572 -176.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 269' ' ' THR . . . . . 0.438 ' HB ' ' HB3' ' A' ' 287' ' ' PRO . 67.4 p -119.08 145.88 45.55 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.526 175.872 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 270' ' ' ILE . . . . . 0.534 HG12 HD12 ' A' ' 332' ' ' ILE . 57.9 mt -111.51 131.97 61.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.696 -177.265 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -66.08 120.13 12.62 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.372 -178.531 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 272' ' ' GLY . . . . . 0.499 ' HA3' ' HG3' ' A' ' 326' ' ' PRO . . . 101.3 -22.32 39.52 Favored Glycine 0 C--O 1.23 -0.1 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.102 -179.673 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . 0.477 HG22 HG21 ' A' ' 270' ' ' ILE . 52.2 t -103.16 102.68 13.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 176.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 7.1 m120 -119.62 156.66 29.98 Favored 'General case' 0 C--N 1.323 -0.583 0 C-N-CA 120.1 -0.64 . . . . 0.0 111.235 -173.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 59.0 p -75.8 166.81 22.98 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.301 0.572 . . . . 0.0 112.41 -173.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 34.3 m -123.96 153.66 30.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 114.909 -1.041 . . . . 0.0 109.851 174.261 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 53.1 m170 -110.35 91.51 3.68 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 179.345 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 16.9 pt20 -79.44 -11.36 59.91 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.92 -0.582 . . . . 0.0 112.435 -172.077 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 2.2 mp -76.42 -55.92 9.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-O 120.935 0.398 . . . . 0.0 109.962 179.003 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 45.6 p -96.12 -1.4 48.65 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.618 -178.865 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 281' ' ' LYS . . . . . 0.441 ' HB3' ' HZ2' ' A' ' 281' ' ' LYS . 3.8 mmmp? 52.74 52.37 14.13 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.06 -177.793 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 52.1 t0 -111.64 146.92 36.59 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.04 -177.464 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 36.4 p -107.1 110.6 22.75 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.938 0.399 . . . . 0.0 110.391 176.576 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 78.3 p -119.05 -26.45 5.96 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.702 -176.755 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 71.35 31.92 65.56 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.925 176.711 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 95.2 mm-40 -82.72 133.18 49.66 Favored Pre-proline 0 C--N 1.325 -0.49 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 179.232 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 287' ' ' PRO . . . . . 0.438 ' HB3' ' HB ' ' A' ' 269' ' ' THR . 82.2 Cg_exo -49.47 133.26 31.18 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.902 2.402 . . . . 0.0 112.851 -177.453 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 3.3 tm0? -83.65 134.89 34.76 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 -176.804 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 40.3 t -98.39 125.23 51.77 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-O 120.986 0.422 . . . . 0.0 110.776 -176.0 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 290' ' ' PHE . . . . . 0.53 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 6.0 m-85 -98.29 165.65 11.77 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.138 0.495 . . . . 0.0 112.181 -173.782 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 40.2 mmt-85 -129.46 120.35 25.31 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 114.889 -1.051 . . . . 0.0 108.763 174.014 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 58.3 t -77.98 135.78 25.5 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.913 0 CA-C-N 116.306 -0.406 . . . . 0.0 112.059 -174.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 293' ' ' LEU . . . . . 0.51 HD13 ' HG3' ' A' ' 252' ' ' GLN . 72.2 mt -102.49 -37.81 7.83 Favored 'General case' 0 N--CA 1.462 0.152 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.674 177.382 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 294' ' ' ALA . . . . . . . . . . . . . . . -151.51 139.91 20.48 Favored 'General case' 0 C--N 1.328 -0.339 0 C-N-CA 120.999 -0.28 . . . . 0.0 111.55 -175.139 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 58.0 t -137.71 110.21 7.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.987 -0.551 . . . . 0.0 109.614 175.339 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 296' ' ' SER . . . . . 0.4 ' O ' ' HB ' ' A' ' 299' ' ' THR . 58.9 p -139.85 104.06 4.79 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.163 -175.672 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 61.16 56.79 21.8 Favored Glycine 0 C--N 1.331 0.266 0 C-N-CA 120.979 -0.629 . . . . 0.0 112.406 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 66.4 p 53.21 17.24 0.95 Allowed 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 123.98 0.912 . . . . 0.0 112.519 -176.12 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 299' ' ' THR . . . . . 0.4 ' HB ' ' O ' ' A' ' 296' ' ' SER . 89.5 m -105.54 108.1 19.44 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 174.115 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . 0.741 HG13 HG22 ' A' ' 302' ' ' ILE . 45.2 t -111.05 135.04 51.43 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.35 -172.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 60.4 m -99.85 114.02 26.93 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 173.129 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 302' ' ' ILE . . . . . 0.741 HG22 HG13 ' A' ' 300' ' ' VAL . 27.2 pt -110.66 137.11 44.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 N-CA-C 113.094 0.775 . . . . 0.0 113.094 -168.801 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 303' ' ' SER . . . . . . . . . . . . . 50.3 m -119.49 157.59 51.28 Favored Pre-proline 0 C--N 1.32 -0.716 0 CA-C-N 114.029 -1.441 . . . . 0.0 107.641 170.569 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 304' ' ' PRO . . . . . 0.492 ' HD3' ' HA ' ' A' ' 290' ' ' PHE . 2.7 Cg_exo -75.23 -172.48 10.88 Favored 'Cis proline' 0 N--CA 1.462 -0.335 0 C-N-CA 124.368 -1.097 . . . . 0.0 111.716 -0.077 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 305' ' ' LYS . . . . . 0.435 ' HD2' ' O ' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -80.89 145.35 31.36 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.271 0.558 . . . . 0.0 111.804 179.462 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 306' ' ' ILE . . . . . 0.417 HG22 ' HE3' ' A' ' 325' ' ' LYS . 2.9 mp -99.86 100.5 10.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.41 -172.783 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 307' ' ' LEU . . . . . 0.468 ' HA ' ' HD3' ' A' ' 308' ' ' PRO . 82.9 mt -117.14 119.74 34.49 Favored Pre-proline 0 CA--C 1.516 -0.363 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.413 179.766 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 308' ' ' PRO . . . . . 0.791 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 7.1 Cg_exo -80.19 139.66 13.45 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 123.183 2.589 . . . . 0.0 113.406 -176.065 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . 0.467 HG22 ' HB3' ' A' ' 320' ' ' ALA . 45.3 t -82.04 -30.16 9.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 167.284 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 89.1 mt-10 -84.73 25.79 0.88 Allowed 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 115.006 -0.997 . . . . 0.0 111.169 177.553 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.707 ' HB2' ' HB2' ' A' ' 308' ' ' PRO . 24.5 t-20 -87.74 141.63 28.45 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 179.638 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 38.0 m -60.3 -28.53 68.18 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.198 -178.019 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 32.7 t70 -79.14 113.46 17.28 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.001 0.429 . . . . 0.0 110.195 177.107 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 314' ' ' VAL . . . . . 0.469 ' O ' ' HD3' ' A' ' 318' ' ' PRO . 40.4 t -69.04 -19.86 24.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.965 -177.543 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -75.03 -17.89 60.42 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 112.218 0.451 . . . . 0.0 112.218 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 59.4 m -96.7 -22.03 17.24 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 112.43 0.53 . . . . 0.0 112.43 -176.394 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 317' ' ' ARG . . . . . 0.415 ' N ' ' CD ' ' A' ' 318' ' ' PRO . 15.9 ptp180 -74.5 -31.65 1.25 Allowed Pre-proline 0 CA--C 1.549 0.92 0 N-CA-C 114.901 1.445 . . . . 0.0 114.901 -175.584 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 318' ' ' PRO . . . . . 0.469 ' HD3' ' O ' ' A' ' 314' ' ' VAL . 33.6 Cg_exo -62.09 -39.09 51.92 Favored 'Trans proline' 0 C--N 1.365 1.412 0 CA-C-N 121.486 1.566 . . . . 0.0 112.68 -178.009 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 54.7 m-85 -112.02 41.33 1.98 Allowed 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.543 -179.731 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . 0.467 ' HB3' HG22 ' A' ' 309' ' ' VAL . . . -78.63 159.87 27.84 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.967 179.699 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 47.2 t30 -111.83 -25.29 9.53 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.76 -178.744 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 322' ' ' VAL . . . . . . . . . . . . . 33.0 m -134.46 172.68 15.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.766 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 53.1 m-20 -67.15 -49.69 63.89 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.557 176.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 324' ' ' ALA . . . . . 0.791 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -173.08 179.64 2.2 Favored 'General case' 0 CA--C 1.518 -0.281 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.555 -177.166 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 325' ' ' LYS . . . . . 0.469 ' HE2' ' O ' ' A' ' 234' ' ' PRO . 8.7 ptpp? -126.83 106.96 22.61 Favored Pre-proline 0 C--N 1.326 -0.414 0 CA-C-N 115.324 -0.853 . . . . 0.0 109.805 171.525 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 326' ' ' PRO . . . . . 0.576 ' O ' ' HG3' ' A' ' 233' ' ' GLN . 67.1 Cg_endo -78.92 167.14 22.52 Favored 'Trans proline' 0 C--N 1.34 0.124 0 C-N-CA 122.535 2.156 . . . . 0.0 112.49 -175.878 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -63.03 129.63 41.18 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.122 176.81 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 47.1 mt-10 73.01 142.72 0.06 Allowed 'General case' 0 N--CA 1.469 0.493 0 O-C-N 123.977 0.798 . . . . 0.0 110.561 -174.564 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 329' ' ' SER . . . . . 0.534 ' O ' ' HB1' ' A' ' 330' ' ' ALA . 17.6 m -77.31 -22.29 52.17 Favored 'General case' 0 C--N 1.323 -0.55 0 C-N-CA 120.865 -0.334 . . . . 0.0 111.383 -174.652 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 330' ' ' ALA . . . . . 0.534 ' HB1' ' O ' ' A' ' 329' ' ' SER . . . 74.15 -162.6 0.08 Allowed 'General case' 0 N--CA 1.47 0.546 0 O-C-N 123.716 0.635 . . . . 0.0 112.686 174.251 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -81.34 145.93 30.61 Favored 'General case' 0 CA--C 1.517 -0.29 0 CA-C-N 115.318 -0.856 . . . . 0.0 110.943 -178.042 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 332' ' ' ILE . . . . . 0.612 HG13 HG21 ' A' ' 230' ' ' VAL . 29.4 mm -115.47 144.55 22.81 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.245 -177.304 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.428 ' HA ' ' O ' ' A' ' 225' ' ' THR . 75.5 m -109.05 96.65 6.46 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 110.094 -0.336 . . . . 0.0 110.094 179.118 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 334' ' ' ILE . . . . . 0.46 HG23 HD12 ' A' ' 334' ' ' ILE . 45.7 mm -81.71 130.61 35.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 N-CA-C 111.912 0.338 . . . . 0.0 111.912 -175.329 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 335' ' ' LEU . . . . . . . . . . . . . 1.9 pt? -156.58 132.43 9.62 Favored 'General case' 0 C--O 1.234 0.244 0 CA-C-O 121.388 0.613 . . . . 0.0 110.982 174.671 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 76.1 m-20 -94.69 52.63 1.53 Allowed 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.451 176.713 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 55.8 tptt . . . . . 0 C--O 1.246 0.897 0 CA-C-O 118.124 -0.941 . . . . 0.0 109.525 -179.807 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.861 0 N-CA-C 112.154 -0.378 . . . . 0.0 112.154 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 44.1 m -78.55 112.84 16.03 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.592 0.196 . . . . 0.0 111.186 -178.407 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 78.9 m 67.4 -78.13 0.04 OUTLIER 'General case' 0 N--CA 1.468 0.435 0 O-C-N 123.777 0.673 . . . . 0.0 111.812 176.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 226' ' ' GLU . . . . . 0.407 ' HA ' ' HB1' ' A' ' 331' ' ' ALA . 54.1 mt-10 56.42 30.51 17.13 Favored 'General case' 0 C--N 1.333 -0.137 0 C-N-CA 122.973 0.509 . . . . 0.0 112.124 -178.384 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 48.3 m -96.04 -27.86 14.9 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.629 174.323 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 228' ' ' LEU . . . . . 0.458 ' HB3' ' CB ' ' A' ' 259' ' ' ALA . 90.5 mt -128.12 141.3 51.53 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.289 -0.869 . . . . 0.0 109.09 176.766 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 38.3 p -130.94 -179.2 5.18 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 120.578 -0.449 . . . . 0.0 111.339 -177.005 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . 0.58 ' HB ' ' CB ' ' A' ' 329' ' ' SER . 40.7 t -140.0 140.01 36.19 Favored 'Isoleucine or valine' 0 C--O 1.239 0.528 0 CA-C-O 120.557 0.218 . . . . 0.0 110.772 -178.651 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 32.1 m -99.24 138.92 35.65 Favored 'General case' 0 C--O 1.234 0.277 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.29 176.004 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 127.73 166.23 12.03 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.51 -0.853 . . . . 0.0 111.959 179.202 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 81.3 mt-30 -117.12 102.03 52.89 Favored Pre-proline 0 C--N 1.324 -0.539 0 CA-C-N 116.782 0.291 . . . . 0.0 111.073 -179.557 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -76.35 126.82 9.36 Favored 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 122.716 2.277 . . . . 0.0 111.155 177.015 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -158.55 141.22 14.44 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.175 -178.739 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 92.8 m-70 -146.72 138.24 24.39 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.495 -177.266 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 237' ' ' LYS . . . . . 0.541 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 6.2 mptt -121.61 135.79 54.98 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 -179.856 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 238' ' ' VAL . . . . . . . . . . . . . 42.5 t -73.82 111.03 8.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 C-N-CA 120.541 -0.464 . . . . 0.0 109.85 179.831 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 239' ' ' GLU . . . . . 0.58 ' HG3' ' HB ' ' A' ' 248' ' ' VAL . 9.6 pt-20 -102.59 140.86 36.31 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.329 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 240' ' ' ALA . . . . . 0.461 ' O ' ' HA ' ' A' ' 247' ' ' PRO . . . -75.47 -86.93 0.04 OUTLIER 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.209 -173.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 241' ' ' LYS . . . . . 0.477 ' HD2' ' N ' ' A' ' 241' ' ' LYS . 11.7 mptt -107.4 128.95 54.93 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.864 0.364 . . . . 0.0 110.5 -179.392 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -76.07 -167.38 0.73 Allowed 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.28 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 46.8 t -60.63 -27.88 68.12 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.868 -176.841 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 244' ' ' ASN . . . . . 0.488 ' OD1' ' HE2' ' A' ' 246' ' ' MET . 0.6 OUTLIER -90.45 -7.82 52.09 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.278 0.561 . . . . 0.0 109.666 179.789 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . 0.455 ' HA2' ' HB3' ' A' ' 241' ' ' LYS . . . 87.07 32.17 15.14 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.861 176.488 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 246' ' ' MET . . . . . 0.488 ' HE2' ' OD1' ' A' ' 244' ' ' ASN . 64.5 mtt -113.12 148.14 38.83 Favored Pre-proline 0 C--N 1.325 -0.494 0 O-C-N 122.785 -0.244 . . . . 0.0 110.862 -179.473 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 247' ' ' PRO . . . . . 0.461 ' HA ' ' O ' ' A' ' 240' ' ' ALA . 24.5 Cg_exo -60.88 131.47 37.45 Favored 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 122.654 2.236 . . . . 0.0 111.359 176.898 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . 0.58 ' HB ' ' HG3' ' A' ' 239' ' ' GLU . 31.7 t -114.09 129.08 70.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 N-CA-C 112.769 0.655 . . . . 0.0 112.769 -171.393 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -102.14 100.4 10.62 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 106.325 -1.731 . . . . 0.0 106.325 163.448 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 250' ' ' ASN . . . . . 0.473 HD22 ' CD2' ' A' ' 307' ' ' LEU . 20.4 p30 -49.07 152.27 1.14 Allowed 'General case' 0 N--CA 1.469 0.486 0 N-CA-C 113.789 1.033 . . . . 0.0 113.789 -165.503 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . 0.46 ' CD ' ' H ' ' A' ' 251' ' ' ARG . 0.3 OUTLIER -68.52 -177.49 0.95 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 114.375 -1.284 . . . . 0.0 112.004 -174.582 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 252' ' ' GLN . . . . . 0.534 ' HB3' ' O ' ' A' ' 302' ' ' ILE . 2.6 mm100 -98.33 174.64 6.39 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.878 -177.393 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -110.28 147.81 17.43 Favored Glycine 0 N--CA 1.447 -0.581 0 C-N-CA 119.842 -1.171 . . . . 0.0 113.019 -176.612 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 70.1 p -118.93 117.73 29.62 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 176.838 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . 0.42 HG23 HD13 ' A' ' 255' ' ' ILE . 0.2 OUTLIER -128.66 165.64 27.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-O 120.951 0.405 . . . . 0.0 111.128 -176.253 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 40.5 m -99.61 116.87 32.74 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 178.273 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . . . . . . . . . 34.1 m -90.44 144.39 9.22 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.774 0 CA-C-O 121.47 0.653 . . . . 0.0 112.494 -172.378 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 258' ' ' SER . . . . . 0.414 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 40.3 m -90.61 8.48 33.99 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 114.359 -1.291 . . . . 0.0 108.721 170.355 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 259' ' ' ALA . . . . . 0.458 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -91.4 163.69 14.1 Favored 'General case' 0 N--CA 1.449 -0.518 0 CA-C-N 114.994 -1.003 . . . . 0.0 109.453 -179.012 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 50.6 m -129.8 149.33 51.59 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 120.762 0.315 . . . . 0.0 111.386 -177.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 68.73 37.53 84.53 Favored Glycine 0 N--CA 1.451 -0.355 0 CA-C-N 115.786 -0.643 . . . . 0.0 113.534 176.453 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 262' ' ' LEU . . . . . . . . . . . . . 60.4 mt -92.45 150.74 20.6 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 117.364 0.582 . . . . 0.0 109.835 176.794 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 84.7 mt-30 -144.41 170.26 16.36 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.113 -0.494 . . . . 0.0 109.675 -179.619 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 50.3 t -78.25 141.89 14.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.844 -179.457 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 94.13 -2.07 68.28 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.701 -0.761 . . . . 0.0 113.206 177.288 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 44.8 m-20 -81.04 155.46 26.33 Favored 'General case' 0 CA--C 1.515 -0.386 0 CA-C-O 121.251 0.548 . . . . 0.0 111.202 178.129 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 267' ' ' ALA . . . . . 0.694 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -116.16 146.97 41.86 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.222 -0.899 . . . . 0.0 109.13 178.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 268' ' ' PHE . . . . . 0.576 ' CD2' HG22 ' A' ' 332' ' ' ILE . 6.6 p90 -164.17 162.06 22.55 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 120.4 -0.52 . . . . 0.0 111.93 -174.935 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 269' ' ' THR . . . . . 0.469 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 71.1 p -115.23 147.74 39.98 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 115.016 -0.993 . . . . 0.0 109.137 173.422 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 270' ' ' ILE . . . . . 0.482 HG23 HD11 ' A' ' 270' ' ' ILE . 54.1 mt -123.13 138.07 54.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-O 120.61 0.243 . . . . 0.0 110.516 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -63.58 125.2 23.47 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.872 -175.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 103.64 -22.6 35.24 Favored Glycine 0 N--CA 1.449 -0.471 0 CA-C-N 115.73 -0.668 . . . . 0.0 112.207 178.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . 0.516 HG13 HG13 ' A' ' 322' ' ' VAL . 39.5 t -95.11 102.31 13.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-O 120.946 0.403 . . . . 0.0 110.058 178.204 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -110.52 135.76 50.69 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.231 -179.892 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 32.5 p -77.94 156.23 30.38 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.229 0.538 . . . . 0.0 112.078 -177.428 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 32.9 m -113.48 160.3 13.04 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.65 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.478 174.845 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 35.7 m80 -132.19 79.86 1.88 Allowed 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.903 177.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 2.5 tp-100 -53.22 -29.55 32.92 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.585 -0.28 . . . . 0.0 111.296 -176.115 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 50.1 mm -63.6 -48.42 86.88 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.352 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.616 178.914 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 75.2 p -97.81 7.14 46.89 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-O 120.762 0.315 . . . . 0.0 111.5 -177.39 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 281' ' ' LYS . . . . . 0.416 ' O ' ' HG3' ' A' ' 281' ' ' LYS . 52.9 tptt 71.59 50.18 0.27 Allowed 'General case' 0 CA--C 1.536 0.408 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.947 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 2.4 p30 29.62 50.41 0.07 Allowed 'General case' 0 N--CA 1.474 0.741 0 N-CA-C 115.801 1.778 . . . . 0.0 115.801 171.471 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.418 ' O ' HG21 ' A' ' 284' ' ' THR . 62.1 p -107.1 88.65 2.78 Favored 'General case' 0 C--N 1.322 -0.612 0 C-N-CA 119.744 -0.782 . . . . 0.0 110.335 167.935 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 284' ' ' THR . . . . . 0.418 HG21 ' O ' ' A' ' 283' ' ' THR . 35.5 p -145.62 -70.36 0.27 Allowed 'General case' 0 C--N 1.319 -0.761 0 CA-C-N 115.499 -0.773 . . . . 0.0 111.339 -177.79 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 89.09 32.3 10.86 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.013 -178.526 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 12.0 mm100 -100.94 127.8 31.24 Favored Pre-proline 0 C--N 1.326 -0.422 0 O-C-N 122.894 -0.18 . . . . 0.0 110.926 -177.244 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 287' ' ' PRO . . . . . 0.469 ' HB2' ' HB ' ' A' ' 269' ' ' THR . 24.2 Cg_exo -58.17 129.84 34.98 Favored 'Trans proline' 0 C--O 1.236 0.406 0 C-N-CA 122.42 2.08 . . . . 0.0 110.734 173.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 40.4 tt0 -72.87 142.06 47.93 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.963 0.411 . . . . 0.0 111.124 -173.773 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 47.7 t -90.6 134.82 28.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 115.465 -0.789 . . . . 0.0 109.931 177.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 290' ' ' PHE . . . . . 0.694 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 45.5 m-85 -111.48 163.06 14.44 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.471 -177.449 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 43.2 mmm-85 -125.25 121.22 33.44 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 173.436 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 47.2 t -66.03 132.16 31.64 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-N 115.597 -0.729 . . . . 0.0 111.591 -175.604 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 293' ' ' LEU . . . . . . . . . . . . . 93.9 mt -93.68 -41.64 9.59 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.906 -0.588 . . . . 0.0 111.562 177.381 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 294' ' ' ALA . . . . . 0.406 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -157.26 142.69 17.3 Favored 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 120.896 -0.322 . . . . 0.0 111.316 -176.601 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 61.2 t -133.92 116.54 23.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 109.238 -0.653 . . . . 0.0 109.238 174.466 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 52.5 p -140.73 92.29 2.49 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.061 -175.741 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 66.84 63.73 3.69 Favored Glycine 0 N--CA 1.453 -0.181 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.222 -179.411 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 76.6 p 51.0 23.21 1.4 Allowed 'General case' 0 N--CA 1.47 0.557 0 C-N-CA 123.614 0.766 . . . . 0.0 112.579 -177.651 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 44.2 m -116.59 113.38 22.64 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 175.361 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . 0.61 HG13 HG23 ' A' ' 302' ' ' ILE . 45.5 t -113.49 130.5 67.4 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.541 -171.325 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 38.3 m -91.16 116.72 29.04 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 108.072 -1.085 . . . . 0.0 108.072 171.484 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 302' ' ' ILE . . . . . 0.61 HG23 HG13 ' A' ' 300' ' ' VAL . 31.0 pt -110.68 137.3 43.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 N-CA-C 112.812 0.671 . . . . 0.0 112.812 -169.047 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 303' ' ' SER . . . . . . . . . . . . . 81.7 p -137.67 153.52 74.15 Favored Pre-proline 0 C--N 1.325 -0.496 0 CA-C-N 114.645 -1.161 . . . . 0.0 108.547 173.889 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 304' ' ' PRO . . . . . 0.513 ' HD2' ' HD1' ' A' ' 290' ' ' PHE . 5.9 Cg_exo -73.67 -173.07 10.83 Favored 'Cis proline' 0 N--CA 1.463 -0.296 0 C-N-CA 124.005 -1.248 . . . . 0.0 112.01 -0.005 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 305' ' ' LYS . . . . . 0.537 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -85.75 170.2 12.69 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 120.873 0.368 . . . . 0.0 110.874 -177.841 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 306' ' ' ILE . . . . . . . . . . . . . 60.3 mt -112.09 93.6 2.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.59 -176.389 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 307' ' ' LEU . . . . . 0.473 ' CD2' HD22 ' A' ' 250' ' ' ASN . 94.4 mt -108.23 104.97 55.58 Favored Pre-proline 0 C--N 1.326 -0.441 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.691 -179.54 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 308' ' ' PRO . . . . . 0.716 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 6.3 Cg_exo -75.96 138.6 20.97 Favored 'Trans proline' 0 N--CA 1.461 -0.422 0 C-N-CA 122.982 2.455 . . . . 0.0 112.467 -177.324 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . 0.439 HG23 ' O ' ' A' ' 322' ' ' VAL . 46.8 t -65.74 -25.59 36.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 121.189 0.518 . . . . 0.0 109.683 174.674 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 310' ' ' GLU . . . . . 0.448 ' HA ' ' OE1' ' A' ' 310' ' ' GLU . 4.8 mm-40 -80.92 33.67 0.33 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.752 -0.658 . . . . 0.0 112.169 177.192 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 21.4 p30 -85.29 -8.08 58.68 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.964 -0.107 . . . . 0.0 111.178 -179.644 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 71.1 m 74.91 -46.61 0.6 Allowed 'General case' 0 N--CA 1.471 0.613 0 C-N-CA 123.457 0.703 . . . . 0.0 112.283 178.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 42.8 m-20 -57.47 115.46 2.75 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-O 121.211 0.529 . . . . 0.0 111.116 -179.073 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 23.3 t -61.55 -33.6 57.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.449 -176.379 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -75.79 -22.14 56.68 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 111.752 0.278 . . . . 0.0 111.752 179.626 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 65.5 m -87.12 -20.66 26.76 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 111.777 0.288 . . . . 0.0 111.777 -178.857 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 317' ' ' ARG . . . . . 0.488 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 75.0 mtp180 -56.04 -48.9 95.82 Favored Pre-proline 0 CA--C 1.539 0.525 0 N-CA-C 113.034 0.754 . . . . 0.0 113.034 -179.282 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 318' ' ' PRO . . . . . 0.488 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 52.0 Cg_exo -58.57 -16.18 28.81 Favored 'Trans proline' 0 C--N 1.36 1.137 0 C-N-CA 122.213 1.942 . . . . 0.0 113.988 -176.758 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 8.8 m-85 -106.69 1.28 24.93 Favored 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 121.116 -0.234 . . . . 0.0 111.568 -179.657 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -66.08 139.03 58.15 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.811 0.339 . . . . 0.0 111.02 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 14.8 p-10 -124.07 -9.5 7.66 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.379 -179.466 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 322' ' ' VAL . . . . . 0.516 HG13 HG13 ' A' ' 273' ' ' VAL . 32.3 m -132.92 163.97 36.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 175.537 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 54.6 m-20 -81.05 -22.16 39.5 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 111.885 0.328 . . . . 0.0 111.885 -177.755 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 324' ' ' ALA . . . . . 0.716 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -171.1 154.66 4.14 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.045 -172.573 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 23.8 pttm -101.31 114.4 65.73 Favored Pre-proline 0 C--N 1.325 -0.488 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 169.314 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -72.57 167.64 26.55 Favored 'Trans proline' 0 C--O 1.235 0.346 0 C-N-CA 122.622 2.215 . . . . 0.0 113.306 -172.47 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -66.62 136.8 56.13 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-N 115.804 -0.634 . . . . 0.0 109.885 175.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 47.1 -155.27 0.05 Allowed 'General case' 0 N--CA 1.471 0.594 0 O-C-N 124.446 1.091 . . . . 0.0 111.19 -173.7 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 329' ' ' SER . . . . . 0.58 ' CB ' ' HB ' ' A' ' 230' ' ' VAL . 53.1 m -98.66 -38.92 8.93 Favored 'General case' 0 C--N 1.322 -0.609 0 C-N-CA 120.548 -0.461 . . . . 0.0 111.024 -177.052 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 330' ' ' ALA . . . . . 0.502 ' HB2' ' O ' ' A' ' 329' ' ' SER . . . 79.39 -164.39 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.923 0 N-CA-C 112.869 0.692 . . . . 0.0 112.869 174.34 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 331' ' ' ALA . . . . . 0.407 ' HB1' ' HA ' ' A' ' 226' ' ' GLU . . . -84.49 149.17 26.12 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 115.507 -0.77 . . . . 0.0 112.429 -172.066 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 332' ' ' ILE . . . . . 0.576 HG22 ' CD2' ' A' ' 268' ' ' PHE . 38.3 mt -111.08 145.78 16.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.663 -0.699 . . . . 0.0 111.16 178.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 95.7 m -120.67 97.2 5.44 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 172.693 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 40.3 mm -79.18 128.96 38.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 N-CA-C 111.92 0.341 . . . . 0.0 111.92 -175.617 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 335' ' ' LEU . . . . . . . . . . . . . 1.5 pt? -152.9 130.74 11.68 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.407 0.622 . . . . 0.0 110.593 174.431 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 23.4 p30 -90.8 5.47 48.24 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.287 -177.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 337' ' ' LYS . . . . . 0.604 ' HZ3' ' HB3' ' A' ' 337' ' ' LYS . 8.0 mtpm? . . . . . 0 C--O 1.245 0.828 0 CA-C-O 118.186 -0.911 . . . . 0.0 110.758 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.807 0 N-CA-C 112.081 -0.408 . . . . 0.0 112.081 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 50.2 m -79.15 124.53 28.42 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 110.407 -0.22 . . . . 0.0 110.407 179.71 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 46.5 m 66.59 -90.03 0.03 OUTLIER 'General case' 0 CA--C 1.533 0.312 0 O-C-N 123.612 0.57 . . . . 0.0 110.326 -177.44 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 4.5 tm-20 62.79 98.54 0.03 OUTLIER 'General case' 0 C--N 1.34 0.177 0 CA-C-O 121.655 0.741 . . . . 0.0 110.027 179.698 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 42.9 m -117.46 -62.65 1.54 Allowed 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.44 -0.8 . . . . 0.0 109.409 178.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 228' ' ' LEU . . . . . 0.684 ' HB3' ' HB3' ' A' ' 259' ' ' ALA . 87.9 mt -127.1 136.07 51.63 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 172.287 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 229' ' ' THR . . . . . 0.518 ' O ' HG21 ' A' ' 230' ' ' VAL . 40.5 p -122.16 172.17 8.46 Favored 'General case' 0 C--N 1.325 -0.462 0 C-N-CA 119.502 -0.879 . . . . 0.0 110.811 -179.72 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . 0.833 HG23 HD11 ' A' ' 332' ' ' ILE . 48.3 t -145.82 146.02 19.72 Favored 'Isoleucine or valine' 0 C--O 1.239 0.537 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.328 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 231' ' ' SER . . . . . 0.435 ' HA ' ' OE1' ' A' ' 328' ' ' GLU . 33.3 t -118.79 127.21 53.32 Favored 'General case' 0 N--CA 1.452 -0.328 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.017 -178.975 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . 0.532 ' O ' ' HD3' ' A' ' 234' ' ' PRO . . . 149.13 160.43 9.13 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.072 179.182 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 14.6 mm-40 -99.34 100.98 11.54 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 116.769 0.285 . . . . 0.0 111.628 -179.069 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 234' ' ' PRO . . . . . 0.532 ' HD3' ' O ' ' A' ' 232' ' ' GLY . 3.2 Cg_endo -84.01 126.44 3.85 Favored 'Trans proline' 0 N--CA 1.455 -0.762 0 C-N-CA 122.711 2.274 . . . . 0.0 111.434 176.352 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 235' ' ' GLU . . . . . 0.441 ' HB3' ' HE2' ' A' ' 237' ' ' LYS . 98.4 mt-10 -126.54 126.79 44.27 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.315 0.578 . . . . 0.0 111.387 -178.7 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 236' ' ' HIS . . . . . 0.505 ' C ' ' HD3' ' A' ' 237' ' ' LYS . 27.8 m80 -139.73 130.3 25.7 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.192 -0.913 . . . . 0.0 109.204 176.358 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 237' ' ' LYS . . . . . 0.619 ' HD3' ' N ' ' A' ' 237' ' ' LYS . 0.1 OUTLIER -167.39 174.35 8.07 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.054 -176.126 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 238' ' ' VAL . . . . . . . . . . . . . 44.7 t -101.4 110.78 29.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 N-CA-C 109.303 -0.629 . . . . 0.0 109.303 176.321 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 239' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -110.4 152.09 26.69 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.604 -179.411 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 240' ' ' ALA . . . . . 0.613 ' O ' ' HA ' ' A' ' 247' ' ' PRO . . . -93.5 -61.23 1.6 Allowed 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.241 -176.377 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 241' ' ' LYS . . . . . . . . . . . . . 11.7 mmmm -98.2 127.58 44.22 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.397 -173.899 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 55.2 p-10 -95.25 -156.94 0.54 Allowed 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 110.033 -0.358 . . . . 0.0 110.033 174.849 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 38.4 t -66.79 -25.52 66.51 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.762 0.315 . . . . 0.0 111.294 -179.779 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 6.0 m120 -98.54 -14.21 20.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.735 0.302 . . . . 0.0 111.189 -179.534 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 93.04 22.5 27.54 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.476 -179.589 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 246' ' ' MET . . . . . 0.406 ' HB2' ' HE1' ' A' ' 246' ' ' MET . 66.5 mtm -113.34 154.0 45.45 Favored Pre-proline 0 C--N 1.326 -0.425 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 177.908 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 247' ' ' PRO . . . . . 0.613 ' HA ' ' O ' ' A' ' 240' ' ' ALA . 3.4 Cg_exo -74.49 119.14 5.62 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.109 1.873 . . . . 0.0 111.787 -179.9 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . 0.452 HG21 ' C ' ' A' ' 247' ' ' PRO . 59.2 t -145.06 138.14 21.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.567 -178.093 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 64.0 t0 -73.04 121.12 19.63 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 174.191 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 250' ' ' ASN . . . . . . . . . . . . . 19.7 p30 -64.66 162.35 15.92 Favored 'General case' 0 C--O 1.234 0.242 0 CA-C-O 121.275 0.559 . . . . 0.0 112.484 -174.633 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 15.6 ptm180 -69.03 -177.06 0.96 Allowed 'General case' 0 C--O 1.235 0.291 0 CA-C-N 114.852 -1.067 . . . . 0.0 112.379 -172.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 252' ' ' GLN . . . . . 0.404 ' HA ' HE21 ' A' ' 252' ' ' GLN . 2.5 mm100 -80.29 176.19 9.98 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.312 -0.858 . . . . 0.0 109.844 177.894 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . 0.476 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -97.4 124.08 8.02 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.216 -0.992 . . . . 0.0 111.881 177.553 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 254' ' ' THR . . . . . 0.445 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 76.8 p -115.52 116.13 27.65 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 178.613 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . 0.445 HG23 HD11 ' A' ' 255' ' ' ILE . 0.2 OUTLIER -135.64 167.13 25.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.628 -175.747 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 86.9 m -92.5 123.34 35.73 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.2 178.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.596 HG13 HG12 ' A' ' 230' ' ' VAL . 33.1 m -91.0 144.94 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.66 0 N-CA-C 113.029 0.751 . . . . 0.0 113.029 -173.106 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 258' ' ' SER . . . . . 0.489 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 29.1 m -91.07 10.33 27.22 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 114.113 -1.403 . . . . 0.0 108.866 169.915 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 259' ' ' ALA . . . . . 0.684 ' HB3' ' HB3' ' A' ' 228' ' ' LEU . . . -98.02 176.97 5.57 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.181 -0.918 . . . . 0.0 109.926 -175.19 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 37.2 t -143.77 146.6 33.24 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 110.191 -0.3 . . . . 0.0 110.191 179.067 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 70.98 45.31 51.89 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.996 -0.621 . . . . 0.0 112.906 179.143 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 262' ' ' LEU . . . . . . . . . . . . . 64.0 mt -99.47 144.25 28.79 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 177.101 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 84.2 mt-30 -139.88 160.94 38.78 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 110.287 -0.264 . . . . 0.0 110.287 -178.735 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 44.0 t -69.36 136.2 26.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.177 177.527 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 96.03 -1.28 62.93 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.561 -0.828 . . . . 0.0 112.94 178.616 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 266' ' ' ASP . . . . . 0.422 ' O ' ' HA ' ' A' ' 291' ' ' ARG . 65.7 m-20 -78.99 164.21 24.58 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.926 0.394 . . . . 0.0 110.537 177.281 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 267' ' ' ALA . . . . . 0.64 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -123.84 154.38 39.71 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.73 -179.183 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 268' ' ' PHE . . . . . 0.686 ' CD2' HG23 ' A' ' 332' ' ' ILE . 9.4 p90 -164.16 171.19 15.37 Favored 'General case' 0 N--CA 1.449 -0.519 0 C-N-CA 120.297 -0.561 . . . . 0.0 112.217 -179.169 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 69.3 p -129.97 126.11 37.01 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 114.86 -1.064 . . . . 0.0 109.329 175.571 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 270' ' ' ILE . . . . . 0.969 HG12 HG13 ' A' ' 332' ' ' ILE . 60.0 mt -96.74 136.09 28.69 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 116.504 -0.316 . . . . 0.0 110.826 -176.554 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -64.96 128.22 34.86 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.873 -176.395 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 100.98 -23.68 34.72 Favored Glycine 0 N--CA 1.452 -0.26 0 CA-C-N 115.64 -0.709 . . . . 0.0 112.653 177.409 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . 0.421 HG23 ' HG3' ' A' ' 326' ' ' PRO . 31.8 t -102.99 102.33 13.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 120.898 0.38 . . . . 0.0 111.025 179.784 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -113.95 166.35 11.69 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 174.248 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 275' ' ' SER . . . . . 0.447 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 36.5 p -83.72 179.39 7.6 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 112.314 0.487 . . . . 0.0 112.314 -176.443 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 35.7 m -141.46 159.72 22.05 Favored 'Isoleucine or valine' 0 C--O 1.232 0.174 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.743 -177.163 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 80.9 m-70 -118.13 99.58 6.97 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 173.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 10.8 mm100 -73.61 -24.03 59.98 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 111.863 0.32 . . . . 0.0 111.863 -175.206 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 50.7 mm -67.07 -49.27 74.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.764 0.316 . . . . 0.0 111.334 -177.719 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 40.8 p -101.62 -0.14 35.26 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.509 -0.314 . . . . 0.0 111.343 -179.123 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 3.9 tmtp? 60.18 53.6 4.4 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-O 121.903 0.859 . . . . 0.0 109.588 179.725 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 64.8 t0 -117.78 115.91 25.95 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.372 -0.831 . . . . 0.0 109.144 179.08 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 59.2 p -93.96 86.03 4.92 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.918 0.866 . . . . 0.0 111.014 -178.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 284' ' ' THR . . . . . 0.45 ' C ' ' H ' ' A' ' 286' ' ' GLN . 40.0 p -148.63 -88.84 0.08 Allowed 'General case' 0 C--N 1.313 -1.015 0 CA-C-N 114.218 -1.356 . . . . 0.0 109.562 179.282 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 285' ' ' GLY . . . . . 0.534 ' O ' ' HB2' ' A' ' 286' ' ' GLN . . . 68.31 -17.33 0.45 Allowed Glycine 0 C--N 1.333 0.411 0 N-CA-C 114.627 0.611 . . . . 0.0 114.627 173.423 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 286' ' ' GLN . . . . . 0.534 ' HB2' ' O ' ' A' ' 285' ' ' GLY . 72.2 mt-30 76.49 164.45 0.13 Allowed Pre-proline 0 C--O 1.235 0.314 0 C-N-CA 123.519 0.728 . . . . 0.0 110.314 -174.671 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 287' ' ' PRO . . . . . . . . . . . . . 78.2 Cg_exo -51.65 128.26 25.58 Favored 'Trans proline' 0 C--N 1.351 0.665 0 C-N-CA 122.641 2.228 . . . . 0.0 112.71 -175.902 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 3.8 tm0? -74.38 135.79 42.45 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 -178.029 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 42.5 t -93.83 121.43 44.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.862 0.363 . . . . 0.0 110.896 -175.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 290' ' ' PHE . . . . . 0.64 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 3.9 m-85 -98.79 160.04 14.54 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.343 -178.517 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 291' ' ' ARG . . . . . 0.424 ' HD2' ' O ' ' A' ' 290' ' ' PHE . 45.2 mmm-85 -131.29 136.97 48.61 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.122 0.487 . . . . 0.0 110.155 175.66 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 46.3 t -83.67 139.86 17.04 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.223 -177.68 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 293' ' ' LEU . . . . . 0.522 HD12 ' HB3' ' A' ' 303' ' ' SER . 86.6 mt -111.71 -26.4 9.01 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.69 178.914 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 294' ' ' ALA . . . . . 0.485 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -156.35 139.76 15.79 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 120.718 -0.393 . . . . 0.0 111.624 179.496 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 64.8 t -137.52 109.58 6.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 115.825 -0.625 . . . . 0.0 109.521 173.778 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 47.6 t -151.4 116.37 5.23 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.51 -177.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 63.2 44.11 97.58 Favored Glycine 0 C--N 1.331 0.282 0 C-N-CA 120.847 -0.692 . . . . 0.0 111.942 -179.202 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 81.0 p 54.76 16.22 1.34 Allowed 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 123.88 0.872 . . . . 0.0 112.332 -175.401 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 35.8 m -101.07 116.06 31.94 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 174.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . 0.569 HG11 HG22 ' A' ' 302' ' ' ILE . 71.8 t -114.64 131.59 66.31 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-O 121.09 0.471 . . . . 0.0 111.867 -172.167 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 301' ' ' THR . . . . . 0.412 ' HB ' ' HB1' ' A' ' 294' ' ' ALA . 51.1 m -93.01 115.99 28.64 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.255 -0.884 . . . . 0.0 108.65 174.056 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 302' ' ' ILE . . . . . 0.569 HG22 HG11 ' A' ' 300' ' ' VAL . 30.4 pt -110.66 139.68 33.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-O 121.722 0.772 . . . . 0.0 112.771 -170.693 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 303' ' ' SER . . . . . 0.595 ' HA ' ' O ' ' A' ' 304' ' ' PRO . 82.5 p -138.41 169.02 13.74 Favored Pre-proline 0 C--N 1.323 -0.547 0 CA-C-N 114.404 -1.271 . . . . 0.0 107.759 177.082 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 304' ' ' PRO . . . . . 0.595 ' O ' ' HA ' ' A' ' 303' ' ' SER . 9.7 Cg_exo -73.01 -133.29 0.09 OUTLIER 'Cis proline' 0 C--N 1.348 0.516 0 CA-C-N 120.776 1.313 . . . . 0.0 112.527 0.251 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 305' ' ' LYS . . . . . 0.894 ' HD3' ' HG ' ' A' ' 307' ' ' LEU . 0.0 OUTLIER -102.07 145.1 29.8 Favored 'General case' 0 N--CA 1.448 -0.574 0 CA-C-O 121.453 0.644 . . . . 0.0 111.333 177.871 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 306' ' ' ILE . . . . . 0.787 HG21 ' HD3' ' A' ' 326' ' ' PRO . 2.7 mp -113.04 85.46 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.049 -177.076 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 307' ' ' LEU . . . . . 0.894 ' HG ' ' HD3' ' A' ' 305' ' ' LYS . 55.7 mt -96.77 116.5 66.12 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.704 -174.66 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 308' ' ' PRO . . . . . 0.67 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 68.7 Cg_endo -79.75 140.52 14.73 Favored 'Trans proline' 0 C--O 1.235 0.36 0 C-N-CA 122.95 2.433 . . . . 0.0 113.899 -174.191 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . 0.561 HG21 ' CB ' ' A' ' 320' ' ' ALA . 15.9 t -93.89 -27.92 4.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.821 174.702 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 62.4 mm-40 -82.21 33.49 0.4 Allowed 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.847 -177.73 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.458 ' OD1' ' HB2' ' A' ' 308' ' ' PRO . 5.5 m120 -126.23 168.95 13.38 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.967 177.955 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 27.3 m -80.64 -18.02 49.42 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.898 -176.427 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 50.7 m-20 -57.19 114.67 2.26 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-O 120.989 0.423 . . . . 0.0 111.387 -179.443 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 38.8 t -74.25 -31.44 29.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.579 -179.694 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -70.06 -30.03 67.18 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.428 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 34.0 t -75.76 -28.9 58.63 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.799 -178.767 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 317' ' ' ARG . . . . . 0.774 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 21.7 mmt85 -51.34 -57.38 14.38 Favored Pre-proline 0 CA--C 1.542 0.672 0 N-CA-C 113.882 1.067 . . . . 0.0 113.882 -176.539 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 318' ' ' PRO . . . . . 0.774 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 22.8 Cg_exo -70.79 -21.49 28.63 Favored 'Trans proline' 0 C--N 1.355 0.893 0 C-N-CA 121.958 1.772 . . . . 0.0 113.522 -173.412 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 319' ' ' TYR . . . . . 0.556 ' O ' HD13 ' A' ' 307' ' ' LEU . 0.9 OUTLIER -108.69 2.78 22.11 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.368 0.604 . . . . 0.0 109.598 -175.855 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . 0.643 ' HA ' ' HB2' ' A' ' 307' ' ' LEU . . . -62.36 138.62 58.47 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.318 -178.757 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 321' ' ' ASN . . . . . 0.401 ' O ' ' HA ' ' A' ' 275' ' ' SER . 16.0 p-10 -128.67 -3.46 5.33 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.007 -179.864 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 322' ' ' VAL . . . . . 0.529 ' O ' HG23 ' A' ' 309' ' ' VAL . 35.7 m -140.66 166.7 18.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.595 -0.275 . . . . 0.0 110.66 -179.836 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 53.8 m-20 -60.81 -49.23 78.3 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.072 0.463 . . . . 0.0 110.872 179.304 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 324' ' ' ALA . . . . . 0.67 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -157.53 170.65 21.93 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.575 -176.028 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 25.0 pttm -83.1 151.36 63.21 Favored Pre-proline 0 C--N 1.328 -0.359 0 N-CA-C 108.104 -1.072 . . . . 0.0 108.104 170.382 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 326' ' ' PRO . . . . . 0.787 ' HD3' HG21 ' A' ' 306' ' ' ILE . 20.6 Cg_exo -68.02 126.25 14.23 Favored 'Trans proline' 0 N--CA 1.461 -0.405 0 C-N-CA 121.731 1.621 . . . . 0.0 112.886 -174.702 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -83.36 117.3 22.92 Favored 'General case' 0 CA--C 1.511 -0.533 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 167.187 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 328' ' ' GLU . . . . . 0.435 ' OE1' ' HA ' ' A' ' 231' ' ' SER . 31.2 tp10 63.95 168.08 0.16 Allowed 'General case' 0 CA--C 1.539 0.554 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 -165.166 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 329' ' ' SER . . . . . 0.575 ' HB2' ' O ' ' A' ' 230' ' ' VAL . 49.3 m -81.09 -22.19 39.38 Favored 'General case' 0 C--N 1.316 -0.882 0 O-C-N 120.775 -1.203 . . . . 0.0 110.678 -176.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 330' ' ' ALA . . . . . 0.409 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 73.5 -160.09 0.09 Allowed 'General case' 0 N--CA 1.473 0.692 0 O-C-N 123.855 0.722 . . . . 0.0 112.872 170.944 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -95.51 129.33 42.72 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.254 -0.885 . . . . 0.0 110.041 179.379 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 332' ' ' ILE . . . . . 0.969 HG13 HG12 ' A' ' 270' ' ' ILE . 1.8 mp -111.16 145.49 17.36 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.442 -175.606 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.41 ' N ' HG21 ' A' ' 332' ' ' ILE . 47.5 m -118.69 97.65 5.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.021 -178.557 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 42.7 mm -80.02 136.46 23.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 N-CA-C 112.959 0.726 . . . . 0.0 112.959 -172.675 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 335' ' ' LEU . . . . . 0.624 HD23 ' N ' ' A' ' 335' ' ' LEU . 1.6 pt? -151.21 -173.82 4.62 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 114.69 -1.141 . . . . 0.0 108.737 172.646 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 76.4 m-20 -111.63 -14.05 13.7 Favored 'General case' 0 C--N 1.325 -0.499 0 O-C-N 122.079 -0.388 . . . . 0.0 111.704 -177.135 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 337' ' ' LYS . . . . . 0.625 ' HZ2' ' HB2' ' A' ' 337' ' ' LYS . 9.8 mtmp? . . . . . 0 C--O 1.244 0.792 0 CA-C-O 118.557 -0.735 . . . . 0.0 110.931 -177.163 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.809 0 N-CA-C 111.859 -0.496 . . . . 0.0 111.859 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 69.7 m -79.61 77.06 6.23 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.105 0.479 . . . . 0.0 111.143 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 41.0 p -124.89 162.27 24.77 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.22 177.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -92.63 52.36 1.87 Allowed 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.53 -0.304 . . . . 0.0 110.396 -179.773 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 40.8 p -76.11 -74.18 0.24 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.564 -0.289 . . . . 0.0 111.118 -177.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 228' ' ' LEU . . . . . 0.402 ' HB3' ' CB ' ' A' ' 259' ' ' ALA . 83.8 mt -104.46 126.15 51.29 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 174.778 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 68.4 p -129.35 177.94 6.81 Favored 'General case' 0 C--N 1.32 -0.692 0 C-N-CA 120.06 -0.656 . . . . 0.0 111.147 -177.059 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . 0.734 HG22 HG13 ' A' ' 332' ' ' ILE . 64.6 t -140.48 142.57 30.72 Favored 'Isoleucine or valine' 0 C--O 1.238 0.474 0 CA-C-O 120.774 0.321 . . . . 0.0 110.309 -179.427 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 43.3 m -109.33 138.17 46.1 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.481 178.627 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 162.39 -170.15 37.9 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.896 -0.669 . . . . 0.0 111.747 -179.728 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 83.6 mt-30 -99.88 116.26 64.86 Favored Pre-proline 0 C--N 1.325 -0.486 0 CA-C-N 116.716 0.258 . . . . 0.0 110.927 179.45 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -69.17 127.6 15.31 Favored 'Trans proline' 0 C--O 1.236 0.412 0 C-N-CA 122.113 1.876 . . . . 0.0 110.971 175.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 235' ' ' GLU . . . . . 0.675 ' HG3' ' HB3' ' A' ' 251' ' ' ARG . 0.3 OUTLIER -125.78 -176.92 3.75 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-O 121.661 0.744 . . . . 0.0 111.63 -174.395 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 22.3 p-80 -156.13 133.13 10.54 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 178.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 237' ' ' LYS . . . . . 0.782 ' HD3' ' HA ' ' A' ' 305' ' ' LYS . 8.9 mptt -104.96 125.51 51.03 Favored 'General case' 0 C--N 1.32 -0.682 0 C-N-CA 119.439 -0.904 . . . . 0.0 111.69 -172.194 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 238' ' ' VAL . . . . . 0.711 ' HB ' HG13 ' A' ' 248' ' ' VAL . 48.1 t -104.08 155.2 5.84 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-N 114.504 -1.225 . . . . 0.0 108.049 171.404 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 239' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -66.71 174.77 2.69 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 117.641 0.2 . . . . 0.0 111.449 -179.53 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 240' ' ' ALA . . . . . . . . . . . . . . . -14.58 -67.03 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.959 0 O-C-N 124.814 1.321 . . . . 0.0 114.371 -176.078 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 241' ' ' LYS . . . . . 0.482 ' H ' ' HD3' ' A' ' 241' ' ' LYS . 0.0 OUTLIER -138.96 165.2 27.72 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 178.093 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 57.8 p30 -91.29 -158.32 0.55 Allowed 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.837 179.479 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 28.5 p -75.52 -7.56 54.49 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 112.324 0.49 . . . . 0.0 112.324 -178.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -111.63 -13.12 13.82 Favored 'General case' 0 C--N 1.327 -0.397 0 O-C-N 122.267 -0.271 . . . . 0.0 110.966 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 83.82 25.64 44.9 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.737 -0.744 . . . . 0.0 111.589 -175.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 246' ' ' MET . . . . . 0.406 ' HB3' ' HE1' ' A' ' 246' ' ' MET . 82.2 mtp -88.19 141.25 30.88 Favored Pre-proline 0 C--N 1.327 -0.4 0 CA-C-N 115.831 -0.185 . . . . 0.0 110.764 -178.887 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 247' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_exo -55.58 121.01 9.18 Favored 'Trans proline' 0 C--N 1.346 0.408 0 C-N-CA 122.836 2.357 . . . . 0.0 112.092 178.694 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . 0.711 HG13 ' HB ' ' A' ' 238' ' ' VAL . 61.1 t -84.5 139.79 17.03 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.086 -178.214 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -92.7 100.25 12.79 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 177.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 250' ' ' ASN . . . . . . . . . . . . . 5.7 m120 -86.66 -21.83 26.49 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.578 -179.518 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . 0.675 ' HB3' ' HG3' ' A' ' 235' ' ' GLU . 2.3 tpm_? 57.62 -108.61 0.43 Allowed 'General case' 0 CA--C 1.535 0.366 0 CA-C-N 115.49 -0.777 . . . . 0.0 111.4 177.395 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 252' ' ' GLN . . . . . 0.446 ' CG ' ' HE2' ' A' ' 237' ' ' LYS . 21.6 mt-30 61.68 170.95 0.12 Allowed 'General case' 0 N--CA 1.471 0.624 0 CA-C-O 121.382 0.61 . . . . 0.0 111.645 -178.272 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . 0.54 ' O ' ' HA ' ' A' ' 301' ' ' THR . . . 126.33 -152.22 18.22 Favored Glycine 0 N--CA 1.446 -0.661 0 C-N-CA 119.141 -1.504 . . . . 0.0 113.401 172.812 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 254' ' ' THR . . . . . 0.448 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 58.4 p -94.21 135.49 35.53 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.13 0.49 . . . . 0.0 111.621 -174.908 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . 0.532 HD12 ' HB ' ' A' ' 300' ' ' VAL . 2.1 pp -132.39 169.07 22.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 115.446 -0.797 . . . . 0.0 111.223 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 83.8 m -105.15 126.25 51.88 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.015 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.646 HG21 HD12 ' A' ' 262' ' ' LEU . 33.5 m -100.81 145.42 11.21 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.643 0 N-CA-C 112.529 0.566 . . . . 0.0 112.529 -174.839 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 52.8 m -91.36 7.26 41.89 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 114.694 -1.139 . . . . 0.0 109.132 167.682 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 259' ' ' ALA . . . . . 0.402 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -95.78 170.09 9.56 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-N 115.492 -0.777 . . . . 0.0 110.13 -177.683 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 51.3 p -137.29 153.29 50.34 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.798 0.333 . . . . 0.0 111.45 -178.708 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 72.37 48.79 22.76 Favored Glycine 0 N--CA 1.452 -0.248 0 CA-C-N 115.929 -0.578 . . . . 0.0 112.847 178.342 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 262' ' ' LEU . . . . . 0.646 HD12 HG21 ' A' ' 257' ' ' VAL . 61.7 mt -102.31 144.28 31.01 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.971 0.415 . . . . 0.0 111.08 -178.873 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 72.1 mt-30 -137.78 172.45 12.94 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.69 -0.687 . . . . 0.0 109.547 176.059 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 264' ' ' VAL . . . . . 0.618 HG22 ' HA ' ' A' ' 294' ' ' ALA . 44.5 t -79.04 136.28 24.07 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 174.909 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 95.67 -0.76 63.26 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.5 -0.857 . . . . 0.0 112.586 179.33 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 266' ' ' ASP . . . . . 0.42 ' HB2' HG23 ' A' ' 292' ' ' VAL . 65.3 m-20 -65.17 152.26 44.05 Favored 'General case' 0 CA--C 1.517 -0.315 0 CA-C-O 121.11 0.481 . . . . 0.0 110.751 178.343 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 267' ' ' ALA . . . . . 0.698 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -124.14 122.76 38.71 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.353 -0.839 . . . . 0.0 109.415 179.544 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 268' ' ' PHE . . . . . . . . . . . . . 5.4 p90 -144.56 169.07 18.68 Favored 'General case' 0 C--N 1.319 -0.741 0 C-N-CA 120.016 -0.673 . . . . 0.0 111.784 -172.816 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 269' ' ' THR . . . . . 0.477 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 42.9 p -119.97 148.81 43.08 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.559 -0.746 . . . . 0.0 109.966 176.615 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 270' ' ' ILE . . . . . 0.642 HG12 HD11 ' A' ' 332' ' ' ILE . 58.5 mt -114.09 138.85 42.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 116.559 -0.291 . . . . 0.0 110.668 -177.226 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -67.99 117.04 9.33 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.948 179.082 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 109.4 -22.49 24.49 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.782 -0.723 . . . . 0.0 111.95 -179.14 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . 0.427 ' O ' ' HA ' ' A' ' 287' ' ' PRO . 50.4 t -96.35 101.27 12.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 175.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 72.5 m-80 -124.44 131.79 53.5 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.494 -177.594 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 54.5 p -64.03 163.99 11.35 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.524 0.678 . . . . 0.0 112.508 -176.488 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 276' ' ' VAL . . . . . 0.47 HG21 ' O ' ' A' ' 321' ' ' ASN . 21.5 m -126.81 149.94 32.26 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.623 0 CA-C-N 114.901 -1.045 . . . . 0.0 109.276 176.029 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 58.7 m170 -103.53 120.87 41.71 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 120.756 0.312 . . . . 0.0 110.738 -175.191 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 3.1 mm100 -82.17 -29.2 31.67 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.764 -177.723 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 2.0 mp -72.12 -52.64 23.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.436 -179.017 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 58.0 p -89.38 -13.06 38.62 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.772 -178.356 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 31.7 mmmt 58.84 45.26 15.64 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.55 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 44.1 t0 -132.8 155.25 49.27 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 110.157 -0.312 . . . . 0.0 110.157 -179.571 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 59.9 p -107.77 113.38 26.59 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 175.072 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 80.6 p -110.93 6.77 21.38 Favored 'General case' 0 C--N 1.32 -0.699 0 C-N-CA 120.285 -0.566 . . . . 0.0 112.077 -170.318 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 66.77 31.6 78.82 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.594 -0.813 . . . . 0.0 113.363 174.414 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 10.6 mm100 -95.89 109.1 44.74 Favored Pre-proline 0 C--N 1.328 -0.338 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 177.817 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 287' ' ' PRO . . . . . 0.477 ' HB2' ' HB ' ' A' ' 269' ' ' THR . 51.5 Cg_exo -58.35 139.34 90.21 Favored 'Trans proline' 0 C--N 1.343 0.288 0 C-N-CA 122.598 2.199 . . . . 0.0 112.888 -176.107 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 40.8 tt0 -77.4 148.37 35.55 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.179 -179.637 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 59.7 t -94.25 137.4 23.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.085 178.063 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 290' ' ' PHE . . . . . 0.698 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 51.7 m-85 -118.34 167.83 11.18 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.758 -176.525 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 37.4 mmt180 -128.66 130.96 47.95 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.77 177.653 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . 0.42 HG23 ' HB2' ' A' ' 266' ' ' ASP . 57.7 t -79.65 139.97 17.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.497 -0.774 . . . . 0.0 111.359 -179.054 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 293' ' ' LEU . . . . . 0.656 HD13 ' HB2' ' A' ' 303' ' ' SER . 6.9 mp -102.25 -31.66 10.44 Favored 'General case' 0 C--N 1.334 -0.089 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.844 179.738 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 294' ' ' ALA . . . . . 0.618 ' HA ' HG22 ' A' ' 264' ' ' VAL . . . -158.55 144.31 16.75 Favored 'General case' 0 N--CA 1.465 0.284 0 C-N-CA 120.664 -0.415 . . . . 0.0 111.763 179.523 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 62.5 t -139.28 112.48 6.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.85 176.085 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 54.2 p -132.67 95.41 3.59 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.368 -0.378 . . . . 0.0 111.114 -178.413 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 65.43 57.78 10.75 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.02 -178.789 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 67.0 p 51.19 22.37 1.31 Allowed 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 123.501 0.72 . . . . 0.0 112.552 -176.174 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 299' ' ' THR . . . . . 0.423 ' HA ' ' O ' ' A' ' 255' ' ' ILE . 91.7 m -112.29 109.55 19.27 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 174.014 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . 0.628 HG12 HG21 ' A' ' 302' ' ' ILE . 47.3 t -107.0 134.1 49.69 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-N 115.704 -0.68 . . . . 0.0 112.02 -168.39 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 301' ' ' THR . . . . . 0.54 ' HA ' ' O ' ' A' ' 253' ' ' GLY . 91.5 m -85.22 114.92 22.68 Favored 'General case' 0 C--O 1.237 0.403 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 169.746 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 302' ' ' ILE . . . . . 0.628 HG21 HG12 ' A' ' 300' ' ' VAL . 30.6 pt -110.7 138.6 38.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 N-CA-C 113.655 0.983 . . . . 0.0 113.655 -167.805 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 303' ' ' SER . . . . . 0.656 ' HB2' HD13 ' A' ' 293' ' ' LEU . 68.7 m -153.87 169.39 10.01 Favored Pre-proline 0 C--N 1.323 -0.557 0 CA-C-N 112.859 -1.973 . . . . 0.0 105.89 175.047 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 304' ' ' PRO . . . . . 0.587 ' HA ' ' HB3' ' A' ' 303' ' ' SER . 22.7 Cg_endo -93.38 -119.83 0.0 OUTLIER 'Cis proline' 0 N--CA 1.455 -0.742 0 CA-C-N 121.02 1.4 . . . . 0.0 113.592 0.822 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 305' ' ' LYS . . . . . 0.782 ' HA ' ' HD3' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -98.41 144.29 27.94 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.081 -0.509 . . . . 0.0 112.357 -172.324 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 306' ' ' ILE . . . . . 0.578 HD12 ' N ' ' A' ' 306' ' ' ILE . 2.2 mp -104.4 127.35 58.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 170.699 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 307' ' ' LEU . . . . . 0.445 ' O ' HG22 ' A' ' 322' ' ' VAL . 59.0 mt -129.09 98.28 24.17 Favored Pre-proline 0 C--N 1.323 -0.548 0 C-N-CA 120.676 -0.41 . . . . 0.0 110.519 -172.779 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 308' ' ' PRO . . . . . 0.554 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 12.7 Cg_exo -74.17 131.34 15.21 Favored 'Trans proline' 0 C--N 1.343 0.252 0 C-N-CA 122.802 2.335 . . . . 0.0 113.495 -175.19 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . 0.795 HG22 ' HB2' ' A' ' 320' ' ' ALA . 61.9 t -87.05 -37.57 11.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.563 173.897 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 63.1 mm-40 -81.08 32.69 0.33 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.859 -0.609 . . . . 0.0 111.484 179.814 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.526 HD22 ' HB3' ' A' ' 317' ' ' ARG . 0.0 OUTLIER -85.38 157.05 20.62 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.945 0.403 . . . . 0.0 111.248 179.16 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 36.4 m -92.15 -18.28 23.73 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.839 178.244 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -76.42 121.49 23.13 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.612 -179.746 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 40.7 t -75.76 -20.19 15.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.129 -177.457 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -80.59 -21.96 41.14 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.739 0.304 . . . . 0.0 111.512 178.582 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 36.0 t -96.3 -23.3 16.73 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.559 -0.291 . . . . 0.0 111.456 -176.138 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 317' ' ' ARG . . . . . 0.526 ' HB3' HD22 ' A' ' 311' ' ' ASN . 2.1 ptp180 -62.23 -34.03 14.07 Favored Pre-proline 0 CA--C 1.548 0.901 0 N-CA-C 113.807 1.04 . . . . 0.0 113.807 -178.886 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 318' ' ' PRO . . . . . 0.42 ' HD3' ' CG ' ' A' ' 317' ' ' ARG . 26.1 Cg_exo -63.13 -18.14 63.57 Favored 'Trans proline' 0 C--N 1.367 1.521 0 CA-C-N 121.263 1.487 . . . . 0.0 112.113 178.266 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 319' ' ' TYR . . . . . 0.428 ' O ' HD12 ' A' ' 307' ' ' LEU . 48.5 m-85 -103.35 -3.2 25.87 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.028 -177.803 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . 0.795 ' HB2' HG22 ' A' ' 309' ' ' VAL . . . -54.06 144.77 18.49 Favored 'General case' 0 C--N 1.33 -0.246 0 N-CA-C 112.144 0.424 . . . . 0.0 112.144 -178.128 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 321' ' ' ASN . . . . . 0.47 ' O ' HG21 ' A' ' 276' ' ' VAL . 48.9 t30 -148.05 -18.61 0.35 Allowed 'General case' 0 CA--C 1.532 0.278 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.472 -178.281 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 322' ' ' VAL . . . . . 0.513 ' O ' HG21 ' A' ' 309' ' ' VAL . 35.1 m -137.43 160.96 34.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 N-CA-C 110.234 -0.284 . . . . 0.0 110.234 177.654 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 71.8 m-20 -41.9 -69.24 0.14 Allowed 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 112.588 0.588 . . . . 0.0 112.588 -177.364 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 324' ' ' ALA . . . . . 0.554 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -165.7 -176.08 3.74 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.962 0.411 . . . . 0.0 111.496 -175.595 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 325' ' ' LYS . . . . . 0.508 ' HG2' HG22 ' A' ' 306' ' ' ILE . 34.4 mtmm -88.02 138.97 30.71 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.592 174.362 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 326' ' ' PRO . . . . . 0.67 ' HB2' ' HB1' ' A' ' 330' ' ' ALA . 43.1 Cg_endo -86.01 167.34 9.57 Favored 'Trans proline' 0 N--CA 1.455 -0.759 0 C-N-CA 122.551 2.167 . . . . 0.0 112.145 178.61 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -70.47 122.98 20.69 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 177.83 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 52.8 mt-10 62.39 -121.04 0.66 Allowed 'General case' 0 N--CA 1.463 0.184 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 -172.328 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 329' ' ' SER . . . . . 0.611 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 33.9 m -111.94 -14.25 13.52 Favored 'General case' 0 C--N 1.322 -0.603 0 C-N-CA 120.535 -0.466 . . . . 0.0 110.118 172.813 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 330' ' ' ALA . . . . . 0.67 ' HB1' ' HB2' ' A' ' 326' ' ' PRO . . . 73.9 -169.19 0.11 Allowed 'General case' 0 N--CA 1.474 0.755 0 O-C-N 124.214 0.946 . . . . 0.0 113.37 172.467 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -80.08 141.54 35.72 Favored 'General case' 0 CA--C 1.517 -0.304 0 CA-C-N 115.101 -0.954 . . . . 0.0 110.611 -179.065 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 332' ' ' ILE . . . . . 0.734 HG13 HG22 ' A' ' 230' ' ' VAL . 16.1 mm -120.68 144.11 30.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.405 -175.503 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 82.3 m -114.04 97.13 6.18 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 175.007 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 334' ' ' ILE . . . . . 0.402 HD11 HG21 ' A' ' 334' ' ' ILE . 38.5 mm -81.65 125.34 39.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 115.999 -0.546 . . . . 0.0 112.339 -172.045 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 335' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -122.73 163.22 20.56 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.187 170.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 20.9 t-20 -94.04 -14.74 25.5 Favored 'General case' 0 C--N 1.319 -0.76 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 171.659 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 26.7 tptp . . . . . 0 C--O 1.244 0.799 0 CA-C-N 114.613 -1.176 . . . . 0.0 111.257 174.431 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.81 0 N-CA-C 111.738 -0.545 . . . . 0.0 111.738 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 35.7 t -86.83 155.04 20.44 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 177.406 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 47.6 p -82.69 160.8 22.32 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.121 0.486 . . . . 0.0 111.189 -178.62 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -98.42 62.99 1.48 Allowed 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 121.651 0.739 . . . . 0.0 109.809 174.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 26.5 m -78.92 -155.09 0.08 Allowed 'General case' 0 N--CA 1.442 -0.858 0 CA-C-N 115.122 -0.945 . . . . 0.0 110.959 -175.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 228' ' ' LEU . . . . . 0.522 HD23 ' HA ' ' A' ' 259' ' ' ALA . 55.2 mt -94.08 129.55 40.57 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.598 -178.6 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 229' ' ' THR . . . . . 0.513 ' O ' HG22 ' A' ' 230' ' ' VAL . 60.6 p -126.97 179.53 5.36 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 120.275 -0.57 . . . . 0.0 111.281 -176.18 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . 0.652 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 75.3 t -146.39 138.8 19.79 Favored 'Isoleucine or valine' 0 C--O 1.237 0.409 0 CA-C-O 120.735 0.302 . . . . 0.0 110.708 -179.359 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 49.4 m -137.99 165.37 26.73 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.746 178.686 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 116.12 -108.84 1.89 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 119.913 -1.137 . . . . 0.0 113.995 172.041 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 11.0 mm-40 -62.49 155.36 68.43 Favored Pre-proline 0 C--N 1.328 -0.354 0 N-CA-C 112.761 0.652 . . . . 0.0 112.761 -173.225 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -63.9 175.56 2.98 Favored 'Trans proline' 0 C--N 1.349 0.573 0 C-N-CA 123.611 2.874 . . . . 0.0 112.661 178.161 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 52.1 mm-40 -92.51 -176.79 4.4 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.695 -176.02 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 236' ' ' HIS . . . . . 0.472 ' HA ' ' HB3' ' A' ' 251' ' ' ARG . 37.9 m-70 -113.82 143.75 44.14 Favored 'General case' 0 C--N 1.321 -0.658 0 C-N-CA 119.842 -0.743 . . . . 0.0 112.199 -165.33 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 237' ' ' LYS . . . . . 0.612 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -126.2 176.21 7.23 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.338 -0.847 . . . . 0.0 109.892 -176.11 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 238' ' ' VAL . . . . . 0.561 HG22 HD11 ' A' ' 307' ' ' LEU . 28.6 t -50.45 155.29 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 O-C-N 123.67 0.606 . . . . 0.0 111.439 -176.939 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 239' ' ' GLU . . . . . . . . . . . . . 52.0 mt-10 -61.96 173.7 1.02 Allowed 'General case' 0 CA--C 1.53 0.185 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.73 -179.287 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 240' ' ' ALA . . . . . 0.592 ' O ' ' HA ' ' A' ' 247' ' ' PRO . . . -46.21 -59.59 2.81 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 115.527 -0.761 . . . . 0.0 112.029 -177.132 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 241' ' ' LYS . . . . . 0.529 ' HD2' ' C ' ' A' ' 240' ' ' ALA . 0.9 OUTLIER -115.76 130.34 56.81 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.957 0.408 . . . . 0.0 110.666 177.045 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 242' ' ' ASP . . . . . 0.457 ' HB2' ' CE2' ' A' ' 319' ' ' TYR . 2.8 p30 -86.59 -163.86 0.97 Allowed 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.514 -0.766 . . . . 0.0 111.155 -178.956 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 24.3 m -63.66 -29.64 70.85 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 112.077 0.399 . . . . 0.0 112.077 -175.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 75.8 m-20 -92.85 -2.51 55.82 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.813 0.339 . . . . 0.0 110.938 -178.719 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 82.59 26.29 47.13 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.599 179.676 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 246' ' ' MET . . . . . 0.418 ' HA ' ' HD3' ' A' ' 247' ' ' PRO . 82.0 mtp -101.2 149.04 35.95 Favored Pre-proline 0 C--N 1.325 -0.473 0 CA-C-O 120.566 0.222 . . . . 0.0 110.637 179.319 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 247' ' ' PRO . . . . . 0.592 ' HA ' ' O ' ' A' ' 240' ' ' ALA . 2.9 Cg_exo -79.06 128.89 8.58 Favored 'Trans proline' 0 C--O 1.234 0.314 0 C-N-CA 122.853 2.369 . . . . 0.0 113.08 -175.958 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . 0.525 HG13 ' HB ' ' A' ' 238' ' ' VAL . 21.7 t -122.32 159.54 25.38 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 175.603 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 249' ' ' ASP . . . . . 0.548 ' O ' ' HB2' ' A' ' 237' ' ' LYS . 64.2 t0 -72.14 89.57 1.16 Allowed 'General case' 0 C--O 1.233 0.234 0 CA-C-O 121.14 0.495 . . . . 0.0 109.87 179.362 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 250' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -77.49 90.89 3.88 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.418 -179.413 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . 0.472 ' HB3' ' HA ' ' A' ' 236' ' ' HIS . 29.1 tpt180 -78.65 -95.3 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.015 -175.523 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 2.6 mm100 60.1 177.9 0.09 Allowed 'General case' 0 N--CA 1.467 0.381 0 C-N-CA 123.133 0.573 . . . . 0.0 111.055 -177.851 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . 0.552 ' O ' ' HA ' ' A' ' 301' ' ' THR . . . 119.05 -153.11 17.03 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 119.25 -1.453 . . . . 0.0 113.752 176.435 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 254' ' ' THR . . . . . 0.545 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 77.8 p -94.78 148.97 21.74 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.219 0.533 . . . . 0.0 112.243 -172.644 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . 0.536 HD11 HG23 ' A' ' 302' ' ' ILE . 22.6 pt -130.65 161.26 40.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.395 -0.82 . . . . 0.0 110.416 177.71 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 93.6 m -94.76 106.19 18.16 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 174.533 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.503 HG21 HD13 ' A' ' 262' ' ' LEU . 34.3 m -93.21 141.46 14.68 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.914 0 C-N-CA 119.565 -0.854 . . . . 0.0 112.329 -174.693 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 53.8 m -93.0 8.91 37.96 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 114.016 -1.447 . . . . 0.0 109.239 169.684 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 259' ' ' ALA . . . . . 0.522 ' HA ' HD23 ' A' ' 228' ' ' LEU . . . -81.17 166.37 20.7 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.861 -177.641 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 42.6 m -124.93 108.26 11.7 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 111.988 0.366 . . . . 0.0 111.988 -174.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 92.71 50.14 2.57 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.617 -0.801 . . . . 0.0 113.429 173.316 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 262' ' ' LEU . . . . . 0.503 HD13 HG21 ' A' ' 257' ' ' VAL . 3.2 mp -86.94 143.59 27.32 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.891 0.346 . . . . 0.0 110.319 179.563 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 68.6 mt-30 -131.12 168.84 16.77 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.605 177.876 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 38.6 t -79.22 128.49 38.5 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 C-N-CA 120.8 -0.36 . . . . 0.0 110.338 178.184 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . 0.53 ' H ' ' HB ' ' A' ' 292' ' ' VAL . . . 102.41 8.67 43.2 Favored Glycine 0 N--CA 1.448 -0.532 0 C-N-CA 120.393 -0.908 . . . . 0.0 113.017 177.605 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -76.94 160.93 28.79 Favored 'General case' 0 CA--C 1.515 -0.373 0 CA-C-O 121.047 0.451 . . . . 0.0 110.579 176.424 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 267' ' ' ALA . . . . . 0.63 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -131.68 131.88 43.48 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 177.851 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 268' ' ' PHE . . . . . . . . . . . . . 3.6 p90 -152.33 169.31 22.83 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 119.468 -0.893 . . . . 0.0 111.76 -172.787 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 269' ' ' THR . . . . . 0.872 HG21 ' HB2' ' A' ' 287' ' ' PRO . 71.1 p -119.61 163.05 17.93 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.235 177.477 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 270' ' ' ILE . . . . . 0.585 HG12 HG12 ' A' ' 332' ' ' ILE . 56.7 mt -124.24 140.46 47.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 C-N-CA 120.815 -0.354 . . . . 0.0 111.432 -178.257 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -62.5 113.17 2.8 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.131 179.655 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 103.51 -21.68 38.31 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 121.083 -0.579 . . . . 0.0 112.031 -178.106 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 51.1 t -101.1 103.77 15.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-O 121.089 0.471 . . . . 0.0 110.77 178.87 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 71.9 m-80 -122.67 156.35 34.52 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.165 -0.471 . . . . 0.0 109.967 179.234 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 53.8 p -71.95 173.83 7.83 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.14 0.495 . . . . 0.0 111.819 -175.842 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 27.1 m -112.02 -178.45 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.674 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 277' ' ' HIS . . . . . 0.401 ' CB ' ' HA ' ' A' ' 281' ' ' LYS . 9.9 m-70 -54.51 93.26 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.023 -0.99 . . . . 0.0 110.965 -173.932 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -81.99 -28.2 32.75 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.981 0.42 . . . . 0.0 109.878 -175.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 279' ' ' ILE . . . . . 0.443 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.6 mp -82.18 -104.31 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.405 0 CA-C-N 116.083 -0.508 . . . . 0.0 109.817 -179.028 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 41.0 p -128.94 76.07 1.69 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.633 0.254 . . . . 0.0 110.676 179.173 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 281' ' ' LYS . . . . . 0.401 ' HA ' ' CB ' ' A' ' 277' ' ' HIS . 34.4 mmtp 54.64 31.5 15.32 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.437 -174.559 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 36.3 t70 -87.32 138.44 31.48 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.647 -176.712 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 54.4 p -95.5 120.33 35.57 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.126 -178.593 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 81.5 p -128.93 -45.43 1.28 Allowed 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.276 -171.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 79.62 28.01 52.76 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.701 -0.761 . . . . 0.0 111.967 -178.58 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 25.5 mt-30 -76.05 134.62 71.05 Favored Pre-proline 0 C--N 1.328 -0.366 0 N-CA-C 110.214 -0.291 . . . . 0.0 110.214 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 287' ' ' PRO . . . . . 0.872 ' HB2' HG21 ' A' ' 269' ' ' THR . 26.3 Cg_exo -64.67 134.19 39.85 Favored 'Trans proline' 0 CA--C 1.53 0.308 0 C-N-CA 122.546 2.164 . . . . 0.0 112.098 -177.9 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 69.7 tp60 -76.65 129.14 35.97 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.578 -178.503 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 25.7 t -97.01 137.61 24.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.831 -178.357 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 290' ' ' PHE . . . . . 0.652 ' HD1' ' HD2' ' A' ' 304' ' ' PRO . 55.0 m-85 -115.58 169.43 9.19 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.046 -178.836 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 9.8 tpt180 -131.06 142.56 50.3 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.167 0.508 . . . . 0.0 110.047 -179.154 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . 0.53 ' HB ' ' H ' ' A' ' 265' ' ' GLY . 55.8 t -92.49 130.57 41.4 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.877 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.683 179.693 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 293' ' ' LEU . . . . . 0.55 HD23 ' N ' ' A' ' 293' ' ' LEU . 2.9 mm? -105.71 -24.34 12.54 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.448 -0.342 . . . . 0.0 111.402 -178.355 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 294' ' ' ALA . . . . . . . . . . . . . . . -164.24 145.39 8.43 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.465 0.174 . . . . 0.0 110.982 179.688 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 45.5 t -135.07 138.28 49.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 175.575 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 36.9 t -139.44 87.31 2.18 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 177.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 73.41 -128.22 11.31 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.118 -1.039 . . . . 0.0 110.544 -169.483 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 31.1 p -102.35 29.34 5.25 Favored 'General case' 0 C--N 1.315 -0.898 0 O-C-N 122.155 -0.615 . . . . 0.0 110.506 172.63 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 63.5 m -112.07 105.42 13.79 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 174.033 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . 0.545 ' O ' ' HA ' ' A' ' 254' ' ' THR . 44.3 t -114.24 130.46 68.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 N-CA-C 112.259 0.466 . . . . 0.0 112.259 -168.797 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 301' ' ' THR . . . . . 0.552 ' HA ' ' O ' ' A' ' 253' ' ' GLY . 51.4 m -84.46 113.63 21.34 Favored 'General case' 0 C--O 1.237 0.402 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.219 173.342 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 302' ' ' ILE . . . . . 0.536 HG23 HD11 ' A' ' 255' ' ' ILE . 38.9 pt -116.39 157.13 17.4 Favored 'Isoleucine or valine' 0 C--O 1.24 0.599 0 CA-C-O 121.85 0.833 . . . . 0.0 112.897 -174.602 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 303' ' ' SER . . . . . 0.477 ' HB3' ' HA ' ' A' ' 304' ' ' PRO . 48.8 m -159.64 163.21 23.58 Favored Pre-proline 0 C--N 1.326 -0.435 0 CA-C-N 113.381 -1.736 . . . . 0.0 106.522 175.012 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 304' ' ' PRO . . . . . 0.652 ' HD2' ' HD1' ' A' ' 290' ' ' PHE . 5.1 Cg_exo -78.63 -134.23 0.14 OUTLIER 'Cis proline' 0 CA--C 1.534 0.518 0 CA-C-N 120.504 1.216 . . . . 0.0 113.047 0.85 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 305' ' ' LYS . . . . . 0.473 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -113.16 156.42 23.25 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.333 0.587 . . . . 0.0 112.375 -176.841 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 306' ' ' ILE . . . . . 0.73 HG23 HG22 ' A' ' 322' ' ' VAL . 2.6 mp -104.34 98.53 6.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.25 -0.886 . . . . 0.0 109.491 179.168 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 307' ' ' LEU . . . . . 0.561 HD11 HG22 ' A' ' 238' ' ' VAL . 76.3 mt -107.52 100.19 32.83 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.517 -0.31 . . . . 0.0 111.188 -175.007 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 308' ' ' PRO . . . . . 0.738 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 32.4 Cg_exo -66.94 138.22 47.42 Favored 'Trans proline' 0 N--CA 1.474 0.346 0 C-N-CA 123.622 2.881 . . . . 0.0 114.588 -173.757 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . 0.556 HG21 ' O ' ' A' ' 322' ' ' VAL . 50.8 t -76.74 -29.9 18.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.051 -0.977 . . . . 0.0 108.771 167.772 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -79.2 30.03 0.22 Allowed 'General case' 0 C--O 1.234 0.289 0 CA-C-N 115.292 -0.867 . . . . 0.0 112.045 179.437 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.409 ' H ' ' C ' ' A' ' 309' ' ' VAL . 74.3 m-80 71.05 154.69 0.14 Allowed 'General case' 0 N--CA 1.469 0.481 0 N-CA-C 113.647 0.98 . . . . 0.0 113.647 173.692 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 312' ' ' THR . . . . . 0.537 ' OG1' ' HG2' ' A' ' 308' ' ' PRO . 44.4 m -168.18 -44.09 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 113.675 -1.602 . . . . 0.0 107.824 173.169 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 39.2 t70 -146.52 167.86 22.64 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 114.246 -1.343 . . . . 0.0 108.59 176.339 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 47.2 t -60.34 -38.26 77.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-O 120.787 0.327 . . . . 0.0 111.104 178.381 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -77.38 -17.83 57.86 Favored 'General case' 0 N--CA 1.463 0.212 0 N-CA-C 111.967 0.358 . . . . 0.0 111.967 -179.844 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 34.7 t -71.51 -25.02 62.08 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.579 -0.282 . . . . 0.0 111.447 -176.765 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 317' ' ' ARG . . . . . 0.755 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 54.2 mtp85 -69.71 -57.96 6.09 Favored Pre-proline 0 CA--C 1.536 0.426 0 N-CA-C 112.257 0.466 . . . . 0.0 112.257 -178.691 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 318' ' ' PRO . . . . . 0.755 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 36.8 Cg_exo -63.69 -35.23 59.27 Favored 'Trans proline' 0 C--N 1.357 0.975 0 C-N-CA 122.051 1.834 . . . . 0.0 112.684 -176.779 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 319' ' ' TYR . . . . . 0.513 ' O ' HD12 ' A' ' 307' ' ' LEU . 6.4 m-85 -99.43 32.11 2.9 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.022 -179.23 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -55.55 127.68 30.92 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.893 178.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 47.9 t30 -120.99 -28.25 4.82 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.185 -176.654 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 322' ' ' VAL . . . . . 0.73 HG22 HG23 ' A' ' 306' ' ' ILE . 27.2 m -135.42 168.51 22.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.582 -0.281 . . . . 0.0 110.624 179.223 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 65.6 m-20 -52.83 -59.98 3.83 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 121.015 0.436 . . . . 0.0 110.769 176.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 324' ' ' ALA . . . . . 0.738 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -171.79 171.94 5.04 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.427 179.668 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 325' ' ' LYS . . . . . 0.543 ' HB3' HG21 ' A' ' 306' ' ' ILE . 21.7 pttp -112.46 117.95 46.27 Favored Pre-proline 0 C--N 1.326 -0.444 0 CA-C-O 121.251 0.548 . . . . 0.0 110.145 172.807 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -72.21 169.33 21.78 Favored 'Trans proline' 0 C--N 1.34 0.103 0 C-N-CA 123.284 2.656 . . . . 0.0 111.884 -177.408 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -63.42 122.27 15.83 Favored 'General case' 0 C--O 1.236 0.372 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 177.607 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 56.0 mt-10 67.79 165.33 0.23 Allowed 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.327 -171.519 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 329' ' ' SER . . . . . 0.652 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 49.0 m -66.65 -14.78 62.89 Favored 'General case' 0 C--N 1.326 -0.423 0 C-N-CA 120.999 -0.28 . . . . 0.0 111.746 -175.673 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 68.17 -162.36 0.2 Allowed 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 113.261 0.837 . . . . 0.0 113.261 171.097 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 331' ' ' ALA . . . . . 0.442 ' HA ' ' HA ' ' A' ' 229' ' ' THR . . . -82.98 150.49 26.35 Favored 'General case' 0 CA--C 1.519 -0.249 0 CA-C-N 115.333 -0.849 . . . . 0.0 111.122 -177.001 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 332' ' ' ILE . . . . . 0.585 HG12 HG12 ' A' ' 270' ' ' ILE . 42.6 mt -122.91 145.23 30.09 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.054 -178.559 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.442 ' HB ' ' OG1' ' A' ' 269' ' ' THR . 31.9 m -111.53 106.77 15.73 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 175.238 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 34.9 mm -83.78 121.67 36.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 112.889 0.7 . . . . 0.0 112.889 -170.203 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 335' ' ' LEU . . . . . 0.489 HD22 ' N ' ' A' ' 335' ' ' LEU . 3.0 mm? -111.62 -168.57 1.33 Allowed 'General case' 0 C--O 1.236 0.394 0 CA-C-N 115.094 -0.957 . . . . 0.0 109.672 171.491 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 74.4 m-80 -116.78 -15.1 10.74 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.806 -0.633 . . . . 0.0 110.989 176.557 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 23.2 pttm . . . . . 0 C--O 1.244 0.779 0 CA-C-O 118.546 -0.74 . . . . 0.0 111.288 -177.619 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.868 0 N-CA-C 112.161 -0.376 . . . . 0.0 112.161 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 224' ' ' SER . . . . . 0.416 ' HA ' ' OG1' ' A' ' 333' ' ' THR . 75.2 p -151.68 -156.93 0.76 Allowed 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 29.1 p -84.44 -85.43 0.13 Allowed 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.749 0.309 . . . . 0.0 110.257 174.81 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 54.3 mt-10 -113.67 62.39 0.65 Allowed 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.761 176.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 41.1 m 55.48 47.83 20.2 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-N 115.782 -0.644 . . . . 0.0 111.525 178.779 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 228' ' ' LEU . . . . . 0.511 ' HB3' ' HB3' ' A' ' 259' ' ' ALA . 69.7 mt -89.3 125.12 34.98 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 109.711 -0.478 . . . . 0.0 109.711 177.658 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 229' ' ' THR . . . . . 0.597 ' O ' HG23 ' A' ' 230' ' ' VAL . 58.4 p -124.27 175.35 7.12 Favored 'General case' 0 C--N 1.323 -0.573 0 C-N-CA 119.891 -0.724 . . . . 0.0 110.32 179.12 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . 0.837 HG22 HD11 ' A' ' 332' ' ' ILE . 89.0 t -148.63 141.82 18.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-O 120.76 0.314 . . . . 0.0 110.654 -177.614 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 49.0 m -92.38 129.13 38.41 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.905 -0.589 . . . . 0.0 109.619 174.142 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . -86.5 118.52 4.91 Favored Glycine 0 N--CA 1.444 -0.829 0 C-N-CA 120.264 -0.97 . . . . 0.0 113.322 -175.622 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 233' ' ' GLN . . . . . 0.941 ' HB3' ' HD2' ' A' ' 234' ' ' PRO . 75.7 mt-30 -80.2 178.97 2.05 Favored Pre-proline 0 C--N 1.328 -0.358 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 169.641 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 234' ' ' PRO . . . . . 0.941 ' HD2' ' HB3' ' A' ' 233' ' ' GLN . 72.9 Cg_exo -32.22 127.53 0.1 OUTLIER 'Trans proline' 0 C--N 1.366 1.463 0 C-N-CA 123.633 2.888 . . . . 0.0 113.861 -176.782 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 235' ' ' GLU . . . . . 0.7 ' OE1' ' HE3' ' A' ' 325' ' ' LYS . 46.1 mt-10 -95.58 -178.78 4.52 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.589 -175.727 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 236' ' ' HIS . . . . . 0.6 ' C ' ' HD3' ' A' ' 237' ' ' LYS . 91.7 m-70 -135.68 143.55 45.5 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 122.559 1.171 . . . . 0.0 113.549 -166.309 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 237' ' ' LYS . . . . . 0.6 ' HD3' ' C ' ' A' ' 236' ' ' HIS . 0.0 OUTLIER -156.76 127.55 6.73 Favored 'General case' 0 C--N 1.314 -0.942 0 CA-C-N 112.531 -2.122 . . . . 0.0 107.729 -179.71 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 238' ' ' VAL . . . . . . . . . . . . . 46.8 t -79.09 111.76 16.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 C-N-CA 120.125 -0.63 . . . . 0.0 110.625 -174.27 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 239' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -119.15 171.5 8.24 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.484 -179.062 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 240' ' ' ALA . . . . . . . . . . . . . . . -80.82 -59.41 2.68 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.861 0.362 . . . . 0.0 110.751 -179.435 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 241' ' ' LYS . . . . . 0.513 ' H ' ' HD3' ' A' ' 241' ' ' LYS . 0.0 OUTLIER -138.32 159.26 42.5 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.837 178.149 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 242' ' ' ASP . . . . . 0.403 ' OD1' ' HG2' ' A' ' 246' ' ' MET . 11.7 p-10 -97.55 -159.34 0.73 Allowed 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 178.156 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 52.9 m -67.62 -27.04 66.55 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.616 -0.265 . . . . 0.0 111.033 177.602 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 23.3 t-20 -83.98 -15.97 45.78 Favored 'General case' 0 CA--C 1.531 0.234 0 CA-C-O 120.999 0.428 . . . . 0.0 110.093 178.893 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 85.58 26.3 36.08 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.692 -0.766 . . . . 0.0 113.376 173.664 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 246' ' ' MET . . . . . 0.43 ' O ' ' HA ' ' A' ' 241' ' ' LYS . 26.8 ptt? -106.72 157.36 35.36 Favored Pre-proline 0 C--N 1.324 -0.505 0 CA-C-N 117.011 0.405 . . . . 0.0 110.078 177.445 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 247' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_exo -63.44 120.83 8.4 Favored 'Trans proline' 0 C--N 1.347 0.458 0 C-N-CA 122.272 1.981 . . . . 0.0 111.033 177.641 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 45.2 t -99.33 111.09 28.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 120.848 0.356 . . . . 0.0 111.849 -173.492 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -100.37 124.22 45.58 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 170.856 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 250' ' ' ASN . . . . . 0.642 ' ND2' ' HG3' ' A' ' 305' ' ' LYS . 14.1 p-10 -76.15 -13.16 60.2 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.04 -0.527 . . . . 0.0 112.022 -174.222 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . 0.596 ' HG2' ' H ' ' A' ' 252' ' ' GLN . 63.1 ttt-85 58.17 -127.76 1.52 Allowed 'General case' 0 CA--C 1.539 0.553 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 176.621 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 252' ' ' GLN . . . . . 0.596 ' H ' ' HG2' ' A' ' 251' ' ' ARG . 2.4 mm100 -115.03 176.73 4.93 Favored 'General case' 0 C--N 1.33 -0.258 0 O-C-N 121.981 -0.449 . . . . 0.0 110.068 178.325 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . 0.5 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -105.81 122.25 7.06 Favored Glycine 0 N--CA 1.443 -0.883 0 C-N-CA 120.282 -0.961 . . . . 0.0 112.088 177.437 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 254' ' ' THR . . . . . 0.498 ' O ' ' HB2' ' A' ' 233' ' ' GLN . 48.3 p -106.33 116.79 32.54 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 109.16 -0.682 . . . . 0.0 109.16 176.439 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . 0.53 HD12 HG12 ' A' ' 230' ' ' VAL . 2.1 pp -125.49 165.63 22.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 N-CA-C 112.868 0.692 . . . . 0.0 112.868 -173.074 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 256' ' ' THR . . . . . 0.466 ' O ' HG13 ' A' ' 230' ' ' VAL . 25.7 m -105.98 117.51 34.23 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 178.649 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.723 HG13 HG21 ' A' ' 230' ' ' VAL . 33.7 m -90.22 143.0 12.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 C-N-CA 119.71 -0.796 . . . . 0.0 112.757 -171.932 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 37.0 m -92.35 9.83 32.41 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 114.076 -1.42 . . . . 0.0 108.791 168.519 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 259' ' ' ALA . . . . . 0.511 ' HB3' ' HB3' ' A' ' 228' ' ' LEU . . . -101.1 168.3 9.68 Favored 'General case' 0 N--CA 1.454 -0.268 0 CA-C-N 115.049 -0.978 . . . . 0.0 109.371 -176.842 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 49.5 m -132.86 163.18 29.69 Favored 'General case' 0 C--N 1.324 -0.529 0 C-N-CA 120.806 -0.358 . . . . 0.0 111.502 -178.487 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 64.29 50.11 61.89 Favored Glycine 0 N--CA 1.452 -0.247 0 CA-C-N 115.729 -0.669 . . . . 0.0 113.128 177.047 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 262' ' ' LEU . . . . . . . . . . . . . 53.4 mt -101.76 159.68 15.12 Favored 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 120.652 -0.419 . . . . 0.0 110.543 179.73 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 73.4 mt-30 -143.35 165.14 28.33 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.988 -0.551 . . . . 0.0 109.812 179.744 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 41.2 t -79.86 134.47 27.49 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 N-CA-C 109.411 -0.588 . . . . 0.0 109.411 173.621 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . 0.458 ' H ' ' HB ' ' A' ' 292' ' ' VAL . . . 95.47 15.81 42.36 Favored Glycine 0 N--CA 1.446 -0.656 0 C-N-CA 120.284 -0.96 . . . . 0.0 112.729 178.918 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 40.7 m-20 -87.82 165.78 15.06 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.956 0.407 . . . . 0.0 110.689 174.784 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 267' ' ' ALA . . . . . 0.727 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -135.8 123.28 22.08 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.541 -0.754 . . . . 0.0 109.503 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 268' ' ' PHE . . . . . 0.463 ' HA ' HD23 ' A' ' 335' ' ' LEU . 5.9 p90 -141.16 175.03 9.97 Favored 'General case' 0 C--N 1.32 -0.704 0 C-N-CA 120.123 -0.631 . . . . 0.0 111.497 -172.554 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 269' ' ' THR . . . . . 0.417 ' OG1' ' HB ' ' A' ' 333' ' ' THR . 64.3 p -118.32 154.22 32.7 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.748 176.542 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 270' ' ' ILE . . . . . 0.912 HG12 HG13 ' A' ' 332' ' ' ILE . 60.1 mt -124.58 141.28 45.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 120.761 0.315 . . . . 0.0 110.78 -178.068 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -76.03 125.49 29.22 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.903 178.472 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 96.58 -21.83 43.54 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.087 -178.749 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . 0.57 HG23 HG21 ' A' ' 270' ' ' ILE . 48.5 t -100.42 103.25 14.54 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 121.059 0.457 . . . . 0.0 110.054 176.976 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 274' ' ' ASN . . . . . 0.51 ' O ' ' HB ' ' A' ' 322' ' ' VAL . 70.8 m-80 -121.01 137.84 54.45 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 -179.756 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 275' ' ' SER . . . . . 0.66 ' HB3' ' HB2' ' A' ' 288' ' ' GLN . 60.3 p -73.01 174.48 7.8 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.006 0.431 . . . . 0.0 111.511 -175.124 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 276' ' ' VAL . . . . . 0.707 HG13 HG22 ' A' ' 309' ' ' VAL . 33.3 m -110.05 178.69 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.284 -179.421 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 277' ' ' HIS . . . . . 0.833 ' HB2' ' HA ' ' A' ' 281' ' ' LYS . 7.7 p80 -36.84 88.73 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.675 0 O-C-N 124.561 1.163 . . . . 0.0 113.985 -177.271 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 39.7 tt0 -84.64 -36.46 21.96 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.518 -178.173 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 2.6 mp -80.94 -84.33 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.305 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.398 -172.788 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 32.6 p -127.69 45.79 2.67 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 111.597 0.221 . . . . 0.0 111.597 -174.686 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 281' ' ' LYS . . . . . 0.833 ' HA ' ' HB2' ' A' ' 277' ' ' HIS . 3.3 tmtp? 56.68 46.3 20.43 Favored 'General case' 0 CA--C 1.533 0.312 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 -176.792 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 49.2 p-10 -104.75 -162.01 0.86 Allowed 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 114.79 -1.095 . . . . 0.0 110.885 -175.085 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 76.1 p -105.97 124.45 49.59 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 178.749 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 81.2 p -127.28 -75.86 0.57 Allowed 'General case' 0 C--N 1.321 -0.643 0 C-N-CA 120.429 -0.508 . . . . 0.0 111.159 -174.26 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 67.09 31.24 77.22 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.898 -0.668 . . . . 0.0 112.002 -179.306 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 95.2 mm-40 -105.35 145.27 30.47 Favored Pre-proline 0 C--N 1.329 -0.311 0 N-CA-C 110.467 -0.197 . . . . 0.0 110.467 -178.142 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 287' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -55.22 137.5 77.06 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.805 2.336 . . . . 0.0 112.267 -179.813 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 288' ' ' GLN . . . . . 0.66 ' HB2' ' HB3' ' A' ' 275' ' ' SER . 52.0 tt0 -88.37 155.48 19.67 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.895 -176.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 59.0 t -89.84 113.34 25.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.349 178.638 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 290' ' ' PHE . . . . . 0.727 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 54.1 m-85 -100.52 131.12 46.6 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.46 -177.331 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 9.8 tpt180 -106.87 120.53 42.29 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.535 0.683 . . . . 0.0 109.877 178.368 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . 0.458 ' HB ' ' H ' ' A' ' 265' ' ' GLY . 57.6 t -67.66 140.01 19.94 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.954 0 CA-C-N 114.656 -1.157 . . . . 0.0 112.531 -176.198 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 293' ' ' LEU . . . . . 0.55 HD13 ' OG ' ' A' ' 303' ' ' SER . 4.4 mp -104.69 -30.94 9.62 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.739 175.534 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 294' ' ' ALA . . . . . 0.462 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -159.71 144.8 15.37 Favored 'General case' 0 C--N 1.333 -0.126 0 CA-C-O 120.534 0.207 . . . . 0.0 111.532 -176.358 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 70.7 t -138.09 100.23 1.68 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 175.589 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 35.8 m -138.49 113.5 9.27 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.439 -0.346 . . . . 0.0 111.085 -175.457 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 63.17 48.49 79.22 Favored Glycine 0 C--N 1.331 0.252 0 C-N-CA 120.834 -0.698 . . . . 0.0 111.922 -178.716 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 71.3 p 51.08 24.33 1.87 Allowed 'General case' 0 N--CA 1.469 0.5 0 C-N-CA 123.77 0.828 . . . . 0.0 112.229 -174.742 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 299' ' ' THR . . . . . 0.476 ' HA ' ' O ' ' A' ' 255' ' ' ILE . 29.0 m -111.48 111.18 22.02 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 176.304 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . 0.565 HG12 HG22 ' A' ' 302' ' ' ILE . 44.7 t -111.02 129.08 66.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.587 -172.445 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 93.5 m -90.97 116.08 28.49 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 172.298 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 302' ' ' ILE . . . . . 0.565 HG22 HG12 ' A' ' 300' ' ' VAL . 29.2 pt -113.26 142.8 24.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 N-CA-C 112.917 0.71 . . . . 0.0 112.917 -171.57 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 303' ' ' SER . . . . . 0.55 ' OG ' HD13 ' A' ' 293' ' ' LEU . 89.5 p -137.71 142.13 35.56 Favored Pre-proline 0 C--N 1.322 -0.599 0 N-CA-C 106.95 -1.5 . . . . 0.0 106.95 169.906 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 304' ' ' PRO . . . . . 0.505 ' HD2' ' HD1' ' A' ' 290' ' ' PHE . 25.2 Cg_exo -66.83 -179.48 13.45 Favored 'Cis proline' 0 C--N 1.331 -0.377 0 CA-C-N 119.913 1.005 . . . . 0.0 112.88 0.868 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 305' ' ' LYS . . . . . 0.642 ' HG3' ' ND2' ' A' ' 250' ' ' ASN . 0.0 OUTLIER -112.87 145.93 39.8 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-O 121.102 0.477 . . . . 0.0 111.543 -179.259 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 306' ' ' ILE . . . . . 0.402 HD11 ' N ' ' A' ' 306' ' ' ILE . 2.2 mp -72.11 106.11 2.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.262 -0.881 . . . . 0.0 111.058 -175.958 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 307' ' ' LEU . . . . . 0.618 HD22 ' ND2' ' A' ' 250' ' ' ASN . 86.7 mt -124.68 108.08 28.82 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.116 -0.493 . . . . 0.0 109.853 178.32 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 308' ' ' PRO . . . . . 0.684 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 23.8 Cg_exo -72.89 136.92 26.0 Favored 'Trans proline' 0 N--CA 1.476 0.452 0 C-N-CA 123.006 2.471 . . . . 0.0 114.423 -170.849 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . 0.707 HG22 HG13 ' A' ' 276' ' ' VAL . 47.5 t -91.14 -23.53 5.87 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.186 0 CA-C-N 115.283 -0.871 . . . . 0.0 109.549 171.675 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 310' ' ' GLU . . . . . 0.492 ' OE1' ' HB1' ' A' ' 324' ' ' ALA . 50.2 mt-10 -80.9 8.53 8.11 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.182 -179.537 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 22.6 t-20 -74.99 137.36 41.5 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 178.399 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 68.6 m -60.67 -35.98 77.6 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 111.608 0.225 . . . . 0.0 111.608 -174.671 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 39.7 m-20 -61.38 126.76 28.52 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-O 121.167 0.508 . . . . 0.0 111.247 179.89 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 57.9 t -69.86 -28.26 36.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.493 -177.466 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -72.03 -17.92 61.99 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 111.997 0.369 . . . . 0.0 111.997 -179.828 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 35.1 t -76.82 -40.52 47.62 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 121.223 -0.191 . . . . 0.0 111.21 -177.41 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 317' ' ' ARG . . . . . 0.456 ' N ' ' HD2' ' A' ' 318' ' ' PRO . 65.9 mtt85 -54.44 -53.24 61.82 Favored Pre-proline 0 CA--C 1.54 0.584 0 N-CA-C 113.652 0.982 . . . . 0.0 113.652 -176.276 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 318' ' ' PRO . . . . . 0.456 ' HD2' ' N ' ' A' ' 317' ' ' ARG . 9.9 Cg_endo -56.36 -23.93 49.21 Favored 'Trans proline' 0 C--N 1.357 0.989 0 C-N-CA 122.468 2.112 . . . . 0.0 113.282 -176.86 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 319' ' ' TYR . . . . . 0.407 ' O ' HD11 ' A' ' 307' ' ' LEU . 53.9 m-85 -115.23 12.38 16.48 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.703 -177.4 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -78.1 161.04 27.69 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.35 -178.306 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 29.2 t-20 -122.42 -44.51 2.25 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.734 -175.416 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 322' ' ' VAL . . . . . 0.51 ' HB ' ' O ' ' A' ' 274' ' ' ASN . 34.7 m -124.95 179.0 3.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.793 -177.884 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 74.9 m-20 -62.3 -60.09 4.07 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.81 -178.736 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 324' ' ' ALA . . . . . 0.684 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -151.27 172.51 15.75 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 112.785 0.661 . . . . 0.0 112.785 -174.27 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 325' ' ' LYS . . . . . 0.7 ' HE3' ' OE1' ' A' ' 235' ' ' GLU . 14.9 ptmt -99.06 126.41 38.29 Favored Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 114.252 -1.34 . . . . 0.0 110.152 170.818 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 326' ' ' PRO . . . . . 0.552 ' HG3' HG21 ' A' ' 273' ' ' VAL . 90.8 Cg_endo -86.21 168.23 9.03 Favored 'Trans proline' 0 N--CA 1.461 -0.403 0 C-N-CA 122.963 2.442 . . . . 0.0 111.857 -179.757 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -69.8 122.71 19.75 Favored 'General case' 0 C--O 1.236 0.385 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 174.448 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 62.2 mm-40 58.22 -140.79 0.75 Allowed 'General case' 0 CA--C 1.528 0.115 0 O-C-N 123.53 0.519 . . . . 0.0 109.647 -172.822 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 329' ' ' SER . . . . . 0.623 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 48.7 m -112.86 -14.12 13.1 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 120.44 -0.504 . . . . 0.0 111.076 176.615 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 67.33 -151.02 0.18 Allowed 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 112.402 0.519 . . . . 0.0 112.402 175.329 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -89.86 127.4 35.99 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.945 -178.293 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 332' ' ' ILE . . . . . 0.912 HG13 HG12 ' A' ' 270' ' ' ILE . 1.7 mp -110.96 140.12 31.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.432 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.417 ' HB ' ' OG1' ' A' ' 269' ' ' THR . 50.8 m -103.43 99.0 8.81 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.147 -0.479 . . . . 0.0 109.739 -178.944 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 22.6 mm -84.27 127.67 39.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 N-CA-C 113.934 1.087 . . . . 0.0 113.934 -171.405 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 335' ' ' LEU . . . . . 0.463 HD23 ' HA ' ' A' ' 268' ' ' PHE . 1.6 pt? -153.36 -172.85 4.37 Favored 'General case' 0 N--CA 1.447 -0.576 0 CA-C-N 114.024 -1.444 . . . . 0.0 107.65 168.816 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 20.6 t-20 -121.35 -23.92 5.57 Favored 'General case' 0 C--N 1.321 -0.649 0 C-N-CA 120.363 -0.535 . . . . 0.0 110.583 -178.599 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 68.1 mttm . . . . . 0 C--O 1.245 0.818 0 CA-C-O 118.097 -0.954 . . . . 0.0 111.399 179.071 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.81 0 N-CA-C 112.268 -0.333 . . . . 0.0 112.268 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 49.5 m -66.25 -32.52 73.99 Favored 'General case' 0 C--O 1.234 0.267 0 CA-C-O 120.39 0.138 . . . . 0.0 111.106 -179.866 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 44.8 m 70.4 -79.93 0.04 OUTLIER 'General case' 0 CA--C 1.534 0.333 0 O-C-N 123.68 0.613 . . . . 0.0 110.158 -178.416 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 226' ' ' GLU . . . . . 0.405 ' O ' ' HG2' ' A' ' 226' ' ' GLU . 37.9 tt0 56.61 34.49 24.54 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-O 121.812 0.815 . . . . 0.0 110.824 175.081 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 54.7 p -128.84 7.0 5.57 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.051 177.686 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 228' ' ' LEU . . . . . 0.557 HD11 ' HB2' ' A' ' 259' ' ' ALA . 91.1 mt -108.52 146.77 32.71 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.116 -0.947 . . . . 0.0 108.871 177.028 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 229' ' ' THR . . . . . 0.529 ' O ' HG23 ' A' ' 230' ' ' VAL . 77.7 p -130.56 179.6 5.84 Favored 'General case' 0 C--N 1.325 -0.477 0 C-N-CA 119.973 -0.691 . . . . 0.0 110.675 -179.013 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . 0.859 HG22 HG13 ' A' ' 332' ' ' ILE . 91.3 t -146.51 136.71 17.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 120.91 0.386 . . . . 0.0 110.592 178.902 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 33.7 t -107.04 146.42 31.17 Favored 'General case' 0 N--CA 1.45 -0.465 0 CA-C-N 116.039 -0.528 . . . . 0.0 109.604 176.498 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . 0.481 ' O ' ' HD3' ' A' ' 234' ' ' PRO . . . 124.4 149.18 7.6 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.396 -0.906 . . . . 0.0 111.592 -176.817 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 66.5 mt-30 -98.6 103.82 20.88 Favored Pre-proline 0 C--N 1.323 -0.568 0 CA-C-N 116.72 0.26 . . . . 0.0 111.117 -176.583 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 234' ' ' PRO . . . . . 0.481 ' HD3' ' O ' ' A' ' 232' ' ' GLY . 4.8 Cg_exo -74.96 125.49 9.38 Favored 'Trans proline' 0 N--CA 1.457 -0.626 0 C-N-CA 122.259 1.972 . . . . 0.0 111.077 177.676 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -131.93 141.07 49.22 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.609 -179.14 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 236' ' ' HIS . . . . . 0.48 ' HE1' ' HA ' ' A' ' 252' ' ' GLN . 87.2 m-70 -141.48 149.04 40.41 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.681 -0.69 . . . . 0.0 109.947 178.207 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 237' ' ' LYS . . . . . 0.648 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -117.31 178.29 4.43 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.498 -175.349 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 238' ' ' VAL . . . . . . . . . . . . . 41.4 t -50.45 154.56 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.566 0 O-C-N 123.622 0.577 . . . . 0.0 111.31 -177.361 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 239' ' ' GLU . . . . . 0.644 ' O ' ' HB ' ' A' ' 248' ' ' VAL . 5.5 mm-40 -47.64 159.08 0.17 Allowed 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 113.032 0.752 . . . . 0.0 113.032 -177.137 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 240' ' ' ALA . . . . . . . . . . . . . . . -47.97 -35.41 10.78 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 115.259 -0.882 . . . . 0.0 112.009 179.069 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 241' ' ' LYS . . . . . 0.592 ' O ' ' HD3' ' A' ' 241' ' ' LYS . 0.0 OUTLIER -134.68 147.44 50.11 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.784 175.83 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -95.84 -175.88 3.55 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.835 179.647 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 44.0 m -67.57 -16.25 64.09 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.166 -0.47 . . . . 0.0 112.027 -175.574 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 5.7 m120 -90.34 -12.88 36.37 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.01 0.434 . . . . 0.0 110.329 176.869 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 89.82 17.74 53.26 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 121.006 -0.616 . . . . 0.0 112.288 -179.667 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 246' ' ' MET . . . . . . . . . . . . . 60.9 mtt -91.26 143.87 28.96 Favored Pre-proline 0 C--N 1.326 -0.442 0 CA-C-O 120.478 0.18 . . . . 0.0 110.621 -178.534 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 247' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -65.81 125.87 15.0 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.885 2.39 . . . . 0.0 112.753 -177.18 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . 0.644 ' HB ' ' O ' ' A' ' 239' ' ' GLU . 31.7 t -120.1 144.43 28.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.009 178.825 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -88.45 112.32 22.81 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.068 178.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 250' ' ' ASN . . . . . . . . . . . . . 26.0 t-20 -99.69 -52.23 3.52 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.844 -176.343 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 98.4 mtt180 68.36 173.79 0.28 Allowed 'General case' 0 N--CA 1.472 0.668 0 N-CA-C 114.104 1.149 . . . . 0.0 114.104 179.832 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 252' ' ' GLN . . . . . 0.48 ' HA ' ' HE1' ' A' ' 236' ' ' HIS . 2.7 mm100 -117.34 177.55 4.69 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 114.312 -1.313 . . . . 0.0 109.341 179.931 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . 0.458 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -113.76 121.92 5.61 Favored Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.126 -1.035 . . . . 0.0 112.305 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 254' ' ' THR . . . . . 0.446 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 65.7 p -104.16 116.71 32.67 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 177.418 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 17.0 pt -123.84 147.38 28.27 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.981 -173.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 85.6 m -95.71 110.92 22.98 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 174.449 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.421 HG22 ' O ' ' A' ' 257' ' ' VAL . 34.0 m -89.8 143.14 11.82 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.723 0 C-N-CA 119.93 -0.708 . . . . 0.0 112.833 -168.137 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 34.4 t -91.91 7.39 42.29 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 114.454 -1.248 . . . . 0.0 108.667 169.77 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 259' ' ' ALA . . . . . 0.828 ' HB3' HD23 ' A' ' 262' ' ' LEU . . . -88.25 175.08 7.83 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-N 115.473 -0.785 . . . . 0.0 109.243 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 32.5 t -134.67 130.19 35.95 Favored 'General case' 0 C--N 1.323 -0.547 0 C-N-CA 120.465 -0.494 . . . . 0.0 111.57 -177.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 97.5 16.76 33.29 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.856 -0.688 . . . . 0.0 113.951 174.081 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 262' ' ' LEU . . . . . 0.828 HD23 ' HB3' ' A' ' 259' ' ' ALA . 2.0 mm? -65.7 128.92 37.91 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-N 117.344 0.572 . . . . 0.0 110.859 -178.841 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -128.83 175.39 8.67 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 176.335 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 43.4 t -78.64 131.2 34.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 174.325 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 100.15 9.19 48.92 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.627 -0.797 . . . . 0.0 112.699 -179.557 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -86.12 165.45 16.58 Favored 'General case' 0 CA--C 1.511 -0.521 0 CA-C-O 121.12 0.486 . . . . 0.0 110.147 175.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 267' ' ' ALA . . . . . 0.68 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -140.27 145.68 37.6 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.471 -179.575 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 268' ' ' PHE . . . . . 0.583 ' HA ' HD23 ' A' ' 335' ' ' LEU . 4.6 p90 -159.73 166.04 31.28 Favored 'General case' 0 C--N 1.319 -0.744 0 C-N-CA 120.127 -0.629 . . . . 0.0 111.328 -178.603 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 71.8 p -119.34 126.76 52.19 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.861 -0.608 . . . . 0.0 109.968 177.776 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 270' ' ' ILE . . . . . 0.636 HG12 HD12 ' A' ' 332' ' ' ILE . 46.6 mt -88.89 135.98 24.5 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.912 -177.49 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -65.31 122.16 16.5 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.23 -179.772 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 99.08 -23.86 34.64 Favored Glycine 0 N--CA 1.452 -0.256 0 CA-C-N 115.996 -0.547 . . . . 0.0 112.241 -179.392 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 49.0 t -94.22 108.42 20.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 121.152 0.501 . . . . 0.0 110.37 176.528 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 274' ' ' ASN . . . . . 0.41 ' HB2' ' OD1' ' A' ' 323' ' ' ASP . 63.7 m-80 -123.9 159.99 28.47 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 116.004 -0.544 . . . . 0.0 109.602 -179.398 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 53.1 p -92.04 164.68 13.52 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-O 121.124 0.487 . . . . 0.0 111.327 -179.048 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 30.0 m -125.9 167.46 20.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.544 178.518 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 28.9 m80 -126.0 92.07 3.51 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.595 -0.275 . . . . 0.0 110.72 178.69 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 84.1 mt-30 -72.59 -14.13 61.54 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.769 0.319 . . . . 0.0 111.081 179.184 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 279' ' ' ILE . . . . . 0.469 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.2 mp -77.05 -59.95 2.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 116.539 -0.3 . . . . 0.0 110.319 -178.475 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 51.4 p -85.36 -10.02 56.85 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.454 -179.878 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 31.9 mmmt 58.35 43.81 19.39 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.7 -178.29 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -112.34 154.49 25.64 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.1 -178.357 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 49.8 p -105.96 123.01 47.3 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 176.731 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 284' ' ' THR . . . . . 0.459 ' HB ' ' HG3' ' A' ' 286' ' ' GLN . 82.0 p -124.53 -37.28 2.52 Favored 'General case' 0 C--N 1.317 -0.814 0 C-N-CA 120.487 -0.485 . . . . 0.0 111.508 -172.06 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 70.45 29.49 69.92 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.601 -0.809 . . . . 0.0 111.809 -177.394 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 286' ' ' GLN . . . . . 0.459 ' HG3' ' HB ' ' A' ' 284' ' ' THR . 24.4 mt-30 -76.25 113.87 32.43 Favored Pre-proline 0 C--N 1.33 -0.243 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.826 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 287' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_exo -51.65 126.55 19.97 Favored 'Trans proline' 0 C--O 1.232 0.224 0 C-N-CA 122.42 2.08 . . . . 0.0 111.928 -179.112 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -77.23 130.06 36.74 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 -175.018 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 57.6 t -90.01 130.74 38.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.006 -176.108 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 290' ' ' PHE . . . . . 0.68 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 4.6 m-85 -98.79 151.18 21.07 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.05 -178.062 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 291' ' ' ARG . . . . . 0.484 ' HD2' ' C ' ' A' ' 290' ' ' PHE . 1.0 OUTLIER -113.18 130.09 56.32 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 174.172 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . 0.462 HG12 HG13 ' A' ' 300' ' ' VAL . 47.9 t -92.49 129.51 42.96 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.231 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.923 -177.625 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 293' ' ' LEU . . . . . 0.525 HD23 ' N ' ' A' ' 293' ' ' LEU . 3.1 mm? -114.6 -20.7 10.6 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.684 -179.251 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 294' ' ' ALA . . . . . . . . . . . . . . . -148.92 136.61 20.49 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.641 -0.424 . . . . 0.0 111.914 -179.303 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . 0.452 HG11 ' O ' ' A' ' 262' ' ' LEU . 80.4 t -142.7 123.0 10.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.681 -0.691 . . . . 0.0 109.79 175.515 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 36.2 t -154.09 108.66 3.06 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.58 -0.282 . . . . 0.0 110.742 179.158 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 63.57 54.8 29.21 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 121.031 -0.604 . . . . 0.0 112.189 -179.296 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 58.4 p 52.28 21.89 1.82 Allowed 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 123.725 0.81 . . . . 0.0 112.754 -176.764 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 45.8 m -107.64 117.83 35.13 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 173.911 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . 0.607 HG11 HG22 ' A' ' 302' ' ' ILE . 48.1 t -117.08 129.96 72.78 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.299 -172.041 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 45.1 m -98.21 116.75 31.09 Favored 'General case' 0 C--O 1.236 0.381 0 N-CA-C 108.744 -0.835 . . . . 0.0 108.744 174.718 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 302' ' ' ILE . . . . . 0.607 HG22 HG11 ' A' ' 300' ' ' VAL . 29.2 pt -111.81 146.17 17.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 113.373 0.879 . . . . 0.0 113.373 -168.627 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 303' ' ' SER . . . . . 0.519 ' HB3' ' HA ' ' A' ' 304' ' ' PRO . 47.4 m -132.25 166.24 30.15 Favored Pre-proline 0 C--N 1.32 -0.698 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 171.899 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 304' ' ' PRO . . . . . 0.519 ' HA ' ' HB3' ' A' ' 303' ' ' SER . 6.0 Cg_exo -79.67 -142.71 0.24 Allowed 'Cis proline' 0 CA--C 1.531 0.327 0 CA-C-N 120.72 1.293 . . . . 0.0 112.636 0.291 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 305' ' ' LYS . . . . . 0.456 ' HD2' ' O ' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -97.51 147.6 24.08 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.389 0.614 . . . . 0.0 112.152 178.784 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 306' ' ' ILE . . . . . 0.589 HG23 HG22 ' A' ' 322' ' ' VAL . 1.9 mp -119.83 110.35 28.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 115.043 -0.98 . . . . 0.0 110.131 -176.534 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 307' ' ' LEU . . . . . 0.423 ' HA ' ' HD3' ' A' ' 308' ' ' PRO . 88.6 mt -126.32 115.08 23.48 Favored Pre-proline 0 C--N 1.332 -0.183 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.221 -177.697 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 308' ' ' PRO . . . . . 0.767 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 35.3 Cg_exo -67.31 147.81 78.83 Favored 'Trans proline' 0 N--CA 1.474 0.339 0 C-N-CA 123.762 2.975 . . . . 0.0 114.714 -173.521 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . 0.635 HG23 ' HB3' ' A' ' 320' ' ' ALA . 26.2 t -93.34 -17.81 7.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 114.866 -1.061 . . . . 0.0 108.607 167.654 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 59.4 mm-40 -76.9 -6.71 53.57 Favored 'General case' 0 C--O 1.233 0.199 0 CA-C-N 115.23 -0.895 . . . . 0.0 112.117 -178.157 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 4.1 m120 -85.62 151.47 23.87 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.917 0.389 . . . . 0.0 111.101 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 30.9 m -93.28 -1.16 56.37 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.579 0.704 . . . . 0.0 109.125 175.347 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 313' ' ' ASP . . . . . 0.638 ' O ' ' HG3' ' A' ' 317' ' ' ARG . 59.7 t0 -58.0 117.57 4.47 Favored 'General case' 0 C--N 1.333 -0.116 0 CA-C-N 115.328 -0.851 . . . . 0.0 110.781 -179.292 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 49.0 t -53.54 -33.8 22.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.835 -0.62 . . . . 0.0 112.172 -178.446 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -85.18 -29.81 24.43 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 112.183 0.438 . . . . 0.0 112.183 -178.017 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 316' ' ' SER . . . . . 0.533 ' HB3' ' HB3' ' A' ' 313' ' ' ASP . 33.5 t -82.03 -27.74 32.88 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 111.759 0.281 . . . . 0.0 111.759 -175.133 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 317' ' ' ARG . . . . . 0.638 ' HG3' ' O ' ' A' ' 313' ' ' ASP . 49.8 mtp85 -63.98 -52.87 53.24 Favored Pre-proline 0 CA--C 1.539 0.548 0 N-CA-C 112.935 0.717 . . . . 0.0 112.935 -176.478 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 318' ' ' PRO . . . . . 0.596 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 22.1 Cg_exo -67.82 -28.93 35.95 Favored 'Trans proline' 0 C--N 1.357 0.991 0 C-N-CA 121.979 1.786 . . . . 0.0 112.871 -177.005 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 319' ' ' TYR . . . . . 0.41 ' O ' HD13 ' A' ' 307' ' ' LEU . 5.1 m-85 -98.42 12.84 33.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.017 -179.005 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . 0.635 ' HB3' HG23 ' A' ' 309' ' ' VAL . . . -59.76 144.27 48.76 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.539 -178.666 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 17.5 p30 -142.98 -12.17 0.75 Allowed 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.53 -177.434 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 322' ' ' VAL . . . . . 0.589 HG22 HG23 ' A' ' 306' ' ' ILE . 35.0 m -139.15 178.65 3.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.404 177.658 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 323' ' ' ASP . . . . . 0.41 ' OD1' ' HB2' ' A' ' 274' ' ' ASN . 51.6 m-20 -64.01 -62.58 1.54 Allowed 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.978 176.87 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 324' ' ' ALA . . . . . 0.767 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -162.94 173.75 13.24 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 116.143 -0.481 . . . . 0.0 112.094 -175.44 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 22.0 pttp -119.28 106.97 42.04 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 115.218 -0.901 . . . . 0.0 109.457 172.277 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -86.29 167.52 9.13 Favored 'Trans proline' 0 C--O 1.235 0.367 0 C-N-CA 122.624 2.216 . . . . 0.0 113.507 -172.204 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 327' ' ' ALA . . . . . 0.429 ' O ' ' HB2' ' A' ' 328' ' ' GLU . . . -79.48 132.79 36.44 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 170.155 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 328' ' ' GLU . . . . . 0.429 ' HB2' ' O ' ' A' ' 327' ' ' ALA . 62.1 mm-40 73.27 166.25 0.3 Allowed 'General case' 0 N--CA 1.467 0.387 0 O-C-N 123.566 0.542 . . . . 0.0 109.576 -170.589 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 329' ' ' SER . . . . . 0.647 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 53.9 m -104.44 -10.53 17.64 Favored 'General case' 0 C--N 1.319 -0.731 0 C-N-CA 120.349 -0.54 . . . . 0.0 111.803 -174.265 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 330' ' ' ALA . . . . . 0.419 ' HB1' ' H ' ' A' ' 331' ' ' ALA . . . 67.62 -161.22 0.22 Allowed 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 113.022 0.749 . . . . 0.0 113.022 172.459 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 331' ' ' ALA . . . . . 0.419 ' H ' ' HB1' ' A' ' 330' ' ' ALA . . . -75.33 142.72 43.15 Favored 'General case' 0 CA--C 1.518 -0.275 0 CA-C-N 115.117 -0.947 . . . . 0.0 110.475 179.414 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 332' ' ' ILE . . . . . 0.859 HG13 HG22 ' A' ' 230' ' ' VAL . 24.8 mm -120.62 144.46 29.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.753 -175.783 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 33.8 m -111.27 97.63 6.92 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 178.404 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 39.5 mm -81.57 131.54 33.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 112.769 0.655 . . . . 0.0 112.769 -173.247 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 335' ' ' LEU . . . . . 0.583 HD23 ' HA ' ' A' ' 268' ' ' PHE . 1.7 pt? -152.03 -167.16 2.69 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 114.685 -1.143 . . . . 0.0 108.723 173.118 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 15.9 p-10 -110.88 -25.41 9.87 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 109.635 -0.505 . . . . 0.0 109.635 176.014 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 27.1 tptp . . . . . 0 C--O 1.247 0.925 0 O-C-N 124.397 1.061 . . . . 0.0 111.407 177.506 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.953 0 N-CA-C 112.131 -0.387 . . . . 0.0 112.131 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 23.3 t 59.72 -141.71 0.61 Allowed 'General case' 0 CA--C 1.533 0.293 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 -179.291 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 60.9 m -112.09 -75.58 0.61 Allowed 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 178.708 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 47.91 66.81 0.95 Allowed 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.646 -0.707 . . . . 0.0 111.033 178.855 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 61.1 p -88.71 98.16 11.54 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.552 177.054 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 228' ' ' LEU . . . . . 0.569 ' HB3' ' CB ' ' A' ' 259' ' ' ALA . 53.4 mt -111.15 127.1 55.47 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.491 -173.31 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 229' ' ' THR . . . . . 0.499 ' HA ' ' HA ' ' A' ' 331' ' ' ALA . 64.3 p -129.91 -178.83 4.88 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 120.694 -0.402 . . . . 0.0 111.22 -178.822 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . 0.731 ' O ' ' HB2' ' A' ' 329' ' ' SER . 34.9 t -134.17 151.59 32.61 Favored 'Isoleucine or valine' 0 C--O 1.24 0.594 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 -179.43 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 41.7 t -126.89 125.37 41.48 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.23 175.383 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 87.61 91.75 1.02 Allowed Glycine 0 CA--C 1.52 0.382 0 C-N-CA 120.888 -0.673 . . . . 0.0 113.97 176.15 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 233' ' ' GLN . . . . . 0.559 ' HG2' ' OG ' ' A' ' 329' ' ' SER . 94.8 mm-40 -97.86 117.01 65.66 Favored Pre-proline 0 CA--C 1.519 -0.242 0 O-C-N 122.821 -0.223 . . . . 0.0 110.623 171.843 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 234' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 233' ' ' GLN . 11.8 Cg_exo -67.09 172.93 9.18 Favored 'Trans proline' 0 N--CA 1.462 -0.353 0 C-N-CA 122.685 2.257 . . . . 0.0 111.741 176.565 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 235' ' ' GLU . . . . . 0.413 ' HG3' ' HE2' ' A' ' 237' ' ' LYS . 9.7 pt-20 -96.42 146.91 24.36 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.013 178.058 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 236' ' ' HIS . . . . . 0.615 ' C ' ' HD2' ' A' ' 237' ' ' LYS . 28.6 m80 -126.07 129.78 49.81 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.088 0.471 . . . . 0.0 111.01 -173.953 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 237' ' ' LYS . . . . . 0.615 ' HD2' ' C ' ' A' ' 236' ' ' HIS . 2.8 mptp? -118.11 177.48 4.78 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.441 -0.799 . . . . 0.0 110.0 -179.114 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 238' ' ' VAL . . . . . 0.612 ' HB ' HG12 ' A' ' 248' ' ' VAL . 52.2 t -48.68 131.35 6.18 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.224 0 O-C-N 123.817 0.698 . . . . 0.0 110.797 -179.446 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 239' ' ' GLU . . . . . 0.985 ' HA ' ' HB3' ' A' ' 251' ' ' ARG . 0.8 OUTLIER -56.16 158.59 3.94 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 113.713 1.005 . . . . 0.0 113.713 -172.811 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 240' ' ' ALA . . . . . 0.492 ' H ' ' HD3' ' A' ' 251' ' ' ARG . . . -26.21 -71.45 0.03 OUTLIER 'General case' 0 N--CA 1.471 0.624 0 CA-C-N 113.826 -1.534 . . . . 0.0 114.274 -172.559 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 241' ' ' LYS . . . . . 0.579 ' O ' ' HD3' ' A' ' 241' ' ' LYS . 0.0 OUTLIER -151.13 145.49 25.49 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.079 0.466 . . . . 0.0 111.681 -176.34 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 12.7 p-10 -103.29 -158.09 0.65 Allowed 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.747 -177.319 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 43.6 t -67.32 -30.99 70.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.733 177.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 5.7 m120 -83.83 -13.56 53.42 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.837 0.351 . . . . 0.0 110.488 177.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 70.34 47.76 41.77 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 121.124 -0.56 . . . . 0.0 113.022 176.575 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 246' ' ' MET . . . . . 0.431 ' HA ' ' HD3' ' A' ' 247' ' ' PRO . 25.0 mmt -99.14 121.46 55.44 Favored Pre-proline 0 C--N 1.326 -0.438 0 CA-C-N 116.794 0.297 . . . . 0.0 110.517 179.085 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 247' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' A' ' 246' ' ' MET . 12.0 Cg_exo -72.71 121.88 7.75 Favored 'Trans proline' 0 C--N 1.343 0.286 0 C-N-CA 122.907 2.405 . . . . 0.0 112.116 -178.068 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . 0.612 HG12 ' HB ' ' A' ' 238' ' ' VAL . 21.5 t -123.24 160.57 26.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 116.374 -0.376 . . . . 0.0 110.005 -178.601 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 249' ' ' ASP . . . . . 0.45 ' HB3' ' HG2' ' A' ' 237' ' ' LYS . 51.7 t0 -52.51 147.51 8.22 Favored 'General case' 0 N--CA 1.469 0.503 0 C-N-CA 123.152 0.581 . . . . 0.0 110.189 178.658 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 250' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -34.9 142.46 0.05 Allowed 'General case' 0 N--CA 1.475 0.796 0 N-CA-C 115.176 1.547 . . . . 0.0 115.176 -169.461 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . 0.985 ' HB3' ' HA ' ' A' ' 239' ' ' GLU . 27.5 ptt180 -89.59 -59.27 2.25 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 114.207 -1.36 . . . . 0.0 111.668 178.445 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 252' ' ' GLN . . . . . 0.614 ' H ' ' HG3' ' A' ' 251' ' ' ARG . 2.2 mm100 -97.61 178.39 5.19 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.043 -174.349 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . 0.452 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -154.47 172.58 32.98 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 119.667 -1.254 . . . . 0.0 113.032 -178.965 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 254' ' ' THR . . . . . 0.532 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 47.0 p -119.38 128.81 54.41 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 177.822 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . 0.472 HD12 HG13 ' A' ' 230' ' ' VAL . 26.6 pt -114.66 149.73 16.83 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.357 -175.659 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 40.8 m -98.4 110.47 23.05 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 177.223 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . . . . . . . . . 35.0 m -92.41 144.99 8.15 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.859 0 CA-C-O 121.631 0.729 . . . . 0.0 112.697 -171.123 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 41.1 m -90.3 7.75 36.83 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 114.046 -1.434 . . . . 0.0 108.41 168.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 259' ' ' ALA . . . . . 0.569 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -91.06 162.04 14.86 Favored 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 115.117 -0.947 . . . . 0.0 110.468 -177.497 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 48.7 m -137.82 138.91 39.64 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.122 -0.49 . . . . 0.0 109.814 177.36 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 94.55 34.26 6.4 Favored Glycine 0 N--CA 1.447 -0.586 0 C-N-CA 120.444 -0.884 . . . . 0.0 112.233 -178.42 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 262' ' ' LEU . . . . . 0.423 ' O ' HG11 ' A' ' 295' ' ' VAL . 67.5 mt -102.37 143.39 32.18 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 178.361 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 3.0 mm100 -142.78 175.32 9.91 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 178.116 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 49.0 t -78.17 132.48 32.37 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.202 177.698 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 103.77 8.24 40.24 Favored Glycine 0 N--CA 1.453 -0.211 0 C-N-CA 120.569 -0.824 . . . . 0.0 112.775 179.406 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -89.05 157.56 18.3 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.915 0.388 . . . . 0.0 110.066 176.838 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 267' ' ' ALA . . . . . 0.588 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -131.23 121.94 25.68 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 178.883 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 268' ' ' PHE . . . . . . . . . . . . . 4.6 p90 -145.14 164.57 30.87 Favored 'General case' 0 C--N 1.32 -0.706 0 C-N-CA 119.4 -0.92 . . . . 0.0 111.988 -173.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 75.7 p -117.64 129.6 55.85 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.531 -0.759 . . . . 0.0 109.76 176.191 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 270' ' ' ILE . . . . . 0.444 HG21 HD13 ' A' ' 270' ' ' ILE . 66.0 mt -97.54 141.52 15.75 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.766 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 179.838 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -63.98 132.84 51.87 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.032 0.444 . . . . 0.0 111.438 -176.577 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 98.68 -22.35 41.37 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.992 -0.623 . . . . 0.0 112.158 -178.56 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . 0.683 HG21 ' HG2' ' A' ' 326' ' ' PRO . 45.2 t -77.95 103.44 5.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 120.665 0.269 . . . . 0.0 110.459 178.476 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 274' ' ' ASN . . . . . 0.405 ' O ' ' HB ' ' A' ' 322' ' ' VAL . 3.3 m120 -96.72 136.97 36.51 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 108.79 -0.819 . . . . 0.0 108.79 174.842 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 8.1 t -99.48 165.58 11.57 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.773 0.321 . . . . 0.0 110.399 -176.219 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 19.0 m -128.76 155.49 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.014 0 CA-C-N 115.092 -0.958 . . . . 0.0 109.987 167.271 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 277' ' ' HIS . . . . . 0.615 ' HB2' ' HB3' ' A' ' 282' ' ' ASP . 29.3 m80 -100.41 89.74 4.06 Favored 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 108.547 -0.909 . . . . 0.0 108.547 175.148 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 5.3 tm0? -59.78 -47.54 85.3 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.091 -172.139 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 279' ' ' ILE . . . . . 0.41 HD13 HG22 ' A' ' 279' ' ' ILE . 59.2 mt -56.44 -48.15 80.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 N-CA-C 111.942 0.349 . . . . 0.0 111.942 -177.166 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 40.6 p -94.97 -3.71 48.0 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 112.414 0.524 . . . . 0.0 112.414 -176.3 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 4.0 tppp? 59.22 53.2 5.52 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 121.285 0.564 . . . . 0.0 110.256 -178.337 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 282' ' ' ASP . . . . . 0.615 ' HB3' ' HB2' ' A' ' 277' ' ' HIS . 37.2 t70 -120.13 116.37 25.52 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.299 -175.416 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 67.8 p -107.16 118.17 35.99 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.3 178.83 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 67.5 p -129.05 -15.98 4.14 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 112.063 0.394 . . . . 0.0 112.063 -174.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 87.23 -3.09 86.89 Favored Glycine 0 N--CA 1.453 -0.179 0 C-N-CA 120.61 -0.805 . . . . 0.0 112.724 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 286' ' ' GLN . . . . . 0.448 ' HA ' ' HD3' ' A' ' 287' ' ' PRO . 82.9 mt-30 -64.76 137.92 97.3 Favored Pre-proline 0 C--N 1.33 -0.27 0 N-CA-C 110.425 -0.213 . . . . 0.0 110.425 179.006 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 287' ' ' PRO . . . . . 0.577 ' HA ' ' O ' ' A' ' 273' ' ' VAL . 32.8 Cg_exo -62.52 149.37 91.23 Favored 'Trans proline' 0 CA--C 1.529 0.257 0 C-N-CA 122.633 2.222 . . . . 0.0 113.448 -174.558 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 288' ' ' GLN . . . . . 0.526 ' HA ' HE21 ' A' ' 288' ' ' GLN . 1.9 tp-100 -87.06 136.82 32.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.075 176.989 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 38.8 t -94.55 130.15 43.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.901 -0.591 . . . . 0.0 109.645 177.592 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 290' ' ' PHE . . . . . 0.588 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 53.6 m-85 -99.97 165.52 11.5 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.926 0.393 . . . . 0.0 111.772 -175.145 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 30.3 mmt-85 -119.76 127.98 53.32 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 174.075 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 57.7 t -86.6 130.74 36.26 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.886 0 CA-C-O 120.785 0.326 . . . . 0.0 111.583 -175.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 293' ' ' LEU . . . . . 0.502 HD23 ' HB2' ' A' ' 303' ' ' SER . 3.1 mm? -103.58 -34.88 8.5 Favored 'General case' 0 C--N 1.333 -0.112 0 CA-C-N 115.945 -0.571 . . . . 0.0 111.297 178.503 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 294' ' ' ALA . . . . . 0.508 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -154.22 140.1 18.19 Favored 'General case' 0 CA--C 1.518 -0.252 0 C-N-CA 120.648 -0.421 . . . . 0.0 111.593 -179.149 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . 0.423 HG11 ' O ' ' A' ' 262' ' ' LEU . 96.9 t -135.73 100.09 2.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.705 175.016 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 50.5 m -141.77 118.29 10.92 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.845 -176.33 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 63.93 46.5 91.36 Favored Glycine 0 C--N 1.33 0.236 0 C-N-CA 121.147 -0.549 . . . . 0.0 112.144 -178.018 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 72.2 p 51.0 23.54 1.53 Allowed 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 123.701 0.8 . . . . 0.0 112.221 -175.739 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 299' ' ' THR . . . . . 0.441 ' HA ' ' O ' ' A' ' 255' ' ' ILE . 50.7 m -114.0 118.47 34.22 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 176.609 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . 0.547 HG11 HG21 ' A' ' 302' ' ' ILE . 43.6 t -110.18 128.39 66.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.412 -172.515 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 59.3 m -83.97 114.14 21.49 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 108.091 -1.078 . . . . 0.0 108.091 171.568 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 302' ' ' ILE . . . . . 0.547 HG21 HG11 ' A' ' 300' ' ' VAL . 31.0 pt -111.01 144.76 18.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 N-CA-C 113.279 0.844 . . . . 0.0 113.279 -167.059 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 303' ' ' SER . . . . . 0.513 ' HA ' ' O ' ' A' ' 304' ' ' PRO . 50.4 m -149.6 157.7 38.43 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-N 114.041 -1.436 . . . . 0.0 107.409 173.018 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 304' ' ' PRO . . . . . 0.513 ' O ' ' HA ' ' A' ' 303' ' ' SER . 15.7 Cg_exo -69.27 -162.21 1.72 Allowed 'Cis proline' 0 CA--C 1.531 0.34 0 CA-C-N 120.151 1.09 . . . . 0.0 112.811 0.742 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 305' ' ' LYS . . . . . 0.577 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -95.27 142.38 27.75 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.401 0.619 . . . . 0.0 111.964 -178.124 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 306' ' ' ILE . . . . . 0.484 ' N ' HD13 ' A' ' 306' ' ' ILE . 2.0 mp -86.35 84.92 2.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.079 -0.964 . . . . 0.0 109.939 -178.397 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 307' ' ' LEU . . . . . . . . . . . . . 96.8 mt -112.38 102.45 54.17 Favored Pre-proline 0 C--N 1.324 -0.501 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.579 -178.757 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 308' ' ' PRO . . . . . 0.626 ' HD2' HD21 ' A' ' 311' ' ' ASN . 12.4 Cg_exo -75.5 150.29 35.86 Favored 'Trans proline' 0 N--CA 1.462 -0.334 0 C-N-CA 122.898 2.399 . . . . 0.0 113.004 -174.398 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . 0.726 HG21 ' HB2' ' A' ' 320' ' ' ALA . 42.5 t -72.26 -27.3 26.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 108.647 -0.872 . . . . 0.0 108.647 170.305 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 54.7 mm-40 -92.21 32.68 1.14 Allowed 'General case' 0 N--CA 1.453 -0.285 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.805 176.3 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.626 HD21 ' HD2' ' A' ' 308' ' ' PRO . 26.0 t-20 -71.98 -31.93 66.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.378 -178.336 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 312' ' ' THR . . . . . 0.47 ' HB ' ' O ' ' A' ' 311' ' ' ASN . 84.9 m 83.34 -25.43 0.14 Allowed 'General case' 0 N--CA 1.469 0.491 0 O-C-N 124.088 0.867 . . . . 0.0 111.116 -178.837 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 65.8 m-20 -81.89 122.9 28.33 Favored 'General case' 0 C--O 1.233 0.216 0 C-N-CA 120.522 -0.471 . . . . 0.0 109.96 172.571 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 38.8 t -59.35 -39.38 78.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 115.188 -0.914 . . . . 0.0 112.229 -173.092 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -66.22 -25.27 66.83 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 112.229 0.455 . . . . 0.0 112.229 -177.332 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 42.4 t -86.54 -12.59 48.32 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 111.773 0.286 . . . . 0.0 111.773 -177.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 317' ' ' ARG . . . . . 0.554 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 51.8 mtp85 -62.8 -50.61 76.78 Favored Pre-proline 0 CA--C 1.538 0.492 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 -178.503 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 318' ' ' PRO . . . . . 0.554 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 39.2 Cg_exo -63.32 -26.05 71.48 Favored 'Trans proline' 0 C--N 1.356 0.936 0 C-N-CA 121.903 1.735 . . . . 0.0 112.788 -177.755 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 6.0 m-85 -93.23 19.99 7.47 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.335 -179.409 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . 0.726 ' HB2' HG21 ' A' ' 309' ' ' VAL . . . -59.49 131.02 49.68 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 112.31 0.485 . . . . 0.0 112.31 -175.799 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 76.3 m-20 -128.15 -18.38 4.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.507 -0.77 . . . . 0.0 110.255 175.052 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 322' ' ' VAL . . . . . 0.489 ' O ' ' HA ' ' A' ' 308' ' ' PRO . 33.8 m -138.7 176.75 5.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.107 -179.576 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -98.74 -18.97 17.73 Favored 'General case' 0 C--N 1.327 -0.385 0 C-N-CA 121.002 -0.279 . . . . 0.0 111.123 -179.773 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 324' ' ' ALA . . . . . 0.461 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -168.62 156.67 8.1 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.98 -173.117 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 325' ' ' LYS . . . . . 0.411 ' HA ' ' HD3' ' A' ' 326' ' ' PRO . 35.4 mtmm -87.02 120.87 71.71 Favored Pre-proline 0 N--CA 1.453 -0.294 0 N-CA-C 107.618 -1.252 . . . . 0.0 107.618 165.442 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 326' ' ' PRO . . . . . 0.683 ' HG2' HG21 ' A' ' 273' ' ' VAL . 51.1 Cg_exo -61.14 162.81 18.53 Favored 'Trans proline' 0 C--O 1.233 0.274 0 C-N-CA 122.525 2.15 . . . . 0.0 113.612 -171.372 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -73.45 132.35 42.84 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 108.593 -0.891 . . . . 0.0 108.593 170.896 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 9.0 pm0 42.38 -137.46 0.25 Allowed 'General case' 0 N--CA 1.47 0.565 0 O-C-N 124.132 0.895 . . . . 0.0 110.338 -169.757 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 329' ' ' SER . . . . . 0.731 ' HB2' ' O ' ' A' ' 230' ' ' VAL . 38.1 m -113.98 -44.87 3.11 Favored 'General case' 0 C--N 1.322 -0.622 0 C-N-CA 119.797 -0.761 . . . . 0.0 111.604 176.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 330' ' ' ALA . . . . . 0.461 ' HB2' ' O ' ' A' ' 329' ' ' SER . . . 78.54 -166.66 0.04 OUTLIER 'General case' 0 N--CA 1.474 0.771 0 O-C-N 123.813 0.696 . . . . 0.0 112.52 176.169 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 331' ' ' ALA . . . . . 0.499 ' HA ' ' HA ' ' A' ' 229' ' ' THR . . . -84.95 157.92 20.67 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.755 -0.657 . . . . 0.0 112.386 -173.764 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 332' ' ' ILE . . . . . 0.501 HG23 HD12 ' A' ' 332' ' ' ILE . 29.1 mt -110.0 144.97 17.15 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.232 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.083 -179.223 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 54.4 m -111.45 98.46 7.48 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 172.35 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 334' ' ' ILE . . . . . 0.477 HD11 HG22 ' A' ' 334' ' ' ILE . 32.2 mm -84.96 134.79 26.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 N-CA-C 113.247 0.832 . . . . 0.0 113.247 -171.074 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 335' ' ' LEU . . . . . 0.409 HD21 ' O ' ' A' ' 267' ' ' ALA . 1.9 pt? -164.39 -166.16 1.07 Allowed 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 115.074 -0.966 . . . . 0.0 109.62 172.418 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 74.3 m-80 -143.84 21.39 1.8 Allowed 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 175.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 68.2 mttm . . . . . 0 C--O 1.242 0.66 0 CA-C-N 115.196 -0.911 . . . . 0.0 110.84 -174.371 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.914 0 N-CA-C 112.429 -0.268 . . . . 0.0 112.429 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 50.6 p -78.68 125.78 29.83 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.595 0.236 . . . . 0.0 111.048 178.784 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 225' ' ' THR . . . . . 0.484 HG23 ' HG ' ' A' ' 228' ' ' LEU . 84.8 m -71.66 -59.21 2.88 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.413 179.545 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 34.6 69.32 0.16 Allowed 'General case' 0 N--CA 1.471 0.609 0 O-C-N 124.356 1.035 . . . . 0.0 113.088 -179.309 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 51.8 m 60.25 90.53 0.06 Allowed 'General case' 0 C--O 1.234 0.285 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.906 176.838 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 228' ' ' LEU . . . . . 0.537 HD13 ' HB1' ' A' ' 259' ' ' ALA . 88.8 mt -68.77 144.77 54.24 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.317 173.891 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 229' ' ' THR . . . . . 0.414 ' O ' HG23 ' A' ' 230' ' ' VAL . 40.7 p -132.29 179.32 6.18 Favored 'General case' 0 C--N 1.326 -0.441 0 C-N-CA 120.262 -0.575 . . . . 0.0 111.137 -176.998 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . 0.757 HG21 HG13 ' A' ' 257' ' ' VAL . 72.1 t -143.22 145.87 22.15 Favored 'Isoleucine or valine' 0 C--O 1.239 0.532 0 CA-C-O 120.775 0.322 . . . . 0.0 110.373 -179.446 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 46.2 t -131.74 97.58 4.24 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 115.234 -0.894 . . . . 0.0 109.181 173.818 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . -142.15 -157.53 7.19 Favored Glycine 0 N--CA 1.447 -0.6 0 C-N-CA 120.184 -1.008 . . . . 0.0 112.639 -176.008 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 83.5 mt-30 -86.1 159.98 52.95 Favored Pre-proline 0 C--N 1.323 -0.571 0 N-CA-C 110.396 -0.224 . . . . 0.0 110.396 179.775 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo -64.51 174.66 4.15 Favored 'Trans proline' 0 C--N 1.35 0.619 0 C-N-CA 122.875 2.383 . . . . 0.0 111.418 176.357 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 235' ' ' GLU . . . . . 0.553 ' HA ' ' OE1' ' A' ' 235' ' ' GLU . 3.9 mm-40 -91.9 167.54 12.05 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 113.461 0.911 . . . . 0.0 113.461 -174.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 236' ' ' HIS . . . . . 0.567 ' HB3' ' ND2' ' A' ' 250' ' ' ASN . 23.2 m80 -111.63 143.21 42.89 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 113.266 -1.788 . . . . 0.0 111.432 -165.239 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 237' ' ' LYS . . . . . 0.46 ' HD3' ' C ' ' A' ' 236' ' ' HIS . 18.7 mmtp -112.64 148.84 33.77 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.793 -173.461 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 238' ' ' VAL . . . . . . . . . . . . . 65.3 t -91.8 115.28 30.49 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-O 121.06 0.457 . . . . 0.0 110.738 178.022 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 239' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -94.37 116.69 29.1 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.408 -0.815 . . . . 0.0 109.123 174.581 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 240' ' ' ALA . . . . . 0.493 ' O ' ' HA ' ' A' ' 247' ' ' PRO . . . -47.73 -51.86 20.57 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 115.671 -0.695 . . . . 0.0 112.698 -169.967 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 241' ' ' LYS . . . . . 0.796 ' HB2' ' HA2' ' A' ' 245' ' ' GLY . 0.1 OUTLIER -113.59 144.17 43.33 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.82 0.343 . . . . 0.0 111.773 -179.167 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 10.8 p-10 -93.24 -157.46 0.54 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.298 -178.016 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 48.0 p -60.68 -29.18 69.15 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.589 177.327 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 6.2 m120 -97.89 2.04 48.75 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.369 -179.583 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . 0.796 ' HA2' ' HB2' ' A' ' 241' ' ' LYS . . . 71.64 31.09 65.55 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.891 -0.671 . . . . 0.0 113.272 177.253 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 246' ' ' MET . . . . . . . . . . . . . 24.1 mmt -110.25 152.46 43.21 Favored Pre-proline 0 C--N 1.325 -0.479 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 178.473 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 247' ' ' PRO . . . . . 0.493 ' HA ' ' O ' ' A' ' 240' ' ' ALA . 23.4 Cg_exo -65.51 120.79 8.04 Favored 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.226 1.951 . . . . 0.0 111.879 -178.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 62.2 t -133.66 134.29 56.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.591 -178.787 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 37.4 t70 -89.82 117.8 28.93 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 174.757 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 250' ' ' ASN . . . . . 0.567 ' ND2' ' HB3' ' A' ' 236' ' ' HIS . 49.5 t30 -65.31 159.9 22.89 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.155 -174.51 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 37.7 ptt180 -66.76 -172.98 0.2 Allowed 'General case' 0 CA--C 1.533 0.303 0 N-CA-C 113.012 0.745 . . . . 0.0 113.012 -175.782 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 252' ' ' GLN . . . . . 0.484 ' HB3' ' O ' ' A' ' 302' ' ' ILE . 3.0 mm100 -96.61 177.96 5.49 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.222 -0.899 . . . . 0.0 110.729 -177.233 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . 0.504 ' HA2' ' CE1' ' A' ' 236' ' ' HIS . . . -95.5 152.22 20.29 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.184 177.877 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 52.1 p -129.5 116.96 19.73 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.758 0.314 . . . . 0.0 110.588 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . 0.404 ' HB ' ' CG1' ' A' ' 230' ' ' VAL . 18.0 pt -125.94 149.92 31.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 N-CA-C 112.25 0.463 . . . . 0.0 112.25 -175.798 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 256' ' ' THR . . . . . 0.499 ' O ' HG13 ' A' ' 230' ' ' VAL . 91.5 m -98.86 113.35 25.43 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 175.124 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.757 HG13 HG21 ' A' ' 230' ' ' VAL . 34.8 m -90.12 143.26 11.56 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.669 0 N-CA-C 113.38 0.881 . . . . 0.0 113.38 -167.009 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 37.4 t -92.73 7.94 41.44 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 113.795 -1.548 . . . . 0.0 108.523 168.163 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 259' ' ' ALA . . . . . 0.537 ' HB1' HD13 ' A' ' 228' ' ' LEU . . . -84.77 165.78 17.51 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-N 115.616 -0.72 . . . . 0.0 109.822 -177.344 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 49.4 m -123.47 142.0 51.44 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 120.814 0.34 . . . . 0.0 111.443 -178.005 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 67.3 50.65 43.27 Favored Glycine 0 N--CA 1.452 -0.25 0 CA-C-N 115.812 -0.631 . . . . 0.0 113.58 175.317 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 262' ' ' LEU . . . . . 0.711 HD12 HG22 ' A' ' 257' ' ' VAL . 77.7 mt -99.64 145.83 27.15 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 117.086 0.443 . . . . 0.0 110.842 178.034 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 83.6 mt-30 -142.94 171.75 13.63 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.928 178.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 264' ' ' VAL . . . . . 0.441 HG12 ' O ' ' A' ' 292' ' ' VAL . 50.8 t -77.16 133.32 31.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 176.731 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . 0.466 ' O ' ' HE3' ' A' ' 337' ' ' LYS . . . 107.62 -7.83 36.76 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.44 -0.886 . . . . 0.0 112.619 -179.372 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 266' ' ' ASP . . . . . 0.568 ' HB2' HG22 ' A' ' 292' ' ' VAL . 63.4 m-20 -69.28 155.63 40.09 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-O 121.069 0.462 . . . . 0.0 110.567 178.262 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 267' ' ' ALA . . . . . 0.601 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -130.2 129.69 43.72 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.45 -0.795 . . . . 0.0 108.884 177.442 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 268' ' ' PHE . . . . . . . . . . . . . 3.2 p90 -151.38 175.63 12.06 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 119.97 -0.692 . . . . 0.0 111.466 -175.456 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 269' ' ' THR . . . . . 0.652 HG23 ' HB2' ' A' ' 287' ' ' PRO . 82.7 p -126.14 147.19 49.67 Favored 'General case' 0 C--N 1.32 -0.674 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 176.571 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 270' ' ' ILE . . . . . 0.429 HG23 HD13 ' A' ' 270' ' ' ILE . 47.1 mm -103.65 138.26 28.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 N-CA-C 110.236 -0.283 . . . . 0.0 110.236 179.381 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -63.34 135.4 56.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.442 -178.608 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 89.41 -23.19 20.02 Favored Glycine 0 CA--C 1.517 0.198 0 CA-C-N 115.92 -0.582 . . . . 0.0 112.712 179.755 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 42.5 t -86.09 130.24 36.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 120.925 0.393 . . . . 0.0 110.879 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 72.3 m-80 -135.24 142.08 45.91 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.329 179.671 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 65.2 p -84.04 165.81 18.25 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.252 0.549 . . . . 0.0 111.746 -178.279 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 35.4 m -113.64 175.82 2.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 115.315 -0.857 . . . . 0.0 110.668 179.432 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 277' ' ' HIS . . . . . 0.418 ' HB3' ' HA ' ' A' ' 281' ' ' LYS . 5.8 p80 22.04 77.75 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.866 0 O-C-N 124.822 1.326 . . . . 0.0 113.866 179.304 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 278' ' ' GLN . . . . . 0.417 ' HG3' HD12 ' A' ' 279' ' ' ILE . 2.7 tp-100 -62.03 -50.52 71.7 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.177 -179.055 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 279' ' ' ILE . . . . . 0.519 ' H ' ' HB3' ' A' ' 282' ' ' ASP . 2.5 mp -104.43 -77.44 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 174.814 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 35.9 p -141.11 92.61 2.5 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 177.477 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 281' ' ' LYS . . . . . 0.418 ' HA ' ' HB3' ' A' ' 277' ' ' HIS . 31.7 mmmt 59.82 26.99 16.23 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.058 -0.973 . . . . 0.0 110.503 -172.6 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 282' ' ' ASP . . . . . 0.519 ' HB3' ' H ' ' A' ' 279' ' ' ILE . 37.3 t70 -81.01 117.38 21.56 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.338 -0.846 . . . . 0.0 109.858 178.605 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 41.1 p -105.52 105.78 15.97 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.991 0.424 . . . . 0.0 110.931 -176.502 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 52.9 p -129.18 -7.58 4.82 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.183 -177.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 67.82 32.6 78.06 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.601 -0.809 . . . . 0.0 113.368 176.249 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 286' ' ' GLN . . . . . 0.4 ' HA ' ' HD3' ' A' ' 287' ' ' PRO . 11.7 mm100 -72.09 135.89 82.32 Favored Pre-proline 0 C--N 1.325 -0.479 0 CA-C-N 117.06 0.43 . . . . 0.0 110.2 179.106 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 287' ' ' PRO . . . . . 0.652 ' HB2' HG23 ' A' ' 269' ' ' THR . 41.0 Cg_exo -57.0 135.0 68.21 Favored 'Trans proline' 0 C--O 1.235 0.333 0 C-N-CA 122.465 2.11 . . . . 0.0 111.958 -178.778 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 2.5 tm0? -75.08 128.93 36.67 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 -177.294 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 46.4 t -94.19 123.83 46.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.935 0.398 . . . . 0.0 110.512 -177.621 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 290' ' ' PHE . . . . . 0.601 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 4.6 m-85 -97.28 168.6 10.32 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.818 -177.214 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 11.9 tpt180 -139.37 121.16 15.41 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 177.355 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . 0.568 HG22 ' HB2' ' A' ' 266' ' ' ASP . 60.7 t -75.61 134.25 29.58 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.913 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.868 -172.824 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 293' ' ' LEU . . . . . 0.5 ' N ' HD13 ' A' ' 293' ' ' LEU . 7.0 mp -104.38 -35.2 8.02 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.628 178.388 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 294' ' ' ALA . . . . . 0.527 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -149.75 137.95 20.51 Favored 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 120.667 -0.413 . . . . 0.0 111.641 -176.545 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 66.5 t -136.03 109.63 9.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.555 174.79 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 50.4 m -151.48 117.02 5.38 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.544 -177.279 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 61.21 46.97 93.4 Favored Glycine 0 C--N 1.33 0.218 0 C-N-CA 120.804 -0.712 . . . . 0.0 111.79 -177.83 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 76.3 p 51.78 19.79 1.01 Allowed 'General case' 0 N--CA 1.471 0.587 0 C-N-CA 123.76 0.824 . . . . 0.0 112.427 -175.169 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 54.3 m -105.22 116.68 32.35 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 176.756 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . 0.578 HG12 HG23 ' A' ' 302' ' ' ILE . 49.0 t -114.21 125.77 71.58 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.288 -172.753 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 53.9 m -87.77 115.76 25.44 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 172.78 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 302' ' ' ILE . . . . . 0.578 HG23 HG12 ' A' ' 300' ' ' VAL . 28.6 pt -110.81 147.81 14.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-O 121.867 0.842 . . . . 0.0 113.156 -169.012 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 303' ' ' SER . . . . . 0.499 ' HB3' HD11 ' A' ' 293' ' ' LEU . 48.2 t -151.23 148.82 23.27 Favored Pre-proline 0 C--N 1.317 -0.812 0 CA-C-N 113.808 -1.542 . . . . 0.0 106.911 174.487 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 304' ' ' PRO . . . . . 0.492 ' C ' ' HA ' ' A' ' 303' ' ' SER . 32.2 Cg_exo -64.31 152.71 74.16 Favored 'Cis proline' 0 C--N 1.332 -0.302 0 C-N-CA 124.252 -1.145 . . . . 0.0 113.299 0.969 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 305' ' ' LYS . . . . . 0.584 ' HE3' HD13 ' A' ' 307' ' ' LEU . 0.0 OUTLIER -82.04 148.81 28.41 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-N 114.888 -1.051 . . . . 0.0 110.184 173.761 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 306' ' ' ILE . . . . . 0.828 HG22 ' HA ' ' A' ' 325' ' ' LYS . 42.5 mm -84.23 117.85 30.47 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 N-CA-C 113.02 0.748 . . . . 0.0 113.02 -167.626 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 307' ' ' LEU . . . . . 0.613 HD12 ' O ' ' A' ' 319' ' ' TYR . 82.1 mt -121.46 100.0 44.94 Favored Pre-proline 0 C--N 1.331 -0.199 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.782 177.314 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 308' ' ' PRO . . . . . 0.708 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 16.0 Cg_exo -72.74 134.48 22.06 Favored 'Trans proline' 0 C--O 1.232 0.218 0 C-N-CA 123.19 2.593 . . . . 0.0 113.611 -176.271 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . 0.652 ' HA ' ' HB2' ' A' ' 316' ' ' SER . 46.4 t -72.18 -34.66 50.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.356 0.598 . . . . 0.0 109.409 171.345 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 87.8 mt-10 -77.07 36.27 0.17 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.288 -0.869 . . . . 0.0 111.939 179.777 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 20.3 t-20 -122.3 56.71 1.1 Allowed 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 -178.751 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 312' ' ' THR . . . . . 0.653 ' HB ' HG21 ' A' ' 314' ' ' VAL . 30.0 m 60.35 17.43 7.12 Favored 'General case' 0 CA--C 1.539 0.553 0 CA-C-O 121.716 0.77 . . . . 0.0 109.411 -171.762 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 37.1 t70 69.53 -2.58 1.88 Allowed 'General case' 0 CA--C 1.537 0.466 0 CA-C-N 114.728 -1.124 . . . . 0.0 111.233 -177.369 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 314' ' ' VAL . . . . . 0.653 HG21 ' HB ' ' A' ' 312' ' ' THR . 57.6 t -57.44 -45.59 85.67 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 N-CA-C 112.723 0.638 . . . . 0.0 112.723 -177.759 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . 0.515 ' HB3' ' O ' ' A' ' 308' ' ' PRO . . . -74.44 -17.54 60.77 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.021 0.439 . . . . 0.0 110.899 -179.714 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 316' ' ' SER . . . . . 0.652 ' HB2' ' HA ' ' A' ' 309' ' ' VAL . 44.3 t -81.36 -18.72 44.64 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.552 177.126 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 317' ' ' ARG . . . . . 0.688 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 37.3 mmm-85 -61.1 -55.84 40.34 Favored Pre-proline 0 CA--C 1.536 0.42 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.635 -176.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 318' ' ' PRO . . . . . 0.688 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 11.8 Cg_exo -71.98 -41.13 2.18 Favored 'Trans proline' 0 C--N 1.357 1.003 0 C-N-CA 121.565 1.51 . . . . 0.0 112.588 -178.516 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 319' ' ' TYR . . . . . 0.613 ' O ' HD12 ' A' ' 307' ' ' LEU . 1.0 OUTLIER 177.35 96.67 0.01 OUTLIER 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.103 177.653 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . 0.597 ' HB3' ' HA ' ' A' ' 316' ' ' SER . . . -69.68 138.51 53.02 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.077 176.899 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 19.6 p30 -129.23 -27.9 2.41 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.479 -0.328 . . . . 0.0 111.57 176.833 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 322' ' ' VAL . . . . . 0.434 ' O ' HG22 ' A' ' 309' ' ' VAL . 35.1 m -138.31 179.49 3.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.703 0.287 . . . . 0.0 110.596 177.758 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 -90.38 -32.72 16.33 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.502 177.776 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 324' ' ' ALA . . . . . 0.708 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -149.2 159.51 44.19 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.638 -0.255 . . . . 0.0 111.478 -175.351 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 325' ' ' LYS . . . . . 0.828 ' HA ' HG22 ' A' ' 306' ' ' ILE . 64.3 pttt -79.94 146.9 64.79 Favored Pre-proline 0 N--CA 1.452 -0.335 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 171.413 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -57.33 129.81 36.02 Favored 'Trans proline' 0 N--CA 1.462 -0.365 0 C-N-CA 122.253 1.969 . . . . 0.0 111.873 -178.299 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -75.13 121.79 22.61 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 174.285 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER 61.95 -135.95 0.52 Allowed 'General case' 0 C--N 1.332 -0.158 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 -167.474 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 329' ' ' SER . . . . . 0.712 ' HB2' ' O ' ' A' ' 230' ' ' VAL . 50.5 m -113.95 -41.45 3.55 Favored 'General case' 0 C--N 1.32 -0.711 0 C-N-CA 120.16 -0.616 . . . . 0.0 109.871 169.67 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 79.77 -171.04 0.04 OUTLIER 'General case' 0 N--CA 1.479 1.008 0 O-C-N 124.129 0.893 . . . . 0.0 113.394 170.819 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -83.77 157.22 22.17 Favored 'General case' 0 C--O 1.233 0.213 0 CA-C-N 115.176 -0.92 . . . . 0.0 111.107 -176.823 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 332' ' ' ILE . . . . . 0.42 HG21 HD12 ' A' ' 270' ' ' ILE . 1.5 mp -126.37 146.37 32.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.474 -174.854 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.446 ' HB ' ' OG1' ' A' ' 269' ' ' THR . 88.6 m -110.66 99.16 8.16 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.998 -0.742 . . . . 0.0 108.998 173.251 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 334' ' ' ILE . . . . . 0.573 HD12 HD21 ' A' ' 262' ' ' LEU . 37.8 mm -81.58 125.7 39.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -171.238 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 335' ' ' LEU . . . . . 0.429 ' HB2' ' O ' ' A' ' 267' ' ' ALA . 8.2 mp -113.07 167.3 10.64 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.074 -0.966 . . . . 0.0 109.958 172.167 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 74.0 m-80 -124.33 6.57 8.4 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 115.315 -0.857 . . . . 0.0 109.271 174.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 337' ' ' LYS . . . . . 0.466 ' HE3' ' O ' ' A' ' 265' ' ' GLY . 21.5 pttp . . . . . 0 C--O 1.244 0.798 0 O-C-N 124.656 1.223 . . . . 0.0 112.565 -179.418 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.833 0 N-CA-C 112.198 -0.361 . . . . 0.0 112.198 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 49.4 m 59.93 71.86 0.55 Allowed 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 121.003 0.43 . . . . 0.0 111.031 -178.021 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 88.8 m -69.14 -49.16 59.47 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.711 -179.238 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 86.7 tt0 53.23 45.83 27.76 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-O 121.588 0.709 . . . . 0.0 110.427 179.378 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 29.0 t -147.81 24.94 1.06 Allowed 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.559 0.695 . . . . 0.0 109.499 179.749 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 228' ' ' LEU . . . . . 0.581 HD13 ' HB1' ' A' ' 259' ' ' ALA . 89.8 mt -99.77 146.79 26.17 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.274 -0.875 . . . . 0.0 109.237 178.533 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 229' ' ' THR . . . . . 0.533 ' O ' HG21 ' A' ' 230' ' ' VAL . 72.5 p -128.93 178.75 6.16 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 119.835 -0.746 . . . . 0.0 111.075 -177.89 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . 0.775 HG23 HD13 ' A' ' 332' ' ' ILE . 75.7 t -147.15 127.68 5.39 Favored 'Isoleucine or valine' 0 C--O 1.237 0.434 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.482 -178.918 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 34.1 t -92.53 145.18 24.64 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.012 176.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 115.46 141.64 7.44 Favored Glycine 0 N--CA 1.444 -0.773 0 C-N-CA 120.619 -0.801 . . . . 0.0 111.647 -179.097 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 233' ' ' GLN . . . . . 0.817 ' HG3' ' H ' ' A' ' 328' ' ' GLU . 15.0 mp0 -101.75 103.69 30.16 Favored Pre-proline 0 C--N 1.321 -0.638 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 -177.739 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -85.3 122.47 2.47 Favored 'Trans proline' 0 N--CA 1.45 -1.084 0 C-N-CA 121.485 1.457 . . . . 0.0 111.751 179.64 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 235' ' ' GLU . . . . . 0.464 ' HG2' ' HB3' ' A' ' 325' ' ' LYS . 54.2 mt-10 -154.07 120.05 5.32 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.328 178.787 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 236' ' ' HIS . . . . . 0.455 ' NE2' ' HB2' ' A' ' 250' ' ' ASN . 63.3 t-80 -138.64 146.77 42.08 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 174.474 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 237' ' ' LYS . . . . . 0.653 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 5.8 mptt -122.34 135.66 54.76 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.765 -169.484 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 238' ' ' VAL . . . . . . . . . . . . . 46.7 t -70.78 124.5 27.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 115.661 -0.7 . . . . 0.0 109.706 175.765 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 239' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 -85.4 154.28 21.95 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.772 0.32 . . . . 0.0 110.347 179.477 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 240' ' ' ALA . . . . . . . . . . . . . . . -65.32 -32.13 73.62 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.352 -179.005 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 241' ' ' LYS . . . . . 0.693 ' O ' ' HD3' ' A' ' 241' ' ' LYS . 0.0 OUTLIER -141.32 144.88 34.84 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 121.256 0.55 . . . . 0.0 111.823 -179.899 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 242' ' ' ASP . . . . . 0.417 ' OD1' HG23 ' A' ' 248' ' ' VAL . 54.6 p-10 -106.97 -156.5 0.58 Allowed 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.081 174.18 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 32.7 p -68.29 -9.25 46.24 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 112.018 0.377 . . . . 0.0 112.018 176.594 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 5.5 m120 -111.18 -10.07 14.31 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.705 0.288 . . . . 0.0 111.253 176.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . 0.456 ' HA2' ' HB2' ' A' ' 241' ' ' LYS . . . 93.01 15.88 50.15 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.723 -0.751 . . . . 0.0 113.571 177.432 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 246' ' ' MET . . . . . . . . . . . . . 26.1 ptt? -113.09 151.19 43.98 Favored Pre-proline 0 C--N 1.324 -0.516 0 CA-C-N 117.121 0.46 . . . . 0.0 110.248 177.592 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 247' ' ' PRO . . . . . 0.471 ' C ' HG21 ' A' ' 248' ' ' VAL . 17.0 Cg_exo -68.84 118.19 5.51 Favored 'Trans proline' 0 C--N 1.346 0.418 0 C-N-CA 121.856 1.704 . . . . 0.0 111.592 -178.253 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . 0.471 HG21 ' C ' ' A' ' 247' ' ' PRO . 43.9 t -145.24 143.61 22.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.142 -177.152 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 249' ' ' ASP . . . . . 0.421 ' CG ' ' HE3' ' A' ' 305' ' ' LYS . 9.0 t70 -89.29 140.64 29.29 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 109.454 -0.572 . . . . 0.0 109.454 175.055 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 250' ' ' ASN . . . . . 0.455 ' HB2' ' NE2' ' A' ' 236' ' ' HIS . 67.4 m-80 -87.91 -64.99 1.06 Allowed 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 112.495 0.554 . . . . 0.0 112.495 -172.406 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . 0.432 ' HB2' ' CD2' ' A' ' 236' ' ' HIS . 68.6 mtp180 -113.61 158.77 20.4 Favored 'General case' 0 CA--C 1.511 -0.525 0 N-CA-C 114.322 1.23 . . . . 0.0 114.322 -171.82 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 4.7 mp0 -91.73 178.0 6.04 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 113.249 -1.796 . . . . 0.0 109.265 179.099 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . 0.588 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -80.75 93.08 1.46 Allowed Glycine 0 N--CA 1.446 -0.643 0 C-N-CA 120.312 -0.947 . . . . 0.0 112.23 177.748 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 72.7 p -94.5 116.33 28.66 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.022 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . 0.65 HD11 HG11 ' A' ' 230' ' ' VAL . 2.1 pp -136.24 171.53 16.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 N-CA-C 113.012 0.745 . . . . 0.0 113.012 -173.121 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 256' ' ' THR . . . . . 0.406 ' O ' HG12 ' A' ' 230' ' ' VAL . 64.9 m -111.65 117.89 34.15 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 177.505 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.501 HG11 HD11 ' A' ' 255' ' ' ILE . 34.9 m -90.9 144.7 8.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 N-CA-C 113.838 1.051 . . . . 0.0 113.838 -169.101 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 39.2 t -92.22 8.42 38.2 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 113.772 -1.558 . . . . 0.0 108.339 166.188 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 259' ' ' ALA . . . . . 0.581 ' HB1' HD13 ' A' ' 228' ' ' LEU . . . -92.85 166.13 12.57 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.274 -0.876 . . . . 0.0 109.908 -177.52 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 32.4 t -139.17 137.09 35.75 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.77 0.319 . . . . 0.0 110.158 178.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 97.26 29.4 7.96 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.199 -177.821 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 262' ' ' LEU . . . . . 0.695 HD22 HD13 ' A' ' 334' ' ' ILE . 79.2 mt -101.63 126.78 48.52 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.107 0.479 . . . . 0.0 111.16 -179.617 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 97.0 mm-40 -134.11 -178.92 5.25 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.257 -0.883 . . . . 0.0 108.873 177.359 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 41.0 t -77.81 131.12 35.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 176.653 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 106.41 9.01 32.16 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.305 -0.95 . . . . 0.0 113.195 179.021 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -88.88 163.32 15.68 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.994 0.426 . . . . 0.0 110.31 176.57 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 267' ' ' ALA . . . . . 0.698 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -135.38 146.52 48.42 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.474 -0.784 . . . . 0.0 109.023 177.917 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 268' ' ' PHE . . . . . . . . . . . . . 2.7 p90 -163.87 175.48 10.38 Favored 'General case' 0 C--N 1.325 -0.489 0 C-N-CA 120.054 -0.658 . . . . 0.0 111.709 -177.841 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 73.9 p -125.41 144.69 50.4 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.471 -0.786 . . . . 0.0 109.131 173.808 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 270' ' ' ILE . . . . . 0.484 HG23 HD13 ' A' ' 270' ' ' ILE . 58.7 mt -103.14 141.66 18.57 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 C-N-CA 121.127 -0.229 . . . . 0.0 110.968 -176.752 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -67.38 125.79 27.23 Favored 'General case' 0 C--O 1.232 0.133 0 CA-C-O 120.869 0.366 . . . . 0.0 110.947 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 91.82 -22.24 32.23 Favored Glycine 0 N--CA 1.453 -0.189 0 C-N-CA 121.058 -0.591 . . . . 0.0 112.194 -178.262 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . 0.515 HG22 ' HG3' ' A' ' 326' ' ' PRO . 48.9 t -94.58 102.55 13.73 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-O 121.33 0.586 . . . . 0.0 110.743 178.346 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 274' ' ' ASN . . . . . 0.695 ' HA ' ' HA ' ' A' ' 287' ' ' PRO . 70.7 m-80 -110.17 150.83 28.08 Favored 'General case' 0 C--N 1.318 -0.801 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 174.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 275' ' ' SER . . . . . 0.483 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 7.6 t -85.35 -169.58 2.71 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 120.301 -0.559 . . . . 0.0 110.092 -174.98 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 27.3 m -113.27 177.46 1.66 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 CA-C-N 115.612 -0.722 . . . . 0.0 112.054 179.553 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 277' ' ' HIS . . . . . 0.788 ' CG ' ' HA ' ' A' ' 281' ' ' LYS . 3.4 p80 -57.03 119.69 6.73 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 113.893 -1.503 . . . . 0.0 111.838 173.695 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -81.94 -49.52 10.21 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.987 -177.867 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 279' ' ' ILE . . . . . 0.438 ' CD1' ' H ' ' A' ' 279' ' ' ILE . 2.7 mp -68.18 -93.74 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.401 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.163 -174.759 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 36.2 p -137.98 68.24 1.4 Allowed 'General case' 0 C--O 1.235 0.307 0 CA-C-O 120.637 0.256 . . . . 0.0 111.393 -174.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 281' ' ' LYS . . . . . 0.788 ' HA ' ' CG ' ' A' ' 277' ' ' HIS . 0.0 OUTLIER 56.59 32.33 20.74 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.675 -177.016 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 282' ' ' ASP . . . . . 0.563 ' O ' ' HB3' ' A' ' 277' ' ' HIS . 1.6 m-20 -74.86 -177.03 3.11 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.645 176.134 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 68.9 p -106.57 108.07 19.39 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 120.76 0.314 . . . . 0.0 110.211 178.258 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 74.8 p -117.07 -58.29 2.08 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.681 -175.314 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 64.24 30.85 78.97 Favored Glycine 0 C--O 1.23 -0.124 0 C-N-CA 121.064 -0.589 . . . . 0.0 113.347 174.633 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 2.9 mm100 -101.12 129.69 26.58 Favored Pre-proline 0 C--N 1.323 -0.584 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 179.259 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 287' ' ' PRO . . . . . 0.695 ' HA ' ' HA ' ' A' ' 274' ' ' ASN . 48.3 Cg_exo -56.16 138.15 82.02 Favored 'Trans proline' 0 C--N 1.344 0.329 0 C-N-CA 122.563 2.175 . . . . 0.0 112.159 -179.356 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 288' ' ' GLN . . . . . 0.449 ' HA ' HE21 ' A' ' 288' ' ' GLN . 2.2 tp-100 -64.81 139.9 58.81 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.78 -179.069 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 52.8 t -97.42 124.0 50.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 176.205 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 290' ' ' PHE . . . . . 0.698 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 6.2 m-85 -98.87 151.44 20.85 Favored 'General case' 0 C--N 1.323 -0.559 0 C-N-CA 120.884 -0.326 . . . . 0.0 110.876 -174.578 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 37.2 mmt180 -116.97 118.86 33.59 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.691 -0.686 . . . . 0.0 109.34 174.187 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 48.9 t -75.56 127.52 37.05 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.954 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.874 -178.517 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 293' ' ' LEU . . . . . . . . . . . . . 84.8 mt -110.84 -19.48 12.81 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.928 -176.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 294' ' ' ALA . . . . . . . . . . . . . . . -155.72 138.3 15.05 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 111.85 0.315 . . . . 0.0 111.85 -178.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 60.5 t -138.14 132.59 42.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 175.039 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 41.5 t -157.95 110.61 2.38 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.677 -0.238 . . . . 0.0 110.97 -176.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 60.76 46.03 95.29 Favored Glycine 0 C--N 1.33 0.25 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.028 179.798 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 75.6 p 53.91 17.9 1.47 Allowed 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 123.887 0.875 . . . . 0.0 112.647 -175.845 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 52.9 m -102.77 109.55 21.18 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 108.015 -1.106 . . . . 0.0 108.015 171.171 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . 0.709 HG12 HG21 ' A' ' 302' ' ' ILE . 39.9 t -104.56 134.69 45.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.715 -169.124 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 94.3 m -96.99 109.31 22.08 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.352 -0.84 . . . . 0.0 108.997 172.626 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 302' ' ' ILE . . . . . 0.709 HG21 HG12 ' A' ' 300' ' ' VAL . 30.2 pt -110.66 138.06 40.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-O 121.648 0.737 . . . . 0.0 111.922 -175.37 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 303' ' ' SER . . . . . . . . . . . . . 50.5 m -129.54 150.95 77.1 Favored Pre-proline 0 C--N 1.317 -0.846 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 173.162 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 304' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_exo -68.22 176.54 27.47 Favored 'Cis proline' 0 C--N 1.333 -0.282 0 C-N-CA 124.637 -0.985 . . . . 0.0 112.892 1.015 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 305' ' ' LYS . . . . . 0.569 ' HE2' ' CD1' ' A' ' 307' ' ' LEU . 0.0 OUTLIER -94.04 166.81 11.96 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.492 178.583 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 306' ' ' ILE . . . . . 0.461 HD12 HG23 ' A' ' 306' ' ' ILE . 42.6 mm -87.47 96.3 5.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.366 -174.144 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 307' ' ' LEU . . . . . 0.569 ' CD1' ' HE2' ' A' ' 305' ' ' LYS . 84.2 mt -106.82 110.32 63.6 Favored Pre-proline 0 C--N 1.33 -0.28 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 175.859 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 308' ' ' PRO . . . . . 0.615 ' HG3' ' HE3' ' A' ' 325' ' ' LYS . 79.1 Cg_endo -82.69 157.8 16.24 Favored 'Trans proline' 0 C--O 1.231 0.143 0 C-N-CA 122.512 2.141 . . . . 0.0 114.364 -172.12 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 39.6 t -81.76 -11.17 12.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 114.958 -1.019 . . . . 0.0 108.467 168.782 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 4.6 mm-40 -70.54 -7.03 40.77 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.19 -0.914 . . . . 0.0 110.219 176.618 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 23.8 t-20 -64.07 118.29 8.3 Favored 'General case' 0 N--CA 1.451 -0.391 0 CA-C-N 115.605 -0.725 . . . . 0.0 109.45 -179.141 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 19.5 m -86.3 -17.19 35.25 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.36 -171.441 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 313' ' ' ASP . . . . . 0.573 ' O ' ' HG3' ' A' ' 317' ' ' ARG . 9.8 t70 -71.83 118.58 14.86 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 178.438 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 41.2 t -59.08 -36.4 62.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.054 -0.521 . . . . 0.0 112.273 -173.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -73.87 -25.36 60.0 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.502 0.191 . . . . 0.0 111.38 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 32.6 t -94.55 -6.22 44.16 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.693 -0.23 . . . . 0.0 111.096 -179.007 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 317' ' ' ARG . . . . . 0.573 ' HG3' ' O ' ' A' ' 313' ' ' ASP . 76.4 mtp180 -59.52 -49.6 91.39 Favored Pre-proline 0 N--CA 1.468 0.464 0 N-CA-C 112.392 0.516 . . . . 0.0 112.392 177.837 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 318' ' ' PRO . . . . . 0.499 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 54.3 Cg_exo -56.5 -24.4 52.86 Favored 'Trans proline' 0 C--N 1.359 1.118 0 C-N-CA 122.477 2.118 . . . . 0.0 112.756 -179.803 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 319' ' ' TYR . . . . . 0.521 ' O ' HD11 ' A' ' 307' ' ' LEU . 11.6 m-30 -77.08 -6.19 51.84 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.369 -0.832 . . . . 0.0 111.495 -175.68 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -54.85 130.28 40.51 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-O 120.976 0.417 . . . . 0.0 111.723 -177.662 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 26.7 t-20 -110.71 -37.88 5.31 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.663 -0.699 . . . . 0.0 109.554 179.294 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 322' ' ' VAL . . . . . 0.483 ' HA ' ' HA ' ' A' ' 275' ' ' SER . 34.4 m -130.74 170.28 19.86 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 115.267 -0.879 . . . . 0.0 110.16 179.083 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 73.2 m-20 -62.11 -44.14 97.31 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 112.386 0.513 . . . . 0.0 112.386 -177.782 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 324' ' ' ALA . . . . . 0.444 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -156.56 168.41 27.47 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 112.666 0.617 . . . . 0.0 112.666 -172.493 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 325' ' ' LYS . . . . . 0.615 ' HE3' ' HG3' ' A' ' 308' ' ' PRO . 9.9 mtmp? -102.05 106.45 47.87 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 114.816 -1.084 . . . . 0.0 108.531 167.582 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 326' ' ' PRO . . . . . 0.515 ' HG3' HG22 ' A' ' 273' ' ' VAL . 74.3 Cg_endo -80.24 162.51 22.77 Favored 'Trans proline' 0 N--CA 1.459 -0.506 0 C-N-CA 122.018 1.812 . . . . 0.0 112.58 -175.59 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -80.03 122.55 26.88 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 174.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 328' ' ' GLU . . . . . 0.817 ' H ' ' HG3' ' A' ' 233' ' ' GLN . 85.0 tt0 71.89 162.81 0.26 Allowed 'General case' 0 CA--C 1.532 0.251 0 O-C-N 124.093 0.87 . . . . 0.0 109.672 -176.006 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 329' ' ' SER . . . . . 0.614 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 50.6 m -85.34 -14.57 46.02 Favored 'General case' 0 C--N 1.323 -0.554 0 C-N-CA 120.913 -0.315 . . . . 0.0 110.861 -177.375 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 330' ' ' ALA . . . . . 0.449 ' H ' ' HG2' ' A' ' 328' ' ' GLU . . . 63.5 -160.36 0.3 Allowed 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 121.381 0.61 . . . . 0.0 112.611 173.015 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 331' ' ' ALA . . . . . 0.414 ' HA ' ' HA ' ' A' ' 229' ' ' THR . . . -82.03 148.14 28.79 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.292 -0.867 . . . . 0.0 110.131 178.253 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 332' ' ' ILE . . . . . 0.775 HD13 HG23 ' A' ' 230' ' ' VAL . 43.4 mt -124.24 144.63 33.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-O 121.169 0.509 . . . . 0.0 111.304 -178.148 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 29.6 m -104.21 97.7 7.62 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.494 -0.775 . . . . 0.0 109.217 179.611 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 334' ' ' ILE . . . . . 0.695 HD13 HD22 ' A' ' 262' ' ' LEU . 36.4 mm -78.55 127.91 38.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 112.858 0.688 . . . . 0.0 112.858 -170.772 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 335' ' ' LEU . . . . . 0.507 ' N ' HD12 ' A' ' 335' ' ' LEU . 8.2 mp -109.15 176.13 5.2 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 114.871 -1.059 . . . . 0.0 110.122 171.541 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 23.0 p30 -131.61 9.57 4.67 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 115.321 -0.854 . . . . 0.0 109.628 173.526 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 337' ' ' LYS . . . . . 0.526 ' NZ ' ' HB3' ' A' ' 337' ' ' LYS . 8.1 mtpm? . . . . . 0 C--O 1.244 0.794 0 CA-C-O 118.552 -0.737 . . . . 0.0 110.891 178.745 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.895 0 N-CA-C 111.948 -0.461 . . . . 0.0 111.948 . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 55.4 p -93.18 -36.9 12.38 Favored 'General case' 0 C--N 1.326 -0.423 0 O-C-N 122.712 -0.287 . . . . 0.0 110.985 179.795 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 41.9 m 73.62 -57.46 0.62 Allowed 'General case' 0 N--CA 1.467 0.424 0 O-C-N 123.921 0.763 . . . . 0.0 110.791 -179.478 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 4.7 mm-40 57.05 34.27 24.65 Favored 'General case' 0 N--CA 1.465 0.302 0 C-N-CA 123.364 0.665 . . . . 0.0 112.41 176.88 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 65.9 p -141.3 21.31 2.23 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.812 173.387 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 228' ' ' LEU . . . . . 0.733 ' HB3' ' HB3' ' A' ' 259' ' ' ALA . 83.4 mt -98.01 126.82 43.6 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-N 115.614 -0.721 . . . . 0.0 109.761 -179.548 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 229' ' ' THR . . . . . 0.568 ' O ' HG23 ' A' ' 230' ' ' VAL . 55.5 p -124.73 179.24 5.07 Favored 'General case' 0 C--N 1.322 -0.625 0 C-N-CA 120.458 -0.497 . . . . 0.0 110.3 -179.611 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . 0.66 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 63.5 t -147.63 146.92 17.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 120.602 0.239 . . . . 0.0 110.672 -178.234 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 231' ' ' SER . . . . . 0.501 ' HA ' ' HB3' ' A' ' 328' ' ' GLU . 48.9 m -132.11 96.62 3.94 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 173.386 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . 0.421 ' HA3' ' HA ' ' A' ' 255' ' ' ILE . . . -122.5 -163.05 11.74 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 119.854 -1.165 . . . . 0.0 113.693 -172.889 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 233' ' ' GLN . . . . . 0.587 ' HB3' ' HD2' ' A' ' 234' ' ' PRO . 94.6 mm-40 -85.49 163.63 43.76 Favored Pre-proline 0 C--N 1.327 -0.397 0 CA-C-N 115.615 -0.293 . . . . 0.0 110.541 -178.833 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 234' ' ' PRO . . . . . 0.587 ' HD2' ' HB3' ' A' ' 233' ' ' GLN . 9.5 Cg_endo -55.37 134.3 63.1 Favored 'Trans proline' 0 C--N 1.35 0.646 0 C-N-CA 122.871 2.38 . . . . 0.0 113.442 -176.51 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 235' ' ' GLU . . . . . 0.554 ' HB2' ' CE ' ' A' ' 325' ' ' LYS . 57.7 mt-10 -97.18 124.79 41.34 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 114.982 -1.008 . . . . 0.0 108.452 177.903 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 6.3 p80 -174.1 172.81 3.27 Favored 'General case' 0 CA--C 1.521 -0.152 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 -175.145 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 237' ' ' LYS . . . . . 0.764 ' HB3' ' HG3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -161.41 125.25 3.32 Favored 'General case' 0 CA--C 1.529 0.172 0 CA-C-O 121.546 0.688 . . . . 0.0 110.881 165.649 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 238' ' ' VAL . . . . . . . . . . . . . 40.9 t -108.85 156.49 9.44 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.81 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 172.266 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 239' ' ' GLU . . . . . . . . . . . . . 16.4 pt-20 -54.57 152.22 7.07 Favored 'General case' 0 C--O 1.235 0.32 0 N-CA-C 111.582 0.216 . . . . 0.0 111.582 -177.863 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 240' ' ' ALA . . . . . . . . . . . . . . . -33.24 -55.15 0.41 Allowed 'General case' 0 N--CA 1.471 0.61 0 N-CA-C 113.729 1.011 . . . . 0.0 113.729 -175.284 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 241' ' ' LYS . . . . . 0.547 ' HD2' ' O ' ' A' ' 241' ' ' LYS . 0.0 OUTLIER -135.05 150.68 50.32 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.763 0.316 . . . . 0.0 111.472 -179.294 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -96.37 -158.2 0.64 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.477 -177.77 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 65.0 m -60.23 -33.02 71.68 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.233 -0.439 . . . . 0.0 112.111 -177.936 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 50.7 t30 -87.87 -13.35 42.27 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 121.038 0.447 . . . . 0.0 110.387 179.247 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . 0.518 ' HA2' ' HB2' ' A' ' 241' ' ' LYS . . . 84.56 24.57 45.99 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.546 -0.835 . . . . 0.0 113.206 176.011 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 246' ' ' MET . . . . . 0.413 ' HA ' ' HD3' ' A' ' 247' ' ' PRO . 19.4 ptp -92.44 141.15 24.44 Favored Pre-proline 0 C--N 1.327 -0.411 0 CA-C-N 117.007 0.403 . . . . 0.0 110.173 176.042 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 247' ' ' PRO . . . . . 0.413 ' HD3' ' HA ' ' A' ' 246' ' ' MET . 20.0 Cg_exo -66.73 121.87 9.16 Favored 'Trans proline' 0 C--N 1.344 0.307 0 C-N-CA 122.547 2.165 . . . . 0.0 112.484 -176.95 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 47.7 t -91.51 140.73 15.57 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 176.188 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -78.0 89.97 4.17 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.231 0.538 . . . . 0.0 110.363 -178.328 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 250' ' ' ASN . . . . . 0.674 ' HB2' ' HB2' ' A' ' 237' ' ' LYS . 22.1 p30 -100.31 9.75 42.23 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.791 -177.067 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 82.9 mtm180 -113.61 161.87 16.91 Favored 'General case' 0 CA--C 1.509 -0.613 0 N-CA-C 113.151 0.796 . . . . 0.0 113.151 -177.712 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 252' ' ' GLN . . . . . 0.47 ' HA ' HE21 ' A' ' 252' ' ' GLN . 2.5 mm100 55.58 179.74 0.04 OUTLIER 'General case' 0 N--CA 1.471 0.606 0 CA-C-N 113.616 -1.629 . . . . 0.0 113.425 170.65 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -172.11 113.33 0.48 Allowed Glycine 0 N--CA 1.448 -0.555 0 CA-C-N 114.723 -1.126 . . . . 0.0 110.644 178.418 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 74.1 p -95.52 117.47 30.47 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 117.399 0.599 . . . . 0.0 110.771 -175.152 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . 0.499 ' HB ' ' CG1' ' A' ' 230' ' ' VAL . 22.7 pt -120.81 132.59 69.93 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-O 121.239 0.542 . . . . 0.0 111.97 -175.447 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 60.7 m -88.34 110.55 20.86 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 173.874 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.658 HG12 HG21 ' A' ' 230' ' ' VAL . 33.2 m -90.1 143.06 11.98 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.84 0 C-N-CA 119.341 -0.943 . . . . 0.0 112.798 -167.89 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 25.0 m -91.61 9.23 33.09 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 113.852 -1.522 . . . . 0.0 108.301 169.915 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 259' ' ' ALA . . . . . 0.733 ' HB3' ' HB3' ' A' ' 228' ' ' LEU . . . -100.5 178.19 4.8 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 114.725 -1.125 . . . . 0.0 109.55 -177.314 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 42.0 t -145.03 151.38 38.46 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.782 0.325 . . . . 0.0 110.79 179.113 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 84.52 15.87 67.57 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.982 -0.628 . . . . 0.0 112.876 178.544 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 262' ' ' LEU . . . . . 0.423 ' O ' HG11 ' A' ' 295' ' ' VAL . 63.4 mt -85.38 129.92 34.7 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.678 0.275 . . . . 0.0 110.703 -179.11 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 14.4 mm-40 -139.95 173.04 11.92 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.726 178.93 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 264' ' ' VAL . . . . . 0.442 HG13 ' O ' ' A' ' 292' ' ' VAL . 36.1 t -67.63 137.89 23.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 C-N-CA 121.001 -0.279 . . . . 0.0 110.34 -179.852 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 101.93 4.7 51.24 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.541 -0.837 . . . . 0.0 112.962 177.648 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 68.4 m-20 -85.84 137.7 32.58 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.257 0.551 . . . . 0.0 110.143 177.193 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 267' ' ' ALA . . . . . 0.603 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -119.85 122.98 42.52 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.262 -0.881 . . . . 0.0 108.741 178.07 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 268' ' ' PHE . . . . . 0.504 ' HB3' ' HA ' ' A' ' 334' ' ' ILE . 7.8 p90 -142.3 168.31 20.05 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.097 -0.641 . . . . 0.0 112.309 -169.893 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 76.0 p -115.4 162.77 16.68 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 114.859 -1.064 . . . . 0.0 108.486 170.89 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 270' ' ' ILE . . . . . 0.508 HG23 HD12 ' A' ' 270' ' ' ILE . 59.5 mt -126.05 141.96 44.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.693 -178.5 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -66.36 112.51 4.06 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.97 179.439 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 272' ' ' GLY . . . . . 0.432 ' HA3' ' HG3' ' A' ' 326' ' ' PRO . . . 104.21 -9.43 50.04 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.642 -0.789 . . . . 0.0 112.467 179.947 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . 0.486 HG21 ' HB ' ' A' ' 270' ' ' ILE . 58.3 t -102.15 102.95 14.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.884 0.373 . . . . 0.0 110.17 178.796 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 6.9 m120 -126.76 116.38 20.83 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.058 -177.352 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 275' ' ' SER . . . . . 0.474 ' HB3' ' HB2' ' A' ' 288' ' ' GLN . 29.2 p -72.72 161.78 30.32 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 113.24 0.83 . . . . 0.0 113.24 -172.401 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 19.4 m -118.21 178.6 2.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 114.644 -1.162 . . . . 0.0 110.165 178.436 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 85.1 m-70 -112.23 105.08 13.31 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 171.548 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 4.9 mp0 -74.18 -35.88 64.01 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.645 -0.252 . . . . 0.0 111.329 -173.445 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 2.1 mp -67.9 -55.94 14.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.983 -176.007 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 75.9 p -88.33 -3.81 58.78 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 111.782 0.289 . . . . 0.0 111.782 -177.64 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 28.0 tptp 58.81 53.1 6.04 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 121.441 0.638 . . . . 0.0 110.23 179.391 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -117.03 136.75 52.72 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.605 -176.93 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 66.8 p -107.63 127.53 53.74 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.149 -179.943 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 70.7 p -134.49 -30.75 1.11 Allowed 'General case' 0 C--N 1.321 -0.645 0 CA-C-O 120.774 0.321 . . . . 0.0 111.424 -176.709 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 79.39 32.48 38.25 Favored Glycine 0 N--CA 1.448 -0.536 0 C-N-CA 120.408 -0.901 . . . . 0.0 112.666 178.214 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 71.3 mt-30 -85.0 124.43 72.39 Favored Pre-proline 0 C--N 1.326 -0.415 0 CA-C-N 116.903 0.352 . . . . 0.0 110.489 179.973 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 287' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_exo -59.53 126.0 19.44 Favored 'Trans proline' 0 C--N 1.345 0.395 0 C-N-CA 122.281 1.988 . . . . 0.0 111.285 178.272 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 288' ' ' GLN . . . . . 0.474 ' HB2' ' HB3' ' A' ' 275' ' ' SER . 50.6 tt0 -80.4 150.55 29.76 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.045 0.45 . . . . 0.0 111.589 -175.212 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 50.0 t -99.16 127.35 51.93 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 CA-C-N 115.327 -0.851 . . . . 0.0 110.221 179.278 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 290' ' ' PHE . . . . . 0.603 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 4.0 m-85 -101.2 168.7 9.4 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.562 -0.29 . . . . 0.0 111.025 -176.771 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 21.6 mmt85 -126.49 120.78 30.55 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.264 0.554 . . . . 0.0 110.745 174.418 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . 0.442 ' O ' HG13 ' A' ' 264' ' ' VAL . 59.5 t -78.24 128.56 38.23 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.829 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.313 176.035 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 293' ' ' LEU . . . . . . . . . . . . . 83.5 mt -109.0 -30.09 8.25 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 111.986 0.365 . . . . 0.0 111.986 -177.762 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 294' ' ' ALA . . . . . . . . . . . . . . . -152.44 139.94 19.65 Favored 'General case' 0 C--N 1.329 -0.296 0 C-N-CA 121.171 -0.212 . . . . 0.0 111.334 179.717 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . 0.423 HG11 ' O ' ' A' ' 262' ' ' LEU . 55.3 t -133.48 128.52 54.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 175.118 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 27.2 m -145.64 97.13 2.93 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.917 -176.316 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 57.45 61.03 7.94 Favored Glycine 0 C--N 1.33 0.224 0 C-N-CA 121.009 -0.615 . . . . 0.0 112.531 178.814 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 81.8 p 56.71 5.4 0.21 Allowed 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 124.395 1.078 . . . . 0.0 113.253 -177.17 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 97.4 m -97.88 106.31 18.6 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 171.623 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . 0.539 HG13 HG23 ' A' ' 302' ' ' ILE . 38.8 t -109.26 120.93 61.48 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.797 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.193 -170.883 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 52.6 m -89.66 105.7 17.98 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 174.526 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 302' ' ' ILE . . . . . 0.539 HG23 HG13 ' A' ' 300' ' ' VAL . 2.4 pp -111.72 179.13 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 121.893 0.854 . . . . 0.0 112.861 -174.898 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 303' ' ' SER . . . . . 0.442 ' HA ' ' O ' ' A' ' 304' ' ' PRO . 67.5 p -160.0 157.47 25.43 Favored Pre-proline 0 C--N 1.314 -0.961 0 CA-C-N 113.668 -1.606 . . . . 0.0 106.678 174.714 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 304' ' ' PRO . . . . . 0.442 ' O ' ' HA ' ' A' ' 303' ' ' SER . 3.8 Cg_exo -78.26 -141.67 0.2 Allowed 'Cis proline' 0 CA--C 1.536 0.605 0 CA-C-N 119.84 0.979 . . . . 0.0 112.993 1.057 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 305' ' ' LYS . . . . . 0.764 ' HG3' ' HB3' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -130.4 171.02 13.42 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.014 -178.545 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 306' ' ' ILE . . . . . 0.585 HG21 HG23 ' A' ' 322' ' ' VAL . 47.2 mm -132.36 129.35 59.38 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.619 0 C-N-CA 119.242 -0.983 . . . . 0.0 113.57 -164.765 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 307' ' ' LEU . . . . . 0.668 HD13 ' HA ' ' A' ' 316' ' ' SER . 88.0 mt -134.39 125.44 17.75 Favored Pre-proline 0 CA--C 1.514 -0.435 0 CA-C-O 120.883 0.373 . . . . 0.0 111.459 170.287 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 308' ' ' PRO . . . . . 0.976 ' HG2' ' HB2' ' A' ' 311' ' ' ASN . 66.8 Cg_endo -84.24 157.71 13.0 Favored 'Trans proline' 0 N--CA 1.455 -0.782 0 C-N-CA 122.89 2.394 . . . . 0.0 112.711 179.041 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 44.5 t -80.79 -18.93 11.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-O 121.587 0.708 . . . . 0.0 109.126 172.104 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 54.7 mt-10 -94.62 34.91 1.27 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.475 -0.784 . . . . 0.0 111.141 177.613 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.976 ' HB2' ' HG2' ' A' ' 308' ' ' PRO . 19.6 t-20 -103.18 142.09 34.75 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -178.443 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 26.3 m -83.27 -7.46 59.59 Favored 'General case' 0 CA--C 1.54 0.587 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.447 -175.05 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 313' ' ' ASP . . . . . 0.411 ' O ' ' HG3' ' A' ' 317' ' ' ARG . 62.9 m-20 -79.62 140.11 37.23 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.684 0.278 . . . . 0.0 110.821 177.818 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 46.1 t -64.4 -45.63 95.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.655 -177.964 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -75.54 -22.42 57.07 Favored 'General case' 0 N--CA 1.464 0.262 0 N-CA-C 111.999 0.37 . . . . 0.0 111.999 -176.204 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 316' ' ' SER . . . . . 0.668 ' HA ' HD13 ' A' ' 307' ' ' LEU . 46.1 t -73.14 -21.52 60.7 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.533 -0.303 . . . . 0.0 111.771 -178.16 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 317' ' ' ARG . . . . . 0.674 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 73.0 mtp180 -74.24 -54.76 3.19 Favored Pre-proline 0 CA--C 1.536 0.434 0 N-CA-C 112.23 0.456 . . . . 0.0 112.23 -176.25 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 318' ' ' PRO . . . . . 0.674 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 16.8 Cg_exo -68.79 -38.66 9.81 Favored 'Trans proline' 0 C--N 1.354 0.848 0 C-N-CA 121.978 1.785 . . . . 0.0 112.268 -178.852 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 319' ' ' TYR . . . . . 0.522 ' O ' HD11 ' A' ' 307' ' ' LEU . 3.2 m-85 -90.11 30.43 1.09 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.089 0.471 . . . . 0.0 110.576 -179.903 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -65.9 159.41 25.6 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.679 -0.692 . . . . 0.0 111.059 179.454 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -142.43 -26.28 0.63 Allowed 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.866 -178.551 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 322' ' ' VAL . . . . . 0.585 HG23 HG21 ' A' ' 306' ' ' ILE . 33.8 m -132.93 174.13 13.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.402 179.458 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -85.4 -12.76 51.28 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 112.068 0.395 . . . . 0.0 112.068 -179.05 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 324' ' ' ALA . . . . . 0.587 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -178.73 163.42 1.45 Allowed 'General case' 0 N--CA 1.469 0.485 0 CA-C-O 120.737 0.304 . . . . 0.0 111.619 -176.313 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 325' ' ' LYS . . . . . 0.622 ' HZ1' ' HB3' ' A' ' 325' ' ' LYS . 6.7 mtpm? -120.56 134.13 24.15 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.731 172.974 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 326' ' ' PRO . . . . . 0.648 ' HB2' ' HB3' ' A' ' 330' ' ' ALA . 3.4 Cg_exo -78.26 167.81 22.6 Favored 'Trans proline' 0 N--CA 1.459 -0.549 0 C-N-CA 122.803 2.335 . . . . 0.0 111.578 177.101 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -65.18 137.15 57.43 Favored 'General case' 0 C--O 1.235 0.334 0 N-CA-C 110.129 -0.323 . . . . 0.0 110.129 177.886 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 328' ' ' GLU . . . . . 0.501 ' HB3' ' HA ' ' A' ' 231' ' ' SER . 55.2 mm-40 59.74 -128.41 1.12 Allowed 'General case' 0 C--O 1.232 0.164 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 -174.163 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 329' ' ' SER . . . . . 0.66 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 42.0 m -111.83 -10.55 14.01 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.548 -0.296 . . . . 0.0 110.204 175.339 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 330' ' ' ALA . . . . . 0.648 ' HB3' ' HB2' ' A' ' 326' ' ' PRO . . . 73.21 -166.39 0.11 Allowed 'General case' 0 N--CA 1.474 0.757 0 N-CA-C 113.56 0.948 . . . . 0.0 113.56 173.824 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -83.16 143.69 30.33 Favored 'General case' 0 CA--C 1.519 -0.223 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.56 -178.852 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 332' ' ' ILE . . . . . 0.495 HG13 HG22 ' A' ' 230' ' ' VAL . 23.1 mm -113.32 145.17 19.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.562 -171.875 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 29.7 m -118.98 96.59 5.3 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 174.314 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 334' ' ' ILE . . . . . 0.504 ' HA ' ' HB3' ' A' ' 268' ' ' PHE . 35.7 mm -83.15 130.07 36.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 N-CA-C 112.636 0.606 . . . . 0.0 112.636 -172.968 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 335' ' ' LEU . . . . . 0.447 ' HB2' ' O ' ' A' ' 267' ' ' ALA . 7.3 mp -112.52 160.95 17.3 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.23 -0.896 . . . . 0.0 110.089 171.962 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 72.8 m-80 -112.22 -0.29 15.56 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.261 -0.882 . . . . 0.0 109.209 174.132 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 27.9 mtpp . . . . . 0 C--O 1.245 0.845 0 O-C-N 124.191 0.932 . . . . 0.0 111.2 -178.281 . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.872 0 N-CA-C 112.044 -0.423 . . . . 0.0 112.044 . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 32.0 t 60.75 81.75 0.18 Allowed 'General case' 0 C--O 1.234 0.239 0 C-N-CA 122.864 0.466 . . . . 0.0 111.075 -179.863 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 34.5 p -77.05 -94.13 0.03 OUTLIER 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.375 176.673 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 17.2 tp10 -123.82 75.15 1.33 Allowed 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 173.607 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 43.6 t 65.56 -98.36 0.06 Allowed 'General case' 0 C--O 1.234 0.273 0 CA-C-N 115.374 -0.83 . . . . 0.0 109.426 -171.183 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 228' ' ' LEU . . . . . 0.527 ' HB3' ' HB2' ' A' ' 259' ' ' ALA . 91.7 mt -130.11 125.18 34.49 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 172.461 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 229' ' ' THR . . . . . 0.582 ' O ' HG21 ' A' ' 230' ' ' VAL . 37.6 p -117.87 175.19 5.78 Favored 'General case' 0 C--N 1.32 -0.674 0 C-N-CA 119.483 -0.887 . . . . 0.0 111.214 -177.087 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . 0.922 HG23 HD12 ' A' ' 332' ' ' ILE . 60.6 t -148.61 141.44 18.4 Favored 'Isoleucine or valine' 0 C--O 1.24 0.56 0 CA-C-O 120.905 0.383 . . . . 0.0 110.788 -176.448 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 50.0 m -109.98 117.74 34.59 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.907 175.123 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 177.61 169.0 38.1 Favored Glycine 0 N--CA 1.447 -0.578 0 N-CA-C 111.087 -0.805 . . . . 0.0 111.087 -177.903 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 72.2 mt-30 -111.75 101.51 51.43 Favored Pre-proline 0 C--N 1.323 -0.57 0 CA-C-N 117.148 0.474 . . . . 0.0 111.62 -177.86 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_endo -83.62 125.99 3.95 Favored 'Trans proline' 0 N--CA 1.453 -0.864 0 C-N-CA 122.986 2.457 . . . . 0.0 110.331 173.932 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 56.0 mm-40 -120.63 163.55 17.86 Favored 'General case' 0 C--N 1.321 -0.674 0 C-N-CA 120.576 -0.45 . . . . 0.0 111.831 -172.572 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 236' ' ' HIS . . . . . 0.533 ' HB3' ' O ' ' A' ' 306' ' ' ILE . 19.3 p-80 -108.76 145.89 34.43 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.339 172.433 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 237' ' ' LYS . . . . . 0.507 ' HZ3' ' NE2' ' A' ' 252' ' ' GLN . 0.0 OUTLIER -166.98 173.99 8.81 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.569 178.099 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 238' ' ' VAL . . . . . 0.564 HG22 ' SD ' ' A' ' 246' ' ' MET . 95.8 t -70.27 147.87 11.31 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-N 115.451 -0.795 . . . . 0.0 110.396 172.63 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 239' ' ' GLU . . . . . 0.552 ' HA ' ' HB2' ' A' ' 249' ' ' ASP . 14.8 pt-20 -68.32 176.5 2.76 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.958 178.111 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 240' ' ' ALA . . . . . 0.656 ' O ' ' HA ' ' A' ' 248' ' ' VAL . . . -29.19 -59.13 0.14 Allowed 'General case' 0 N--CA 1.473 0.691 0 O-C-N 124.318 1.011 . . . . 0.0 113.29 -177.647 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 241' ' ' LYS . . . . . 0.581 ' HD2' ' O ' ' A' ' 241' ' ' LYS . 0.1 OUTLIER -158.47 148.53 19.81 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-O 121.175 0.512 . . . . 0.0 111.78 177.647 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 242' ' ' ASP . . . . . 0.579 ' OD1' ' HG2' ' A' ' 246' ' ' MET . 13.1 p-10 -105.92 -157.89 0.63 Allowed 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 177.239 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 48.4 t -65.79 -33.05 74.96 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.748 0.308 . . . . 0.0 110.493 175.162 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 43.9 t30 -86.63 -15.61 39.18 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.564 -179.852 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 72.03 44.82 44.28 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.519 -0.848 . . . . 0.0 112.805 178.004 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 246' ' ' MET . . . . . 0.647 ' HB2' ' HD2' ' A' ' 247' ' ' PRO . 25.1 ptm -77.26 170.04 18.22 Favored Pre-proline 0 CA--C 1.533 0.321 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 177.539 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 247' ' ' PRO . . . . . 0.647 ' HD2' ' HB2' ' A' ' 246' ' ' MET . 51.7 Cg_exo -42.81 142.96 1.89 Allowed 'Trans proline' 0 C--N 1.36 1.143 0 C-N-CA 123.304 2.67 . . . . 0.0 114.677 -172.322 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . 0.656 ' HA ' ' O ' ' A' ' 240' ' ' ALA . 57.5 t -68.02 152.81 9.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 114.55 -1.205 . . . . 0.0 111.065 -177.978 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 249' ' ' ASP . . . . . 0.575 ' N ' HG11 ' A' ' 248' ' ' VAL . 9.8 t0 -49.9 115.02 1.22 Allowed 'General case' 0 CA--C 1.528 0.125 0 O-C-N 123.96 0.788 . . . . 0.0 109.367 179.109 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 250' ' ' ASN . . . . . 0.489 ' H ' ' HG3' ' A' ' 237' ' ' LYS . 19.9 p30 -93.57 166.4 12.26 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 113.762 1.023 . . . . 0.0 113.762 -164.086 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . 0.452 ' HG2' ' OD1' ' A' ' 250' ' ' ASN . 18.7 ptp180 43.86 -145.4 0.1 Allowed 'General case' 0 N--CA 1.475 0.788 0 CA-C-N 113.789 -1.551 . . . . 0.0 113.301 -179.316 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 252' ' ' GLN . . . . . 0.507 ' NE2' ' HZ3' ' A' ' 237' ' ' LYS . 53.8 mt-30 69.18 160.57 0.19 Allowed 'General case' 0 N--CA 1.471 0.583 0 CA-C-O 121.391 0.615 . . . . 0.0 110.959 -173.018 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . 0.9 ' O ' ' HA ' ' A' ' 301' ' ' THR . . . 100.35 -23.76 34.62 Favored Glycine 0 N--CA 1.438 -1.203 0 C-N-CA 120.068 -1.063 . . . . 0.0 112.74 -179.248 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 60.0 p -135.81 118.79 16.36 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 118.01 0.905 . . . . 0.0 112.724 -176.676 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . 0.766 HD11 ' HB ' ' A' ' 300' ' ' VAL . 2.1 pp -144.83 170.79 6.75 Favored 'Isoleucine or valine' 0 C--O 1.234 0.283 0 CA-C-O 121.032 0.444 . . . . 0.0 112.001 172.445 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 75.2 m -115.62 114.35 24.79 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.344 177.057 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.513 HG22 ' O ' ' A' ' 298' ' ' THR . 34.9 m -90.86 145.21 7.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 N-CA-C 113.004 0.742 . . . . 0.0 113.004 -173.114 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 30.9 m -91.35 8.83 34.22 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 114.077 -1.42 . . . . 0.0 108.502 166.818 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 259' ' ' ALA . . . . . 0.527 ' HB2' ' HB3' ' A' ' 228' ' ' LEU . . . -88.25 175.65 7.58 Favored 'General case' 0 N--CA 1.452 -0.364 0 CA-C-N 115.115 -0.948 . . . . 0.0 109.402 -177.899 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 27.4 p -140.61 117.22 10.88 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 112.356 0.502 . . . . 0.0 112.356 -177.412 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 78.91 50.04 6.12 Favored Glycine 0 N--CA 1.45 -0.392 0 CA-C-N 115.596 -0.729 . . . . 0.0 113.391 175.632 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 262' ' ' LEU . . . . . . . . . . . . . 77.6 mt -85.06 146.53 27.12 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 117.346 0.573 . . . . 0.0 110.268 176.837 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 98.9 mm-40 -123.77 163.25 21.54 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.551 -178.757 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 264' ' ' VAL . . . . . 0.638 HG21 ' HA ' ' A' ' 294' ' ' ALA . 20.2 t -79.48 145.1 9.86 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.215 177.626 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 86.4 10.07 74.67 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.623 -0.799 . . . . 0.0 112.186 177.832 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -88.5 159.59 17.88 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.147 0.499 . . . . 0.0 110.482 177.208 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 267' ' ' ALA . . . . . 0.532 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -121.82 151.48 40.57 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 115.334 -0.848 . . . . 0.0 108.869 178.238 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 268' ' ' PHE . . . . . 0.49 ' HA ' HD22 ' A' ' 335' ' ' LEU . 4.1 p90 -164.27 168.75 18.4 Favored 'General case' 0 C--N 1.318 -0.761 0 C-N-CA 119.777 -0.769 . . . . 0.0 111.648 -178.029 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 269' ' ' THR . . . . . 0.502 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 73.3 p -122.85 141.83 51.44 Favored 'General case' 0 N--CA 1.442 -0.848 0 CA-C-N 115.438 -0.801 . . . . 0.0 109.621 177.078 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 270' ' ' ILE . . . . . 0.706 HG12 HG12 ' A' ' 332' ' ' ILE . 61.6 mt -105.49 139.18 27.43 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.57 -178.525 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -61.22 125.86 25.28 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.695 179.512 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 93.51 -22.45 35.31 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.473 -178.811 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . 0.492 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 42.4 t -96.5 114.59 33.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 O-C-N 122.573 -0.369 . . . . 0.0 110.296 177.504 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 72.3 m-80 -129.2 160.87 31.55 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.304 -179.223 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 68.9 p -86.37 169.61 12.76 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.239 0.542 . . . . 0.0 111.803 -174.883 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 276' ' ' VAL . . . . . 0.407 ' O ' ' HG2' ' A' ' 278' ' ' GLN . 27.3 m -112.03 -178.07 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 115.499 -0.773 . . . . 0.0 111.152 -178.47 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 277' ' ' HIS . . . . . 0.519 ' HB3' ' HA ' ' A' ' 281' ' ' LYS . 5.0 m80 -66.16 80.97 0.08 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.703 -0.681 . . . . 0.0 110.392 -175.33 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 278' ' ' GLN . . . . . 0.458 HE21 ' HA ' ' A' ' 278' ' ' GLN . 2.4 mm100 -80.32 -32.99 37.86 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 111.72 0.267 . . . . 0.0 111.72 -174.418 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 2.4 mp -69.89 -89.48 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.375 0 CA-C-O 120.831 0.348 . . . . 0.0 110.533 -174.641 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 35.5 p -133.69 60.03 1.72 Allowed 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.076 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 281' ' ' LYS . . . . . 0.519 ' HA ' ' HB3' ' A' ' 277' ' ' HIS . 31.4 mmmt 54.52 41.13 32.14 Favored 'General case' 0 CA--C 1.522 -0.122 0 CA-C-N 115.562 -0.745 . . . . 0.0 109.208 -170.874 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 282' ' ' ASP . . . . . 0.464 ' N ' ' HB3' ' A' ' 277' ' ' HIS . 9.3 t70 -92.33 137.84 32.03 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 114.445 -1.252 . . . . 0.0 110.484 -175.15 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 46.2 p -85.44 105.1 15.82 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.185 -178.387 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 73.1 p -110.72 -41.62 4.24 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.915 -171.804 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 63.64 28.31 72.34 Favored Glycine 0 C--N 1.33 0.24 0 C-N-CA 120.877 -0.677 . . . . 0.0 112.498 177.222 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 84.6 mt-30 -94.5 145.7 30.15 Favored Pre-proline 0 C--N 1.323 -0.547 0 CA-C-O 120.419 0.152 . . . . 0.0 110.647 -176.792 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 287' ' ' PRO . . . . . 0.502 ' HB2' ' HB ' ' A' ' 269' ' ' THR . 27.5 Cg_endo -62.2 143.77 94.75 Favored 'Trans proline' 0 CA--C 1.53 0.31 0 C-N-CA 122.445 2.097 . . . . 0.0 112.029 178.589 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 288' ' ' GLN . . . . . 0.414 ' HB3' HG13 ' A' ' 273' ' ' VAL . 70.8 tp60 -76.3 128.43 34.86 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.872 0.367 . . . . 0.0 110.945 -177.486 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 45.6 t -93.74 133.18 35.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.059 179.17 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 290' ' ' PHE . . . . . 0.532 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 60.9 m-85 -113.5 168.81 9.44 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.826 -176.996 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 291' ' ' ARG . . . . . 0.42 ' O ' HD13 ' A' ' 293' ' ' LEU . 35.8 mmt180 -126.74 120.38 29.25 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 177.765 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 56.4 t -67.18 125.59 24.96 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.227 -179.755 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 293' ' ' LEU . . . . . 0.682 HD11 ' HB2' ' A' ' 303' ' ' SER . 5.2 mp -85.07 -38.44 19.13 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.841 179.865 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 294' ' ' ALA . . . . . 0.638 ' HA ' HG21 ' A' ' 264' ' ' VAL . . . -167.13 155.48 9.73 Favored 'General case' 0 C--O 1.225 -0.21 0 CA-C-N 116.681 -0.236 . . . . 0.0 110.94 179.059 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . 0.607 HG11 HG22 ' A' ' 300' ' ' VAL . 61.7 t -140.49 124.74 18.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 175.384 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 32.4 m -139.73 89.54 2.33 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 120.76 0.314 . . . . 0.0 110.835 -177.189 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . 0.471 ' C ' ' H ' ' A' ' 299' ' ' THR . . . 63.95 65.76 2.87 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.487 179.434 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 298' ' ' THR . . . . . 0.513 ' O ' HG22 ' A' ' 257' ' ' VAL . 81.0 p 63.06 -25.18 0.06 Allowed 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 124.994 1.317 . . . . 0.0 113.683 -178.774 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 299' ' ' THR . . . . . 0.471 ' H ' ' C ' ' A' ' 297' ' ' GLY . 75.3 m -77.43 108.9 10.91 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 174.333 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . 0.766 ' HB ' HD11 ' A' ' 255' ' ' ILE . 48.8 t -106.08 134.42 47.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.025 -173.017 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 301' ' ' THR . . . . . 0.9 ' HA ' ' O ' ' A' ' 253' ' ' GLY . 97.1 m -78.02 105.37 9.19 Favored 'General case' 0 N--CA 1.446 -0.632 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 173.009 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 302' ' ' ILE . . . . . 0.672 HD13 ' O ' ' A' ' 302' ' ' ILE . 2.6 pp -111.24 141.35 26.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 122.179 0.99 . . . . 0.0 113.671 -170.989 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 303' ' ' SER . . . . . 0.682 ' HB2' HD11 ' A' ' 293' ' ' LEU . 57.2 m -167.48 169.55 5.56 Favored Pre-proline 0 C--N 1.317 -0.826 0 N-CA-C 105.342 -2.096 . . . . 0.0 105.342 179.02 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 304' ' ' PRO . . . . . 0.556 ' HA ' ' HB3' ' A' ' 303' ' ' SER . 2.7 Cg_endo -82.65 -157.28 1.35 Allowed 'Cis proline' 0 C--N 1.347 0.458 0 CA-C-N 121.571 1.597 . . . . 0.0 113.473 0.278 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 305' ' ' LYS . . . . . 0.782 ' HD3' ' HG ' ' A' ' 307' ' ' LEU . 0.0 OUTLIER -83.51 163.34 20.51 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.27 -0.877 . . . . 0.0 112.884 -176.069 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 306' ' ' ILE . . . . . 0.533 ' O ' ' HB3' ' A' ' 236' ' ' HIS . 2.7 mp -114.02 94.32 3.06 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.793 -176.761 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 307' ' ' LEU . . . . . 0.782 ' HG ' ' HD3' ' A' ' 305' ' ' LYS . 86.0 mt -108.81 107.24 59.9 Favored Pre-proline 0 C--N 1.327 -0.392 0 C-N-CA 120.81 -0.356 . . . . 0.0 111.606 -177.768 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 308' ' ' PRO . . . . . 0.761 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 23.0 Cg_exo -69.85 145.39 56.5 Favored 'Trans proline' 0 C--N 1.343 0.253 0 C-N-CA 123.505 2.804 . . . . 0.0 113.467 -178.038 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . 0.513 HG22 ' HB3' ' A' ' 320' ' ' ALA . 40.3 t -93.69 -25.6 4.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 169.35 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 54.7 mm-40 -79.83 -0.36 34.32 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.113 -0.949 . . . . 0.0 112.144 -177.602 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -80.85 163.34 23.48 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-O 121.004 0.431 . . . . 0.0 111.174 -179.091 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 50.2 m -92.32 -15.87 26.79 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.362 -179.029 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 313' ' ' ASP . . . . . 0.553 ' O ' ' HG3' ' A' ' 317' ' ' ARG . 62.9 t0 -64.26 104.05 0.71 Allowed 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.065 178.93 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 314' ' ' VAL . . . . . 0.404 ' O ' ' HD3' ' A' ' 318' ' ' PRO . 48.5 t -63.63 -30.84 50.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.683 -176.012 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -70.44 -25.17 63.07 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 111.718 0.266 . . . . 0.0 111.718 179.984 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 32.4 t -95.09 -8.28 37.02 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.604 0.24 . . . . 0.0 111.211 -178.115 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 317' ' ' ARG . . . . . 0.553 ' HG3' ' O ' ' A' ' 313' ' ' ASP . 54.4 mtp85 -67.43 -49.96 39.85 Favored Pre-proline 0 CA--C 1.54 0.564 0 N-CA-C 112.938 0.718 . . . . 0.0 112.938 -179.26 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 318' ' ' PRO . . . . . 0.504 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 37.1 Cg_exo -63.41 -31.98 71.95 Favored 'Trans proline' 0 C--N 1.357 1.016 0 C-N-CA 121.951 1.768 . . . . 0.0 112.679 -178.51 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 48.8 m-85 -84.13 -14.95 48.97 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.511 -178.214 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . 0.513 ' HB3' HG22 ' A' ' 309' ' ' VAL . . . -49.7 135.29 19.17 Favored 'General case' 0 N--CA 1.464 0.254 0 N-CA-C 112.71 0.633 . . . . 0.0 112.71 -174.097 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 16.1 p-10 -128.38 -10.36 5.18 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.939 178.964 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 322' ' ' VAL . . . . . 0.409 ' O ' HG21 ' A' ' 309' ' ' VAL . 33.7 m -132.27 167.29 26.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 N-CA-C 109.986 -0.375 . . . . 0.0 109.986 177.017 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -67.2 -51.89 47.95 Favored 'General case' 0 C--N 1.326 -0.434 0 C-N-CA 121.026 -0.27 . . . . 0.0 111.702 -177.93 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 324' ' ' ALA . . . . . 0.761 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -162.47 -178.04 6.02 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.044 0.449 . . . . 0.0 111.779 -176.388 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 14.5 ptmm? -112.56 132.07 22.37 Favored Pre-proline 0 C--N 1.327 -0.384 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.314 176.949 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -86.15 168.44 9.04 Favored 'Trans proline' 0 N--CA 1.456 -0.71 0 C-N-CA 122.921 2.414 . . . . 0.0 112.412 179.51 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -72.83 123.77 24.05 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.053 -0.522 . . . . 0.0 109.718 175.202 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 66.6 mm-40 65.6 -161.43 0.26 Allowed 'General case' 0 N--CA 1.465 0.307 0 O-C-N 123.574 0.546 . . . . 0.0 110.424 -174.97 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 329' ' ' SER . . . . . 0.522 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 43.0 m -91.16 -13.48 32.88 Favored 'General case' 0 C--N 1.323 -0.578 0 C-N-CA 120.825 -0.35 . . . . 0.0 110.347 178.174 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 330' ' ' ALA . . . . . 0.428 ' HB2' ' H ' ' A' ' 331' ' ' ALA . . . 64.5 -161.55 0.28 Allowed 'General case' 0 N--CA 1.467 0.425 0 CA-C-N 115.412 -0.813 . . . . 0.0 113.128 171.323 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 331' ' ' ALA . . . . . 0.428 ' H ' ' HB2' ' A' ' 330' ' ' ALA . . . -86.71 136.72 32.91 Favored 'General case' 0 CA--C 1.517 -0.323 0 CA-C-N 115.09 -0.959 . . . . 0.0 110.577 -179.983 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 332' ' ' ILE . . . . . 0.922 HD12 HG23 ' A' ' 230' ' ' VAL . 45.8 mt -116.12 144.42 23.83 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.847 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.822 -178.735 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 78.1 m -116.26 99.24 7.07 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.156 -178.016 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 334' ' ' ILE . . . . . 0.469 HD12 HG22 ' A' ' 334' ' ' ILE . 38.3 mm -75.99 131.12 35.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.43 -174.992 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 335' ' ' LEU . . . . . 0.49 HD22 ' HA ' ' A' ' 268' ' ' PHE . 2.0 pt? -148.61 133.68 18.23 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.217 173.68 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 5.6 m120 -78.16 70.93 4.59 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.223 178.406 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 59.4 tttp . . . . . 0 C--O 1.243 0.738 0 CA-C-O 118.315 -0.85 . . . . 0.0 110.713 -174.989 . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.731 0 N-CA-C 111.851 -0.5 . . . . 0.0 111.851 . . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 51.7 p -73.36 -38.93 65.55 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.413 0.149 . . . . 0.0 111.081 179.69 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 51.2 m 62.93 -84.96 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.366 0 O-C-N 123.719 0.637 . . . . 0.0 111.294 177.954 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 226' ' ' GLU . . . . . 0.418 ' O ' ' HB2' ' A' ' 227' ' ' SER . 5.2 tp10 -124.71 78.91 1.72 Allowed 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 175.096 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 227' ' ' SER . . . . . 0.418 ' HB2' ' O ' ' A' ' 226' ' ' GLU . 54.0 m 74.2 -77.89 0.05 Allowed 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 115.243 -0.889 . . . . 0.0 111.304 -175.877 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 228' ' ' LEU . . . . . 0.732 HD13 ' HB1' ' A' ' 259' ' ' ALA . 85.3 mt -131.5 158.9 39.66 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.982 -0.553 . . . . 0.0 109.845 -177.288 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 229' ' ' THR . . . . . 0.555 ' HA ' ' HA ' ' A' ' 331' ' ' ALA . 37.9 p -132.76 178.87 6.53 Favored 'General case' 0 C--N 1.33 -0.274 0 C-N-CA 120.324 -0.55 . . . . 0.0 111.186 177.851 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . 0.57 HG23 HD12 ' A' ' 332' ' ' ILE . 58.7 t -147.47 123.94 2.92 Favored 'Isoleucine or valine' 0 C--O 1.235 0.336 0 CA-C-N 116.654 -0.248 . . . . 0.0 110.921 -179.165 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 49.8 m -109.14 97.68 7.25 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.107 -0.497 . . . . 0.0 109.86 174.446 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . 0.903 ' HA3' ' HB ' ' A' ' 255' ' ' ILE . . . -133.94 -152.14 6.65 Favored Glycine 0 N--CA 1.443 -0.859 0 C-N-CA 119.743 -1.218 . . . . 0.0 113.163 -176.735 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 233' ' ' GLN . . . . . 0.49 ' HB3' ' HD2' ' A' ' 234' ' ' PRO . 11.7 mm100 -72.34 171.45 9.7 Favored Pre-proline 0 C--N 1.324 -0.521 0 CA-C-N 115.2 -0.5 . . . . 0.0 110.988 -179.172 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 234' ' ' PRO . . . . . 0.49 ' HD2' ' HB3' ' A' ' 233' ' ' GLN . 41.7 Cg_exo -56.74 176.29 0.23 Allowed 'Trans proline' 0 C--N 1.356 0.923 0 C-N-CA 123.346 2.697 . . . . 0.0 112.741 177.801 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 235' ' ' GLU . . . . . 0.717 ' HG3' ' HD2' ' A' ' 325' ' ' LYS . 2.6 pm0 -91.38 -176.74 4.64 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.031 0.444 . . . . 0.0 111.102 -174.467 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 236' ' ' HIS . . . . . 0.43 ' CE1' ' HB2' ' A' ' 305' ' ' LYS . 18.9 t-80 -100.87 147.6 25.93 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.509 -0.769 . . . . 0.0 111.702 -171.135 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 237' ' ' LYS . . . . . 0.502 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -166.68 147.87 6.15 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 114.735 -1.12 . . . . 0.0 109.914 179.066 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 238' ' ' VAL . . . . . 0.628 HG21 HD13 ' A' ' 307' ' ' LEU . 56.8 t -99.53 111.95 30.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 174.073 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 239' ' ' GLU . . . . . 0.423 ' O ' ' HA ' ' A' ' 247' ' ' PRO . 91.4 mt-10 -92.55 144.56 25.22 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.953 -173.165 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 240' ' ' ALA . . . . . . . . . . . . . . . -63.29 -39.03 93.43 Favored 'General case' 0 CA--C 1.522 -0.111 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.808 179.486 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 241' ' ' LYS . . . . . 0.662 ' O ' ' HD3' ' A' ' 241' ' ' LYS . 0.1 OUTLIER -141.89 139.9 32.7 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.061 176.763 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 9.5 p-10 -105.95 -156.55 0.58 Allowed 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 -179.519 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 48.8 m -63.48 -19.55 64.83 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.192 175.208 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -104.65 -6.04 20.82 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.838 0.351 . . . . 0.0 111.06 177.716 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . 0.583 ' HA2' ' HB2' ' A' ' 241' ' ' LYS . . . 85.09 19.09 59.75 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.712 -0.756 . . . . 0.0 113.675 175.583 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 246' ' ' MET . . . . . . . . . . . . . 83.4 mtp -113.28 157.74 40.23 Favored Pre-proline 0 C--N 1.326 -0.451 0 CA-C-N 117.12 0.46 . . . . 0.0 110.676 178.51 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 247' ' ' PRO . . . . . 0.423 ' HA ' ' O ' ' A' ' 239' ' ' GLU . 12.1 Cg_exo -68.29 120.6 7.56 Favored 'Trans proline' 0 C--N 1.348 0.524 0 C-N-CA 122.34 2.027 . . . . 0.0 111.055 177.123 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 62.6 t -129.89 137.56 56.3 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -173.951 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -79.87 101.66 8.68 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 107.842 -1.17 . . . . 0.0 107.842 170.35 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 250' ' ' ASN . . . . . . . . . . . . . 44.4 t30 -98.95 147.45 24.98 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.464 -0.789 . . . . 0.0 112.925 -165.933 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . 0.408 ' HG3' ' N ' ' A' ' 252' ' ' GLN . 19.7 tpp180 93.15 -125.32 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 125.616 1.566 . . . . 0.0 111.241 173.332 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 252' ' ' GLN . . . . . 0.444 ' OE1' ' HA ' ' A' ' 305' ' ' LYS . 2.2 mm100 63.31 179.29 0.15 Allowed 'General case' 0 N--CA 1.472 0.659 0 CA-C-O 120.888 0.375 . . . . 0.0 110.566 -173.331 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 101.91 -148.55 17.79 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 119.587 -1.292 . . . . 0.0 113.984 174.778 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 254' ' ' THR . . . . . 0.606 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 71.0 p -101.49 148.66 24.93 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 112.65 0.611 . . . . 0.0 112.65 -171.674 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . 0.903 ' HB ' ' HA3' ' A' ' 232' ' ' GLY . 0.2 OUTLIER -138.01 172.96 13.48 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.243 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.288 173.632 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 256' ' ' THR . . . . . 0.488 ' O ' HG13 ' A' ' 230' ' ' VAL . 58.2 m -100.54 125.81 46.93 Favored 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 109.406 -0.59 . . . . 0.0 109.406 176.729 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.62 HG21 HD13 ' A' ' 262' ' ' LEU . 34.0 m -98.73 143.37 13.28 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.828 0 C-N-CA 119.65 -0.82 . . . . 0.0 112.483 -174.541 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 258' ' ' SER . . . . . 0.405 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 38.8 t -91.56 8.48 36.4 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 114.443 -1.253 . . . . 0.0 108.405 169.505 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 259' ' ' ALA . . . . . 0.732 ' HB1' HD13 ' A' ' 228' ' ' LEU . . . -91.32 169.3 10.92 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-N 115.021 -0.99 . . . . 0.0 110.018 -177.442 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 37.9 t -136.95 148.57 47.04 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 110.194 -0.298 . . . . 0.0 110.194 -179.751 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 71.27 39.6 61.98 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.977 -0.63 . . . . 0.0 113.083 178.108 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 262' ' ' LEU . . . . . 0.62 HD13 HG21 ' A' ' 257' ' ' VAL . 77.6 mt -97.64 142.31 29.6 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.944 0.372 . . . . 0.0 110.395 178.348 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 71.6 mt-30 -143.72 179.96 6.83 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 176.284 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 264' ' ' VAL . . . . . 0.574 HG22 ' HA ' ' A' ' 294' ' ' ALA . 34.0 t -79.31 140.43 16.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 N-CA-C 109.897 -0.408 . . . . 0.0 109.897 176.201 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 93.52 4.72 63.82 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.526 -0.845 . . . . 0.0 112.453 178.797 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 266' ' ' ASP . . . . . 0.43 ' HB2' HG23 ' A' ' 292' ' ' VAL . 1.1 m-20 -78.89 152.81 30.97 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.083 0.468 . . . . 0.0 110.072 176.578 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 267' ' ' ALA . . . . . 0.699 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -126.96 121.67 32.36 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 178.696 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 268' ' ' PHE . . . . . 0.568 ' CD1' HG21 ' A' ' 332' ' ' ILE . 0.0 OUTLIER -148.04 171.53 15.68 Favored 'General case' 0 C--N 1.318 -0.791 0 C-N-CA 120.218 -0.593 . . . . 0.0 111.026 -172.071 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 269' ' ' THR . . . . . 0.551 ' OG1' ' HB ' ' A' ' 333' ' ' THR . 72.6 p -123.82 156.39 36.23 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 110.2 -0.296 . . . . 0.0 110.2 -179.379 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 270' ' ' ILE . . . . . 0.551 HG12 HG12 ' A' ' 332' ' ' ILE . 60.9 mt -115.02 139.36 41.68 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 120.794 0.33 . . . . 0.0 111.144 -179.332 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -65.82 112.64 3.84 Favored 'General case' 0 C--O 1.231 0.125 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.037 -179.903 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 109.22 -21.85 26.04 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.021 -179.14 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . 0.587 ' O ' ' HA ' ' A' ' 287' ' ' PRO . 47.1 t -93.11 102.67 13.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.885 0.374 . . . . 0.0 110.93 178.722 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 3.8 m120 -103.76 150.98 23.57 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 173.504 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 275' ' ' SER . . . . . 0.438 ' HB2' ' HB2' ' A' ' 288' ' ' GLN . 6.0 t -88.76 -177.96 5.66 Favored 'General case' 0 C--N 1.325 -0.473 0 C-N-CA 120.332 -0.547 . . . . 0.0 110.231 -176.496 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 35.0 m -112.25 -179.01 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.917 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.171 172.887 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 6.3 p80 -39.74 111.66 0.21 Allowed 'General case' 0 CA--C 1.533 0.298 0 O-C-N 123.972 0.795 . . . . 0.0 112.568 -179.882 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 80.7 mt-30 -80.16 -42.38 23.55 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.475 -176.439 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 279' ' ' ILE . . . . . 0.571 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.7 mp -110.21 -76.16 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.175 177.858 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 21.7 p -142.11 90.78 2.28 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-O 121.124 0.487 . . . . 0.0 111.661 -178.418 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 74.8 mmtt 61.05 23.98 14.12 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 115.145 -0.934 . . . . 0.0 112.463 175.584 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 11.2 p-10 -86.46 81.64 8.24 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.615 0.721 . . . . 0.0 110.867 176.769 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 37.2 p -102.34 106.9 17.76 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.854 177.753 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 73.1 p -114.67 2.16 14.4 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.835 -0.62 . . . . 0.0 112.174 -170.081 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 71.02 31.29 66.88 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.515 -0.85 . . . . 0.0 112.652 177.859 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 26.2 mt-30 -102.11 142.54 24.79 Favored Pre-proline 0 C--N 1.325 -0.467 0 O-C-N 122.682 -0.305 . . . . 0.0 111.155 179.503 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 287' ' ' PRO . . . . . 0.587 ' HA ' ' O ' ' A' ' 273' ' ' VAL . 39.0 Cg_exo -59.1 136.95 76.46 Favored 'Trans proline' 0 C--N 1.343 0.276 0 C-N-CA 122.988 2.459 . . . . 0.0 112.106 177.89 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 288' ' ' GLN . . . . . 0.438 ' HB2' ' HB2' ' A' ' 275' ' ' SER . 41.5 tt0 -79.52 142.92 35.34 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.827 0.346 . . . . 0.0 111.013 -178.008 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 289' ' ' VAL . . . . . 0.473 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 42.7 t -90.81 126.68 43.54 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.295 179.496 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 290' ' ' PHE . . . . . 0.699 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 33.3 m-85 -110.42 158.76 18.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.677 -0.238 . . . . 0.0 110.583 -176.323 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 291' ' ' ARG . . . . . 0.522 ' HD2' ' C ' ' A' ' 290' ' ' PHE . 9.0 mpt_? -115.88 131.06 57.05 Favored 'General case' 0 CA--C 1.516 -0.357 0 CA-C-O 121.48 0.657 . . . . 0.0 110.74 173.606 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . 0.43 HG23 ' HB2' ' A' ' 266' ' ' ASP . 40.9 t -82.86 140.0 16.97 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 CA-C-N 114.722 -1.126 . . . . 0.0 111.402 -176.354 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 293' ' ' LEU . . . . . 0.45 ' CD2' ' HB2' ' A' ' 303' ' ' SER . 3.3 mm? -103.79 -32.38 9.36 Favored 'General case' 0 C--N 1.334 -0.08 0 N-CA-C 112.353 0.501 . . . . 0.0 112.353 -177.684 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 294' ' ' ALA . . . . . 0.574 ' HA ' HG22 ' A' ' 264' ' ' VAL . . . -157.83 139.27 13.67 Favored 'General case' 0 N--CA 1.464 0.241 0 C-N-CA 120.715 -0.394 . . . . 0.0 111.798 -178.245 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . 0.419 HG11 ' O ' ' A' ' 262' ' ' LEU . 73.0 t -141.39 111.99 3.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.457 177.612 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 50.2 m -140.38 114.63 9.19 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.584 -0.28 . . . . 0.0 110.707 178.542 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 59.53 54.59 36.44 Favored Glycine 0 C--N 1.33 0.25 0 C-N-CA 121.146 -0.549 . . . . 0.0 112.891 179.172 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 82.8 p 53.08 21.09 1.97 Allowed 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 123.61 0.764 . . . . 0.0 112.302 -177.1 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 58.6 m -111.45 105.89 14.63 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 176.358 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . 0.606 ' O ' ' HA ' ' A' ' 254' ' ' THR . 55.2 t -105.32 131.62 54.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 115.954 -0.567 . . . . 0.0 111.547 -171.881 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 28.5 m -89.1 114.49 25.75 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 108.277 -1.009 . . . . 0.0 108.277 173.454 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 302' ' ' ILE . . . . . 0.481 ' O ' HD11 ' A' ' 302' ' ' ILE . 2.5 pp -110.58 149.07 13.6 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 N-CA-C 113.676 0.991 . . . . 0.0 113.676 -170.558 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 303' ' ' SER . . . . . 0.511 ' HB3' ' HA ' ' A' ' 304' ' ' PRO . 60.3 m -166.21 165.87 9.97 Favored Pre-proline 0 C--N 1.325 -0.487 0 N-CA-C 105.952 -1.87 . . . . 0.0 105.952 -179.724 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 304' ' ' PRO . . . . . 0.511 ' HA ' ' HB3' ' A' ' 303' ' ' SER . 5.8 Cg_exo -79.41 -146.44 0.37 Allowed 'Cis proline' 0 C--N 1.345 0.362 0 CA-C-N 120.996 1.391 . . . . 0.0 113.579 0.64 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 305' ' ' LYS . . . . . 0.542 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -84.11 146.71 27.75 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.478 -0.783 . . . . 0.0 111.739 -176.173 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 306' ' ' ILE . . . . . 0.458 ' N ' HD13 ' A' ' 306' ' ' ILE . 2.9 mp -115.26 113.73 44.35 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.199 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.92 179.227 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 307' ' ' LEU . . . . . 0.628 HD13 HG21 ' A' ' 238' ' ' VAL . 95.5 mt -133.97 107.37 11.54 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-O 120.563 0.22 . . . . 0.0 111.308 -179.309 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 308' ' ' PRO . . . . . 0.668 ' HG2' ' HB2' ' A' ' 311' ' ' ASN . 45.3 Cg_endo -74.51 148.0 37.03 Favored 'Trans proline' 0 C--O 1.233 0.232 0 C-N-CA 122.796 2.331 . . . . 0.0 113.573 -176.631 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . 0.418 HG23 ' O ' ' A' ' 322' ' ' VAL . 46.5 t -73.58 -34.26 41.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.059 173.0 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -86.35 34.35 0.63 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.371 -0.832 . . . . 0.0 111.143 178.468 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.668 ' HB2' ' HG2' ' A' ' 308' ' ' PRO . 25.7 t-20 -81.32 -34.2 32.04 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -178.287 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 41.8 m 73.91 -11.27 0.98 Allowed 'General case' 0 CA--C 1.539 0.529 0 CA-C-N 115.328 -0.851 . . . . 0.0 111.679 178.662 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 313' ' ' ASP . . . . . 0.495 ' HB3' ' HG ' ' A' ' 316' ' ' SER . 31.1 t70 -79.67 117.42 20.57 Favored 'General case' 0 C--N 1.329 -0.286 0 O-C-N 121.951 -0.468 . . . . 0.0 110.27 175.119 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 314' ' ' VAL . . . . . 0.427 HG11 ' O ' ' A' ' 314' ' ' VAL . 26.5 t -59.32 -20.4 18.07 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.473 0 CA-C-N 115.781 -0.645 . . . . 0.0 112.268 -174.706 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -84.89 -38.41 19.45 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 111.949 0.352 . . . . 0.0 111.949 -179.364 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 316' ' ' SER . . . . . 0.495 ' HG ' ' HB3' ' A' ' 313' ' ' ASP . 38.3 p -97.93 -28.83 13.64 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 113.511 0.93 . . . . 0.0 113.511 -172.33 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 317' ' ' ARG . . . . . 0.616 ' N ' ' HD2' ' A' ' 318' ' ' PRO . 16.1 ptm180 -66.18 -35.76 11.37 Favored Pre-proline 0 CA--C 1.547 0.86 0 N-CA-C 113.656 0.984 . . . . 0.0 113.656 -176.182 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 318' ' ' PRO . . . . . 0.616 ' HD2' ' N ' ' A' ' 317' ' ' ARG . 12.8 Cg_endo -58.38 -34.13 98.42 Favored 'Trans proline' 0 C--N 1.366 1.468 0 C-N-CA 121.666 1.577 . . . . 0.0 112.512 -179.861 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 51.0 m-85 -101.02 36.8 1.88 Allowed 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.6 -178.085 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -67.86 139.64 56.53 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.485 -178.183 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 321' ' ' ASN . . . . . 0.405 ' OD1' HG11 ' A' ' 322' ' ' VAL . 20.5 p30 -121.78 -14.66 8.07 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.516 178.012 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 322' ' ' VAL . . . . . 0.458 HG23 HG23 ' A' ' 306' ' ' ILE . 34.1 m -133.59 166.74 28.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 115.618 -0.719 . . . . 0.0 109.195 173.458 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 65.0 m-20 -82.7 -27.53 31.16 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 112.164 0.431 . . . . 0.0 112.164 -176.375 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 324' ' ' ALA . . . . . 0.517 ' CA ' ' HB3' ' A' ' 308' ' ' PRO . . . -160.58 158.21 28.66 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.973 0.416 . . . . 0.0 111.716 -175.209 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 325' ' ' LYS . . . . . 0.717 ' HD2' ' HG3' ' A' ' 235' ' ' GLU . 21.5 pttp -114.01 127.26 27.01 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 115.714 -0.676 . . . . 0.0 110.157 177.318 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -86.08 167.84 9.32 Favored 'Trans proline' 0 N--CA 1.457 -0.651 0 C-N-CA 122.814 2.343 . . . . 0.0 112.758 -178.213 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -71.71 124.4 24.69 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.471 178.927 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 61.69 -118.44 0.68 Allowed 'General case' 0 N--CA 1.464 0.239 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.323 -175.578 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 329' ' ' SER . . . . . 0.568 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 32.6 m -112.18 -33.94 6.08 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.59 -0.277 . . . . 0.0 111.309 179.863 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 76.24 -165.99 0.06 Allowed 'General case' 0 N--CA 1.474 0.725 0 O-C-N 123.844 0.715 . . . . 0.0 112.432 177.429 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 331' ' ' ALA . . . . . 0.555 ' HA ' ' HA ' ' A' ' 229' ' ' THR . . . -82.88 153.92 24.87 Favored 'General case' 0 CA--C 1.519 -0.236 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.899 -177.226 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 332' ' ' ILE . . . . . 0.57 HD12 HG23 ' A' ' 230' ' ' VAL . 44.4 mt -128.49 144.85 36.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 121.233 0.54 . . . . 0.0 111.762 -177.616 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.551 ' HB ' ' OG1' ' A' ' 269' ' ' THR . 94.7 m -108.63 118.75 37.59 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.291 -0.868 . . . . 0.0 109.207 175.23 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 31.9 mm -97.26 132.33 42.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 N-CA-C 113.761 1.023 . . . . 0.0 113.761 -168.025 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 335' ' ' LEU . . . . . 0.575 HD22 ' N ' ' A' ' 335' ' ' LEU . 1.5 pt? -150.78 -162.32 1.53 Allowed 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 113.977 -1.465 . . . . 0.0 108.129 167.993 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 14.9 p-10 -159.34 35.49 0.2 Allowed 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 120.949 0.404 . . . . 0.0 110.212 178.055 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 88.4 tttt . . . . . 0 C--O 1.245 0.83 0 CA-C-N 115.023 -0.99 . . . . 0.0 110.722 -179.433 . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.903 0 N-CA-C 112.283 -0.327 . . . . 0.0 112.283 . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 42.8 m -93.42 63.09 3.48 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.916 0.389 . . . . 0.0 110.688 -179.951 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 41.8 p -100.05 -124.03 0.16 Allowed 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.462 -0.335 . . . . 0.0 110.5 179.505 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 24.4 pt-20 40.24 41.68 1.04 Allowed 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 123.993 0.917 . . . . 0.0 112.961 178.904 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 20.3 m -86.99 -34.83 19.13 Favored 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 110.018 -0.364 . . . . 0.0 110.018 177.71 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 228' ' ' LEU . . . . . 0.52 HD22 ' HA ' ' A' ' 259' ' ' ALA . 87.7 mt -69.49 136.98 52.17 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.509 176.936 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 229' ' ' THR . . . . . 0.543 ' O ' HG21 ' A' ' 230' ' ' VAL . 61.3 p -125.22 173.99 8.41 Favored 'General case' 0 C--N 1.325 -0.49 0 C-N-CA 119.721 -0.792 . . . . 0.0 110.374 179.766 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . 0.614 HG23 HD12 ' A' ' 332' ' ' ILE . 94.5 t -146.06 139.8 20.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-O 120.873 0.368 . . . . 0.0 110.549 -178.801 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 231' ' ' SER . . . . . 0.61 ' HA ' ' OE1' ' A' ' 328' ' ' GLU . 45.8 t -106.04 150.75 25.45 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-N 115.485 -0.779 . . . . 0.0 110.64 178.145 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . 0.424 ' O ' HG23 ' A' ' 255' ' ' ILE . . . 79.32 92.67 0.36 Allowed Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.409 178.408 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 233' ' ' GLN . . . . . 0.445 ' O ' ' HG3' ' A' ' 235' ' ' GLU . 82.8 mt-30 -42.74 135.37 2.75 Favored Pre-proline 0 N--CA 1.47 0.531 0 N-CA-C 112.595 0.591 . . . . 0.0 112.595 -177.997 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -62.97 127.94 21.69 Favored 'Trans proline' 0 C--N 1.349 0.59 0 C-N-CA 122.521 2.147 . . . . 0.0 111.18 175.018 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 235' ' ' GLU . . . . . 0.445 ' HG3' ' O ' ' A' ' 233' ' ' GLN . 49.0 mt-10 -113.64 117.46 31.65 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 112.281 0.475 . . . . 0.0 112.281 -170.419 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 236' ' ' HIS . . . . . 0.686 ' ND1' ' HA ' ' A' ' 251' ' ' ARG . 27.6 t60 -138.32 130.92 29.25 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.507 172.984 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 237' ' ' LYS . . . . . 0.545 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -126.71 157.65 38.51 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.527 -179.624 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 238' ' ' VAL . . . . . 0.423 ' CG2' HD13 ' A' ' 307' ' ' LEU . 41.9 t -97.5 117.16 41.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 171.948 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 239' ' ' GLU . . . . . 0.406 ' O ' ' HA ' ' A' ' 247' ' ' PRO . 46.3 mm-40 -84.54 121.25 27.34 Favored 'General case' 0 C--N 1.322 -0.602 0 C-N-CA 121.032 -0.267 . . . . 0.0 110.659 -177.663 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 240' ' ' ALA . . . . . . . . . . . . . . . -68.21 -38.94 82.47 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.19 0.519 . . . . 0.0 109.941 175.441 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 241' ' ' LYS . . . . . 0.742 ' HB2' ' HA2' ' A' ' 245' ' ' GLY . 0.0 OUTLIER -153.14 140.88 20.02 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.006 176.421 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -95.92 -156.99 0.55 Allowed 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.492 178.733 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 61.9 p -67.01 -20.14 65.82 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.547 0.213 . . . . 0.0 111.137 176.656 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 50.3 t30 -98.78 -14.17 19.83 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.892 0.377 . . . . 0.0 110.664 177.966 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . 0.742 ' HA2' ' HB2' ' A' ' 241' ' ' LYS . . . 95.14 25.92 13.41 Favored Glycine 0 CA--C 1.518 0.266 0 C-N-CA 120.57 -0.824 . . . . 0.0 113.292 175.949 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 246' ' ' MET . . . . . . . . . . . . . 49.0 mtm -111.6 150.12 41.72 Favored Pre-proline 0 C--N 1.322 -0.628 0 O-C-N 122.722 -0.281 . . . . 0.0 110.418 -179.648 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 247' ' ' PRO . . . . . 0.406 ' HA ' ' O ' ' A' ' 239' ' ' GLU . 6.7 Cg_exo -70.23 120.34 7.08 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.209 1.939 . . . . 0.0 110.697 174.939 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 47.5 t -124.24 143.2 38.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-O 121.049 0.452 . . . . 0.0 111.615 -174.139 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 249' ' ' ASP . . . . . 0.44 ' OD1' ' HB3' ' A' ' 251' ' ' ARG . 9.0 t70 -85.43 90.76 8.03 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 173.847 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 250' ' ' ASN . . . . . . . . . . . . . 49.1 t30 -84.96 69.69 10.82 Favored 'General case' 0 N--CA 1.464 0.231 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 -175.996 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . 0.686 ' HA ' ' ND1' ' A' ' 236' ' ' HIS . 14.0 ptp180 -75.71 -146.51 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.327 -0.851 . . . . 0.0 113.239 -170.107 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 40.7 mt-30 66.34 178.69 0.21 Allowed 'General case' 0 N--CA 1.466 0.351 0 C-N-CA 123.842 0.857 . . . . 0.0 111.515 -178.958 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . 0.423 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -169.1 105.87 0.23 Allowed Glycine 0 N--CA 1.444 -0.799 0 CA-C-N 115.352 -0.84 . . . . 0.0 111.309 177.391 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 62.8 p -93.47 116.15 28.68 Favored 'General case' 0 C--N 1.324 -0.515 0 C-N-CA 120.579 -0.448 . . . . 0.0 110.006 -177.993 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . 0.424 HG23 ' O ' ' A' ' 232' ' ' GLY . 19.0 pt -129.27 157.18 42.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.807 -0.633 . . . . 0.0 112.01 -172.162 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 28.8 m -96.3 109.66 22.12 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 174.606 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.478 HG13 HG22 ' A' ' 230' ' ' VAL . 33.6 m -89.94 142.37 13.01 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 C-N-CA 119.429 -0.908 . . . . 0.0 112.235 -173.022 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 31.6 m -93.2 9.53 35.68 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 114.377 -1.283 . . . . 0.0 109.44 171.974 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 259' ' ' ALA . . . . . 0.52 ' HA ' HD22 ' A' ' 228' ' ' LEU . . . -80.97 -177.37 6.39 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.189 -175.709 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 50.9 m -125.07 118.92 27.24 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 112.232 0.456 . . . . 0.0 112.232 -175.522 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 59.49 51.35 59.59 Favored Glycine 0 C--N 1.331 0.284 0 CA-C-N 115.656 -0.702 . . . . 0.0 114.127 172.19 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 262' ' ' LEU . . . . . . . . . . . . . 67.9 mt -77.96 160.13 28.39 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 117.453 0.626 . . . . 0.0 110.559 177.753 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 85.7 mt-30 -141.74 167.09 22.96 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.453 179.864 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 264' ' ' VAL . . . . . 0.441 HG22 ' HA ' ' A' ' 294' ' ' ALA . 44.0 t -78.67 141.47 15.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.496 178.32 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 93.55 1.2 66.36 Favored Glycine 0 N--CA 1.453 -0.229 0 C-N-CA 120.535 -0.84 . . . . 0.0 112.757 177.174 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 266' ' ' ASP . . . . . 0.439 ' HB3' ' CG2' ' A' ' 334' ' ' ILE . 1.3 m-20 -81.09 164.82 22.14 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.032 0.444 . . . . 0.0 110.585 178.243 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 267' ' ' ALA . . . . . 0.53 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -124.37 146.77 48.65 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.796 -178.086 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 268' ' ' PHE . . . . . 0.674 ' HB3' ' HA ' ' A' ' 334' ' ' ILE . 11.1 p90 -164.09 177.88 8.09 Favored 'General case' 0 C--N 1.322 -0.629 0 C-N-CA 120.152 -0.619 . . . . 0.0 112.405 -176.177 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 269' ' ' THR . . . . . 0.492 HG21 ' HB2' ' A' ' 287' ' ' PRO . 43.2 p -134.03 156.55 48.02 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 114.646 -1.161 . . . . 0.0 109.002 173.138 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 270' ' ' ILE . . . . . 0.934 HG12 HG13 ' A' ' 332' ' ' ILE . 77.6 mt -119.15 141.78 37.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-O 120.569 0.223 . . . . 0.0 110.682 -177.524 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -70.16 128.7 37.2 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.768 0.318 . . . . 0.0 110.973 178.112 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 90.56 -23.3 23.12 Favored Glycine 0 N--CA 1.453 -0.172 0 C-N-CA 121.267 -0.492 . . . . 0.0 112.023 -177.822 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . 0.452 ' HB ' ' HB ' ' A' ' 270' ' ' ILE . 57.2 t -94.58 103.23 14.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 175.043 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 274' ' ' ASN . . . . . 0.446 ' HB3' ' O ' ' A' ' 285' ' ' GLY . 8.1 m120 -125.03 129.43 50.27 Favored 'General case' 0 C--N 1.316 -0.865 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 -179.613 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 275' ' ' SER . . . . . 0.523 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 48.8 m -84.18 173.52 10.97 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.751 0.786 . . . . 0.0 112.974 -167.031 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 276' ' ' VAL . . . . . 0.622 HG11 HG23 ' A' ' 283' ' ' THR . 18.5 m -122.95 166.87 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 CA-C-N 114.676 -1.147 . . . . 0.0 109.327 176.41 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 277' ' ' HIS . . . . . 0.499 ' O ' ' HA ' ' A' ' 281' ' ' LYS . 33.6 m80 -88.16 123.89 33.26 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 177.853 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 10.5 mm100 -80.29 -17.16 52.94 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.086 -176.614 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 46.7 mm -70.31 -65.19 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.736 -179.531 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 64.6 p -108.05 11.58 27.6 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.506 -0.316 . . . . 0.0 111.851 -177.323 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 281' ' ' LYS . . . . . 0.499 ' HA ' ' O ' ' A' ' 277' ' ' HIS . 12.7 mptt 55.41 47.47 21.12 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-O 121.122 0.487 . . . . 0.0 111.192 -177.489 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 282' ' ' ASP . . . . . 0.477 ' HB3' ' HB2' ' A' ' 277' ' ' HIS . 7.3 t70 -79.91 108.96 13.9 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.619 176.971 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.622 HG23 HG11 ' A' ' 276' ' ' VAL . 64.4 p -102.97 98.22 8.22 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.591 -178.142 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 31.1 p -140.55 10.8 2.28 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.613 -0.721 . . . . 0.0 111.763 -177.737 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 285' ' ' GLY . . . . . 0.446 ' O ' ' HB3' ' A' ' 274' ' ' ASN . . . 75.66 33.57 51.49 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.177 -1.011 . . . . 0.0 113.26 175.651 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 286' ' ' GLN . . . . . 0.464 ' O ' ' HB2' ' A' ' 275' ' ' SER . 11.6 mm100 -91.27 111.77 50.52 Favored Pre-proline 0 C--N 1.325 -0.469 0 CA-C-N 117.006 0.403 . . . . 0.0 110.782 -179.636 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 287' ' ' PRO . . . . . 0.492 ' HB2' HG21 ' A' ' 269' ' ' THR . 14.7 Cg_endo -59.59 134.26 56.8 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.916 2.41 . . . . 0.0 113.155 -177.057 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 5.4 tm0? -110.13 152.31 26.18 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 176.806 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 289' ' ' VAL . . . . . 0.463 ' CG1' ' HB3' ' A' ' 267' ' ' ALA . 53.8 t -68.18 134.03 30.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 CA-C-O 120.924 0.392 . . . . 0.0 111.988 -171.806 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 290' ' ' PHE . . . . . 0.8 ' HA ' ' HD3' ' A' ' 304' ' ' PRO . 4.5 m-85 -97.88 159.48 14.9 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.75 178.051 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 20.3 mmt85 -131.45 125.63 33.0 Favored 'General case' 0 N--CA 1.453 -0.316 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.622 -179.02 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 53.2 t -76.01 135.34 27.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.161 179.318 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 293' ' ' LEU . . . . . 0.473 ' CD1' ' HG ' ' A' ' 303' ' ' SER . 85.4 mt -99.49 -43.0 6.69 Favored 'General case' 0 C--N 1.333 -0.13 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.502 179.769 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 294' ' ' ALA . . . . . 0.449 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -154.34 144.23 21.77 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.496 -0.32 . . . . 0.0 111.183 -175.52 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 59.0 t -135.91 113.3 14.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.714 176.87 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 45.6 t -157.33 125.02 5.34 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.55 -177.738 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 61.26 43.7 99.04 Favored Glycine 0 C--N 1.331 0.25 0 C-N-CA 120.987 -0.625 . . . . 0.0 111.773 -177.93 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 67.1 p 50.82 23.02 1.27 Allowed 'General case' 0 N--CA 1.471 0.604 0 C-N-CA 123.709 0.804 . . . . 0.0 112.23 -175.052 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 59.6 m -111.9 116.96 31.48 Favored 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 176.852 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . 0.455 HG23 HG11 ' A' ' 257' ' ' VAL . 61.5 t -113.1 126.67 70.54 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.176 -173.15 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 54.5 m -91.24 116.2 28.63 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 173.987 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 302' ' ' ILE . . . . . 0.423 HG12 ' O ' ' A' ' 253' ' ' GLY . 29.5 pt -111.5 158.78 11.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 N-CA-C 113.234 0.828 . . . . 0.0 113.234 -170.013 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 303' ' ' SER . . . . . 0.512 ' HB3' ' HA ' ' A' ' 304' ' ' PRO . 72.1 m -144.47 166.16 19.97 Favored Pre-proline 0 C--N 1.323 -0.584 0 CA-C-N 113.631 -1.622 . . . . 0.0 107.05 172.521 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 304' ' ' PRO . . . . . 0.8 ' HD3' ' HA ' ' A' ' 290' ' ' PHE . 10.5 Cg_exo -72.7 -169.8 6.86 Favored 'Cis proline' 0 C--N 1.346 0.423 0 CA-C-N 120.719 1.293 . . . . 0.0 113.484 0.605 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 305' ' ' LYS . . . . . 0.532 ' HB2' ' CD2' ' A' ' 236' ' ' HIS . 0.0 OUTLIER -78.18 147.73 34.37 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.471 -0.786 . . . . 0.0 111.333 -177.774 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 306' ' ' ILE . . . . . 0.641 HD12 ' HE2' ' A' ' 290' ' ' PHE . 51.1 mm -114.07 110.71 33.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.718 -174.244 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 307' ' ' LEU . . . . . 0.455 ' HG ' ' CD2' ' A' ' 236' ' ' HIS . 90.7 mt -134.04 123.06 16.66 Favored Pre-proline 0 N--CA 1.465 0.28 0 CA-C-N 116.62 -0.264 . . . . 0.0 111.46 175.776 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 308' ' ' PRO . . . . . 0.739 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 32.7 Cg_exo -67.68 148.92 78.7 Favored 'Trans proline' 0 C--O 1.233 0.236 0 C-N-CA 123.705 2.937 . . . . 0.0 114.284 -176.333 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . 0.447 HG12 ' O ' ' A' ' 309' ' ' VAL . 45.2 t -94.14 -13.79 8.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.132 -0.94 . . . . 0.0 109.055 168.988 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 53.1 mt-10 -78.51 35.79 0.24 Allowed 'General case' 0 CA--C 1.533 0.317 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.959 177.225 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.768 ' HA ' ' HD3' ' A' ' 317' ' ' ARG . 15.5 p30 40.74 66.23 0.67 Allowed 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 114.258 1.207 . . . . 0.0 114.258 173.733 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 85.0 m -81.35 -41.55 21.84 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.753 -0.658 . . . . 0.0 109.657 170.118 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 59.0 t0 -137.83 146.05 43.0 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 175.541 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 61.3 t -62.02 -43.36 97.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 O-C-N 123.191 0.307 . . . . 0.0 111.078 178.858 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -69.96 -19.88 63.34 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.005 0.431 . . . . 0.0 111.094 178.58 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 316' ' ' SER . . . . . 0.439 ' HG ' ' HB3' ' A' ' 307' ' ' LEU . 35.0 t -78.74 -15.24 58.69 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.502 179.804 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 317' ' ' ARG . . . . . 0.768 ' HD3' ' HA ' ' A' ' 311' ' ' ASN . 2.4 mmm180 -74.52 -51.87 4.04 Favored Pre-proline 0 CA--C 1.536 0.437 0 N-CA-C 112.883 0.697 . . . . 0.0 112.883 -177.709 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 318' ' ' PRO . . . . . 0.578 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 23.5 Cg_exo -64.95 -18.95 63.69 Favored 'Trans proline' 0 C--N 1.355 0.874 0 C-N-CA 121.844 1.696 . . . . 0.0 112.388 -178.407 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 319' ' ' TYR . . . . . 0.407 ' O ' HD11 ' A' ' 307' ' ' LEU . 3.7 m-85 -113.52 22.08 14.49 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.284 -179.499 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -59.68 142.29 53.32 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.226 -177.408 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 50.3 t30 -135.2 -21.57 1.6 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.942 -178.917 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 322' ' ' VAL . . . . . 0.523 ' HA ' ' HA ' ' A' ' 275' ' ' SER . 34.7 m -140.53 172.04 12.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.141 178.658 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 51.1 m-20 -65.94 -44.76 84.09 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.647 -0.251 . . . . 0.0 111.427 179.203 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 324' ' ' ALA . . . . . 0.739 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -174.97 -178.86 1.29 Allowed 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 112.358 0.503 . . . . 0.0 112.358 -177.229 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 36.5 mtmm -108.01 116.72 56.59 Favored Pre-proline 0 N--CA 1.452 -0.364 0 CA-C-N 114.51 -1.223 . . . . 0.0 108.404 168.261 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -71.64 167.09 27.45 Favored 'Trans proline' 0 C--O 1.233 0.236 0 C-N-CA 122.411 2.074 . . . . 0.0 112.22 -177.905 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -67.58 121.58 16.17 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 175.541 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 328' ' ' GLU . . . . . 0.61 ' OE1' ' HA ' ' A' ' 231' ' ' SER . 31.2 tp10 67.53 164.4 0.21 Allowed 'General case' 0 CA--C 1.537 0.45 0 O-C-N 123.986 0.804 . . . . 0.0 109.562 -174.204 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 329' ' ' SER . . . . . 0.486 ' HB2' ' O ' ' A' ' 230' ' ' VAL . 53.5 m -71.21 -29.65 65.41 Favored 'General case' 0 C--N 1.327 -0.403 0 O-C-N 121.65 -0.656 . . . . 0.0 110.875 -177.838 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 74.86 -153.11 0.04 OUTLIER 'General case' 0 N--CA 1.469 0.514 0 O-C-N 123.971 0.794 . . . . 0.0 112.499 173.342 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -87.22 116.61 25.42 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.149 -0.932 . . . . 0.0 111.167 -176.816 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 332' ' ' ILE . . . . . 0.934 HG13 HG12 ' A' ' 270' ' ' ILE . 1.8 mp -107.67 139.92 27.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 177.556 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.419 ' N ' HG22 ' A' ' 332' ' ' ILE . 61.6 m -129.68 103.89 7.11 Favored 'General case' 0 C--N 1.327 -0.392 0 C-N-CA 120.853 -0.339 . . . . 0.0 111.306 -174.624 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 334' ' ' ILE . . . . . 0.674 ' HA ' ' HB3' ' A' ' 268' ' ' PHE . 3.1 mp -90.73 134.98 27.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.491 -177.161 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 335' ' ' LEU . . . . . 0.447 HD21 ' O ' ' A' ' 267' ' ' ALA . 1.6 pt? -116.73 136.35 53.03 Favored 'General case' 0 N--CA 1.441 -0.897 0 N-CA-C 107.721 -1.215 . . . . 0.0 107.721 166.366 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 15.4 p-10 -75.46 47.56 0.39 Allowed 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.141 0.496 . . . . 0.0 110.822 -177.277 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 337' ' ' LYS . . . . . 0.618 ' HZ2' ' HB2' ' A' ' 337' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.243 0.722 0 CA-C-O 118.364 -0.827 . . . . 0.0 110.603 179.442 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.714 0 N-CA-C 112.238 -0.345 . . . . 0.0 112.238 . . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 33.6 p -132.84 46.5 2.61 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.88 0.371 . . . . 0.0 111.359 179.923 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 68.9 p -85.96 177.53 7.57 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.394 177.971 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 5.3 tp10 -118.55 38.55 3.71 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.896 0.855 . . . . 0.0 109.4 177.665 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 26.9 m -129.59 117.7 20.84 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.368 -0.833 . . . . 0.0 109.532 178.065 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 228' ' ' LEU . . . . . 0.401 HD11 ' CG1' ' A' ' 334' ' ' ILE . 72.9 mt -91.54 87.94 6.58 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 -178.836 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 229' ' ' THR . . . . . 0.462 ' O ' HG22 ' A' ' 230' ' ' VAL . 22.7 p -113.76 173.43 6.43 Favored 'General case' 0 C--N 1.316 -0.865 0 C-N-CA 119.739 -0.784 . . . . 0.0 110.386 -177.953 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 230' ' ' VAL . . . . . 0.632 HG21 HD11 ' A' ' 332' ' ' ILE . 78.9 t -142.75 133.12 23.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-O 121.023 0.439 . . . . 0.0 110.785 -176.542 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 39.5 t -108.31 100.28 9.59 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-N 115.339 -0.846 . . . . 0.0 109.482 175.725 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . -173.27 166.77 39.32 Favored Glycine 0 N--CA 1.444 -0.786 0 N-CA-C 111.391 -0.684 . . . . 0.0 111.391 -178.35 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 12.9 mm-40 -107.49 102.03 42.34 Favored Pre-proline 0 C--N 1.321 -0.659 0 CA-C-N 116.706 0.253 . . . . 0.0 110.72 -179.866 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 234' ' ' PRO . . . . . 0.585 ' HB2' HD13 ' A' ' 306' ' ' ILE . 33.7 Cg_endo -98.11 127.14 0.22 Allowed 'Trans proline' 0 N--CA 1.451 -1.002 0 C-N-CA 123.034 2.489 . . . . 0.0 112.227 -178.479 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -160.28 -177.39 6.22 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.709 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 236' ' ' HIS . . . . . 0.976 ' HA ' ' HG2' ' A' ' 251' ' ' ARG . 33.4 t-80 -159.14 132.98 7.47 Favored 'General case' 0 CA--C 1.517 -0.297 0 CA-C-O 121.605 0.716 . . . . 0.0 111.941 176.38 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 237' ' ' LYS . . . . . 0.607 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -114.61 134.65 54.89 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 114.67 -1.15 . . . . 0.0 110.012 178.203 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 238' ' ' VAL . . . . . 0.416 HG22 ' CE1' ' A' ' 236' ' ' HIS . 41.2 t -103.96 112.21 36.62 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 177.423 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 239' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -90.75 147.24 23.37 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 120.724 -0.39 . . . . 0.0 110.408 177.481 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 240' ' ' ALA . . . . . 0.465 ' C ' ' HD2' ' A' ' 241' ' ' LYS . . . -76.48 -68.74 0.56 Allowed 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.235 -176.654 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 241' ' ' LYS . . . . . 0.465 ' HD2' ' C ' ' A' ' 240' ' ' ALA . 3.5 mptp? -112.69 129.01 56.55 Favored 'General case' 0 CA--C 1.514 -0.416 0 CA-C-O 120.956 0.408 . . . . 0.0 110.886 -179.51 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -96.23 -157.65 0.6 Allowed 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.549 -0.75 . . . . 0.0 109.048 174.52 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 34.9 t -62.55 -29.9 70.91 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.859 0.361 . . . . 0.0 110.798 175.848 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 22.4 t-20 -94.73 -15.22 24.04 Favored 'General case' 0 CA--C 1.532 0.254 0 CA-C-O 121.035 0.445 . . . . 0.0 110.387 179.235 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 92.13 20.0 37.44 Favored Glycine 0 CA--C 1.517 0.209 0 C-N-CA 120.751 -0.737 . . . . 0.0 113.01 175.607 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 246' ' ' MET . . . . . . . . . . . . . 26.5 ptt? -113.67 160.3 32.39 Favored Pre-proline 0 C--N 1.324 -0.514 0 N-CA-C 110.235 -0.283 . . . . 0.0 110.235 179.05 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 247' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -72.74 120.5 6.72 Favored 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 121.993 1.795 . . . . 0.0 110.548 175.276 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 62.7 t -115.46 131.11 68.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 121.214 0.53 . . . . 0.0 112.111 -173.645 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 61.3 t0 -87.82 87.71 7.44 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.008 -0.997 . . . . 0.0 108.688 172.232 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 250' ' ' ASN . . . . . . . . . . . . . 21.6 p30 -101.62 -14.24 17.5 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.881 -0.6 . . . . 0.0 112.456 -173.417 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 251' ' ' ARG . . . . . 0.976 ' HG2' ' HA ' ' A' ' 236' ' ' HIS . 2.7 tpm_? -75.04 -84.34 0.05 Allowed 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 111.92 0.341 . . . . 0.0 111.92 -168.957 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 3.1 mm100 61.79 179.22 0.12 Allowed 'General case' 0 C--N 1.344 0.345 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 -173.373 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 253' ' ' GLY . . . . . 0.44 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -128.19 116.06 2.22 Favored Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 118.941 -1.6 . . . . 0.0 113.423 -174.275 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 254' ' ' THR . . . . . 0.47 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 80.9 p -109.41 115.45 29.98 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 170.605 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 255' ' ' ILE . . . . . 0.595 HD11 HG11 ' A' ' 230' ' ' VAL . 2.0 pp -131.52 164.85 33.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 N-CA-C 112.733 0.642 . . . . 0.0 112.733 -172.79 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 256' ' ' THR . . . . . 0.413 ' O ' HG12 ' A' ' 230' ' ' VAL . 28.9 m -102.17 118.29 36.59 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 178.789 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 257' ' ' VAL . . . . . 0.402 ' O ' HG23 ' A' ' 257' ' ' VAL . 35.0 m -90.4 142.91 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.728 0 C-N-CA 119.768 -0.773 . . . . 0.0 112.762 -172.17 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 32.1 t -91.96 9.56 32.6 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 113.772 -1.558 . . . . 0.0 108.317 168.679 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 259' ' ' ALA . . . . . . . . . . . . . . . -92.19 160.94 14.93 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-N 115.303 -0.862 . . . . 0.0 109.184 179.588 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 34.9 t -118.22 131.06 56.4 Favored 'General case' 0 C--N 1.322 -0.627 0 C-N-CA 120.779 -0.368 . . . . 0.0 111.491 -175.794 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 69.96 51.05 25.71 Favored Glycine 0 N--CA 1.449 -0.445 0 CA-C-N 115.607 -0.724 . . . . 0.0 113.655 173.656 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 262' ' ' LEU . . . . . . . . . . . . . 62.6 mt -91.23 151.55 20.88 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 117.044 0.422 . . . . 0.0 110.161 176.63 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 82.5 mt-30 -137.42 168.22 20.08 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.026 0.441 . . . . 0.0 110.883 -178.427 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 264' ' ' VAL . . . . . 0.521 HG11 ' O ' ' A' ' 292' ' ' VAL . 57.6 t -78.23 123.74 35.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.971 176.915 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . 0.438 ' H ' ' HB ' ' A' ' 292' ' ' VAL . . . 114.15 6.98 19.81 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.51 -0.852 . . . . 0.0 112.808 -179.978 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 61.7 m-20 -89.7 166.02 13.84 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.157 0.503 . . . . 0.0 110.611 176.205 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 267' ' ' ALA . . . . . 0.684 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -129.61 153.3 48.21 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.287 -0.87 . . . . 0.0 109.008 177.676 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 268' ' ' PHE . . . . . 0.648 ' HD2' HG23 ' A' ' 332' ' ' ILE . 9.9 p90 -164.0 165.73 22.21 Favored 'General case' 0 C--N 1.32 -0.675 0 C-N-CA 119.701 -0.8 . . . . 0.0 112.498 -176.887 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 269' ' ' THR . . . . . 0.52 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 66.4 p -115.45 149.51 37.94 Favored 'General case' 0 N--CA 1.444 -0.763 0 CA-C-N 114.624 -1.171 . . . . 0.0 109.224 173.302 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 270' ' ' ILE . . . . . 0.968 HG12 HG13 ' A' ' 332' ' ' ILE . 60.5 mt -121.46 131.47 72.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 N-CA-C 110.416 -0.216 . . . . 0.0 110.416 -179.26 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -62.24 132.91 54.26 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.124 -179.499 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 91.47 -21.72 33.94 Favored Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.182 -178.08 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 273' ' ' VAL . . . . . 0.653 HG23 HD12 ' A' ' 306' ' ' ILE . 31.0 t -105.38 104.36 16.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 C-N-CA 122.402 0.281 . . . . 0.0 110.367 -179.483 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 274' ' ' ASN . . . . . 0.473 ' HA ' ' HA ' ' A' ' 287' ' ' PRO . 7.3 m120 -126.11 144.42 50.74 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.509 -0.476 . . . . 0.0 111.408 -175.429 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 275' ' ' SER . . . . . 0.47 ' HB3' ' OE1' ' A' ' 288' ' ' GLN . 29.5 p -63.77 160.98 16.09 Favored 'General case' 0 CA--C 1.515 -0.377 0 CA-C-N 115.826 -0.624 . . . . 0.0 112.494 -179.377 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 33.8 m -119.36 149.94 21.85 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.663 0 CA-C-N 114.916 -1.038 . . . . 0.0 110.618 176.246 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 87.9 m-70 -109.73 71.62 0.77 Allowed 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 173.323 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 -74.42 -9.62 58.77 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.379 -0.828 . . . . 0.0 112.136 -173.459 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 279' ' ' ILE . . . . . 0.416 HD11 HG23 ' A' ' 279' ' ' ILE . 47.1 mm -92.4 -56.6 5.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 120.732 0.301 . . . . 0.0 110.761 -179.676 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 280' ' ' THR . . . . . 0.413 ' HG1' ' CG ' ' A' ' 282' ' ' ASP . 73.0 p -86.48 -14.42 43.2 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.321 -178.716 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 281' ' ' LYS . . . . . 0.434 ' HZ3' ' HB3' ' A' ' 281' ' ' LYS . 3.1 mmmp? 62.27 48.47 4.8 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.994 -178.231 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 282' ' ' ASP . . . . . 0.413 ' CG ' ' HG1' ' A' ' 280' ' ' THR . 52.6 m-20 -92.28 122.92 35.21 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.285 176.943 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 60.9 p -89.35 102.68 15.35 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.052 0.453 . . . . 0.0 110.054 176.616 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 68.5 p -130.91 -40.22 1.19 Allowed 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.837 -0.619 . . . . 0.0 111.242 -174.972 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 73.07 32.36 60.66 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 120.518 -0.848 . . . . 0.0 112.254 -179.624 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 73.6 mt-30 -76.19 140.41 69.48 Favored Pre-proline 0 C--O 1.223 -0.321 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.603 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 287' ' ' PRO . . . . . 0.52 ' HB2' ' HB ' ' A' ' 269' ' ' THR . 36.2 Cg_endo -69.78 150.57 68.26 Favored 'Trans proline' 0 CA--C 1.529 0.255 0 C-N-CA 122.057 1.838 . . . . 0.0 112.566 -177.163 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 288' ' ' GLN . . . . . 0.47 ' OE1' ' HB3' ' A' ' 275' ' ' SER . 5.5 mm100 -78.34 149.28 33.47 Favored 'General case' 0 CA--C 1.514 -0.422 0 CA-C-O 121.186 0.517 . . . . 0.0 112.2 176.929 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 49.7 t -104.61 112.7 39.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 114.877 -1.056 . . . . 0.0 109.37 175.569 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 290' ' ' PHE . . . . . 0.684 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 53.9 m-85 -98.85 160.23 14.41 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.384 -175.584 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 32.7 mmt180 -118.02 150.54 39.12 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 178.588 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 292' ' ' VAL . . . . . 0.521 ' O ' HG11 ' A' ' 264' ' ' VAL . 52.5 t -100.25 122.92 52.76 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.913 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.57 -177.87 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 293' ' ' LEU . . . . . 0.575 HD21 ' N ' ' A' ' 293' ' ' LEU . 3.4 mm? -104.41 -24.1 13.1 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.465 -0.334 . . . . 0.0 111.674 -177.332 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 294' ' ' ALA . . . . . 0.493 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -154.4 136.59 14.79 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 120.762 -0.375 . . . . 0.0 111.638 179.898 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 58.0 t -135.51 120.1 27.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 175.104 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 31.2 t -157.41 111.69 2.65 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.604 -178.331 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 63.34 50.2 64.43 Favored Glycine 0 C--N 1.33 0.229 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.059 -178.315 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 72.2 p 50.82 23.38 1.4 Allowed 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 123.445 0.698 . . . . 0.0 112.524 -175.576 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 299' ' ' THR . . . . . 0.453 ' HA ' ' O ' ' A' ' 255' ' ' ILE . 40.6 m -111.75 116.87 31.43 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 176.148 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . 0.557 HG13 HG22 ' A' ' 302' ' ' ILE . 59.1 t -113.69 133.91 58.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.619 -172.34 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 43.5 m -96.82 120.61 37.46 Favored 'General case' 0 C--O 1.235 0.32 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 172.548 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 302' ' ' ILE . . . . . 0.557 HG22 HG13 ' A' ' 300' ' ' VAL . 27.7 pt -111.26 143.72 20.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-O 121.626 0.727 . . . . 0.0 112.811 -169.725 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 303' ' ' SER . . . . . 0.455 ' HB3' ' CD2' ' A' ' 293' ' ' LEU . 46.8 t -156.29 129.11 4.26 Favored Pre-proline 0 C--N 1.323 -0.578 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 173.24 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 304' ' ' PRO . . . . . 0.616 ' HD2' ' HA ' ' A' ' 290' ' ' PHE . 34.8 Cg_exo -63.0 -176.05 4.24 Favored 'Cis proline' 0 N--CA 1.477 0.505 0 CA-C-N 119.912 1.004 . . . . 0.0 114.324 1.807 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 305' ' ' LYS . . . . . 0.658 ' HE2' HD13 ' A' ' 307' ' ' LEU . 0.0 OUTLIER -136.57 -175.52 4.04 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.938 -176.205 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 306' ' ' ILE . . . . . 0.653 HD12 HG23 ' A' ' 273' ' ' VAL . 41.8 mt -94.29 99.97 10.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.946 -173.525 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 307' ' ' LEU . . . . . 0.658 HD13 ' HE2' ' A' ' 305' ' ' LYS . 2.7 mp -114.43 105.55 53.63 Favored Pre-proline 0 C--N 1.33 -0.277 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 175.729 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 308' ' ' PRO . . . . . 0.727 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 24.1 Cg_exo -68.92 127.66 15.61 Favored 'Trans proline' 0 CA--C 1.53 0.286 0 C-N-CA 122.955 2.437 . . . . 0.0 113.394 -176.07 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . 0.475 HG23 ' HB1' ' A' ' 320' ' ' ALA . 76.9 t -84.27 -37.14 12.6 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.088 174.966 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -75.29 -6.65 50.93 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.256 179.243 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.481 ' HB2' ' HB2' ' A' ' 308' ' ' PRO . 69.7 m-80 -136.87 -158.69 0.88 Allowed 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.262 -0.427 . . . . 0.0 109.996 -176.633 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 16.5 m 71.23 -73.16 0.1 Allowed 'General case' 0 C--O 1.234 0.275 0 C-N-CA 123.755 0.822 . . . . 0.0 110.903 177.005 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 51.0 t0 -176.44 159.81 2.0 Allowed 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 177.253 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 61.7 t -64.45 -39.73 86.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-O 120.908 0.385 . . . . 0.0 110.55 176.038 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -72.5 -18.87 61.62 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.637 178.732 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 50.3 m -83.86 -25.86 29.92 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.535 -0.302 . . . . 0.0 111.177 -179.221 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 317' ' ' ARG . . . . . 0.659 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 74.1 mtm180 -49.14 -52.57 46.88 Favored Pre-proline 0 CA--C 1.539 0.52 0 N-CA-C 112.641 0.608 . . . . 0.0 112.641 -178.574 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 318' ' ' PRO . . . . . 0.659 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 51.8 Cg_exo -59.74 -13.97 24.56 Favored 'Trans proline' 0 C--N 1.36 1.14 0 C-N-CA 122.53 2.154 . . . . 0.0 113.833 -177.232 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 44.9 m-85 -110.75 -0.55 17.0 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.99 0.424 . . . . 0.0 110.77 -179.282 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 320' ' ' ALA . . . . . 0.647 ' HB3' ' O ' ' A' ' 307' ' ' LEU . . . -90.5 159.85 16.3 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.155 -178.899 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 321' ' ' ASN . . . . . 0.427 ' O ' ' HA ' ' A' ' 275' ' ' SER . 0.1 OUTLIER -130.68 -0.69 4.33 Favored 'General case' 0 N--CA 1.464 0.255 0 N-CA-C 112.75 0.648 . . . . 0.0 112.75 -178.977 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 322' ' ' VAL . . . . . 0.537 HG11 HG11 ' A' ' 273' ' ' VAL . 32.8 m -136.11 162.08 36.71 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.258 0 N-CA-C 110.097 -0.334 . . . . 0.0 110.097 176.988 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 51.6 m-20 -72.92 -39.82 65.97 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 111.731 0.271 . . . . 0.0 111.731 -176.376 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 324' ' ' ALA . . . . . 0.727 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -155.5 174.61 15.02 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 112.149 0.426 . . . . 0.0 112.149 -173.353 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 24.6 pttm -119.12 107.44 41.73 Favored Pre-proline 0 N--CA 1.454 -0.233 0 CA-C-N 115.472 -0.785 . . . . 0.0 110.031 170.923 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 55.0 Cg_endo -74.04 167.82 26.28 Favored 'Trans proline' 0 C--O 1.233 0.232 0 C-N-CA 122.695 2.263 . . . . 0.0 112.562 -176.525 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -71.6 123.81 23.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.875 -179.289 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 54.8 mt-10 66.36 -170.14 0.2 Allowed 'General case' 0 N--CA 1.465 0.32 0 O-C-N 123.674 0.609 . . . . 0.0 111.004 -175.998 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 329' ' ' SER . . . . . 0.552 ' HB2' ' O ' ' A' ' 230' ' ' VAL . 50.9 m -94.29 -27.81 15.93 Favored 'General case' 0 C--N 1.325 -0.467 0 C-N-CA 120.727 -0.389 . . . . 0.0 111.995 -174.458 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 75.62 -151.32 0.03 OUTLIER 'General case' 0 N--CA 1.478 0.95 0 N-CA-C 113.273 0.842 . . . . 0.0 113.273 173.023 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 331' ' ' ALA . . . . . 0.407 ' C ' HD12 ' A' ' 332' ' ' ILE . . . -92.98 120.64 33.49 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 114.741 -1.118 . . . . 0.0 110.818 -177.735 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 332' ' ' ILE . . . . . 0.968 HG13 HG12 ' A' ' 270' ' ' ILE . 1.7 mp -106.54 145.87 13.73 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 115.682 -0.69 . . . . 0.0 111.221 -176.903 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.415 ' N ' HG21 ' A' ' 332' ' ' ILE . 44.1 m -118.29 95.33 4.83 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.0 -178.077 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 334' ' ' ILE . . . . . 0.528 ' HA ' ' HB3' ' A' ' 268' ' ' PHE . 39.8 mm -78.34 133.48 30.18 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-O 120.949 0.404 . . . . 0.0 111.35 -176.276 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 335' ' ' LEU . . . . . 0.603 HD13 ' H ' ' A' ' 337' ' ' LYS . 1.8 pp -152.44 -172.65 4.3 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.429 177.875 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -124.96 44.23 2.84 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.776 0.322 . . . . 0.0 110.844 -178.925 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 337' ' ' LYS . . . . . 0.603 ' H ' HD13 ' A' ' 335' ' ' LEU . 60.8 tttm . . . . . 0 C--O 1.245 0.836 0 CA-C-O 118.635 -0.698 . . . . 0.0 110.509 -178.943 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 38.2 p . . . . . 0 N--CA 1.452 -0.327 0 CA-C-O 121.136 0.494 . . . . 0.0 110.286 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 228' ' ' LEU . . . . . . . . . . . . . 73.0 mt -107.62 100.72 10.1 Favored 'General case' 0 N--CA 1.445 -0.692 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 -178.325 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 76.1 p -126.39 172.19 10.36 Favored 'General case' 0 C--N 1.325 -0.459 0 C-N-CA 119.924 -0.71 . . . . 0.0 110.41 -178.621 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 230' ' ' VAL . . . . . 0.771 HG11 ' HB ' ' A' ' 255' ' ' ILE . 61.5 t -143.96 136.36 23.21 Favored 'Isoleucine or valine' 0 C--O 1.24 0.565 0 CA-C-O 120.779 0.324 . . . . 0.0 110.845 -178.176 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 29.7 m -97.28 160.16 14.5 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.125 177.201 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 92.52 161.58 36.57 Favored Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.462 -0.875 . . . . 0.0 111.177 -177.281 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 233' ' ' GLN . . . . . 0.598 ' HG2' ' HA ' ' A' ' 328' ' ' GLU . 83.4 mt-30 -118.16 102.85 50.38 Favored Pre-proline 0 C--N 1.319 -0.723 0 CA-C-N 117.081 0.44 . . . . 0.0 111.739 -177.354 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 234' ' ' PRO . . . . . 0.414 ' HD3' ' OG ' ' A' ' 329' ' ' SER . 73.9 Cg_endo -75.86 123.75 7.61 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 121.468 1.445 . . . . 0.0 110.444 171.829 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 20.3 pt-20 -166.19 127.1 1.76 Allowed 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.605 -178.584 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 236' ' ' HIS . . . . . 0.479 ' C ' ' HD3' ' A' ' 237' ' ' LYS . 41.0 m80 -141.04 143.36 34.35 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.219 174.794 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 237' ' ' LYS . . . . . 0.479 ' HD3' ' C ' ' A' ' 236' ' ' HIS . 13.7 mmtm . . . . . 0 C--N 1.313 -1.018 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.207 -172.62 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 252' ' ' GLN . . . . . 0.566 ' HA ' ' O ' ' A' ' 302' ' ' ILE . 86.3 mt-30 . . . . . 0 N--CA 1.468 0.474 0 N-CA-C 114.13 1.159 . . . . 0.0 114.13 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 174.72 109.47 0.24 Allowed Glycine 0 N--CA 1.446 -0.648 0 CA-C-N 114.338 -1.301 . . . . 0.0 109.933 -177.145 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 41.5 p -95.44 125.09 39.81 Favored 'General case' 0 C--N 1.324 -0.522 0 O-C-N 122.32 -0.517 . . . . 0.0 111.706 -171.726 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.771 ' HB ' HG11 ' A' ' 230' ' ' VAL . 20.5 pt -124.37 145.18 31.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.901 -176.181 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 31.0 m -99.56 106.05 17.99 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 174.232 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.557 ' HA ' HG13 ' A' ' 230' ' ' VAL . 32.8 m -88.13 141.57 14.13 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.595 0 C-N-CA 119.27 -0.972 . . . . 0.0 113.607 -165.04 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 36.4 m -94.23 10.3 34.57 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 113.404 -1.725 . . . . 0.0 109.275 169.593 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 259' ' ' ALA . . . . . . . . . . . . . . . -126.76 145.58 50.56 Favored 'General case' 0 CA--C 1.518 -0.256 0 N-CA-C 113.037 0.755 . . . . 0.0 113.037 -167.209 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 62.5 m 57.94 -68.51 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.558 0 CA-C-N 113.822 -1.535 . . . . 0.0 114.919 167.354 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 107.49 51.39 0.76 Allowed Glycine 0 N--CA 1.449 -0.466 0 N-CA-C 109.861 -1.296 . . . . 0.0 109.861 -167.408 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 262' ' ' LEU . . . . . 0.409 HD21 HD12 ' A' ' 334' ' ' ILE . 92.4 mt -65.0 163.93 13.71 Favored 'General case' 0 C--O 1.235 0.332 0 N-CA-C 113.709 1.003 . . . . 0.0 113.709 -168.021 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 73.0 mt-30 -135.23 -179.42 5.62 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 113.694 -1.594 . . . . 0.0 108.042 173.425 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 264' ' ' VAL . . . . . 0.43 ' HA ' ' CG1' ' A' ' 292' ' ' VAL . 38.5 t -73.76 127.81 35.84 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 C-N-CA 120.679 -0.408 . . . . 0.0 111.062 -179.79 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 265' ' ' GLY . . . . . 0.617 ' H ' ' HB ' ' A' ' 292' ' ' VAL . . . 121.49 8.05 7.88 Favored Glycine 0 C--N 1.335 0.486 0 C-N-CA 120.363 -0.922 . . . . 0.0 114.395 175.246 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 65.6 m-20 -90.71 164.93 13.95 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 117.831 0.816 . . . . 0.0 111.517 178.511 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 267' ' ' ALA . . . . . 0.766 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -139.9 126.0 19.84 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.199 -0.909 . . . . 0.0 109.052 174.536 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 268' ' ' PHE . . . . . 0.48 ' HZ ' HG21 ' A' ' 302' ' ' ILE . 4.7 p90 -147.6 166.74 26.47 Favored 'General case' 0 C--N 1.327 -0.413 0 C-N-CA 119.74 -0.784 . . . . 0.0 111.829 -173.353 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 269' ' ' THR . . . . . 0.435 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 44.2 p -117.73 139.82 50.53 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.853 176.09 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 270' ' ' ILE . . . . . 0.546 HG12 HG12 ' A' ' 332' ' ' ILE . 59.6 mt -106.71 144.37 15.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 120.668 0.27 . . . . 0.0 110.964 -177.425 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -67.83 119.51 12.64 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.442 -179.827 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 106.04 -22.69 30.91 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 121.098 -0.572 . . . . 0.0 112.386 178.615 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 273' ' ' VAL . . . . . 0.818 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 36.5 t -87.02 101.44 11.16 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-O 121.046 0.45 . . . . 0.0 110.286 178.756 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 274' ' ' ASN . . . . . 0.526 ' HB3' ' HA2' ' A' ' 285' ' ' GLY . 54.7 m-20 -110.01 129.6 55.65 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.272 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 51.0 p -73.01 160.47 32.03 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.588 0.709 . . . . 0.0 112.148 -178.902 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 276' ' ' VAL . . . . . 0.863 HG21 HG21 ' A' ' 309' ' ' VAL . 22.8 m -127.9 -176.67 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 CA-C-N 114.748 -1.115 . . . . 0.0 110.432 -178.561 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 277' ' ' HIS . . . . . 0.669 ' HB3' ' HA ' ' A' ' 281' ' ' LYS . 0.0 OUTLIER 29.84 51.21 0.08 Allowed 'General case' 0 N--CA 1.473 0.69 0 O-C-N 124.826 1.328 . . . . 0.0 113.624 177.89 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 4.1 tp-100 -74.84 -43.15 56.1 Favored 'General case' 0 N--CA 1.439 -1.018 0 N-CA-C 108.488 -0.931 . . . . 0.0 108.488 171.248 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 279' ' ' ILE . . . . . 0.446 ' O ' ' HB2' ' A' ' 282' ' ' ASP . 26.5 mm -117.32 75.08 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.278 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.269 177.464 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 58.3 p 51.4 81.93 0.07 Allowed 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 123.665 0.786 . . . . 0.0 112.642 -178.998 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 281' ' ' LYS . . . . . 0.669 ' HA ' ' HB3' ' A' ' 277' ' ' HIS . 1.0 OUTLIER 56.96 27.63 13.47 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-N 115.42 -0.809 . . . . 0.0 112.011 -179.555 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 282' ' ' ASP . . . . . 0.446 ' HB2' ' O ' ' A' ' 279' ' ' ILE . 57.3 t0 -90.1 128.55 36.34 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.947 -0.57 . . . . 0.0 109.677 177.323 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 44.7 p -101.18 114.94 29.36 Favored 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.819 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 76.0 p -116.19 -11.35 11.34 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.649 -0.705 . . . . 0.0 112.145 -167.924 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 285' ' ' GLY . . . . . 0.526 ' HA2' ' HB3' ' A' ' 274' ' ' ASN . . . 76.83 10.83 85.9 Favored Glycine 0 CA--C 1.517 0.196 0 C-N-CA 120.814 -0.707 . . . . 0.0 113.267 177.249 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 83.2 mt-30 -71.81 131.09 86.14 Favored Pre-proline 0 C--N 1.327 -0.39 0 CA-C-N 116.824 0.312 . . . . 0.0 110.596 179.616 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 287' ' ' PRO . . . . . 0.435 ' HB2' ' HB ' ' A' ' 269' ' ' THR . 15.8 Cg_endo -59.3 131.32 40.3 Favored 'Trans proline' 0 C--N 1.343 0.254 0 C-N-CA 122.699 2.266 . . . . 0.0 112.292 -178.646 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 69.2 tp60 -78.3 132.16 37.35 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.847 -178.528 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 46.9 t -92.13 136.3 24.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.356 179.345 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 290' ' ' PHE . . . . . 0.818 ' HZ ' HG11 ' A' ' 273' ' ' VAL . 55.7 m-85 -117.16 150.67 38.33 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.806 -177.081 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 21.2 mmt85 -108.02 157.69 18.02 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.797 -0.638 . . . . 0.0 109.835 172.252 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 292' ' ' VAL . . . . . 0.617 ' HB ' ' H ' ' A' ' 265' ' ' GLY . 52.2 t -102.6 128.77 55.07 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.03 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.509 177.406 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 293' ' ' LEU . . . . . 0.659 HD21 ' HB3' ' A' ' 303' ' ' SER . 2.8 mm? -103.99 -37.05 7.53 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.108 -178.578 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 294' ' ' ALA . . . . . . . . . . . . . . . -156.96 141.54 16.75 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.562 -0.29 . . . . 0.0 111.009 -178.819 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 295' ' ' VAL . . . . . 0.471 HG22 HG13 ' A' ' 300' ' ' VAL . 46.3 t -131.64 129.01 61.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.052 0.453 . . . . 0.0 110.122 176.176 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 56.5 p -122.3 88.81 3.0 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.793 -0.64 . . . . 0.0 109.897 178.295 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 75.42 -124.3 7.56 Favored Glycine 0 N--CA 1.446 -0.671 0 C-N-CA 119.932 -1.128 . . . . 0.0 110.552 -171.425 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 41.7 p -99.72 26.37 6.3 Favored 'General case' 0 C--N 1.319 -0.745 0 O-C-N 122.142 -0.622 . . . . 0.0 110.87 173.505 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 54.1 m -107.95 106.3 16.49 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 176.009 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 300' ' ' VAL . . . . . 0.471 HG13 HG22 ' A' ' 295' ' ' VAL . 42.0 t -104.44 124.87 59.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.952 -175.001 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 47.3 m -94.89 109.67 21.64 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 176.149 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 302' ' ' ILE . . . . . 0.566 ' O ' ' HA ' ' A' ' 252' ' ' GLN . 28.8 pt -111.25 160.93 10.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-O 121.459 0.647 . . . . 0.0 112.343 -173.412 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 303' ' ' SER . . . . . 0.659 ' HB3' HD21 ' A' ' 293' ' ' LEU . 34.6 t -167.24 155.9 9.09 Favored Pre-proline 0 C--N 1.32 -0.713 0 N-CA-C 105.964 -1.865 . . . . 0.0 105.964 178.331 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 304' ' ' PRO . . . . . 0.507 ' HA ' ' OG ' ' A' ' 303' ' ' SER . 65.2 Cg_exo -56.46 151.54 27.16 Favored 'Cis proline' 0 N--CA 1.473 0.291 0 CA-C-N 121.23 1.475 . . . . 0.0 114.642 1.715 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 305' ' ' LYS . . . . . 0.613 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -67.34 169.01 9.56 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 114.085 -1.416 . . . . 0.0 111.763 -179.04 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 306' ' ' ILE . . . . . 0.593 HG23 HG21 ' A' ' 322' ' ' VAL . 62.6 mt -108.59 114.09 45.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.85 -178.154 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 307' ' ' LEU . . . . . 0.537 ' O ' ' HB1' ' A' ' 320' ' ' ALA . 94.0 mt -125.94 118.45 23.97 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-N 116.753 -0.203 . . . . 0.0 111.021 -179.72 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 308' ' ' PRO . . . . . 0.741 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 9.9 Cg_exo -74.18 122.31 7.49 Favored 'Trans proline' 0 CA--C 1.534 0.493 0 C-N-CA 123.519 2.813 . . . . 0.0 113.742 -178.557 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 309' ' ' VAL . . . . . 0.863 HG21 HG21 ' A' ' 276' ' ' VAL . 48.1 t -80.58 -19.44 11.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 121.189 0.518 . . . . 0.0 110.48 176.014 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 59.5 mm-40 -92.77 -5.32 51.42 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.904 0.383 . . . . 0.0 110.834 179.206 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.568 ' HB2' ' HB2' ' A' ' 308' ' ' PRO . 5.5 m120 -132.5 -129.98 0.18 Allowed 'General case' 0 CA--C 1.532 0.285 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.26 -178.531 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 312' ' ' THR . . . . . 0.493 ' OG1' ' HD2' ' A' ' 308' ' ' PRO . 59.6 m 60.84 -78.61 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.281 0 C-N-CA 124.28 1.032 . . . . 0.0 112.121 177.655 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 38.3 t70 -176.68 150.29 0.82 Allowed 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 -177.864 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 46.7 t -53.18 -37.61 28.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 120.748 0.309 . . . . 0.0 111.53 -179.516 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -84.91 -36.3 21.55 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 112.377 0.51 . . . . 0.0 112.377 -178.314 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 316' ' ' SER . . . . . 0.523 ' HA ' ' CZ ' ' A' ' 319' ' ' TYR . 67.9 m -93.53 -12.68 29.06 Favored 'General case' 0 C--N 1.327 -0.398 0 N-CA-C 113.364 0.875 . . . . 0.0 113.364 -172.346 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 317' ' ' ARG . . . . . 0.525 ' HG2' ' HD3' ' A' ' 318' ' ' PRO . 33.6 ptt85 -75.44 -34.4 1.59 Allowed Pre-proline 0 CA--C 1.548 0.882 0 N-CA-C 113.171 0.804 . . . . 0.0 113.171 -179.47 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 318' ' ' PRO . . . . . 0.525 ' HD3' ' HG2' ' A' ' 317' ' ' ARG . 33.9 Cg_exo -60.36 -26.79 83.53 Favored 'Trans proline' 0 C--N 1.371 1.718 0 C-N-CA 121.702 1.602 . . . . 0.0 113.17 -177.785 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 319' ' ' TYR . . . . . 0.523 ' CZ ' ' HA ' ' A' ' 316' ' ' SER . 2.7 p90 -106.82 30.0 6.5 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.076 0.465 . . . . 0.0 111.312 177.863 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 320' ' ' ALA . . . . . 0.706 ' HB3' HG22 ' A' ' 309' ' ' VAL . . . -89.87 162.68 15.34 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.404 -0.817 . . . . 0.0 109.838 173.628 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 321' ' ' ASN . . . . . 0.406 ' OD1' HG13 ' A' ' 322' ' ' VAL . 19.4 p30 -100.71 -19.18 16.16 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 113.788 1.032 . . . . 0.0 113.788 -171.457 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 322' ' ' VAL . . . . . 0.593 HG21 HG23 ' A' ' 306' ' ' ILE . 35.6 m -136.77 161.08 36.78 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.401 0 CA-C-N 118.073 0.397 . . . . 0.0 111.155 -179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 54.5 m-20 -60.91 -41.03 95.34 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 111.849 0.314 . . . . 0.0 111.849 -178.781 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 324' ' ' ALA . . . . . 0.741 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -157.09 166.24 33.82 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.398 -0.364 . . . . 0.0 111.77 -175.346 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 24.5 pttm -106.31 108.93 62.67 Favored Pre-proline 0 C--N 1.327 -0.411 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 169.016 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_exo -65.0 167.24 16.39 Favored 'Trans proline' 0 C--N 1.343 0.244 0 C-N-CA 122.581 2.187 . . . . 0.0 113.107 -170.543 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -62.85 143.53 57.51 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 115.753 -0.658 . . . . 0.0 109.767 175.089 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 328' ' ' GLU . . . . . 0.598 ' HA ' ' HG2' ' A' ' 233' ' ' GLN . 15.6 pt-20 44.86 -135.25 0.65 Allowed 'General case' 0 N--CA 1.468 0.449 0 O-C-N 124.227 0.955 . . . . 0.0 110.941 -174.132 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 329' ' ' SER . . . . . 0.648 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 53.3 m -111.7 -31.63 6.91 Favored 'General case' 0 C--N 1.321 -0.636 0 C-N-CA 120.743 -0.383 . . . . 0.0 110.535 178.317 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 330' ' ' ALA . . . . . 0.432 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 78.6 -167.42 0.04 OUTLIER 'General case' 0 N--CA 1.475 0.824 0 O-C-N 124.111 0.882 . . . . 0.0 112.902 174.634 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -83.85 152.91 24.32 Favored 'General case' 0 CA--C 1.52 -0.182 0 CA-C-N 115.361 -0.836 . . . . 0.0 111.193 -176.179 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 332' ' ' ILE . . . . . 0.582 HD11 HG21 ' A' ' 230' ' ' VAL . 48.7 mt -126.58 145.0 34.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 121.202 0.525 . . . . 0.0 112.034 -176.56 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 87.8 m -111.22 97.57 6.88 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.459 -0.792 . . . . 0.0 109.103 173.486 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 334' ' ' ILE . . . . . 0.409 HD12 HD21 ' A' ' 262' ' ' LEU . 30.2 mm -79.11 132.27 32.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -171.705 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 335' ' ' LEU . . . . . . . . . . . . . 8.4 mp -119.79 151.59 38.57 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.412 -0.813 . . . . 0.0 109.818 170.468 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 75.0 m-80 -110.3 9.95 23.62 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.293 174.193 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 38.8 ttpt . . . . . 0 C--O 1.244 0.788 0 CA-C-O 118.493 -0.765 . . . . 0.0 110.181 179.295 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 35.7 t . . . . . 0 C--O 1.235 0.305 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 228' ' ' LEU . . . . . 0.652 HD12 HG13 ' A' ' 334' ' ' ILE . 80.3 mt -103.61 146.9 27.88 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.352 -0.84 . . . . 0.0 109.548 -175.523 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 229' ' ' THR . . . . . 0.593 HG22 ' HA ' ' A' ' 331' ' ' ALA . 40.9 p -126.43 178.77 5.65 Favored 'General case' 0 C--N 1.323 -0.547 0 C-N-CA 119.729 -0.788 . . . . 0.0 111.042 -179.835 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 230' ' ' VAL . . . . . 0.857 HG11 HD12 ' A' ' 255' ' ' ILE . 58.1 t -146.28 137.15 18.6 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 -179.599 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 70.8 m -111.18 155.41 22.95 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.944 0.402 . . . . 0.0 110.854 178.188 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 86.03 169.63 46.14 Favored Glycine 0 N--CA 1.449 -0.499 0 N-CA-C 110.76 -0.936 . . . . 0.0 110.76 -172.471 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 233' ' ' GLN . . . . . 0.419 ' HA ' ' HD3' ' A' ' 234' ' ' PRO . 86.1 mt-30 -117.54 145.56 36.54 Favored Pre-proline 0 C--N 1.323 -0.572 0 CA-C-N 117.626 0.713 . . . . 0.0 111.482 179.761 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 234' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 233' ' ' GLN . 3.8 Cg_exo -71.94 172.29 14.91 Favored 'Trans proline' 0 N--CA 1.462 -0.374 0 C-N-CA 122.751 2.301 . . . . 0.0 111.55 176.249 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 55.7 mp0 -96.89 151.19 19.92 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.174 0.512 . . . . 0.0 110.911 -179.063 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 4.2 p80 -140.48 125.73 18.7 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.33 -0.85 . . . . 0.0 108.9 174.338 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 237' ' ' LYS . . . . . 0.563 ' HD3' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.326 -0.414 0 N-CA-C 111.76 0.282 . . . . 0.0 111.76 -176.385 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 252' ' ' GLN . . . . . 0.493 ' HA ' ' O ' ' A' ' 302' ' ' ILE . 86.0 mt-30 . . . . . 0 N--CA 1.47 0.562 0 N-CA-C 114.894 1.442 . . . . 0.0 114.894 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 253' ' ' GLY . . . . . 0.556 ' O ' HG12 ' A' ' 302' ' ' ILE . . . 179.96 110.43 0.28 Allowed Glycine 0 N--CA 1.451 -0.349 0 CA-C-N 113.738 -1.574 . . . . 0.0 110.588 178.581 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 41.6 p -97.12 126.49 42.32 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 117.378 0.589 . . . . 0.0 111.406 -174.887 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.857 HD12 HG11 ' A' ' 230' ' ' VAL . 12.7 pt -132.18 157.79 43.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.62 -176.406 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 32.7 m -98.98 107.57 20.04 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 175.06 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.567 ' HA ' HG13 ' A' ' 230' ' ' VAL . 29.8 m -89.79 143.31 11.45 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.575 0 C-N-CA 119.556 -0.858 . . . . 0.0 113.012 -168.206 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 258' ' ' SER . . . . . 0.516 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 37.2 m -91.04 9.32 31.3 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 114.023 -1.444 . . . . 0.0 108.893 169.789 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 259' ' ' ALA . . . . . 0.618 ' HB1' HD13 ' A' ' 228' ' ' LEU . . . -84.78 161.56 19.93 Favored 'General case' 0 N--CA 1.448 -0.525 0 CA-C-N 115.119 -0.946 . . . . 0.0 109.502 -177.624 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 34.3 t -126.63 130.77 51.11 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 120.639 0.257 . . . . 0.0 110.61 -178.831 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 75.87 43.79 21.51 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.963 -0.637 . . . . 0.0 113.328 177.179 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 262' ' ' LEU . . . . . 0.481 HD12 HG21 ' A' ' 257' ' ' VAL . 79.3 mt -89.99 142.92 27.24 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 117.17 0.485 . . . . 0.0 110.478 175.757 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 73.0 mt-30 -133.84 171.43 14.17 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.51 176.845 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 44.0 t -76.58 142.05 14.87 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 N-CA-C 110.195 -0.298 . . . . 0.0 110.195 179.1 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 94.87 -4.9 68.77 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.5 -0.857 . . . . 0.0 113.257 177.255 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 266' ' ' ASP . . . . . 0.506 ' O ' ' HA ' ' A' ' 291' ' ' ARG . 48.7 m-20 -78.88 158.03 28.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 117.172 0.486 . . . . 0.0 110.837 178.287 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 267' ' ' ALA . . . . . 0.652 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -122.72 147.67 46.21 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.974 -176.658 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 268' ' ' PHE . . . . . 0.581 ' HA ' ' CD2' ' A' ' 335' ' ' LEU . 3.6 p90 -164.04 173.28 12.73 Favored 'General case' 0 C--N 1.33 -0.259 0 C-N-CA 120.056 -0.657 . . . . 0.0 111.895 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 54.1 p -121.58 129.98 53.21 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.345 176.866 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 270' ' ' ILE . . . . . 0.846 HG12 HG13 ' A' ' 332' ' ' ILE . 62.6 mt -98.35 134.4 37.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.72 -178.839 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -76.07 118.47 18.85 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.828 179.206 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 109.62 -21.44 25.84 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.629 -0.796 . . . . 0.0 111.938 -178.778 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 40.9 t -104.35 102.12 13.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 N-CA-C 109.557 -0.535 . . . . 0.0 109.557 175.293 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 59.6 m-20 -104.44 151.57 23.37 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 -179.481 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 275' ' ' SER . . . . . 0.98 ' HB3' ' HB3' ' A' ' 288' ' ' GLN . 23.2 p -88.17 157.53 18.79 Favored 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 112.13 0.419 . . . . 0.0 112.13 -178.079 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 276' ' ' VAL . . . . . 0.536 HG11 HG21 ' A' ' 309' ' ' VAL . 18.8 m -125.98 162.76 28.88 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.605 0 CA-C-N 115.332 -0.849 . . . . 0.0 109.959 172.744 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 39.2 m80 -130.04 91.29 3.1 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 175.526 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 4.1 tp-100 -80.64 -23.42 39.71 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.361 -172.112 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 279' ' ' ILE . . . . . 0.505 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.1 mp -64.99 -41.56 92.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 121.069 0.461 . . . . 0.0 109.884 177.972 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 77.8 p -87.45 -16.44 34.8 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.316 174.966 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 5.6 tmtm? 59.49 53.65 5.03 Favored 'General case' 0 CA--C 1.531 0.216 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 -176.086 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -110.91 142.26 43.23 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.336 -0.847 . . . . 0.0 109.401 -175.256 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 36.0 p -102.28 106.19 16.96 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 178.295 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 82.5 p -110.13 -53.47 2.67 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.655 -0.702 . . . . 0.0 111.406 -171.628 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 66.13 31.48 79.41 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 121.001 -0.618 . . . . 0.0 111.966 -179.364 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 286' ' ' GLN . . . . . 0.408 ' HA ' ' HD3' ' A' ' 287' ' ' PRO . 11.2 mm100 -106.11 142.15 24.25 Favored Pre-proline 0 C--N 1.326 -0.451 0 CA-C-N 116.026 -0.087 . . . . 0.0 110.772 -177.311 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 287' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 286' ' ' GLN . 38.6 Cg_exo -59.3 127.82 25.32 Favored 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 122.648 2.232 . . . . 0.0 111.671 178.161 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 288' ' ' GLN . . . . . 0.98 ' HB3' ' HB3' ' A' ' 275' ' ' SER . 15.9 pt20 -93.55 159.18 15.34 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.984 -178.163 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 289' ' ' VAL . . . . . 0.482 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 45.6 t -88.53 126.26 41.76 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 CA-C-N 115.446 -0.797 . . . . 0.0 110.002 175.246 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 290' ' ' PHE . . . . . 0.652 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 4.1 m-85 -99.67 169.21 9.43 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 178.762 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 291' ' ' ARG . . . . . 0.506 ' HA ' ' O ' ' A' ' 266' ' ' ASP . 12.5 ttp-105 -144.14 127.47 16.79 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-O 121.808 0.813 . . . . 0.0 110.947 172.417 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 292' ' ' VAL . . . . . 0.402 HG11 ' CG2' ' A' ' 295' ' ' VAL . 57.5 t -65.84 139.91 20.48 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.979 0 CA-C-N 114.044 -1.434 . . . . 0.0 112.175 -176.347 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 293' ' ' LEU . . . . . 0.513 HD11 ' HB2' ' A' ' 303' ' ' SER . 89.4 mt -105.56 -32.69 8.37 Favored 'General case' 0 CA--C 1.529 0.157 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.193 177.035 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 294' ' ' ALA . . . . . . . . . . . . . . . -158.6 144.94 17.1 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-O 120.463 0.173 . . . . 0.0 111.15 -179.18 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 295' ' ' VAL . . . . . 0.402 ' CG2' HG11 ' A' ' 292' ' ' VAL . 57.4 t -136.34 126.8 41.33 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 176.836 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 47.0 t -157.54 112.54 2.73 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.897 -178.56 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 57.6 49.76 70.93 Favored Glycine 0 C--N 1.333 0.376 0 C-N-CA 121.148 -0.548 . . . . 0.0 112.469 178.925 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 298' ' ' THR . . . . . 0.438 ' O ' HG22 ' A' ' 257' ' ' VAL . 66.8 p 55.4 10.3 0.46 Allowed 'General case' 0 N--CA 1.473 0.675 0 C-N-CA 124.201 1.0 . . . . 0.0 112.89 -175.722 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 42.6 m -97.81 106.02 18.26 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 173.351 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 300' ' ' VAL . . . . . 0.4 HG13 HG22 ' A' ' 295' ' ' VAL . 53.1 t -109.86 127.02 67.03 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.51 -170.494 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 57.3 m -90.54 113.89 25.98 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 172.655 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 302' ' ' ILE . . . . . 0.556 HG12 ' O ' ' A' ' 253' ' ' GLY . 31.0 pt -110.4 174.76 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-O 121.643 0.735 . . . . 0.0 111.727 -173.321 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 303' ' ' SER . . . . . 0.562 ' OG ' ' HA ' ' A' ' 304' ' ' PRO . 31.8 t -163.1 156.67 16.98 Favored Pre-proline 0 C--N 1.317 -0.811 0 N-CA-C 105.759 -1.941 . . . . 0.0 105.759 178.732 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 304' ' ' PRO . . . . . 0.562 ' HA ' ' OG ' ' A' ' 303' ' ' SER . 24.9 Cg_exo -66.33 -179.42 12.34 Favored 'Cis proline' 0 N--CA 1.474 0.339 0 CA-C-N 121.004 1.394 . . . . 0.0 113.906 1.404 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 305' ' ' LYS . . . . . 0.618 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -77.48 160.98 28.29 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.317 -0.856 . . . . 0.0 112.254 -175.264 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 306' ' ' ILE . . . . . 0.526 HD12 ' N ' ' A' ' 306' ' ' ILE . 2.2 mp -94.05 109.91 22.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.18 179.03 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 307' ' ' LEU . . . . . 0.485 ' H ' HG22 ' A' ' 322' ' ' VAL . 96.0 mt -141.51 99.39 6.36 Favored Pre-proline 0 CA--C 1.516 -0.361 0 CA-C-O 120.455 0.169 . . . . 0.0 111.052 178.411 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 308' ' ' PRO . . . . . 0.755 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 22.6 Cg_exo -69.43 148.19 66.63 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 123.077 2.518 . . . . 0.0 113.297 -177.354 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 309' ' ' VAL . . . . . 0.536 HG21 HG11 ' A' ' 276' ' ' VAL . 45.5 t -93.7 -23.98 5.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 170.452 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -76.05 34.37 0.13 Allowed 'General case' 0 CA--C 1.532 0.272 0 CA-C-N 115.375 -0.83 . . . . 0.0 112.726 -177.3 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 33.7 m120 -99.07 162.87 12.83 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 174.77 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 61.5 m -78.43 -32.81 48.77 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 176.615 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -65.31 119.57 11.18 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.781 179.699 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 60.1 t -68.39 -35.43 70.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.767 -0.651 . . . . 0.0 111.16 -178.657 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 315' ' ' ALA . . . . . 0.423 ' O ' ' HD2' ' A' ' 318' ' ' PRO . . . -65.07 -17.9 64.85 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 112.157 0.428 . . . . 0.0 112.157 -178.787 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 316' ' ' SER . . . . . 0.593 ' HA ' ' CZ ' ' A' ' 319' ' ' TYR . 52.4 m -78.92 -17.21 55.89 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 111.812 0.301 . . . . 0.0 111.812 -179.313 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 317' ' ' ARG . . . . . 0.427 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 70.0 mtm180 -74.4 -46.88 5.86 Favored Pre-proline 0 CA--C 1.539 0.542 0 N-CA-C 112.928 0.714 . . . . 0.0 112.928 -176.569 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 318' ' ' PRO . . . . . 0.427 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 75.9 Cg_exo -54.85 -38.48 92.32 Favored 'Trans proline' 0 C--N 1.358 1.033 0 C-N-CA 122.126 1.884 . . . . 0.0 113.685 -175.78 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 319' ' ' TYR . . . . . 0.593 ' CZ ' ' HA ' ' A' ' 316' ' ' SER . 2.1 p90 -98.72 7.58 45.92 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 120.76 -0.376 . . . . 0.0 111.937 -178.536 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -60.43 156.02 16.93 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-O 121.122 0.487 . . . . 0.0 111.834 -177.28 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 321' ' ' ASN . . . . . 0.473 ' HB2' ' HE2' ' A' ' 305' ' ' LYS . 16.3 t-20 -132.59 -27.61 1.71 Allowed 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.952 -179.04 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 322' ' ' VAL . . . . . 0.485 HG22 ' H ' ' A' ' 307' ' ' LEU . 28.7 m -131.59 166.95 27.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.759 -179.733 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -68.43 -48.05 65.61 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.612 -0.267 . . . . 0.0 111.154 177.832 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 324' ' ' ALA . . . . . 0.755 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -164.63 177.35 8.12 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.988 -0.551 . . . . 0.0 111.59 -176.132 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 21.9 pttp -118.61 119.52 32.64 Favored Pre-proline 0 C--N 1.325 -0.462 0 CA-C-N 115.346 -0.843 . . . . 0.0 109.692 172.529 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_endo -79.23 169.13 19.4 Favored 'Trans proline' 0 C--O 1.233 0.243 0 C-N-CA 122.962 2.441 . . . . 0.0 112.901 -176.171 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -67.57 129.15 39.02 Favored 'General case' 0 C--O 1.238 0.455 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 175.643 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 57.0 mm-40 65.48 -156.17 0.28 Allowed 'General case' 0 N--CA 1.463 0.216 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 -172.089 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 329' ' ' SER . . . . . 0.661 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 69.3 m -112.5 -12.27 13.5 Favored 'General case' 0 C--N 1.322 -0.606 0 C-N-CA 120.544 -0.462 . . . . 0.0 110.869 176.785 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 70.24 -154.01 0.12 Allowed 'General case' 0 N--CA 1.469 0.502 0 N-CA-C 113.209 0.818 . . . . 0.0 113.209 172.408 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 331' ' ' ALA . . . . . 0.593 ' HA ' HG22 ' A' ' 229' ' ' THR . . . -93.09 137.61 32.28 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.75 -177.801 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 332' ' ' ILE . . . . . 0.846 HG13 HG12 ' A' ' 270' ' ' ILE . 1.9 mp -116.33 144.27 24.41 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.113 -178.685 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 40.8 m -109.87 106.29 15.81 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.609 -0.515 . . . . 0.0 109.609 179.728 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 334' ' ' ILE . . . . . 0.652 HG13 HD12 ' A' ' 228' ' ' LEU . 19.5 mm -81.39 133.55 29.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 N-CA-C 113.755 1.02 . . . . 0.0 113.755 -172.208 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 335' ' ' LEU . . . . . 0.581 ' CD2' ' HA ' ' A' ' 268' ' ' PHE . 1.6 pt? -148.02 -147.62 0.23 Allowed 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 113.61 -1.632 . . . . 0.0 108.344 169.071 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 55.7 t-20 -163.38 -39.97 0.03 OUTLIER 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 108.393 -0.965 . . . . 0.0 108.393 177.801 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 62.4 tttp . . . . . 0 C--O 1.243 0.716 0 CA-C-N 114.55 -1.204 . . . . 0.0 109.5 174.82 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 26.2 t . . . . . 0 N--CA 1.452 -0.326 0 N-CA-C 109.527 -0.545 . . . . 0.0 109.527 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 228' ' ' LEU . . . . . 0.525 ' HB3' ' HA ' ' A' ' 259' ' ' ALA . 83.8 mt -108.37 140.79 41.16 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 109.689 -0.486 . . . . 0.0 109.689 179.293 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 70.8 p -124.27 177.12 6.02 Favored 'General case' 0 C--N 1.325 -0.464 0 C-N-CA 119.957 -0.697 . . . . 0.0 110.978 -178.506 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 230' ' ' VAL . . . . . 0.63 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 61.3 t -146.61 146.84 18.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.014 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 41.3 t -132.08 133.85 44.82 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.822 0.344 . . . . 0.0 110.402 178.755 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 104.21 73.28 0.92 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.41 -0.9 . . . . 0.0 112.929 177.625 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 13.8 mm-40 -66.86 133.0 93.93 Favored Pre-proline 0 C--N 1.33 -0.248 0 CA-C-O 120.84 0.353 . . . . 0.0 111.377 176.546 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 234' ' ' PRO . . . . . 0.58 ' HB2' ' HE1' ' A' ' 236' ' ' HIS . 56.9 Cg_endo -69.97 138.38 37.03 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 122.373 2.049 . . . . 0.0 111.515 176.974 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -97.88 126.41 43.25 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 121.391 0.615 . . . . 0.0 111.532 -176.261 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 236' ' ' HIS . . . . . 0.58 ' HE1' ' HB2' ' A' ' 234' ' ' PRO . 24.2 m80 -130.41 133.83 46.66 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.404 -0.817 . . . . 0.0 109.562 -178.548 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 237' ' ' LYS . . . . . 0.584 ' HA ' HG21 ' A' ' 312' ' ' THR . 6.8 mptt . . . . . 0 C--N 1.327 -0.379 0 C-N-CA 120.556 -0.458 . . . . 0.0 110.551 178.923 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 78.2 mt-30 . . . . . 0 N--CA 1.468 0.461 0 CA-C-O 121.519 0.676 . . . . 0.0 112.42 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 253' ' ' GLY . . . . . 0.468 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -172.65 95.71 0.11 Allowed Glycine 0 N--CA 1.447 -0.631 0 CA-C-N 115.429 -0.805 . . . . 0.0 111.178 179.099 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 59.9 p -95.39 116.98 29.53 Favored 'General case' 0 C--N 1.323 -0.561 0 O-C-N 122.48 -0.424 . . . . 0.0 110.914 -175.113 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.476 HD12 HG11 ' A' ' 230' ' ' VAL . 21.2 pt -128.78 148.39 33.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.831 -177.618 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 59.8 m -101.27 107.26 18.58 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 174.096 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.691 HG21 HD12 ' A' ' 262' ' ' LEU . 32.8 m -90.73 143.65 10.77 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.728 0 N-CA-C 112.975 0.731 . . . . 0.0 112.975 -168.649 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 35.3 t -91.44 8.04 38.23 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 114.112 -1.404 . . . . 0.0 107.963 167.165 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 259' ' ' ALA . . . . . 0.525 ' HA ' ' HB3' ' A' ' 228' ' ' LEU . . . -85.64 158.12 20.16 Favored 'General case' 0 N--CA 1.448 -0.565 0 CA-C-N 114.926 -1.034 . . . . 0.0 109.626 -178.953 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 34.1 t -131.94 137.31 47.9 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 116.577 -0.283 . . . . 0.0 110.325 -179.217 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 90.27 39.28 6.07 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.6 -0.809 . . . . 0.0 112.571 -179.437 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 262' ' ' LEU . . . . . 0.691 HD12 HG21 ' A' ' 257' ' ' VAL . 60.2 mt -101.46 139.81 36.6 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.711 0.291 . . . . 0.0 110.877 179.788 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 68.5 mt-30 -142.2 167.72 21.45 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.82 -0.627 . . . . 0.0 109.436 179.298 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 264' ' ' VAL . . . . . 0.418 HG22 ' HA ' ' A' ' 294' ' ' ALA . 48.7 t -70.83 132.87 32.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 C-N-CA 120.772 -0.371 . . . . 0.0 110.161 177.834 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 105.58 8.63 34.72 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.548 -0.834 . . . . 0.0 112.401 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 59.7 m-20 -88.64 162.48 16.31 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.988 0.423 . . . . 0.0 110.861 179.045 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 267' ' ' ALA . . . . . 0.699 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -139.34 123.12 17.57 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.487 -0.779 . . . . 0.0 109.475 179.75 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 268' ' ' PHE . . . . . 0.413 ' HB3' ' HA ' ' A' ' 334' ' ' ILE . 3.5 p90 -142.15 173.66 11.32 Favored 'General case' 0 C--N 1.32 -0.676 0 C-N-CA 120.114 -0.634 . . . . 0.0 111.465 -174.974 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 269' ' ' THR . . . . . 0.577 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 63.8 p -118.89 132.37 56.1 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.53 178.115 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 270' ' ' ILE . . . . . 0.708 HG12 HG13 ' A' ' 332' ' ' ILE . 50.6 mt -100.61 134.02 41.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.57 179.625 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -72.72 143.47 48.01 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.956 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 85.78 -21.55 14.54 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.189 -177.522 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 53.5 t -105.69 102.46 13.9 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-O 120.983 0.42 . . . . 0.0 110.799 -179.593 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 274' ' ' ASN . . . . . 0.407 ' HB2' ' OD1' ' A' ' 323' ' ' ASP . 61.5 m-20 -100.72 154.94 18.19 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.22 -0.659 . . . . 0.0 109.22 174.702 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 6.7 t -83.7 179.98 7.46 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.912 0.387 . . . . 0.0 109.96 -177.853 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 276' ' ' VAL . . . . . 0.411 HG22 ' O ' ' A' ' 321' ' ' ASN . 34.2 m -131.92 153.11 38.0 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.712 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.236 172.775 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 26.4 m80 -136.94 137.08 39.17 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.091 179.236 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 65.8 tt0 -67.99 -31.67 71.53 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.916 0.389 . . . . 0.0 110.315 177.196 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 72.3 mt -66.54 -50.36 67.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.861 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 71.5 p -85.42 -5.08 59.33 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 111.674 0.25 . . . . 0.0 111.674 -178.615 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 281' ' ' LYS . . . . . 0.512 ' HB3' ' NZ ' ' A' ' 281' ' ' LYS . 0.0 OUTLIER 70.94 52.97 0.27 Allowed 'General case' 0 CA--C 1.535 0.403 0 CA-C-O 121.742 0.782 . . . . 0.0 109.161 179.479 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 56.6 m-20 62.26 10.51 3.87 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 114.732 -1.122 . . . . 0.0 113.95 173.485 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 59.9 p -107.09 107.97 19.22 Favored 'General case' 0 C--N 1.314 -0.956 0 CA-C-O 121.041 0.448 . . . . 0.0 110.589 175.605 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 59.8 p -125.76 -52.37 1.57 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.061 -175.385 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 76.42 10.61 85.58 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.732 -0.747 . . . . 0.0 111.267 -173.363 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 286' ' ' GLN . . . . . 0.42 ' HA ' ' HD3' ' A' ' 287' ' ' PRO . 93.4 mm-40 -111.11 130.42 22.99 Favored Pre-proline 0 C--N 1.326 -0.445 0 N-CA-C 110.322 -0.251 . . . . 0.0 110.322 -177.609 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 287' ' ' PRO . . . . . 0.577 ' HB2' ' HB ' ' A' ' 269' ' ' THR . 27.3 Cg_exo -60.76 142.05 96.63 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.627 2.218 . . . . 0.0 111.696 177.978 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 4.1 tp60 -68.18 145.05 54.69 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 120.877 0.37 . . . . 0.0 110.711 -179.637 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 47.6 t -99.73 121.77 50.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.492 176.631 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 290' ' ' PHE . . . . . 0.699 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 7.3 m-85 -103.31 156.17 17.92 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.028 0.442 . . . . 0.0 111.775 -174.02 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 36.3 mmt180 -122.31 121.18 36.14 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.112 -0.949 . . . . 0.0 109.408 174.9 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 61.7 t -78.51 135.51 25.84 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.89 -174.476 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 293' ' ' LEU . . . . . 0.401 ' N ' HD12 ' A' ' 293' ' ' LEU . 6.6 mp -106.95 -33.8 7.4 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.674 179.034 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 294' ' ' ALA . . . . . 0.418 ' HA ' HG22 ' A' ' 264' ' ' VAL . . . -155.54 146.7 22.59 Favored 'General case' 0 N--CA 1.463 0.19 0 N-CA-C 111.677 0.251 . . . . 0.0 111.677 -177.365 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 295' ' ' VAL . . . . . 0.467 HG22 HG13 ' A' ' 300' ' ' VAL . 61.6 t -137.66 126.37 33.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.086 -0.506 . . . . 0.0 109.74 177.169 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 40.3 t -156.69 109.69 2.59 Favored 'General case' 0 C--N 1.326 -0.418 0 C-N-CA 121.139 -0.224 . . . . 0.0 110.944 -177.638 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 59.81 48.57 85.41 Favored Glycine 0 C--N 1.333 0.373 0 C-N-CA 121.077 -0.583 . . . . 0.0 112.488 179.447 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 298' ' ' THR . . . . . 0.422 ' O ' HG22 ' A' ' 257' ' ' VAL . 60.5 p 55.71 10.93 0.58 Allowed 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 124.342 1.057 . . . . 0.0 112.728 -176.361 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 58.3 m -99.92 106.47 18.29 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 173.024 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 300' ' ' VAL . . . . . 0.574 HG12 HG23 ' A' ' 302' ' ' ILE . 40.2 t -108.9 132.03 58.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.35 -169.519 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 51.6 m -100.87 111.35 23.54 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 175.422 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 302' ' ' ILE . . . . . 0.574 HG23 HG12 ' A' ' 300' ' ' VAL . 27.7 pt -121.64 164.6 18.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-O 121.284 0.564 . . . . 0.0 112.027 -174.262 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 303' ' ' SER . . . . . 0.531 ' HB3' ' HA ' ' A' ' 304' ' ' PRO . 53.1 m -135.29 165.28 37.58 Favored Pre-proline 0 C--N 1.313 -0.984 0 N-CA-C 106.325 -1.732 . . . . 0.0 106.325 168.775 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 304' ' ' PRO . . . . . 0.531 ' HA ' ' HB3' ' A' ' 303' ' ' SER . 17.4 Cg_exo -70.38 176.52 34.05 Favored 'Cis proline' 0 N--CA 1.472 0.243 0 CA-C-N 120.816 1.327 . . . . 0.0 113.71 0.923 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 305' ' ' LYS . . . . . 0.737 ' HG2' ' HG ' ' A' ' 307' ' ' LEU . 0.1 OUTLIER -73.86 152.69 40.15 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 114.986 -1.007 . . . . 0.0 111.284 -178.501 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 306' ' ' ILE . . . . . 0.589 HD11 ' HE2' ' A' ' 290' ' ' PHE . 46.4 mm -94.66 85.29 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.634 -178.967 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 307' ' ' LEU . . . . . 0.737 ' HG ' ' HG2' ' A' ' 305' ' ' LYS . 66.9 mt -106.12 110.32 63.89 Favored Pre-proline 0 C--N 1.325 -0.462 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 178.109 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 308' ' ' PRO . . . . . 0.481 ' CG ' ' HB2' ' A' ' 311' ' ' ASN . 65.1 Cg_endo -80.9 148.66 17.49 Favored 'Trans proline' 0 N--CA 1.463 -0.275 0 C-N-CA 122.548 2.166 . . . . 0.0 113.609 -172.993 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 309' ' ' VAL . . . . . 0.545 HG23 ' O ' ' A' ' 322' ' ' VAL . 47.0 t -87.65 -43.09 15.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.829 175.252 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 65.4 mm-40 -91.51 6.47 45.47 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 112.437 0.532 . . . . 0.0 112.437 -176.287 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.481 ' HB2' ' CG ' ' A' ' 308' ' ' PRO . 5.9 m120 -130.0 173.33 10.82 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 110.231 -0.285 . . . . 0.0 110.231 178.597 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 312' ' ' THR . . . . . 0.584 HG21 ' HA ' ' A' ' 237' ' ' LYS . 23.7 m 60.07 31.03 20.43 Favored 'General case' 0 CA--C 1.539 0.543 0 CA-C-O 121.758 0.79 . . . . 0.0 110.656 176.887 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 44.5 m-20 63.87 -177.71 0.16 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 114.883 -1.053 . . . . 0.0 112.208 177.106 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 314' ' ' VAL . . . . . 0.685 HG13 ' HD2' ' A' ' 317' ' ' ARG . 50.0 t -68.31 -24.66 30.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.426 -176.441 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -60.63 -23.73 64.98 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 111.976 0.362 . . . . 0.0 111.976 -179.859 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 31.2 t -86.89 -22.02 25.97 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.31 -177.845 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 317' ' ' ARG . . . . . 0.685 ' HD2' HG13 ' A' ' 314' ' ' VAL . 83.3 mtt-85 -56.6 -53.68 61.8 Favored Pre-proline 0 CA--C 1.541 0.605 0 N-CA-C 113.499 0.926 . . . . 0.0 113.499 -177.525 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 318' ' ' PRO . . . . . 0.613 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 44.1 Cg_exo -61.97 -35.39 77.32 Favored 'Trans proline' 0 C--N 1.356 0.931 0 C-N-CA 122.018 1.812 . . . . 0.0 113.677 -174.587 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 7.4 m-85 -105.62 21.67 16.83 Favored 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 121.152 -0.219 . . . . 0.0 111.089 -179.065 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 320' ' ' ALA . . . . . 0.42 ' CB ' HG22 ' A' ' 309' ' ' VAL . . . -65.79 160.0 24.03 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.096 0.474 . . . . 0.0 111.685 -177.39 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 321' ' ' ASN . . . . . 0.411 ' O ' HG22 ' A' ' 276' ' ' VAL . 20.6 t-20 -123.58 -33.19 3.25 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.85 -0.613 . . . . 0.0 109.956 177.983 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 322' ' ' VAL . . . . . 0.545 ' O ' HG23 ' A' ' 309' ' ' VAL . 35.4 m -135.42 163.76 34.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.345 177.308 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 323' ' ' ASP . . . . . 0.407 ' OD1' ' HB2' ' A' ' 274' ' ' ASN . 63.6 m-20 -55.89 -41.28 74.21 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 112.684 0.624 . . . . 0.0 112.684 -176.407 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 324' ' ' ALA . . . . . 0.463 ' HA ' ' CB ' ' A' ' 308' ' ' PRO . . . -169.49 167.49 9.82 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.876 0.369 . . . . 0.0 111.746 -173.759 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 325' ' ' LYS . . . . . 0.461 ' NZ ' ' HB2' ' A' ' 325' ' ' LYS . 0.0 OUTLIER -108.7 106.25 58.42 Favored Pre-proline 0 C--N 1.325 -0.49 0 CA-C-N 114.968 -1.014 . . . . 0.0 109.26 168.732 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 76.0 Cg_endo -85.21 168.47 10.32 Favored 'Trans proline' 0 C--O 1.234 0.276 0 C-N-CA 122.8 2.333 . . . . 0.0 112.769 -173.472 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -69.6 121.86 17.94 Favored 'General case' 0 C--O 1.235 0.327 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 176.588 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 328' ' ' GLU . . . . . 0.459 ' HA ' ' OE2' ' A' ' 328' ' ' GLU . 43.6 mm-40 64.16 164.24 0.13 Allowed 'General case' 0 C--O 1.234 0.243 0 O-C-N 123.891 0.744 . . . . 0.0 111.417 -175.288 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 329' ' ' SER . . . . . 0.63 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 22.2 m -86.49 -14.49 42.95 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.35 -174.306 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 330' ' ' ALA . . . . . 0.426 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 71.26 -154.43 0.1 Allowed 'General case' 0 N--CA 1.467 0.403 0 CA-C-O 121.332 0.586 . . . . 0.0 112.287 175.532 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -90.04 125.79 35.53 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.147 -0.933 . . . . 0.0 110.168 179.35 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 332' ' ' ILE . . . . . 0.708 HG13 HG12 ' A' ' 270' ' ' ILE . 1.7 mp -106.35 144.72 15.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.31 -178.917 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 333' ' ' THR . . . . . 0.402 ' HB ' ' OG1' ' A' ' 269' ' ' THR . 88.5 m -109.97 103.02 11.72 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.069 -0.514 . . . . 0.0 109.711 -178.171 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 334' ' ' ILE . . . . . 0.434 ' C ' HD12 ' A' ' 335' ' ' LEU . 37.9 mm -83.1 129.3 37.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 115.57 -0.741 . . . . 0.0 112.42 -171.209 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 335' ' ' LEU . . . . . 0.434 HD12 ' C ' ' A' ' 334' ' ' ILE . 6.8 mp -123.67 153.04 41.36 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.264 -0.88 . . . . 0.0 109.823 172.644 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 22.9 p30 -110.9 5.02 20.19 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 170.442 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 23.1 tptm . . . . . 0 C--O 1.245 0.82 0 CA-C-N 114.541 -1.209 . . . . 0.0 110.99 -179.412 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 31.5 t . . . . . 0 CA--C 1.531 0.243 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 228' ' ' LEU . . . . . 0.525 ' HB3' ' CB ' ' A' ' 259' ' ' ALA . 85.1 mt -96.46 130.93 43.5 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 109.511 -0.552 . . . . 0.0 109.511 175.728 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 41.3 p -129.63 179.54 5.77 Favored 'General case' 0 C--N 1.325 -0.465 0 C-N-CA 120.296 -0.562 . . . . 0.0 110.986 -178.631 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 230' ' ' VAL . . . . . 0.806 ' HB ' ' HB3' ' A' ' 329' ' ' SER . 89.5 t -146.18 130.85 11.58 Favored 'Isoleucine or valine' 0 C--O 1.24 0.571 0 CA-C-O 120.601 0.239 . . . . 0.0 111.549 -177.2 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 18.7 m -97.29 97.84 9.49 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.194 -0.912 . . . . 0.0 109.733 172.834 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 163.02 134.74 1.69 Allowed Glycine 0 C--O 1.226 -0.344 0 C-N-CA 120.719 -0.753 . . . . 0.0 111.72 -177.429 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 11.0 mm100 -61.62 144.73 92.44 Favored Pre-proline 0 C--N 1.328 -0.369 0 N-CA-C 112.688 0.625 . . . . 0.0 112.688 -174.516 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -70.7 175.22 9.18 Favored 'Trans proline' 0 C--N 1.348 0.521 0 C-N-CA 123.381 2.721 . . . . 0.0 111.793 175.891 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 235' ' ' GLU . . . . . 0.506 ' OE1' HD12 ' A' ' 302' ' ' ILE . 87.6 mt-10 -94.3 138.11 32.67 Favored 'General case' 0 C--O 1.211 -0.962 0 C-N-CA 120.833 -0.347 . . . . 0.0 111.688 -176.524 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 236' ' ' HIS . . . . . 0.439 ' HB3' ' O ' ' A' ' 306' ' ' ILE . 25.5 p-80 -169.04 126.82 0.99 Allowed 'General case' 0 C--N 1.307 -1.256 0 CA-C-N 115.097 -0.956 . . . . 0.0 109.366 166.975 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 237' ' ' LYS . . . . . 0.548 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.327 -0.377 0 C-N-CA 120.32 -0.552 . . . . 0.0 110.473 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 70.5 mt-30 . . . . . 0 C--O 1.237 0.413 0 CA-C-O 121.769 0.795 . . . . 0.0 112.83 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 253' ' ' GLY . . . . . 0.433 ' O ' ' HA ' ' A' ' 301' ' ' THR . . . -160.86 145.33 10.89 Favored Glycine 0 N--CA 1.449 -0.467 0 CA-C-N 115.007 -0.997 . . . . 0.0 111.94 177.714 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 34.1 p -95.32 117.99 31.28 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.843 0.354 . . . . 0.0 111.13 -179.797 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.611 HD12 HG11 ' A' ' 230' ' ' VAL . 24.7 pt -114.75 142.84 26.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.08 0.467 . . . . 0.0 111.494 -178.724 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 58.1 m -92.49 109.63 21.03 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 176.354 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 257' ' ' VAL . . . . . . . . . . . . . 33.9 m -90.21 143.78 10.48 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.703 0 C-N-CA 119.646 -0.821 . . . . 0.0 113.004 -168.351 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 258' ' ' SER . . . . . 0.467 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 24.0 t -91.59 9.07 33.7 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 114.051 -1.432 . . . . 0.0 108.192 168.883 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 259' ' ' ALA . . . . . 0.525 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -99.05 169.8 9.16 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-N 114.774 -1.103 . . . . 0.0 109.484 -178.592 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 33.8 t -142.57 155.28 44.97 Favored 'General case' 0 C--N 1.324 -0.54 0 C-N-CA 120.828 -0.349 . . . . 0.0 110.733 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 74.34 42.8 33.54 Favored Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.47 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 262' ' ' LEU . . . . . . . . . . . . . 64.5 mt -102.39 140.02 37.21 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 110.17 -0.308 . . . . 0.0 110.17 179.37 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 81.5 mt-30 -135.24 169.45 17.44 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.479 -0.328 . . . . 0.0 110.206 179.822 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 45.5 t -77.77 136.26 24.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.594 179.63 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 92.13 7.65 63.81 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.442 -0.885 . . . . 0.0 112.292 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 72.8 m-20 -81.73 160.47 23.63 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.232 0.539 . . . . 0.0 110.133 176.785 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 267' ' ' ALA . . . . . 0.548 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -126.84 145.37 50.67 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 115.332 -0.849 . . . . 0.0 108.822 178.952 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 268' ' ' PHE . . . . . 0.55 ' HA ' HD23 ' A' ' 335' ' ' LEU . 4.6 p90 -162.53 170.66 18.27 Favored 'General case' 0 C--N 1.32 -0.713 0 C-N-CA 119.971 -0.692 . . . . 0.0 111.452 -177.124 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 269' ' ' THR . . . . . 0.474 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 72.7 p -121.85 150.84 41.35 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.009 178.499 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 270' ' ' ILE . . . . . 0.577 HG12 HG12 ' A' ' 332' ' ' ILE . 54.4 mt -115.51 138.33 46.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 120.864 0.364 . . . . 0.0 111.622 -177.396 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -66.12 117.58 8.64 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 115.571 -0.74 . . . . 0.0 111.062 178.353 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 104.46 -23.05 32.66 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.932 -0.651 . . . . 0.0 112.182 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 273' ' ' VAL . . . . . 0.876 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 91.0 t -88.36 112.39 23.74 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-O 120.71 0.291 . . . . 0.0 110.491 175.986 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 72.9 m-80 -129.54 143.58 50.89 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.663 -178.071 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 52.3 p -70.86 164.75 24.68 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.152 0.501 . . . . 0.0 111.699 -177.7 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 29.3 m -112.58 179.48 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-N 115.652 -0.704 . . . . 0.0 112.469 -176.834 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 19.2 p-80 -46.19 106.92 0.09 Allowed 'General case' 0 C--O 1.235 0.304 0 CA-C-N 114.631 -1.168 . . . . 0.0 111.817 176.772 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 278' ' ' GLN . . . . . 0.512 ' H ' ' HB2' ' A' ' 282' ' ' ASP . 65.7 tt0 -83.94 -51.29 7.27 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.19 -176.467 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 279' ' ' ILE . . . . . 0.569 HG22 HG23 ' A' ' 280' ' ' THR . 3.2 mp -105.59 -66.81 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.828 0.347 . . . . 0.0 110.78 -178.955 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 280' ' ' THR . . . . . 0.569 HG23 HG22 ' A' ' 279' ' ' ILE . 21.3 p -139.58 86.46 2.11 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.61 -177.545 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt 59.56 29.57 19.14 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.759 -0.655 . . . . 0.0 112.044 177.108 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 282' ' ' ASP . . . . . 0.512 ' HB2' ' H ' ' A' ' 278' ' ' GLN . 1.7 m-20 -58.05 101.48 0.08 Allowed 'General case' 0 N--CA 1.468 0.43 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.68 -179.535 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 45.1 p -105.88 105.65 15.78 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.159 175.117 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 65.7 p -127.6 -35.0 2.17 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.589 -174.449 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 82.23 26.18 48.97 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.306 -177.926 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 36.1 mt-30 -79.71 121.13 82.09 Favored Pre-proline 0 C--N 1.329 -0.295 0 O-C-N 122.891 -0.182 . . . . 0.0 110.667 -179.658 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 287' ' ' PRO . . . . . 0.474 ' HB2' ' HB ' ' A' ' 269' ' ' THR . 26.4 Cg_exo -60.33 126.75 20.89 Favored 'Trans proline' 0 C--O 1.234 0.296 0 C-N-CA 122.518 2.145 . . . . 0.0 111.408 177.451 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 4.4 tm0? -74.49 136.54 42.23 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 -175.062 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 289' ' ' VAL . . . . . 0.429 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 44.5 t -86.91 124.54 40.57 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-O 121.038 0.447 . . . . 0.0 111.524 -172.915 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 290' ' ' PHE . . . . . 0.876 ' HZ ' HG11 ' A' ' 273' ' ' VAL . 60.6 m-85 -98.5 168.44 10.19 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.31 -174.694 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 27.8 mmm180 -125.12 148.42 48.57 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.224 -0.898 . . . . 0.0 109.736 178.463 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 47.9 t -100.92 136.75 31.08 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-N 116.607 -0.27 . . . . 0.0 111.098 179.628 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 293' ' ' LEU . . . . . 0.455 ' N ' HD12 ' A' ' 293' ' ' LEU . 5.5 mp -103.95 -39.94 6.4 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.128 -178.868 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 294' ' ' ALA . . . . . . . . . . . . . . . -156.9 139.61 15.09 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.646 0.26 . . . . 0.0 111.473 -178.493 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 295' ' ' VAL . . . . . 0.519 HG22 HG13 ' A' ' 300' ' ' VAL . 60.6 t -131.21 125.56 57.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-N 116.104 -0.498 . . . . 0.0 109.688 175.842 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 33.9 t -157.29 111.37 2.64 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.583 -0.281 . . . . 0.0 110.758 -178.018 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 60.58 50.82 63.39 Favored Glycine 0 C--N 1.333 0.372 0 C-N-CA 121.087 -0.578 . . . . 0.0 112.615 179.787 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 45.9 p 50.6 23.71 1.42 Allowed 'General case' 0 N--CA 1.47 0.552 0 C-N-CA 123.477 0.711 . . . . 0.0 112.434 -176.395 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 43.7 m -113.21 106.58 14.8 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 174.072 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 300' ' ' VAL . . . . . 0.572 HG12 HG23 ' A' ' 302' ' ' ILE . 39.4 t -112.99 131.63 64.06 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 115.944 -0.571 . . . . 0.0 111.557 -168.633 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 301' ' ' THR . . . . . 0.433 ' HA ' ' O ' ' A' ' 253' ' ' GLY . 91.6 m -96.7 110.62 23.03 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 108.725 -0.842 . . . . 0.0 108.725 172.299 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 302' ' ' ILE . . . . . 0.572 HG23 HG12 ' A' ' 300' ' ' VAL . 2.5 pp -111.75 -172.54 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 N-CA-C 112.12 0.415 . . . . 0.0 112.12 -175.134 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 303' ' ' SER . . . . . 0.71 ' OG ' ' HA ' ' A' ' 304' ' ' PRO . 14.8 t 169.95 161.16 0.2 Allowed Pre-proline 0 C--O 1.221 -0.397 0 N-CA-C 106.224 -1.769 . . . . 0.0 106.224 -175.563 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 304' ' ' PRO . . . . . 0.71 ' HA ' ' OG ' ' A' ' 303' ' ' SER . 9.4 Cg_exo -72.94 -172.66 9.87 Favored 'Cis proline' 0 C--N 1.348 0.522 0 CA-C-N 121.384 1.53 . . . . 0.0 113.506 0.948 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 305' ' ' LYS . . . . . 0.739 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -84.3 176.3 8.82 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 114.751 -1.113 . . . . 0.0 112.644 -175.382 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 306' ' ' ILE . . . . . 0.456 ' HB ' ' O ' ' A' ' 235' ' ' GLU . 50.8 mm -119.46 86.2 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 114.485 -1.234 . . . . 0.0 109.878 -174.017 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 307' ' ' LEU . . . . . 0.575 HD13 ' HD1' ' A' ' 319' ' ' TYR . 83.9 mt -108.84 101.59 44.69 Favored Pre-proline 0 C--N 1.321 -0.633 0 C-N-CA 120.918 -0.313 . . . . 0.0 111.652 -173.618 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 308' ' ' PRO . . . . . 0.774 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 17.9 Cg_exo -69.92 148.44 64.01 Favored 'Trans proline' 0 C--O 1.233 0.232 0 C-N-CA 123.197 2.598 . . . . 0.0 113.336 -177.019 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 44.2 t -93.16 -21.36 6.11 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.529 -0.76 . . . . 0.0 109.44 173.1 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 53.5 mt-10 -74.62 13.65 0.59 Allowed 'General case' 0 CA--C 1.531 0.223 0 N-CA-C 112.797 0.665 . . . . 0.0 112.797 -178.448 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.406 ' O ' ' HB ' ' A' ' 312' ' ' THR . 32.2 m120 -82.25 -24.66 34.66 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 120.846 -0.341 . . . . 0.0 110.92 177.468 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 312' ' ' THR . . . . . 0.406 ' HB ' ' O ' ' A' ' 311' ' ' ASN . 58.2 m 72.01 -13.64 0.58 Allowed 'General case' 0 CA--C 1.541 0.634 0 O-C-N 123.743 0.652 . . . . 0.0 112.233 178.159 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -74.13 152.98 39.75 Favored 'General case' 0 C--N 1.331 -0.21 0 O-C-N 121.905 -0.497 . . . . 0.0 110.803 178.347 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 30.8 t -79.35 -19.33 12.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.306 -0.861 . . . . 0.0 111.485 -173.259 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -78.49 -36.88 44.47 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 113.019 0.748 . . . . 0.0 113.019 -174.096 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 16.2 m -88.18 -35.03 17.6 Favored 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -172.657 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 317' ' ' ARG . . . . . 0.424 ' N ' ' CD ' ' A' ' 318' ' ' PRO . 16.9 ptm180 -62.12 -33.05 11.03 Favored Pre-proline 0 CA--C 1.546 0.801 0 N-CA-C 114.516 1.302 . . . . 0.0 114.516 -175.263 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 318' ' ' PRO . . . . . 0.424 ' CD ' ' N ' ' A' ' 317' ' ' ARG . 35.2 Cg_exo -54.86 -38.87 92.26 Favored 'Trans proline' 0 C--N 1.368 1.587 0 C-N-CA 121.587 1.525 . . . . 0.0 112.795 178.874 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 319' ' ' TYR . . . . . 0.575 ' HD1' HD13 ' A' ' 307' ' ' LEU . 2.2 p90 -122.83 32.73 5.63 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 120.504 -0.479 . . . . 0.0 111.83 -179.251 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -63.34 157.15 23.73 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.605 178.171 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 46.2 t30 -128.49 -36.86 1.85 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.068 -0.514 . . . . 0.0 111.49 -177.662 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 322' ' ' VAL . . . . . 0.624 HG11 HG13 ' A' ' 273' ' ' VAL . 34.8 m -131.86 175.62 10.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 120.711 0.291 . . . . 0.0 111.217 -178.847 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 54.7 m-20 -78.62 -44.12 24.71 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.536 -0.302 . . . . 0.0 111.569 -177.272 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 324' ' ' ALA . . . . . 0.774 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -144.55 166.48 25.04 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.458 -175.589 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 325' ' ' LYS . . . . . 0.408 ' HA ' ' HD3' ' A' ' 326' ' ' PRO . 24.1 pttm -115.12 113.89 43.65 Favored Pre-proline 0 C--N 1.327 -0.383 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.729 175.153 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 326' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 325' ' ' LYS . 8.6 Cg_exo -72.92 167.84 26.24 Favored 'Trans proline' 0 C--O 1.233 0.236 0 C-N-CA 122.867 2.378 . . . . 0.0 112.167 -178.991 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -76.76 128.33 34.44 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 175.084 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 51.0 mt-10 64.96 -167.83 0.21 Allowed 'General case' 0 N--CA 1.466 0.333 0 O-C-N 123.5 0.5 . . . . 0.0 110.463 -176.191 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 329' ' ' SER . . . . . 0.806 ' HB3' ' HB ' ' A' ' 230' ' ' VAL . 42.6 t -90.88 -12.19 36.95 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 177.265 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 63.03 -160.36 0.31 Allowed 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 113.033 0.753 . . . . 0.0 113.033 171.261 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -76.36 127.96 33.9 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 115.182 -0.917 . . . . 0.0 110.676 -178.018 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 332' ' ' ILE . . . . . 0.577 HG12 HG12 ' A' ' 270' ' ' ILE . 50.0 mt -113.61 144.61 20.88 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.962 -177.432 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 95.7 m -115.63 106.09 13.51 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.675 176.824 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 41.2 mm -83.62 138.02 19.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.753 -0.658 . . . . 0.0 112.379 -170.94 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 335' ' ' LEU . . . . . 0.55 HD23 ' HA ' ' A' ' 268' ' ' PHE . 1.3 pt? -145.16 -159.14 0.96 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 114.978 -1.01 . . . . 0.0 108.814 171.184 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 45.7 p-10 -152.36 48.36 0.76 Allowed 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.837 0.351 . . . . 0.0 111.592 179.709 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 337' ' ' LYS . . . . . 0.464 ' HB2' ' NZ ' ' A' ' 337' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.246 0.911 0 CA-C-O 118.827 -0.606 . . . . 0.0 110.515 178.908 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 24.8 m . . . . . 0 N--CA 1.453 -0.304 0 CA-C-O 121.111 0.482 . . . . 0.0 109.952 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 228' ' ' LEU . . . . . 0.546 HD22 ' H ' ' A' ' 260' ' ' SER . 83.7 mt -110.59 113.88 26.85 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 174.678 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 41.6 p -120.71 177.68 4.98 Favored 'General case' 0 C--N 1.32 -0.676 0 C-N-CA 119.926 -0.709 . . . . 0.0 110.617 -177.856 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 230' ' ' VAL . . . . . 0.738 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 89.7 t -150.88 134.78 8.23 Favored 'Isoleucine or valine' 0 C--O 1.239 0.548 0 CA-C-O 120.826 0.346 . . . . 0.0 110.898 -178.365 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 44.3 t -97.98 153.01 18.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.027 175.674 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 232' ' ' GLY . . . . . 0.554 ' O ' ' HD3' ' A' ' 234' ' ' PRO . . . 108.42 127.21 5.54 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.449 -0.882 . . . . 0.0 111.489 -178.467 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 233' ' ' GLN . . . . . 0.822 ' HG2' ' H ' ' A' ' 328' ' ' GLU . 64.2 mt-30 -95.27 102.38 9.5 Favored Pre-proline 0 C--N 1.324 -0.507 0 CA-C-N 116.53 0.165 . . . . 0.0 110.56 -177.553 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 234' ' ' PRO . . . . . 0.554 ' HD3' ' O ' ' A' ' 232' ' ' GLY . 74.4 Cg_endo -96.78 125.65 0.26 Allowed 'Trans proline' 0 N--CA 1.45 -1.076 0 C-N-CA 122.294 1.996 . . . . 0.0 112.388 -178.195 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 235' ' ' GLU . . . . . 0.946 ' HA ' ' HE3' ' A' ' 325' ' ' LYS . 24.2 pt-20 -105.72 147.67 28.3 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 173.377 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 236' ' ' HIS . . . . . 0.783 ' HB2' ' H ' ' A' ' 306' ' ' ILE . 39.4 m170 -134.62 130.57 36.64 Favored 'General case' 0 CA--C 1.503 -0.85 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 -178.94 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 237' ' ' LYS . . . . . 0.669 ' HA ' ' HE3' ' A' ' 237' ' ' LYS . 7.5 mmmt . . . . . 0 C--N 1.315 -0.9 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 -178.815 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 252' ' ' GLN . . . . . 0.556 ' HA ' ' CD2' ' A' ' 236' ' ' HIS . 23.4 mt-30 . . . . . 0 N--CA 1.468 0.441 0 CA-C-O 120.723 0.297 . . . . 0.0 111.2 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 157.4 -168.7 34.24 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 119.242 -1.456 . . . . 0.0 113.358 -179.691 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 254' ' ' THR . . . . . 0.563 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 67.2 p -99.53 149.92 22.74 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.911 0.386 . . . . 0.0 111.378 -177.671 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.732 HD12 HG11 ' A' ' 230' ' ' VAL . 18.8 pt -125.32 152.94 32.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.959 178.243 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 39.2 m -96.2 105.65 17.74 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.028 -0.731 . . . . 0.0 109.028 177.126 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.554 ' HA ' HG13 ' A' ' 230' ' ' VAL . 22.7 m -89.93 143.19 11.7 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.681 0 CA-C-O 121.725 0.774 . . . . 0.0 112.73 -169.251 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 258' ' ' SER . . . . . 0.462 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 50.3 m -93.15 8.63 39.34 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 114.219 -1.355 . . . . 0.0 109.129 170.358 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 259' ' ' ALA . . . . . 0.48 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -99.1 174.76 6.17 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.209 -175.098 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 260' ' ' SER . . . . . 0.546 ' H ' HD22 ' A' ' 228' ' ' LEU . 64.7 p -141.88 149.88 40.83 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.889 0.376 . . . . 0.0 110.981 178.43 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 87.59 32.22 13.91 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.823 -0.704 . . . . 0.0 112.992 179.373 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 262' ' ' LEU . . . . . 0.484 HD12 ' N ' ' A' ' 262' ' ' LEU . 3.2 mp -97.68 135.53 39.34 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-N 116.995 0.398 . . . . 0.0 110.226 178.894 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 23.6 mp0 -134.04 171.85 13.63 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 177.315 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 38.4 t -78.78 136.65 23.4 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 C-N-CA 120.593 -0.443 . . . . 0.0 109.951 176.658 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 95.61 15.25 44.05 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.538 -0.839 . . . . 0.0 112.141 -179.152 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 266' ' ' ASP . . . . . 0.476 ' HB2' HG21 ' A' ' 292' ' ' VAL . 64.0 m-20 -88.79 166.07 14.27 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.164 0.507 . . . . 0.0 110.779 178.507 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 267' ' ' ALA . . . . . 0.645 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -140.61 122.7 15.68 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.39 -0.823 . . . . 0.0 109.437 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 268' ' ' PHE . . . . . . . . . . . . . 4.6 p90 -142.68 174.11 10.94 Favored 'General case' 0 C--N 1.323 -0.579 0 C-N-CA 119.752 -0.779 . . . . 0.0 111.718 -172.819 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 81.9 p -122.18 148.51 44.85 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.179 177.498 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 270' ' ' ILE . . . . . 0.636 HD12 ' HE1' ' A' ' 290' ' ' PHE . 26.6 mt -113.62 137.53 46.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.212 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -61.47 130.53 46.48 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.343 179.881 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 272' ' ' GLY . . . . . 0.549 ' HA3' ' HG2' ' A' ' 326' ' ' PRO . . . 91.91 -23.12 27.86 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 121.189 -0.529 . . . . 0.0 112.113 -178.878 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 273' ' ' VAL . . . . . 0.611 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 59.7 t -95.94 103.14 14.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-O 120.96 0.409 . . . . 0.0 110.285 177.222 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 274' ' ' ASN . . . . . 0.621 ' HA ' ' HA ' ' A' ' 287' ' ' PRO . 70.0 m-80 -119.81 149.6 41.8 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.212 -178.306 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 77.7 p -81.45 162.25 23.37 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.387 0.613 . . . . 0.0 111.474 -176.813 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 276' ' ' VAL . . . . . 0.491 HG21 HG21 ' A' ' 309' ' ' VAL . 29.8 m -112.14 -179.27 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-N 114.968 -1.014 . . . . 0.0 110.939 179.63 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 277' ' ' HIS . . . . . 0.547 ' CD2' ' HD2' ' A' ' 281' ' ' LYS . 26.7 p-80 -43.15 115.53 0.77 Allowed 'General case' 0 C--N 1.331 -0.213 0 O-C-N 124.331 1.02 . . . . 0.0 111.732 177.66 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 278' ' ' GLN . . . . . 0.549 ' HB3' HD12 ' A' ' 279' ' ' ILE . 71.2 tp60 -83.57 -38.65 21.38 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.731 -178.059 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 279' ' ' ILE . . . . . 0.94 HG22 HG23 ' A' ' 280' ' ' THR . 2.9 mp -107.25 -80.85 0.32 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.431 0 C-N-CA 120.892 -0.323 . . . . 0.0 111.577 -176.969 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 280' ' ' THR . . . . . 0.94 HG23 HG22 ' A' ' 279' ' ' ILE . 35.7 p -127.48 70.74 1.32 Allowed 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 112.787 0.662 . . . . 0.0 112.787 -172.35 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 281' ' ' LYS . . . . . 0.547 ' HD2' ' CD2' ' A' ' 277' ' ' HIS . 14.6 mmmm 53.79 35.45 21.52 Favored 'General case' 0 N--CA 1.47 0.534 0 CA-C-O 121.203 0.525 . . . . 0.0 110.801 178.397 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 52.8 m-20 -69.44 174.04 5.28 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.264 -0.88 . . . . 0.0 111.595 -177.539 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 73.8 p -104.47 109.98 22.07 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.209 178.156 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 67.8 p -116.1 -76.69 0.57 Allowed 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.167 -174.001 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 70.29 7.74 60.85 Favored Glycine 0 C--N 1.329 0.156 0 C-N-CA 121.028 -0.605 . . . . 0.0 113.289 176.577 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 286' ' ' GLN . . . . . 0.434 ' HA ' ' HD3' ' A' ' 287' ' ' PRO . 96.1 mm-40 -93.29 142.43 25.27 Favored Pre-proline 0 C--N 1.324 -0.511 0 N-CA-C 110.314 -0.254 . . . . 0.0 110.314 -179.1 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 287' ' ' PRO . . . . . 0.621 ' HA ' ' HA ' ' A' ' 274' ' ' ASN . 48.2 Cg_exo -56.76 140.78 91.86 Favored 'Trans proline' 0 CA--C 1.529 0.266 0 C-N-CA 122.737 2.291 . . . . 0.0 112.601 -178.549 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 69.5 tp60 -78.22 140.88 38.91 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.006 -178.77 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 289' ' ' VAL . . . . . 0.581 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 42.2 t -92.48 131.25 40.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.706 -179.918 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 290' ' ' PHE . . . . . 0.645 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 8.2 m-30 -106.89 170.31 8.02 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 116.295 -0.412 . . . . 0.0 111.075 -175.939 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 26.2 mmm180 -118.28 145.02 45.37 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.995 0.426 . . . . 0.0 110.578 176.645 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 292' ' ' VAL . . . . . 0.476 HG21 ' HB2' ' A' ' 266' ' ' ASP . 59.6 t -101.02 130.42 50.44 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.589 177.716 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 293' ' ' LEU . . . . . 0.914 HD21 ' HB3' ' A' ' 303' ' ' SER . 2.3 mm? -106.1 -29.53 9.83 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.023 -176.504 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 294' ' ' ALA . . . . . 0.449 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -161.89 140.67 9.46 Favored 'General case' 0 C--N 1.331 -0.197 0 C-N-CA 121.013 -0.275 . . . . 0.0 111.442 -178.141 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 58.7 t -135.78 121.08 28.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 176.496 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 62.3 m -150.76 105.61 3.3 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.06 -179.515 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 64.52 57.52 12.66 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.142 179.754 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 298' ' ' THR . . . . . 0.419 ' HB ' HG22 ' A' ' 257' ' ' VAL . 65.5 p 49.42 25.9 1.48 Allowed 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 123.468 0.707 . . . . 0.0 112.448 -176.218 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 299' ' ' THR . . . . . 0.417 ' HA ' ' O ' ' A' ' 255' ' ' ILE . 70.8 m -115.59 111.66 21.0 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 177.166 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 300' ' ' VAL . . . . . 0.563 ' O ' ' HA ' ' A' ' 254' ' ' THR . 47.4 t -114.4 126.87 72.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.81 -170.817 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 66.3 m -81.55 115.65 20.95 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 172.93 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 302' ' ' ILE . . . . . 0.466 HD13 HD13 ' A' ' 255' ' ' ILE . 28.3 pt -112.82 148.84 15.54 Favored 'Isoleucine or valine' 0 C--O 1.24 0.594 0 N-CA-C 113.395 0.887 . . . . 0.0 113.395 -171.119 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 303' ' ' SER . . . . . 0.914 ' HB3' HD21 ' A' ' 293' ' ' LEU . 36.1 t -163.59 163.63 16.08 Favored Pre-proline 0 CA--C 1.537 0.458 0 N-CA-C 106.807 -1.553 . . . . 0.0 106.807 -178.314 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 304' ' ' PRO . . . . . 0.743 ' HA ' ' OG ' ' A' ' 303' ' ' SER . 1.0 OUTLIER -83.49 -151.55 0.68 Allowed 'Cis proline' 0 C--N 1.349 0.588 0 CA-C-N 120.752 1.304 . . . . 0.0 112.694 0.565 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 305' ' ' LYS . . . . . 0.572 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -71.52 144.85 49.47 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.346 0.593 . . . . 0.0 111.046 -177.838 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 306' ' ' ILE . . . . . 0.783 ' H ' ' HB2' ' A' ' 236' ' ' HIS . 52.5 mt -108.44 76.64 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-N 115.513 -0.767 . . . . 0.0 109.135 176.6 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 307' ' ' LEU . . . . . 0.674 ' HB2' ' HA ' ' A' ' 320' ' ' ALA . 91.0 mt -98.83 120.23 59.21 Favored Pre-proline 0 C--N 1.322 -0.617 0 CA-C-N 115.505 -0.771 . . . . 0.0 112.261 -172.688 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 308' ' ' PRO . . . . . 0.763 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 15.8 Cg_exo -68.71 147.12 68.86 Favored 'Trans proline' 0 N--CA 1.462 -0.381 0 C-N-CA 123.309 2.673 . . . . 0.0 111.995 175.469 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 309' ' ' VAL . . . . . 0.558 HG22 ' HB3' ' A' ' 320' ' ' ALA . 35.1 t -93.88 -16.09 7.68 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 N-CA-C 108.018 -1.105 . . . . 0.0 108.018 170.305 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 51.5 mm-40 -96.02 34.06 1.61 Allowed 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 115.218 -0.901 . . . . 0.0 112.422 -177.782 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 25.5 p30 -111.67 -177.18 3.12 Favored 'General case' 0 N--CA 1.464 0.241 0 C-N-CA 120.711 -0.396 . . . . 0.0 110.811 175.523 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 26.2 m -91.07 -20.13 22.4 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.923 -177.334 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 313' ' ' ASP . . . . . 0.546 ' O ' ' HG3' ' A' ' 317' ' ' ARG . 1.3 m-20 -63.58 104.03 0.6 Allowed 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.997 -178.063 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 48.9 t -64.34 -22.95 32.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.119 177.412 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -85.3 -20.87 29.36 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 111.955 0.354 . . . . 0.0 111.955 -179.747 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 67.6 m -94.24 -36.26 12.09 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 112.151 0.426 . . . . 0.0 112.151 -177.162 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 317' ' ' ARG . . . . . 0.546 ' HG3' ' O ' ' A' ' 313' ' ' ASP . 81.5 mtp180 -54.43 -46.88 98.95 Favored Pre-proline 0 CA--C 1.544 0.748 0 N-CA-C 113.228 0.825 . . . . 0.0 113.228 -177.71 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 318' ' ' PRO . . . . . 0.545 ' HD2' ' N ' ' A' ' 317' ' ' ARG . 11.9 Cg_endo -59.45 -38.46 83.41 Favored 'Trans proline' 0 C--N 1.359 1.115 0 C-N-CA 122.075 1.85 . . . . 0.0 112.807 -178.943 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 38.4 m-85 -97.75 15.34 23.96 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.651 -177.579 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 320' ' ' ALA . . . . . 0.674 ' HA ' ' HB2' ' A' ' 307' ' ' LEU . . . -82.18 153.51 25.95 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.723 -0.672 . . . . 0.0 111.001 -178.333 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 44.1 p30 -136.51 -0.18 2.43 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.988 179.756 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 322' ' ' VAL . . . . . 0.447 ' O ' ' HA ' ' A' ' 308' ' ' PRO . 33.1 m -134.21 164.7 33.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 175.574 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -74.63 -33.64 62.61 Favored 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 120.807 -0.357 . . . . 0.0 110.61 -179.385 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 324' ' ' ALA . . . . . 0.763 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -173.22 172.56 3.8 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.402 -0.817 . . . . 0.0 111.282 -175.243 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 325' ' ' LYS . . . . . 0.946 ' HE3' ' HA ' ' A' ' 235' ' ' GLU . 10.7 ptmm? -131.84 106.73 13.99 Favored Pre-proline 0 C--N 1.326 -0.441 0 CA-C-N 115.285 -0.87 . . . . 0.0 110.768 172.616 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 326' ' ' PRO . . . . . 0.549 ' HG2' ' HA3' ' A' ' 272' ' ' GLY . 16.4 Cg_exo -67.39 170.56 13.26 Favored 'Trans proline' 0 C--O 1.233 0.234 0 C-N-CA 123.507 2.804 . . . . 0.0 112.065 178.433 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -58.63 163.85 3.02 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.807 -178.718 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 328' ' ' GLU . . . . . 0.822 ' H ' ' HG2' ' A' ' 233' ' ' GLN . 1.1 pm0 39.26 -153.28 0.01 OUTLIER 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 124.385 1.074 . . . . 0.0 112.748 -175.064 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 329' ' ' SER . . . . . 0.738 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 48.8 m -112.59 -14.33 13.2 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.859 -176.861 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 61.15 -161.51 0.29 Allowed 'General case' 0 N--CA 1.469 0.525 0 N-CA-C 113.5 0.926 . . . . 0.0 113.5 171.38 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -78.04 138.46 38.8 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-N 114.975 -1.011 . . . . 0.0 110.551 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 332' ' ' ILE . . . . . 0.622 HG12 HG12 ' A' ' 270' ' ' ILE . 54.0 mt -122.8 145.14 30.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-O 121.151 0.5 . . . . 0.0 111.473 -176.182 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 89.8 m -106.23 97.44 7.24 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.82 177.437 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 30.5 mm -86.84 117.6 31.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.376 -0.375 . . . . 0.0 112.002 -174.804 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 335' ' ' LEU . . . . . 0.462 HD23 ' N ' ' A' ' 335' ' ' LEU . 1.8 pt? -141.68 134.84 29.2 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.609 -0.723 . . . . 0.0 109.57 173.279 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 53.2 t-20 -106.19 83.29 1.87 Allowed 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -177.768 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 25.4 pttm . . . . . 0 C--O 1.243 0.74 0 CA-C-O 118.578 -0.725 . . . . 0.0 110.158 -179.894 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 36.5 t . . . . . 0 N--CA 1.445 -0.678 0 CA-C-O 121.005 0.431 . . . . 0.0 110.407 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 228' ' ' LEU . . . . . 0.603 ' HB3' ' CB ' ' A' ' 259' ' ' ALA . 84.5 mt -69.42 134.31 48.82 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.383 -0.826 . . . . 0.0 109.477 176.421 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 229' ' ' THR . . . . . 0.617 HG22 ' HA ' ' A' ' 331' ' ' ALA . 41.4 p -131.18 179.38 6.04 Favored 'General case' 0 C--N 1.326 -0.432 0 C-N-CA 119.904 -0.719 . . . . 0.0 112.174 -175.082 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 230' ' ' VAL . . . . . 0.677 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 53.3 t -122.26 127.81 75.3 Favored 'Isoleucine or valine' 0 C--O 1.238 0.472 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.039 178.482 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 35.7 m -105.86 115.75 30.77 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.317 178.186 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 134.92 170.17 12.11 Favored Glycine 0 N--CA 1.443 -0.851 0 C-N-CA 120.211 -0.995 . . . . 0.0 111.86 -178.499 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 233' ' ' GLN . . . . . 0.427 ' OE1' ' HA ' ' A' ' 327' ' ' ALA . 87.9 mm-40 -113.5 107.96 52.62 Favored Pre-proline 0 C--N 1.321 -0.637 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 -178.473 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 234' ' ' PRO . . . . . 0.652 ' O ' ' HD3' ' A' ' 325' ' ' LYS . 6.3 Cg_exo -74.88 125.74 9.59 Favored 'Trans proline' 0 N--CA 1.454 -0.812 0 C-N-CA 122.072 1.848 . . . . 0.0 111.007 178.073 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 70.0 mm-40 -124.15 149.92 45.73 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.731 178.36 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 78.9 t60 -161.04 130.54 4.81 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-N 115.778 -0.647 . . . . 0.0 110.235 172.39 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 237' ' ' LYS . . . . . 0.6 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.316 -0.862 0 CA-C-N 114.918 -1.037 . . . . 0.0 108.67 177.166 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 252' ' ' GLN . . . . . 0.655 ' HB3' ' O ' ' A' ' 302' ' ' ILE . 45.1 mm-40 . . . . . 0 N--CA 1.452 -0.361 0 N-CA-C 110.311 -0.255 . . . . 0.0 110.311 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -85.3 135.34 13.37 Favored Glycine 0 N--CA 1.448 -0.504 0 C-N-CA 120.317 -0.944 . . . . 0.0 111.848 177.564 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 67.8 p -107.36 118.12 35.89 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.02 0.438 . . . . 0.0 110.162 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.402 ' HB ' ' CG1' ' A' ' 230' ' ' VAL . 24.2 pt -119.39 146.05 24.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.73 -174.975 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 92.4 m -97.16 115.81 28.23 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 172.871 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.634 HG21 HD12 ' A' ' 262' ' ' LEU . 32.8 m -92.08 143.19 11.85 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.974 0 C-N-CA 119.388 -0.925 . . . . 0.0 112.697 -170.94 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 258' ' ' SER . . . . . 0.415 ' HB3' ' OG1' ' A' ' 229' ' ' THR . 23.1 t -90.72 9.92 28.01 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 114.005 -1.452 . . . . 0.0 107.968 169.671 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 259' ' ' ALA . . . . . 0.603 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -93.38 -179.27 5.0 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 114.862 -1.063 . . . . 0.0 110.262 -177.979 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 32.2 t -152.8 150.92 29.86 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 176.433 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 84.98 22.74 51.84 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.42 -178.649 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 262' ' ' LEU . . . . . 0.634 HD12 HG21 ' A' ' 257' ' ' VAL . 78.6 mt -90.08 140.51 29.58 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.683 0.278 . . . . 0.0 110.439 179.439 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 41.4 mm-40 -137.55 168.71 19.12 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.58 -178.28 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 264' ' ' VAL . . . . . 0.496 HG22 ' HA ' ' A' ' 294' ' ' ALA . 45.6 t -74.81 138.58 20.74 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-O 120.743 0.306 . . . . 0.0 110.312 177.645 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 91.37 0.57 73.14 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.685 178.316 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 55.1 m-20 -81.32 165.32 21.49 Favored 'General case' 0 CA--C 1.514 -0.419 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 176.385 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 267' ' ' ALA . . . . . 0.838 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -130.7 148.65 52.51 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 176.869 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 268' ' ' PHE . . . . . 0.633 ' HB3' HD13 ' A' ' 334' ' ' ILE . 3.3 p90 -164.88 168.78 17.32 Favored 'General case' 0 C--N 1.321 -0.649 0 C-N-CA 120.176 -0.61 . . . . 0.0 111.3 -179.216 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 269' ' ' THR . . . . . 0.613 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 63.3 p -113.49 149.5 34.22 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.037 175.55 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 270' ' ' ILE . . . . . . . . . . . . . 59.4 mt -121.53 129.92 75.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 178.186 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -61.29 139.13 58.22 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.242 0.544 . . . . 0.0 112.242 -173.038 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 88.17 -24.95 9.69 Favored Glycine 0 C--O 1.231 -0.074 0 CA-C-N 115.778 -0.646 . . . . 0.0 112.678 179.199 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 38.2 t -97.21 101.49 12.31 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 174.288 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 274' ' ' ASN . . . . . 1.027 ' HA ' ' HA ' ' A' ' 287' ' ' PRO . 55.4 m-20 -94.46 169.11 10.44 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.316 -179.084 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 275' ' ' SER . . . . . 0.408 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 8.3 t -104.72 179.79 4.17 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 107.876 -1.157 . . . . 0.0 107.876 171.555 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 32.7 m -126.28 149.15 31.0 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.07 0 C-N-CA 120.472 -0.491 . . . . 0.0 111.196 173.421 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 277' ' ' HIS . . . . . 0.431 ' CD2' ' HB2' ' A' ' 282' ' ' ASP . 90.6 m-70 -78.08 117.2 19.15 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.065 -0.516 . . . . 0.0 109.621 175.169 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 39.4 tt0 -62.91 -35.25 79.44 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.906 -173.137 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 279' ' ' ILE . . . . . 0.642 HG22 HG23 ' A' ' 280' ' ' THR . 60.7 mt -60.09 -69.41 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 112.295 0.48 . . . . 0.0 112.295 -173.57 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 280' ' ' THR . . . . . 0.642 HG23 HG22 ' A' ' 279' ' ' ILE . 46.4 p -114.52 17.22 17.45 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 112.424 0.527 . . . . 0.0 112.424 -174.426 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 281' ' ' LYS . . . . . 0.418 ' HE3' HG11 ' A' ' 309' ' ' VAL . 2.8 tmtp? 60.04 53.02 4.79 Favored 'General case' 0 CA--C 1.535 0.397 0 CA-C-O 121.328 0.585 . . . . 0.0 109.527 177.688 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 282' ' ' ASP . . . . . 0.431 ' HB2' ' CD2' ' A' ' 277' ' ' HIS . 58.5 m-20 -94.27 129.98 40.71 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.892 0.377 . . . . 0.0 111.007 -178.804 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 76.1 p -107.2 107.43 18.38 Favored 'General case' 0 C--N 1.321 -0.656 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 173.842 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 47.0 p -118.68 7.27 11.65 Favored 'General case' 0 C--N 1.322 -0.587 0 C-N-CA 120.737 -0.385 . . . . 0.0 111.999 -172.217 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 285' ' ' GLY . . . . . 0.486 ' HA2' ' ND2' ' A' ' 274' ' ' ASN . . . 85.58 26.65 34.91 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.403 -0.903 . . . . 0.0 112.646 176.386 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 286' ' ' GLN . . . . . 0.417 ' HA ' ' HD3' ' A' ' 287' ' ' PRO . 84.7 mt-30 -105.03 117.17 59.28 Favored Pre-proline 0 C--N 1.324 -0.535 0 N-CA-C 110.328 -0.249 . . . . 0.0 110.328 178.616 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 287' ' ' PRO . . . . . 1.027 ' HA ' ' HA ' ' A' ' 274' ' ' ASN . 39.5 Cg_exo -61.7 167.36 10.21 Favored 'Trans proline' 0 C--O 1.233 0.274 0 C-N-CA 123.222 2.615 . . . . 0.0 113.559 -175.67 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 62.9 tp60 -88.05 136.45 32.96 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.278 -0.874 . . . . 0.0 110.564 178.165 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 289' ' ' VAL . . . . . 0.549 HG12 ' HB1' ' A' ' 267' ' ' ALA . 43.8 t -94.47 123.24 46.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.069 -0.514 . . . . 0.0 109.888 177.974 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 290' ' ' PHE . . . . . 0.838 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 60.1 m-85 -104.07 133.56 48.81 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 112.082 0.401 . . . . 0.0 112.082 -173.396 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 291' ' ' ARG . . . . . 0.635 ' HD2' ' HB2' ' A' ' 267' ' ' ALA . 40.2 mmm-85 -94.91 119.59 33.71 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-O 121.5 0.667 . . . . 0.0 109.414 167.761 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 292' ' ' VAL . . . . . 0.627 HG11 HG23 ' A' ' 295' ' ' VAL . 54.9 t -71.37 140.91 17.45 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 CA-C-N 114.705 -1.134 . . . . 0.0 112.409 -174.905 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 293' ' ' LEU . . . . . 0.509 ' N ' HD12 ' A' ' 293' ' ' LEU . 3.9 mp -102.34 -30.89 10.79 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.41 175.604 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 294' ' ' ALA . . . . . 0.496 ' HA ' HG22 ' A' ' 264' ' ' VAL . . . -158.02 138.85 13.07 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.558 -177.394 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 295' ' ' VAL . . . . . 0.627 HG23 HG11 ' A' ' 292' ' ' VAL . 59.4 t -133.84 97.67 2.35 Favored 'Isoleucine or valine' 0 C--O 1.236 0.358 0 CA-C-N 115.851 -0.613 . . . . 0.0 109.378 173.826 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 30.5 m -133.98 114.57 13.38 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.848 -176.064 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 60.96 51.04 61.07 Favored Glycine 0 C--N 1.329 0.179 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.336 -179.515 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 70.4 p 52.32 19.5 1.14 Allowed 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 123.635 0.774 . . . . 0.0 112.654 -176.267 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 32.8 m -109.45 108.95 19.64 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 177.174 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 300' ' ' VAL . . . . . 0.579 HG12 HG23 ' A' ' 302' ' ' ILE . 43.7 t -112.04 126.96 69.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.54 -170.931 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 301' ' ' THR . . . . . 0.456 ' CG2' ' HB2' ' A' ' 252' ' ' GLN . 69.1 m -98.29 117.92 33.77 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 174.259 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 302' ' ' ILE . . . . . 0.655 ' O ' ' HB3' ' A' ' 252' ' ' GLN . 2.4 pp -116.18 149.82 18.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 N-CA-C 114.116 1.154 . . . . 0.0 114.116 -171.033 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 303' ' ' SER . . . . . 0.51 ' HA ' ' O ' ' A' ' 304' ' ' PRO . 86.1 p -140.64 162.62 48.05 Favored Pre-proline 0 C--O 1.216 -0.682 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 173.185 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 304' ' ' PRO . . . . . 0.51 ' O ' ' HA ' ' A' ' 303' ' ' SER . 17.6 Cg_endo -55.83 174.39 3.55 Favored 'Cis proline' 0 N--CA 1.477 0.554 0 CA-C-N 121.479 1.564 . . . . 0.0 113.825 0.038 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 305' ' ' LYS . . . . . 0.473 ' HD2' ' N ' ' A' ' 305' ' ' LYS . 0.4 OUTLIER -65.3 158.42 26.42 Favored 'General case' 0 CA--C 1.511 -0.553 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.38 179.502 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 306' ' ' ILE . . . . . 0.483 HD11 HD11 ' A' ' 302' ' ' ILE . 43.3 mt -101.62 73.02 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -0.987 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.779 178.453 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 307' ' ' LEU . . . . . 0.518 ' HB2' ' HA ' ' A' ' 320' ' ' ALA . 91.7 mt -107.11 112.14 63.2 Favored Pre-proline 0 C--N 1.324 -0.543 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.216 -176.262 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 308' ' ' PRO . . . . . 0.585 ' HA ' ' O ' ' A' ' 322' ' ' VAL . 11.3 Cg_exo -69.79 146.35 59.74 Favored 'Trans proline' 0 N--CA 1.462 -0.324 0 C-N-CA 122.708 2.272 . . . . 0.0 111.034 177.708 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 309' ' ' VAL . . . . . 0.418 HG11 ' HE3' ' A' ' 281' ' ' LYS . 20.0 t -83.41 -21.32 8.85 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 CA-C-O 121.282 0.563 . . . . 0.0 110.39 -177.694 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -76.24 -6.95 53.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.58 -0.736 . . . . 0.0 112.28 -175.994 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 47.4 p30 -75.46 153.94 37.31 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.143 0.497 . . . . 0.0 111.749 -177.005 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 53.1 m -96.88 -7.58 33.06 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.835 -0.62 . . . . 0.0 109.402 178.24 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 313' ' ' ASP . . . . . 0.464 ' HB3' ' HB2' ' A' ' 316' ' ' SER . 9.8 t70 -54.25 119.0 4.54 Favored 'General case' 0 C--O 1.232 0.153 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.507 179.868 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 46.7 t -56.57 -49.61 76.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.41 -0.814 . . . . 0.0 112.679 -173.071 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -81.82 -19.73 40.5 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 112.352 0.501 . . . . 0.0 112.352 -174.668 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 316' ' ' SER . . . . . 0.464 ' HB2' ' HB3' ' A' ' 313' ' ' ASP . 49.2 m -91.81 -25.26 19.09 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 112.283 0.475 . . . . 0.0 112.283 -175.742 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 317' ' ' ARG . . . . . 0.466 ' CG ' ' HD3' ' A' ' 318' ' ' PRO . 1.6 ptm85 -71.62 -35.79 4.04 Favored Pre-proline 0 CA--C 1.545 0.771 0 N-CA-C 114.293 1.22 . . . . 0.0 114.293 -175.902 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 318' ' ' PRO . . . . . 0.466 ' HD3' ' CG ' ' A' ' 317' ' ' ARG . 24.2 Cg_exo -65.89 -38.92 21.33 Favored 'Trans proline' 0 C--N 1.362 1.268 0 CA-C-N 121.132 1.44 . . . . 0.0 112.476 -177.463 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 3.9 m-85 -95.94 17.37 15.5 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.075 -179.719 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 320' ' ' ALA . . . . . 0.518 ' HA ' ' HB2' ' A' ' 307' ' ' LEU . . . -64.67 134.34 54.07 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.523 177.805 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 15.2 p-10 -144.11 1.44 1.11 Allowed 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -174.023 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 322' ' ' VAL . . . . . 0.585 ' O ' ' HA ' ' A' ' 308' ' ' PRO . 29.4 m -133.93 161.45 40.92 Favored 'Isoleucine or valine' 0 C--O 1.234 0.266 0 CA-C-O 121.288 0.566 . . . . 0.0 112.262 -177.82 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 323' ' ' ASP . . . . . 0.687 ' HB2' ' HB2' ' A' ' 274' ' ' ASN . 57.2 m-20 -93.24 77.59 4.54 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.865 174.958 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 324' ' ' ALA . . . . . 0.403 ' HB3' ' O ' ' A' ' 323' ' ' ASP . . . 72.37 163.85 0.28 Allowed 'General case' 0 N--CA 1.471 0.621 0 N-CA-C 113.387 0.884 . . . . 0.0 113.387 175.12 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 325' ' ' LYS . . . . . 0.652 ' HD3' ' O ' ' A' ' 234' ' ' PRO . 9.9 ptpp? -119.15 105.93 43.93 Favored Pre-proline 0 C--N 1.325 -0.459 0 CA-C-N 114.485 -1.234 . . . . 0.0 108.715 166.902 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 326' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 325' ' ' LYS . 3.8 Cg_exo -84.17 167.21 12.43 Favored 'Trans proline' 0 C--O 1.234 0.299 0 C-N-CA 122.657 2.238 . . . . 0.0 112.992 -171.363 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 327' ' ' ALA . . . . . 0.427 ' HA ' ' OE1' ' A' ' 233' ' ' GLN . . . -72.82 134.85 45.07 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 115.605 -0.725 . . . . 0.0 109.689 174.136 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 70.1 mm-40 71.3 111.18 0.06 Allowed 'General case' 0 N--CA 1.464 0.256 0 O-C-N 124.089 0.868 . . . . 0.0 110.432 -173.243 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 329' ' ' SER . . . . . 0.677 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 58.2 m -63.36 -41.28 98.83 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.603 -176.561 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 330' ' ' ALA . . . . . 0.466 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 79.35 -160.66 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.762 0 N-CA-C 112.828 0.677 . . . . 0.0 112.828 174.968 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 331' ' ' ALA . . . . . 0.617 ' HA ' HG22 ' A' ' 229' ' ' THR . . . -68.43 157.73 35.21 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-N 115.091 -0.958 . . . . 0.0 113.562 -170.405 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 332' ' ' ILE . . . . . 0.507 HD12 ' HB2' ' A' ' 259' ' ' ALA . 17.5 mt -119.16 146.11 24.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.075 -0.966 . . . . 0.0 110.223 179.555 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 333' ' ' THR . . . . . 0.518 ' HB ' ' OG1' ' A' ' 269' ' ' THR . 59.5 m -127.18 111.67 14.24 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 175.544 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 334' ' ' ILE . . . . . 0.633 HD13 ' HB3' ' A' ' 268' ' ' PHE . 46.9 mm -83.87 134.93 25.85 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.359 0 N-CA-C 113.295 0.85 . . . . 0.0 113.295 -171.538 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 335' ' ' LEU . . . . . 0.543 ' O ' ' HB3' ' A' ' 267' ' ' ALA . 1.8 pt? -158.45 130.36 6.75 Favored 'General case' 0 C--O 1.222 -0.366 0 CA-C-N 115.083 -0.962 . . . . 0.0 109.906 170.562 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -102.65 2.74 36.34 Favored 'General case' 0 C--N 1.318 -0.801 0 O-C-N 122.011 -0.43 . . . . 0.0 111.144 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 40.1 ttmt . . . . . 0 C--O 1.244 0.773 0 CA-C-O 118.279 -0.867 . . . . 0.0 110.246 -178.388 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 35.4 m . . . . . 0 C--O 1.236 0.363 0 CA-C-O 120.904 0.383 . . . . 0.0 111.015 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 228' ' ' LEU . . . . . 0.701 ' H ' HD22 ' A' ' 228' ' ' LEU . 1.9 mm? -60.39 150.56 30.49 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.252 -179.665 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 229' ' ' THR . . . . . 0.405 ' HA ' ' HA ' ' A' ' 331' ' ' ALA . 53.6 p -129.96 176.18 8.26 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 119.787 -0.765 . . . . 0.0 111.1 -179.773 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 230' ' ' VAL . . . . . 0.527 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 64.9 t -148.69 138.87 16.56 Favored 'Isoleucine or valine' 0 C--O 1.238 0.478 0 CA-C-O 120.789 0.328 . . . . 0.0 110.926 -177.128 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 47.1 t -122.72 97.39 5.43 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.419 -0.809 . . . . 0.0 109.101 173.284 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . -126.22 -151.8 7.96 Favored Glycine 0 N--CA 1.445 -0.762 0 C-N-CA 119.951 -1.119 . . . . 0.0 113.102 -175.036 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 233' ' ' GLN . . . . . 0.777 ' H ' HG22 ' A' ' 255' ' ' ILE . 80.3 mt-30 -70.58 169.61 13.53 Favored Pre-proline 0 C--N 1.325 -0.468 0 CA-C-N 115.212 -0.494 . . . . 0.0 110.991 -178.609 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 234' ' ' PRO . . . . . 0.768 ' HD2' ' HB3' ' A' ' 233' ' ' GLN . 18.7 Cg_endo -57.53 175.08 0.43 Allowed 'Trans proline' 0 C--N 1.354 0.833 0 C-N-CA 123.404 2.736 . . . . 0.0 112.833 177.777 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 235' ' ' GLU . . . . . 0.476 ' HB2' ' HD2' ' A' ' 325' ' ' LYS . 25.1 mp0 -91.86 155.18 18.39 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 108.96 -0.756 . . . . 0.0 108.96 -177.052 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 65.6 m-70 -108.5 148.76 29.76 Favored 'General case' 0 C--N 1.323 -0.581 0 C-N-CA 120.521 -0.472 . . . . 0.0 111.177 -171.511 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 237' ' ' LYS . . . . . 0.44 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.324 -0.527 0 CA-C-N 115.5 -0.773 . . . . 0.0 108.957 -178.38 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 19.2 mt-30 . . . . . 0 N--CA 1.471 0.614 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 253' ' ' GLY . . . . . 0.586 ' O ' ' HA ' ' A' ' 301' ' ' THR . . . 133.29 -146.45 18.36 Favored Glycine 0 N--CA 1.445 -0.76 0 C-N-CA 118.576 -1.773 . . . . 0.0 114.223 174.314 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 51.4 p -93.98 130.1 40.21 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.036 -0.582 . . . . 0.0 112.443 -170.905 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.777 HG22 ' H ' ' A' ' 233' ' ' GLN . 2.3 pp -129.79 163.4 35.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.902 177.432 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 31.3 m -100.47 116.38 32.28 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 -178.51 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.454 ' HA ' HG13 ' A' ' 230' ' ' VAL . 31.8 m -90.78 142.56 12.77 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.573 0 C-N-CA 120.192 -0.603 . . . . 0.0 112.593 -176.098 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 36.8 t -91.94 9.03 34.74 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 114.495 -1.23 . . . . 0.0 108.379 167.575 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 259' ' ' ALA . . . . . 0.537 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -91.07 171.54 9.19 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.138 -0.937 . . . . 0.0 109.748 -178.023 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 34.5 t -143.65 132.02 22.11 Favored 'General case' 0 C--N 1.324 -0.504 0 C-N-CA 120.991 -0.283 . . . . 0.0 110.857 179.508 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 99.24 25.49 9.43 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.682 -0.771 . . . . 0.0 113.083 177.705 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 262' ' ' LEU . . . . . 0.507 HD11 ' CB ' ' A' ' 259' ' ' ALA . 3.4 mp -87.79 146.26 25.71 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 117.034 0.417 . . . . 0.0 110.195 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 83.6 mt-30 -141.04 169.16 18.13 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.105 -0.498 . . . . 0.0 109.768 177.404 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 264' ' ' VAL . . . . . 0.674 HG22 ' HA ' ' A' ' 294' ' ' ALA . 31.8 t -77.86 139.69 18.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 C-N-CA 121.032 -0.267 . . . . 0.0 110.594 -179.677 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 91.71 3.35 68.71 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.13 179.462 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 70.5 m-20 -80.46 166.78 20.89 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.295 0.569 . . . . 0.0 111.039 179.145 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 267' ' ' ALA . . . . . 0.723 ' HB2' ' NH1' ' A' ' 291' ' ' ARG . . . -125.84 144.11 50.79 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 114.802 -1.09 . . . . 0.0 108.551 175.22 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 268' ' ' PHE . . . . . 0.583 ' CD1' HG21 ' A' ' 332' ' ' ILE . 0.0 OUTLIER -163.45 163.82 24.72 Favored 'General case' 0 C--N 1.313 -1.002 0 C-N-CA 120.125 -0.63 . . . . 0.0 110.167 -179.955 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 63.3 p -125.89 137.99 53.77 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 120.822 0.344 . . . . 0.0 110.934 -175.397 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 270' ' ' ILE . . . . . 0.671 HG12 HG12 ' A' ' 332' ' ' ILE . 60.5 mt -95.89 138.63 20.89 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.806 -179.316 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -62.23 125.52 24.18 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.97 179.577 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 94.4 -21.57 41.93 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.125 -178.62 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 273' ' ' VAL . . . . . 0.461 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 57.0 t -90.73 101.4 12.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.282 0.563 . . . . 0.0 110.106 177.976 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 64.5 m-20 -115.91 134.32 55.11 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 178.791 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 35.6 p -70.8 152.81 43.36 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.258 0.552 . . . . 0.0 111.97 -179.125 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 276' ' ' VAL . . . . . 0.686 HG11 HG21 ' A' ' 309' ' ' VAL . 33.8 m -114.7 156.07 15.75 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-N 115.221 -0.899 . . . . 0.0 110.157 174.588 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 21.7 m80 -116.6 71.27 0.78 Allowed 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 177.473 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 26.8 mt-30 -70.58 -9.62 57.27 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 112.17 0.433 . . . . 0.0 112.17 -175.239 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 279' ' ' ILE . . . . . 0.49 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.0 mp -67.67 -49.08 73.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 176.024 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 70.1 p -90.93 -12.75 35.11 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.117 0.484 . . . . 0.0 109.925 174.288 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 26.5 tptp 68.28 50.8 0.73 Allowed 'General case' 0 CA--C 1.531 0.237 0 CA-C-N 114.902 -1.045 . . . . 0.0 110.342 -177.929 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -118.34 142.15 47.8 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.889 177.553 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 62.8 p -107.43 109.93 21.77 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.48 174.745 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 68.0 p -114.33 -12.19 12.45 Favored 'General case' 0 C--N 1.32 -0.691 0 C-N-CA 120.721 -0.392 . . . . 0.0 111.999 -171.429 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 64.16 31.46 80.91 Favored Glycine 0 CA--C 1.518 0.252 0 C-N-CA 120.964 -0.636 . . . . 0.0 113.313 175.963 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 98.1 mm-40 -89.14 122.46 68.71 Favored Pre-proline 0 C--N 1.327 -0.37 0 CA-C-N 116.941 0.37 . . . . 0.0 110.197 178.871 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 287' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_exo -48.29 131.08 22.1 Favored 'Trans proline' 0 C--N 1.346 0.42 0 C-N-CA 123.033 2.489 . . . . 0.0 112.989 -177.695 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 67.1 tp60 -70.1 127.28 32.28 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.868 -178.867 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 289' ' ' VAL . . . . . 0.442 HG13 ' HB1' ' A' ' 267' ' ' ALA . 65.7 t -91.73 131.74 38.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 116.042 -0.527 . . . . 0.0 110.578 178.47 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 290' ' ' PHE . . . . . 0.695 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 57.8 m-85 -113.5 154.5 26.96 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.72 -178.272 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 291' ' ' ARG . . . . . 0.723 ' NH1' ' HB2' ' A' ' 267' ' ' ALA . 0.1 OUTLIER -114.5 121.58 43.96 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.15 0.5 . . . . 0.0 110.196 172.812 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 292' ' ' VAL . . . . . 0.512 HG11 HG23 ' A' ' 295' ' ' VAL . 56.9 t -70.39 136.46 25.99 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-N 115.037 -0.983 . . . . 0.0 111.889 -175.291 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 293' ' ' LEU . . . . . 0.667 HD11 ' HB2' ' A' ' 303' ' ' SER . 5.5 mp -96.22 -35.69 11.19 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.91 -0.587 . . . . 0.0 111.085 179.048 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 294' ' ' ALA . . . . . 0.674 ' HA ' HG22 ' A' ' 264' ' ' VAL . . . -163.63 140.8 7.21 Favored 'General case' 0 C--N 1.332 -0.184 0 C-N-CA 121.058 -0.257 . . . . 0.0 111.641 -179.579 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 295' ' ' VAL . . . . . 0.512 HG23 HG11 ' A' ' 292' ' ' VAL . 59.9 t -134.77 103.37 4.48 Favored 'Isoleucine or valine' 0 C--O 1.235 0.303 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.784 175.191 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 51.0 m -143.81 114.64 7.73 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.559 -179.013 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 67.05 48.43 59.99 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.276 -178.551 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 77.9 p 51.5 21.53 1.28 Allowed 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 123.608 0.763 . . . . 0.0 112.106 -176.198 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 37.0 m -110.04 105.9 15.2 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 177.954 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 300' ' ' VAL . . . . . 0.562 ' HA ' ' O ' ' A' ' 294' ' ' ALA . 48.9 t -108.52 128.09 64.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.4 -172.119 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 301' ' ' THR . . . . . 0.586 ' HA ' ' O ' ' A' ' 253' ' ' GLY . 54.1 m -86.75 115.82 24.44 Favored 'General case' 0 N--CA 1.451 -0.423 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 173.631 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 302' ' ' ILE . . . . . 0.549 HD12 ' O ' ' A' ' 302' ' ' ILE . 2.4 pp -111.74 151.04 13.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 N-CA-C 113.527 0.936 . . . . 0.0 113.527 -171.05 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 303' ' ' SER . . . . . 0.667 ' HB2' HD11 ' A' ' 293' ' ' LEU . 64.9 m -166.99 166.5 8.48 Favored Pre-proline 0 C--N 1.322 -0.595 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 179.326 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 304' ' ' PRO . . . . . 0.586 ' HA ' ' HB3' ' A' ' 303' ' ' SER . 4.3 Cg_exo -77.62 -113.81 0.0 OUTLIER 'Cis proline' 0 C--N 1.347 0.48 0 CA-C-N 120.907 1.36 . . . . 0.0 113.438 0.516 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 305' ' ' LYS . . . . . 0.519 ' HB3' ' HG ' ' A' ' 307' ' ' LEU . 31.2 mmtp -93.04 155.74 17.32 Favored 'General case' 0 CA--C 1.515 -0.385 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.354 -171.473 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 306' ' ' ILE . . . . . 0.456 HD12 ' N ' ' A' ' 306' ' ' ILE . 3.1 mp -131.09 74.18 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.641 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 167.283 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 307' ' ' LEU . . . . . 0.519 ' HG ' ' HB3' ' A' ' 305' ' ' LYS . 73.7 mt -112.67 113.91 50.08 Favored Pre-proline 0 C--N 1.328 -0.366 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.183 -171.092 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 308' ' ' PRO . . . . . 0.743 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 37.8 Cg_exo -66.91 148.62 82.43 Favored 'Trans proline' 0 N--CA 1.472 0.254 0 C-N-CA 123.378 2.719 . . . . 0.0 113.924 -175.137 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 309' ' ' VAL . . . . . 0.686 HG21 HG11 ' A' ' 276' ' ' VAL . 46.0 t -94.06 -7.92 9.99 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.362 0 CA-C-N 115.421 -0.809 . . . . 0.0 109.303 171.966 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 310' ' ' GLU . . . . . 0.428 ' HG2' ' O ' ' A' ' 323' ' ' ASP . 65.3 mm-40 -77.17 11.83 1.7 Allowed 'General case' 0 CA--C 1.531 0.248 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.928 179.076 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.519 ' OD1' ' HB2' ' A' ' 308' ' ' PRO . 4.6 m120 -80.41 158.69 25.89 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.888 0.375 . . . . 0.0 110.669 178.472 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 31.5 m -107.74 -13.28 15.06 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.168 0.508 . . . . 0.0 110.494 -176.027 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 11.8 p-10 -87.58 156.25 19.59 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 121.091 0.472 . . . . 0.0 111.172 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 314' ' ' VAL . . . . . 0.411 ' O ' ' HD3' ' A' ' 318' ' ' PRO . 49.1 t -81.79 -24.06 9.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 115.707 -0.678 . . . . 0.0 111.112 -178.295 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -61.9 -42.72 99.42 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 111.913 0.338 . . . . 0.0 111.913 -178.114 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 26.3 t -82.1 -10.31 59.24 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.609 -0.268 . . . . 0.0 111.293 -176.431 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 317' ' ' ARG . . . . . 0.638 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 36.8 mmt180 -58.37 -54.5 55.24 Favored Pre-proline 0 N--CA 1.468 0.464 0 N-CA-C 113.554 0.946 . . . . 0.0 113.554 -179.704 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 318' ' ' PRO . . . . . 0.638 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 24.5 Cg_exo -68.21 -19.19 44.81 Favored 'Trans proline' 0 C--N 1.353 0.78 0 C-N-CA 122.017 1.811 . . . . 0.0 113.232 -175.178 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 55.4 m-85 -102.16 -18.37 15.57 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 111.965 0.357 . . . . 0.0 111.965 -174.245 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -55.64 126.49 25.61 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.795 0.331 . . . . 0.0 111.244 -178.666 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 321' ' ' ASN . . . . . 0.411 ' C ' HG22 ' A' ' 276' ' ' VAL . 15.3 p-10 -126.51 -4.94 6.54 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.288 -177.631 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 322' ' ' VAL . . . . . 0.571 ' O ' HG23 ' A' ' 309' ' ' VAL . 29.9 m -136.35 156.43 36.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.637 0.256 . . . . 0.0 110.885 178.511 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 323' ' ' ASP . . . . . 0.428 ' O ' ' HG2' ' A' ' 310' ' ' GLU . 71.9 m-20 -52.93 -50.97 62.93 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.889 -178.065 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 324' ' ' ALA . . . . . 0.743 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -163.05 -179.94 7.07 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.006 0.431 . . . . 0.0 111.135 -177.066 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 325' ' ' LYS . . . . . 0.476 ' HD2' ' HB2' ' A' ' 235' ' ' GLU . 22.0 pttp -105.84 137.43 19.34 Favored Pre-proline 0 C--N 1.325 -0.481 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.122 176.575 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 326' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 325' ' ' LYS . 57.4 Cg_endo -86.35 167.46 9.05 Favored 'Trans proline' 0 N--CA 1.454 -0.809 0 C-N-CA 122.712 2.275 . . . . 0.0 112.306 -179.411 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -75.6 138.34 41.37 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 175.777 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 62.64 -132.42 0.51 Allowed 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 -174.021 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 329' ' ' SER . . . . . 0.527 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 48.6 m -111.49 -17.34 13.1 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 171.185 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 74.47 -173.67 0.13 Allowed 'General case' 0 N--CA 1.474 0.759 0 N-CA-C 113.65 0.981 . . . . 0.0 113.65 170.887 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 331' ' ' ALA . . . . . 0.435 ' HA ' ' O ' ' A' ' 228' ' ' LEU . . . -80.76 146.75 30.84 Favored 'General case' 0 CA--C 1.518 -0.264 0 CA-C-N 114.997 -1.001 . . . . 0.0 111.171 -176.604 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 332' ' ' ILE . . . . . 0.671 HG12 HG12 ' A' ' 270' ' ' ILE . 47.5 mt -128.45 147.18 33.0 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-O 120.956 0.408 . . . . 0.0 111.528 -176.938 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 88.1 m -116.71 112.96 21.94 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.857 -179.591 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 38.4 mm -79.56 131.87 33.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 113.044 0.757 . . . . 0.0 113.044 -171.482 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 335' ' ' LEU . . . . . . . . . . . . . 9.6 mp -115.92 168.61 9.91 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 114.562 -1.199 . . . . 0.0 109.643 171.5 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 68.5 m-20 -116.82 3.96 12.95 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.473 176.69 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 14.8 ptmm? . . . . . 0 C--O 1.246 0.889 0 CA-C-O 118.611 -0.709 . . . . 0.0 111.687 -176.415 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 51.1 m . . . . . 0 N--CA 1.453 -0.281 0 CA-C-O 121.057 0.456 . . . . 0.0 110.506 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 228' ' ' LEU . . . . . 0.471 HD13 ' HB1' ' A' ' 259' ' ' ALA . 89.9 mt -70.28 147.27 49.89 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 175.148 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 63.8 p -126.29 171.65 10.77 Favored 'General case' 0 C--N 1.324 -0.54 0 C-N-CA 119.163 -1.015 . . . . 0.0 111.334 -176.919 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 230' ' ' VAL . . . . . 0.893 HG11 HD12 ' A' ' 255' ' ' ILE . 48.0 t -147.1 141.08 20.0 Favored 'Isoleucine or valine' 0 C--O 1.24 0.577 0 CA-C-O 120.657 0.265 . . . . 0.0 110.754 -177.662 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 30.6 t -106.48 148.84 27.7 Favored 'General case' 0 C--O 1.237 0.428 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.985 176.634 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 124.8 157.15 9.61 Favored Glycine 0 N--CA 1.449 -0.486 0 N-CA-C 110.944 -0.862 . . . . 0.0 110.944 -176.712 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 30.0 mm100 -110.01 101.48 47.52 Favored Pre-proline 0 C--N 1.324 -0.534 0 CA-C-N 117.419 0.609 . . . . 0.0 111.305 -177.819 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -91.83 126.36 0.92 Allowed 'Trans proline' 0 N--CA 1.448 -1.159 0 C-N-CA 122.806 2.337 . . . . 0.0 111.756 177.605 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -132.54 149.36 52.33 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.525 -0.307 . . . . 0.0 110.214 177.027 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 236' ' ' HIS . . . . . 0.735 ' CD2' ' HA ' ' A' ' 305' ' ' LYS . 29.3 m80 -136.55 136.11 39.02 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.182 -179.532 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 237' ' ' LYS . . . . . 0.519 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.324 -0.531 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.024 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 76.9 mt-30 . . . . . 0 N--CA 1.468 0.473 0 CA-C-O 120.951 0.405 . . . . 0.0 110.693 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 136.0 -160.86 24.75 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 119.031 -1.557 . . . . 0.0 113.613 176.125 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 254' ' ' THR . . . . . 0.57 ' HB ' HG22 ' A' ' 299' ' ' THR . 66.0 p -94.63 135.73 35.75 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-O 121.331 0.586 . . . . 0.0 111.88 -175.307 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.893 HD12 HG11 ' A' ' 230' ' ' VAL . 14.6 pt -121.77 156.42 26.04 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-N 115.535 -0.757 . . . . 0.0 110.179 177.151 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 28.3 m -94.66 111.26 23.04 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 -179.755 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.528 ' HA ' HG13 ' A' ' 230' ' ' VAL . 23.1 m -93.45 144.54 9.28 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.76 0 CA-C-O 121.642 0.734 . . . . 0.0 112.717 -170.213 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 35.4 t -91.19 9.65 30.29 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 114.088 -1.415 . . . . 0.0 108.049 167.857 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 259' ' ' ALA . . . . . 0.471 ' HB1' HD13 ' A' ' 228' ' ' LEU . . . -87.08 163.72 16.85 Favored 'General case' 0 N--CA 1.45 -0.427 0 CA-C-N 115.004 -0.998 . . . . 0.0 109.66 -177.826 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 37.5 t -144.13 143.99 31.37 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 120.683 0.278 . . . . 0.0 110.384 -179.726 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 80.94 36.75 21.11 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.649 179.625 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 262' ' ' LEU . . . . . . . . . . . . . 66.4 mt -98.83 150.8 21.51 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.941 0.401 . . . . 0.0 110.432 179.52 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 73.4 mt-30 -142.26 164.73 29.37 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.241 176.29 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 264' ' ' VAL . . . . . 0.514 HG22 ' HA ' ' A' ' 294' ' ' ALA . 39.9 t -74.83 139.28 19.42 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 177.856 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 96.43 -1.91 62.55 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.42 -0.895 . . . . 0.0 113.504 177.737 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 39.7 m-20 -80.09 155.75 27.37 Favored 'General case' 0 CA--C 1.516 -0.353 0 CA-C-N 117.177 0.488 . . . . 0.0 111.053 177.094 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 267' ' ' ALA . . . . . 0.64 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -112.97 152.83 28.93 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.433 -0.803 . . . . 0.0 109.316 178.164 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 268' ' ' PHE . . . . . 0.76 ' HB3' HD13 ' A' ' 334' ' ' ILE . 7.9 p90 -164.84 172.36 13.02 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-O 121.189 0.518 . . . . 0.0 112.156 -175.952 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 74.4 p -127.84 149.89 50.08 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 114.758 -1.11 . . . . 0.0 108.789 173.131 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 270' ' ' ILE . . . . . 0.641 HG12 HG12 ' A' ' 332' ' ' ILE . 61.1 mt -118.6 136.94 54.18 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.674 0 CA-C-O 120.66 0.267 . . . . 0.0 110.478 -179.194 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -60.41 123.1 16.28 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.936 -0.575 . . . . 0.0 111.766 -176.581 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 100.43 -22.48 39.74 Favored Glycine 0 N--CA 1.451 -0.311 0 CA-C-N 115.915 -0.584 . . . . 0.0 112.223 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 273' ' ' VAL . . . . . 0.577 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 41.8 t -95.03 109.96 23.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 120.803 0.335 . . . . 0.0 110.294 177.818 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 69.6 m-80 -129.48 160.39 33.32 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 179.204 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 35.7 p -85.22 -171.68 3.75 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 111.966 0.358 . . . . 0.0 111.966 -176.359 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 276' ' ' VAL . . . . . 0.472 HG22 ' O ' ' A' ' 321' ' ' ASN . 29.6 m -145.98 173.24 3.36 Favored 'Isoleucine or valine' 0 C--O 1.232 0.176 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.098 178.79 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 29.8 m-70 -118.82 127.13 53.24 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.328 -0.396 . . . . 0.0 109.988 171.629 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 83.6 mt-30 -79.32 -23.42 43.5 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 173.891 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 279' ' ' ILE . . . . . 0.565 ' H ' HD12 ' A' ' 279' ' ' ILE . 2.5 mp -63.27 -51.1 75.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.362 179.349 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 70.9 p -100.04 -15.09 18.36 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.022 -0.536 . . . . 0.0 111.799 -176.057 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 34.5 mmtp 65.25 30.13 11.4 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 123.037 0.535 . . . . 0.0 111.429 -177.186 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 67.0 m-20 -105.83 151.55 24.36 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.072 176.084 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.437 ' HA ' HG12 ' A' ' 276' ' ' VAL . 72.6 p -96.21 92.3 6.32 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.3 0.571 . . . . 0.0 110.412 176.569 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 284' ' ' THR . . . . . 0.415 ' C ' ' H ' ' A' ' 286' ' ' GLN . 47.5 p -141.48 -112.14 0.13 Allowed 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.884 -179.082 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 63.65 -8.62 0.32 Allowed Glycine 0 CA--C 1.522 0.491 0 N-CA-C 114.529 0.572 . . . . 0.0 114.529 174.543 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 286' ' ' GLN . . . . . 0.571 ' HB3' ' HD2' ' A' ' 287' ' ' PRO . 2.0 mp0 67.45 167.72 0.12 Allowed Pre-proline 0 CA--C 1.537 0.453 0 C-N-CA 123.416 0.687 . . . . 0.0 111.045 -177.885 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 287' ' ' PRO . . . . . 0.571 ' HD2' ' HB3' ' A' ' 286' ' ' GLN . 81.3 Cg_exo -47.72 133.66 21.94 Favored 'Trans proline' 0 C--N 1.353 0.8 0 C-N-CA 122.821 2.347 . . . . 0.0 113.77 -172.658 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 71.2 tp60 -69.23 136.61 52.23 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.711 -178.982 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 48.8 t -94.89 134.13 33.34 Favored 'Isoleucine or valine' 0 C--O 1.236 0.376 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.543 179.586 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 290' ' ' PHE . . . . . 0.64 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 33.4 m-85 -116.81 168.74 9.95 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.443 -176.817 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 42.5 mmm-85 -131.08 125.46 33.23 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 173.819 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 292' ' ' VAL . . . . . 0.42 HG11 HG23 ' A' ' 295' ' ' VAL . 47.3 t -65.16 134.78 29.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.701 -177.243 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 293' ' ' LEU . . . . . 0.85 HD21 ' HB2' ' A' ' 303' ' ' SER . 2.5 mm? -96.19 -38.72 10.02 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.101 179.397 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 294' ' ' ALA . . . . . 0.514 ' HA ' HG22 ' A' ' 264' ' ' VAL . . . -159.69 142.11 13.58 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 121.088 -0.245 . . . . 0.0 111.452 -178.382 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 295' ' ' VAL . . . . . 0.437 HG22 HG22 ' A' ' 300' ' ' VAL . 77.8 t -136.16 112.11 12.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.288 -0.415 . . . . 0.0 109.938 175.436 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 37.4 t -150.03 120.42 7.37 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.337 -179.367 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 58.19 51.11 60.39 Favored Glycine 0 C--N 1.33 0.195 0 C-N-CA 121.086 -0.578 . . . . 0.0 112.386 -179.24 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 298' ' ' THR . . . . . 0.505 ' O ' HG22 ' A' ' 257' ' ' VAL . 73.6 p 48.54 27.85 1.57 Allowed 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 123.536 0.734 . . . . 0.0 112.112 -176.526 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 299' ' ' THR . . . . . 0.57 HG22 ' HB ' ' A' ' 254' ' ' THR . 65.3 m -119.66 115.26 23.58 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 176.706 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 300' ' ' VAL . . . . . 0.483 ' HA ' ' O ' ' A' ' 294' ' ' ALA . 59.7 t -113.79 130.93 67.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.587 -171.69 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 57.0 m -80.62 116.19 20.52 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 172.266 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 302' ' ' ILE . . . . . 0.6 HD12 ' O ' ' A' ' 302' ' ' ILE . 2.5 pp -111.36 140.79 29.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-O 122.264 1.03 . . . . 0.0 113.715 -171.463 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 303' ' ' SER . . . . . 0.85 ' HB2' HD21 ' A' ' 293' ' ' LEU . 49.4 m -165.02 170.98 5.8 Favored Pre-proline 0 C--N 1.325 -0.493 0 N-CA-C 105.829 -1.915 . . . . 0.0 105.829 -178.913 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 304' ' ' PRO . . . . . 0.643 ' HA ' ' HB3' ' A' ' 303' ' ' SER . 5.1 Cg_exo -74.98 -135.57 0.14 OUTLIER 'Cis proline' 0 C--N 1.351 0.664 0 CA-C-N 121.49 1.568 . . . . 0.0 113.578 0.646 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 305' ' ' LYS . . . . . 0.735 ' HA ' ' CD2' ' A' ' 236' ' ' HIS . 0.0 OUTLIER -90.68 144.41 25.77 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.47 -0.786 . . . . 0.0 112.088 -173.303 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 306' ' ' ILE . . . . . 0.635 ' H ' ' CG ' ' A' ' 236' ' ' HIS . 47.3 mm -116.0 86.93 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 114.824 -1.08 . . . . 0.0 108.611 175.121 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 307' ' ' LEU . . . . . 0.524 HD13 ' CD1' ' A' ' 319' ' ' TYR . 58.7 mt -102.29 101.04 17.28 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.196 -173.599 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 308' ' ' PRO . . . . . 0.703 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 32.3 Cg_exo -65.56 134.07 36.87 Favored 'Trans proline' 0 C--N 1.343 0.253 0 C-N-CA 123.14 2.56 . . . . 0.0 113.76 -173.678 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 309' ' ' VAL . . . . . 0.561 HG23 ' O ' ' A' ' 322' ' ' VAL . 60.4 t -80.59 -28.56 11.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 169.291 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 -79.38 36.03 0.29 Allowed 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 115.279 -0.873 . . . . 0.0 111.186 176.511 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 22.6 p30 -83.7 -175.34 5.77 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.971 0.415 . . . . 0.0 111.137 -176.678 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 85.6 m -123.38 -28.58 3.93 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.407 177.792 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 57.5 m-20 -74.45 132.93 42.36 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.074 -178.94 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 43.8 t -62.7 -33.05 57.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.982 179.078 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -70.37 -20.45 62.96 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.749 179.752 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 316' ' ' SER . . . . . 0.532 ' HA ' ' CZ ' ' A' ' 319' ' ' TYR . 50.4 m -88.25 -7.02 57.44 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 111.936 0.347 . . . . 0.0 111.936 -176.897 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 317' ' ' ARG . . . . . 0.598 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 38.6 mmt180 -63.67 -51.38 66.36 Favored Pre-proline 0 CA--C 1.539 0.528 0 N-CA-C 112.598 0.592 . . . . 0.0 112.598 -179.005 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 318' ' ' PRO . . . . . 0.598 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 26.8 Cg_exo -68.78 -39.55 8.46 Favored 'Trans proline' 0 C--N 1.356 0.964 0 C-N-CA 121.9 1.733 . . . . 0.0 114.441 -172.055 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 319' ' ' TYR . . . . . 0.532 ' CZ ' ' HA ' ' A' ' 316' ' ' SER . 1.8 p90 -88.47 -6.77 57.43 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 113.004 0.742 . . . . 0.0 113.004 -171.598 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -52.99 135.51 36.72 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 111.634 0.235 . . . . 0.0 111.634 -178.799 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 321' ' ' ASN . . . . . 0.472 ' O ' HG22 ' A' ' 276' ' ' VAL . 14.4 p-10 -132.05 -11.25 3.34 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 116.639 -0.255 . . . . 0.0 111.444 -178.187 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 322' ' ' VAL . . . . . 0.561 ' O ' HG23 ' A' ' 309' ' ' VAL . 33.6 m -131.96 166.52 28.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 N-CA-C 110.488 -0.19 . . . . 0.0 110.488 178.855 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -51.84 -66.35 0.4 Allowed 'General case' 0 N--CA 1.465 0.293 0 CA-C-O 121.252 0.548 . . . . 0.0 111.266 178.372 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 324' ' ' ALA . . . . . 0.703 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -167.24 -179.29 4.46 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.584 -177.09 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 325' ' ' LYS . . . . . 0.434 ' HA ' ' HD3' ' A' ' 326' ' ' PRO . 21.5 pttp -109.65 112.34 58.65 Favored Pre-proline 0 N--CA 1.447 -0.624 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 170.342 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 326' ' ' PRO . . . . . 0.434 ' HD3' ' HA ' ' A' ' 325' ' ' LYS . 25.4 Cg_exo -66.49 168.87 15.32 Favored 'Trans proline' 0 C--O 1.234 0.287 0 C-N-CA 122.704 2.269 . . . . 0.0 112.044 -175.954 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -58.48 146.29 35.82 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 116.009 -0.541 . . . . 0.0 109.787 176.531 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 328' ' ' GLU . . . . . 0.414 ' HG3' ' H ' ' A' ' 330' ' ' ALA . 16.0 pt-20 48.01 -145.13 0.34 Allowed 'General case' 0 N--CA 1.474 0.759 0 O-C-N 124.09 0.869 . . . . 0.0 110.995 -173.47 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 329' ' ' SER . . . . . 0.663 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 49.2 m -104.66 -19.38 13.98 Favored 'General case' 0 C--N 1.322 -0.602 0 C-N-CA 120.608 -0.437 . . . . 0.0 110.52 -179.448 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 330' ' ' ALA . . . . . 0.414 ' H ' ' HG3' ' A' ' 328' ' ' GLU . . . 73.79 -167.54 0.11 Allowed 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 113.427 0.899 . . . . 0.0 113.427 171.371 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 331' ' ' ALA . . . . . 0.427 ' HA ' ' O ' ' A' ' 228' ' ' LEU . . . -87.26 144.0 27.01 Favored 'General case' 0 C--O 1.232 0.15 0 CA-C-N 115.153 -0.93 . . . . 0.0 111.611 -175.018 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 332' ' ' ILE . . . . . 0.641 HG12 HG12 ' A' ' 270' ' ' ILE . 50.1 mt -120.7 145.33 27.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.74 -178.861 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 61.3 m -130.98 106.07 8.16 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 110.121 -0.326 . . . . 0.0 110.121 178.396 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 334' ' ' ILE . . . . . 0.76 HD13 ' HB3' ' A' ' 268' ' ' PHE . 49.0 mm -78.85 138.12 20.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.022 -0.536 . . . . 0.0 112.191 -174.109 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 335' ' ' LEU . . . . . 0.441 HD23 ' HA ' ' A' ' 268' ' ' PHE . 1.8 pt? -157.55 135.94 11.18 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.289 -0.869 . . . . 0.0 109.327 173.712 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 50.2 p30 -85.21 2.69 42.67 Favored 'General case' 0 C--N 1.325 -0.499 0 C-N-CA 120.841 -0.344 . . . . 0.0 111.283 -178.958 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 337' ' ' LYS . . . . . 0.481 ' C ' ' HD3' ' A' ' 337' ' ' LYS . 9.8 tmtt? . . . . . 0 C--O 1.245 0.862 0 CA-C-O 118.056 -0.973 . . . . 0.0 108.381 177.673 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 49.6 m . . . . . 0 C--O 1.231 0.083 0 CA-C-O 120.638 0.256 . . . . 0.0 111.333 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 228' ' ' LEU . . . . . 0.431 HD13 ' HB1' ' A' ' 259' ' ' ALA . 81.9 mt -102.35 142.8 32.98 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.292 -178.182 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 229' ' ' THR . . . . . 0.42 ' OG1' ' HB2' ' A' ' 258' ' ' SER . 35.4 p -120.63 171.37 8.62 Favored 'General case' 0 C--N 1.325 -0.467 0 C-N-CA 119.866 -0.733 . . . . 0.0 110.589 177.372 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 230' ' ' VAL . . . . . 0.518 ' HA ' ' H ' ' A' ' 258' ' ' SER . 72.4 t -146.69 130.62 10.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 120.916 0.389 . . . . 0.0 110.376 -179.597 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 231' ' ' SER . . . . . 0.508 ' O ' ' HB ' ' A' ' 255' ' ' ILE . 37.4 m -96.02 164.32 12.75 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.821 177.481 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 101.41 142.02 12.38 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.2 -1.0 . . . . 0.0 111.961 -179.283 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 233' ' ' GLN . . . . . 0.425 ' HA ' ' HD2' ' A' ' 234' ' ' PRO . 64.0 mt-30 -100.02 107.81 48.76 Favored Pre-proline 0 C--N 1.322 -0.606 0 O-C-N 123.073 -0.075 . . . . 0.0 111.03 -176.461 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 234' ' ' PRO . . . . . 0.57 ' HB2' HG13 ' A' ' 306' ' ' ILE . 29.0 Cg_endo -61.56 127.62 22.29 Favored 'Trans proline' 0 C--N 1.348 0.511 0 C-N-CA 122.173 1.916 . . . . 0.0 110.718 176.174 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 235' ' ' GLU . . . . . 0.585 ' OE1' ' HE2' ' A' ' 237' ' ' LYS . 0.3 OUTLIER -116.79 -178.34 3.41 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 113.418 0.896 . . . . 0.0 113.418 -170.995 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 55.4 t60 -167.5 135.61 2.47 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 114.632 -1.167 . . . . 0.0 110.915 -173.803 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 237' ' ' LYS . . . . . 0.585 ' HE2' ' OE1' ' A' ' 235' ' ' GLU . 0.0 OUTLIER . . . . . 0 C--N 1.323 -0.571 0 CA-C-N 114.979 -1.009 . . . . 0.0 111.762 173.072 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 42.8 mm-40 . . . . . 0 N--CA 1.451 -0.378 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -85.41 138.5 16.5 Favored Glycine 0 N--CA 1.447 -0.579 0 C-N-CA 120.327 -0.94 . . . . 0.0 112.338 -179.144 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 66.9 p -121.89 116.51 24.53 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 176.728 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.638 HD13 ' H ' ' A' ' 255' ' ' ILE . 0.2 OUTLIER -129.69 158.95 42.18 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 121.038 0.447 . . . . 0.0 111.399 -176.493 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 18.5 m -96.82 116.64 29.5 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 177.681 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.554 HG21 HD12 ' A' ' 262' ' ' LEU . 32.8 m -88.82 143.3 11.46 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.739 0 C-N-CA 119.709 -0.796 . . . . 0.0 112.349 -170.98 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 258' ' ' SER . . . . . 0.518 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 25.1 m -92.79 9.44 35.17 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 114.341 -1.3 . . . . 0.0 109.33 172.809 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 259' ' ' ALA . . . . . 0.431 ' HB1' HD13 ' A' ' 228' ' ' LEU . . . -83.05 179.9 7.62 Favored 'General case' 0 N--CA 1.452 -0.338 0 CA-C-N 115.417 -0.811 . . . . 0.0 108.942 179.659 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 22.9 t -140.98 127.34 19.82 Favored 'General case' 0 C--N 1.32 -0.693 0 C-N-CA 120.23 -0.588 . . . . 0.0 111.348 -177.484 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 78.8 50.9 5.72 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.891 -0.671 . . . . 0.0 113.276 176.207 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 262' ' ' LEU . . . . . 0.554 HD12 HG21 ' A' ' 257' ' ' VAL . 64.8 mt -95.1 160.13 14.7 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 117.147 0.474 . . . . 0.0 110.559 178.08 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 66.0 mt-30 -142.9 165.23 27.93 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 -179.311 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 27.1 t -79.58 124.14 37.38 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 C-N-CA 120.409 -0.516 . . . . 0.0 109.701 175.531 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 265' ' ' GLY . . . . . 0.609 ' H ' ' HB ' ' A' ' 292' ' ' VAL . . . 116.0 14.39 7.88 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.316 -0.945 . . . . 0.0 112.835 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 57.1 m-20 -90.51 165.83 13.56 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.186 0.517 . . . . 0.0 111.044 176.346 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 267' ' ' ALA . . . . . 0.585 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -130.59 143.92 51.07 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 175.094 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 268' ' ' PHE . . . . . 0.504 ' HB3' HD13 ' A' ' 334' ' ' ILE . 7.8 p90 -159.5 168.71 25.53 Favored 'General case' 0 C--N 1.323 -0.582 0 C-N-CA 118.958 -1.097 . . . . 0.0 112.644 -173.547 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 269' ' ' THR . . . . . 0.554 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 43.7 p -116.72 144.08 44.87 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.063 -0.971 . . . . 0.0 109.704 175.683 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 270' ' ' ILE . . . . . 0.994 HG12 HG13 ' A' ' 332' ' ' ILE . 57.2 mt -112.0 127.91 68.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 116.563 -0.29 . . . . 0.0 110.469 -178.73 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -65.15 120.04 11.96 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.077 0.465 . . . . 0.0 111.227 -179.478 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 102.7 -23.93 32.37 Favored Glycine 0 N--CA 1.452 -0.28 0 CA-C-N 115.887 -0.597 . . . . 0.0 112.315 179.278 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 39.0 t -96.34 102.48 13.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 174.574 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 274' ' ' ASN . . . . . 0.739 ' HB2' ' HB2' ' A' ' 323' ' ' ASP . 4.2 m120 -91.99 169.63 10.5 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.275 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 8.3 t -109.74 162.48 14.42 Favored 'General case' 0 CA--C 1.507 -0.704 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 178.961 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 276' ' ' VAL . . . . . 0.405 HG22 ' C ' ' A' ' 321' ' ' ASN . 13.0 m -122.52 178.84 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.067 0 CA-C-N 115.24 -0.891 . . . . 0.0 109.372 166.402 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 22.3 m80 -100.5 133.21 45.27 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 178.922 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 278' ' ' GLN . . . . . 0.421 ' HG3' ' ND2' ' A' ' 321' ' ' ASN . 2.3 mp0 -72.29 -10.22 59.5 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.79 0.329 . . . . 0.0 111.401 -178.924 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 279' ' ' ILE . . . . . 0.493 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.0 mp -102.43 -57.48 4.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 120.729 0.3 . . . . 0.0 110.946 -178.312 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 60.9 p -101.13 -6.21 24.63 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 112.663 0.616 . . . . 0.0 112.663 -174.226 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 13.9 mmmm 57.54 29.35 16.98 Favored 'General case' 0 N--CA 1.47 0.574 0 N-CA-C 111.591 0.219 . . . . 0.0 111.591 -178.499 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -77.78 139.61 39.36 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.265 -176.489 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 70.3 p -108.2 118.8 37.71 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.862 -0.608 . . . . 0.0 109.806 179.486 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 72.0 p -115.2 -14.36 11.73 Favored 'General case' 0 C--N 1.315 -0.894 0 C-N-CA 120.67 -0.412 . . . . 0.0 111.798 -172.408 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 88.17 5.13 76.94 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.521 -0.847 . . . . 0.0 112.388 179.709 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 286' ' ' GLN . . . . . 0.461 ' HA ' ' HD3' ' A' ' 287' ' ' PRO . 71.0 mt-30 -92.18 138.53 24.37 Favored Pre-proline 0 C--N 1.327 -0.382 0 N-CA-C 110.23 -0.285 . . . . 0.0 110.23 178.677 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 287' ' ' PRO . . . . . 0.635 ' HA ' ' HA ' ' A' ' 274' ' ' ASN . 21.7 Cg_exo -65.58 152.7 81.01 Favored 'Trans proline' 0 C--O 1.233 0.236 0 C-N-CA 122.615 2.21 . . . . 0.0 112.445 -179.031 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 3.9 tp-100 -81.54 150.72 28.08 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.542 177.626 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 62.1 t -94.86 125.04 47.58 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.401 0 CA-C-N 116.096 -0.502 . . . . 0.0 109.657 176.441 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 290' ' ' PHE . . . . . 0.759 ' HD1' ' HD2' ' A' ' 304' ' ' PRO . 69.9 m-85 -106.58 168.42 9.18 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.085 -174.072 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 27.1 tpt180 -132.8 120.89 22.18 Favored 'General case' 0 N--CA 1.448 -0.539 0 CA-C-O 121.222 0.534 . . . . 0.0 109.573 179.842 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 292' ' ' VAL . . . . . 0.609 ' HB ' ' H ' ' A' ' 265' ' ' GLY . 57.7 t -65.99 132.42 31.56 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.919 -177.037 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 293' ' ' LEU . . . . . 0.77 HD11 ' HB2' ' A' ' 303' ' ' SER . 88.5 mt -101.42 -44.55 5.59 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.475 178.332 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 294' ' ' ALA . . . . . 0.452 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -150.05 139.11 21.1 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.592 0.234 . . . . 0.0 111.334 -175.123 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 62.0 t -134.11 117.75 26.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.126 176.958 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 60.6 m -157.01 120.14 4.09 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.471 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 62.32 40.37 98.94 Favored Glycine 0 C--N 1.331 0.305 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.003 -177.539 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 82.1 p 53.35 20.78 2.07 Favored 'General case' 0 N--CA 1.469 0.519 0 C-N-CA 123.939 0.896 . . . . 0.0 112.27 -174.721 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 60.3 m -103.18 107.7 18.62 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 174.493 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 300' ' ' VAL . . . . . 0.452 ' HA ' ' O ' ' A' ' 294' ' ' ALA . 47.2 t -104.09 128.03 57.81 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.36 -173.247 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 42.0 m -90.48 117.36 29.12 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 172.559 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 302' ' ' ILE . . . . . . . . . . . . . 29.1 pt -110.74 140.74 28.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 N-CA-C 112.83 0.678 . . . . 0.0 112.83 -169.269 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 303' ' ' SER . . . . . 0.77 ' HB2' HD11 ' A' ' 293' ' ' LEU . 48.2 t -130.35 151.39 78.45 Favored Pre-proline 0 C--N 1.323 -0.55 0 CA-C-N 114.104 -1.407 . . . . 0.0 107.207 172.715 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 304' ' ' PRO . . . . . 0.759 ' HD2' ' HD1' ' A' ' 290' ' ' PHE . 34.3 Cg_exo -63.04 179.14 8.44 Favored 'Cis proline' 0 N--CA 1.473 0.308 0 CA-C-N 120.163 1.094 . . . . 0.0 113.09 0.781 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 305' ' ' LYS . . . . . 0.671 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -87.86 148.74 24.5 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.24 177.643 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 306' ' ' ILE . . . . . 0.57 HG13 ' HB2' ' A' ' 234' ' ' PRO . 43.7 mm -65.75 98.66 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.663 -175.075 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 307' ' ' LEU . . . . . . . . . . . . . 72.6 mt -119.25 95.57 49.39 Favored Pre-proline 0 C--N 1.325 -0.498 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 -179.506 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 308' ' ' PRO . . . . . 0.723 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 6.2 Cg_exo -77.67 169.6 20.58 Favored 'Trans proline' 0 N--CA 1.463 -0.32 0 C-N-CA 123.121 2.547 . . . . 0.0 112.635 -176.8 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 309' ' ' VAL . . . . . 0.534 HG22 ' HB1' ' A' ' 320' ' ' ALA . 39.2 t -93.56 -30.72 4.41 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-O 121.251 0.548 . . . . 0.0 109.683 177.343 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 42.5 mp0 -86.64 35.68 0.68 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.133 -0.94 . . . . 0.0 112.254 -173.833 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 79.1 m-20 -74.33 158.81 33.33 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.301 0.572 . . . . 0.0 111.845 -178.644 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 28.9 m -90.44 -36.63 14.46 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.129 -0.941 . . . . 0.0 110.22 179.266 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 313' ' ' ASP . . . . . 0.455 ' HB2' ' HB3' ' A' ' 316' ' ' SER . 1.6 m-20 -67.98 133.31 48.86 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.32 179.406 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 39.3 t -60.45 -52.23 63.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.172 -177.768 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -68.46 -17.82 64.28 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.852 -178.234 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 316' ' ' SER . . . . . 0.455 ' HB3' ' HB2' ' A' ' 313' ' ' ASP . 39.1 t -84.07 -11.02 57.36 Favored 'General case' 0 C--N 1.323 -0.546 0 C-N-CA 120.973 -0.291 . . . . 0.0 111.357 -178.376 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 317' ' ' ARG . . . . . 0.534 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 81.0 mtm180 -73.65 -49.2 6.46 Favored Pre-proline 0 CA--C 1.536 0.432 0 N-CA-C 112.506 0.558 . . . . 0.0 112.506 -179.082 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 318' ' ' PRO . . . . . 0.534 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 42.3 Cg_exo -61.07 -25.87 81.99 Favored 'Trans proline' 0 C--N 1.361 1.197 0 C-N-CA 122.17 1.914 . . . . 0.0 113.218 -176.973 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 46.6 m-85 -91.41 27.67 1.9 Allowed 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.473 -0.331 . . . . 0.0 111.313 -177.946 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 320' ' ' ALA . . . . . 0.534 ' HB1' HG22 ' A' ' 309' ' ' VAL . . . -77.72 127.55 32.61 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.073 179.297 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 321' ' ' ASN . . . . . 0.421 ' ND2' ' HG3' ' A' ' 278' ' ' GLN . 34.9 m120 -130.47 -9.24 4.13 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 111.859 0.318 . . . . 0.0 111.859 179.216 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 322' ' ' VAL . . . . . 0.508 ' O ' ' HA ' ' A' ' 308' ' ' PRO . 33.1 m -138.5 156.93 30.18 Favored 'Isoleucine or valine' 0 C--O 1.233 0.215 0 CA-C-O 120.944 0.402 . . . . 0.0 111.094 177.691 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 323' ' ' ASP . . . . . 0.739 ' HB2' ' HB2' ' A' ' 274' ' ' ASN . 2.1 m-20 -86.66 86.84 7.35 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.417 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 324' ' ' ALA . . . . . 0.723 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . 77.06 151.0 0.12 Allowed 'General case' 0 N--CA 1.473 0.685 0 CA-C-N 114.66 -1.154 . . . . 0.0 113.791 171.502 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 325' ' ' LYS . . . . . 0.436 ' HA ' ' HD3' ' A' ' 326' ' ' PRO . 55.5 pttt -98.71 105.95 33.88 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 114.435 -1.257 . . . . 0.0 109.287 168.525 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 326' ' ' PRO . . . . . 0.436 ' HD3' ' HA ' ' A' ' 325' ' ' LYS . 5.8 Cg_exo -85.99 169.27 8.99 Favored 'Trans proline' 0 C--O 1.235 0.367 0 C-N-CA 123.483 2.788 . . . . 0.0 113.195 -171.837 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -59.52 127.51 32.41 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.626 177.633 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 24.5 pt-20 44.65 -158.07 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.66 0 O-C-N 124.402 1.064 . . . . 0.0 112.034 -176.363 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 329' ' ' SER . . . . . 0.424 ' O ' ' HB3' ' A' ' 330' ' ' ALA . 54.6 m -102.9 -31.16 10.39 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 112.204 0.446 . . . . 0.0 112.204 -173.643 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 330' ' ' ALA . . . . . 0.424 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 71.95 -152.25 0.08 Allowed 'General case' 0 N--CA 1.471 0.59 0 CA-C-O 121.037 0.446 . . . . 0.0 111.534 178.359 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -85.47 116.34 23.73 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.248 -178.85 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 332' ' ' ILE . . . . . 0.994 HG13 HG12 ' A' ' 270' ' ' ILE . 1.7 mp -101.84 140.85 19.38 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 115.826 -0.624 . . . . 0.0 109.537 176.293 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 73.4 m -110.11 103.32 12.03 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 110.206 -0.294 . . . . 0.0 110.206 -176.624 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 334' ' ' ILE . . . . . 0.504 HD13 ' HB3' ' A' ' 268' ' ' PHE . 34.6 mm -85.89 125.87 40.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 N-CA-C 112.588 0.588 . . . . 0.0 112.588 -174.155 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 335' ' ' LEU . . . . . 0.485 ' N ' HD13 ' A' ' 335' ' ' LEU . 0.0 OUTLIER -139.41 172.43 12.82 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.3 -0.864 . . . . 0.0 109.804 171.259 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 50.9 t30 -136.87 59.11 1.7 Allowed 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 178.552 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 337' ' ' LYS . . . . . 0.431 ' H ' HD23 ' A' ' 335' ' ' LEU . 62.3 tttp . . . . . 0 C--O 1.244 0.768 0 CA-C-O 118.173 -0.918 . . . . 0.0 110.457 -176.106 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 68.3 m . . . . . 0 C--O 1.235 0.299 0 CA-C-O 121.254 0.55 . . . . 0.0 110.854 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 228' ' ' LEU . . . . . 0.738 ' O ' ' HA ' ' A' ' 331' ' ' ALA . 5.3 mp -67.91 119.32 12.39 Favored 'General case' 0 N--CA 1.433 -1.316 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.821 179.463 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 229' ' ' THR . . . . . 0.456 ' OG1' ' HB3' ' A' ' 258' ' ' SER . 22.3 p -128.08 178.68 6.04 Favored 'General case' 0 C--N 1.324 -0.533 0 C-N-CA 120.513 -0.475 . . . . 0.0 111.07 178.644 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 230' ' ' VAL . . . . . 0.965 HG23 HD11 ' A' ' 332' ' ' ILE . 98.3 t -144.82 130.72 14.64 Favored 'Isoleucine or valine' 0 C--O 1.235 0.303 0 CA-C-O 120.578 0.228 . . . . 0.0 111.078 -177.218 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 38.9 t -101.1 112.28 24.71 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.538 -0.755 . . . . 0.0 109.484 172.438 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 232' ' ' GLY . . . . . 0.854 ' H ' ' HG3' ' A' ' 328' ' ' GLU . . . 141.69 125.51 2.08 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.788 -0.72 . . . . 0.0 111.71 -176.319 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 233' ' ' GLN . . . . . 0.824 ' HG2' ' H ' ' A' ' 328' ' ' GLU . 73.4 mt-30 -83.5 123.33 76.75 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-N 116.49 0.145 . . . . 0.0 111.063 -177.12 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -92.71 126.26 0.71 Allowed 'Trans proline' 0 N--CA 1.451 -0.986 0 C-N-CA 122.643 2.228 . . . . 0.0 111.978 177.517 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 235' ' ' GLU . . . . . 0.418 ' HG2' ' HE3' ' A' ' 237' ' ' LYS . 0.7 OUTLIER -157.0 158.36 36.4 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.865 0.364 . . . . 0.0 110.748 177.569 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 236' ' ' HIS . . . . . 0.431 ' CG ' ' H ' ' A' ' 306' ' ' ILE . 25.5 m80 -136.07 146.19 46.78 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.322 0.582 . . . . 0.0 111.85 177.93 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 237' ' ' LYS . . . . . 0.636 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.325 -0.48 0 N-CA-C 107.664 -1.235 . . . . 0.0 107.664 178.149 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 44.3 mm-40 . . . . . 0 N--CA 1.453 -0.286 0 N-CA-C 110.219 -0.289 . . . . 0.0 110.219 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 253' ' ' GLY . . . . . 0.464 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -87.65 121.07 5.74 Favored Glycine 0 N--CA 1.447 -0.616 0 C-N-CA 120.4 -0.905 . . . . 0.0 111.88 179.269 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 52.3 p -105.1 117.35 33.79 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 178.33 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 2.1 pp -131.46 165.13 32.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -175.121 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 32.6 m -102.53 113.95 27.74 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 179.2 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.622 HG12 HG22 ' A' ' 230' ' ' VAL . 30.6 m -90.61 143.89 10.27 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.718 0 CA-C-O 121.48 0.657 . . . . 0.0 112.589 -174.907 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 258' ' ' SER . . . . . 0.456 ' HB3' ' OG1' ' A' ' 229' ' ' THR . 25.8 t -92.06 7.31 42.91 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 113.911 -1.495 . . . . 0.0 108.146 167.514 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 259' ' ' ALA . . . . . 0.443 ' H ' ' HB ' ' A' ' 257' ' ' VAL . . . -86.48 172.57 10.24 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 115.128 -0.942 . . . . 0.0 109.713 -178.989 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 50.2 m -145.65 148.63 33.28 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.833 0.349 . . . . 0.0 111.043 -179.328 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 81.14 15.9 75.81 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.992 -0.623 . . . . 0.0 113.184 178.236 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 262' ' ' LEU . . . . . 0.406 HD12 HG21 ' A' ' 257' ' ' VAL . 70.7 mt -76.31 145.73 39.36 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.971 0.385 . . . . 0.0 110.351 179.234 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 85.0 mt-30 -140.8 164.75 29.39 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.092 -0.504 . . . . 0.0 109.911 -179.126 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 45.7 t -76.24 122.87 31.34 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.257 177.489 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 113.43 -3.07 25.02 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.44 -0.886 . . . . 0.0 112.795 179.085 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 266' ' ' ASP . . . . . 0.479 ' HA ' ' OD1' ' A' ' 336' ' ' ASN . 58.6 m-20 -81.58 151.76 27.53 Favored 'General case' 0 CA--C 1.513 -0.475 0 CA-C-O 120.82 0.343 . . . . 0.0 110.296 177.074 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 267' ' ' ALA . . . . . 0.606 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -114.47 149.35 36.46 Favored 'General case' 0 N--CA 1.443 -0.806 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 173.792 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 268' ' ' PHE . . . . . 0.687 ' HB3' HD13 ' A' ' 334' ' ' ILE . 4.1 p90 -163.95 172.36 14.03 Favored 'General case' 0 C--N 1.318 -0.782 0 C-N-CA 119.632 -0.827 . . . . 0.0 111.699 -177.13 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 74.9 p -118.12 127.36 53.7 Favored 'General case' 0 N--CA 1.443 -0.801 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.337 177.688 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 270' ' ' ILE . . . . . 0.533 HG23 ' O ' ' A' ' 329' ' ' SER . 25.8 mm -95.23 129.92 44.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 CA-C-N 115.3 -0.863 . . . . 0.0 110.454 -178.27 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 271' ' ' ALA . . . . . 0.596 ' HB3' ' HB3' ' A' ' 330' ' ' ALA . . . -66.47 129.57 40.3 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 121.007 0.432 . . . . 0.0 111.133 -178.518 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 92.98 -22.87 31.94 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 121.032 -0.604 . . . . 0.0 112.065 -178.036 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 273' ' ' VAL . . . . . 0.498 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 45.8 t -101.14 117.79 46.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 121.195 0.521 . . . . 0.0 110.294 176.491 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -130.67 142.19 50.43 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.701 -178.556 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 4.8 t -81.87 172.45 13.3 Favored 'General case' 0 CA--C 1.512 -0.518 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 -177.047 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 29.9 m -130.5 178.43 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.835 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.713 173.29 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 86.2 m-70 -109.68 86.39 2.29 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 173.715 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 278' ' ' GLN . . . . . 0.424 ' HB3' ' O ' ' A' ' 320' ' ' ALA . 23.7 pt20 -72.35 -14.85 61.83 Favored 'General case' 0 N--CA 1.464 0.261 0 N-CA-C 111.964 0.357 . . . . 0.0 111.964 -173.45 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 279' ' ' ILE . . . . . 0.538 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.4 mp -73.15 -52.11 23.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 121.126 0.489 . . . . 0.0 110.038 -179.538 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 42.9 p -97.95 -3.14 38.98 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.505 -178.799 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 64.85 54.57 1.31 Allowed 'General case' 0 N--CA 1.466 0.35 0 CA-C-O 121.547 0.689 . . . . 0.0 110.012 178.466 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 58.9 m-20 -115.43 130.78 57.0 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.033 0.444 . . . . 0.0 110.817 177.824 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 65.7 p -106.32 117.8 34.97 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.246 176.906 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 70.4 p -123.44 -23.19 4.87 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.809 -171.602 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 75.19 31.73 56.97 Favored Glycine 0 N--CA 1.453 -0.186 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.817 177.95 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 47.1 mm-40 -89.77 131.27 40.11 Favored Pre-proline 0 C--N 1.327 -0.375 0 N-CA-C 110.359 -0.237 . . . . 0.0 110.359 179.7 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 287' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_exo -50.21 128.22 22.05 Favored 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 122.78 2.32 . . . . 0.0 112.546 -178.951 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 16.0 tt0 -74.56 148.03 41.22 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.668 -176.381 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 52.7 t -94.48 117.97 39.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.459 -0.791 . . . . 0.0 109.639 175.384 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 290' ' ' PHE . . . . . 0.744 ' HA ' ' HD3' ' A' ' 304' ' ' PRO . 5.0 m-85 -99.06 170.13 8.92 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.014 0.435 . . . . 0.0 111.604 -175.799 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 21.1 tpp180 -140.03 123.74 17.33 Favored 'General case' 0 N--CA 1.446 -0.668 0 CA-C-N 115.533 -0.758 . . . . 0.0 109.358 177.011 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 44.0 t -81.42 136.62 22.74 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.591 -176.211 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 293' ' ' LEU . . . . . 0.465 HD22 ' N ' ' A' ' 293' ' ' LEU . 2.2 mm? -108.0 -30.51 8.41 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.164 178.299 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 294' ' ' ALA . . . . . . . . . . . . . . . -156.12 136.92 13.43 Favored 'General case' 0 C--N 1.331 -0.201 0 C-N-CA 121.06 -0.256 . . . . 0.0 111.603 -177.508 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 60.6 t -132.49 117.86 33.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.034 -0.53 . . . . 0.0 109.641 175.063 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 34.9 t -157.52 119.52 3.75 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.519 -177.404 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 58.85 44.24 96.11 Favored Glycine 0 C--N 1.333 0.383 0 C-N-CA 121.163 -0.541 . . . . 0.0 112.318 -179.029 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 51.4 p 50.51 24.06 1.49 Allowed 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 123.703 0.801 . . . . 0.0 112.583 -175.343 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 41.0 m -111.12 112.78 24.82 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 108.388 -0.968 . . . . 0.0 108.388 173.61 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 39.0 t -111.91 132.29 60.93 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.731 -169.216 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 88.0 m -91.92 109.35 20.69 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 172.554 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 302' ' ' ILE . . . . . 0.464 HG12 ' O ' ' A' ' 253' ' ' GLY . 29.1 pt -111.33 150.87 13.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 N-CA-C 113.099 0.777 . . . . 0.0 113.099 -170.958 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 303' ' ' SER . . . . . 0.543 ' HB2' ' HA ' ' A' ' 304' ' ' PRO . 85.8 p -135.06 166.39 29.51 Favored Pre-proline 0 C--N 1.322 -0.597 0 N-CA-C 106.52 -1.659 . . . . 0.0 106.52 170.063 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 304' ' ' PRO . . . . . 0.744 ' HD3' ' HA ' ' A' ' 290' ' ' PHE . 14.7 Cg_exo -70.45 -167.58 4.14 Favored 'Cis proline' 0 CA--C 1.53 0.28 0 CA-C-N 120.75 1.303 . . . . 0.0 113.282 0.57 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 305' ' ' LYS . . . . . 0.607 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -81.31 162.84 23.3 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.736 179.803 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 306' ' ' ILE . . . . . 0.445 HG23 HG21 ' A' ' 322' ' ' VAL . 43.5 mm -111.55 84.3 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-O 120.831 0.348 . . . . 0.0 110.525 -177.373 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 307' ' ' LEU . . . . . . . . . . . . . 85.0 mt -108.35 103.49 50.91 Favored Pre-proline 0 C--N 1.327 -0.371 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.434 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 308' ' ' PRO . . . . . 0.807 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 13.5 Cg_exo -76.94 156.09 34.36 Favored 'Trans proline' 0 N--CA 1.465 -0.184 0 C-N-CA 122.611 2.207 . . . . 0.0 113.848 -171.472 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 46.7 t -78.89 -16.22 13.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 N-CA-C 108.18 -1.044 . . . . 0.0 108.18 168.069 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 67.0 mm-40 -83.61 7.05 18.54 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 114.805 -1.088 . . . . 0.0 110.885 175.033 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -68.74 128.24 35.94 Favored 'General case' 0 C--O 1.233 0.232 0 CA-C-O 120.764 0.316 . . . . 0.0 110.167 -176.59 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 61.7 m -75.89 -34.3 59.97 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.562 -175.916 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 313' ' ' ASP . . . . . 0.598 ' O ' ' HG3' ' A' ' 317' ' ' ARG . 28.0 t70 -68.85 114.32 7.06 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.976 0.417 . . . . 0.0 110.491 177.584 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 314' ' ' VAL . . . . . 0.667 ' HA ' ' HD3' ' A' ' 317' ' ' ARG . 41.5 t -63.86 -20.23 26.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.634 -0.712 . . . . 0.0 111.652 -175.836 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -75.09 -34.13 61.71 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.545 0.212 . . . . 0.0 111.468 178.97 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 316' ' ' SER . . . . . 0.419 ' HA ' ' CE1' ' A' ' 319' ' ' TYR . 34.2 t -89.4 -6.78 56.27 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.619 0.247 . . . . 0.0 111.359 -177.158 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 317' ' ' ARG . . . . . 0.667 ' HD3' ' HA ' ' A' ' 314' ' ' VAL . 56.8 mtp85 -69.68 -47.03 25.35 Favored Pre-proline 0 CA--C 1.541 0.609 0 N-CA-C 113.302 0.852 . . . . 0.0 113.302 -179.495 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 318' ' ' PRO . . . . . 0.454 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 87.2 Cg_exo -52.2 -38.49 71.67 Favored 'Trans proline' 0 C--N 1.361 1.224 0 C-N-CA 122.444 2.096 . . . . 0.0 113.796 -174.536 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 319' ' ' TYR . . . . . 0.419 ' CE1' ' HA ' ' A' ' 316' ' ' SER . 1.5 p90 -109.17 39.13 2.12 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 112.077 0.399 . . . . 0.0 112.077 -178.35 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 320' ' ' ALA . . . . . 0.424 ' O ' ' HB3' ' A' ' 278' ' ' GLN . . . -71.99 135.66 46.48 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.896 174.219 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 16.0 p-10 -119.01 -2.41 10.8 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 120.82 -0.352 . . . . 0.0 111.485 -176.703 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 322' ' ' VAL . . . . . 0.445 HG21 HG23 ' A' ' 306' ' ' ILE . 30.8 m -135.11 163.17 36.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 N-CA-C 110.34 -0.244 . . . . 0.0 110.34 175.112 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 56.7 m-20 -72.37 -38.18 68.6 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 111.657 0.243 . . . . 0.0 111.657 -178.677 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 324' ' ' ALA . . . . . 0.807 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -159.84 162.29 34.67 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.694 -171.867 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 325' ' ' LYS . . . . . 0.465 ' HA ' ' HD3' ' A' ' 326' ' ' PRO . 54.2 pttt -105.21 106.41 55.64 Favored Pre-proline 0 C--N 1.324 -0.501 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.279 169.424 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 326' ' ' PRO . . . . . 0.465 ' HD3' ' HA ' ' A' ' 325' ' ' LYS . 5.9 Cg_exo -86.49 166.83 9.03 Favored 'Trans proline' 0 C--O 1.233 0.256 0 C-N-CA 122.946 2.431 . . . . 0.0 113.566 -170.4 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 327' ' ' ALA . . . . . 0.513 ' HA ' ' HG2' ' A' ' 233' ' ' GLN . . . -81.69 122.02 27.11 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.235 -0.893 . . . . 0.0 109.444 172.032 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 328' ' ' GLU . . . . . 0.854 ' HG3' ' H ' ' A' ' 232' ' ' GLY . 53.6 mp0 60.48 175.42 0.1 Allowed 'General case' 0 N--CA 1.465 0.323 0 O-C-N 123.608 0.568 . . . . 0.0 111.084 -173.666 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 329' ' ' SER . . . . . 0.738 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 37.7 m -106.47 -15.46 14.8 Favored 'General case' 0 C--N 1.324 -0.532 0 C-N-CA 120.33 -0.548 . . . . 0.0 111.085 -177.347 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 330' ' ' ALA . . . . . 0.596 ' HB3' ' HB3' ' A' ' 271' ' ' ALA . . . 62.95 -152.8 0.34 Allowed 'General case' 0 N--CA 1.465 0.312 0 CA-C-O 120.852 0.358 . . . . 0.0 111.857 175.094 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 331' ' ' ALA . . . . . 0.738 ' HA ' ' O ' ' A' ' 228' ' ' LEU . . . -68.5 139.78 55.67 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.56 -0.745 . . . . 0.0 112.203 -175.153 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 332' ' ' ILE . . . . . 0.965 HD11 HG23 ' A' ' 230' ' ' VAL . 2.2 mp -111.7 144.59 19.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.279 179.379 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 84.8 m -121.07 105.71 10.88 Favored 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 175.522 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 334' ' ' ILE . . . . . 0.687 HD13 ' HB3' ' A' ' 268' ' ' PHE . 39.8 mm -79.95 127.73 39.07 Favored 'Isoleucine or valine' 0 C--O 1.235 0.3 0 N-CA-C 112.432 0.53 . . . . 0.0 112.432 -175.831 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 335' ' ' LEU . . . . . 0.562 HD23 ' HA ' ' A' ' 268' ' ' PHE . 1.8 pt? -148.91 132.46 16.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.58 174.036 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 336' ' ' ASN . . . . . 0.479 ' OD1' ' HA ' ' A' ' 266' ' ' ASP . 72.3 m-80 -109.0 77.38 1.06 Allowed 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.386 176.454 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 22.0 pttp . . . . . 0 C--O 1.243 0.743 0 O-C-N 124.589 1.18 . . . . 0.0 112.179 -179.078 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 39.6 t . . . . . 0 C--O 1.232 0.173 0 CA-C-O 121.133 0.492 . . . . 0.0 110.565 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 228' ' ' LEU . . . . . 0.602 ' HB3' ' CB ' ' A' ' 259' ' ' ALA . 80.9 mt -82.26 138.95 34.48 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.884 178.61 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 229' ' ' THR . . . . . 0.412 HG22 ' HA ' ' A' ' 331' ' ' ALA . 70.8 p -126.63 178.25 6.02 Favored 'General case' 0 C--N 1.325 -0.478 0 C-N-CA 120.104 -0.638 . . . . 0.0 110.752 -179.043 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 230' ' ' VAL . . . . . 0.56 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 84.1 t -143.42 150.21 17.64 Favored 'Isoleucine or valine' 0 C--O 1.239 0.544 0 N-CA-C 110.356 -0.239 . . . . 0.0 110.356 -178.574 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 33.1 t -126.08 129.1 48.44 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.298 178.597 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 110.2 109.95 3.23 Favored Glycine 0 C--O 1.228 -0.277 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.852 178.258 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 233' ' ' GLN . . . . . 0.58 ' HG3' ' O ' ' A' ' 326' ' ' PRO . 14.3 mm-40 -111.43 101.41 50.66 Favored Pre-proline 0 C--N 1.324 -0.505 0 O-C-N 122.807 -0.231 . . . . 0.0 111.135 178.989 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 234' ' ' PRO . . . . . 0.478 ' O ' ' HE2' ' A' ' 325' ' ' LYS . 7.0 Cg_exo -70.25 126.13 12.64 Favored 'Trans proline' 0 N--CA 1.459 -0.513 0 C-N-CA 122.247 1.964 . . . . 0.0 110.855 176.202 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 235' ' ' GLU . . . . . 0.408 ' HA ' ' CD ' ' A' ' 325' ' ' LYS . 13.0 pt-20 -97.41 124.42 41.59 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 121.634 0.731 . . . . 0.0 111.502 -177.639 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 26.1 m80 -122.2 147.51 46.09 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.49 179.745 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 237' ' ' LYS . . . . . 0.455 ' H ' ' HD2' ' A' ' 237' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.317 -0.837 0 CA-C-N 115.137 -0.938 . . . . 0.0 109.214 -178.912 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 44.5 mm-40 . . . . . 0 N--CA 1.451 -0.421 0 CA-C-O 120.515 0.198 . . . . 0.0 110.561 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -106.23 138.52 14.4 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.186 -1.007 . . . . 0.0 112.942 -176.166 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 254' ' ' THR . . . . . 0.493 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 75.6 p -111.0 117.98 34.81 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 176.595 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.695 HD13 ' H ' ' A' ' 255' ' ' ILE . 0.2 OUTLIER -123.09 163.91 21.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 120.733 0.302 . . . . 0.0 111.269 -176.058 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 85.7 m -100.93 112.61 25.09 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 172.327 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.611 HG21 HD12 ' A' ' 262' ' ' LEU . 35.2 m -90.01 144.97 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.783 0 CA-C-O 121.663 0.744 . . . . 0.0 112.663 -169.764 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 258' ' ' SER . . . . . 0.511 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 23.2 m -90.31 7.7 37.1 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 114.376 -1.284 . . . . 0.0 108.637 171.283 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 259' ' ' ALA . . . . . 0.602 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -96.19 159.53 14.91 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-N 114.89 -1.05 . . . . 0.0 110.162 -177.509 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 260' ' ' SER . . . . . 0.476 ' H ' HD22 ' A' ' 228' ' ' LEU . 45.8 p -127.97 154.14 45.93 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.362 -179.129 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 73.83 20.25 79.75 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 121.113 -0.565 . . . . 0.0 113.377 178.117 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 262' ' ' LEU . . . . . 0.611 HD12 HG21 ' A' ' 257' ' ' VAL . 77.5 mt -78.32 142.82 37.47 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 117.11 0.455 . . . . 0.0 110.606 179.347 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 81.6 mt-30 -141.3 174.5 10.48 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.975 -0.557 . . . . 0.0 109.866 -179.894 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 44.1 t -78.72 132.95 31.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 N-CA-C 110.098 -0.334 . . . . 0.0 110.098 176.332 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 102.89 4.4 48.42 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.378 -0.915 . . . . 0.0 112.61 179.071 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -86.05 153.8 21.87 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.871 0.367 . . . . 0.0 110.185 177.181 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 267' ' ' ALA . . . . . 0.546 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -125.08 142.48 51.46 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 177.985 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 268' ' ' PHE . . . . . 0.461 ' HB3' HD13 ' A' ' 334' ' ' ILE . 3.8 p90 -160.13 169.85 22.46 Favored 'General case' 0 C--N 1.323 -0.562 0 C-N-CA 120.097 -0.641 . . . . 0.0 111.572 -176.929 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 269' ' ' THR . . . . . 0.427 ' HB ' ' HB3' ' A' ' 287' ' ' PRO . 67.4 p -119.08 145.88 45.55 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.526 175.872 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 270' ' ' ILE . . . . . 0.729 HG12 HD12 ' A' ' 332' ' ' ILE . 57.9 mt -111.51 131.97 61.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.696 -177.265 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -66.08 120.13 12.62 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.372 -178.531 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 272' ' ' GLY . . . . . 0.533 ' HA3' ' HG3' ' A' ' 326' ' ' PRO . . . 101.3 -22.32 39.52 Favored Glycine 0 C--O 1.23 -0.1 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.102 -179.673 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 52.2 t -103.16 102.68 13.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 176.968 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 7.1 m120 -119.62 156.66 29.98 Favored 'General case' 0 C--N 1.323 -0.583 0 C-N-CA 120.1 -0.64 . . . . 0.0 111.235 -173.9 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 59.0 p -75.8 166.81 22.98 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.301 0.572 . . . . 0.0 112.41 -173.973 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 34.3 m -123.96 153.66 30.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 114.909 -1.041 . . . . 0.0 109.851 174.261 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 2.9 m-70 -110.35 91.51 3.68 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 179.345 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 16.9 pt20 -79.44 -11.36 59.91 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.92 -0.582 . . . . 0.0 112.435 -172.077 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 279' ' ' ILE . . . . . 0.484 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.2 mp -76.42 -55.92 9.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-O 120.935 0.398 . . . . 0.0 109.962 179.003 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 45.6 p -96.12 -1.4 48.65 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.618 -178.865 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 281' ' ' LYS . . . . . 0.418 ' HB3' ' NZ ' ' A' ' 281' ' ' LYS . 3.8 mmmp? 52.74 52.37 14.13 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.06 -177.793 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 52.1 t0 -111.64 146.92 36.59 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.04 -177.464 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 36.4 p -107.1 110.6 22.75 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.938 0.399 . . . . 0.0 110.391 176.576 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 78.3 p -119.05 -26.45 5.96 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.702 -176.755 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 71.35 31.92 65.56 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.925 176.711 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 95.2 mm-40 -82.72 133.18 49.66 Favored Pre-proline 0 C--N 1.325 -0.49 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 179.232 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 287' ' ' PRO . . . . . 0.427 ' HB3' ' HB ' ' A' ' 269' ' ' THR . 82.2 Cg_exo -49.47 133.26 31.18 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.902 2.402 . . . . 0.0 112.851 -177.453 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 3.3 tm0? -83.65 134.89 34.76 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 -176.804 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 40.3 t -98.39 125.23 51.77 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-O 120.986 0.422 . . . . 0.0 110.776 -176.0 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 290' ' ' PHE . . . . . 0.546 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 6.0 m-85 -98.29 165.65 11.77 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.138 0.495 . . . . 0.0 112.181 -173.782 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 40.2 mmt-85 -129.46 120.35 25.31 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 114.889 -1.051 . . . . 0.0 108.763 174.014 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 58.3 t -77.98 135.78 25.5 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.913 0 CA-C-N 116.306 -0.406 . . . . 0.0 112.059 -174.844 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 293' ' ' LEU . . . . . . . . . . . . . 72.2 mt -102.49 -37.81 7.83 Favored 'General case' 0 N--CA 1.462 0.152 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.674 177.382 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 294' ' ' ALA . . . . . . . . . . . . . . . -151.51 139.91 20.48 Favored 'General case' 0 C--N 1.328 -0.339 0 C-N-CA 120.999 -0.28 . . . . 0.0 111.55 -175.139 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 58.0 t -137.71 110.21 7.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.987 -0.551 . . . . 0.0 109.614 175.339 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 58.9 p -139.85 104.06 4.79 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.163 -175.672 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 61.16 56.79 21.8 Favored Glycine 0 C--N 1.331 0.266 0 C-N-CA 120.979 -0.629 . . . . 0.0 112.406 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 66.4 p 53.21 17.24 0.95 Allowed 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 123.98 0.912 . . . . 0.0 112.519 -176.12 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 89.5 m -105.54 108.1 19.44 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 174.115 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 300' ' ' VAL . . . . . 0.493 ' O ' ' HA ' ' A' ' 254' ' ' THR . 45.2 t -111.05 135.04 51.43 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.35 -172.898 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 60.4 m -99.85 114.02 26.93 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 173.129 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 302' ' ' ILE . . . . . . . . . . . . . 27.2 pt -110.66 137.11 44.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 N-CA-C 113.094 0.775 . . . . 0.0 113.094 -168.801 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 303' ' ' SER . . . . . . . . . . . . . 50.3 m -119.49 157.59 51.28 Favored Pre-proline 0 C--N 1.32 -0.716 0 CA-C-N 114.029 -1.441 . . . . 0.0 107.641 170.569 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 304' ' ' PRO . . . . . 0.525 ' HD3' ' HA ' ' A' ' 290' ' ' PHE . 2.7 Cg_exo -75.23 -172.48 10.88 Favored 'Cis proline' 0 N--CA 1.462 -0.335 0 C-N-CA 124.368 -1.097 . . . . 0.0 111.716 -0.077 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 305' ' ' LYS . . . . . 0.449 ' HD2' ' O ' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -80.89 145.35 31.36 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.271 0.558 . . . . 0.0 111.804 179.462 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 306' ' ' ILE . . . . . 0.731 HG23 HG21 ' A' ' 322' ' ' VAL . 2.9 mp -99.86 100.5 10.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.41 -172.783 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 307' ' ' LEU . . . . . 0.468 ' HA ' ' HD3' ' A' ' 308' ' ' PRO . 82.9 mt -117.14 119.74 34.49 Favored Pre-proline 0 CA--C 1.516 -0.363 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.413 179.766 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 308' ' ' PRO . . . . . 0.792 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 7.1 Cg_exo -80.19 139.66 13.45 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 123.183 2.589 . . . . 0.0 113.406 -176.065 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 309' ' ' VAL . . . . . 0.474 HG22 ' HB3' ' A' ' 320' ' ' ALA . 45.3 t -82.04 -30.16 9.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 167.284 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 310' ' ' GLU . . . . . 0.405 ' HB2' ' HB2' ' A' ' 324' ' ' ALA . 89.1 mt-10 -84.73 25.79 0.88 Allowed 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 115.006 -0.997 . . . . 0.0 111.169 177.553 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.711 ' HB2' ' HB2' ' A' ' 308' ' ' PRO . 24.5 t-20 -87.74 141.63 28.45 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 179.638 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 38.0 m -60.3 -28.53 68.18 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.198 -178.019 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 32.7 t70 -79.14 113.46 17.28 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.001 0.429 . . . . 0.0 110.195 177.107 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 314' ' ' VAL . . . . . 0.477 ' O ' ' HD3' ' A' ' 318' ' ' PRO . 40.4 t -69.04 -19.86 24.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.965 -177.543 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -75.03 -17.89 60.42 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 112.218 0.451 . . . . 0.0 112.218 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 59.4 m -96.7 -22.03 17.24 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 112.43 0.53 . . . . 0.0 112.43 -176.394 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 317' ' ' ARG . . . . . 0.415 ' N ' ' CD ' ' A' ' 318' ' ' PRO . 15.9 ptp180 -74.5 -31.65 1.25 Allowed Pre-proline 0 CA--C 1.549 0.92 0 N-CA-C 114.901 1.445 . . . . 0.0 114.901 -175.584 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 318' ' ' PRO . . . . . 0.477 ' HD3' ' O ' ' A' ' 314' ' ' VAL . 33.6 Cg_exo -62.09 -39.09 51.92 Favored 'Trans proline' 0 C--N 1.365 1.412 0 CA-C-N 121.486 1.566 . . . . 0.0 112.68 -178.009 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 54.7 m-85 -112.02 41.33 1.98 Allowed 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.543 -179.731 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 320' ' ' ALA . . . . . 0.474 ' HB3' HG22 ' A' ' 309' ' ' VAL . . . -78.63 159.87 27.84 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.967 179.699 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 47.2 t30 -111.83 -25.29 9.53 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.76 -178.744 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 322' ' ' VAL . . . . . 0.731 HG21 HG23 ' A' ' 306' ' ' ILE . 33.0 m -134.46 172.68 15.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.766 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 53.1 m-20 -67.15 -49.69 63.89 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.557 176.917 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 324' ' ' ALA . . . . . 0.792 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -173.08 179.64 2.2 Favored 'General case' 0 CA--C 1.518 -0.281 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.555 -177.166 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 325' ' ' LYS . . . . . 0.478 ' HE2' ' O ' ' A' ' 234' ' ' PRO . 8.7 ptpp? -126.83 106.96 22.61 Favored Pre-proline 0 C--N 1.326 -0.414 0 CA-C-N 115.324 -0.853 . . . . 0.0 109.805 171.525 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 326' ' ' PRO . . . . . 0.58 ' O ' ' HG3' ' A' ' 233' ' ' GLN . 67.1 Cg_endo -78.92 167.14 22.52 Favored 'Trans proline' 0 C--N 1.34 0.124 0 C-N-CA 122.535 2.156 . . . . 0.0 112.49 -175.878 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -63.03 129.63 41.18 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.122 176.81 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 47.1 mt-10 73.01 142.72 0.06 Allowed 'General case' 0 N--CA 1.469 0.493 0 O-C-N 123.977 0.798 . . . . 0.0 110.561 -174.564 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 329' ' ' SER . . . . . 0.56 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 17.6 m -77.31 -22.29 52.17 Favored 'General case' 0 C--N 1.323 -0.55 0 C-N-CA 120.865 -0.334 . . . . 0.0 111.383 -174.652 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 330' ' ' ALA . . . . . 0.445 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 74.15 -162.6 0.08 Allowed 'General case' 0 N--CA 1.47 0.546 0 O-C-N 123.716 0.635 . . . . 0.0 112.686 174.251 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 331' ' ' ALA . . . . . 0.412 ' HA ' HG22 ' A' ' 229' ' ' THR . . . -81.34 145.93 30.61 Favored 'General case' 0 CA--C 1.517 -0.29 0 CA-C-N 115.318 -0.856 . . . . 0.0 110.943 -178.042 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 332' ' ' ILE . . . . . 0.729 HD12 HG12 ' A' ' 270' ' ' ILE . 29.4 mm -115.47 144.55 22.81 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.245 -177.304 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 75.5 m -109.05 96.65 6.46 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 110.094 -0.336 . . . . 0.0 110.094 179.118 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 334' ' ' ILE . . . . . 0.461 HD13 ' HB3' ' A' ' 268' ' ' PHE . 45.7 mm -81.71 130.61 35.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 N-CA-C 111.912 0.338 . . . . 0.0 111.912 -175.329 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 335' ' ' LEU . . . . . 0.431 HD23 ' N ' ' A' ' 335' ' ' LEU . 1.9 pt? -156.58 132.43 9.62 Favored 'General case' 0 C--O 1.234 0.244 0 CA-C-O 121.388 0.613 . . . . 0.0 110.982 174.671 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 76.1 m-20 -94.69 52.63 1.53 Allowed 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.451 176.713 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 55.8 tptt . . . . . 0 C--O 1.246 0.897 0 CA-C-O 118.124 -0.941 . . . . 0.0 109.525 -179.807 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 48.3 m . . . . . 0 C--O 1.233 0.184 0 CA-C-O 121.284 0.564 . . . . 0.0 109.629 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 228' ' ' LEU . . . . . 0.471 ' HB3' ' CB ' ' A' ' 259' ' ' ALA . 90.5 mt -128.12 141.3 51.53 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.289 -0.869 . . . . 0.0 109.09 176.766 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 38.3 p -130.94 -179.2 5.18 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 120.578 -0.449 . . . . 0.0 111.339 -177.005 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 230' ' ' VAL . . . . . 0.586 ' HB ' ' CB ' ' A' ' 329' ' ' SER . 40.7 t -140.0 140.01 36.19 Favored 'Isoleucine or valine' 0 C--O 1.239 0.528 0 CA-C-O 120.557 0.218 . . . . 0.0 110.772 -178.651 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 32.1 m -99.24 138.92 35.65 Favored 'General case' 0 C--O 1.234 0.277 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.29 176.004 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 127.73 166.23 12.03 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.51 -0.853 . . . . 0.0 111.959 179.202 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 81.3 mt-30 -117.12 102.03 52.89 Favored Pre-proline 0 C--N 1.324 -0.539 0 CA-C-N 116.782 0.291 . . . . 0.0 111.073 -179.557 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 234' ' ' PRO . . . . . 0.412 ' HB2' HD12 ' A' ' 306' ' ' ILE . 6.1 Cg_exo -76.35 126.82 9.36 Favored 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 122.716 2.277 . . . . 0.0 111.155 177.015 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -158.55 141.22 14.44 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.175 -178.739 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 49.2 m80 -146.72 138.24 24.39 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.495 -177.266 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 237' ' ' LYS . . . . . 0.542 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 6.2 mptt . . . . . 0 C--N 1.323 -0.548 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 252' ' ' GLN . . . . . 0.535 ' HB3' ' O ' ' A' ' 302' ' ' ILE . 41.9 mm-40 . . . . . 0 N--CA 1.45 -0.434 0 CA-C-O 120.695 0.284 . . . . 0.0 110.878 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -110.28 147.81 17.43 Favored Glycine 0 N--CA 1.447 -0.581 0 C-N-CA 119.842 -1.171 . . . . 0.0 113.019 -176.612 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 70.1 p -118.93 117.73 29.62 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 176.838 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.658 HD13 ' H ' ' A' ' 255' ' ' ILE . 0.2 OUTLIER -128.66 165.64 27.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-O 120.951 0.405 . . . . 0.0 111.128 -176.253 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 40.5 m -99.61 116.87 32.74 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 178.273 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.473 ' HA ' HG13 ' A' ' 230' ' ' VAL . 34.1 m -90.44 144.39 9.22 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.774 0 CA-C-O 121.47 0.653 . . . . 0.0 112.494 -172.378 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 258' ' ' SER . . . . . 0.487 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 40.3 m -90.61 8.48 33.99 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 114.359 -1.291 . . . . 0.0 108.721 170.355 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 259' ' ' ALA . . . . . 0.471 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -91.4 163.69 14.1 Favored 'General case' 0 N--CA 1.449 -0.518 0 CA-C-N 114.994 -1.003 . . . . 0.0 109.453 -179.012 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 260' ' ' SER . . . . . 0.457 ' H ' HD13 ' A' ' 228' ' ' LEU . 50.6 m -129.8 149.33 51.59 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 120.762 0.315 . . . . 0.0 111.386 -177.888 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 68.73 37.53 84.53 Favored Glycine 0 N--CA 1.451 -0.355 0 CA-C-N 115.786 -0.643 . . . . 0.0 113.534 176.453 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 262' ' ' LEU . . . . . 0.406 HD11 ' HB3' ' A' ' 259' ' ' ALA . 60.4 mt -92.45 150.74 20.6 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 117.364 0.582 . . . . 0.0 109.835 176.794 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 84.7 mt-30 -144.41 170.26 16.36 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.113 -0.494 . . . . 0.0 109.675 -179.619 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 50.3 t -78.25 141.89 14.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.844 -179.457 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 94.13 -2.07 68.28 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.701 -0.761 . . . . 0.0 113.206 177.288 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 44.8 m-20 -81.04 155.46 26.33 Favored 'General case' 0 CA--C 1.515 -0.386 0 CA-C-O 121.251 0.548 . . . . 0.0 111.202 178.129 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 267' ' ' ALA . . . . . 0.713 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -116.16 146.97 41.86 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.222 -0.899 . . . . 0.0 109.13 178.963 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 268' ' ' PHE . . . . . 0.671 ' HB3' HD13 ' A' ' 334' ' ' ILE . 6.6 p90 -164.17 162.06 22.55 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 120.4 -0.52 . . . . 0.0 111.93 -174.935 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 269' ' ' THR . . . . . 0.468 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 71.1 p -115.23 147.74 39.98 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 115.016 -0.993 . . . . 0.0 109.137 173.422 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 270' ' ' ILE . . . . . 0.593 HD11 ' HE2' ' A' ' 268' ' ' PHE . 54.1 mt -123.13 138.07 54.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-O 120.61 0.243 . . . . 0.0 110.516 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -63.58 125.2 23.47 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.872 -175.956 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 103.64 -22.6 35.24 Favored Glycine 0 N--CA 1.449 -0.471 0 CA-C-N 115.73 -0.668 . . . . 0.0 112.207 178.976 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 273' ' ' VAL . . . . . 0.657 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 39.5 t -95.11 102.31 13.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-O 120.946 0.403 . . . . 0.0 110.058 178.204 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 61.7 m-20 -110.52 135.76 50.69 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.231 -179.892 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 32.5 p -77.94 156.23 30.38 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.229 0.538 . . . . 0.0 112.078 -177.428 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 32.9 m -113.48 160.3 13.04 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.65 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.478 174.845 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 35.7 m80 -132.19 79.86 1.88 Allowed 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.903 177.962 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 30.0 tp60 -53.22 -29.55 32.92 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.585 -0.28 . . . . 0.0 111.296 -176.115 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 50.1 mm -63.6 -48.42 86.88 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.352 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.616 178.914 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 75.2 p -97.81 7.14 46.89 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-O 120.762 0.315 . . . . 0.0 111.5 -177.39 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 52.9 tptt 71.59 50.18 0.27 Allowed 'General case' 0 CA--C 1.536 0.408 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.947 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 2.4 p30 29.62 50.41 0.07 Allowed 'General case' 0 N--CA 1.474 0.741 0 N-CA-C 115.801 1.778 . . . . 0.0 115.801 171.471 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 62.1 p -107.1 88.65 2.78 Favored 'General case' 0 C--N 1.322 -0.612 0 C-N-CA 119.744 -0.782 . . . . 0.0 110.335 167.935 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 35.5 p -145.62 -70.36 0.27 Allowed 'General case' 0 C--N 1.319 -0.761 0 CA-C-N 115.499 -0.773 . . . . 0.0 111.339 -177.79 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 89.09 32.3 10.86 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.013 -178.526 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 286' ' ' GLN . . . . . 0.4 ' HA ' ' HD3' ' A' ' 287' ' ' PRO . 12.0 mm100 -100.94 127.8 31.24 Favored Pre-proline 0 C--N 1.326 -0.422 0 O-C-N 122.894 -0.18 . . . . 0.0 110.926 -177.244 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 287' ' ' PRO . . . . . 0.468 ' HB2' ' HB ' ' A' ' 269' ' ' THR . 24.2 Cg_exo -58.17 129.84 34.98 Favored 'Trans proline' 0 C--O 1.236 0.406 0 C-N-CA 122.42 2.08 . . . . 0.0 110.734 173.985 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 40.4 tt0 -72.87 142.06 47.93 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.963 0.411 . . . . 0.0 111.124 -173.773 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 289' ' ' VAL . . . . . 0.431 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 47.7 t -90.6 134.82 28.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 115.465 -0.789 . . . . 0.0 109.931 177.956 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 290' ' ' PHE . . . . . 0.713 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 45.5 m-85 -111.48 163.06 14.44 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.471 -177.449 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 43.2 mmm-85 -125.25 121.22 33.44 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 173.436 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 47.2 t -66.03 132.16 31.64 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-N 115.597 -0.729 . . . . 0.0 111.591 -175.604 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 293' ' ' LEU . . . . . 0.483 HD11 ' HG3' ' A' ' 252' ' ' GLN . 93.9 mt -93.68 -41.64 9.59 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.906 -0.588 . . . . 0.0 111.562 177.381 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 294' ' ' ALA . . . . . 0.412 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -157.26 142.69 17.3 Favored 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 120.896 -0.322 . . . . 0.0 111.316 -176.601 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 61.2 t -133.92 116.54 23.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 109.238 -0.653 . . . . 0.0 109.238 174.466 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 52.5 p -140.73 92.29 2.49 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.061 -175.741 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 66.84 63.73 3.69 Favored Glycine 0 N--CA 1.453 -0.181 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.222 -179.411 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 76.6 p 51.0 23.21 1.4 Allowed 'General case' 0 N--CA 1.47 0.557 0 C-N-CA 123.614 0.766 . . . . 0.0 112.579 -177.651 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 44.2 m -116.59 113.38 22.64 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 175.361 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 300' ' ' VAL . . . . . 0.412 ' HA ' ' O ' ' A' ' 294' ' ' ALA . 45.5 t -113.49 130.5 67.4 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.541 -171.325 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 38.3 m -91.16 116.72 29.04 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 108.072 -1.085 . . . . 0.0 108.072 171.484 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 302' ' ' ILE . . . . . 0.535 ' O ' ' HB3' ' A' ' 252' ' ' GLN . 31.0 pt -110.68 137.3 43.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 N-CA-C 112.812 0.671 . . . . 0.0 112.812 -169.047 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 303' ' ' SER . . . . . 0.426 ' HB3' HD11 ' A' ' 293' ' ' LEU . 81.7 p -137.67 153.52 74.15 Favored Pre-proline 0 C--N 1.325 -0.496 0 CA-C-N 114.645 -1.161 . . . . 0.0 108.547 173.889 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 304' ' ' PRO . . . . . 0.53 ' HD2' ' HD1' ' A' ' 290' ' ' PHE . 5.9 Cg_exo -73.67 -173.07 10.83 Favored 'Cis proline' 0 N--CA 1.463 -0.296 0 C-N-CA 124.005 -1.248 . . . . 0.0 112.01 -0.005 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 305' ' ' LYS . . . . . 0.639 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -85.75 170.2 12.69 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 120.873 0.368 . . . . 0.0 110.874 -177.841 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 306' ' ' ILE . . . . . 0.444 HG23 HG21 ' A' ' 322' ' ' VAL . 60.3 mt -112.09 93.6 2.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.59 -176.389 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 307' ' ' LEU . . . . . 0.435 ' HG ' ' HG2' ' A' ' 305' ' ' LYS . 94.4 mt -108.23 104.97 55.58 Favored Pre-proline 0 C--N 1.326 -0.441 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.691 -179.54 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 308' ' ' PRO . . . . . 0.778 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 6.3 Cg_exo -75.96 138.6 20.97 Favored 'Trans proline' 0 N--CA 1.461 -0.422 0 C-N-CA 122.982 2.455 . . . . 0.0 112.467 -177.324 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 309' ' ' VAL . . . . . 0.471 HG23 ' O ' ' A' ' 322' ' ' VAL . 46.8 t -65.74 -25.59 36.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 121.189 0.518 . . . . 0.0 109.683 174.674 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 310' ' ' GLU . . . . . 0.436 ' HA ' ' OE1' ' A' ' 310' ' ' GLU . 4.8 mm-40 -80.92 33.67 0.33 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.752 -0.658 . . . . 0.0 112.169 177.192 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.417 ' O ' ' HB ' ' A' ' 312' ' ' THR . 21.4 p30 -85.29 -8.08 58.68 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.964 -0.107 . . . . 0.0 111.178 -179.644 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 312' ' ' THR . . . . . 0.417 ' HB ' ' O ' ' A' ' 311' ' ' ASN . 71.1 m 74.91 -46.61 0.6 Allowed 'General case' 0 N--CA 1.471 0.613 0 C-N-CA 123.457 0.703 . . . . 0.0 112.283 178.948 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 42.8 m-20 -57.47 115.46 2.75 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-O 121.211 0.529 . . . . 0.0 111.116 -179.073 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 23.3 t -61.55 -33.6 57.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.449 -176.379 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -75.79 -22.14 56.68 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 111.752 0.278 . . . . 0.0 111.752 179.626 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 65.5 m -87.12 -20.66 26.76 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 111.777 0.288 . . . . 0.0 111.777 -178.857 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 317' ' ' ARG . . . . . 0.505 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 75.0 mtp180 -56.04 -48.9 95.82 Favored Pre-proline 0 CA--C 1.539 0.525 0 N-CA-C 113.034 0.754 . . . . 0.0 113.034 -179.282 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 318' ' ' PRO . . . . . 0.505 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 52.0 Cg_exo -58.57 -16.18 28.81 Favored 'Trans proline' 0 C--N 1.36 1.137 0 C-N-CA 122.213 1.942 . . . . 0.0 113.988 -176.758 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 8.8 m-85 -106.69 1.28 24.93 Favored 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 121.116 -0.234 . . . . 0.0 111.568 -179.657 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -66.08 139.03 58.15 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.811 0.339 . . . . 0.0 111.02 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 14.8 p-10 -124.07 -9.5 7.66 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.379 -179.466 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 322' ' ' VAL . . . . . 0.471 ' O ' HG23 ' A' ' 309' ' ' VAL . 32.3 m -132.92 163.97 36.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 175.537 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 54.6 m-20 -81.05 -22.16 39.5 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 111.885 0.328 . . . . 0.0 111.885 -177.755 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 324' ' ' ALA . . . . . 0.778 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -171.1 154.66 4.14 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.045 -172.573 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 23.8 pttm -101.31 114.4 65.73 Favored Pre-proline 0 C--N 1.325 -0.488 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 169.314 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -72.57 167.64 26.55 Favored 'Trans proline' 0 C--O 1.235 0.346 0 C-N-CA 122.622 2.215 . . . . 0.0 113.306 -172.47 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -66.62 136.8 56.13 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-N 115.804 -0.634 . . . . 0.0 109.885 175.93 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 47.1 -155.27 0.05 Allowed 'General case' 0 N--CA 1.471 0.594 0 O-C-N 124.446 1.091 . . . . 0.0 111.19 -173.7 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 329' ' ' SER . . . . . 0.586 ' CB ' ' HB ' ' A' ' 230' ' ' VAL . 53.1 m -98.66 -38.92 8.93 Favored 'General case' 0 C--N 1.322 -0.609 0 C-N-CA 120.548 -0.461 . . . . 0.0 111.024 -177.052 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 330' ' ' ALA . . . . . 0.453 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 79.39 -164.39 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.923 0 N-CA-C 112.869 0.692 . . . . 0.0 112.869 174.34 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -84.49 149.17 26.12 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 115.507 -0.77 . . . . 0.0 112.429 -172.066 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 332' ' ' ILE . . . . . 0.602 HG23 ' CD2' ' A' ' 268' ' ' PHE . 38.3 mt -111.08 145.78 16.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.663 -0.699 . . . . 0.0 111.16 178.967 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 95.7 m -120.67 97.2 5.44 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 172.693 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 334' ' ' ILE . . . . . 0.671 HD13 ' HB3' ' A' ' 268' ' ' PHE . 40.3 mm -79.18 128.96 38.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 N-CA-C 111.92 0.341 . . . . 0.0 111.92 -175.617 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 335' ' ' LEU . . . . . 0.442 HD23 ' N ' ' A' ' 335' ' ' LEU . 1.5 pt? -152.9 130.74 11.68 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.407 0.622 . . . . 0.0 110.593 174.431 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 23.4 p30 -90.8 5.47 48.24 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.287 -177.949 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 337' ' ' LYS . . . . . 0.442 ' NZ ' ' HB3' ' A' ' 337' ' ' LYS . 8.0 mtpm? . . . . . 0 C--O 1.245 0.828 0 CA-C-O 118.186 -0.911 . . . . 0.0 110.758 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 42.9 m . . . . . 0 N--CA 1.453 -0.311 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 228' ' ' LEU . . . . . 0.544 ' HB3' ' CB ' ' A' ' 259' ' ' ALA . 87.9 mt -127.1 136.07 51.63 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 172.287 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 40.5 p -122.16 172.17 8.46 Favored 'General case' 0 C--N 1.325 -0.462 0 C-N-CA 119.502 -0.879 . . . . 0.0 110.811 -179.72 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 230' ' ' VAL . . . . . 0.721 HG13 ' HA ' ' A' ' 257' ' ' VAL . 48.3 t -145.82 146.02 19.72 Favored 'Isoleucine or valine' 0 C--O 1.239 0.537 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.328 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 231' ' ' SER . . . . . 0.444 ' HA ' ' OE1' ' A' ' 328' ' ' GLU . 33.3 t -118.79 127.21 53.32 Favored 'General case' 0 N--CA 1.452 -0.328 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.017 -178.975 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 232' ' ' GLY . . . . . 0.528 ' O ' ' HD3' ' A' ' 234' ' ' PRO . . . 149.13 160.43 9.13 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.072 179.182 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 14.6 mm-40 -99.34 100.98 11.54 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 116.769 0.285 . . . . 0.0 111.628 -179.069 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 234' ' ' PRO . . . . . 0.528 ' HD3' ' O ' ' A' ' 232' ' ' GLY . 3.2 Cg_endo -84.01 126.44 3.85 Favored 'Trans proline' 0 N--CA 1.455 -0.762 0 C-N-CA 122.711 2.274 . . . . 0.0 111.434 176.352 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 235' ' ' GLU . . . . . 0.445 ' HB3' ' HE2' ' A' ' 237' ' ' LYS . 98.4 mt-10 -126.54 126.79 44.27 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.315 0.578 . . . . 0.0 111.387 -178.7 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 236' ' ' HIS . . . . . 0.523 ' C ' ' HD3' ' A' ' 237' ' ' LYS . 27.8 m80 -139.73 130.3 25.7 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.192 -0.913 . . . . 0.0 109.204 176.358 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 237' ' ' LYS . . . . . 0.621 ' HD3' ' N ' ' A' ' 237' ' ' LYS . 0.1 OUTLIER . . . . . 0 C--N 1.324 -0.54 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.054 -176.126 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 252' ' ' GLN . . . . . 0.556 ' HG3' HD12 ' A' ' 293' ' ' LEU . 40.8 mm-40 . . . . . 0 N--CA 1.454 -0.254 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 253' ' ' GLY . . . . . 0.494 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -97.4 124.08 8.02 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.216 -0.992 . . . . 0.0 111.881 177.553 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 254' ' ' THR . . . . . 0.454 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 76.8 p -115.52 116.13 27.65 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 178.613 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.53 ' N ' HD13 ' A' ' 255' ' ' ILE . 0.2 OUTLIER -135.64 167.13 25.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.628 -175.747 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 86.9 m -92.5 123.34 35.73 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.2 178.964 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.721 ' HA ' HG13 ' A' ' 230' ' ' VAL . 33.1 m -91.0 144.94 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.66 0 N-CA-C 113.029 0.751 . . . . 0.0 113.029 -173.106 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 258' ' ' SER . . . . . 0.575 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 29.1 m -91.07 10.33 27.22 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 114.113 -1.403 . . . . 0.0 108.866 169.915 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 259' ' ' ALA . . . . . 0.544 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -98.02 176.97 5.57 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.181 -0.918 . . . . 0.0 109.926 -175.19 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 37.2 t -143.77 146.6 33.24 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 110.191 -0.3 . . . . 0.0 110.191 179.067 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 70.98 45.31 51.89 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.996 -0.621 . . . . 0.0 112.906 179.143 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 262' ' ' LEU . . . . . 0.509 HD11 ' HB3' ' A' ' 259' ' ' ALA . 64.0 mt -99.47 144.25 28.79 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 177.101 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 84.2 mt-30 -139.88 160.94 38.78 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 110.287 -0.264 . . . . 0.0 110.287 -178.735 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 264' ' ' VAL . . . . . 0.455 HG22 ' HA ' ' A' ' 294' ' ' ALA . 44.0 t -69.36 136.2 26.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.177 177.527 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 96.03 -1.28 62.93 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.561 -0.828 . . . . 0.0 112.94 178.616 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 266' ' ' ASP . . . . . 0.427 ' O ' ' HA ' ' A' ' 291' ' ' ARG . 65.7 m-20 -78.99 164.21 24.58 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.926 0.394 . . . . 0.0 110.537 177.281 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 267' ' ' ALA . . . . . 0.651 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -123.84 154.38 39.71 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.73 -179.183 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 268' ' ' PHE . . . . . 0.786 ' HB3' HD13 ' A' ' 334' ' ' ILE . 9.4 p90 -164.16 171.19 15.37 Favored 'General case' 0 N--CA 1.449 -0.519 0 C-N-CA 120.297 -0.561 . . . . 0.0 112.217 -179.169 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 69.3 p -129.97 126.11 37.01 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 114.86 -1.064 . . . . 0.0 109.329 175.571 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 270' ' ' ILE . . . . . 0.99 HG12 HG13 ' A' ' 332' ' ' ILE . 60.0 mt -96.74 136.09 28.69 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 116.504 -0.316 . . . . 0.0 110.826 -176.554 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -64.96 128.22 34.86 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.873 -176.395 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 100.98 -23.68 34.72 Favored Glycine 0 N--CA 1.452 -0.26 0 CA-C-N 115.64 -0.709 . . . . 0.0 112.653 177.409 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 273' ' ' VAL . . . . . 0.726 HG21 ' HG3' ' A' ' 326' ' ' PRO . 31.8 t -102.99 102.33 13.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 120.898 0.38 . . . . 0.0 111.025 179.784 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 59.8 m-20 -113.95 166.35 11.69 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 174.248 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 275' ' ' SER . . . . . 0.486 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 36.5 p -83.72 179.39 7.6 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 112.314 0.487 . . . . 0.0 112.314 -176.443 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 35.7 m -141.46 159.72 22.05 Favored 'Isoleucine or valine' 0 C--O 1.232 0.174 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.743 -177.163 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 80.9 m-70 -118.13 99.58 6.97 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 173.989 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 10.8 mm100 -73.61 -24.03 59.98 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 111.863 0.32 . . . . 0.0 111.863 -175.206 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 50.7 mm -67.07 -49.27 74.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.764 0.316 . . . . 0.0 111.334 -177.719 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 40.8 p -101.62 -0.14 35.26 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.509 -0.314 . . . . 0.0 111.343 -179.123 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 3.9 tmtp? 60.18 53.6 4.4 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-O 121.903 0.859 . . . . 0.0 109.588 179.725 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 64.8 t0 -117.78 115.91 25.95 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.372 -0.831 . . . . 0.0 109.144 179.08 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 59.2 p -93.96 86.03 4.92 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.918 0.866 . . . . 0.0 111.014 -178.927 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 284' ' ' THR . . . . . 0.418 ' C ' ' H ' ' A' ' 286' ' ' GLN . 40.0 p -148.63 -88.84 0.08 Allowed 'General case' 0 C--N 1.313 -1.015 0 CA-C-N 114.218 -1.356 . . . . 0.0 109.562 179.282 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 285' ' ' GLY . . . . . 0.507 ' O ' ' HB2' ' A' ' 286' ' ' GLN . . . 68.31 -17.33 0.45 Allowed Glycine 0 C--N 1.333 0.411 0 N-CA-C 114.627 0.611 . . . . 0.0 114.627 173.423 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 286' ' ' GLN . . . . . 0.507 ' HB2' ' O ' ' A' ' 285' ' ' GLY . 72.2 mt-30 76.49 164.45 0.13 Allowed Pre-proline 0 C--O 1.235 0.314 0 C-N-CA 123.519 0.728 . . . . 0.0 110.314 -174.671 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 287' ' ' PRO . . . . . 0.424 ' HD2' ' HB3' ' A' ' 286' ' ' GLN . 78.2 Cg_exo -51.65 128.26 25.58 Favored 'Trans proline' 0 C--N 1.351 0.665 0 C-N-CA 122.641 2.228 . . . . 0.0 112.71 -175.902 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 3.8 tm0? -74.38 135.79 42.45 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 -178.029 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 42.5 t -93.83 121.43 44.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.862 0.363 . . . . 0.0 110.896 -175.977 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 290' ' ' PHE . . . . . 0.651 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 3.9 m-85 -98.79 160.04 14.54 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.343 -178.517 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 291' ' ' ARG . . . . . 0.432 ' HD2' ' O ' ' A' ' 290' ' ' PHE . 45.2 mmm-85 -131.29 136.97 48.61 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.122 0.487 . . . . 0.0 110.155 175.66 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 46.3 t -83.67 139.86 17.04 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.223 -177.68 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 293' ' ' LEU . . . . . 0.556 HD12 ' HG3' ' A' ' 252' ' ' GLN . 86.6 mt -111.71 -26.4 9.01 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.69 178.914 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 294' ' ' ALA . . . . . 0.486 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -156.35 139.76 15.79 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 120.718 -0.393 . . . . 0.0 111.624 179.496 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 64.8 t -137.52 109.58 6.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 115.825 -0.625 . . . . 0.0 109.521 173.778 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 47.6 t -151.4 116.37 5.23 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.51 -177.892 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 63.2 44.11 97.58 Favored Glycine 0 C--N 1.331 0.282 0 C-N-CA 120.847 -0.692 . . . . 0.0 111.942 -179.202 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 81.0 p 54.76 16.22 1.34 Allowed 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 123.88 0.872 . . . . 0.0 112.332 -175.401 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 35.8 m -101.07 116.06 31.94 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 174.995 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 300' ' ' VAL . . . . . 0.486 ' HA ' ' O ' ' A' ' 294' ' ' ALA . 71.8 t -114.64 131.59 66.31 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-O 121.09 0.471 . . . . 0.0 111.867 -172.167 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 51.1 m -93.01 115.99 28.64 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.255 -0.884 . . . . 0.0 108.65 174.056 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 302' ' ' ILE . . . . . 0.494 HG12 ' O ' ' A' ' 253' ' ' GLY . 30.4 pt -110.66 139.68 33.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-O 121.722 0.772 . . . . 0.0 112.771 -170.693 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 303' ' ' SER . . . . . 0.607 ' HA ' ' O ' ' A' ' 304' ' ' PRO . 82.5 p -138.41 169.02 13.74 Favored Pre-proline 0 C--N 1.323 -0.547 0 CA-C-N 114.404 -1.271 . . . . 0.0 107.759 177.082 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 304' ' ' PRO . . . . . 0.607 ' O ' ' HA ' ' A' ' 303' ' ' SER . 9.7 Cg_exo -73.01 -133.29 0.09 OUTLIER 'Cis proline' 0 C--N 1.348 0.516 0 CA-C-N 120.776 1.313 . . . . 0.0 112.527 0.251 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 305' ' ' LYS . . . . . 0.909 ' HD3' ' HG ' ' A' ' 307' ' ' LEU . 0.0 OUTLIER -102.07 145.1 29.8 Favored 'General case' 0 N--CA 1.448 -0.574 0 CA-C-O 121.453 0.644 . . . . 0.0 111.333 177.871 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 306' ' ' ILE . . . . . 0.819 HG23 HG21 ' A' ' 322' ' ' VAL . 2.7 mp -113.04 85.46 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.049 -177.076 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 307' ' ' LEU . . . . . 0.909 ' HG ' ' HD3' ' A' ' 305' ' ' LYS . 55.7 mt -96.77 116.5 66.12 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.704 -174.66 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 308' ' ' PRO . . . . . 0.705 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 68.7 Cg_endo -79.75 140.52 14.73 Favored 'Trans proline' 0 C--O 1.235 0.36 0 C-N-CA 122.95 2.433 . . . . 0.0 113.899 -174.191 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 309' ' ' VAL . . . . . 0.537 HG22 ' CB ' ' A' ' 320' ' ' ALA . 15.9 t -93.89 -27.92 4.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.821 174.702 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 62.4 mm-40 -82.21 33.49 0.4 Allowed 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.847 -177.73 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.484 ' OD1' ' HB2' ' A' ' 308' ' ' PRO . 5.5 m120 -126.23 168.95 13.38 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.967 177.955 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 27.3 m -80.64 -18.02 49.42 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.898 -176.427 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 50.7 m-20 -57.19 114.67 2.26 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-O 120.989 0.423 . . . . 0.0 111.387 -179.443 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 38.8 t -74.25 -31.44 29.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.579 -179.694 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -70.06 -30.03 67.18 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.428 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 34.0 t -75.76 -28.9 58.63 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.799 -178.767 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 317' ' ' ARG . . . . . 0.769 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 21.7 mmt85 -51.34 -57.38 14.38 Favored Pre-proline 0 CA--C 1.542 0.672 0 N-CA-C 113.882 1.067 . . . . 0.0 113.882 -176.539 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 318' ' ' PRO . . . . . 0.769 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 22.8 Cg_exo -70.79 -21.49 28.63 Favored 'Trans proline' 0 C--N 1.355 0.893 0 C-N-CA 121.958 1.772 . . . . 0.0 113.522 -173.412 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 319' ' ' TYR . . . . . 0.514 ' O ' HD12 ' A' ' 307' ' ' LEU . 0.9 OUTLIER -108.69 2.78 22.11 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.368 0.604 . . . . 0.0 109.598 -175.855 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 320' ' ' ALA . . . . . 0.677 ' HA ' ' HB2' ' A' ' 307' ' ' LEU . . . -62.36 138.62 58.47 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.318 -178.757 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 321' ' ' ASN . . . . . 0.403 ' O ' ' HA ' ' A' ' 275' ' ' SER . 16.0 p-10 -128.67 -3.46 5.33 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.007 -179.864 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 322' ' ' VAL . . . . . 0.819 HG21 HG23 ' A' ' 306' ' ' ILE . 35.7 m -140.66 166.7 18.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.595 -0.275 . . . . 0.0 110.66 -179.836 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 53.8 m-20 -60.81 -49.23 78.3 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.072 0.463 . . . . 0.0 110.872 179.304 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 324' ' ' ALA . . . . . 0.705 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -157.53 170.65 21.93 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.575 -176.028 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 25.0 pttm -83.1 151.36 63.21 Favored Pre-proline 0 C--N 1.328 -0.359 0 N-CA-C 108.104 -1.072 . . . . 0.0 108.104 170.382 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 326' ' ' PRO . . . . . 0.728 ' HD3' HG21 ' A' ' 306' ' ' ILE . 20.6 Cg_exo -68.02 126.25 14.23 Favored 'Trans proline' 0 N--CA 1.461 -0.405 0 C-N-CA 121.731 1.621 . . . . 0.0 112.886 -174.702 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -83.36 117.3 22.92 Favored 'General case' 0 CA--C 1.511 -0.533 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 167.187 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 328' ' ' GLU . . . . . 0.444 ' OE1' ' HA ' ' A' ' 231' ' ' SER . 31.2 tp10 63.95 168.08 0.16 Allowed 'General case' 0 CA--C 1.539 0.554 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 -165.166 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 329' ' ' SER . . . . . 0.581 ' HB2' ' C ' ' A' ' 230' ' ' VAL . 49.3 m -81.09 -22.19 39.38 Favored 'General case' 0 C--N 1.316 -0.882 0 O-C-N 120.775 -1.203 . . . . 0.0 110.678 -176.948 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 73.5 -160.09 0.09 Allowed 'General case' 0 N--CA 1.473 0.692 0 O-C-N 123.855 0.722 . . . . 0.0 112.872 170.944 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 331' ' ' ALA . . . . . 0.433 ' C ' HD12 ' A' ' 332' ' ' ILE . . . -95.51 129.33 42.72 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.254 -0.885 . . . . 0.0 110.041 179.379 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 332' ' ' ILE . . . . . 0.99 HG13 HG12 ' A' ' 270' ' ' ILE . 1.8 mp -111.16 145.49 17.36 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.442 -175.606 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 47.5 m -118.69 97.65 5.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.021 -178.557 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 334' ' ' ILE . . . . . 0.786 HD13 ' HB3' ' A' ' 268' ' ' PHE . 42.7 mm -80.02 136.46 23.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 N-CA-C 112.959 0.726 . . . . 0.0 112.959 -172.675 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 335' ' ' LEU . . . . . 0.473 HD23 ' N ' ' A' ' 335' ' ' LEU . 1.6 pt? -151.21 -173.82 4.62 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 114.69 -1.141 . . . . 0.0 108.737 172.646 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 76.4 m-20 -111.63 -14.05 13.7 Favored 'General case' 0 C--N 1.325 -0.499 0 O-C-N 122.079 -0.388 . . . . 0.0 111.704 -177.135 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 337' ' ' LYS . . . . . 0.544 ' HB2' ' NZ ' ' A' ' 337' ' ' LYS . 9.8 mtmp? . . . . . 0 C--O 1.244 0.792 0 CA-C-O 118.557 -0.735 . . . . 0.0 110.931 -177.163 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 40.8 p . . . . . 0 C--O 1.232 0.147 0 CA-C-O 120.488 0.185 . . . . 0.0 111.118 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 228' ' ' LEU . . . . . 0.413 ' HB3' ' CB ' ' A' ' 259' ' ' ALA . 83.8 mt -104.46 126.15 51.29 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 174.778 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 229' ' ' THR . . . . . 0.561 HG22 ' HA ' ' A' ' 331' ' ' ALA . 68.4 p -129.35 177.94 6.81 Favored 'General case' 0 C--N 1.32 -0.692 0 C-N-CA 120.06 -0.656 . . . . 0.0 111.147 -177.059 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 230' ' ' VAL . . . . . 0.655 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 64.6 t -140.48 142.57 30.72 Favored 'Isoleucine or valine' 0 C--O 1.238 0.474 0 CA-C-O 120.774 0.321 . . . . 0.0 110.309 -179.427 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 43.3 m -109.33 138.17 46.1 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.481 178.627 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 162.39 -170.15 37.9 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.896 -0.669 . . . . 0.0 111.747 -179.728 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 83.6 mt-30 -99.88 116.26 64.86 Favored Pre-proline 0 C--N 1.325 -0.486 0 CA-C-N 116.716 0.258 . . . . 0.0 110.927 179.45 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -69.17 127.6 15.31 Favored 'Trans proline' 0 C--O 1.236 0.412 0 C-N-CA 122.113 1.876 . . . . 0.0 110.971 175.912 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 235' ' ' GLU . . . . . 0.544 ' O ' ' HB ' ' A' ' 306' ' ' ILE . 0.3 OUTLIER -125.78 -176.92 3.75 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-O 121.661 0.744 . . . . 0.0 111.63 -174.395 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 22.3 p-80 -156.13 133.13 10.54 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 178.964 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 237' ' ' LYS . . . . . 0.788 ' HD3' ' HA ' ' A' ' 305' ' ' LYS . 8.9 mptt . . . . . 0 C--N 1.32 -0.682 0 C-N-CA 119.439 -0.904 . . . . 0.0 111.69 -172.194 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 252' ' ' GLN . . . . . 0.458 ' CG ' ' HE2' ' A' ' 237' ' ' LYS . 21.6 mt-30 . . . . . 0 N--CA 1.471 0.624 0 CA-C-O 121.382 0.61 . . . . 0.0 111.645 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 253' ' ' GLY . . . . . 0.537 ' O ' ' HA ' ' A' ' 301' ' ' THR . . . 126.33 -152.22 18.22 Favored Glycine 0 N--CA 1.446 -0.661 0 C-N-CA 119.141 -1.504 . . . . 0.0 113.401 172.812 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 254' ' ' THR . . . . . 0.478 ' HB ' HG22 ' A' ' 299' ' ' THR . 58.4 p -94.21 135.49 35.53 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.13 0.49 . . . . 0.0 111.621 -174.908 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.448 ' O ' ' HA ' ' A' ' 299' ' ' THR . 2.1 pp -132.39 169.07 22.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 115.446 -0.797 . . . . 0.0 111.223 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 83.8 m -105.15 126.25 51.88 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.015 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.432 HG12 HG13 ' A' ' 230' ' ' VAL . 33.5 m -100.81 145.42 11.21 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.643 0 N-CA-C 112.529 0.566 . . . . 0.0 112.529 -174.839 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 258' ' ' SER . . . . . 0.405 ' HB2' ' OG1' ' A' ' 229' ' ' THR . 52.8 m -91.36 7.26 41.89 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 114.694 -1.139 . . . . 0.0 109.132 167.682 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 259' ' ' ALA . . . . . 0.413 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -95.78 170.09 9.56 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-N 115.492 -0.777 . . . . 0.0 110.13 -177.683 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 51.3 p -137.29 153.29 50.34 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.798 0.333 . . . . 0.0 111.45 -178.708 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 72.37 48.79 22.76 Favored Glycine 0 N--CA 1.452 -0.248 0 CA-C-N 115.929 -0.578 . . . . 0.0 112.847 178.342 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 262' ' ' LEU . . . . . 0.422 HD12 HG21 ' A' ' 257' ' ' VAL . 61.7 mt -102.31 144.28 31.01 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.971 0.415 . . . . 0.0 111.08 -178.873 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 72.1 mt-30 -137.78 172.45 12.94 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.69 -0.687 . . . . 0.0 109.547 176.059 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 264' ' ' VAL . . . . . 0.431 HG22 ' HA ' ' A' ' 294' ' ' ALA . 44.5 t -79.04 136.28 24.07 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 174.909 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 95.67 -0.76 63.26 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.5 -0.857 . . . . 0.0 112.586 179.33 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 65.3 m-20 -65.17 152.26 44.05 Favored 'General case' 0 CA--C 1.517 -0.315 0 CA-C-O 121.11 0.481 . . . . 0.0 110.751 178.343 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 267' ' ' ALA . . . . . 0.707 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -124.14 122.76 38.71 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.353 -0.839 . . . . 0.0 109.415 179.544 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 268' ' ' PHE . . . . . 0.414 ' HB3' ' HA ' ' A' ' 334' ' ' ILE . 5.4 p90 -144.56 169.07 18.68 Favored 'General case' 0 C--N 1.319 -0.741 0 C-N-CA 120.016 -0.673 . . . . 0.0 111.784 -172.816 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 269' ' ' THR . . . . . 0.467 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 42.9 p -119.97 148.81 43.08 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.559 -0.746 . . . . 0.0 109.966 176.615 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 270' ' ' ILE . . . . . 0.586 HG12 HD12 ' A' ' 332' ' ' ILE . 58.5 mt -114.09 138.85 42.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 116.559 -0.291 . . . . 0.0 110.668 -177.226 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -67.99 117.04 9.33 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.948 179.082 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 109.4 -22.49 24.49 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.782 -0.723 . . . . 0.0 111.95 -179.14 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 273' ' ' VAL . . . . . 0.657 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 50.4 t -96.35 101.27 12.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 175.994 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 274' ' ' ASN . . . . . 0.429 ' HA ' ' HA ' ' A' ' 287' ' ' PRO . 72.5 m-80 -124.44 131.79 53.5 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.494 -177.594 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 54.5 p -64.03 163.99 11.35 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.524 0.678 . . . . 0.0 112.508 -176.488 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 276' ' ' VAL . . . . . 0.866 HG11 HG21 ' A' ' 309' ' ' VAL . 21.5 m -126.81 149.94 32.26 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.623 0 CA-C-N 114.901 -1.045 . . . . 0.0 109.276 176.029 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 58.7 m170 -103.53 120.87 41.71 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 120.756 0.312 . . . . 0.0 110.738 -175.191 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 47.5 mm-40 -82.17 -29.2 31.67 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.764 -177.723 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 279' ' ' ILE . . . . . 0.487 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.0 mp -72.12 -52.64 23.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.436 -179.017 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 58.0 p -89.38 -13.06 38.62 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.772 -178.356 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 31.7 mmmt 58.84 45.26 15.64 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.55 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 44.1 t0 -132.8 155.25 49.27 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 110.157 -0.312 . . . . 0.0 110.157 -179.571 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.516 HG22 HG12 ' A' ' 276' ' ' VAL . 59.9 p -107.77 113.38 26.59 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 175.072 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 80.6 p -110.93 6.77 21.38 Favored 'General case' 0 C--N 1.32 -0.699 0 C-N-CA 120.285 -0.566 . . . . 0.0 112.077 -170.318 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 285' ' ' GLY . . . . . 0.4 ' O ' ' HD3' ' A' ' 287' ' ' PRO . . . 66.77 31.6 78.82 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.594 -0.813 . . . . 0.0 113.363 174.414 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 10.6 mm100 -95.89 109.1 44.74 Favored Pre-proline 0 C--N 1.328 -0.338 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 177.817 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 287' ' ' PRO . . . . . 0.467 ' HB2' ' HB ' ' A' ' 269' ' ' THR . 51.5 Cg_exo -58.35 139.34 90.21 Favored 'Trans proline' 0 C--N 1.343 0.288 0 C-N-CA 122.598 2.199 . . . . 0.0 112.888 -176.107 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 40.8 tt0 -77.4 148.37 35.55 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.179 -179.637 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 289' ' ' VAL . . . . . 0.533 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 59.7 t -94.25 137.4 23.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.085 178.063 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 290' ' ' PHE . . . . . 0.707 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 51.7 m-85 -118.34 167.83 11.18 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.758 -176.525 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 37.4 mmt180 -128.66 130.96 47.95 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.77 177.653 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 57.7 t -79.65 139.97 17.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.497 -0.774 . . . . 0.0 111.359 -179.054 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 293' ' ' LEU . . . . . 0.512 ' CD1' ' HB2' ' A' ' 303' ' ' SER . 6.9 mp -102.25 -31.66 10.44 Favored 'General case' 0 C--N 1.334 -0.089 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.844 179.738 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 294' ' ' ALA . . . . . 0.458 ' HB3' ' HB ' ' A' ' 301' ' ' THR . . . -158.55 144.31 16.75 Favored 'General case' 0 N--CA 1.465 0.284 0 C-N-CA 120.664 -0.415 . . . . 0.0 111.763 179.523 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 62.5 t -139.28 112.48 6.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.85 176.085 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 54.2 p -132.67 95.41 3.59 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.368 -0.378 . . . . 0.0 111.114 -178.413 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 65.43 57.78 10.75 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.02 -178.789 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 67.0 p 51.19 22.37 1.31 Allowed 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 123.501 0.72 . . . . 0.0 112.552 -176.174 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 299' ' ' THR . . . . . 0.478 HG22 ' HB ' ' A' ' 254' ' ' THR . 91.7 m -112.29 109.55 19.27 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 174.014 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 300' ' ' VAL . . . . . 0.467 ' O ' ' HA ' ' A' ' 254' ' ' THR . 47.3 t -107.0 134.1 49.69 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-N 115.704 -0.68 . . . . 0.0 112.02 -168.39 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 301' ' ' THR . . . . . 0.537 ' HA ' ' O ' ' A' ' 253' ' ' GLY . 91.5 m -85.22 114.92 22.68 Favored 'General case' 0 C--O 1.237 0.403 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 169.746 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 302' ' ' ILE . . . . . 0.418 HD13 HG12 ' A' ' 255' ' ' ILE . 30.6 pt -110.7 138.6 38.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 N-CA-C 113.655 0.983 . . . . 0.0 113.655 -167.805 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 303' ' ' SER . . . . . 0.572 ' HB3' ' HA ' ' A' ' 304' ' ' PRO . 68.7 m -153.87 169.39 10.01 Favored Pre-proline 0 C--N 1.323 -0.557 0 CA-C-N 112.859 -1.973 . . . . 0.0 105.89 175.047 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 304' ' ' PRO . . . . . 0.572 ' HA ' ' HB3' ' A' ' 303' ' ' SER . 22.7 Cg_endo -93.38 -119.83 0.0 OUTLIER 'Cis proline' 0 N--CA 1.455 -0.742 0 CA-C-N 121.02 1.4 . . . . 0.0 113.592 0.822 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 305' ' ' LYS . . . . . 0.788 ' HA ' ' HD3' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -98.41 144.29 27.94 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.081 -0.509 . . . . 0.0 112.357 -172.324 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 306' ' ' ILE . . . . . 0.544 ' HB ' ' O ' ' A' ' 235' ' ' GLU . 2.2 mp -104.4 127.35 58.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 170.699 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 307' ' ' LEU . . . . . 0.544 HD13 ' O ' ' A' ' 319' ' ' TYR . 59.0 mt -129.09 98.28 24.17 Favored Pre-proline 0 C--N 1.323 -0.548 0 C-N-CA 120.676 -0.41 . . . . 0.0 110.519 -172.779 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 308' ' ' PRO . . . . . 0.545 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 12.7 Cg_exo -74.17 131.34 15.21 Favored 'Trans proline' 0 C--N 1.343 0.252 0 C-N-CA 122.802 2.335 . . . . 0.0 113.495 -175.19 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 309' ' ' VAL . . . . . 0.866 HG21 HG11 ' A' ' 276' ' ' VAL . 61.9 t -87.05 -37.57 11.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.563 173.897 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 63.1 mm-40 -81.08 32.69 0.33 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.859 -0.609 . . . . 0.0 111.484 179.814 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.433 HD22 ' N ' ' A' ' 317' ' ' ARG . 43.3 p-10 -85.38 157.05 20.62 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.945 0.403 . . . . 0.0 111.248 179.16 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 36.4 m -92.15 -18.28 23.73 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.839 178.244 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -76.42 121.49 23.13 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.612 -179.746 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 40.7 t -75.76 -20.19 15.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.129 -177.457 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -80.59 -21.96 41.14 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.739 0.304 . . . . 0.0 111.512 178.582 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 36.0 t -96.3 -23.3 16.73 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.559 -0.291 . . . . 0.0 111.456 -176.138 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 317' ' ' ARG . . . . . 0.433 ' N ' HD22 ' A' ' 311' ' ' ASN . 2.1 ptp180 -62.23 -34.03 14.07 Favored Pre-proline 0 CA--C 1.548 0.901 0 N-CA-C 113.807 1.04 . . . . 0.0 113.807 -178.886 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 318' ' ' PRO . . . . . 0.415 ' CD ' ' N ' ' A' ' 317' ' ' ARG . 26.1 Cg_exo -63.13 -18.14 63.57 Favored 'Trans proline' 0 C--N 1.367 1.521 0 CA-C-N 121.263 1.487 . . . . 0.0 112.113 178.266 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 319' ' ' TYR . . . . . 0.544 ' O ' HD13 ' A' ' 307' ' ' LEU . 48.5 m-85 -103.35 -3.2 25.87 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.028 -177.803 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 320' ' ' ALA . . . . . 0.723 ' HB1' HG22 ' A' ' 309' ' ' VAL . . . -54.06 144.77 18.49 Favored 'General case' 0 C--N 1.33 -0.246 0 N-CA-C 112.144 0.424 . . . . 0.0 112.144 -178.128 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 321' ' ' ASN . . . . . 0.479 ' O ' HG22 ' A' ' 276' ' ' VAL . 48.9 t30 -148.05 -18.61 0.35 Allowed 'General case' 0 CA--C 1.532 0.278 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.472 -178.281 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 322' ' ' VAL . . . . . 0.532 ' O ' HG23 ' A' ' 309' ' ' VAL . 35.1 m -137.43 160.96 34.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 N-CA-C 110.234 -0.284 . . . . 0.0 110.234 177.654 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 71.8 m-20 -41.9 -69.24 0.14 Allowed 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 112.588 0.588 . . . . 0.0 112.588 -177.364 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 324' ' ' ALA . . . . . 0.545 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -165.7 -176.08 3.74 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.962 0.411 . . . . 0.0 111.496 -175.595 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 325' ' ' LYS . . . . . 0.454 ' HG3' ' HG3' ' A' ' 308' ' ' PRO . 34.4 mtmm -88.02 138.97 30.71 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.592 174.362 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 326' ' ' PRO . . . . . 0.706 ' HB2' ' HB2' ' A' ' 330' ' ' ALA . 43.1 Cg_endo -86.01 167.34 9.57 Favored 'Trans proline' 0 N--CA 1.455 -0.759 0 C-N-CA 122.551 2.167 . . . . 0.0 112.145 178.61 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -70.47 122.98 20.69 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 177.83 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 52.8 mt-10 62.39 -121.04 0.66 Allowed 'General case' 0 N--CA 1.463 0.184 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 -172.328 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 329' ' ' SER . . . . . 0.655 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 33.9 m -111.94 -14.25 13.52 Favored 'General case' 0 C--N 1.322 -0.603 0 C-N-CA 120.535 -0.466 . . . . 0.0 110.118 172.813 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 330' ' ' ALA . . . . . 0.706 ' HB2' ' HB2' ' A' ' 326' ' ' PRO . . . 73.9 -169.19 0.11 Allowed 'General case' 0 N--CA 1.474 0.755 0 O-C-N 124.214 0.946 . . . . 0.0 113.37 172.467 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 331' ' ' ALA . . . . . 0.561 ' HA ' HG22 ' A' ' 229' ' ' THR . . . -80.08 141.54 35.72 Favored 'General case' 0 CA--C 1.517 -0.304 0 CA-C-N 115.101 -0.954 . . . . 0.0 110.611 -179.065 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 332' ' ' ILE . . . . . 0.586 HD12 HG12 ' A' ' 270' ' ' ILE . 16.1 mm -120.68 144.11 30.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.405 -175.503 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 82.3 m -114.04 97.13 6.18 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 175.007 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 334' ' ' ILE . . . . . 0.414 ' HA ' ' HB3' ' A' ' 268' ' ' PHE . 38.5 mm -81.65 125.34 39.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 115.999 -0.546 . . . . 0.0 112.339 -172.045 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 335' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -122.73 163.22 20.56 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.187 170.971 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 20.9 t-20 -94.04 -14.74 25.5 Favored 'General case' 0 C--N 1.319 -0.76 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 171.659 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 337' ' ' LYS . . . . . 0.65 ' HB2' ' HB3' ' A' ' 267' ' ' ALA . 26.7 tptp . . . . . 0 C--O 1.244 0.799 0 CA-C-N 114.613 -1.176 . . . . 0.0 111.257 174.431 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 26.5 m . . . . . 0 N--CA 1.442 -0.858 0 CA-C-O 121.314 0.578 . . . . 0.0 110.959 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 228' ' ' LEU . . . . . 0.488 ' HB3' ' HA ' ' A' ' 259' ' ' ALA . 55.2 mt -94.08 129.55 40.57 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.598 -178.6 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 229' ' ' THR . . . . . 0.456 ' HA ' ' HA ' ' A' ' 331' ' ' ALA . 60.6 p -126.97 179.53 5.36 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 120.275 -0.57 . . . . 0.0 111.281 -176.18 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 230' ' ' VAL . . . . . 0.756 HG11 HD12 ' A' ' 255' ' ' ILE . 75.3 t -146.39 138.8 19.79 Favored 'Isoleucine or valine' 0 C--O 1.237 0.409 0 CA-C-O 120.735 0.302 . . . . 0.0 110.708 -179.359 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 231' ' ' SER . . . . . 0.425 ' O ' ' HB ' ' A' ' 256' ' ' THR . 49.4 m -137.99 165.37 26.73 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.746 178.686 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 116.12 -108.84 1.89 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 119.913 -1.137 . . . . 0.0 113.995 172.041 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 11.0 mm-40 -62.49 155.36 68.43 Favored Pre-proline 0 C--N 1.328 -0.354 0 N-CA-C 112.761 0.652 . . . . 0.0 112.761 -173.225 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -63.9 175.56 2.98 Favored 'Trans proline' 0 C--N 1.349 0.573 0 C-N-CA 123.611 2.874 . . . . 0.0 112.661 178.161 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 235' ' ' GLU . . . . . 0.425 ' CB ' ' HD2' ' A' ' 325' ' ' LYS . 52.1 mm-40 -92.51 -176.79 4.4 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.695 -176.02 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 37.9 m-70 -113.82 143.75 44.14 Favored 'General case' 0 C--N 1.321 -0.658 0 C-N-CA 119.842 -0.743 . . . . 0.0 112.199 -165.33 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 237' ' ' LYS . . . . . 0.616 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.325 -0.484 0 CA-C-N 115.338 -0.847 . . . . 0.0 109.892 -176.11 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 252' ' ' GLN . . . . . 0.403 ' HA ' HE21 ' A' ' 252' ' ' GLN . 2.6 mm100 . . . . . 0 N--CA 1.467 0.381 0 CA-C-O 120.897 0.38 . . . . 0.0 111.055 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 253' ' ' GLY . . . . . 0.556 ' O ' ' HA ' ' A' ' 301' ' ' THR . . . 119.05 -153.11 17.03 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 119.25 -1.453 . . . . 0.0 113.752 176.435 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 254' ' ' THR . . . . . 0.562 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 77.8 p -94.78 148.97 21.74 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.219 0.533 . . . . 0.0 112.243 -172.644 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.756 HD12 HG11 ' A' ' 230' ' ' VAL . 22.6 pt -130.65 161.26 40.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.395 -0.82 . . . . 0.0 110.416 177.71 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 256' ' ' THR . . . . . 0.425 ' HB ' ' O ' ' A' ' 231' ' ' SER . 93.6 m -94.76 106.19 18.16 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 174.533 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.42 HG12 HG22 ' A' ' 230' ' ' VAL . 34.3 m -93.21 141.46 14.68 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.914 0 C-N-CA 119.565 -0.854 . . . . 0.0 112.329 -174.693 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 53.8 m -93.0 8.91 37.96 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 114.016 -1.447 . . . . 0.0 109.239 169.684 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 259' ' ' ALA . . . . . 0.76 ' HB3' HD11 ' A' ' 262' ' ' LEU . . . -81.17 166.37 20.7 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.861 -177.641 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 42.6 m -124.93 108.26 11.7 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 111.988 0.366 . . . . 0.0 111.988 -174.97 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 92.71 50.14 2.57 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.617 -0.801 . . . . 0.0 113.429 173.316 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 262' ' ' LEU . . . . . 0.76 HD11 ' HB3' ' A' ' 259' ' ' ALA . 3.2 mp -86.94 143.59 27.32 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.891 0.346 . . . . 0.0 110.319 179.563 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 68.6 mt-30 -131.12 168.84 16.77 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.605 177.876 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 38.6 t -79.22 128.49 38.5 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 C-N-CA 120.8 -0.36 . . . . 0.0 110.338 178.184 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 265' ' ' GLY . . . . . 0.593 ' H ' ' HB ' ' A' ' 292' ' ' VAL . . . 102.41 8.67 43.2 Favored Glycine 0 N--CA 1.448 -0.532 0 C-N-CA 120.393 -0.908 . . . . 0.0 113.017 177.605 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -76.94 160.93 28.79 Favored 'General case' 0 CA--C 1.515 -0.373 0 CA-C-O 121.047 0.451 . . . . 0.0 110.579 176.424 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 267' ' ' ALA . . . . . 0.647 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -131.68 131.88 43.48 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 177.851 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 268' ' ' PHE . . . . . . . . . . . . . 3.6 p90 -152.33 169.31 22.83 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 119.468 -0.893 . . . . 0.0 111.76 -172.787 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 269' ' ' THR . . . . . 0.739 HG21 ' HB2' ' A' ' 287' ' ' PRO . 71.1 p -119.61 163.05 17.93 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.235 177.477 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 270' ' ' ILE . . . . . 0.593 HG12 HG12 ' A' ' 332' ' ' ILE . 56.7 mt -124.24 140.46 47.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 C-N-CA 120.815 -0.354 . . . . 0.0 111.432 -178.257 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -62.5 113.17 2.8 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.131 179.655 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 103.51 -21.68 38.31 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 121.083 -0.579 . . . . 0.0 112.031 -178.106 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 273' ' ' VAL . . . . . 0.604 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 51.1 t -101.1 103.77 15.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-O 121.089 0.471 . . . . 0.0 110.77 178.87 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 71.9 m-80 -122.67 156.35 34.52 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.165 -0.471 . . . . 0.0 109.967 179.234 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 53.8 p -71.95 173.83 7.83 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.14 0.495 . . . . 0.0 111.819 -175.842 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 27.1 m -112.02 -178.45 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.674 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 9.9 m-70 -54.51 93.26 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.023 -0.99 . . . . 0.0 110.965 -173.932 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 19.2 tm0? -81.99 -28.2 32.75 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.981 0.42 . . . . 0.0 109.878 -175.968 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 279' ' ' ILE . . . . . 0.56 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.6 mp -82.18 -104.31 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.405 0 CA-C-N 116.083 -0.508 . . . . 0.0 109.817 -179.028 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 41.0 p -128.94 76.07 1.69 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.633 0.254 . . . . 0.0 110.676 179.173 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 34.4 mmtp 54.64 31.5 15.32 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.437 -174.559 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 36.3 t70 -87.32 138.44 31.48 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.647 -176.712 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 54.4 p -95.5 120.33 35.57 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.126 -178.593 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 81.5 p -128.93 -45.43 1.28 Allowed 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.276 -171.992 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 79.62 28.01 52.76 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.701 -0.761 . . . . 0.0 111.967 -178.58 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 85.3 mt-30 -76.05 134.62 71.05 Favored Pre-proline 0 C--N 1.328 -0.366 0 N-CA-C 110.214 -0.291 . . . . 0.0 110.214 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 287' ' ' PRO . . . . . 0.739 ' HB2' HG21 ' A' ' 269' ' ' THR . 26.3 Cg_exo -64.67 134.19 39.85 Favored 'Trans proline' 0 CA--C 1.53 0.308 0 C-N-CA 122.546 2.164 . . . . 0.0 112.098 -177.9 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 69.7 tp60 -76.65 129.14 35.97 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.578 -178.503 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 289' ' ' VAL . . . . . 0.486 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 25.7 t -97.01 137.61 24.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.831 -178.357 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 290' ' ' PHE . . . . . 0.669 ' HD1' ' HD2' ' A' ' 304' ' ' PRO . 55.0 m-85 -115.58 169.43 9.19 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.046 -178.836 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 9.8 tpt180 -131.06 142.56 50.3 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.167 0.508 . . . . 0.0 110.047 -179.154 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 292' ' ' VAL . . . . . 0.593 ' HB ' ' H ' ' A' ' 265' ' ' GLY . 55.8 t -92.49 130.57 41.4 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.877 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.683 179.693 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 293' ' ' LEU . . . . . 0.564 HD21 ' HB2' ' A' ' 303' ' ' SER . 2.9 mm? -105.71 -24.34 12.54 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.448 -0.342 . . . . 0.0 111.402 -178.355 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 294' ' ' ALA . . . . . . . . . . . . . . . -164.24 145.39 8.43 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.465 0.174 . . . . 0.0 110.982 179.688 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 295' ' ' VAL . . . . . 0.581 HG13 HG22 ' A' ' 300' ' ' VAL . 45.5 t -135.07 138.28 49.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 175.575 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 36.9 t -139.44 87.31 2.18 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 177.922 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 73.41 -128.22 11.31 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.118 -1.039 . . . . 0.0 110.544 -169.483 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 298' ' ' THR . . . . . 0.401 ' O ' HG22 ' A' ' 257' ' ' VAL . 31.1 p -102.35 29.34 5.25 Favored 'General case' 0 C--N 1.315 -0.898 0 O-C-N 122.155 -0.615 . . . . 0.0 110.506 172.63 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 63.5 m -112.07 105.42 13.79 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 174.033 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 300' ' ' VAL . . . . . 0.707 HG21 HD22 ' A' ' 262' ' ' LEU . 44.3 t -114.24 130.46 68.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 N-CA-C 112.259 0.466 . . . . 0.0 112.259 -168.797 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 301' ' ' THR . . . . . 0.556 ' HA ' ' O ' ' A' ' 253' ' ' GLY . 51.4 m -84.46 113.63 21.34 Favored 'General case' 0 C--O 1.237 0.402 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.219 173.342 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 302' ' ' ILE . . . . . 0.754 HD13 HD13 ' A' ' 255' ' ' ILE . 38.9 pt -116.39 157.13 17.4 Favored 'Isoleucine or valine' 0 C--O 1.24 0.599 0 CA-C-O 121.85 0.833 . . . . 0.0 112.897 -174.602 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 303' ' ' SER . . . . . 0.564 ' HB2' HD21 ' A' ' 293' ' ' LEU . 48.8 m -159.64 163.21 23.58 Favored Pre-proline 0 C--N 1.326 -0.435 0 CA-C-N 113.381 -1.736 . . . . 0.0 106.522 175.012 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 304' ' ' PRO . . . . . 0.669 ' HD2' ' HD1' ' A' ' 290' ' ' PHE . 5.1 Cg_exo -78.63 -134.23 0.14 OUTLIER 'Cis proline' 0 CA--C 1.534 0.518 0 CA-C-N 120.504 1.216 . . . . 0.0 113.047 0.85 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 305' ' ' LYS . . . . . 0.467 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -113.16 156.42 23.25 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.333 0.587 . . . . 0.0 112.375 -176.841 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 306' ' ' ILE . . . . . 0.86 HG23 HG21 ' A' ' 322' ' ' VAL . 2.6 mp -104.34 98.53 6.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.25 -0.886 . . . . 0.0 109.491 179.168 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 307' ' ' LEU . . . . . . . . . . . . . 76.3 mt -107.52 100.19 32.83 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.517 -0.31 . . . . 0.0 111.188 -175.007 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 308' ' ' PRO . . . . . 0.74 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 32.4 Cg_exo -66.94 138.22 47.42 Favored 'Trans proline' 0 N--CA 1.474 0.346 0 C-N-CA 123.622 2.881 . . . . 0.0 114.588 -173.757 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 309' ' ' VAL . . . . . 0.717 HG22 ' HB1' ' A' ' 320' ' ' ALA . 50.8 t -76.74 -29.9 18.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.051 -0.977 . . . . 0.0 108.771 167.772 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -79.2 30.03 0.22 Allowed 'General case' 0 C--O 1.234 0.289 0 CA-C-N 115.292 -0.867 . . . . 0.0 112.045 179.437 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 74.3 m-80 71.05 154.69 0.14 Allowed 'General case' 0 N--CA 1.469 0.481 0 N-CA-C 113.647 0.98 . . . . 0.0 113.647 173.692 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 312' ' ' THR . . . . . 0.526 ' OG1' ' HG2' ' A' ' 308' ' ' PRO . 44.4 m -168.18 -44.09 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 113.675 -1.602 . . . . 0.0 107.824 173.169 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 39.2 t70 -146.52 167.86 22.64 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 114.246 -1.343 . . . . 0.0 108.59 176.339 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 47.2 t -60.34 -38.26 77.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-O 120.787 0.327 . . . . 0.0 111.104 178.381 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -77.38 -17.83 57.86 Favored 'General case' 0 N--CA 1.463 0.212 0 N-CA-C 111.967 0.358 . . . . 0.0 111.967 -179.844 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 34.7 t -71.51 -25.02 62.08 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.579 -0.282 . . . . 0.0 111.447 -176.765 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 317' ' ' ARG . . . . . 0.768 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 54.2 mtp85 -69.71 -57.96 6.09 Favored Pre-proline 0 CA--C 1.536 0.426 0 N-CA-C 112.257 0.466 . . . . 0.0 112.257 -178.691 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 318' ' ' PRO . . . . . 0.768 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 36.8 Cg_exo -63.69 -35.23 59.27 Favored 'Trans proline' 0 C--N 1.357 0.975 0 C-N-CA 122.051 1.834 . . . . 0.0 112.684 -176.779 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 6.4 m-85 -99.43 32.11 2.9 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.022 -179.23 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 320' ' ' ALA . . . . . 0.717 ' HB1' HG22 ' A' ' 309' ' ' VAL . . . -55.55 127.68 30.92 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.893 178.945 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 47.9 t30 -120.99 -28.25 4.82 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.185 -176.654 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 322' ' ' VAL . . . . . 0.86 HG21 HG23 ' A' ' 306' ' ' ILE . 27.2 m -135.42 168.51 22.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.582 -0.281 . . . . 0.0 110.624 179.223 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 65.6 m-20 -52.83 -59.98 3.83 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 121.015 0.436 . . . . 0.0 110.769 176.981 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 324' ' ' ALA . . . . . 0.74 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -171.79 171.94 5.04 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.427 179.668 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 325' ' ' LYS . . . . . 0.489 ' HB3' ' CG2' ' A' ' 306' ' ' ILE . 21.7 pttp -112.46 117.95 46.27 Favored Pre-proline 0 C--N 1.326 -0.444 0 CA-C-O 121.251 0.548 . . . . 0.0 110.145 172.807 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -72.21 169.33 21.78 Favored 'Trans proline' 0 C--N 1.34 0.103 0 C-N-CA 123.284 2.656 . . . . 0.0 111.884 -177.408 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -63.42 122.27 15.83 Favored 'General case' 0 C--O 1.236 0.372 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 177.607 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 56.0 mt-10 67.79 165.33 0.23 Allowed 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.327 -171.519 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 329' ' ' SER . . . . . 0.681 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 49.0 m -66.65 -14.78 62.89 Favored 'General case' 0 C--N 1.326 -0.423 0 C-N-CA 120.999 -0.28 . . . . 0.0 111.746 -175.673 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 68.17 -162.36 0.2 Allowed 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 113.261 0.837 . . . . 0.0 113.261 171.097 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 331' ' ' ALA . . . . . 0.456 ' HA ' ' HA ' ' A' ' 229' ' ' THR . . . -82.98 150.49 26.35 Favored 'General case' 0 CA--C 1.519 -0.249 0 CA-C-N 115.333 -0.849 . . . . 0.0 111.122 -177.001 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 332' ' ' ILE . . . . . 0.593 HG12 HG12 ' A' ' 270' ' ' ILE . 42.6 mt -122.91 145.23 30.09 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.054 -178.559 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 333' ' ' THR . . . . . 0.425 ' HB ' ' OG1' ' A' ' 269' ' ' THR . 31.9 m -111.53 106.77 15.73 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 175.238 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 34.9 mm -83.78 121.67 36.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 112.889 0.7 . . . . 0.0 112.889 -170.203 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 335' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -111.62 -168.57 1.33 Allowed 'General case' 0 C--O 1.236 0.394 0 CA-C-N 115.094 -0.957 . . . . 0.0 109.672 171.491 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 74.4 m-80 -116.78 -15.1 10.74 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.806 -0.633 . . . . 0.0 110.989 176.557 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 23.2 pttm . . . . . 0 C--O 1.244 0.779 0 CA-C-O 118.546 -0.74 . . . . 0.0 111.288 -177.619 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 41.1 m . . . . . 0 C--O 1.234 0.264 0 CA-C-O 120.919 0.39 . . . . 0.0 111.525 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 228' ' ' LEU . . . . . 0.442 ' HB3' ' HB2' ' A' ' 259' ' ' ALA . 69.7 mt -89.3 125.12 34.98 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 109.711 -0.478 . . . . 0.0 109.711 177.658 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 58.4 p -124.27 175.35 7.12 Favored 'General case' 0 C--N 1.323 -0.573 0 C-N-CA 119.891 -0.724 . . . . 0.0 110.32 179.12 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 230' ' ' VAL . . . . . 0.669 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 89.0 t -148.63 141.82 18.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-O 120.76 0.314 . . . . 0.0 110.654 -177.614 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 49.0 m -92.38 129.13 38.41 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.905 -0.589 . . . . 0.0 109.619 174.142 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . -86.5 118.52 4.91 Favored Glycine 0 N--CA 1.444 -0.829 0 C-N-CA 120.264 -0.97 . . . . 0.0 113.322 -175.622 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 233' ' ' GLN . . . . . 0.941 ' HB3' ' HD2' ' A' ' 234' ' ' PRO . 34.9 mt-30 -80.2 178.97 2.05 Favored Pre-proline 0 C--N 1.328 -0.358 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 169.641 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 234' ' ' PRO . . . . . 0.941 ' HD2' ' HB3' ' A' ' 233' ' ' GLN . 72.9 Cg_exo -32.22 127.53 0.1 OUTLIER 'Trans proline' 0 C--N 1.366 1.463 0 C-N-CA 123.633 2.888 . . . . 0.0 113.861 -176.782 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 235' ' ' GLU . . . . . 0.701 ' OE1' ' HE3' ' A' ' 325' ' ' LYS . 46.1 mt-10 -95.58 -178.78 4.52 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.589 -175.727 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 236' ' ' HIS . . . . . 0.591 ' C ' ' HD3' ' A' ' 237' ' ' LYS . 91.7 m-70 -135.68 143.55 45.5 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 122.559 1.171 . . . . 0.0 113.549 -166.309 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 237' ' ' LYS . . . . . 0.591 ' HD3' ' C ' ' A' ' 236' ' ' HIS . 0.0 OUTLIER . . . . . 0 C--N 1.314 -0.942 0 CA-C-N 112.531 -2.122 . . . . 0.0 107.729 -179.71 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 40.7 mm-40 . . . . . 0 N--CA 1.454 -0.231 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 253' ' ' GLY . . . . . 0.515 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -105.81 122.25 7.06 Favored Glycine 0 N--CA 1.443 -0.883 0 C-N-CA 120.282 -0.961 . . . . 0.0 112.088 177.437 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 254' ' ' THR . . . . . 0.504 ' O ' ' HB2' ' A' ' 233' ' ' GLN . 48.3 p -106.33 116.79 32.54 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 109.16 -0.682 . . . . 0.0 109.16 176.439 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.725 HG22 ' H ' ' A' ' 233' ' ' GLN . 2.1 pp -125.49 165.63 22.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 N-CA-C 112.868 0.692 . . . . 0.0 112.868 -173.074 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 25.7 m -105.98 117.51 34.23 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 178.649 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.508 ' HA ' HG13 ' A' ' 230' ' ' VAL . 33.7 m -90.22 143.0 12.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 C-N-CA 119.71 -0.796 . . . . 0.0 112.757 -171.932 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 258' ' ' SER . . . . . 0.502 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 37.0 m -92.35 9.83 32.41 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 114.076 -1.42 . . . . 0.0 108.791 168.519 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 259' ' ' ALA . . . . . 0.442 ' HB2' ' HB3' ' A' ' 228' ' ' LEU . . . -101.1 168.3 9.68 Favored 'General case' 0 N--CA 1.454 -0.268 0 CA-C-N 115.049 -0.978 . . . . 0.0 109.371 -176.842 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 49.5 m -132.86 163.18 29.69 Favored 'General case' 0 C--N 1.324 -0.529 0 C-N-CA 120.806 -0.358 . . . . 0.0 111.502 -178.487 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 64.29 50.11 61.89 Favored Glycine 0 N--CA 1.452 -0.247 0 CA-C-N 115.729 -0.669 . . . . 0.0 113.128 177.047 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 262' ' ' LEU . . . . . . . . . . . . . 53.4 mt -101.76 159.68 15.12 Favored 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 120.652 -0.419 . . . . 0.0 110.543 179.73 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 73.4 mt-30 -143.35 165.14 28.33 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.988 -0.551 . . . . 0.0 109.812 179.744 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 41.2 t -79.86 134.47 27.49 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 N-CA-C 109.411 -0.588 . . . . 0.0 109.411 173.621 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 265' ' ' GLY . . . . . 0.512 ' H ' ' HB ' ' A' ' 292' ' ' VAL . . . 95.47 15.81 42.36 Favored Glycine 0 N--CA 1.446 -0.656 0 C-N-CA 120.284 -0.96 . . . . 0.0 112.729 178.918 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 40.7 m-20 -87.82 165.78 15.06 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.956 0.407 . . . . 0.0 110.689 174.784 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 267' ' ' ALA . . . . . 0.737 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -135.8 123.28 22.08 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.541 -0.754 . . . . 0.0 109.503 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 268' ' ' PHE . . . . . 0.42 ' HB2' ' O ' ' A' ' 333' ' ' THR . 5.9 p90 -141.16 175.03 9.97 Favored 'General case' 0 C--N 1.32 -0.704 0 C-N-CA 120.123 -0.631 . . . . 0.0 111.497 -172.554 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 64.3 p -118.32 154.22 32.7 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.748 176.542 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 270' ' ' ILE . . . . . 0.924 HG12 HG13 ' A' ' 332' ' ' ILE . 60.1 mt -124.58 141.28 45.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 120.761 0.315 . . . . 0.0 110.78 -178.068 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -76.03 125.49 29.22 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.903 178.472 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 96.58 -21.83 43.54 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.087 -178.749 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 273' ' ' VAL . . . . . 0.451 HG23 ' HG3' ' A' ' 326' ' ' PRO . 48.5 t -100.42 103.25 14.54 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 121.059 0.457 . . . . 0.0 110.054 176.976 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 274' ' ' ASN . . . . . 0.519 ' O ' ' HB ' ' A' ' 322' ' ' VAL . 70.8 m-80 -121.01 137.84 54.45 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 -179.756 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 275' ' ' SER . . . . . 0.666 ' HB3' ' HB2' ' A' ' 288' ' ' GLN . 60.3 p -73.01 174.48 7.8 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.006 0.431 . . . . 0.0 111.511 -175.124 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 276' ' ' VAL . . . . . 0.538 HG11 HG21 ' A' ' 309' ' ' VAL . 33.3 m -110.05 178.69 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.284 -179.421 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 277' ' ' HIS . . . . . 0.78 ' HB2' ' HA ' ' A' ' 281' ' ' LYS . 7.7 p80 -36.84 88.73 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.675 0 O-C-N 124.561 1.163 . . . . 0.0 113.985 -177.271 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 39.7 tt0 -84.64 -36.46 21.96 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.518 -178.173 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 279' ' ' ILE . . . . . 0.782 HG22 HG23 ' A' ' 280' ' ' THR . 2.6 mp -80.94 -84.33 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.305 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.398 -172.788 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 280' ' ' THR . . . . . 0.782 HG23 HG22 ' A' ' 279' ' ' ILE . 32.6 p -127.69 45.79 2.67 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 111.597 0.221 . . . . 0.0 111.597 -174.686 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 281' ' ' LYS . . . . . 0.78 ' HA ' ' HB2' ' A' ' 277' ' ' HIS . 3.3 tmtp? 56.68 46.3 20.43 Favored 'General case' 0 CA--C 1.533 0.312 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 -176.792 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 49.2 p-10 -104.75 -162.01 0.86 Allowed 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 114.79 -1.095 . . . . 0.0 110.885 -175.085 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 76.1 p -105.97 124.45 49.59 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 178.749 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 81.2 p -127.28 -75.86 0.57 Allowed 'General case' 0 C--N 1.321 -0.643 0 C-N-CA 120.429 -0.508 . . . . 0.0 111.159 -174.26 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 67.09 31.24 77.22 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.898 -0.668 . . . . 0.0 112.002 -179.306 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 95.2 mm-40 -105.35 145.27 30.47 Favored Pre-proline 0 C--N 1.329 -0.311 0 N-CA-C 110.467 -0.197 . . . . 0.0 110.467 -178.142 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 287' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -55.22 137.5 77.06 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.805 2.336 . . . . 0.0 112.267 -179.813 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 288' ' ' GLN . . . . . 0.666 ' HB2' ' HB3' ' A' ' 275' ' ' SER . 52.0 tt0 -88.37 155.48 19.67 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.895 -176.992 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 59.0 t -89.84 113.34 25.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.349 178.638 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 290' ' ' PHE . . . . . 0.737 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 54.1 m-85 -100.52 131.12 46.6 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.46 -177.331 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 9.8 tpt180 -106.87 120.53 42.29 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.535 0.683 . . . . 0.0 109.877 178.368 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 292' ' ' VAL . . . . . 0.512 ' HB ' ' H ' ' A' ' 265' ' ' GLY . 57.6 t -67.66 140.01 19.94 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.954 0 CA-C-N 114.656 -1.157 . . . . 0.0 112.531 -176.198 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 293' ' ' LEU . . . . . 0.571 HD11 ' OG ' ' A' ' 303' ' ' SER . 4.4 mp -104.69 -30.94 9.62 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.739 175.534 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 294' ' ' ALA . . . . . 0.46 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -159.71 144.8 15.37 Favored 'General case' 0 C--N 1.333 -0.126 0 CA-C-O 120.534 0.207 . . . . 0.0 111.532 -176.358 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 70.7 t -138.09 100.23 1.68 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 175.589 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 35.8 m -138.49 113.5 9.27 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.439 -0.346 . . . . 0.0 111.085 -175.457 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 63.17 48.49 79.22 Favored Glycine 0 C--N 1.331 0.252 0 C-N-CA 120.834 -0.698 . . . . 0.0 111.922 -178.716 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 71.3 p 51.08 24.33 1.87 Allowed 'General case' 0 N--CA 1.469 0.5 0 C-N-CA 123.77 0.828 . . . . 0.0 112.229 -174.742 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 299' ' ' THR . . . . . 0.49 ' HA ' ' O ' ' A' ' 255' ' ' ILE . 29.0 m -111.48 111.18 22.02 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 176.304 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 300' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 294' ' ' ALA . 44.7 t -111.02 129.08 66.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.587 -172.445 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 93.5 m -90.97 116.08 28.49 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 172.298 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 302' ' ' ILE . . . . . 0.515 HG12 ' O ' ' A' ' 253' ' ' GLY . 29.2 pt -113.26 142.8 24.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 N-CA-C 112.917 0.71 . . . . 0.0 112.917 -171.57 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 303' ' ' SER . . . . . 0.571 ' OG ' HD11 ' A' ' 293' ' ' LEU . 89.5 p -137.71 142.13 35.56 Favored Pre-proline 0 C--N 1.322 -0.599 0 N-CA-C 106.95 -1.5 . . . . 0.0 106.95 169.906 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 304' ' ' PRO . . . . . 0.511 ' HD2' ' HD1' ' A' ' 290' ' ' PHE . 25.2 Cg_exo -66.83 -179.48 13.45 Favored 'Cis proline' 0 C--N 1.331 -0.377 0 CA-C-N 119.913 1.005 . . . . 0.0 112.88 0.868 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 305' ' ' LYS . . . . . 0.563 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -112.87 145.93 39.8 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-O 121.102 0.477 . . . . 0.0 111.543 -179.259 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 306' ' ' ILE . . . . . 0.519 HD12 ' N ' ' A' ' 306' ' ' ILE . 2.2 mp -72.11 106.11 2.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.262 -0.881 . . . . 0.0 111.058 -175.958 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 307' ' ' LEU . . . . . . . . . . . . . 86.7 mt -124.68 108.08 28.82 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.116 -0.493 . . . . 0.0 109.853 178.32 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 308' ' ' PRO . . . . . 0.679 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 23.8 Cg_exo -72.89 136.92 26.0 Favored 'Trans proline' 0 N--CA 1.476 0.452 0 C-N-CA 123.006 2.471 . . . . 0.0 114.423 -170.849 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 309' ' ' VAL . . . . . 0.539 HG23 ' O ' ' A' ' 322' ' ' VAL . 47.5 t -91.14 -23.53 5.87 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.186 0 CA-C-N 115.283 -0.871 . . . . 0.0 109.549 171.675 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 310' ' ' GLU . . . . . 0.45 ' OE1' ' HB2' ' A' ' 324' ' ' ALA . 50.2 mt-10 -80.9 8.53 8.11 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.182 -179.537 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 22.6 t-20 -74.99 137.36 41.5 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 178.399 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 68.6 m -60.67 -35.98 77.6 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 111.608 0.225 . . . . 0.0 111.608 -174.671 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 39.7 m-20 -61.38 126.76 28.52 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-O 121.167 0.508 . . . . 0.0 111.247 179.89 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 57.9 t -69.86 -28.26 36.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.493 -177.466 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -72.03 -17.92 61.99 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 111.997 0.369 . . . . 0.0 111.997 -179.828 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 35.1 t -76.82 -40.52 47.62 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 121.223 -0.191 . . . . 0.0 111.21 -177.41 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 317' ' ' ARG . . . . . 0.465 ' N ' ' HD2' ' A' ' 318' ' ' PRO . 65.9 mtt85 -54.44 -53.24 61.82 Favored Pre-proline 0 CA--C 1.54 0.584 0 N-CA-C 113.652 0.982 . . . . 0.0 113.652 -176.276 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 318' ' ' PRO . . . . . 0.465 ' HD2' ' N ' ' A' ' 317' ' ' ARG . 9.9 Cg_endo -56.36 -23.93 49.21 Favored 'Trans proline' 0 C--N 1.357 0.989 0 C-N-CA 122.468 2.112 . . . . 0.0 113.282 -176.86 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 53.9 m-85 -115.23 12.38 16.48 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.703 -177.4 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 320' ' ' ALA . . . . . 0.509 ' HB3' HG22 ' A' ' 309' ' ' VAL . . . -78.1 161.04 27.69 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.35 -178.306 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 29.2 t-20 -122.42 -44.51 2.25 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.734 -175.416 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 322' ' ' VAL . . . . . 0.539 ' O ' HG23 ' A' ' 309' ' ' VAL . 34.7 m -124.95 179.0 3.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.793 -177.884 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 74.9 m-20 -62.3 -60.09 4.07 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.81 -178.736 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 324' ' ' ALA . . . . . 0.679 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -151.27 172.51 15.75 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 112.785 0.661 . . . . 0.0 112.785 -174.27 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 325' ' ' LYS . . . . . 0.701 ' HE3' ' OE1' ' A' ' 235' ' ' GLU . 14.9 ptmt -99.06 126.41 38.29 Favored Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 114.252 -1.34 . . . . 0.0 110.152 170.818 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 326' ' ' PRO . . . . . 0.451 ' HG3' HG23 ' A' ' 273' ' ' VAL . 90.8 Cg_endo -86.21 168.23 9.03 Favored 'Trans proline' 0 N--CA 1.461 -0.403 0 C-N-CA 122.963 2.442 . . . . 0.0 111.857 -179.757 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -69.8 122.71 19.75 Favored 'General case' 0 C--O 1.236 0.385 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 174.448 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 62.2 mm-40 58.22 -140.79 0.75 Allowed 'General case' 0 CA--C 1.528 0.115 0 O-C-N 123.53 0.519 . . . . 0.0 109.647 -172.822 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 329' ' ' SER . . . . . 0.669 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 48.7 m -112.86 -14.12 13.1 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 120.44 -0.504 . . . . 0.0 111.076 176.615 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 67.33 -151.02 0.18 Allowed 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 112.402 0.519 . . . . 0.0 112.402 175.329 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 331' ' ' ALA . . . . . 0.447 ' C ' HD12 ' A' ' 332' ' ' ILE . . . -89.86 127.4 35.99 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.945 -178.293 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 332' ' ' ILE . . . . . 0.924 HG13 HG12 ' A' ' 270' ' ' ILE . 1.7 mp -110.96 140.12 31.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.432 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 333' ' ' THR . . . . . 0.42 ' O ' ' HB2' ' A' ' 268' ' ' PHE . 50.8 m -103.43 99.0 8.81 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.147 -0.479 . . . . 0.0 109.739 -178.944 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 22.6 mm -84.27 127.67 39.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 N-CA-C 113.934 1.087 . . . . 0.0 113.934 -171.405 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 335' ' ' LEU . . . . . 0.469 HD23 ' N ' ' A' ' 335' ' ' LEU . 1.6 pt? -153.36 -172.85 4.37 Favored 'General case' 0 N--CA 1.447 -0.576 0 CA-C-N 114.024 -1.444 . . . . 0.0 107.65 168.816 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 20.6 t-20 -121.35 -23.92 5.57 Favored 'General case' 0 C--N 1.321 -0.649 0 C-N-CA 120.363 -0.535 . . . . 0.0 110.583 -178.599 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 68.1 mttm . . . . . 0 C--O 1.245 0.818 0 CA-C-O 118.097 -0.954 . . . . 0.0 111.399 179.071 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 54.7 p . . . . . 0 C--O 1.233 0.232 0 CA-C-O 121.349 0.595 . . . . 0.0 110.051 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 228' ' ' LEU . . . . . 0.528 HD13 ' H ' ' A' ' 260' ' ' SER . 91.1 mt -108.52 146.77 32.71 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.116 -0.947 . . . . 0.0 108.871 177.028 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 77.7 p -130.56 179.6 5.84 Favored 'General case' 0 C--N 1.325 -0.477 0 C-N-CA 119.973 -0.691 . . . . 0.0 110.675 -179.013 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 230' ' ' VAL . . . . . 0.88 HG11 HD12 ' A' ' 255' ' ' ILE . 91.3 t -146.51 136.71 17.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 120.91 0.386 . . . . 0.0 110.592 178.902 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 33.7 t -107.04 146.42 31.17 Favored 'General case' 0 N--CA 1.45 -0.465 0 CA-C-N 116.039 -0.528 . . . . 0.0 109.604 176.498 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 232' ' ' GLY . . . . . 0.478 ' O ' ' HD3' ' A' ' 234' ' ' PRO . . . 124.4 149.18 7.6 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.396 -0.906 . . . . 0.0 111.592 -176.817 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 66.5 mt-30 -98.6 103.82 20.88 Favored Pre-proline 0 C--N 1.323 -0.568 0 CA-C-N 116.72 0.26 . . . . 0.0 111.117 -176.583 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 234' ' ' PRO . . . . . 0.478 ' HD3' ' O ' ' A' ' 232' ' ' GLY . 4.8 Cg_exo -74.96 125.49 9.38 Favored 'Trans proline' 0 N--CA 1.457 -0.626 0 C-N-CA 122.259 1.972 . . . . 0.0 111.077 177.676 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -131.93 141.07 49.22 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.609 -179.14 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 35.7 m80 -141.48 149.04 40.41 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.681 -0.69 . . . . 0.0 109.947 178.207 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 237' ' ' LYS . . . . . 0.652 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.32 -0.685 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.498 -175.349 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 42.2 mm-40 . . . . . 0 N--CA 1.449 -0.481 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 253' ' ' GLY . . . . . 0.47 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -113.76 121.92 5.61 Favored Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.126 -1.035 . . . . 0.0 112.305 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 254' ' ' THR . . . . . 0.451 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 65.7 p -104.16 116.71 32.67 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 177.418 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.88 HD12 HG11 ' A' ' 230' ' ' VAL . 17.0 pt -123.84 147.38 28.27 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.981 -173.93 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 85.6 m -95.71 110.92 22.98 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 174.449 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.471 ' HA ' HG13 ' A' ' 230' ' ' VAL . 34.0 m -89.8 143.14 11.82 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.723 0 C-N-CA 119.93 -0.708 . . . . 0.0 112.833 -168.137 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 258' ' ' SER . . . . . 0.421 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 34.4 t -91.91 7.39 42.29 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 114.454 -1.248 . . . . 0.0 108.667 169.77 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 259' ' ' ALA . . . . . 0.693 ' HB3' HD21 ' A' ' 262' ' ' LEU . . . -88.25 175.08 7.83 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-N 115.473 -0.785 . . . . 0.0 109.243 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 260' ' ' SER . . . . . 0.528 ' H ' HD13 ' A' ' 228' ' ' LEU . 32.5 t -134.67 130.19 35.95 Favored 'General case' 0 C--N 1.323 -0.547 0 C-N-CA 120.465 -0.494 . . . . 0.0 111.57 -177.93 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 97.5 16.76 33.29 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.856 -0.688 . . . . 0.0 113.951 174.081 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 262' ' ' LEU . . . . . 0.693 HD21 ' HB3' ' A' ' 259' ' ' ALA . 2.0 mm? -65.7 128.92 37.91 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-N 117.344 0.572 . . . . 0.0 110.859 -178.841 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -128.83 175.39 8.67 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 176.335 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 43.4 t -78.64 131.2 34.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 174.325 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 100.15 9.19 48.92 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.627 -0.797 . . . . 0.0 112.699 -179.557 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -86.12 165.45 16.58 Favored 'General case' 0 CA--C 1.511 -0.521 0 CA-C-O 121.12 0.486 . . . . 0.0 110.147 175.95 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 267' ' ' ALA . . . . . 0.693 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -140.27 145.68 37.6 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.471 -179.575 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 268' ' ' PHE . . . . . 0.525 ' HB3' HD13 ' A' ' 334' ' ' ILE . 4.6 p90 -159.73 166.04 31.28 Favored 'General case' 0 C--N 1.319 -0.744 0 C-N-CA 120.127 -0.629 . . . . 0.0 111.328 -178.603 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 71.8 p -119.34 126.76 52.19 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.861 -0.608 . . . . 0.0 109.968 177.776 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 270' ' ' ILE . . . . . 0.595 HG12 HD12 ' A' ' 332' ' ' ILE . 46.6 mt -88.89 135.98 24.5 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.912 -177.49 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -65.31 122.16 16.5 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.23 -179.772 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 99.08 -23.86 34.64 Favored Glycine 0 N--CA 1.452 -0.256 0 CA-C-N 115.996 -0.547 . . . . 0.0 112.241 -179.392 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 49.0 t -94.22 108.42 20.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 121.152 0.501 . . . . 0.0 110.37 176.528 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 274' ' ' ASN . . . . . 0.409 ' HB2' ' OD1' ' A' ' 323' ' ' ASP . 63.7 m-80 -123.9 159.99 28.47 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 116.004 -0.544 . . . . 0.0 109.602 -179.398 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 53.1 p -92.04 164.68 13.52 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-O 121.124 0.487 . . . . 0.0 111.327 -179.048 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 276' ' ' VAL . . . . . 0.538 HG11 HG21 ' A' ' 309' ' ' VAL . 30.0 m -125.9 167.46 20.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.544 178.518 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 28.9 m80 -126.0 92.07 3.51 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.595 -0.275 . . . . 0.0 110.72 178.69 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 84.1 mt-30 -72.59 -14.13 61.54 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.769 0.319 . . . . 0.0 111.081 179.184 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 279' ' ' ILE . . . . . 0.513 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.2 mp -77.05 -59.95 2.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 116.539 -0.3 . . . . 0.0 110.319 -178.475 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 51.4 p -85.36 -10.02 56.85 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.454 -179.878 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 31.9 mmmt 58.35 43.81 19.39 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.7 -178.29 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -112.34 154.49 25.64 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.1 -178.357 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 49.8 p -105.96 123.01 47.3 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 176.731 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 284' ' ' THR . . . . . 0.432 ' HB ' ' HG3' ' A' ' 286' ' ' GLN . 82.0 p -124.53 -37.28 2.52 Favored 'General case' 0 C--N 1.317 -0.814 0 C-N-CA 120.487 -0.485 . . . . 0.0 111.508 -172.06 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 70.45 29.49 69.92 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.601 -0.809 . . . . 0.0 111.809 -177.394 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 286' ' ' GLN . . . . . 0.432 ' HG3' ' HB ' ' A' ' 284' ' ' THR . 83.3 mt-30 -76.25 113.87 32.43 Favored Pre-proline 0 C--N 1.33 -0.243 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.826 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 287' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_exo -51.65 126.55 19.97 Favored 'Trans proline' 0 C--O 1.232 0.224 0 C-N-CA 122.42 2.08 . . . . 0.0 111.928 -179.112 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -77.23 130.06 36.74 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 -175.018 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 289' ' ' VAL . . . . . 0.675 HG11 ' HG2' ' A' ' 337' ' ' LYS . 57.6 t -90.01 130.74 38.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.006 -176.108 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 290' ' ' PHE . . . . . 0.693 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 4.6 m-85 -98.79 151.18 21.07 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.05 -178.062 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 291' ' ' ARG . . . . . 0.495 ' HD2' ' C ' ' A' ' 290' ' ' PHE . 1.0 OUTLIER -113.18 130.09 56.32 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 174.172 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 47.9 t -92.49 129.51 42.96 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.231 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.923 -177.625 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 293' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -114.6 -20.7 10.6 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.684 -179.251 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 294' ' ' ALA . . . . . 0.586 ' HB3' ' HB ' ' A' ' 301' ' ' THR . . . -148.92 136.61 20.49 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.641 -0.424 . . . . 0.0 111.914 -179.303 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 295' ' ' VAL . . . . . 0.46 HG11 ' O ' ' A' ' 262' ' ' LEU . 80.4 t -142.7 123.0 10.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.681 -0.691 . . . . 0.0 109.79 175.515 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 36.2 t -154.09 108.66 3.06 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.58 -0.282 . . . . 0.0 110.742 179.158 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 63.57 54.8 29.21 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 121.031 -0.604 . . . . 0.0 112.189 -179.296 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 58.4 p 52.28 21.89 1.82 Allowed 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 123.725 0.81 . . . . 0.0 112.754 -176.764 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 45.8 m -107.64 117.83 35.13 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 173.911 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 300' ' ' VAL . . . . . 0.451 ' O ' ' HA ' ' A' ' 254' ' ' THR . 48.1 t -117.08 129.96 72.78 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.299 -172.041 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 301' ' ' THR . . . . . 0.586 ' HB ' ' HB3' ' A' ' 294' ' ' ALA . 45.1 m -98.21 116.75 31.09 Favored 'General case' 0 C--O 1.236 0.381 0 N-CA-C 108.744 -0.835 . . . . 0.0 108.744 174.718 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 302' ' ' ILE . . . . . 0.47 HG12 ' O ' ' A' ' 253' ' ' GLY . 29.2 pt -111.81 146.17 17.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 113.373 0.879 . . . . 0.0 113.373 -168.627 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 303' ' ' SER . . . . . 0.526 ' HB3' ' HA ' ' A' ' 304' ' ' PRO . 47.4 m -132.25 166.24 30.15 Favored Pre-proline 0 C--N 1.32 -0.698 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 171.899 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 304' ' ' PRO . . . . . 0.526 ' HA ' ' HB3' ' A' ' 303' ' ' SER . 6.0 Cg_exo -79.67 -142.71 0.24 Allowed 'Cis proline' 0 CA--C 1.531 0.327 0 CA-C-N 120.72 1.293 . . . . 0.0 112.636 0.291 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 305' ' ' LYS . . . . . 0.508 ' C ' HD12 ' A' ' 306' ' ' ILE . 0.0 OUTLIER -97.51 147.6 24.08 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.389 0.614 . . . . 0.0 112.152 178.784 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 306' ' ' ILE . . . . . 1.017 HG23 HG21 ' A' ' 322' ' ' VAL . 1.9 mp -119.83 110.35 28.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 115.043 -0.98 . . . . 0.0 110.131 -176.534 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 307' ' ' LEU . . . . . 0.434 ' HA ' ' HD3' ' A' ' 308' ' ' PRO . 88.6 mt -126.32 115.08 23.48 Favored Pre-proline 0 C--N 1.332 -0.183 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.221 -177.697 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 308' ' ' PRO . . . . . 0.774 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 35.3 Cg_exo -67.31 147.81 78.83 Favored 'Trans proline' 0 N--CA 1.474 0.339 0 C-N-CA 123.762 2.975 . . . . 0.0 114.714 -173.521 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 309' ' ' VAL . . . . . 0.617 HG22 ' HB1' ' A' ' 320' ' ' ALA . 26.2 t -93.34 -17.81 7.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 114.866 -1.061 . . . . 0.0 108.607 167.654 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 59.4 mm-40 -76.9 -6.71 53.57 Favored 'General case' 0 C--O 1.233 0.199 0 CA-C-N 115.23 -0.895 . . . . 0.0 112.117 -178.157 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 4.1 m120 -85.62 151.47 23.87 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.917 0.389 . . . . 0.0 111.101 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 30.9 m -93.28 -1.16 56.37 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.579 0.704 . . . . 0.0 109.125 175.347 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 313' ' ' ASP . . . . . 0.638 ' O ' ' HG3' ' A' ' 317' ' ' ARG . 59.7 t0 -58.0 117.57 4.47 Favored 'General case' 0 C--N 1.333 -0.116 0 CA-C-N 115.328 -0.851 . . . . 0.0 110.781 -179.292 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 49.0 t -53.54 -33.8 22.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.835 -0.62 . . . . 0.0 112.172 -178.446 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -85.18 -29.81 24.43 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 112.183 0.438 . . . . 0.0 112.183 -178.017 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 316' ' ' SER . . . . . 0.559 ' HB3' ' HB3' ' A' ' 313' ' ' ASP . 33.5 t -82.03 -27.74 32.88 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 111.759 0.281 . . . . 0.0 111.759 -175.133 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 317' ' ' ARG . . . . . 0.638 ' HG3' ' O ' ' A' ' 313' ' ' ASP . 49.8 mtp85 -63.98 -52.87 53.24 Favored Pre-proline 0 CA--C 1.539 0.548 0 N-CA-C 112.935 0.717 . . . . 0.0 112.935 -176.478 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 318' ' ' PRO . . . . . 0.604 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 22.1 Cg_exo -67.82 -28.93 35.95 Favored 'Trans proline' 0 C--N 1.357 0.991 0 C-N-CA 121.979 1.786 . . . . 0.0 112.871 -177.005 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 5.1 m-85 -98.42 12.84 33.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.017 -179.005 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 320' ' ' ALA . . . . . 0.617 ' HB1' HG22 ' A' ' 309' ' ' VAL . . . -59.76 144.27 48.76 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.539 -178.666 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 321' ' ' ASN . . . . . 0.452 ' OD1' HG13 ' A' ' 322' ' ' VAL . 17.5 p30 -142.98 -12.17 0.75 Allowed 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.53 -177.434 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 322' ' ' VAL . . . . . 1.017 HG21 HG23 ' A' ' 306' ' ' ILE . 35.0 m -139.15 178.65 3.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.404 177.658 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 323' ' ' ASP . . . . . 0.409 ' OD1' ' HB2' ' A' ' 274' ' ' ASN . 51.6 m-20 -64.01 -62.58 1.54 Allowed 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.978 176.87 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 324' ' ' ALA . . . . . 0.774 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -162.94 173.75 13.24 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 116.143 -0.481 . . . . 0.0 112.094 -175.44 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 22.0 pttp -119.28 106.97 42.04 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 115.218 -0.901 . . . . 0.0 109.457 172.277 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -86.29 167.52 9.13 Favored 'Trans proline' 0 C--O 1.235 0.367 0 C-N-CA 122.624 2.216 . . . . 0.0 113.507 -172.204 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 327' ' ' ALA . . . . . 0.424 ' O ' ' HB2' ' A' ' 328' ' ' GLU . . . -79.48 132.79 36.44 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 170.155 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 328' ' ' GLU . . . . . 0.424 ' HB2' ' O ' ' A' ' 327' ' ' ALA . 62.1 mm-40 73.27 166.25 0.3 Allowed 'General case' 0 N--CA 1.467 0.387 0 O-C-N 123.566 0.542 . . . . 0.0 109.576 -170.589 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 329' ' ' SER . . . . . 0.686 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 53.9 m -104.44 -10.53 17.64 Favored 'General case' 0 C--N 1.319 -0.731 0 C-N-CA 120.349 -0.54 . . . . 0.0 111.803 -174.265 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 67.62 -161.22 0.22 Allowed 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 113.022 0.749 . . . . 0.0 113.022 172.459 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -75.33 142.72 43.15 Favored 'General case' 0 CA--C 1.518 -0.275 0 CA-C-N 115.117 -0.947 . . . . 0.0 110.475 179.414 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 332' ' ' ILE . . . . . 0.686 HG13 HG23 ' A' ' 230' ' ' VAL . 24.8 mm -120.62 144.46 29.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.753 -175.783 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 33.8 m -111.27 97.63 6.92 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 178.404 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 334' ' ' ILE . . . . . 0.525 HD13 ' HB3' ' A' ' 268' ' ' PHE . 39.5 mm -81.57 131.54 33.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 112.769 0.655 . . . . 0.0 112.769 -173.247 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 335' ' ' LEU . . . . . 0.46 HD23 ' N ' ' A' ' 335' ' ' LEU . 1.7 pt? -152.03 -167.16 2.69 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 114.685 -1.143 . . . . 0.0 108.723 173.118 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 15.9 p-10 -110.88 -25.41 9.87 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 109.635 -0.505 . . . . 0.0 109.635 176.014 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 337' ' ' LYS . . . . . 0.675 ' HG2' HG11 ' A' ' 289' ' ' VAL . 27.1 tptp . . . . . 0 C--O 1.247 0.925 0 O-C-N 124.397 1.061 . . . . 0.0 111.407 177.506 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 61.1 p . . . . . 0 N--CA 1.453 -0.32 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 228' ' ' LEU . . . . . 0.608 HD22 ' H ' ' A' ' 260' ' ' SER . 53.4 mt -111.15 127.1 55.47 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.491 -173.31 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 229' ' ' THR . . . . . 0.527 ' HA ' ' HA ' ' A' ' 331' ' ' ALA . 64.3 p -129.91 -178.83 4.88 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 120.694 -0.402 . . . . 0.0 111.22 -178.822 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 230' ' ' VAL . . . . . 0.744 ' O ' ' HB2' ' A' ' 329' ' ' SER . 34.9 t -134.17 151.59 32.61 Favored 'Isoleucine or valine' 0 C--O 1.24 0.594 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 -179.43 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 41.7 t -126.89 125.37 41.48 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.23 175.383 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 87.61 91.75 1.02 Allowed Glycine 0 CA--C 1.52 0.382 0 C-N-CA 120.888 -0.673 . . . . 0.0 113.97 176.15 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 233' ' ' GLN . . . . . 0.562 ' HG2' ' OG ' ' A' ' 329' ' ' SER . 30.3 mm100 -97.86 117.01 65.66 Favored Pre-proline 0 CA--C 1.519 -0.242 0 O-C-N 122.821 -0.223 . . . . 0.0 110.623 171.843 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 234' ' ' PRO . . . . . 0.523 ' HD3' HG22 ' A' ' 255' ' ' ILE . 11.8 Cg_exo -67.09 172.93 9.18 Favored 'Trans proline' 0 N--CA 1.462 -0.353 0 C-N-CA 122.685 2.257 . . . . 0.0 111.741 176.565 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 235' ' ' GLU . . . . . 0.416 ' HG3' ' HE2' ' A' ' 237' ' ' LYS . 9.7 pt-20 -96.42 146.91 24.36 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.013 178.058 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 236' ' ' HIS . . . . . 0.629 ' C ' ' HD2' ' A' ' 237' ' ' LYS . 28.6 m80 -126.07 129.78 49.81 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.088 0.471 . . . . 0.0 111.01 -173.953 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 237' ' ' LYS . . . . . 0.629 ' HD2' ' C ' ' A' ' 236' ' ' HIS . 2.8 mptp? . . . . . 0 C--N 1.323 -0.546 0 CA-C-N 115.441 -0.799 . . . . 0.0 110.0 -179.114 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 252' ' ' GLN . . . . . 0.438 ' HB3' ' O ' ' A' ' 302' ' ' ILE . 34.2 mm-40 . . . . . 0 N--CA 1.447 -0.591 0 N-CA-C 110.043 -0.354 . . . . 0.0 110.043 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 253' ' ' GLY . . . . . 0.469 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -154.47 172.58 32.98 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 119.667 -1.254 . . . . 0.0 113.032 -178.965 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 254' ' ' THR . . . . . 0.549 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 47.0 p -119.38 128.81 54.41 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 177.822 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.523 HG22 ' HD3' ' A' ' 234' ' ' PRO . 26.6 pt -114.66 149.73 16.83 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.357 -175.659 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 40.8 m -98.4 110.47 23.05 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 177.223 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.525 HG21 HD12 ' A' ' 262' ' ' LEU . 35.0 m -92.41 144.99 8.15 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.859 0 CA-C-O 121.631 0.729 . . . . 0.0 112.697 -171.123 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 41.1 m -90.3 7.75 36.83 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 114.046 -1.434 . . . . 0.0 108.41 168.949 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 259' ' ' ALA . . . . . 0.579 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -91.06 162.04 14.86 Favored 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 115.117 -0.947 . . . . 0.0 110.468 -177.497 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 260' ' ' SER . . . . . 0.608 ' H ' HD22 ' A' ' 228' ' ' LEU . 48.7 m -137.82 138.91 39.64 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.122 -0.49 . . . . 0.0 109.814 177.36 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 94.55 34.26 6.4 Favored Glycine 0 N--CA 1.447 -0.586 0 C-N-CA 120.444 -0.884 . . . . 0.0 112.233 -178.42 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 262' ' ' LEU . . . . . 0.525 HD12 HG21 ' A' ' 257' ' ' VAL . 67.5 mt -102.37 143.39 32.18 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 178.361 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 46.2 mm-40 -142.78 175.32 9.91 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 178.116 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 264' ' ' VAL . . . . . 0.434 HG22 ' HA ' ' A' ' 294' ' ' ALA . 49.0 t -78.17 132.48 32.37 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.202 177.698 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 103.77 8.24 40.24 Favored Glycine 0 N--CA 1.453 -0.211 0 C-N-CA 120.569 -0.824 . . . . 0.0 112.775 179.406 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -89.05 157.56 18.3 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.915 0.388 . . . . 0.0 110.066 176.838 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 267' ' ' ALA . . . . . 0.605 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -131.23 121.94 25.68 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 178.883 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 268' ' ' PHE . . . . . 0.408 ' HB3' HD13 ' A' ' 334' ' ' ILE . 4.6 p90 -145.14 164.57 30.87 Favored 'General case' 0 C--N 1.32 -0.706 0 C-N-CA 119.4 -0.92 . . . . 0.0 111.988 -173.929 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 75.7 p -117.64 129.6 55.85 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.531 -0.759 . . . . 0.0 109.76 176.191 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 270' ' ' ILE . . . . . . . . . . . . . 66.0 mt -97.54 141.52 15.75 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.766 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 179.838 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 271' ' ' ALA . . . . . 0.47 ' HB3' ' HB1' ' A' ' 330' ' ' ALA . . . -63.98 132.84 51.87 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.032 0.444 . . . . 0.0 111.438 -176.577 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 98.68 -22.35 41.37 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.992 -0.623 . . . . 0.0 112.158 -178.56 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 273' ' ' VAL . . . . . 0.565 ' O ' ' HA ' ' A' ' 287' ' ' PRO . 45.2 t -77.95 103.44 5.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 120.665 0.269 . . . . 0.0 110.459 178.476 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 274' ' ' ASN . . . . . 0.416 ' O ' ' HB ' ' A' ' 322' ' ' VAL . 46.8 m-20 -96.72 136.97 36.51 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 108.79 -0.819 . . . . 0.0 108.79 174.842 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 275' ' ' SER . . . . . 0.404 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 8.1 t -99.48 165.58 11.57 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.773 0.321 . . . . 0.0 110.399 -176.219 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 19.0 m -128.76 155.49 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.014 0 CA-C-N 115.092 -0.958 . . . . 0.0 109.987 167.271 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 277' ' ' HIS . . . . . 0.623 ' HB2' ' HB3' ' A' ' 282' ' ' ASP . 29.3 m80 -100.41 89.74 4.06 Favored 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 108.547 -0.909 . . . . 0.0 108.547 175.148 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 5.3 tm0? -59.78 -47.54 85.3 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.091 -172.139 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 59.2 mt -56.44 -48.15 80.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 N-CA-C 111.942 0.349 . . . . 0.0 111.942 -177.166 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 40.6 p -94.97 -3.71 48.0 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 112.414 0.524 . . . . 0.0 112.414 -176.3 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 4.0 tppp? 59.22 53.2 5.52 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 121.285 0.564 . . . . 0.0 110.256 -178.337 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 282' ' ' ASP . . . . . 0.623 ' HB3' ' HB2' ' A' ' 277' ' ' HIS . 37.2 t70 -120.13 116.37 25.52 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.299 -175.416 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 67.8 p -107.16 118.17 35.99 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.3 178.83 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 67.5 p -129.05 -15.98 4.14 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 112.063 0.394 . . . . 0.0 112.063 -174.968 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 87.23 -3.09 86.89 Favored Glycine 0 N--CA 1.453 -0.179 0 C-N-CA 120.61 -0.805 . . . . 0.0 112.724 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 286' ' ' GLN . . . . . 0.472 ' HA ' ' HD3' ' A' ' 287' ' ' PRO . 82.9 mt-30 -64.76 137.92 97.3 Favored Pre-proline 0 C--N 1.33 -0.27 0 N-CA-C 110.425 -0.213 . . . . 0.0 110.425 179.006 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 287' ' ' PRO . . . . . 0.565 ' HA ' ' O ' ' A' ' 273' ' ' VAL . 32.8 Cg_exo -62.52 149.37 91.23 Favored 'Trans proline' 0 CA--C 1.529 0.257 0 C-N-CA 122.633 2.222 . . . . 0.0 113.448 -174.558 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 29.3 tp60 -87.06 136.82 32.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.075 176.989 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 289' ' ' VAL . . . . . 0.405 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 38.8 t -94.55 130.15 43.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.901 -0.591 . . . . 0.0 109.645 177.592 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 290' ' ' PHE . . . . . 0.605 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 53.6 m-85 -99.97 165.52 11.5 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.926 0.393 . . . . 0.0 111.772 -175.145 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 30.3 mmt-85 -119.76 127.98 53.32 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 174.075 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 57.7 t -86.6 130.74 36.26 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.886 0 CA-C-O 120.785 0.326 . . . . 0.0 111.583 -175.966 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 293' ' ' LEU . . . . . 0.511 HD21 ' HB2' ' A' ' 303' ' ' SER . 3.1 mm? -103.58 -34.88 8.5 Favored 'General case' 0 C--N 1.333 -0.112 0 CA-C-N 115.945 -0.571 . . . . 0.0 111.297 178.503 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 294' ' ' ALA . . . . . 0.51 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -154.22 140.1 18.19 Favored 'General case' 0 CA--C 1.518 -0.252 0 C-N-CA 120.648 -0.421 . . . . 0.0 111.593 -179.149 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 96.9 t -135.73 100.09 2.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.705 175.016 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 50.5 m -141.77 118.29 10.92 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.845 -176.33 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 63.93 46.5 91.36 Favored Glycine 0 C--N 1.33 0.236 0 C-N-CA 121.147 -0.549 . . . . 0.0 112.144 -178.018 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 72.2 p 51.0 23.54 1.53 Allowed 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 123.701 0.8 . . . . 0.0 112.221 -175.739 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 299' ' ' THR . . . . . 0.45 ' HA ' ' O ' ' A' ' 255' ' ' ILE . 50.7 m -114.0 118.47 34.22 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 176.609 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 300' ' ' VAL . . . . . 0.549 ' O ' ' HA ' ' A' ' 254' ' ' THR . 43.6 t -110.18 128.39 66.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.412 -172.515 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 59.3 m -83.97 114.14 21.49 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 108.091 -1.078 . . . . 0.0 108.091 171.568 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 302' ' ' ILE . . . . . 0.469 HG12 ' O ' ' A' ' 253' ' ' GLY . 31.0 pt -111.01 144.76 18.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 N-CA-C 113.279 0.844 . . . . 0.0 113.279 -167.059 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 303' ' ' SER . . . . . 0.511 ' HB2' HD21 ' A' ' 293' ' ' LEU . 50.4 m -149.6 157.7 38.43 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-N 114.041 -1.436 . . . . 0.0 107.409 173.018 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 304' ' ' PRO . . . . . 0.496 ' O ' ' HA ' ' A' ' 303' ' ' SER . 15.7 Cg_exo -69.27 -162.21 1.72 Allowed 'Cis proline' 0 CA--C 1.531 0.34 0 CA-C-N 120.151 1.09 . . . . 0.0 112.811 0.742 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 305' ' ' LYS . . . . . 0.611 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -95.27 142.38 27.75 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.401 0.619 . . . . 0.0 111.964 -178.124 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 306' ' ' ILE . . . . . 0.643 HG23 HG21 ' A' ' 322' ' ' VAL . 2.0 mp -86.35 84.92 2.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.079 -0.964 . . . . 0.0 109.939 -178.397 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 307' ' ' LEU . . . . . . . . . . . . . 96.8 mt -112.38 102.45 54.17 Favored Pre-proline 0 C--N 1.324 -0.501 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.579 -178.757 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 308' ' ' PRO . . . . . 0.684 ' HD2' HD22 ' A' ' 311' ' ' ASN . 12.4 Cg_exo -75.5 150.29 35.86 Favored 'Trans proline' 0 N--CA 1.462 -0.334 0 C-N-CA 122.898 2.399 . . . . 0.0 113.004 -174.398 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 42.5 t -72.26 -27.3 26.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 108.647 -0.872 . . . . 0.0 108.647 170.305 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 54.7 mm-40 -92.21 32.68 1.14 Allowed 'General case' 0 N--CA 1.453 -0.285 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.805 176.3 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.684 HD22 ' HD2' ' A' ' 308' ' ' PRO . 26.0 t-20 -71.98 -31.93 66.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.378 -178.336 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 312' ' ' THR . . . . . 0.5 ' HB ' ' O ' ' A' ' 311' ' ' ASN . 84.9 m 83.34 -25.43 0.14 Allowed 'General case' 0 N--CA 1.469 0.491 0 O-C-N 124.088 0.867 . . . . 0.0 111.116 -178.837 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 65.8 m-20 -81.89 122.9 28.33 Favored 'General case' 0 C--O 1.233 0.216 0 C-N-CA 120.522 -0.471 . . . . 0.0 109.96 172.571 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 38.8 t -59.35 -39.38 78.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 115.188 -0.914 . . . . 0.0 112.229 -173.092 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -66.22 -25.27 66.83 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 112.229 0.455 . . . . 0.0 112.229 -177.332 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 42.4 t -86.54 -12.59 48.32 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 111.773 0.286 . . . . 0.0 111.773 -177.848 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 317' ' ' ARG . . . . . 0.564 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 51.8 mtp85 -62.8 -50.61 76.78 Favored Pre-proline 0 CA--C 1.538 0.492 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 -178.503 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 318' ' ' PRO . . . . . 0.564 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 39.2 Cg_exo -63.32 -26.05 71.48 Favored 'Trans proline' 0 C--N 1.356 0.936 0 C-N-CA 121.903 1.735 . . . . 0.0 112.788 -177.755 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 6.0 m-85 -93.23 19.99 7.47 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.335 -179.409 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -59.49 131.02 49.68 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 112.31 0.485 . . . . 0.0 112.31 -175.799 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 76.3 m-20 -128.15 -18.38 4.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.507 -0.77 . . . . 0.0 110.255 175.052 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 322' ' ' VAL . . . . . 0.643 HG21 HG23 ' A' ' 306' ' ' ILE . 33.8 m -138.7 176.75 5.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.107 -179.576 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -98.74 -18.97 17.73 Favored 'General case' 0 C--N 1.327 -0.385 0 C-N-CA 121.002 -0.279 . . . . 0.0 111.123 -179.773 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 324' ' ' ALA . . . . . 0.529 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -168.62 156.67 8.1 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.98 -173.117 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 325' ' ' LYS . . . . . 0.401 ' HA ' ' HD3' ' A' ' 326' ' ' PRO . 35.4 mtmm -87.02 120.87 71.71 Favored Pre-proline 0 N--CA 1.453 -0.294 0 N-CA-C 107.618 -1.252 . . . . 0.0 107.618 165.442 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 326' ' ' PRO . . . . . 0.476 ' HG2' HG22 ' A' ' 273' ' ' VAL . 51.1 Cg_exo -61.14 162.81 18.53 Favored 'Trans proline' 0 C--O 1.233 0.274 0 C-N-CA 122.525 2.15 . . . . 0.0 113.612 -171.372 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -73.45 132.35 42.84 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 108.593 -0.891 . . . . 0.0 108.593 170.896 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 9.0 pm0 42.38 -137.46 0.25 Allowed 'General case' 0 N--CA 1.47 0.565 0 O-C-N 124.132 0.895 . . . . 0.0 110.338 -169.757 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 329' ' ' SER . . . . . 0.744 ' HB2' ' O ' ' A' ' 230' ' ' VAL . 38.1 m -113.98 -44.87 3.11 Favored 'General case' 0 C--N 1.322 -0.622 0 C-N-CA 119.797 -0.761 . . . . 0.0 111.604 176.973 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 330' ' ' ALA . . . . . 0.47 ' HB1' ' HB3' ' A' ' 271' ' ' ALA . . . 78.54 -166.66 0.04 OUTLIER 'General case' 0 N--CA 1.474 0.771 0 O-C-N 123.813 0.696 . . . . 0.0 112.52 176.169 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 331' ' ' ALA . . . . . 0.527 ' HA ' ' HA ' ' A' ' 229' ' ' THR . . . -84.95 157.92 20.67 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.755 -0.657 . . . . 0.0 112.386 -173.764 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 332' ' ' ILE . . . . . 0.479 HD11 ' CG2' ' A' ' 230' ' ' VAL . 29.1 mt -110.0 144.97 17.15 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.232 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.083 -179.223 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 54.4 m -111.45 98.46 7.48 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 172.35 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 334' ' ' ILE . . . . . 0.408 HD13 ' HB3' ' A' ' 268' ' ' PHE . 32.2 mm -84.96 134.79 26.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 N-CA-C 113.247 0.832 . . . . 0.0 113.247 -171.074 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 335' ' ' LEU . . . . . 0.427 HD23 ' N ' ' A' ' 335' ' ' LEU . 1.9 pt? -164.39 -166.16 1.07 Allowed 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 115.074 -0.966 . . . . 0.0 109.62 172.418 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 74.3 m-80 -143.84 21.39 1.8 Allowed 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 175.978 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 68.2 mttm . . . . . 0 C--O 1.242 0.66 0 CA-C-N 115.196 -0.911 . . . . 0.0 110.84 -174.371 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 51.8 m . . . . . 0 C--O 1.234 0.285 0 CA-C-O 121.051 0.453 . . . . 0.0 111.906 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 228' ' ' LEU . . . . . 0.531 HD13 ' H ' ' A' ' 260' ' ' SER . 88.8 mt -68.77 144.77 54.24 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.317 173.891 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 40.7 p -132.29 179.32 6.18 Favored 'General case' 0 C--N 1.326 -0.441 0 C-N-CA 120.262 -0.575 . . . . 0.0 111.137 -176.998 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 230' ' ' VAL . . . . . 1.056 HG23 HD11 ' A' ' 332' ' ' ILE . 72.1 t -143.22 145.87 22.15 Favored 'Isoleucine or valine' 0 C--O 1.239 0.532 0 CA-C-O 120.775 0.322 . . . . 0.0 110.373 -179.446 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 46.2 t -131.74 97.58 4.24 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 115.234 -0.894 . . . . 0.0 109.181 173.818 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . -142.15 -157.53 7.19 Favored Glycine 0 N--CA 1.447 -0.6 0 C-N-CA 120.184 -1.008 . . . . 0.0 112.639 -176.008 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 83.5 mt-30 -86.1 159.98 52.95 Favored Pre-proline 0 C--N 1.323 -0.571 0 N-CA-C 110.396 -0.224 . . . . 0.0 110.396 179.775 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo -64.51 174.66 4.15 Favored 'Trans proline' 0 C--N 1.35 0.619 0 C-N-CA 122.875 2.383 . . . . 0.0 111.418 176.357 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 235' ' ' GLU . . . . . 0.538 ' HA ' ' OE1' ' A' ' 235' ' ' GLU . 3.9 mm-40 -91.9 167.54 12.05 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 113.461 0.911 . . . . 0.0 113.461 -174.977 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 236' ' ' HIS . . . . . 0.519 ' CE1' ' HA2' ' A' ' 253' ' ' GLY . 23.2 m80 -111.63 143.21 42.89 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 113.266 -1.788 . . . . 0.0 111.432 -165.239 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 237' ' ' LYS . . . . . 0.431 ' HD3' ' C ' ' A' ' 236' ' ' HIS . 18.7 mmtp . . . . . 0 C--N 1.317 -0.833 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.793 -173.461 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 252' ' ' GLN . . . . . 0.49 ' HB3' ' O ' ' A' ' 302' ' ' ILE . 45.2 mm-40 . . . . . 0 CA--C 1.527 0.095 0 CA-C-O 120.503 0.192 . . . . 0.0 110.729 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 253' ' ' GLY . . . . . 0.519 ' HA2' ' CE1' ' A' ' 236' ' ' HIS . . . -95.5 152.22 20.29 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.184 177.877 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 52.1 p -129.5 116.96 19.73 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.758 0.314 . . . . 0.0 110.588 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.755 HD12 HG11 ' A' ' 230' ' ' VAL . 18.0 pt -125.94 149.92 31.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 N-CA-C 112.25 0.463 . . . . 0.0 112.25 -175.798 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 91.5 m -98.86 113.35 25.43 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 175.124 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.667 HG21 HD12 ' A' ' 262' ' ' LEU . 34.8 m -90.12 143.26 11.56 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.669 0 N-CA-C 113.38 0.881 . . . . 0.0 113.38 -167.009 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 258' ' ' SER . . . . . 0.433 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 37.4 t -92.73 7.94 41.44 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 113.795 -1.548 . . . . 0.0 108.523 168.163 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 259' ' ' ALA . . . . . 0.522 ' HB3' HD11 ' A' ' 262' ' ' LEU . . . -84.77 165.78 17.51 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-N 115.616 -0.72 . . . . 0.0 109.822 -177.344 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 260' ' ' SER . . . . . 0.531 ' H ' HD13 ' A' ' 228' ' ' LEU . 49.4 m -123.47 142.0 51.44 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 120.814 0.34 . . . . 0.0 111.443 -178.005 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 67.3 50.65 43.27 Favored Glycine 0 N--CA 1.452 -0.25 0 CA-C-N 115.812 -0.631 . . . . 0.0 113.58 175.317 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 262' ' ' LEU . . . . . 0.667 HD12 HG21 ' A' ' 257' ' ' VAL . 77.7 mt -99.64 145.83 27.15 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 117.086 0.443 . . . . 0.0 110.842 178.034 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 83.6 mt-30 -142.94 171.75 13.63 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.928 178.954 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 50.8 t -77.16 133.32 31.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 176.731 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 265' ' ' GLY . . . . . 0.483 ' O ' ' HE3' ' A' ' 337' ' ' LYS . . . 107.62 -7.83 36.76 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.44 -0.886 . . . . 0.0 112.619 -179.372 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 63.4 m-20 -69.28 155.63 40.09 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-O 121.069 0.462 . . . . 0.0 110.567 178.262 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 267' ' ' ALA . . . . . 0.621 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -130.2 129.69 43.72 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.45 -0.795 . . . . 0.0 108.884 177.442 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 268' ' ' PHE . . . . . . . . . . . . . 3.2 p90 -151.38 175.63 12.06 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 119.97 -0.692 . . . . 0.0 111.466 -175.456 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 269' ' ' THR . . . . . 0.468 HG21 ' HB2' ' A' ' 287' ' ' PRO . 82.7 p -126.14 147.19 49.67 Favored 'General case' 0 C--N 1.32 -0.674 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 176.571 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 270' ' ' ILE . . . . . . . . . . . . . 47.1 mm -103.65 138.26 28.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 N-CA-C 110.236 -0.283 . . . . 0.0 110.236 179.381 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -63.34 135.4 56.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.442 -178.608 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 89.41 -23.19 20.02 Favored Glycine 0 CA--C 1.517 0.198 0 CA-C-N 115.92 -0.582 . . . . 0.0 112.712 179.755 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 273' ' ' VAL . . . . . 0.473 HG21 ' HG3' ' A' ' 326' ' ' PRO . 42.5 t -86.09 130.24 36.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 120.925 0.393 . . . . 0.0 110.879 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 72.3 m-80 -135.24 142.08 45.91 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.329 179.671 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 65.2 p -84.04 165.81 18.25 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.252 0.549 . . . . 0.0 111.746 -178.279 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 276' ' ' VAL . . . . . 0.428 HG11 HG21 ' A' ' 309' ' ' VAL . 35.4 m -113.64 175.82 2.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 115.315 -0.857 . . . . 0.0 110.668 179.432 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 277' ' ' HIS . . . . . 0.43 ' HB3' ' HA ' ' A' ' 281' ' ' LYS . 5.8 p80 22.04 77.75 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.866 0 O-C-N 124.822 1.326 . . . . 0.0 113.866 179.304 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 32.3 tp60 -62.03 -50.52 71.7 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.177 -179.055 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 279' ' ' ILE . . . . . 0.582 ' H ' ' HB3' ' A' ' 282' ' ' ASP . 2.5 mp -104.43 -77.44 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 174.814 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 35.9 p -141.11 92.61 2.5 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 177.477 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 281' ' ' LYS . . . . . 0.43 ' HA ' ' HB3' ' A' ' 277' ' ' HIS . 31.7 mmmt 59.82 26.99 16.23 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.058 -0.973 . . . . 0.0 110.503 -172.6 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 282' ' ' ASP . . . . . 0.582 ' HB3' ' H ' ' A' ' 279' ' ' ILE . 37.3 t70 -81.01 117.38 21.56 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.338 -0.846 . . . . 0.0 109.858 178.605 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 41.1 p -105.52 105.78 15.97 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.991 0.424 . . . . 0.0 110.931 -176.502 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 52.9 p -129.18 -7.58 4.82 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.183 -177.953 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 67.82 32.6 78.06 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.601 -0.809 . . . . 0.0 113.368 176.249 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 286' ' ' GLN . . . . . 0.415 ' HA ' ' HD3' ' A' ' 287' ' ' PRO . 11.7 mm100 -72.09 135.89 82.32 Favored Pre-proline 0 C--N 1.325 -0.479 0 CA-C-N 117.06 0.43 . . . . 0.0 110.2 179.106 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 287' ' ' PRO . . . . . 0.468 ' HB2' HG21 ' A' ' 269' ' ' THR . 41.0 Cg_exo -57.0 135.0 68.21 Favored 'Trans proline' 0 C--O 1.235 0.333 0 C-N-CA 122.465 2.11 . . . . 0.0 111.958 -178.778 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 2.5 tm0? -75.08 128.93 36.67 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 -177.294 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 46.4 t -94.19 123.83 46.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.935 0.398 . . . . 0.0 110.512 -177.621 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 290' ' ' PHE . . . . . 0.621 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 4.6 m-85 -97.28 168.6 10.32 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.818 -177.214 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 11.9 tpt180 -139.37 121.16 15.41 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 177.355 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 60.7 t -75.61 134.25 29.58 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.913 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.868 -172.824 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 293' ' ' LEU . . . . . 0.621 HD11 ' HB3' ' A' ' 303' ' ' SER . 7.0 mp -104.38 -35.2 8.02 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.628 178.388 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 294' ' ' ALA . . . . . 0.529 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -149.75 137.95 20.51 Favored 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 120.667 -0.413 . . . . 0.0 111.641 -176.545 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 66.5 t -136.03 109.63 9.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.555 174.79 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 50.4 m -151.48 117.02 5.38 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.544 -177.279 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 61.21 46.97 93.4 Favored Glycine 0 C--N 1.33 0.218 0 C-N-CA 120.804 -0.712 . . . . 0.0 111.79 -177.83 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 76.3 p 51.78 19.79 1.01 Allowed 'General case' 0 N--CA 1.471 0.587 0 C-N-CA 123.76 0.824 . . . . 0.0 112.427 -175.169 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 54.3 m -105.22 116.68 32.35 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 176.756 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 300' ' ' VAL . . . . . 0.529 ' HA ' ' O ' ' A' ' 294' ' ' ALA . 49.0 t -114.21 125.77 71.58 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.288 -172.753 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 53.9 m -87.77 115.76 25.44 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 172.78 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 302' ' ' ILE . . . . . 0.49 ' O ' ' HB3' ' A' ' 252' ' ' GLN . 28.6 pt -110.81 147.81 14.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-O 121.867 0.842 . . . . 0.0 113.156 -169.012 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 303' ' ' SER . . . . . 0.621 ' HB3' HD11 ' A' ' 293' ' ' LEU . 48.2 t -151.23 148.82 23.27 Favored Pre-proline 0 C--N 1.317 -0.812 0 CA-C-N 113.808 -1.542 . . . . 0.0 106.911 174.487 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 304' ' ' PRO . . . . . 0.476 ' C ' ' HA ' ' A' ' 303' ' ' SER . 32.2 Cg_exo -64.31 152.71 74.16 Favored 'Cis proline' 0 C--N 1.332 -0.302 0 C-N-CA 124.252 -1.145 . . . . 0.0 113.299 0.969 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 305' ' ' LYS . . . . . 0.452 ' HE3' HD11 ' A' ' 307' ' ' LEU . 0.0 OUTLIER -82.04 148.81 28.41 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-N 114.888 -1.051 . . . . 0.0 110.184 173.761 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 306' ' ' ILE . . . . . 1.011 HG21 ' HA ' ' A' ' 325' ' ' LYS . 42.5 mm -84.23 117.85 30.47 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 N-CA-C 113.02 0.748 . . . . 0.0 113.02 -167.626 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 307' ' ' LEU . . . . . 0.452 HD11 ' HE3' ' A' ' 305' ' ' LYS . 82.1 mt -121.46 100.0 44.94 Favored Pre-proline 0 C--N 1.331 -0.199 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.782 177.314 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 308' ' ' PRO . . . . . 0.756 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 16.0 Cg_exo -72.74 134.48 22.06 Favored 'Trans proline' 0 C--O 1.232 0.218 0 C-N-CA 123.19 2.593 . . . . 0.0 113.611 -176.271 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 309' ' ' VAL . . . . . 0.678 ' HA ' ' HB2' ' A' ' 316' ' ' SER . 46.4 t -72.18 -34.66 50.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.356 0.598 . . . . 0.0 109.409 171.345 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 87.8 mt-10 -77.07 36.27 0.17 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.288 -0.869 . . . . 0.0 111.939 179.777 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.404 ' HB2' ' HB2' ' A' ' 308' ' ' PRO . 0.4 OUTLIER -122.3 56.71 1.1 Allowed 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 -178.751 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 312' ' ' THR . . . . . 0.568 ' HB ' HG23 ' A' ' 314' ' ' VAL . 30.0 m 60.35 17.43 7.12 Favored 'General case' 0 CA--C 1.539 0.553 0 CA-C-O 121.716 0.77 . . . . 0.0 109.411 -171.762 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 37.1 t70 69.53 -2.58 1.88 Allowed 'General case' 0 CA--C 1.537 0.466 0 CA-C-N 114.728 -1.124 . . . . 0.0 111.233 -177.369 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 314' ' ' VAL . . . . . 0.568 HG23 ' HB ' ' A' ' 312' ' ' THR . 57.6 t -57.44 -45.59 85.67 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 N-CA-C 112.723 0.638 . . . . 0.0 112.723 -177.759 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 315' ' ' ALA . . . . . 0.53 ' HB3' ' O ' ' A' ' 308' ' ' PRO . . . -74.44 -17.54 60.77 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.021 0.439 . . . . 0.0 110.899 -179.714 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 316' ' ' SER . . . . . 0.678 ' HB2' ' HA ' ' A' ' 309' ' ' VAL . 44.3 t -81.36 -18.72 44.64 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.552 177.126 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 317' ' ' ARG . . . . . 0.684 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 37.3 mmm-85 -61.1 -55.84 40.34 Favored Pre-proline 0 CA--C 1.536 0.42 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.635 -176.97 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 318' ' ' PRO . . . . . 0.684 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 11.8 Cg_exo -71.98 -41.13 2.18 Favored 'Trans proline' 0 C--N 1.357 1.003 0 C-N-CA 121.565 1.51 . . . . 0.0 112.588 -178.516 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER 177.35 96.67 0.01 OUTLIER 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.103 177.653 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 320' ' ' ALA . . . . . 0.617 ' HB2' ' HA ' ' A' ' 316' ' ' SER . . . -69.68 138.51 53.02 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.077 176.899 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 19.6 p30 -129.23 -27.9 2.41 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.479 -0.328 . . . . 0.0 111.57 176.833 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 322' ' ' VAL . . . . . 0.843 HG21 HG23 ' A' ' 306' ' ' ILE . 35.1 m -138.31 179.49 3.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.703 0.287 . . . . 0.0 110.596 177.758 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 -90.38 -32.72 16.33 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.502 177.776 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 324' ' ' ALA . . . . . 0.756 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -149.2 159.51 44.19 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.638 -0.255 . . . . 0.0 111.478 -175.351 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 325' ' ' LYS . . . . . 1.011 ' HA ' HG21 ' A' ' 306' ' ' ILE . 64.3 pttt -79.94 146.9 64.79 Favored Pre-proline 0 N--CA 1.452 -0.335 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 171.413 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 326' ' ' PRO . . . . . 0.548 ' HD3' HG21 ' A' ' 306' ' ' ILE . 50.6 Cg_exo -57.33 129.81 36.02 Favored 'Trans proline' 0 N--CA 1.462 -0.365 0 C-N-CA 122.253 1.969 . . . . 0.0 111.873 -178.299 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -75.13 121.79 22.61 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 174.285 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER 61.95 -135.95 0.52 Allowed 'General case' 0 C--N 1.332 -0.158 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 -167.474 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 329' ' ' SER . . . . . 0.718 ' HB2' ' O ' ' A' ' 230' ' ' VAL . 50.5 m -113.95 -41.45 3.55 Favored 'General case' 0 C--N 1.32 -0.711 0 C-N-CA 120.16 -0.616 . . . . 0.0 109.871 169.67 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 330' ' ' ALA . . . . . 0.436 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 79.77 -171.04 0.04 OUTLIER 'General case' 0 N--CA 1.479 1.008 0 O-C-N 124.129 0.893 . . . . 0.0 113.394 170.819 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -83.77 157.22 22.17 Favored 'General case' 0 C--O 1.233 0.213 0 CA-C-N 115.176 -0.92 . . . . 0.0 111.107 -176.823 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 332' ' ' ILE . . . . . 1.056 HD11 HG23 ' A' ' 230' ' ' VAL . 1.5 mp -126.37 146.37 32.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.474 -174.854 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 333' ' ' THR . . . . . 0.417 ' HB ' ' OG1' ' A' ' 269' ' ' THR . 88.6 m -110.66 99.16 8.16 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.998 -0.742 . . . . 0.0 108.998 173.251 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 37.8 mm -81.58 125.7 39.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -171.238 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 335' ' ' LEU . . . . . 0.432 ' HB2' ' O ' ' A' ' 267' ' ' ALA . 8.2 mp -113.07 167.3 10.64 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.074 -0.966 . . . . 0.0 109.958 172.167 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 74.0 m-80 -124.33 6.57 8.4 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 115.315 -0.857 . . . . 0.0 109.271 174.969 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 337' ' ' LYS . . . . . 0.483 ' HE3' ' O ' ' A' ' 265' ' ' GLY . 21.5 pttp . . . . . 0 C--O 1.244 0.798 0 O-C-N 124.656 1.223 . . . . 0.0 112.565 -179.418 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 29.0 t . . . . . 0 N--CA 1.457 -0.114 0 CA-C-O 121.559 0.695 . . . . 0.0 109.499 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 228' ' ' LEU . . . . . 0.498 HD13 ' H ' ' A' ' 260' ' ' SER . 89.8 mt -99.77 146.79 26.17 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.274 -0.875 . . . . 0.0 109.237 178.533 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 229' ' ' THR . . . . . 0.429 ' HA ' ' HA ' ' A' ' 331' ' ' ALA . 72.5 p -128.93 178.75 6.16 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 119.835 -0.746 . . . . 0.0 111.075 -177.89 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 230' ' ' VAL . . . . . 0.652 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 75.7 t -147.15 127.68 5.39 Favored 'Isoleucine or valine' 0 C--O 1.237 0.434 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.482 -178.918 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 34.1 t -92.53 145.18 24.64 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.012 176.961 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 115.46 141.64 7.44 Favored Glycine 0 N--CA 1.444 -0.773 0 C-N-CA 120.619 -0.801 . . . . 0.0 111.647 -179.097 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 233' ' ' GLN . . . . . 0.922 ' HG3' ' H ' ' A' ' 328' ' ' GLU . 15.0 mp0 -101.75 103.69 30.16 Favored Pre-proline 0 C--N 1.321 -0.638 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 -177.739 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -85.3 122.47 2.47 Favored 'Trans proline' 0 N--CA 1.45 -1.084 0 C-N-CA 121.485 1.457 . . . . 0.0 111.751 179.64 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 235' ' ' GLU . . . . . 0.479 ' HG2' ' HB3' ' A' ' 325' ' ' LYS . 54.2 mt-10 -154.07 120.05 5.32 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.328 178.787 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 63.3 t-80 -138.64 146.77 42.08 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 174.474 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 237' ' ' LYS . . . . . 0.659 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 5.8 mptt . . . . . 0 C--N 1.326 -0.415 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.765 -169.484 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 4.7 mp0 . . . . . 0 N--CA 1.444 -0.749 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 253' ' ' GLY . . . . . 0.605 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -80.75 93.08 1.46 Allowed Glycine 0 N--CA 1.446 -0.643 0 C-N-CA 120.312 -0.947 . . . . 0.0 112.23 177.748 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 72.7 p -94.5 116.33 28.66 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.022 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 2.1 pp -136.24 171.53 16.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 N-CA-C 113.012 0.745 . . . . 0.0 113.012 -173.121 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 64.9 m -111.65 117.89 34.15 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 177.505 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.461 ' HB ' ' H ' ' A' ' 259' ' ' ALA . 34.9 m -90.9 144.7 8.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 N-CA-C 113.838 1.051 . . . . 0.0 113.838 -169.101 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 258' ' ' SER . . . . . 0.417 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 39.2 t -92.22 8.42 38.2 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 113.772 -1.558 . . . . 0.0 108.339 166.188 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 259' ' ' ALA . . . . . 0.461 ' H ' ' HB ' ' A' ' 257' ' ' VAL . . . -92.85 166.13 12.57 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.274 -0.876 . . . . 0.0 109.908 -177.52 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 260' ' ' SER . . . . . 0.498 ' H ' HD13 ' A' ' 228' ' ' LEU . 32.4 t -139.17 137.09 35.75 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.77 0.319 . . . . 0.0 110.158 178.949 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 97.26 29.4 7.96 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.199 -177.821 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 262' ' ' LEU . . . . . 0.442 HD12 HG21 ' A' ' 257' ' ' VAL . 79.2 mt -101.63 126.78 48.52 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.107 0.479 . . . . 0.0 111.16 -179.617 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 97.0 mm-40 -134.11 -178.92 5.25 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.257 -0.883 . . . . 0.0 108.873 177.359 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 41.0 t -77.81 131.12 35.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 176.653 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 106.41 9.01 32.16 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.305 -0.95 . . . . 0.0 113.195 179.021 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -88.88 163.32 15.68 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.994 0.426 . . . . 0.0 110.31 176.57 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 267' ' ' ALA . . . . . 0.715 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -135.38 146.52 48.42 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.474 -0.784 . . . . 0.0 109.023 177.917 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 268' ' ' PHE . . . . . 0.407 ' HZ ' HG21 ' A' ' 302' ' ' ILE . 2.7 p90 -163.87 175.48 10.38 Favored 'General case' 0 C--N 1.325 -0.489 0 C-N-CA 120.054 -0.658 . . . . 0.0 111.709 -177.841 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 73.9 p -125.41 144.69 50.4 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.471 -0.786 . . . . 0.0 109.131 173.808 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 270' ' ' ILE . . . . . 0.402 ' HB ' ' HB ' ' A' ' 273' ' ' VAL . 58.7 mt -103.14 141.66 18.57 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 C-N-CA 121.127 -0.229 . . . . 0.0 110.968 -176.752 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -67.38 125.79 27.23 Favored 'General case' 0 C--O 1.232 0.133 0 CA-C-O 120.869 0.366 . . . . 0.0 110.947 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 91.82 -22.24 32.23 Favored Glycine 0 N--CA 1.453 -0.189 0 C-N-CA 121.058 -0.591 . . . . 0.0 112.194 -178.262 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 273' ' ' VAL . . . . . 0.402 ' HB ' ' HB ' ' A' ' 270' ' ' ILE . 48.9 t -94.58 102.55 13.73 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-O 121.33 0.586 . . . . 0.0 110.743 178.346 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 274' ' ' ASN . . . . . 0.687 ' HA ' ' HA ' ' A' ' 287' ' ' PRO . 70.7 m-80 -110.17 150.83 28.08 Favored 'General case' 0 C--N 1.318 -0.801 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 174.967 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 275' ' ' SER . . . . . 0.488 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 7.6 t -85.35 -169.58 2.71 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 120.301 -0.559 . . . . 0.0 110.092 -174.98 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 27.3 m -113.27 177.46 1.66 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 CA-C-N 115.612 -0.722 . . . . 0.0 112.054 179.553 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 277' ' ' HIS . . . . . 0.792 ' CG ' ' HA ' ' A' ' 281' ' ' LYS . 3.4 p80 -57.03 119.69 6.73 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 113.893 -1.503 . . . . 0.0 111.838 173.695 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -81.94 -49.52 10.21 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.987 -177.867 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 279' ' ' ILE . . . . . 0.659 ' H ' HD12 ' A' ' 279' ' ' ILE . 2.7 mp -68.18 -93.74 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.401 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.163 -174.759 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 280' ' ' THR . . . . . 0.431 HG23 HG22 ' A' ' 279' ' ' ILE . 36.2 p -137.98 68.24 1.4 Allowed 'General case' 0 C--O 1.235 0.307 0 CA-C-O 120.637 0.256 . . . . 0.0 111.393 -174.939 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 281' ' ' LYS . . . . . 0.792 ' HA ' ' CG ' ' A' ' 277' ' ' HIS . 0.0 OUTLIER 56.59 32.33 20.74 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.675 -177.016 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 282' ' ' ASP . . . . . 0.579 ' O ' ' HB3' ' A' ' 277' ' ' HIS . 1.6 m-20 -74.86 -177.03 3.11 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.645 176.134 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 68.9 p -106.57 108.07 19.39 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 120.76 0.314 . . . . 0.0 110.211 178.258 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 74.8 p -117.07 -58.29 2.08 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.681 -175.314 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 64.24 30.85 78.97 Favored Glycine 0 C--O 1.23 -0.124 0 C-N-CA 121.064 -0.589 . . . . 0.0 113.347 174.633 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 46.2 mm-40 -101.12 129.69 26.58 Favored Pre-proline 0 C--N 1.323 -0.584 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 179.259 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 287' ' ' PRO . . . . . 0.687 ' HA ' ' HA ' ' A' ' 274' ' ' ASN . 48.3 Cg_exo -56.16 138.15 82.02 Favored 'Trans proline' 0 C--N 1.344 0.329 0 C-N-CA 122.563 2.175 . . . . 0.0 112.159 -179.356 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 288' ' ' GLN . . . . . 0.47 ' HA ' HE21 ' A' ' 288' ' ' GLN . 2.2 tp-100 -64.81 139.9 58.81 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.78 -179.069 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 52.8 t -97.42 124.0 50.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 176.205 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 290' ' ' PHE . . . . . 0.715 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 6.2 m-85 -98.87 151.44 20.85 Favored 'General case' 0 C--N 1.323 -0.559 0 C-N-CA 120.884 -0.326 . . . . 0.0 110.876 -174.578 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 37.2 mmt180 -116.97 118.86 33.59 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.691 -0.686 . . . . 0.0 109.34 174.187 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 48.9 t -75.56 127.52 37.05 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.954 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.874 -178.517 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 293' ' ' LEU . . . . . . . . . . . . . 84.8 mt -110.84 -19.48 12.81 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.928 -176.957 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 294' ' ' ALA . . . . . 0.663 ' HB3' ' HB ' ' A' ' 301' ' ' THR . . . -155.72 138.3 15.05 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 111.85 0.315 . . . . 0.0 111.85 -178.887 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 295' ' ' VAL . . . . . 0.438 HG22 HG13 ' A' ' 300' ' ' VAL . 60.5 t -138.14 132.59 42.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 175.039 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 41.5 t -157.95 110.61 2.38 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.677 -0.238 . . . . 0.0 110.97 -176.954 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 60.76 46.03 95.29 Favored Glycine 0 C--N 1.33 0.25 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.028 179.798 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 298' ' ' THR . . . . . 0.42 ' O ' HG22 ' A' ' 257' ' ' VAL . 75.6 p 53.91 17.9 1.47 Allowed 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 123.887 0.875 . . . . 0.0 112.647 -175.845 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 52.9 m -102.77 109.55 21.18 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 108.015 -1.106 . . . . 0.0 108.015 171.171 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 300' ' ' VAL . . . . . 0.438 HG13 HG22 ' A' ' 295' ' ' VAL . 39.9 t -104.56 134.69 45.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.715 -169.124 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 301' ' ' THR . . . . . 0.663 ' HB ' ' HB3' ' A' ' 294' ' ' ALA . 94.3 m -96.99 109.31 22.08 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.352 -0.84 . . . . 0.0 108.997 172.626 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 302' ' ' ILE . . . . . 0.605 HG12 ' O ' ' A' ' 253' ' ' GLY . 30.2 pt -110.66 138.06 40.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-O 121.648 0.737 . . . . 0.0 111.922 -175.37 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 303' ' ' SER . . . . . . . . . . . . . 50.5 m -129.54 150.95 77.1 Favored Pre-proline 0 C--N 1.317 -0.846 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 173.162 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 304' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_exo -68.22 176.54 27.47 Favored 'Cis proline' 0 C--N 1.333 -0.282 0 C-N-CA 124.637 -0.985 . . . . 0.0 112.892 1.015 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 305' ' ' LYS . . . . . 0.888 ' HE2' HD11 ' A' ' 307' ' ' LEU . 0.0 OUTLIER -94.04 166.81 11.96 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.492 178.583 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 306' ' ' ILE . . . . . 0.599 HG22 ' HG2' ' A' ' 325' ' ' LYS . 42.6 mm -87.47 96.3 5.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.366 -174.144 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 307' ' ' LEU . . . . . 0.888 HD11 ' HE2' ' A' ' 305' ' ' LYS . 84.2 mt -106.82 110.32 63.6 Favored Pre-proline 0 C--N 1.33 -0.28 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 175.859 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 308' ' ' PRO . . . . . 0.632 ' HG3' ' HE3' ' A' ' 325' ' ' LYS . 79.1 Cg_endo -82.69 157.8 16.24 Favored 'Trans proline' 0 C--O 1.231 0.143 0 C-N-CA 122.512 2.141 . . . . 0.0 114.364 -172.12 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 39.6 t -81.76 -11.17 12.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 114.958 -1.019 . . . . 0.0 108.467 168.782 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 4.6 mm-40 -70.54 -7.03 40.77 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.19 -0.914 . . . . 0.0 110.219 176.618 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 23.8 t-20 -64.07 118.29 8.3 Favored 'General case' 0 N--CA 1.451 -0.391 0 CA-C-N 115.605 -0.725 . . . . 0.0 109.45 -179.141 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 19.5 m -86.3 -17.19 35.25 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.36 -171.441 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 313' ' ' ASP . . . . . 0.589 ' O ' ' HG3' ' A' ' 317' ' ' ARG . 9.8 t70 -71.83 118.58 14.86 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 178.438 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 314' ' ' VAL . . . . . 0.406 ' HA ' ' CD ' ' A' ' 317' ' ' ARG . 41.2 t -59.08 -36.4 62.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.054 -0.521 . . . . 0.0 112.273 -173.906 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -73.87 -25.36 60.0 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.502 0.191 . . . . 0.0 111.38 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 32.6 t -94.55 -6.22 44.16 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.693 -0.23 . . . . 0.0 111.096 -179.007 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 317' ' ' ARG . . . . . 0.589 ' HG3' ' O ' ' A' ' 313' ' ' ASP . 76.4 mtp180 -59.52 -49.6 91.39 Favored Pre-proline 0 N--CA 1.468 0.464 0 N-CA-C 112.392 0.516 . . . . 0.0 112.392 177.837 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 318' ' ' PRO . . . . . 0.515 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 54.3 Cg_exo -56.5 -24.4 52.86 Favored 'Trans proline' 0 C--N 1.359 1.118 0 C-N-CA 122.477 2.118 . . . . 0.0 112.756 -179.803 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 11.6 m-30 -77.08 -6.19 51.84 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.369 -0.832 . . . . 0.0 111.495 -175.68 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -54.85 130.28 40.51 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-O 120.976 0.417 . . . . 0.0 111.723 -177.662 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 26.7 t-20 -110.71 -37.88 5.31 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.663 -0.699 . . . . 0.0 109.554 179.294 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 322' ' ' VAL . . . . . 0.521 HG21 HG23 ' A' ' 306' ' ' ILE . 34.4 m -130.74 170.28 19.86 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 115.267 -0.879 . . . . 0.0 110.16 179.083 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 73.2 m-20 -62.11 -44.14 97.31 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 112.386 0.513 . . . . 0.0 112.386 -177.782 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 324' ' ' ALA . . . . . 0.509 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -156.56 168.41 27.47 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 112.666 0.617 . . . . 0.0 112.666 -172.493 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 325' ' ' LYS . . . . . 0.632 ' HE3' ' HG3' ' A' ' 308' ' ' PRO . 9.9 mtmp? -102.05 106.45 47.87 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 114.816 -1.084 . . . . 0.0 108.531 167.582 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -80.24 162.51 22.77 Favored 'Trans proline' 0 N--CA 1.459 -0.506 0 C-N-CA 122.018 1.812 . . . . 0.0 112.58 -175.59 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -80.03 122.55 26.88 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 174.953 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 328' ' ' GLU . . . . . 0.922 ' H ' ' HG3' ' A' ' 233' ' ' GLN . 85.0 tt0 71.89 162.81 0.26 Allowed 'General case' 0 CA--C 1.532 0.251 0 O-C-N 124.093 0.87 . . . . 0.0 109.672 -176.006 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 329' ' ' SER . . . . . 0.652 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 50.6 m -85.34 -14.57 46.02 Favored 'General case' 0 C--N 1.323 -0.554 0 C-N-CA 120.913 -0.315 . . . . 0.0 110.861 -177.375 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 330' ' ' ALA . . . . . 0.48 ' H ' ' HG2' ' A' ' 328' ' ' GLU . . . 63.5 -160.36 0.3 Allowed 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 121.381 0.61 . . . . 0.0 112.611 173.015 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 331' ' ' ALA . . . . . 0.429 ' HA ' ' HA ' ' A' ' 229' ' ' THR . . . -82.03 148.14 28.79 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.292 -0.867 . . . . 0.0 110.131 178.253 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 332' ' ' ILE . . . . . . . . . . . . . 43.4 mt -124.24 144.63 33.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-O 121.169 0.509 . . . . 0.0 111.304 -178.148 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 29.6 m -104.21 97.7 7.62 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.494 -0.775 . . . . 0.0 109.217 179.611 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 36.4 mm -78.55 127.91 38.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 112.858 0.688 . . . . 0.0 112.858 -170.772 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 335' ' ' LEU . . . . . . . . . . . . . 8.2 mp -109.15 176.13 5.2 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 114.871 -1.059 . . . . 0.0 110.122 171.541 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 23.0 p30 -131.61 9.57 4.67 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 115.321 -0.854 . . . . 0.0 109.628 173.526 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 337' ' ' LYS . . . . . 0.536 ' NZ ' ' HB3' ' A' ' 337' ' ' LYS . 8.1 mtpm? . . . . . 0 C--O 1.244 0.794 0 CA-C-O 118.552 -0.737 . . . . 0.0 110.891 178.745 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 65.9 p . . . . . 0 N--CA 1.453 -0.313 0 CA-C-O 121.329 0.585 . . . . 0.0 109.812 . . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 228' ' ' LEU . . . . . 0.617 HD22 ' HA ' ' A' ' 259' ' ' ALA . 83.4 mt -98.01 126.82 43.6 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-N 115.614 -0.721 . . . . 0.0 109.761 -179.548 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 55.5 p -124.73 179.24 5.07 Favored 'General case' 0 C--N 1.322 -0.625 0 C-N-CA 120.458 -0.497 . . . . 0.0 110.3 -179.611 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 230' ' ' VAL . . . . . 0.712 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 63.5 t -147.63 146.92 17.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 120.602 0.239 . . . . 0.0 110.672 -178.234 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 231' ' ' SER . . . . . 0.528 ' HA ' ' HB3' ' A' ' 328' ' ' GLU . 48.9 m -132.11 96.62 3.94 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 173.386 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 232' ' ' GLY . . . . . 0.628 ' HA3' HG22 ' A' ' 255' ' ' ILE . . . -122.5 -163.05 11.74 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 119.854 -1.165 . . . . 0.0 113.693 -172.889 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 233' ' ' GLN . . . . . 0.581 ' HB3' ' HD2' ' A' ' 234' ' ' PRO . 94.6 mm-40 -85.49 163.63 43.76 Favored Pre-proline 0 C--N 1.327 -0.397 0 CA-C-N 115.615 -0.293 . . . . 0.0 110.541 -178.833 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 234' ' ' PRO . . . . . 0.581 ' HD2' ' HB3' ' A' ' 233' ' ' GLN . 9.5 Cg_endo -55.37 134.3 63.1 Favored 'Trans proline' 0 C--N 1.35 0.646 0 C-N-CA 122.871 2.38 . . . . 0.0 113.442 -176.51 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 235' ' ' GLU . . . . . 0.564 ' HB2' ' CE ' ' A' ' 325' ' ' LYS . 57.7 mt-10 -97.18 124.79 41.34 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 114.982 -1.008 . . . . 0.0 108.452 177.903 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 236' ' ' HIS . . . . . 0.441 ' HB2' HD21 ' A' ' 307' ' ' LEU . 6.3 p80 -174.1 172.81 3.27 Favored 'General case' 0 CA--C 1.521 -0.152 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 -175.145 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 237' ' ' LYS . . . . . 0.793 ' HB3' ' HG3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER . . . . . 0 CA--C 1.529 0.172 0 CA-C-O 121.546 0.688 . . . . 0.0 110.881 165.649 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 42.0 mm-40 . . . . . 0 N--CA 1.471 0.606 0 CA-C-O 122.039 0.923 . . . . 0.0 113.425 . . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -172.11 113.33 0.48 Allowed Glycine 0 N--CA 1.448 -0.555 0 CA-C-N 114.723 -1.126 . . . . 0.0 110.644 178.418 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 74.1 p -95.52 117.47 30.47 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 117.399 0.599 . . . . 0.0 110.771 -175.152 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.628 HG22 ' HA3' ' A' ' 232' ' ' GLY . 22.7 pt -120.81 132.59 69.93 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-O 121.239 0.542 . . . . 0.0 111.97 -175.447 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 60.7 m -88.34 110.55 20.86 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 173.874 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.42 ' HA ' HG13 ' A' ' 230' ' ' VAL . 33.2 m -90.1 143.06 11.98 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.84 0 C-N-CA 119.341 -0.943 . . . . 0.0 112.798 -167.89 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 25.0 m -91.61 9.23 33.09 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 113.852 -1.522 . . . . 0.0 108.301 169.915 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 259' ' ' ALA . . . . . 0.617 ' HA ' HD22 ' A' ' 228' ' ' LEU . . . -100.5 178.19 4.8 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 114.725 -1.125 . . . . 0.0 109.55 -177.314 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 42.0 t -145.03 151.38 38.46 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.782 0.325 . . . . 0.0 110.79 179.113 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 84.52 15.87 67.57 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.982 -0.628 . . . . 0.0 112.876 178.544 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 262' ' ' LEU . . . . . 0.437 ' O ' HG11 ' A' ' 295' ' ' VAL . 63.4 mt -85.38 129.92 34.7 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.678 0.275 . . . . 0.0 110.703 -179.11 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 14.4 mm-40 -139.95 173.04 11.92 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.726 178.93 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 36.1 t -67.63 137.89 23.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 C-N-CA 121.001 -0.279 . . . . 0.0 110.34 -179.852 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 101.93 4.7 51.24 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.541 -0.837 . . . . 0.0 112.962 177.648 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 68.4 m-20 -85.84 137.7 32.58 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.257 0.551 . . . . 0.0 110.143 177.193 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 267' ' ' ALA . . . . . 0.624 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -119.85 122.98 42.52 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.262 -0.881 . . . . 0.0 108.741 178.07 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 268' ' ' PHE . . . . . 0.531 ' HB3' ' HA ' ' A' ' 334' ' ' ILE . 7.8 p90 -142.3 168.31 20.05 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.097 -0.641 . . . . 0.0 112.309 -169.893 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 76.0 p -115.4 162.77 16.68 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 114.859 -1.064 . . . . 0.0 108.486 170.89 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 270' ' ' ILE . . . . . . . . . . . . . 59.5 mt -126.05 141.96 44.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.693 -178.5 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -66.36 112.51 4.06 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.97 179.439 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 272' ' ' GLY . . . . . 0.434 ' HA3' ' HG3' ' A' ' 326' ' ' PRO . . . 104.21 -9.43 50.04 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.642 -0.789 . . . . 0.0 112.467 179.947 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 273' ' ' VAL . . . . . 0.502 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 58.3 t -102.15 102.95 14.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.884 0.373 . . . . 0.0 110.17 178.796 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 6.9 m120 -126.76 116.38 20.83 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.058 -177.352 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 275' ' ' SER . . . . . 0.478 ' HB3' ' HB2' ' A' ' 288' ' ' GLN . 29.2 p -72.72 161.78 30.32 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 113.24 0.83 . . . . 0.0 113.24 -172.401 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 19.4 m -118.21 178.6 2.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 114.644 -1.162 . . . . 0.0 110.165 178.436 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 85.1 m-70 -112.23 105.08 13.31 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 171.548 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 4.9 mp0 -74.18 -35.88 64.01 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.645 -0.252 . . . . 0.0 111.329 -173.445 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 279' ' ' ILE . . . . . 0.507 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.1 mp -67.9 -55.94 14.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.983 -176.007 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 75.9 p -88.33 -3.81 58.78 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 111.782 0.289 . . . . 0.0 111.782 -177.64 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 28.0 tptp 58.81 53.1 6.04 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 121.441 0.638 . . . . 0.0 110.23 179.391 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -117.03 136.75 52.72 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.605 -176.93 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 66.8 p -107.63 127.53 53.74 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.149 -179.943 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 70.7 p -134.49 -30.75 1.11 Allowed 'General case' 0 C--N 1.321 -0.645 0 CA-C-O 120.774 0.321 . . . . 0.0 111.424 -176.709 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 79.39 32.48 38.25 Favored Glycine 0 N--CA 1.448 -0.536 0 C-N-CA 120.408 -0.901 . . . . 0.0 112.666 178.214 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 71.3 mt-30 -85.0 124.43 72.39 Favored Pre-proline 0 C--N 1.326 -0.415 0 CA-C-N 116.903 0.352 . . . . 0.0 110.489 179.973 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 287' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_exo -59.53 126.0 19.44 Favored 'Trans proline' 0 C--N 1.345 0.395 0 C-N-CA 122.281 1.988 . . . . 0.0 111.285 178.272 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 288' ' ' GLN . . . . . 0.478 ' HB2' ' HB3' ' A' ' 275' ' ' SER . 50.6 tt0 -80.4 150.55 29.76 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.045 0.45 . . . . 0.0 111.589 -175.212 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 289' ' ' VAL . . . . . 0.497 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 50.0 t -99.16 127.35 51.93 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 CA-C-N 115.327 -0.851 . . . . 0.0 110.221 179.278 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 290' ' ' PHE . . . . . 0.624 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 4.0 m-85 -101.2 168.7 9.4 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.562 -0.29 . . . . 0.0 111.025 -176.771 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 21.6 mmt85 -126.49 120.78 30.55 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.264 0.554 . . . . 0.0 110.745 174.418 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 59.5 t -78.24 128.56 38.23 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.829 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.313 176.035 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 293' ' ' LEU . . . . . . . . . . . . . 83.5 mt -109.0 -30.09 8.25 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 111.986 0.365 . . . . 0.0 111.986 -177.762 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 294' ' ' ALA . . . . . 0.585 ' HB3' ' HB ' ' A' ' 301' ' ' THR . . . -152.44 139.94 19.65 Favored 'General case' 0 C--N 1.329 -0.296 0 C-N-CA 121.171 -0.212 . . . . 0.0 111.334 179.717 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 295' ' ' VAL . . . . . 0.685 HG22 HG13 ' A' ' 300' ' ' VAL . 55.3 t -133.48 128.52 54.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 175.118 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 27.2 m -145.64 97.13 2.93 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.917 -176.316 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 57.45 61.03 7.94 Favored Glycine 0 C--N 1.33 0.224 0 C-N-CA 121.009 -0.615 . . . . 0.0 112.531 178.814 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 81.8 p 56.71 5.4 0.21 Allowed 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 124.395 1.078 . . . . 0.0 113.253 -177.17 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 97.4 m -97.88 106.31 18.6 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 171.623 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 300' ' ' VAL . . . . . 0.733 HG12 HG23 ' A' ' 302' ' ' ILE . 38.8 t -109.26 120.93 61.48 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.797 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.193 -170.883 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 301' ' ' THR . . . . . 0.585 ' HB ' ' HB3' ' A' ' 294' ' ' ALA . 52.6 m -89.66 105.7 17.98 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 174.526 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 302' ' ' ILE . . . . . 0.733 HG23 HG12 ' A' ' 300' ' ' VAL . 2.4 pp -111.72 179.13 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 121.893 0.854 . . . . 0.0 112.861 -174.898 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 303' ' ' SER . . . . . 0.419 ' HA ' ' O ' ' A' ' 304' ' ' PRO . 67.5 p -160.0 157.47 25.43 Favored Pre-proline 0 C--N 1.314 -0.961 0 CA-C-N 113.668 -1.606 . . . . 0.0 106.678 174.714 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 304' ' ' PRO . . . . . 0.419 ' O ' ' HA ' ' A' ' 303' ' ' SER . 3.8 Cg_exo -78.26 -141.67 0.2 Allowed 'Cis proline' 0 CA--C 1.536 0.605 0 CA-C-N 119.84 0.979 . . . . 0.0 112.993 1.057 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 305' ' ' LYS . . . . . 0.793 ' HG3' ' HB3' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -130.4 171.02 13.42 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.014 -178.545 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 306' ' ' ILE . . . . . 0.415 ' HB ' ' CB ' ' A' ' 235' ' ' GLU . 47.2 mm -132.36 129.35 59.38 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.619 0 C-N-CA 119.242 -0.983 . . . . 0.0 113.57 -164.765 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 307' ' ' LEU . . . . . 0.71 HD13 ' HA ' ' A' ' 316' ' ' SER . 88.0 mt -134.39 125.44 17.75 Favored Pre-proline 0 CA--C 1.514 -0.435 0 CA-C-O 120.883 0.373 . . . . 0.0 111.459 170.287 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 308' ' ' PRO . . . . . 0.991 ' HG2' ' HB2' ' A' ' 311' ' ' ASN . 66.8 Cg_endo -84.24 157.71 13.0 Favored 'Trans proline' 0 N--CA 1.455 -0.782 0 C-N-CA 122.89 2.394 . . . . 0.0 112.711 179.041 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 44.5 t -80.79 -18.93 11.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-O 121.587 0.708 . . . . 0.0 109.126 172.104 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 54.7 mt-10 -94.62 34.91 1.27 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.475 -0.784 . . . . 0.0 111.141 177.613 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.991 ' HB2' ' HG2' ' A' ' 308' ' ' PRO . 19.6 t-20 -103.18 142.09 34.75 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -178.443 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 26.3 m -83.27 -7.46 59.59 Favored 'General case' 0 CA--C 1.54 0.587 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.447 -175.05 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 313' ' ' ASP . . . . . 0.42 ' O ' ' HG3' ' A' ' 317' ' ' ARG . 62.9 m-20 -79.62 140.11 37.23 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.684 0.278 . . . . 0.0 110.821 177.818 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 46.1 t -64.4 -45.63 95.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.655 -177.964 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -75.54 -22.42 57.07 Favored 'General case' 0 N--CA 1.464 0.262 0 N-CA-C 111.999 0.37 . . . . 0.0 111.999 -176.204 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 316' ' ' SER . . . . . 0.71 ' HA ' HD13 ' A' ' 307' ' ' LEU . 46.1 t -73.14 -21.52 60.7 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.533 -0.303 . . . . 0.0 111.771 -178.16 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 317' ' ' ARG . . . . . 0.687 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 73.0 mtp180 -74.24 -54.76 3.19 Favored Pre-proline 0 CA--C 1.536 0.434 0 N-CA-C 112.23 0.456 . . . . 0.0 112.23 -176.25 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 318' ' ' PRO . . . . . 0.687 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 16.8 Cg_exo -68.79 -38.66 9.81 Favored 'Trans proline' 0 C--N 1.354 0.848 0 C-N-CA 121.978 1.785 . . . . 0.0 112.268 -178.852 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 319' ' ' TYR . . . . . 0.436 ' O ' HD12 ' A' ' 307' ' ' LEU . 3.2 m-85 -90.11 30.43 1.09 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.089 0.471 . . . . 0.0 110.576 -179.903 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -65.9 159.41 25.6 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.679 -0.692 . . . . 0.0 111.059 179.454 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -142.43 -26.28 0.63 Allowed 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.866 -178.551 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 322' ' ' VAL . . . . . 0.461 HG12 ' HA ' ' A' ' 275' ' ' SER . 33.8 m -132.93 174.13 13.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.402 179.458 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -85.4 -12.76 51.28 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 112.068 0.395 . . . . 0.0 112.068 -179.05 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 324' ' ' ALA . . . . . 0.646 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -178.73 163.42 1.45 Allowed 'General case' 0 N--CA 1.469 0.485 0 CA-C-O 120.737 0.304 . . . . 0.0 111.619 -176.313 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 325' ' ' LYS . . . . . 0.596 ' HD2' ' HD3' ' A' ' 308' ' ' PRO . 6.7 mtpm? -120.56 134.13 24.15 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.731 172.974 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 326' ' ' PRO . . . . . 0.689 ' HB2' ' HB2' ' A' ' 330' ' ' ALA . 3.4 Cg_exo -78.26 167.81 22.6 Favored 'Trans proline' 0 N--CA 1.459 -0.549 0 C-N-CA 122.803 2.335 . . . . 0.0 111.578 177.101 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -65.18 137.15 57.43 Favored 'General case' 0 C--O 1.235 0.334 0 N-CA-C 110.129 -0.323 . . . . 0.0 110.129 177.886 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 328' ' ' GLU . . . . . 0.528 ' HB3' ' HA ' ' A' ' 231' ' ' SER . 55.2 mm-40 59.74 -128.41 1.12 Allowed 'General case' 0 C--O 1.232 0.164 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 -174.163 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 329' ' ' SER . . . . . 0.712 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 42.0 m -111.83 -10.55 14.01 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.548 -0.296 . . . . 0.0 110.204 175.339 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 330' ' ' ALA . . . . . 0.689 ' HB2' ' HB2' ' A' ' 326' ' ' PRO . . . 73.21 -166.39 0.11 Allowed 'General case' 0 N--CA 1.474 0.757 0 N-CA-C 113.56 0.948 . . . . 0.0 113.56 173.824 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -83.16 143.69 30.33 Favored 'General case' 0 CA--C 1.519 -0.223 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.56 -178.852 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 332' ' ' ILE . . . . . . . . . . . . . 23.1 mm -113.32 145.17 19.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.562 -171.875 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 29.7 m -118.98 96.59 5.3 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 174.314 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 334' ' ' ILE . . . . . 0.531 ' HA ' ' HB3' ' A' ' 268' ' ' PHE . 35.7 mm -83.15 130.07 36.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 N-CA-C 112.636 0.606 . . . . 0.0 112.636 -172.968 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 335' ' ' LEU . . . . . 0.449 ' HB2' ' O ' ' A' ' 267' ' ' ALA . 7.3 mp -112.52 160.95 17.3 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.23 -0.896 . . . . 0.0 110.089 171.962 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 72.8 m-80 -112.22 -0.29 15.56 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.261 -0.882 . . . . 0.0 109.209 174.132 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 27.9 mtpp . . . . . 0 C--O 1.245 0.845 0 O-C-N 124.191 0.932 . . . . 0.0 111.2 -178.281 . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 43.6 t . . . . . 0 C--O 1.234 0.273 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 228' ' ' LEU . . . . . 0.466 ' HB3' ' CB ' ' A' ' 259' ' ' ALA . 91.7 mt -130.11 125.18 34.49 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 172.461 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 37.6 p -117.87 175.19 5.78 Favored 'General case' 0 C--N 1.32 -0.674 0 C-N-CA 119.483 -0.887 . . . . 0.0 111.214 -177.087 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 230' ' ' VAL . . . . . 0.561 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 60.6 t -148.61 141.44 18.4 Favored 'Isoleucine or valine' 0 C--O 1.24 0.56 0 CA-C-O 120.905 0.383 . . . . 0.0 110.788 -176.448 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 50.0 m -109.98 117.74 34.59 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.907 175.123 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 177.61 169.0 38.1 Favored Glycine 0 N--CA 1.447 -0.578 0 N-CA-C 111.087 -0.805 . . . . 0.0 111.087 -177.903 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 72.2 mt-30 -111.75 101.51 51.43 Favored Pre-proline 0 C--N 1.323 -0.57 0 CA-C-N 117.148 0.474 . . . . 0.0 111.62 -177.86 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_endo -83.62 125.99 3.95 Favored 'Trans proline' 0 N--CA 1.453 -0.864 0 C-N-CA 122.986 2.457 . . . . 0.0 110.331 173.932 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 56.0 mm-40 -120.63 163.55 17.86 Favored 'General case' 0 C--N 1.321 -0.674 0 C-N-CA 120.576 -0.45 . . . . 0.0 111.831 -172.572 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 236' ' ' HIS . . . . . 0.542 ' HB3' ' O ' ' A' ' 306' ' ' ILE . 19.3 p-80 -108.76 145.89 34.43 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.339 172.433 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 237' ' ' LYS . . . . . 0.478 ' H ' HD21 ' A' ' 307' ' ' LEU . 0.0 OUTLIER . . . . . 0 C--N 1.32 -0.679 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.569 178.099 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 35.5 mt-30 . . . . . 0 N--CA 1.471 0.583 0 CA-C-O 121.391 0.615 . . . . 0.0 110.959 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 253' ' ' GLY . . . . . 0.911 ' O ' ' HA ' ' A' ' 301' ' ' THR . . . 100.35 -23.76 34.62 Favored Glycine 0 N--CA 1.438 -1.203 0 C-N-CA 120.068 -1.063 . . . . 0.0 112.74 -179.248 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 60.0 p -135.81 118.79 16.36 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 118.01 0.905 . . . . 0.0 112.724 -176.676 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.756 HD11 ' HB ' ' A' ' 300' ' ' VAL . 2.1 pp -144.83 170.79 6.75 Favored 'Isoleucine or valine' 0 C--O 1.234 0.283 0 CA-C-O 121.032 0.444 . . . . 0.0 112.001 172.445 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 75.2 m -115.62 114.35 24.79 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.344 177.057 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.446 ' HB ' ' H ' ' A' ' 259' ' ' ALA . 34.9 m -90.86 145.21 7.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 N-CA-C 113.004 0.742 . . . . 0.0 113.004 -173.114 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 258' ' ' SER . . . . . 0.448 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 30.9 m -91.35 8.83 34.22 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 114.077 -1.42 . . . . 0.0 108.502 166.818 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 259' ' ' ALA . . . . . 0.466 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -88.25 175.65 7.58 Favored 'General case' 0 N--CA 1.452 -0.364 0 CA-C-N 115.115 -0.948 . . . . 0.0 109.402 -177.899 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 27.4 p -140.61 117.22 10.88 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 112.356 0.502 . . . . 0.0 112.356 -177.412 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 78.91 50.04 6.12 Favored Glycine 0 N--CA 1.45 -0.392 0 CA-C-N 115.596 -0.729 . . . . 0.0 113.391 175.632 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 262' ' ' LEU . . . . . . . . . . . . . 77.6 mt -85.06 146.53 27.12 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 117.346 0.573 . . . . 0.0 110.268 176.837 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 98.9 mm-40 -123.77 163.25 21.54 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.551 -178.757 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 264' ' ' VAL . . . . . 0.487 HG22 ' HA ' ' A' ' 294' ' ' ALA . 20.2 t -79.48 145.1 9.86 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.215 177.626 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 86.4 10.07 74.67 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.623 -0.799 . . . . 0.0 112.186 177.832 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -88.5 159.59 17.88 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.147 0.499 . . . . 0.0 110.482 177.208 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 267' ' ' ALA . . . . . 0.549 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -121.82 151.48 40.57 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 115.334 -0.848 . . . . 0.0 108.869 178.238 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 268' ' ' PHE . . . . . 0.496 ' HB3' ' HA ' ' A' ' 334' ' ' ILE . 4.1 p90 -164.27 168.75 18.4 Favored 'General case' 0 C--N 1.318 -0.761 0 C-N-CA 119.777 -0.769 . . . . 0.0 111.648 -178.029 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 269' ' ' THR . . . . . 0.497 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 73.3 p -122.85 141.83 51.44 Favored 'General case' 0 N--CA 1.442 -0.848 0 CA-C-N 115.438 -0.801 . . . . 0.0 109.621 177.078 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 270' ' ' ILE . . . . . 0.713 HG12 HG12 ' A' ' 332' ' ' ILE . 61.6 mt -105.49 139.18 27.43 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.57 -178.525 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -61.22 125.86 25.28 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.695 179.512 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 93.51 -22.45 35.31 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.473 -178.811 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 273' ' ' VAL . . . . . 0.742 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 42.4 t -96.5 114.59 33.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 O-C-N 122.573 -0.369 . . . . 0.0 110.296 177.504 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 274' ' ' ASN . . . . . 0.411 ' HA ' ' HA ' ' A' ' 287' ' ' PRO . 72.3 m-80 -129.2 160.87 31.55 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.304 -179.223 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 68.9 p -86.37 169.61 12.76 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.239 0.542 . . . . 0.0 111.803 -174.883 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 276' ' ' VAL . . . . . 0.41 ' O ' ' HG2' ' A' ' 278' ' ' GLN . 27.3 m -112.03 -178.07 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 115.499 -0.773 . . . . 0.0 111.152 -178.47 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 277' ' ' HIS . . . . . 0.523 ' HB3' ' HA ' ' A' ' 281' ' ' LYS . 5.0 m80 -66.16 80.97 0.08 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.703 -0.681 . . . . 0.0 110.392 -175.33 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 278' ' ' GLN . . . . . 0.41 ' HG2' ' O ' ' A' ' 276' ' ' VAL . 41.5 mm-40 -80.32 -32.99 37.86 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 111.72 0.267 . . . . 0.0 111.72 -174.418 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 279' ' ' ILE . . . . . 0.548 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.4 mp -69.89 -89.48 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.375 0 CA-C-O 120.831 0.348 . . . . 0.0 110.533 -174.641 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 35.5 p -133.69 60.03 1.72 Allowed 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.076 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 281' ' ' LYS . . . . . 0.523 ' HA ' ' HB3' ' A' ' 277' ' ' HIS . 31.4 mmmt 54.52 41.13 32.14 Favored 'General case' 0 CA--C 1.522 -0.122 0 CA-C-N 115.562 -0.745 . . . . 0.0 109.208 -170.874 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 282' ' ' ASP . . . . . 0.463 ' N ' ' HB3' ' A' ' 277' ' ' HIS . 9.3 t70 -92.33 137.84 32.03 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 114.445 -1.252 . . . . 0.0 110.484 -175.15 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 46.2 p -85.44 105.1 15.82 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.185 -178.387 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 73.1 p -110.72 -41.62 4.24 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.915 -171.804 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 63.64 28.31 72.34 Favored Glycine 0 C--N 1.33 0.24 0 C-N-CA 120.877 -0.677 . . . . 0.0 112.498 177.222 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 84.6 mt-30 -94.5 145.7 30.15 Favored Pre-proline 0 C--N 1.323 -0.547 0 CA-C-O 120.419 0.152 . . . . 0.0 110.647 -176.792 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 287' ' ' PRO . . . . . 0.497 ' HB2' ' HB ' ' A' ' 269' ' ' THR . 27.5 Cg_endo -62.2 143.77 94.75 Favored 'Trans proline' 0 CA--C 1.53 0.31 0 C-N-CA 122.445 2.097 . . . . 0.0 112.029 178.589 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 70.8 tp60 -76.3 128.43 34.86 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.872 0.367 . . . . 0.0 110.945 -177.486 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 289' ' ' VAL . . . . . 0.401 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 45.6 t -93.74 133.18 35.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.059 179.17 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 290' ' ' PHE . . . . . 0.742 ' HZ ' HG11 ' A' ' 273' ' ' VAL . 60.9 m-85 -113.5 168.81 9.44 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.826 -176.996 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 291' ' ' ARG . . . . . 0.452 ' NH1' ' HB2' ' A' ' 267' ' ' ALA . 35.8 mmt180 -126.74 120.38 29.25 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 177.765 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 56.4 t -67.18 125.59 24.96 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.227 -179.755 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 293' ' ' LEU . . . . . 0.656 HD11 ' HB2' ' A' ' 303' ' ' SER . 5.2 mp -85.07 -38.44 19.13 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.841 179.865 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 294' ' ' ALA . . . . . 0.487 ' HA ' HG22 ' A' ' 264' ' ' VAL . . . -167.13 155.48 9.73 Favored 'General case' 0 C--O 1.225 -0.21 0 CA-C-N 116.681 -0.236 . . . . 0.0 110.94 179.059 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 295' ' ' VAL . . . . . 0.672 HG22 HG13 ' A' ' 300' ' ' VAL . 61.7 t -140.49 124.74 18.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 175.384 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 32.4 m -139.73 89.54 2.33 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 120.76 0.314 . . . . 0.0 110.835 -177.189 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 297' ' ' GLY . . . . . 0.427 ' C ' ' H ' ' A' ' 299' ' ' THR . . . 63.95 65.76 2.87 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.487 179.434 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 81.0 p 63.06 -25.18 0.06 Allowed 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 124.994 1.317 . . . . 0.0 113.683 -178.774 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 299' ' ' THR . . . . . 0.427 ' H ' ' C ' ' A' ' 297' ' ' GLY . 75.3 m -77.43 108.9 10.91 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 174.333 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 300' ' ' VAL . . . . . 0.756 ' HB ' HD11 ' A' ' 255' ' ' ILE . 48.8 t -106.08 134.42 47.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.025 -173.017 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 301' ' ' THR . . . . . 0.911 ' HA ' ' O ' ' A' ' 253' ' ' GLY . 97.1 m -78.02 105.37 9.19 Favored 'General case' 0 N--CA 1.446 -0.632 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 173.009 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 302' ' ' ILE . . . . . 0.64 HD12 ' O ' ' A' ' 302' ' ' ILE . 2.6 pp -111.24 141.35 26.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 122.179 0.99 . . . . 0.0 113.671 -170.989 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 303' ' ' SER . . . . . 0.656 ' HB2' HD11 ' A' ' 293' ' ' LEU . 57.2 m -167.48 169.55 5.56 Favored Pre-proline 0 C--N 1.317 -0.826 0 N-CA-C 105.342 -2.096 . . . . 0.0 105.342 179.02 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 304' ' ' PRO . . . . . 0.587 ' HA ' ' HB3' ' A' ' 303' ' ' SER . 2.7 Cg_endo -82.65 -157.28 1.35 Allowed 'Cis proline' 0 C--N 1.347 0.458 0 CA-C-N 121.571 1.597 . . . . 0.0 113.473 0.278 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 305' ' ' LYS . . . . . 0.8 ' HD3' ' HG ' ' A' ' 307' ' ' LEU . 0.0 OUTLIER -83.51 163.34 20.51 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.27 -0.877 . . . . 0.0 112.884 -176.069 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 306' ' ' ILE . . . . . 0.542 ' O ' ' HB3' ' A' ' 236' ' ' HIS . 2.7 mp -114.02 94.32 3.06 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.793 -176.761 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 307' ' ' LEU . . . . . 0.8 ' HG ' ' HD3' ' A' ' 305' ' ' LYS . 86.0 mt -108.81 107.24 59.9 Favored Pre-proline 0 C--N 1.327 -0.392 0 C-N-CA 120.81 -0.356 . . . . 0.0 111.606 -177.768 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 308' ' ' PRO . . . . . 0.761 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 23.0 Cg_exo -69.85 145.39 56.5 Favored 'Trans proline' 0 C--N 1.343 0.253 0 C-N-CA 123.505 2.804 . . . . 0.0 113.467 -178.038 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 309' ' ' VAL . . . . . 0.416 HG23 ' O ' ' A' ' 322' ' ' VAL . 40.3 t -93.69 -25.6 4.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 169.35 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 54.7 mm-40 -79.83 -0.36 34.32 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.113 -0.949 . . . . 0.0 112.144 -177.602 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -80.85 163.34 23.48 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-O 121.004 0.431 . . . . 0.0 111.174 -179.091 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 50.2 m -92.32 -15.87 26.79 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.362 -179.029 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 313' ' ' ASP . . . . . 0.566 ' O ' ' HG3' ' A' ' 317' ' ' ARG . 62.9 t0 -64.26 104.05 0.71 Allowed 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.065 178.93 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 314' ' ' VAL . . . . . 0.432 ' O ' ' HD3' ' A' ' 318' ' ' PRO . 48.5 t -63.63 -30.84 50.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.683 -176.012 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -70.44 -25.17 63.07 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 111.718 0.266 . . . . 0.0 111.718 179.984 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 32.4 t -95.09 -8.28 37.02 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.604 0.24 . . . . 0.0 111.211 -178.115 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 317' ' ' ARG . . . . . 0.566 ' HG3' ' O ' ' A' ' 313' ' ' ASP . 54.4 mtp85 -67.43 -49.96 39.85 Favored Pre-proline 0 CA--C 1.54 0.564 0 N-CA-C 112.938 0.718 . . . . 0.0 112.938 -179.26 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 318' ' ' PRO . . . . . 0.506 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 37.1 Cg_exo -63.41 -31.98 71.95 Favored 'Trans proline' 0 C--N 1.357 1.016 0 C-N-CA 121.951 1.768 . . . . 0.0 112.679 -178.51 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 48.8 m-85 -84.13 -14.95 48.97 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.511 -178.214 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 320' ' ' ALA . . . . . 0.528 ' HA ' ' CB ' ' A' ' 307' ' ' LEU . . . -49.7 135.29 19.17 Favored 'General case' 0 N--CA 1.464 0.254 0 N-CA-C 112.71 0.633 . . . . 0.0 112.71 -174.097 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 16.1 p-10 -128.38 -10.36 5.18 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.939 178.964 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 322' ' ' VAL . . . . . 0.488 HG21 HG23 ' A' ' 306' ' ' ILE . 33.7 m -132.27 167.29 26.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 N-CA-C 109.986 -0.375 . . . . 0.0 109.986 177.017 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -67.2 -51.89 47.95 Favored 'General case' 0 C--N 1.326 -0.434 0 C-N-CA 121.026 -0.27 . . . . 0.0 111.702 -177.93 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 324' ' ' ALA . . . . . 0.761 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -162.47 -178.04 6.02 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.044 0.449 . . . . 0.0 111.779 -176.388 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 14.5 ptmm? -112.56 132.07 22.37 Favored Pre-proline 0 C--N 1.327 -0.384 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.314 176.949 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -86.15 168.44 9.04 Favored 'Trans proline' 0 N--CA 1.456 -0.71 0 C-N-CA 122.921 2.414 . . . . 0.0 112.412 179.51 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -72.83 123.77 24.05 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.053 -0.522 . . . . 0.0 109.718 175.202 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 66.6 mm-40 65.6 -161.43 0.26 Allowed 'General case' 0 N--CA 1.465 0.307 0 O-C-N 123.574 0.546 . . . . 0.0 110.424 -174.97 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 329' ' ' SER . . . . . 0.561 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 43.0 m -91.16 -13.48 32.88 Favored 'General case' 0 C--N 1.323 -0.578 0 C-N-CA 120.825 -0.35 . . . . 0.0 110.347 178.174 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 64.5 -161.55 0.28 Allowed 'General case' 0 N--CA 1.467 0.425 0 CA-C-N 115.412 -0.813 . . . . 0.0 113.128 171.323 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -86.71 136.72 32.91 Favored 'General case' 0 CA--C 1.517 -0.323 0 CA-C-N 115.09 -0.959 . . . . 0.0 110.577 -179.983 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 332' ' ' ILE . . . . . 0.713 HG12 HG12 ' A' ' 270' ' ' ILE . 45.8 mt -116.12 144.42 23.83 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.847 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.822 -178.735 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 78.1 m -116.26 99.24 7.07 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.156 -178.016 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 334' ' ' ILE . . . . . 0.496 ' HA ' ' HB3' ' A' ' 268' ' ' PHE . 38.3 mm -75.99 131.12 35.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.43 -174.992 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 335' ' ' LEU . . . . . 0.479 HD23 ' HA ' ' A' ' 268' ' ' PHE . 2.0 pt? -148.61 133.68 18.23 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.217 173.68 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 5.6 m120 -78.16 70.93 4.59 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.223 178.406 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 59.4 tttp . . . . . 0 C--O 1.243 0.738 0 CA-C-O 118.315 -0.85 . . . . 0.0 110.713 -174.989 . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 54.0 m . . . . . 0 N--CA 1.465 0.322 0 CA-C-O 120.791 0.329 . . . . 0.0 111.304 . . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 228' ' ' LEU . . . . . 0.568 HD13 ' HB1' ' A' ' 259' ' ' ALA . 85.3 mt -131.5 158.9 39.66 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.982 -0.553 . . . . 0.0 109.845 -177.288 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 229' ' ' THR . . . . . 0.578 ' HA ' ' HA ' ' A' ' 331' ' ' ALA . 37.9 p -132.76 178.87 6.53 Favored 'General case' 0 C--N 1.33 -0.274 0 C-N-CA 120.324 -0.55 . . . . 0.0 111.186 177.851 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 230' ' ' VAL . . . . . 0.597 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 58.7 t -147.47 123.94 2.92 Favored 'Isoleucine or valine' 0 C--O 1.235 0.336 0 CA-C-N 116.654 -0.248 . . . . 0.0 110.921 -179.165 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 49.8 m -109.14 97.68 7.25 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.107 -0.497 . . . . 0.0 109.86 174.446 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 232' ' ' GLY . . . . . 0.915 ' HA3' ' HB ' ' A' ' 255' ' ' ILE . . . -133.94 -152.14 6.65 Favored Glycine 0 N--CA 1.443 -0.859 0 C-N-CA 119.743 -1.218 . . . . 0.0 113.163 -176.735 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 233' ' ' GLN . . . . . 0.583 ' H ' HG22 ' A' ' 255' ' ' ILE . 11.7 mm100 -72.34 171.45 9.7 Favored Pre-proline 0 C--N 1.324 -0.521 0 CA-C-N 115.2 -0.5 . . . . 0.0 110.988 -179.172 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 234' ' ' PRO . . . . . 0.525 ' HD2' ' HB3' ' A' ' 233' ' ' GLN . 41.7 Cg_exo -56.74 176.29 0.23 Allowed 'Trans proline' 0 C--N 1.356 0.923 0 C-N-CA 123.346 2.697 . . . . 0.0 112.741 177.801 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 235' ' ' GLU . . . . . 0.735 ' HG3' ' HD2' ' A' ' 325' ' ' LYS . 2.6 pm0 -91.38 -176.74 4.64 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.031 0.444 . . . . 0.0 111.102 -174.467 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 236' ' ' HIS . . . . . 0.445 ' CE1' ' HB2' ' A' ' 305' ' ' LYS . 18.9 t-80 -100.87 147.6 25.93 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.509 -0.769 . . . . 0.0 111.702 -171.135 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 237' ' ' LYS . . . . . 0.487 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.327 -0.409 0 CA-C-N 114.735 -1.12 . . . . 0.0 109.914 179.066 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 252' ' ' GLN . . . . . 0.452 ' OE1' ' HA ' ' A' ' 305' ' ' LYS . 2.2 mm100 . . . . . 0 N--CA 1.472 0.659 0 CA-C-O 120.888 0.375 . . . . 0.0 110.566 . . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 101.91 -148.55 17.79 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 119.587 -1.292 . . . . 0.0 113.984 174.778 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 254' ' ' THR . . . . . 0.62 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 71.0 p -101.49 148.66 24.93 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 112.65 0.611 . . . . 0.0 112.65 -171.674 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.915 ' HB ' ' HA3' ' A' ' 232' ' ' GLY . 0.2 OUTLIER -138.01 172.96 13.48 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.243 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.288 173.632 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 58.2 m -100.54 125.81 46.93 Favored 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 109.406 -0.59 . . . . 0.0 109.406 176.729 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.524 ' HA ' HG13 ' A' ' 230' ' ' VAL . 34.0 m -98.73 143.37 13.28 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.828 0 C-N-CA 119.65 -0.82 . . . . 0.0 112.483 -174.541 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 258' ' ' SER . . . . . 0.494 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 38.8 t -91.56 8.48 36.4 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 114.443 -1.253 . . . . 0.0 108.405 169.505 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 259' ' ' ALA . . . . . 0.58 ' HB3' HD11 ' A' ' 262' ' ' LEU . . . -91.32 169.3 10.92 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-N 115.021 -0.99 . . . . 0.0 110.018 -177.442 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 260' ' ' SER . . . . . 0.55 ' H ' HD13 ' A' ' 228' ' ' LEU . 37.9 t -136.95 148.57 47.04 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 110.194 -0.298 . . . . 0.0 110.194 -179.751 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 71.27 39.6 61.98 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.977 -0.63 . . . . 0.0 113.083 178.108 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 262' ' ' LEU . . . . . 0.58 HD11 ' HB3' ' A' ' 259' ' ' ALA . 77.6 mt -97.64 142.31 29.6 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.944 0.372 . . . . 0.0 110.395 178.348 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 71.6 mt-30 -143.72 179.96 6.83 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 176.284 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 264' ' ' VAL . . . . . 0.517 HG22 ' HA ' ' A' ' 294' ' ' ALA . 34.0 t -79.31 140.43 16.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 N-CA-C 109.897 -0.408 . . . . 0.0 109.897 176.201 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 93.52 4.72 63.82 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.526 -0.845 . . . . 0.0 112.453 178.797 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -78.89 152.81 30.97 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.083 0.468 . . . . 0.0 110.072 176.578 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 267' ' ' ALA . . . . . 0.709 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -126.96 121.67 32.36 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 178.696 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 268' ' ' PHE . . . . . 0.574 ' CD1' HG21 ' A' ' 332' ' ' ILE . 0.0 OUTLIER -148.04 171.53 15.68 Favored 'General case' 0 C--N 1.318 -0.791 0 C-N-CA 120.218 -0.593 . . . . 0.0 111.026 -172.071 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 269' ' ' THR . . . . . 0.538 ' OG1' ' HB ' ' A' ' 333' ' ' THR . 72.6 p -123.82 156.39 36.23 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 110.2 -0.296 . . . . 0.0 110.2 -179.379 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 270' ' ' ILE . . . . . 0.557 HG12 HG12 ' A' ' 332' ' ' ILE . 60.9 mt -115.02 139.36 41.68 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 120.794 0.33 . . . . 0.0 111.144 -179.332 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -65.82 112.64 3.84 Favored 'General case' 0 C--O 1.231 0.125 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.037 -179.903 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 109.22 -21.85 26.04 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.021 -179.14 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 273' ' ' VAL . . . . . 0.598 ' O ' ' HA ' ' A' ' 287' ' ' PRO . 47.1 t -93.11 102.67 13.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.885 0.374 . . . . 0.0 110.93 178.722 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 56.5 m-20 -103.76 150.98 23.57 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 173.504 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 275' ' ' SER . . . . . 0.445 ' HB2' ' HB2' ' A' ' 288' ' ' GLN . 6.0 t -88.76 -177.96 5.66 Favored 'General case' 0 C--N 1.325 -0.473 0 C-N-CA 120.332 -0.547 . . . . 0.0 110.231 -176.496 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 35.0 m -112.25 -179.01 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.917 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.171 172.887 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 277' ' ' HIS . . . . . 0.425 ' HB3' ' HA ' ' A' ' 281' ' ' LYS . 6.3 p80 -39.74 111.66 0.21 Allowed 'General case' 0 CA--C 1.533 0.298 0 O-C-N 123.972 0.795 . . . . 0.0 112.568 -179.882 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 80.7 mt-30 -80.16 -42.38 23.55 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.475 -176.439 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 279' ' ' ILE . . . . . 0.467 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.7 mp -110.21 -76.16 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.175 177.858 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 21.7 p -142.11 90.78 2.28 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-O 121.124 0.487 . . . . 0.0 111.661 -178.418 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 281' ' ' LYS . . . . . 0.425 ' HA ' ' HB3' ' A' ' 277' ' ' HIS . 74.8 mmtt 61.05 23.98 14.12 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 115.145 -0.934 . . . . 0.0 112.463 175.584 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 11.2 p-10 -86.46 81.64 8.24 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.615 0.721 . . . . 0.0 110.867 176.769 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 37.2 p -102.34 106.9 17.76 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.854 177.753 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 73.1 p -114.67 2.16 14.4 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.835 -0.62 . . . . 0.0 112.174 -170.081 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 71.02 31.29 66.88 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.515 -0.85 . . . . 0.0 112.652 177.859 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 84.2 mt-30 -102.11 142.54 24.79 Favored Pre-proline 0 C--N 1.325 -0.467 0 O-C-N 122.682 -0.305 . . . . 0.0 111.155 179.503 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 287' ' ' PRO . . . . . 0.598 ' HA ' ' O ' ' A' ' 273' ' ' VAL . 39.0 Cg_exo -59.1 136.95 76.46 Favored 'Trans proline' 0 C--N 1.343 0.276 0 C-N-CA 122.988 2.459 . . . . 0.0 112.106 177.89 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 288' ' ' GLN . . . . . 0.445 ' HB2' ' HB2' ' A' ' 275' ' ' SER . 41.5 tt0 -79.52 142.92 35.34 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.827 0.346 . . . . 0.0 111.013 -178.008 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 289' ' ' VAL . . . . . 0.488 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 42.7 t -90.81 126.68 43.54 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.295 179.496 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 290' ' ' PHE . . . . . 0.709 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 33.3 m-85 -110.42 158.76 18.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.677 -0.238 . . . . 0.0 110.583 -176.323 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 291' ' ' ARG . . . . . 0.529 ' HD2' ' C ' ' A' ' 290' ' ' PHE . 9.0 mpt_? -115.88 131.06 57.05 Favored 'General case' 0 CA--C 1.516 -0.357 0 CA-C-O 121.48 0.657 . . . . 0.0 110.74 173.606 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 40.9 t -82.86 140.0 16.97 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 CA-C-N 114.722 -1.126 . . . . 0.0 111.402 -176.354 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 293' ' ' LEU . . . . . 0.448 ' CD2' ' HB2' ' A' ' 303' ' ' SER . 3.3 mm? -103.79 -32.38 9.36 Favored 'General case' 0 C--N 1.334 -0.08 0 N-CA-C 112.353 0.501 . . . . 0.0 112.353 -177.684 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 294' ' ' ALA . . . . . 0.517 ' HA ' HG22 ' A' ' 264' ' ' VAL . . . -157.83 139.27 13.67 Favored 'General case' 0 N--CA 1.464 0.241 0 C-N-CA 120.715 -0.394 . . . . 0.0 111.798 -178.245 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 295' ' ' VAL . . . . . 0.424 HG22 HG22 ' A' ' 300' ' ' VAL . 73.0 t -141.39 111.99 3.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.457 177.612 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 50.2 m -140.38 114.63 9.19 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.584 -0.28 . . . . 0.0 110.707 178.542 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 59.53 54.59 36.44 Favored Glycine 0 C--N 1.33 0.25 0 C-N-CA 121.146 -0.549 . . . . 0.0 112.891 179.172 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 82.8 p 53.08 21.09 1.97 Allowed 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 123.61 0.764 . . . . 0.0 112.302 -177.1 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 58.6 m -111.45 105.89 14.63 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 176.358 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 300' ' ' VAL . . . . . 0.62 ' O ' ' HA ' ' A' ' 254' ' ' THR . 55.2 t -105.32 131.62 54.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 115.954 -0.567 . . . . 0.0 111.547 -171.881 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 28.5 m -89.1 114.49 25.75 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 108.277 -1.009 . . . . 0.0 108.277 173.454 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 302' ' ' ILE . . . . . 0.538 HD12 ' O ' ' A' ' 302' ' ' ILE . 2.5 pp -110.58 149.07 13.6 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 N-CA-C 113.676 0.991 . . . . 0.0 113.676 -170.558 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 303' ' ' SER . . . . . 0.557 ' HB3' ' HA ' ' A' ' 304' ' ' PRO . 60.3 m -166.21 165.87 9.97 Favored Pre-proline 0 C--N 1.325 -0.487 0 N-CA-C 105.952 -1.87 . . . . 0.0 105.952 -179.724 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 304' ' ' PRO . . . . . 0.557 ' HA ' ' HB3' ' A' ' 303' ' ' SER . 5.8 Cg_exo -79.41 -146.44 0.37 Allowed 'Cis proline' 0 C--N 1.345 0.362 0 CA-C-N 120.996 1.391 . . . . 0.0 113.579 0.64 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 305' ' ' LYS . . . . . 0.682 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -84.11 146.71 27.75 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.478 -0.783 . . . . 0.0 111.739 -176.173 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 306' ' ' ILE . . . . . 0.482 HG23 HG21 ' A' ' 322' ' ' VAL . 2.9 mp -115.26 113.73 44.35 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.199 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.92 179.227 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 307' ' ' LEU . . . . . . . . . . . . . 95.5 mt -133.97 107.37 11.54 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-O 120.563 0.22 . . . . 0.0 111.308 -179.309 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 308' ' ' PRO . . . . . 0.652 ' HG2' ' HB2' ' A' ' 311' ' ' ASN . 45.3 Cg_endo -74.51 148.0 37.03 Favored 'Trans proline' 0 C--O 1.233 0.232 0 C-N-CA 122.796 2.331 . . . . 0.0 113.573 -176.631 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 46.5 t -73.58 -34.26 41.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.059 173.0 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -86.35 34.35 0.63 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.371 -0.832 . . . . 0.0 111.143 178.468 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.652 ' HB2' ' HG2' ' A' ' 308' ' ' PRO . 25.7 t-20 -81.32 -34.2 32.04 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -178.287 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 312' ' ' THR . . . . . 0.401 ' HB ' ' O ' ' A' ' 311' ' ' ASN . 41.8 m 73.91 -11.27 0.98 Allowed 'General case' 0 CA--C 1.539 0.529 0 CA-C-N 115.328 -0.851 . . . . 0.0 111.679 178.662 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 313' ' ' ASP . . . . . 0.477 ' O ' ' HG2' ' A' ' 317' ' ' ARG . 31.1 t70 -79.67 117.42 20.57 Favored 'General case' 0 C--N 1.329 -0.286 0 O-C-N 121.951 -0.468 . . . . 0.0 110.27 175.119 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 26.5 t -59.32 -20.4 18.07 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.473 0 CA-C-N 115.781 -0.645 . . . . 0.0 112.268 -174.706 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -84.89 -38.41 19.45 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 111.949 0.352 . . . . 0.0 111.949 -179.364 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 316' ' ' SER . . . . . 0.423 ' OG ' ' HB3' ' A' ' 313' ' ' ASP . 38.3 p -97.93 -28.83 13.64 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 113.511 0.93 . . . . 0.0 113.511 -172.33 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 317' ' ' ARG . . . . . 0.624 ' N ' ' HD2' ' A' ' 318' ' ' PRO . 16.1 ptm180 -66.18 -35.76 11.37 Favored Pre-proline 0 CA--C 1.547 0.86 0 N-CA-C 113.656 0.984 . . . . 0.0 113.656 -176.182 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 318' ' ' PRO . . . . . 0.624 ' HD2' ' N ' ' A' ' 317' ' ' ARG . 12.8 Cg_endo -58.38 -34.13 98.42 Favored 'Trans proline' 0 C--N 1.366 1.468 0 C-N-CA 121.666 1.577 . . . . 0.0 112.512 -179.861 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 51.0 m-85 -101.02 36.8 1.88 Allowed 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.6 -178.085 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -67.86 139.64 56.53 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.485 -178.183 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 321' ' ' ASN . . . . . 0.44 ' OD1' HG13 ' A' ' 322' ' ' VAL . 20.5 p30 -121.78 -14.66 8.07 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.516 178.012 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 322' ' ' VAL . . . . . 0.482 HG21 HG23 ' A' ' 306' ' ' ILE . 34.1 m -133.59 166.74 28.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 115.618 -0.719 . . . . 0.0 109.195 173.458 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 65.0 m-20 -82.7 -27.53 31.16 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 112.164 0.431 . . . . 0.0 112.164 -176.375 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 324' ' ' ALA . . . . . 0.562 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -160.58 158.21 28.66 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.973 0.416 . . . . 0.0 111.716 -175.209 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 325' ' ' LYS . . . . . 0.735 ' HD2' ' HG3' ' A' ' 235' ' ' GLU . 21.5 pttp -114.01 127.26 27.01 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 115.714 -0.676 . . . . 0.0 110.157 177.318 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -86.08 167.84 9.32 Favored 'Trans proline' 0 N--CA 1.457 -0.651 0 C-N-CA 122.814 2.343 . . . . 0.0 112.758 -178.213 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -71.71 124.4 24.69 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.471 178.927 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 61.69 -118.44 0.68 Allowed 'General case' 0 N--CA 1.464 0.239 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.323 -175.578 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 329' ' ' SER . . . . . 0.597 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 32.6 m -112.18 -33.94 6.08 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.59 -0.277 . . . . 0.0 111.309 179.863 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 330' ' ' ALA . . . . . 0.418 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 76.24 -165.99 0.06 Allowed 'General case' 0 N--CA 1.474 0.725 0 O-C-N 123.844 0.715 . . . . 0.0 112.432 177.429 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 331' ' ' ALA . . . . . 0.578 ' HA ' ' HA ' ' A' ' 229' ' ' THR . . . -82.88 153.92 24.87 Favored 'General case' 0 CA--C 1.519 -0.236 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.899 -177.226 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 332' ' ' ILE . . . . . 0.574 HG21 ' CD1' ' A' ' 268' ' ' PHE . 44.4 mt -128.49 144.85 36.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 121.233 0.54 . . . . 0.0 111.762 -177.616 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 333' ' ' THR . . . . . 0.538 ' HB ' ' OG1' ' A' ' 269' ' ' THR . 94.7 m -108.63 118.75 37.59 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.291 -0.868 . . . . 0.0 109.207 175.23 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 334' ' ' ILE . . . . . 0.491 HG13 HD12 ' A' ' 228' ' ' LEU . 31.9 mm -97.26 132.33 42.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 N-CA-C 113.761 1.023 . . . . 0.0 113.761 -168.025 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 335' ' ' LEU . . . . . 0.467 HD23 ' N ' ' A' ' 335' ' ' LEU . 1.5 pt? -150.78 -162.32 1.53 Allowed 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 113.977 -1.465 . . . . 0.0 108.129 167.993 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 14.9 p-10 -159.34 35.49 0.2 Allowed 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 120.949 0.404 . . . . 0.0 110.212 178.055 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 88.4 tttt . . . . . 0 C--O 1.245 0.83 0 CA-C-N 115.023 -0.99 . . . . 0.0 110.722 -179.433 . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 20.3 m . . . . . 0 C--O 1.231 0.131 0 N-CA-C 110.018 -0.364 . . . . 0.0 110.018 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 228' ' ' LEU . . . . . 0.425 HD13 ' HB1' ' A' ' 259' ' ' ALA . 87.7 mt -69.49 136.98 52.17 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.509 176.936 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 61.3 p -125.22 173.99 8.41 Favored 'General case' 0 C--N 1.325 -0.49 0 C-N-CA 119.721 -0.792 . . . . 0.0 110.374 179.766 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 230' ' ' VAL . . . . . 0.916 HG11 HD12 ' A' ' 255' ' ' ILE . 94.5 t -146.06 139.8 20.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-O 120.873 0.368 . . . . 0.0 110.549 -178.801 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 231' ' ' SER . . . . . 0.622 ' HA ' ' OE1' ' A' ' 328' ' ' GLU . 45.8 t -106.04 150.75 25.45 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-N 115.485 -0.779 . . . . 0.0 110.64 178.145 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 79.32 92.67 0.36 Allowed Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.409 178.408 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 233' ' ' GLN . . . . . 0.461 ' O ' ' HG3' ' A' ' 235' ' ' GLU . 82.8 mt-30 -42.74 135.37 2.75 Favored Pre-proline 0 N--CA 1.47 0.531 0 N-CA-C 112.595 0.591 . . . . 0.0 112.595 -177.997 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 234' ' ' PRO . . . . . 0.434 ' HB3' HD11 ' A' ' 302' ' ' ILE . 34.0 Cg_endo -62.97 127.94 21.69 Favored 'Trans proline' 0 C--N 1.349 0.59 0 C-N-CA 122.521 2.147 . . . . 0.0 111.18 175.018 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 235' ' ' GLU . . . . . 0.461 ' HG3' ' O ' ' A' ' 233' ' ' GLN . 49.0 mt-10 -113.64 117.46 31.65 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 112.281 0.475 . . . . 0.0 112.281 -170.419 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 236' ' ' HIS . . . . . 0.522 ' CE1' ' HB2' ' A' ' 305' ' ' LYS . 9.8 t-80 -138.32 130.92 29.25 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.507 172.984 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 237' ' ' LYS . . . . . 0.55 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.322 -0.608 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.527 -179.624 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 40.7 mt-30 . . . . . 0 N--CA 1.466 0.351 0 CA-C-O 121.414 0.626 . . . . 0.0 111.515 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 253' ' ' GLY . . . . . 0.441 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -169.1 105.87 0.23 Allowed Glycine 0 N--CA 1.444 -0.799 0 CA-C-N 115.352 -0.84 . . . . 0.0 111.309 177.391 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 254' ' ' THR . . . . . 0.473 HG22 ' OG1' ' A' ' 301' ' ' THR . 62.8 p -93.47 116.15 28.68 Favored 'General case' 0 C--N 1.324 -0.515 0 C-N-CA 120.579 -0.448 . . . . 0.0 110.006 -177.993 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.916 HD12 HG11 ' A' ' 230' ' ' VAL . 19.0 pt -129.27 157.18 42.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.807 -0.633 . . . . 0.0 112.01 -172.162 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 28.8 m -96.3 109.66 22.12 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 174.606 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.438 ' HA ' HG13 ' A' ' 230' ' ' VAL . 33.6 m -89.94 142.37 13.01 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 C-N-CA 119.429 -0.908 . . . . 0.0 112.235 -173.022 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 258' ' ' SER . . . . . 0.429 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 31.6 m -93.2 9.53 35.68 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 114.377 -1.283 . . . . 0.0 109.44 171.974 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 259' ' ' ALA . . . . . 0.425 ' HB1' HD13 ' A' ' 228' ' ' LEU . . . -80.97 -177.37 6.39 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.189 -175.709 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 50.9 m -125.07 118.92 27.24 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 112.232 0.456 . . . . 0.0 112.232 -175.522 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 59.49 51.35 59.59 Favored Glycine 0 C--N 1.331 0.284 0 CA-C-N 115.656 -0.702 . . . . 0.0 114.127 172.19 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 262' ' ' LEU . . . . . . . . . . . . . 67.9 mt -77.96 160.13 28.39 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 117.453 0.626 . . . . 0.0 110.559 177.753 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 85.7 mt-30 -141.74 167.09 22.96 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.453 179.864 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 44.0 t -78.67 141.47 15.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.496 178.32 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 93.55 1.2 66.36 Favored Glycine 0 N--CA 1.453 -0.229 0 C-N-CA 120.535 -0.84 . . . . 0.0 112.757 177.174 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 266' ' ' ASP . . . . . 0.453 ' HB3' ' CG2' ' A' ' 334' ' ' ILE . 1.3 m-20 -81.09 164.82 22.14 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.032 0.444 . . . . 0.0 110.585 178.243 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 267' ' ' ALA . . . . . 0.54 ' HB1' HG13 ' A' ' 289' ' ' VAL . . . -124.37 146.77 48.65 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.796 -178.086 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 268' ' ' PHE . . . . . 0.721 ' HB3' ' HA ' ' A' ' 334' ' ' ILE . 11.1 p90 -164.09 177.88 8.09 Favored 'General case' 0 C--N 1.322 -0.629 0 C-N-CA 120.152 -0.619 . . . . 0.0 112.405 -176.177 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 43.2 p -134.03 156.55 48.02 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 114.646 -1.161 . . . . 0.0 109.002 173.138 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 270' ' ' ILE . . . . . 0.944 HG12 HG13 ' A' ' 332' ' ' ILE . 77.6 mt -119.15 141.78 37.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-O 120.569 0.223 . . . . 0.0 110.682 -177.524 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -70.16 128.7 37.2 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.768 0.318 . . . . 0.0 110.973 178.112 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 90.56 -23.3 23.12 Favored Glycine 0 N--CA 1.453 -0.172 0 C-N-CA 121.267 -0.492 . . . . 0.0 112.023 -177.822 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 273' ' ' VAL . . . . . 0.473 ' HB ' ' HB ' ' A' ' 270' ' ' ILE . 57.2 t -94.58 103.23 14.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 175.043 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 274' ' ' ASN . . . . . 0.451 ' HB3' ' O ' ' A' ' 285' ' ' GLY . 8.1 m120 -125.03 129.43 50.27 Favored 'General case' 0 C--N 1.316 -0.865 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 -179.613 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 275' ' ' SER . . . . . 0.571 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 48.8 m -84.18 173.52 10.97 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.751 0.786 . . . . 0.0 112.974 -167.031 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 276' ' ' VAL . . . . . 0.675 HG11 HG21 ' A' ' 309' ' ' VAL . 18.5 m -122.95 166.87 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 CA-C-N 114.676 -1.147 . . . . 0.0 109.327 176.41 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 277' ' ' HIS . . . . . 0.494 ' O ' ' HA ' ' A' ' 281' ' ' LYS . 33.6 m80 -88.16 123.89 33.26 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 177.853 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 10.5 mm100 -80.29 -17.16 52.94 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.086 -176.614 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 46.7 mm -70.31 -65.19 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.736 -179.531 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 64.6 p -108.05 11.58 27.6 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.506 -0.316 . . . . 0.0 111.851 -177.323 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 281' ' ' LYS . . . . . 0.494 ' HA ' ' O ' ' A' ' 277' ' ' HIS . 12.7 mptt 55.41 47.47 21.12 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-O 121.122 0.487 . . . . 0.0 111.192 -177.489 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 282' ' ' ASP . . . . . 0.48 ' HB3' ' HB2' ' A' ' 277' ' ' HIS . 7.3 t70 -79.91 108.96 13.9 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.619 176.971 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.46 HG21 HG11 ' A' ' 309' ' ' VAL . 64.4 p -102.97 98.22 8.22 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.591 -178.142 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 31.1 p -140.55 10.8 2.28 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.613 -0.721 . . . . 0.0 111.763 -177.737 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 285' ' ' GLY . . . . . 0.451 ' O ' ' HB3' ' A' ' 274' ' ' ASN . . . 75.66 33.57 51.49 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.177 -1.011 . . . . 0.0 113.26 175.651 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 286' ' ' GLN . . . . . 0.463 ' O ' ' HB2' ' A' ' 275' ' ' SER . 11.6 mm100 -91.27 111.77 50.52 Favored Pre-proline 0 C--N 1.325 -0.469 0 CA-C-N 117.006 0.403 . . . . 0.0 110.782 -179.636 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 287' ' ' PRO . . . . . 0.408 ' HD2' ' HA ' ' A' ' 286' ' ' GLN . 14.7 Cg_endo -59.59 134.26 56.8 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.916 2.41 . . . . 0.0 113.155 -177.057 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? -110.13 152.31 26.18 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 176.806 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 289' ' ' VAL . . . . . 0.54 HG13 ' HB1' ' A' ' 267' ' ' ALA . 53.8 t -68.18 134.03 30.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 CA-C-O 120.924 0.392 . . . . 0.0 111.988 -171.806 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 290' ' ' PHE . . . . . 0.836 ' HA ' ' HD3' ' A' ' 304' ' ' PRO . 4.5 m-85 -97.88 159.48 14.9 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.75 178.051 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 20.3 mmt85 -131.45 125.63 33.0 Favored 'General case' 0 N--CA 1.453 -0.316 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.622 -179.02 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 53.2 t -76.01 135.34 27.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.161 179.318 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 293' ' ' LEU . . . . . 0.589 HD12 HG22 ' A' ' 301' ' ' THR . 85.4 mt -99.49 -43.0 6.69 Favored 'General case' 0 C--N 1.333 -0.13 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.502 179.769 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 294' ' ' ALA . . . . . 0.451 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -154.34 144.23 21.77 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.496 -0.32 . . . . 0.0 111.183 -175.52 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 59.0 t -135.91 113.3 14.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.714 176.87 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 45.6 t -157.33 125.02 5.34 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.55 -177.738 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 61.26 43.7 99.04 Favored Glycine 0 C--N 1.331 0.25 0 C-N-CA 120.987 -0.625 . . . . 0.0 111.773 -177.93 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 67.1 p 50.82 23.02 1.27 Allowed 'General case' 0 N--CA 1.471 0.604 0 C-N-CA 123.709 0.804 . . . . 0.0 112.23 -175.052 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 59.6 m -111.9 116.96 31.48 Favored 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 176.852 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 300' ' ' VAL . . . . . 0.451 ' HA ' ' O ' ' A' ' 294' ' ' ALA . 61.5 t -113.1 126.67 70.54 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.176 -173.15 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 301' ' ' THR . . . . . 0.589 HG22 HD12 ' A' ' 293' ' ' LEU . 54.5 m -91.24 116.2 28.63 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 173.987 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 302' ' ' ILE . . . . . 0.441 HG12 ' O ' ' A' ' 253' ' ' GLY . 29.5 pt -111.5 158.78 11.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 N-CA-C 113.234 0.828 . . . . 0.0 113.234 -170.013 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 303' ' ' SER . . . . . 0.543 ' HB3' ' HA ' ' A' ' 304' ' ' PRO . 72.1 m -144.47 166.16 19.97 Favored Pre-proline 0 C--N 1.323 -0.584 0 CA-C-N 113.631 -1.622 . . . . 0.0 107.05 172.521 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 304' ' ' PRO . . . . . 0.836 ' HD3' ' HA ' ' A' ' 290' ' ' PHE . 10.5 Cg_exo -72.7 -169.8 6.86 Favored 'Cis proline' 0 C--N 1.346 0.423 0 CA-C-N 120.719 1.293 . . . . 0.0 113.484 0.605 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 305' ' ' LYS . . . . . 0.633 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -78.18 147.73 34.37 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.471 -0.786 . . . . 0.0 111.333 -177.774 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 306' ' ' ILE . . . . . 0.627 HG23 HG21 ' A' ' 322' ' ' VAL . 51.1 mm -114.07 110.71 33.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.718 -174.244 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 307' ' ' LEU . . . . . 0.504 ' HA ' ' HD3' ' A' ' 308' ' ' PRO . 90.7 mt -134.04 123.06 16.66 Favored Pre-proline 0 N--CA 1.465 0.28 0 CA-C-N 116.62 -0.264 . . . . 0.0 111.46 175.776 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 308' ' ' PRO . . . . . 0.723 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 32.7 Cg_exo -67.68 148.92 78.7 Favored 'Trans proline' 0 C--O 1.233 0.236 0 C-N-CA 123.705 2.937 . . . . 0.0 114.284 -176.333 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 309' ' ' VAL . . . . . 0.675 HG21 HG11 ' A' ' 276' ' ' VAL . 45.2 t -94.14 -13.79 8.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.132 -0.94 . . . . 0.0 109.055 168.988 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 53.1 mt-10 -78.51 35.79 0.24 Allowed 'General case' 0 CA--C 1.533 0.317 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.959 177.225 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.771 ' HA ' ' HD3' ' A' ' 317' ' ' ARG . 1.0 OUTLIER 40.74 66.23 0.67 Allowed 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 114.258 1.207 . . . . 0.0 114.258 173.733 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 85.0 m -81.35 -41.55 21.84 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.753 -0.658 . . . . 0.0 109.657 170.118 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 59.0 t0 -137.83 146.05 43.0 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 175.541 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 61.3 t -62.02 -43.36 97.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 O-C-N 123.191 0.307 . . . . 0.0 111.078 178.858 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -69.96 -19.88 63.34 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.005 0.431 . . . . 0.0 111.094 178.58 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 35.0 t -78.74 -15.24 58.69 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.502 179.804 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 317' ' ' ARG . . . . . 0.771 ' HD3' ' HA ' ' A' ' 311' ' ' ASN . 2.4 mmm180 -74.52 -51.87 4.04 Favored Pre-proline 0 CA--C 1.536 0.437 0 N-CA-C 112.883 0.697 . . . . 0.0 112.883 -177.709 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 318' ' ' PRO . . . . . 0.591 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 23.5 Cg_exo -64.95 -18.95 63.69 Favored 'Trans proline' 0 C--N 1.355 0.874 0 C-N-CA 121.844 1.696 . . . . 0.0 112.388 -178.407 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 319' ' ' TYR . . . . . 0.409 ' O ' HD12 ' A' ' 307' ' ' LEU . 3.7 m-85 -113.52 22.08 14.49 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.284 -179.499 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 320' ' ' ALA . . . . . 0.461 ' HB1' HG22 ' A' ' 309' ' ' VAL . . . -59.68 142.29 53.32 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.226 -177.408 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 50.3 t30 -135.2 -21.57 1.6 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.942 -178.917 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 322' ' ' VAL . . . . . 0.627 HG21 HG23 ' A' ' 306' ' ' ILE . 34.7 m -140.53 172.04 12.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.141 178.658 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 51.1 m-20 -65.94 -44.76 84.09 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.647 -0.251 . . . . 0.0 111.427 179.203 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 324' ' ' ALA . . . . . 0.723 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -174.97 -178.86 1.29 Allowed 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 112.358 0.503 . . . . 0.0 112.358 -177.229 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 36.5 mtmm -108.01 116.72 56.59 Favored Pre-proline 0 N--CA 1.452 -0.364 0 CA-C-N 114.51 -1.223 . . . . 0.0 108.404 168.261 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -71.64 167.09 27.45 Favored 'Trans proline' 0 C--O 1.233 0.236 0 C-N-CA 122.411 2.074 . . . . 0.0 112.22 -177.905 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -67.58 121.58 16.17 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 175.541 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 328' ' ' GLU . . . . . 0.622 ' OE1' ' HA ' ' A' ' 231' ' ' SER . 31.2 tp10 67.53 164.4 0.21 Allowed 'General case' 0 CA--C 1.537 0.45 0 O-C-N 123.986 0.804 . . . . 0.0 109.562 -174.204 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 329' ' ' SER . . . . . 0.486 ' HB2' ' O ' ' A' ' 230' ' ' VAL . 53.5 m -71.21 -29.65 65.41 Favored 'General case' 0 C--N 1.327 -0.403 0 O-C-N 121.65 -0.656 . . . . 0.0 110.875 -177.838 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 330' ' ' ALA . . . . . 0.427 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 74.86 -153.11 0.04 OUTLIER 'General case' 0 N--CA 1.469 0.514 0 O-C-N 123.971 0.794 . . . . 0.0 112.499 173.342 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -87.22 116.61 25.42 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.149 -0.932 . . . . 0.0 111.167 -176.816 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 332' ' ' ILE . . . . . 0.944 HG13 HG12 ' A' ' 270' ' ' ILE . 1.8 mp -107.67 139.92 27.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 177.556 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 61.6 m -129.68 103.89 7.11 Favored 'General case' 0 C--N 1.327 -0.392 0 C-N-CA 120.853 -0.339 . . . . 0.0 111.306 -174.624 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 334' ' ' ILE . . . . . 0.721 ' HA ' ' HB3' ' A' ' 268' ' ' PHE . 3.1 mp -90.73 134.98 27.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.491 -177.161 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 335' ' ' LEU . . . . . 0.711 HD23 ' H ' ' A' ' 335' ' ' LEU . 1.6 pt? -116.73 136.35 53.03 Favored 'General case' 0 N--CA 1.441 -0.897 0 N-CA-C 107.721 -1.215 . . . . 0.0 107.721 166.366 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 15.4 p-10 -75.46 47.56 0.39 Allowed 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.141 0.496 . . . . 0.0 110.822 -177.277 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 337' ' ' LYS . . . . . 0.405 ' HB2' ' NZ ' ' A' ' 337' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.243 0.722 0 CA-C-O 118.364 -0.827 . . . . 0.0 110.603 179.442 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 26.9 m . . . . . 0 N--CA 1.454 -0.268 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 . . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 228' ' ' LEU . . . . . . . . . . . . . 72.9 mt -91.54 87.94 6.58 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 -178.836 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 229' ' ' THR . . . . . 0.591 HG22 ' HA ' ' A' ' 331' ' ' ALA . 22.7 p -113.76 173.43 6.43 Favored 'General case' 0 C--N 1.316 -0.865 0 C-N-CA 119.739 -0.784 . . . . 0.0 110.386 -177.953 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 230' ' ' VAL . . . . . 0.557 ' O ' ' HB2' ' A' ' 329' ' ' SER . 78.9 t -142.75 133.12 23.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-O 121.023 0.439 . . . . 0.0 110.785 -176.542 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 39.5 t -108.31 100.28 9.59 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-N 115.339 -0.846 . . . . 0.0 109.482 175.725 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . -173.27 166.77 39.32 Favored Glycine 0 N--CA 1.444 -0.786 0 N-CA-C 111.391 -0.684 . . . . 0.0 111.391 -178.35 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 233' ' ' GLN . . . . . 0.4 ' HA ' ' HD3' ' A' ' 234' ' ' PRO . 12.9 mm-40 -107.49 102.03 42.34 Favored Pre-proline 0 C--N 1.321 -0.659 0 CA-C-N 116.706 0.253 . . . . 0.0 110.72 -179.866 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 234' ' ' PRO . . . . . 0.76 ' HB2' HD12 ' A' ' 306' ' ' ILE . 33.7 Cg_endo -98.11 127.14 0.22 Allowed 'Trans proline' 0 N--CA 1.451 -1.002 0 C-N-CA 123.034 2.489 . . . . 0.0 112.227 -178.479 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -160.28 -177.39 6.22 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.709 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 33.4 t-80 -159.14 132.98 7.47 Favored 'General case' 0 CA--C 1.517 -0.297 0 CA-C-O 121.605 0.716 . . . . 0.0 111.941 176.38 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 237' ' ' LYS . . . . . 0.614 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.322 -0.608 0 CA-C-N 114.67 -1.15 . . . . 0.0 110.012 178.203 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 48.2 mm-40 . . . . . 0 N--CA 1.463 0.176 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 . . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 253' ' ' GLY . . . . . 0.446 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -128.19 116.06 2.22 Favored Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 118.941 -1.6 . . . . 0.0 113.423 -174.275 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 254' ' ' THR . . . . . 0.467 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 80.9 p -109.41 115.45 29.98 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 170.605 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 255' ' ' ILE . . . . . 0.463 ' O ' ' HA ' ' A' ' 299' ' ' THR . 2.0 pp -131.52 164.85 33.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 N-CA-C 112.733 0.642 . . . . 0.0 112.733 -172.79 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 28.9 m -102.17 118.29 36.59 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 178.789 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 257' ' ' VAL . . . . . 0.422 HG12 HG22 ' A' ' 230' ' ' VAL . 35.0 m -90.4 142.91 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.728 0 C-N-CA 119.768 -0.773 . . . . 0.0 112.762 -172.17 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 32.1 t -91.96 9.56 32.6 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 113.772 -1.558 . . . . 0.0 108.317 168.679 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 259' ' ' ALA . . . . . 0.467 ' HB3' HD11 ' A' ' 262' ' ' LEU . . . -92.19 160.94 14.93 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-N 115.303 -0.862 . . . . 0.0 109.184 179.588 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 34.9 t -118.22 131.06 56.4 Favored 'General case' 0 C--N 1.322 -0.627 0 C-N-CA 120.779 -0.368 . . . . 0.0 111.491 -175.794 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 69.96 51.05 25.71 Favored Glycine 0 N--CA 1.449 -0.445 0 CA-C-N 115.607 -0.724 . . . . 0.0 113.655 173.656 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 262' ' ' LEU . . . . . 0.467 HD11 ' HB3' ' A' ' 259' ' ' ALA . 62.6 mt -91.23 151.55 20.88 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 117.044 0.422 . . . . 0.0 110.161 176.63 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 82.5 mt-30 -137.42 168.22 20.08 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.026 0.441 . . . . 0.0 110.883 -178.427 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 57.6 t -78.23 123.74 35.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.971 176.915 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 265' ' ' GLY . . . . . 0.452 ' H ' ' HB ' ' A' ' 292' ' ' VAL . . . 114.15 6.98 19.81 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.51 -0.852 . . . . 0.0 112.808 -179.978 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 61.7 m-20 -89.7 166.02 13.84 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.157 0.503 . . . . 0.0 110.611 176.205 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 267' ' ' ALA . . . . . 0.698 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -129.61 153.3 48.21 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.287 -0.87 . . . . 0.0 109.008 177.676 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 268' ' ' PHE . . . . . 0.613 ' HB3' HD13 ' A' ' 334' ' ' ILE . 9.9 p90 -164.0 165.73 22.21 Favored 'General case' 0 C--N 1.32 -0.675 0 C-N-CA 119.701 -0.8 . . . . 0.0 112.498 -176.887 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 269' ' ' THR . . . . . 0.56 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 66.4 p -115.45 149.51 37.94 Favored 'General case' 0 N--CA 1.444 -0.763 0 CA-C-N 114.624 -1.171 . . . . 0.0 109.224 173.302 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 270' ' ' ILE . . . . . 0.999 HG12 HG13 ' A' ' 332' ' ' ILE . 60.5 mt -121.46 131.47 72.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 N-CA-C 110.416 -0.216 . . . . 0.0 110.416 -179.26 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -62.24 132.91 54.26 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.124 -179.499 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 91.47 -21.72 33.94 Favored Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.182 -178.08 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 31.0 t -105.38 104.36 16.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 C-N-CA 122.402 0.281 . . . . 0.0 110.367 -179.483 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 274' ' ' ASN . . . . . 0.529 ' HA ' ' HA ' ' A' ' 287' ' ' PRO . 7.3 m120 -126.11 144.42 50.74 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.509 -0.476 . . . . 0.0 111.408 -175.429 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 275' ' ' SER . . . . . 0.48 ' HB3' ' OE1' ' A' ' 288' ' ' GLN . 29.5 p -63.77 160.98 16.09 Favored 'General case' 0 CA--C 1.515 -0.377 0 CA-C-N 115.826 -0.624 . . . . 0.0 112.494 -179.377 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 276' ' ' VAL . . . . . 0.543 HG21 HG21 ' A' ' 309' ' ' VAL . 33.8 m -119.36 149.94 21.85 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.663 0 CA-C-N 114.916 -1.038 . . . . 0.0 110.618 176.246 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 38.6 m80 -109.73 71.62 0.77 Allowed 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 173.323 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 19.0 pt20 -74.42 -9.62 58.77 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.379 -0.828 . . . . 0.0 112.136 -173.459 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 47.1 mm -92.4 -56.6 5.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 120.732 0.301 . . . . 0.0 110.761 -179.676 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 73.0 p -86.48 -14.42 43.2 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.321 -178.716 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 3.1 mmmp? 62.27 48.47 4.8 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.994 -178.231 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 52.6 m-20 -92.28 122.92 35.21 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.285 176.943 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 60.9 p -89.35 102.68 15.35 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.052 0.453 . . . . 0.0 110.054 176.616 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 68.5 p -130.91 -40.22 1.19 Allowed 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.837 -0.619 . . . . 0.0 111.242 -174.972 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 73.07 32.36 60.66 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 120.518 -0.848 . . . . 0.0 112.254 -179.624 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 35.6 mt-30 -76.19 140.41 69.48 Favored Pre-proline 0 C--O 1.223 -0.321 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.603 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 287' ' ' PRO . . . . . 0.56 ' HB2' ' HB ' ' A' ' 269' ' ' THR . 36.2 Cg_endo -69.78 150.57 68.26 Favored 'Trans proline' 0 CA--C 1.529 0.255 0 C-N-CA 122.057 1.838 . . . . 0.0 112.566 -177.163 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 288' ' ' GLN . . . . . 0.48 ' OE1' ' HB3' ' A' ' 275' ' ' SER . 5.5 mm100 -78.34 149.28 33.47 Favored 'General case' 0 CA--C 1.514 -0.422 0 CA-C-O 121.186 0.517 . . . . 0.0 112.2 176.929 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 289' ' ' VAL . . . . . 0.409 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 49.7 t -104.61 112.7 39.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 114.877 -1.056 . . . . 0.0 109.37 175.569 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 290' ' ' PHE . . . . . 0.698 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 53.9 m-85 -98.85 160.23 14.41 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.384 -175.584 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 291' ' ' ARG . . . . . 0.47 ' NH1' ' HB2' ' A' ' 267' ' ' ALA . 32.7 mmt180 -118.02 150.54 39.12 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 178.588 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 292' ' ' VAL . . . . . 0.546 HG13 HG13 ' A' ' 300' ' ' VAL . 52.5 t -100.25 122.92 52.76 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.913 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.57 -177.87 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 293' ' ' LEU . . . . . 0.505 HD21 ' HB3' ' A' ' 303' ' ' SER . 3.4 mm? -104.41 -24.1 13.1 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.465 -0.334 . . . . 0.0 111.674 -177.332 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 294' ' ' ALA . . . . . 0.496 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -154.4 136.59 14.79 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 120.762 -0.375 . . . . 0.0 111.638 179.898 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 58.0 t -135.51 120.1 27.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 175.104 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 31.2 t -157.41 111.69 2.65 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.604 -178.331 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 63.34 50.2 64.43 Favored Glycine 0 C--N 1.33 0.229 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.059 -178.315 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 72.2 p 50.82 23.38 1.4 Allowed 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 123.445 0.698 . . . . 0.0 112.524 -175.576 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 299' ' ' THR . . . . . 0.463 ' HA ' ' O ' ' A' ' 255' ' ' ILE . 40.6 m -111.75 116.87 31.43 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 176.148 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 300' ' ' VAL . . . . . 0.546 HG13 HG13 ' A' ' 292' ' ' VAL . 59.1 t -113.69 133.91 58.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.619 -172.34 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 43.5 m -96.82 120.61 37.46 Favored 'General case' 0 C--O 1.235 0.32 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 172.548 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 302' ' ' ILE . . . . . 0.446 HG12 ' O ' ' A' ' 253' ' ' GLY . 27.7 pt -111.26 143.72 20.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-O 121.626 0.727 . . . . 0.0 112.811 -169.725 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 303' ' ' SER . . . . . 0.505 ' HB3' HD21 ' A' ' 293' ' ' LEU . 46.8 t -156.29 129.11 4.26 Favored Pre-proline 0 C--N 1.323 -0.578 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 173.24 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 304' ' ' PRO . . . . . 0.653 ' HD2' ' HA ' ' A' ' 290' ' ' PHE . 34.8 Cg_exo -63.0 -176.05 4.24 Favored 'Cis proline' 0 N--CA 1.477 0.505 0 CA-C-N 119.912 1.004 . . . . 0.0 114.324 1.807 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 305' ' ' LYS . . . . . 0.661 ' HE2' HD11 ' A' ' 307' ' ' LEU . 0.0 OUTLIER -136.57 -175.52 4.04 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.938 -176.205 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 306' ' ' ILE . . . . . 0.76 HD12 ' HB2' ' A' ' 234' ' ' PRO . 41.8 mt -94.29 99.97 10.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.946 -173.525 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 307' ' ' LEU . . . . . 0.661 HD11 ' HE2' ' A' ' 305' ' ' LYS . 2.7 mp -114.43 105.55 53.63 Favored Pre-proline 0 C--N 1.33 -0.277 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 175.729 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 308' ' ' PRO . . . . . 0.745 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 24.1 Cg_exo -68.92 127.66 15.61 Favored 'Trans proline' 0 CA--C 1.53 0.286 0 C-N-CA 122.955 2.437 . . . . 0.0 113.394 -176.07 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 309' ' ' VAL . . . . . 0.659 HG22 ' HB3' ' A' ' 320' ' ' ALA . 76.9 t -84.27 -37.14 12.6 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.088 174.966 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -75.29 -6.65 50.93 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.256 179.243 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.52 ' HB2' ' HB2' ' A' ' 308' ' ' PRO . 69.7 m-80 -136.87 -158.69 0.88 Allowed 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.262 -0.427 . . . . 0.0 109.996 -176.633 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 16.5 m 71.23 -73.16 0.1 Allowed 'General case' 0 C--O 1.234 0.275 0 C-N-CA 123.755 0.822 . . . . 0.0 110.903 177.005 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 51.0 t0 -176.44 159.81 2.0 Allowed 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 177.253 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 61.7 t -64.45 -39.73 86.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-O 120.908 0.385 . . . . 0.0 110.55 176.038 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -72.5 -18.87 61.62 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.637 178.732 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 50.3 m -83.86 -25.86 29.92 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.535 -0.302 . . . . 0.0 111.177 -179.221 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 317' ' ' ARG . . . . . 0.659 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 74.1 mtm180 -49.14 -52.57 46.88 Favored Pre-proline 0 CA--C 1.539 0.52 0 N-CA-C 112.641 0.608 . . . . 0.0 112.641 -178.574 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 318' ' ' PRO . . . . . 0.659 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 51.8 Cg_exo -59.74 -13.97 24.56 Favored 'Trans proline' 0 C--N 1.36 1.14 0 C-N-CA 122.53 2.154 . . . . 0.0 113.833 -177.232 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 44.9 m-85 -110.75 -0.55 17.0 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.99 0.424 . . . . 0.0 110.77 -179.282 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 320' ' ' ALA . . . . . 0.659 ' HB3' HG22 ' A' ' 309' ' ' VAL . . . -90.5 159.85 16.3 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.155 -178.899 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 321' ' ' ASN . . . . . 0.431 ' O ' ' HA ' ' A' ' 275' ' ' SER . 51.1 p30 -130.68 -0.69 4.33 Favored 'General case' 0 N--CA 1.464 0.255 0 N-CA-C 112.75 0.648 . . . . 0.0 112.75 -178.977 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 322' ' ' VAL . . . . . 0.676 HG21 HG23 ' A' ' 306' ' ' ILE . 32.8 m -136.11 162.08 36.71 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.258 0 N-CA-C 110.097 -0.334 . . . . 0.0 110.097 176.988 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 51.6 m-20 -72.92 -39.82 65.97 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 111.731 0.271 . . . . 0.0 111.731 -176.376 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 324' ' ' ALA . . . . . 0.745 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -155.5 174.61 15.02 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 112.149 0.426 . . . . 0.0 112.149 -173.353 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 24.6 pttm -119.12 107.44 41.73 Favored Pre-proline 0 N--CA 1.454 -0.233 0 CA-C-N 115.472 -0.785 . . . . 0.0 110.031 170.923 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 55.0 Cg_endo -74.04 167.82 26.28 Favored 'Trans proline' 0 C--O 1.233 0.232 0 C-N-CA 122.695 2.263 . . . . 0.0 112.562 -176.525 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -71.6 123.81 23.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.875 -179.289 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 54.8 mt-10 66.36 -170.14 0.2 Allowed 'General case' 0 N--CA 1.465 0.32 0 O-C-N 123.674 0.609 . . . . 0.0 111.004 -175.998 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 329' ' ' SER . . . . . 0.557 ' HB2' ' O ' ' A' ' 230' ' ' VAL . 50.9 m -94.29 -27.81 15.93 Favored 'General case' 0 C--N 1.325 -0.467 0 C-N-CA 120.727 -0.389 . . . . 0.0 111.995 -174.458 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 330' ' ' ALA . . . . . 0.477 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 75.62 -151.32 0.03 OUTLIER 'General case' 0 N--CA 1.478 0.95 0 N-CA-C 113.273 0.842 . . . . 0.0 113.273 173.023 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 331' ' ' ALA . . . . . 0.591 ' HA ' HG22 ' A' ' 229' ' ' THR . . . -92.98 120.64 33.49 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 114.741 -1.118 . . . . 0.0 110.818 -177.735 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 332' ' ' ILE . . . . . 0.999 HG13 HG12 ' A' ' 270' ' ' ILE . 1.7 mp -106.54 145.87 13.73 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 115.682 -0.69 . . . . 0.0 111.221 -176.903 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 44.1 m -118.29 95.33 4.83 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.0 -178.077 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 334' ' ' ILE . . . . . 0.613 HD13 ' HB3' ' A' ' 268' ' ' PHE . 39.8 mm -78.34 133.48 30.18 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-O 120.949 0.404 . . . . 0.0 111.35 -176.276 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 335' ' ' LEU . . . . . 0.579 HD13 ' H ' ' A' ' 337' ' ' LYS . 1.8 pp -152.44 -172.65 4.3 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.429 177.875 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -124.96 44.23 2.84 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.776 0.322 . . . . 0.0 110.844 -178.925 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 337' ' ' LYS . . . . . 0.579 ' H ' HD13 ' A' ' 335' ' ' LEU . 60.8 tttm . . . . . 0 C--O 1.245 0.836 0 CA-C-O 118.635 -0.698 . . . . 0.0 110.509 -178.943 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.86 0 N-CA-C 112.545 -0.222 . . . . 0.0 112.545 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 64.3 p -125.2 168.6 13.23 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 122.704 -0.292 . . . . 0.0 110.631 178.725 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 73.8 p -70.18 161.06 30.96 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.613 178.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 23.3 pt-20 -112.73 29.37 8.01 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-O 121.192 0.52 . . . . 0.0 111.0 178.473 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 38.2 p -89.36 81.76 6.58 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.286 176.642 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 228' ' ' LEU . . . . . . . . . . . . . 73.0 mt -107.62 100.72 10.1 Favored 'General case' 0 N--CA 1.445 -0.692 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 -178.325 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 76.1 p -126.39 172.19 10.36 Favored 'General case' 0 C--N 1.325 -0.459 0 C-N-CA 119.924 -0.71 . . . . 0.0 110.41 -178.621 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 230' ' ' VAL . . . . . 0.771 HG11 ' HB ' ' A' ' 255' ' ' ILE . 61.5 t -143.96 136.36 23.21 Favored 'Isoleucine or valine' 0 C--O 1.24 0.565 0 CA-C-O 120.779 0.324 . . . . 0.0 110.845 -178.176 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 29.7 m -97.28 160.16 14.5 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.125 177.201 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 92.52 161.58 36.57 Favored Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.462 -0.875 . . . . 0.0 111.177 -177.281 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 233' ' ' GLN . . . . . 0.598 ' HG2' ' HA ' ' A' ' 328' ' ' GLU . 83.4 mt-30 -118.16 102.85 50.38 Favored Pre-proline 0 C--N 1.319 -0.723 0 CA-C-N 117.081 0.44 . . . . 0.0 111.739 -177.354 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 234' ' ' PRO . . . . . 0.414 ' HD3' ' OG ' ' A' ' 329' ' ' SER . 73.9 Cg_endo -75.86 123.75 7.61 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 121.468 1.445 . . . . 0.0 110.444 171.829 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 20.3 pt-20 -166.19 127.1 1.76 Allowed 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.605 -178.584 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 236' ' ' HIS . . . . . 0.479 ' C ' ' HD3' ' A' ' 237' ' ' LYS . 41.0 m80 -141.04 143.36 34.35 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.219 174.794 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 237' ' ' LYS . . . . . 0.479 ' HD3' ' C ' ' A' ' 236' ' ' HIS . 13.7 mmtm -106.1 159.12 16.31 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.207 -172.62 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 238' ' ' VAL . . . . . . . . . . . . . 51.7 t -67.33 111.73 2.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 177.31 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 239' ' ' GLU . . . . . 0.45 ' HB2' ' HB ' ' A' ' 248' ' ' VAL . 53.6 mt-10 -85.87 135.12 33.83 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.56 -176.539 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 240' ' ' ALA . . . . . 0.595 ' O ' ' HA ' ' A' ' 247' ' ' PRO . . . -67.63 -53.29 29.22 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.025 177.75 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 241' ' ' LYS . . . . . 0.53 ' HD2' ' O ' ' A' ' 241' ' ' LYS . 0.0 OUTLIER -146.25 154.58 41.89 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.38 178.024 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 242' ' ' ASP . . . . . 0.481 ' HB3' HG21 ' A' ' 248' ' ' VAL . 2.7 p30 -98.5 -158.02 0.64 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.609 -179.607 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 34.1 t -62.78 -30.5 71.51 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.326 -177.211 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 47.5 t30 -82.84 -14.27 54.64 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-O 121.191 0.519 . . . . 0.0 109.8 178.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 84.7 26.96 36.56 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.536 -0.84 . . . . 0.0 112.421 177.901 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 246' ' ' MET . . . . . 0.474 ' O ' ' HA ' ' A' ' 241' ' ' LYS . 24.3 ptt? -112.74 152.8 45.05 Favored Pre-proline 0 C--N 1.324 -0.529 0 N-CA-C 110.335 -0.246 . . . . 0.0 110.335 178.895 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 247' ' ' PRO . . . . . 0.595 ' HA ' ' O ' ' A' ' 240' ' ' ALA . 71.0 Cg_exo -53.2 135.89 60.78 Favored 'Trans proline' 0 C--N 1.351 0.67 0 C-N-CA 122.948 2.432 . . . . 0.0 112.537 -177.996 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.481 HG21 ' HB3' ' A' ' 242' ' ' ASP . 42.1 t -120.1 133.78 65.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 N-CA-C 112.065 0.395 . . . . 0.0 112.065 -174.57 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -103.44 95.27 5.96 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 167.41 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 250' ' ' ASN . . . . . 0.539 HD21 ' H ' ' A' ' 250' ' ' ASN . 0.5 OUTLIER -59.59 154.15 18.23 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.272 -172.122 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 251' ' ' ARG . . . . . 0.571 ' HG3' ' HG3' ' A' ' 252' ' ' GLN . 22.2 ptt-85 -143.65 -178.97 6.16 Favored 'General case' 0 C--N 1.326 -0.438 0 C-N-CA 120.936 -0.305 . . . . 0.0 111.45 -177.137 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 252' ' ' GLN . . . . . 0.571 ' HG3' ' HG3' ' A' ' 251' ' ' ARG . 86.3 mt-30 62.12 178.19 0.13 Allowed 'General case' 0 N--CA 1.468 0.474 0 N-CA-C 114.13 1.159 . . . . 0.0 114.13 170.86 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 174.72 109.47 0.24 Allowed Glycine 0 N--CA 1.446 -0.648 0 CA-C-N 114.338 -1.301 . . . . 0.0 109.933 -177.145 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 41.5 p -95.44 125.09 39.81 Favored 'General case' 0 C--N 1.324 -0.522 0 O-C-N 122.32 -0.517 . . . . 0.0 111.706 -171.726 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.771 ' HB ' HG11 ' A' ' 230' ' ' VAL . 20.5 pt -124.37 145.18 31.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.901 -176.181 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 31.0 m -99.56 106.05 17.99 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 174.232 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.557 ' HA ' HG13 ' A' ' 230' ' ' VAL . 32.8 m -88.13 141.57 14.13 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.595 0 C-N-CA 119.27 -0.972 . . . . 0.0 113.607 -165.04 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 36.4 m -94.23 10.3 34.57 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 113.404 -1.725 . . . . 0.0 109.275 169.593 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 259' ' ' ALA . . . . . . . . . . . . . . . -126.76 145.58 50.56 Favored 'General case' 0 CA--C 1.518 -0.256 0 N-CA-C 113.037 0.755 . . . . 0.0 113.037 -167.209 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 62.5 m 57.94 -68.51 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.558 0 CA-C-N 113.822 -1.535 . . . . 0.0 114.919 167.354 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 107.49 51.39 0.76 Allowed Glycine 0 N--CA 1.449 -0.466 0 N-CA-C 109.861 -1.296 . . . . 0.0 109.861 -167.408 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 262' ' ' LEU . . . . . 0.409 HD21 HD12 ' A' ' 334' ' ' ILE . 92.4 mt -65.0 163.93 13.71 Favored 'General case' 0 C--O 1.235 0.332 0 N-CA-C 113.709 1.003 . . . . 0.0 113.709 -168.021 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 73.0 mt-30 -135.23 -179.42 5.62 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 113.694 -1.594 . . . . 0.0 108.042 173.425 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 264' ' ' VAL . . . . . 0.43 ' HA ' ' CG1' ' A' ' 292' ' ' VAL . 38.5 t -73.76 127.81 35.84 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 C-N-CA 120.679 -0.408 . . . . 0.0 111.062 -179.79 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 265' ' ' GLY . . . . . 0.617 ' H ' ' HB ' ' A' ' 292' ' ' VAL . . . 121.49 8.05 7.88 Favored Glycine 0 C--N 1.335 0.486 0 C-N-CA 120.363 -0.922 . . . . 0.0 114.395 175.246 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 65.6 m-20 -90.71 164.93 13.95 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 117.831 0.816 . . . . 0.0 111.517 178.511 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 267' ' ' ALA . . . . . 0.766 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -139.9 126.0 19.84 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.199 -0.909 . . . . 0.0 109.052 174.536 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 268' ' ' PHE . . . . . 0.48 ' HZ ' HG21 ' A' ' 302' ' ' ILE . 4.7 p90 -147.6 166.74 26.47 Favored 'General case' 0 C--N 1.327 -0.413 0 C-N-CA 119.74 -0.784 . . . . 0.0 111.829 -173.353 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 269' ' ' THR . . . . . 0.435 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 44.2 p -117.73 139.82 50.53 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.853 176.09 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 270' ' ' ILE . . . . . 0.546 HG12 HG12 ' A' ' 332' ' ' ILE . 59.6 mt -106.71 144.37 15.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 120.668 0.27 . . . . 0.0 110.964 -177.425 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -67.83 119.51 12.64 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.442 -179.827 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 106.04 -22.69 30.91 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 121.098 -0.572 . . . . 0.0 112.386 178.615 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 273' ' ' VAL . . . . . 0.818 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 36.5 t -87.02 101.44 11.16 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-O 121.046 0.45 . . . . 0.0 110.286 178.756 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 274' ' ' ASN . . . . . 0.526 ' HB3' ' HA2' ' A' ' 285' ' ' GLY . 54.7 m-20 -110.01 129.6 55.65 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.272 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 51.0 p -73.01 160.47 32.03 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.588 0.709 . . . . 0.0 112.148 -178.902 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 276' ' ' VAL . . . . . 0.863 HG21 HG21 ' A' ' 309' ' ' VAL . 22.8 m -127.9 -176.67 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 CA-C-N 114.748 -1.115 . . . . 0.0 110.432 -178.561 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 277' ' ' HIS . . . . . 0.669 ' HB3' ' HA ' ' A' ' 281' ' ' LYS . 0.0 OUTLIER 29.84 51.21 0.08 Allowed 'General case' 0 N--CA 1.473 0.69 0 O-C-N 124.826 1.328 . . . . 0.0 113.624 177.89 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 4.1 tp-100 -74.84 -43.15 56.1 Favored 'General case' 0 N--CA 1.439 -1.018 0 N-CA-C 108.488 -0.931 . . . . 0.0 108.488 171.248 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 279' ' ' ILE . . . . . 0.446 ' O ' ' HB2' ' A' ' 282' ' ' ASP . 26.5 mm -117.32 75.08 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.278 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.269 177.464 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 58.3 p 51.4 81.93 0.07 Allowed 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 123.665 0.786 . . . . 0.0 112.642 -178.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 281' ' ' LYS . . . . . 0.669 ' HA ' ' HB3' ' A' ' 277' ' ' HIS . 1.0 OUTLIER 56.96 27.63 13.47 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-N 115.42 -0.809 . . . . 0.0 112.011 -179.555 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 282' ' ' ASP . . . . . 0.446 ' HB2' ' O ' ' A' ' 279' ' ' ILE . 57.3 t0 -90.1 128.55 36.34 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.947 -0.57 . . . . 0.0 109.677 177.323 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 44.7 p -101.18 114.94 29.36 Favored 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.819 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 76.0 p -116.19 -11.35 11.34 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.649 -0.705 . . . . 0.0 112.145 -167.924 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 285' ' ' GLY . . . . . 0.526 ' HA2' ' HB3' ' A' ' 274' ' ' ASN . . . 76.83 10.83 85.9 Favored Glycine 0 CA--C 1.517 0.196 0 C-N-CA 120.814 -0.707 . . . . 0.0 113.267 177.249 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 83.2 mt-30 -71.81 131.09 86.14 Favored Pre-proline 0 C--N 1.327 -0.39 0 CA-C-N 116.824 0.312 . . . . 0.0 110.596 179.616 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 287' ' ' PRO . . . . . 0.435 ' HB2' ' HB ' ' A' ' 269' ' ' THR . 15.8 Cg_endo -59.3 131.32 40.3 Favored 'Trans proline' 0 C--N 1.343 0.254 0 C-N-CA 122.699 2.266 . . . . 0.0 112.292 -178.646 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 69.2 tp60 -78.3 132.16 37.35 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.847 -178.528 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 46.9 t -92.13 136.3 24.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.356 179.345 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 290' ' ' PHE . . . . . 0.818 ' HZ ' HG11 ' A' ' 273' ' ' VAL . 55.7 m-85 -117.16 150.67 38.33 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.806 -177.081 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 21.2 mmt85 -108.02 157.69 18.02 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.797 -0.638 . . . . 0.0 109.835 172.252 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 292' ' ' VAL . . . . . 0.617 ' HB ' ' H ' ' A' ' 265' ' ' GLY . 52.2 t -102.6 128.77 55.07 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.03 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.509 177.406 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 293' ' ' LEU . . . . . 0.659 HD21 ' HB3' ' A' ' 303' ' ' SER . 2.8 mm? -103.99 -37.05 7.53 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.108 -178.578 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 294' ' ' ALA . . . . . . . . . . . . . . . -156.96 141.54 16.75 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.562 -0.29 . . . . 0.0 111.009 -178.819 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 295' ' ' VAL . . . . . 0.471 HG22 HG13 ' A' ' 300' ' ' VAL . 46.3 t -131.64 129.01 61.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.052 0.453 . . . . 0.0 110.122 176.176 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 56.5 p -122.3 88.81 3.0 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.793 -0.64 . . . . 0.0 109.897 178.295 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 75.42 -124.3 7.56 Favored Glycine 0 N--CA 1.446 -0.671 0 C-N-CA 119.932 -1.128 . . . . 0.0 110.552 -171.425 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 41.7 p -99.72 26.37 6.3 Favored 'General case' 0 C--N 1.319 -0.745 0 O-C-N 122.142 -0.622 . . . . 0.0 110.87 173.505 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 54.1 m -107.95 106.3 16.49 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 176.009 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 300' ' ' VAL . . . . . 0.471 HG13 HG22 ' A' ' 295' ' ' VAL . 42.0 t -104.44 124.87 59.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.952 -175.001 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 47.3 m -94.89 109.67 21.64 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 176.149 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 302' ' ' ILE . . . . . 0.566 ' O ' ' HA ' ' A' ' 252' ' ' GLN . 28.8 pt -111.25 160.93 10.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-O 121.459 0.647 . . . . 0.0 112.343 -173.412 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 303' ' ' SER . . . . . 0.659 ' HB3' HD21 ' A' ' 293' ' ' LEU . 34.6 t -167.24 155.9 9.09 Favored Pre-proline 0 C--N 1.32 -0.713 0 N-CA-C 105.964 -1.865 . . . . 0.0 105.964 178.331 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 304' ' ' PRO . . . . . 0.507 ' HA ' ' OG ' ' A' ' 303' ' ' SER . 65.2 Cg_exo -56.46 151.54 27.16 Favored 'Cis proline' 0 N--CA 1.473 0.291 0 CA-C-N 121.23 1.475 . . . . 0.0 114.642 1.715 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 305' ' ' LYS . . . . . 0.613 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -67.34 169.01 9.56 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 114.085 -1.416 . . . . 0.0 111.763 -179.04 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 306' ' ' ILE . . . . . 0.593 HG23 HG21 ' A' ' 322' ' ' VAL . 62.6 mt -108.59 114.09 45.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.85 -178.154 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 307' ' ' LEU . . . . . 0.537 ' O ' ' HB1' ' A' ' 320' ' ' ALA . 94.0 mt -125.94 118.45 23.97 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-N 116.753 -0.203 . . . . 0.0 111.021 -179.72 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 308' ' ' PRO . . . . . 0.741 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 9.9 Cg_exo -74.18 122.31 7.49 Favored 'Trans proline' 0 CA--C 1.534 0.493 0 C-N-CA 123.519 2.813 . . . . 0.0 113.742 -178.557 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 309' ' ' VAL . . . . . 0.863 HG21 HG21 ' A' ' 276' ' ' VAL . 48.1 t -80.58 -19.44 11.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 121.189 0.518 . . . . 0.0 110.48 176.014 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 59.5 mm-40 -92.77 -5.32 51.42 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.904 0.383 . . . . 0.0 110.834 179.206 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.568 ' HB2' ' HB2' ' A' ' 308' ' ' PRO . 5.5 m120 -132.5 -129.98 0.18 Allowed 'General case' 0 CA--C 1.532 0.285 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.26 -178.531 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 312' ' ' THR . . . . . 0.493 ' OG1' ' HD2' ' A' ' 308' ' ' PRO . 59.6 m 60.84 -78.61 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.281 0 C-N-CA 124.28 1.032 . . . . 0.0 112.121 177.655 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 38.3 t70 -176.68 150.29 0.82 Allowed 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 -177.864 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 46.7 t -53.18 -37.61 28.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 120.748 0.309 . . . . 0.0 111.53 -179.516 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -84.91 -36.3 21.55 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 112.377 0.51 . . . . 0.0 112.377 -178.314 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 316' ' ' SER . . . . . 0.523 ' HA ' ' CZ ' ' A' ' 319' ' ' TYR . 67.9 m -93.53 -12.68 29.06 Favored 'General case' 0 C--N 1.327 -0.398 0 N-CA-C 113.364 0.875 . . . . 0.0 113.364 -172.346 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 317' ' ' ARG . . . . . 0.525 ' HG2' ' HD3' ' A' ' 318' ' ' PRO . 33.6 ptt85 -75.44 -34.4 1.59 Allowed Pre-proline 0 CA--C 1.548 0.882 0 N-CA-C 113.171 0.804 . . . . 0.0 113.171 -179.47 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 318' ' ' PRO . . . . . 0.525 ' HD3' ' HG2' ' A' ' 317' ' ' ARG . 33.9 Cg_exo -60.36 -26.79 83.53 Favored 'Trans proline' 0 C--N 1.371 1.718 0 C-N-CA 121.702 1.602 . . . . 0.0 113.17 -177.785 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 319' ' ' TYR . . . . . 0.523 ' CZ ' ' HA ' ' A' ' 316' ' ' SER . 2.7 p90 -106.82 30.0 6.5 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.076 0.465 . . . . 0.0 111.312 177.863 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 320' ' ' ALA . . . . . 0.706 ' HB3' HG22 ' A' ' 309' ' ' VAL . . . -89.87 162.68 15.34 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.404 -0.817 . . . . 0.0 109.838 173.628 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 321' ' ' ASN . . . . . 0.406 ' OD1' HG13 ' A' ' 322' ' ' VAL . 19.4 p30 -100.71 -19.18 16.16 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 113.788 1.032 . . . . 0.0 113.788 -171.457 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 322' ' ' VAL . . . . . 0.593 HG21 HG23 ' A' ' 306' ' ' ILE . 35.6 m -136.77 161.08 36.78 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.401 0 CA-C-N 118.073 0.397 . . . . 0.0 111.155 -179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 54.5 m-20 -60.91 -41.03 95.34 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 111.849 0.314 . . . . 0.0 111.849 -178.781 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 324' ' ' ALA . . . . . 0.741 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -157.09 166.24 33.82 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.398 -0.364 . . . . 0.0 111.77 -175.346 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 24.5 pttm -106.31 108.93 62.67 Favored Pre-proline 0 C--N 1.327 -0.411 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 169.016 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_exo -65.0 167.24 16.39 Favored 'Trans proline' 0 C--N 1.343 0.244 0 C-N-CA 122.581 2.187 . . . . 0.0 113.107 -170.543 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -62.85 143.53 57.51 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 115.753 -0.658 . . . . 0.0 109.767 175.089 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 328' ' ' GLU . . . . . 0.598 ' HA ' ' HG2' ' A' ' 233' ' ' GLN . 15.6 pt-20 44.86 -135.25 0.65 Allowed 'General case' 0 N--CA 1.468 0.449 0 O-C-N 124.227 0.955 . . . . 0.0 110.941 -174.132 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 329' ' ' SER . . . . . 0.648 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 53.3 m -111.7 -31.63 6.91 Favored 'General case' 0 C--N 1.321 -0.636 0 C-N-CA 120.743 -0.383 . . . . 0.0 110.535 178.317 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 330' ' ' ALA . . . . . 0.432 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 78.6 -167.42 0.04 OUTLIER 'General case' 0 N--CA 1.475 0.824 0 O-C-N 124.111 0.882 . . . . 0.0 112.902 174.634 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -83.85 152.91 24.32 Favored 'General case' 0 CA--C 1.52 -0.182 0 CA-C-N 115.361 -0.836 . . . . 0.0 111.193 -176.179 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 332' ' ' ILE . . . . . 0.582 HD11 HG21 ' A' ' 230' ' ' VAL . 48.7 mt -126.58 145.0 34.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 121.202 0.525 . . . . 0.0 112.034 -176.56 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 87.8 m -111.22 97.57 6.88 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.459 -0.792 . . . . 0.0 109.103 173.486 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 334' ' ' ILE . . . . . 0.409 HD12 HD21 ' A' ' 262' ' ' LEU . 30.2 mm -79.11 132.27 32.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -171.705 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 335' ' ' LEU . . . . . . . . . . . . . 8.4 mp -119.79 151.59 38.57 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.412 -0.813 . . . . 0.0 109.818 170.468 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 75.0 m-80 -110.3 9.95 23.62 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.293 174.193 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 38.8 ttpt . . . . . 0 C--O 1.244 0.788 0 CA-C-O 118.493 -0.765 . . . . 0.0 110.181 179.295 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.776 0 N-CA-C 112.056 -0.418 . . . . 0.0 112.056 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 75.0 p 44.29 42.34 5.12 Favored 'General case' 0 N--CA 1.47 0.547 0 C-N-CA 123.67 0.788 . . . . 0.0 112.509 179.23 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 65.8 p -90.85 -176.2 4.6 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.367 178.871 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 226' ' ' GLU . . . . . 0.573 ' CD ' ' H ' ' A' ' 226' ' ' GLU . 0.7 OUTLIER -86.46 57.64 4.61 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.323 0.582 . . . . 0.0 110.224 176.252 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 35.7 t -77.54 80.54 4.02 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.237 177.616 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 228' ' ' LEU . . . . . 0.652 HD12 HG13 ' A' ' 334' ' ' ILE . 80.3 mt -103.61 146.9 27.88 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.352 -0.84 . . . . 0.0 109.548 -175.523 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 229' ' ' THR . . . . . 0.593 HG22 ' HA ' ' A' ' 331' ' ' ALA . 40.9 p -126.43 178.77 5.65 Favored 'General case' 0 C--N 1.323 -0.547 0 C-N-CA 119.729 -0.788 . . . . 0.0 111.042 -179.835 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 230' ' ' VAL . . . . . 0.857 HG11 HD12 ' A' ' 255' ' ' ILE . 58.1 t -146.28 137.15 18.6 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 -179.599 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 70.8 m -111.18 155.41 22.95 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.944 0.402 . . . . 0.0 110.854 178.188 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 86.03 169.63 46.14 Favored Glycine 0 N--CA 1.449 -0.499 0 N-CA-C 110.76 -0.936 . . . . 0.0 110.76 -172.471 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 233' ' ' GLN . . . . . 0.419 ' HA ' ' HD3' ' A' ' 234' ' ' PRO . 86.1 mt-30 -117.54 145.56 36.54 Favored Pre-proline 0 C--N 1.323 -0.572 0 CA-C-N 117.626 0.713 . . . . 0.0 111.482 179.761 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 234' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 233' ' ' GLN . 3.8 Cg_exo -71.94 172.29 14.91 Favored 'Trans proline' 0 N--CA 1.462 -0.374 0 C-N-CA 122.751 2.301 . . . . 0.0 111.55 176.249 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 55.7 mp0 -96.89 151.19 19.92 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.174 0.512 . . . . 0.0 110.911 -179.063 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 4.2 p80 -140.48 125.73 18.7 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.33 -0.85 . . . . 0.0 108.9 174.338 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 237' ' ' LYS . . . . . 0.563 ' HD3' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -169.56 140.05 2.16 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 111.76 0.282 . . . . 0.0 111.76 -176.385 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 238' ' ' VAL . . . . . . . . . . . . . 24.8 t -89.94 111.16 22.8 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.364 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 169.777 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 239' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -116.26 124.76 50.99 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-O 121.074 0.464 . . . . 0.0 111.168 -174.106 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 240' ' ' ALA . . . . . . . . . . . . . . . -66.65 -40.92 88.89 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.568 -177.86 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 241' ' ' LYS . . . . . 0.568 ' HD2' ' O ' ' A' ' 241' ' ' LYS . 0.6 OUTLIER -145.0 149.82 35.81 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.24 178.876 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 54.4 p-10 -102.0 -156.4 0.56 Allowed 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.369 -179.561 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 43.1 t -63.46 -21.34 66.25 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.218 178.046 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 48.2 t-20 -87.25 -15.27 38.63 Favored 'General case' 0 CA--C 1.533 0.322 0 CA-C-O 121.308 0.575 . . . . 0.0 109.718 178.273 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 245' ' ' GLY . . . . . 0.549 ' HA2' ' HB2' ' A' ' 241' ' ' LYS . . . 72.36 26.66 71.43 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.892 -0.67 . . . . 0.0 112.848 176.586 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 246' ' ' MET . . . . . 0.562 ' O ' HG23 ' A' ' 248' ' ' VAL . 0.0 OUTLIER -111.76 165.95 11.85 Favored Pre-proline 0 C--N 1.325 -0.496 0 N-CA-C 110.326 -0.25 . . . . 0.0 110.326 179.496 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 247' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_exo -58.81 121.09 9.37 Favored 'Trans proline' 0 C--N 1.352 0.725 0 C-N-CA 122.402 2.068 . . . . 0.0 112.172 -176.953 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.562 HG23 ' O ' ' A' ' 246' ' ' MET . 61.4 t -119.22 152.32 21.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 120.87 0.366 . . . . 0.0 111.73 -174.823 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -120.53 144.46 48.04 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 170.664 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 250' ' ' ASN . . . . . 0.816 HD21 ' H ' ' A' ' 250' ' ' ASN . 1.0 OUTLIER -37.66 121.6 0.9 Allowed 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 123.423 0.689 . . . . 0.0 112.253 -175.291 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 251' ' ' ARG . . . . . 0.564 ' HG3' ' HG3' ' A' ' 252' ' ' GLN . 17.5 ptt-85 -150.31 171.64 16.65 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 120.869 -0.332 . . . . 0.0 111.364 -179.231 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 252' ' ' GLN . . . . . 0.564 ' HG3' ' HG3' ' A' ' 251' ' ' ARG . 86.0 mt-30 61.24 168.97 0.1 Allowed 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 114.894 1.442 . . . . 0.0 114.894 169.737 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 253' ' ' GLY . . . . . 0.556 ' O ' HG12 ' A' ' 302' ' ' ILE . . . 179.96 110.43 0.28 Allowed Glycine 0 N--CA 1.451 -0.349 0 CA-C-N 113.738 -1.574 . . . . 0.0 110.588 178.581 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 41.6 p -97.12 126.49 42.32 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 117.378 0.589 . . . . 0.0 111.406 -174.887 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.857 HD12 HG11 ' A' ' 230' ' ' VAL . 12.7 pt -132.18 157.79 43.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.62 -176.406 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 32.7 m -98.98 107.57 20.04 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 175.06 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.567 ' HA ' HG13 ' A' ' 230' ' ' VAL . 29.8 m -89.79 143.31 11.45 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.575 0 C-N-CA 119.556 -0.858 . . . . 0.0 113.012 -168.206 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 258' ' ' SER . . . . . 0.516 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 37.2 m -91.04 9.32 31.3 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 114.023 -1.444 . . . . 0.0 108.893 169.789 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 259' ' ' ALA . . . . . 0.618 ' HB1' HD13 ' A' ' 228' ' ' LEU . . . -84.78 161.56 19.93 Favored 'General case' 0 N--CA 1.448 -0.525 0 CA-C-N 115.119 -0.946 . . . . 0.0 109.502 -177.624 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 34.3 t -126.63 130.77 51.11 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 120.639 0.257 . . . . 0.0 110.61 -178.831 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 75.87 43.79 21.51 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.963 -0.637 . . . . 0.0 113.328 177.179 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 262' ' ' LEU . . . . . 0.481 HD12 HG21 ' A' ' 257' ' ' VAL . 79.3 mt -89.99 142.92 27.24 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 117.17 0.485 . . . . 0.0 110.478 175.757 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 73.0 mt-30 -133.84 171.43 14.17 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.51 176.845 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 44.0 t -76.58 142.05 14.87 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 N-CA-C 110.195 -0.298 . . . . 0.0 110.195 179.1 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 94.87 -4.9 68.77 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.5 -0.857 . . . . 0.0 113.257 177.255 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 266' ' ' ASP . . . . . 0.506 ' O ' ' HA ' ' A' ' 291' ' ' ARG . 48.7 m-20 -78.88 158.03 28.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 117.172 0.486 . . . . 0.0 110.837 178.287 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 267' ' ' ALA . . . . . 0.652 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -122.72 147.67 46.21 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.974 -176.658 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 268' ' ' PHE . . . . . 0.581 ' HA ' ' CD2' ' A' ' 335' ' ' LEU . 3.6 p90 -164.04 173.28 12.73 Favored 'General case' 0 C--N 1.33 -0.259 0 C-N-CA 120.056 -0.657 . . . . 0.0 111.895 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 54.1 p -121.58 129.98 53.21 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.345 176.866 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 270' ' ' ILE . . . . . 0.846 HG12 HG13 ' A' ' 332' ' ' ILE . 62.6 mt -98.35 134.4 37.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.72 -178.839 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -76.07 118.47 18.85 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.828 179.206 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 109.62 -21.44 25.84 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.629 -0.796 . . . . 0.0 111.938 -178.778 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 40.9 t -104.35 102.12 13.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 N-CA-C 109.557 -0.535 . . . . 0.0 109.557 175.293 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 59.6 m-20 -104.44 151.57 23.37 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 -179.481 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 275' ' ' SER . . . . . 0.98 ' HB3' ' HB3' ' A' ' 288' ' ' GLN . 23.2 p -88.17 157.53 18.79 Favored 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 112.13 0.419 . . . . 0.0 112.13 -178.079 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 276' ' ' VAL . . . . . 0.536 HG11 HG21 ' A' ' 309' ' ' VAL . 18.8 m -125.98 162.76 28.88 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.605 0 CA-C-N 115.332 -0.849 . . . . 0.0 109.959 172.744 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 39.2 m80 -130.04 91.29 3.1 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 175.526 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 4.1 tp-100 -80.64 -23.42 39.71 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.361 -172.112 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 279' ' ' ILE . . . . . 0.505 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.1 mp -64.99 -41.56 92.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 121.069 0.461 . . . . 0.0 109.884 177.972 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 77.8 p -87.45 -16.44 34.8 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.316 174.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 5.6 tmtm? 59.49 53.65 5.03 Favored 'General case' 0 CA--C 1.531 0.216 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 -176.086 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -110.91 142.26 43.23 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.336 -0.847 . . . . 0.0 109.401 -175.256 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 36.0 p -102.28 106.19 16.96 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 178.295 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 82.5 p -110.13 -53.47 2.67 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.655 -0.702 . . . . 0.0 111.406 -171.628 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 66.13 31.48 79.41 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 121.001 -0.618 . . . . 0.0 111.966 -179.364 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 286' ' ' GLN . . . . . 0.408 ' HA ' ' HD3' ' A' ' 287' ' ' PRO . 11.2 mm100 -106.11 142.15 24.25 Favored Pre-proline 0 C--N 1.326 -0.451 0 CA-C-N 116.026 -0.087 . . . . 0.0 110.772 -177.311 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 287' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 286' ' ' GLN . 38.6 Cg_exo -59.3 127.82 25.32 Favored 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 122.648 2.232 . . . . 0.0 111.671 178.161 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 288' ' ' GLN . . . . . 0.98 ' HB3' ' HB3' ' A' ' 275' ' ' SER . 15.9 pt20 -93.55 159.18 15.34 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.984 -178.163 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 289' ' ' VAL . . . . . 0.482 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 45.6 t -88.53 126.26 41.76 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 CA-C-N 115.446 -0.797 . . . . 0.0 110.002 175.246 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 290' ' ' PHE . . . . . 0.652 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 4.1 m-85 -99.67 169.21 9.43 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 178.762 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 291' ' ' ARG . . . . . 0.506 ' HA ' ' O ' ' A' ' 266' ' ' ASP . 12.5 ttp-105 -144.14 127.47 16.79 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-O 121.808 0.813 . . . . 0.0 110.947 172.417 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 292' ' ' VAL . . . . . 0.402 HG11 ' CG2' ' A' ' 295' ' ' VAL . 57.5 t -65.84 139.91 20.48 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.979 0 CA-C-N 114.044 -1.434 . . . . 0.0 112.175 -176.347 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 293' ' ' LEU . . . . . 0.513 HD11 ' HB2' ' A' ' 303' ' ' SER . 89.4 mt -105.56 -32.69 8.37 Favored 'General case' 0 CA--C 1.529 0.157 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.193 177.035 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 294' ' ' ALA . . . . . . . . . . . . . . . -158.6 144.94 17.1 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-O 120.463 0.173 . . . . 0.0 111.15 -179.18 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 295' ' ' VAL . . . . . 0.402 ' CG2' HG11 ' A' ' 292' ' ' VAL . 57.4 t -136.34 126.8 41.33 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 176.836 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 47.0 t -157.54 112.54 2.73 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.897 -178.56 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 57.6 49.76 70.93 Favored Glycine 0 C--N 1.333 0.376 0 C-N-CA 121.148 -0.548 . . . . 0.0 112.469 178.925 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 298' ' ' THR . . . . . 0.438 ' O ' HG22 ' A' ' 257' ' ' VAL . 66.8 p 55.4 10.3 0.46 Allowed 'General case' 0 N--CA 1.473 0.675 0 C-N-CA 124.201 1.0 . . . . 0.0 112.89 -175.722 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 42.6 m -97.81 106.02 18.26 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 173.351 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 300' ' ' VAL . . . . . 0.4 HG13 HG22 ' A' ' 295' ' ' VAL . 53.1 t -109.86 127.02 67.03 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.51 -170.494 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 57.3 m -90.54 113.89 25.98 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 172.655 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 302' ' ' ILE . . . . . 0.556 HG12 ' O ' ' A' ' 253' ' ' GLY . 31.0 pt -110.4 174.76 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-O 121.643 0.735 . . . . 0.0 111.727 -173.321 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 303' ' ' SER . . . . . 0.562 ' OG ' ' HA ' ' A' ' 304' ' ' PRO . 31.8 t -163.1 156.67 16.98 Favored Pre-proline 0 C--N 1.317 -0.811 0 N-CA-C 105.759 -1.941 . . . . 0.0 105.759 178.732 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 304' ' ' PRO . . . . . 0.562 ' HA ' ' OG ' ' A' ' 303' ' ' SER . 24.9 Cg_exo -66.33 -179.42 12.34 Favored 'Cis proline' 0 N--CA 1.474 0.339 0 CA-C-N 121.004 1.394 . . . . 0.0 113.906 1.404 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 305' ' ' LYS . . . . . 0.618 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -77.48 160.98 28.29 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.317 -0.856 . . . . 0.0 112.254 -175.264 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 306' ' ' ILE . . . . . 0.526 HD12 ' N ' ' A' ' 306' ' ' ILE . 2.2 mp -94.05 109.91 22.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.18 179.03 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 307' ' ' LEU . . . . . 0.485 ' H ' HG22 ' A' ' 322' ' ' VAL . 96.0 mt -141.51 99.39 6.36 Favored Pre-proline 0 CA--C 1.516 -0.361 0 CA-C-O 120.455 0.169 . . . . 0.0 111.052 178.411 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 308' ' ' PRO . . . . . 0.755 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 22.6 Cg_exo -69.43 148.19 66.63 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 123.077 2.518 . . . . 0.0 113.297 -177.354 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 309' ' ' VAL . . . . . 0.536 HG21 HG11 ' A' ' 276' ' ' VAL . 45.5 t -93.7 -23.98 5.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 170.452 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -76.05 34.37 0.13 Allowed 'General case' 0 CA--C 1.532 0.272 0 CA-C-N 115.375 -0.83 . . . . 0.0 112.726 -177.3 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 33.7 m120 -99.07 162.87 12.83 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 174.77 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 61.5 m -78.43 -32.81 48.77 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 176.615 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -65.31 119.57 11.18 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.781 179.699 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 60.1 t -68.39 -35.43 70.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.767 -0.651 . . . . 0.0 111.16 -178.657 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 315' ' ' ALA . . . . . 0.423 ' O ' ' HD2' ' A' ' 318' ' ' PRO . . . -65.07 -17.9 64.85 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 112.157 0.428 . . . . 0.0 112.157 -178.787 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 316' ' ' SER . . . . . 0.593 ' HA ' ' CZ ' ' A' ' 319' ' ' TYR . 52.4 m -78.92 -17.21 55.89 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 111.812 0.301 . . . . 0.0 111.812 -179.313 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 317' ' ' ARG . . . . . 0.427 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 70.0 mtm180 -74.4 -46.88 5.86 Favored Pre-proline 0 CA--C 1.539 0.542 0 N-CA-C 112.928 0.714 . . . . 0.0 112.928 -176.569 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 318' ' ' PRO . . . . . 0.427 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 75.9 Cg_exo -54.85 -38.48 92.32 Favored 'Trans proline' 0 C--N 1.358 1.033 0 C-N-CA 122.126 1.884 . . . . 0.0 113.685 -175.78 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 319' ' ' TYR . . . . . 0.593 ' CZ ' ' HA ' ' A' ' 316' ' ' SER . 2.1 p90 -98.72 7.58 45.92 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 120.76 -0.376 . . . . 0.0 111.937 -178.536 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -60.43 156.02 16.93 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-O 121.122 0.487 . . . . 0.0 111.834 -177.28 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 321' ' ' ASN . . . . . 0.473 ' HB2' ' HE2' ' A' ' 305' ' ' LYS . 16.3 t-20 -132.59 -27.61 1.71 Allowed 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.952 -179.04 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 322' ' ' VAL . . . . . 0.485 HG22 ' H ' ' A' ' 307' ' ' LEU . 28.7 m -131.59 166.95 27.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.759 -179.733 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -68.43 -48.05 65.61 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.612 -0.267 . . . . 0.0 111.154 177.832 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 324' ' ' ALA . . . . . 0.755 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -164.63 177.35 8.12 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.988 -0.551 . . . . 0.0 111.59 -176.132 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 21.9 pttp -118.61 119.52 32.64 Favored Pre-proline 0 C--N 1.325 -0.462 0 CA-C-N 115.346 -0.843 . . . . 0.0 109.692 172.529 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_endo -79.23 169.13 19.4 Favored 'Trans proline' 0 C--O 1.233 0.243 0 C-N-CA 122.962 2.441 . . . . 0.0 112.901 -176.171 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -67.57 129.15 39.02 Favored 'General case' 0 C--O 1.238 0.455 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 175.643 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 57.0 mm-40 65.48 -156.17 0.28 Allowed 'General case' 0 N--CA 1.463 0.216 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 -172.089 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 329' ' ' SER . . . . . 0.661 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 69.3 m -112.5 -12.27 13.5 Favored 'General case' 0 C--N 1.322 -0.606 0 C-N-CA 120.544 -0.462 . . . . 0.0 110.869 176.785 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 70.24 -154.01 0.12 Allowed 'General case' 0 N--CA 1.469 0.502 0 N-CA-C 113.209 0.818 . . . . 0.0 113.209 172.408 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 331' ' ' ALA . . . . . 0.593 ' HA ' HG22 ' A' ' 229' ' ' THR . . . -93.09 137.61 32.28 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.75 -177.801 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 332' ' ' ILE . . . . . 0.846 HG13 HG12 ' A' ' 270' ' ' ILE . 1.9 mp -116.33 144.27 24.41 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.113 -178.685 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 40.8 m -109.87 106.29 15.81 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.609 -0.515 . . . . 0.0 109.609 179.728 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 334' ' ' ILE . . . . . 0.652 HG13 HD12 ' A' ' 228' ' ' LEU . 19.5 mm -81.39 133.55 29.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 N-CA-C 113.755 1.02 . . . . 0.0 113.755 -172.208 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 335' ' ' LEU . . . . . 0.581 ' CD2' ' HA ' ' A' ' 268' ' ' PHE . 1.6 pt? -148.02 -147.62 0.23 Allowed 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 113.61 -1.632 . . . . 0.0 108.344 169.071 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 55.7 t-20 -163.38 -39.97 0.03 OUTLIER 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 108.393 -0.965 . . . . 0.0 108.393 177.801 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 62.4 tttp . . . . . 0 C--O 1.243 0.716 0 CA-C-N 114.55 -1.204 . . . . 0.0 109.5 174.82 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.809 0 N-CA-C 111.966 -0.454 . . . . 0.0 111.966 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 51.0 m -82.87 -24.6 33.15 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.81 0.338 . . . . 0.0 111.038 -177.452 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 66.2 p -106.46 164.69 11.84 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.505 178.098 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 9.0 mp0 -92.73 58.61 3.1 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.021 0.438 . . . . 0.0 109.902 178.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 26.2 t -91.8 -147.75 0.22 Allowed 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.527 -178.139 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 228' ' ' LEU . . . . . 0.525 ' HB3' ' HA ' ' A' ' 259' ' ' ALA . 83.8 mt -108.37 140.79 41.16 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 109.689 -0.486 . . . . 0.0 109.689 179.293 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 70.8 p -124.27 177.12 6.02 Favored 'General case' 0 C--N 1.325 -0.464 0 C-N-CA 119.957 -0.697 . . . . 0.0 110.978 -178.506 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 230' ' ' VAL . . . . . 0.63 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 61.3 t -146.61 146.84 18.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.014 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 41.3 t -132.08 133.85 44.82 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.822 0.344 . . . . 0.0 110.402 178.755 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 104.21 73.28 0.92 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.41 -0.9 . . . . 0.0 112.929 177.625 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 13.8 mm-40 -66.86 133.0 93.93 Favored Pre-proline 0 C--N 1.33 -0.248 0 CA-C-O 120.84 0.353 . . . . 0.0 111.377 176.546 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 234' ' ' PRO . . . . . 0.58 ' HB2' ' HE1' ' A' ' 236' ' ' HIS . 56.9 Cg_endo -69.97 138.38 37.03 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 122.373 2.049 . . . . 0.0 111.515 176.974 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -97.88 126.41 43.25 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 121.391 0.615 . . . . 0.0 111.532 -176.261 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 236' ' ' HIS . . . . . 0.58 ' HE1' ' HB2' ' A' ' 234' ' ' PRO . 24.2 m80 -130.41 133.83 46.66 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.404 -0.817 . . . . 0.0 109.562 -178.548 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 237' ' ' LYS . . . . . 0.584 ' HA ' HG21 ' A' ' 312' ' ' THR . 6.8 mptt -120.06 128.02 53.11 Favored 'General case' 0 C--N 1.327 -0.379 0 C-N-CA 120.556 -0.458 . . . . 0.0 110.551 178.923 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 238' ' ' VAL . . . . . 0.777 ' HB ' ' HA ' ' A' ' 316' ' ' SER . 47.4 t -101.9 126.28 55.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.675 178.401 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 239' ' ' GLU . . . . . . . . . . . . . 72.1 mt-10 -126.04 154.78 42.52 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 172.338 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 240' ' ' ALA . . . . . . . . . . . . . . . -57.9 -46.89 84.25 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.728 0.299 . . . . 0.0 111.144 -176.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 241' ' ' LYS . . . . . 0.698 ' HB2' ' HA2' ' A' ' 245' ' ' GLY . 0.0 OUTLIER -145.62 164.48 31.57 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.228 179.089 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 242' ' ' ASP . . . . . 0.476 ' OD1' ' HG2' ' A' ' 246' ' ' MET . 9.4 p-10 -105.28 -158.31 0.65 Allowed 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 109.692 -0.484 . . . . 0.0 109.692 179.12 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 46.6 t -60.18 -36.61 78.0 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.767 175.294 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 60.2 m-20 -87.68 -14.12 40.74 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.632 -0.258 . . . . 0.0 111.652 -179.479 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 245' ' ' GLY . . . . . 0.698 ' HA2' ' HB2' ' A' ' 241' ' ' LYS . . . 94.42 26.04 14.64 Favored Glycine 0 CA--C 1.519 0.322 0 C-N-CA 120.517 -0.849 . . . . 0.0 114.064 174.335 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 246' ' ' MET . . . . . 0.476 ' HG2' ' OD1' ' A' ' 242' ' ' ASP . 22.8 ptp -113.54 155.96 44.09 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 117.532 0.666 . . . . 0.0 110.596 176.944 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 247' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_exo -57.6 125.42 18.7 Favored 'Trans proline' 0 C--N 1.35 0.624 0 C-N-CA 122.61 2.207 . . . . 0.0 112.245 -179.331 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 41.5 t -80.38 113.35 19.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.219 -177.197 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 61.5 t0 -122.68 113.93 19.89 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 176.506 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 250' ' ' ASN . . . . . . . . . . . . . 6.5 m120 -75.27 -39.33 59.88 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.567 -0.288 . . . . 0.0 111.191 -177.039 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 251' ' ' ARG . . . . . 0.906 ' HA ' ' HB3' ' A' ' 305' ' ' LYS . 81.8 mtm180 60.75 -173.97 0.12 Allowed 'General case' 0 N--CA 1.466 0.337 0 N-CA-C 112.362 0.504 . . . . 0.0 112.362 -175.652 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 78.2 mt-30 60.45 178.41 0.1 Allowed 'General case' 0 N--CA 1.468 0.461 0 CA-C-N 114.843 -1.072 . . . . 0.0 112.42 177.02 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 253' ' ' GLY . . . . . 0.468 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -172.65 95.71 0.11 Allowed Glycine 0 N--CA 1.447 -0.631 0 CA-C-N 115.429 -0.805 . . . . 0.0 111.178 179.099 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 59.9 p -95.39 116.98 29.53 Favored 'General case' 0 C--N 1.323 -0.561 0 O-C-N 122.48 -0.424 . . . . 0.0 110.914 -175.113 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.476 HD12 HG11 ' A' ' 230' ' ' VAL . 21.2 pt -128.78 148.39 33.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.831 -177.618 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 59.8 m -101.27 107.26 18.58 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 174.096 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.691 HG21 HD12 ' A' ' 262' ' ' LEU . 32.8 m -90.73 143.65 10.77 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.728 0 N-CA-C 112.975 0.731 . . . . 0.0 112.975 -168.649 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 35.3 t -91.44 8.04 38.23 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 114.112 -1.404 . . . . 0.0 107.963 167.165 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 259' ' ' ALA . . . . . 0.525 ' HA ' ' HB3' ' A' ' 228' ' ' LEU . . . -85.64 158.12 20.16 Favored 'General case' 0 N--CA 1.448 -0.565 0 CA-C-N 114.926 -1.034 . . . . 0.0 109.626 -178.953 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 34.1 t -131.94 137.31 47.9 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 116.577 -0.283 . . . . 0.0 110.325 -179.217 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 90.27 39.28 6.07 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.6 -0.809 . . . . 0.0 112.571 -179.437 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 262' ' ' LEU . . . . . 0.691 HD12 HG21 ' A' ' 257' ' ' VAL . 60.2 mt -101.46 139.81 36.6 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.711 0.291 . . . . 0.0 110.877 179.788 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 68.5 mt-30 -142.2 167.72 21.45 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.82 -0.627 . . . . 0.0 109.436 179.298 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 264' ' ' VAL . . . . . 0.418 HG22 ' HA ' ' A' ' 294' ' ' ALA . 48.7 t -70.83 132.87 32.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 C-N-CA 120.772 -0.371 . . . . 0.0 110.161 177.834 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 105.58 8.63 34.72 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.548 -0.834 . . . . 0.0 112.401 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 59.7 m-20 -88.64 162.48 16.31 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.988 0.423 . . . . 0.0 110.861 179.045 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 267' ' ' ALA . . . . . 0.699 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -139.34 123.12 17.57 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.487 -0.779 . . . . 0.0 109.475 179.75 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 268' ' ' PHE . . . . . 0.413 ' HB3' ' HA ' ' A' ' 334' ' ' ILE . 3.5 p90 -142.15 173.66 11.32 Favored 'General case' 0 C--N 1.32 -0.676 0 C-N-CA 120.114 -0.634 . . . . 0.0 111.465 -174.974 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 269' ' ' THR . . . . . 0.577 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 63.8 p -118.89 132.37 56.1 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.53 178.115 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 270' ' ' ILE . . . . . 0.708 HG12 HG13 ' A' ' 332' ' ' ILE . 50.6 mt -100.61 134.02 41.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.57 179.625 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -72.72 143.47 48.01 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.956 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 85.78 -21.55 14.54 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.189 -177.522 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 53.5 t -105.69 102.46 13.9 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-O 120.983 0.42 . . . . 0.0 110.799 -179.593 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 274' ' ' ASN . . . . . 0.407 ' HB2' ' OD1' ' A' ' 323' ' ' ASP . 61.5 m-20 -100.72 154.94 18.19 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.22 -0.659 . . . . 0.0 109.22 174.702 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 6.7 t -83.7 179.98 7.46 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.912 0.387 . . . . 0.0 109.96 -177.853 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 276' ' ' VAL . . . . . 0.411 HG22 ' O ' ' A' ' 321' ' ' ASN . 34.2 m -131.92 153.11 38.0 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.712 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.236 172.775 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 26.4 m80 -136.94 137.08 39.17 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.091 179.236 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 65.8 tt0 -67.99 -31.67 71.53 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.916 0.389 . . . . 0.0 110.315 177.196 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 72.3 mt -66.54 -50.36 67.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.861 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 71.5 p -85.42 -5.08 59.33 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 111.674 0.25 . . . . 0.0 111.674 -178.615 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 281' ' ' LYS . . . . . 0.512 ' HB3' ' NZ ' ' A' ' 281' ' ' LYS . 0.0 OUTLIER 70.94 52.97 0.27 Allowed 'General case' 0 CA--C 1.535 0.403 0 CA-C-O 121.742 0.782 . . . . 0.0 109.161 179.479 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 56.6 m-20 62.26 10.51 3.87 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 114.732 -1.122 . . . . 0.0 113.95 173.485 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 59.9 p -107.09 107.97 19.22 Favored 'General case' 0 C--N 1.314 -0.956 0 CA-C-O 121.041 0.448 . . . . 0.0 110.589 175.605 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 59.8 p -125.76 -52.37 1.57 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.061 -175.385 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 76.42 10.61 85.58 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.732 -0.747 . . . . 0.0 111.267 -173.363 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 286' ' ' GLN . . . . . 0.42 ' HA ' ' HD3' ' A' ' 287' ' ' PRO . 93.4 mm-40 -111.11 130.42 22.99 Favored Pre-proline 0 C--N 1.326 -0.445 0 N-CA-C 110.322 -0.251 . . . . 0.0 110.322 -177.609 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 287' ' ' PRO . . . . . 0.577 ' HB2' ' HB ' ' A' ' 269' ' ' THR . 27.3 Cg_exo -60.76 142.05 96.63 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.627 2.218 . . . . 0.0 111.696 177.978 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 4.1 tp60 -68.18 145.05 54.69 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 120.877 0.37 . . . . 0.0 110.711 -179.637 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 47.6 t -99.73 121.77 50.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.492 176.631 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 290' ' ' PHE . . . . . 0.699 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 7.3 m-85 -103.31 156.17 17.92 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.028 0.442 . . . . 0.0 111.775 -174.02 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 36.3 mmt180 -122.31 121.18 36.14 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.112 -0.949 . . . . 0.0 109.408 174.9 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 61.7 t -78.51 135.51 25.84 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.89 -174.476 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 293' ' ' LEU . . . . . 0.401 ' N ' HD12 ' A' ' 293' ' ' LEU . 6.6 mp -106.95 -33.8 7.4 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.674 179.034 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 294' ' ' ALA . . . . . 0.418 ' HA ' HG22 ' A' ' 264' ' ' VAL . . . -155.54 146.7 22.59 Favored 'General case' 0 N--CA 1.463 0.19 0 N-CA-C 111.677 0.251 . . . . 0.0 111.677 -177.365 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 295' ' ' VAL . . . . . 0.467 HG22 HG13 ' A' ' 300' ' ' VAL . 61.6 t -137.66 126.37 33.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.086 -0.506 . . . . 0.0 109.74 177.169 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 40.3 t -156.69 109.69 2.59 Favored 'General case' 0 C--N 1.326 -0.418 0 C-N-CA 121.139 -0.224 . . . . 0.0 110.944 -177.638 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 59.81 48.57 85.41 Favored Glycine 0 C--N 1.333 0.373 0 C-N-CA 121.077 -0.583 . . . . 0.0 112.488 179.447 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 298' ' ' THR . . . . . 0.422 ' O ' HG22 ' A' ' 257' ' ' VAL . 60.5 p 55.71 10.93 0.58 Allowed 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 124.342 1.057 . . . . 0.0 112.728 -176.361 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 58.3 m -99.92 106.47 18.29 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 173.024 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 300' ' ' VAL . . . . . 0.574 HG12 HG23 ' A' ' 302' ' ' ILE . 40.2 t -108.9 132.03 58.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.35 -169.519 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 51.6 m -100.87 111.35 23.54 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 175.422 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 302' ' ' ILE . . . . . 0.574 HG23 HG12 ' A' ' 300' ' ' VAL . 27.7 pt -121.64 164.6 18.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-O 121.284 0.564 . . . . 0.0 112.027 -174.262 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 303' ' ' SER . . . . . 0.531 ' HB3' ' HA ' ' A' ' 304' ' ' PRO . 53.1 m -135.29 165.28 37.58 Favored Pre-proline 0 C--N 1.313 -0.984 0 N-CA-C 106.325 -1.732 . . . . 0.0 106.325 168.775 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 304' ' ' PRO . . . . . 0.531 ' HA ' ' HB3' ' A' ' 303' ' ' SER . 17.4 Cg_exo -70.38 176.52 34.05 Favored 'Cis proline' 0 N--CA 1.472 0.243 0 CA-C-N 120.816 1.327 . . . . 0.0 113.71 0.923 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 305' ' ' LYS . . . . . 0.906 ' HB3' ' HA ' ' A' ' 251' ' ' ARG . 0.1 OUTLIER -73.86 152.69 40.15 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 114.986 -1.007 . . . . 0.0 111.284 -178.501 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 306' ' ' ILE . . . . . 0.589 HD11 ' HE2' ' A' ' 290' ' ' PHE . 46.4 mm -94.66 85.29 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.634 -178.967 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 307' ' ' LEU . . . . . 0.737 ' HG ' ' HG2' ' A' ' 305' ' ' LYS . 66.9 mt -106.12 110.32 63.89 Favored Pre-proline 0 C--N 1.325 -0.462 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 178.109 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 308' ' ' PRO . . . . . 0.481 ' CG ' ' HB2' ' A' ' 311' ' ' ASN . 65.1 Cg_endo -80.9 148.66 17.49 Favored 'Trans proline' 0 N--CA 1.463 -0.275 0 C-N-CA 122.548 2.166 . . . . 0.0 113.609 -172.993 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 309' ' ' VAL . . . . . 0.545 HG23 ' O ' ' A' ' 322' ' ' VAL . 47.0 t -87.65 -43.09 15.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.829 175.252 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 65.4 mm-40 -91.51 6.47 45.47 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 112.437 0.532 . . . . 0.0 112.437 -176.287 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.481 ' HB2' ' CG ' ' A' ' 308' ' ' PRO . 5.9 m120 -130.0 173.33 10.82 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 110.231 -0.285 . . . . 0.0 110.231 178.597 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 312' ' ' THR . . . . . 0.584 HG21 ' HA ' ' A' ' 237' ' ' LYS . 23.7 m 60.07 31.03 20.43 Favored 'General case' 0 CA--C 1.539 0.543 0 CA-C-O 121.758 0.79 . . . . 0.0 110.656 176.887 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 44.5 m-20 63.87 -177.71 0.16 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 114.883 -1.053 . . . . 0.0 112.208 177.106 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 314' ' ' VAL . . . . . 0.685 HG13 ' HD2' ' A' ' 317' ' ' ARG . 50.0 t -68.31 -24.66 30.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.426 -176.441 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -60.63 -23.73 64.98 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 111.976 0.362 . . . . 0.0 111.976 -179.859 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 316' ' ' SER . . . . . 0.777 ' HA ' ' HB ' ' A' ' 238' ' ' VAL . 31.2 t -86.89 -22.02 25.97 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.31 -177.845 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 317' ' ' ARG . . . . . 0.685 ' HD2' HG13 ' A' ' 314' ' ' VAL . 83.3 mtt-85 -56.6 -53.68 61.8 Favored Pre-proline 0 CA--C 1.541 0.605 0 N-CA-C 113.499 0.926 . . . . 0.0 113.499 -177.525 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 318' ' ' PRO . . . . . 0.613 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 44.1 Cg_exo -61.97 -35.39 77.32 Favored 'Trans proline' 0 C--N 1.356 0.931 0 C-N-CA 122.018 1.812 . . . . 0.0 113.677 -174.587 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 319' ' ' TYR . . . . . 0.666 ' HB2' HG11 ' A' ' 238' ' ' VAL . 7.4 m-85 -105.62 21.67 16.83 Favored 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 121.152 -0.219 . . . . 0.0 111.089 -179.065 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 320' ' ' ALA . . . . . 0.42 ' CB ' HG22 ' A' ' 309' ' ' VAL . . . -65.79 160.0 24.03 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.096 0.474 . . . . 0.0 111.685 -177.39 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 321' ' ' ASN . . . . . 0.411 ' O ' HG22 ' A' ' 276' ' ' VAL . 20.6 t-20 -123.58 -33.19 3.25 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.85 -0.613 . . . . 0.0 109.956 177.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 322' ' ' VAL . . . . . 0.545 ' O ' HG23 ' A' ' 309' ' ' VAL . 35.4 m -135.42 163.76 34.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.345 177.308 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 323' ' ' ASP . . . . . 0.407 ' OD1' ' HB2' ' A' ' 274' ' ' ASN . 63.6 m-20 -55.89 -41.28 74.21 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 112.684 0.624 . . . . 0.0 112.684 -176.407 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 324' ' ' ALA . . . . . 0.463 ' HA ' ' CB ' ' A' ' 308' ' ' PRO . . . -169.49 167.49 9.82 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.876 0.369 . . . . 0.0 111.746 -173.759 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 325' ' ' LYS . . . . . 0.461 ' NZ ' ' HB2' ' A' ' 325' ' ' LYS . 0.0 OUTLIER -108.7 106.25 58.42 Favored Pre-proline 0 C--N 1.325 -0.49 0 CA-C-N 114.968 -1.014 . . . . 0.0 109.26 168.732 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 76.0 Cg_endo -85.21 168.47 10.32 Favored 'Trans proline' 0 C--O 1.234 0.276 0 C-N-CA 122.8 2.333 . . . . 0.0 112.769 -173.472 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -69.6 121.86 17.94 Favored 'General case' 0 C--O 1.235 0.327 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 176.588 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 328' ' ' GLU . . . . . 0.459 ' HA ' ' OE2' ' A' ' 328' ' ' GLU . 43.6 mm-40 64.16 164.24 0.13 Allowed 'General case' 0 C--O 1.234 0.243 0 O-C-N 123.891 0.744 . . . . 0.0 111.417 -175.288 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 329' ' ' SER . . . . . 0.63 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 22.2 m -86.49 -14.49 42.95 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.35 -174.306 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 330' ' ' ALA . . . . . 0.426 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 71.26 -154.43 0.1 Allowed 'General case' 0 N--CA 1.467 0.403 0 CA-C-O 121.332 0.586 . . . . 0.0 112.287 175.532 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -90.04 125.79 35.53 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.147 -0.933 . . . . 0.0 110.168 179.35 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 332' ' ' ILE . . . . . 0.708 HG13 HG12 ' A' ' 270' ' ' ILE . 1.7 mp -106.35 144.72 15.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.31 -178.917 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.402 ' HB ' ' OG1' ' A' ' 269' ' ' THR . 88.5 m -109.97 103.02 11.72 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.069 -0.514 . . . . 0.0 109.711 -178.171 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 334' ' ' ILE . . . . . 0.434 ' C ' HD12 ' A' ' 335' ' ' LEU . 37.9 mm -83.1 129.3 37.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 115.57 -0.741 . . . . 0.0 112.42 -171.209 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 335' ' ' LEU . . . . . 0.434 HD12 ' C ' ' A' ' 334' ' ' ILE . 6.8 mp -123.67 153.04 41.36 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.264 -0.88 . . . . 0.0 109.823 172.644 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 22.9 p30 -110.9 5.02 20.19 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 170.442 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 23.1 tptm . . . . . 0 C--O 1.245 0.82 0 CA-C-N 114.541 -1.209 . . . . 0.0 110.99 -179.412 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.842 0 N-CA-C 112.093 -0.403 . . . . 0.0 112.093 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 46.5 t -84.56 -73.66 0.42 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.784 0.326 . . . . 0.0 110.596 179.397 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 35.1 p -128.82 -88.96 0.52 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.676 178.37 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 41.1 tp10 58.42 82.79 0.13 Allowed 'General case' 0 C--O 1.234 0.268 0 C-N-CA 122.991 0.516 . . . . 0.0 110.749 178.277 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 31.5 t -168.6 -129.83 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 -179.733 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 228' ' ' LEU . . . . . 0.525 ' HB3' ' CB ' ' A' ' 259' ' ' ALA . 85.1 mt -96.46 130.93 43.5 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 109.511 -0.552 . . . . 0.0 109.511 175.728 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 41.3 p -129.63 179.54 5.77 Favored 'General case' 0 C--N 1.325 -0.465 0 C-N-CA 120.296 -0.562 . . . . 0.0 110.986 -178.631 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 230' ' ' VAL . . . . . 0.806 ' HB ' ' HB3' ' A' ' 329' ' ' SER . 89.5 t -146.18 130.85 11.58 Favored 'Isoleucine or valine' 0 C--O 1.24 0.571 0 CA-C-O 120.601 0.239 . . . . 0.0 111.549 -177.2 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 18.7 m -97.29 97.84 9.49 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.194 -0.912 . . . . 0.0 109.733 172.834 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 163.02 134.74 1.69 Allowed Glycine 0 C--O 1.226 -0.344 0 C-N-CA 120.719 -0.753 . . . . 0.0 111.72 -177.429 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 11.0 mm100 -61.62 144.73 92.44 Favored Pre-proline 0 C--N 1.328 -0.369 0 N-CA-C 112.688 0.625 . . . . 0.0 112.688 -174.516 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -70.7 175.22 9.18 Favored 'Trans proline' 0 C--N 1.348 0.521 0 C-N-CA 123.381 2.721 . . . . 0.0 111.793 175.891 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 235' ' ' GLU . . . . . 0.506 ' OE1' HD12 ' A' ' 302' ' ' ILE . 87.6 mt-10 -94.3 138.11 32.67 Favored 'General case' 0 C--O 1.211 -0.962 0 C-N-CA 120.833 -0.347 . . . . 0.0 111.688 -176.524 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 236' ' ' HIS . . . . . 0.439 ' HB3' ' O ' ' A' ' 306' ' ' ILE . 25.5 p-80 -169.04 126.82 0.99 Allowed 'General case' 0 C--N 1.307 -1.256 0 CA-C-N 115.097 -0.956 . . . . 0.0 109.366 166.975 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 237' ' ' LYS . . . . . 0.548 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -138.44 122.37 17.78 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.32 -0.552 . . . . 0.0 110.473 -179.987 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 238' ' ' VAL . . . . . . . . . . . . . 62.0 t -107.35 111.05 34.07 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 C-N-CA 120.484 -0.486 . . . . 0.0 110.023 169.943 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 239' ' ' GLU . . . . . 0.479 ' O ' ' HA ' ' A' ' 247' ' ' PRO . 54.3 mt-10 -125.82 116.38 21.48 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.01 178.078 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 240' ' ' ALA . . . . . 0.479 ' C ' ' HD2' ' A' ' 241' ' ' LYS . . . -74.83 -51.35 14.22 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.641 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 241' ' ' LYS . . . . . 0.479 ' HD2' ' C ' ' A' ' 240' ' ' ALA . 1.0 OUTLIER -115.83 127.33 54.97 Favored 'General case' 0 CA--C 1.515 -0.384 0 CA-C-O 121.233 0.54 . . . . 0.0 110.696 173.451 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 9.8 p-10 -106.06 -156.45 0.58 Allowed 'General case' 0 C--N 1.315 -0.901 0 CA-C-N 114.912 -1.04 . . . . 0.0 108.665 172.897 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 51.0 m -56.84 -36.04 69.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.51 -0.314 . . . . 0.0 111.047 174.588 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 6.0 m120 -96.74 -14.07 22.26 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.475 -0.329 . . . . 0.0 111.751 -178.488 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 85.61 20.87 55.49 Favored Glycine 0 CA--C 1.519 0.282 0 C-N-CA 120.685 -0.769 . . . . 0.0 113.433 177.201 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 246' ' ' MET . . . . . 0.438 ' HA ' ' HD3' ' A' ' 247' ' ' PRO . 94.6 mmm -114.09 133.03 22.43 Favored Pre-proline 0 C--N 1.326 -0.418 0 CA-C-N 116.964 0.382 . . . . 0.0 110.207 177.156 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 247' ' ' PRO . . . . . 0.479 ' HA ' ' O ' ' A' ' 239' ' ' GLU . 24.4 Cg_exo -64.9 116.68 3.96 Favored 'Trans proline' 0 C--N 1.349 0.573 0 C-N-CA 121.738 1.625 . . . . 0.0 112.175 -177.591 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 46.2 t -147.51 148.93 15.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.674 178.885 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 249' ' ' ASP . . . . . 0.577 ' OD2' HD21 ' A' ' 307' ' ' LEU . 8.5 t70 -89.21 123.96 33.92 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 170.779 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 250' ' ' ASN . . . . . . . . . . . . . 22.1 p30 -80.83 -11.73 59.55 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 112.167 0.432 . . . . 0.0 112.167 -173.369 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 251' ' ' ARG . . . . . 0.565 ' HB3' ' HD2' ' A' ' 305' ' ' LYS . 36.8 ptt85 44.55 -164.07 0.01 OUTLIER 'General case' 0 N--CA 1.475 0.808 0 C-N-CA 124.592 1.157 . . . . 0.0 113.456 179.368 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 252' ' ' GLN . . . . . 0.487 ' HG3' ' HG3' ' A' ' 251' ' ' ARG . 17.2 mt-30 65.12 132.65 0.02 OUTLIER 'General case' 0 C--O 1.237 0.413 0 C-N-CA 123.995 0.918 . . . . 0.0 112.83 -178.028 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 253' ' ' GLY . . . . . 0.433 ' O ' ' HA ' ' A' ' 301' ' ' THR . . . -160.86 145.33 10.89 Favored Glycine 0 N--CA 1.449 -0.467 0 CA-C-N 115.007 -0.997 . . . . 0.0 111.94 177.714 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 34.1 p -95.32 117.99 31.28 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.843 0.354 . . . . 0.0 111.13 -179.797 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.611 HD12 HG11 ' A' ' 230' ' ' VAL . 24.7 pt -114.75 142.84 26.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.08 0.467 . . . . 0.0 111.494 -178.724 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 58.1 m -92.49 109.63 21.03 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 176.354 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 257' ' ' VAL . . . . . . . . . . . . . 33.9 m -90.21 143.78 10.48 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.703 0 C-N-CA 119.646 -0.821 . . . . 0.0 113.004 -168.351 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 258' ' ' SER . . . . . 0.467 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 24.0 t -91.59 9.07 33.7 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 114.051 -1.432 . . . . 0.0 108.192 168.883 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 259' ' ' ALA . . . . . 0.525 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -99.05 169.8 9.16 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-N 114.774 -1.103 . . . . 0.0 109.484 -178.592 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 33.8 t -142.57 155.28 44.97 Favored 'General case' 0 C--N 1.324 -0.54 0 C-N-CA 120.828 -0.349 . . . . 0.0 110.733 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 74.34 42.8 33.54 Favored Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.47 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 262' ' ' LEU . . . . . . . . . . . . . 64.5 mt -102.39 140.02 37.21 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 110.17 -0.308 . . . . 0.0 110.17 179.37 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 81.5 mt-30 -135.24 169.45 17.44 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.479 -0.328 . . . . 0.0 110.206 179.822 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 45.5 t -77.77 136.26 24.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.594 179.63 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 92.13 7.65 63.81 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.442 -0.885 . . . . 0.0 112.292 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 72.8 m-20 -81.73 160.47 23.63 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.232 0.539 . . . . 0.0 110.133 176.785 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 267' ' ' ALA . . . . . 0.548 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -126.84 145.37 50.67 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 115.332 -0.849 . . . . 0.0 108.822 178.952 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 268' ' ' PHE . . . . . 0.55 ' HA ' HD23 ' A' ' 335' ' ' LEU . 4.6 p90 -162.53 170.66 18.27 Favored 'General case' 0 C--N 1.32 -0.713 0 C-N-CA 119.971 -0.692 . . . . 0.0 111.452 -177.124 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 269' ' ' THR . . . . . 0.474 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 72.7 p -121.85 150.84 41.35 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.009 178.499 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 270' ' ' ILE . . . . . 0.577 HG12 HG12 ' A' ' 332' ' ' ILE . 54.4 mt -115.51 138.33 46.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 120.864 0.364 . . . . 0.0 111.622 -177.396 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -66.12 117.58 8.64 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 115.571 -0.74 . . . . 0.0 111.062 178.353 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 104.46 -23.05 32.66 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.932 -0.651 . . . . 0.0 112.182 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 273' ' ' VAL . . . . . 0.876 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 91.0 t -88.36 112.39 23.74 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-O 120.71 0.291 . . . . 0.0 110.491 175.986 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 72.9 m-80 -129.54 143.58 50.89 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.663 -178.071 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 52.3 p -70.86 164.75 24.68 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.152 0.501 . . . . 0.0 111.699 -177.7 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 29.3 m -112.58 179.48 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-N 115.652 -0.704 . . . . 0.0 112.469 -176.834 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 19.2 p-80 -46.19 106.92 0.09 Allowed 'General case' 0 C--O 1.235 0.304 0 CA-C-N 114.631 -1.168 . . . . 0.0 111.817 176.772 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 278' ' ' GLN . . . . . 0.512 ' H ' ' HB2' ' A' ' 282' ' ' ASP . 65.7 tt0 -83.94 -51.29 7.27 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.19 -176.467 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 279' ' ' ILE . . . . . 0.569 HG22 HG23 ' A' ' 280' ' ' THR . 3.2 mp -105.59 -66.81 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.828 0.347 . . . . 0.0 110.78 -178.955 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 280' ' ' THR . . . . . 0.569 HG23 HG22 ' A' ' 279' ' ' ILE . 21.3 p -139.58 86.46 2.11 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.61 -177.545 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt 59.56 29.57 19.14 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.759 -0.655 . . . . 0.0 112.044 177.108 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 282' ' ' ASP . . . . . 0.512 ' HB2' ' H ' ' A' ' 278' ' ' GLN . 1.7 m-20 -58.05 101.48 0.08 Allowed 'General case' 0 N--CA 1.468 0.43 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.68 -179.535 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 45.1 p -105.88 105.65 15.78 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.159 175.117 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 65.7 p -127.6 -35.0 2.17 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.589 -174.449 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 82.23 26.18 48.97 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.306 -177.926 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 36.1 mt-30 -79.71 121.13 82.09 Favored Pre-proline 0 C--N 1.329 -0.295 0 O-C-N 122.891 -0.182 . . . . 0.0 110.667 -179.658 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 287' ' ' PRO . . . . . 0.474 ' HB2' ' HB ' ' A' ' 269' ' ' THR . 26.4 Cg_exo -60.33 126.75 20.89 Favored 'Trans proline' 0 C--O 1.234 0.296 0 C-N-CA 122.518 2.145 . . . . 0.0 111.408 177.451 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 4.4 tm0? -74.49 136.54 42.23 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 -175.062 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 289' ' ' VAL . . . . . 0.429 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 44.5 t -86.91 124.54 40.57 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-O 121.038 0.447 . . . . 0.0 111.524 -172.915 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 290' ' ' PHE . . . . . 0.876 ' HZ ' HG11 ' A' ' 273' ' ' VAL . 60.6 m-85 -98.5 168.44 10.19 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.31 -174.694 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 27.8 mmm180 -125.12 148.42 48.57 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.224 -0.898 . . . . 0.0 109.736 178.463 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 47.9 t -100.92 136.75 31.08 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-N 116.607 -0.27 . . . . 0.0 111.098 179.628 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 293' ' ' LEU . . . . . 0.455 ' N ' HD12 ' A' ' 293' ' ' LEU . 5.5 mp -103.95 -39.94 6.4 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.128 -178.868 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 294' ' ' ALA . . . . . . . . . . . . . . . -156.9 139.61 15.09 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.646 0.26 . . . . 0.0 111.473 -178.493 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 295' ' ' VAL . . . . . 0.519 HG22 HG13 ' A' ' 300' ' ' VAL . 60.6 t -131.21 125.56 57.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-N 116.104 -0.498 . . . . 0.0 109.688 175.842 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 33.9 t -157.29 111.37 2.64 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.583 -0.281 . . . . 0.0 110.758 -178.018 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 60.58 50.82 63.39 Favored Glycine 0 C--N 1.333 0.372 0 C-N-CA 121.087 -0.578 . . . . 0.0 112.615 179.787 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 45.9 p 50.6 23.71 1.42 Allowed 'General case' 0 N--CA 1.47 0.552 0 C-N-CA 123.477 0.711 . . . . 0.0 112.434 -176.395 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 43.7 m -113.21 106.58 14.8 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 174.072 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 300' ' ' VAL . . . . . 0.572 HG12 HG23 ' A' ' 302' ' ' ILE . 39.4 t -112.99 131.63 64.06 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 115.944 -0.571 . . . . 0.0 111.557 -168.633 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 301' ' ' THR . . . . . 0.433 ' HA ' ' O ' ' A' ' 253' ' ' GLY . 91.6 m -96.7 110.62 23.03 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 108.725 -0.842 . . . . 0.0 108.725 172.299 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 302' ' ' ILE . . . . . 0.572 HG23 HG12 ' A' ' 300' ' ' VAL . 2.5 pp -111.75 -172.54 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 N-CA-C 112.12 0.415 . . . . 0.0 112.12 -175.134 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 303' ' ' SER . . . . . 0.71 ' OG ' ' HA ' ' A' ' 304' ' ' PRO . 14.8 t 169.95 161.16 0.2 Allowed Pre-proline 0 C--O 1.221 -0.397 0 N-CA-C 106.224 -1.769 . . . . 0.0 106.224 -175.563 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 304' ' ' PRO . . . . . 0.71 ' HA ' ' OG ' ' A' ' 303' ' ' SER . 9.4 Cg_exo -72.94 -172.66 9.87 Favored 'Cis proline' 0 C--N 1.348 0.522 0 CA-C-N 121.384 1.53 . . . . 0.0 113.506 0.948 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 305' ' ' LYS . . . . . 0.739 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -84.3 176.3 8.82 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 114.751 -1.113 . . . . 0.0 112.644 -175.382 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 306' ' ' ILE . . . . . 0.456 ' HB ' ' O ' ' A' ' 235' ' ' GLU . 50.8 mm -119.46 86.2 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 114.485 -1.234 . . . . 0.0 109.878 -174.017 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 307' ' ' LEU . . . . . 0.577 HD21 ' OD2' ' A' ' 249' ' ' ASP . 83.9 mt -108.84 101.59 44.69 Favored Pre-proline 0 C--N 1.321 -0.633 0 C-N-CA 120.918 -0.313 . . . . 0.0 111.652 -173.618 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 308' ' ' PRO . . . . . 0.774 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 17.9 Cg_exo -69.92 148.44 64.01 Favored 'Trans proline' 0 C--O 1.233 0.232 0 C-N-CA 123.197 2.598 . . . . 0.0 113.336 -177.019 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 44.2 t -93.16 -21.36 6.11 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.529 -0.76 . . . . 0.0 109.44 173.1 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 53.5 mt-10 -74.62 13.65 0.59 Allowed 'General case' 0 CA--C 1.531 0.223 0 N-CA-C 112.797 0.665 . . . . 0.0 112.797 -178.448 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.406 ' O ' ' HB ' ' A' ' 312' ' ' THR . 32.2 m120 -82.25 -24.66 34.66 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 120.846 -0.341 . . . . 0.0 110.92 177.468 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 312' ' ' THR . . . . . 0.406 ' HB ' ' O ' ' A' ' 311' ' ' ASN . 58.2 m 72.01 -13.64 0.58 Allowed 'General case' 0 CA--C 1.541 0.634 0 O-C-N 123.743 0.652 . . . . 0.0 112.233 178.159 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -74.13 152.98 39.75 Favored 'General case' 0 C--N 1.331 -0.21 0 O-C-N 121.905 -0.497 . . . . 0.0 110.803 178.347 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 30.8 t -79.35 -19.33 12.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.306 -0.861 . . . . 0.0 111.485 -173.259 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -78.49 -36.88 44.47 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 113.019 0.748 . . . . 0.0 113.019 -174.096 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 16.2 m -88.18 -35.03 17.6 Favored 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -172.657 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 317' ' ' ARG . . . . . 0.424 ' N ' ' CD ' ' A' ' 318' ' ' PRO . 16.9 ptm180 -62.12 -33.05 11.03 Favored Pre-proline 0 CA--C 1.546 0.801 0 N-CA-C 114.516 1.302 . . . . 0.0 114.516 -175.263 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 318' ' ' PRO . . . . . 0.424 ' CD ' ' N ' ' A' ' 317' ' ' ARG . 35.2 Cg_exo -54.86 -38.87 92.26 Favored 'Trans proline' 0 C--N 1.368 1.587 0 C-N-CA 121.587 1.525 . . . . 0.0 112.795 178.874 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 319' ' ' TYR . . . . . 0.575 ' HD1' HD13 ' A' ' 307' ' ' LEU . 2.2 p90 -122.83 32.73 5.63 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 120.504 -0.479 . . . . 0.0 111.83 -179.251 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -63.34 157.15 23.73 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.605 178.171 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 46.2 t30 -128.49 -36.86 1.85 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.068 -0.514 . . . . 0.0 111.49 -177.662 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 322' ' ' VAL . . . . . 0.624 HG11 HG13 ' A' ' 273' ' ' VAL . 34.8 m -131.86 175.62 10.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 120.711 0.291 . . . . 0.0 111.217 -178.847 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 54.7 m-20 -78.62 -44.12 24.71 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.536 -0.302 . . . . 0.0 111.569 -177.272 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 324' ' ' ALA . . . . . 0.774 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -144.55 166.48 25.04 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.458 -175.589 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 325' ' ' LYS . . . . . 0.408 ' HA ' ' HD3' ' A' ' 326' ' ' PRO . 24.1 pttm -115.12 113.89 43.65 Favored Pre-proline 0 C--N 1.327 -0.383 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.729 175.153 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 326' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 325' ' ' LYS . 8.6 Cg_exo -72.92 167.84 26.24 Favored 'Trans proline' 0 C--O 1.233 0.236 0 C-N-CA 122.867 2.378 . . . . 0.0 112.167 -178.991 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -76.76 128.33 34.44 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 175.084 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 51.0 mt-10 64.96 -167.83 0.21 Allowed 'General case' 0 N--CA 1.466 0.333 0 O-C-N 123.5 0.5 . . . . 0.0 110.463 -176.191 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 329' ' ' SER . . . . . 0.806 ' HB3' ' HB ' ' A' ' 230' ' ' VAL . 42.6 t -90.88 -12.19 36.95 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 177.265 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 63.03 -160.36 0.31 Allowed 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 113.033 0.753 . . . . 0.0 113.033 171.261 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -76.36 127.96 33.9 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 115.182 -0.917 . . . . 0.0 110.676 -178.018 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 332' ' ' ILE . . . . . 0.577 HG12 HG12 ' A' ' 270' ' ' ILE . 50.0 mt -113.61 144.61 20.88 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.962 -177.432 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 95.7 m -115.63 106.09 13.51 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.675 176.824 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 41.2 mm -83.62 138.02 19.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.753 -0.658 . . . . 0.0 112.379 -170.94 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 335' ' ' LEU . . . . . 0.55 HD23 ' HA ' ' A' ' 268' ' ' PHE . 1.3 pt? -145.16 -159.14 0.96 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 114.978 -1.01 . . . . 0.0 108.814 171.184 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 45.7 p-10 -152.36 48.36 0.76 Allowed 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.837 0.351 . . . . 0.0 111.592 179.709 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 337' ' ' LYS . . . . . 0.464 ' HB2' ' NZ ' ' A' ' 337' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.246 0.911 0 CA-C-O 118.827 -0.606 . . . . 0.0 110.515 178.908 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.952 0 N-CA-C 112.282 -0.327 . . . . 0.0 112.282 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 50.6 m -86.34 68.86 10.36 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.801 0.334 . . . . 0.0 111.164 179.661 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 36.8 p -102.0 -124.69 0.19 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.394 -0.367 . . . . 0.0 110.456 177.912 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 37.2 tt0 -86.95 37.71 0.77 Allowed 'General case' 0 C--O 1.236 0.365 0 CA-C-O 121.921 0.867 . . . . 0.0 109.698 177.256 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 24.8 m -86.76 -37.17 18.12 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.474 -0.785 . . . . 0.0 109.952 179.196 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 228' ' ' LEU . . . . . 0.546 HD22 ' H ' ' A' ' 260' ' ' SER . 83.7 mt -110.59 113.88 26.85 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 174.678 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 41.6 p -120.71 177.68 4.98 Favored 'General case' 0 C--N 1.32 -0.676 0 C-N-CA 119.926 -0.709 . . . . 0.0 110.617 -177.856 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 230' ' ' VAL . . . . . 0.738 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 89.7 t -150.88 134.78 8.23 Favored 'Isoleucine or valine' 0 C--O 1.239 0.548 0 CA-C-O 120.826 0.346 . . . . 0.0 110.898 -178.365 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 44.3 t -97.98 153.01 18.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.027 175.674 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 232' ' ' GLY . . . . . 0.554 ' O ' ' HD3' ' A' ' 234' ' ' PRO . . . 108.42 127.21 5.54 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.449 -0.882 . . . . 0.0 111.489 -178.467 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 233' ' ' GLN . . . . . 0.822 ' HG2' ' H ' ' A' ' 328' ' ' GLU . 64.2 mt-30 -95.27 102.38 9.5 Favored Pre-proline 0 C--N 1.324 -0.507 0 CA-C-N 116.53 0.165 . . . . 0.0 110.56 -177.553 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 234' ' ' PRO . . . . . 0.554 ' HD3' ' O ' ' A' ' 232' ' ' GLY . 74.4 Cg_endo -96.78 125.65 0.26 Allowed 'Trans proline' 0 N--CA 1.45 -1.076 0 C-N-CA 122.294 1.996 . . . . 0.0 112.388 -178.195 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 235' ' ' GLU . . . . . 0.946 ' HA ' ' HE3' ' A' ' 325' ' ' LYS . 24.2 pt-20 -105.72 147.67 28.3 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 173.377 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 236' ' ' HIS . . . . . 0.783 ' HB2' ' H ' ' A' ' 306' ' ' ILE . 39.4 m170 -134.62 130.57 36.64 Favored 'General case' 0 CA--C 1.503 -0.85 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 -178.94 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 237' ' ' LYS . . . . . 0.743 ' HG2' ' HB2' ' A' ' 251' ' ' ARG . 7.5 mmmt -105.24 175.56 5.45 Favored 'General case' 0 C--N 1.315 -0.9 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 -178.815 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 238' ' ' VAL . . . . . 0.992 ' HB ' HG11 ' A' ' 248' ' ' VAL . 43.5 t -48.56 144.82 1.08 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.338 0 O-C-N 123.601 0.563 . . . . 0.0 111.145 -178.072 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 239' ' ' GLU . . . . . 0.671 ' HA ' HD22 ' A' ' 250' ' ' ASN . 7.8 pt-20 -59.85 166.26 2.75 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 115.723 -0.671 . . . . 0.0 112.545 -176.81 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 240' ' ' ALA . . . . . 0.45 ' O ' ' HA ' ' A' ' 247' ' ' PRO . . . -44.05 -44.03 7.18 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-N 115.365 -0.834 . . . . 0.0 113.048 -173.06 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 241' ' ' LYS . . . . . 0.528 ' O ' ' HD3' ' A' ' 241' ' ' LYS . 0.0 OUTLIER -146.26 144.98 30.21 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.835 0.35 . . . . 0.0 111.081 178.677 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 57.0 p30 -89.49 -158.38 0.51 Allowed 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.971 -177.366 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 58.6 m -76.99 -15.59 59.59 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.489 -0.323 . . . . 0.0 111.586 -179.112 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 21.1 t-20 -95.81 -15.48 22.49 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.214 0.531 . . . . 0.0 110.164 -179.807 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 94.74 16.61 41.54 Favored Glycine 0 N--CA 1.448 -0.555 0 C-N-CA 120.635 -0.793 . . . . 0.0 111.905 179.495 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 246' ' ' MET . . . . . 0.418 ' HA ' ' HD3' ' A' ' 247' ' ' PRO . 80.7 mtp -83.3 122.2 77.16 Favored Pre-proline 0 C--N 1.326 -0.441 0 CA-C-O 120.604 0.24 . . . . 0.0 110.384 178.75 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 247' ' ' PRO . . . . . 0.45 ' HA ' ' O ' ' A' ' 240' ' ' ALA . 14.0 Cg_exo -69.73 121.15 7.85 Favored 'Trans proline' 0 N--CA 1.461 -0.406 0 C-N-CA 122.583 2.189 . . . . 0.0 112.152 -179.029 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.992 HG11 ' HB ' ' A' ' 238' ' ' VAL . 41.2 t -109.36 146.53 14.74 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 176.615 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -70.83 93.22 0.95 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.068 0.461 . . . . 0.0 110.195 -178.931 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 250' ' ' ASN . . . . . 0.671 HD22 ' HA ' ' A' ' 239' ' ' GLU . 21.1 t-20 -73.5 133.31 43.59 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.311 -176.807 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 251' ' ' ARG . . . . . 0.743 ' HB2' ' HG2' ' A' ' 237' ' ' LYS . 27.0 tpt85 -94.67 -98.14 0.16 Allowed 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.815 -178.049 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 252' ' ' GLN . . . . . 0.556 ' HA ' ' CD2' ' A' ' 236' ' ' HIS . 23.4 mt-30 60.5 179.33 0.1 Allowed 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 122.453 0.301 . . . . 0.0 111.2 -178.539 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 157.4 -168.7 34.24 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 119.242 -1.456 . . . . 0.0 113.358 -179.691 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 254' ' ' THR . . . . . 0.563 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 67.2 p -99.53 149.92 22.74 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.911 0.386 . . . . 0.0 111.378 -177.671 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.732 HD12 HG11 ' A' ' 230' ' ' VAL . 18.8 pt -125.32 152.94 32.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.959 178.243 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 39.2 m -96.2 105.65 17.74 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.028 -0.731 . . . . 0.0 109.028 177.126 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.554 ' HA ' HG13 ' A' ' 230' ' ' VAL . 22.7 m -89.93 143.19 11.7 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.681 0 CA-C-O 121.725 0.774 . . . . 0.0 112.73 -169.251 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 258' ' ' SER . . . . . 0.462 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 50.3 m -93.15 8.63 39.34 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 114.219 -1.355 . . . . 0.0 109.129 170.358 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 259' ' ' ALA . . . . . 0.48 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -99.1 174.76 6.17 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.209 -175.098 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 260' ' ' SER . . . . . 0.546 ' H ' HD22 ' A' ' 228' ' ' LEU . 64.7 p -141.88 149.88 40.83 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.889 0.376 . . . . 0.0 110.981 178.43 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 87.59 32.22 13.91 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.823 -0.704 . . . . 0.0 112.992 179.373 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 262' ' ' LEU . . . . . 0.484 HD12 ' N ' ' A' ' 262' ' ' LEU . 3.2 mp -97.68 135.53 39.34 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-N 116.995 0.398 . . . . 0.0 110.226 178.894 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 23.6 mp0 -134.04 171.85 13.63 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 177.315 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 38.4 t -78.78 136.65 23.4 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 C-N-CA 120.593 -0.443 . . . . 0.0 109.951 176.658 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 95.61 15.25 44.05 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.538 -0.839 . . . . 0.0 112.141 -179.152 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 266' ' ' ASP . . . . . 0.476 ' HB2' HG21 ' A' ' 292' ' ' VAL . 64.0 m-20 -88.79 166.07 14.27 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.164 0.507 . . . . 0.0 110.779 178.507 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 267' ' ' ALA . . . . . 0.645 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -140.61 122.7 15.68 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.39 -0.823 . . . . 0.0 109.437 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 268' ' ' PHE . . . . . . . . . . . . . 4.6 p90 -142.68 174.11 10.94 Favored 'General case' 0 C--N 1.323 -0.579 0 C-N-CA 119.752 -0.779 . . . . 0.0 111.718 -172.819 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 81.9 p -122.18 148.51 44.85 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.179 177.498 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 270' ' ' ILE . . . . . 0.636 HD12 ' HE1' ' A' ' 290' ' ' PHE . 26.6 mt -113.62 137.53 46.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.212 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -61.47 130.53 46.48 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.343 179.881 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 272' ' ' GLY . . . . . 0.549 ' HA3' ' HG2' ' A' ' 326' ' ' PRO . . . 91.91 -23.12 27.86 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 121.189 -0.529 . . . . 0.0 112.113 -178.878 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 273' ' ' VAL . . . . . 0.611 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 59.7 t -95.94 103.14 14.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-O 120.96 0.409 . . . . 0.0 110.285 177.222 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 274' ' ' ASN . . . . . 0.621 ' HA ' ' HA ' ' A' ' 287' ' ' PRO . 70.0 m-80 -119.81 149.6 41.8 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.212 -178.306 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 77.7 p -81.45 162.25 23.37 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.387 0.613 . . . . 0.0 111.474 -176.813 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 276' ' ' VAL . . . . . 0.491 HG21 HG21 ' A' ' 309' ' ' VAL . 29.8 m -112.14 -179.27 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-N 114.968 -1.014 . . . . 0.0 110.939 179.63 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 277' ' ' HIS . . . . . 0.547 ' CD2' ' HD2' ' A' ' 281' ' ' LYS . 26.7 p-80 -43.15 115.53 0.77 Allowed 'General case' 0 C--N 1.331 -0.213 0 O-C-N 124.331 1.02 . . . . 0.0 111.732 177.66 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 278' ' ' GLN . . . . . 0.549 ' HB3' HD12 ' A' ' 279' ' ' ILE . 71.2 tp60 -83.57 -38.65 21.38 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.731 -178.059 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 279' ' ' ILE . . . . . 0.94 HG22 HG23 ' A' ' 280' ' ' THR . 2.9 mp -107.25 -80.85 0.32 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.431 0 C-N-CA 120.892 -0.323 . . . . 0.0 111.577 -176.969 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 280' ' ' THR . . . . . 0.94 HG23 HG22 ' A' ' 279' ' ' ILE . 35.7 p -127.48 70.74 1.32 Allowed 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 112.787 0.662 . . . . 0.0 112.787 -172.35 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 281' ' ' LYS . . . . . 0.547 ' HD2' ' CD2' ' A' ' 277' ' ' HIS . 14.6 mmmm 53.79 35.45 21.52 Favored 'General case' 0 N--CA 1.47 0.534 0 CA-C-O 121.203 0.525 . . . . 0.0 110.801 178.397 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 52.8 m-20 -69.44 174.04 5.28 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.264 -0.88 . . . . 0.0 111.595 -177.539 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 73.8 p -104.47 109.98 22.07 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.209 178.156 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 67.8 p -116.1 -76.69 0.57 Allowed 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.167 -174.001 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 70.29 7.74 60.85 Favored Glycine 0 C--N 1.329 0.156 0 C-N-CA 121.028 -0.605 . . . . 0.0 113.289 176.577 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 286' ' ' GLN . . . . . 0.434 ' HA ' ' HD3' ' A' ' 287' ' ' PRO . 96.1 mm-40 -93.29 142.43 25.27 Favored Pre-proline 0 C--N 1.324 -0.511 0 N-CA-C 110.314 -0.254 . . . . 0.0 110.314 -179.1 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 287' ' ' PRO . . . . . 0.621 ' HA ' ' HA ' ' A' ' 274' ' ' ASN . 48.2 Cg_exo -56.76 140.78 91.86 Favored 'Trans proline' 0 CA--C 1.529 0.266 0 C-N-CA 122.737 2.291 . . . . 0.0 112.601 -178.549 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 69.5 tp60 -78.22 140.88 38.91 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.006 -178.77 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 289' ' ' VAL . . . . . 0.581 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 42.2 t -92.48 131.25 40.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.706 -179.918 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 290' ' ' PHE . . . . . 0.645 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 8.2 m-30 -106.89 170.31 8.02 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 116.295 -0.412 . . . . 0.0 111.075 -175.939 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 26.2 mmm180 -118.28 145.02 45.37 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.995 0.426 . . . . 0.0 110.578 176.645 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 292' ' ' VAL . . . . . 0.476 HG21 ' HB2' ' A' ' 266' ' ' ASP . 59.6 t -101.02 130.42 50.44 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.589 177.716 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 293' ' ' LEU . . . . . 0.914 HD21 ' HB3' ' A' ' 303' ' ' SER . 2.3 mm? -106.1 -29.53 9.83 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.023 -176.504 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 294' ' ' ALA . . . . . 0.449 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -161.89 140.67 9.46 Favored 'General case' 0 C--N 1.331 -0.197 0 C-N-CA 121.013 -0.275 . . . . 0.0 111.442 -178.141 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 58.7 t -135.78 121.08 28.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 176.496 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 62.3 m -150.76 105.61 3.3 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.06 -179.515 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 64.52 57.52 12.66 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.142 179.754 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 298' ' ' THR . . . . . 0.419 ' HB ' HG22 ' A' ' 257' ' ' VAL . 65.5 p 49.42 25.9 1.48 Allowed 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 123.468 0.707 . . . . 0.0 112.448 -176.218 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 299' ' ' THR . . . . . 0.417 ' HA ' ' O ' ' A' ' 255' ' ' ILE . 70.8 m -115.59 111.66 21.0 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 177.166 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 300' ' ' VAL . . . . . 0.563 ' O ' ' HA ' ' A' ' 254' ' ' THR . 47.4 t -114.4 126.87 72.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.81 -170.817 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 66.3 m -81.55 115.65 20.95 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 172.93 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 302' ' ' ILE . . . . . 0.466 HD13 HD13 ' A' ' 255' ' ' ILE . 28.3 pt -112.82 148.84 15.54 Favored 'Isoleucine or valine' 0 C--O 1.24 0.594 0 N-CA-C 113.395 0.887 . . . . 0.0 113.395 -171.119 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 303' ' ' SER . . . . . 0.914 ' HB3' HD21 ' A' ' 293' ' ' LEU . 36.1 t -163.59 163.63 16.08 Favored Pre-proline 0 CA--C 1.537 0.458 0 N-CA-C 106.807 -1.553 . . . . 0.0 106.807 -178.314 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 304' ' ' PRO . . . . . 0.743 ' HA ' ' OG ' ' A' ' 303' ' ' SER . 1.0 OUTLIER -83.49 -151.55 0.68 Allowed 'Cis proline' 0 C--N 1.349 0.588 0 CA-C-N 120.752 1.304 . . . . 0.0 112.694 0.565 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 305' ' ' LYS . . . . . 0.572 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -71.52 144.85 49.47 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.346 0.593 . . . . 0.0 111.046 -177.838 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 306' ' ' ILE . . . . . 0.783 ' H ' ' HB2' ' A' ' 236' ' ' HIS . 52.5 mt -108.44 76.64 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-N 115.513 -0.767 . . . . 0.0 109.135 176.6 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 307' ' ' LEU . . . . . 0.674 ' HB2' ' HA ' ' A' ' 320' ' ' ALA . 91.0 mt -98.83 120.23 59.21 Favored Pre-proline 0 C--N 1.322 -0.617 0 CA-C-N 115.505 -0.771 . . . . 0.0 112.261 -172.688 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 308' ' ' PRO . . . . . 0.763 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 15.8 Cg_exo -68.71 147.12 68.86 Favored 'Trans proline' 0 N--CA 1.462 -0.381 0 C-N-CA 123.309 2.673 . . . . 0.0 111.995 175.469 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 309' ' ' VAL . . . . . 0.558 HG22 ' HB3' ' A' ' 320' ' ' ALA . 35.1 t -93.88 -16.09 7.68 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 N-CA-C 108.018 -1.105 . . . . 0.0 108.018 170.305 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 51.5 mm-40 -96.02 34.06 1.61 Allowed 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 115.218 -0.901 . . . . 0.0 112.422 -177.782 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 25.5 p30 -111.67 -177.18 3.12 Favored 'General case' 0 N--CA 1.464 0.241 0 C-N-CA 120.711 -0.396 . . . . 0.0 110.811 175.523 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 26.2 m -91.07 -20.13 22.4 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.923 -177.334 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 313' ' ' ASP . . . . . 0.546 ' O ' ' HG3' ' A' ' 317' ' ' ARG . 1.3 m-20 -63.58 104.03 0.6 Allowed 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.997 -178.063 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 48.9 t -64.34 -22.95 32.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.119 177.412 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -85.3 -20.87 29.36 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 111.955 0.354 . . . . 0.0 111.955 -179.747 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 67.6 m -94.24 -36.26 12.09 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 112.151 0.426 . . . . 0.0 112.151 -177.162 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 317' ' ' ARG . . . . . 0.546 ' HG3' ' O ' ' A' ' 313' ' ' ASP . 81.5 mtp180 -54.43 -46.88 98.95 Favored Pre-proline 0 CA--C 1.544 0.748 0 N-CA-C 113.228 0.825 . . . . 0.0 113.228 -177.71 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 318' ' ' PRO . . . . . 0.545 ' HD2' ' N ' ' A' ' 317' ' ' ARG . 11.9 Cg_endo -59.45 -38.46 83.41 Favored 'Trans proline' 0 C--N 1.359 1.115 0 C-N-CA 122.075 1.85 . . . . 0.0 112.807 -178.943 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 38.4 m-85 -97.75 15.34 23.96 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.651 -177.579 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 320' ' ' ALA . . . . . 0.674 ' HA ' ' HB2' ' A' ' 307' ' ' LEU . . . -82.18 153.51 25.95 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.723 -0.672 . . . . 0.0 111.001 -178.333 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 44.1 p30 -136.51 -0.18 2.43 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.988 179.756 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 322' ' ' VAL . . . . . 0.447 ' O ' ' HA ' ' A' ' 308' ' ' PRO . 33.1 m -134.21 164.7 33.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 175.574 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -74.63 -33.64 62.61 Favored 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 120.807 -0.357 . . . . 0.0 110.61 -179.385 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 324' ' ' ALA . . . . . 0.763 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -173.22 172.56 3.8 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.402 -0.817 . . . . 0.0 111.282 -175.243 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 325' ' ' LYS . . . . . 0.946 ' HE3' ' HA ' ' A' ' 235' ' ' GLU . 10.7 ptmm? -131.84 106.73 13.99 Favored Pre-proline 0 C--N 1.326 -0.441 0 CA-C-N 115.285 -0.87 . . . . 0.0 110.768 172.616 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 326' ' ' PRO . . . . . 0.549 ' HG2' ' HA3' ' A' ' 272' ' ' GLY . 16.4 Cg_exo -67.39 170.56 13.26 Favored 'Trans proline' 0 C--O 1.233 0.234 0 C-N-CA 123.507 2.804 . . . . 0.0 112.065 178.433 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -58.63 163.85 3.02 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.807 -178.718 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 328' ' ' GLU . . . . . 0.822 ' H ' ' HG2' ' A' ' 233' ' ' GLN . 1.1 pm0 39.26 -153.28 0.01 OUTLIER 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 124.385 1.074 . . . . 0.0 112.748 -175.064 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 329' ' ' SER . . . . . 0.738 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 48.8 m -112.59 -14.33 13.2 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.859 -176.861 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 61.15 -161.51 0.29 Allowed 'General case' 0 N--CA 1.469 0.525 0 N-CA-C 113.5 0.926 . . . . 0.0 113.5 171.38 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -78.04 138.46 38.8 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-N 114.975 -1.011 . . . . 0.0 110.551 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 332' ' ' ILE . . . . . 0.622 HG12 HG12 ' A' ' 270' ' ' ILE . 54.0 mt -122.8 145.14 30.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-O 121.151 0.5 . . . . 0.0 111.473 -176.182 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 89.8 m -106.23 97.44 7.24 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.82 177.437 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 30.5 mm -86.84 117.6 31.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.376 -0.375 . . . . 0.0 112.002 -174.804 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 335' ' ' LEU . . . . . 0.462 HD23 ' N ' ' A' ' 335' ' ' LEU . 1.8 pt? -141.68 134.84 29.2 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.609 -0.723 . . . . 0.0 109.57 173.279 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 53.2 t-20 -106.19 83.29 1.87 Allowed 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -177.768 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 25.4 pttm . . . . . 0 C--O 1.243 0.74 0 CA-C-O 118.578 -0.725 . . . . 0.0 110.158 -179.894 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.769 0 N-CA-C 112.019 -0.432 . . . . 0.0 112.019 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 34.0 t -85.39 -62.03 1.63 Allowed 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 110.318 -0.253 . . . . 0.0 110.318 -178.909 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 75.1 p 48.28 -140.39 0.64 Allowed 'General case' 0 N--CA 1.466 0.33 0 C-N-CA 123.358 0.663 . . . . 0.0 111.695 179.701 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 35.74 60.25 0.79 Allowed 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 124.101 0.96 . . . . 0.0 112.289 -178.539 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 36.5 t -95.04 121.67 36.9 Favored 'General case' 0 N--CA 1.445 -0.678 0 CA-C-N 115.659 -0.701 . . . . 0.0 110.407 -177.914 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 228' ' ' LEU . . . . . 0.603 ' HB3' ' CB ' ' A' ' 259' ' ' ALA . 84.5 mt -69.42 134.31 48.82 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.383 -0.826 . . . . 0.0 109.477 176.421 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 229' ' ' THR . . . . . 0.617 HG22 ' HA ' ' A' ' 331' ' ' ALA . 41.4 p -131.18 179.38 6.04 Favored 'General case' 0 C--N 1.326 -0.432 0 C-N-CA 119.904 -0.719 . . . . 0.0 112.174 -175.082 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 230' ' ' VAL . . . . . 0.677 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 53.3 t -122.26 127.81 75.3 Favored 'Isoleucine or valine' 0 C--O 1.238 0.472 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.039 178.482 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 35.7 m -105.86 115.75 30.77 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.317 178.186 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 134.92 170.17 12.11 Favored Glycine 0 N--CA 1.443 -0.851 0 C-N-CA 120.211 -0.995 . . . . 0.0 111.86 -178.499 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 233' ' ' GLN . . . . . 0.427 ' OE1' ' HA ' ' A' ' 327' ' ' ALA . 87.9 mm-40 -113.5 107.96 52.62 Favored Pre-proline 0 C--N 1.321 -0.637 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 -178.473 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 234' ' ' PRO . . . . . 0.652 ' O ' ' HD3' ' A' ' 325' ' ' LYS . 6.3 Cg_exo -74.88 125.74 9.59 Favored 'Trans proline' 0 N--CA 1.454 -0.812 0 C-N-CA 122.072 1.848 . . . . 0.0 111.007 178.073 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 70.0 mm-40 -124.15 149.92 45.73 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.731 178.36 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 78.9 t60 -161.04 130.54 4.81 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-N 115.778 -0.647 . . . . 0.0 110.235 172.39 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 237' ' ' LYS . . . . . 0.6 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -130.39 132.49 45.8 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 114.918 -1.037 . . . . 0.0 108.67 177.166 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 238' ' ' VAL . . . . . 0.576 HG23 HD21 ' A' ' 307' ' ' LEU . 41.4 t -103.63 123.76 57.46 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 C-N-CA 120.115 -0.634 . . . . 0.0 110.767 178.82 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 239' ' ' GLU . . . . . . . . . . . . . 22.7 pt-20 -138.65 143.11 39.08 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 115.649 -0.705 . . . . 0.0 109.442 173.7 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 240' ' ' ALA . . . . . 0.756 ' O ' ' HA ' ' A' ' 247' ' ' PRO . . . -76.62 -91.55 0.03 OUTLIER 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 -178.889 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 241' ' ' LYS . . . . . 0.585 ' O ' ' HD3' ' A' ' 241' ' ' LYS . 0.0 OUTLIER -119.84 144.26 47.45 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.136 175.512 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -101.31 -157.85 0.63 Allowed 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.855 -178.63 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 29.0 p -59.5 -26.38 65.25 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 113.047 0.758 . . . . 0.0 113.047 -177.379 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 17.3 t-20 -88.85 -14.61 36.5 Favored 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 120.706 -0.398 . . . . 0.0 110.678 179.389 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 245' ' ' GLY . . . . . 0.502 ' HA2' ' HE2' ' A' ' 241' ' ' LYS . . . 93.98 3.78 63.64 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.402 -0.904 . . . . 0.0 114.822 170.37 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 246' ' ' MET . . . . . . . . . . . . . 51.8 mtm -95.59 138.35 21.83 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 118.405 1.102 . . . . 0.0 111.258 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 247' ' ' PRO . . . . . 0.756 ' HA ' ' O ' ' A' ' 240' ' ' ALA . 4.7 Cg_exo -76.98 120.32 5.4 Favored 'Trans proline' 0 C--N 1.347 0.479 0 C-N-CA 122.905 2.403 . . . . 0.0 111.389 176.537 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 48.0 t -135.81 109.96 10.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-O 121.035 0.445 . . . . 0.0 110.487 -179.424 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 32.4 t70 -99.53 141.77 31.89 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 174.459 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 250' ' ' ASN . . . . . . . . . . . . . 73.8 m-80 -83.0 37.74 0.56 Allowed 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.812 -0.176 . . . . 0.0 111.356 -178.722 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 251' ' ' ARG . . . . . 0.803 ' HG3' ' H ' ' A' ' 252' ' ' GLN . 38.1 ptt180 38.08 -108.05 0.06 Allowed 'General case' 0 N--CA 1.473 0.693 0 O-C-N 124.318 1.012 . . . . 0.0 113.038 178.923 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 252' ' ' GLN . . . . . 0.803 ' H ' ' HG3' ' A' ' 251' ' ' ARG . 45.1 mm-40 -127.3 175.21 8.35 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 110.311 -0.255 . . . . 0.0 110.311 -176.88 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -85.3 135.34 13.37 Favored Glycine 0 N--CA 1.448 -0.504 0 C-N-CA 120.317 -0.944 . . . . 0.0 111.848 177.564 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 67.8 p -107.36 118.12 35.89 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.02 0.438 . . . . 0.0 110.162 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.402 ' HB ' ' CG1' ' A' ' 230' ' ' VAL . 24.2 pt -119.39 146.05 24.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.73 -174.975 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 92.4 m -97.16 115.81 28.23 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 172.871 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.634 HG21 HD12 ' A' ' 262' ' ' LEU . 32.8 m -92.08 143.19 11.85 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.974 0 C-N-CA 119.388 -0.925 . . . . 0.0 112.697 -170.94 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 258' ' ' SER . . . . . 0.415 ' HB3' ' OG1' ' A' ' 229' ' ' THR . 23.1 t -90.72 9.92 28.01 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 114.005 -1.452 . . . . 0.0 107.968 169.671 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 259' ' ' ALA . . . . . 0.603 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -93.38 -179.27 5.0 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 114.862 -1.063 . . . . 0.0 110.262 -177.979 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 32.2 t -152.8 150.92 29.86 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 176.433 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 84.98 22.74 51.84 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.42 -178.649 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 262' ' ' LEU . . . . . 0.634 HD12 HG21 ' A' ' 257' ' ' VAL . 78.6 mt -90.08 140.51 29.58 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.683 0.278 . . . . 0.0 110.439 179.439 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 41.4 mm-40 -137.55 168.71 19.12 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.58 -178.28 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 264' ' ' VAL . . . . . 0.496 HG22 ' HA ' ' A' ' 294' ' ' ALA . 45.6 t -74.81 138.58 20.74 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-O 120.743 0.306 . . . . 0.0 110.312 177.645 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 91.37 0.57 73.14 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.685 178.316 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 55.1 m-20 -81.32 165.32 21.49 Favored 'General case' 0 CA--C 1.514 -0.419 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 176.385 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 267' ' ' ALA . . . . . 0.838 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -130.7 148.65 52.51 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 176.869 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 268' ' ' PHE . . . . . 0.633 ' HB3' HD13 ' A' ' 334' ' ' ILE . 3.3 p90 -164.88 168.78 17.32 Favored 'General case' 0 C--N 1.321 -0.649 0 C-N-CA 120.176 -0.61 . . . . 0.0 111.3 -179.216 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 269' ' ' THR . . . . . 0.613 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 63.3 p -113.49 149.5 34.22 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.037 175.55 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 270' ' ' ILE . . . . . . . . . . . . . 59.4 mt -121.53 129.92 75.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 178.186 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -61.29 139.13 58.22 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.242 0.544 . . . . 0.0 112.242 -173.038 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 88.17 -24.95 9.69 Favored Glycine 0 C--O 1.231 -0.074 0 CA-C-N 115.778 -0.646 . . . . 0.0 112.678 179.199 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 38.2 t -97.21 101.49 12.31 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 174.288 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 274' ' ' ASN . . . . . 1.027 ' HA ' ' HA ' ' A' ' 287' ' ' PRO . 55.4 m-20 -94.46 169.11 10.44 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.316 -179.084 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 275' ' ' SER . . . . . 0.408 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 8.3 t -104.72 179.79 4.17 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 107.876 -1.157 . . . . 0.0 107.876 171.555 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 32.7 m -126.28 149.15 31.0 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.07 0 C-N-CA 120.472 -0.491 . . . . 0.0 111.196 173.421 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 277' ' ' HIS . . . . . 0.431 ' CD2' ' HB2' ' A' ' 282' ' ' ASP . 90.6 m-70 -78.08 117.2 19.15 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.065 -0.516 . . . . 0.0 109.621 175.169 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 39.4 tt0 -62.91 -35.25 79.44 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.906 -173.137 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 279' ' ' ILE . . . . . 0.642 HG22 HG23 ' A' ' 280' ' ' THR . 60.7 mt -60.09 -69.41 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 112.295 0.48 . . . . 0.0 112.295 -173.57 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 280' ' ' THR . . . . . 0.642 HG23 HG22 ' A' ' 279' ' ' ILE . 46.4 p -114.52 17.22 17.45 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 112.424 0.527 . . . . 0.0 112.424 -174.426 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 281' ' ' LYS . . . . . 0.418 ' HE3' HG11 ' A' ' 309' ' ' VAL . 2.8 tmtp? 60.04 53.02 4.79 Favored 'General case' 0 CA--C 1.535 0.397 0 CA-C-O 121.328 0.585 . . . . 0.0 109.527 177.688 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 282' ' ' ASP . . . . . 0.431 ' HB2' ' CD2' ' A' ' 277' ' ' HIS . 58.5 m-20 -94.27 129.98 40.71 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.892 0.377 . . . . 0.0 111.007 -178.804 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 76.1 p -107.2 107.43 18.38 Favored 'General case' 0 C--N 1.321 -0.656 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 173.842 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 47.0 p -118.68 7.27 11.65 Favored 'General case' 0 C--N 1.322 -0.587 0 C-N-CA 120.737 -0.385 . . . . 0.0 111.999 -172.217 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 285' ' ' GLY . . . . . 0.486 ' HA2' ' ND2' ' A' ' 274' ' ' ASN . . . 85.58 26.65 34.91 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.403 -0.903 . . . . 0.0 112.646 176.386 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 286' ' ' GLN . . . . . 0.417 ' HA ' ' HD3' ' A' ' 287' ' ' PRO . 84.7 mt-30 -105.03 117.17 59.28 Favored Pre-proline 0 C--N 1.324 -0.535 0 N-CA-C 110.328 -0.249 . . . . 0.0 110.328 178.616 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 287' ' ' PRO . . . . . 1.027 ' HA ' ' HA ' ' A' ' 274' ' ' ASN . 39.5 Cg_exo -61.7 167.36 10.21 Favored 'Trans proline' 0 C--O 1.233 0.274 0 C-N-CA 123.222 2.615 . . . . 0.0 113.559 -175.67 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 62.9 tp60 -88.05 136.45 32.96 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.278 -0.874 . . . . 0.0 110.564 178.165 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 289' ' ' VAL . . . . . 0.549 HG12 ' HB1' ' A' ' 267' ' ' ALA . 43.8 t -94.47 123.24 46.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.069 -0.514 . . . . 0.0 109.888 177.974 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 290' ' ' PHE . . . . . 0.838 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 60.1 m-85 -104.07 133.56 48.81 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 112.082 0.401 . . . . 0.0 112.082 -173.396 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 291' ' ' ARG . . . . . 0.635 ' HD2' ' HB2' ' A' ' 267' ' ' ALA . 40.2 mmm-85 -94.91 119.59 33.71 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-O 121.5 0.667 . . . . 0.0 109.414 167.761 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 292' ' ' VAL . . . . . 0.627 HG11 HG23 ' A' ' 295' ' ' VAL . 54.9 t -71.37 140.91 17.45 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 CA-C-N 114.705 -1.134 . . . . 0.0 112.409 -174.905 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 293' ' ' LEU . . . . . 0.509 ' N ' HD12 ' A' ' 293' ' ' LEU . 3.9 mp -102.34 -30.89 10.79 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.41 175.604 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 294' ' ' ALA . . . . . 0.496 ' HA ' HG22 ' A' ' 264' ' ' VAL . . . -158.02 138.85 13.07 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.558 -177.394 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 295' ' ' VAL . . . . . 0.627 HG23 HG11 ' A' ' 292' ' ' VAL . 59.4 t -133.84 97.67 2.35 Favored 'Isoleucine or valine' 0 C--O 1.236 0.358 0 CA-C-N 115.851 -0.613 . . . . 0.0 109.378 173.826 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 30.5 m -133.98 114.57 13.38 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.848 -176.064 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 60.96 51.04 61.07 Favored Glycine 0 C--N 1.329 0.179 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.336 -179.515 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 70.4 p 52.32 19.5 1.14 Allowed 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 123.635 0.774 . . . . 0.0 112.654 -176.267 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 32.8 m -109.45 108.95 19.64 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 177.174 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 300' ' ' VAL . . . . . 0.579 HG12 HG23 ' A' ' 302' ' ' ILE . 43.7 t -112.04 126.96 69.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.54 -170.931 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 301' ' ' THR . . . . . 0.456 ' CG2' ' HB2' ' A' ' 252' ' ' GLN . 69.1 m -98.29 117.92 33.77 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 174.259 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 302' ' ' ILE . . . . . 0.655 ' O ' ' HB3' ' A' ' 252' ' ' GLN . 2.4 pp -116.18 149.82 18.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 N-CA-C 114.116 1.154 . . . . 0.0 114.116 -171.033 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 303' ' ' SER . . . . . 0.51 ' HA ' ' O ' ' A' ' 304' ' ' PRO . 86.1 p -140.64 162.62 48.05 Favored Pre-proline 0 C--O 1.216 -0.682 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 173.185 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 304' ' ' PRO . . . . . 0.51 ' O ' ' HA ' ' A' ' 303' ' ' SER . 17.6 Cg_endo -55.83 174.39 3.55 Favored 'Cis proline' 0 N--CA 1.477 0.554 0 CA-C-N 121.479 1.564 . . . . 0.0 113.825 0.038 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 305' ' ' LYS . . . . . 0.473 ' HD2' ' N ' ' A' ' 305' ' ' LYS . 0.4 OUTLIER -65.3 158.42 26.42 Favored 'General case' 0 CA--C 1.511 -0.553 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.38 179.502 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 306' ' ' ILE . . . . . 0.483 HD11 HD11 ' A' ' 302' ' ' ILE . 43.3 mt -101.62 73.02 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -0.987 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.779 178.453 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 307' ' ' LEU . . . . . 0.576 HD21 HG23 ' A' ' 238' ' ' VAL . 91.7 mt -107.11 112.14 63.2 Favored Pre-proline 0 C--N 1.324 -0.543 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.216 -176.262 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 308' ' ' PRO . . . . . 0.585 ' HA ' ' O ' ' A' ' 322' ' ' VAL . 11.3 Cg_exo -69.79 146.35 59.74 Favored 'Trans proline' 0 N--CA 1.462 -0.324 0 C-N-CA 122.708 2.272 . . . . 0.0 111.034 177.708 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 309' ' ' VAL . . . . . 0.418 HG11 ' HE3' ' A' ' 281' ' ' LYS . 20.0 t -83.41 -21.32 8.85 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 CA-C-O 121.282 0.563 . . . . 0.0 110.39 -177.694 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -76.24 -6.95 53.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.58 -0.736 . . . . 0.0 112.28 -175.994 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 47.4 p30 -75.46 153.94 37.31 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.143 0.497 . . . . 0.0 111.749 -177.005 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 53.1 m -96.88 -7.58 33.06 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.835 -0.62 . . . . 0.0 109.402 178.24 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 313' ' ' ASP . . . . . 0.464 ' HB3' ' HB2' ' A' ' 316' ' ' SER . 9.8 t70 -54.25 119.0 4.54 Favored 'General case' 0 C--O 1.232 0.153 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.507 179.868 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 46.7 t -56.57 -49.61 76.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.41 -0.814 . . . . 0.0 112.679 -173.071 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -81.82 -19.73 40.5 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 112.352 0.501 . . . . 0.0 112.352 -174.668 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 316' ' ' SER . . . . . 0.464 ' HB2' ' HB3' ' A' ' 313' ' ' ASP . 49.2 m -91.81 -25.26 19.09 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 112.283 0.475 . . . . 0.0 112.283 -175.742 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 317' ' ' ARG . . . . . 0.466 ' CG ' ' HD3' ' A' ' 318' ' ' PRO . 1.6 ptm85 -71.62 -35.79 4.04 Favored Pre-proline 0 CA--C 1.545 0.771 0 N-CA-C 114.293 1.22 . . . . 0.0 114.293 -175.902 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 318' ' ' PRO . . . . . 0.466 ' HD3' ' CG ' ' A' ' 317' ' ' ARG . 24.2 Cg_exo -65.89 -38.92 21.33 Favored 'Trans proline' 0 C--N 1.362 1.268 0 CA-C-N 121.132 1.44 . . . . 0.0 112.476 -177.463 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 3.9 m-85 -95.94 17.37 15.5 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.075 -179.719 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 320' ' ' ALA . . . . . 0.518 ' HA ' ' HB2' ' A' ' 307' ' ' LEU . . . -64.67 134.34 54.07 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.523 177.805 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 15.2 p-10 -144.11 1.44 1.11 Allowed 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -174.023 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 322' ' ' VAL . . . . . 0.585 ' O ' ' HA ' ' A' ' 308' ' ' PRO . 29.4 m -133.93 161.45 40.92 Favored 'Isoleucine or valine' 0 C--O 1.234 0.266 0 CA-C-O 121.288 0.566 . . . . 0.0 112.262 -177.82 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 323' ' ' ASP . . . . . 0.687 ' HB2' ' HB2' ' A' ' 274' ' ' ASN . 57.2 m-20 -93.24 77.59 4.54 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.865 174.958 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 324' ' ' ALA . . . . . 0.403 ' HB3' ' O ' ' A' ' 323' ' ' ASP . . . 72.37 163.85 0.28 Allowed 'General case' 0 N--CA 1.471 0.621 0 N-CA-C 113.387 0.884 . . . . 0.0 113.387 175.12 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 325' ' ' LYS . . . . . 0.652 ' HD3' ' O ' ' A' ' 234' ' ' PRO . 9.9 ptpp? -119.15 105.93 43.93 Favored Pre-proline 0 C--N 1.325 -0.459 0 CA-C-N 114.485 -1.234 . . . . 0.0 108.715 166.902 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 326' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 325' ' ' LYS . 3.8 Cg_exo -84.17 167.21 12.43 Favored 'Trans proline' 0 C--O 1.234 0.299 0 C-N-CA 122.657 2.238 . . . . 0.0 112.992 -171.363 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 327' ' ' ALA . . . . . 0.427 ' HA ' ' OE1' ' A' ' 233' ' ' GLN . . . -72.82 134.85 45.07 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 115.605 -0.725 . . . . 0.0 109.689 174.136 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 70.1 mm-40 71.3 111.18 0.06 Allowed 'General case' 0 N--CA 1.464 0.256 0 O-C-N 124.089 0.868 . . . . 0.0 110.432 -173.243 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 329' ' ' SER . . . . . 0.677 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 58.2 m -63.36 -41.28 98.83 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.603 -176.561 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 330' ' ' ALA . . . . . 0.466 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 79.35 -160.66 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.762 0 N-CA-C 112.828 0.677 . . . . 0.0 112.828 174.968 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 331' ' ' ALA . . . . . 0.617 ' HA ' HG22 ' A' ' 229' ' ' THR . . . -68.43 157.73 35.21 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-N 115.091 -0.958 . . . . 0.0 113.562 -170.405 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 332' ' ' ILE . . . . . 0.507 HD12 ' HB2' ' A' ' 259' ' ' ALA . 17.5 mt -119.16 146.11 24.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.075 -0.966 . . . . 0.0 110.223 179.555 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.518 ' HB ' ' OG1' ' A' ' 269' ' ' THR . 59.5 m -127.18 111.67 14.24 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 175.544 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 334' ' ' ILE . . . . . 0.633 HD13 ' HB3' ' A' ' 268' ' ' PHE . 46.9 mm -83.87 134.93 25.85 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.359 0 N-CA-C 113.295 0.85 . . . . 0.0 113.295 -171.538 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 335' ' ' LEU . . . . . 0.543 ' O ' ' HB3' ' A' ' 267' ' ' ALA . 1.8 pt? -158.45 130.36 6.75 Favored 'General case' 0 C--O 1.222 -0.366 0 CA-C-N 115.083 -0.962 . . . . 0.0 109.906 170.562 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -102.65 2.74 36.34 Favored 'General case' 0 C--N 1.318 -0.801 0 O-C-N 122.011 -0.43 . . . . 0.0 111.144 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 40.1 ttmt . . . . . 0 C--O 1.244 0.773 0 CA-C-O 118.279 -0.867 . . . . 0.0 110.246 -178.388 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.776 0 N-CA-C 112.277 -0.329 . . . . 0.0 112.277 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 33.9 t 65.33 -131.89 0.25 Allowed 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 122.574 0.35 . . . . 0.0 110.073 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 50.1 p -83.15 162.41 21.29 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-O 120.905 0.383 . . . . 0.0 110.653 179.736 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -152.83 86.24 1.25 Allowed 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.197 179.487 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 35.4 m 62.46 77.52 0.33 Allowed 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.015 179.235 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 228' ' ' LEU . . . . . 0.701 ' H ' HD22 ' A' ' 228' ' ' LEU . 1.9 mm? -60.39 150.56 30.49 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.252 -179.665 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 229' ' ' THR . . . . . 0.405 ' HA ' ' HA ' ' A' ' 331' ' ' ALA . 53.6 p -129.96 176.18 8.26 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 119.787 -0.765 . . . . 0.0 111.1 -179.773 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 230' ' ' VAL . . . . . 0.527 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 64.9 t -148.69 138.87 16.56 Favored 'Isoleucine or valine' 0 C--O 1.238 0.478 0 CA-C-O 120.789 0.328 . . . . 0.0 110.926 -177.128 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 47.1 t -122.72 97.39 5.43 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.419 -0.809 . . . . 0.0 109.101 173.284 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . -126.22 -151.8 7.96 Favored Glycine 0 N--CA 1.445 -0.762 0 C-N-CA 119.951 -1.119 . . . . 0.0 113.102 -175.036 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 233' ' ' GLN . . . . . 0.777 ' H ' HG22 ' A' ' 255' ' ' ILE . 80.3 mt-30 -70.58 169.61 13.53 Favored Pre-proline 0 C--N 1.325 -0.468 0 CA-C-N 115.212 -0.494 . . . . 0.0 110.991 -178.609 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 234' ' ' PRO . . . . . 0.768 ' HD2' ' HB3' ' A' ' 233' ' ' GLN . 18.7 Cg_endo -57.53 175.08 0.43 Allowed 'Trans proline' 0 C--N 1.354 0.833 0 C-N-CA 123.404 2.736 . . . . 0.0 112.833 177.777 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 235' ' ' GLU . . . . . 0.476 ' HB2' ' HD2' ' A' ' 325' ' ' LYS . 25.1 mp0 -91.86 155.18 18.39 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 108.96 -0.756 . . . . 0.0 108.96 -177.052 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 236' ' ' HIS . . . . . 0.618 ' CE1' ' HB3' ' A' ' 251' ' ' ARG . 65.6 m-70 -108.5 148.76 29.76 Favored 'General case' 0 C--N 1.323 -0.581 0 C-N-CA 120.521 -0.472 . . . . 0.0 111.177 -171.511 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 237' ' ' LYS . . . . . 0.44 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -160.23 161.92 33.6 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.5 -0.773 . . . . 0.0 108.957 -178.38 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 238' ' ' VAL . . . . . 0.467 ' HB ' ' HA ' ' A' ' 316' ' ' SER . 45.8 t -103.43 120.82 53.97 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 C-N-CA 120.874 -0.331 . . . . 0.0 110.46 179.728 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 239' ' ' GLU . . . . . 0.469 ' O ' ' HA ' ' A' ' 247' ' ' PRO . 53.7 mt-10 -120.71 154.17 35.95 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.049 176.965 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 240' ' ' ALA . . . . . . . . . . . . . . . -62.6 -40.02 95.6 Favored 'General case' 0 C--N 1.328 -0.344 0 O-C-N 123.369 0.418 . . . . 0.0 110.944 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 241' ' ' LYS . . . . . 0.595 ' O ' ' HD3' ' A' ' 241' ' ' LYS . 0.0 OUTLIER -149.54 143.29 25.51 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.433 0.635 . . . . 0.0 112.07 178.723 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 242' ' ' ASP . . . . . 0.456 ' HB3' HG22 ' A' ' 248' ' ' VAL . 56.3 p-10 -106.38 -156.56 0.58 Allowed 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.258 179.449 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 47.1 t -58.71 -33.59 70.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.176 178.421 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 51.0 t30 -91.04 -13.83 32.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.875 0.369 . . . . 0.0 111.129 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 245' ' ' GLY . . . . . 0.514 ' HA2' ' HB2' ' A' ' 241' ' ' LYS . . . 95.5 22.14 22.46 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.622 -0.799 . . . . 0.0 112.571 178.975 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 246' ' ' MET . . . . . . . . . . . . . 83.8 mtp -113.44 151.5 44.49 Favored Pre-proline 0 C--N 1.325 -0.464 0 O-C-N 122.952 -0.146 . . . . 0.0 110.706 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 247' ' ' PRO . . . . . 0.469 ' HA ' ' O ' ' A' ' 239' ' ' GLU . 26.0 Cg_exo -58.9 130.06 34.94 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.277 1.985 . . . . 0.0 111.0 175.352 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.456 HG22 ' HB3' ' A' ' 242' ' ' ASP . 48.5 t -70.21 118.17 14.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-O 121.179 0.514 . . . . 0.0 110.591 -175.077 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 27.2 t70 -79.35 144.21 34.41 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.557 -179.337 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 250' ' ' ASN . . . . . 0.437 HD21 HG22 ' A' ' 238' ' ' VAL . 3.2 m120 -62.27 101.15 0.21 Allowed 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 178.117 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 251' ' ' ARG . . . . . 0.618 ' HB3' ' CE1' ' A' ' 236' ' ' HIS . 0.6 OUTLIER -67.08 -68.47 0.37 Allowed 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.469 -0.787 . . . . 0.0 112.141 -169.742 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 19.2 mt-30 62.84 178.89 0.14 Allowed 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 -176.769 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 253' ' ' GLY . . . . . 0.586 ' O ' ' HA ' ' A' ' 301' ' ' THR . . . 133.29 -146.45 18.36 Favored Glycine 0 N--CA 1.445 -0.76 0 C-N-CA 118.576 -1.773 . . . . 0.0 114.223 174.314 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 51.4 p -93.98 130.1 40.21 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.036 -0.582 . . . . 0.0 112.443 -170.905 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.777 HG22 ' H ' ' A' ' 233' ' ' GLN . 2.3 pp -129.79 163.4 35.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.902 177.432 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 31.3 m -100.47 116.38 32.28 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 -178.51 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.454 ' HA ' HG13 ' A' ' 230' ' ' VAL . 31.8 m -90.78 142.56 12.77 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.573 0 C-N-CA 120.192 -0.603 . . . . 0.0 112.593 -176.098 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 36.8 t -91.94 9.03 34.74 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 114.495 -1.23 . . . . 0.0 108.379 167.575 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 259' ' ' ALA . . . . . 0.537 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -91.07 171.54 9.19 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.138 -0.937 . . . . 0.0 109.748 -178.023 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 34.5 t -143.65 132.02 22.11 Favored 'General case' 0 C--N 1.324 -0.504 0 C-N-CA 120.991 -0.283 . . . . 0.0 110.857 179.508 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 99.24 25.49 9.43 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.682 -0.771 . . . . 0.0 113.083 177.705 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 262' ' ' LEU . . . . . 0.507 HD11 ' CB ' ' A' ' 259' ' ' ALA . 3.4 mp -87.79 146.26 25.71 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 117.034 0.417 . . . . 0.0 110.195 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 83.6 mt-30 -141.04 169.16 18.13 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.105 -0.498 . . . . 0.0 109.768 177.404 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 264' ' ' VAL . . . . . 0.674 HG22 ' HA ' ' A' ' 294' ' ' ALA . 31.8 t -77.86 139.69 18.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 C-N-CA 121.032 -0.267 . . . . 0.0 110.594 -179.677 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 91.71 3.35 68.71 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.13 179.462 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 70.5 m-20 -80.46 166.78 20.89 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.295 0.569 . . . . 0.0 111.039 179.145 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 267' ' ' ALA . . . . . 0.723 ' HB2' ' NH1' ' A' ' 291' ' ' ARG . . . -125.84 144.11 50.79 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 114.802 -1.09 . . . . 0.0 108.551 175.22 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 268' ' ' PHE . . . . . 0.583 ' CD1' HG21 ' A' ' 332' ' ' ILE . 0.0 OUTLIER -163.45 163.82 24.72 Favored 'General case' 0 C--N 1.313 -1.002 0 C-N-CA 120.125 -0.63 . . . . 0.0 110.167 -179.955 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 63.3 p -125.89 137.99 53.77 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 120.822 0.344 . . . . 0.0 110.934 -175.397 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 270' ' ' ILE . . . . . 0.671 HG12 HG12 ' A' ' 332' ' ' ILE . 60.5 mt -95.89 138.63 20.89 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.806 -179.316 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -62.23 125.52 24.18 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.97 179.577 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 94.4 -21.57 41.93 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.125 -178.62 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 273' ' ' VAL . . . . . 0.461 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 57.0 t -90.73 101.4 12.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.282 0.563 . . . . 0.0 110.106 177.976 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 64.5 m-20 -115.91 134.32 55.11 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 178.791 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 35.6 p -70.8 152.81 43.36 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.258 0.552 . . . . 0.0 111.97 -179.125 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 276' ' ' VAL . . . . . 0.686 HG11 HG21 ' A' ' 309' ' ' VAL . 33.8 m -114.7 156.07 15.75 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-N 115.221 -0.899 . . . . 0.0 110.157 174.588 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 21.7 m80 -116.6 71.27 0.78 Allowed 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 177.473 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 26.8 mt-30 -70.58 -9.62 57.27 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 112.17 0.433 . . . . 0.0 112.17 -175.239 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 279' ' ' ILE . . . . . 0.49 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.0 mp -67.67 -49.08 73.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 176.024 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 70.1 p -90.93 -12.75 35.11 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.117 0.484 . . . . 0.0 109.925 174.288 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 26.5 tptp 68.28 50.8 0.73 Allowed 'General case' 0 CA--C 1.531 0.237 0 CA-C-N 114.902 -1.045 . . . . 0.0 110.342 -177.929 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -118.34 142.15 47.8 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.889 177.553 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 62.8 p -107.43 109.93 21.77 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.48 174.745 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 68.0 p -114.33 -12.19 12.45 Favored 'General case' 0 C--N 1.32 -0.691 0 C-N-CA 120.721 -0.392 . . . . 0.0 111.999 -171.429 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 64.16 31.46 80.91 Favored Glycine 0 CA--C 1.518 0.252 0 C-N-CA 120.964 -0.636 . . . . 0.0 113.313 175.963 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 98.1 mm-40 -89.14 122.46 68.71 Favored Pre-proline 0 C--N 1.327 -0.37 0 CA-C-N 116.941 0.37 . . . . 0.0 110.197 178.871 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 287' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_exo -48.29 131.08 22.1 Favored 'Trans proline' 0 C--N 1.346 0.42 0 C-N-CA 123.033 2.489 . . . . 0.0 112.989 -177.695 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 67.1 tp60 -70.1 127.28 32.28 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.868 -178.867 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 289' ' ' VAL . . . . . 0.442 HG13 ' HB1' ' A' ' 267' ' ' ALA . 65.7 t -91.73 131.74 38.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 116.042 -0.527 . . . . 0.0 110.578 178.47 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 290' ' ' PHE . . . . . 0.695 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 57.8 m-85 -113.5 154.5 26.96 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.72 -178.272 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 291' ' ' ARG . . . . . 0.723 ' NH1' ' HB2' ' A' ' 267' ' ' ALA . 0.1 OUTLIER -114.5 121.58 43.96 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.15 0.5 . . . . 0.0 110.196 172.812 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 292' ' ' VAL . . . . . 0.512 HG11 HG23 ' A' ' 295' ' ' VAL . 56.9 t -70.39 136.46 25.99 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-N 115.037 -0.983 . . . . 0.0 111.889 -175.291 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 293' ' ' LEU . . . . . 0.667 HD11 ' HB2' ' A' ' 303' ' ' SER . 5.5 mp -96.22 -35.69 11.19 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.91 -0.587 . . . . 0.0 111.085 179.048 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 294' ' ' ALA . . . . . 0.674 ' HA ' HG22 ' A' ' 264' ' ' VAL . . . -163.63 140.8 7.21 Favored 'General case' 0 C--N 1.332 -0.184 0 C-N-CA 121.058 -0.257 . . . . 0.0 111.641 -179.579 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 295' ' ' VAL . . . . . 0.512 HG23 HG11 ' A' ' 292' ' ' VAL . 59.9 t -134.77 103.37 4.48 Favored 'Isoleucine or valine' 0 C--O 1.235 0.303 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.784 175.191 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 51.0 m -143.81 114.64 7.73 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.559 -179.013 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 67.05 48.43 59.99 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.276 -178.551 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 77.9 p 51.5 21.53 1.28 Allowed 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 123.608 0.763 . . . . 0.0 112.106 -176.198 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 37.0 m -110.04 105.9 15.2 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 177.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 300' ' ' VAL . . . . . 0.562 ' HA ' ' O ' ' A' ' 294' ' ' ALA . 48.9 t -108.52 128.09 64.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.4 -172.119 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 301' ' ' THR . . . . . 0.586 ' HA ' ' O ' ' A' ' 253' ' ' GLY . 54.1 m -86.75 115.82 24.44 Favored 'General case' 0 N--CA 1.451 -0.423 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 173.631 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 302' ' ' ILE . . . . . 0.549 HD12 ' O ' ' A' ' 302' ' ' ILE . 2.4 pp -111.74 151.04 13.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 N-CA-C 113.527 0.936 . . . . 0.0 113.527 -171.05 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 303' ' ' SER . . . . . 0.667 ' HB2' HD11 ' A' ' 293' ' ' LEU . 64.9 m -166.99 166.5 8.48 Favored Pre-proline 0 C--N 1.322 -0.595 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 179.326 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 304' ' ' PRO . . . . . 0.586 ' HA ' ' HB3' ' A' ' 303' ' ' SER . 4.3 Cg_exo -77.62 -113.81 0.0 OUTLIER 'Cis proline' 0 C--N 1.347 0.48 0 CA-C-N 120.907 1.36 . . . . 0.0 113.438 0.516 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 305' ' ' LYS . . . . . 0.519 ' HB3' ' HG ' ' A' ' 307' ' ' LEU . 31.2 mmtp -93.04 155.74 17.32 Favored 'General case' 0 CA--C 1.515 -0.385 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.354 -171.473 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 306' ' ' ILE . . . . . 0.456 HD12 ' N ' ' A' ' 306' ' ' ILE . 3.1 mp -131.09 74.18 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.641 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 167.283 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 307' ' ' LEU . . . . . 0.519 ' HG ' ' HB3' ' A' ' 305' ' ' LYS . 73.7 mt -112.67 113.91 50.08 Favored Pre-proline 0 C--N 1.328 -0.366 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.183 -171.092 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 308' ' ' PRO . . . . . 0.743 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 37.8 Cg_exo -66.91 148.62 82.43 Favored 'Trans proline' 0 N--CA 1.472 0.254 0 C-N-CA 123.378 2.719 . . . . 0.0 113.924 -175.137 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 309' ' ' VAL . . . . . 0.686 HG21 HG11 ' A' ' 276' ' ' VAL . 46.0 t -94.06 -7.92 9.99 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.362 0 CA-C-N 115.421 -0.809 . . . . 0.0 109.303 171.966 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 310' ' ' GLU . . . . . 0.428 ' HG2' ' O ' ' A' ' 323' ' ' ASP . 65.3 mm-40 -77.17 11.83 1.7 Allowed 'General case' 0 CA--C 1.531 0.248 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.928 179.076 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.519 ' OD1' ' HB2' ' A' ' 308' ' ' PRO . 4.6 m120 -80.41 158.69 25.89 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.888 0.375 . . . . 0.0 110.669 178.472 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 31.5 m -107.74 -13.28 15.06 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.168 0.508 . . . . 0.0 110.494 -176.027 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 11.8 p-10 -87.58 156.25 19.59 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 121.091 0.472 . . . . 0.0 111.172 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 314' ' ' VAL . . . . . 0.411 ' O ' ' HD3' ' A' ' 318' ' ' PRO . 49.1 t -81.79 -24.06 9.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 115.707 -0.678 . . . . 0.0 111.112 -178.295 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -61.9 -42.72 99.42 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 111.913 0.338 . . . . 0.0 111.913 -178.114 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 316' ' ' SER . . . . . 0.467 ' HA ' ' HB ' ' A' ' 238' ' ' VAL . 26.3 t -82.1 -10.31 59.24 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.609 -0.268 . . . . 0.0 111.293 -176.431 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 317' ' ' ARG . . . . . 0.638 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 36.8 mmt180 -58.37 -54.5 55.24 Favored Pre-proline 0 N--CA 1.468 0.464 0 N-CA-C 113.554 0.946 . . . . 0.0 113.554 -179.704 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 318' ' ' PRO . . . . . 0.638 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 24.5 Cg_exo -68.21 -19.19 44.81 Favored 'Trans proline' 0 C--N 1.353 0.78 0 C-N-CA 122.017 1.811 . . . . 0.0 113.232 -175.178 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 55.4 m-85 -102.16 -18.37 15.57 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 111.965 0.357 . . . . 0.0 111.965 -174.245 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -55.64 126.49 25.61 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.795 0.331 . . . . 0.0 111.244 -178.666 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 321' ' ' ASN . . . . . 0.411 ' C ' HG22 ' A' ' 276' ' ' VAL . 15.3 p-10 -126.51 -4.94 6.54 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.288 -177.631 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 322' ' ' VAL . . . . . 0.571 ' O ' HG23 ' A' ' 309' ' ' VAL . 29.9 m -136.35 156.43 36.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.637 0.256 . . . . 0.0 110.885 178.511 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 323' ' ' ASP . . . . . 0.428 ' O ' ' HG2' ' A' ' 310' ' ' GLU . 71.9 m-20 -52.93 -50.97 62.93 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.889 -178.065 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 324' ' ' ALA . . . . . 0.743 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -163.05 -179.94 7.07 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.006 0.431 . . . . 0.0 111.135 -177.066 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 325' ' ' LYS . . . . . 0.476 ' HD2' ' HB2' ' A' ' 235' ' ' GLU . 22.0 pttp -105.84 137.43 19.34 Favored Pre-proline 0 C--N 1.325 -0.481 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.122 176.575 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 326' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 325' ' ' LYS . 57.4 Cg_endo -86.35 167.46 9.05 Favored 'Trans proline' 0 N--CA 1.454 -0.809 0 C-N-CA 122.712 2.275 . . . . 0.0 112.306 -179.411 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -75.6 138.34 41.37 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 175.777 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 62.64 -132.42 0.51 Allowed 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 -174.021 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 329' ' ' SER . . . . . 0.527 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 48.6 m -111.49 -17.34 13.1 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 171.185 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 74.47 -173.67 0.13 Allowed 'General case' 0 N--CA 1.474 0.759 0 N-CA-C 113.65 0.981 . . . . 0.0 113.65 170.887 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 331' ' ' ALA . . . . . 0.435 ' HA ' ' O ' ' A' ' 228' ' ' LEU . . . -80.76 146.75 30.84 Favored 'General case' 0 CA--C 1.518 -0.264 0 CA-C-N 114.997 -1.001 . . . . 0.0 111.171 -176.604 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 332' ' ' ILE . . . . . 0.671 HG12 HG12 ' A' ' 270' ' ' ILE . 47.5 mt -128.45 147.18 33.0 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-O 120.956 0.408 . . . . 0.0 111.528 -176.938 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 88.1 m -116.71 112.96 21.94 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.857 -179.591 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 38.4 mm -79.56 131.87 33.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 113.044 0.757 . . . . 0.0 113.044 -171.482 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 335' ' ' LEU . . . . . . . . . . . . . 9.6 mp -115.92 168.61 9.91 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 114.562 -1.199 . . . . 0.0 109.643 171.5 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 68.5 m-20 -116.82 3.96 12.95 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.473 176.69 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 14.8 ptmm? . . . . . 0 C--O 1.246 0.889 0 CA-C-O 118.611 -0.709 . . . . 0.0 111.687 -176.415 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.848 0 N-CA-C 112.467 -0.253 . . . . 0.0 112.467 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 50.4 m -104.63 -116.04 0.23 Allowed 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 177.734 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 50.3 m -68.32 -42.56 79.2 Favored 'General case' 0 C--O 1.234 0.239 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 175.722 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 226' ' ' GLU . . . . . 0.755 ' HB3' HG23 ' A' ' 333' ' ' THR . 50.8 mm-40 56.53 39.25 29.99 Favored 'General case' 0 C--N 1.333 -0.116 0 CA-C-N 115.053 -0.976 . . . . 0.0 110.954 178.442 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 51.1 m -119.92 49.5 1.39 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.506 -179.236 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 228' ' ' LEU . . . . . 0.471 HD13 ' HB1' ' A' ' 259' ' ' ALA . 89.9 mt -70.28 147.27 49.89 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 175.148 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 63.8 p -126.29 171.65 10.77 Favored 'General case' 0 C--N 1.324 -0.54 0 C-N-CA 119.163 -1.015 . . . . 0.0 111.334 -176.919 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 230' ' ' VAL . . . . . 0.893 HG11 HD12 ' A' ' 255' ' ' ILE . 48.0 t -147.1 141.08 20.0 Favored 'Isoleucine or valine' 0 C--O 1.24 0.577 0 CA-C-O 120.657 0.265 . . . . 0.0 110.754 -177.662 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 30.6 t -106.48 148.84 27.7 Favored 'General case' 0 C--O 1.237 0.428 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.985 176.634 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 124.8 157.15 9.61 Favored Glycine 0 N--CA 1.449 -0.486 0 N-CA-C 110.944 -0.862 . . . . 0.0 110.944 -176.712 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 30.0 mm100 -110.01 101.48 47.52 Favored Pre-proline 0 C--N 1.324 -0.534 0 CA-C-N 117.419 0.609 . . . . 0.0 111.305 -177.819 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -91.83 126.36 0.92 Allowed 'Trans proline' 0 N--CA 1.448 -1.159 0 C-N-CA 122.806 2.337 . . . . 0.0 111.756 177.605 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 235' ' ' GLU . . . . . 0.594 ' O ' ' HB3' ' A' ' 251' ' ' ARG . 11.0 pt-20 -132.54 149.36 52.33 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.525 -0.307 . . . . 0.0 110.214 177.027 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 236' ' ' HIS . . . . . 0.735 ' CD2' ' HA ' ' A' ' 305' ' ' LYS . 29.3 m80 -136.55 136.11 39.02 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.182 -179.532 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 237' ' ' LYS . . . . . 0.543 ' H ' ' HA ' ' A' ' 250' ' ' ASN . 0.0 OUTLIER -155.16 128.09 8.14 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.024 -179.968 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 238' ' ' VAL . . . . . . . . . . . . . 46.4 t -84.94 147.74 5.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.597 -0.274 . . . . 0.0 110.671 -176.465 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 239' ' ' GLU . . . . . 0.982 ' HA ' ' HB ' ' A' ' 248' ' ' VAL . 7.7 pt-20 -52.85 116.87 2.56 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.869 -0.605 . . . . 0.0 112.499 179.678 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 240' ' ' ALA . . . . . . . . . . . . . . . -81.73 -56.38 4.03 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 174.284 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 241' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -97.98 177.43 5.43 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.195 -0.912 . . . . 0.0 108.996 175.484 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 11.9 p-10 -105.88 -161.47 0.8 Allowed 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 120.852 0.358 . . . . 0.0 110.077 176.379 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 25.1 p -71.5 2.27 5.28 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 112.336 0.495 . . . . 0.0 112.336 178.498 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 49.8 t30 -79.27 -15.14 58.45 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.96 0.41 . . . . 0.0 110.763 178.388 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 245' ' ' GLY . . . . . 0.42 ' O ' ' HE3' ' A' ' 246' ' ' MET . . . -156.88 -77.68 0.02 OUTLIER Glycine 0 N--CA 1.445 -0.738 0 C-N-CA 120.177 -1.011 . . . . 0.0 112.651 -179.449 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 246' ' ' MET . . . . . 0.6 ' CE ' ' HA ' ' A' ' 246' ' ' MET . 1.6 mmt -112.29 118.06 46.41 Favored Pre-proline 0 C--N 1.326 -0.445 0 CA-C-O 120.967 0.413 . . . . 0.0 111.836 -178.769 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 247' ' ' PRO . . . . . 0.484 ' HD3' ' HA ' ' A' ' 246' ' ' MET . 11.4 Cg_endo -86.64 120.48 1.74 Allowed 'Trans proline' 0 N--CA 1.45 -1.035 0 C-N-CA 123.336 2.69 . . . . 0.0 111.584 174.051 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.982 ' HB ' ' HA ' ' A' ' 239' ' ' GLU . 32.5 t -119.82 120.19 62.54 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 C-N-CA 120.656 -0.418 . . . . 0.0 110.074 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 36.7 t70 -118.31 146.1 44.59 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.604 -0.271 . . . . 0.0 110.66 -176.867 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 250' ' ' ASN . . . . . 0.543 ' HA ' ' H ' ' A' ' 237' ' ' LYS . 73.6 m-80 -61.39 -0.28 0.37 Allowed 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 113.11 0.782 . . . . 0.0 113.11 -176.844 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 251' ' ' ARG . . . . . 0.594 ' HB3' ' O ' ' A' ' 235' ' ' GLU . 36.0 tpt85 66.31 -93.12 0.03 OUTLIER 'General case' 0 N--CA 1.453 -0.31 0 C-N-CA 123.083 0.553 . . . . 0.0 110.506 179.394 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 76.9 mt-30 59.49 179.08 0.08 Allowed 'General case' 0 N--CA 1.468 0.473 0 CA-C-O 120.951 0.405 . . . . 0.0 110.693 179.223 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 136.0 -160.86 24.75 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 119.031 -1.557 . . . . 0.0 113.613 176.125 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 254' ' ' THR . . . . . 0.57 ' HB ' HG22 ' A' ' 299' ' ' THR . 66.0 p -94.63 135.73 35.75 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-O 121.331 0.586 . . . . 0.0 111.88 -175.307 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.893 HD12 HG11 ' A' ' 230' ' ' VAL . 14.6 pt -121.77 156.42 26.04 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-N 115.535 -0.757 . . . . 0.0 110.179 177.151 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 28.3 m -94.66 111.26 23.04 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 -179.755 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.528 ' HA ' HG13 ' A' ' 230' ' ' VAL . 23.1 m -93.45 144.54 9.28 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.76 0 CA-C-O 121.642 0.734 . . . . 0.0 112.717 -170.213 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 35.4 t -91.19 9.65 30.29 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 114.088 -1.415 . . . . 0.0 108.049 167.857 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 259' ' ' ALA . . . . . 0.471 ' HB1' HD13 ' A' ' 228' ' ' LEU . . . -87.08 163.72 16.85 Favored 'General case' 0 N--CA 1.45 -0.427 0 CA-C-N 115.004 -0.998 . . . . 0.0 109.66 -177.826 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 37.5 t -144.13 143.99 31.37 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 120.683 0.278 . . . . 0.0 110.384 -179.726 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 80.94 36.75 21.11 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.649 179.625 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 262' ' ' LEU . . . . . . . . . . . . . 66.4 mt -98.83 150.8 21.51 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.941 0.401 . . . . 0.0 110.432 179.52 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 73.4 mt-30 -142.26 164.73 29.37 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.241 176.29 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 264' ' ' VAL . . . . . 0.514 HG22 ' HA ' ' A' ' 294' ' ' ALA . 39.9 t -74.83 139.28 19.42 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 177.856 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 96.43 -1.91 62.55 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.42 -0.895 . . . . 0.0 113.504 177.737 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 39.7 m-20 -80.09 155.75 27.37 Favored 'General case' 0 CA--C 1.516 -0.353 0 CA-C-N 117.177 0.488 . . . . 0.0 111.053 177.094 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 267' ' ' ALA . . . . . 0.64 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -112.97 152.83 28.93 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.433 -0.803 . . . . 0.0 109.316 178.164 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 268' ' ' PHE . . . . . 0.76 ' HB3' HD13 ' A' ' 334' ' ' ILE . 7.9 p90 -164.84 172.36 13.02 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-O 121.189 0.518 . . . . 0.0 112.156 -175.952 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 74.4 p -127.84 149.89 50.08 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 114.758 -1.11 . . . . 0.0 108.789 173.131 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 270' ' ' ILE . . . . . 0.641 HG12 HG12 ' A' ' 332' ' ' ILE . 61.1 mt -118.6 136.94 54.18 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.674 0 CA-C-O 120.66 0.267 . . . . 0.0 110.478 -179.194 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -60.41 123.1 16.28 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.936 -0.575 . . . . 0.0 111.766 -176.581 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 100.43 -22.48 39.74 Favored Glycine 0 N--CA 1.451 -0.311 0 CA-C-N 115.915 -0.584 . . . . 0.0 112.223 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 273' ' ' VAL . . . . . 0.577 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 41.8 t -95.03 109.96 23.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 120.803 0.335 . . . . 0.0 110.294 177.818 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 69.6 m-80 -129.48 160.39 33.32 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 179.204 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 35.7 p -85.22 -171.68 3.75 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 111.966 0.358 . . . . 0.0 111.966 -176.359 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 276' ' ' VAL . . . . . 0.472 HG22 ' O ' ' A' ' 321' ' ' ASN . 29.6 m -145.98 173.24 3.36 Favored 'Isoleucine or valine' 0 C--O 1.232 0.176 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.098 178.79 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 29.8 m-70 -118.82 127.13 53.24 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.328 -0.396 . . . . 0.0 109.988 171.629 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 83.6 mt-30 -79.32 -23.42 43.5 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 173.891 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 279' ' ' ILE . . . . . 0.565 ' H ' HD12 ' A' ' 279' ' ' ILE . 2.5 mp -63.27 -51.1 75.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.362 179.349 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 70.9 p -100.04 -15.09 18.36 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.022 -0.536 . . . . 0.0 111.799 -176.057 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 34.5 mmtp 65.25 30.13 11.4 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 123.037 0.535 . . . . 0.0 111.429 -177.186 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 67.0 m-20 -105.83 151.55 24.36 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.072 176.084 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.437 ' HA ' HG12 ' A' ' 276' ' ' VAL . 72.6 p -96.21 92.3 6.32 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.3 0.571 . . . . 0.0 110.412 176.569 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 284' ' ' THR . . . . . 0.415 ' C ' ' H ' ' A' ' 286' ' ' GLN . 47.5 p -141.48 -112.14 0.13 Allowed 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.884 -179.082 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 63.65 -8.62 0.32 Allowed Glycine 0 CA--C 1.522 0.491 0 N-CA-C 114.529 0.572 . . . . 0.0 114.529 174.543 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 286' ' ' GLN . . . . . 0.571 ' HB3' ' HD2' ' A' ' 287' ' ' PRO . 2.0 mp0 67.45 167.72 0.12 Allowed Pre-proline 0 CA--C 1.537 0.453 0 C-N-CA 123.416 0.687 . . . . 0.0 111.045 -177.885 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 287' ' ' PRO . . . . . 0.571 ' HD2' ' HB3' ' A' ' 286' ' ' GLN . 81.3 Cg_exo -47.72 133.66 21.94 Favored 'Trans proline' 0 C--N 1.353 0.8 0 C-N-CA 122.821 2.347 . . . . 0.0 113.77 -172.658 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 71.2 tp60 -69.23 136.61 52.23 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.711 -178.982 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 48.8 t -94.89 134.13 33.34 Favored 'Isoleucine or valine' 0 C--O 1.236 0.376 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.543 179.586 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 290' ' ' PHE . . . . . 0.64 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 33.4 m-85 -116.81 168.74 9.95 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.443 -176.817 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 42.5 mmm-85 -131.08 125.46 33.23 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 173.819 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 292' ' ' VAL . . . . . 0.42 HG11 HG23 ' A' ' 295' ' ' VAL . 47.3 t -65.16 134.78 29.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.701 -177.243 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 293' ' ' LEU . . . . . 0.85 HD21 ' HB2' ' A' ' 303' ' ' SER . 2.5 mm? -96.19 -38.72 10.02 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.101 179.397 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 294' ' ' ALA . . . . . 0.514 ' HA ' HG22 ' A' ' 264' ' ' VAL . . . -159.69 142.11 13.58 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 121.088 -0.245 . . . . 0.0 111.452 -178.382 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 295' ' ' VAL . . . . . 0.437 HG22 HG22 ' A' ' 300' ' ' VAL . 77.8 t -136.16 112.11 12.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.288 -0.415 . . . . 0.0 109.938 175.436 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 37.4 t -150.03 120.42 7.37 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.337 -179.367 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 58.19 51.11 60.39 Favored Glycine 0 C--N 1.33 0.195 0 C-N-CA 121.086 -0.578 . . . . 0.0 112.386 -179.24 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 298' ' ' THR . . . . . 0.505 ' O ' HG22 ' A' ' 257' ' ' VAL . 73.6 p 48.54 27.85 1.57 Allowed 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 123.536 0.734 . . . . 0.0 112.112 -176.526 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 299' ' ' THR . . . . . 0.57 HG22 ' HB ' ' A' ' 254' ' ' THR . 65.3 m -119.66 115.26 23.58 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 176.706 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 300' ' ' VAL . . . . . 0.483 ' HA ' ' O ' ' A' ' 294' ' ' ALA . 59.7 t -113.79 130.93 67.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.587 -171.69 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 57.0 m -80.62 116.19 20.52 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 172.266 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 302' ' ' ILE . . . . . 0.6 HD12 ' O ' ' A' ' 302' ' ' ILE . 2.5 pp -111.36 140.79 29.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-O 122.264 1.03 . . . . 0.0 113.715 -171.463 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 303' ' ' SER . . . . . 0.85 ' HB2' HD21 ' A' ' 293' ' ' LEU . 49.4 m -165.02 170.98 5.8 Favored Pre-proline 0 C--N 1.325 -0.493 0 N-CA-C 105.829 -1.915 . . . . 0.0 105.829 -178.913 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 304' ' ' PRO . . . . . 0.643 ' HA ' ' HB3' ' A' ' 303' ' ' SER . 5.1 Cg_exo -74.98 -135.57 0.14 OUTLIER 'Cis proline' 0 C--N 1.351 0.664 0 CA-C-N 121.49 1.568 . . . . 0.0 113.578 0.646 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 305' ' ' LYS . . . . . 0.735 ' HA ' ' CD2' ' A' ' 236' ' ' HIS . 0.0 OUTLIER -90.68 144.41 25.77 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.47 -0.786 . . . . 0.0 112.088 -173.303 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 306' ' ' ILE . . . . . 0.635 ' H ' ' CG ' ' A' ' 236' ' ' HIS . 47.3 mm -116.0 86.93 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 114.824 -1.08 . . . . 0.0 108.611 175.121 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 307' ' ' LEU . . . . . 0.524 HD13 ' CD1' ' A' ' 319' ' ' TYR . 58.7 mt -102.29 101.04 17.28 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.196 -173.599 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 308' ' ' PRO . . . . . 0.703 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 32.3 Cg_exo -65.56 134.07 36.87 Favored 'Trans proline' 0 C--N 1.343 0.253 0 C-N-CA 123.14 2.56 . . . . 0.0 113.76 -173.678 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 309' ' ' VAL . . . . . 0.561 HG23 ' O ' ' A' ' 322' ' ' VAL . 60.4 t -80.59 -28.56 11.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 169.291 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 -79.38 36.03 0.29 Allowed 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 115.279 -0.873 . . . . 0.0 111.186 176.511 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 22.6 p30 -83.7 -175.34 5.77 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.971 0.415 . . . . 0.0 111.137 -176.678 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 85.6 m -123.38 -28.58 3.93 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.407 177.792 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 57.5 m-20 -74.45 132.93 42.36 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.074 -178.94 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 43.8 t -62.7 -33.05 57.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.982 179.078 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -70.37 -20.45 62.96 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.749 179.752 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 316' ' ' SER . . . . . 0.532 ' HA ' ' CZ ' ' A' ' 319' ' ' TYR . 50.4 m -88.25 -7.02 57.44 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 111.936 0.347 . . . . 0.0 111.936 -176.897 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 317' ' ' ARG . . . . . 0.598 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 38.6 mmt180 -63.67 -51.38 66.36 Favored Pre-proline 0 CA--C 1.539 0.528 0 N-CA-C 112.598 0.592 . . . . 0.0 112.598 -179.005 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 318' ' ' PRO . . . . . 0.598 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 26.8 Cg_exo -68.78 -39.55 8.46 Favored 'Trans proline' 0 C--N 1.356 0.964 0 C-N-CA 121.9 1.733 . . . . 0.0 114.441 -172.055 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 319' ' ' TYR . . . . . 0.532 ' CZ ' ' HA ' ' A' ' 316' ' ' SER . 1.8 p90 -88.47 -6.77 57.43 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 113.004 0.742 . . . . 0.0 113.004 -171.598 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -52.99 135.51 36.72 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 111.634 0.235 . . . . 0.0 111.634 -178.799 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 321' ' ' ASN . . . . . 0.472 ' O ' HG22 ' A' ' 276' ' ' VAL . 14.4 p-10 -132.05 -11.25 3.34 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 116.639 -0.255 . . . . 0.0 111.444 -178.187 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 322' ' ' VAL . . . . . 0.561 ' O ' HG23 ' A' ' 309' ' ' VAL . 33.6 m -131.96 166.52 28.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 N-CA-C 110.488 -0.19 . . . . 0.0 110.488 178.855 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -51.84 -66.35 0.4 Allowed 'General case' 0 N--CA 1.465 0.293 0 CA-C-O 121.252 0.548 . . . . 0.0 111.266 178.372 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 324' ' ' ALA . . . . . 0.703 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -167.24 -179.29 4.46 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.584 -177.09 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 325' ' ' LYS . . . . . 0.434 ' HA ' ' HD3' ' A' ' 326' ' ' PRO . 21.5 pttp -109.65 112.34 58.65 Favored Pre-proline 0 N--CA 1.447 -0.624 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 170.342 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 326' ' ' PRO . . . . . 0.434 ' HD3' ' HA ' ' A' ' 325' ' ' LYS . 25.4 Cg_exo -66.49 168.87 15.32 Favored 'Trans proline' 0 C--O 1.234 0.287 0 C-N-CA 122.704 2.269 . . . . 0.0 112.044 -175.954 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -58.48 146.29 35.82 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 116.009 -0.541 . . . . 0.0 109.787 176.531 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 328' ' ' GLU . . . . . 0.414 ' HG3' ' H ' ' A' ' 330' ' ' ALA . 16.0 pt-20 48.01 -145.13 0.34 Allowed 'General case' 0 N--CA 1.474 0.759 0 O-C-N 124.09 0.869 . . . . 0.0 110.995 -173.47 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 329' ' ' SER . . . . . 0.663 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 49.2 m -104.66 -19.38 13.98 Favored 'General case' 0 C--N 1.322 -0.602 0 C-N-CA 120.608 -0.437 . . . . 0.0 110.52 -179.448 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 330' ' ' ALA . . . . . 0.414 ' H ' ' HG3' ' A' ' 328' ' ' GLU . . . 73.79 -167.54 0.11 Allowed 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 113.427 0.899 . . . . 0.0 113.427 171.371 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 331' ' ' ALA . . . . . 0.427 ' HA ' ' O ' ' A' ' 228' ' ' LEU . . . -87.26 144.0 27.01 Favored 'General case' 0 C--O 1.232 0.15 0 CA-C-N 115.153 -0.93 . . . . 0.0 111.611 -175.018 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 332' ' ' ILE . . . . . 0.641 HG12 HG12 ' A' ' 270' ' ' ILE . 50.1 mt -120.7 145.33 27.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.74 -178.861 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.755 HG23 ' HB3' ' A' ' 226' ' ' GLU . 61.3 m -130.98 106.07 8.16 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 110.121 -0.326 . . . . 0.0 110.121 178.396 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 334' ' ' ILE . . . . . 0.76 HD13 ' HB3' ' A' ' 268' ' ' PHE . 49.0 mm -78.85 138.12 20.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.022 -0.536 . . . . 0.0 112.191 -174.109 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 335' ' ' LEU . . . . . 0.441 HD23 ' HA ' ' A' ' 268' ' ' PHE . 1.8 pt? -157.55 135.94 11.18 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.289 -0.869 . . . . 0.0 109.327 173.712 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 50.2 p30 -85.21 2.69 42.67 Favored 'General case' 0 C--N 1.325 -0.499 0 C-N-CA 120.841 -0.344 . . . . 0.0 111.283 -178.958 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 337' ' ' LYS . . . . . 0.481 ' C ' ' HD3' ' A' ' 337' ' ' LYS . 9.8 tmtt? . . . . . 0 C--O 1.245 0.862 0 CA-C-O 118.056 -0.973 . . . . 0.0 108.381 177.673 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.791 0 N-CA-C 112.226 -0.35 . . . . 0.0 112.226 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 44.4 m -98.23 168.05 10.48 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.505 0.153 . . . . 0.0 110.983 -178.549 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 47.0 m 66.56 -74.93 0.06 Allowed 'General case' 0 N--CA 1.466 0.348 0 O-C-N 123.912 0.757 . . . . 0.0 111.77 177.916 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 47.6 mt-10 62.5 61.84 1.19 Allowed 'General case' 0 CA--C 1.531 0.25 0 C-N-CA 122.591 0.356 . . . . 0.0 110.659 179.723 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 49.6 m 72.19 -98.34 0.03 OUTLIER 'General case' 0 C--O 1.231 0.083 0 CA-C-N 115.39 -0.823 . . . . 0.0 111.333 -178.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 228' ' ' LEU . . . . . 0.431 HD13 ' HB1' ' A' ' 259' ' ' ALA . 81.9 mt -102.35 142.8 32.98 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.292 -178.182 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 229' ' ' THR . . . . . 0.42 ' OG1' ' HB2' ' A' ' 258' ' ' SER . 35.4 p -120.63 171.37 8.62 Favored 'General case' 0 C--N 1.325 -0.467 0 C-N-CA 119.866 -0.733 . . . . 0.0 110.589 177.372 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 230' ' ' VAL . . . . . 0.518 ' HA ' ' H ' ' A' ' 258' ' ' SER . 72.4 t -146.69 130.62 10.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 120.916 0.389 . . . . 0.0 110.376 -179.597 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 231' ' ' SER . . . . . 0.508 ' O ' ' HB ' ' A' ' 255' ' ' ILE . 37.4 m -96.02 164.32 12.75 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.821 177.481 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 101.41 142.02 12.38 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.2 -1.0 . . . . 0.0 111.961 -179.283 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 233' ' ' GLN . . . . . 0.425 ' HA ' ' HD2' ' A' ' 234' ' ' PRO . 64.0 mt-30 -100.02 107.81 48.76 Favored Pre-proline 0 C--N 1.322 -0.606 0 O-C-N 123.073 -0.075 . . . . 0.0 111.03 -176.461 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 234' ' ' PRO . . . . . 0.57 ' HB2' HG13 ' A' ' 306' ' ' ILE . 29.0 Cg_endo -61.56 127.62 22.29 Favored 'Trans proline' 0 C--N 1.348 0.511 0 C-N-CA 122.173 1.916 . . . . 0.0 110.718 176.174 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 235' ' ' GLU . . . . . 0.585 ' OE1' ' HE2' ' A' ' 237' ' ' LYS . 0.3 OUTLIER -116.79 -178.34 3.41 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 113.418 0.896 . . . . 0.0 113.418 -170.995 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 55.4 t60 -167.5 135.61 2.47 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 114.632 -1.167 . . . . 0.0 110.915 -173.803 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 237' ' ' LYS . . . . . 0.585 ' HE2' ' OE1' ' A' ' 235' ' ' GLU . 0.0 OUTLIER -168.14 130.81 1.5 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 114.979 -1.009 . . . . 0.0 111.762 173.072 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 238' ' ' VAL . . . . . . . . . . . . . 46.2 t -97.08 112.11 28.41 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-N 115.117 -0.947 . . . . 0.0 108.981 174.125 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 239' ' ' GLU . . . . . 0.851 ' HG3' ' HB ' ' A' ' 248' ' ' VAL . 10.9 pt-20 -115.31 125.84 53.75 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 121.283 0.563 . . . . 0.0 111.414 -175.901 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 240' ' ' ALA . . . . . 0.593 ' O ' ' HA ' ' A' ' 247' ' ' PRO . . . -66.04 -35.68 81.2 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.461 -0.79 . . . . 0.0 111.289 -176.484 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 241' ' ' LYS . . . . . 0.54 ' O ' ' HD3' ' A' ' 241' ' ' LYS . 0.0 OUTLIER -147.98 146.1 28.81 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.117 0.484 . . . . 0.0 111.925 179.711 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 242' ' ' ASP . . . . . 0.54 ' HB3' HG21 ' A' ' 248' ' ' VAL . 12.5 p-10 -98.3 -158.24 0.66 Allowed 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.194 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 56.2 p -69.95 -14.88 62.92 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.412 -0.358 . . . . 0.0 111.62 178.167 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 49.5 t30 -99.21 -13.49 19.7 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.017 0.437 . . . . 0.0 110.352 178.223 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 89.35 23.39 34.41 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.691 -0.766 . . . . 0.0 113.157 175.298 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 246' ' ' MET . . . . . 0.431 ' O ' ' HA ' ' A' ' 241' ' ' LYS . 26.6 mmt -112.61 154.12 44.79 Favored Pre-proline 0 C--N 1.325 -0.475 0 CA-C-N 116.948 0.374 . . . . 0.0 110.487 178.58 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 247' ' ' PRO . . . . . 0.593 ' HA ' ' O ' ' A' ' 240' ' ' ALA . 31.6 Cg_exo -57.09 140.55 92.99 Favored 'Trans proline' 0 C--N 1.348 0.519 0 C-N-CA 122.7 2.267 . . . . 0.0 112.053 178.132 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.851 ' HB ' ' HG3' ' A' ' 239' ' ' GLU . 41.8 t -125.81 126.43 70.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.856 0.36 . . . . 0.0 111.026 -178.248 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 31.1 t70 -89.14 143.92 26.49 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 175.1 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 250' ' ' ASN . . . . . . . . . . . . . 74.6 m-80 -41.13 124.13 2.18 Favored 'General case' 0 N--CA 1.469 0.498 0 O-C-N 124.007 0.817 . . . . 0.0 112.215 -177.052 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 251' ' ' ARG . . . . . 0.648 ' HG3' ' H ' ' A' ' 252' ' ' GLN . 16.6 tpp180 -77.36 -178.6 5.25 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 109.522 -0.548 . . . . 0.0 109.522 -177.991 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 252' ' ' GLN . . . . . 0.648 ' H ' ' HG3' ' A' ' 251' ' ' ARG . 42.8 mm-40 -100.2 157.11 16.82 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 178.347 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -85.41 138.5 16.5 Favored Glycine 0 N--CA 1.447 -0.579 0 C-N-CA 120.327 -0.94 . . . . 0.0 112.338 -179.144 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 66.9 p -121.89 116.51 24.53 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 176.728 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.638 HD13 ' H ' ' A' ' 255' ' ' ILE . 0.2 OUTLIER -129.69 158.95 42.18 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 121.038 0.447 . . . . 0.0 111.399 -176.493 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 18.5 m -96.82 116.64 29.5 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 177.681 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.554 HG21 HD12 ' A' ' 262' ' ' LEU . 32.8 m -88.82 143.3 11.46 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.739 0 C-N-CA 119.709 -0.796 . . . . 0.0 112.349 -170.98 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 258' ' ' SER . . . . . 0.518 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 25.1 m -92.79 9.44 35.17 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 114.341 -1.3 . . . . 0.0 109.33 172.809 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 259' ' ' ALA . . . . . 0.431 ' HB1' HD13 ' A' ' 228' ' ' LEU . . . -83.05 179.9 7.62 Favored 'General case' 0 N--CA 1.452 -0.338 0 CA-C-N 115.417 -0.811 . . . . 0.0 108.942 179.659 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 22.9 t -140.98 127.34 19.82 Favored 'General case' 0 C--N 1.32 -0.693 0 C-N-CA 120.23 -0.588 . . . . 0.0 111.348 -177.484 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 78.8 50.9 5.72 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.891 -0.671 . . . . 0.0 113.276 176.207 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 262' ' ' LEU . . . . . 0.554 HD12 HG21 ' A' ' 257' ' ' VAL . 64.8 mt -95.1 160.13 14.7 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 117.147 0.474 . . . . 0.0 110.559 178.08 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 66.0 mt-30 -142.9 165.23 27.93 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 -179.311 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 27.1 t -79.58 124.14 37.38 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 C-N-CA 120.409 -0.516 . . . . 0.0 109.701 175.531 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 265' ' ' GLY . . . . . 0.609 ' H ' ' HB ' ' A' ' 292' ' ' VAL . . . 116.0 14.39 7.88 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.316 -0.945 . . . . 0.0 112.835 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 57.1 m-20 -90.51 165.83 13.56 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.186 0.517 . . . . 0.0 111.044 176.346 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 267' ' ' ALA . . . . . 0.585 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -130.59 143.92 51.07 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 175.094 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 268' ' ' PHE . . . . . 0.504 ' HB3' HD13 ' A' ' 334' ' ' ILE . 7.8 p90 -159.5 168.71 25.53 Favored 'General case' 0 C--N 1.323 -0.582 0 C-N-CA 118.958 -1.097 . . . . 0.0 112.644 -173.547 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 269' ' ' THR . . . . . 0.554 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 43.7 p -116.72 144.08 44.87 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.063 -0.971 . . . . 0.0 109.704 175.683 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 270' ' ' ILE . . . . . 0.994 HG12 HG13 ' A' ' 332' ' ' ILE . 57.2 mt -112.0 127.91 68.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 116.563 -0.29 . . . . 0.0 110.469 -178.73 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -65.15 120.04 11.96 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.077 0.465 . . . . 0.0 111.227 -179.478 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 102.7 -23.93 32.37 Favored Glycine 0 N--CA 1.452 -0.28 0 CA-C-N 115.887 -0.597 . . . . 0.0 112.315 179.278 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 39.0 t -96.34 102.48 13.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 174.574 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 274' ' ' ASN . . . . . 0.739 ' HB2' ' HB2' ' A' ' 323' ' ' ASP . 4.2 m120 -91.99 169.63 10.5 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.275 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 8.3 t -109.74 162.48 14.42 Favored 'General case' 0 CA--C 1.507 -0.704 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 178.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 276' ' ' VAL . . . . . 0.405 HG22 ' C ' ' A' ' 321' ' ' ASN . 13.0 m -122.52 178.84 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.067 0 CA-C-N 115.24 -0.891 . . . . 0.0 109.372 166.402 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 22.3 m80 -100.5 133.21 45.27 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 178.922 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 278' ' ' GLN . . . . . 0.421 ' HG3' ' ND2' ' A' ' 321' ' ' ASN . 2.3 mp0 -72.29 -10.22 59.5 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.79 0.329 . . . . 0.0 111.401 -178.924 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 279' ' ' ILE . . . . . 0.493 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.0 mp -102.43 -57.48 4.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 120.729 0.3 . . . . 0.0 110.946 -178.312 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 60.9 p -101.13 -6.21 24.63 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 112.663 0.616 . . . . 0.0 112.663 -174.226 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 13.9 mmmm 57.54 29.35 16.98 Favored 'General case' 0 N--CA 1.47 0.574 0 N-CA-C 111.591 0.219 . . . . 0.0 111.591 -178.499 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -77.78 139.61 39.36 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.265 -176.489 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 70.3 p -108.2 118.8 37.71 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.862 -0.608 . . . . 0.0 109.806 179.486 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 72.0 p -115.2 -14.36 11.73 Favored 'General case' 0 C--N 1.315 -0.894 0 C-N-CA 120.67 -0.412 . . . . 0.0 111.798 -172.408 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 88.17 5.13 76.94 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.521 -0.847 . . . . 0.0 112.388 179.709 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 286' ' ' GLN . . . . . 0.461 ' HA ' ' HD3' ' A' ' 287' ' ' PRO . 71.0 mt-30 -92.18 138.53 24.37 Favored Pre-proline 0 C--N 1.327 -0.382 0 N-CA-C 110.23 -0.285 . . . . 0.0 110.23 178.677 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 287' ' ' PRO . . . . . 0.635 ' HA ' ' HA ' ' A' ' 274' ' ' ASN . 21.7 Cg_exo -65.58 152.7 81.01 Favored 'Trans proline' 0 C--O 1.233 0.236 0 C-N-CA 122.615 2.21 . . . . 0.0 112.445 -179.031 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 3.9 tp-100 -81.54 150.72 28.08 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.542 177.626 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 62.1 t -94.86 125.04 47.58 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.401 0 CA-C-N 116.096 -0.502 . . . . 0.0 109.657 176.441 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 290' ' ' PHE . . . . . 0.759 ' HD1' ' HD2' ' A' ' 304' ' ' PRO . 69.9 m-85 -106.58 168.42 9.18 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.085 -174.072 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 27.1 tpt180 -132.8 120.89 22.18 Favored 'General case' 0 N--CA 1.448 -0.539 0 CA-C-O 121.222 0.534 . . . . 0.0 109.573 179.842 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 292' ' ' VAL . . . . . 0.609 ' HB ' ' H ' ' A' ' 265' ' ' GLY . 57.7 t -65.99 132.42 31.56 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.919 -177.037 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 293' ' ' LEU . . . . . 0.77 HD11 ' HB2' ' A' ' 303' ' ' SER . 88.5 mt -101.42 -44.55 5.59 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.475 178.332 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 294' ' ' ALA . . . . . 0.452 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -150.05 139.11 21.1 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.592 0.234 . . . . 0.0 111.334 -175.123 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 62.0 t -134.11 117.75 26.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.126 176.958 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 60.6 m -157.01 120.14 4.09 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.471 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 62.32 40.37 98.94 Favored Glycine 0 C--N 1.331 0.305 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.003 -177.539 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 82.1 p 53.35 20.78 2.07 Favored 'General case' 0 N--CA 1.469 0.519 0 C-N-CA 123.939 0.896 . . . . 0.0 112.27 -174.721 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 60.3 m -103.18 107.7 18.62 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 174.493 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 300' ' ' VAL . . . . . 0.452 ' HA ' ' O ' ' A' ' 294' ' ' ALA . 47.2 t -104.09 128.03 57.81 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.36 -173.247 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 42.0 m -90.48 117.36 29.12 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 172.559 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 302' ' ' ILE . . . . . . . . . . . . . 29.1 pt -110.74 140.74 28.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 N-CA-C 112.83 0.678 . . . . 0.0 112.83 -169.269 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 303' ' ' SER . . . . . 0.77 ' HB2' HD11 ' A' ' 293' ' ' LEU . 48.2 t -130.35 151.39 78.45 Favored Pre-proline 0 C--N 1.323 -0.55 0 CA-C-N 114.104 -1.407 . . . . 0.0 107.207 172.715 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 304' ' ' PRO . . . . . 0.759 ' HD2' ' HD1' ' A' ' 290' ' ' PHE . 34.3 Cg_exo -63.04 179.14 8.44 Favored 'Cis proline' 0 N--CA 1.473 0.308 0 CA-C-N 120.163 1.094 . . . . 0.0 113.09 0.781 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 305' ' ' LYS . . . . . 0.671 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -87.86 148.74 24.5 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.24 177.643 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 306' ' ' ILE . . . . . 0.57 HG13 ' HB2' ' A' ' 234' ' ' PRO . 43.7 mm -65.75 98.66 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.663 -175.075 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 307' ' ' LEU . . . . . . . . . . . . . 72.6 mt -119.25 95.57 49.39 Favored Pre-proline 0 C--N 1.325 -0.498 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 -179.506 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 308' ' ' PRO . . . . . 0.723 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 6.2 Cg_exo -77.67 169.6 20.58 Favored 'Trans proline' 0 N--CA 1.463 -0.32 0 C-N-CA 123.121 2.547 . . . . 0.0 112.635 -176.8 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 309' ' ' VAL . . . . . 0.534 HG22 ' HB1' ' A' ' 320' ' ' ALA . 39.2 t -93.56 -30.72 4.41 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-O 121.251 0.548 . . . . 0.0 109.683 177.343 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 42.5 mp0 -86.64 35.68 0.68 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.133 -0.94 . . . . 0.0 112.254 -173.833 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 79.1 m-20 -74.33 158.81 33.33 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.301 0.572 . . . . 0.0 111.845 -178.644 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 28.9 m -90.44 -36.63 14.46 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.129 -0.941 . . . . 0.0 110.22 179.266 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 313' ' ' ASP . . . . . 0.455 ' HB2' ' HB3' ' A' ' 316' ' ' SER . 1.6 m-20 -67.98 133.31 48.86 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.32 179.406 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 39.3 t -60.45 -52.23 63.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.172 -177.768 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -68.46 -17.82 64.28 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.852 -178.234 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 316' ' ' SER . . . . . 0.455 ' HB3' ' HB2' ' A' ' 313' ' ' ASP . 39.1 t -84.07 -11.02 57.36 Favored 'General case' 0 C--N 1.323 -0.546 0 C-N-CA 120.973 -0.291 . . . . 0.0 111.357 -178.376 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 317' ' ' ARG . . . . . 0.534 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 81.0 mtm180 -73.65 -49.2 6.46 Favored Pre-proline 0 CA--C 1.536 0.432 0 N-CA-C 112.506 0.558 . . . . 0.0 112.506 -179.082 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 318' ' ' PRO . . . . . 0.534 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 42.3 Cg_exo -61.07 -25.87 81.99 Favored 'Trans proline' 0 C--N 1.361 1.197 0 C-N-CA 122.17 1.914 . . . . 0.0 113.218 -176.973 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 46.6 m-85 -91.41 27.67 1.9 Allowed 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.473 -0.331 . . . . 0.0 111.313 -177.946 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 320' ' ' ALA . . . . . 0.534 ' HB1' HG22 ' A' ' 309' ' ' VAL . . . -77.72 127.55 32.61 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.073 179.297 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 321' ' ' ASN . . . . . 0.421 ' ND2' ' HG3' ' A' ' 278' ' ' GLN . 34.9 m120 -130.47 -9.24 4.13 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 111.859 0.318 . . . . 0.0 111.859 179.216 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 322' ' ' VAL . . . . . 0.508 ' O ' ' HA ' ' A' ' 308' ' ' PRO . 33.1 m -138.5 156.93 30.18 Favored 'Isoleucine or valine' 0 C--O 1.233 0.215 0 CA-C-O 120.944 0.402 . . . . 0.0 111.094 177.691 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 323' ' ' ASP . . . . . 0.739 ' HB2' ' HB2' ' A' ' 274' ' ' ASN . 2.1 m-20 -86.66 86.84 7.35 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.417 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 324' ' ' ALA . . . . . 0.723 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . 77.06 151.0 0.12 Allowed 'General case' 0 N--CA 1.473 0.685 0 CA-C-N 114.66 -1.154 . . . . 0.0 113.791 171.502 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 325' ' ' LYS . . . . . 0.436 ' HA ' ' HD3' ' A' ' 326' ' ' PRO . 55.5 pttt -98.71 105.95 33.88 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 114.435 -1.257 . . . . 0.0 109.287 168.525 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 326' ' ' PRO . . . . . 0.436 ' HD3' ' HA ' ' A' ' 325' ' ' LYS . 5.8 Cg_exo -85.99 169.27 8.99 Favored 'Trans proline' 0 C--O 1.235 0.367 0 C-N-CA 123.483 2.788 . . . . 0.0 113.195 -171.837 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -59.52 127.51 32.41 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.626 177.633 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 24.5 pt-20 44.65 -158.07 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.66 0 O-C-N 124.402 1.064 . . . . 0.0 112.034 -176.363 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 329' ' ' SER . . . . . 0.424 ' O ' ' HB3' ' A' ' 330' ' ' ALA . 54.6 m -102.9 -31.16 10.39 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 112.204 0.446 . . . . 0.0 112.204 -173.643 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 330' ' ' ALA . . . . . 0.424 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 71.95 -152.25 0.08 Allowed 'General case' 0 N--CA 1.471 0.59 0 CA-C-O 121.037 0.446 . . . . 0.0 111.534 178.359 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -85.47 116.34 23.73 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.248 -178.85 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 332' ' ' ILE . . . . . 0.994 HG13 HG12 ' A' ' 270' ' ' ILE . 1.7 mp -101.84 140.85 19.38 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 115.826 -0.624 . . . . 0.0 109.537 176.293 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 73.4 m -110.11 103.32 12.03 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 110.206 -0.294 . . . . 0.0 110.206 -176.624 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 334' ' ' ILE . . . . . 0.504 HD13 ' HB3' ' A' ' 268' ' ' PHE . 34.6 mm -85.89 125.87 40.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 N-CA-C 112.588 0.588 . . . . 0.0 112.588 -174.155 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 335' ' ' LEU . . . . . 0.485 ' N ' HD13 ' A' ' 335' ' ' LEU . 0.0 OUTLIER -139.41 172.43 12.82 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.3 -0.864 . . . . 0.0 109.804 171.259 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 50.9 t30 -136.87 59.11 1.7 Allowed 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 178.552 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 337' ' ' LYS . . . . . 0.431 ' H ' HD23 ' A' ' 335' ' ' LEU . 62.3 tttp . . . . . 0 C--O 1.244 0.768 0 CA-C-O 118.173 -0.918 . . . . 0.0 110.457 -176.106 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.727 0 N-CA-C 112.162 -0.375 . . . . 0.0 112.162 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 61.9 p -91.29 106.55 18.59 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.78 0.324 . . . . 0.0 110.772 179.351 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 71.7 p -110.9 161.4 15.87 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 120.976 0.417 . . . . 0.0 110.701 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 10.3 pm0 -102.98 32.27 3.8 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.9 -176.9 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 68.3 m 54.49 71.5 0.52 Allowed 'General case' 0 C--O 1.235 0.299 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.854 -178.239 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 228' ' ' LEU . . . . . 0.738 ' O ' ' HA ' ' A' ' 331' ' ' ALA . 5.3 mp -67.91 119.32 12.39 Favored 'General case' 0 N--CA 1.433 -1.316 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.821 179.463 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 229' ' ' THR . . . . . 0.456 ' OG1' ' HB3' ' A' ' 258' ' ' SER . 22.3 p -128.08 178.68 6.04 Favored 'General case' 0 C--N 1.324 -0.533 0 C-N-CA 120.513 -0.475 . . . . 0.0 111.07 178.644 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 230' ' ' VAL . . . . . 0.965 HG23 HD11 ' A' ' 332' ' ' ILE . 98.3 t -144.82 130.72 14.64 Favored 'Isoleucine or valine' 0 C--O 1.235 0.303 0 CA-C-O 120.578 0.228 . . . . 0.0 111.078 -177.218 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 38.9 t -101.1 112.28 24.71 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.538 -0.755 . . . . 0.0 109.484 172.438 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 232' ' ' GLY . . . . . 0.854 ' H ' ' HG3' ' A' ' 328' ' ' GLU . . . 141.69 125.51 2.08 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.788 -0.72 . . . . 0.0 111.71 -176.319 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 233' ' ' GLN . . . . . 0.824 ' HG2' ' H ' ' A' ' 328' ' ' GLU . 73.4 mt-30 -83.5 123.33 76.75 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-N 116.49 0.145 . . . . 0.0 111.063 -177.12 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -92.71 126.26 0.71 Allowed 'Trans proline' 0 N--CA 1.451 -0.986 0 C-N-CA 122.643 2.228 . . . . 0.0 111.978 177.517 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 235' ' ' GLU . . . . . 0.418 ' HG2' ' HE3' ' A' ' 237' ' ' LYS . 0.7 OUTLIER -157.0 158.36 36.4 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.865 0.364 . . . . 0.0 110.748 177.569 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 236' ' ' HIS . . . . . 0.444 ' HD2' ' OD2' ' A' ' 249' ' ' ASP . 25.5 m80 -136.07 146.19 46.78 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.322 0.582 . . . . 0.0 111.85 177.93 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 237' ' ' LYS . . . . . 0.636 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -132.15 129.1 39.38 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 107.664 -1.235 . . . . 0.0 107.664 178.149 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 238' ' ' VAL . . . . . . . . . . . . . 44.5 t -103.78 110.93 31.57 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 C-N-CA 119.908 -0.717 . . . . 0.0 110.819 -179.578 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 239' ' ' GLU . . . . . 0.817 ' HB2' ' HB ' ' A' ' 248' ' ' VAL . 0.6 OUTLIER -65.59 129.54 40.13 Favored 'General case' 0 N--CA 1.448 -0.565 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 174.272 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 240' ' ' ALA . . . . . . . . . . . . . . . -58.68 -38.6 78.56 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-O 120.77 0.319 . . . . 0.0 110.732 -178.563 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 241' ' ' LYS . . . . . 0.883 ' HB2' ' HA2' ' A' ' 245' ' ' GLY . 0.4 OUTLIER -154.96 149.66 26.53 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.665 177.481 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 242' ' ' ASP . . . . . 0.681 ' HB3' HG21 ' A' ' 248' ' ' VAL . 53.7 p-10 -106.12 -156.29 0.57 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.816 -0.629 . . . . 0.0 109.619 175.466 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 41.2 t -60.6 -27.96 68.14 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.885 177.75 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 5.7 m120 -93.97 -13.74 26.7 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.57 -0.286 . . . . 0.0 111.576 178.592 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 245' ' ' GLY . . . . . 0.883 ' HA2' ' HB2' ' A' ' 241' ' ' LYS . . . 87.48 28.23 25.18 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.663 -0.779 . . . . 0.0 113.342 179.089 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 246' ' ' MET . . . . . . . . . . . . . 21.5 ptp -113.68 156.29 43.79 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 117.035 0.418 . . . . 0.0 110.861 178.028 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 247' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_exo -63.13 121.78 9.76 Favored 'Trans proline' 0 C--N 1.349 0.601 0 C-N-CA 122.834 2.356 . . . . 0.0 112.144 -179.827 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.817 ' HB ' ' HB2' ' A' ' 239' ' ' GLU . 41.0 t -101.76 126.5 55.69 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.474 -176.68 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 249' ' ' ASP . . . . . 0.444 ' OD2' ' HD2' ' A' ' 236' ' ' HIS . 60.1 t0 -106.28 140.04 39.85 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 170.417 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 250' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -78.7 48.38 0.8 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.928 0.394 . . . . 0.0 111.646 -177.007 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 251' ' ' ARG . . . . . 0.494 ' HG3' ' H ' ' A' ' 252' ' ' GLN . 18.2 tpt85 61.39 -135.04 0.6 Allowed 'General case' 0 N--CA 1.452 -0.373 0 CA-C-N 115.569 -0.741 . . . . 0.0 109.258 176.246 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 252' ' ' GLN . . . . . 0.494 ' H ' ' HG3' ' A' ' 251' ' ' ARG . 44.3 mm-40 -112.21 169.99 8.48 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 121.91 -0.493 . . . . 0.0 110.219 177.231 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 253' ' ' GLY . . . . . 0.464 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -87.65 121.07 5.74 Favored Glycine 0 N--CA 1.447 -0.616 0 C-N-CA 120.4 -0.905 . . . . 0.0 111.88 179.269 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 52.3 p -105.1 117.35 33.79 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 178.33 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 2.1 pp -131.46 165.13 32.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -175.121 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 32.6 m -102.53 113.95 27.74 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 179.2 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.622 HG12 HG22 ' A' ' 230' ' ' VAL . 30.6 m -90.61 143.89 10.27 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.718 0 CA-C-O 121.48 0.657 . . . . 0.0 112.589 -174.907 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 258' ' ' SER . . . . . 0.456 ' HB3' ' OG1' ' A' ' 229' ' ' THR . 25.8 t -92.06 7.31 42.91 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 113.911 -1.495 . . . . 0.0 108.146 167.514 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 259' ' ' ALA . . . . . 0.443 ' H ' ' HB ' ' A' ' 257' ' ' VAL . . . -86.48 172.57 10.24 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 115.128 -0.942 . . . . 0.0 109.713 -178.989 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 50.2 m -145.65 148.63 33.28 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.833 0.349 . . . . 0.0 111.043 -179.328 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 81.14 15.9 75.81 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.992 -0.623 . . . . 0.0 113.184 178.236 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 262' ' ' LEU . . . . . 0.406 HD12 HG21 ' A' ' 257' ' ' VAL . 70.7 mt -76.31 145.73 39.36 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.971 0.385 . . . . 0.0 110.351 179.234 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 85.0 mt-30 -140.8 164.75 29.39 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.092 -0.504 . . . . 0.0 109.911 -179.126 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 45.7 t -76.24 122.87 31.34 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.257 177.489 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 113.43 -3.07 25.02 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.44 -0.886 . . . . 0.0 112.795 179.085 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 266' ' ' ASP . . . . . 0.479 ' HA ' ' OD1' ' A' ' 336' ' ' ASN . 58.6 m-20 -81.58 151.76 27.53 Favored 'General case' 0 CA--C 1.513 -0.475 0 CA-C-O 120.82 0.343 . . . . 0.0 110.296 177.074 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 267' ' ' ALA . . . . . 0.606 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -114.47 149.35 36.46 Favored 'General case' 0 N--CA 1.443 -0.806 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 173.792 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 268' ' ' PHE . . . . . 0.687 ' HB3' HD13 ' A' ' 334' ' ' ILE . 4.1 p90 -163.95 172.36 14.03 Favored 'General case' 0 C--N 1.318 -0.782 0 C-N-CA 119.632 -0.827 . . . . 0.0 111.699 -177.13 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 74.9 p -118.12 127.36 53.7 Favored 'General case' 0 N--CA 1.443 -0.801 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.337 177.688 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 270' ' ' ILE . . . . . 0.533 HG23 ' O ' ' A' ' 329' ' ' SER . 25.8 mm -95.23 129.92 44.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 CA-C-N 115.3 -0.863 . . . . 0.0 110.454 -178.27 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 271' ' ' ALA . . . . . 0.596 ' HB3' ' HB3' ' A' ' 330' ' ' ALA . . . -66.47 129.57 40.3 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 121.007 0.432 . . . . 0.0 111.133 -178.518 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 92.98 -22.87 31.94 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 121.032 -0.604 . . . . 0.0 112.065 -178.036 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 273' ' ' VAL . . . . . 0.498 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 45.8 t -101.14 117.79 46.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 121.195 0.521 . . . . 0.0 110.294 176.491 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -130.67 142.19 50.43 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.701 -178.556 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 4.8 t -81.87 172.45 13.3 Favored 'General case' 0 CA--C 1.512 -0.518 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 -177.047 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 29.9 m -130.5 178.43 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.835 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.713 173.29 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 86.2 m-70 -109.68 86.39 2.29 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 173.715 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 278' ' ' GLN . . . . . 0.424 ' HB3' ' O ' ' A' ' 320' ' ' ALA . 23.7 pt20 -72.35 -14.85 61.83 Favored 'General case' 0 N--CA 1.464 0.261 0 N-CA-C 111.964 0.357 . . . . 0.0 111.964 -173.45 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 279' ' ' ILE . . . . . 0.538 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.4 mp -73.15 -52.11 23.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 121.126 0.489 . . . . 0.0 110.038 -179.538 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 42.9 p -97.95 -3.14 38.98 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.505 -178.799 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 64.85 54.57 1.31 Allowed 'General case' 0 N--CA 1.466 0.35 0 CA-C-O 121.547 0.689 . . . . 0.0 110.012 178.466 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 58.9 m-20 -115.43 130.78 57.0 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.033 0.444 . . . . 0.0 110.817 177.824 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 65.7 p -106.32 117.8 34.97 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.246 176.906 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 70.4 p -123.44 -23.19 4.87 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.809 -171.602 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 75.19 31.73 56.97 Favored Glycine 0 N--CA 1.453 -0.186 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.817 177.95 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 47.1 mm-40 -89.77 131.27 40.11 Favored Pre-proline 0 C--N 1.327 -0.375 0 N-CA-C 110.359 -0.237 . . . . 0.0 110.359 179.7 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 287' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_exo -50.21 128.22 22.05 Favored 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 122.78 2.32 . . . . 0.0 112.546 -178.951 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 16.0 tt0 -74.56 148.03 41.22 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.668 -176.381 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 52.7 t -94.48 117.97 39.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.459 -0.791 . . . . 0.0 109.639 175.384 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 290' ' ' PHE . . . . . 0.744 ' HA ' ' HD3' ' A' ' 304' ' ' PRO . 5.0 m-85 -99.06 170.13 8.92 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.014 0.435 . . . . 0.0 111.604 -175.799 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 21.1 tpp180 -140.03 123.74 17.33 Favored 'General case' 0 N--CA 1.446 -0.668 0 CA-C-N 115.533 -0.758 . . . . 0.0 109.358 177.011 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 44.0 t -81.42 136.62 22.74 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.591 -176.211 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 293' ' ' LEU . . . . . 0.465 HD22 ' N ' ' A' ' 293' ' ' LEU . 2.2 mm? -108.0 -30.51 8.41 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.164 178.299 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 294' ' ' ALA . . . . . . . . . . . . . . . -156.12 136.92 13.43 Favored 'General case' 0 C--N 1.331 -0.201 0 C-N-CA 121.06 -0.256 . . . . 0.0 111.603 -177.508 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 60.6 t -132.49 117.86 33.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.034 -0.53 . . . . 0.0 109.641 175.063 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 34.9 t -157.52 119.52 3.75 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.519 -177.404 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 58.85 44.24 96.11 Favored Glycine 0 C--N 1.333 0.383 0 C-N-CA 121.163 -0.541 . . . . 0.0 112.318 -179.029 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 51.4 p 50.51 24.06 1.49 Allowed 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 123.703 0.801 . . . . 0.0 112.583 -175.343 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 41.0 m -111.12 112.78 24.82 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 108.388 -0.968 . . . . 0.0 108.388 173.61 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 39.0 t -111.91 132.29 60.93 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.731 -169.216 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 88.0 m -91.92 109.35 20.69 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 172.554 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 302' ' ' ILE . . . . . 0.464 HG12 ' O ' ' A' ' 253' ' ' GLY . 29.1 pt -111.33 150.87 13.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 N-CA-C 113.099 0.777 . . . . 0.0 113.099 -170.958 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 303' ' ' SER . . . . . 0.543 ' HB2' ' HA ' ' A' ' 304' ' ' PRO . 85.8 p -135.06 166.39 29.51 Favored Pre-proline 0 C--N 1.322 -0.597 0 N-CA-C 106.52 -1.659 . . . . 0.0 106.52 170.063 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 304' ' ' PRO . . . . . 0.744 ' HD3' ' HA ' ' A' ' 290' ' ' PHE . 14.7 Cg_exo -70.45 -167.58 4.14 Favored 'Cis proline' 0 CA--C 1.53 0.28 0 CA-C-N 120.75 1.303 . . . . 0.0 113.282 0.57 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 305' ' ' LYS . . . . . 0.607 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -81.31 162.84 23.3 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.736 179.803 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 306' ' ' ILE . . . . . 0.445 HG23 HG21 ' A' ' 322' ' ' VAL . 43.5 mm -111.55 84.3 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-O 120.831 0.348 . . . . 0.0 110.525 -177.373 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 307' ' ' LEU . . . . . . . . . . . . . 85.0 mt -108.35 103.49 50.91 Favored Pre-proline 0 C--N 1.327 -0.371 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.434 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 308' ' ' PRO . . . . . 0.807 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 13.5 Cg_exo -76.94 156.09 34.36 Favored 'Trans proline' 0 N--CA 1.465 -0.184 0 C-N-CA 122.611 2.207 . . . . 0.0 113.848 -171.472 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 46.7 t -78.89 -16.22 13.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 N-CA-C 108.18 -1.044 . . . . 0.0 108.18 168.069 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 67.0 mm-40 -83.61 7.05 18.54 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 114.805 -1.088 . . . . 0.0 110.885 175.033 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -68.74 128.24 35.94 Favored 'General case' 0 C--O 1.233 0.232 0 CA-C-O 120.764 0.316 . . . . 0.0 110.167 -176.59 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 61.7 m -75.89 -34.3 59.97 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.562 -175.916 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 313' ' ' ASP . . . . . 0.598 ' O ' ' HG3' ' A' ' 317' ' ' ARG . 28.0 t70 -68.85 114.32 7.06 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.976 0.417 . . . . 0.0 110.491 177.584 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 314' ' ' VAL . . . . . 0.667 ' HA ' ' HD3' ' A' ' 317' ' ' ARG . 41.5 t -63.86 -20.23 26.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.634 -0.712 . . . . 0.0 111.652 -175.836 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -75.09 -34.13 61.71 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.545 0.212 . . . . 0.0 111.468 178.97 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 316' ' ' SER . . . . . 0.419 ' HA ' ' CE1' ' A' ' 319' ' ' TYR . 34.2 t -89.4 -6.78 56.27 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.619 0.247 . . . . 0.0 111.359 -177.158 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 317' ' ' ARG . . . . . 0.667 ' HD3' ' HA ' ' A' ' 314' ' ' VAL . 56.8 mtp85 -69.68 -47.03 25.35 Favored Pre-proline 0 CA--C 1.541 0.609 0 N-CA-C 113.302 0.852 . . . . 0.0 113.302 -179.495 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 318' ' ' PRO . . . . . 0.454 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 87.2 Cg_exo -52.2 -38.49 71.67 Favored 'Trans proline' 0 C--N 1.361 1.224 0 C-N-CA 122.444 2.096 . . . . 0.0 113.796 -174.536 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 319' ' ' TYR . . . . . 0.419 ' CE1' ' HA ' ' A' ' 316' ' ' SER . 1.5 p90 -109.17 39.13 2.12 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 112.077 0.399 . . . . 0.0 112.077 -178.35 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 320' ' ' ALA . . . . . 0.424 ' O ' ' HB3' ' A' ' 278' ' ' GLN . . . -71.99 135.66 46.48 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.896 174.219 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 16.0 p-10 -119.01 -2.41 10.8 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 120.82 -0.352 . . . . 0.0 111.485 -176.703 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 322' ' ' VAL . . . . . 0.445 HG21 HG23 ' A' ' 306' ' ' ILE . 30.8 m -135.11 163.17 36.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 N-CA-C 110.34 -0.244 . . . . 0.0 110.34 175.112 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 56.7 m-20 -72.37 -38.18 68.6 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 111.657 0.243 . . . . 0.0 111.657 -178.677 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 324' ' ' ALA . . . . . 0.807 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -159.84 162.29 34.67 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.694 -171.867 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 325' ' ' LYS . . . . . 0.465 ' HA ' ' HD3' ' A' ' 326' ' ' PRO . 54.2 pttt -105.21 106.41 55.64 Favored Pre-proline 0 C--N 1.324 -0.501 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.279 169.424 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 326' ' ' PRO . . . . . 0.465 ' HD3' ' HA ' ' A' ' 325' ' ' LYS . 5.9 Cg_exo -86.49 166.83 9.03 Favored 'Trans proline' 0 C--O 1.233 0.256 0 C-N-CA 122.946 2.431 . . . . 0.0 113.566 -170.4 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 327' ' ' ALA . . . . . 0.513 ' HA ' ' HG2' ' A' ' 233' ' ' GLN . . . -81.69 122.02 27.11 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.235 -0.893 . . . . 0.0 109.444 172.032 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 328' ' ' GLU . . . . . 0.854 ' HG3' ' H ' ' A' ' 232' ' ' GLY . 53.6 mp0 60.48 175.42 0.1 Allowed 'General case' 0 N--CA 1.465 0.323 0 O-C-N 123.608 0.568 . . . . 0.0 111.084 -173.666 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 329' ' ' SER . . . . . 0.738 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 37.7 m -106.47 -15.46 14.8 Favored 'General case' 0 C--N 1.324 -0.532 0 C-N-CA 120.33 -0.548 . . . . 0.0 111.085 -177.347 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 330' ' ' ALA . . . . . 0.596 ' HB3' ' HB3' ' A' ' 271' ' ' ALA . . . 62.95 -152.8 0.34 Allowed 'General case' 0 N--CA 1.465 0.312 0 CA-C-O 120.852 0.358 . . . . 0.0 111.857 175.094 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 331' ' ' ALA . . . . . 0.738 ' HA ' ' O ' ' A' ' 228' ' ' LEU . . . -68.5 139.78 55.67 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.56 -0.745 . . . . 0.0 112.203 -175.153 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 332' ' ' ILE . . . . . 0.965 HD11 HG23 ' A' ' 230' ' ' VAL . 2.2 mp -111.7 144.59 19.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.279 179.379 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 84.8 m -121.07 105.71 10.88 Favored 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 175.522 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 334' ' ' ILE . . . . . 0.687 HD13 ' HB3' ' A' ' 268' ' ' PHE . 39.8 mm -79.95 127.73 39.07 Favored 'Isoleucine or valine' 0 C--O 1.235 0.3 0 N-CA-C 112.432 0.53 . . . . 0.0 112.432 -175.831 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 335' ' ' LEU . . . . . 0.562 HD23 ' HA ' ' A' ' 268' ' ' PHE . 1.8 pt? -148.91 132.46 16.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.58 174.036 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 336' ' ' ASN . . . . . 0.479 ' OD1' ' HA ' ' A' ' 266' ' ' ASP . 72.3 m-80 -109.0 77.38 1.06 Allowed 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.386 176.454 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 22.0 pttp . . . . . 0 C--O 1.243 0.743 0 O-C-N 124.589 1.18 . . . . 0.0 112.179 -179.078 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.784 0 N-CA-C 112.221 -0.351 . . . . 0.0 112.221 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 41.5 m -72.23 127.42 32.5 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.67 0.271 . . . . 0.0 110.451 179.789 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 225' ' ' THR . . . . . 0.436 ' O ' ' HA ' ' A' ' 333' ' ' THR . 48.3 p -110.98 -118.58 0.29 Allowed 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.617 -179.653 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 226' ' ' GLU . . . . . 0.517 ' HA ' ' O ' ' A' ' 332' ' ' ILE . 42.1 mt-10 -122.35 31.61 6.08 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.182 0.515 . . . . 0.0 110.004 178.399 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 39.6 t -75.62 -30.92 59.68 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.565 -177.659 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 228' ' ' LEU . . . . . 0.602 ' HB3' ' CB ' ' A' ' 259' ' ' ALA . 80.9 mt -82.26 138.95 34.48 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.884 178.61 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 229' ' ' THR . . . . . 0.412 HG22 ' HA ' ' A' ' 331' ' ' ALA . 70.8 p -126.63 178.25 6.02 Favored 'General case' 0 C--N 1.325 -0.478 0 C-N-CA 120.104 -0.638 . . . . 0.0 110.752 -179.043 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 230' ' ' VAL . . . . . 0.56 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 84.1 t -143.42 150.21 17.64 Favored 'Isoleucine or valine' 0 C--O 1.239 0.544 0 N-CA-C 110.356 -0.239 . . . . 0.0 110.356 -178.574 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 33.1 t -126.08 129.1 48.44 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.298 178.597 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 110.2 109.95 3.23 Favored Glycine 0 C--O 1.228 -0.277 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.852 178.258 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 233' ' ' GLN . . . . . 0.58 ' HG3' ' O ' ' A' ' 326' ' ' PRO . 14.3 mm-40 -111.43 101.41 50.66 Favored Pre-proline 0 C--N 1.324 -0.505 0 O-C-N 122.807 -0.231 . . . . 0.0 111.135 178.989 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 234' ' ' PRO . . . . . 0.478 ' O ' ' HE2' ' A' ' 325' ' ' LYS . 7.0 Cg_exo -70.25 126.13 12.64 Favored 'Trans proline' 0 N--CA 1.459 -0.513 0 C-N-CA 122.247 1.964 . . . . 0.0 110.855 176.202 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 235' ' ' GLU . . . . . 0.408 ' HA ' ' CD ' ' A' ' 325' ' ' LYS . 13.0 pt-20 -97.41 124.42 41.59 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 121.634 0.731 . . . . 0.0 111.502 -177.639 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 236' ' ' HIS . . . . . 0.701 ' HB3' HD22 ' A' ' 250' ' ' ASN . 26.1 m80 -122.2 147.51 46.09 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.49 179.745 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 237' ' ' LYS . . . . . 0.455 ' H ' ' HD2' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -145.63 158.5 43.84 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 115.137 -0.938 . . . . 0.0 109.214 -178.912 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 238' ' ' VAL . . . . . 0.44 HG22 ' OD1' ' A' ' 250' ' ' ASN . 30.0 t -100.73 111.67 31.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 C-N-CA 120.306 -0.558 . . . . 0.0 111.097 -174.686 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 239' ' ' GLU . . . . . 0.868 ' HG2' HG21 ' A' ' 248' ' ' VAL . 8.3 pm0 -105.42 167.71 9.57 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.969 -0.56 . . . . 0.0 109.989 174.335 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 240' ' ' ALA . . . . . . . . . . . . . . . -73.52 -60.49 2.22 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.872 0.368 . . . . 0.0 111.02 -178.229 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 241' ' ' LYS . . . . . 0.693 ' HB2' ' HA2' ' A' ' 245' ' ' GLY . 0.0 OUTLIER -121.98 147.37 46.14 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.435 179.842 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -100.78 -160.0 0.77 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.128 -0.487 . . . . 0.0 109.801 -179.122 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 37.8 t -59.54 -30.15 68.41 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.267 178.546 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 5.8 m120 -98.72 1.49 46.16 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 111.836 0.31 . . . . 0.0 111.836 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 245' ' ' GLY . . . . . 0.693 ' HA2' ' HB2' ' A' ' 241' ' ' LYS . . . 69.0 38.99 85.27 Favored Glycine 0 N--CA 1.455 -0.092 0 C-N-CA 120.621 -0.799 . . . . 0.0 113.006 177.054 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 246' ' ' MET . . . . . . . . . . . . . 24.9 mmt -112.19 157.58 39.46 Favored Pre-proline 0 C--N 1.323 -0.565 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 178.021 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 247' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_exo -59.09 119.69 7.09 Favored 'Trans proline' 0 C--N 1.348 0.535 0 C-N-CA 121.803 1.669 . . . . 0.0 110.516 177.065 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.868 HG21 ' HG2' ' A' ' 239' ' ' GLU . 59.7 t -79.66 113.41 18.99 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 N-CA-C 112.562 0.579 . . . . 0.0 112.562 -170.805 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -108.8 115.87 30.91 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 114.64 -1.164 . . . . 0.0 108.08 169.357 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 250' ' ' ASN . . . . . 0.701 HD22 ' HB3' ' A' ' 236' ' ' HIS . 6.7 m120 -57.38 138.28 55.13 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 112.547 0.573 . . . . 0.0 112.547 -170.115 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -80.19 -177.04 5.89 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.188 -0.914 . . . . 0.0 111.123 173.44 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 44.5 mm-40 -94.88 172.23 8.28 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.561 -176.786 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -106.23 138.52 14.4 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.186 -1.007 . . . . 0.0 112.942 -176.166 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 254' ' ' THR . . . . . 0.493 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 75.6 p -111.0 117.98 34.81 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 176.595 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.695 HD13 ' H ' ' A' ' 255' ' ' ILE . 0.2 OUTLIER -123.09 163.91 21.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 120.733 0.302 . . . . 0.0 111.269 -176.058 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 85.7 m -100.93 112.61 25.09 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 172.327 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.611 HG21 HD12 ' A' ' 262' ' ' LEU . 35.2 m -90.01 144.97 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.783 0 CA-C-O 121.663 0.744 . . . . 0.0 112.663 -169.764 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 258' ' ' SER . . . . . 0.511 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 23.2 m -90.31 7.7 37.1 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 114.376 -1.284 . . . . 0.0 108.637 171.283 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 259' ' ' ALA . . . . . 0.602 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -96.19 159.53 14.91 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-N 114.89 -1.05 . . . . 0.0 110.162 -177.509 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 260' ' ' SER . . . . . 0.476 ' H ' HD22 ' A' ' 228' ' ' LEU . 45.8 p -127.97 154.14 45.93 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.362 -179.129 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 73.83 20.25 79.75 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 121.113 -0.565 . . . . 0.0 113.377 178.117 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 262' ' ' LEU . . . . . 0.611 HD12 HG21 ' A' ' 257' ' ' VAL . 77.5 mt -78.32 142.82 37.47 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 117.11 0.455 . . . . 0.0 110.606 179.347 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 81.6 mt-30 -141.3 174.5 10.48 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.975 -0.557 . . . . 0.0 109.866 -179.894 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 44.1 t -78.72 132.95 31.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 N-CA-C 110.098 -0.334 . . . . 0.0 110.098 176.332 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 102.89 4.4 48.42 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.378 -0.915 . . . . 0.0 112.61 179.071 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -86.05 153.8 21.87 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.871 0.367 . . . . 0.0 110.185 177.181 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 267' ' ' ALA . . . . . 0.546 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -125.08 142.48 51.46 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 177.985 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 268' ' ' PHE . . . . . 0.461 ' HB3' HD13 ' A' ' 334' ' ' ILE . 3.8 p90 -160.13 169.85 22.46 Favored 'General case' 0 C--N 1.323 -0.562 0 C-N-CA 120.097 -0.641 . . . . 0.0 111.572 -176.929 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 269' ' ' THR . . . . . 0.427 ' HB ' ' HB3' ' A' ' 287' ' ' PRO . 67.4 p -119.08 145.88 45.55 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.526 175.872 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 270' ' ' ILE . . . . . 0.729 HG12 HD12 ' A' ' 332' ' ' ILE . 57.9 mt -111.51 131.97 61.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.696 -177.265 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -66.08 120.13 12.62 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.372 -178.531 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 272' ' ' GLY . . . . . 0.533 ' HA3' ' HG3' ' A' ' 326' ' ' PRO . . . 101.3 -22.32 39.52 Favored Glycine 0 C--O 1.23 -0.1 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.102 -179.673 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 52.2 t -103.16 102.68 13.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 176.968 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 7.1 m120 -119.62 156.66 29.98 Favored 'General case' 0 C--N 1.323 -0.583 0 C-N-CA 120.1 -0.64 . . . . 0.0 111.235 -173.9 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 59.0 p -75.8 166.81 22.98 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.301 0.572 . . . . 0.0 112.41 -173.973 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 34.3 m -123.96 153.66 30.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 114.909 -1.041 . . . . 0.0 109.851 174.261 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 2.9 m-70 -110.35 91.51 3.68 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 179.345 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 16.9 pt20 -79.44 -11.36 59.91 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.92 -0.582 . . . . 0.0 112.435 -172.077 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 279' ' ' ILE . . . . . 0.484 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.2 mp -76.42 -55.92 9.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-O 120.935 0.398 . . . . 0.0 109.962 179.003 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 45.6 p -96.12 -1.4 48.65 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.618 -178.865 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 281' ' ' LYS . . . . . 0.418 ' HB3' ' NZ ' ' A' ' 281' ' ' LYS . 3.8 mmmp? 52.74 52.37 14.13 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.06 -177.793 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 52.1 t0 -111.64 146.92 36.59 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.04 -177.464 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 36.4 p -107.1 110.6 22.75 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.938 0.399 . . . . 0.0 110.391 176.576 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 78.3 p -119.05 -26.45 5.96 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.702 -176.755 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 71.35 31.92 65.56 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.925 176.711 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 95.2 mm-40 -82.72 133.18 49.66 Favored Pre-proline 0 C--N 1.325 -0.49 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 179.232 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 287' ' ' PRO . . . . . 0.427 ' HB3' ' HB ' ' A' ' 269' ' ' THR . 82.2 Cg_exo -49.47 133.26 31.18 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.902 2.402 . . . . 0.0 112.851 -177.453 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 3.3 tm0? -83.65 134.89 34.76 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 -176.804 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 40.3 t -98.39 125.23 51.77 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-O 120.986 0.422 . . . . 0.0 110.776 -176.0 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 290' ' ' PHE . . . . . 0.546 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 6.0 m-85 -98.29 165.65 11.77 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.138 0.495 . . . . 0.0 112.181 -173.782 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 40.2 mmt-85 -129.46 120.35 25.31 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 114.889 -1.051 . . . . 0.0 108.763 174.014 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 58.3 t -77.98 135.78 25.5 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.913 0 CA-C-N 116.306 -0.406 . . . . 0.0 112.059 -174.844 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 293' ' ' LEU . . . . . . . . . . . . . 72.2 mt -102.49 -37.81 7.83 Favored 'General case' 0 N--CA 1.462 0.152 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.674 177.382 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 294' ' ' ALA . . . . . . . . . . . . . . . -151.51 139.91 20.48 Favored 'General case' 0 C--N 1.328 -0.339 0 C-N-CA 120.999 -0.28 . . . . 0.0 111.55 -175.139 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 58.0 t -137.71 110.21 7.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.987 -0.551 . . . . 0.0 109.614 175.339 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 58.9 p -139.85 104.06 4.79 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.163 -175.672 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 61.16 56.79 21.8 Favored Glycine 0 C--N 1.331 0.266 0 C-N-CA 120.979 -0.629 . . . . 0.0 112.406 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 66.4 p 53.21 17.24 0.95 Allowed 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 123.98 0.912 . . . . 0.0 112.519 -176.12 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 89.5 m -105.54 108.1 19.44 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 174.115 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 300' ' ' VAL . . . . . 0.493 ' O ' ' HA ' ' A' ' 254' ' ' THR . 45.2 t -111.05 135.04 51.43 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.35 -172.898 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 60.4 m -99.85 114.02 26.93 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 173.129 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 302' ' ' ILE . . . . . . . . . . . . . 27.2 pt -110.66 137.11 44.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 N-CA-C 113.094 0.775 . . . . 0.0 113.094 -168.801 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 303' ' ' SER . . . . . . . . . . . . . 50.3 m -119.49 157.59 51.28 Favored Pre-proline 0 C--N 1.32 -0.716 0 CA-C-N 114.029 -1.441 . . . . 0.0 107.641 170.569 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 304' ' ' PRO . . . . . 0.525 ' HD3' ' HA ' ' A' ' 290' ' ' PHE . 2.7 Cg_exo -75.23 -172.48 10.88 Favored 'Cis proline' 0 N--CA 1.462 -0.335 0 C-N-CA 124.368 -1.097 . . . . 0.0 111.716 -0.077 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 305' ' ' LYS . . . . . 0.449 ' HD2' ' O ' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -80.89 145.35 31.36 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.271 0.558 . . . . 0.0 111.804 179.462 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 306' ' ' ILE . . . . . 0.731 HG23 HG21 ' A' ' 322' ' ' VAL . 2.9 mp -99.86 100.5 10.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.41 -172.783 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 307' ' ' LEU . . . . . 0.468 ' HA ' ' HD3' ' A' ' 308' ' ' PRO . 82.9 mt -117.14 119.74 34.49 Favored Pre-proline 0 CA--C 1.516 -0.363 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.413 179.766 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 308' ' ' PRO . . . . . 0.792 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 7.1 Cg_exo -80.19 139.66 13.45 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 123.183 2.589 . . . . 0.0 113.406 -176.065 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 309' ' ' VAL . . . . . 0.474 HG22 ' HB3' ' A' ' 320' ' ' ALA . 45.3 t -82.04 -30.16 9.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 167.284 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 310' ' ' GLU . . . . . 0.405 ' HB2' ' HB2' ' A' ' 324' ' ' ALA . 89.1 mt-10 -84.73 25.79 0.88 Allowed 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 115.006 -0.997 . . . . 0.0 111.169 177.553 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.711 ' HB2' ' HB2' ' A' ' 308' ' ' PRO . 24.5 t-20 -87.74 141.63 28.45 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 179.638 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 38.0 m -60.3 -28.53 68.18 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.198 -178.019 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 32.7 t70 -79.14 113.46 17.28 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.001 0.429 . . . . 0.0 110.195 177.107 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 314' ' ' VAL . . . . . 0.477 ' O ' ' HD3' ' A' ' 318' ' ' PRO . 40.4 t -69.04 -19.86 24.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.965 -177.543 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -75.03 -17.89 60.42 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 112.218 0.451 . . . . 0.0 112.218 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 59.4 m -96.7 -22.03 17.24 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 112.43 0.53 . . . . 0.0 112.43 -176.394 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 317' ' ' ARG . . . . . 0.415 ' N ' ' CD ' ' A' ' 318' ' ' PRO . 15.9 ptp180 -74.5 -31.65 1.25 Allowed Pre-proline 0 CA--C 1.549 0.92 0 N-CA-C 114.901 1.445 . . . . 0.0 114.901 -175.584 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 318' ' ' PRO . . . . . 0.477 ' HD3' ' O ' ' A' ' 314' ' ' VAL . 33.6 Cg_exo -62.09 -39.09 51.92 Favored 'Trans proline' 0 C--N 1.365 1.412 0 CA-C-N 121.486 1.566 . . . . 0.0 112.68 -178.009 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 54.7 m-85 -112.02 41.33 1.98 Allowed 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.543 -179.731 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 320' ' ' ALA . . . . . 0.474 ' HB3' HG22 ' A' ' 309' ' ' VAL . . . -78.63 159.87 27.84 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.967 179.699 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 47.2 t30 -111.83 -25.29 9.53 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.76 -178.744 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 322' ' ' VAL . . . . . 0.731 HG21 HG23 ' A' ' 306' ' ' ILE . 33.0 m -134.46 172.68 15.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.766 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 53.1 m-20 -67.15 -49.69 63.89 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.557 176.917 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 324' ' ' ALA . . . . . 0.792 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -173.08 179.64 2.2 Favored 'General case' 0 CA--C 1.518 -0.281 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.555 -177.166 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 325' ' ' LYS . . . . . 0.478 ' HE2' ' O ' ' A' ' 234' ' ' PRO . 8.7 ptpp? -126.83 106.96 22.61 Favored Pre-proline 0 C--N 1.326 -0.414 0 CA-C-N 115.324 -0.853 . . . . 0.0 109.805 171.525 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 326' ' ' PRO . . . . . 0.58 ' O ' ' HG3' ' A' ' 233' ' ' GLN . 67.1 Cg_endo -78.92 167.14 22.52 Favored 'Trans proline' 0 C--N 1.34 0.124 0 C-N-CA 122.535 2.156 . . . . 0.0 112.49 -175.878 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -63.03 129.63 41.18 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.122 176.81 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 47.1 mt-10 73.01 142.72 0.06 Allowed 'General case' 0 N--CA 1.469 0.493 0 O-C-N 123.977 0.798 . . . . 0.0 110.561 -174.564 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 329' ' ' SER . . . . . 0.56 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 17.6 m -77.31 -22.29 52.17 Favored 'General case' 0 C--N 1.323 -0.55 0 C-N-CA 120.865 -0.334 . . . . 0.0 111.383 -174.652 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 330' ' ' ALA . . . . . 0.445 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 74.15 -162.6 0.08 Allowed 'General case' 0 N--CA 1.47 0.546 0 O-C-N 123.716 0.635 . . . . 0.0 112.686 174.251 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 331' ' ' ALA . . . . . 0.412 ' HA ' HG22 ' A' ' 229' ' ' THR . . . -81.34 145.93 30.61 Favored 'General case' 0 CA--C 1.517 -0.29 0 CA-C-N 115.318 -0.856 . . . . 0.0 110.943 -178.042 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 332' ' ' ILE . . . . . 0.729 HD12 HG12 ' A' ' 270' ' ' ILE . 29.4 mm -115.47 144.55 22.81 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.245 -177.304 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.436 ' HA ' ' O ' ' A' ' 225' ' ' THR . 75.5 m -109.05 96.65 6.46 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 110.094 -0.336 . . . . 0.0 110.094 179.118 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 334' ' ' ILE . . . . . 0.461 HD13 ' HB3' ' A' ' 268' ' ' PHE . 45.7 mm -81.71 130.61 35.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 N-CA-C 111.912 0.338 . . . . 0.0 111.912 -175.329 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 335' ' ' LEU . . . . . 0.431 HD23 ' N ' ' A' ' 335' ' ' LEU . 1.9 pt? -156.58 132.43 9.62 Favored 'General case' 0 C--O 1.234 0.244 0 CA-C-O 121.388 0.613 . . . . 0.0 110.982 174.671 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 76.1 m-20 -94.69 52.63 1.53 Allowed 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.451 176.713 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 55.8 tptt . . . . . 0 C--O 1.246 0.897 0 CA-C-O 118.124 -0.941 . . . . 0.0 109.525 -179.807 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.861 0 N-CA-C 112.154 -0.378 . . . . 0.0 112.154 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 44.1 m -78.55 112.84 16.03 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.592 0.196 . . . . 0.0 111.186 -178.407 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 225' ' ' THR . . . . . 0.711 HG22 ' H ' ' A' ' 227' ' ' SER . 78.9 m 67.4 -78.13 0.04 OUTLIER 'General case' 0 N--CA 1.468 0.435 0 O-C-N 123.777 0.673 . . . . 0.0 111.812 176.936 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 54.1 mt-10 56.42 30.51 17.13 Favored 'General case' 0 C--N 1.333 -0.137 0 C-N-CA 122.973 0.509 . . . . 0.0 112.124 -178.384 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 227' ' ' SER . . . . . 0.711 ' H ' HG22 ' A' ' 225' ' ' THR . 48.3 m -96.04 -27.86 14.9 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.629 174.323 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 228' ' ' LEU . . . . . 0.471 ' HB3' ' CB ' ' A' ' 259' ' ' ALA . 90.5 mt -128.12 141.3 51.53 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.289 -0.869 . . . . 0.0 109.09 176.766 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 38.3 p -130.94 -179.2 5.18 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 120.578 -0.449 . . . . 0.0 111.339 -177.005 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 230' ' ' VAL . . . . . 0.586 ' HB ' ' CB ' ' A' ' 329' ' ' SER . 40.7 t -140.0 140.01 36.19 Favored 'Isoleucine or valine' 0 C--O 1.239 0.528 0 CA-C-O 120.557 0.218 . . . . 0.0 110.772 -178.651 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 32.1 m -99.24 138.92 35.65 Favored 'General case' 0 C--O 1.234 0.277 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.29 176.004 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 127.73 166.23 12.03 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.51 -0.853 . . . . 0.0 111.959 179.202 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 81.3 mt-30 -117.12 102.03 52.89 Favored Pre-proline 0 C--N 1.324 -0.539 0 CA-C-N 116.782 0.291 . . . . 0.0 111.073 -179.557 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 234' ' ' PRO . . . . . 0.412 ' HB2' HD12 ' A' ' 306' ' ' ILE . 6.1 Cg_exo -76.35 126.82 9.36 Favored 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 122.716 2.277 . . . . 0.0 111.155 177.015 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -158.55 141.22 14.44 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.175 -178.739 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 49.2 m80 -146.72 138.24 24.39 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.495 -177.266 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 237' ' ' LYS . . . . . 0.542 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 6.2 mptt -121.61 135.79 54.98 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 -179.856 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 238' ' ' VAL . . . . . 0.517 HG22 HD13 ' A' ' 307' ' ' LEU . 42.5 t -73.82 111.03 8.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 C-N-CA 120.541 -0.464 . . . . 0.0 109.85 179.831 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 239' ' ' GLU . . . . . 0.598 ' HG3' ' HB ' ' A' ' 248' ' ' VAL . 9.6 pt-20 -102.59 140.86 36.31 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.329 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 240' ' ' ALA . . . . . 0.501 ' O ' ' HA ' ' A' ' 247' ' ' PRO . . . -75.47 -86.93 0.04 OUTLIER 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.209 -173.963 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 241' ' ' LYS . . . . . 0.491 ' HD2' ' N ' ' A' ' 241' ' ' LYS . 11.7 mptt -107.4 128.95 54.93 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.864 0.364 . . . . 0.0 110.5 -179.392 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 242' ' ' ASP . . . . . 0.439 ' HB3' HG21 ' A' ' 248' ' ' VAL . 2.9 p30 -76.07 -167.38 0.73 Allowed 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.28 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 46.8 t -60.63 -27.88 68.12 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.868 -176.841 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 44.7 t-20 -90.45 -7.82 52.09 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.278 0.561 . . . . 0.0 109.666 179.789 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 245' ' ' GLY . . . . . 0.464 ' HA2' ' HB3' ' A' ' 241' ' ' LYS . . . 87.07 32.17 15.14 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.861 176.488 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 246' ' ' MET . . . . . 0.466 ' O ' ' HA ' ' A' ' 241' ' ' LYS . 64.5 mtt -113.12 148.14 38.83 Favored Pre-proline 0 C--N 1.325 -0.494 0 O-C-N 122.785 -0.244 . . . . 0.0 110.862 -179.473 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 247' ' ' PRO . . . . . 0.501 ' HA ' ' O ' ' A' ' 240' ' ' ALA . 24.5 Cg_exo -60.88 131.47 37.45 Favored 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 122.654 2.236 . . . . 0.0 111.359 176.898 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.598 ' HB ' ' HG3' ' A' ' 239' ' ' GLU . 31.7 t -114.09 129.08 70.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 N-CA-C 112.769 0.655 . . . . 0.0 112.769 -171.393 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -102.14 100.4 10.62 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 106.325 -1.731 . . . . 0.0 106.325 163.448 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 250' ' ' ASN . . . . . 0.761 HD22 ' HG3' ' A' ' 305' ' ' LYS . 0.5 OUTLIER -49.07 152.27 1.14 Allowed 'General case' 0 N--CA 1.469 0.486 0 N-CA-C 113.789 1.033 . . . . 0.0 113.789 -165.503 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 251' ' ' ARG . . . . . 0.571 ' CD ' ' H ' ' A' ' 251' ' ' ARG . 0.3 OUTLIER -68.52 -177.49 0.95 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 114.375 -1.284 . . . . 0.0 112.004 -174.582 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 252' ' ' GLN . . . . . 0.535 ' HB3' ' O ' ' A' ' 302' ' ' ILE . 41.9 mm-40 -98.33 174.64 6.39 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.878 -177.393 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -110.28 147.81 17.43 Favored Glycine 0 N--CA 1.447 -0.581 0 C-N-CA 119.842 -1.171 . . . . 0.0 113.019 -176.612 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 70.1 p -118.93 117.73 29.62 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 176.838 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.658 HD13 ' H ' ' A' ' 255' ' ' ILE . 0.2 OUTLIER -128.66 165.64 27.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-O 120.951 0.405 . . . . 0.0 111.128 -176.253 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 40.5 m -99.61 116.87 32.74 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 178.273 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.473 ' HA ' HG13 ' A' ' 230' ' ' VAL . 34.1 m -90.44 144.39 9.22 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.774 0 CA-C-O 121.47 0.653 . . . . 0.0 112.494 -172.378 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 258' ' ' SER . . . . . 0.487 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 40.3 m -90.61 8.48 33.99 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 114.359 -1.291 . . . . 0.0 108.721 170.355 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 259' ' ' ALA . . . . . 0.471 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -91.4 163.69 14.1 Favored 'General case' 0 N--CA 1.449 -0.518 0 CA-C-N 114.994 -1.003 . . . . 0.0 109.453 -179.012 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 260' ' ' SER . . . . . 0.457 ' H ' HD13 ' A' ' 228' ' ' LEU . 50.6 m -129.8 149.33 51.59 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 120.762 0.315 . . . . 0.0 111.386 -177.888 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 68.73 37.53 84.53 Favored Glycine 0 N--CA 1.451 -0.355 0 CA-C-N 115.786 -0.643 . . . . 0.0 113.534 176.453 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 262' ' ' LEU . . . . . 0.406 HD11 ' HB3' ' A' ' 259' ' ' ALA . 60.4 mt -92.45 150.74 20.6 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 117.364 0.582 . . . . 0.0 109.835 176.794 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 84.7 mt-30 -144.41 170.26 16.36 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.113 -0.494 . . . . 0.0 109.675 -179.619 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 50.3 t -78.25 141.89 14.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.844 -179.457 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 94.13 -2.07 68.28 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.701 -0.761 . . . . 0.0 113.206 177.288 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 44.8 m-20 -81.04 155.46 26.33 Favored 'General case' 0 CA--C 1.515 -0.386 0 CA-C-O 121.251 0.548 . . . . 0.0 111.202 178.129 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 267' ' ' ALA . . . . . 0.713 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -116.16 146.97 41.86 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.222 -0.899 . . . . 0.0 109.13 178.963 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 268' ' ' PHE . . . . . 0.671 ' HB3' HD13 ' A' ' 334' ' ' ILE . 6.6 p90 -164.17 162.06 22.55 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 120.4 -0.52 . . . . 0.0 111.93 -174.935 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 269' ' ' THR . . . . . 0.468 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 71.1 p -115.23 147.74 39.98 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 115.016 -0.993 . . . . 0.0 109.137 173.422 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 270' ' ' ILE . . . . . 0.593 HD11 ' HE2' ' A' ' 268' ' ' PHE . 54.1 mt -123.13 138.07 54.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-O 120.61 0.243 . . . . 0.0 110.516 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -63.58 125.2 23.47 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.872 -175.956 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 103.64 -22.6 35.24 Favored Glycine 0 N--CA 1.449 -0.471 0 CA-C-N 115.73 -0.668 . . . . 0.0 112.207 178.976 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 273' ' ' VAL . . . . . 0.657 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 39.5 t -95.11 102.31 13.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-O 120.946 0.403 . . . . 0.0 110.058 178.204 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 61.7 m-20 -110.52 135.76 50.69 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.231 -179.892 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 32.5 p -77.94 156.23 30.38 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.229 0.538 . . . . 0.0 112.078 -177.428 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 32.9 m -113.48 160.3 13.04 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.65 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.478 174.845 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 35.7 m80 -132.19 79.86 1.88 Allowed 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.903 177.962 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 30.0 tp60 -53.22 -29.55 32.92 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.585 -0.28 . . . . 0.0 111.296 -176.115 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 50.1 mm -63.6 -48.42 86.88 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.352 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.616 178.914 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 75.2 p -97.81 7.14 46.89 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-O 120.762 0.315 . . . . 0.0 111.5 -177.39 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 52.9 tptt 71.59 50.18 0.27 Allowed 'General case' 0 CA--C 1.536 0.408 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.947 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 2.4 p30 29.62 50.41 0.07 Allowed 'General case' 0 N--CA 1.474 0.741 0 N-CA-C 115.801 1.778 . . . . 0.0 115.801 171.471 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 62.1 p -107.1 88.65 2.78 Favored 'General case' 0 C--N 1.322 -0.612 0 C-N-CA 119.744 -0.782 . . . . 0.0 110.335 167.935 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 35.5 p -145.62 -70.36 0.27 Allowed 'General case' 0 C--N 1.319 -0.761 0 CA-C-N 115.499 -0.773 . . . . 0.0 111.339 -177.79 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 89.09 32.3 10.86 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.013 -178.526 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 286' ' ' GLN . . . . . 0.4 ' HA ' ' HD3' ' A' ' 287' ' ' PRO . 12.0 mm100 -100.94 127.8 31.24 Favored Pre-proline 0 C--N 1.326 -0.422 0 O-C-N 122.894 -0.18 . . . . 0.0 110.926 -177.244 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 287' ' ' PRO . . . . . 0.468 ' HB2' ' HB ' ' A' ' 269' ' ' THR . 24.2 Cg_exo -58.17 129.84 34.98 Favored 'Trans proline' 0 C--O 1.236 0.406 0 C-N-CA 122.42 2.08 . . . . 0.0 110.734 173.985 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 40.4 tt0 -72.87 142.06 47.93 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.963 0.411 . . . . 0.0 111.124 -173.773 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 289' ' ' VAL . . . . . 0.431 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 47.7 t -90.6 134.82 28.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 115.465 -0.789 . . . . 0.0 109.931 177.956 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 290' ' ' PHE . . . . . 0.713 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 45.5 m-85 -111.48 163.06 14.44 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.471 -177.449 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 43.2 mmm-85 -125.25 121.22 33.44 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 173.436 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 47.2 t -66.03 132.16 31.64 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-N 115.597 -0.729 . . . . 0.0 111.591 -175.604 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 293' ' ' LEU . . . . . 0.483 HD11 ' HG3' ' A' ' 252' ' ' GLN . 93.9 mt -93.68 -41.64 9.59 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.906 -0.588 . . . . 0.0 111.562 177.381 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 294' ' ' ALA . . . . . 0.412 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -157.26 142.69 17.3 Favored 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 120.896 -0.322 . . . . 0.0 111.316 -176.601 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 61.2 t -133.92 116.54 23.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 109.238 -0.653 . . . . 0.0 109.238 174.466 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 52.5 p -140.73 92.29 2.49 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.061 -175.741 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 66.84 63.73 3.69 Favored Glycine 0 N--CA 1.453 -0.181 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.222 -179.411 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 76.6 p 51.0 23.21 1.4 Allowed 'General case' 0 N--CA 1.47 0.557 0 C-N-CA 123.614 0.766 . . . . 0.0 112.579 -177.651 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 44.2 m -116.59 113.38 22.64 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 175.361 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 300' ' ' VAL . . . . . 0.412 ' HA ' ' O ' ' A' ' 294' ' ' ALA . 45.5 t -113.49 130.5 67.4 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.541 -171.325 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 38.3 m -91.16 116.72 29.04 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 108.072 -1.085 . . . . 0.0 108.072 171.484 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 302' ' ' ILE . . . . . 0.535 ' O ' ' HB3' ' A' ' 252' ' ' GLN . 31.0 pt -110.68 137.3 43.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 N-CA-C 112.812 0.671 . . . . 0.0 112.812 -169.047 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 303' ' ' SER . . . . . 0.426 ' HB3' HD11 ' A' ' 293' ' ' LEU . 81.7 p -137.67 153.52 74.15 Favored Pre-proline 0 C--N 1.325 -0.496 0 CA-C-N 114.645 -1.161 . . . . 0.0 108.547 173.889 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 304' ' ' PRO . . . . . 0.53 ' HD2' ' HD1' ' A' ' 290' ' ' PHE . 5.9 Cg_exo -73.67 -173.07 10.83 Favored 'Cis proline' 0 N--CA 1.463 -0.296 0 C-N-CA 124.005 -1.248 . . . . 0.0 112.01 -0.005 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 305' ' ' LYS . . . . . 0.761 ' HG3' HD22 ' A' ' 250' ' ' ASN . 0.0 OUTLIER -85.75 170.2 12.69 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 120.873 0.368 . . . . 0.0 110.874 -177.841 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 306' ' ' ILE . . . . . 0.444 HG23 HG21 ' A' ' 322' ' ' VAL . 60.3 mt -112.09 93.6 2.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.59 -176.389 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 307' ' ' LEU . . . . . 0.517 HD13 HG22 ' A' ' 238' ' ' VAL . 94.4 mt -108.23 104.97 55.58 Favored Pre-proline 0 C--N 1.326 -0.441 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.691 -179.54 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 308' ' ' PRO . . . . . 0.778 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 6.3 Cg_exo -75.96 138.6 20.97 Favored 'Trans proline' 0 N--CA 1.461 -0.422 0 C-N-CA 122.982 2.455 . . . . 0.0 112.467 -177.324 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 309' ' ' VAL . . . . . 0.471 HG23 ' O ' ' A' ' 322' ' ' VAL . 46.8 t -65.74 -25.59 36.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 121.189 0.518 . . . . 0.0 109.683 174.674 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 310' ' ' GLU . . . . . 0.436 ' HA ' ' OE1' ' A' ' 310' ' ' GLU . 4.8 mm-40 -80.92 33.67 0.33 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.752 -0.658 . . . . 0.0 112.169 177.192 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.417 ' O ' ' HB ' ' A' ' 312' ' ' THR . 21.4 p30 -85.29 -8.08 58.68 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.964 -0.107 . . . . 0.0 111.178 -179.644 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 312' ' ' THR . . . . . 0.417 ' HB ' ' O ' ' A' ' 311' ' ' ASN . 71.1 m 74.91 -46.61 0.6 Allowed 'General case' 0 N--CA 1.471 0.613 0 C-N-CA 123.457 0.703 . . . . 0.0 112.283 178.948 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 42.8 m-20 -57.47 115.46 2.75 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-O 121.211 0.529 . . . . 0.0 111.116 -179.073 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 23.3 t -61.55 -33.6 57.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.449 -176.379 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -75.79 -22.14 56.68 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 111.752 0.278 . . . . 0.0 111.752 179.626 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 65.5 m -87.12 -20.66 26.76 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 111.777 0.288 . . . . 0.0 111.777 -178.857 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 317' ' ' ARG . . . . . 0.505 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 75.0 mtp180 -56.04 -48.9 95.82 Favored Pre-proline 0 CA--C 1.539 0.525 0 N-CA-C 113.034 0.754 . . . . 0.0 113.034 -179.282 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 318' ' ' PRO . . . . . 0.505 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 52.0 Cg_exo -58.57 -16.18 28.81 Favored 'Trans proline' 0 C--N 1.36 1.137 0 C-N-CA 122.213 1.942 . . . . 0.0 113.988 -176.758 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 8.8 m-85 -106.69 1.28 24.93 Favored 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 121.116 -0.234 . . . . 0.0 111.568 -179.657 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -66.08 139.03 58.15 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.811 0.339 . . . . 0.0 111.02 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 14.8 p-10 -124.07 -9.5 7.66 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.379 -179.466 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 322' ' ' VAL . . . . . 0.471 ' O ' HG23 ' A' ' 309' ' ' VAL . 32.3 m -132.92 163.97 36.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 175.537 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 54.6 m-20 -81.05 -22.16 39.5 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 111.885 0.328 . . . . 0.0 111.885 -177.755 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 324' ' ' ALA . . . . . 0.778 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -171.1 154.66 4.14 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.045 -172.573 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 23.8 pttm -101.31 114.4 65.73 Favored Pre-proline 0 C--N 1.325 -0.488 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 169.314 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -72.57 167.64 26.55 Favored 'Trans proline' 0 C--O 1.235 0.346 0 C-N-CA 122.622 2.215 . . . . 0.0 113.306 -172.47 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -66.62 136.8 56.13 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-N 115.804 -0.634 . . . . 0.0 109.885 175.93 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 47.1 -155.27 0.05 Allowed 'General case' 0 N--CA 1.471 0.594 0 O-C-N 124.446 1.091 . . . . 0.0 111.19 -173.7 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 329' ' ' SER . . . . . 0.586 ' CB ' ' HB ' ' A' ' 230' ' ' VAL . 53.1 m -98.66 -38.92 8.93 Favored 'General case' 0 C--N 1.322 -0.609 0 C-N-CA 120.548 -0.461 . . . . 0.0 111.024 -177.052 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 330' ' ' ALA . . . . . 0.453 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 79.39 -164.39 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.923 0 N-CA-C 112.869 0.692 . . . . 0.0 112.869 174.34 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -84.49 149.17 26.12 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 115.507 -0.77 . . . . 0.0 112.429 -172.066 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 332' ' ' ILE . . . . . 0.602 HG23 ' CD2' ' A' ' 268' ' ' PHE . 38.3 mt -111.08 145.78 16.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.663 -0.699 . . . . 0.0 111.16 178.967 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 95.7 m -120.67 97.2 5.44 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 172.693 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 334' ' ' ILE . . . . . 0.671 HD13 ' HB3' ' A' ' 268' ' ' PHE . 40.3 mm -79.18 128.96 38.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 N-CA-C 111.92 0.341 . . . . 0.0 111.92 -175.617 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 335' ' ' LEU . . . . . 0.442 HD23 ' N ' ' A' ' 335' ' ' LEU . 1.5 pt? -152.9 130.74 11.68 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.407 0.622 . . . . 0.0 110.593 174.431 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 23.4 p30 -90.8 5.47 48.24 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.287 -177.949 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 337' ' ' LYS . . . . . 0.442 ' NZ ' ' HB3' ' A' ' 337' ' ' LYS . 8.0 mtpm? . . . . . 0 C--O 1.245 0.828 0 CA-C-O 118.186 -0.911 . . . . 0.0 110.758 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.807 0 N-CA-C 112.081 -0.408 . . . . 0.0 112.081 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 50.2 m -79.15 124.53 28.42 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 110.407 -0.22 . . . . 0.0 110.407 179.71 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 46.5 m 66.59 -90.03 0.03 OUTLIER 'General case' 0 CA--C 1.533 0.312 0 O-C-N 123.612 0.57 . . . . 0.0 110.326 -177.44 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 4.5 tm-20 62.79 98.54 0.03 OUTLIER 'General case' 0 C--N 1.34 0.177 0 CA-C-O 121.655 0.741 . . . . 0.0 110.027 179.698 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 42.9 m -117.46 -62.65 1.54 Allowed 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.44 -0.8 . . . . 0.0 109.409 178.993 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 228' ' ' LEU . . . . . 0.544 ' HB3' ' CB ' ' A' ' 259' ' ' ALA . 87.9 mt -127.1 136.07 51.63 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 172.287 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 40.5 p -122.16 172.17 8.46 Favored 'General case' 0 C--N 1.325 -0.462 0 C-N-CA 119.502 -0.879 . . . . 0.0 110.811 -179.72 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 230' ' ' VAL . . . . . 0.721 HG13 ' HA ' ' A' ' 257' ' ' VAL . 48.3 t -145.82 146.02 19.72 Favored 'Isoleucine or valine' 0 C--O 1.239 0.537 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.328 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 231' ' ' SER . . . . . 0.444 ' HA ' ' OE1' ' A' ' 328' ' ' GLU . 33.3 t -118.79 127.21 53.32 Favored 'General case' 0 N--CA 1.452 -0.328 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.017 -178.975 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 232' ' ' GLY . . . . . 0.528 ' O ' ' HD3' ' A' ' 234' ' ' PRO . . . 149.13 160.43 9.13 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.072 179.182 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 14.6 mm-40 -99.34 100.98 11.54 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 116.769 0.285 . . . . 0.0 111.628 -179.069 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 234' ' ' PRO . . . . . 0.528 ' HD3' ' O ' ' A' ' 232' ' ' GLY . 3.2 Cg_endo -84.01 126.44 3.85 Favored 'Trans proline' 0 N--CA 1.455 -0.762 0 C-N-CA 122.711 2.274 . . . . 0.0 111.434 176.352 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 235' ' ' GLU . . . . . 0.445 ' HB3' ' HE2' ' A' ' 237' ' ' LYS . 98.4 mt-10 -126.54 126.79 44.27 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.315 0.578 . . . . 0.0 111.387 -178.7 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 236' ' ' HIS . . . . . 0.523 ' C ' ' HD3' ' A' ' 237' ' ' LYS . 27.8 m80 -139.73 130.3 25.7 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.192 -0.913 . . . . 0.0 109.204 176.358 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 237' ' ' LYS . . . . . 0.621 ' HD3' ' N ' ' A' ' 237' ' ' LYS . 0.1 OUTLIER -167.39 174.35 8.07 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.054 -176.126 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 238' ' ' VAL . . . . . . . . . . . . . 44.7 t -101.4 110.78 29.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 N-CA-C 109.303 -0.629 . . . . 0.0 109.303 176.321 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 239' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -110.4 152.09 26.69 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.604 -179.411 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 240' ' ' ALA . . . . . 0.589 ' O ' ' HA ' ' A' ' 247' ' ' PRO . . . -93.5 -61.23 1.6 Allowed 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.241 -176.377 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 241' ' ' LYS . . . . . . . . . . . . . 11.7 mmmm -98.2 127.58 44.22 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.397 -173.899 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 55.2 p-10 -95.25 -156.94 0.54 Allowed 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 110.033 -0.358 . . . . 0.0 110.033 174.849 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 38.4 t -66.79 -25.52 66.51 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.762 0.315 . . . . 0.0 111.294 -179.779 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 6.0 m120 -98.54 -14.21 20.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.735 0.302 . . . . 0.0 111.189 -179.534 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 93.04 22.5 27.54 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.476 -179.589 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 246' ' ' MET . . . . . . . . . . . . . 66.5 mtm -113.34 154.0 45.45 Favored Pre-proline 0 C--N 1.326 -0.425 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 177.908 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 247' ' ' PRO . . . . . 0.589 ' HA ' ' O ' ' A' ' 240' ' ' ALA . 3.4 Cg_exo -74.49 119.14 5.62 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.109 1.873 . . . . 0.0 111.787 -179.9 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 59.2 t -145.06 138.14 21.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.567 -178.093 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 64.0 t0 -73.04 121.12 19.63 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 174.191 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 250' ' ' ASN . . . . . . . . . . . . . 19.7 p30 -64.66 162.35 15.92 Favored 'General case' 0 C--O 1.234 0.242 0 CA-C-O 121.275 0.559 . . . . 0.0 112.484 -174.633 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 15.6 ptm180 -69.03 -177.06 0.96 Allowed 'General case' 0 C--O 1.235 0.291 0 CA-C-N 114.852 -1.067 . . . . 0.0 112.379 -172.982 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 252' ' ' GLN . . . . . 0.556 ' HG3' HD12 ' A' ' 293' ' ' LEU . 40.8 mm-40 -80.29 176.19 9.98 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.312 -0.858 . . . . 0.0 109.844 177.894 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 253' ' ' GLY . . . . . 0.494 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -97.4 124.08 8.02 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.216 -0.992 . . . . 0.0 111.881 177.553 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 254' ' ' THR . . . . . 0.454 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 76.8 p -115.52 116.13 27.65 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 178.613 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.53 ' N ' HD13 ' A' ' 255' ' ' ILE . 0.2 OUTLIER -135.64 167.13 25.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.628 -175.747 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 86.9 m -92.5 123.34 35.73 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.2 178.964 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.721 ' HA ' HG13 ' A' ' 230' ' ' VAL . 33.1 m -91.0 144.94 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.66 0 N-CA-C 113.029 0.751 . . . . 0.0 113.029 -173.106 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 258' ' ' SER . . . . . 0.575 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 29.1 m -91.07 10.33 27.22 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 114.113 -1.403 . . . . 0.0 108.866 169.915 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 259' ' ' ALA . . . . . 0.544 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -98.02 176.97 5.57 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.181 -0.918 . . . . 0.0 109.926 -175.19 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 37.2 t -143.77 146.6 33.24 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 110.191 -0.3 . . . . 0.0 110.191 179.067 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 70.98 45.31 51.89 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.996 -0.621 . . . . 0.0 112.906 179.143 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 262' ' ' LEU . . . . . 0.509 HD11 ' HB3' ' A' ' 259' ' ' ALA . 64.0 mt -99.47 144.25 28.79 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 177.101 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 84.2 mt-30 -139.88 160.94 38.78 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 110.287 -0.264 . . . . 0.0 110.287 -178.735 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 264' ' ' VAL . . . . . 0.455 HG22 ' HA ' ' A' ' 294' ' ' ALA . 44.0 t -69.36 136.2 26.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.177 177.527 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 96.03 -1.28 62.93 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.561 -0.828 . . . . 0.0 112.94 178.616 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 266' ' ' ASP . . . . . 0.427 ' O ' ' HA ' ' A' ' 291' ' ' ARG . 65.7 m-20 -78.99 164.21 24.58 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.926 0.394 . . . . 0.0 110.537 177.281 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 267' ' ' ALA . . . . . 0.651 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -123.84 154.38 39.71 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.73 -179.183 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 268' ' ' PHE . . . . . 0.786 ' HB3' HD13 ' A' ' 334' ' ' ILE . 9.4 p90 -164.16 171.19 15.37 Favored 'General case' 0 N--CA 1.449 -0.519 0 C-N-CA 120.297 -0.561 . . . . 0.0 112.217 -179.169 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 69.3 p -129.97 126.11 37.01 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 114.86 -1.064 . . . . 0.0 109.329 175.571 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 270' ' ' ILE . . . . . 0.99 HG12 HG13 ' A' ' 332' ' ' ILE . 60.0 mt -96.74 136.09 28.69 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 116.504 -0.316 . . . . 0.0 110.826 -176.554 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -64.96 128.22 34.86 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.873 -176.395 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 100.98 -23.68 34.72 Favored Glycine 0 N--CA 1.452 -0.26 0 CA-C-N 115.64 -0.709 . . . . 0.0 112.653 177.409 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 273' ' ' VAL . . . . . 0.726 HG21 ' HG3' ' A' ' 326' ' ' PRO . 31.8 t -102.99 102.33 13.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 120.898 0.38 . . . . 0.0 111.025 179.784 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 59.8 m-20 -113.95 166.35 11.69 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 174.248 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 275' ' ' SER . . . . . 0.486 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 36.5 p -83.72 179.39 7.6 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 112.314 0.487 . . . . 0.0 112.314 -176.443 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 35.7 m -141.46 159.72 22.05 Favored 'Isoleucine or valine' 0 C--O 1.232 0.174 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.743 -177.163 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 80.9 m-70 -118.13 99.58 6.97 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 173.989 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 10.8 mm100 -73.61 -24.03 59.98 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 111.863 0.32 . . . . 0.0 111.863 -175.206 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 50.7 mm -67.07 -49.27 74.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.764 0.316 . . . . 0.0 111.334 -177.719 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 40.8 p -101.62 -0.14 35.26 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.509 -0.314 . . . . 0.0 111.343 -179.123 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 3.9 tmtp? 60.18 53.6 4.4 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-O 121.903 0.859 . . . . 0.0 109.588 179.725 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 64.8 t0 -117.78 115.91 25.95 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.372 -0.831 . . . . 0.0 109.144 179.08 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 59.2 p -93.96 86.03 4.92 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.918 0.866 . . . . 0.0 111.014 -178.927 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 284' ' ' THR . . . . . 0.418 ' C ' ' H ' ' A' ' 286' ' ' GLN . 40.0 p -148.63 -88.84 0.08 Allowed 'General case' 0 C--N 1.313 -1.015 0 CA-C-N 114.218 -1.356 . . . . 0.0 109.562 179.282 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 285' ' ' GLY . . . . . 0.507 ' O ' ' HB2' ' A' ' 286' ' ' GLN . . . 68.31 -17.33 0.45 Allowed Glycine 0 C--N 1.333 0.411 0 N-CA-C 114.627 0.611 . . . . 0.0 114.627 173.423 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 286' ' ' GLN . . . . . 0.507 ' HB2' ' O ' ' A' ' 285' ' ' GLY . 72.2 mt-30 76.49 164.45 0.13 Allowed Pre-proline 0 C--O 1.235 0.314 0 C-N-CA 123.519 0.728 . . . . 0.0 110.314 -174.671 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 287' ' ' PRO . . . . . 0.424 ' HD2' ' HB3' ' A' ' 286' ' ' GLN . 78.2 Cg_exo -51.65 128.26 25.58 Favored 'Trans proline' 0 C--N 1.351 0.665 0 C-N-CA 122.641 2.228 . . . . 0.0 112.71 -175.902 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 3.8 tm0? -74.38 135.79 42.45 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 -178.029 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 42.5 t -93.83 121.43 44.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.862 0.363 . . . . 0.0 110.896 -175.977 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 290' ' ' PHE . . . . . 0.651 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 3.9 m-85 -98.79 160.04 14.54 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.343 -178.517 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 291' ' ' ARG . . . . . 0.432 ' HD2' ' O ' ' A' ' 290' ' ' PHE . 45.2 mmm-85 -131.29 136.97 48.61 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.122 0.487 . . . . 0.0 110.155 175.66 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 46.3 t -83.67 139.86 17.04 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.223 -177.68 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 293' ' ' LEU . . . . . 0.556 HD12 ' HG3' ' A' ' 252' ' ' GLN . 86.6 mt -111.71 -26.4 9.01 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.69 178.914 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 294' ' ' ALA . . . . . 0.486 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -156.35 139.76 15.79 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 120.718 -0.393 . . . . 0.0 111.624 179.496 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 64.8 t -137.52 109.58 6.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 115.825 -0.625 . . . . 0.0 109.521 173.778 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 47.6 t -151.4 116.37 5.23 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.51 -177.892 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 63.2 44.11 97.58 Favored Glycine 0 C--N 1.331 0.282 0 C-N-CA 120.847 -0.692 . . . . 0.0 111.942 -179.202 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 81.0 p 54.76 16.22 1.34 Allowed 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 123.88 0.872 . . . . 0.0 112.332 -175.401 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 35.8 m -101.07 116.06 31.94 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 174.995 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 300' ' ' VAL . . . . . 0.486 ' HA ' ' O ' ' A' ' 294' ' ' ALA . 71.8 t -114.64 131.59 66.31 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-O 121.09 0.471 . . . . 0.0 111.867 -172.167 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 51.1 m -93.01 115.99 28.64 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.255 -0.884 . . . . 0.0 108.65 174.056 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 302' ' ' ILE . . . . . 0.494 HG12 ' O ' ' A' ' 253' ' ' GLY . 30.4 pt -110.66 139.68 33.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-O 121.722 0.772 . . . . 0.0 112.771 -170.693 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 303' ' ' SER . . . . . 0.607 ' HA ' ' O ' ' A' ' 304' ' ' PRO . 82.5 p -138.41 169.02 13.74 Favored Pre-proline 0 C--N 1.323 -0.547 0 CA-C-N 114.404 -1.271 . . . . 0.0 107.759 177.082 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 304' ' ' PRO . . . . . 0.607 ' O ' ' HA ' ' A' ' 303' ' ' SER . 9.7 Cg_exo -73.01 -133.29 0.09 OUTLIER 'Cis proline' 0 C--N 1.348 0.516 0 CA-C-N 120.776 1.313 . . . . 0.0 112.527 0.251 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 305' ' ' LYS . . . . . 0.909 ' HD3' ' HG ' ' A' ' 307' ' ' LEU . 0.0 OUTLIER -102.07 145.1 29.8 Favored 'General case' 0 N--CA 1.448 -0.574 0 CA-C-O 121.453 0.644 . . . . 0.0 111.333 177.871 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 306' ' ' ILE . . . . . 0.819 HG23 HG21 ' A' ' 322' ' ' VAL . 2.7 mp -113.04 85.46 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.049 -177.076 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 307' ' ' LEU . . . . . 0.909 ' HG ' ' HD3' ' A' ' 305' ' ' LYS . 55.7 mt -96.77 116.5 66.12 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.704 -174.66 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 308' ' ' PRO . . . . . 0.705 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 68.7 Cg_endo -79.75 140.52 14.73 Favored 'Trans proline' 0 C--O 1.235 0.36 0 C-N-CA 122.95 2.433 . . . . 0.0 113.899 -174.191 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 309' ' ' VAL . . . . . 0.537 HG22 ' CB ' ' A' ' 320' ' ' ALA . 15.9 t -93.89 -27.92 4.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.821 174.702 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 62.4 mm-40 -82.21 33.49 0.4 Allowed 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.847 -177.73 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.484 ' OD1' ' HB2' ' A' ' 308' ' ' PRO . 5.5 m120 -126.23 168.95 13.38 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.967 177.955 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 27.3 m -80.64 -18.02 49.42 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.898 -176.427 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 50.7 m-20 -57.19 114.67 2.26 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-O 120.989 0.423 . . . . 0.0 111.387 -179.443 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 38.8 t -74.25 -31.44 29.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.579 -179.694 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -70.06 -30.03 67.18 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.428 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 34.0 t -75.76 -28.9 58.63 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.799 -178.767 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 317' ' ' ARG . . . . . 0.769 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 21.7 mmt85 -51.34 -57.38 14.38 Favored Pre-proline 0 CA--C 1.542 0.672 0 N-CA-C 113.882 1.067 . . . . 0.0 113.882 -176.539 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 318' ' ' PRO . . . . . 0.769 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 22.8 Cg_exo -70.79 -21.49 28.63 Favored 'Trans proline' 0 C--N 1.355 0.893 0 C-N-CA 121.958 1.772 . . . . 0.0 113.522 -173.412 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 319' ' ' TYR . . . . . 0.514 ' O ' HD12 ' A' ' 307' ' ' LEU . 0.9 OUTLIER -108.69 2.78 22.11 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.368 0.604 . . . . 0.0 109.598 -175.855 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 320' ' ' ALA . . . . . 0.677 ' HA ' ' HB2' ' A' ' 307' ' ' LEU . . . -62.36 138.62 58.47 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.318 -178.757 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 321' ' ' ASN . . . . . 0.403 ' O ' ' HA ' ' A' ' 275' ' ' SER . 16.0 p-10 -128.67 -3.46 5.33 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.007 -179.864 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 322' ' ' VAL . . . . . 0.819 HG21 HG23 ' A' ' 306' ' ' ILE . 35.7 m -140.66 166.7 18.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.595 -0.275 . . . . 0.0 110.66 -179.836 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 53.8 m-20 -60.81 -49.23 78.3 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.072 0.463 . . . . 0.0 110.872 179.304 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 324' ' ' ALA . . . . . 0.705 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -157.53 170.65 21.93 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.575 -176.028 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 25.0 pttm -83.1 151.36 63.21 Favored Pre-proline 0 C--N 1.328 -0.359 0 N-CA-C 108.104 -1.072 . . . . 0.0 108.104 170.382 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 326' ' ' PRO . . . . . 0.728 ' HD3' HG21 ' A' ' 306' ' ' ILE . 20.6 Cg_exo -68.02 126.25 14.23 Favored 'Trans proline' 0 N--CA 1.461 -0.405 0 C-N-CA 121.731 1.621 . . . . 0.0 112.886 -174.702 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -83.36 117.3 22.92 Favored 'General case' 0 CA--C 1.511 -0.533 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 167.187 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 328' ' ' GLU . . . . . 0.444 ' OE1' ' HA ' ' A' ' 231' ' ' SER . 31.2 tp10 63.95 168.08 0.16 Allowed 'General case' 0 CA--C 1.539 0.554 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 -165.166 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 329' ' ' SER . . . . . 0.581 ' HB2' ' C ' ' A' ' 230' ' ' VAL . 49.3 m -81.09 -22.19 39.38 Favored 'General case' 0 C--N 1.316 -0.882 0 O-C-N 120.775 -1.203 . . . . 0.0 110.678 -176.948 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 73.5 -160.09 0.09 Allowed 'General case' 0 N--CA 1.473 0.692 0 O-C-N 123.855 0.722 . . . . 0.0 112.872 170.944 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 331' ' ' ALA . . . . . 0.433 ' C ' HD12 ' A' ' 332' ' ' ILE . . . -95.51 129.33 42.72 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.254 -0.885 . . . . 0.0 110.041 179.379 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 332' ' ' ILE . . . . . 0.99 HG13 HG12 ' A' ' 270' ' ' ILE . 1.8 mp -111.16 145.49 17.36 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.442 -175.606 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 47.5 m -118.69 97.65 5.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.021 -178.557 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 334' ' ' ILE . . . . . 0.786 HD13 ' HB3' ' A' ' 268' ' ' PHE . 42.7 mm -80.02 136.46 23.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 N-CA-C 112.959 0.726 . . . . 0.0 112.959 -172.675 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 335' ' ' LEU . . . . . 0.473 HD23 ' N ' ' A' ' 335' ' ' LEU . 1.6 pt? -151.21 -173.82 4.62 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 114.69 -1.141 . . . . 0.0 108.737 172.646 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 76.4 m-20 -111.63 -14.05 13.7 Favored 'General case' 0 C--N 1.325 -0.499 0 O-C-N 122.079 -0.388 . . . . 0.0 111.704 -177.135 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 337' ' ' LYS . . . . . 0.544 ' HB2' ' NZ ' ' A' ' 337' ' ' LYS . 9.8 mtmp? . . . . . 0 C--O 1.244 0.792 0 CA-C-O 118.557 -0.735 . . . . 0.0 110.931 -177.163 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.809 0 N-CA-C 111.859 -0.496 . . . . 0.0 111.859 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 69.7 m -79.61 77.06 6.23 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.105 0.479 . . . . 0.0 111.143 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 41.0 p -124.89 162.27 24.77 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.22 177.997 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -92.63 52.36 1.87 Allowed 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.53 -0.304 . . . . 0.0 110.396 -179.773 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 40.8 p -76.11 -74.18 0.24 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.564 -0.289 . . . . 0.0 111.118 -177.893 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 228' ' ' LEU . . . . . 0.413 ' HB3' ' CB ' ' A' ' 259' ' ' ALA . 83.8 mt -104.46 126.15 51.29 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 174.778 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 229' ' ' THR . . . . . 0.561 HG22 ' HA ' ' A' ' 331' ' ' ALA . 68.4 p -129.35 177.94 6.81 Favored 'General case' 0 C--N 1.32 -0.692 0 C-N-CA 120.06 -0.656 . . . . 0.0 111.147 -177.059 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 230' ' ' VAL . . . . . 0.655 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 64.6 t -140.48 142.57 30.72 Favored 'Isoleucine or valine' 0 C--O 1.238 0.474 0 CA-C-O 120.774 0.321 . . . . 0.0 110.309 -179.427 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 43.3 m -109.33 138.17 46.1 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.481 178.627 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 162.39 -170.15 37.9 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.896 -0.669 . . . . 0.0 111.747 -179.728 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 83.6 mt-30 -99.88 116.26 64.86 Favored Pre-proline 0 C--N 1.325 -0.486 0 CA-C-N 116.716 0.258 . . . . 0.0 110.927 179.45 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -69.17 127.6 15.31 Favored 'Trans proline' 0 C--O 1.236 0.412 0 C-N-CA 122.113 1.876 . . . . 0.0 110.971 175.912 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 235' ' ' GLU . . . . . 0.679 ' HG3' ' HB3' ' A' ' 251' ' ' ARG . 0.3 OUTLIER -125.78 -176.92 3.75 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-O 121.661 0.744 . . . . 0.0 111.63 -174.395 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 22.3 p-80 -156.13 133.13 10.54 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 178.964 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 237' ' ' LYS . . . . . 0.788 ' HD3' ' HA ' ' A' ' 305' ' ' LYS . 8.9 mptt -104.96 125.51 51.03 Favored 'General case' 0 C--N 1.32 -0.682 0 C-N-CA 119.439 -0.904 . . . . 0.0 111.69 -172.194 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 238' ' ' VAL . . . . . 0.656 ' HB ' HG11 ' A' ' 248' ' ' VAL . 48.1 t -104.08 155.2 5.84 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-N 114.504 -1.225 . . . . 0.0 108.049 171.404 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 239' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -66.71 174.77 2.69 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 117.641 0.2 . . . . 0.0 111.449 -179.53 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 240' ' ' ALA . . . . . . . . . . . . . . . -14.58 -67.03 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.959 0 O-C-N 124.814 1.321 . . . . 0.0 114.371 -176.078 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 241' ' ' LYS . . . . . 0.584 ' H ' ' HD3' ' A' ' 241' ' ' LYS . 0.0 OUTLIER -138.96 165.2 27.72 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 178.093 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 57.8 p30 -91.29 -158.32 0.55 Allowed 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.837 179.479 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 28.5 p -75.52 -7.56 54.49 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 112.324 0.49 . . . . 0.0 112.324 -178.977 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 244' ' ' ASN . . . . . 0.42 ' HB2' ' HG3' ' A' ' 246' ' ' MET . 67.3 m-20 -111.63 -13.12 13.82 Favored 'General case' 0 C--N 1.327 -0.397 0 O-C-N 122.267 -0.271 . . . . 0.0 110.966 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 83.82 25.64 44.9 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.737 -0.744 . . . . 0.0 111.589 -175.926 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 246' ' ' MET . . . . . 0.42 ' HG3' ' HB2' ' A' ' 244' ' ' ASN . 82.2 mtp -88.19 141.25 30.88 Favored Pre-proline 0 C--N 1.327 -0.4 0 CA-C-N 115.831 -0.185 . . . . 0.0 110.764 -178.887 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 247' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_exo -55.58 121.01 9.18 Favored 'Trans proline' 0 C--N 1.346 0.408 0 C-N-CA 122.836 2.357 . . . . 0.0 112.092 178.694 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.656 HG11 ' HB ' ' A' ' 238' ' ' VAL . 61.1 t -84.5 139.79 17.03 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.086 -178.214 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -92.7 100.25 12.79 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 177.951 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 250' ' ' ASN . . . . . . . . . . . . . 5.7 m120 -86.66 -21.83 26.49 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.578 -179.518 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 251' ' ' ARG . . . . . 0.679 ' HB3' ' HG3' ' A' ' 235' ' ' GLU . 2.3 tpm_? 57.62 -108.61 0.43 Allowed 'General case' 0 CA--C 1.535 0.366 0 CA-C-N 115.49 -0.777 . . . . 0.0 111.4 177.395 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 252' ' ' GLN . . . . . 0.458 ' CG ' ' HE2' ' A' ' 237' ' ' LYS . 21.6 mt-30 61.68 170.95 0.12 Allowed 'General case' 0 N--CA 1.471 0.624 0 CA-C-O 121.382 0.61 . . . . 0.0 111.645 -178.272 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 253' ' ' GLY . . . . . 0.537 ' O ' ' HA ' ' A' ' 301' ' ' THR . . . 126.33 -152.22 18.22 Favored Glycine 0 N--CA 1.446 -0.661 0 C-N-CA 119.141 -1.504 . . . . 0.0 113.401 172.812 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 254' ' ' THR . . . . . 0.478 ' HB ' HG22 ' A' ' 299' ' ' THR . 58.4 p -94.21 135.49 35.53 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.13 0.49 . . . . 0.0 111.621 -174.908 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.448 ' O ' ' HA ' ' A' ' 299' ' ' THR . 2.1 pp -132.39 169.07 22.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 115.446 -0.797 . . . . 0.0 111.223 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 83.8 m -105.15 126.25 51.88 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.015 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.432 HG12 HG13 ' A' ' 230' ' ' VAL . 33.5 m -100.81 145.42 11.21 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.643 0 N-CA-C 112.529 0.566 . . . . 0.0 112.529 -174.839 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 258' ' ' SER . . . . . 0.405 ' HB2' ' OG1' ' A' ' 229' ' ' THR . 52.8 m -91.36 7.26 41.89 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 114.694 -1.139 . . . . 0.0 109.132 167.682 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 259' ' ' ALA . . . . . 0.413 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -95.78 170.09 9.56 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-N 115.492 -0.777 . . . . 0.0 110.13 -177.683 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 51.3 p -137.29 153.29 50.34 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.798 0.333 . . . . 0.0 111.45 -178.708 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 72.37 48.79 22.76 Favored Glycine 0 N--CA 1.452 -0.248 0 CA-C-N 115.929 -0.578 . . . . 0.0 112.847 178.342 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 262' ' ' LEU . . . . . 0.422 HD12 HG21 ' A' ' 257' ' ' VAL . 61.7 mt -102.31 144.28 31.01 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.971 0.415 . . . . 0.0 111.08 -178.873 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 72.1 mt-30 -137.78 172.45 12.94 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.69 -0.687 . . . . 0.0 109.547 176.059 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 264' ' ' VAL . . . . . 0.431 HG22 ' HA ' ' A' ' 294' ' ' ALA . 44.5 t -79.04 136.28 24.07 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 174.909 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 95.67 -0.76 63.26 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.5 -0.857 . . . . 0.0 112.586 179.33 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 65.3 m-20 -65.17 152.26 44.05 Favored 'General case' 0 CA--C 1.517 -0.315 0 CA-C-O 121.11 0.481 . . . . 0.0 110.751 178.343 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 267' ' ' ALA . . . . . 0.707 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -124.14 122.76 38.71 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.353 -0.839 . . . . 0.0 109.415 179.544 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 268' ' ' PHE . . . . . 0.414 ' HB3' ' HA ' ' A' ' 334' ' ' ILE . 5.4 p90 -144.56 169.07 18.68 Favored 'General case' 0 C--N 1.319 -0.741 0 C-N-CA 120.016 -0.673 . . . . 0.0 111.784 -172.816 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 269' ' ' THR . . . . . 0.467 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 42.9 p -119.97 148.81 43.08 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.559 -0.746 . . . . 0.0 109.966 176.615 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 270' ' ' ILE . . . . . 0.586 HG12 HD12 ' A' ' 332' ' ' ILE . 58.5 mt -114.09 138.85 42.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 116.559 -0.291 . . . . 0.0 110.668 -177.226 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -67.99 117.04 9.33 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.948 179.082 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 109.4 -22.49 24.49 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.782 -0.723 . . . . 0.0 111.95 -179.14 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 273' ' ' VAL . . . . . 0.657 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 50.4 t -96.35 101.27 12.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 175.994 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 274' ' ' ASN . . . . . 0.429 ' HA ' ' HA ' ' A' ' 287' ' ' PRO . 72.5 m-80 -124.44 131.79 53.5 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.494 -177.594 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 54.5 p -64.03 163.99 11.35 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.524 0.678 . . . . 0.0 112.508 -176.488 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 276' ' ' VAL . . . . . 0.866 HG11 HG21 ' A' ' 309' ' ' VAL . 21.5 m -126.81 149.94 32.26 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.623 0 CA-C-N 114.901 -1.045 . . . . 0.0 109.276 176.029 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 58.7 m170 -103.53 120.87 41.71 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 120.756 0.312 . . . . 0.0 110.738 -175.191 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 47.5 mm-40 -82.17 -29.2 31.67 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.764 -177.723 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 279' ' ' ILE . . . . . 0.487 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.0 mp -72.12 -52.64 23.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.436 -179.017 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 58.0 p -89.38 -13.06 38.62 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.772 -178.356 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 31.7 mmmt 58.84 45.26 15.64 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.55 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 44.1 t0 -132.8 155.25 49.27 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 110.157 -0.312 . . . . 0.0 110.157 -179.571 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.516 HG22 HG12 ' A' ' 276' ' ' VAL . 59.9 p -107.77 113.38 26.59 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 175.072 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 80.6 p -110.93 6.77 21.38 Favored 'General case' 0 C--N 1.32 -0.699 0 C-N-CA 120.285 -0.566 . . . . 0.0 112.077 -170.318 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 285' ' ' GLY . . . . . 0.4 ' O ' ' HD3' ' A' ' 287' ' ' PRO . . . 66.77 31.6 78.82 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.594 -0.813 . . . . 0.0 113.363 174.414 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 10.6 mm100 -95.89 109.1 44.74 Favored Pre-proline 0 C--N 1.328 -0.338 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 177.817 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 287' ' ' PRO . . . . . 0.467 ' HB2' ' HB ' ' A' ' 269' ' ' THR . 51.5 Cg_exo -58.35 139.34 90.21 Favored 'Trans proline' 0 C--N 1.343 0.288 0 C-N-CA 122.598 2.199 . . . . 0.0 112.888 -176.107 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 40.8 tt0 -77.4 148.37 35.55 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.179 -179.637 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 289' ' ' VAL . . . . . 0.533 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 59.7 t -94.25 137.4 23.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.085 178.063 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 290' ' ' PHE . . . . . 0.707 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 51.7 m-85 -118.34 167.83 11.18 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.758 -176.525 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 37.4 mmt180 -128.66 130.96 47.95 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.77 177.653 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 57.7 t -79.65 139.97 17.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.497 -0.774 . . . . 0.0 111.359 -179.054 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 293' ' ' LEU . . . . . 0.512 ' CD1' ' HB2' ' A' ' 303' ' ' SER . 6.9 mp -102.25 -31.66 10.44 Favored 'General case' 0 C--N 1.334 -0.089 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.844 179.738 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 294' ' ' ALA . . . . . 0.458 ' HB3' ' HB ' ' A' ' 301' ' ' THR . . . -158.55 144.31 16.75 Favored 'General case' 0 N--CA 1.465 0.284 0 C-N-CA 120.664 -0.415 . . . . 0.0 111.763 179.523 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 62.5 t -139.28 112.48 6.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.85 176.085 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 54.2 p -132.67 95.41 3.59 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.368 -0.378 . . . . 0.0 111.114 -178.413 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 65.43 57.78 10.75 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.02 -178.789 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 67.0 p 51.19 22.37 1.31 Allowed 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 123.501 0.72 . . . . 0.0 112.552 -176.174 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 299' ' ' THR . . . . . 0.478 HG22 ' HB ' ' A' ' 254' ' ' THR . 91.7 m -112.29 109.55 19.27 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 174.014 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 300' ' ' VAL . . . . . 0.467 ' O ' ' HA ' ' A' ' 254' ' ' THR . 47.3 t -107.0 134.1 49.69 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-N 115.704 -0.68 . . . . 0.0 112.02 -168.39 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 301' ' ' THR . . . . . 0.537 ' HA ' ' O ' ' A' ' 253' ' ' GLY . 91.5 m -85.22 114.92 22.68 Favored 'General case' 0 C--O 1.237 0.403 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 169.746 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 302' ' ' ILE . . . . . 0.418 HD13 HG12 ' A' ' 255' ' ' ILE . 30.6 pt -110.7 138.6 38.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 N-CA-C 113.655 0.983 . . . . 0.0 113.655 -167.805 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 303' ' ' SER . . . . . 0.572 ' HB3' ' HA ' ' A' ' 304' ' ' PRO . 68.7 m -153.87 169.39 10.01 Favored Pre-proline 0 C--N 1.323 -0.557 0 CA-C-N 112.859 -1.973 . . . . 0.0 105.89 175.047 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 304' ' ' PRO . . . . . 0.572 ' HA ' ' HB3' ' A' ' 303' ' ' SER . 22.7 Cg_endo -93.38 -119.83 0.0 OUTLIER 'Cis proline' 0 N--CA 1.455 -0.742 0 CA-C-N 121.02 1.4 . . . . 0.0 113.592 0.822 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 305' ' ' LYS . . . . . 0.788 ' HA ' ' HD3' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -98.41 144.29 27.94 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.081 -0.509 . . . . 0.0 112.357 -172.324 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 306' ' ' ILE . . . . . 0.544 ' HB ' ' O ' ' A' ' 235' ' ' GLU . 2.2 mp -104.4 127.35 58.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 170.699 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 307' ' ' LEU . . . . . 0.544 HD13 ' O ' ' A' ' 319' ' ' TYR . 59.0 mt -129.09 98.28 24.17 Favored Pre-proline 0 C--N 1.323 -0.548 0 C-N-CA 120.676 -0.41 . . . . 0.0 110.519 -172.779 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 308' ' ' PRO . . . . . 0.545 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 12.7 Cg_exo -74.17 131.34 15.21 Favored 'Trans proline' 0 C--N 1.343 0.252 0 C-N-CA 122.802 2.335 . . . . 0.0 113.495 -175.19 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 309' ' ' VAL . . . . . 0.866 HG21 HG11 ' A' ' 276' ' ' VAL . 61.9 t -87.05 -37.57 11.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.563 173.897 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 63.1 mm-40 -81.08 32.69 0.33 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.859 -0.609 . . . . 0.0 111.484 179.814 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.433 HD22 ' N ' ' A' ' 317' ' ' ARG . 43.3 p-10 -85.38 157.05 20.62 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.945 0.403 . . . . 0.0 111.248 179.16 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 36.4 m -92.15 -18.28 23.73 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.839 178.244 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -76.42 121.49 23.13 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.612 -179.746 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 40.7 t -75.76 -20.19 15.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.129 -177.457 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -80.59 -21.96 41.14 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.739 0.304 . . . . 0.0 111.512 178.582 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 36.0 t -96.3 -23.3 16.73 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.559 -0.291 . . . . 0.0 111.456 -176.138 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 317' ' ' ARG . . . . . 0.433 ' N ' HD22 ' A' ' 311' ' ' ASN . 2.1 ptp180 -62.23 -34.03 14.07 Favored Pre-proline 0 CA--C 1.548 0.901 0 N-CA-C 113.807 1.04 . . . . 0.0 113.807 -178.886 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 318' ' ' PRO . . . . . 0.415 ' CD ' ' N ' ' A' ' 317' ' ' ARG . 26.1 Cg_exo -63.13 -18.14 63.57 Favored 'Trans proline' 0 C--N 1.367 1.521 0 CA-C-N 121.263 1.487 . . . . 0.0 112.113 178.266 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 319' ' ' TYR . . . . . 0.544 ' O ' HD13 ' A' ' 307' ' ' LEU . 48.5 m-85 -103.35 -3.2 25.87 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.028 -177.803 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 320' ' ' ALA . . . . . 0.723 ' HB1' HG22 ' A' ' 309' ' ' VAL . . . -54.06 144.77 18.49 Favored 'General case' 0 C--N 1.33 -0.246 0 N-CA-C 112.144 0.424 . . . . 0.0 112.144 -178.128 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 321' ' ' ASN . . . . . 0.479 ' O ' HG22 ' A' ' 276' ' ' VAL . 48.9 t30 -148.05 -18.61 0.35 Allowed 'General case' 0 CA--C 1.532 0.278 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.472 -178.281 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 322' ' ' VAL . . . . . 0.532 ' O ' HG23 ' A' ' 309' ' ' VAL . 35.1 m -137.43 160.96 34.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 N-CA-C 110.234 -0.284 . . . . 0.0 110.234 177.654 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 71.8 m-20 -41.9 -69.24 0.14 Allowed 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 112.588 0.588 . . . . 0.0 112.588 -177.364 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 324' ' ' ALA . . . . . 0.545 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -165.7 -176.08 3.74 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.962 0.411 . . . . 0.0 111.496 -175.595 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 325' ' ' LYS . . . . . 0.454 ' HG3' ' HG3' ' A' ' 308' ' ' PRO . 34.4 mtmm -88.02 138.97 30.71 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.592 174.362 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 326' ' ' PRO . . . . . 0.706 ' HB2' ' HB2' ' A' ' 330' ' ' ALA . 43.1 Cg_endo -86.01 167.34 9.57 Favored 'Trans proline' 0 N--CA 1.455 -0.759 0 C-N-CA 122.551 2.167 . . . . 0.0 112.145 178.61 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -70.47 122.98 20.69 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 177.83 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 52.8 mt-10 62.39 -121.04 0.66 Allowed 'General case' 0 N--CA 1.463 0.184 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 -172.328 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 329' ' ' SER . . . . . 0.655 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 33.9 m -111.94 -14.25 13.52 Favored 'General case' 0 C--N 1.322 -0.603 0 C-N-CA 120.535 -0.466 . . . . 0.0 110.118 172.813 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 330' ' ' ALA . . . . . 0.706 ' HB2' ' HB2' ' A' ' 326' ' ' PRO . . . 73.9 -169.19 0.11 Allowed 'General case' 0 N--CA 1.474 0.755 0 O-C-N 124.214 0.946 . . . . 0.0 113.37 172.467 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 331' ' ' ALA . . . . . 0.561 ' HA ' HG22 ' A' ' 229' ' ' THR . . . -80.08 141.54 35.72 Favored 'General case' 0 CA--C 1.517 -0.304 0 CA-C-N 115.101 -0.954 . . . . 0.0 110.611 -179.065 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 332' ' ' ILE . . . . . 0.586 HD12 HG12 ' A' ' 270' ' ' ILE . 16.1 mm -120.68 144.11 30.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.405 -175.503 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 82.3 m -114.04 97.13 6.18 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 175.007 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 334' ' ' ILE . . . . . 0.414 ' HA ' ' HB3' ' A' ' 268' ' ' PHE . 38.5 mm -81.65 125.34 39.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 115.999 -0.546 . . . . 0.0 112.339 -172.045 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 335' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -122.73 163.22 20.56 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.187 170.971 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 20.9 t-20 -94.04 -14.74 25.5 Favored 'General case' 0 C--N 1.319 -0.76 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 171.659 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 337' ' ' LYS . . . . . 0.65 ' HB2' ' HB3' ' A' ' 267' ' ' ALA . 26.7 tptp . . . . . 0 C--O 1.244 0.799 0 CA-C-N 114.613 -1.176 . . . . 0.0 111.257 174.431 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.81 0 N-CA-C 111.738 -0.545 . . . . 0.0 111.738 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 35.7 t -86.83 155.04 20.44 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 177.406 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 47.6 p -82.69 160.8 22.32 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.121 0.486 . . . . 0.0 111.189 -178.62 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -98.42 62.99 1.48 Allowed 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 121.651 0.739 . . . . 0.0 109.809 174.909 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 26.5 m -78.92 -155.09 0.08 Allowed 'General case' 0 N--CA 1.442 -0.858 0 CA-C-N 115.122 -0.945 . . . . 0.0 110.959 -175.917 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 228' ' ' LEU . . . . . 0.488 ' HB3' ' HA ' ' A' ' 259' ' ' ALA . 55.2 mt -94.08 129.55 40.57 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.598 -178.6 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 229' ' ' THR . . . . . 0.456 ' HA ' ' HA ' ' A' ' 331' ' ' ALA . 60.6 p -126.97 179.53 5.36 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 120.275 -0.57 . . . . 0.0 111.281 -176.18 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 230' ' ' VAL . . . . . 0.756 HG11 HD12 ' A' ' 255' ' ' ILE . 75.3 t -146.39 138.8 19.79 Favored 'Isoleucine or valine' 0 C--O 1.237 0.409 0 CA-C-O 120.735 0.302 . . . . 0.0 110.708 -179.359 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 231' ' ' SER . . . . . 0.425 ' O ' ' HB ' ' A' ' 256' ' ' THR . 49.4 m -137.99 165.37 26.73 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.746 178.686 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 116.12 -108.84 1.89 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 119.913 -1.137 . . . . 0.0 113.995 172.041 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 11.0 mm-40 -62.49 155.36 68.43 Favored Pre-proline 0 C--N 1.328 -0.354 0 N-CA-C 112.761 0.652 . . . . 0.0 112.761 -173.225 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -63.9 175.56 2.98 Favored 'Trans proline' 0 C--N 1.349 0.573 0 C-N-CA 123.611 2.874 . . . . 0.0 112.661 178.161 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 235' ' ' GLU . . . . . 0.425 ' CB ' ' HD2' ' A' ' 325' ' ' LYS . 52.1 mm-40 -92.51 -176.79 4.4 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.695 -176.02 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 236' ' ' HIS . . . . . 0.501 ' HA ' ' HB3' ' A' ' 251' ' ' ARG . 37.9 m-70 -113.82 143.75 44.14 Favored 'General case' 0 C--N 1.321 -0.658 0 C-N-CA 119.842 -0.743 . . . . 0.0 112.199 -165.33 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 237' ' ' LYS . . . . . 0.616 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -126.2 176.21 7.23 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.338 -0.847 . . . . 0.0 109.892 -176.11 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 238' ' ' VAL . . . . . 0.78 ' HB ' HG11 ' A' ' 248' ' ' VAL . 28.6 t -50.45 155.29 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 O-C-N 123.67 0.606 . . . . 0.0 111.439 -176.939 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 239' ' ' GLU . . . . . . . . . . . . . 52.0 mt-10 -61.96 173.7 1.02 Allowed 'General case' 0 CA--C 1.53 0.185 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.73 -179.287 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 240' ' ' ALA . . . . . 0.626 ' O ' ' HA ' ' A' ' 247' ' ' PRO . . . -46.21 -59.59 2.81 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 115.527 -0.761 . . . . 0.0 112.029 -177.132 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 241' ' ' LYS . . . . . 0.537 ' HD2' ' C ' ' A' ' 240' ' ' ALA . 0.9 OUTLIER -115.76 130.34 56.81 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.957 0.408 . . . . 0.0 110.666 177.045 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 242' ' ' ASP . . . . . 0.469 ' HB2' ' CE2' ' A' ' 319' ' ' TYR . 2.8 p30 -86.59 -163.86 0.97 Allowed 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.514 -0.766 . . . . 0.0 111.155 -178.956 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 24.3 m -63.66 -29.64 70.85 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 112.077 0.399 . . . . 0.0 112.077 -175.944 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 75.8 m-20 -92.85 -2.51 55.82 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.813 0.339 . . . . 0.0 110.938 -178.719 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 82.59 26.29 47.13 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.599 179.676 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 246' ' ' MET . . . . . 0.43 ' HA ' ' HD3' ' A' ' 247' ' ' PRO . 82.0 mtp -101.2 149.04 35.95 Favored Pre-proline 0 C--N 1.325 -0.473 0 CA-C-O 120.566 0.222 . . . . 0.0 110.637 179.319 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 247' ' ' PRO . . . . . 0.626 ' HA ' ' O ' ' A' ' 240' ' ' ALA . 2.9 Cg_exo -79.06 128.89 8.58 Favored 'Trans proline' 0 C--O 1.234 0.314 0 C-N-CA 122.853 2.369 . . . . 0.0 113.08 -175.958 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.78 HG11 ' HB ' ' A' ' 238' ' ' VAL . 21.7 t -122.32 159.54 25.38 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 175.603 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 249' ' ' ASP . . . . . 0.555 ' O ' ' HB2' ' A' ' 237' ' ' LYS . 64.2 t0 -72.14 89.57 1.16 Allowed 'General case' 0 C--O 1.233 0.234 0 CA-C-O 121.14 0.495 . . . . 0.0 109.87 179.362 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 250' ' ' ASN . . . . . . . . . . . . . 51.2 t-20 -77.49 90.89 3.88 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.418 -179.413 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 251' ' ' ARG . . . . . 0.501 ' HB3' ' HA ' ' A' ' 236' ' ' HIS . 29.1 tpt180 -78.65 -95.3 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.015 -175.523 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 252' ' ' GLN . . . . . 0.403 ' HA ' HE21 ' A' ' 252' ' ' GLN . 2.6 mm100 60.1 177.9 0.09 Allowed 'General case' 0 N--CA 1.467 0.381 0 C-N-CA 123.133 0.573 . . . . 0.0 111.055 -177.851 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 253' ' ' GLY . . . . . 0.556 ' O ' ' HA ' ' A' ' 301' ' ' THR . . . 119.05 -153.11 17.03 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 119.25 -1.453 . . . . 0.0 113.752 176.435 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 254' ' ' THR . . . . . 0.562 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 77.8 p -94.78 148.97 21.74 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.219 0.533 . . . . 0.0 112.243 -172.644 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.756 HD12 HG11 ' A' ' 230' ' ' VAL . 22.6 pt -130.65 161.26 40.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.395 -0.82 . . . . 0.0 110.416 177.71 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 256' ' ' THR . . . . . 0.425 ' HB ' ' O ' ' A' ' 231' ' ' SER . 93.6 m -94.76 106.19 18.16 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 174.533 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.42 HG12 HG22 ' A' ' 230' ' ' VAL . 34.3 m -93.21 141.46 14.68 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.914 0 C-N-CA 119.565 -0.854 . . . . 0.0 112.329 -174.693 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 53.8 m -93.0 8.91 37.96 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 114.016 -1.447 . . . . 0.0 109.239 169.684 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 259' ' ' ALA . . . . . 0.76 ' HB3' HD11 ' A' ' 262' ' ' LEU . . . -81.17 166.37 20.7 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.861 -177.641 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 42.6 m -124.93 108.26 11.7 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 111.988 0.366 . . . . 0.0 111.988 -174.97 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 92.71 50.14 2.57 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.617 -0.801 . . . . 0.0 113.429 173.316 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 262' ' ' LEU . . . . . 0.76 HD11 ' HB3' ' A' ' 259' ' ' ALA . 3.2 mp -86.94 143.59 27.32 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.891 0.346 . . . . 0.0 110.319 179.563 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 68.6 mt-30 -131.12 168.84 16.77 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.605 177.876 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 38.6 t -79.22 128.49 38.5 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 C-N-CA 120.8 -0.36 . . . . 0.0 110.338 178.184 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 265' ' ' GLY . . . . . 0.593 ' H ' ' HB ' ' A' ' 292' ' ' VAL . . . 102.41 8.67 43.2 Favored Glycine 0 N--CA 1.448 -0.532 0 C-N-CA 120.393 -0.908 . . . . 0.0 113.017 177.605 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -76.94 160.93 28.79 Favored 'General case' 0 CA--C 1.515 -0.373 0 CA-C-O 121.047 0.451 . . . . 0.0 110.579 176.424 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 267' ' ' ALA . . . . . 0.647 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -131.68 131.88 43.48 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 177.851 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 268' ' ' PHE . . . . . . . . . . . . . 3.6 p90 -152.33 169.31 22.83 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 119.468 -0.893 . . . . 0.0 111.76 -172.787 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 269' ' ' THR . . . . . 0.739 HG21 ' HB2' ' A' ' 287' ' ' PRO . 71.1 p -119.61 163.05 17.93 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.235 177.477 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 270' ' ' ILE . . . . . 0.593 HG12 HG12 ' A' ' 332' ' ' ILE . 56.7 mt -124.24 140.46 47.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 C-N-CA 120.815 -0.354 . . . . 0.0 111.432 -178.257 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -62.5 113.17 2.8 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.131 179.655 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 103.51 -21.68 38.31 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 121.083 -0.579 . . . . 0.0 112.031 -178.106 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 273' ' ' VAL . . . . . 0.604 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 51.1 t -101.1 103.77 15.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-O 121.089 0.471 . . . . 0.0 110.77 178.87 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 71.9 m-80 -122.67 156.35 34.52 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.165 -0.471 . . . . 0.0 109.967 179.234 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 53.8 p -71.95 173.83 7.83 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.14 0.495 . . . . 0.0 111.819 -175.842 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 27.1 m -112.02 -178.45 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.674 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 9.9 m-70 -54.51 93.26 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.023 -0.99 . . . . 0.0 110.965 -173.932 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 19.2 tm0? -81.99 -28.2 32.75 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.981 0.42 . . . . 0.0 109.878 -175.968 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 279' ' ' ILE . . . . . 0.56 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.6 mp -82.18 -104.31 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.405 0 CA-C-N 116.083 -0.508 . . . . 0.0 109.817 -179.028 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 41.0 p -128.94 76.07 1.69 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.633 0.254 . . . . 0.0 110.676 179.173 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 34.4 mmtp 54.64 31.5 15.32 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.437 -174.559 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 36.3 t70 -87.32 138.44 31.48 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.647 -176.712 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 54.4 p -95.5 120.33 35.57 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.126 -178.593 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 81.5 p -128.93 -45.43 1.28 Allowed 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.276 -171.992 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 79.62 28.01 52.76 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.701 -0.761 . . . . 0.0 111.967 -178.58 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 85.3 mt-30 -76.05 134.62 71.05 Favored Pre-proline 0 C--N 1.328 -0.366 0 N-CA-C 110.214 -0.291 . . . . 0.0 110.214 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 287' ' ' PRO . . . . . 0.739 ' HB2' HG21 ' A' ' 269' ' ' THR . 26.3 Cg_exo -64.67 134.19 39.85 Favored 'Trans proline' 0 CA--C 1.53 0.308 0 C-N-CA 122.546 2.164 . . . . 0.0 112.098 -177.9 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 69.7 tp60 -76.65 129.14 35.97 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.578 -178.503 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 289' ' ' VAL . . . . . 0.486 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 25.7 t -97.01 137.61 24.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.831 -178.357 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 290' ' ' PHE . . . . . 0.669 ' HD1' ' HD2' ' A' ' 304' ' ' PRO . 55.0 m-85 -115.58 169.43 9.19 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.046 -178.836 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 9.8 tpt180 -131.06 142.56 50.3 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.167 0.508 . . . . 0.0 110.047 -179.154 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 292' ' ' VAL . . . . . 0.593 ' HB ' ' H ' ' A' ' 265' ' ' GLY . 55.8 t -92.49 130.57 41.4 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.877 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.683 179.693 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 293' ' ' LEU . . . . . 0.564 HD21 ' HB2' ' A' ' 303' ' ' SER . 2.9 mm? -105.71 -24.34 12.54 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.448 -0.342 . . . . 0.0 111.402 -178.355 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 294' ' ' ALA . . . . . . . . . . . . . . . -164.24 145.39 8.43 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.465 0.174 . . . . 0.0 110.982 179.688 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 295' ' ' VAL . . . . . 0.581 HG13 HG22 ' A' ' 300' ' ' VAL . 45.5 t -135.07 138.28 49.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 175.575 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 36.9 t -139.44 87.31 2.18 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 177.922 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 73.41 -128.22 11.31 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.118 -1.039 . . . . 0.0 110.544 -169.483 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 298' ' ' THR . . . . . 0.401 ' O ' HG22 ' A' ' 257' ' ' VAL . 31.1 p -102.35 29.34 5.25 Favored 'General case' 0 C--N 1.315 -0.898 0 O-C-N 122.155 -0.615 . . . . 0.0 110.506 172.63 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 63.5 m -112.07 105.42 13.79 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 174.033 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 300' ' ' VAL . . . . . 0.707 HG21 HD22 ' A' ' 262' ' ' LEU . 44.3 t -114.24 130.46 68.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 N-CA-C 112.259 0.466 . . . . 0.0 112.259 -168.797 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 301' ' ' THR . . . . . 0.556 ' HA ' ' O ' ' A' ' 253' ' ' GLY . 51.4 m -84.46 113.63 21.34 Favored 'General case' 0 C--O 1.237 0.402 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.219 173.342 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 302' ' ' ILE . . . . . 0.754 HD13 HD13 ' A' ' 255' ' ' ILE . 38.9 pt -116.39 157.13 17.4 Favored 'Isoleucine or valine' 0 C--O 1.24 0.599 0 CA-C-O 121.85 0.833 . . . . 0.0 112.897 -174.602 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 303' ' ' SER . . . . . 0.564 ' HB2' HD21 ' A' ' 293' ' ' LEU . 48.8 m -159.64 163.21 23.58 Favored Pre-proline 0 C--N 1.326 -0.435 0 CA-C-N 113.381 -1.736 . . . . 0.0 106.522 175.012 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 304' ' ' PRO . . . . . 0.669 ' HD2' ' HD1' ' A' ' 290' ' ' PHE . 5.1 Cg_exo -78.63 -134.23 0.14 OUTLIER 'Cis proline' 0 CA--C 1.534 0.518 0 CA-C-N 120.504 1.216 . . . . 0.0 113.047 0.85 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 305' ' ' LYS . . . . . 0.467 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -113.16 156.42 23.25 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.333 0.587 . . . . 0.0 112.375 -176.841 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 306' ' ' ILE . . . . . 0.86 HG23 HG21 ' A' ' 322' ' ' VAL . 2.6 mp -104.34 98.53 6.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.25 -0.886 . . . . 0.0 109.491 179.168 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 307' ' ' LEU . . . . . . . . . . . . . 76.3 mt -107.52 100.19 32.83 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.517 -0.31 . . . . 0.0 111.188 -175.007 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 308' ' ' PRO . . . . . 0.74 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 32.4 Cg_exo -66.94 138.22 47.42 Favored 'Trans proline' 0 N--CA 1.474 0.346 0 C-N-CA 123.622 2.881 . . . . 0.0 114.588 -173.757 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 309' ' ' VAL . . . . . 0.717 HG22 ' HB1' ' A' ' 320' ' ' ALA . 50.8 t -76.74 -29.9 18.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.051 -0.977 . . . . 0.0 108.771 167.772 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -79.2 30.03 0.22 Allowed 'General case' 0 C--O 1.234 0.289 0 CA-C-N 115.292 -0.867 . . . . 0.0 112.045 179.437 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 74.3 m-80 71.05 154.69 0.14 Allowed 'General case' 0 N--CA 1.469 0.481 0 N-CA-C 113.647 0.98 . . . . 0.0 113.647 173.692 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 312' ' ' THR . . . . . 0.526 ' OG1' ' HG2' ' A' ' 308' ' ' PRO . 44.4 m -168.18 -44.09 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 113.675 -1.602 . . . . 0.0 107.824 173.169 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 39.2 t70 -146.52 167.86 22.64 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 114.246 -1.343 . . . . 0.0 108.59 176.339 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 47.2 t -60.34 -38.26 77.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-O 120.787 0.327 . . . . 0.0 111.104 178.381 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -77.38 -17.83 57.86 Favored 'General case' 0 N--CA 1.463 0.212 0 N-CA-C 111.967 0.358 . . . . 0.0 111.967 -179.844 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 34.7 t -71.51 -25.02 62.08 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.579 -0.282 . . . . 0.0 111.447 -176.765 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 317' ' ' ARG . . . . . 0.768 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 54.2 mtp85 -69.71 -57.96 6.09 Favored Pre-proline 0 CA--C 1.536 0.426 0 N-CA-C 112.257 0.466 . . . . 0.0 112.257 -178.691 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 318' ' ' PRO . . . . . 0.768 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 36.8 Cg_exo -63.69 -35.23 59.27 Favored 'Trans proline' 0 C--N 1.357 0.975 0 C-N-CA 122.051 1.834 . . . . 0.0 112.684 -176.779 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 319' ' ' TYR . . . . . 0.469 ' CE2' ' HB2' ' A' ' 242' ' ' ASP . 6.4 m-85 -99.43 32.11 2.9 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.022 -179.23 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 320' ' ' ALA . . . . . 0.717 ' HB1' HG22 ' A' ' 309' ' ' VAL . . . -55.55 127.68 30.92 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.893 178.945 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 47.9 t30 -120.99 -28.25 4.82 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.185 -176.654 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 322' ' ' VAL . . . . . 0.86 HG21 HG23 ' A' ' 306' ' ' ILE . 27.2 m -135.42 168.51 22.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.582 -0.281 . . . . 0.0 110.624 179.223 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 65.6 m-20 -52.83 -59.98 3.83 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 121.015 0.436 . . . . 0.0 110.769 176.981 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 324' ' ' ALA . . . . . 0.74 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -171.79 171.94 5.04 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.427 179.668 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 325' ' ' LYS . . . . . 0.489 ' HB3' ' CG2' ' A' ' 306' ' ' ILE . 21.7 pttp -112.46 117.95 46.27 Favored Pre-proline 0 C--N 1.326 -0.444 0 CA-C-O 121.251 0.548 . . . . 0.0 110.145 172.807 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -72.21 169.33 21.78 Favored 'Trans proline' 0 C--N 1.34 0.103 0 C-N-CA 123.284 2.656 . . . . 0.0 111.884 -177.408 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -63.42 122.27 15.83 Favored 'General case' 0 C--O 1.236 0.372 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 177.607 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 56.0 mt-10 67.79 165.33 0.23 Allowed 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.327 -171.519 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 329' ' ' SER . . . . . 0.681 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 49.0 m -66.65 -14.78 62.89 Favored 'General case' 0 C--N 1.326 -0.423 0 C-N-CA 120.999 -0.28 . . . . 0.0 111.746 -175.673 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 68.17 -162.36 0.2 Allowed 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 113.261 0.837 . . . . 0.0 113.261 171.097 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 331' ' ' ALA . . . . . 0.456 ' HA ' ' HA ' ' A' ' 229' ' ' THR . . . -82.98 150.49 26.35 Favored 'General case' 0 CA--C 1.519 -0.249 0 CA-C-N 115.333 -0.849 . . . . 0.0 111.122 -177.001 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 332' ' ' ILE . . . . . 0.593 HG12 HG12 ' A' ' 270' ' ' ILE . 42.6 mt -122.91 145.23 30.09 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.054 -178.559 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.425 ' HB ' ' OG1' ' A' ' 269' ' ' THR . 31.9 m -111.53 106.77 15.73 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 175.238 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 34.9 mm -83.78 121.67 36.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 112.889 0.7 . . . . 0.0 112.889 -170.203 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 335' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -111.62 -168.57 1.33 Allowed 'General case' 0 C--O 1.236 0.394 0 CA-C-N 115.094 -0.957 . . . . 0.0 109.672 171.491 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 74.4 m-80 -116.78 -15.1 10.74 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.806 -0.633 . . . . 0.0 110.989 176.557 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 23.2 pttm . . . . . 0 C--O 1.244 0.779 0 CA-C-O 118.546 -0.74 . . . . 0.0 111.288 -177.619 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.868 0 N-CA-C 112.161 -0.376 . . . . 0.0 112.161 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 224' ' ' SER . . . . . 0.532 ' HB3' ' HB1' ' A' ' 331' ' ' ALA . 75.2 p -151.68 -156.93 0.76 Allowed 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 29.1 p -84.44 -85.43 0.13 Allowed 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.749 0.309 . . . . 0.0 110.257 174.81 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 54.3 mt-10 -113.67 62.39 0.65 Allowed 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.761 176.965 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 41.1 m 55.48 47.83 20.2 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-N 115.782 -0.644 . . . . 0.0 111.525 178.779 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 228' ' ' LEU . . . . . 0.442 ' HB3' ' HB2' ' A' ' 259' ' ' ALA . 69.7 mt -89.3 125.12 34.98 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 109.711 -0.478 . . . . 0.0 109.711 177.658 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 58.4 p -124.27 175.35 7.12 Favored 'General case' 0 C--N 1.323 -0.573 0 C-N-CA 119.891 -0.724 . . . . 0.0 110.32 179.12 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 230' ' ' VAL . . . . . 0.669 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 89.0 t -148.63 141.82 18.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-O 120.76 0.314 . . . . 0.0 110.654 -177.614 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 49.0 m -92.38 129.13 38.41 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.905 -0.589 . . . . 0.0 109.619 174.142 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . -86.5 118.52 4.91 Favored Glycine 0 N--CA 1.444 -0.829 0 C-N-CA 120.264 -0.97 . . . . 0.0 113.322 -175.622 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 233' ' ' GLN . . . . . 0.941 ' HB3' ' HD2' ' A' ' 234' ' ' PRO . 34.9 mt-30 -80.2 178.97 2.05 Favored Pre-proline 0 C--N 1.328 -0.358 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 169.641 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 234' ' ' PRO . . . . . 0.941 ' HD2' ' HB3' ' A' ' 233' ' ' GLN . 72.9 Cg_exo -32.22 127.53 0.1 OUTLIER 'Trans proline' 0 C--N 1.366 1.463 0 C-N-CA 123.633 2.888 . . . . 0.0 113.861 -176.782 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 235' ' ' GLU . . . . . 0.701 ' OE1' ' HE3' ' A' ' 325' ' ' LYS . 46.1 mt-10 -95.58 -178.78 4.52 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.589 -175.727 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 236' ' ' HIS . . . . . 0.591 ' C ' ' HD3' ' A' ' 237' ' ' LYS . 91.7 m-70 -135.68 143.55 45.5 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 122.559 1.171 . . . . 0.0 113.549 -166.309 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 237' ' ' LYS . . . . . 0.591 ' HD3' ' C ' ' A' ' 236' ' ' HIS . 0.0 OUTLIER -156.76 127.55 6.73 Favored 'General case' 0 C--N 1.314 -0.942 0 CA-C-N 112.531 -2.122 . . . . 0.0 107.729 -179.71 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 238' ' ' VAL . . . . . . . . . . . . . 46.8 t -79.09 111.76 16.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 C-N-CA 120.125 -0.63 . . . . 0.0 110.625 -174.27 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 239' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -119.15 171.5 8.24 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.484 -179.062 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 240' ' ' ALA . . . . . 0.402 ' O ' ' HA ' ' A' ' 247' ' ' PRO . . . -80.82 -59.41 2.68 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.861 0.362 . . . . 0.0 110.751 -179.435 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 241' ' ' LYS . . . . . 0.6 ' H ' ' HD3' ' A' ' 241' ' ' LYS . 0.0 OUTLIER -138.32 159.26 42.5 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.837 178.149 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 242' ' ' ASP . . . . . 0.422 ' OD1' ' HG2' ' A' ' 246' ' ' MET . 11.7 p-10 -97.55 -159.34 0.73 Allowed 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 178.156 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 52.9 m -67.62 -27.04 66.55 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.616 -0.265 . . . . 0.0 111.033 177.602 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 23.3 t-20 -83.98 -15.97 45.78 Favored 'General case' 0 CA--C 1.531 0.234 0 CA-C-O 120.999 0.428 . . . . 0.0 110.093 178.893 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 85.58 26.3 36.08 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.692 -0.766 . . . . 0.0 113.376 173.664 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 246' ' ' MET . . . . . 0.436 ' O ' ' HA ' ' A' ' 241' ' ' LYS . 26.8 ptt? -106.72 157.36 35.36 Favored Pre-proline 0 C--N 1.324 -0.505 0 CA-C-N 117.011 0.405 . . . . 0.0 110.078 177.445 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 247' ' ' PRO . . . . . 0.402 ' HA ' ' O ' ' A' ' 240' ' ' ALA . 22.0 Cg_exo -63.44 120.83 8.4 Favored 'Trans proline' 0 C--N 1.347 0.458 0 C-N-CA 122.272 1.981 . . . . 0.0 111.033 177.641 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 45.2 t -99.33 111.09 28.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 120.848 0.356 . . . . 0.0 111.849 -173.492 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -100.37 124.22 45.58 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 170.856 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 250' ' ' ASN . . . . . 0.702 HD21 ' HG3' ' A' ' 305' ' ' LYS . 14.1 p-10 -76.15 -13.16 60.2 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.04 -0.527 . . . . 0.0 112.022 -174.222 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 251' ' ' ARG . . . . . 0.609 ' HG2' ' H ' ' A' ' 252' ' ' GLN . 63.1 ttt-85 58.17 -127.76 1.52 Allowed 'General case' 0 CA--C 1.539 0.553 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 176.621 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 252' ' ' GLN . . . . . 0.609 ' H ' ' HG2' ' A' ' 251' ' ' ARG . 40.7 mm-40 -115.03 176.73 4.93 Favored 'General case' 0 C--N 1.33 -0.258 0 O-C-N 121.981 -0.449 . . . . 0.0 110.068 178.325 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 253' ' ' GLY . . . . . 0.515 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -105.81 122.25 7.06 Favored Glycine 0 N--CA 1.443 -0.883 0 C-N-CA 120.282 -0.961 . . . . 0.0 112.088 177.437 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 254' ' ' THR . . . . . 0.504 ' O ' ' HB2' ' A' ' 233' ' ' GLN . 48.3 p -106.33 116.79 32.54 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 109.16 -0.682 . . . . 0.0 109.16 176.439 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.725 HG22 ' H ' ' A' ' 233' ' ' GLN . 2.1 pp -125.49 165.63 22.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 N-CA-C 112.868 0.692 . . . . 0.0 112.868 -173.074 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 25.7 m -105.98 117.51 34.23 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 178.649 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.508 ' HA ' HG13 ' A' ' 230' ' ' VAL . 33.7 m -90.22 143.0 12.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 C-N-CA 119.71 -0.796 . . . . 0.0 112.757 -171.932 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 258' ' ' SER . . . . . 0.502 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 37.0 m -92.35 9.83 32.41 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 114.076 -1.42 . . . . 0.0 108.791 168.519 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 259' ' ' ALA . . . . . 0.442 ' HB2' ' HB3' ' A' ' 228' ' ' LEU . . . -101.1 168.3 9.68 Favored 'General case' 0 N--CA 1.454 -0.268 0 CA-C-N 115.049 -0.978 . . . . 0.0 109.371 -176.842 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 49.5 m -132.86 163.18 29.69 Favored 'General case' 0 C--N 1.324 -0.529 0 C-N-CA 120.806 -0.358 . . . . 0.0 111.502 -178.487 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 64.29 50.11 61.89 Favored Glycine 0 N--CA 1.452 -0.247 0 CA-C-N 115.729 -0.669 . . . . 0.0 113.128 177.047 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 262' ' ' LEU . . . . . . . . . . . . . 53.4 mt -101.76 159.68 15.12 Favored 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 120.652 -0.419 . . . . 0.0 110.543 179.73 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 73.4 mt-30 -143.35 165.14 28.33 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.988 -0.551 . . . . 0.0 109.812 179.744 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 41.2 t -79.86 134.47 27.49 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 N-CA-C 109.411 -0.588 . . . . 0.0 109.411 173.621 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 265' ' ' GLY . . . . . 0.512 ' H ' ' HB ' ' A' ' 292' ' ' VAL . . . 95.47 15.81 42.36 Favored Glycine 0 N--CA 1.446 -0.656 0 C-N-CA 120.284 -0.96 . . . . 0.0 112.729 178.918 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 40.7 m-20 -87.82 165.78 15.06 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.956 0.407 . . . . 0.0 110.689 174.784 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 267' ' ' ALA . . . . . 0.737 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -135.8 123.28 22.08 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.541 -0.754 . . . . 0.0 109.503 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 268' ' ' PHE . . . . . 0.42 ' HB2' ' O ' ' A' ' 333' ' ' THR . 5.9 p90 -141.16 175.03 9.97 Favored 'General case' 0 C--N 1.32 -0.704 0 C-N-CA 120.123 -0.631 . . . . 0.0 111.497 -172.554 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 64.3 p -118.32 154.22 32.7 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.748 176.542 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 270' ' ' ILE . . . . . 0.924 HG12 HG13 ' A' ' 332' ' ' ILE . 60.1 mt -124.58 141.28 45.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 120.761 0.315 . . . . 0.0 110.78 -178.068 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -76.03 125.49 29.22 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.903 178.472 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 96.58 -21.83 43.54 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.087 -178.749 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 273' ' ' VAL . . . . . 0.451 HG23 ' HG3' ' A' ' 326' ' ' PRO . 48.5 t -100.42 103.25 14.54 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 121.059 0.457 . . . . 0.0 110.054 176.976 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 274' ' ' ASN . . . . . 0.519 ' O ' ' HB ' ' A' ' 322' ' ' VAL . 70.8 m-80 -121.01 137.84 54.45 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 -179.756 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 275' ' ' SER . . . . . 0.666 ' HB3' ' HB2' ' A' ' 288' ' ' GLN . 60.3 p -73.01 174.48 7.8 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.006 0.431 . . . . 0.0 111.511 -175.124 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 276' ' ' VAL . . . . . 0.538 HG11 HG21 ' A' ' 309' ' ' VAL . 33.3 m -110.05 178.69 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.284 -179.421 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 277' ' ' HIS . . . . . 0.78 ' HB2' ' HA ' ' A' ' 281' ' ' LYS . 7.7 p80 -36.84 88.73 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.675 0 O-C-N 124.561 1.163 . . . . 0.0 113.985 -177.271 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 39.7 tt0 -84.64 -36.46 21.96 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.518 -178.173 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 279' ' ' ILE . . . . . 0.782 HG22 HG23 ' A' ' 280' ' ' THR . 2.6 mp -80.94 -84.33 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.305 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.398 -172.788 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 280' ' ' THR . . . . . 0.782 HG23 HG22 ' A' ' 279' ' ' ILE . 32.6 p -127.69 45.79 2.67 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 111.597 0.221 . . . . 0.0 111.597 -174.686 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 281' ' ' LYS . . . . . 0.78 ' HA ' ' HB2' ' A' ' 277' ' ' HIS . 3.3 tmtp? 56.68 46.3 20.43 Favored 'General case' 0 CA--C 1.533 0.312 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 -176.792 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 49.2 p-10 -104.75 -162.01 0.86 Allowed 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 114.79 -1.095 . . . . 0.0 110.885 -175.085 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 76.1 p -105.97 124.45 49.59 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 178.749 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 81.2 p -127.28 -75.86 0.57 Allowed 'General case' 0 C--N 1.321 -0.643 0 C-N-CA 120.429 -0.508 . . . . 0.0 111.159 -174.26 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 67.09 31.24 77.22 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.898 -0.668 . . . . 0.0 112.002 -179.306 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 95.2 mm-40 -105.35 145.27 30.47 Favored Pre-proline 0 C--N 1.329 -0.311 0 N-CA-C 110.467 -0.197 . . . . 0.0 110.467 -178.142 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 287' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -55.22 137.5 77.06 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.805 2.336 . . . . 0.0 112.267 -179.813 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 288' ' ' GLN . . . . . 0.666 ' HB2' ' HB3' ' A' ' 275' ' ' SER . 52.0 tt0 -88.37 155.48 19.67 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.895 -176.992 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 59.0 t -89.84 113.34 25.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.349 178.638 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 290' ' ' PHE . . . . . 0.737 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 54.1 m-85 -100.52 131.12 46.6 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.46 -177.331 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 9.8 tpt180 -106.87 120.53 42.29 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.535 0.683 . . . . 0.0 109.877 178.368 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 292' ' ' VAL . . . . . 0.512 ' HB ' ' H ' ' A' ' 265' ' ' GLY . 57.6 t -67.66 140.01 19.94 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.954 0 CA-C-N 114.656 -1.157 . . . . 0.0 112.531 -176.198 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 293' ' ' LEU . . . . . 0.571 HD11 ' OG ' ' A' ' 303' ' ' SER . 4.4 mp -104.69 -30.94 9.62 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.739 175.534 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 294' ' ' ALA . . . . . 0.46 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -159.71 144.8 15.37 Favored 'General case' 0 C--N 1.333 -0.126 0 CA-C-O 120.534 0.207 . . . . 0.0 111.532 -176.358 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 70.7 t -138.09 100.23 1.68 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 175.589 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 35.8 m -138.49 113.5 9.27 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.439 -0.346 . . . . 0.0 111.085 -175.457 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 63.17 48.49 79.22 Favored Glycine 0 C--N 1.331 0.252 0 C-N-CA 120.834 -0.698 . . . . 0.0 111.922 -178.716 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 71.3 p 51.08 24.33 1.87 Allowed 'General case' 0 N--CA 1.469 0.5 0 C-N-CA 123.77 0.828 . . . . 0.0 112.229 -174.742 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 299' ' ' THR . . . . . 0.49 ' HA ' ' O ' ' A' ' 255' ' ' ILE . 29.0 m -111.48 111.18 22.02 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 176.304 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 300' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 294' ' ' ALA . 44.7 t -111.02 129.08 66.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.587 -172.445 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 93.5 m -90.97 116.08 28.49 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 172.298 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 302' ' ' ILE . . . . . 0.515 HG12 ' O ' ' A' ' 253' ' ' GLY . 29.2 pt -113.26 142.8 24.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 N-CA-C 112.917 0.71 . . . . 0.0 112.917 -171.57 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 303' ' ' SER . . . . . 0.571 ' OG ' HD11 ' A' ' 293' ' ' LEU . 89.5 p -137.71 142.13 35.56 Favored Pre-proline 0 C--N 1.322 -0.599 0 N-CA-C 106.95 -1.5 . . . . 0.0 106.95 169.906 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 304' ' ' PRO . . . . . 0.511 ' HD2' ' HD1' ' A' ' 290' ' ' PHE . 25.2 Cg_exo -66.83 -179.48 13.45 Favored 'Cis proline' 0 C--N 1.331 -0.377 0 CA-C-N 119.913 1.005 . . . . 0.0 112.88 0.868 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 305' ' ' LYS . . . . . 0.702 ' HG3' HD21 ' A' ' 250' ' ' ASN . 0.0 OUTLIER -112.87 145.93 39.8 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-O 121.102 0.477 . . . . 0.0 111.543 -179.259 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 306' ' ' ILE . . . . . 0.519 HD12 ' N ' ' A' ' 306' ' ' ILE . 2.2 mp -72.11 106.11 2.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.262 -0.881 . . . . 0.0 111.058 -175.958 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 307' ' ' LEU . . . . . 0.628 HD21 ' ND2' ' A' ' 250' ' ' ASN . 86.7 mt -124.68 108.08 28.82 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.116 -0.493 . . . . 0.0 109.853 178.32 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 308' ' ' PRO . . . . . 0.679 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 23.8 Cg_exo -72.89 136.92 26.0 Favored 'Trans proline' 0 N--CA 1.476 0.452 0 C-N-CA 123.006 2.471 . . . . 0.0 114.423 -170.849 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 309' ' ' VAL . . . . . 0.539 HG23 ' O ' ' A' ' 322' ' ' VAL . 47.5 t -91.14 -23.53 5.87 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.186 0 CA-C-N 115.283 -0.871 . . . . 0.0 109.549 171.675 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 310' ' ' GLU . . . . . 0.45 ' OE1' ' HB2' ' A' ' 324' ' ' ALA . 50.2 mt-10 -80.9 8.53 8.11 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.182 -179.537 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 22.6 t-20 -74.99 137.36 41.5 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 178.399 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 68.6 m -60.67 -35.98 77.6 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 111.608 0.225 . . . . 0.0 111.608 -174.671 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 39.7 m-20 -61.38 126.76 28.52 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-O 121.167 0.508 . . . . 0.0 111.247 179.89 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 57.9 t -69.86 -28.26 36.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.493 -177.466 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -72.03 -17.92 61.99 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 111.997 0.369 . . . . 0.0 111.997 -179.828 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 35.1 t -76.82 -40.52 47.62 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 121.223 -0.191 . . . . 0.0 111.21 -177.41 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 317' ' ' ARG . . . . . 0.465 ' N ' ' HD2' ' A' ' 318' ' ' PRO . 65.9 mtt85 -54.44 -53.24 61.82 Favored Pre-proline 0 CA--C 1.54 0.584 0 N-CA-C 113.652 0.982 . . . . 0.0 113.652 -176.276 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 318' ' ' PRO . . . . . 0.465 ' HD2' ' N ' ' A' ' 317' ' ' ARG . 9.9 Cg_endo -56.36 -23.93 49.21 Favored 'Trans proline' 0 C--N 1.357 0.989 0 C-N-CA 122.468 2.112 . . . . 0.0 113.282 -176.86 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 53.9 m-85 -115.23 12.38 16.48 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.703 -177.4 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 320' ' ' ALA . . . . . 0.509 ' HB3' HG22 ' A' ' 309' ' ' VAL . . . -78.1 161.04 27.69 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.35 -178.306 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 29.2 t-20 -122.42 -44.51 2.25 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.734 -175.416 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 322' ' ' VAL . . . . . 0.539 ' O ' HG23 ' A' ' 309' ' ' VAL . 34.7 m -124.95 179.0 3.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.793 -177.884 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 74.9 m-20 -62.3 -60.09 4.07 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.81 -178.736 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 324' ' ' ALA . . . . . 0.679 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -151.27 172.51 15.75 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 112.785 0.661 . . . . 0.0 112.785 -174.27 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 325' ' ' LYS . . . . . 0.701 ' HE3' ' OE1' ' A' ' 235' ' ' GLU . 14.9 ptmt -99.06 126.41 38.29 Favored Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 114.252 -1.34 . . . . 0.0 110.152 170.818 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 326' ' ' PRO . . . . . 0.451 ' HG3' HG23 ' A' ' 273' ' ' VAL . 90.8 Cg_endo -86.21 168.23 9.03 Favored 'Trans proline' 0 N--CA 1.461 -0.403 0 C-N-CA 122.963 2.442 . . . . 0.0 111.857 -179.757 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -69.8 122.71 19.75 Favored 'General case' 0 C--O 1.236 0.385 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 174.448 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 62.2 mm-40 58.22 -140.79 0.75 Allowed 'General case' 0 CA--C 1.528 0.115 0 O-C-N 123.53 0.519 . . . . 0.0 109.647 -172.822 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 329' ' ' SER . . . . . 0.669 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 48.7 m -112.86 -14.12 13.1 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 120.44 -0.504 . . . . 0.0 111.076 176.615 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 67.33 -151.02 0.18 Allowed 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 112.402 0.519 . . . . 0.0 112.402 175.329 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 331' ' ' ALA . . . . . 0.532 ' HB1' ' HB3' ' A' ' 224' ' ' SER . . . -89.86 127.4 35.99 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.945 -178.293 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 332' ' ' ILE . . . . . 0.924 HG13 HG12 ' A' ' 270' ' ' ILE . 1.7 mp -110.96 140.12 31.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.432 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.426 ' OG1' ' HA ' ' A' ' 224' ' ' SER . 50.8 m -103.43 99.0 8.81 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.147 -0.479 . . . . 0.0 109.739 -178.944 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 22.6 mm -84.27 127.67 39.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 N-CA-C 113.934 1.087 . . . . 0.0 113.934 -171.405 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 335' ' ' LEU . . . . . 0.469 HD23 ' N ' ' A' ' 335' ' ' LEU . 1.6 pt? -153.36 -172.85 4.37 Favored 'General case' 0 N--CA 1.447 -0.576 0 CA-C-N 114.024 -1.444 . . . . 0.0 107.65 168.816 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 20.6 t-20 -121.35 -23.92 5.57 Favored 'General case' 0 C--N 1.321 -0.649 0 C-N-CA 120.363 -0.535 . . . . 0.0 110.583 -178.599 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 68.1 mttm . . . . . 0 C--O 1.245 0.818 0 CA-C-O 118.097 -0.954 . . . . 0.0 111.399 179.071 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.81 0 N-CA-C 112.268 -0.333 . . . . 0.0 112.268 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 49.5 m -66.25 -32.52 73.99 Favored 'General case' 0 C--O 1.234 0.267 0 CA-C-O 120.39 0.138 . . . . 0.0 111.106 -179.866 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 44.8 m 70.4 -79.93 0.04 OUTLIER 'General case' 0 CA--C 1.534 0.333 0 O-C-N 123.68 0.613 . . . . 0.0 110.158 -178.416 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 226' ' ' GLU . . . . . 0.41 ' O ' ' HG2' ' A' ' 226' ' ' GLU . 37.9 tt0 56.61 34.49 24.54 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-O 121.812 0.815 . . . . 0.0 110.824 175.081 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 54.7 p -128.84 7.0 5.57 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.051 177.686 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 228' ' ' LEU . . . . . 0.528 HD13 ' H ' ' A' ' 260' ' ' SER . 91.1 mt -108.52 146.77 32.71 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.116 -0.947 . . . . 0.0 108.871 177.028 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 77.7 p -130.56 179.6 5.84 Favored 'General case' 0 C--N 1.325 -0.477 0 C-N-CA 119.973 -0.691 . . . . 0.0 110.675 -179.013 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 230' ' ' VAL . . . . . 0.88 HG11 HD12 ' A' ' 255' ' ' ILE . 91.3 t -146.51 136.71 17.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 120.91 0.386 . . . . 0.0 110.592 178.902 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 33.7 t -107.04 146.42 31.17 Favored 'General case' 0 N--CA 1.45 -0.465 0 CA-C-N 116.039 -0.528 . . . . 0.0 109.604 176.498 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 232' ' ' GLY . . . . . 0.478 ' O ' ' HD3' ' A' ' 234' ' ' PRO . . . 124.4 149.18 7.6 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.396 -0.906 . . . . 0.0 111.592 -176.817 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 66.5 mt-30 -98.6 103.82 20.88 Favored Pre-proline 0 C--N 1.323 -0.568 0 CA-C-N 116.72 0.26 . . . . 0.0 111.117 -176.583 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 234' ' ' PRO . . . . . 0.478 ' HD3' ' O ' ' A' ' 232' ' ' GLY . 4.8 Cg_exo -74.96 125.49 9.38 Favored 'Trans proline' 0 N--CA 1.457 -0.626 0 C-N-CA 122.259 1.972 . . . . 0.0 111.077 177.676 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -131.93 141.07 49.22 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.609 -179.14 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 35.7 m80 -141.48 149.04 40.41 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.681 -0.69 . . . . 0.0 109.947 178.207 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 237' ' ' LYS . . . . . 0.652 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -117.31 178.29 4.43 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.498 -175.349 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 238' ' ' VAL . . . . . 0.716 ' HB ' HG11 ' A' ' 248' ' ' VAL . 41.4 t -50.45 154.56 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.566 0 O-C-N 123.622 0.577 . . . . 0.0 111.31 -177.361 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 239' ' ' GLU . . . . . 0.646 ' O ' ' HB ' ' A' ' 248' ' ' VAL . 5.5 mm-40 -47.64 159.08 0.17 Allowed 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 113.032 0.752 . . . . 0.0 113.032 -177.137 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 240' ' ' ALA . . . . . . . . . . . . . . . -47.97 -35.41 10.78 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 115.259 -0.882 . . . . 0.0 112.009 179.069 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 241' ' ' LYS . . . . . 0.587 ' O ' ' HD3' ' A' ' 241' ' ' LYS . 0.0 OUTLIER -134.68 147.44 50.11 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.784 175.83 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -95.84 -175.88 3.55 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.835 179.647 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 44.0 m -67.57 -16.25 64.09 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.166 -0.47 . . . . 0.0 112.027 -175.574 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 5.7 m120 -90.34 -12.88 36.37 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.01 0.434 . . . . 0.0 110.329 176.869 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 89.82 17.74 53.26 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 121.006 -0.616 . . . . 0.0 112.288 -179.667 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 246' ' ' MET . . . . . 0.421 ' HA ' ' HD3' ' A' ' 247' ' ' PRO . 60.9 mtt -91.26 143.87 28.96 Favored Pre-proline 0 C--N 1.326 -0.442 0 CA-C-O 120.478 0.18 . . . . 0.0 110.621 -178.534 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 247' ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' ' 246' ' ' MET . 25.7 Cg_exo -65.81 125.87 15.0 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.885 2.39 . . . . 0.0 112.753 -177.18 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.716 HG11 ' HB ' ' A' ' 238' ' ' VAL . 31.7 t -120.1 144.43 28.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.009 178.825 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -88.45 112.32 22.81 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.068 178.957 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 250' ' ' ASN . . . . . . . . . . . . . 26.0 t-20 -99.69 -52.23 3.52 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.844 -176.343 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 98.4 mtt180 68.36 173.79 0.28 Allowed 'General case' 0 N--CA 1.472 0.668 0 N-CA-C 114.104 1.149 . . . . 0.0 114.104 179.832 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 42.2 mm-40 -117.34 177.55 4.69 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 114.312 -1.313 . . . . 0.0 109.341 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 253' ' ' GLY . . . . . 0.47 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -113.76 121.92 5.61 Favored Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.126 -1.035 . . . . 0.0 112.305 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 254' ' ' THR . . . . . 0.451 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 65.7 p -104.16 116.71 32.67 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 177.418 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.88 HD12 HG11 ' A' ' 230' ' ' VAL . 17.0 pt -123.84 147.38 28.27 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.981 -173.93 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 85.6 m -95.71 110.92 22.98 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 174.449 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.471 ' HA ' HG13 ' A' ' 230' ' ' VAL . 34.0 m -89.8 143.14 11.82 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.723 0 C-N-CA 119.93 -0.708 . . . . 0.0 112.833 -168.137 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 258' ' ' SER . . . . . 0.421 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 34.4 t -91.91 7.39 42.29 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 114.454 -1.248 . . . . 0.0 108.667 169.77 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 259' ' ' ALA . . . . . 0.693 ' HB3' HD21 ' A' ' 262' ' ' LEU . . . -88.25 175.08 7.83 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-N 115.473 -0.785 . . . . 0.0 109.243 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 260' ' ' SER . . . . . 0.528 ' H ' HD13 ' A' ' 228' ' ' LEU . 32.5 t -134.67 130.19 35.95 Favored 'General case' 0 C--N 1.323 -0.547 0 C-N-CA 120.465 -0.494 . . . . 0.0 111.57 -177.93 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 97.5 16.76 33.29 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.856 -0.688 . . . . 0.0 113.951 174.081 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 262' ' ' LEU . . . . . 0.693 HD21 ' HB3' ' A' ' 259' ' ' ALA . 2.0 mm? -65.7 128.92 37.91 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-N 117.344 0.572 . . . . 0.0 110.859 -178.841 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -128.83 175.39 8.67 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 176.335 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 43.4 t -78.64 131.2 34.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 174.325 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 100.15 9.19 48.92 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.627 -0.797 . . . . 0.0 112.699 -179.557 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -86.12 165.45 16.58 Favored 'General case' 0 CA--C 1.511 -0.521 0 CA-C-O 121.12 0.486 . . . . 0.0 110.147 175.95 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 267' ' ' ALA . . . . . 0.693 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -140.27 145.68 37.6 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.471 -179.575 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 268' ' ' PHE . . . . . 0.525 ' HB3' HD13 ' A' ' 334' ' ' ILE . 4.6 p90 -159.73 166.04 31.28 Favored 'General case' 0 C--N 1.319 -0.744 0 C-N-CA 120.127 -0.629 . . . . 0.0 111.328 -178.603 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 71.8 p -119.34 126.76 52.19 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.861 -0.608 . . . . 0.0 109.968 177.776 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 270' ' ' ILE . . . . . 0.595 HG12 HD12 ' A' ' 332' ' ' ILE . 46.6 mt -88.89 135.98 24.5 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.912 -177.49 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -65.31 122.16 16.5 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.23 -179.772 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 99.08 -23.86 34.64 Favored Glycine 0 N--CA 1.452 -0.256 0 CA-C-N 115.996 -0.547 . . . . 0.0 112.241 -179.392 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 49.0 t -94.22 108.42 20.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 121.152 0.501 . . . . 0.0 110.37 176.528 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 274' ' ' ASN . . . . . 0.409 ' HB2' ' OD1' ' A' ' 323' ' ' ASP . 63.7 m-80 -123.9 159.99 28.47 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 116.004 -0.544 . . . . 0.0 109.602 -179.398 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 53.1 p -92.04 164.68 13.52 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-O 121.124 0.487 . . . . 0.0 111.327 -179.048 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 276' ' ' VAL . . . . . 0.538 HG11 HG21 ' A' ' 309' ' ' VAL . 30.0 m -125.9 167.46 20.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.544 178.518 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 28.9 m80 -126.0 92.07 3.51 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.595 -0.275 . . . . 0.0 110.72 178.69 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 84.1 mt-30 -72.59 -14.13 61.54 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.769 0.319 . . . . 0.0 111.081 179.184 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 279' ' ' ILE . . . . . 0.513 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.2 mp -77.05 -59.95 2.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 116.539 -0.3 . . . . 0.0 110.319 -178.475 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 51.4 p -85.36 -10.02 56.85 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.454 -179.878 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 31.9 mmmt 58.35 43.81 19.39 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.7 -178.29 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -112.34 154.49 25.64 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.1 -178.357 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 49.8 p -105.96 123.01 47.3 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 176.731 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 284' ' ' THR . . . . . 0.432 ' HB ' ' HG3' ' A' ' 286' ' ' GLN . 82.0 p -124.53 -37.28 2.52 Favored 'General case' 0 C--N 1.317 -0.814 0 C-N-CA 120.487 -0.485 . . . . 0.0 111.508 -172.06 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 70.45 29.49 69.92 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.601 -0.809 . . . . 0.0 111.809 -177.394 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 286' ' ' GLN . . . . . 0.432 ' HG3' ' HB ' ' A' ' 284' ' ' THR . 83.3 mt-30 -76.25 113.87 32.43 Favored Pre-proline 0 C--N 1.33 -0.243 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.826 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 287' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_exo -51.65 126.55 19.97 Favored 'Trans proline' 0 C--O 1.232 0.224 0 C-N-CA 122.42 2.08 . . . . 0.0 111.928 -179.112 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -77.23 130.06 36.74 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 -175.018 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 289' ' ' VAL . . . . . 0.675 HG11 ' HG2' ' A' ' 337' ' ' LYS . 57.6 t -90.01 130.74 38.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.006 -176.108 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 290' ' ' PHE . . . . . 0.693 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 4.6 m-85 -98.79 151.18 21.07 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.05 -178.062 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 291' ' ' ARG . . . . . 0.495 ' HD2' ' C ' ' A' ' 290' ' ' PHE . 1.0 OUTLIER -113.18 130.09 56.32 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 174.172 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 47.9 t -92.49 129.51 42.96 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.231 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.923 -177.625 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 293' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -114.6 -20.7 10.6 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.684 -179.251 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 294' ' ' ALA . . . . . 0.586 ' HB3' ' HB ' ' A' ' 301' ' ' THR . . . -148.92 136.61 20.49 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.641 -0.424 . . . . 0.0 111.914 -179.303 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 295' ' ' VAL . . . . . 0.46 HG11 ' O ' ' A' ' 262' ' ' LEU . 80.4 t -142.7 123.0 10.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.681 -0.691 . . . . 0.0 109.79 175.515 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 36.2 t -154.09 108.66 3.06 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.58 -0.282 . . . . 0.0 110.742 179.158 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 63.57 54.8 29.21 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 121.031 -0.604 . . . . 0.0 112.189 -179.296 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 58.4 p 52.28 21.89 1.82 Allowed 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 123.725 0.81 . . . . 0.0 112.754 -176.764 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 45.8 m -107.64 117.83 35.13 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 173.911 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 300' ' ' VAL . . . . . 0.451 ' O ' ' HA ' ' A' ' 254' ' ' THR . 48.1 t -117.08 129.96 72.78 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.299 -172.041 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 301' ' ' THR . . . . . 0.586 ' HB ' ' HB3' ' A' ' 294' ' ' ALA . 45.1 m -98.21 116.75 31.09 Favored 'General case' 0 C--O 1.236 0.381 0 N-CA-C 108.744 -0.835 . . . . 0.0 108.744 174.718 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 302' ' ' ILE . . . . . 0.47 HG12 ' O ' ' A' ' 253' ' ' GLY . 29.2 pt -111.81 146.17 17.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 113.373 0.879 . . . . 0.0 113.373 -168.627 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 303' ' ' SER . . . . . 0.526 ' HB3' ' HA ' ' A' ' 304' ' ' PRO . 47.4 m -132.25 166.24 30.15 Favored Pre-proline 0 C--N 1.32 -0.698 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 171.899 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 304' ' ' PRO . . . . . 0.526 ' HA ' ' HB3' ' A' ' 303' ' ' SER . 6.0 Cg_exo -79.67 -142.71 0.24 Allowed 'Cis proline' 0 CA--C 1.531 0.327 0 CA-C-N 120.72 1.293 . . . . 0.0 112.636 0.291 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 305' ' ' LYS . . . . . 0.508 ' C ' HD12 ' A' ' 306' ' ' ILE . 0.0 OUTLIER -97.51 147.6 24.08 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.389 0.614 . . . . 0.0 112.152 178.784 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 306' ' ' ILE . . . . . 1.017 HG23 HG21 ' A' ' 322' ' ' VAL . 1.9 mp -119.83 110.35 28.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 115.043 -0.98 . . . . 0.0 110.131 -176.534 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 307' ' ' LEU . . . . . 0.434 ' HA ' ' HD3' ' A' ' 308' ' ' PRO . 88.6 mt -126.32 115.08 23.48 Favored Pre-proline 0 C--N 1.332 -0.183 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.221 -177.697 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 308' ' ' PRO . . . . . 0.774 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 35.3 Cg_exo -67.31 147.81 78.83 Favored 'Trans proline' 0 N--CA 1.474 0.339 0 C-N-CA 123.762 2.975 . . . . 0.0 114.714 -173.521 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 309' ' ' VAL . . . . . 0.617 HG22 ' HB1' ' A' ' 320' ' ' ALA . 26.2 t -93.34 -17.81 7.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 114.866 -1.061 . . . . 0.0 108.607 167.654 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 59.4 mm-40 -76.9 -6.71 53.57 Favored 'General case' 0 C--O 1.233 0.199 0 CA-C-N 115.23 -0.895 . . . . 0.0 112.117 -178.157 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 4.1 m120 -85.62 151.47 23.87 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.917 0.389 . . . . 0.0 111.101 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 30.9 m -93.28 -1.16 56.37 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.579 0.704 . . . . 0.0 109.125 175.347 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 313' ' ' ASP . . . . . 0.638 ' O ' ' HG3' ' A' ' 317' ' ' ARG . 59.7 t0 -58.0 117.57 4.47 Favored 'General case' 0 C--N 1.333 -0.116 0 CA-C-N 115.328 -0.851 . . . . 0.0 110.781 -179.292 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 49.0 t -53.54 -33.8 22.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.835 -0.62 . . . . 0.0 112.172 -178.446 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -85.18 -29.81 24.43 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 112.183 0.438 . . . . 0.0 112.183 -178.017 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 316' ' ' SER . . . . . 0.559 ' HB3' ' HB3' ' A' ' 313' ' ' ASP . 33.5 t -82.03 -27.74 32.88 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 111.759 0.281 . . . . 0.0 111.759 -175.133 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 317' ' ' ARG . . . . . 0.638 ' HG3' ' O ' ' A' ' 313' ' ' ASP . 49.8 mtp85 -63.98 -52.87 53.24 Favored Pre-proline 0 CA--C 1.539 0.548 0 N-CA-C 112.935 0.717 . . . . 0.0 112.935 -176.478 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 318' ' ' PRO . . . . . 0.604 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 22.1 Cg_exo -67.82 -28.93 35.95 Favored 'Trans proline' 0 C--N 1.357 0.991 0 C-N-CA 121.979 1.786 . . . . 0.0 112.871 -177.005 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 5.1 m-85 -98.42 12.84 33.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.017 -179.005 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 320' ' ' ALA . . . . . 0.617 ' HB1' HG22 ' A' ' 309' ' ' VAL . . . -59.76 144.27 48.76 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.539 -178.666 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 321' ' ' ASN . . . . . 0.452 ' OD1' HG13 ' A' ' 322' ' ' VAL . 17.5 p30 -142.98 -12.17 0.75 Allowed 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.53 -177.434 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 322' ' ' VAL . . . . . 1.017 HG21 HG23 ' A' ' 306' ' ' ILE . 35.0 m -139.15 178.65 3.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.404 177.658 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 323' ' ' ASP . . . . . 0.409 ' OD1' ' HB2' ' A' ' 274' ' ' ASN . 51.6 m-20 -64.01 -62.58 1.54 Allowed 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.978 176.87 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 324' ' ' ALA . . . . . 0.774 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -162.94 173.75 13.24 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 116.143 -0.481 . . . . 0.0 112.094 -175.44 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 22.0 pttp -119.28 106.97 42.04 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 115.218 -0.901 . . . . 0.0 109.457 172.277 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -86.29 167.52 9.13 Favored 'Trans proline' 0 C--O 1.235 0.367 0 C-N-CA 122.624 2.216 . . . . 0.0 113.507 -172.204 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 327' ' ' ALA . . . . . 0.424 ' O ' ' HB2' ' A' ' 328' ' ' GLU . . . -79.48 132.79 36.44 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 170.155 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 328' ' ' GLU . . . . . 0.424 ' HB2' ' O ' ' A' ' 327' ' ' ALA . 62.1 mm-40 73.27 166.25 0.3 Allowed 'General case' 0 N--CA 1.467 0.387 0 O-C-N 123.566 0.542 . . . . 0.0 109.576 -170.589 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 329' ' ' SER . . . . . 0.686 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 53.9 m -104.44 -10.53 17.64 Favored 'General case' 0 C--N 1.319 -0.731 0 C-N-CA 120.349 -0.54 . . . . 0.0 111.803 -174.265 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 67.62 -161.22 0.22 Allowed 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 113.022 0.749 . . . . 0.0 113.022 172.459 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -75.33 142.72 43.15 Favored 'General case' 0 CA--C 1.518 -0.275 0 CA-C-N 115.117 -0.947 . . . . 0.0 110.475 179.414 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 332' ' ' ILE . . . . . 0.686 HG13 HG23 ' A' ' 230' ' ' VAL . 24.8 mm -120.62 144.46 29.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.753 -175.783 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 33.8 m -111.27 97.63 6.92 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 178.404 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 334' ' ' ILE . . . . . 0.525 HD13 ' HB3' ' A' ' 268' ' ' PHE . 39.5 mm -81.57 131.54 33.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 112.769 0.655 . . . . 0.0 112.769 -173.247 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 335' ' ' LEU . . . . . 0.46 HD23 ' N ' ' A' ' 335' ' ' LEU . 1.7 pt? -152.03 -167.16 2.69 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 114.685 -1.143 . . . . 0.0 108.723 173.118 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 15.9 p-10 -110.88 -25.41 9.87 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 109.635 -0.505 . . . . 0.0 109.635 176.014 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 337' ' ' LYS . . . . . 0.675 ' HG2' HG11 ' A' ' 289' ' ' VAL . 27.1 tptp . . . . . 0 C--O 1.247 0.925 0 O-C-N 124.397 1.061 . . . . 0.0 111.407 177.506 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.953 0 N-CA-C 112.131 -0.387 . . . . 0.0 112.131 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 23.3 t 59.72 -141.71 0.61 Allowed 'General case' 0 CA--C 1.533 0.293 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 -179.291 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 60.9 m -112.09 -75.58 0.61 Allowed 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 178.708 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 47.91 66.81 0.95 Allowed 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.646 -0.707 . . . . 0.0 111.033 178.855 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 61.1 p -88.71 98.16 11.54 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.552 177.054 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 228' ' ' LEU . . . . . 0.608 HD22 ' H ' ' A' ' 260' ' ' SER . 53.4 mt -111.15 127.1 55.47 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.491 -173.31 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 229' ' ' THR . . . . . 0.527 ' HA ' ' HA ' ' A' ' 331' ' ' ALA . 64.3 p -129.91 -178.83 4.88 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 120.694 -0.402 . . . . 0.0 111.22 -178.822 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 230' ' ' VAL . . . . . 0.744 ' O ' ' HB2' ' A' ' 329' ' ' SER . 34.9 t -134.17 151.59 32.61 Favored 'Isoleucine or valine' 0 C--O 1.24 0.594 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 -179.43 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 41.7 t -126.89 125.37 41.48 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.23 175.383 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 87.61 91.75 1.02 Allowed Glycine 0 CA--C 1.52 0.382 0 C-N-CA 120.888 -0.673 . . . . 0.0 113.97 176.15 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 233' ' ' GLN . . . . . 0.562 ' HG2' ' OG ' ' A' ' 329' ' ' SER . 30.3 mm100 -97.86 117.01 65.66 Favored Pre-proline 0 CA--C 1.519 -0.242 0 O-C-N 122.821 -0.223 . . . . 0.0 110.623 171.843 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 234' ' ' PRO . . . . . 0.523 ' HD3' HG22 ' A' ' 255' ' ' ILE . 11.8 Cg_exo -67.09 172.93 9.18 Favored 'Trans proline' 0 N--CA 1.462 -0.353 0 C-N-CA 122.685 2.257 . . . . 0.0 111.741 176.565 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 235' ' ' GLU . . . . . 0.416 ' HG3' ' HE2' ' A' ' 237' ' ' LYS . 9.7 pt-20 -96.42 146.91 24.36 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.013 178.058 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 236' ' ' HIS . . . . . 0.629 ' C ' ' HD2' ' A' ' 237' ' ' LYS . 28.6 m80 -126.07 129.78 49.81 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.088 0.471 . . . . 0.0 111.01 -173.953 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 237' ' ' LYS . . . . . 0.629 ' HD2' ' C ' ' A' ' 236' ' ' HIS . 2.8 mptp? -118.11 177.48 4.78 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.441 -0.799 . . . . 0.0 110.0 -179.114 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 238' ' ' VAL . . . . . 0.893 ' HB ' HG11 ' A' ' 248' ' ' VAL . 52.2 t -48.68 131.35 6.18 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.224 0 O-C-N 123.817 0.698 . . . . 0.0 110.797 -179.446 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 239' ' ' GLU . . . . . 1.021 ' HA ' ' HB3' ' A' ' 251' ' ' ARG . 0.8 OUTLIER -56.16 158.59 3.94 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 113.713 1.005 . . . . 0.0 113.713 -172.811 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 240' ' ' ALA . . . . . 0.57 ' H ' ' HD3' ' A' ' 251' ' ' ARG . . . -26.21 -71.45 0.03 OUTLIER 'General case' 0 N--CA 1.471 0.624 0 CA-C-N 113.826 -1.534 . . . . 0.0 114.274 -172.559 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 241' ' ' LYS . . . . . 0.574 ' O ' ' HD3' ' A' ' 241' ' ' LYS . 0.0 OUTLIER -151.13 145.49 25.49 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.079 0.466 . . . . 0.0 111.681 -176.34 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 12.7 p-10 -103.29 -158.09 0.65 Allowed 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.747 -177.319 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 43.6 t -67.32 -30.99 70.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.733 177.924 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 5.7 m120 -83.83 -13.56 53.42 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.837 0.351 . . . . 0.0 110.488 177.993 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 70.34 47.76 41.77 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 121.124 -0.56 . . . . 0.0 113.022 176.575 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 246' ' ' MET . . . . . 0.438 ' HA ' ' HD3' ' A' ' 247' ' ' PRO . 25.0 mmt -99.14 121.46 55.44 Favored Pre-proline 0 C--N 1.326 -0.438 0 CA-C-N 116.794 0.297 . . . . 0.0 110.517 179.085 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 247' ' ' PRO . . . . . 0.438 ' HD3' ' HA ' ' A' ' 246' ' ' MET . 12.0 Cg_exo -72.71 121.88 7.75 Favored 'Trans proline' 0 C--N 1.343 0.286 0 C-N-CA 122.907 2.405 . . . . 0.0 112.116 -178.068 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.893 HG11 ' HB ' ' A' ' 238' ' ' VAL . 21.5 t -123.24 160.57 26.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 116.374 -0.376 . . . . 0.0 110.005 -178.601 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 249' ' ' ASP . . . . . 0.443 ' HB3' ' HG2' ' A' ' 237' ' ' LYS . 51.7 t0 -52.51 147.51 8.22 Favored 'General case' 0 N--CA 1.469 0.503 0 C-N-CA 123.152 0.581 . . . . 0.0 110.189 178.658 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 250' ' ' ASN . . . . . . . . . . . . . 46.6 p30 -34.9 142.46 0.05 Allowed 'General case' 0 N--CA 1.475 0.796 0 N-CA-C 115.176 1.547 . . . . 0.0 115.176 -169.461 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 251' ' ' ARG . . . . . 1.021 ' HB3' ' HA ' ' A' ' 239' ' ' GLU . 27.5 ptt180 -89.59 -59.27 2.25 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 114.207 -1.36 . . . . 0.0 111.668 178.445 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 252' ' ' GLN . . . . . 0.566 ' HG2' ' HG3' ' A' ' 251' ' ' ARG . 34.2 mm-40 -97.61 178.39 5.19 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.043 -174.349 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 253' ' ' GLY . . . . . 0.469 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -154.47 172.58 32.98 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 119.667 -1.254 . . . . 0.0 113.032 -178.965 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 254' ' ' THR . . . . . 0.549 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 47.0 p -119.38 128.81 54.41 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 177.822 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.523 HG22 ' HD3' ' A' ' 234' ' ' PRO . 26.6 pt -114.66 149.73 16.83 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.357 -175.659 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 40.8 m -98.4 110.47 23.05 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 177.223 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.525 HG21 HD12 ' A' ' 262' ' ' LEU . 35.0 m -92.41 144.99 8.15 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.859 0 CA-C-O 121.631 0.729 . . . . 0.0 112.697 -171.123 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 41.1 m -90.3 7.75 36.83 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 114.046 -1.434 . . . . 0.0 108.41 168.949 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 259' ' ' ALA . . . . . 0.579 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -91.06 162.04 14.86 Favored 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 115.117 -0.947 . . . . 0.0 110.468 -177.497 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 260' ' ' SER . . . . . 0.608 ' H ' HD22 ' A' ' 228' ' ' LEU . 48.7 m -137.82 138.91 39.64 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.122 -0.49 . . . . 0.0 109.814 177.36 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 94.55 34.26 6.4 Favored Glycine 0 N--CA 1.447 -0.586 0 C-N-CA 120.444 -0.884 . . . . 0.0 112.233 -178.42 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 262' ' ' LEU . . . . . 0.525 HD12 HG21 ' A' ' 257' ' ' VAL . 67.5 mt -102.37 143.39 32.18 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 178.361 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 46.2 mm-40 -142.78 175.32 9.91 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 178.116 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 264' ' ' VAL . . . . . 0.434 HG22 ' HA ' ' A' ' 294' ' ' ALA . 49.0 t -78.17 132.48 32.37 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.202 177.698 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 103.77 8.24 40.24 Favored Glycine 0 N--CA 1.453 -0.211 0 C-N-CA 120.569 -0.824 . . . . 0.0 112.775 179.406 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -89.05 157.56 18.3 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.915 0.388 . . . . 0.0 110.066 176.838 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 267' ' ' ALA . . . . . 0.605 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -131.23 121.94 25.68 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 178.883 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 268' ' ' PHE . . . . . 0.408 ' HB3' HD13 ' A' ' 334' ' ' ILE . 4.6 p90 -145.14 164.57 30.87 Favored 'General case' 0 C--N 1.32 -0.706 0 C-N-CA 119.4 -0.92 . . . . 0.0 111.988 -173.929 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 75.7 p -117.64 129.6 55.85 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.531 -0.759 . . . . 0.0 109.76 176.191 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 270' ' ' ILE . . . . . . . . . . . . . 66.0 mt -97.54 141.52 15.75 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.766 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 179.838 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 271' ' ' ALA . . . . . 0.47 ' HB3' ' HB1' ' A' ' 330' ' ' ALA . . . -63.98 132.84 51.87 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.032 0.444 . . . . 0.0 111.438 -176.577 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 98.68 -22.35 41.37 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.992 -0.623 . . . . 0.0 112.158 -178.56 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 273' ' ' VAL . . . . . 0.565 ' O ' ' HA ' ' A' ' 287' ' ' PRO . 45.2 t -77.95 103.44 5.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 120.665 0.269 . . . . 0.0 110.459 178.476 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 274' ' ' ASN . . . . . 0.416 ' O ' ' HB ' ' A' ' 322' ' ' VAL . 46.8 m-20 -96.72 136.97 36.51 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 108.79 -0.819 . . . . 0.0 108.79 174.842 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 275' ' ' SER . . . . . 0.404 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 8.1 t -99.48 165.58 11.57 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.773 0.321 . . . . 0.0 110.399 -176.219 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 19.0 m -128.76 155.49 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.014 0 CA-C-N 115.092 -0.958 . . . . 0.0 109.987 167.271 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 277' ' ' HIS . . . . . 0.623 ' HB2' ' HB3' ' A' ' 282' ' ' ASP . 29.3 m80 -100.41 89.74 4.06 Favored 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 108.547 -0.909 . . . . 0.0 108.547 175.148 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 5.3 tm0? -59.78 -47.54 85.3 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.091 -172.139 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 59.2 mt -56.44 -48.15 80.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 N-CA-C 111.942 0.349 . . . . 0.0 111.942 -177.166 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 40.6 p -94.97 -3.71 48.0 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 112.414 0.524 . . . . 0.0 112.414 -176.3 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 4.0 tppp? 59.22 53.2 5.52 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 121.285 0.564 . . . . 0.0 110.256 -178.337 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 282' ' ' ASP . . . . . 0.623 ' HB3' ' HB2' ' A' ' 277' ' ' HIS . 37.2 t70 -120.13 116.37 25.52 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.299 -175.416 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 67.8 p -107.16 118.17 35.99 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.3 178.83 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 67.5 p -129.05 -15.98 4.14 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 112.063 0.394 . . . . 0.0 112.063 -174.968 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 87.23 -3.09 86.89 Favored Glycine 0 N--CA 1.453 -0.179 0 C-N-CA 120.61 -0.805 . . . . 0.0 112.724 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 286' ' ' GLN . . . . . 0.472 ' HA ' ' HD3' ' A' ' 287' ' ' PRO . 82.9 mt-30 -64.76 137.92 97.3 Favored Pre-proline 0 C--N 1.33 -0.27 0 N-CA-C 110.425 -0.213 . . . . 0.0 110.425 179.006 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 287' ' ' PRO . . . . . 0.565 ' HA ' ' O ' ' A' ' 273' ' ' VAL . 32.8 Cg_exo -62.52 149.37 91.23 Favored 'Trans proline' 0 CA--C 1.529 0.257 0 C-N-CA 122.633 2.222 . . . . 0.0 113.448 -174.558 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 29.3 tp60 -87.06 136.82 32.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.075 176.989 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 289' ' ' VAL . . . . . 0.405 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 38.8 t -94.55 130.15 43.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.901 -0.591 . . . . 0.0 109.645 177.592 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 290' ' ' PHE . . . . . 0.605 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 53.6 m-85 -99.97 165.52 11.5 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.926 0.393 . . . . 0.0 111.772 -175.145 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 30.3 mmt-85 -119.76 127.98 53.32 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 174.075 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 57.7 t -86.6 130.74 36.26 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.886 0 CA-C-O 120.785 0.326 . . . . 0.0 111.583 -175.966 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 293' ' ' LEU . . . . . 0.511 HD21 ' HB2' ' A' ' 303' ' ' SER . 3.1 mm? -103.58 -34.88 8.5 Favored 'General case' 0 C--N 1.333 -0.112 0 CA-C-N 115.945 -0.571 . . . . 0.0 111.297 178.503 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 294' ' ' ALA . . . . . 0.51 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -154.22 140.1 18.19 Favored 'General case' 0 CA--C 1.518 -0.252 0 C-N-CA 120.648 -0.421 . . . . 0.0 111.593 -179.149 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 96.9 t -135.73 100.09 2.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.705 175.016 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 50.5 m -141.77 118.29 10.92 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.845 -176.33 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 63.93 46.5 91.36 Favored Glycine 0 C--N 1.33 0.236 0 C-N-CA 121.147 -0.549 . . . . 0.0 112.144 -178.018 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 72.2 p 51.0 23.54 1.53 Allowed 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 123.701 0.8 . . . . 0.0 112.221 -175.739 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 299' ' ' THR . . . . . 0.45 ' HA ' ' O ' ' A' ' 255' ' ' ILE . 50.7 m -114.0 118.47 34.22 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 176.609 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 300' ' ' VAL . . . . . 0.549 ' O ' ' HA ' ' A' ' 254' ' ' THR . 43.6 t -110.18 128.39 66.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.412 -172.515 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 59.3 m -83.97 114.14 21.49 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 108.091 -1.078 . . . . 0.0 108.091 171.568 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 302' ' ' ILE . . . . . 0.469 HG12 ' O ' ' A' ' 253' ' ' GLY . 31.0 pt -111.01 144.76 18.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 N-CA-C 113.279 0.844 . . . . 0.0 113.279 -167.059 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 303' ' ' SER . . . . . 0.511 ' HB2' HD21 ' A' ' 293' ' ' LEU . 50.4 m -149.6 157.7 38.43 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-N 114.041 -1.436 . . . . 0.0 107.409 173.018 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 304' ' ' PRO . . . . . 0.496 ' O ' ' HA ' ' A' ' 303' ' ' SER . 15.7 Cg_exo -69.27 -162.21 1.72 Allowed 'Cis proline' 0 CA--C 1.531 0.34 0 CA-C-N 120.151 1.09 . . . . 0.0 112.811 0.742 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 305' ' ' LYS . . . . . 0.611 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -95.27 142.38 27.75 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.401 0.619 . . . . 0.0 111.964 -178.124 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 306' ' ' ILE . . . . . 0.643 HG23 HG21 ' A' ' 322' ' ' VAL . 2.0 mp -86.35 84.92 2.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.079 -0.964 . . . . 0.0 109.939 -178.397 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 307' ' ' LEU . . . . . . . . . . . . . 96.8 mt -112.38 102.45 54.17 Favored Pre-proline 0 C--N 1.324 -0.501 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.579 -178.757 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 308' ' ' PRO . . . . . 0.684 ' HD2' HD22 ' A' ' 311' ' ' ASN . 12.4 Cg_exo -75.5 150.29 35.86 Favored 'Trans proline' 0 N--CA 1.462 -0.334 0 C-N-CA 122.898 2.399 . . . . 0.0 113.004 -174.398 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 42.5 t -72.26 -27.3 26.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 108.647 -0.872 . . . . 0.0 108.647 170.305 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 54.7 mm-40 -92.21 32.68 1.14 Allowed 'General case' 0 N--CA 1.453 -0.285 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.805 176.3 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.684 HD22 ' HD2' ' A' ' 308' ' ' PRO . 26.0 t-20 -71.98 -31.93 66.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.378 -178.336 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 312' ' ' THR . . . . . 0.5 ' HB ' ' O ' ' A' ' 311' ' ' ASN . 84.9 m 83.34 -25.43 0.14 Allowed 'General case' 0 N--CA 1.469 0.491 0 O-C-N 124.088 0.867 . . . . 0.0 111.116 -178.837 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 65.8 m-20 -81.89 122.9 28.33 Favored 'General case' 0 C--O 1.233 0.216 0 C-N-CA 120.522 -0.471 . . . . 0.0 109.96 172.571 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 38.8 t -59.35 -39.38 78.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 115.188 -0.914 . . . . 0.0 112.229 -173.092 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -66.22 -25.27 66.83 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 112.229 0.455 . . . . 0.0 112.229 -177.332 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 42.4 t -86.54 -12.59 48.32 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 111.773 0.286 . . . . 0.0 111.773 -177.848 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 317' ' ' ARG . . . . . 0.564 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 51.8 mtp85 -62.8 -50.61 76.78 Favored Pre-proline 0 CA--C 1.538 0.492 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 -178.503 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 318' ' ' PRO . . . . . 0.564 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 39.2 Cg_exo -63.32 -26.05 71.48 Favored 'Trans proline' 0 C--N 1.356 0.936 0 C-N-CA 121.903 1.735 . . . . 0.0 112.788 -177.755 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 6.0 m-85 -93.23 19.99 7.47 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.335 -179.409 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -59.49 131.02 49.68 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 112.31 0.485 . . . . 0.0 112.31 -175.799 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 76.3 m-20 -128.15 -18.38 4.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.507 -0.77 . . . . 0.0 110.255 175.052 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 322' ' ' VAL . . . . . 0.643 HG21 HG23 ' A' ' 306' ' ' ILE . 33.8 m -138.7 176.75 5.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.107 -179.576 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -98.74 -18.97 17.73 Favored 'General case' 0 C--N 1.327 -0.385 0 C-N-CA 121.002 -0.279 . . . . 0.0 111.123 -179.773 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 324' ' ' ALA . . . . . 0.529 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -168.62 156.67 8.1 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.98 -173.117 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 325' ' ' LYS . . . . . 0.401 ' HA ' ' HD3' ' A' ' 326' ' ' PRO . 35.4 mtmm -87.02 120.87 71.71 Favored Pre-proline 0 N--CA 1.453 -0.294 0 N-CA-C 107.618 -1.252 . . . . 0.0 107.618 165.442 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 326' ' ' PRO . . . . . 0.476 ' HG2' HG22 ' A' ' 273' ' ' VAL . 51.1 Cg_exo -61.14 162.81 18.53 Favored 'Trans proline' 0 C--O 1.233 0.274 0 C-N-CA 122.525 2.15 . . . . 0.0 113.612 -171.372 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -73.45 132.35 42.84 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 108.593 -0.891 . . . . 0.0 108.593 170.896 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 9.0 pm0 42.38 -137.46 0.25 Allowed 'General case' 0 N--CA 1.47 0.565 0 O-C-N 124.132 0.895 . . . . 0.0 110.338 -169.757 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 329' ' ' SER . . . . . 0.744 ' HB2' ' O ' ' A' ' 230' ' ' VAL . 38.1 m -113.98 -44.87 3.11 Favored 'General case' 0 C--N 1.322 -0.622 0 C-N-CA 119.797 -0.761 . . . . 0.0 111.604 176.973 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 330' ' ' ALA . . . . . 0.47 ' HB1' ' HB3' ' A' ' 271' ' ' ALA . . . 78.54 -166.66 0.04 OUTLIER 'General case' 0 N--CA 1.474 0.771 0 O-C-N 123.813 0.696 . . . . 0.0 112.52 176.169 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 331' ' ' ALA . . . . . 0.527 ' HA ' ' HA ' ' A' ' 229' ' ' THR . . . -84.95 157.92 20.67 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.755 -0.657 . . . . 0.0 112.386 -173.764 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 332' ' ' ILE . . . . . 0.479 HD11 ' CG2' ' A' ' 230' ' ' VAL . 29.1 mt -110.0 144.97 17.15 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.232 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.083 -179.223 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 54.4 m -111.45 98.46 7.48 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 172.35 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 334' ' ' ILE . . . . . 0.408 HD13 ' HB3' ' A' ' 268' ' ' PHE . 32.2 mm -84.96 134.79 26.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 N-CA-C 113.247 0.832 . . . . 0.0 113.247 -171.074 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 335' ' ' LEU . . . . . 0.427 HD23 ' N ' ' A' ' 335' ' ' LEU . 1.9 pt? -164.39 -166.16 1.07 Allowed 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 115.074 -0.966 . . . . 0.0 109.62 172.418 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 74.3 m-80 -143.84 21.39 1.8 Allowed 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 175.978 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 68.2 mttm . . . . . 0 C--O 1.242 0.66 0 CA-C-N 115.196 -0.911 . . . . 0.0 110.84 -174.371 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.914 0 N-CA-C 112.429 -0.268 . . . . 0.0 112.429 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 50.6 p -78.68 125.78 29.83 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.595 0.236 . . . . 0.0 111.048 178.784 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 84.8 m -71.66 -59.21 2.88 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.413 179.545 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 34.6 69.32 0.16 Allowed 'General case' 0 N--CA 1.471 0.609 0 O-C-N 124.356 1.035 . . . . 0.0 113.088 -179.309 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 51.8 m 60.25 90.53 0.06 Allowed 'General case' 0 C--O 1.234 0.285 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.906 176.838 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 228' ' ' LEU . . . . . 0.531 HD13 ' H ' ' A' ' 260' ' ' SER . 88.8 mt -68.77 144.77 54.24 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.317 173.891 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 40.7 p -132.29 179.32 6.18 Favored 'General case' 0 C--N 1.326 -0.441 0 C-N-CA 120.262 -0.575 . . . . 0.0 111.137 -176.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 230' ' ' VAL . . . . . 1.056 HG23 HD11 ' A' ' 332' ' ' ILE . 72.1 t -143.22 145.87 22.15 Favored 'Isoleucine or valine' 0 C--O 1.239 0.532 0 CA-C-O 120.775 0.322 . . . . 0.0 110.373 -179.446 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 46.2 t -131.74 97.58 4.24 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 115.234 -0.894 . . . . 0.0 109.181 173.818 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . -142.15 -157.53 7.19 Favored Glycine 0 N--CA 1.447 -0.6 0 C-N-CA 120.184 -1.008 . . . . 0.0 112.639 -176.008 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 83.5 mt-30 -86.1 159.98 52.95 Favored Pre-proline 0 C--N 1.323 -0.571 0 N-CA-C 110.396 -0.224 . . . . 0.0 110.396 179.775 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo -64.51 174.66 4.15 Favored 'Trans proline' 0 C--N 1.35 0.619 0 C-N-CA 122.875 2.383 . . . . 0.0 111.418 176.357 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 235' ' ' GLU . . . . . 0.538 ' HA ' ' OE1' ' A' ' 235' ' ' GLU . 3.9 mm-40 -91.9 167.54 12.05 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 113.461 0.911 . . . . 0.0 113.461 -174.977 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 236' ' ' HIS . . . . . 0.519 ' CE1' ' HA2' ' A' ' 253' ' ' GLY . 23.2 m80 -111.63 143.21 42.89 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 113.266 -1.788 . . . . 0.0 111.432 -165.239 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 237' ' ' LYS . . . . . 0.431 ' HD3' ' C ' ' A' ' 236' ' ' HIS . 18.7 mmtp -112.64 148.84 33.77 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.793 -173.461 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 238' ' ' VAL . . . . . 0.643 HG23 HD21 ' A' ' 307' ' ' LEU . 65.3 t -91.8 115.28 30.49 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-O 121.06 0.457 . . . . 0.0 110.738 178.022 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 239' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -94.37 116.69 29.1 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.408 -0.815 . . . . 0.0 109.123 174.581 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 240' ' ' ALA . . . . . 0.522 ' O ' ' HA ' ' A' ' 247' ' ' PRO . . . -47.73 -51.86 20.57 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 115.671 -0.695 . . . . 0.0 112.698 -169.967 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 241' ' ' LYS . . . . . 0.813 ' HB2' ' HA2' ' A' ' 245' ' ' GLY . 0.1 OUTLIER -113.59 144.17 43.33 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.82 0.343 . . . . 0.0 111.773 -179.167 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 10.8 p-10 -93.24 -157.46 0.54 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.298 -178.016 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 48.0 p -60.68 -29.18 69.15 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.589 177.327 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 6.2 m120 -97.89 2.04 48.75 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.369 -179.583 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 245' ' ' GLY . . . . . 0.813 ' HA2' ' HB2' ' A' ' 241' ' ' LYS . . . 71.64 31.09 65.55 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.891 -0.671 . . . . 0.0 113.272 177.253 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 246' ' ' MET . . . . . . . . . . . . . 24.1 mmt -110.25 152.46 43.21 Favored Pre-proline 0 C--N 1.325 -0.479 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 178.473 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 247' ' ' PRO . . . . . 0.522 ' HA ' ' O ' ' A' ' 240' ' ' ALA . 23.4 Cg_exo -65.51 120.79 8.04 Favored 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.226 1.951 . . . . 0.0 111.879 -178.982 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 62.2 t -133.66 134.29 56.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.591 -178.787 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 37.4 t70 -89.82 117.8 28.93 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 174.757 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 250' ' ' ASN . . . . . 0.435 ' OD1' ' HB3' ' A' ' 236' ' ' HIS . 16.2 t-20 -65.31 159.9 22.89 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.155 -174.51 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 37.7 ptt180 -66.76 -172.98 0.2 Allowed 'General case' 0 CA--C 1.533 0.303 0 N-CA-C 113.012 0.745 . . . . 0.0 113.012 -175.782 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 252' ' ' GLN . . . . . 0.49 ' HB3' ' O ' ' A' ' 302' ' ' ILE . 45.2 mm-40 -96.61 177.96 5.49 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.222 -0.899 . . . . 0.0 110.729 -177.233 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 253' ' ' GLY . . . . . 0.519 ' HA2' ' CE1' ' A' ' 236' ' ' HIS . . . -95.5 152.22 20.29 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.184 177.877 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 52.1 p -129.5 116.96 19.73 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.758 0.314 . . . . 0.0 110.588 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.755 HD12 HG11 ' A' ' 230' ' ' VAL . 18.0 pt -125.94 149.92 31.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 N-CA-C 112.25 0.463 . . . . 0.0 112.25 -175.798 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 91.5 m -98.86 113.35 25.43 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 175.124 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.667 HG21 HD12 ' A' ' 262' ' ' LEU . 34.8 m -90.12 143.26 11.56 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.669 0 N-CA-C 113.38 0.881 . . . . 0.0 113.38 -167.009 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 258' ' ' SER . . . . . 0.433 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 37.4 t -92.73 7.94 41.44 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 113.795 -1.548 . . . . 0.0 108.523 168.163 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 259' ' ' ALA . . . . . 0.522 ' HB3' HD11 ' A' ' 262' ' ' LEU . . . -84.77 165.78 17.51 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-N 115.616 -0.72 . . . . 0.0 109.822 -177.344 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 260' ' ' SER . . . . . 0.531 ' H ' HD13 ' A' ' 228' ' ' LEU . 49.4 m -123.47 142.0 51.44 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 120.814 0.34 . . . . 0.0 111.443 -178.005 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 67.3 50.65 43.27 Favored Glycine 0 N--CA 1.452 -0.25 0 CA-C-N 115.812 -0.631 . . . . 0.0 113.58 175.317 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 262' ' ' LEU . . . . . 0.667 HD12 HG21 ' A' ' 257' ' ' VAL . 77.7 mt -99.64 145.83 27.15 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 117.086 0.443 . . . . 0.0 110.842 178.034 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 83.6 mt-30 -142.94 171.75 13.63 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.928 178.954 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 50.8 t -77.16 133.32 31.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 176.731 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 265' ' ' GLY . . . . . 0.483 ' O ' ' HE3' ' A' ' 337' ' ' LYS . . . 107.62 -7.83 36.76 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.44 -0.886 . . . . 0.0 112.619 -179.372 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 63.4 m-20 -69.28 155.63 40.09 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-O 121.069 0.462 . . . . 0.0 110.567 178.262 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 267' ' ' ALA . . . . . 0.621 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -130.2 129.69 43.72 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.45 -0.795 . . . . 0.0 108.884 177.442 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 268' ' ' PHE . . . . . . . . . . . . . 3.2 p90 -151.38 175.63 12.06 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 119.97 -0.692 . . . . 0.0 111.466 -175.456 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 269' ' ' THR . . . . . 0.468 HG21 ' HB2' ' A' ' 287' ' ' PRO . 82.7 p -126.14 147.19 49.67 Favored 'General case' 0 C--N 1.32 -0.674 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 176.571 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 270' ' ' ILE . . . . . . . . . . . . . 47.1 mm -103.65 138.26 28.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 N-CA-C 110.236 -0.283 . . . . 0.0 110.236 179.381 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -63.34 135.4 56.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.442 -178.608 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 89.41 -23.19 20.02 Favored Glycine 0 CA--C 1.517 0.198 0 CA-C-N 115.92 -0.582 . . . . 0.0 112.712 179.755 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 273' ' ' VAL . . . . . 0.473 HG21 ' HG3' ' A' ' 326' ' ' PRO . 42.5 t -86.09 130.24 36.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 120.925 0.393 . . . . 0.0 110.879 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 72.3 m-80 -135.24 142.08 45.91 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.329 179.671 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 65.2 p -84.04 165.81 18.25 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.252 0.549 . . . . 0.0 111.746 -178.279 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 276' ' ' VAL . . . . . 0.428 HG11 HG21 ' A' ' 309' ' ' VAL . 35.4 m -113.64 175.82 2.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 115.315 -0.857 . . . . 0.0 110.668 179.432 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 277' ' ' HIS . . . . . 0.43 ' HB3' ' HA ' ' A' ' 281' ' ' LYS . 5.8 p80 22.04 77.75 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.866 0 O-C-N 124.822 1.326 . . . . 0.0 113.866 179.304 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 32.3 tp60 -62.03 -50.52 71.7 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.177 -179.055 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 279' ' ' ILE . . . . . 0.582 ' H ' ' HB3' ' A' ' 282' ' ' ASP . 2.5 mp -104.43 -77.44 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 174.814 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 35.9 p -141.11 92.61 2.5 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 177.477 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 281' ' ' LYS . . . . . 0.43 ' HA ' ' HB3' ' A' ' 277' ' ' HIS . 31.7 mmmt 59.82 26.99 16.23 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.058 -0.973 . . . . 0.0 110.503 -172.6 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 282' ' ' ASP . . . . . 0.582 ' HB3' ' H ' ' A' ' 279' ' ' ILE . 37.3 t70 -81.01 117.38 21.56 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.338 -0.846 . . . . 0.0 109.858 178.605 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 41.1 p -105.52 105.78 15.97 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.991 0.424 . . . . 0.0 110.931 -176.502 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 52.9 p -129.18 -7.58 4.82 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.183 -177.953 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 67.82 32.6 78.06 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.601 -0.809 . . . . 0.0 113.368 176.249 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 286' ' ' GLN . . . . . 0.415 ' HA ' ' HD3' ' A' ' 287' ' ' PRO . 11.7 mm100 -72.09 135.89 82.32 Favored Pre-proline 0 C--N 1.325 -0.479 0 CA-C-N 117.06 0.43 . . . . 0.0 110.2 179.106 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 287' ' ' PRO . . . . . 0.468 ' HB2' HG21 ' A' ' 269' ' ' THR . 41.0 Cg_exo -57.0 135.0 68.21 Favored 'Trans proline' 0 C--O 1.235 0.333 0 C-N-CA 122.465 2.11 . . . . 0.0 111.958 -178.778 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 2.5 tm0? -75.08 128.93 36.67 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 -177.294 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 46.4 t -94.19 123.83 46.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.935 0.398 . . . . 0.0 110.512 -177.621 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 290' ' ' PHE . . . . . 0.621 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 4.6 m-85 -97.28 168.6 10.32 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.818 -177.214 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 11.9 tpt180 -139.37 121.16 15.41 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 177.355 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 60.7 t -75.61 134.25 29.58 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.913 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.868 -172.824 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 293' ' ' LEU . . . . . 0.621 HD11 ' HB3' ' A' ' 303' ' ' SER . 7.0 mp -104.38 -35.2 8.02 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.628 178.388 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 294' ' ' ALA . . . . . 0.529 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -149.75 137.95 20.51 Favored 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 120.667 -0.413 . . . . 0.0 111.641 -176.545 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 66.5 t -136.03 109.63 9.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.555 174.79 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 50.4 m -151.48 117.02 5.38 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.544 -177.279 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 61.21 46.97 93.4 Favored Glycine 0 C--N 1.33 0.218 0 C-N-CA 120.804 -0.712 . . . . 0.0 111.79 -177.83 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 76.3 p 51.78 19.79 1.01 Allowed 'General case' 0 N--CA 1.471 0.587 0 C-N-CA 123.76 0.824 . . . . 0.0 112.427 -175.169 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 54.3 m -105.22 116.68 32.35 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 176.756 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 300' ' ' VAL . . . . . 0.529 ' HA ' ' O ' ' A' ' 294' ' ' ALA . 49.0 t -114.21 125.77 71.58 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.288 -172.753 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 53.9 m -87.77 115.76 25.44 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 172.78 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 302' ' ' ILE . . . . . 0.49 ' O ' ' HB3' ' A' ' 252' ' ' GLN . 28.6 pt -110.81 147.81 14.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-O 121.867 0.842 . . . . 0.0 113.156 -169.012 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 303' ' ' SER . . . . . 0.621 ' HB3' HD11 ' A' ' 293' ' ' LEU . 48.2 t -151.23 148.82 23.27 Favored Pre-proline 0 C--N 1.317 -0.812 0 CA-C-N 113.808 -1.542 . . . . 0.0 106.911 174.487 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 304' ' ' PRO . . . . . 0.476 ' C ' ' HA ' ' A' ' 303' ' ' SER . 32.2 Cg_exo -64.31 152.71 74.16 Favored 'Cis proline' 0 C--N 1.332 -0.302 0 C-N-CA 124.252 -1.145 . . . . 0.0 113.299 0.969 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 305' ' ' LYS . . . . . 0.452 ' HE3' HD11 ' A' ' 307' ' ' LEU . 0.0 OUTLIER -82.04 148.81 28.41 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-N 114.888 -1.051 . . . . 0.0 110.184 173.761 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 306' ' ' ILE . . . . . 1.011 HG21 ' HA ' ' A' ' 325' ' ' LYS . 42.5 mm -84.23 117.85 30.47 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 N-CA-C 113.02 0.748 . . . . 0.0 113.02 -167.626 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 307' ' ' LEU . . . . . 0.643 HD21 HG23 ' A' ' 238' ' ' VAL . 82.1 mt -121.46 100.0 44.94 Favored Pre-proline 0 C--N 1.331 -0.199 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.782 177.314 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 308' ' ' PRO . . . . . 0.756 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 16.0 Cg_exo -72.74 134.48 22.06 Favored 'Trans proline' 0 C--O 1.232 0.218 0 C-N-CA 123.19 2.593 . . . . 0.0 113.611 -176.271 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 309' ' ' VAL . . . . . 0.678 ' HA ' ' HB2' ' A' ' 316' ' ' SER . 46.4 t -72.18 -34.66 50.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.356 0.598 . . . . 0.0 109.409 171.345 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 87.8 mt-10 -77.07 36.27 0.17 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.288 -0.869 . . . . 0.0 111.939 179.777 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.404 ' HB2' ' HB2' ' A' ' 308' ' ' PRO . 0.4 OUTLIER -122.3 56.71 1.1 Allowed 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 -178.751 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 312' ' ' THR . . . . . 0.568 ' HB ' HG23 ' A' ' 314' ' ' VAL . 30.0 m 60.35 17.43 7.12 Favored 'General case' 0 CA--C 1.539 0.553 0 CA-C-O 121.716 0.77 . . . . 0.0 109.411 -171.762 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 37.1 t70 69.53 -2.58 1.88 Allowed 'General case' 0 CA--C 1.537 0.466 0 CA-C-N 114.728 -1.124 . . . . 0.0 111.233 -177.369 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 314' ' ' VAL . . . . . 0.568 HG23 ' HB ' ' A' ' 312' ' ' THR . 57.6 t -57.44 -45.59 85.67 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 N-CA-C 112.723 0.638 . . . . 0.0 112.723 -177.759 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 315' ' ' ALA . . . . . 0.53 ' HB3' ' O ' ' A' ' 308' ' ' PRO . . . -74.44 -17.54 60.77 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.021 0.439 . . . . 0.0 110.899 -179.714 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 316' ' ' SER . . . . . 0.678 ' HB2' ' HA ' ' A' ' 309' ' ' VAL . 44.3 t -81.36 -18.72 44.64 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.552 177.126 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 317' ' ' ARG . . . . . 0.684 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 37.3 mmm-85 -61.1 -55.84 40.34 Favored Pre-proline 0 CA--C 1.536 0.42 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.635 -176.97 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 318' ' ' PRO . . . . . 0.684 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 11.8 Cg_exo -71.98 -41.13 2.18 Favored 'Trans proline' 0 C--N 1.357 1.003 0 C-N-CA 121.565 1.51 . . . . 0.0 112.588 -178.516 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER 177.35 96.67 0.01 OUTLIER 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.103 177.653 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 320' ' ' ALA . . . . . 0.617 ' HB2' ' HA ' ' A' ' 316' ' ' SER . . . -69.68 138.51 53.02 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.077 176.899 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 19.6 p30 -129.23 -27.9 2.41 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.479 -0.328 . . . . 0.0 111.57 176.833 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 322' ' ' VAL . . . . . 0.843 HG21 HG23 ' A' ' 306' ' ' ILE . 35.1 m -138.31 179.49 3.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.703 0.287 . . . . 0.0 110.596 177.758 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 -90.38 -32.72 16.33 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.502 177.776 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 324' ' ' ALA . . . . . 0.756 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -149.2 159.51 44.19 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.638 -0.255 . . . . 0.0 111.478 -175.351 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 325' ' ' LYS . . . . . 1.011 ' HA ' HG21 ' A' ' 306' ' ' ILE . 64.3 pttt -79.94 146.9 64.79 Favored Pre-proline 0 N--CA 1.452 -0.335 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 171.413 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 326' ' ' PRO . . . . . 0.548 ' HD3' HG21 ' A' ' 306' ' ' ILE . 50.6 Cg_exo -57.33 129.81 36.02 Favored 'Trans proline' 0 N--CA 1.462 -0.365 0 C-N-CA 122.253 1.969 . . . . 0.0 111.873 -178.299 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -75.13 121.79 22.61 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 174.285 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER 61.95 -135.95 0.52 Allowed 'General case' 0 C--N 1.332 -0.158 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 -167.474 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 329' ' ' SER . . . . . 0.718 ' HB2' ' O ' ' A' ' 230' ' ' VAL . 50.5 m -113.95 -41.45 3.55 Favored 'General case' 0 C--N 1.32 -0.711 0 C-N-CA 120.16 -0.616 . . . . 0.0 109.871 169.67 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 330' ' ' ALA . . . . . 0.436 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 79.77 -171.04 0.04 OUTLIER 'General case' 0 N--CA 1.479 1.008 0 O-C-N 124.129 0.893 . . . . 0.0 113.394 170.819 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -83.77 157.22 22.17 Favored 'General case' 0 C--O 1.233 0.213 0 CA-C-N 115.176 -0.92 . . . . 0.0 111.107 -176.823 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 332' ' ' ILE . . . . . 1.056 HD11 HG23 ' A' ' 230' ' ' VAL . 1.5 mp -126.37 146.37 32.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.474 -174.854 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.417 ' HB ' ' OG1' ' A' ' 269' ' ' THR . 88.6 m -110.66 99.16 8.16 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.998 -0.742 . . . . 0.0 108.998 173.251 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 37.8 mm -81.58 125.7 39.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -171.238 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 335' ' ' LEU . . . . . 0.432 ' HB2' ' O ' ' A' ' 267' ' ' ALA . 8.2 mp -113.07 167.3 10.64 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.074 -0.966 . . . . 0.0 109.958 172.167 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 74.0 m-80 -124.33 6.57 8.4 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 115.315 -0.857 . . . . 0.0 109.271 174.969 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 337' ' ' LYS . . . . . 0.483 ' HE3' ' O ' ' A' ' 265' ' ' GLY . 21.5 pttp . . . . . 0 C--O 1.244 0.798 0 O-C-N 124.656 1.223 . . . . 0.0 112.565 -179.418 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.833 0 N-CA-C 112.198 -0.361 . . . . 0.0 112.198 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 49.4 m 59.93 71.86 0.55 Allowed 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 121.003 0.43 . . . . 0.0 111.031 -178.021 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 88.8 m -69.14 -49.16 59.47 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.711 -179.238 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 86.7 tt0 53.23 45.83 27.76 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-O 121.588 0.709 . . . . 0.0 110.427 179.378 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 29.0 t -147.81 24.94 1.06 Allowed 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.559 0.695 . . . . 0.0 109.499 179.749 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 228' ' ' LEU . . . . . 0.498 HD13 ' H ' ' A' ' 260' ' ' SER . 89.8 mt -99.77 146.79 26.17 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.274 -0.875 . . . . 0.0 109.237 178.533 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 229' ' ' THR . . . . . 0.429 ' HA ' ' HA ' ' A' ' 331' ' ' ALA . 72.5 p -128.93 178.75 6.16 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 119.835 -0.746 . . . . 0.0 111.075 -177.89 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 230' ' ' VAL . . . . . 0.652 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 75.7 t -147.15 127.68 5.39 Favored 'Isoleucine or valine' 0 C--O 1.237 0.434 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.482 -178.918 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 34.1 t -92.53 145.18 24.64 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.012 176.961 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 115.46 141.64 7.44 Favored Glycine 0 N--CA 1.444 -0.773 0 C-N-CA 120.619 -0.801 . . . . 0.0 111.647 -179.097 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 233' ' ' GLN . . . . . 0.922 ' HG3' ' H ' ' A' ' 328' ' ' GLU . 15.0 mp0 -101.75 103.69 30.16 Favored Pre-proline 0 C--N 1.321 -0.638 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 -177.739 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -85.3 122.47 2.47 Favored 'Trans proline' 0 N--CA 1.45 -1.084 0 C-N-CA 121.485 1.457 . . . . 0.0 111.751 179.64 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 235' ' ' GLU . . . . . 0.479 ' HG2' ' HB3' ' A' ' 325' ' ' LYS . 54.2 mt-10 -154.07 120.05 5.32 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.328 178.787 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 236' ' ' HIS . . . . . 0.462 ' NE2' ' HB2' ' A' ' 250' ' ' ASN . 63.3 t-80 -138.64 146.77 42.08 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 174.474 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 237' ' ' LYS . . . . . 0.659 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 5.8 mptt -122.34 135.66 54.76 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.765 -169.484 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 238' ' ' VAL . . . . . 0.915 HG22 ' HB2' ' A' ' 249' ' ' ASP . 46.7 t -70.78 124.5 27.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 115.661 -0.7 . . . . 0.0 109.706 175.765 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 239' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 -85.4 154.28 21.95 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.772 0.32 . . . . 0.0 110.347 179.477 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 240' ' ' ALA . . . . . . . . . . . . . . . -65.32 -32.13 73.62 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.352 -179.005 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 241' ' ' LYS . . . . . 0.69 ' O ' ' HD3' ' A' ' 241' ' ' LYS . 0.0 OUTLIER -141.32 144.88 34.84 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 121.256 0.55 . . . . 0.0 111.823 -179.899 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 54.6 p-10 -106.97 -156.5 0.58 Allowed 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.081 174.18 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 32.7 p -68.29 -9.25 46.24 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 112.018 0.377 . . . . 0.0 112.018 176.594 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 5.5 m120 -111.18 -10.07 14.31 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.705 0.288 . . . . 0.0 111.253 176.999 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 245' ' ' GLY . . . . . 0.48 ' HA2' ' HB2' ' A' ' 241' ' ' LYS . . . 93.01 15.88 50.15 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.723 -0.751 . . . . 0.0 113.571 177.432 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 246' ' ' MET . . . . . . . . . . . . . 26.1 ptt? -113.09 151.19 43.98 Favored Pre-proline 0 C--N 1.324 -0.516 0 CA-C-N 117.121 0.46 . . . . 0.0 110.248 177.592 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 247' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_exo -68.84 118.19 5.51 Favored 'Trans proline' 0 C--N 1.346 0.418 0 C-N-CA 121.856 1.704 . . . . 0.0 111.592 -178.253 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 43.9 t -145.24 143.61 22.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.142 -177.152 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 249' ' ' ASP . . . . . 0.915 ' HB2' HG22 ' A' ' 238' ' ' VAL . 9.0 t70 -89.29 140.64 29.29 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 109.454 -0.572 . . . . 0.0 109.454 175.055 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 250' ' ' ASN . . . . . 0.462 ' HB2' ' NE2' ' A' ' 236' ' ' HIS . 67.4 m-80 -87.91 -64.99 1.06 Allowed 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 112.495 0.554 . . . . 0.0 112.495 -172.406 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 251' ' ' ARG . . . . . 0.441 ' HB2' ' CD2' ' A' ' 236' ' ' HIS . 68.6 mtp180 -113.61 158.77 20.4 Favored 'General case' 0 CA--C 1.511 -0.525 0 N-CA-C 114.322 1.23 . . . . 0.0 114.322 -171.82 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 4.7 mp0 -91.73 178.0 6.04 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 113.249 -1.796 . . . . 0.0 109.265 179.099 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 253' ' ' GLY . . . . . 0.605 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -80.75 93.08 1.46 Allowed Glycine 0 N--CA 1.446 -0.643 0 C-N-CA 120.312 -0.947 . . . . 0.0 112.23 177.748 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 72.7 p -94.5 116.33 28.66 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.022 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 2.1 pp -136.24 171.53 16.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 N-CA-C 113.012 0.745 . . . . 0.0 113.012 -173.121 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 64.9 m -111.65 117.89 34.15 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 177.505 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.461 ' HB ' ' H ' ' A' ' 259' ' ' ALA . 34.9 m -90.9 144.7 8.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 N-CA-C 113.838 1.051 . . . . 0.0 113.838 -169.101 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 258' ' ' SER . . . . . 0.417 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 39.2 t -92.22 8.42 38.2 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 113.772 -1.558 . . . . 0.0 108.339 166.188 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 259' ' ' ALA . . . . . 0.461 ' H ' ' HB ' ' A' ' 257' ' ' VAL . . . -92.85 166.13 12.57 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.274 -0.876 . . . . 0.0 109.908 -177.52 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 260' ' ' SER . . . . . 0.498 ' H ' HD13 ' A' ' 228' ' ' LEU . 32.4 t -139.17 137.09 35.75 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.77 0.319 . . . . 0.0 110.158 178.949 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 97.26 29.4 7.96 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.199 -177.821 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 262' ' ' LEU . . . . . 0.442 HD12 HG21 ' A' ' 257' ' ' VAL . 79.2 mt -101.63 126.78 48.52 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.107 0.479 . . . . 0.0 111.16 -179.617 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 97.0 mm-40 -134.11 -178.92 5.25 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.257 -0.883 . . . . 0.0 108.873 177.359 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 41.0 t -77.81 131.12 35.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 176.653 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 106.41 9.01 32.16 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.305 -0.95 . . . . 0.0 113.195 179.021 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -88.88 163.32 15.68 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.994 0.426 . . . . 0.0 110.31 176.57 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 267' ' ' ALA . . . . . 0.715 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -135.38 146.52 48.42 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.474 -0.784 . . . . 0.0 109.023 177.917 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 268' ' ' PHE . . . . . 0.407 ' HZ ' HG21 ' A' ' 302' ' ' ILE . 2.7 p90 -163.87 175.48 10.38 Favored 'General case' 0 C--N 1.325 -0.489 0 C-N-CA 120.054 -0.658 . . . . 0.0 111.709 -177.841 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 73.9 p -125.41 144.69 50.4 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.471 -0.786 . . . . 0.0 109.131 173.808 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 270' ' ' ILE . . . . . 0.402 ' HB ' ' HB ' ' A' ' 273' ' ' VAL . 58.7 mt -103.14 141.66 18.57 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 C-N-CA 121.127 -0.229 . . . . 0.0 110.968 -176.752 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -67.38 125.79 27.23 Favored 'General case' 0 C--O 1.232 0.133 0 CA-C-O 120.869 0.366 . . . . 0.0 110.947 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 91.82 -22.24 32.23 Favored Glycine 0 N--CA 1.453 -0.189 0 C-N-CA 121.058 -0.591 . . . . 0.0 112.194 -178.262 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 273' ' ' VAL . . . . . 0.402 ' HB ' ' HB ' ' A' ' 270' ' ' ILE . 48.9 t -94.58 102.55 13.73 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-O 121.33 0.586 . . . . 0.0 110.743 178.346 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 274' ' ' ASN . . . . . 0.687 ' HA ' ' HA ' ' A' ' 287' ' ' PRO . 70.7 m-80 -110.17 150.83 28.08 Favored 'General case' 0 C--N 1.318 -0.801 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 174.967 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 275' ' ' SER . . . . . 0.488 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 7.6 t -85.35 -169.58 2.71 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 120.301 -0.559 . . . . 0.0 110.092 -174.98 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 27.3 m -113.27 177.46 1.66 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 CA-C-N 115.612 -0.722 . . . . 0.0 112.054 179.553 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 277' ' ' HIS . . . . . 0.792 ' CG ' ' HA ' ' A' ' 281' ' ' LYS . 3.4 p80 -57.03 119.69 6.73 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 113.893 -1.503 . . . . 0.0 111.838 173.695 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -81.94 -49.52 10.21 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.987 -177.867 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 279' ' ' ILE . . . . . 0.659 ' H ' HD12 ' A' ' 279' ' ' ILE . 2.7 mp -68.18 -93.74 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.401 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.163 -174.759 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 280' ' ' THR . . . . . 0.431 HG23 HG22 ' A' ' 279' ' ' ILE . 36.2 p -137.98 68.24 1.4 Allowed 'General case' 0 C--O 1.235 0.307 0 CA-C-O 120.637 0.256 . . . . 0.0 111.393 -174.939 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 281' ' ' LYS . . . . . 0.792 ' HA ' ' CG ' ' A' ' 277' ' ' HIS . 0.0 OUTLIER 56.59 32.33 20.74 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.675 -177.016 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 282' ' ' ASP . . . . . 0.579 ' O ' ' HB3' ' A' ' 277' ' ' HIS . 1.6 m-20 -74.86 -177.03 3.11 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.645 176.134 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 68.9 p -106.57 108.07 19.39 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 120.76 0.314 . . . . 0.0 110.211 178.258 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 74.8 p -117.07 -58.29 2.08 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.681 -175.314 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 64.24 30.85 78.97 Favored Glycine 0 C--O 1.23 -0.124 0 C-N-CA 121.064 -0.589 . . . . 0.0 113.347 174.633 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 46.2 mm-40 -101.12 129.69 26.58 Favored Pre-proline 0 C--N 1.323 -0.584 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 179.259 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 287' ' ' PRO . . . . . 0.687 ' HA ' ' HA ' ' A' ' 274' ' ' ASN . 48.3 Cg_exo -56.16 138.15 82.02 Favored 'Trans proline' 0 C--N 1.344 0.329 0 C-N-CA 122.563 2.175 . . . . 0.0 112.159 -179.356 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 288' ' ' GLN . . . . . 0.47 ' HA ' HE21 ' A' ' 288' ' ' GLN . 2.2 tp-100 -64.81 139.9 58.81 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.78 -179.069 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 52.8 t -97.42 124.0 50.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 176.205 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 290' ' ' PHE . . . . . 0.715 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 6.2 m-85 -98.87 151.44 20.85 Favored 'General case' 0 C--N 1.323 -0.559 0 C-N-CA 120.884 -0.326 . . . . 0.0 110.876 -174.578 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 37.2 mmt180 -116.97 118.86 33.59 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.691 -0.686 . . . . 0.0 109.34 174.187 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 48.9 t -75.56 127.52 37.05 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.954 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.874 -178.517 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 293' ' ' LEU . . . . . . . . . . . . . 84.8 mt -110.84 -19.48 12.81 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.928 -176.957 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 294' ' ' ALA . . . . . 0.663 ' HB3' ' HB ' ' A' ' 301' ' ' THR . . . -155.72 138.3 15.05 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 111.85 0.315 . . . . 0.0 111.85 -178.887 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 295' ' ' VAL . . . . . 0.438 HG22 HG13 ' A' ' 300' ' ' VAL . 60.5 t -138.14 132.59 42.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 175.039 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 41.5 t -157.95 110.61 2.38 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.677 -0.238 . . . . 0.0 110.97 -176.954 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 60.76 46.03 95.29 Favored Glycine 0 C--N 1.33 0.25 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.028 179.798 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 298' ' ' THR . . . . . 0.42 ' O ' HG22 ' A' ' 257' ' ' VAL . 75.6 p 53.91 17.9 1.47 Allowed 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 123.887 0.875 . . . . 0.0 112.647 -175.845 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 52.9 m -102.77 109.55 21.18 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 108.015 -1.106 . . . . 0.0 108.015 171.171 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 300' ' ' VAL . . . . . 0.438 HG13 HG22 ' A' ' 295' ' ' VAL . 39.9 t -104.56 134.69 45.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.715 -169.124 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 301' ' ' THR . . . . . 0.663 ' HB ' ' HB3' ' A' ' 294' ' ' ALA . 94.3 m -96.99 109.31 22.08 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.352 -0.84 . . . . 0.0 108.997 172.626 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 302' ' ' ILE . . . . . 0.605 HG12 ' O ' ' A' ' 253' ' ' GLY . 30.2 pt -110.66 138.06 40.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-O 121.648 0.737 . . . . 0.0 111.922 -175.37 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 303' ' ' SER . . . . . . . . . . . . . 50.5 m -129.54 150.95 77.1 Favored Pre-proline 0 C--N 1.317 -0.846 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 173.162 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 304' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_exo -68.22 176.54 27.47 Favored 'Cis proline' 0 C--N 1.333 -0.282 0 C-N-CA 124.637 -0.985 . . . . 0.0 112.892 1.015 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 305' ' ' LYS . . . . . 0.888 ' HE2' HD11 ' A' ' 307' ' ' LEU . 0.0 OUTLIER -94.04 166.81 11.96 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.492 178.583 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 306' ' ' ILE . . . . . 0.599 HG22 ' HG2' ' A' ' 325' ' ' LYS . 42.6 mm -87.47 96.3 5.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.366 -174.144 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 307' ' ' LEU . . . . . 0.888 HD11 ' HE2' ' A' ' 305' ' ' LYS . 84.2 mt -106.82 110.32 63.6 Favored Pre-proline 0 C--N 1.33 -0.28 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 175.859 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 308' ' ' PRO . . . . . 0.632 ' HG3' ' HE3' ' A' ' 325' ' ' LYS . 79.1 Cg_endo -82.69 157.8 16.24 Favored 'Trans proline' 0 C--O 1.231 0.143 0 C-N-CA 122.512 2.141 . . . . 0.0 114.364 -172.12 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 39.6 t -81.76 -11.17 12.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 114.958 -1.019 . . . . 0.0 108.467 168.782 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 4.6 mm-40 -70.54 -7.03 40.77 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.19 -0.914 . . . . 0.0 110.219 176.618 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 23.8 t-20 -64.07 118.29 8.3 Favored 'General case' 0 N--CA 1.451 -0.391 0 CA-C-N 115.605 -0.725 . . . . 0.0 109.45 -179.141 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 19.5 m -86.3 -17.19 35.25 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.36 -171.441 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 313' ' ' ASP . . . . . 0.589 ' O ' ' HG3' ' A' ' 317' ' ' ARG . 9.8 t70 -71.83 118.58 14.86 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 178.438 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 314' ' ' VAL . . . . . 0.406 ' HA ' ' CD ' ' A' ' 317' ' ' ARG . 41.2 t -59.08 -36.4 62.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.054 -0.521 . . . . 0.0 112.273 -173.906 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -73.87 -25.36 60.0 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.502 0.191 . . . . 0.0 111.38 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 32.6 t -94.55 -6.22 44.16 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.693 -0.23 . . . . 0.0 111.096 -179.007 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 317' ' ' ARG . . . . . 0.589 ' HG3' ' O ' ' A' ' 313' ' ' ASP . 76.4 mtp180 -59.52 -49.6 91.39 Favored Pre-proline 0 N--CA 1.468 0.464 0 N-CA-C 112.392 0.516 . . . . 0.0 112.392 177.837 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 318' ' ' PRO . . . . . 0.515 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 54.3 Cg_exo -56.5 -24.4 52.86 Favored 'Trans proline' 0 C--N 1.359 1.118 0 C-N-CA 122.477 2.118 . . . . 0.0 112.756 -179.803 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 11.6 m-30 -77.08 -6.19 51.84 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.369 -0.832 . . . . 0.0 111.495 -175.68 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -54.85 130.28 40.51 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-O 120.976 0.417 . . . . 0.0 111.723 -177.662 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 26.7 t-20 -110.71 -37.88 5.31 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.663 -0.699 . . . . 0.0 109.554 179.294 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 322' ' ' VAL . . . . . 0.521 HG21 HG23 ' A' ' 306' ' ' ILE . 34.4 m -130.74 170.28 19.86 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 115.267 -0.879 . . . . 0.0 110.16 179.083 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 73.2 m-20 -62.11 -44.14 97.31 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 112.386 0.513 . . . . 0.0 112.386 -177.782 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 324' ' ' ALA . . . . . 0.509 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -156.56 168.41 27.47 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 112.666 0.617 . . . . 0.0 112.666 -172.493 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 325' ' ' LYS . . . . . 0.632 ' HE3' ' HG3' ' A' ' 308' ' ' PRO . 9.9 mtmp? -102.05 106.45 47.87 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 114.816 -1.084 . . . . 0.0 108.531 167.582 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -80.24 162.51 22.77 Favored 'Trans proline' 0 N--CA 1.459 -0.506 0 C-N-CA 122.018 1.812 . . . . 0.0 112.58 -175.59 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -80.03 122.55 26.88 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 174.953 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 328' ' ' GLU . . . . . 0.922 ' H ' ' HG3' ' A' ' 233' ' ' GLN . 85.0 tt0 71.89 162.81 0.26 Allowed 'General case' 0 CA--C 1.532 0.251 0 O-C-N 124.093 0.87 . . . . 0.0 109.672 -176.006 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 329' ' ' SER . . . . . 0.652 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 50.6 m -85.34 -14.57 46.02 Favored 'General case' 0 C--N 1.323 -0.554 0 C-N-CA 120.913 -0.315 . . . . 0.0 110.861 -177.375 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 330' ' ' ALA . . . . . 0.48 ' H ' ' HG2' ' A' ' 328' ' ' GLU . . . 63.5 -160.36 0.3 Allowed 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 121.381 0.61 . . . . 0.0 112.611 173.015 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 331' ' ' ALA . . . . . 0.429 ' HA ' ' HA ' ' A' ' 229' ' ' THR . . . -82.03 148.14 28.79 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.292 -0.867 . . . . 0.0 110.131 178.253 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 332' ' ' ILE . . . . . . . . . . . . . 43.4 mt -124.24 144.63 33.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-O 121.169 0.509 . . . . 0.0 111.304 -178.148 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 29.6 m -104.21 97.7 7.62 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.494 -0.775 . . . . 0.0 109.217 179.611 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 36.4 mm -78.55 127.91 38.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 112.858 0.688 . . . . 0.0 112.858 -170.772 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 335' ' ' LEU . . . . . . . . . . . . . 8.2 mp -109.15 176.13 5.2 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 114.871 -1.059 . . . . 0.0 110.122 171.541 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 23.0 p30 -131.61 9.57 4.67 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 115.321 -0.854 . . . . 0.0 109.628 173.526 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 337' ' ' LYS . . . . . 0.536 ' NZ ' ' HB3' ' A' ' 337' ' ' LYS . 8.1 mtpm? . . . . . 0 C--O 1.244 0.794 0 CA-C-O 118.552 -0.737 . . . . 0.0 110.891 178.745 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.895 0 N-CA-C 111.948 -0.461 . . . . 0.0 111.948 . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 55.4 p -93.18 -36.9 12.38 Favored 'General case' 0 C--N 1.326 -0.423 0 O-C-N 122.712 -0.287 . . . . 0.0 110.985 179.795 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 41.9 m 73.62 -57.46 0.62 Allowed 'General case' 0 N--CA 1.467 0.424 0 O-C-N 123.921 0.763 . . . . 0.0 110.791 -179.478 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 4.7 mm-40 57.05 34.27 24.65 Favored 'General case' 0 N--CA 1.465 0.302 0 C-N-CA 123.364 0.665 . . . . 0.0 112.41 176.88 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 65.9 p -141.3 21.31 2.23 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.812 173.387 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 228' ' ' LEU . . . . . 0.617 HD22 ' HA ' ' A' ' 259' ' ' ALA . 83.4 mt -98.01 126.82 43.6 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-N 115.614 -0.721 . . . . 0.0 109.761 -179.548 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 55.5 p -124.73 179.24 5.07 Favored 'General case' 0 C--N 1.322 -0.625 0 C-N-CA 120.458 -0.497 . . . . 0.0 110.3 -179.611 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 230' ' ' VAL . . . . . 0.712 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 63.5 t -147.63 146.92 17.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 120.602 0.239 . . . . 0.0 110.672 -178.234 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 231' ' ' SER . . . . . 0.528 ' HA ' ' HB3' ' A' ' 328' ' ' GLU . 48.9 m -132.11 96.62 3.94 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 173.386 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 232' ' ' GLY . . . . . 0.628 ' HA3' HG22 ' A' ' 255' ' ' ILE . . . -122.5 -163.05 11.74 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 119.854 -1.165 . . . . 0.0 113.693 -172.889 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 233' ' ' GLN . . . . . 0.581 ' HB3' ' HD2' ' A' ' 234' ' ' PRO . 94.6 mm-40 -85.49 163.63 43.76 Favored Pre-proline 0 C--N 1.327 -0.397 0 CA-C-N 115.615 -0.293 . . . . 0.0 110.541 -178.833 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 234' ' ' PRO . . . . . 0.581 ' HD2' ' HB3' ' A' ' 233' ' ' GLN . 9.5 Cg_endo -55.37 134.3 63.1 Favored 'Trans proline' 0 C--N 1.35 0.646 0 C-N-CA 122.871 2.38 . . . . 0.0 113.442 -176.51 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 235' ' ' GLU . . . . . 0.564 ' HB2' ' CE ' ' A' ' 325' ' ' LYS . 57.7 mt-10 -97.18 124.79 41.34 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 114.982 -1.008 . . . . 0.0 108.452 177.903 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 236' ' ' HIS . . . . . 0.441 ' HB2' HD21 ' A' ' 307' ' ' LEU . 6.3 p80 -174.1 172.81 3.27 Favored 'General case' 0 CA--C 1.521 -0.152 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 -175.145 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 237' ' ' LYS . . . . . 0.793 ' HB3' ' HG3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -161.41 125.25 3.32 Favored 'General case' 0 CA--C 1.529 0.172 0 CA-C-O 121.546 0.688 . . . . 0.0 110.881 165.649 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 238' ' ' VAL . . . . . 0.696 ' HB ' HG11 ' A' ' 248' ' ' VAL . 40.9 t -108.85 156.49 9.44 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.81 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 172.266 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 239' ' ' GLU . . . . . . . . . . . . . 16.4 pt-20 -54.57 152.22 7.07 Favored 'General case' 0 C--O 1.235 0.32 0 N-CA-C 111.582 0.216 . . . . 0.0 111.582 -177.863 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 240' ' ' ALA . . . . . 0.438 ' O ' ' HA ' ' A' ' 247' ' ' PRO . . . -33.24 -55.15 0.41 Allowed 'General case' 0 N--CA 1.471 0.61 0 N-CA-C 113.729 1.011 . . . . 0.0 113.729 -175.284 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 241' ' ' LYS . . . . . 0.56 ' HD2' ' O ' ' A' ' 241' ' ' LYS . 0.0 OUTLIER -135.05 150.68 50.32 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.763 0.316 . . . . 0.0 111.472 -179.294 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -96.37 -158.2 0.64 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.477 -177.77 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 65.0 m -60.23 -33.02 71.68 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.233 -0.439 . . . . 0.0 112.111 -177.936 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 15.8 t-20 -87.87 -13.35 42.27 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 121.038 0.447 . . . . 0.0 110.387 179.247 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 245' ' ' GLY . . . . . 0.526 ' HA2' ' HB2' ' A' ' 241' ' ' LYS . . . 84.56 24.57 45.99 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.546 -0.835 . . . . 0.0 113.206 176.011 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 246' ' ' MET . . . . . 0.426 ' HA ' ' HD3' ' A' ' 247' ' ' PRO . 19.4 ptp -92.44 141.15 24.44 Favored Pre-proline 0 C--N 1.327 -0.411 0 CA-C-N 117.007 0.403 . . . . 0.0 110.173 176.042 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 247' ' ' PRO . . . . . 0.438 ' HA ' ' O ' ' A' ' 240' ' ' ALA . 20.0 Cg_exo -66.73 121.87 9.16 Favored 'Trans proline' 0 C--N 1.344 0.307 0 C-N-CA 122.547 2.165 . . . . 0.0 112.484 -176.95 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.696 HG11 ' HB ' ' A' ' 238' ' ' VAL . 47.7 t -91.51 140.73 15.57 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 176.188 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -78.0 89.97 4.17 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.231 0.538 . . . . 0.0 110.363 -178.328 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 250' ' ' ASN . . . . . 0.705 ' HB2' ' HB2' ' A' ' 237' ' ' LYS . 22.1 p30 -100.31 9.75 42.23 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.791 -177.067 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 82.9 mtm180 -113.61 161.87 16.91 Favored 'General case' 0 CA--C 1.509 -0.613 0 N-CA-C 113.151 0.796 . . . . 0.0 113.151 -177.712 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 42.0 mm-40 55.58 179.74 0.04 OUTLIER 'General case' 0 N--CA 1.471 0.606 0 CA-C-N 113.616 -1.629 . . . . 0.0 113.425 170.65 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -172.11 113.33 0.48 Allowed Glycine 0 N--CA 1.448 -0.555 0 CA-C-N 114.723 -1.126 . . . . 0.0 110.644 178.418 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 74.1 p -95.52 117.47 30.47 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 117.399 0.599 . . . . 0.0 110.771 -175.152 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.628 HG22 ' HA3' ' A' ' 232' ' ' GLY . 22.7 pt -120.81 132.59 69.93 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-O 121.239 0.542 . . . . 0.0 111.97 -175.447 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 60.7 m -88.34 110.55 20.86 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 173.874 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.42 ' HA ' HG13 ' A' ' 230' ' ' VAL . 33.2 m -90.1 143.06 11.98 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.84 0 C-N-CA 119.341 -0.943 . . . . 0.0 112.798 -167.89 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 25.0 m -91.61 9.23 33.09 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 113.852 -1.522 . . . . 0.0 108.301 169.915 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 259' ' ' ALA . . . . . 0.617 ' HA ' HD22 ' A' ' 228' ' ' LEU . . . -100.5 178.19 4.8 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 114.725 -1.125 . . . . 0.0 109.55 -177.314 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 42.0 t -145.03 151.38 38.46 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.782 0.325 . . . . 0.0 110.79 179.113 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 84.52 15.87 67.57 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.982 -0.628 . . . . 0.0 112.876 178.544 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 262' ' ' LEU . . . . . 0.437 ' O ' HG11 ' A' ' 295' ' ' VAL . 63.4 mt -85.38 129.92 34.7 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.678 0.275 . . . . 0.0 110.703 -179.11 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 14.4 mm-40 -139.95 173.04 11.92 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.726 178.93 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 36.1 t -67.63 137.89 23.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 C-N-CA 121.001 -0.279 . . . . 0.0 110.34 -179.852 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 101.93 4.7 51.24 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.541 -0.837 . . . . 0.0 112.962 177.648 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 68.4 m-20 -85.84 137.7 32.58 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.257 0.551 . . . . 0.0 110.143 177.193 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 267' ' ' ALA . . . . . 0.624 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -119.85 122.98 42.52 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.262 -0.881 . . . . 0.0 108.741 178.07 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 268' ' ' PHE . . . . . 0.531 ' HB3' ' HA ' ' A' ' 334' ' ' ILE . 7.8 p90 -142.3 168.31 20.05 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.097 -0.641 . . . . 0.0 112.309 -169.893 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 76.0 p -115.4 162.77 16.68 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 114.859 -1.064 . . . . 0.0 108.486 170.89 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 270' ' ' ILE . . . . . . . . . . . . . 59.5 mt -126.05 141.96 44.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.693 -178.5 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -66.36 112.51 4.06 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.97 179.439 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 272' ' ' GLY . . . . . 0.434 ' HA3' ' HG3' ' A' ' 326' ' ' PRO . . . 104.21 -9.43 50.04 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.642 -0.789 . . . . 0.0 112.467 179.947 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 273' ' ' VAL . . . . . 0.502 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 58.3 t -102.15 102.95 14.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.884 0.373 . . . . 0.0 110.17 178.796 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 6.9 m120 -126.76 116.38 20.83 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.058 -177.352 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 275' ' ' SER . . . . . 0.478 ' HB3' ' HB2' ' A' ' 288' ' ' GLN . 29.2 p -72.72 161.78 30.32 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 113.24 0.83 . . . . 0.0 113.24 -172.401 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 19.4 m -118.21 178.6 2.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 114.644 -1.162 . . . . 0.0 110.165 178.436 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 85.1 m-70 -112.23 105.08 13.31 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 171.548 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 4.9 mp0 -74.18 -35.88 64.01 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.645 -0.252 . . . . 0.0 111.329 -173.445 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 279' ' ' ILE . . . . . 0.507 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.1 mp -67.9 -55.94 14.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.983 -176.007 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 75.9 p -88.33 -3.81 58.78 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 111.782 0.289 . . . . 0.0 111.782 -177.64 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 28.0 tptp 58.81 53.1 6.04 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 121.441 0.638 . . . . 0.0 110.23 179.391 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -117.03 136.75 52.72 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.605 -176.93 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 66.8 p -107.63 127.53 53.74 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.149 -179.943 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 70.7 p -134.49 -30.75 1.11 Allowed 'General case' 0 C--N 1.321 -0.645 0 CA-C-O 120.774 0.321 . . . . 0.0 111.424 -176.709 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 79.39 32.48 38.25 Favored Glycine 0 N--CA 1.448 -0.536 0 C-N-CA 120.408 -0.901 . . . . 0.0 112.666 178.214 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 71.3 mt-30 -85.0 124.43 72.39 Favored Pre-proline 0 C--N 1.326 -0.415 0 CA-C-N 116.903 0.352 . . . . 0.0 110.489 179.973 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 287' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_exo -59.53 126.0 19.44 Favored 'Trans proline' 0 C--N 1.345 0.395 0 C-N-CA 122.281 1.988 . . . . 0.0 111.285 178.272 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 288' ' ' GLN . . . . . 0.478 ' HB2' ' HB3' ' A' ' 275' ' ' SER . 50.6 tt0 -80.4 150.55 29.76 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.045 0.45 . . . . 0.0 111.589 -175.212 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 289' ' ' VAL . . . . . 0.497 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 50.0 t -99.16 127.35 51.93 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 CA-C-N 115.327 -0.851 . . . . 0.0 110.221 179.278 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 290' ' ' PHE . . . . . 0.624 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 4.0 m-85 -101.2 168.7 9.4 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.562 -0.29 . . . . 0.0 111.025 -176.771 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 21.6 mmt85 -126.49 120.78 30.55 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.264 0.554 . . . . 0.0 110.745 174.418 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 59.5 t -78.24 128.56 38.23 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.829 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.313 176.035 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 293' ' ' LEU . . . . . . . . . . . . . 83.5 mt -109.0 -30.09 8.25 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 111.986 0.365 . . . . 0.0 111.986 -177.762 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 294' ' ' ALA . . . . . 0.585 ' HB3' ' HB ' ' A' ' 301' ' ' THR . . . -152.44 139.94 19.65 Favored 'General case' 0 C--N 1.329 -0.296 0 C-N-CA 121.171 -0.212 . . . . 0.0 111.334 179.717 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 295' ' ' VAL . . . . . 0.685 HG22 HG13 ' A' ' 300' ' ' VAL . 55.3 t -133.48 128.52 54.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 175.118 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 27.2 m -145.64 97.13 2.93 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.917 -176.316 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 57.45 61.03 7.94 Favored Glycine 0 C--N 1.33 0.224 0 C-N-CA 121.009 -0.615 . . . . 0.0 112.531 178.814 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 81.8 p 56.71 5.4 0.21 Allowed 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 124.395 1.078 . . . . 0.0 113.253 -177.17 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 97.4 m -97.88 106.31 18.6 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 171.623 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 300' ' ' VAL . . . . . 0.733 HG12 HG23 ' A' ' 302' ' ' ILE . 38.8 t -109.26 120.93 61.48 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.797 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.193 -170.883 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 301' ' ' THR . . . . . 0.585 ' HB ' ' HB3' ' A' ' 294' ' ' ALA . 52.6 m -89.66 105.7 17.98 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 174.526 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 302' ' ' ILE . . . . . 0.733 HG23 HG12 ' A' ' 300' ' ' VAL . 2.4 pp -111.72 179.13 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 121.893 0.854 . . . . 0.0 112.861 -174.898 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 303' ' ' SER . . . . . 0.419 ' HA ' ' O ' ' A' ' 304' ' ' PRO . 67.5 p -160.0 157.47 25.43 Favored Pre-proline 0 C--N 1.314 -0.961 0 CA-C-N 113.668 -1.606 . . . . 0.0 106.678 174.714 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 304' ' ' PRO . . . . . 0.419 ' O ' ' HA ' ' A' ' 303' ' ' SER . 3.8 Cg_exo -78.26 -141.67 0.2 Allowed 'Cis proline' 0 CA--C 1.536 0.605 0 CA-C-N 119.84 0.979 . . . . 0.0 112.993 1.057 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 305' ' ' LYS . . . . . 0.793 ' HG3' ' HB3' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -130.4 171.02 13.42 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.014 -178.545 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 306' ' ' ILE . . . . . 0.415 ' HB ' ' CB ' ' A' ' 235' ' ' GLU . 47.2 mm -132.36 129.35 59.38 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.619 0 C-N-CA 119.242 -0.983 . . . . 0.0 113.57 -164.765 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 307' ' ' LEU . . . . . 0.71 HD13 ' HA ' ' A' ' 316' ' ' SER . 88.0 mt -134.39 125.44 17.75 Favored Pre-proline 0 CA--C 1.514 -0.435 0 CA-C-O 120.883 0.373 . . . . 0.0 111.459 170.287 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 308' ' ' PRO . . . . . 0.991 ' HG2' ' HB2' ' A' ' 311' ' ' ASN . 66.8 Cg_endo -84.24 157.71 13.0 Favored 'Trans proline' 0 N--CA 1.455 -0.782 0 C-N-CA 122.89 2.394 . . . . 0.0 112.711 179.041 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 44.5 t -80.79 -18.93 11.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-O 121.587 0.708 . . . . 0.0 109.126 172.104 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 54.7 mt-10 -94.62 34.91 1.27 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.475 -0.784 . . . . 0.0 111.141 177.613 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.991 ' HB2' ' HG2' ' A' ' 308' ' ' PRO . 19.6 t-20 -103.18 142.09 34.75 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -178.443 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 26.3 m -83.27 -7.46 59.59 Favored 'General case' 0 CA--C 1.54 0.587 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.447 -175.05 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 313' ' ' ASP . . . . . 0.42 ' O ' ' HG3' ' A' ' 317' ' ' ARG . 62.9 m-20 -79.62 140.11 37.23 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.684 0.278 . . . . 0.0 110.821 177.818 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 46.1 t -64.4 -45.63 95.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.655 -177.964 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -75.54 -22.42 57.07 Favored 'General case' 0 N--CA 1.464 0.262 0 N-CA-C 111.999 0.37 . . . . 0.0 111.999 -176.204 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 316' ' ' SER . . . . . 0.71 ' HA ' HD13 ' A' ' 307' ' ' LEU . 46.1 t -73.14 -21.52 60.7 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.533 -0.303 . . . . 0.0 111.771 -178.16 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 317' ' ' ARG . . . . . 0.687 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 73.0 mtp180 -74.24 -54.76 3.19 Favored Pre-proline 0 CA--C 1.536 0.434 0 N-CA-C 112.23 0.456 . . . . 0.0 112.23 -176.25 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 318' ' ' PRO . . . . . 0.687 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 16.8 Cg_exo -68.79 -38.66 9.81 Favored 'Trans proline' 0 C--N 1.354 0.848 0 C-N-CA 121.978 1.785 . . . . 0.0 112.268 -178.852 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 319' ' ' TYR . . . . . 0.436 ' O ' HD12 ' A' ' 307' ' ' LEU . 3.2 m-85 -90.11 30.43 1.09 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.089 0.471 . . . . 0.0 110.576 -179.903 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -65.9 159.41 25.6 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.679 -0.692 . . . . 0.0 111.059 179.454 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -142.43 -26.28 0.63 Allowed 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.866 -178.551 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 322' ' ' VAL . . . . . 0.461 HG12 ' HA ' ' A' ' 275' ' ' SER . 33.8 m -132.93 174.13 13.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.402 179.458 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -85.4 -12.76 51.28 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 112.068 0.395 . . . . 0.0 112.068 -179.05 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 324' ' ' ALA . . . . . 0.646 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -178.73 163.42 1.45 Allowed 'General case' 0 N--CA 1.469 0.485 0 CA-C-O 120.737 0.304 . . . . 0.0 111.619 -176.313 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 325' ' ' LYS . . . . . 0.596 ' HD2' ' HD3' ' A' ' 308' ' ' PRO . 6.7 mtpm? -120.56 134.13 24.15 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.731 172.974 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 326' ' ' PRO . . . . . 0.689 ' HB2' ' HB2' ' A' ' 330' ' ' ALA . 3.4 Cg_exo -78.26 167.81 22.6 Favored 'Trans proline' 0 N--CA 1.459 -0.549 0 C-N-CA 122.803 2.335 . . . . 0.0 111.578 177.101 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -65.18 137.15 57.43 Favored 'General case' 0 C--O 1.235 0.334 0 N-CA-C 110.129 -0.323 . . . . 0.0 110.129 177.886 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 328' ' ' GLU . . . . . 0.528 ' HB3' ' HA ' ' A' ' 231' ' ' SER . 55.2 mm-40 59.74 -128.41 1.12 Allowed 'General case' 0 C--O 1.232 0.164 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 -174.163 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 329' ' ' SER . . . . . 0.712 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 42.0 m -111.83 -10.55 14.01 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.548 -0.296 . . . . 0.0 110.204 175.339 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 330' ' ' ALA . . . . . 0.689 ' HB2' ' HB2' ' A' ' 326' ' ' PRO . . . 73.21 -166.39 0.11 Allowed 'General case' 0 N--CA 1.474 0.757 0 N-CA-C 113.56 0.948 . . . . 0.0 113.56 173.824 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -83.16 143.69 30.33 Favored 'General case' 0 CA--C 1.519 -0.223 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.56 -178.852 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 332' ' ' ILE . . . . . . . . . . . . . 23.1 mm -113.32 145.17 19.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.562 -171.875 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 29.7 m -118.98 96.59 5.3 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 174.314 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 334' ' ' ILE . . . . . 0.531 ' HA ' ' HB3' ' A' ' 268' ' ' PHE . 35.7 mm -83.15 130.07 36.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 N-CA-C 112.636 0.606 . . . . 0.0 112.636 -172.968 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 335' ' ' LEU . . . . . 0.449 ' HB2' ' O ' ' A' ' 267' ' ' ALA . 7.3 mp -112.52 160.95 17.3 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.23 -0.896 . . . . 0.0 110.089 171.962 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 72.8 m-80 -112.22 -0.29 15.56 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.261 -0.882 . . . . 0.0 109.209 174.132 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 27.9 mtpp . . . . . 0 C--O 1.245 0.845 0 O-C-N 124.191 0.932 . . . . 0.0 111.2 -178.281 . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.872 0 N-CA-C 112.044 -0.423 . . . . 0.0 112.044 . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 32.0 t 60.75 81.75 0.18 Allowed 'General case' 0 C--O 1.234 0.239 0 C-N-CA 122.864 0.466 . . . . 0.0 111.075 -179.863 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 34.5 p -77.05 -94.13 0.03 OUTLIER 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.375 176.673 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 17.2 tp10 -123.82 75.15 1.33 Allowed 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 173.607 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 43.6 t 65.56 -98.36 0.06 Allowed 'General case' 0 C--O 1.234 0.273 0 CA-C-N 115.374 -0.83 . . . . 0.0 109.426 -171.183 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 228' ' ' LEU . . . . . 0.466 ' HB3' ' CB ' ' A' ' 259' ' ' ALA . 91.7 mt -130.11 125.18 34.49 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 172.461 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 37.6 p -117.87 175.19 5.78 Favored 'General case' 0 C--N 1.32 -0.674 0 C-N-CA 119.483 -0.887 . . . . 0.0 111.214 -177.087 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 230' ' ' VAL . . . . . 0.561 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 60.6 t -148.61 141.44 18.4 Favored 'Isoleucine or valine' 0 C--O 1.24 0.56 0 CA-C-O 120.905 0.383 . . . . 0.0 110.788 -176.448 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 50.0 m -109.98 117.74 34.59 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.907 175.123 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 177.61 169.0 38.1 Favored Glycine 0 N--CA 1.447 -0.578 0 N-CA-C 111.087 -0.805 . . . . 0.0 111.087 -177.903 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 72.2 mt-30 -111.75 101.51 51.43 Favored Pre-proline 0 C--N 1.323 -0.57 0 CA-C-N 117.148 0.474 . . . . 0.0 111.62 -177.86 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_endo -83.62 125.99 3.95 Favored 'Trans proline' 0 N--CA 1.453 -0.864 0 C-N-CA 122.986 2.457 . . . . 0.0 110.331 173.932 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 56.0 mm-40 -120.63 163.55 17.86 Favored 'General case' 0 C--N 1.321 -0.674 0 C-N-CA 120.576 -0.45 . . . . 0.0 111.831 -172.572 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 236' ' ' HIS . . . . . 0.542 ' HB3' ' O ' ' A' ' 306' ' ' ILE . 19.3 p-80 -108.76 145.89 34.43 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.339 172.433 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 237' ' ' LYS . . . . . 0.566 ' HG3' ' H ' ' A' ' 250' ' ' ASN . 0.0 OUTLIER -166.98 173.99 8.81 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.569 178.099 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 238' ' ' VAL . . . . . 0.573 HG21 ' SD ' ' A' ' 246' ' ' MET . 95.8 t -70.27 147.87 11.31 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-N 115.451 -0.795 . . . . 0.0 110.396 172.63 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 239' ' ' GLU . . . . . 0.565 ' HA ' ' HB2' ' A' ' 249' ' ' ASP . 14.8 pt-20 -68.32 176.5 2.76 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.958 178.111 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 240' ' ' ALA . . . . . 0.82 ' HA ' HG13 ' A' ' 248' ' ' VAL . . . -29.19 -59.13 0.14 Allowed 'General case' 0 N--CA 1.473 0.691 0 O-C-N 124.318 1.011 . . . . 0.0 113.29 -177.647 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 241' ' ' LYS . . . . . 0.597 ' HD2' ' O ' ' A' ' 241' ' ' LYS . 0.1 OUTLIER -158.47 148.53 19.81 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-O 121.175 0.512 . . . . 0.0 111.78 177.647 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 242' ' ' ASP . . . . . 0.58 ' OD1' ' HG2' ' A' ' 246' ' ' MET . 13.1 p-10 -105.92 -157.89 0.63 Allowed 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 177.239 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 48.4 t -65.79 -33.05 74.96 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.748 0.308 . . . . 0.0 110.493 175.162 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 43.9 t30 -86.63 -15.61 39.18 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.564 -179.852 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 72.03 44.82 44.28 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.519 -0.848 . . . . 0.0 112.805 178.004 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 246' ' ' MET . . . . . 0.665 ' HB2' ' HD2' ' A' ' 247' ' ' PRO . 25.1 ptm -77.26 170.04 18.22 Favored Pre-proline 0 CA--C 1.533 0.321 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 177.539 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 247' ' ' PRO . . . . . 0.665 ' HD2' ' HB2' ' A' ' 246' ' ' MET . 51.7 Cg_exo -42.81 142.96 1.89 Allowed 'Trans proline' 0 C--N 1.36 1.143 0 C-N-CA 123.304 2.67 . . . . 0.0 114.677 -172.322 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.82 HG13 ' HA ' ' A' ' 240' ' ' ALA . 57.5 t -68.02 152.81 9.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 114.55 -1.205 . . . . 0.0 111.065 -177.978 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 249' ' ' ASP . . . . . 0.565 ' HB2' ' HA ' ' A' ' 239' ' ' GLU . 9.8 t0 -49.9 115.02 1.22 Allowed 'General case' 0 CA--C 1.528 0.125 0 O-C-N 123.96 0.788 . . . . 0.0 109.367 179.109 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 250' ' ' ASN . . . . . 0.566 ' H ' ' HG3' ' A' ' 237' ' ' LYS . 19.9 p30 -93.57 166.4 12.26 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 113.762 1.023 . . . . 0.0 113.762 -164.086 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 251' ' ' ARG . . . . . 0.454 ' HG2' ' OD1' ' A' ' 250' ' ' ASN . 18.7 ptp180 43.86 -145.4 0.1 Allowed 'General case' 0 N--CA 1.475 0.788 0 CA-C-N 113.789 -1.551 . . . . 0.0 113.301 -179.316 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 53.8 mt-30 69.18 160.57 0.19 Allowed 'General case' 0 N--CA 1.471 0.583 0 CA-C-O 121.391 0.615 . . . . 0.0 110.959 -173.018 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 253' ' ' GLY . . . . . 0.911 ' O ' ' HA ' ' A' ' 301' ' ' THR . . . 100.35 -23.76 34.62 Favored Glycine 0 N--CA 1.438 -1.203 0 C-N-CA 120.068 -1.063 . . . . 0.0 112.74 -179.248 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 60.0 p -135.81 118.79 16.36 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 118.01 0.905 . . . . 0.0 112.724 -176.676 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.756 HD11 ' HB ' ' A' ' 300' ' ' VAL . 2.1 pp -144.83 170.79 6.75 Favored 'Isoleucine or valine' 0 C--O 1.234 0.283 0 CA-C-O 121.032 0.444 . . . . 0.0 112.001 172.445 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 75.2 m -115.62 114.35 24.79 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.344 177.057 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.446 ' HB ' ' H ' ' A' ' 259' ' ' ALA . 34.9 m -90.86 145.21 7.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 N-CA-C 113.004 0.742 . . . . 0.0 113.004 -173.114 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 258' ' ' SER . . . . . 0.448 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 30.9 m -91.35 8.83 34.22 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 114.077 -1.42 . . . . 0.0 108.502 166.818 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 259' ' ' ALA . . . . . 0.466 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -88.25 175.65 7.58 Favored 'General case' 0 N--CA 1.452 -0.364 0 CA-C-N 115.115 -0.948 . . . . 0.0 109.402 -177.899 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 27.4 p -140.61 117.22 10.88 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 112.356 0.502 . . . . 0.0 112.356 -177.412 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 78.91 50.04 6.12 Favored Glycine 0 N--CA 1.45 -0.392 0 CA-C-N 115.596 -0.729 . . . . 0.0 113.391 175.632 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 262' ' ' LEU . . . . . . . . . . . . . 77.6 mt -85.06 146.53 27.12 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 117.346 0.573 . . . . 0.0 110.268 176.837 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 98.9 mm-40 -123.77 163.25 21.54 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.551 -178.757 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 264' ' ' VAL . . . . . 0.487 HG22 ' HA ' ' A' ' 294' ' ' ALA . 20.2 t -79.48 145.1 9.86 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.215 177.626 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 86.4 10.07 74.67 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.623 -0.799 . . . . 0.0 112.186 177.832 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -88.5 159.59 17.88 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.147 0.499 . . . . 0.0 110.482 177.208 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 267' ' ' ALA . . . . . 0.549 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -121.82 151.48 40.57 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 115.334 -0.848 . . . . 0.0 108.869 178.238 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 268' ' ' PHE . . . . . 0.496 ' HB3' ' HA ' ' A' ' 334' ' ' ILE . 4.1 p90 -164.27 168.75 18.4 Favored 'General case' 0 C--N 1.318 -0.761 0 C-N-CA 119.777 -0.769 . . . . 0.0 111.648 -178.029 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 269' ' ' THR . . . . . 0.497 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 73.3 p -122.85 141.83 51.44 Favored 'General case' 0 N--CA 1.442 -0.848 0 CA-C-N 115.438 -0.801 . . . . 0.0 109.621 177.078 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 270' ' ' ILE . . . . . 0.713 HG12 HG12 ' A' ' 332' ' ' ILE . 61.6 mt -105.49 139.18 27.43 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.57 -178.525 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -61.22 125.86 25.28 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.695 179.512 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 93.51 -22.45 35.31 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.473 -178.811 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 273' ' ' VAL . . . . . 0.742 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 42.4 t -96.5 114.59 33.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 O-C-N 122.573 -0.369 . . . . 0.0 110.296 177.504 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 274' ' ' ASN . . . . . 0.411 ' HA ' ' HA ' ' A' ' 287' ' ' PRO . 72.3 m-80 -129.2 160.87 31.55 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.304 -179.223 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 68.9 p -86.37 169.61 12.76 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.239 0.542 . . . . 0.0 111.803 -174.883 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 276' ' ' VAL . . . . . 0.41 ' O ' ' HG2' ' A' ' 278' ' ' GLN . 27.3 m -112.03 -178.07 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 115.499 -0.773 . . . . 0.0 111.152 -178.47 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 277' ' ' HIS . . . . . 0.523 ' HB3' ' HA ' ' A' ' 281' ' ' LYS . 5.0 m80 -66.16 80.97 0.08 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.703 -0.681 . . . . 0.0 110.392 -175.33 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 278' ' ' GLN . . . . . 0.41 ' HG2' ' O ' ' A' ' 276' ' ' VAL . 41.5 mm-40 -80.32 -32.99 37.86 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 111.72 0.267 . . . . 0.0 111.72 -174.418 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 279' ' ' ILE . . . . . 0.548 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.4 mp -69.89 -89.48 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.375 0 CA-C-O 120.831 0.348 . . . . 0.0 110.533 -174.641 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 35.5 p -133.69 60.03 1.72 Allowed 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.076 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 281' ' ' LYS . . . . . 0.523 ' HA ' ' HB3' ' A' ' 277' ' ' HIS . 31.4 mmmt 54.52 41.13 32.14 Favored 'General case' 0 CA--C 1.522 -0.122 0 CA-C-N 115.562 -0.745 . . . . 0.0 109.208 -170.874 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 282' ' ' ASP . . . . . 0.463 ' N ' ' HB3' ' A' ' 277' ' ' HIS . 9.3 t70 -92.33 137.84 32.03 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 114.445 -1.252 . . . . 0.0 110.484 -175.15 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 46.2 p -85.44 105.1 15.82 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.185 -178.387 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 73.1 p -110.72 -41.62 4.24 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.915 -171.804 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 63.64 28.31 72.34 Favored Glycine 0 C--N 1.33 0.24 0 C-N-CA 120.877 -0.677 . . . . 0.0 112.498 177.222 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 84.6 mt-30 -94.5 145.7 30.15 Favored Pre-proline 0 C--N 1.323 -0.547 0 CA-C-O 120.419 0.152 . . . . 0.0 110.647 -176.792 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 287' ' ' PRO . . . . . 0.497 ' HB2' ' HB ' ' A' ' 269' ' ' THR . 27.5 Cg_endo -62.2 143.77 94.75 Favored 'Trans proline' 0 CA--C 1.53 0.31 0 C-N-CA 122.445 2.097 . . . . 0.0 112.029 178.589 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 70.8 tp60 -76.3 128.43 34.86 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.872 0.367 . . . . 0.0 110.945 -177.486 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 289' ' ' VAL . . . . . 0.401 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 45.6 t -93.74 133.18 35.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.059 179.17 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 290' ' ' PHE . . . . . 0.742 ' HZ ' HG11 ' A' ' 273' ' ' VAL . 60.9 m-85 -113.5 168.81 9.44 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.826 -176.996 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 291' ' ' ARG . . . . . 0.452 ' NH1' ' HB2' ' A' ' 267' ' ' ALA . 35.8 mmt180 -126.74 120.38 29.25 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 177.765 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 56.4 t -67.18 125.59 24.96 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.227 -179.755 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 293' ' ' LEU . . . . . 0.656 HD11 ' HB2' ' A' ' 303' ' ' SER . 5.2 mp -85.07 -38.44 19.13 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.841 179.865 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 294' ' ' ALA . . . . . 0.487 ' HA ' HG22 ' A' ' 264' ' ' VAL . . . -167.13 155.48 9.73 Favored 'General case' 0 C--O 1.225 -0.21 0 CA-C-N 116.681 -0.236 . . . . 0.0 110.94 179.059 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 295' ' ' VAL . . . . . 0.672 HG22 HG13 ' A' ' 300' ' ' VAL . 61.7 t -140.49 124.74 18.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 175.384 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 32.4 m -139.73 89.54 2.33 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 120.76 0.314 . . . . 0.0 110.835 -177.189 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 297' ' ' GLY . . . . . 0.427 ' C ' ' H ' ' A' ' 299' ' ' THR . . . 63.95 65.76 2.87 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.487 179.434 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 81.0 p 63.06 -25.18 0.06 Allowed 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 124.994 1.317 . . . . 0.0 113.683 -178.774 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 299' ' ' THR . . . . . 0.427 ' H ' ' C ' ' A' ' 297' ' ' GLY . 75.3 m -77.43 108.9 10.91 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 174.333 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 300' ' ' VAL . . . . . 0.756 ' HB ' HD11 ' A' ' 255' ' ' ILE . 48.8 t -106.08 134.42 47.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.025 -173.017 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 301' ' ' THR . . . . . 0.911 ' HA ' ' O ' ' A' ' 253' ' ' GLY . 97.1 m -78.02 105.37 9.19 Favored 'General case' 0 N--CA 1.446 -0.632 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 173.009 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 302' ' ' ILE . . . . . 0.64 HD12 ' O ' ' A' ' 302' ' ' ILE . 2.6 pp -111.24 141.35 26.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 122.179 0.99 . . . . 0.0 113.671 -170.989 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 303' ' ' SER . . . . . 0.656 ' HB2' HD11 ' A' ' 293' ' ' LEU . 57.2 m -167.48 169.55 5.56 Favored Pre-proline 0 C--N 1.317 -0.826 0 N-CA-C 105.342 -2.096 . . . . 0.0 105.342 179.02 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 304' ' ' PRO . . . . . 0.587 ' HA ' ' HB3' ' A' ' 303' ' ' SER . 2.7 Cg_endo -82.65 -157.28 1.35 Allowed 'Cis proline' 0 C--N 1.347 0.458 0 CA-C-N 121.571 1.597 . . . . 0.0 113.473 0.278 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 305' ' ' LYS . . . . . 0.8 ' HD3' ' HG ' ' A' ' 307' ' ' LEU . 0.0 OUTLIER -83.51 163.34 20.51 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.27 -0.877 . . . . 0.0 112.884 -176.069 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 306' ' ' ILE . . . . . 0.542 ' O ' ' HB3' ' A' ' 236' ' ' HIS . 2.7 mp -114.02 94.32 3.06 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.793 -176.761 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 307' ' ' LEU . . . . . 0.8 ' HG ' ' HD3' ' A' ' 305' ' ' LYS . 86.0 mt -108.81 107.24 59.9 Favored Pre-proline 0 C--N 1.327 -0.392 0 C-N-CA 120.81 -0.356 . . . . 0.0 111.606 -177.768 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 308' ' ' PRO . . . . . 0.761 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 23.0 Cg_exo -69.85 145.39 56.5 Favored 'Trans proline' 0 C--N 1.343 0.253 0 C-N-CA 123.505 2.804 . . . . 0.0 113.467 -178.038 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 309' ' ' VAL . . . . . 0.416 HG23 ' O ' ' A' ' 322' ' ' VAL . 40.3 t -93.69 -25.6 4.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 169.35 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 54.7 mm-40 -79.83 -0.36 34.32 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.113 -0.949 . . . . 0.0 112.144 -177.602 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -80.85 163.34 23.48 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-O 121.004 0.431 . . . . 0.0 111.174 -179.091 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 50.2 m -92.32 -15.87 26.79 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.362 -179.029 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 313' ' ' ASP . . . . . 0.566 ' O ' ' HG3' ' A' ' 317' ' ' ARG . 62.9 t0 -64.26 104.05 0.71 Allowed 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.065 178.93 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 314' ' ' VAL . . . . . 0.432 ' O ' ' HD3' ' A' ' 318' ' ' PRO . 48.5 t -63.63 -30.84 50.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.683 -176.012 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -70.44 -25.17 63.07 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 111.718 0.266 . . . . 0.0 111.718 179.984 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 32.4 t -95.09 -8.28 37.02 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.604 0.24 . . . . 0.0 111.211 -178.115 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 317' ' ' ARG . . . . . 0.566 ' HG3' ' O ' ' A' ' 313' ' ' ASP . 54.4 mtp85 -67.43 -49.96 39.85 Favored Pre-proline 0 CA--C 1.54 0.564 0 N-CA-C 112.938 0.718 . . . . 0.0 112.938 -179.26 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 318' ' ' PRO . . . . . 0.506 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 37.1 Cg_exo -63.41 -31.98 71.95 Favored 'Trans proline' 0 C--N 1.357 1.016 0 C-N-CA 121.951 1.768 . . . . 0.0 112.679 -178.51 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 48.8 m-85 -84.13 -14.95 48.97 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.511 -178.214 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 320' ' ' ALA . . . . . 0.528 ' HA ' ' CB ' ' A' ' 307' ' ' LEU . . . -49.7 135.29 19.17 Favored 'General case' 0 N--CA 1.464 0.254 0 N-CA-C 112.71 0.633 . . . . 0.0 112.71 -174.097 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 16.1 p-10 -128.38 -10.36 5.18 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.939 178.964 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 322' ' ' VAL . . . . . 0.488 HG21 HG23 ' A' ' 306' ' ' ILE . 33.7 m -132.27 167.29 26.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 N-CA-C 109.986 -0.375 . . . . 0.0 109.986 177.017 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -67.2 -51.89 47.95 Favored 'General case' 0 C--N 1.326 -0.434 0 C-N-CA 121.026 -0.27 . . . . 0.0 111.702 -177.93 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 324' ' ' ALA . . . . . 0.761 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -162.47 -178.04 6.02 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.044 0.449 . . . . 0.0 111.779 -176.388 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 14.5 ptmm? -112.56 132.07 22.37 Favored Pre-proline 0 C--N 1.327 -0.384 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.314 176.949 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -86.15 168.44 9.04 Favored 'Trans proline' 0 N--CA 1.456 -0.71 0 C-N-CA 122.921 2.414 . . . . 0.0 112.412 179.51 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -72.83 123.77 24.05 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.053 -0.522 . . . . 0.0 109.718 175.202 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 66.6 mm-40 65.6 -161.43 0.26 Allowed 'General case' 0 N--CA 1.465 0.307 0 O-C-N 123.574 0.546 . . . . 0.0 110.424 -174.97 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 329' ' ' SER . . . . . 0.561 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 43.0 m -91.16 -13.48 32.88 Favored 'General case' 0 C--N 1.323 -0.578 0 C-N-CA 120.825 -0.35 . . . . 0.0 110.347 178.174 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 64.5 -161.55 0.28 Allowed 'General case' 0 N--CA 1.467 0.425 0 CA-C-N 115.412 -0.813 . . . . 0.0 113.128 171.323 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -86.71 136.72 32.91 Favored 'General case' 0 CA--C 1.517 -0.323 0 CA-C-N 115.09 -0.959 . . . . 0.0 110.577 -179.983 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 332' ' ' ILE . . . . . 0.713 HG12 HG12 ' A' ' 270' ' ' ILE . 45.8 mt -116.12 144.42 23.83 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.847 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.822 -178.735 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 78.1 m -116.26 99.24 7.07 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.156 -178.016 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 334' ' ' ILE . . . . . 0.496 ' HA ' ' HB3' ' A' ' 268' ' ' PHE . 38.3 mm -75.99 131.12 35.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.43 -174.992 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 335' ' ' LEU . . . . . 0.479 HD23 ' HA ' ' A' ' 268' ' ' PHE . 2.0 pt? -148.61 133.68 18.23 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.217 173.68 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 5.6 m120 -78.16 70.93 4.59 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.223 178.406 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 59.4 tttp . . . . . 0 C--O 1.243 0.738 0 CA-C-O 118.315 -0.85 . . . . 0.0 110.713 -174.989 . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.731 0 N-CA-C 111.851 -0.5 . . . . 0.0 111.851 . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 51.7 p -73.36 -38.93 65.55 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.413 0.149 . . . . 0.0 111.081 179.69 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 51.2 m 62.93 -84.96 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.366 0 O-C-N 123.719 0.637 . . . . 0.0 111.294 177.954 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 226' ' ' GLU . . . . . 0.406 ' O ' ' HB2' ' A' ' 227' ' ' SER . 5.2 tp10 -124.71 78.91 1.72 Allowed 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 175.096 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 227' ' ' SER . . . . . 0.406 ' HB2' ' O ' ' A' ' 226' ' ' GLU . 54.0 m 74.2 -77.89 0.05 Allowed 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 115.243 -0.889 . . . . 0.0 111.304 -175.877 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 228' ' ' LEU . . . . . 0.568 HD13 ' HB1' ' A' ' 259' ' ' ALA . 85.3 mt -131.5 158.9 39.66 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.982 -0.553 . . . . 0.0 109.845 -177.288 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 229' ' ' THR . . . . . 0.578 ' HA ' ' HA ' ' A' ' 331' ' ' ALA . 37.9 p -132.76 178.87 6.53 Favored 'General case' 0 C--N 1.33 -0.274 0 C-N-CA 120.324 -0.55 . . . . 0.0 111.186 177.851 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 230' ' ' VAL . . . . . 0.597 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 58.7 t -147.47 123.94 2.92 Favored 'Isoleucine or valine' 0 C--O 1.235 0.336 0 CA-C-N 116.654 -0.248 . . . . 0.0 110.921 -179.165 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 49.8 m -109.14 97.68 7.25 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.107 -0.497 . . . . 0.0 109.86 174.446 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 232' ' ' GLY . . . . . 0.915 ' HA3' ' HB ' ' A' ' 255' ' ' ILE . . . -133.94 -152.14 6.65 Favored Glycine 0 N--CA 1.443 -0.859 0 C-N-CA 119.743 -1.218 . . . . 0.0 113.163 -176.735 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 233' ' ' GLN . . . . . 0.583 ' H ' HG22 ' A' ' 255' ' ' ILE . 11.7 mm100 -72.34 171.45 9.7 Favored Pre-proline 0 C--N 1.324 -0.521 0 CA-C-N 115.2 -0.5 . . . . 0.0 110.988 -179.172 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 234' ' ' PRO . . . . . 0.525 ' HD2' ' HB3' ' A' ' 233' ' ' GLN . 41.7 Cg_exo -56.74 176.29 0.23 Allowed 'Trans proline' 0 C--N 1.356 0.923 0 C-N-CA 123.346 2.697 . . . . 0.0 112.741 177.801 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 235' ' ' GLU . . . . . 0.735 ' HG3' ' HD2' ' A' ' 325' ' ' LYS . 2.6 pm0 -91.38 -176.74 4.64 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.031 0.444 . . . . 0.0 111.102 -174.467 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 236' ' ' HIS . . . . . 0.445 ' CE1' ' HB2' ' A' ' 305' ' ' LYS . 18.9 t-80 -100.87 147.6 25.93 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.509 -0.769 . . . . 0.0 111.702 -171.135 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 237' ' ' LYS . . . . . 0.487 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -166.68 147.87 6.15 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 114.735 -1.12 . . . . 0.0 109.914 179.066 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 238' ' ' VAL . . . . . 0.568 HG23 HD21 ' A' ' 307' ' ' LEU . 56.8 t -99.53 111.95 30.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 174.073 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 239' ' ' GLU . . . . . 0.442 ' O ' ' HA ' ' A' ' 247' ' ' PRO . 91.4 mt-10 -92.55 144.56 25.22 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.953 -173.165 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 240' ' ' ALA . . . . . . . . . . . . . . . -63.29 -39.03 93.43 Favored 'General case' 0 CA--C 1.522 -0.111 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.808 179.486 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 241' ' ' LYS . . . . . 0.659 ' O ' ' HD3' ' A' ' 241' ' ' LYS . 0.1 OUTLIER -141.89 139.9 32.7 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.061 176.763 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 242' ' ' ASP . . . . . 0.441 ' CG ' ' H ' ' A' ' 244' ' ' ASN . 9.5 p-10 -105.95 -156.55 0.58 Allowed 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 -179.519 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 48.8 m -63.48 -19.55 64.83 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.192 175.208 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 244' ' ' ASN . . . . . 0.441 ' H ' ' CG ' ' A' ' 242' ' ' ASP . 5.3 m120 -104.65 -6.04 20.82 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.838 0.351 . . . . 0.0 111.06 177.716 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 245' ' ' GLY . . . . . 0.608 ' HA2' ' HB2' ' A' ' 241' ' ' LYS . . . 85.09 19.09 59.75 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.712 -0.756 . . . . 0.0 113.675 175.583 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 246' ' ' MET . . . . . 0.431 ' O ' HG23 ' A' ' 248' ' ' VAL . 83.4 mtp -113.28 157.74 40.23 Favored Pre-proline 0 C--N 1.326 -0.451 0 CA-C-N 117.12 0.46 . . . . 0.0 110.676 178.51 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 247' ' ' PRO . . . . . 0.442 ' HA ' ' O ' ' A' ' 239' ' ' GLU . 12.1 Cg_exo -68.29 120.6 7.56 Favored 'Trans proline' 0 C--N 1.348 0.524 0 C-N-CA 122.34 2.027 . . . . 0.0 111.055 177.123 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.431 HG23 ' O ' ' A' ' 246' ' ' MET . 62.6 t -129.89 137.56 56.3 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -173.951 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -79.87 101.66 8.68 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 107.842 -1.17 . . . . 0.0 107.842 170.35 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 250' ' ' ASN . . . . . . . . . . . . . 16.0 t-20 -98.95 147.45 24.98 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.464 -0.789 . . . . 0.0 112.925 -165.933 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 251' ' ' ARG . . . . . 0.41 ' HD3' ' HA ' ' A' ' 251' ' ' ARG . 19.7 tpp180 93.15 -125.32 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 125.616 1.566 . . . . 0.0 111.241 173.332 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 252' ' ' GLN . . . . . 0.452 ' OE1' ' HA ' ' A' ' 305' ' ' LYS . 2.2 mm100 63.31 179.29 0.15 Allowed 'General case' 0 N--CA 1.472 0.659 0 CA-C-O 120.888 0.375 . . . . 0.0 110.566 -173.331 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 101.91 -148.55 17.79 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 119.587 -1.292 . . . . 0.0 113.984 174.778 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 254' ' ' THR . . . . . 0.62 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 71.0 p -101.49 148.66 24.93 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 112.65 0.611 . . . . 0.0 112.65 -171.674 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.915 ' HB ' ' HA3' ' A' ' 232' ' ' GLY . 0.2 OUTLIER -138.01 172.96 13.48 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.243 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.288 173.632 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 58.2 m -100.54 125.81 46.93 Favored 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 109.406 -0.59 . . . . 0.0 109.406 176.729 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.524 ' HA ' HG13 ' A' ' 230' ' ' VAL . 34.0 m -98.73 143.37 13.28 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.828 0 C-N-CA 119.65 -0.82 . . . . 0.0 112.483 -174.541 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 258' ' ' SER . . . . . 0.494 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 38.8 t -91.56 8.48 36.4 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 114.443 -1.253 . . . . 0.0 108.405 169.505 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 259' ' ' ALA . . . . . 0.58 ' HB3' HD11 ' A' ' 262' ' ' LEU . . . -91.32 169.3 10.92 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-N 115.021 -0.99 . . . . 0.0 110.018 -177.442 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 260' ' ' SER . . . . . 0.55 ' H ' HD13 ' A' ' 228' ' ' LEU . 37.9 t -136.95 148.57 47.04 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 110.194 -0.298 . . . . 0.0 110.194 -179.751 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 71.27 39.6 61.98 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.977 -0.63 . . . . 0.0 113.083 178.108 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 262' ' ' LEU . . . . . 0.58 HD11 ' HB3' ' A' ' 259' ' ' ALA . 77.6 mt -97.64 142.31 29.6 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.944 0.372 . . . . 0.0 110.395 178.348 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 71.6 mt-30 -143.72 179.96 6.83 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 176.284 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 264' ' ' VAL . . . . . 0.517 HG22 ' HA ' ' A' ' 294' ' ' ALA . 34.0 t -79.31 140.43 16.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 N-CA-C 109.897 -0.408 . . . . 0.0 109.897 176.201 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 93.52 4.72 63.82 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.526 -0.845 . . . . 0.0 112.453 178.797 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -78.89 152.81 30.97 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.083 0.468 . . . . 0.0 110.072 176.578 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 267' ' ' ALA . . . . . 0.709 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -126.96 121.67 32.36 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 178.696 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 268' ' ' PHE . . . . . 0.574 ' CD1' HG21 ' A' ' 332' ' ' ILE . 0.0 OUTLIER -148.04 171.53 15.68 Favored 'General case' 0 C--N 1.318 -0.791 0 C-N-CA 120.218 -0.593 . . . . 0.0 111.026 -172.071 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 269' ' ' THR . . . . . 0.538 ' OG1' ' HB ' ' A' ' 333' ' ' THR . 72.6 p -123.82 156.39 36.23 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 110.2 -0.296 . . . . 0.0 110.2 -179.379 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 270' ' ' ILE . . . . . 0.557 HG12 HG12 ' A' ' 332' ' ' ILE . 60.9 mt -115.02 139.36 41.68 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 120.794 0.33 . . . . 0.0 111.144 -179.332 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -65.82 112.64 3.84 Favored 'General case' 0 C--O 1.231 0.125 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.037 -179.903 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 109.22 -21.85 26.04 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.021 -179.14 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 273' ' ' VAL . . . . . 0.598 ' O ' ' HA ' ' A' ' 287' ' ' PRO . 47.1 t -93.11 102.67 13.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.885 0.374 . . . . 0.0 110.93 178.722 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 56.5 m-20 -103.76 150.98 23.57 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 173.504 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 275' ' ' SER . . . . . 0.445 ' HB2' ' HB2' ' A' ' 288' ' ' GLN . 6.0 t -88.76 -177.96 5.66 Favored 'General case' 0 C--N 1.325 -0.473 0 C-N-CA 120.332 -0.547 . . . . 0.0 110.231 -176.496 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 35.0 m -112.25 -179.01 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.917 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.171 172.887 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 277' ' ' HIS . . . . . 0.425 ' HB3' ' HA ' ' A' ' 281' ' ' LYS . 6.3 p80 -39.74 111.66 0.21 Allowed 'General case' 0 CA--C 1.533 0.298 0 O-C-N 123.972 0.795 . . . . 0.0 112.568 -179.882 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 80.7 mt-30 -80.16 -42.38 23.55 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.475 -176.439 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 279' ' ' ILE . . . . . 0.467 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.7 mp -110.21 -76.16 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.175 177.858 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 21.7 p -142.11 90.78 2.28 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-O 121.124 0.487 . . . . 0.0 111.661 -178.418 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 281' ' ' LYS . . . . . 0.425 ' HA ' ' HB3' ' A' ' 277' ' ' HIS . 74.8 mmtt 61.05 23.98 14.12 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 115.145 -0.934 . . . . 0.0 112.463 175.584 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 11.2 p-10 -86.46 81.64 8.24 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.615 0.721 . . . . 0.0 110.867 176.769 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 37.2 p -102.34 106.9 17.76 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.854 177.753 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 73.1 p -114.67 2.16 14.4 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.835 -0.62 . . . . 0.0 112.174 -170.081 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 71.02 31.29 66.88 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.515 -0.85 . . . . 0.0 112.652 177.859 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 84.2 mt-30 -102.11 142.54 24.79 Favored Pre-proline 0 C--N 1.325 -0.467 0 O-C-N 122.682 -0.305 . . . . 0.0 111.155 179.503 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 287' ' ' PRO . . . . . 0.598 ' HA ' ' O ' ' A' ' 273' ' ' VAL . 39.0 Cg_exo -59.1 136.95 76.46 Favored 'Trans proline' 0 C--N 1.343 0.276 0 C-N-CA 122.988 2.459 . . . . 0.0 112.106 177.89 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 288' ' ' GLN . . . . . 0.445 ' HB2' ' HB2' ' A' ' 275' ' ' SER . 41.5 tt0 -79.52 142.92 35.34 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.827 0.346 . . . . 0.0 111.013 -178.008 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 289' ' ' VAL . . . . . 0.488 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 42.7 t -90.81 126.68 43.54 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.295 179.496 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 290' ' ' PHE . . . . . 0.709 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 33.3 m-85 -110.42 158.76 18.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.677 -0.238 . . . . 0.0 110.583 -176.323 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 291' ' ' ARG . . . . . 0.529 ' HD2' ' C ' ' A' ' 290' ' ' PHE . 9.0 mpt_? -115.88 131.06 57.05 Favored 'General case' 0 CA--C 1.516 -0.357 0 CA-C-O 121.48 0.657 . . . . 0.0 110.74 173.606 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 40.9 t -82.86 140.0 16.97 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 CA-C-N 114.722 -1.126 . . . . 0.0 111.402 -176.354 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 293' ' ' LEU . . . . . 0.448 ' CD2' ' HB2' ' A' ' 303' ' ' SER . 3.3 mm? -103.79 -32.38 9.36 Favored 'General case' 0 C--N 1.334 -0.08 0 N-CA-C 112.353 0.501 . . . . 0.0 112.353 -177.684 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 294' ' ' ALA . . . . . 0.517 ' HA ' HG22 ' A' ' 264' ' ' VAL . . . -157.83 139.27 13.67 Favored 'General case' 0 N--CA 1.464 0.241 0 C-N-CA 120.715 -0.394 . . . . 0.0 111.798 -178.245 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 295' ' ' VAL . . . . . 0.424 HG22 HG22 ' A' ' 300' ' ' VAL . 73.0 t -141.39 111.99 3.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.457 177.612 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 50.2 m -140.38 114.63 9.19 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.584 -0.28 . . . . 0.0 110.707 178.542 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 59.53 54.59 36.44 Favored Glycine 0 C--N 1.33 0.25 0 C-N-CA 121.146 -0.549 . . . . 0.0 112.891 179.172 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 82.8 p 53.08 21.09 1.97 Allowed 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 123.61 0.764 . . . . 0.0 112.302 -177.1 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 58.6 m -111.45 105.89 14.63 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 176.358 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 300' ' ' VAL . . . . . 0.62 ' O ' ' HA ' ' A' ' 254' ' ' THR . 55.2 t -105.32 131.62 54.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 115.954 -0.567 . . . . 0.0 111.547 -171.881 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 28.5 m -89.1 114.49 25.75 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 108.277 -1.009 . . . . 0.0 108.277 173.454 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 302' ' ' ILE . . . . . 0.538 HD12 ' O ' ' A' ' 302' ' ' ILE . 2.5 pp -110.58 149.07 13.6 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 N-CA-C 113.676 0.991 . . . . 0.0 113.676 -170.558 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 303' ' ' SER . . . . . 0.557 ' HB3' ' HA ' ' A' ' 304' ' ' PRO . 60.3 m -166.21 165.87 9.97 Favored Pre-proline 0 C--N 1.325 -0.487 0 N-CA-C 105.952 -1.87 . . . . 0.0 105.952 -179.724 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 304' ' ' PRO . . . . . 0.557 ' HA ' ' HB3' ' A' ' 303' ' ' SER . 5.8 Cg_exo -79.41 -146.44 0.37 Allowed 'Cis proline' 0 C--N 1.345 0.362 0 CA-C-N 120.996 1.391 . . . . 0.0 113.579 0.64 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 305' ' ' LYS . . . . . 0.682 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -84.11 146.71 27.75 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.478 -0.783 . . . . 0.0 111.739 -176.173 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 306' ' ' ILE . . . . . 0.482 HG23 HG21 ' A' ' 322' ' ' VAL . 2.9 mp -115.26 113.73 44.35 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.199 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.92 179.227 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 307' ' ' LEU . . . . . 0.568 HD21 HG23 ' A' ' 238' ' ' VAL . 95.5 mt -133.97 107.37 11.54 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-O 120.563 0.22 . . . . 0.0 111.308 -179.309 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 308' ' ' PRO . . . . . 0.652 ' HG2' ' HB2' ' A' ' 311' ' ' ASN . 45.3 Cg_endo -74.51 148.0 37.03 Favored 'Trans proline' 0 C--O 1.233 0.232 0 C-N-CA 122.796 2.331 . . . . 0.0 113.573 -176.631 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 46.5 t -73.58 -34.26 41.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.059 173.0 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -86.35 34.35 0.63 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.371 -0.832 . . . . 0.0 111.143 178.468 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.652 ' HB2' ' HG2' ' A' ' 308' ' ' PRO . 25.7 t-20 -81.32 -34.2 32.04 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -178.287 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 312' ' ' THR . . . . . 0.401 ' HB ' ' O ' ' A' ' 311' ' ' ASN . 41.8 m 73.91 -11.27 0.98 Allowed 'General case' 0 CA--C 1.539 0.529 0 CA-C-N 115.328 -0.851 . . . . 0.0 111.679 178.662 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 313' ' ' ASP . . . . . 0.477 ' O ' ' HG2' ' A' ' 317' ' ' ARG . 31.1 t70 -79.67 117.42 20.57 Favored 'General case' 0 C--N 1.329 -0.286 0 O-C-N 121.951 -0.468 . . . . 0.0 110.27 175.119 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 26.5 t -59.32 -20.4 18.07 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.473 0 CA-C-N 115.781 -0.645 . . . . 0.0 112.268 -174.706 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -84.89 -38.41 19.45 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 111.949 0.352 . . . . 0.0 111.949 -179.364 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 316' ' ' SER . . . . . 0.423 ' OG ' ' HB3' ' A' ' 313' ' ' ASP . 38.3 p -97.93 -28.83 13.64 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 113.511 0.93 . . . . 0.0 113.511 -172.33 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 317' ' ' ARG . . . . . 0.624 ' N ' ' HD2' ' A' ' 318' ' ' PRO . 16.1 ptm180 -66.18 -35.76 11.37 Favored Pre-proline 0 CA--C 1.547 0.86 0 N-CA-C 113.656 0.984 . . . . 0.0 113.656 -176.182 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 318' ' ' PRO . . . . . 0.624 ' HD2' ' N ' ' A' ' 317' ' ' ARG . 12.8 Cg_endo -58.38 -34.13 98.42 Favored 'Trans proline' 0 C--N 1.366 1.468 0 C-N-CA 121.666 1.577 . . . . 0.0 112.512 -179.861 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 51.0 m-85 -101.02 36.8 1.88 Allowed 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.6 -178.085 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -67.86 139.64 56.53 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.485 -178.183 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 321' ' ' ASN . . . . . 0.44 ' OD1' HG13 ' A' ' 322' ' ' VAL . 20.5 p30 -121.78 -14.66 8.07 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.516 178.012 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 322' ' ' VAL . . . . . 0.482 HG21 HG23 ' A' ' 306' ' ' ILE . 34.1 m -133.59 166.74 28.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 115.618 -0.719 . . . . 0.0 109.195 173.458 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 65.0 m-20 -82.7 -27.53 31.16 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 112.164 0.431 . . . . 0.0 112.164 -176.375 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 324' ' ' ALA . . . . . 0.562 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -160.58 158.21 28.66 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.973 0.416 . . . . 0.0 111.716 -175.209 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 325' ' ' LYS . . . . . 0.735 ' HD2' ' HG3' ' A' ' 235' ' ' GLU . 21.5 pttp -114.01 127.26 27.01 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 115.714 -0.676 . . . . 0.0 110.157 177.318 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -86.08 167.84 9.32 Favored 'Trans proline' 0 N--CA 1.457 -0.651 0 C-N-CA 122.814 2.343 . . . . 0.0 112.758 -178.213 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -71.71 124.4 24.69 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.471 178.927 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 61.69 -118.44 0.68 Allowed 'General case' 0 N--CA 1.464 0.239 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.323 -175.578 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 329' ' ' SER . . . . . 0.597 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 32.6 m -112.18 -33.94 6.08 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.59 -0.277 . . . . 0.0 111.309 179.863 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 330' ' ' ALA . . . . . 0.418 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 76.24 -165.99 0.06 Allowed 'General case' 0 N--CA 1.474 0.725 0 O-C-N 123.844 0.715 . . . . 0.0 112.432 177.429 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 331' ' ' ALA . . . . . 0.578 ' HA ' ' HA ' ' A' ' 229' ' ' THR . . . -82.88 153.92 24.87 Favored 'General case' 0 CA--C 1.519 -0.236 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.899 -177.226 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 332' ' ' ILE . . . . . 0.574 HG21 ' CD1' ' A' ' 268' ' ' PHE . 44.4 mt -128.49 144.85 36.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 121.233 0.54 . . . . 0.0 111.762 -177.616 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.538 ' HB ' ' OG1' ' A' ' 269' ' ' THR . 94.7 m -108.63 118.75 37.59 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.291 -0.868 . . . . 0.0 109.207 175.23 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 334' ' ' ILE . . . . . 0.491 HG13 HD12 ' A' ' 228' ' ' LEU . 31.9 mm -97.26 132.33 42.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 N-CA-C 113.761 1.023 . . . . 0.0 113.761 -168.025 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 335' ' ' LEU . . . . . 0.467 HD23 ' N ' ' A' ' 335' ' ' LEU . 1.5 pt? -150.78 -162.32 1.53 Allowed 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 113.977 -1.465 . . . . 0.0 108.129 167.993 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 14.9 p-10 -159.34 35.49 0.2 Allowed 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 120.949 0.404 . . . . 0.0 110.212 178.055 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 88.4 tttt . . . . . 0 C--O 1.245 0.83 0 CA-C-N 115.023 -0.99 . . . . 0.0 110.722 -179.433 . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.903 0 N-CA-C 112.283 -0.327 . . . . 0.0 112.283 . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 42.8 m -93.42 63.09 3.48 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.916 0.389 . . . . 0.0 110.688 -179.951 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 41.8 p -100.05 -124.03 0.16 Allowed 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.462 -0.335 . . . . 0.0 110.5 179.505 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 226' ' ' GLU . . . . . 0.465 ' HB2' ' HB1' ' A' ' 331' ' ' ALA . 24.4 pt-20 40.24 41.68 1.04 Allowed 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 123.993 0.917 . . . . 0.0 112.961 178.904 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 20.3 m -86.99 -34.83 19.13 Favored 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 110.018 -0.364 . . . . 0.0 110.018 177.71 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 228' ' ' LEU . . . . . 0.425 HD13 ' HB1' ' A' ' 259' ' ' ALA . 87.7 mt -69.49 136.98 52.17 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.509 176.936 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 61.3 p -125.22 173.99 8.41 Favored 'General case' 0 C--N 1.325 -0.49 0 C-N-CA 119.721 -0.792 . . . . 0.0 110.374 179.766 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 230' ' ' VAL . . . . . 0.916 HG11 HD12 ' A' ' 255' ' ' ILE . 94.5 t -146.06 139.8 20.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-O 120.873 0.368 . . . . 0.0 110.549 -178.801 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 231' ' ' SER . . . . . 0.622 ' HA ' ' OE1' ' A' ' 328' ' ' GLU . 45.8 t -106.04 150.75 25.45 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-N 115.485 -0.779 . . . . 0.0 110.64 178.145 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 79.32 92.67 0.36 Allowed Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.409 178.408 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 233' ' ' GLN . . . . . 0.461 ' O ' ' HG3' ' A' ' 235' ' ' GLU . 82.8 mt-30 -42.74 135.37 2.75 Favored Pre-proline 0 N--CA 1.47 0.531 0 N-CA-C 112.595 0.591 . . . . 0.0 112.595 -177.997 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 234' ' ' PRO . . . . . 0.434 ' HB3' HD11 ' A' ' 302' ' ' ILE . 34.0 Cg_endo -62.97 127.94 21.69 Favored 'Trans proline' 0 C--N 1.349 0.59 0 C-N-CA 122.521 2.147 . . . . 0.0 111.18 175.018 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 235' ' ' GLU . . . . . 0.461 ' HG3' ' O ' ' A' ' 233' ' ' GLN . 49.0 mt-10 -113.64 117.46 31.65 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 112.281 0.475 . . . . 0.0 112.281 -170.419 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 236' ' ' HIS . . . . . 0.694 ' ND1' ' HA ' ' A' ' 251' ' ' ARG . 27.6 t60 -138.32 130.92 29.25 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.507 172.984 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 237' ' ' LYS . . . . . 0.55 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -126.71 157.65 38.51 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.527 -179.624 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 238' ' ' VAL . . . . . . . . . . . . . 41.9 t -97.5 117.16 41.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 171.948 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 239' ' ' GLU . . . . . 0.426 ' O ' ' HA ' ' A' ' 247' ' ' PRO . 46.3 mm-40 -84.54 121.25 27.34 Favored 'General case' 0 C--N 1.322 -0.602 0 C-N-CA 121.032 -0.267 . . . . 0.0 110.659 -177.663 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 240' ' ' ALA . . . . . . . . . . . . . . . -68.21 -38.94 82.47 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.19 0.519 . . . . 0.0 109.941 175.441 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 241' ' ' LYS . . . . . 0.759 ' HB2' ' HA2' ' A' ' 245' ' ' GLY . 0.0 OUTLIER -153.14 140.88 20.02 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.006 176.421 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -95.92 -156.99 0.55 Allowed 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.492 178.733 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 61.9 p -67.01 -20.14 65.82 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.547 0.213 . . . . 0.0 111.137 176.656 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 50.3 t30 -98.78 -14.17 19.83 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.892 0.377 . . . . 0.0 110.664 177.966 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 245' ' ' GLY . . . . . 0.759 ' HA2' ' HB2' ' A' ' 241' ' ' LYS . . . 95.14 25.92 13.41 Favored Glycine 0 CA--C 1.518 0.266 0 C-N-CA 120.57 -0.824 . . . . 0.0 113.292 175.949 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 246' ' ' MET . . . . . 0.41 ' O ' HG23 ' A' ' 248' ' ' VAL . 49.0 mtm -111.6 150.12 41.72 Favored Pre-proline 0 C--N 1.322 -0.628 0 O-C-N 122.722 -0.281 . . . . 0.0 110.418 -179.648 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 247' ' ' PRO . . . . . 0.426 ' HA ' ' O ' ' A' ' 239' ' ' GLU . 6.7 Cg_exo -70.23 120.34 7.08 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.209 1.939 . . . . 0.0 110.697 174.939 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 248' ' ' VAL . . . . . 0.41 HG23 ' O ' ' A' ' 246' ' ' MET . 47.5 t -124.24 143.2 38.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-O 121.049 0.452 . . . . 0.0 111.615 -174.139 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 249' ' ' ASP . . . . . 0.438 ' OD1' ' HB3' ' A' ' 251' ' ' ARG . 9.0 t70 -85.43 90.76 8.03 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 173.847 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 250' ' ' ASN . . . . . . . . . . . . . 49.1 t30 -84.96 69.69 10.82 Favored 'General case' 0 N--CA 1.464 0.231 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 -175.996 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 251' ' ' ARG . . . . . 0.694 ' HA ' ' ND1' ' A' ' 236' ' ' HIS . 14.0 ptp180 -75.71 -146.51 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.327 -0.851 . . . . 0.0 113.239 -170.107 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 252' ' ' GLN . . . . . 0.417 ' H ' ' HB2' ' A' ' 251' ' ' ARG . 40.7 mt-30 66.34 178.69 0.21 Allowed 'General case' 0 N--CA 1.466 0.351 0 C-N-CA 123.842 0.857 . . . . 0.0 111.515 -178.958 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 253' ' ' GLY . . . . . 0.441 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -169.1 105.87 0.23 Allowed Glycine 0 N--CA 1.444 -0.799 0 CA-C-N 115.352 -0.84 . . . . 0.0 111.309 177.391 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 254' ' ' THR . . . . . 0.473 HG22 ' OG1' ' A' ' 301' ' ' THR . 62.8 p -93.47 116.15 28.68 Favored 'General case' 0 C--N 1.324 -0.515 0 C-N-CA 120.579 -0.448 . . . . 0.0 110.006 -177.993 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.916 HD12 HG11 ' A' ' 230' ' ' VAL . 19.0 pt -129.27 157.18 42.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.807 -0.633 . . . . 0.0 112.01 -172.162 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 28.8 m -96.3 109.66 22.12 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 174.606 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.438 ' HA ' HG13 ' A' ' 230' ' ' VAL . 33.6 m -89.94 142.37 13.01 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 C-N-CA 119.429 -0.908 . . . . 0.0 112.235 -173.022 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 258' ' ' SER . . . . . 0.429 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 31.6 m -93.2 9.53 35.68 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 114.377 -1.283 . . . . 0.0 109.44 171.974 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 259' ' ' ALA . . . . . 0.425 ' HB1' HD13 ' A' ' 228' ' ' LEU . . . -80.97 -177.37 6.39 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.189 -175.709 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 50.9 m -125.07 118.92 27.24 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 112.232 0.456 . . . . 0.0 112.232 -175.522 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 59.49 51.35 59.59 Favored Glycine 0 C--N 1.331 0.284 0 CA-C-N 115.656 -0.702 . . . . 0.0 114.127 172.19 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 262' ' ' LEU . . . . . . . . . . . . . 67.9 mt -77.96 160.13 28.39 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 117.453 0.626 . . . . 0.0 110.559 177.753 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 85.7 mt-30 -141.74 167.09 22.96 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.453 179.864 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 44.0 t -78.67 141.47 15.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.496 178.32 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 93.55 1.2 66.36 Favored Glycine 0 N--CA 1.453 -0.229 0 C-N-CA 120.535 -0.84 . . . . 0.0 112.757 177.174 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 266' ' ' ASP . . . . . 0.453 ' HB3' ' CG2' ' A' ' 334' ' ' ILE . 1.3 m-20 -81.09 164.82 22.14 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.032 0.444 . . . . 0.0 110.585 178.243 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 267' ' ' ALA . . . . . 0.54 ' HB1' HG13 ' A' ' 289' ' ' VAL . . . -124.37 146.77 48.65 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.796 -178.086 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 268' ' ' PHE . . . . . 0.721 ' HB3' ' HA ' ' A' ' 334' ' ' ILE . 11.1 p90 -164.09 177.88 8.09 Favored 'General case' 0 C--N 1.322 -0.629 0 C-N-CA 120.152 -0.619 . . . . 0.0 112.405 -176.177 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 43.2 p -134.03 156.55 48.02 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 114.646 -1.161 . . . . 0.0 109.002 173.138 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 270' ' ' ILE . . . . . 0.944 HG12 HG13 ' A' ' 332' ' ' ILE . 77.6 mt -119.15 141.78 37.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-O 120.569 0.223 . . . . 0.0 110.682 -177.524 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -70.16 128.7 37.2 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.768 0.318 . . . . 0.0 110.973 178.112 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 90.56 -23.3 23.12 Favored Glycine 0 N--CA 1.453 -0.172 0 C-N-CA 121.267 -0.492 . . . . 0.0 112.023 -177.822 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 273' ' ' VAL . . . . . 0.473 ' HB ' ' HB ' ' A' ' 270' ' ' ILE . 57.2 t -94.58 103.23 14.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 175.043 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 274' ' ' ASN . . . . . 0.451 ' HB3' ' O ' ' A' ' 285' ' ' GLY . 8.1 m120 -125.03 129.43 50.27 Favored 'General case' 0 C--N 1.316 -0.865 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 -179.613 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 275' ' ' SER . . . . . 0.571 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 48.8 m -84.18 173.52 10.97 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.751 0.786 . . . . 0.0 112.974 -167.031 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 276' ' ' VAL . . . . . 0.675 HG11 HG21 ' A' ' 309' ' ' VAL . 18.5 m -122.95 166.87 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 CA-C-N 114.676 -1.147 . . . . 0.0 109.327 176.41 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 277' ' ' HIS . . . . . 0.494 ' O ' ' HA ' ' A' ' 281' ' ' LYS . 33.6 m80 -88.16 123.89 33.26 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 177.853 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 10.5 mm100 -80.29 -17.16 52.94 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.086 -176.614 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 46.7 mm -70.31 -65.19 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.736 -179.531 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 64.6 p -108.05 11.58 27.6 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.506 -0.316 . . . . 0.0 111.851 -177.323 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 281' ' ' LYS . . . . . 0.494 ' HA ' ' O ' ' A' ' 277' ' ' HIS . 12.7 mptt 55.41 47.47 21.12 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-O 121.122 0.487 . . . . 0.0 111.192 -177.489 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 282' ' ' ASP . . . . . 0.48 ' HB3' ' HB2' ' A' ' 277' ' ' HIS . 7.3 t70 -79.91 108.96 13.9 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.619 176.971 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.46 HG21 HG11 ' A' ' 309' ' ' VAL . 64.4 p -102.97 98.22 8.22 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.591 -178.142 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 31.1 p -140.55 10.8 2.28 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.613 -0.721 . . . . 0.0 111.763 -177.737 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 285' ' ' GLY . . . . . 0.451 ' O ' ' HB3' ' A' ' 274' ' ' ASN . . . 75.66 33.57 51.49 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.177 -1.011 . . . . 0.0 113.26 175.651 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 286' ' ' GLN . . . . . 0.463 ' O ' ' HB2' ' A' ' 275' ' ' SER . 11.6 mm100 -91.27 111.77 50.52 Favored Pre-proline 0 C--N 1.325 -0.469 0 CA-C-N 117.006 0.403 . . . . 0.0 110.782 -179.636 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 287' ' ' PRO . . . . . 0.408 ' HD2' ' HA ' ' A' ' 286' ' ' GLN . 14.7 Cg_endo -59.59 134.26 56.8 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.916 2.41 . . . . 0.0 113.155 -177.057 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? -110.13 152.31 26.18 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 176.806 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 289' ' ' VAL . . . . . 0.54 HG13 ' HB1' ' A' ' 267' ' ' ALA . 53.8 t -68.18 134.03 30.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 CA-C-O 120.924 0.392 . . . . 0.0 111.988 -171.806 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 290' ' ' PHE . . . . . 0.836 ' HA ' ' HD3' ' A' ' 304' ' ' PRO . 4.5 m-85 -97.88 159.48 14.9 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.75 178.051 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 20.3 mmt85 -131.45 125.63 33.0 Favored 'General case' 0 N--CA 1.453 -0.316 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.622 -179.02 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 53.2 t -76.01 135.34 27.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.161 179.318 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 293' ' ' LEU . . . . . 0.589 HD12 HG22 ' A' ' 301' ' ' THR . 85.4 mt -99.49 -43.0 6.69 Favored 'General case' 0 C--N 1.333 -0.13 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.502 179.769 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 294' ' ' ALA . . . . . 0.451 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -154.34 144.23 21.77 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.496 -0.32 . . . . 0.0 111.183 -175.52 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 59.0 t -135.91 113.3 14.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.714 176.87 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 45.6 t -157.33 125.02 5.34 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.55 -177.738 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 61.26 43.7 99.04 Favored Glycine 0 C--N 1.331 0.25 0 C-N-CA 120.987 -0.625 . . . . 0.0 111.773 -177.93 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 67.1 p 50.82 23.02 1.27 Allowed 'General case' 0 N--CA 1.471 0.604 0 C-N-CA 123.709 0.804 . . . . 0.0 112.23 -175.052 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 59.6 m -111.9 116.96 31.48 Favored 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 176.852 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 300' ' ' VAL . . . . . 0.451 ' HA ' ' O ' ' A' ' 294' ' ' ALA . 61.5 t -113.1 126.67 70.54 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.176 -173.15 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 301' ' ' THR . . . . . 0.589 HG22 HD12 ' A' ' 293' ' ' LEU . 54.5 m -91.24 116.2 28.63 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 173.987 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 302' ' ' ILE . . . . . 0.441 HG12 ' O ' ' A' ' 253' ' ' GLY . 29.5 pt -111.5 158.78 11.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 N-CA-C 113.234 0.828 . . . . 0.0 113.234 -170.013 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 303' ' ' SER . . . . . 0.543 ' HB3' ' HA ' ' A' ' 304' ' ' PRO . 72.1 m -144.47 166.16 19.97 Favored Pre-proline 0 C--N 1.323 -0.584 0 CA-C-N 113.631 -1.622 . . . . 0.0 107.05 172.521 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 304' ' ' PRO . . . . . 0.836 ' HD3' ' HA ' ' A' ' 290' ' ' PHE . 10.5 Cg_exo -72.7 -169.8 6.86 Favored 'Cis proline' 0 C--N 1.346 0.423 0 CA-C-N 120.719 1.293 . . . . 0.0 113.484 0.605 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 305' ' ' LYS . . . . . 0.633 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -78.18 147.73 34.37 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.471 -0.786 . . . . 0.0 111.333 -177.774 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 306' ' ' ILE . . . . . 0.627 HG23 HG21 ' A' ' 322' ' ' VAL . 51.1 mm -114.07 110.71 33.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.718 -174.244 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 307' ' ' LEU . . . . . 0.504 ' HA ' ' HD3' ' A' ' 308' ' ' PRO . 90.7 mt -134.04 123.06 16.66 Favored Pre-proline 0 N--CA 1.465 0.28 0 CA-C-N 116.62 -0.264 . . . . 0.0 111.46 175.776 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 308' ' ' PRO . . . . . 0.723 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 32.7 Cg_exo -67.68 148.92 78.7 Favored 'Trans proline' 0 C--O 1.233 0.236 0 C-N-CA 123.705 2.937 . . . . 0.0 114.284 -176.333 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 309' ' ' VAL . . . . . 0.675 HG21 HG11 ' A' ' 276' ' ' VAL . 45.2 t -94.14 -13.79 8.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.132 -0.94 . . . . 0.0 109.055 168.988 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 53.1 mt-10 -78.51 35.79 0.24 Allowed 'General case' 0 CA--C 1.533 0.317 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.959 177.225 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.771 ' HA ' ' HD3' ' A' ' 317' ' ' ARG . 1.0 OUTLIER 40.74 66.23 0.67 Allowed 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 114.258 1.207 . . . . 0.0 114.258 173.733 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 85.0 m -81.35 -41.55 21.84 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.753 -0.658 . . . . 0.0 109.657 170.118 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 59.0 t0 -137.83 146.05 43.0 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 175.541 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 61.3 t -62.02 -43.36 97.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 O-C-N 123.191 0.307 . . . . 0.0 111.078 178.858 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -69.96 -19.88 63.34 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.005 0.431 . . . . 0.0 111.094 178.58 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 35.0 t -78.74 -15.24 58.69 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.502 179.804 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 317' ' ' ARG . . . . . 0.771 ' HD3' ' HA ' ' A' ' 311' ' ' ASN . 2.4 mmm180 -74.52 -51.87 4.04 Favored Pre-proline 0 CA--C 1.536 0.437 0 N-CA-C 112.883 0.697 . . . . 0.0 112.883 -177.709 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 318' ' ' PRO . . . . . 0.591 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 23.5 Cg_exo -64.95 -18.95 63.69 Favored 'Trans proline' 0 C--N 1.355 0.874 0 C-N-CA 121.844 1.696 . . . . 0.0 112.388 -178.407 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 319' ' ' TYR . . . . . 0.409 ' O ' HD12 ' A' ' 307' ' ' LEU . 3.7 m-85 -113.52 22.08 14.49 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.284 -179.499 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 320' ' ' ALA . . . . . 0.461 ' HB1' HG22 ' A' ' 309' ' ' VAL . . . -59.68 142.29 53.32 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.226 -177.408 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 50.3 t30 -135.2 -21.57 1.6 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.942 -178.917 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 322' ' ' VAL . . . . . 0.627 HG21 HG23 ' A' ' 306' ' ' ILE . 34.7 m -140.53 172.04 12.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.141 178.658 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 51.1 m-20 -65.94 -44.76 84.09 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.647 -0.251 . . . . 0.0 111.427 179.203 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 324' ' ' ALA . . . . . 0.723 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -174.97 -178.86 1.29 Allowed 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 112.358 0.503 . . . . 0.0 112.358 -177.229 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 36.5 mtmm -108.01 116.72 56.59 Favored Pre-proline 0 N--CA 1.452 -0.364 0 CA-C-N 114.51 -1.223 . . . . 0.0 108.404 168.261 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -71.64 167.09 27.45 Favored 'Trans proline' 0 C--O 1.233 0.236 0 C-N-CA 122.411 2.074 . . . . 0.0 112.22 -177.905 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -67.58 121.58 16.17 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 175.541 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 328' ' ' GLU . . . . . 0.622 ' OE1' ' HA ' ' A' ' 231' ' ' SER . 31.2 tp10 67.53 164.4 0.21 Allowed 'General case' 0 CA--C 1.537 0.45 0 O-C-N 123.986 0.804 . . . . 0.0 109.562 -174.204 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 329' ' ' SER . . . . . 0.486 ' HB2' ' O ' ' A' ' 230' ' ' VAL . 53.5 m -71.21 -29.65 65.41 Favored 'General case' 0 C--N 1.327 -0.403 0 O-C-N 121.65 -0.656 . . . . 0.0 110.875 -177.838 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 330' ' ' ALA . . . . . 0.427 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 74.86 -153.11 0.04 OUTLIER 'General case' 0 N--CA 1.469 0.514 0 O-C-N 123.971 0.794 . . . . 0.0 112.499 173.342 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 331' ' ' ALA . . . . . 0.465 ' HB1' ' HB2' ' A' ' 226' ' ' GLU . . . -87.22 116.61 25.42 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.149 -0.932 . . . . 0.0 111.167 -176.816 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 332' ' ' ILE . . . . . 0.944 HG13 HG12 ' A' ' 270' ' ' ILE . 1.8 mp -107.67 139.92 27.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 177.556 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 61.6 m -129.68 103.89 7.11 Favored 'General case' 0 C--N 1.327 -0.392 0 C-N-CA 120.853 -0.339 . . . . 0.0 111.306 -174.624 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 334' ' ' ILE . . . . . 0.721 ' HA ' ' HB3' ' A' ' 268' ' ' PHE . 3.1 mp -90.73 134.98 27.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.491 -177.161 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 335' ' ' LEU . . . . . 0.711 HD23 ' H ' ' A' ' 335' ' ' LEU . 1.6 pt? -116.73 136.35 53.03 Favored 'General case' 0 N--CA 1.441 -0.897 0 N-CA-C 107.721 -1.215 . . . . 0.0 107.721 166.366 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 15.4 p-10 -75.46 47.56 0.39 Allowed 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.141 0.496 . . . . 0.0 110.822 -177.277 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 337' ' ' LYS . . . . . 0.405 ' HB2' ' NZ ' ' A' ' 337' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.243 0.722 0 CA-C-O 118.364 -0.827 . . . . 0.0 110.603 179.442 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.714 0 N-CA-C 112.238 -0.345 . . . . 0.0 112.238 . . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 33.6 p -132.84 46.5 2.61 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.88 0.371 . . . . 0.0 111.359 179.923 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 68.9 p -85.96 177.53 7.57 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.394 177.971 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 5.3 tp10 -118.55 38.55 3.71 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.896 0.855 . . . . 0.0 109.4 177.665 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 26.9 m -129.59 117.7 20.84 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.368 -0.833 . . . . 0.0 109.532 178.065 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 228' ' ' LEU . . . . . . . . . . . . . 72.9 mt -91.54 87.94 6.58 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 -178.836 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 229' ' ' THR . . . . . 0.591 HG22 ' HA ' ' A' ' 331' ' ' ALA . 22.7 p -113.76 173.43 6.43 Favored 'General case' 0 C--N 1.316 -0.865 0 C-N-CA 119.739 -0.784 . . . . 0.0 110.386 -177.953 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 230' ' ' VAL . . . . . 0.557 ' O ' ' HB2' ' A' ' 329' ' ' SER . 78.9 t -142.75 133.12 23.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-O 121.023 0.439 . . . . 0.0 110.785 -176.542 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 39.5 t -108.31 100.28 9.59 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-N 115.339 -0.846 . . . . 0.0 109.482 175.725 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . -173.27 166.77 39.32 Favored Glycine 0 N--CA 1.444 -0.786 0 N-CA-C 111.391 -0.684 . . . . 0.0 111.391 -178.35 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 233' ' ' GLN . . . . . 0.4 ' HA ' ' HD3' ' A' ' 234' ' ' PRO . 12.9 mm-40 -107.49 102.03 42.34 Favored Pre-proline 0 C--N 1.321 -0.659 0 CA-C-N 116.706 0.253 . . . . 0.0 110.72 -179.866 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 234' ' ' PRO . . . . . 0.76 ' HB2' HD12 ' A' ' 306' ' ' ILE . 33.7 Cg_endo -98.11 127.14 0.22 Allowed 'Trans proline' 0 N--CA 1.451 -1.002 0 C-N-CA 123.034 2.489 . . . . 0.0 112.227 -178.479 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -160.28 -177.39 6.22 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.709 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 236' ' ' HIS . . . . . 0.977 ' HA ' ' HG2' ' A' ' 251' ' ' ARG . 33.4 t-80 -159.14 132.98 7.47 Favored 'General case' 0 CA--C 1.517 -0.297 0 CA-C-O 121.605 0.716 . . . . 0.0 111.941 176.38 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 237' ' ' LYS . . . . . 0.614 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -114.61 134.65 54.89 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 114.67 -1.15 . . . . 0.0 110.012 178.203 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 238' ' ' VAL . . . . . 0.411 HG22 ' HE1' ' A' ' 236' ' ' HIS . 41.2 t -103.96 112.21 36.62 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 177.423 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 239' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -90.75 147.24 23.37 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 120.724 -0.39 . . . . 0.0 110.408 177.481 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 240' ' ' ALA . . . . . 0.474 ' C ' ' HD2' ' A' ' 241' ' ' LYS . . . -76.48 -68.74 0.56 Allowed 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.235 -176.654 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 241' ' ' LYS . . . . . 0.474 ' HD2' ' C ' ' A' ' 240' ' ' ALA . 3.5 mptp? -112.69 129.01 56.55 Favored 'General case' 0 CA--C 1.514 -0.416 0 CA-C-O 120.956 0.408 . . . . 0.0 110.886 -179.51 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 242' ' ' ASP . . . . . 0.414 ' CG ' ' H ' ' A' ' 244' ' ' ASN . 7.3 p-10 -96.23 -157.65 0.6 Allowed 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.549 -0.75 . . . . 0.0 109.048 174.52 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 34.9 t -62.55 -29.9 70.91 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.859 0.361 . . . . 0.0 110.798 175.848 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 244' ' ' ASN . . . . . 0.414 ' H ' ' CG ' ' A' ' 242' ' ' ASP . 22.4 t-20 -94.73 -15.22 24.04 Favored 'General case' 0 CA--C 1.532 0.254 0 CA-C-O 121.035 0.445 . . . . 0.0 110.387 179.235 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 92.13 20.0 37.44 Favored Glycine 0 CA--C 1.517 0.209 0 C-N-CA 120.751 -0.737 . . . . 0.0 113.01 175.607 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 246' ' ' MET . . . . . . . . . . . . . 26.5 ptt? -113.67 160.3 32.39 Favored Pre-proline 0 C--N 1.324 -0.514 0 N-CA-C 110.235 -0.283 . . . . 0.0 110.235 179.05 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 247' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -72.74 120.5 6.72 Favored 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 121.993 1.795 . . . . 0.0 110.548 175.276 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 62.7 t -115.46 131.11 68.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 121.214 0.53 . . . . 0.0 112.111 -173.645 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 61.3 t0 -87.82 87.71 7.44 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.008 -0.997 . . . . 0.0 108.688 172.232 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 250' ' ' ASN . . . . . . . . . . . . . 21.6 p30 -101.62 -14.24 17.5 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.881 -0.6 . . . . 0.0 112.456 -173.417 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 251' ' ' ARG . . . . . 0.977 ' HG2' ' HA ' ' A' ' 236' ' ' HIS . 2.7 tpm_? -75.04 -84.34 0.05 Allowed 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 111.92 0.341 . . . . 0.0 111.92 -168.957 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 48.2 mm-40 61.79 179.22 0.12 Allowed 'General case' 0 C--N 1.344 0.345 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 -173.373 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 253' ' ' GLY . . . . . 0.446 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -128.19 116.06 2.22 Favored Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 118.941 -1.6 . . . . 0.0 113.423 -174.275 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 254' ' ' THR . . . . . 0.467 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 80.9 p -109.41 115.45 29.98 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 170.605 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 255' ' ' ILE . . . . . 0.463 ' O ' ' HA ' ' A' ' 299' ' ' THR . 2.0 pp -131.52 164.85 33.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 N-CA-C 112.733 0.642 . . . . 0.0 112.733 -172.79 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 28.9 m -102.17 118.29 36.59 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 178.789 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 257' ' ' VAL . . . . . 0.422 HG12 HG22 ' A' ' 230' ' ' VAL . 35.0 m -90.4 142.91 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.728 0 C-N-CA 119.768 -0.773 . . . . 0.0 112.762 -172.17 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 32.1 t -91.96 9.56 32.6 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 113.772 -1.558 . . . . 0.0 108.317 168.679 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 259' ' ' ALA . . . . . 0.467 ' HB3' HD11 ' A' ' 262' ' ' LEU . . . -92.19 160.94 14.93 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-N 115.303 -0.862 . . . . 0.0 109.184 179.588 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 34.9 t -118.22 131.06 56.4 Favored 'General case' 0 C--N 1.322 -0.627 0 C-N-CA 120.779 -0.368 . . . . 0.0 111.491 -175.794 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 69.96 51.05 25.71 Favored Glycine 0 N--CA 1.449 -0.445 0 CA-C-N 115.607 -0.724 . . . . 0.0 113.655 173.656 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 262' ' ' LEU . . . . . 0.467 HD11 ' HB3' ' A' ' 259' ' ' ALA . 62.6 mt -91.23 151.55 20.88 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 117.044 0.422 . . . . 0.0 110.161 176.63 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 82.5 mt-30 -137.42 168.22 20.08 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.026 0.441 . . . . 0.0 110.883 -178.427 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 57.6 t -78.23 123.74 35.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.971 176.915 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 265' ' ' GLY . . . . . 0.452 ' H ' ' HB ' ' A' ' 292' ' ' VAL . . . 114.15 6.98 19.81 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.51 -0.852 . . . . 0.0 112.808 -179.978 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 61.7 m-20 -89.7 166.02 13.84 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.157 0.503 . . . . 0.0 110.611 176.205 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 267' ' ' ALA . . . . . 0.698 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -129.61 153.3 48.21 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.287 -0.87 . . . . 0.0 109.008 177.676 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 268' ' ' PHE . . . . . 0.613 ' HB3' HD13 ' A' ' 334' ' ' ILE . 9.9 p90 -164.0 165.73 22.21 Favored 'General case' 0 C--N 1.32 -0.675 0 C-N-CA 119.701 -0.8 . . . . 0.0 112.498 -176.887 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 269' ' ' THR . . . . . 0.56 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 66.4 p -115.45 149.51 37.94 Favored 'General case' 0 N--CA 1.444 -0.763 0 CA-C-N 114.624 -1.171 . . . . 0.0 109.224 173.302 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 270' ' ' ILE . . . . . 0.999 HG12 HG13 ' A' ' 332' ' ' ILE . 60.5 mt -121.46 131.47 72.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 N-CA-C 110.416 -0.216 . . . . 0.0 110.416 -179.26 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -62.24 132.91 54.26 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.124 -179.499 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 91.47 -21.72 33.94 Favored Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.182 -178.08 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 31.0 t -105.38 104.36 16.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 C-N-CA 122.402 0.281 . . . . 0.0 110.367 -179.483 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 274' ' ' ASN . . . . . 0.529 ' HA ' ' HA ' ' A' ' 287' ' ' PRO . 7.3 m120 -126.11 144.42 50.74 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.509 -0.476 . . . . 0.0 111.408 -175.429 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 275' ' ' SER . . . . . 0.48 ' HB3' ' OE1' ' A' ' 288' ' ' GLN . 29.5 p -63.77 160.98 16.09 Favored 'General case' 0 CA--C 1.515 -0.377 0 CA-C-N 115.826 -0.624 . . . . 0.0 112.494 -179.377 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 276' ' ' VAL . . . . . 0.543 HG21 HG21 ' A' ' 309' ' ' VAL . 33.8 m -119.36 149.94 21.85 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.663 0 CA-C-N 114.916 -1.038 . . . . 0.0 110.618 176.246 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 38.6 m80 -109.73 71.62 0.77 Allowed 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 173.323 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 19.0 pt20 -74.42 -9.62 58.77 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.379 -0.828 . . . . 0.0 112.136 -173.459 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 47.1 mm -92.4 -56.6 5.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 120.732 0.301 . . . . 0.0 110.761 -179.676 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 73.0 p -86.48 -14.42 43.2 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.321 -178.716 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 3.1 mmmp? 62.27 48.47 4.8 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.994 -178.231 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 52.6 m-20 -92.28 122.92 35.21 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.285 176.943 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 60.9 p -89.35 102.68 15.35 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.052 0.453 . . . . 0.0 110.054 176.616 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 68.5 p -130.91 -40.22 1.19 Allowed 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.837 -0.619 . . . . 0.0 111.242 -174.972 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 73.07 32.36 60.66 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 120.518 -0.848 . . . . 0.0 112.254 -179.624 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 35.6 mt-30 -76.19 140.41 69.48 Favored Pre-proline 0 C--O 1.223 -0.321 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.603 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 287' ' ' PRO . . . . . 0.56 ' HB2' ' HB ' ' A' ' 269' ' ' THR . 36.2 Cg_endo -69.78 150.57 68.26 Favored 'Trans proline' 0 CA--C 1.529 0.255 0 C-N-CA 122.057 1.838 . . . . 0.0 112.566 -177.163 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 288' ' ' GLN . . . . . 0.48 ' OE1' ' HB3' ' A' ' 275' ' ' SER . 5.5 mm100 -78.34 149.28 33.47 Favored 'General case' 0 CA--C 1.514 -0.422 0 CA-C-O 121.186 0.517 . . . . 0.0 112.2 176.929 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 289' ' ' VAL . . . . . 0.409 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 49.7 t -104.61 112.7 39.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 114.877 -1.056 . . . . 0.0 109.37 175.569 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 290' ' ' PHE . . . . . 0.698 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 53.9 m-85 -98.85 160.23 14.41 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.384 -175.584 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 291' ' ' ARG . . . . . 0.47 ' NH1' ' HB2' ' A' ' 267' ' ' ALA . 32.7 mmt180 -118.02 150.54 39.12 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 178.588 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 292' ' ' VAL . . . . . 0.546 HG13 HG13 ' A' ' 300' ' ' VAL . 52.5 t -100.25 122.92 52.76 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.913 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.57 -177.87 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 293' ' ' LEU . . . . . 0.505 HD21 ' HB3' ' A' ' 303' ' ' SER . 3.4 mm? -104.41 -24.1 13.1 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.465 -0.334 . . . . 0.0 111.674 -177.332 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 294' ' ' ALA . . . . . 0.496 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -154.4 136.59 14.79 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 120.762 -0.375 . . . . 0.0 111.638 179.898 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 58.0 t -135.51 120.1 27.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 175.104 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 31.2 t -157.41 111.69 2.65 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.604 -178.331 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 63.34 50.2 64.43 Favored Glycine 0 C--N 1.33 0.229 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.059 -178.315 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 72.2 p 50.82 23.38 1.4 Allowed 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 123.445 0.698 . . . . 0.0 112.524 -175.576 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 299' ' ' THR . . . . . 0.463 ' HA ' ' O ' ' A' ' 255' ' ' ILE . 40.6 m -111.75 116.87 31.43 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 176.148 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 300' ' ' VAL . . . . . 0.546 HG13 HG13 ' A' ' 292' ' ' VAL . 59.1 t -113.69 133.91 58.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.619 -172.34 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 43.5 m -96.82 120.61 37.46 Favored 'General case' 0 C--O 1.235 0.32 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 172.548 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 302' ' ' ILE . . . . . 0.446 HG12 ' O ' ' A' ' 253' ' ' GLY . 27.7 pt -111.26 143.72 20.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-O 121.626 0.727 . . . . 0.0 112.811 -169.725 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 303' ' ' SER . . . . . 0.505 ' HB3' HD21 ' A' ' 293' ' ' LEU . 46.8 t -156.29 129.11 4.26 Favored Pre-proline 0 C--N 1.323 -0.578 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 173.24 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 304' ' ' PRO . . . . . 0.653 ' HD2' ' HA ' ' A' ' 290' ' ' PHE . 34.8 Cg_exo -63.0 -176.05 4.24 Favored 'Cis proline' 0 N--CA 1.477 0.505 0 CA-C-N 119.912 1.004 . . . . 0.0 114.324 1.807 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 305' ' ' LYS . . . . . 0.661 ' HE2' HD11 ' A' ' 307' ' ' LEU . 0.0 OUTLIER -136.57 -175.52 4.04 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.938 -176.205 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 306' ' ' ILE . . . . . 0.76 HD12 ' HB2' ' A' ' 234' ' ' PRO . 41.8 mt -94.29 99.97 10.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.946 -173.525 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 307' ' ' LEU . . . . . 0.661 HD11 ' HE2' ' A' ' 305' ' ' LYS . 2.7 mp -114.43 105.55 53.63 Favored Pre-proline 0 C--N 1.33 -0.277 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 175.729 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 308' ' ' PRO . . . . . 0.745 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 24.1 Cg_exo -68.92 127.66 15.61 Favored 'Trans proline' 0 CA--C 1.53 0.286 0 C-N-CA 122.955 2.437 . . . . 0.0 113.394 -176.07 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 309' ' ' VAL . . . . . 0.659 HG22 ' HB3' ' A' ' 320' ' ' ALA . 76.9 t -84.27 -37.14 12.6 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.088 174.966 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -75.29 -6.65 50.93 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.256 179.243 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.52 ' HB2' ' HB2' ' A' ' 308' ' ' PRO . 69.7 m-80 -136.87 -158.69 0.88 Allowed 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.262 -0.427 . . . . 0.0 109.996 -176.633 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 16.5 m 71.23 -73.16 0.1 Allowed 'General case' 0 C--O 1.234 0.275 0 C-N-CA 123.755 0.822 . . . . 0.0 110.903 177.005 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 51.0 t0 -176.44 159.81 2.0 Allowed 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 177.253 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 61.7 t -64.45 -39.73 86.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-O 120.908 0.385 . . . . 0.0 110.55 176.038 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -72.5 -18.87 61.62 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.637 178.732 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 50.3 m -83.86 -25.86 29.92 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.535 -0.302 . . . . 0.0 111.177 -179.221 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 317' ' ' ARG . . . . . 0.659 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 74.1 mtm180 -49.14 -52.57 46.88 Favored Pre-proline 0 CA--C 1.539 0.52 0 N-CA-C 112.641 0.608 . . . . 0.0 112.641 -178.574 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 318' ' ' PRO . . . . . 0.659 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 51.8 Cg_exo -59.74 -13.97 24.56 Favored 'Trans proline' 0 C--N 1.36 1.14 0 C-N-CA 122.53 2.154 . . . . 0.0 113.833 -177.232 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 44.9 m-85 -110.75 -0.55 17.0 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.99 0.424 . . . . 0.0 110.77 -179.282 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 320' ' ' ALA . . . . . 0.659 ' HB3' HG22 ' A' ' 309' ' ' VAL . . . -90.5 159.85 16.3 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.155 -178.899 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 321' ' ' ASN . . . . . 0.431 ' O ' ' HA ' ' A' ' 275' ' ' SER . 51.1 p30 -130.68 -0.69 4.33 Favored 'General case' 0 N--CA 1.464 0.255 0 N-CA-C 112.75 0.648 . . . . 0.0 112.75 -178.977 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 322' ' ' VAL . . . . . 0.676 HG21 HG23 ' A' ' 306' ' ' ILE . 32.8 m -136.11 162.08 36.71 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.258 0 N-CA-C 110.097 -0.334 . . . . 0.0 110.097 176.988 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 51.6 m-20 -72.92 -39.82 65.97 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 111.731 0.271 . . . . 0.0 111.731 -176.376 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 324' ' ' ALA . . . . . 0.745 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -155.5 174.61 15.02 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 112.149 0.426 . . . . 0.0 112.149 -173.353 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 24.6 pttm -119.12 107.44 41.73 Favored Pre-proline 0 N--CA 1.454 -0.233 0 CA-C-N 115.472 -0.785 . . . . 0.0 110.031 170.923 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 55.0 Cg_endo -74.04 167.82 26.28 Favored 'Trans proline' 0 C--O 1.233 0.232 0 C-N-CA 122.695 2.263 . . . . 0.0 112.562 -176.525 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -71.6 123.81 23.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.875 -179.289 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 54.8 mt-10 66.36 -170.14 0.2 Allowed 'General case' 0 N--CA 1.465 0.32 0 O-C-N 123.674 0.609 . . . . 0.0 111.004 -175.998 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 329' ' ' SER . . . . . 0.557 ' HB2' ' O ' ' A' ' 230' ' ' VAL . 50.9 m -94.29 -27.81 15.93 Favored 'General case' 0 C--N 1.325 -0.467 0 C-N-CA 120.727 -0.389 . . . . 0.0 111.995 -174.458 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 330' ' ' ALA . . . . . 0.477 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 75.62 -151.32 0.03 OUTLIER 'General case' 0 N--CA 1.478 0.95 0 N-CA-C 113.273 0.842 . . . . 0.0 113.273 173.023 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 331' ' ' ALA . . . . . 0.591 ' HA ' HG22 ' A' ' 229' ' ' THR . . . -92.98 120.64 33.49 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 114.741 -1.118 . . . . 0.0 110.818 -177.735 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 332' ' ' ILE . . . . . 0.999 HG13 HG12 ' A' ' 270' ' ' ILE . 1.7 mp -106.54 145.87 13.73 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 115.682 -0.69 . . . . 0.0 111.221 -176.903 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 44.1 m -118.29 95.33 4.83 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.0 -178.077 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 334' ' ' ILE . . . . . 0.613 HD13 ' HB3' ' A' ' 268' ' ' PHE . 39.8 mm -78.34 133.48 30.18 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-O 120.949 0.404 . . . . 0.0 111.35 -176.276 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 335' ' ' LEU . . . . . 0.579 HD13 ' H ' ' A' ' 337' ' ' LYS . 1.8 pp -152.44 -172.65 4.3 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.429 177.875 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -124.96 44.23 2.84 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.776 0.322 . . . . 0.0 110.844 -178.925 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 337' ' ' LYS . . . . . 0.579 ' H ' HD13 ' A' ' 335' ' ' LEU . 60.8 tttm . . . . . 0 C--O 1.245 0.836 0 CA-C-O 118.635 -0.698 . . . . 0.0 110.509 -178.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 38.2 p . . . . . 0 N--CA 1.452 -0.327 0 CA-C-O 121.136 0.494 . . . . 0.0 110.286 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 228' ' ' LEU . . . . . . . . . . . . . 73.0 mt -107.62 100.72 10.1 Favored 'General case' 0 N--CA 1.445 -0.692 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 -178.325 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 76.1 p -126.39 172.19 10.36 Favored 'General case' 0 C--N 1.325 -0.459 0 C-N-CA 119.924 -0.71 . . . . 0.0 110.41 -178.621 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 230' ' ' VAL . . . . . 0.771 HG11 ' HB ' ' A' ' 255' ' ' ILE . 61.5 t -143.96 136.36 23.21 Favored 'Isoleucine or valine' 0 C--O 1.24 0.565 0 CA-C-O 120.779 0.324 . . . . 0.0 110.845 -178.176 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 29.7 m -97.28 160.16 14.5 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.125 177.201 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 92.52 161.58 36.57 Favored Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.462 -0.875 . . . . 0.0 111.177 -177.281 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 233' ' ' GLN . . . . . 0.598 ' HG2' ' HA ' ' A' ' 328' ' ' GLU . 83.4 mt-30 -118.16 102.85 50.38 Favored Pre-proline 0 C--N 1.319 -0.723 0 CA-C-N 117.081 0.44 . . . . 0.0 111.739 -177.354 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 234' ' ' PRO . . . . . 0.414 ' HD3' ' OG ' ' A' ' 329' ' ' SER . 73.9 Cg_endo -75.86 123.75 7.61 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 121.468 1.445 . . . . 0.0 110.444 171.829 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 20.3 pt-20 -166.19 127.1 1.76 Allowed 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.605 -178.584 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 236' ' ' HIS . . . . . 0.479 ' C ' ' HD3' ' A' ' 237' ' ' LYS . 92.1 m-70 -141.04 143.36 34.35 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.219 174.794 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 237' ' ' LYS . . . . . 0.479 ' HD3' ' C ' ' A' ' 236' ' ' HIS . 13.7 mmtm . . . . . 0 C--N 1.313 -1.018 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.207 -172.62 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 252' ' ' GLN . . . . . 0.566 ' HA ' ' O ' ' A' ' 302' ' ' ILE . 25.2 mt-30 . . . . . 0 N--CA 1.468 0.474 0 N-CA-C 114.13 1.159 . . . . 0.0 114.13 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 174.72 109.47 0.24 Allowed Glycine 0 N--CA 1.446 -0.648 0 CA-C-N 114.338 -1.301 . . . . 0.0 109.933 -177.145 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 41.5 p -95.44 125.09 39.81 Favored 'General case' 0 C--N 1.324 -0.522 0 O-C-N 122.32 -0.517 . . . . 0.0 111.706 -171.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.771 ' HB ' HG11 ' A' ' 230' ' ' VAL . 20.5 pt -124.37 145.18 31.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.901 -176.181 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 31.0 m -99.56 106.05 17.99 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 174.232 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.557 ' HA ' HG13 ' A' ' 230' ' ' VAL . 32.8 m -88.13 141.57 14.13 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.595 0 C-N-CA 119.27 -0.972 . . . . 0.0 113.607 -165.04 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 36.4 m -94.23 10.3 34.57 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 113.404 -1.725 . . . . 0.0 109.275 169.593 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 259' ' ' ALA . . . . . . . . . . . . . . . -126.76 145.58 50.56 Favored 'General case' 0 CA--C 1.518 -0.256 0 N-CA-C 113.037 0.755 . . . . 0.0 113.037 -167.209 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 62.5 m 57.94 -68.51 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.558 0 CA-C-N 113.822 -1.535 . . . . 0.0 114.919 167.354 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 107.49 51.39 0.76 Allowed Glycine 0 N--CA 1.449 -0.466 0 N-CA-C 109.861 -1.296 . . . . 0.0 109.861 -167.408 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 262' ' ' LEU . . . . . 0.409 HD21 HD12 ' A' ' 334' ' ' ILE . 92.4 mt -65.0 163.93 13.71 Favored 'General case' 0 C--O 1.235 0.332 0 N-CA-C 113.709 1.003 . . . . 0.0 113.709 -168.021 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 73.0 mt-30 -135.23 -179.42 5.62 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 113.694 -1.594 . . . . 0.0 108.042 173.425 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 264' ' ' VAL . . . . . 0.43 ' HA ' ' CG1' ' A' ' 292' ' ' VAL . 38.5 t -73.76 127.81 35.84 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 C-N-CA 120.679 -0.408 . . . . 0.0 111.062 -179.79 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . 0.617 ' H ' ' HB ' ' A' ' 292' ' ' VAL . . . 121.49 8.05 7.88 Favored Glycine 0 C--N 1.335 0.486 0 C-N-CA 120.363 -0.922 . . . . 0.0 114.395 175.246 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 65.6 m-20 -90.71 164.93 13.95 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 117.831 0.816 . . . . 0.0 111.517 178.511 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 267' ' ' ALA . . . . . 0.766 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -139.9 126.0 19.84 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.199 -0.909 . . . . 0.0 109.052 174.536 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 268' ' ' PHE . . . . . 0.48 ' HZ ' HG21 ' A' ' 302' ' ' ILE . 4.7 p90 -147.6 166.74 26.47 Favored 'General case' 0 C--N 1.327 -0.413 0 C-N-CA 119.74 -0.784 . . . . 0.0 111.829 -173.353 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 269' ' ' THR . . . . . 0.435 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 44.2 p -117.73 139.82 50.53 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.853 176.09 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 270' ' ' ILE . . . . . 0.546 HG12 HG12 ' A' ' 332' ' ' ILE . 59.6 mt -106.71 144.37 15.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 120.668 0.27 . . . . 0.0 110.964 -177.425 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -67.83 119.51 12.64 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.442 -179.827 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 106.04 -22.69 30.91 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 121.098 -0.572 . . . . 0.0 112.386 178.615 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . 0.818 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 36.5 t -87.02 101.44 11.16 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-O 121.046 0.45 . . . . 0.0 110.286 178.756 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 274' ' ' ASN . . . . . 0.526 ' HB3' ' HA2' ' A' ' 285' ' ' GLY . 3.6 m120 -110.01 129.6 55.65 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.272 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 51.0 p -73.01 160.47 32.03 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.588 0.709 . . . . 0.0 112.148 -178.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 276' ' ' VAL . . . . . 0.863 HG21 HG21 ' A' ' 309' ' ' VAL . 22.8 m -127.9 -176.67 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 CA-C-N 114.748 -1.115 . . . . 0.0 110.432 -178.561 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 277' ' ' HIS . . . . . 0.669 ' HB3' ' HA ' ' A' ' 281' ' ' LYS . 0.7 OUTLIER 29.84 51.21 0.08 Allowed 'General case' 0 N--CA 1.473 0.69 0 O-C-N 124.826 1.328 . . . . 0.0 113.624 177.89 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 4.1 tp-100 -74.84 -43.15 56.1 Favored 'General case' 0 N--CA 1.439 -1.018 0 N-CA-C 108.488 -0.931 . . . . 0.0 108.488 171.248 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 279' ' ' ILE . . . . . 0.446 ' O ' ' HB2' ' A' ' 282' ' ' ASP . 26.5 mm -117.32 75.08 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.278 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.269 177.464 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 58.3 p 51.4 81.93 0.07 Allowed 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 123.665 0.786 . . . . 0.0 112.642 -178.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 281' ' ' LYS . . . . . 0.669 ' HA ' ' HB3' ' A' ' 277' ' ' HIS . 1.0 OUTLIER 56.96 27.63 13.47 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-N 115.42 -0.809 . . . . 0.0 112.011 -179.555 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 282' ' ' ASP . . . . . 0.446 ' HB2' ' O ' ' A' ' 279' ' ' ILE . 57.3 t0 -90.1 128.55 36.34 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.947 -0.57 . . . . 0.0 109.677 177.323 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 44.7 p -101.18 114.94 29.36 Favored 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 76.0 p -116.19 -11.35 11.34 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.649 -0.705 . . . . 0.0 112.145 -167.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 285' ' ' GLY . . . . . 0.526 ' HA2' ' HB3' ' A' ' 274' ' ' ASN . . . 76.83 10.83 85.9 Favored Glycine 0 CA--C 1.517 0.196 0 C-N-CA 120.814 -0.707 . . . . 0.0 113.267 177.249 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 83.2 mt-30 -71.81 131.09 86.14 Favored Pre-proline 0 C--N 1.327 -0.39 0 CA-C-N 116.824 0.312 . . . . 0.0 110.596 179.616 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 287' ' ' PRO . . . . . 0.435 ' HB2' ' HB ' ' A' ' 269' ' ' THR . 15.8 Cg_endo -59.3 131.32 40.3 Favored 'Trans proline' 0 C--N 1.343 0.254 0 C-N-CA 122.699 2.266 . . . . 0.0 112.292 -178.646 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 69.2 tp60 -78.3 132.16 37.35 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.847 -178.528 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 46.9 t -92.13 136.3 24.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.356 179.345 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 290' ' ' PHE . . . . . 0.818 ' HZ ' HG11 ' A' ' 273' ' ' VAL . 55.7 m-85 -117.16 150.67 38.33 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.806 -177.081 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 21.2 mmt85 -108.02 157.69 18.02 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.797 -0.638 . . . . 0.0 109.835 172.252 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . 0.617 ' HB ' ' H ' ' A' ' 265' ' ' GLY . 52.2 t -102.6 128.77 55.07 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.03 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.509 177.406 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 293' ' ' LEU . . . . . 0.659 HD21 ' HB3' ' A' ' 303' ' ' SER . 2.8 mm? -103.99 -37.05 7.53 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.108 -178.578 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 294' ' ' ALA . . . . . . . . . . . . . . . -156.96 141.54 16.75 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.562 -0.29 . . . . 0.0 111.009 -178.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 295' ' ' VAL . . . . . 0.471 HG22 HG13 ' A' ' 300' ' ' VAL . 46.3 t -131.64 129.01 61.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.052 0.453 . . . . 0.0 110.122 176.176 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 56.5 p -122.3 88.81 3.0 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.793 -0.64 . . . . 0.0 109.897 178.295 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 75.42 -124.3 7.56 Favored Glycine 0 N--CA 1.446 -0.671 0 C-N-CA 119.932 -1.128 . . . . 0.0 110.552 -171.425 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 41.7 p -99.72 26.37 6.3 Favored 'General case' 0 C--N 1.319 -0.745 0 O-C-N 122.142 -0.622 . . . . 0.0 110.87 173.505 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 54.1 m -107.95 106.3 16.49 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 176.009 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . 0.471 HG13 HG22 ' A' ' 295' ' ' VAL . 42.0 t -104.44 124.87 59.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.952 -175.001 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 47.3 m -94.89 109.67 21.64 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 176.149 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 302' ' ' ILE . . . . . 0.566 ' O ' ' HA ' ' A' ' 252' ' ' GLN . 28.8 pt -111.25 160.93 10.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-O 121.459 0.647 . . . . 0.0 112.343 -173.412 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 303' ' ' SER . . . . . 0.659 ' HB3' HD21 ' A' ' 293' ' ' LEU . 34.6 t -167.24 155.9 9.09 Favored Pre-proline 0 C--N 1.32 -0.713 0 N-CA-C 105.964 -1.865 . . . . 0.0 105.964 178.331 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 304' ' ' PRO . . . . . 0.507 ' HA ' ' OG ' ' A' ' 303' ' ' SER . 65.2 Cg_exo -56.46 151.54 27.16 Favored 'Cis proline' 0 N--CA 1.473 0.291 0 CA-C-N 121.23 1.475 . . . . 0.0 114.642 1.715 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 305' ' ' LYS . . . . . 0.613 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -67.34 169.01 9.56 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 114.085 -1.416 . . . . 0.0 111.763 -179.04 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 306' ' ' ILE . . . . . 0.593 HG23 HG21 ' A' ' 322' ' ' VAL . 62.6 mt -108.59 114.09 45.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.85 -178.154 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 307' ' ' LEU . . . . . 0.537 ' O ' ' HB1' ' A' ' 320' ' ' ALA . 94.0 mt -125.94 118.45 23.97 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-N 116.753 -0.203 . . . . 0.0 111.021 -179.72 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 308' ' ' PRO . . . . . 0.741 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 9.9 Cg_exo -74.18 122.31 7.49 Favored 'Trans proline' 0 CA--C 1.534 0.493 0 C-N-CA 123.519 2.813 . . . . 0.0 113.742 -178.557 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . 0.863 HG21 HG21 ' A' ' 276' ' ' VAL . 48.1 t -80.58 -19.44 11.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 121.189 0.518 . . . . 0.0 110.48 176.014 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 59.5 mm-40 -92.77 -5.32 51.42 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.904 0.383 . . . . 0.0 110.834 179.206 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.568 ' HB2' ' HB2' ' A' ' 308' ' ' PRO . 5.5 m120 -132.5 -129.98 0.18 Allowed 'General case' 0 CA--C 1.532 0.285 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.26 -178.531 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 312' ' ' THR . . . . . 0.493 ' OG1' ' HD2' ' A' ' 308' ' ' PRO . 59.6 m 60.84 -78.61 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.281 0 C-N-CA 124.28 1.032 . . . . 0.0 112.121 177.655 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 38.3 t70 -176.68 150.29 0.82 Allowed 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 -177.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 46.7 t -53.18 -37.61 28.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 120.748 0.309 . . . . 0.0 111.53 -179.516 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -84.91 -36.3 21.55 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 112.377 0.51 . . . . 0.0 112.377 -178.314 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . 0.523 ' HA ' ' CZ ' ' A' ' 319' ' ' TYR . 67.9 m -93.53 -12.68 29.06 Favored 'General case' 0 C--N 1.327 -0.398 0 N-CA-C 113.364 0.875 . . . . 0.0 113.364 -172.346 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 317' ' ' ARG . . . . . 0.525 ' HG2' ' HD3' ' A' ' 318' ' ' PRO . 33.6 ptt85 -75.44 -34.4 1.59 Allowed Pre-proline 0 CA--C 1.548 0.882 0 N-CA-C 113.171 0.804 . . . . 0.0 113.171 -179.47 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 318' ' ' PRO . . . . . 0.525 ' HD3' ' HG2' ' A' ' 317' ' ' ARG . 33.9 Cg_exo -60.36 -26.79 83.53 Favored 'Trans proline' 0 C--N 1.371 1.718 0 C-N-CA 121.702 1.602 . . . . 0.0 113.17 -177.785 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 319' ' ' TYR . . . . . 0.523 ' CZ ' ' HA ' ' A' ' 316' ' ' SER . 2.7 p90 -106.82 30.0 6.5 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.076 0.465 . . . . 0.0 111.312 177.863 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . 0.706 ' HB3' HG22 ' A' ' 309' ' ' VAL . . . -89.87 162.68 15.34 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.404 -0.817 . . . . 0.0 109.838 173.628 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 321' ' ' ASN . . . . . 0.406 ' OD1' HG13 ' A' ' 322' ' ' VAL . 19.4 p30 -100.71 -19.18 16.16 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 113.788 1.032 . . . . 0.0 113.788 -171.457 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 322' ' ' VAL . . . . . 0.593 HG21 HG23 ' A' ' 306' ' ' ILE . 35.6 m -136.77 161.08 36.78 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.401 0 CA-C-N 118.073 0.397 . . . . 0.0 111.155 -179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 54.5 m-20 -60.91 -41.03 95.34 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 111.849 0.314 . . . . 0.0 111.849 -178.781 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 324' ' ' ALA . . . . . 0.741 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -157.09 166.24 33.82 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.398 -0.364 . . . . 0.0 111.77 -175.346 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 24.5 pttm -106.31 108.93 62.67 Favored Pre-proline 0 C--N 1.327 -0.411 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 169.016 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_exo -65.0 167.24 16.39 Favored 'Trans proline' 0 C--N 1.343 0.244 0 C-N-CA 122.581 2.187 . . . . 0.0 113.107 -170.543 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -62.85 143.53 57.51 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 115.753 -0.658 . . . . 0.0 109.767 175.089 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 328' ' ' GLU . . . . . 0.598 ' HA ' ' HG2' ' A' ' 233' ' ' GLN . 15.6 pt-20 44.86 -135.25 0.65 Allowed 'General case' 0 N--CA 1.468 0.449 0 O-C-N 124.227 0.955 . . . . 0.0 110.941 -174.132 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 329' ' ' SER . . . . . 0.648 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 53.3 m -111.7 -31.63 6.91 Favored 'General case' 0 C--N 1.321 -0.636 0 C-N-CA 120.743 -0.383 . . . . 0.0 110.535 178.317 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 330' ' ' ALA . . . . . 0.432 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 78.6 -167.42 0.04 OUTLIER 'General case' 0 N--CA 1.475 0.824 0 O-C-N 124.111 0.882 . . . . 0.0 112.902 174.634 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -83.85 152.91 24.32 Favored 'General case' 0 CA--C 1.52 -0.182 0 CA-C-N 115.361 -0.836 . . . . 0.0 111.193 -176.179 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 332' ' ' ILE . . . . . 0.582 HD11 HG21 ' A' ' 230' ' ' VAL . 48.7 mt -126.58 145.0 34.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 121.202 0.525 . . . . 0.0 112.034 -176.56 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 87.8 m -111.22 97.57 6.88 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.459 -0.792 . . . . 0.0 109.103 173.486 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 334' ' ' ILE . . . . . 0.409 HD12 HD21 ' A' ' 262' ' ' LEU . 30.2 mm -79.11 132.27 32.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -171.705 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 335' ' ' LEU . . . . . . . . . . . . . 8.4 mp -119.79 151.59 38.57 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.412 -0.813 . . . . 0.0 109.818 170.468 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 75.0 m-80 -110.3 9.95 23.62 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.293 174.193 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 38.8 ttpt . . . . . 0 C--O 1.244 0.788 0 CA-C-O 118.493 -0.765 . . . . 0.0 110.181 179.295 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 35.7 t . . . . . 0 C--O 1.235 0.305 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 228' ' ' LEU . . . . . 0.652 HD12 HG13 ' A' ' 334' ' ' ILE . 80.3 mt -103.61 146.9 27.88 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.352 -0.84 . . . . 0.0 109.548 -175.523 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 229' ' ' THR . . . . . 0.593 HG22 ' HA ' ' A' ' 331' ' ' ALA . 40.9 p -126.43 178.77 5.65 Favored 'General case' 0 C--N 1.323 -0.547 0 C-N-CA 119.729 -0.788 . . . . 0.0 111.042 -179.835 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 230' ' ' VAL . . . . . 0.857 HG11 HD12 ' A' ' 255' ' ' ILE . 58.1 t -146.28 137.15 18.6 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 -179.599 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 70.8 m -111.18 155.41 22.95 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.944 0.402 . . . . 0.0 110.854 178.188 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 86.03 169.63 46.14 Favored Glycine 0 N--CA 1.449 -0.499 0 N-CA-C 110.76 -0.936 . . . . 0.0 110.76 -172.471 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 233' ' ' GLN . . . . . 0.419 ' HA ' ' HD3' ' A' ' 234' ' ' PRO . 86.1 mt-30 -117.54 145.56 36.54 Favored Pre-proline 0 C--N 1.323 -0.572 0 CA-C-N 117.626 0.713 . . . . 0.0 111.482 179.761 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 234' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 233' ' ' GLN . 3.8 Cg_exo -71.94 172.29 14.91 Favored 'Trans proline' 0 N--CA 1.462 -0.374 0 C-N-CA 122.751 2.301 . . . . 0.0 111.55 176.249 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 55.7 mp0 -96.89 151.19 19.92 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.174 0.512 . . . . 0.0 110.911 -179.063 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 236' ' ' HIS . . . . . 0.591 ' CE1' ' HE2' ' A' ' 325' ' ' LYS . 17.1 p-80 -140.48 125.73 18.7 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.33 -0.85 . . . . 0.0 108.9 174.338 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 237' ' ' LYS . . . . . 0.563 ' HD3' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.326 -0.414 0 N-CA-C 111.76 0.282 . . . . 0.0 111.76 -176.385 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 252' ' ' GLN . . . . . 0.493 ' HA ' ' O ' ' A' ' 302' ' ' ILE . 26.2 mt-30 . . . . . 0 N--CA 1.47 0.562 0 N-CA-C 114.894 1.442 . . . . 0.0 114.894 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . 0.556 ' O ' HG12 ' A' ' 302' ' ' ILE . . . 179.96 110.43 0.28 Allowed Glycine 0 N--CA 1.451 -0.349 0 CA-C-N 113.738 -1.574 . . . . 0.0 110.588 178.581 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 41.6 p -97.12 126.49 42.32 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 117.378 0.589 . . . . 0.0 111.406 -174.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.857 HD12 HG11 ' A' ' 230' ' ' VAL . 12.7 pt -132.18 157.79 43.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.62 -176.406 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 32.7 m -98.98 107.57 20.04 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 175.06 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.567 ' HA ' HG13 ' A' ' 230' ' ' VAL . 29.8 m -89.79 143.31 11.45 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.575 0 C-N-CA 119.556 -0.858 . . . . 0.0 113.012 -168.206 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 258' ' ' SER . . . . . 0.516 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 37.2 m -91.04 9.32 31.3 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 114.023 -1.444 . . . . 0.0 108.893 169.789 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 259' ' ' ALA . . . . . 0.618 ' HB1' HD13 ' A' ' 228' ' ' LEU . . . -84.78 161.56 19.93 Favored 'General case' 0 N--CA 1.448 -0.525 0 CA-C-N 115.119 -0.946 . . . . 0.0 109.502 -177.624 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 34.3 t -126.63 130.77 51.11 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 120.639 0.257 . . . . 0.0 110.61 -178.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 75.87 43.79 21.51 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.963 -0.637 . . . . 0.0 113.328 177.179 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 262' ' ' LEU . . . . . 0.481 HD12 HG21 ' A' ' 257' ' ' VAL . 79.3 mt -89.99 142.92 27.24 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 117.17 0.485 . . . . 0.0 110.478 175.757 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 73.0 mt-30 -133.84 171.43 14.17 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.51 176.845 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 44.0 t -76.58 142.05 14.87 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 N-CA-C 110.195 -0.298 . . . . 0.0 110.195 179.1 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 94.87 -4.9 68.77 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.5 -0.857 . . . . 0.0 113.257 177.255 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 266' ' ' ASP . . . . . 0.506 ' O ' ' HA ' ' A' ' 291' ' ' ARG . 48.7 m-20 -78.88 158.03 28.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 117.172 0.486 . . . . 0.0 110.837 178.287 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 267' ' ' ALA . . . . . 0.652 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -122.72 147.67 46.21 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.974 -176.658 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 268' ' ' PHE . . . . . 0.581 ' HA ' ' CD2' ' A' ' 335' ' ' LEU . 3.6 p90 -164.04 173.28 12.73 Favored 'General case' 0 C--N 1.33 -0.259 0 C-N-CA 120.056 -0.657 . . . . 0.0 111.895 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 54.1 p -121.58 129.98 53.21 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.345 176.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 270' ' ' ILE . . . . . 0.846 HG12 HG13 ' A' ' 332' ' ' ILE . 62.6 mt -98.35 134.4 37.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.72 -178.839 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -76.07 118.47 18.85 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.828 179.206 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 109.62 -21.44 25.84 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.629 -0.796 . . . . 0.0 111.938 -178.778 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 40.9 t -104.35 102.12 13.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 N-CA-C 109.557 -0.535 . . . . 0.0 109.557 175.293 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 4.1 m120 -104.44 151.57 23.37 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 -179.481 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 275' ' ' SER . . . . . 0.98 ' HB3' ' HB3' ' A' ' 288' ' ' GLN . 23.2 p -88.17 157.53 18.79 Favored 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 112.13 0.419 . . . . 0.0 112.13 -178.079 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 276' ' ' VAL . . . . . 0.536 HG11 HG21 ' A' ' 309' ' ' VAL . 18.8 m -125.98 162.76 28.88 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.605 0 CA-C-N 115.332 -0.849 . . . . 0.0 109.959 172.744 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 277' ' ' HIS . . . . . 0.412 ' HD2' HG21 ' A' ' 284' ' ' THR . 88.8 m-70 -130.04 91.29 3.1 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 175.526 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 4.1 tp-100 -80.64 -23.42 39.71 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.361 -172.112 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 279' ' ' ILE . . . . . 0.505 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.1 mp -64.99 -41.56 92.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 121.069 0.461 . . . . 0.0 109.884 177.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 77.8 p -87.45 -16.44 34.8 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.316 174.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 5.6 tmtm? 59.49 53.65 5.03 Favored 'General case' 0 CA--C 1.531 0.216 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 -176.086 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -110.91 142.26 43.23 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.336 -0.847 . . . . 0.0 109.401 -175.256 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 36.0 p -102.28 106.19 16.96 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 178.295 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 284' ' ' THR . . . . . 0.412 HG21 ' HD2' ' A' ' 277' ' ' HIS . 82.5 p -110.13 -53.47 2.67 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.655 -0.702 . . . . 0.0 111.406 -171.628 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 66.13 31.48 79.41 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 121.001 -0.618 . . . . 0.0 111.966 -179.364 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 286' ' ' GLN . . . . . 0.408 ' HA ' ' HD3' ' A' ' 287' ' ' PRO . 11.2 mm100 -106.11 142.15 24.25 Favored Pre-proline 0 C--N 1.326 -0.451 0 CA-C-N 116.026 -0.087 . . . . 0.0 110.772 -177.311 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 287' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 286' ' ' GLN . 38.6 Cg_exo -59.3 127.82 25.32 Favored 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 122.648 2.232 . . . . 0.0 111.671 178.161 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 288' ' ' GLN . . . . . 0.98 ' HB3' ' HB3' ' A' ' 275' ' ' SER . 15.9 pt20 -93.55 159.18 15.34 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.984 -178.163 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 289' ' ' VAL . . . . . 0.482 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 45.6 t -88.53 126.26 41.76 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 CA-C-N 115.446 -0.797 . . . . 0.0 110.002 175.246 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 290' ' ' PHE . . . . . 0.652 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 4.1 m-85 -99.67 169.21 9.43 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 178.762 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 291' ' ' ARG . . . . . 0.506 ' HA ' ' O ' ' A' ' 266' ' ' ASP . 12.5 ttp-105 -144.14 127.47 16.79 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-O 121.808 0.813 . . . . 0.0 110.947 172.417 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . 0.402 HG11 ' CG2' ' A' ' 295' ' ' VAL . 57.5 t -65.84 139.91 20.48 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.979 0 CA-C-N 114.044 -1.434 . . . . 0.0 112.175 -176.347 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 293' ' ' LEU . . . . . 0.513 HD11 ' HB2' ' A' ' 303' ' ' SER . 89.4 mt -105.56 -32.69 8.37 Favored 'General case' 0 CA--C 1.529 0.157 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.193 177.035 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 294' ' ' ALA . . . . . . . . . . . . . . . -158.6 144.94 17.1 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-O 120.463 0.173 . . . . 0.0 111.15 -179.18 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 295' ' ' VAL . . . . . 0.402 ' CG2' HG11 ' A' ' 292' ' ' VAL . 57.4 t -136.34 126.8 41.33 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 176.836 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 47.0 t -157.54 112.54 2.73 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.897 -178.56 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 57.6 49.76 70.93 Favored Glycine 0 C--N 1.333 0.376 0 C-N-CA 121.148 -0.548 . . . . 0.0 112.469 178.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 298' ' ' THR . . . . . 0.438 ' O ' HG22 ' A' ' 257' ' ' VAL . 66.8 p 55.4 10.3 0.46 Allowed 'General case' 0 N--CA 1.473 0.675 0 C-N-CA 124.201 1.0 . . . . 0.0 112.89 -175.722 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 42.6 m -97.81 106.02 18.26 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 173.351 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . 0.4 HG13 HG22 ' A' ' 295' ' ' VAL . 53.1 t -109.86 127.02 67.03 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.51 -170.494 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 57.3 m -90.54 113.89 25.98 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 172.655 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 302' ' ' ILE . . . . . 0.556 HG12 ' O ' ' A' ' 253' ' ' GLY . 31.0 pt -110.4 174.76 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-O 121.643 0.735 . . . . 0.0 111.727 -173.321 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 303' ' ' SER . . . . . 0.562 ' OG ' ' HA ' ' A' ' 304' ' ' PRO . 31.8 t -163.1 156.67 16.98 Favored Pre-proline 0 C--N 1.317 -0.811 0 N-CA-C 105.759 -1.941 . . . . 0.0 105.759 178.732 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 304' ' ' PRO . . . . . 0.562 ' HA ' ' OG ' ' A' ' 303' ' ' SER . 24.9 Cg_exo -66.33 -179.42 12.34 Favored 'Cis proline' 0 N--CA 1.474 0.339 0 CA-C-N 121.004 1.394 . . . . 0.0 113.906 1.404 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 305' ' ' LYS . . . . . 0.618 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -77.48 160.98 28.29 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.317 -0.856 . . . . 0.0 112.254 -175.264 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 306' ' ' ILE . . . . . 0.526 HD12 ' N ' ' A' ' 306' ' ' ILE . 2.2 mp -94.05 109.91 22.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.18 179.03 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 307' ' ' LEU . . . . . 0.485 ' H ' HG22 ' A' ' 322' ' ' VAL . 96.0 mt -141.51 99.39 6.36 Favored Pre-proline 0 CA--C 1.516 -0.361 0 CA-C-O 120.455 0.169 . . . . 0.0 111.052 178.411 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 308' ' ' PRO . . . . . 0.755 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 22.6 Cg_exo -69.43 148.19 66.63 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 123.077 2.518 . . . . 0.0 113.297 -177.354 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . 0.536 HG21 HG11 ' A' ' 276' ' ' VAL . 45.5 t -93.7 -23.98 5.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 170.452 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -76.05 34.37 0.13 Allowed 'General case' 0 CA--C 1.532 0.272 0 CA-C-N 115.375 -0.83 . . . . 0.0 112.726 -177.3 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 77.3 m-20 -99.07 162.87 12.83 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 174.77 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 61.5 m -78.43 -32.81 48.77 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 176.615 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -65.31 119.57 11.18 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.781 179.699 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 60.1 t -68.39 -35.43 70.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.767 -0.651 . . . . 0.0 111.16 -178.657 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . 0.423 ' O ' ' HD2' ' A' ' 318' ' ' PRO . . . -65.07 -17.9 64.85 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 112.157 0.428 . . . . 0.0 112.157 -178.787 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . 0.593 ' HA ' ' CZ ' ' A' ' 319' ' ' TYR . 52.4 m -78.92 -17.21 55.89 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 111.812 0.301 . . . . 0.0 111.812 -179.313 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 317' ' ' ARG . . . . . 0.427 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 70.0 mtm180 -74.4 -46.88 5.86 Favored Pre-proline 0 CA--C 1.539 0.542 0 N-CA-C 112.928 0.714 . . . . 0.0 112.928 -176.569 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 318' ' ' PRO . . . . . 0.427 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 75.9 Cg_exo -54.85 -38.48 92.32 Favored 'Trans proline' 0 C--N 1.358 1.033 0 C-N-CA 122.126 1.884 . . . . 0.0 113.685 -175.78 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 319' ' ' TYR . . . . . 0.593 ' CZ ' ' HA ' ' A' ' 316' ' ' SER . 2.1 p90 -98.72 7.58 45.92 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 120.76 -0.376 . . . . 0.0 111.937 -178.536 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -60.43 156.02 16.93 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-O 121.122 0.487 . . . . 0.0 111.834 -177.28 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 321' ' ' ASN . . . . . 0.473 ' HB2' ' HE2' ' A' ' 305' ' ' LYS . 46.7 t30 -132.59 -27.61 1.71 Allowed 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.952 -179.04 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 322' ' ' VAL . . . . . 0.485 HG22 ' H ' ' A' ' 307' ' ' LEU . 28.7 m -131.59 166.95 27.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.759 -179.733 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -68.43 -48.05 65.61 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.612 -0.267 . . . . 0.0 111.154 177.832 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 324' ' ' ALA . . . . . 0.755 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -164.63 177.35 8.12 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.988 -0.551 . . . . 0.0 111.59 -176.132 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 325' ' ' LYS . . . . . 0.591 ' HE2' ' CE1' ' A' ' 236' ' ' HIS . 21.9 pttp -118.61 119.52 32.64 Favored Pre-proline 0 C--N 1.325 -0.462 0 CA-C-N 115.346 -0.843 . . . . 0.0 109.692 172.529 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_endo -79.23 169.13 19.4 Favored 'Trans proline' 0 C--O 1.233 0.243 0 C-N-CA 122.962 2.441 . . . . 0.0 112.901 -176.171 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -67.57 129.15 39.02 Favored 'General case' 0 C--O 1.238 0.455 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 175.643 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 57.0 mm-40 65.48 -156.17 0.28 Allowed 'General case' 0 N--CA 1.463 0.216 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 -172.089 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 329' ' ' SER . . . . . 0.661 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 69.3 m -112.5 -12.27 13.5 Favored 'General case' 0 C--N 1.322 -0.606 0 C-N-CA 120.544 -0.462 . . . . 0.0 110.869 176.785 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 70.24 -154.01 0.12 Allowed 'General case' 0 N--CA 1.469 0.502 0 N-CA-C 113.209 0.818 . . . . 0.0 113.209 172.408 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 331' ' ' ALA . . . . . 0.593 ' HA ' HG22 ' A' ' 229' ' ' THR . . . -93.09 137.61 32.28 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.75 -177.801 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 332' ' ' ILE . . . . . 0.846 HG13 HG12 ' A' ' 270' ' ' ILE . 1.9 mp -116.33 144.27 24.41 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.113 -178.685 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 40.8 m -109.87 106.29 15.81 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.609 -0.515 . . . . 0.0 109.609 179.728 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 334' ' ' ILE . . . . . 0.652 HG13 HD12 ' A' ' 228' ' ' LEU . 19.5 mm -81.39 133.55 29.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 N-CA-C 113.755 1.02 . . . . 0.0 113.755 -172.208 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 335' ' ' LEU . . . . . 0.581 ' CD2' ' HA ' ' A' ' 268' ' ' PHE . 1.6 pt? -148.02 -147.62 0.23 Allowed 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 113.61 -1.632 . . . . 0.0 108.344 169.071 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -163.38 -39.97 0.03 OUTLIER 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 108.393 -0.965 . . . . 0.0 108.393 177.801 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 62.4 tttp . . . . . 0 C--O 1.243 0.716 0 CA-C-N 114.55 -1.204 . . . . 0.0 109.5 174.82 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 26.2 t . . . . . 0 N--CA 1.452 -0.326 0 N-CA-C 109.527 -0.545 . . . . 0.0 109.527 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 228' ' ' LEU . . . . . 0.525 ' HB3' ' HA ' ' A' ' 259' ' ' ALA . 83.8 mt -108.37 140.79 41.16 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 109.689 -0.486 . . . . 0.0 109.689 179.293 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 70.8 p -124.27 177.12 6.02 Favored 'General case' 0 C--N 1.325 -0.464 0 C-N-CA 119.957 -0.697 . . . . 0.0 110.978 -178.506 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 230' ' ' VAL . . . . . 0.63 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 61.3 t -146.61 146.84 18.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.014 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 41.3 t -132.08 133.85 44.82 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.822 0.344 . . . . 0.0 110.402 178.755 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 104.21 73.28 0.92 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.41 -0.9 . . . . 0.0 112.929 177.625 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 13.8 mm-40 -66.86 133.0 93.93 Favored Pre-proline 0 C--N 1.33 -0.248 0 CA-C-O 120.84 0.353 . . . . 0.0 111.377 176.546 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 234' ' ' PRO . . . . . 0.58 ' HB2' ' HE1' ' A' ' 236' ' ' HIS . 56.9 Cg_endo -69.97 138.38 37.03 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 122.373 2.049 . . . . 0.0 111.515 176.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -97.88 126.41 43.25 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 121.391 0.615 . . . . 0.0 111.532 -176.261 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 236' ' ' HIS . . . . . 0.58 ' HE1' ' HB2' ' A' ' 234' ' ' PRO . 24.2 m80 -130.41 133.83 46.66 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.404 -0.817 . . . . 0.0 109.562 -178.548 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 237' ' ' LYS . . . . . 0.584 ' HA ' HG21 ' A' ' 312' ' ' THR . 6.8 mptt . . . . . 0 C--N 1.327 -0.379 0 C-N-CA 120.556 -0.458 . . . . 0.0 110.551 178.923 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 20.4 mt-30 . . . . . 0 N--CA 1.468 0.461 0 CA-C-O 121.519 0.676 . . . . 0.0 112.42 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . 0.468 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -172.65 95.71 0.11 Allowed Glycine 0 N--CA 1.447 -0.631 0 CA-C-N 115.429 -0.805 . . . . 0.0 111.178 179.099 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 59.9 p -95.39 116.98 29.53 Favored 'General case' 0 C--N 1.323 -0.561 0 O-C-N 122.48 -0.424 . . . . 0.0 110.914 -175.113 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.476 HD12 HG11 ' A' ' 230' ' ' VAL . 21.2 pt -128.78 148.39 33.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.831 -177.618 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 59.8 m -101.27 107.26 18.58 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 174.096 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.691 HG21 HD12 ' A' ' 262' ' ' LEU . 32.8 m -90.73 143.65 10.77 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.728 0 N-CA-C 112.975 0.731 . . . . 0.0 112.975 -168.649 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 35.3 t -91.44 8.04 38.23 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 114.112 -1.404 . . . . 0.0 107.963 167.165 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 259' ' ' ALA . . . . . 0.525 ' HA ' ' HB3' ' A' ' 228' ' ' LEU . . . -85.64 158.12 20.16 Favored 'General case' 0 N--CA 1.448 -0.565 0 CA-C-N 114.926 -1.034 . . . . 0.0 109.626 -178.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 34.1 t -131.94 137.31 47.9 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 116.577 -0.283 . . . . 0.0 110.325 -179.217 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 90.27 39.28 6.07 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.6 -0.809 . . . . 0.0 112.571 -179.437 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 262' ' ' LEU . . . . . 0.691 HD12 HG21 ' A' ' 257' ' ' VAL . 60.2 mt -101.46 139.81 36.6 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.711 0.291 . . . . 0.0 110.877 179.788 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 68.5 mt-30 -142.2 167.72 21.45 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.82 -0.627 . . . . 0.0 109.436 179.298 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 264' ' ' VAL . . . . . 0.418 HG22 ' HA ' ' A' ' 294' ' ' ALA . 48.7 t -70.83 132.87 32.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 C-N-CA 120.772 -0.371 . . . . 0.0 110.161 177.834 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 105.58 8.63 34.72 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.548 -0.834 . . . . 0.0 112.401 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 59.7 m-20 -88.64 162.48 16.31 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.988 0.423 . . . . 0.0 110.861 179.045 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 267' ' ' ALA . . . . . 0.699 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -139.34 123.12 17.57 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.487 -0.779 . . . . 0.0 109.475 179.75 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 268' ' ' PHE . . . . . 0.413 ' HB3' ' HA ' ' A' ' 334' ' ' ILE . 3.5 p90 -142.15 173.66 11.32 Favored 'General case' 0 C--N 1.32 -0.676 0 C-N-CA 120.114 -0.634 . . . . 0.0 111.465 -174.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 269' ' ' THR . . . . . 0.577 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 63.8 p -118.89 132.37 56.1 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.53 178.115 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 270' ' ' ILE . . . . . 0.708 HG12 HG13 ' A' ' 332' ' ' ILE . 50.6 mt -100.61 134.02 41.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.57 179.625 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -72.72 143.47 48.01 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.956 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 85.78 -21.55 14.54 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.189 -177.522 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 53.5 t -105.69 102.46 13.9 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-O 120.983 0.42 . . . . 0.0 110.799 -179.593 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 274' ' ' ASN . . . . . 0.407 ' HB2' ' OD1' ' A' ' 323' ' ' ASP . 4.0 m120 -100.72 154.94 18.19 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.22 -0.659 . . . . 0.0 109.22 174.702 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 6.7 t -83.7 179.98 7.46 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.912 0.387 . . . . 0.0 109.96 -177.853 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 276' ' ' VAL . . . . . 0.411 HG22 ' O ' ' A' ' 321' ' ' ASN . 34.2 m -131.92 153.11 38.0 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.712 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.236 172.775 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 26.4 m80 -136.94 137.08 39.17 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.091 179.236 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 8.5 tt0 -67.99 -31.67 71.53 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.916 0.389 . . . . 0.0 110.315 177.196 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 72.3 mt -66.54 -50.36 67.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.861 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 71.5 p -85.42 -5.08 59.33 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 111.674 0.25 . . . . 0.0 111.674 -178.615 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 281' ' ' LYS . . . . . 0.512 ' HB3' ' NZ ' ' A' ' 281' ' ' LYS . 0.0 OUTLIER 70.94 52.97 0.27 Allowed 'General case' 0 CA--C 1.535 0.403 0 CA-C-O 121.742 0.782 . . . . 0.0 109.161 179.479 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 56.6 m-20 62.26 10.51 3.87 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 114.732 -1.122 . . . . 0.0 113.95 173.485 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 59.9 p -107.09 107.97 19.22 Favored 'General case' 0 C--N 1.314 -0.956 0 CA-C-O 121.041 0.448 . . . . 0.0 110.589 175.605 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 59.8 p -125.76 -52.37 1.57 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.061 -175.385 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 76.42 10.61 85.58 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.732 -0.747 . . . . 0.0 111.267 -173.363 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 286' ' ' GLN . . . . . 0.42 ' HA ' ' HD3' ' A' ' 287' ' ' PRO . 93.4 mm-40 -111.11 130.42 22.99 Favored Pre-proline 0 C--N 1.326 -0.445 0 N-CA-C 110.322 -0.251 . . . . 0.0 110.322 -177.609 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 287' ' ' PRO . . . . . 0.577 ' HB2' ' HB ' ' A' ' 269' ' ' THR . 27.3 Cg_exo -60.76 142.05 96.63 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.627 2.218 . . . . 0.0 111.696 177.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 4.1 tp60 -68.18 145.05 54.69 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 120.877 0.37 . . . . 0.0 110.711 -179.637 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 47.6 t -99.73 121.77 50.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.492 176.631 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 290' ' ' PHE . . . . . 0.699 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 7.3 m-85 -103.31 156.17 17.92 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.028 0.442 . . . . 0.0 111.775 -174.02 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 36.3 mmt180 -122.31 121.18 36.14 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.112 -0.949 . . . . 0.0 109.408 174.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 61.7 t -78.51 135.51 25.84 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.89 -174.476 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 293' ' ' LEU . . . . . 0.401 ' N ' HD12 ' A' ' 293' ' ' LEU . 6.6 mp -106.95 -33.8 7.4 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.674 179.034 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 294' ' ' ALA . . . . . 0.418 ' HA ' HG22 ' A' ' 264' ' ' VAL . . . -155.54 146.7 22.59 Favored 'General case' 0 N--CA 1.463 0.19 0 N-CA-C 111.677 0.251 . . . . 0.0 111.677 -177.365 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 295' ' ' VAL . . . . . 0.467 HG22 HG13 ' A' ' 300' ' ' VAL . 61.6 t -137.66 126.37 33.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.086 -0.506 . . . . 0.0 109.74 177.169 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 40.3 t -156.69 109.69 2.59 Favored 'General case' 0 C--N 1.326 -0.418 0 C-N-CA 121.139 -0.224 . . . . 0.0 110.944 -177.638 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 59.81 48.57 85.41 Favored Glycine 0 C--N 1.333 0.373 0 C-N-CA 121.077 -0.583 . . . . 0.0 112.488 179.447 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 298' ' ' THR . . . . . 0.422 ' O ' HG22 ' A' ' 257' ' ' VAL . 60.5 p 55.71 10.93 0.58 Allowed 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 124.342 1.057 . . . . 0.0 112.728 -176.361 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 58.3 m -99.92 106.47 18.29 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 173.024 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . 0.574 HG12 HG23 ' A' ' 302' ' ' ILE . 40.2 t -108.9 132.03 58.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.35 -169.519 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 51.6 m -100.87 111.35 23.54 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 175.422 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 302' ' ' ILE . . . . . 0.574 HG23 HG12 ' A' ' 300' ' ' VAL . 27.7 pt -121.64 164.6 18.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-O 121.284 0.564 . . . . 0.0 112.027 -174.262 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 303' ' ' SER . . . . . 0.531 ' HB3' ' HA ' ' A' ' 304' ' ' PRO . 53.1 m -135.29 165.28 37.58 Favored Pre-proline 0 C--N 1.313 -0.984 0 N-CA-C 106.325 -1.732 . . . . 0.0 106.325 168.775 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 304' ' ' PRO . . . . . 0.531 ' HA ' ' HB3' ' A' ' 303' ' ' SER . 17.4 Cg_exo -70.38 176.52 34.05 Favored 'Cis proline' 0 N--CA 1.472 0.243 0 CA-C-N 120.816 1.327 . . . . 0.0 113.71 0.923 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 305' ' ' LYS . . . . . 0.737 ' HG2' ' HG ' ' A' ' 307' ' ' LEU . 0.1 OUTLIER -73.86 152.69 40.15 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 114.986 -1.007 . . . . 0.0 111.284 -178.501 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 306' ' ' ILE . . . . . 0.589 HD11 ' HE2' ' A' ' 290' ' ' PHE . 46.4 mm -94.66 85.29 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.634 -178.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 307' ' ' LEU . . . . . 0.737 ' HG ' ' HG2' ' A' ' 305' ' ' LYS . 66.9 mt -106.12 110.32 63.89 Favored Pre-proline 0 C--N 1.325 -0.462 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 178.109 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 308' ' ' PRO . . . . . 0.481 ' CG ' ' HB2' ' A' ' 311' ' ' ASN . 65.1 Cg_endo -80.9 148.66 17.49 Favored 'Trans proline' 0 N--CA 1.463 -0.275 0 C-N-CA 122.548 2.166 . . . . 0.0 113.609 -172.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . 0.545 HG23 ' O ' ' A' ' 322' ' ' VAL . 47.0 t -87.65 -43.09 15.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.829 175.252 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 65.4 mm-40 -91.51 6.47 45.47 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 112.437 0.532 . . . . 0.0 112.437 -176.287 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.481 ' HB2' ' CG ' ' A' ' 308' ' ' PRO . 5.9 m120 -130.0 173.33 10.82 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 110.231 -0.285 . . . . 0.0 110.231 178.597 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 312' ' ' THR . . . . . 0.584 HG21 ' HA ' ' A' ' 237' ' ' LYS . 23.7 m 60.07 31.03 20.43 Favored 'General case' 0 CA--C 1.539 0.543 0 CA-C-O 121.758 0.79 . . . . 0.0 110.656 176.887 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 44.5 m-20 63.87 -177.71 0.16 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 114.883 -1.053 . . . . 0.0 112.208 177.106 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 314' ' ' VAL . . . . . 0.685 HG13 ' HD2' ' A' ' 317' ' ' ARG . 50.0 t -68.31 -24.66 30.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.426 -176.441 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -60.63 -23.73 64.98 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 111.976 0.362 . . . . 0.0 111.976 -179.859 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 31.2 t -86.89 -22.02 25.97 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.31 -177.845 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 317' ' ' ARG . . . . . 0.685 ' HD2' HG13 ' A' ' 314' ' ' VAL . 83.3 mtt-85 -56.6 -53.68 61.8 Favored Pre-proline 0 CA--C 1.541 0.605 0 N-CA-C 113.499 0.926 . . . . 0.0 113.499 -177.525 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 318' ' ' PRO . . . . . 0.613 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 44.1 Cg_exo -61.97 -35.39 77.32 Favored 'Trans proline' 0 C--N 1.356 0.931 0 C-N-CA 122.018 1.812 . . . . 0.0 113.677 -174.587 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 7.4 m-85 -105.62 21.67 16.83 Favored 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 121.152 -0.219 . . . . 0.0 111.089 -179.065 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . 0.42 ' CB ' HG22 ' A' ' 309' ' ' VAL . . . -65.79 160.0 24.03 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.096 0.474 . . . . 0.0 111.685 -177.39 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 321' ' ' ASN . . . . . 0.411 ' O ' HG22 ' A' ' 276' ' ' VAL . 20.6 t-20 -123.58 -33.19 3.25 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.85 -0.613 . . . . 0.0 109.956 177.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 322' ' ' VAL . . . . . 0.545 ' O ' HG23 ' A' ' 309' ' ' VAL . 35.4 m -135.42 163.76 34.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.345 177.308 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 323' ' ' ASP . . . . . 0.407 ' OD1' ' HB2' ' A' ' 274' ' ' ASN . 63.6 m-20 -55.89 -41.28 74.21 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 112.684 0.624 . . . . 0.0 112.684 -176.407 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 324' ' ' ALA . . . . . 0.463 ' HA ' ' CB ' ' A' ' 308' ' ' PRO . . . -169.49 167.49 9.82 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.876 0.369 . . . . 0.0 111.746 -173.759 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 325' ' ' LYS . . . . . 0.461 ' NZ ' ' HB2' ' A' ' 325' ' ' LYS . 0.0 OUTLIER -108.7 106.25 58.42 Favored Pre-proline 0 C--N 1.325 -0.49 0 CA-C-N 114.968 -1.014 . . . . 0.0 109.26 168.732 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 76.0 Cg_endo -85.21 168.47 10.32 Favored 'Trans proline' 0 C--O 1.234 0.276 0 C-N-CA 122.8 2.333 . . . . 0.0 112.769 -173.472 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -69.6 121.86 17.94 Favored 'General case' 0 C--O 1.235 0.327 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 176.588 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 328' ' ' GLU . . . . . 0.459 ' HA ' ' OE2' ' A' ' 328' ' ' GLU . 43.6 mm-40 64.16 164.24 0.13 Allowed 'General case' 0 C--O 1.234 0.243 0 O-C-N 123.891 0.744 . . . . 0.0 111.417 -175.288 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 329' ' ' SER . . . . . 0.63 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 22.2 m -86.49 -14.49 42.95 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.35 -174.306 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 330' ' ' ALA . . . . . 0.426 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 71.26 -154.43 0.1 Allowed 'General case' 0 N--CA 1.467 0.403 0 CA-C-O 121.332 0.586 . . . . 0.0 112.287 175.532 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -90.04 125.79 35.53 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.147 -0.933 . . . . 0.0 110.168 179.35 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 332' ' ' ILE . . . . . 0.708 HG13 HG12 ' A' ' 270' ' ' ILE . 1.7 mp -106.35 144.72 15.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.31 -178.917 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 0.402 ' HB ' ' OG1' ' A' ' 269' ' ' THR . 88.5 m -109.97 103.02 11.72 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.069 -0.514 . . . . 0.0 109.711 -178.171 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 334' ' ' ILE . . . . . 0.434 ' C ' HD12 ' A' ' 335' ' ' LEU . 37.9 mm -83.1 129.3 37.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 115.57 -0.741 . . . . 0.0 112.42 -171.209 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 335' ' ' LEU . . . . . 0.434 HD12 ' C ' ' A' ' 334' ' ' ILE . 6.8 mp -123.67 153.04 41.36 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.264 -0.88 . . . . 0.0 109.823 172.644 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 22.9 p30 -110.9 5.02 20.19 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 170.442 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 23.1 tptm . . . . . 0 C--O 1.245 0.82 0 CA-C-N 114.541 -1.209 . . . . 0.0 110.99 -179.412 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 31.5 t . . . . . 0 CA--C 1.531 0.243 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 228' ' ' LEU . . . . . 0.525 ' HB3' ' CB ' ' A' ' 259' ' ' ALA . 85.1 mt -96.46 130.93 43.5 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 109.511 -0.552 . . . . 0.0 109.511 175.728 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 41.3 p -129.63 179.54 5.77 Favored 'General case' 0 C--N 1.325 -0.465 0 C-N-CA 120.296 -0.562 . . . . 0.0 110.986 -178.631 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 230' ' ' VAL . . . . . 0.806 ' HB ' ' HB3' ' A' ' 329' ' ' SER . 89.5 t -146.18 130.85 11.58 Favored 'Isoleucine or valine' 0 C--O 1.24 0.571 0 CA-C-O 120.601 0.239 . . . . 0.0 111.549 -177.2 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 18.7 m -97.29 97.84 9.49 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.194 -0.912 . . . . 0.0 109.733 172.834 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 163.02 134.74 1.69 Allowed Glycine 0 C--O 1.226 -0.344 0 C-N-CA 120.719 -0.753 . . . . 0.0 111.72 -177.429 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 11.0 mm100 -61.62 144.73 92.44 Favored Pre-proline 0 C--N 1.328 -0.369 0 N-CA-C 112.688 0.625 . . . . 0.0 112.688 -174.516 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -70.7 175.22 9.18 Favored 'Trans proline' 0 C--N 1.348 0.521 0 C-N-CA 123.381 2.721 . . . . 0.0 111.793 175.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 235' ' ' GLU . . . . . 0.506 ' OE1' HD12 ' A' ' 302' ' ' ILE . 87.6 mt-10 -94.3 138.11 32.67 Favored 'General case' 0 C--O 1.211 -0.962 0 C-N-CA 120.833 -0.347 . . . . 0.0 111.688 -176.524 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 236' ' ' HIS . . . . . 0.439 ' HB3' ' O ' ' A' ' 306' ' ' ILE . 25.5 p-80 -169.04 126.82 0.99 Allowed 'General case' 0 C--N 1.307 -1.256 0 CA-C-N 115.097 -0.956 . . . . 0.0 109.366 166.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 237' ' ' LYS . . . . . 0.548 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.327 -0.377 0 C-N-CA 120.32 -0.552 . . . . 0.0 110.473 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 17.2 mt-30 . . . . . 0 C--O 1.237 0.413 0 CA-C-O 121.769 0.795 . . . . 0.0 112.83 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . 0.433 ' O ' ' HA ' ' A' ' 301' ' ' THR . . . -160.86 145.33 10.89 Favored Glycine 0 N--CA 1.449 -0.467 0 CA-C-N 115.007 -0.997 . . . . 0.0 111.94 177.714 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 34.1 p -95.32 117.99 31.28 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.843 0.354 . . . . 0.0 111.13 -179.797 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.611 HD12 HG11 ' A' ' 230' ' ' VAL . 24.7 pt -114.75 142.84 26.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.08 0.467 . . . . 0.0 111.494 -178.724 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 58.1 m -92.49 109.63 21.03 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 176.354 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . . . . . . . . . 33.9 m -90.21 143.78 10.48 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.703 0 C-N-CA 119.646 -0.821 . . . . 0.0 113.004 -168.351 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 258' ' ' SER . . . . . 0.467 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 24.0 t -91.59 9.07 33.7 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 114.051 -1.432 . . . . 0.0 108.192 168.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 259' ' ' ALA . . . . . 0.525 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -99.05 169.8 9.16 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-N 114.774 -1.103 . . . . 0.0 109.484 -178.592 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 33.8 t -142.57 155.28 44.97 Favored 'General case' 0 C--N 1.324 -0.54 0 C-N-CA 120.828 -0.349 . . . . 0.0 110.733 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 74.34 42.8 33.54 Favored Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.47 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 262' ' ' LEU . . . . . . . . . . . . . 64.5 mt -102.39 140.02 37.21 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 110.17 -0.308 . . . . 0.0 110.17 179.37 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 81.5 mt-30 -135.24 169.45 17.44 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.479 -0.328 . . . . 0.0 110.206 179.822 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 45.5 t -77.77 136.26 24.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.594 179.63 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 92.13 7.65 63.81 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.442 -0.885 . . . . 0.0 112.292 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 72.8 m-20 -81.73 160.47 23.63 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.232 0.539 . . . . 0.0 110.133 176.785 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 267' ' ' ALA . . . . . 0.548 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -126.84 145.37 50.67 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 115.332 -0.849 . . . . 0.0 108.822 178.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 268' ' ' PHE . . . . . 0.55 ' HA ' HD23 ' A' ' 335' ' ' LEU . 4.6 p90 -162.53 170.66 18.27 Favored 'General case' 0 C--N 1.32 -0.713 0 C-N-CA 119.971 -0.692 . . . . 0.0 111.452 -177.124 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 269' ' ' THR . . . . . 0.474 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 72.7 p -121.85 150.84 41.35 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.009 178.499 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 270' ' ' ILE . . . . . 0.577 HG12 HG12 ' A' ' 332' ' ' ILE . 54.4 mt -115.51 138.33 46.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 120.864 0.364 . . . . 0.0 111.622 -177.396 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -66.12 117.58 8.64 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 115.571 -0.74 . . . . 0.0 111.062 178.353 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 104.46 -23.05 32.66 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.932 -0.651 . . . . 0.0 112.182 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . 0.876 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 91.0 t -88.36 112.39 23.74 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-O 120.71 0.291 . . . . 0.0 110.491 175.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 72.9 m-80 -129.54 143.58 50.89 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.663 -178.071 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 52.3 p -70.86 164.75 24.68 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.152 0.501 . . . . 0.0 111.699 -177.7 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 29.3 m -112.58 179.48 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-N 115.652 -0.704 . . . . 0.0 112.469 -176.834 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 19.2 p-80 -46.19 106.92 0.09 Allowed 'General case' 0 C--O 1.235 0.304 0 CA-C-N 114.631 -1.168 . . . . 0.0 111.817 176.772 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 278' ' ' GLN . . . . . 0.512 ' H ' ' HB2' ' A' ' 282' ' ' ASP . 8.4 tt0 -83.94 -51.29 7.27 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.19 -176.467 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 279' ' ' ILE . . . . . 0.569 HG22 HG23 ' A' ' 280' ' ' THR . 3.2 mp -105.59 -66.81 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.828 0.347 . . . . 0.0 110.78 -178.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . 0.569 HG23 HG22 ' A' ' 279' ' ' ILE . 21.3 p -139.58 86.46 2.11 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.61 -177.545 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt 59.56 29.57 19.14 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.759 -0.655 . . . . 0.0 112.044 177.108 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 282' ' ' ASP . . . . . 0.512 ' HB2' ' H ' ' A' ' 278' ' ' GLN . 1.7 m-20 -58.05 101.48 0.08 Allowed 'General case' 0 N--CA 1.468 0.43 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.68 -179.535 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 45.1 p -105.88 105.65 15.78 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.159 175.117 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 65.7 p -127.6 -35.0 2.17 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.589 -174.449 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 82.23 26.18 48.97 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.306 -177.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 70.7 mt-30 -79.71 121.13 82.09 Favored Pre-proline 0 C--N 1.329 -0.295 0 O-C-N 122.891 -0.182 . . . . 0.0 110.667 -179.658 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 287' ' ' PRO . . . . . 0.474 ' HB2' ' HB ' ' A' ' 269' ' ' THR . 26.4 Cg_exo -60.33 126.75 20.89 Favored 'Trans proline' 0 C--O 1.234 0.296 0 C-N-CA 122.518 2.145 . . . . 0.0 111.408 177.451 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 4.4 tm0? -74.49 136.54 42.23 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 -175.062 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 289' ' ' VAL . . . . . 0.429 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 44.5 t -86.91 124.54 40.57 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-O 121.038 0.447 . . . . 0.0 111.524 -172.915 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 290' ' ' PHE . . . . . 0.876 ' HZ ' HG11 ' A' ' 273' ' ' VAL . 60.6 m-85 -98.5 168.44 10.19 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.31 -174.694 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 27.8 mmm180 -125.12 148.42 48.57 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.224 -0.898 . . . . 0.0 109.736 178.463 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 47.9 t -100.92 136.75 31.08 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-N 116.607 -0.27 . . . . 0.0 111.098 179.628 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 293' ' ' LEU . . . . . 0.455 ' N ' HD12 ' A' ' 293' ' ' LEU . 5.5 mp -103.95 -39.94 6.4 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.128 -178.868 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 294' ' ' ALA . . . . . . . . . . . . . . . -156.9 139.61 15.09 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.646 0.26 . . . . 0.0 111.473 -178.493 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 295' ' ' VAL . . . . . 0.519 HG22 HG13 ' A' ' 300' ' ' VAL . 60.6 t -131.21 125.56 57.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-N 116.104 -0.498 . . . . 0.0 109.688 175.842 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 33.9 t -157.29 111.37 2.64 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.583 -0.281 . . . . 0.0 110.758 -178.018 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 60.58 50.82 63.39 Favored Glycine 0 C--N 1.333 0.372 0 C-N-CA 121.087 -0.578 . . . . 0.0 112.615 179.787 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 45.9 p 50.6 23.71 1.42 Allowed 'General case' 0 N--CA 1.47 0.552 0 C-N-CA 123.477 0.711 . . . . 0.0 112.434 -176.395 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 43.7 m -113.21 106.58 14.8 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 174.072 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . 0.572 HG12 HG23 ' A' ' 302' ' ' ILE . 39.4 t -112.99 131.63 64.06 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 115.944 -0.571 . . . . 0.0 111.557 -168.633 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 301' ' ' THR . . . . . 0.433 ' HA ' ' O ' ' A' ' 253' ' ' GLY . 91.6 m -96.7 110.62 23.03 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 108.725 -0.842 . . . . 0.0 108.725 172.299 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 302' ' ' ILE . . . . . 0.572 HG23 HG12 ' A' ' 300' ' ' VAL . 2.5 pp -111.75 -172.54 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 N-CA-C 112.12 0.415 . . . . 0.0 112.12 -175.134 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 303' ' ' SER . . . . . 0.71 ' OG ' ' HA ' ' A' ' 304' ' ' PRO . 14.8 t 169.95 161.16 0.2 Allowed Pre-proline 0 C--O 1.221 -0.397 0 N-CA-C 106.224 -1.769 . . . . 0.0 106.224 -175.563 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 304' ' ' PRO . . . . . 0.71 ' HA ' ' OG ' ' A' ' 303' ' ' SER . 9.4 Cg_exo -72.94 -172.66 9.87 Favored 'Cis proline' 0 C--N 1.348 0.522 0 CA-C-N 121.384 1.53 . . . . 0.0 113.506 0.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 305' ' ' LYS . . . . . 0.739 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -84.3 176.3 8.82 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 114.751 -1.113 . . . . 0.0 112.644 -175.382 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 306' ' ' ILE . . . . . 0.456 ' HB ' ' O ' ' A' ' 235' ' ' GLU . 50.8 mm -119.46 86.2 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 114.485 -1.234 . . . . 0.0 109.878 -174.017 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 307' ' ' LEU . . . . . 0.575 HD13 ' HD1' ' A' ' 319' ' ' TYR . 83.9 mt -108.84 101.59 44.69 Favored Pre-proline 0 C--N 1.321 -0.633 0 C-N-CA 120.918 -0.313 . . . . 0.0 111.652 -173.618 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 308' ' ' PRO . . . . . 0.774 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 17.9 Cg_exo -69.92 148.44 64.01 Favored 'Trans proline' 0 C--O 1.233 0.232 0 C-N-CA 123.197 2.598 . . . . 0.0 113.336 -177.019 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 44.2 t -93.16 -21.36 6.11 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.529 -0.76 . . . . 0.0 109.44 173.1 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 53.5 mt-10 -74.62 13.65 0.59 Allowed 'General case' 0 CA--C 1.531 0.223 0 N-CA-C 112.797 0.665 . . . . 0.0 112.797 -178.448 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.406 ' O ' ' HB ' ' A' ' 312' ' ' THR . 77.8 m-20 -82.25 -24.66 34.66 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 120.846 -0.341 . . . . 0.0 110.92 177.468 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 312' ' ' THR . . . . . 0.406 ' HB ' ' O ' ' A' ' 311' ' ' ASN . 58.2 m 72.01 -13.64 0.58 Allowed 'General case' 0 CA--C 1.541 0.634 0 O-C-N 123.743 0.652 . . . . 0.0 112.233 178.159 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -74.13 152.98 39.75 Favored 'General case' 0 C--N 1.331 -0.21 0 O-C-N 121.905 -0.497 . . . . 0.0 110.803 178.347 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 30.8 t -79.35 -19.33 12.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.306 -0.861 . . . . 0.0 111.485 -173.259 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -78.49 -36.88 44.47 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 113.019 0.748 . . . . 0.0 113.019 -174.096 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 16.2 m -88.18 -35.03 17.6 Favored 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -172.657 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 317' ' ' ARG . . . . . 0.424 ' N ' ' CD ' ' A' ' 318' ' ' PRO . 16.9 ptm180 -62.12 -33.05 11.03 Favored Pre-proline 0 CA--C 1.546 0.801 0 N-CA-C 114.516 1.302 . . . . 0.0 114.516 -175.263 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 318' ' ' PRO . . . . . 0.424 ' CD ' ' N ' ' A' ' 317' ' ' ARG . 35.2 Cg_exo -54.86 -38.87 92.26 Favored 'Trans proline' 0 C--N 1.368 1.587 0 C-N-CA 121.587 1.525 . . . . 0.0 112.795 178.874 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 319' ' ' TYR . . . . . 0.575 ' HD1' HD13 ' A' ' 307' ' ' LEU . 2.2 p90 -122.83 32.73 5.63 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 120.504 -0.479 . . . . 0.0 111.83 -179.251 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -63.34 157.15 23.73 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.605 178.171 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 46.2 t30 -128.49 -36.86 1.85 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.068 -0.514 . . . . 0.0 111.49 -177.662 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 322' ' ' VAL . . . . . 0.624 HG11 HG13 ' A' ' 273' ' ' VAL . 34.8 m -131.86 175.62 10.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 120.711 0.291 . . . . 0.0 111.217 -178.847 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 54.7 m-20 -78.62 -44.12 24.71 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.536 -0.302 . . . . 0.0 111.569 -177.272 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 324' ' ' ALA . . . . . 0.774 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -144.55 166.48 25.04 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.458 -175.589 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 325' ' ' LYS . . . . . 0.408 ' HA ' ' HD3' ' A' ' 326' ' ' PRO . 24.1 pttm -115.12 113.89 43.65 Favored Pre-proline 0 C--N 1.327 -0.383 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.729 175.153 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 326' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 325' ' ' LYS . 8.6 Cg_exo -72.92 167.84 26.24 Favored 'Trans proline' 0 C--O 1.233 0.236 0 C-N-CA 122.867 2.378 . . . . 0.0 112.167 -178.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -76.76 128.33 34.44 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 175.084 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 51.0 mt-10 64.96 -167.83 0.21 Allowed 'General case' 0 N--CA 1.466 0.333 0 O-C-N 123.5 0.5 . . . . 0.0 110.463 -176.191 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 329' ' ' SER . . . . . 0.806 ' HB3' ' HB ' ' A' ' 230' ' ' VAL . 42.6 t -90.88 -12.19 36.95 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 177.265 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 63.03 -160.36 0.31 Allowed 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 113.033 0.753 . . . . 0.0 113.033 171.261 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -76.36 127.96 33.9 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 115.182 -0.917 . . . . 0.0 110.676 -178.018 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 332' ' ' ILE . . . . . 0.577 HG12 HG12 ' A' ' 270' ' ' ILE . 50.0 mt -113.61 144.61 20.88 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.962 -177.432 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 95.7 m -115.63 106.09 13.51 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.675 176.824 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 41.2 mm -83.62 138.02 19.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.753 -0.658 . . . . 0.0 112.379 -170.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 335' ' ' LEU . . . . . 0.55 HD23 ' HA ' ' A' ' 268' ' ' PHE . 1.3 pt? -145.16 -159.14 0.96 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 114.978 -1.01 . . . . 0.0 108.814 171.184 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -152.36 48.36 0.76 Allowed 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.837 0.351 . . . . 0.0 111.592 179.709 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 337' ' ' LYS . . . . . 0.464 ' HB2' ' NZ ' ' A' ' 337' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.246 0.911 0 CA-C-O 118.827 -0.606 . . . . 0.0 110.515 178.908 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 24.8 m . . . . . 0 N--CA 1.453 -0.304 0 CA-C-O 121.111 0.482 . . . . 0.0 109.952 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 228' ' ' LEU . . . . . 0.546 HD22 ' H ' ' A' ' 260' ' ' SER . 83.7 mt -110.59 113.88 26.85 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 174.678 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 41.6 p -120.71 177.68 4.98 Favored 'General case' 0 C--N 1.32 -0.676 0 C-N-CA 119.926 -0.709 . . . . 0.0 110.617 -177.856 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 230' ' ' VAL . . . . . 0.738 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 89.7 t -150.88 134.78 8.23 Favored 'Isoleucine or valine' 0 C--O 1.239 0.548 0 CA-C-O 120.826 0.346 . . . . 0.0 110.898 -178.365 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 44.3 t -97.98 153.01 18.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.027 175.674 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . 0.554 ' O ' ' HD3' ' A' ' 234' ' ' PRO . . . 108.42 127.21 5.54 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.449 -0.882 . . . . 0.0 111.489 -178.467 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 233' ' ' GLN . . . . . 0.822 ' HG2' ' H ' ' A' ' 328' ' ' GLU . 64.2 mt-30 -95.27 102.38 9.5 Favored Pre-proline 0 C--N 1.324 -0.507 0 CA-C-N 116.53 0.165 . . . . 0.0 110.56 -177.553 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 234' ' ' PRO . . . . . 0.554 ' HD3' ' O ' ' A' ' 232' ' ' GLY . 74.4 Cg_endo -96.78 125.65 0.26 Allowed 'Trans proline' 0 N--CA 1.45 -1.076 0 C-N-CA 122.294 1.996 . . . . 0.0 112.388 -178.195 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 235' ' ' GLU . . . . . 0.946 ' HA ' ' HE3' ' A' ' 325' ' ' LYS . 24.2 pt-20 -105.72 147.67 28.3 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 173.377 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 236' ' ' HIS . . . . . 0.783 ' HB2' ' H ' ' A' ' 306' ' ' ILE . 39.4 m170 -134.62 130.57 36.64 Favored 'General case' 0 CA--C 1.503 -0.85 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 -178.94 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 237' ' ' LYS . . . . . 0.669 ' HA ' ' HE3' ' A' ' 237' ' ' LYS . 7.5 mmmt . . . . . 0 C--N 1.315 -0.9 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 -178.815 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 252' ' ' GLN . . . . . 0.556 ' HA ' ' CD2' ' A' ' 236' ' ' HIS . 23.4 mt-30 . . . . . 0 N--CA 1.468 0.441 0 CA-C-O 120.723 0.297 . . . . 0.0 111.2 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 157.4 -168.7 34.24 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 119.242 -1.456 . . . . 0.0 113.358 -179.691 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 254' ' ' THR . . . . . 0.563 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 67.2 p -99.53 149.92 22.74 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.911 0.386 . . . . 0.0 111.378 -177.671 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.732 HD12 HG11 ' A' ' 230' ' ' VAL . 18.8 pt -125.32 152.94 32.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.959 178.243 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 39.2 m -96.2 105.65 17.74 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.028 -0.731 . . . . 0.0 109.028 177.126 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.554 ' HA ' HG13 ' A' ' 230' ' ' VAL . 22.7 m -89.93 143.19 11.7 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.681 0 CA-C-O 121.725 0.774 . . . . 0.0 112.73 -169.251 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 258' ' ' SER . . . . . 0.462 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 50.3 m -93.15 8.63 39.34 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 114.219 -1.355 . . . . 0.0 109.129 170.358 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 259' ' ' ALA . . . . . 0.48 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -99.1 174.76 6.17 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.209 -175.098 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . 0.546 ' H ' HD22 ' A' ' 228' ' ' LEU . 64.7 p -141.88 149.88 40.83 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.889 0.376 . . . . 0.0 110.981 178.43 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 87.59 32.22 13.91 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.823 -0.704 . . . . 0.0 112.992 179.373 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 262' ' ' LEU . . . . . 0.484 HD12 ' N ' ' A' ' 262' ' ' LEU . 3.2 mp -97.68 135.53 39.34 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-N 116.995 0.398 . . . . 0.0 110.226 178.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -134.04 171.85 13.63 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 177.315 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 38.4 t -78.78 136.65 23.4 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 C-N-CA 120.593 -0.443 . . . . 0.0 109.951 176.658 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 95.61 15.25 44.05 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.538 -0.839 . . . . 0.0 112.141 -179.152 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 266' ' ' ASP . . . . . 0.476 ' HB2' HG21 ' A' ' 292' ' ' VAL . 64.0 m-20 -88.79 166.07 14.27 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.164 0.507 . . . . 0.0 110.779 178.507 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 267' ' ' ALA . . . . . 0.645 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -140.61 122.7 15.68 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.39 -0.823 . . . . 0.0 109.437 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 268' ' ' PHE . . . . . . . . . . . . . 4.6 p90 -142.68 174.11 10.94 Favored 'General case' 0 C--N 1.323 -0.579 0 C-N-CA 119.752 -0.779 . . . . 0.0 111.718 -172.819 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 81.9 p -122.18 148.51 44.85 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.179 177.498 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 270' ' ' ILE . . . . . 0.636 HD12 ' HE1' ' A' ' 290' ' ' PHE . 26.6 mt -113.62 137.53 46.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.212 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -61.47 130.53 46.48 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.343 179.881 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 272' ' ' GLY . . . . . 0.549 ' HA3' ' HG2' ' A' ' 326' ' ' PRO . . . 91.91 -23.12 27.86 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 121.189 -0.529 . . . . 0.0 112.113 -178.878 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . 0.611 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 59.7 t -95.94 103.14 14.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-O 120.96 0.409 . . . . 0.0 110.285 177.222 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 274' ' ' ASN . . . . . 0.621 ' HA ' ' HA ' ' A' ' 287' ' ' PRO . 70.0 m-80 -119.81 149.6 41.8 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.212 -178.306 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 77.7 p -81.45 162.25 23.37 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.387 0.613 . . . . 0.0 111.474 -176.813 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 276' ' ' VAL . . . . . 0.491 HG21 HG21 ' A' ' 309' ' ' VAL . 29.8 m -112.14 -179.27 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-N 114.968 -1.014 . . . . 0.0 110.939 179.63 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 277' ' ' HIS . . . . . 0.547 ' CD2' ' HD2' ' A' ' 281' ' ' LYS . 26.7 p-80 -43.15 115.53 0.77 Allowed 'General case' 0 C--N 1.331 -0.213 0 O-C-N 124.331 1.02 . . . . 0.0 111.732 177.66 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 278' ' ' GLN . . . . . 0.549 ' HB3' HD12 ' A' ' 279' ' ' ILE . 71.2 tp60 -83.57 -38.65 21.38 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.731 -178.059 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 279' ' ' ILE . . . . . 0.94 HG22 HG23 ' A' ' 280' ' ' THR . 2.9 mp -107.25 -80.85 0.32 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.431 0 C-N-CA 120.892 -0.323 . . . . 0.0 111.577 -176.969 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . 0.94 HG23 HG22 ' A' ' 279' ' ' ILE . 35.7 p -127.48 70.74 1.32 Allowed 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 112.787 0.662 . . . . 0.0 112.787 -172.35 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 281' ' ' LYS . . . . . 0.547 ' HD2' ' CD2' ' A' ' 277' ' ' HIS . 14.6 mmmm 53.79 35.45 21.52 Favored 'General case' 0 N--CA 1.47 0.534 0 CA-C-O 121.203 0.525 . . . . 0.0 110.801 178.397 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 52.8 m-20 -69.44 174.04 5.28 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.264 -0.88 . . . . 0.0 111.595 -177.539 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 73.8 p -104.47 109.98 22.07 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.209 178.156 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 67.8 p -116.1 -76.69 0.57 Allowed 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.167 -174.001 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 70.29 7.74 60.85 Favored Glycine 0 C--N 1.329 0.156 0 C-N-CA 121.028 -0.605 . . . . 0.0 113.289 176.577 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 286' ' ' GLN . . . . . 0.434 ' HA ' ' HD3' ' A' ' 287' ' ' PRO . 96.1 mm-40 -93.29 142.43 25.27 Favored Pre-proline 0 C--N 1.324 -0.511 0 N-CA-C 110.314 -0.254 . . . . 0.0 110.314 -179.1 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 287' ' ' PRO . . . . . 0.621 ' HA ' ' HA ' ' A' ' 274' ' ' ASN . 48.2 Cg_exo -56.76 140.78 91.86 Favored 'Trans proline' 0 CA--C 1.529 0.266 0 C-N-CA 122.737 2.291 . . . . 0.0 112.601 -178.549 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 69.5 tp60 -78.22 140.88 38.91 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.006 -178.77 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 289' ' ' VAL . . . . . 0.581 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 42.2 t -92.48 131.25 40.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.706 -179.918 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 290' ' ' PHE . . . . . 0.645 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 8.2 m-30 -106.89 170.31 8.02 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 116.295 -0.412 . . . . 0.0 111.075 -175.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 26.2 mmm180 -118.28 145.02 45.37 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.995 0.426 . . . . 0.0 110.578 176.645 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . 0.476 HG21 ' HB2' ' A' ' 266' ' ' ASP . 59.6 t -101.02 130.42 50.44 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.589 177.716 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 293' ' ' LEU . . . . . 0.914 HD21 ' HB3' ' A' ' 303' ' ' SER . 2.3 mm? -106.1 -29.53 9.83 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.023 -176.504 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 294' ' ' ALA . . . . . 0.449 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -161.89 140.67 9.46 Favored 'General case' 0 C--N 1.331 -0.197 0 C-N-CA 121.013 -0.275 . . . . 0.0 111.442 -178.141 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 58.7 t -135.78 121.08 28.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 176.496 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 62.3 m -150.76 105.61 3.3 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.06 -179.515 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 64.52 57.52 12.66 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.142 179.754 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 298' ' ' THR . . . . . 0.419 ' HB ' HG22 ' A' ' 257' ' ' VAL . 65.5 p 49.42 25.9 1.48 Allowed 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 123.468 0.707 . . . . 0.0 112.448 -176.218 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 299' ' ' THR . . . . . 0.417 ' HA ' ' O ' ' A' ' 255' ' ' ILE . 70.8 m -115.59 111.66 21.0 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 177.166 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . 0.563 ' O ' ' HA ' ' A' ' 254' ' ' THR . 47.4 t -114.4 126.87 72.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.81 -170.817 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 66.3 m -81.55 115.65 20.95 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 172.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 302' ' ' ILE . . . . . 0.466 HD13 HD13 ' A' ' 255' ' ' ILE . 28.3 pt -112.82 148.84 15.54 Favored 'Isoleucine or valine' 0 C--O 1.24 0.594 0 N-CA-C 113.395 0.887 . . . . 0.0 113.395 -171.119 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 303' ' ' SER . . . . . 0.914 ' HB3' HD21 ' A' ' 293' ' ' LEU . 36.1 t -163.59 163.63 16.08 Favored Pre-proline 0 CA--C 1.537 0.458 0 N-CA-C 106.807 -1.553 . . . . 0.0 106.807 -178.314 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 304' ' ' PRO . . . . . 0.743 ' HA ' ' OG ' ' A' ' 303' ' ' SER . 1.0 OUTLIER -83.49 -151.55 0.68 Allowed 'Cis proline' 0 C--N 1.349 0.588 0 CA-C-N 120.752 1.304 . . . . 0.0 112.694 0.565 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 305' ' ' LYS . . . . . 0.572 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -71.52 144.85 49.47 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.346 0.593 . . . . 0.0 111.046 -177.838 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 306' ' ' ILE . . . . . 0.783 ' H ' ' HB2' ' A' ' 236' ' ' HIS . 52.5 mt -108.44 76.64 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-N 115.513 -0.767 . . . . 0.0 109.135 176.6 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 307' ' ' LEU . . . . . 0.674 ' HB2' ' HA ' ' A' ' 320' ' ' ALA . 91.0 mt -98.83 120.23 59.21 Favored Pre-proline 0 C--N 1.322 -0.617 0 CA-C-N 115.505 -0.771 . . . . 0.0 112.261 -172.688 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 308' ' ' PRO . . . . . 0.763 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 15.8 Cg_exo -68.71 147.12 68.86 Favored 'Trans proline' 0 N--CA 1.462 -0.381 0 C-N-CA 123.309 2.673 . . . . 0.0 111.995 175.469 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . 0.558 HG22 ' HB3' ' A' ' 320' ' ' ALA . 35.1 t -93.88 -16.09 7.68 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 N-CA-C 108.018 -1.105 . . . . 0.0 108.018 170.305 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 51.5 mm-40 -96.02 34.06 1.61 Allowed 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 115.218 -0.901 . . . . 0.0 112.422 -177.782 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 25.5 p30 -111.67 -177.18 3.12 Favored 'General case' 0 N--CA 1.464 0.241 0 C-N-CA 120.711 -0.396 . . . . 0.0 110.811 175.523 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 26.2 m -91.07 -20.13 22.4 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.923 -177.334 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 313' ' ' ASP . . . . . 0.546 ' O ' ' HG3' ' A' ' 317' ' ' ARG . 1.3 m-20 -63.58 104.03 0.6 Allowed 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.997 -178.063 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 48.9 t -64.34 -22.95 32.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.119 177.412 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -85.3 -20.87 29.36 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 111.955 0.354 . . . . 0.0 111.955 -179.747 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 67.6 m -94.24 -36.26 12.09 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 112.151 0.426 . . . . 0.0 112.151 -177.162 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 317' ' ' ARG . . . . . 0.546 ' HG3' ' O ' ' A' ' 313' ' ' ASP . 81.5 mtp180 -54.43 -46.88 98.95 Favored Pre-proline 0 CA--C 1.544 0.748 0 N-CA-C 113.228 0.825 . . . . 0.0 113.228 -177.71 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 318' ' ' PRO . . . . . 0.545 ' HD2' ' N ' ' A' ' 317' ' ' ARG . 11.9 Cg_endo -59.45 -38.46 83.41 Favored 'Trans proline' 0 C--N 1.359 1.115 0 C-N-CA 122.075 1.85 . . . . 0.0 112.807 -178.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 38.4 m-85 -97.75 15.34 23.96 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.651 -177.579 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . 0.674 ' HA ' ' HB2' ' A' ' 307' ' ' LEU . . . -82.18 153.51 25.95 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.723 -0.672 . . . . 0.0 111.001 -178.333 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 321' ' ' ASN . . . . . 0.407 HD22 ' H ' ' A' ' 321' ' ' ASN . 0.1 OUTLIER -136.51 -0.18 2.43 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.988 179.756 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 322' ' ' VAL . . . . . 0.447 ' O ' ' HA ' ' A' ' 308' ' ' PRO . 33.1 m -134.21 164.7 33.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 175.574 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -74.63 -33.64 62.61 Favored 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 120.807 -0.357 . . . . 0.0 110.61 -179.385 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 324' ' ' ALA . . . . . 0.763 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -173.22 172.56 3.8 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.402 -0.817 . . . . 0.0 111.282 -175.243 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 325' ' ' LYS . . . . . 0.946 ' HE3' ' HA ' ' A' ' 235' ' ' GLU . 10.7 ptmm? -131.84 106.73 13.99 Favored Pre-proline 0 C--N 1.326 -0.441 0 CA-C-N 115.285 -0.87 . . . . 0.0 110.768 172.616 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 326' ' ' PRO . . . . . 0.549 ' HG2' ' HA3' ' A' ' 272' ' ' GLY . 16.4 Cg_exo -67.39 170.56 13.26 Favored 'Trans proline' 0 C--O 1.233 0.234 0 C-N-CA 123.507 2.804 . . . . 0.0 112.065 178.433 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -58.63 163.85 3.02 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.807 -178.718 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 328' ' ' GLU . . . . . 0.822 ' H ' ' HG2' ' A' ' 233' ' ' GLN . 1.1 pm0 39.26 -153.28 0.01 OUTLIER 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 124.385 1.074 . . . . 0.0 112.748 -175.064 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 329' ' ' SER . . . . . 0.738 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 48.8 m -112.59 -14.33 13.2 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.859 -176.861 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 61.15 -161.51 0.29 Allowed 'General case' 0 N--CA 1.469 0.525 0 N-CA-C 113.5 0.926 . . . . 0.0 113.5 171.38 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -78.04 138.46 38.8 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-N 114.975 -1.011 . . . . 0.0 110.551 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 332' ' ' ILE . . . . . 0.622 HG12 HG12 ' A' ' 270' ' ' ILE . 54.0 mt -122.8 145.14 30.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-O 121.151 0.5 . . . . 0.0 111.473 -176.182 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 89.8 m -106.23 97.44 7.24 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.82 177.437 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 30.5 mm -86.84 117.6 31.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.376 -0.375 . . . . 0.0 112.002 -174.804 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 335' ' ' LEU . . . . . 0.462 HD23 ' N ' ' A' ' 335' ' ' LEU . 1.8 pt? -141.68 134.84 29.2 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.609 -0.723 . . . . 0.0 109.57 173.279 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -106.19 83.29 1.87 Allowed 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -177.768 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 25.4 pttm . . . . . 0 C--O 1.243 0.74 0 CA-C-O 118.578 -0.725 . . . . 0.0 110.158 -179.894 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 36.5 t . . . . . 0 N--CA 1.445 -0.678 0 CA-C-O 121.005 0.431 . . . . 0.0 110.407 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 228' ' ' LEU . . . . . 0.603 ' HB3' ' CB ' ' A' ' 259' ' ' ALA . 84.5 mt -69.42 134.31 48.82 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.383 -0.826 . . . . 0.0 109.477 176.421 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 229' ' ' THR . . . . . 0.617 HG22 ' HA ' ' A' ' 331' ' ' ALA . 41.4 p -131.18 179.38 6.04 Favored 'General case' 0 C--N 1.326 -0.432 0 C-N-CA 119.904 -0.719 . . . . 0.0 112.174 -175.082 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 230' ' ' VAL . . . . . 0.677 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 53.3 t -122.26 127.81 75.3 Favored 'Isoleucine or valine' 0 C--O 1.238 0.472 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.039 178.482 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 35.7 m -105.86 115.75 30.77 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.317 178.186 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 134.92 170.17 12.11 Favored Glycine 0 N--CA 1.443 -0.851 0 C-N-CA 120.211 -0.995 . . . . 0.0 111.86 -178.499 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 233' ' ' GLN . . . . . 0.427 ' OE1' ' HA ' ' A' ' 327' ' ' ALA . 87.9 mm-40 -113.5 107.96 52.62 Favored Pre-proline 0 C--N 1.321 -0.637 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 -178.473 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 234' ' ' PRO . . . . . 0.652 ' O ' ' HD3' ' A' ' 325' ' ' LYS . 6.3 Cg_exo -74.88 125.74 9.59 Favored 'Trans proline' 0 N--CA 1.454 -0.812 0 C-N-CA 122.072 1.848 . . . . 0.0 111.007 178.073 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 70.0 mm-40 -124.15 149.92 45.73 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.731 178.36 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 78.9 t60 -161.04 130.54 4.81 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-N 115.778 -0.647 . . . . 0.0 110.235 172.39 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 237' ' ' LYS . . . . . 0.6 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.316 -0.862 0 CA-C-N 114.918 -1.037 . . . . 0.0 108.67 177.166 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 252' ' ' GLN . . . . . 0.655 ' HB3' ' O ' ' A' ' 302' ' ' ILE . 2.9 mm100 . . . . . 0 N--CA 1.452 -0.361 0 N-CA-C 110.311 -0.255 . . . . 0.0 110.311 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -85.3 135.34 13.37 Favored Glycine 0 N--CA 1.448 -0.504 0 C-N-CA 120.317 -0.944 . . . . 0.0 111.848 177.564 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 67.8 p -107.36 118.12 35.89 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.02 0.438 . . . . 0.0 110.162 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.402 ' HB ' ' CG1' ' A' ' 230' ' ' VAL . 24.2 pt -119.39 146.05 24.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.73 -174.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 92.4 m -97.16 115.81 28.23 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 172.871 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.634 HG21 HD12 ' A' ' 262' ' ' LEU . 32.8 m -92.08 143.19 11.85 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.974 0 C-N-CA 119.388 -0.925 . . . . 0.0 112.697 -170.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 258' ' ' SER . . . . . 0.415 ' HB3' ' OG1' ' A' ' 229' ' ' THR . 23.1 t -90.72 9.92 28.01 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 114.005 -1.452 . . . . 0.0 107.968 169.671 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 259' ' ' ALA . . . . . 0.603 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -93.38 -179.27 5.0 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 114.862 -1.063 . . . . 0.0 110.262 -177.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 32.2 t -152.8 150.92 29.86 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 176.433 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 84.98 22.74 51.84 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.42 -178.649 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 262' ' ' LEU . . . . . 0.634 HD12 HG21 ' A' ' 257' ' ' VAL . 78.6 mt -90.08 140.51 29.58 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.683 0.278 . . . . 0.0 110.439 179.439 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . 0.433 ' HA ' HE21 ' A' ' 263' ' ' GLN . 2.6 mm100 -137.55 168.71 19.12 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.58 -178.28 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 264' ' ' VAL . . . . . 0.496 HG22 ' HA ' ' A' ' 294' ' ' ALA . 45.6 t -74.81 138.58 20.74 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-O 120.743 0.306 . . . . 0.0 110.312 177.645 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 91.37 0.57 73.14 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.685 178.316 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 55.1 m-20 -81.32 165.32 21.49 Favored 'General case' 0 CA--C 1.514 -0.419 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 176.385 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 267' ' ' ALA . . . . . 0.838 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -130.7 148.65 52.51 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 176.869 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 268' ' ' PHE . . . . . 0.633 ' HB3' HD13 ' A' ' 334' ' ' ILE . 3.3 p90 -164.88 168.78 17.32 Favored 'General case' 0 C--N 1.321 -0.649 0 C-N-CA 120.176 -0.61 . . . . 0.0 111.3 -179.216 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 269' ' ' THR . . . . . 0.613 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 63.3 p -113.49 149.5 34.22 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.037 175.55 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 270' ' ' ILE . . . . . . . . . . . . . 59.4 mt -121.53 129.92 75.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 178.186 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -61.29 139.13 58.22 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.242 0.544 . . . . 0.0 112.242 -173.038 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 88.17 -24.95 9.69 Favored Glycine 0 C--O 1.231 -0.074 0 CA-C-N 115.778 -0.646 . . . . 0.0 112.678 179.199 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 38.2 t -97.21 101.49 12.31 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 174.288 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 274' ' ' ASN . . . . . 1.027 ' HA ' ' HA ' ' A' ' 287' ' ' PRO . 3.6 m120 -94.46 169.11 10.44 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.316 -179.084 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 275' ' ' SER . . . . . 0.408 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 8.3 t -104.72 179.79 4.17 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 107.876 -1.157 . . . . 0.0 107.876 171.555 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 32.7 m -126.28 149.15 31.0 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.07 0 C-N-CA 120.472 -0.491 . . . . 0.0 111.196 173.421 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 277' ' ' HIS . . . . . 0.431 ' CD2' ' HB2' ' A' ' 282' ' ' ASP . 90.6 m-70 -78.08 117.2 19.15 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.065 -0.516 . . . . 0.0 109.621 175.169 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 39.4 tt0 -62.91 -35.25 79.44 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.906 -173.137 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 279' ' ' ILE . . . . . 0.642 HG22 HG23 ' A' ' 280' ' ' THR . 60.7 mt -60.09 -69.41 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 112.295 0.48 . . . . 0.0 112.295 -173.57 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . 0.642 HG23 HG22 ' A' ' 279' ' ' ILE . 46.4 p -114.52 17.22 17.45 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 112.424 0.527 . . . . 0.0 112.424 -174.426 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 281' ' ' LYS . . . . . 0.418 ' HE3' HG11 ' A' ' 309' ' ' VAL . 2.8 tmtp? 60.04 53.02 4.79 Favored 'General case' 0 CA--C 1.535 0.397 0 CA-C-O 121.328 0.585 . . . . 0.0 109.527 177.688 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 282' ' ' ASP . . . . . 0.431 ' HB2' ' CD2' ' A' ' 277' ' ' HIS . 58.5 m-20 -94.27 129.98 40.71 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.892 0.377 . . . . 0.0 111.007 -178.804 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 76.1 p -107.2 107.43 18.38 Favored 'General case' 0 C--N 1.321 -0.656 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 173.842 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 47.0 p -118.68 7.27 11.65 Favored 'General case' 0 C--N 1.322 -0.587 0 C-N-CA 120.737 -0.385 . . . . 0.0 111.999 -172.217 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 85.58 26.65 34.91 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.403 -0.903 . . . . 0.0 112.646 176.386 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 286' ' ' GLN . . . . . 0.417 ' HA ' ' HD3' ' A' ' 287' ' ' PRO . 84.7 mt-30 -105.03 117.17 59.28 Favored Pre-proline 0 C--N 1.324 -0.535 0 N-CA-C 110.328 -0.249 . . . . 0.0 110.328 178.616 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 287' ' ' PRO . . . . . 1.027 ' HA ' ' HA ' ' A' ' 274' ' ' ASN . 39.5 Cg_exo -61.7 167.36 10.21 Favored 'Trans proline' 0 C--O 1.233 0.274 0 C-N-CA 123.222 2.615 . . . . 0.0 113.559 -175.67 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 62.9 tp60 -88.05 136.45 32.96 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.278 -0.874 . . . . 0.0 110.564 178.165 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 289' ' ' VAL . . . . . 0.549 HG12 ' HB1' ' A' ' 267' ' ' ALA . 43.8 t -94.47 123.24 46.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.069 -0.514 . . . . 0.0 109.888 177.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 290' ' ' PHE . . . . . 0.838 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 60.1 m-85 -104.07 133.56 48.81 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 112.082 0.401 . . . . 0.0 112.082 -173.396 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 291' ' ' ARG . . . . . 0.635 ' HD2' ' HB2' ' A' ' 267' ' ' ALA . 40.2 mmm-85 -94.91 119.59 33.71 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-O 121.5 0.667 . . . . 0.0 109.414 167.761 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . 0.627 HG11 HG23 ' A' ' 295' ' ' VAL . 54.9 t -71.37 140.91 17.45 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 CA-C-N 114.705 -1.134 . . . . 0.0 112.409 -174.905 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 293' ' ' LEU . . . . . 0.509 ' N ' HD12 ' A' ' 293' ' ' LEU . 3.9 mp -102.34 -30.89 10.79 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.41 175.604 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 294' ' ' ALA . . . . . 0.496 ' HA ' HG22 ' A' ' 264' ' ' VAL . . . -158.02 138.85 13.07 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.558 -177.394 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 295' ' ' VAL . . . . . 0.627 HG23 HG11 ' A' ' 292' ' ' VAL . 59.4 t -133.84 97.67 2.35 Favored 'Isoleucine or valine' 0 C--O 1.236 0.358 0 CA-C-N 115.851 -0.613 . . . . 0.0 109.378 173.826 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 30.5 m -133.98 114.57 13.38 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.848 -176.064 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 60.96 51.04 61.07 Favored Glycine 0 C--N 1.329 0.179 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.336 -179.515 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 70.4 p 52.32 19.5 1.14 Allowed 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 123.635 0.774 . . . . 0.0 112.654 -176.267 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 32.8 m -109.45 108.95 19.64 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 177.174 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . 0.579 HG12 HG23 ' A' ' 302' ' ' ILE . 43.7 t -112.04 126.96 69.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.54 -170.931 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 301' ' ' THR . . . . . 0.456 ' CG2' ' HB2' ' A' ' 252' ' ' GLN . 69.1 m -98.29 117.92 33.77 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 174.259 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 302' ' ' ILE . . . . . 0.655 ' O ' ' HB3' ' A' ' 252' ' ' GLN . 2.4 pp -116.18 149.82 18.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 N-CA-C 114.116 1.154 . . . . 0.0 114.116 -171.033 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 303' ' ' SER . . . . . 0.51 ' HA ' ' O ' ' A' ' 304' ' ' PRO . 86.1 p -140.64 162.62 48.05 Favored Pre-proline 0 C--O 1.216 -0.682 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 173.185 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 304' ' ' PRO . . . . . 0.51 ' O ' ' HA ' ' A' ' 303' ' ' SER . 17.6 Cg_endo -55.83 174.39 3.55 Favored 'Cis proline' 0 N--CA 1.477 0.554 0 CA-C-N 121.479 1.564 . . . . 0.0 113.825 0.038 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 305' ' ' LYS . . . . . 0.473 ' HD2' ' N ' ' A' ' 305' ' ' LYS . 0.4 OUTLIER -65.3 158.42 26.42 Favored 'General case' 0 CA--C 1.511 -0.553 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.38 179.502 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 306' ' ' ILE . . . . . 0.483 HD11 HD11 ' A' ' 302' ' ' ILE . 43.3 mt -101.62 73.02 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -0.987 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.779 178.453 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 307' ' ' LEU . . . . . 0.518 ' HB2' ' HA ' ' A' ' 320' ' ' ALA . 91.7 mt -107.11 112.14 63.2 Favored Pre-proline 0 C--N 1.324 -0.543 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.216 -176.262 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 308' ' ' PRO . . . . . 0.585 ' HA ' ' O ' ' A' ' 322' ' ' VAL . 11.3 Cg_exo -69.79 146.35 59.74 Favored 'Trans proline' 0 N--CA 1.462 -0.324 0 C-N-CA 122.708 2.272 . . . . 0.0 111.034 177.708 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . 0.418 HG11 ' HE3' ' A' ' 281' ' ' LYS . 20.0 t -83.41 -21.32 8.85 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 CA-C-O 121.282 0.563 . . . . 0.0 110.39 -177.694 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -76.24 -6.95 53.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.58 -0.736 . . . . 0.0 112.28 -175.994 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -75.46 153.94 37.31 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.143 0.497 . . . . 0.0 111.749 -177.005 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 53.1 m -96.88 -7.58 33.06 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.835 -0.62 . . . . 0.0 109.402 178.24 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 313' ' ' ASP . . . . . 0.464 ' HB3' ' HB2' ' A' ' 316' ' ' SER . 9.8 t70 -54.25 119.0 4.54 Favored 'General case' 0 C--O 1.232 0.153 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.507 179.868 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 46.7 t -56.57 -49.61 76.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.41 -0.814 . . . . 0.0 112.679 -173.071 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -81.82 -19.73 40.5 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 112.352 0.501 . . . . 0.0 112.352 -174.668 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . 0.464 ' HB2' ' HB3' ' A' ' 313' ' ' ASP . 49.2 m -91.81 -25.26 19.09 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 112.283 0.475 . . . . 0.0 112.283 -175.742 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 317' ' ' ARG . . . . . 0.466 ' CG ' ' HD3' ' A' ' 318' ' ' PRO . 1.6 ptm85 -71.62 -35.79 4.04 Favored Pre-proline 0 CA--C 1.545 0.771 0 N-CA-C 114.293 1.22 . . . . 0.0 114.293 -175.902 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 318' ' ' PRO . . . . . 0.466 ' HD3' ' CG ' ' A' ' 317' ' ' ARG . 24.2 Cg_exo -65.89 -38.92 21.33 Favored 'Trans proline' 0 C--N 1.362 1.268 0 CA-C-N 121.132 1.44 . . . . 0.0 112.476 -177.463 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 3.9 m-85 -95.94 17.37 15.5 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.075 -179.719 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . 0.518 ' HA ' ' HB2' ' A' ' 307' ' ' LEU . . . -64.67 134.34 54.07 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.523 177.805 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 15.2 p-10 -144.11 1.44 1.11 Allowed 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -174.023 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 322' ' ' VAL . . . . . 0.585 ' O ' ' HA ' ' A' ' 308' ' ' PRO . 29.4 m -133.93 161.45 40.92 Favored 'Isoleucine or valine' 0 C--O 1.234 0.266 0 CA-C-O 121.288 0.566 . . . . 0.0 112.262 -177.82 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 323' ' ' ASP . . . . . 0.687 ' HB2' ' HB2' ' A' ' 274' ' ' ASN . 57.2 m-20 -93.24 77.59 4.54 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.865 174.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 324' ' ' ALA . . . . . 0.403 ' HB3' ' O ' ' A' ' 323' ' ' ASP . . . 72.37 163.85 0.28 Allowed 'General case' 0 N--CA 1.471 0.621 0 N-CA-C 113.387 0.884 . . . . 0.0 113.387 175.12 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 325' ' ' LYS . . . . . 0.652 ' HD3' ' O ' ' A' ' 234' ' ' PRO . 9.9 ptpp? -119.15 105.93 43.93 Favored Pre-proline 0 C--N 1.325 -0.459 0 CA-C-N 114.485 -1.234 . . . . 0.0 108.715 166.902 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 326' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 325' ' ' LYS . 3.8 Cg_exo -84.17 167.21 12.43 Favored 'Trans proline' 0 C--O 1.234 0.299 0 C-N-CA 122.657 2.238 . . . . 0.0 112.992 -171.363 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 327' ' ' ALA . . . . . 0.427 ' HA ' ' OE1' ' A' ' 233' ' ' GLN . . . -72.82 134.85 45.07 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 115.605 -0.725 . . . . 0.0 109.689 174.136 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 70.1 mm-40 71.3 111.18 0.06 Allowed 'General case' 0 N--CA 1.464 0.256 0 O-C-N 124.089 0.868 . . . . 0.0 110.432 -173.243 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 329' ' ' SER . . . . . 0.677 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 58.2 m -63.36 -41.28 98.83 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.603 -176.561 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 330' ' ' ALA . . . . . 0.466 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 79.35 -160.66 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.762 0 N-CA-C 112.828 0.677 . . . . 0.0 112.828 174.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 331' ' ' ALA . . . . . 0.617 ' HA ' HG22 ' A' ' 229' ' ' THR . . . -68.43 157.73 35.21 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-N 115.091 -0.958 . . . . 0.0 113.562 -170.405 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 332' ' ' ILE . . . . . 0.507 HD12 ' HB2' ' A' ' 259' ' ' ALA . 17.5 mt -119.16 146.11 24.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.075 -0.966 . . . . 0.0 110.223 179.555 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 0.518 ' HB ' ' OG1' ' A' ' 269' ' ' THR . 59.5 m -127.18 111.67 14.24 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 175.544 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 334' ' ' ILE . . . . . 0.633 HD13 ' HB3' ' A' ' 268' ' ' PHE . 46.9 mm -83.87 134.93 25.85 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.359 0 N-CA-C 113.295 0.85 . . . . 0.0 113.295 -171.538 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 335' ' ' LEU . . . . . 0.543 ' O ' ' HB3' ' A' ' 267' ' ' ALA . 1.8 pt? -158.45 130.36 6.75 Favored 'General case' 0 C--O 1.222 -0.366 0 CA-C-N 115.083 -0.962 . . . . 0.0 109.906 170.562 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -102.65 2.74 36.34 Favored 'General case' 0 C--N 1.318 -0.801 0 O-C-N 122.011 -0.43 . . . . 0.0 111.144 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 40.1 ttmt . . . . . 0 C--O 1.244 0.773 0 CA-C-O 118.279 -0.867 . . . . 0.0 110.246 -178.388 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 35.4 m . . . . . 0 C--O 1.236 0.363 0 CA-C-O 120.904 0.383 . . . . 0.0 111.015 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 228' ' ' LEU . . . . . 0.701 ' H ' HD22 ' A' ' 228' ' ' LEU . 1.9 mm? -60.39 150.56 30.49 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.252 -179.665 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 229' ' ' THR . . . . . 0.405 ' HA ' ' HA ' ' A' ' 331' ' ' ALA . 53.6 p -129.96 176.18 8.26 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 119.787 -0.765 . . . . 0.0 111.1 -179.773 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 230' ' ' VAL . . . . . 0.527 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 64.9 t -148.69 138.87 16.56 Favored 'Isoleucine or valine' 0 C--O 1.238 0.478 0 CA-C-O 120.789 0.328 . . . . 0.0 110.926 -177.128 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 47.1 t -122.72 97.39 5.43 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.419 -0.809 . . . . 0.0 109.101 173.284 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . -126.22 -151.8 7.96 Favored Glycine 0 N--CA 1.445 -0.762 0 C-N-CA 119.951 -1.119 . . . . 0.0 113.102 -175.036 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 233' ' ' GLN . . . . . 0.777 ' H ' HG22 ' A' ' 255' ' ' ILE . 80.3 mt-30 -70.58 169.61 13.53 Favored Pre-proline 0 C--N 1.325 -0.468 0 CA-C-N 115.212 -0.494 . . . . 0.0 110.991 -178.609 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 234' ' ' PRO . . . . . 0.768 ' HD2' ' HB3' ' A' ' 233' ' ' GLN . 18.7 Cg_endo -57.53 175.08 0.43 Allowed 'Trans proline' 0 C--N 1.354 0.833 0 C-N-CA 123.404 2.736 . . . . 0.0 112.833 177.777 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 235' ' ' GLU . . . . . 0.476 ' HB2' ' HD2' ' A' ' 325' ' ' LYS . 25.1 mp0 -91.86 155.18 18.39 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 108.96 -0.756 . . . . 0.0 108.96 -177.052 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 65.6 m-70 -108.5 148.76 29.76 Favored 'General case' 0 C--N 1.323 -0.581 0 C-N-CA 120.521 -0.472 . . . . 0.0 111.177 -171.511 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 237' ' ' LYS . . . . . 0.44 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.324 -0.527 0 CA-C-N 115.5 -0.773 . . . . 0.0 108.957 -178.38 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 19.2 mt-30 . . . . . 0 N--CA 1.471 0.614 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . 0.586 ' O ' ' HA ' ' A' ' 301' ' ' THR . . . 133.29 -146.45 18.36 Favored Glycine 0 N--CA 1.445 -0.76 0 C-N-CA 118.576 -1.773 . . . . 0.0 114.223 174.314 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 51.4 p -93.98 130.1 40.21 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.036 -0.582 . . . . 0.0 112.443 -170.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.777 HG22 ' H ' ' A' ' 233' ' ' GLN . 2.3 pp -129.79 163.4 35.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.902 177.432 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 31.3 m -100.47 116.38 32.28 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 -178.51 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.454 ' HA ' HG13 ' A' ' 230' ' ' VAL . 31.8 m -90.78 142.56 12.77 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.573 0 C-N-CA 120.192 -0.603 . . . . 0.0 112.593 -176.098 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 36.8 t -91.94 9.03 34.74 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 114.495 -1.23 . . . . 0.0 108.379 167.575 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 259' ' ' ALA . . . . . 0.537 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -91.07 171.54 9.19 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.138 -0.937 . . . . 0.0 109.748 -178.023 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 34.5 t -143.65 132.02 22.11 Favored 'General case' 0 C--N 1.324 -0.504 0 C-N-CA 120.991 -0.283 . . . . 0.0 110.857 179.508 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 99.24 25.49 9.43 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.682 -0.771 . . . . 0.0 113.083 177.705 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 262' ' ' LEU . . . . . 0.507 HD11 ' CB ' ' A' ' 259' ' ' ALA . 3.4 mp -87.79 146.26 25.71 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 117.034 0.417 . . . . 0.0 110.195 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 83.6 mt-30 -141.04 169.16 18.13 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.105 -0.498 . . . . 0.0 109.768 177.404 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 264' ' ' VAL . . . . . 0.674 HG22 ' HA ' ' A' ' 294' ' ' ALA . 31.8 t -77.86 139.69 18.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 C-N-CA 121.032 -0.267 . . . . 0.0 110.594 -179.677 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 91.71 3.35 68.71 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.13 179.462 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 70.5 m-20 -80.46 166.78 20.89 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.295 0.569 . . . . 0.0 111.039 179.145 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 267' ' ' ALA . . . . . 0.723 ' HB2' ' NH1' ' A' ' 291' ' ' ARG . . . -125.84 144.11 50.79 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 114.802 -1.09 . . . . 0.0 108.551 175.22 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 268' ' ' PHE . . . . . 0.583 ' CD1' HG21 ' A' ' 332' ' ' ILE . 0.0 OUTLIER -163.45 163.82 24.72 Favored 'General case' 0 C--N 1.313 -1.002 0 C-N-CA 120.125 -0.63 . . . . 0.0 110.167 -179.955 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 63.3 p -125.89 137.99 53.77 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 120.822 0.344 . . . . 0.0 110.934 -175.397 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 270' ' ' ILE . . . . . 0.671 HG12 HG12 ' A' ' 332' ' ' ILE . 60.5 mt -95.89 138.63 20.89 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.806 -179.316 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -62.23 125.52 24.18 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.97 179.577 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 94.4 -21.57 41.93 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.125 -178.62 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . 0.461 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 57.0 t -90.73 101.4 12.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.282 0.563 . . . . 0.0 110.106 177.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -115.91 134.32 55.11 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 178.791 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 35.6 p -70.8 152.81 43.36 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.258 0.552 . . . . 0.0 111.97 -179.125 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 276' ' ' VAL . . . . . 0.686 HG11 HG21 ' A' ' 309' ' ' VAL . 33.8 m -114.7 156.07 15.75 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-N 115.221 -0.899 . . . . 0.0 110.157 174.588 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 21.7 m80 -116.6 71.27 0.78 Allowed 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 177.473 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 26.8 mt-30 -70.58 -9.62 57.27 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 112.17 0.433 . . . . 0.0 112.17 -175.239 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 279' ' ' ILE . . . . . 0.49 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.0 mp -67.67 -49.08 73.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 176.024 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 70.1 p -90.93 -12.75 35.11 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.117 0.484 . . . . 0.0 109.925 174.288 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 26.5 tptp 68.28 50.8 0.73 Allowed 'General case' 0 CA--C 1.531 0.237 0 CA-C-N 114.902 -1.045 . . . . 0.0 110.342 -177.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -118.34 142.15 47.8 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.889 177.553 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 62.8 p -107.43 109.93 21.77 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.48 174.745 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 68.0 p -114.33 -12.19 12.45 Favored 'General case' 0 C--N 1.32 -0.691 0 C-N-CA 120.721 -0.392 . . . . 0.0 111.999 -171.429 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 64.16 31.46 80.91 Favored Glycine 0 CA--C 1.518 0.252 0 C-N-CA 120.964 -0.636 . . . . 0.0 113.313 175.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 98.1 mm-40 -89.14 122.46 68.71 Favored Pre-proline 0 C--N 1.327 -0.37 0 CA-C-N 116.941 0.37 . . . . 0.0 110.197 178.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 287' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_exo -48.29 131.08 22.1 Favored 'Trans proline' 0 C--N 1.346 0.42 0 C-N-CA 123.033 2.489 . . . . 0.0 112.989 -177.695 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 67.1 tp60 -70.1 127.28 32.28 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.868 -178.867 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 289' ' ' VAL . . . . . 0.442 HG13 ' HB1' ' A' ' 267' ' ' ALA . 65.7 t -91.73 131.74 38.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 116.042 -0.527 . . . . 0.0 110.578 178.47 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 290' ' ' PHE . . . . . 0.695 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 57.8 m-85 -113.5 154.5 26.96 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.72 -178.272 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 291' ' ' ARG . . . . . 0.723 ' NH1' ' HB2' ' A' ' 267' ' ' ALA . 0.1 OUTLIER -114.5 121.58 43.96 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.15 0.5 . . . . 0.0 110.196 172.812 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . 0.512 HG11 HG23 ' A' ' 295' ' ' VAL . 56.9 t -70.39 136.46 25.99 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-N 115.037 -0.983 . . . . 0.0 111.889 -175.291 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 293' ' ' LEU . . . . . 0.667 HD11 ' HB2' ' A' ' 303' ' ' SER . 5.5 mp -96.22 -35.69 11.19 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.91 -0.587 . . . . 0.0 111.085 179.048 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 294' ' ' ALA . . . . . 0.674 ' HA ' HG22 ' A' ' 264' ' ' VAL . . . -163.63 140.8 7.21 Favored 'General case' 0 C--N 1.332 -0.184 0 C-N-CA 121.058 -0.257 . . . . 0.0 111.641 -179.579 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 295' ' ' VAL . . . . . 0.512 HG23 HG11 ' A' ' 292' ' ' VAL . 59.9 t -134.77 103.37 4.48 Favored 'Isoleucine or valine' 0 C--O 1.235 0.303 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.784 175.191 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 51.0 m -143.81 114.64 7.73 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.559 -179.013 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 67.05 48.43 59.99 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.276 -178.551 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 77.9 p 51.5 21.53 1.28 Allowed 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 123.608 0.763 . . . . 0.0 112.106 -176.198 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 37.0 m -110.04 105.9 15.2 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 177.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . 0.562 ' HA ' ' O ' ' A' ' 294' ' ' ALA . 48.9 t -108.52 128.09 64.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.4 -172.119 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 301' ' ' THR . . . . . 0.586 ' HA ' ' O ' ' A' ' 253' ' ' GLY . 54.1 m -86.75 115.82 24.44 Favored 'General case' 0 N--CA 1.451 -0.423 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 173.631 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 302' ' ' ILE . . . . . 0.549 HD12 ' O ' ' A' ' 302' ' ' ILE . 2.4 pp -111.74 151.04 13.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 N-CA-C 113.527 0.936 . . . . 0.0 113.527 -171.05 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 303' ' ' SER . . . . . 0.667 ' HB2' HD11 ' A' ' 293' ' ' LEU . 64.9 m -166.99 166.5 8.48 Favored Pre-proline 0 C--N 1.322 -0.595 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 179.326 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 304' ' ' PRO . . . . . 0.586 ' HA ' ' HB3' ' A' ' 303' ' ' SER . 4.3 Cg_exo -77.62 -113.81 0.0 OUTLIER 'Cis proline' 0 C--N 1.347 0.48 0 CA-C-N 120.907 1.36 . . . . 0.0 113.438 0.516 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 305' ' ' LYS . . . . . 0.519 ' HB3' ' HG ' ' A' ' 307' ' ' LEU . 31.2 mmtp -93.04 155.74 17.32 Favored 'General case' 0 CA--C 1.515 -0.385 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.354 -171.473 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 306' ' ' ILE . . . . . 0.456 HD12 ' N ' ' A' ' 306' ' ' ILE . 3.1 mp -131.09 74.18 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.641 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 167.283 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 307' ' ' LEU . . . . . 0.519 ' HG ' ' HB3' ' A' ' 305' ' ' LYS . 73.7 mt -112.67 113.91 50.08 Favored Pre-proline 0 C--N 1.328 -0.366 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.183 -171.092 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 308' ' ' PRO . . . . . 0.743 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 37.8 Cg_exo -66.91 148.62 82.43 Favored 'Trans proline' 0 N--CA 1.472 0.254 0 C-N-CA 123.378 2.719 . . . . 0.0 113.924 -175.137 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . 0.686 HG21 HG11 ' A' ' 276' ' ' VAL . 46.0 t -94.06 -7.92 9.99 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.362 0 CA-C-N 115.421 -0.809 . . . . 0.0 109.303 171.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 310' ' ' GLU . . . . . 0.428 ' HG2' ' O ' ' A' ' 323' ' ' ASP . 65.3 mm-40 -77.17 11.83 1.7 Allowed 'General case' 0 CA--C 1.531 0.248 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.928 179.076 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.519 ' OD1' ' HB2' ' A' ' 308' ' ' PRO . 4.6 m120 -80.41 158.69 25.89 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.888 0.375 . . . . 0.0 110.669 178.472 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 31.5 m -107.74 -13.28 15.06 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.168 0.508 . . . . 0.0 110.494 -176.027 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 11.8 p-10 -87.58 156.25 19.59 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 121.091 0.472 . . . . 0.0 111.172 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 314' ' ' VAL . . . . . 0.411 ' O ' ' HD3' ' A' ' 318' ' ' PRO . 49.1 t -81.79 -24.06 9.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 115.707 -0.678 . . . . 0.0 111.112 -178.295 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -61.9 -42.72 99.42 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 111.913 0.338 . . . . 0.0 111.913 -178.114 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 26.3 t -82.1 -10.31 59.24 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.609 -0.268 . . . . 0.0 111.293 -176.431 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 317' ' ' ARG . . . . . 0.638 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 36.8 mmt180 -58.37 -54.5 55.24 Favored Pre-proline 0 N--CA 1.468 0.464 0 N-CA-C 113.554 0.946 . . . . 0.0 113.554 -179.704 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 318' ' ' PRO . . . . . 0.638 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 24.5 Cg_exo -68.21 -19.19 44.81 Favored 'Trans proline' 0 C--N 1.353 0.78 0 C-N-CA 122.017 1.811 . . . . 0.0 113.232 -175.178 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 55.4 m-85 -102.16 -18.37 15.57 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 111.965 0.357 . . . . 0.0 111.965 -174.245 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -55.64 126.49 25.61 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.795 0.331 . . . . 0.0 111.244 -178.666 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 321' ' ' ASN . . . . . 0.411 ' C ' HG22 ' A' ' 276' ' ' VAL . 15.3 p-10 -126.51 -4.94 6.54 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.288 -177.631 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 322' ' ' VAL . . . . . 0.571 ' O ' HG23 ' A' ' 309' ' ' VAL . 29.9 m -136.35 156.43 36.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.637 0.256 . . . . 0.0 110.885 178.511 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 323' ' ' ASP . . . . . 0.428 ' O ' ' HG2' ' A' ' 310' ' ' GLU . 71.9 m-20 -52.93 -50.97 62.93 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.889 -178.065 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 324' ' ' ALA . . . . . 0.743 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -163.05 -179.94 7.07 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.006 0.431 . . . . 0.0 111.135 -177.066 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 325' ' ' LYS . . . . . 0.476 ' HD2' ' HB2' ' A' ' 235' ' ' GLU . 22.0 pttp -105.84 137.43 19.34 Favored Pre-proline 0 C--N 1.325 -0.481 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.122 176.575 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 326' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 325' ' ' LYS . 57.4 Cg_endo -86.35 167.46 9.05 Favored 'Trans proline' 0 N--CA 1.454 -0.809 0 C-N-CA 122.712 2.275 . . . . 0.0 112.306 -179.411 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -75.6 138.34 41.37 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 175.777 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 62.64 -132.42 0.51 Allowed 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 -174.021 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 329' ' ' SER . . . . . 0.527 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 48.6 m -111.49 -17.34 13.1 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 171.185 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 74.47 -173.67 0.13 Allowed 'General case' 0 N--CA 1.474 0.759 0 N-CA-C 113.65 0.981 . . . . 0.0 113.65 170.887 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 331' ' ' ALA . . . . . 0.435 ' HA ' ' O ' ' A' ' 228' ' ' LEU . . . -80.76 146.75 30.84 Favored 'General case' 0 CA--C 1.518 -0.264 0 CA-C-N 114.997 -1.001 . . . . 0.0 111.171 -176.604 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 332' ' ' ILE . . . . . 0.671 HG12 HG12 ' A' ' 270' ' ' ILE . 47.5 mt -128.45 147.18 33.0 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-O 120.956 0.408 . . . . 0.0 111.528 -176.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 88.1 m -116.71 112.96 21.94 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.857 -179.591 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 38.4 mm -79.56 131.87 33.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 113.044 0.757 . . . . 0.0 113.044 -171.482 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 335' ' ' LEU . . . . . . . . . . . . . 9.6 mp -115.92 168.61 9.91 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 114.562 -1.199 . . . . 0.0 109.643 171.5 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -116.82 3.96 12.95 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.473 176.69 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 14.8 ptmm? . . . . . 0 C--O 1.246 0.889 0 CA-C-O 118.611 -0.709 . . . . 0.0 111.687 -176.415 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 51.1 m . . . . . 0 N--CA 1.453 -0.281 0 CA-C-O 121.057 0.456 . . . . 0.0 110.506 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 228' ' ' LEU . . . . . 0.471 HD13 ' HB1' ' A' ' 259' ' ' ALA . 89.9 mt -70.28 147.27 49.89 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 175.148 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 63.8 p -126.29 171.65 10.77 Favored 'General case' 0 C--N 1.324 -0.54 0 C-N-CA 119.163 -1.015 . . . . 0.0 111.334 -176.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 230' ' ' VAL . . . . . 0.893 HG11 HD12 ' A' ' 255' ' ' ILE . 48.0 t -147.1 141.08 20.0 Favored 'Isoleucine or valine' 0 C--O 1.24 0.577 0 CA-C-O 120.657 0.265 . . . . 0.0 110.754 -177.662 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 30.6 t -106.48 148.84 27.7 Favored 'General case' 0 C--O 1.237 0.428 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.985 176.634 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 124.8 157.15 9.61 Favored Glycine 0 N--CA 1.449 -0.486 0 N-CA-C 110.944 -0.862 . . . . 0.0 110.944 -176.712 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 233' ' ' GLN . . . . . 0.54 ' NE2' ' HA ' ' A' ' 328' ' ' GLU . 96.6 mm-40 -110.01 101.48 47.52 Favored Pre-proline 0 C--N 1.324 -0.534 0 CA-C-N 117.419 0.609 . . . . 0.0 111.305 -177.819 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -91.83 126.36 0.92 Allowed 'Trans proline' 0 N--CA 1.448 -1.159 0 C-N-CA 122.806 2.337 . . . . 0.0 111.756 177.605 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -132.54 149.36 52.33 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.525 -0.307 . . . . 0.0 110.214 177.027 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 236' ' ' HIS . . . . . 0.735 ' CD2' ' HA ' ' A' ' 305' ' ' LYS . 29.3 m80 -136.55 136.11 39.02 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.182 -179.532 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 237' ' ' LYS . . . . . 0.519 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.324 -0.531 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.024 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 21.3 mt-30 . . . . . 0 N--CA 1.468 0.473 0 CA-C-O 120.951 0.405 . . . . 0.0 110.693 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 136.0 -160.86 24.75 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 119.031 -1.557 . . . . 0.0 113.613 176.125 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 254' ' ' THR . . . . . 0.57 ' HB ' HG22 ' A' ' 299' ' ' THR . 66.0 p -94.63 135.73 35.75 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-O 121.331 0.586 . . . . 0.0 111.88 -175.307 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.893 HD12 HG11 ' A' ' 230' ' ' VAL . 14.6 pt -121.77 156.42 26.04 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-N 115.535 -0.757 . . . . 0.0 110.179 177.151 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 28.3 m -94.66 111.26 23.04 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 -179.755 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.528 ' HA ' HG13 ' A' ' 230' ' ' VAL . 23.1 m -93.45 144.54 9.28 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.76 0 CA-C-O 121.642 0.734 . . . . 0.0 112.717 -170.213 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 35.4 t -91.19 9.65 30.29 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 114.088 -1.415 . . . . 0.0 108.049 167.857 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 259' ' ' ALA . . . . . 0.471 ' HB1' HD13 ' A' ' 228' ' ' LEU . . . -87.08 163.72 16.85 Favored 'General case' 0 N--CA 1.45 -0.427 0 CA-C-N 115.004 -0.998 . . . . 0.0 109.66 -177.826 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 37.5 t -144.13 143.99 31.37 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 120.683 0.278 . . . . 0.0 110.384 -179.726 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 80.94 36.75 21.11 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.649 179.625 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 262' ' ' LEU . . . . . . . . . . . . . 66.4 mt -98.83 150.8 21.51 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.941 0.401 . . . . 0.0 110.432 179.52 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 73.4 mt-30 -142.26 164.73 29.37 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.241 176.29 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 264' ' ' VAL . . . . . 0.514 HG22 ' HA ' ' A' ' 294' ' ' ALA . 39.9 t -74.83 139.28 19.42 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 177.856 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 96.43 -1.91 62.55 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.42 -0.895 . . . . 0.0 113.504 177.737 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 39.7 m-20 -80.09 155.75 27.37 Favored 'General case' 0 CA--C 1.516 -0.353 0 CA-C-N 117.177 0.488 . . . . 0.0 111.053 177.094 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 267' ' ' ALA . . . . . 0.64 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -112.97 152.83 28.93 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.433 -0.803 . . . . 0.0 109.316 178.164 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 268' ' ' PHE . . . . . 0.76 ' HB3' HD13 ' A' ' 334' ' ' ILE . 7.9 p90 -164.84 172.36 13.02 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-O 121.189 0.518 . . . . 0.0 112.156 -175.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 74.4 p -127.84 149.89 50.08 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 114.758 -1.11 . . . . 0.0 108.789 173.131 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 270' ' ' ILE . . . . . 0.641 HG12 HG12 ' A' ' 332' ' ' ILE . 61.1 mt -118.6 136.94 54.18 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.674 0 CA-C-O 120.66 0.267 . . . . 0.0 110.478 -179.194 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -60.41 123.1 16.28 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.936 -0.575 . . . . 0.0 111.766 -176.581 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 100.43 -22.48 39.74 Favored Glycine 0 N--CA 1.451 -0.311 0 CA-C-N 115.915 -0.584 . . . . 0.0 112.223 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . 0.577 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 41.8 t -95.03 109.96 23.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 120.803 0.335 . . . . 0.0 110.294 177.818 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 69.6 m-80 -129.48 160.39 33.32 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 179.204 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 35.7 p -85.22 -171.68 3.75 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 111.966 0.358 . . . . 0.0 111.966 -176.359 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 276' ' ' VAL . . . . . 0.472 HG22 ' O ' ' A' ' 321' ' ' ASN . 29.6 m -145.98 173.24 3.36 Favored 'Isoleucine or valine' 0 C--O 1.232 0.176 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.098 178.79 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 39.5 m80 -118.82 127.13 53.24 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.328 -0.396 . . . . 0.0 109.988 171.629 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 83.6 mt-30 -79.32 -23.42 43.5 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 173.891 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 279' ' ' ILE . . . . . 0.565 ' H ' HD12 ' A' ' 279' ' ' ILE . 2.5 mp -63.27 -51.1 75.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.362 179.349 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 70.9 p -100.04 -15.09 18.36 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.022 -0.536 . . . . 0.0 111.799 -176.057 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 34.5 mmtp 65.25 30.13 11.4 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 123.037 0.535 . . . . 0.0 111.429 -177.186 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 67.0 m-20 -105.83 151.55 24.36 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.072 176.084 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.437 ' HA ' HG12 ' A' ' 276' ' ' VAL . 72.6 p -96.21 92.3 6.32 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.3 0.571 . . . . 0.0 110.412 176.569 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 284' ' ' THR . . . . . 0.415 ' C ' ' H ' ' A' ' 286' ' ' GLN . 47.5 p -141.48 -112.14 0.13 Allowed 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.884 -179.082 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 63.65 -8.62 0.32 Allowed Glycine 0 CA--C 1.522 0.491 0 N-CA-C 114.529 0.572 . . . . 0.0 114.529 174.543 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 286' ' ' GLN . . . . . 0.571 ' HB3' ' HD2' ' A' ' 287' ' ' PRO . 2.0 mp0 67.45 167.72 0.12 Allowed Pre-proline 0 CA--C 1.537 0.453 0 C-N-CA 123.416 0.687 . . . . 0.0 111.045 -177.885 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 287' ' ' PRO . . . . . 0.571 ' HD2' ' HB3' ' A' ' 286' ' ' GLN . 81.3 Cg_exo -47.72 133.66 21.94 Favored 'Trans proline' 0 C--N 1.353 0.8 0 C-N-CA 122.821 2.347 . . . . 0.0 113.77 -172.658 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 71.2 tp60 -69.23 136.61 52.23 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.711 -178.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 48.8 t -94.89 134.13 33.34 Favored 'Isoleucine or valine' 0 C--O 1.236 0.376 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.543 179.586 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 290' ' ' PHE . . . . . 0.64 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 33.4 m-85 -116.81 168.74 9.95 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.443 -176.817 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 42.5 mmm-85 -131.08 125.46 33.23 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 173.819 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . 0.42 HG11 HG23 ' A' ' 295' ' ' VAL . 47.3 t -65.16 134.78 29.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.701 -177.243 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 293' ' ' LEU . . . . . 0.85 HD21 ' HB2' ' A' ' 303' ' ' SER . 2.5 mm? -96.19 -38.72 10.02 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.101 179.397 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 294' ' ' ALA . . . . . 0.514 ' HA ' HG22 ' A' ' 264' ' ' VAL . . . -159.69 142.11 13.58 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 121.088 -0.245 . . . . 0.0 111.452 -178.382 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 295' ' ' VAL . . . . . 0.437 HG22 HG22 ' A' ' 300' ' ' VAL . 77.8 t -136.16 112.11 12.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.288 -0.415 . . . . 0.0 109.938 175.436 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 37.4 t -150.03 120.42 7.37 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.337 -179.367 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 58.19 51.11 60.39 Favored Glycine 0 C--N 1.33 0.195 0 C-N-CA 121.086 -0.578 . . . . 0.0 112.386 -179.24 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 298' ' ' THR . . . . . 0.505 ' O ' HG22 ' A' ' 257' ' ' VAL . 73.6 p 48.54 27.85 1.57 Allowed 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 123.536 0.734 . . . . 0.0 112.112 -176.526 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 299' ' ' THR . . . . . 0.57 HG22 ' HB ' ' A' ' 254' ' ' THR . 65.3 m -119.66 115.26 23.58 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 176.706 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . 0.483 ' HA ' ' O ' ' A' ' 294' ' ' ALA . 59.7 t -113.79 130.93 67.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.587 -171.69 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 57.0 m -80.62 116.19 20.52 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 172.266 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 302' ' ' ILE . . . . . 0.6 HD12 ' O ' ' A' ' 302' ' ' ILE . 2.5 pp -111.36 140.79 29.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-O 122.264 1.03 . . . . 0.0 113.715 -171.463 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 303' ' ' SER . . . . . 0.85 ' HB2' HD21 ' A' ' 293' ' ' LEU . 49.4 m -165.02 170.98 5.8 Favored Pre-proline 0 C--N 1.325 -0.493 0 N-CA-C 105.829 -1.915 . . . . 0.0 105.829 -178.913 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 304' ' ' PRO . . . . . 0.643 ' HA ' ' HB3' ' A' ' 303' ' ' SER . 5.1 Cg_exo -74.98 -135.57 0.14 OUTLIER 'Cis proline' 0 C--N 1.351 0.664 0 CA-C-N 121.49 1.568 . . . . 0.0 113.578 0.646 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 305' ' ' LYS . . . . . 0.735 ' HA ' ' CD2' ' A' ' 236' ' ' HIS . 0.0 OUTLIER -90.68 144.41 25.77 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.47 -0.786 . . . . 0.0 112.088 -173.303 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 306' ' ' ILE . . . . . 0.635 ' H ' ' CG ' ' A' ' 236' ' ' HIS . 47.3 mm -116.0 86.93 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 114.824 -1.08 . . . . 0.0 108.611 175.121 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 307' ' ' LEU . . . . . 0.524 HD13 ' CD1' ' A' ' 319' ' ' TYR . 58.7 mt -102.29 101.04 17.28 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.196 -173.599 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 308' ' ' PRO . . . . . 0.703 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 32.3 Cg_exo -65.56 134.07 36.87 Favored 'Trans proline' 0 C--N 1.343 0.253 0 C-N-CA 123.14 2.56 . . . . 0.0 113.76 -173.678 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . 0.561 HG23 ' O ' ' A' ' 322' ' ' VAL . 60.4 t -80.59 -28.56 11.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 169.291 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 -79.38 36.03 0.29 Allowed 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 115.279 -0.873 . . . . 0.0 111.186 176.511 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 22.6 p30 -83.7 -175.34 5.77 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.971 0.415 . . . . 0.0 111.137 -176.678 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 85.6 m -123.38 -28.58 3.93 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.407 177.792 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 57.5 m-20 -74.45 132.93 42.36 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.074 -178.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 43.8 t -62.7 -33.05 57.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.982 179.078 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -70.37 -20.45 62.96 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.749 179.752 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . 0.532 ' HA ' ' CZ ' ' A' ' 319' ' ' TYR . 50.4 m -88.25 -7.02 57.44 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 111.936 0.347 . . . . 0.0 111.936 -176.897 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 317' ' ' ARG . . . . . 0.598 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 38.6 mmt180 -63.67 -51.38 66.36 Favored Pre-proline 0 CA--C 1.539 0.528 0 N-CA-C 112.598 0.592 . . . . 0.0 112.598 -179.005 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 318' ' ' PRO . . . . . 0.598 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 26.8 Cg_exo -68.78 -39.55 8.46 Favored 'Trans proline' 0 C--N 1.356 0.964 0 C-N-CA 121.9 1.733 . . . . 0.0 114.441 -172.055 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 319' ' ' TYR . . . . . 0.532 ' CZ ' ' HA ' ' A' ' 316' ' ' SER . 1.8 p90 -88.47 -6.77 57.43 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 113.004 0.742 . . . . 0.0 113.004 -171.598 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -52.99 135.51 36.72 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 111.634 0.235 . . . . 0.0 111.634 -178.799 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 321' ' ' ASN . . . . . 0.472 ' O ' HG22 ' A' ' 276' ' ' VAL . 14.4 p-10 -132.05 -11.25 3.34 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 116.639 -0.255 . . . . 0.0 111.444 -178.187 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 322' ' ' VAL . . . . . 0.561 ' O ' HG23 ' A' ' 309' ' ' VAL . 33.6 m -131.96 166.52 28.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 N-CA-C 110.488 -0.19 . . . . 0.0 110.488 178.855 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -51.84 -66.35 0.4 Allowed 'General case' 0 N--CA 1.465 0.293 0 CA-C-O 121.252 0.548 . . . . 0.0 111.266 178.372 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 324' ' ' ALA . . . . . 0.703 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -167.24 -179.29 4.46 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.584 -177.09 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 325' ' ' LYS . . . . . 0.434 ' HA ' ' HD3' ' A' ' 326' ' ' PRO . 21.5 pttp -109.65 112.34 58.65 Favored Pre-proline 0 N--CA 1.447 -0.624 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 170.342 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 326' ' ' PRO . . . . . 0.434 ' HD3' ' HA ' ' A' ' 325' ' ' LYS . 25.4 Cg_exo -66.49 168.87 15.32 Favored 'Trans proline' 0 C--O 1.234 0.287 0 C-N-CA 122.704 2.269 . . . . 0.0 112.044 -175.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -58.48 146.29 35.82 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 116.009 -0.541 . . . . 0.0 109.787 176.531 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 328' ' ' GLU . . . . . 0.54 ' HA ' ' NE2' ' A' ' 233' ' ' GLN . 16.0 pt-20 48.01 -145.13 0.34 Allowed 'General case' 0 N--CA 1.474 0.759 0 O-C-N 124.09 0.869 . . . . 0.0 110.995 -173.47 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 329' ' ' SER . . . . . 0.663 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 49.2 m -104.66 -19.38 13.98 Favored 'General case' 0 C--N 1.322 -0.602 0 C-N-CA 120.608 -0.437 . . . . 0.0 110.52 -179.448 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 330' ' ' ALA . . . . . 0.414 ' H ' ' HG3' ' A' ' 328' ' ' GLU . . . 73.79 -167.54 0.11 Allowed 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 113.427 0.899 . . . . 0.0 113.427 171.371 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 331' ' ' ALA . . . . . 0.427 ' HA ' ' O ' ' A' ' 228' ' ' LEU . . . -87.26 144.0 27.01 Favored 'General case' 0 C--O 1.232 0.15 0 CA-C-N 115.153 -0.93 . . . . 0.0 111.611 -175.018 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 332' ' ' ILE . . . . . 0.641 HG12 HG12 ' A' ' 270' ' ' ILE . 50.1 mt -120.7 145.33 27.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.74 -178.861 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 61.3 m -130.98 106.07 8.16 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 110.121 -0.326 . . . . 0.0 110.121 178.396 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 334' ' ' ILE . . . . . 0.76 HD13 ' HB3' ' A' ' 268' ' ' PHE . 49.0 mm -78.85 138.12 20.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.022 -0.536 . . . . 0.0 112.191 -174.109 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 335' ' ' LEU . . . . . 0.441 HD23 ' HA ' ' A' ' 268' ' ' PHE . 1.8 pt? -157.55 135.94 11.18 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.289 -0.869 . . . . 0.0 109.327 173.712 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -85.21 2.69 42.67 Favored 'General case' 0 C--N 1.325 -0.499 0 C-N-CA 120.841 -0.344 . . . . 0.0 111.283 -178.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 337' ' ' LYS . . . . . 0.481 ' C ' ' HD3' ' A' ' 337' ' ' LYS . 9.8 tmtt? . . . . . 0 C--O 1.245 0.862 0 CA-C-O 118.056 -0.973 . . . . 0.0 108.381 177.673 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 49.6 m . . . . . 0 C--O 1.231 0.083 0 CA-C-O 120.638 0.256 . . . . 0.0 111.333 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 228' ' ' LEU . . . . . 0.431 HD13 ' HB1' ' A' ' 259' ' ' ALA . 81.9 mt -102.35 142.8 32.98 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.292 -178.182 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 229' ' ' THR . . . . . 0.42 ' OG1' ' HB2' ' A' ' 258' ' ' SER . 35.4 p -120.63 171.37 8.62 Favored 'General case' 0 C--N 1.325 -0.467 0 C-N-CA 119.866 -0.733 . . . . 0.0 110.589 177.372 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 230' ' ' VAL . . . . . 0.518 ' HA ' ' H ' ' A' ' 258' ' ' SER . 72.4 t -146.69 130.62 10.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 120.916 0.389 . . . . 0.0 110.376 -179.597 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 231' ' ' SER . . . . . 0.508 ' O ' ' HB ' ' A' ' 255' ' ' ILE . 37.4 m -96.02 164.32 12.75 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.821 177.481 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 101.41 142.02 12.38 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.2 -1.0 . . . . 0.0 111.961 -179.283 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 233' ' ' GLN . . . . . 0.425 ' HA ' ' HD2' ' A' ' 234' ' ' PRO . 64.0 mt-30 -100.02 107.81 48.76 Favored Pre-proline 0 C--N 1.322 -0.606 0 O-C-N 123.073 -0.075 . . . . 0.0 111.03 -176.461 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 234' ' ' PRO . . . . . 0.57 ' HB2' HG13 ' A' ' 306' ' ' ILE . 29.0 Cg_endo -61.56 127.62 22.29 Favored 'Trans proline' 0 C--N 1.348 0.511 0 C-N-CA 122.173 1.916 . . . . 0.0 110.718 176.174 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 235' ' ' GLU . . . . . 0.585 ' OE1' ' HE2' ' A' ' 237' ' ' LYS . 0.3 OUTLIER -116.79 -178.34 3.41 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 113.418 0.896 . . . . 0.0 113.418 -170.995 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 55.4 t60 -167.5 135.61 2.47 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 114.632 -1.167 . . . . 0.0 110.915 -173.803 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 237' ' ' LYS . . . . . 0.585 ' HE2' ' OE1' ' A' ' 235' ' ' GLU . 0.0 OUTLIER . . . . . 0 C--N 1.323 -0.571 0 CA-C-N 114.979 -1.009 . . . . 0.0 111.762 173.072 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 252' ' ' GLN . . . . . 0.476 ' HA ' HE21 ' A' ' 252' ' ' GLN . 2.8 mm100 . . . . . 0 N--CA 1.451 -0.378 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -85.41 138.5 16.5 Favored Glycine 0 N--CA 1.447 -0.579 0 C-N-CA 120.327 -0.94 . . . . 0.0 112.338 -179.144 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 66.9 p -121.89 116.51 24.53 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 176.728 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.638 HD13 ' H ' ' A' ' 255' ' ' ILE . 0.2 OUTLIER -129.69 158.95 42.18 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 121.038 0.447 . . . . 0.0 111.399 -176.493 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 18.5 m -96.82 116.64 29.5 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 177.681 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.554 HG21 HD12 ' A' ' 262' ' ' LEU . 32.8 m -88.82 143.3 11.46 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.739 0 C-N-CA 119.709 -0.796 . . . . 0.0 112.349 -170.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 258' ' ' SER . . . . . 0.518 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 25.1 m -92.79 9.44 35.17 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 114.341 -1.3 . . . . 0.0 109.33 172.809 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 259' ' ' ALA . . . . . 0.431 ' HB1' HD13 ' A' ' 228' ' ' LEU . . . -83.05 179.9 7.62 Favored 'General case' 0 N--CA 1.452 -0.338 0 CA-C-N 115.417 -0.811 . . . . 0.0 108.942 179.659 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 22.9 t -140.98 127.34 19.82 Favored 'General case' 0 C--N 1.32 -0.693 0 C-N-CA 120.23 -0.588 . . . . 0.0 111.348 -177.484 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 78.8 50.9 5.72 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.891 -0.671 . . . . 0.0 113.276 176.207 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 262' ' ' LEU . . . . . 0.554 HD12 HG21 ' A' ' 257' ' ' VAL . 64.8 mt -95.1 160.13 14.7 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 117.147 0.474 . . . . 0.0 110.559 178.08 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 66.0 mt-30 -142.9 165.23 27.93 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 -179.311 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 27.1 t -79.58 124.14 37.38 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 C-N-CA 120.409 -0.516 . . . . 0.0 109.701 175.531 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . 0.609 ' H ' ' HB ' ' A' ' 292' ' ' VAL . . . 116.0 14.39 7.88 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.316 -0.945 . . . . 0.0 112.835 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 57.1 m-20 -90.51 165.83 13.56 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.186 0.517 . . . . 0.0 111.044 176.346 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 267' ' ' ALA . . . . . 0.585 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -130.59 143.92 51.07 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 175.094 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 268' ' ' PHE . . . . . 0.504 ' HB3' HD13 ' A' ' 334' ' ' ILE . 7.8 p90 -159.5 168.71 25.53 Favored 'General case' 0 C--N 1.323 -0.582 0 C-N-CA 118.958 -1.097 . . . . 0.0 112.644 -173.547 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 269' ' ' THR . . . . . 0.554 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 43.7 p -116.72 144.08 44.87 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.063 -0.971 . . . . 0.0 109.704 175.683 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 270' ' ' ILE . . . . . 0.994 HG12 HG13 ' A' ' 332' ' ' ILE . 57.2 mt -112.0 127.91 68.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 116.563 -0.29 . . . . 0.0 110.469 -178.73 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -65.15 120.04 11.96 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.077 0.465 . . . . 0.0 111.227 -179.478 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 102.7 -23.93 32.37 Favored Glycine 0 N--CA 1.452 -0.28 0 CA-C-N 115.887 -0.597 . . . . 0.0 112.315 179.278 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 39.0 t -96.34 102.48 13.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 174.574 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 274' ' ' ASN . . . . . 0.739 ' HB2' ' HB2' ' A' ' 323' ' ' ASP . 4.2 m120 -91.99 169.63 10.5 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.275 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 8.3 t -109.74 162.48 14.42 Favored 'General case' 0 CA--C 1.507 -0.704 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 178.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 276' ' ' VAL . . . . . 0.405 HG22 ' C ' ' A' ' 321' ' ' ASN . 13.0 m -122.52 178.84 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.067 0 CA-C-N 115.24 -0.891 . . . . 0.0 109.372 166.402 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 22.3 m80 -100.5 133.21 45.27 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 178.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 2.3 mp0 -72.29 -10.22 59.5 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.79 0.329 . . . . 0.0 111.401 -178.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 279' ' ' ILE . . . . . 0.493 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.0 mp -102.43 -57.48 4.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 120.729 0.3 . . . . 0.0 110.946 -178.312 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 60.9 p -101.13 -6.21 24.63 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 112.663 0.616 . . . . 0.0 112.663 -174.226 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 13.9 mmmm 57.54 29.35 16.98 Favored 'General case' 0 N--CA 1.47 0.574 0 N-CA-C 111.591 0.219 . . . . 0.0 111.591 -178.499 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -77.78 139.61 39.36 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.265 -176.489 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 70.3 p -108.2 118.8 37.71 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.862 -0.608 . . . . 0.0 109.806 179.486 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 72.0 p -115.2 -14.36 11.73 Favored 'General case' 0 C--N 1.315 -0.894 0 C-N-CA 120.67 -0.412 . . . . 0.0 111.798 -172.408 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 88.17 5.13 76.94 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.521 -0.847 . . . . 0.0 112.388 179.709 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 286' ' ' GLN . . . . . 0.461 ' HA ' ' HD3' ' A' ' 287' ' ' PRO . 71.0 mt-30 -92.18 138.53 24.37 Favored Pre-proline 0 C--N 1.327 -0.382 0 N-CA-C 110.23 -0.285 . . . . 0.0 110.23 178.677 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 287' ' ' PRO . . . . . 0.635 ' HA ' ' HA ' ' A' ' 274' ' ' ASN . 21.7 Cg_exo -65.58 152.7 81.01 Favored 'Trans proline' 0 C--O 1.233 0.236 0 C-N-CA 122.615 2.21 . . . . 0.0 112.445 -179.031 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 3.9 tp-100 -81.54 150.72 28.08 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.542 177.626 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 62.1 t -94.86 125.04 47.58 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.401 0 CA-C-N 116.096 -0.502 . . . . 0.0 109.657 176.441 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 290' ' ' PHE . . . . . 0.759 ' HD1' ' HD2' ' A' ' 304' ' ' PRO . 69.9 m-85 -106.58 168.42 9.18 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.085 -174.072 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 27.1 tpt180 -132.8 120.89 22.18 Favored 'General case' 0 N--CA 1.448 -0.539 0 CA-C-O 121.222 0.534 . . . . 0.0 109.573 179.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . 0.609 ' HB ' ' H ' ' A' ' 265' ' ' GLY . 57.7 t -65.99 132.42 31.56 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.919 -177.037 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 293' ' ' LEU . . . . . 0.77 HD11 ' HB2' ' A' ' 303' ' ' SER . 88.5 mt -101.42 -44.55 5.59 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.475 178.332 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 294' ' ' ALA . . . . . 0.452 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -150.05 139.11 21.1 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.592 0.234 . . . . 0.0 111.334 -175.123 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 62.0 t -134.11 117.75 26.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.126 176.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 60.6 m -157.01 120.14 4.09 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.471 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 62.32 40.37 98.94 Favored Glycine 0 C--N 1.331 0.305 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.003 -177.539 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 82.1 p 53.35 20.78 2.07 Favored 'General case' 0 N--CA 1.469 0.519 0 C-N-CA 123.939 0.896 . . . . 0.0 112.27 -174.721 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 60.3 m -103.18 107.7 18.62 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 174.493 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . 0.452 ' HA ' ' O ' ' A' ' 294' ' ' ALA . 47.2 t -104.09 128.03 57.81 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.36 -173.247 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 42.0 m -90.48 117.36 29.12 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 172.559 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 302' ' ' ILE . . . . . . . . . . . . . 29.1 pt -110.74 140.74 28.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 N-CA-C 112.83 0.678 . . . . 0.0 112.83 -169.269 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 303' ' ' SER . . . . . 0.77 ' HB2' HD11 ' A' ' 293' ' ' LEU . 48.2 t -130.35 151.39 78.45 Favored Pre-proline 0 C--N 1.323 -0.55 0 CA-C-N 114.104 -1.407 . . . . 0.0 107.207 172.715 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 304' ' ' PRO . . . . . 0.759 ' HD2' ' HD1' ' A' ' 290' ' ' PHE . 34.3 Cg_exo -63.04 179.14 8.44 Favored 'Cis proline' 0 N--CA 1.473 0.308 0 CA-C-N 120.163 1.094 . . . . 0.0 113.09 0.781 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 305' ' ' LYS . . . . . 0.671 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -87.86 148.74 24.5 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.24 177.643 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 306' ' ' ILE . . . . . 0.57 HG13 ' HB2' ' A' ' 234' ' ' PRO . 43.7 mm -65.75 98.66 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.663 -175.075 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 307' ' ' LEU . . . . . 0.721 HD12 HD22 ' A' ' 321' ' ' ASN . 72.6 mt -119.25 95.57 49.39 Favored Pre-proline 0 C--N 1.325 -0.498 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 -179.506 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 308' ' ' PRO . . . . . 0.723 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 6.2 Cg_exo -77.67 169.6 20.58 Favored 'Trans proline' 0 N--CA 1.463 -0.32 0 C-N-CA 123.121 2.547 . . . . 0.0 112.635 -176.8 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . 0.534 HG22 ' HB1' ' A' ' 320' ' ' ALA . 39.2 t -93.56 -30.72 4.41 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-O 121.251 0.548 . . . . 0.0 109.683 177.343 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 42.5 mp0 -86.64 35.68 0.68 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.133 -0.94 . . . . 0.0 112.254 -173.833 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 79.1 m-20 -74.33 158.81 33.33 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.301 0.572 . . . . 0.0 111.845 -178.644 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 28.9 m -90.44 -36.63 14.46 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.129 -0.941 . . . . 0.0 110.22 179.266 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 313' ' ' ASP . . . . . 0.455 ' HB2' ' HB3' ' A' ' 316' ' ' SER . 1.6 m-20 -67.98 133.31 48.86 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.32 179.406 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 39.3 t -60.45 -52.23 63.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.172 -177.768 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -68.46 -17.82 64.28 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.852 -178.234 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . 0.455 ' HB3' ' HB2' ' A' ' 313' ' ' ASP . 39.1 t -84.07 -11.02 57.36 Favored 'General case' 0 C--N 1.323 -0.546 0 C-N-CA 120.973 -0.291 . . . . 0.0 111.357 -178.376 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 317' ' ' ARG . . . . . 0.534 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 81.0 mtm180 -73.65 -49.2 6.46 Favored Pre-proline 0 CA--C 1.536 0.432 0 N-CA-C 112.506 0.558 . . . . 0.0 112.506 -179.082 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 318' ' ' PRO . . . . . 0.534 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 42.3 Cg_exo -61.07 -25.87 81.99 Favored 'Trans proline' 0 C--N 1.361 1.197 0 C-N-CA 122.17 1.914 . . . . 0.0 113.218 -176.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 46.6 m-85 -91.41 27.67 1.9 Allowed 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.473 -0.331 . . . . 0.0 111.313 -177.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . 0.534 ' HB1' HG22 ' A' ' 309' ' ' VAL . . . -77.72 127.55 32.61 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.073 179.297 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 321' ' ' ASN . . . . . 0.721 HD22 HD12 ' A' ' 307' ' ' LEU . 75.5 m-80 -130.47 -9.24 4.13 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 111.859 0.318 . . . . 0.0 111.859 179.216 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 322' ' ' VAL . . . . . 0.508 ' O ' ' HA ' ' A' ' 308' ' ' PRO . 33.1 m -138.5 156.93 30.18 Favored 'Isoleucine or valine' 0 C--O 1.233 0.215 0 CA-C-O 120.944 0.402 . . . . 0.0 111.094 177.691 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 323' ' ' ASP . . . . . 0.739 ' HB2' ' HB2' ' A' ' 274' ' ' ASN . 2.1 m-20 -86.66 86.84 7.35 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.417 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 324' ' ' ALA . . . . . 0.723 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . 77.06 151.0 0.12 Allowed 'General case' 0 N--CA 1.473 0.685 0 CA-C-N 114.66 -1.154 . . . . 0.0 113.791 171.502 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 325' ' ' LYS . . . . . 0.436 ' HA ' ' HD3' ' A' ' 326' ' ' PRO . 55.5 pttt -98.71 105.95 33.88 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 114.435 -1.257 . . . . 0.0 109.287 168.525 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 326' ' ' PRO . . . . . 0.436 ' HD3' ' HA ' ' A' ' 325' ' ' LYS . 5.8 Cg_exo -85.99 169.27 8.99 Favored 'Trans proline' 0 C--O 1.235 0.367 0 C-N-CA 123.483 2.788 . . . . 0.0 113.195 -171.837 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -59.52 127.51 32.41 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.626 177.633 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 24.5 pt-20 44.65 -158.07 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.66 0 O-C-N 124.402 1.064 . . . . 0.0 112.034 -176.363 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 329' ' ' SER . . . . . 0.424 ' O ' ' HB3' ' A' ' 330' ' ' ALA . 54.6 m -102.9 -31.16 10.39 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 112.204 0.446 . . . . 0.0 112.204 -173.643 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 330' ' ' ALA . . . . . 0.424 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 71.95 -152.25 0.08 Allowed 'General case' 0 N--CA 1.471 0.59 0 CA-C-O 121.037 0.446 . . . . 0.0 111.534 178.359 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -85.47 116.34 23.73 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.248 -178.85 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 332' ' ' ILE . . . . . 0.994 HG13 HG12 ' A' ' 270' ' ' ILE . 1.7 mp -101.84 140.85 19.38 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 115.826 -0.624 . . . . 0.0 109.537 176.293 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 73.4 m -110.11 103.32 12.03 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 110.206 -0.294 . . . . 0.0 110.206 -176.624 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 334' ' ' ILE . . . . . 0.504 HD13 ' HB3' ' A' ' 268' ' ' PHE . 34.6 mm -85.89 125.87 40.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 N-CA-C 112.588 0.588 . . . . 0.0 112.588 -174.155 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 335' ' ' LEU . . . . . 0.485 ' N ' HD13 ' A' ' 335' ' ' LEU . 0.0 OUTLIER -139.41 172.43 12.82 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.3 -0.864 . . . . 0.0 109.804 171.259 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 50.9 t30 -136.87 59.11 1.7 Allowed 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 178.552 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 337' ' ' LYS . . . . . 0.431 ' H ' HD23 ' A' ' 335' ' ' LEU . 62.3 tttp . . . . . 0 C--O 1.244 0.768 0 CA-C-O 118.173 -0.918 . . . . 0.0 110.457 -176.106 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 68.3 m . . . . . 0 C--O 1.235 0.299 0 CA-C-O 121.254 0.55 . . . . 0.0 110.854 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 228' ' ' LEU . . . . . 0.738 ' O ' ' HA ' ' A' ' 331' ' ' ALA . 5.3 mp -67.91 119.32 12.39 Favored 'General case' 0 N--CA 1.433 -1.316 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.821 179.463 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 229' ' ' THR . . . . . 0.456 ' OG1' ' HB3' ' A' ' 258' ' ' SER . 22.3 p -128.08 178.68 6.04 Favored 'General case' 0 C--N 1.324 -0.533 0 C-N-CA 120.513 -0.475 . . . . 0.0 111.07 178.644 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 230' ' ' VAL . . . . . 0.965 HG23 HD11 ' A' ' 332' ' ' ILE . 98.3 t -144.82 130.72 14.64 Favored 'Isoleucine or valine' 0 C--O 1.235 0.303 0 CA-C-O 120.578 0.228 . . . . 0.0 111.078 -177.218 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 38.9 t -101.1 112.28 24.71 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.538 -0.755 . . . . 0.0 109.484 172.438 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . 0.854 ' H ' ' HG3' ' A' ' 328' ' ' GLU . . . 141.69 125.51 2.08 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.788 -0.72 . . . . 0.0 111.71 -176.319 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 233' ' ' GLN . . . . . 0.824 ' HG2' ' H ' ' A' ' 328' ' ' GLU . 21.8 mt-30 -83.5 123.33 76.75 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-N 116.49 0.145 . . . . 0.0 111.063 -177.12 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -92.71 126.26 0.71 Allowed 'Trans proline' 0 N--CA 1.451 -0.986 0 C-N-CA 122.643 2.228 . . . . 0.0 111.978 177.517 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 235' ' ' GLU . . . . . 0.418 ' HG2' ' HE3' ' A' ' 237' ' ' LYS . 0.7 OUTLIER -157.0 158.36 36.4 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.865 0.364 . . . . 0.0 110.748 177.569 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 236' ' ' HIS . . . . . 0.431 ' CG ' ' H ' ' A' ' 306' ' ' ILE . 25.5 m80 -136.07 146.19 46.78 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.322 0.582 . . . . 0.0 111.85 177.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 237' ' ' LYS . . . . . 0.636 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.325 -0.48 0 N-CA-C 107.664 -1.235 . . . . 0.0 107.664 178.149 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 252' ' ' GLN . . . . . 0.455 ' HA ' HE21 ' A' ' 252' ' ' GLN . 2.7 mm100 . . . . . 0 N--CA 1.453 -0.286 0 N-CA-C 110.219 -0.289 . . . . 0.0 110.219 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . 0.464 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -87.65 121.07 5.74 Favored Glycine 0 N--CA 1.447 -0.616 0 C-N-CA 120.4 -0.905 . . . . 0.0 111.88 179.269 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 52.3 p -105.1 117.35 33.79 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 178.33 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 2.1 pp -131.46 165.13 32.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -175.121 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 32.6 m -102.53 113.95 27.74 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 179.2 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.622 HG12 HG22 ' A' ' 230' ' ' VAL . 30.6 m -90.61 143.89 10.27 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.718 0 CA-C-O 121.48 0.657 . . . . 0.0 112.589 -174.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 258' ' ' SER . . . . . 0.456 ' HB3' ' OG1' ' A' ' 229' ' ' THR . 25.8 t -92.06 7.31 42.91 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 113.911 -1.495 . . . . 0.0 108.146 167.514 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 259' ' ' ALA . . . . . 0.443 ' H ' ' HB ' ' A' ' 257' ' ' VAL . . . -86.48 172.57 10.24 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 115.128 -0.942 . . . . 0.0 109.713 -178.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 50.2 m -145.65 148.63 33.28 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.833 0.349 . . . . 0.0 111.043 -179.328 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 81.14 15.9 75.81 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.992 -0.623 . . . . 0.0 113.184 178.236 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 262' ' ' LEU . . . . . 0.406 HD12 HG21 ' A' ' 257' ' ' VAL . 70.7 mt -76.31 145.73 39.36 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.971 0.385 . . . . 0.0 110.351 179.234 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 85.0 mt-30 -140.8 164.75 29.39 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.092 -0.504 . . . . 0.0 109.911 -179.126 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 45.7 t -76.24 122.87 31.34 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.257 177.489 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 113.43 -3.07 25.02 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.44 -0.886 . . . . 0.0 112.795 179.085 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 266' ' ' ASP . . . . . 0.479 ' HA ' ' OD1' ' A' ' 336' ' ' ASN . 58.6 m-20 -81.58 151.76 27.53 Favored 'General case' 0 CA--C 1.513 -0.475 0 CA-C-O 120.82 0.343 . . . . 0.0 110.296 177.074 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 267' ' ' ALA . . . . . 0.606 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -114.47 149.35 36.46 Favored 'General case' 0 N--CA 1.443 -0.806 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 173.792 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 268' ' ' PHE . . . . . 0.687 ' HB3' HD13 ' A' ' 334' ' ' ILE . 4.1 p90 -163.95 172.36 14.03 Favored 'General case' 0 C--N 1.318 -0.782 0 C-N-CA 119.632 -0.827 . . . . 0.0 111.699 -177.13 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 74.9 p -118.12 127.36 53.7 Favored 'General case' 0 N--CA 1.443 -0.801 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.337 177.688 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 270' ' ' ILE . . . . . 0.533 HG23 ' O ' ' A' ' 329' ' ' SER . 25.8 mm -95.23 129.92 44.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 CA-C-N 115.3 -0.863 . . . . 0.0 110.454 -178.27 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 271' ' ' ALA . . . . . 0.596 ' HB3' ' HB3' ' A' ' 330' ' ' ALA . . . -66.47 129.57 40.3 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 121.007 0.432 . . . . 0.0 111.133 -178.518 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 92.98 -22.87 31.94 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 121.032 -0.604 . . . . 0.0 112.065 -178.036 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . 0.498 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 45.8 t -101.14 117.79 46.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 121.195 0.521 . . . . 0.0 110.294 176.491 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -130.67 142.19 50.43 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.701 -178.556 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 4.8 t -81.87 172.45 13.3 Favored 'General case' 0 CA--C 1.512 -0.518 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 -177.047 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 29.9 m -130.5 178.43 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.835 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.713 173.29 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 86.2 m-70 -109.68 86.39 2.29 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 173.715 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 278' ' ' GLN . . . . . 0.424 ' HB3' ' O ' ' A' ' 320' ' ' ALA . 23.7 pt20 -72.35 -14.85 61.83 Favored 'General case' 0 N--CA 1.464 0.261 0 N-CA-C 111.964 0.357 . . . . 0.0 111.964 -173.45 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 279' ' ' ILE . . . . . 0.538 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.4 mp -73.15 -52.11 23.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 121.126 0.489 . . . . 0.0 110.038 -179.538 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 42.9 p -97.95 -3.14 38.98 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.505 -178.799 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 64.85 54.57 1.31 Allowed 'General case' 0 N--CA 1.466 0.35 0 CA-C-O 121.547 0.689 . . . . 0.0 110.012 178.466 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 58.9 m-20 -115.43 130.78 57.0 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.033 0.444 . . . . 0.0 110.817 177.824 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 65.7 p -106.32 117.8 34.97 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.246 176.906 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 70.4 p -123.44 -23.19 4.87 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.809 -171.602 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 75.19 31.73 56.97 Favored Glycine 0 N--CA 1.453 -0.186 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.817 177.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 3.0 mm100 -89.77 131.27 40.11 Favored Pre-proline 0 C--N 1.327 -0.375 0 N-CA-C 110.359 -0.237 . . . . 0.0 110.359 179.7 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 287' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_exo -50.21 128.22 22.05 Favored 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 122.78 2.32 . . . . 0.0 112.546 -178.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 50.1 tt0 -74.56 148.03 41.22 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.668 -176.381 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 52.7 t -94.48 117.97 39.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.459 -0.791 . . . . 0.0 109.639 175.384 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 290' ' ' PHE . . . . . 0.744 ' HA ' ' HD3' ' A' ' 304' ' ' PRO . 5.0 m-85 -99.06 170.13 8.92 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.014 0.435 . . . . 0.0 111.604 -175.799 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 21.1 tpp180 -140.03 123.74 17.33 Favored 'General case' 0 N--CA 1.446 -0.668 0 CA-C-N 115.533 -0.758 . . . . 0.0 109.358 177.011 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 44.0 t -81.42 136.62 22.74 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.591 -176.211 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 293' ' ' LEU . . . . . 0.465 HD22 ' N ' ' A' ' 293' ' ' LEU . 2.2 mm? -108.0 -30.51 8.41 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.164 178.299 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 294' ' ' ALA . . . . . . . . . . . . . . . -156.12 136.92 13.43 Favored 'General case' 0 C--N 1.331 -0.201 0 C-N-CA 121.06 -0.256 . . . . 0.0 111.603 -177.508 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 60.6 t -132.49 117.86 33.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.034 -0.53 . . . . 0.0 109.641 175.063 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 34.9 t -157.52 119.52 3.75 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.519 -177.404 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 58.85 44.24 96.11 Favored Glycine 0 C--N 1.333 0.383 0 C-N-CA 121.163 -0.541 . . . . 0.0 112.318 -179.029 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 51.4 p 50.51 24.06 1.49 Allowed 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 123.703 0.801 . . . . 0.0 112.583 -175.343 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 41.0 m -111.12 112.78 24.82 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 108.388 -0.968 . . . . 0.0 108.388 173.61 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 39.0 t -111.91 132.29 60.93 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.731 -169.216 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 88.0 m -91.92 109.35 20.69 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 172.554 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 302' ' ' ILE . . . . . 0.464 HG12 ' O ' ' A' ' 253' ' ' GLY . 29.1 pt -111.33 150.87 13.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 N-CA-C 113.099 0.777 . . . . 0.0 113.099 -170.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 303' ' ' SER . . . . . 0.543 ' HB2' ' HA ' ' A' ' 304' ' ' PRO . 85.8 p -135.06 166.39 29.51 Favored Pre-proline 0 C--N 1.322 -0.597 0 N-CA-C 106.52 -1.659 . . . . 0.0 106.52 170.063 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 304' ' ' PRO . . . . . 0.744 ' HD3' ' HA ' ' A' ' 290' ' ' PHE . 14.7 Cg_exo -70.45 -167.58 4.14 Favored 'Cis proline' 0 CA--C 1.53 0.28 0 CA-C-N 120.75 1.303 . . . . 0.0 113.282 0.57 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 305' ' ' LYS . . . . . 0.607 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -81.31 162.84 23.3 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.736 179.803 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 306' ' ' ILE . . . . . 0.445 HG23 HG21 ' A' ' 322' ' ' VAL . 43.5 mm -111.55 84.3 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-O 120.831 0.348 . . . . 0.0 110.525 -177.373 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 307' ' ' LEU . . . . . . . . . . . . . 85.0 mt -108.35 103.49 50.91 Favored Pre-proline 0 C--N 1.327 -0.371 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.434 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 308' ' ' PRO . . . . . 0.807 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 13.5 Cg_exo -76.94 156.09 34.36 Favored 'Trans proline' 0 N--CA 1.465 -0.184 0 C-N-CA 122.611 2.207 . . . . 0.0 113.848 -171.472 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 46.7 t -78.89 -16.22 13.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 N-CA-C 108.18 -1.044 . . . . 0.0 108.18 168.069 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 67.0 mm-40 -83.61 7.05 18.54 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 114.805 -1.088 . . . . 0.0 110.885 175.033 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -68.74 128.24 35.94 Favored 'General case' 0 C--O 1.233 0.232 0 CA-C-O 120.764 0.316 . . . . 0.0 110.167 -176.59 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 61.7 m -75.89 -34.3 59.97 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.562 -175.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 313' ' ' ASP . . . . . 0.598 ' O ' ' HG3' ' A' ' 317' ' ' ARG . 28.0 t70 -68.85 114.32 7.06 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.976 0.417 . . . . 0.0 110.491 177.584 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 314' ' ' VAL . . . . . 0.667 ' HA ' ' HD3' ' A' ' 317' ' ' ARG . 41.5 t -63.86 -20.23 26.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.634 -0.712 . . . . 0.0 111.652 -175.836 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -75.09 -34.13 61.71 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.545 0.212 . . . . 0.0 111.468 178.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . 0.419 ' HA ' ' CE1' ' A' ' 319' ' ' TYR . 34.2 t -89.4 -6.78 56.27 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.619 0.247 . . . . 0.0 111.359 -177.158 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 317' ' ' ARG . . . . . 0.667 ' HD3' ' HA ' ' A' ' 314' ' ' VAL . 56.8 mtp85 -69.68 -47.03 25.35 Favored Pre-proline 0 CA--C 1.541 0.609 0 N-CA-C 113.302 0.852 . . . . 0.0 113.302 -179.495 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 318' ' ' PRO . . . . . 0.454 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 87.2 Cg_exo -52.2 -38.49 71.67 Favored 'Trans proline' 0 C--N 1.361 1.224 0 C-N-CA 122.444 2.096 . . . . 0.0 113.796 -174.536 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 319' ' ' TYR . . . . . 0.419 ' CE1' ' HA ' ' A' ' 316' ' ' SER . 1.5 p90 -109.17 39.13 2.12 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 112.077 0.399 . . . . 0.0 112.077 -178.35 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . 0.424 ' O ' ' HB3' ' A' ' 278' ' ' GLN . . . -71.99 135.66 46.48 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.896 174.219 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 16.0 p-10 -119.01 -2.41 10.8 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 120.82 -0.352 . . . . 0.0 111.485 -176.703 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 322' ' ' VAL . . . . . 0.445 HG21 HG23 ' A' ' 306' ' ' ILE . 30.8 m -135.11 163.17 36.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 N-CA-C 110.34 -0.244 . . . . 0.0 110.34 175.112 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 56.7 m-20 -72.37 -38.18 68.6 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 111.657 0.243 . . . . 0.0 111.657 -178.677 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 324' ' ' ALA . . . . . 0.807 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -159.84 162.29 34.67 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.694 -171.867 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 325' ' ' LYS . . . . . 0.465 ' HA ' ' HD3' ' A' ' 326' ' ' PRO . 54.2 pttt -105.21 106.41 55.64 Favored Pre-proline 0 C--N 1.324 -0.501 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.279 169.424 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 326' ' ' PRO . . . . . 0.465 ' HD3' ' HA ' ' A' ' 325' ' ' LYS . 5.9 Cg_exo -86.49 166.83 9.03 Favored 'Trans proline' 0 C--O 1.233 0.256 0 C-N-CA 122.946 2.431 . . . . 0.0 113.566 -170.4 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 327' ' ' ALA . . . . . 0.513 ' HA ' ' HG2' ' A' ' 233' ' ' GLN . . . -81.69 122.02 27.11 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.235 -0.893 . . . . 0.0 109.444 172.032 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 328' ' ' GLU . . . . . 0.854 ' HG3' ' H ' ' A' ' 232' ' ' GLY . 53.6 mp0 60.48 175.42 0.1 Allowed 'General case' 0 N--CA 1.465 0.323 0 O-C-N 123.608 0.568 . . . . 0.0 111.084 -173.666 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 329' ' ' SER . . . . . 0.738 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 37.7 m -106.47 -15.46 14.8 Favored 'General case' 0 C--N 1.324 -0.532 0 C-N-CA 120.33 -0.548 . . . . 0.0 111.085 -177.347 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 330' ' ' ALA . . . . . 0.596 ' HB3' ' HB3' ' A' ' 271' ' ' ALA . . . 62.95 -152.8 0.34 Allowed 'General case' 0 N--CA 1.465 0.312 0 CA-C-O 120.852 0.358 . . . . 0.0 111.857 175.094 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 331' ' ' ALA . . . . . 0.738 ' HA ' ' O ' ' A' ' 228' ' ' LEU . . . -68.5 139.78 55.67 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.56 -0.745 . . . . 0.0 112.203 -175.153 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 332' ' ' ILE . . . . . 0.965 HD11 HG23 ' A' ' 230' ' ' VAL . 2.2 mp -111.7 144.59 19.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.279 179.379 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 84.8 m -121.07 105.71 10.88 Favored 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 175.522 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 334' ' ' ILE . . . . . 0.687 HD13 ' HB3' ' A' ' 268' ' ' PHE . 39.8 mm -79.95 127.73 39.07 Favored 'Isoleucine or valine' 0 C--O 1.235 0.3 0 N-CA-C 112.432 0.53 . . . . 0.0 112.432 -175.831 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 335' ' ' LEU . . . . . 0.562 HD23 ' HA ' ' A' ' 268' ' ' PHE . 1.8 pt? -148.91 132.46 16.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.58 174.036 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 336' ' ' ASN . . . . . 0.479 ' OD1' ' HA ' ' A' ' 266' ' ' ASP . 72.3 m-80 -109.0 77.38 1.06 Allowed 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.386 176.454 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 22.0 pttp . . . . . 0 C--O 1.243 0.743 0 O-C-N 124.589 1.18 . . . . 0.0 112.179 -179.078 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 39.6 t . . . . . 0 C--O 1.232 0.173 0 CA-C-O 121.133 0.492 . . . . 0.0 110.565 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 228' ' ' LEU . . . . . 0.602 ' HB3' ' CB ' ' A' ' 259' ' ' ALA . 80.9 mt -82.26 138.95 34.48 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.884 178.61 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 229' ' ' THR . . . . . 0.412 HG22 ' HA ' ' A' ' 331' ' ' ALA . 70.8 p -126.63 178.25 6.02 Favored 'General case' 0 C--N 1.325 -0.478 0 C-N-CA 120.104 -0.638 . . . . 0.0 110.752 -179.043 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 230' ' ' VAL . . . . . 0.56 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 84.1 t -143.42 150.21 17.64 Favored 'Isoleucine or valine' 0 C--O 1.239 0.544 0 N-CA-C 110.356 -0.239 . . . . 0.0 110.356 -178.574 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 33.1 t -126.08 129.1 48.44 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.298 178.597 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 110.2 109.95 3.23 Favored Glycine 0 C--O 1.228 -0.277 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.852 178.258 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 233' ' ' GLN . . . . . 0.58 ' HG3' ' O ' ' A' ' 326' ' ' PRO . 14.3 mm-40 -111.43 101.41 50.66 Favored Pre-proline 0 C--N 1.324 -0.505 0 O-C-N 122.807 -0.231 . . . . 0.0 111.135 178.989 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 234' ' ' PRO . . . . . 0.478 ' O ' ' HE2' ' A' ' 325' ' ' LYS . 7.0 Cg_exo -70.25 126.13 12.64 Favored 'Trans proline' 0 N--CA 1.459 -0.513 0 C-N-CA 122.247 1.964 . . . . 0.0 110.855 176.202 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 235' ' ' GLU . . . . . 0.408 ' HA ' ' CD ' ' A' ' 325' ' ' LYS . 13.0 pt-20 -97.41 124.42 41.59 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 121.634 0.731 . . . . 0.0 111.502 -177.639 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 26.1 m80 -122.2 147.51 46.09 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.49 179.745 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 237' ' ' LYS . . . . . 0.455 ' H ' ' HD2' ' A' ' 237' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.317 -0.837 0 CA-C-N 115.137 -0.938 . . . . 0.0 109.214 -178.912 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 252' ' ' GLN . . . . . 0.481 ' HA ' HE21 ' A' ' 252' ' ' GLN . 3.0 mm100 . . . . . 0 N--CA 1.451 -0.421 0 CA-C-O 120.515 0.198 . . . . 0.0 110.561 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -106.23 138.52 14.4 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.186 -1.007 . . . . 0.0 112.942 -176.166 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 254' ' ' THR . . . . . 0.493 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 75.6 p -111.0 117.98 34.81 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 176.595 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.695 HD13 ' H ' ' A' ' 255' ' ' ILE . 0.2 OUTLIER -123.09 163.91 21.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 120.733 0.302 . . . . 0.0 111.269 -176.058 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 85.7 m -100.93 112.61 25.09 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 172.327 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.611 HG21 HD12 ' A' ' 262' ' ' LEU . 35.2 m -90.01 144.97 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.783 0 CA-C-O 121.663 0.744 . . . . 0.0 112.663 -169.764 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 258' ' ' SER . . . . . 0.511 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 23.2 m -90.31 7.7 37.1 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 114.376 -1.284 . . . . 0.0 108.637 171.283 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 259' ' ' ALA . . . . . 0.602 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -96.19 159.53 14.91 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-N 114.89 -1.05 . . . . 0.0 110.162 -177.509 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . 0.476 ' H ' HD22 ' A' ' 228' ' ' LEU . 45.8 p -127.97 154.14 45.93 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.362 -179.129 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 73.83 20.25 79.75 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 121.113 -0.565 . . . . 0.0 113.377 178.117 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 262' ' ' LEU . . . . . 0.611 HD12 HG21 ' A' ' 257' ' ' VAL . 77.5 mt -78.32 142.82 37.47 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 117.11 0.455 . . . . 0.0 110.606 179.347 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 81.6 mt-30 -141.3 174.5 10.48 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.975 -0.557 . . . . 0.0 109.866 -179.894 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 44.1 t -78.72 132.95 31.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 N-CA-C 110.098 -0.334 . . . . 0.0 110.098 176.332 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 102.89 4.4 48.42 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.378 -0.915 . . . . 0.0 112.61 179.071 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -86.05 153.8 21.87 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.871 0.367 . . . . 0.0 110.185 177.181 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 267' ' ' ALA . . . . . 0.546 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -125.08 142.48 51.46 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 177.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 268' ' ' PHE . . . . . 0.461 ' HB3' HD13 ' A' ' 334' ' ' ILE . 3.8 p90 -160.13 169.85 22.46 Favored 'General case' 0 C--N 1.323 -0.562 0 C-N-CA 120.097 -0.641 . . . . 0.0 111.572 -176.929 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 269' ' ' THR . . . . . 0.427 ' HB ' ' HB3' ' A' ' 287' ' ' PRO . 67.4 p -119.08 145.88 45.55 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.526 175.872 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 270' ' ' ILE . . . . . 0.729 HG12 HD12 ' A' ' 332' ' ' ILE . 57.9 mt -111.51 131.97 61.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.696 -177.265 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -66.08 120.13 12.62 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.372 -178.531 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 272' ' ' GLY . . . . . 0.533 ' HA3' ' HG3' ' A' ' 326' ' ' PRO . . . 101.3 -22.32 39.52 Favored Glycine 0 C--O 1.23 -0.1 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.102 -179.673 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 52.2 t -103.16 102.68 13.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 176.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 7.1 m120 -119.62 156.66 29.98 Favored 'General case' 0 C--N 1.323 -0.583 0 C-N-CA 120.1 -0.64 . . . . 0.0 111.235 -173.9 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 59.0 p -75.8 166.81 22.98 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.301 0.572 . . . . 0.0 112.41 -173.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 34.3 m -123.96 153.66 30.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 114.909 -1.041 . . . . 0.0 109.851 174.261 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 53.1 m170 -110.35 91.51 3.68 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 179.345 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 16.9 pt20 -79.44 -11.36 59.91 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.92 -0.582 . . . . 0.0 112.435 -172.077 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 279' ' ' ILE . . . . . 0.484 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.2 mp -76.42 -55.92 9.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-O 120.935 0.398 . . . . 0.0 109.962 179.003 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 45.6 p -96.12 -1.4 48.65 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.618 -178.865 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 281' ' ' LYS . . . . . 0.418 ' HB3' ' NZ ' ' A' ' 281' ' ' LYS . 3.8 mmmp? 52.74 52.37 14.13 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.06 -177.793 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 52.1 t0 -111.64 146.92 36.59 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.04 -177.464 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 36.4 p -107.1 110.6 22.75 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.938 0.399 . . . . 0.0 110.391 176.576 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 78.3 p -119.05 -26.45 5.96 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.702 -176.755 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 71.35 31.92 65.56 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.925 176.711 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 95.2 mm-40 -82.72 133.18 49.66 Favored Pre-proline 0 C--N 1.325 -0.49 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 179.232 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 287' ' ' PRO . . . . . 0.427 ' HB3' ' HB ' ' A' ' 269' ' ' THR . 82.2 Cg_exo -49.47 133.26 31.18 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.902 2.402 . . . . 0.0 112.851 -177.453 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 3.3 tm0? -83.65 134.89 34.76 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 -176.804 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 40.3 t -98.39 125.23 51.77 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-O 120.986 0.422 . . . . 0.0 110.776 -176.0 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 290' ' ' PHE . . . . . 0.546 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 6.0 m-85 -98.29 165.65 11.77 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.138 0.495 . . . . 0.0 112.181 -173.782 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 40.2 mmt-85 -129.46 120.35 25.31 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 114.889 -1.051 . . . . 0.0 108.763 174.014 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 58.3 t -77.98 135.78 25.5 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.913 0 CA-C-N 116.306 -0.406 . . . . 0.0 112.059 -174.844 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 293' ' ' LEU . . . . . . . . . . . . . 72.2 mt -102.49 -37.81 7.83 Favored 'General case' 0 N--CA 1.462 0.152 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.674 177.382 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 294' ' ' ALA . . . . . . . . . . . . . . . -151.51 139.91 20.48 Favored 'General case' 0 C--N 1.328 -0.339 0 C-N-CA 120.999 -0.28 . . . . 0.0 111.55 -175.139 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 58.0 t -137.71 110.21 7.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.987 -0.551 . . . . 0.0 109.614 175.339 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 58.9 p -139.85 104.06 4.79 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.163 -175.672 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 61.16 56.79 21.8 Favored Glycine 0 C--N 1.331 0.266 0 C-N-CA 120.979 -0.629 . . . . 0.0 112.406 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 66.4 p 53.21 17.24 0.95 Allowed 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 123.98 0.912 . . . . 0.0 112.519 -176.12 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 89.5 m -105.54 108.1 19.44 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 174.115 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . 0.493 ' O ' ' HA ' ' A' ' 254' ' ' THR . 45.2 t -111.05 135.04 51.43 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.35 -172.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 60.4 m -99.85 114.02 26.93 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 173.129 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 302' ' ' ILE . . . . . . . . . . . . . 27.2 pt -110.66 137.11 44.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 N-CA-C 113.094 0.775 . . . . 0.0 113.094 -168.801 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 303' ' ' SER . . . . . . . . . . . . . 50.3 m -119.49 157.59 51.28 Favored Pre-proline 0 C--N 1.32 -0.716 0 CA-C-N 114.029 -1.441 . . . . 0.0 107.641 170.569 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 304' ' ' PRO . . . . . 0.525 ' HD3' ' HA ' ' A' ' 290' ' ' PHE . 2.7 Cg_exo -75.23 -172.48 10.88 Favored 'Cis proline' 0 N--CA 1.462 -0.335 0 C-N-CA 124.368 -1.097 . . . . 0.0 111.716 -0.077 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 305' ' ' LYS . . . . . 0.449 ' HD2' ' O ' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -80.89 145.35 31.36 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.271 0.558 . . . . 0.0 111.804 179.462 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 306' ' ' ILE . . . . . 0.731 HG23 HG21 ' A' ' 322' ' ' VAL . 2.9 mp -99.86 100.5 10.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.41 -172.783 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 307' ' ' LEU . . . . . 0.468 ' HA ' ' HD3' ' A' ' 308' ' ' PRO . 82.9 mt -117.14 119.74 34.49 Favored Pre-proline 0 CA--C 1.516 -0.363 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.413 179.766 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 308' ' ' PRO . . . . . 0.792 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 7.1 Cg_exo -80.19 139.66 13.45 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 123.183 2.589 . . . . 0.0 113.406 -176.065 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . 0.474 HG22 ' HB3' ' A' ' 320' ' ' ALA . 45.3 t -82.04 -30.16 9.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 167.284 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 310' ' ' GLU . . . . . 0.405 ' HB2' ' HB2' ' A' ' 324' ' ' ALA . 89.1 mt-10 -84.73 25.79 0.88 Allowed 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 115.006 -0.997 . . . . 0.0 111.169 177.553 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.711 ' HB2' ' HB2' ' A' ' 308' ' ' PRO . 24.5 t-20 -87.74 141.63 28.45 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 179.638 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 38.0 m -60.3 -28.53 68.18 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.198 -178.019 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 32.7 t70 -79.14 113.46 17.28 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.001 0.429 . . . . 0.0 110.195 177.107 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 314' ' ' VAL . . . . . 0.477 ' O ' ' HD3' ' A' ' 318' ' ' PRO . 40.4 t -69.04 -19.86 24.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.965 -177.543 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -75.03 -17.89 60.42 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 112.218 0.451 . . . . 0.0 112.218 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 59.4 m -96.7 -22.03 17.24 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 112.43 0.53 . . . . 0.0 112.43 -176.394 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 317' ' ' ARG . . . . . 0.415 ' N ' ' CD ' ' A' ' 318' ' ' PRO . 15.9 ptp180 -74.5 -31.65 1.25 Allowed Pre-proline 0 CA--C 1.549 0.92 0 N-CA-C 114.901 1.445 . . . . 0.0 114.901 -175.584 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 318' ' ' PRO . . . . . 0.477 ' HD3' ' O ' ' A' ' 314' ' ' VAL . 33.6 Cg_exo -62.09 -39.09 51.92 Favored 'Trans proline' 0 C--N 1.365 1.412 0 CA-C-N 121.486 1.566 . . . . 0.0 112.68 -178.009 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 54.7 m-85 -112.02 41.33 1.98 Allowed 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.543 -179.731 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . 0.474 ' HB3' HG22 ' A' ' 309' ' ' VAL . . . -78.63 159.87 27.84 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.967 179.699 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 47.2 t30 -111.83 -25.29 9.53 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.76 -178.744 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 322' ' ' VAL . . . . . 0.731 HG21 HG23 ' A' ' 306' ' ' ILE . 33.0 m -134.46 172.68 15.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.766 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 53.1 m-20 -67.15 -49.69 63.89 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.557 176.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 324' ' ' ALA . . . . . 0.792 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -173.08 179.64 2.2 Favored 'General case' 0 CA--C 1.518 -0.281 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.555 -177.166 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 325' ' ' LYS . . . . . 0.478 ' HE2' ' O ' ' A' ' 234' ' ' PRO . 8.7 ptpp? -126.83 106.96 22.61 Favored Pre-proline 0 C--N 1.326 -0.414 0 CA-C-N 115.324 -0.853 . . . . 0.0 109.805 171.525 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 326' ' ' PRO . . . . . 0.58 ' O ' ' HG3' ' A' ' 233' ' ' GLN . 67.1 Cg_endo -78.92 167.14 22.52 Favored 'Trans proline' 0 C--N 1.34 0.124 0 C-N-CA 122.535 2.156 . . . . 0.0 112.49 -175.878 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -63.03 129.63 41.18 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.122 176.81 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 47.1 mt-10 73.01 142.72 0.06 Allowed 'General case' 0 N--CA 1.469 0.493 0 O-C-N 123.977 0.798 . . . . 0.0 110.561 -174.564 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 329' ' ' SER . . . . . 0.56 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 17.6 m -77.31 -22.29 52.17 Favored 'General case' 0 C--N 1.323 -0.55 0 C-N-CA 120.865 -0.334 . . . . 0.0 111.383 -174.652 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 330' ' ' ALA . . . . . 0.445 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 74.15 -162.6 0.08 Allowed 'General case' 0 N--CA 1.47 0.546 0 O-C-N 123.716 0.635 . . . . 0.0 112.686 174.251 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 331' ' ' ALA . . . . . 0.412 ' HA ' HG22 ' A' ' 229' ' ' THR . . . -81.34 145.93 30.61 Favored 'General case' 0 CA--C 1.517 -0.29 0 CA-C-N 115.318 -0.856 . . . . 0.0 110.943 -178.042 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 332' ' ' ILE . . . . . 0.729 HD12 HG12 ' A' ' 270' ' ' ILE . 29.4 mm -115.47 144.55 22.81 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.245 -177.304 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 75.5 m -109.05 96.65 6.46 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 110.094 -0.336 . . . . 0.0 110.094 179.118 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 334' ' ' ILE . . . . . 0.461 HD13 ' HB3' ' A' ' 268' ' ' PHE . 45.7 mm -81.71 130.61 35.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 N-CA-C 111.912 0.338 . . . . 0.0 111.912 -175.329 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 335' ' ' LEU . . . . . 0.431 HD23 ' N ' ' A' ' 335' ' ' LEU . 1.9 pt? -156.58 132.43 9.62 Favored 'General case' 0 C--O 1.234 0.244 0 CA-C-O 121.388 0.613 . . . . 0.0 110.982 174.671 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 76.1 m-20 -94.69 52.63 1.53 Allowed 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.451 176.713 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 55.8 tptt . . . . . 0 C--O 1.246 0.897 0 CA-C-O 118.124 -0.941 . . . . 0.0 109.525 -179.807 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 48.3 m . . . . . 0 C--O 1.233 0.184 0 CA-C-O 121.284 0.564 . . . . 0.0 109.629 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 228' ' ' LEU . . . . . 0.471 ' HB3' ' CB ' ' A' ' 259' ' ' ALA . 90.5 mt -128.12 141.3 51.53 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.289 -0.869 . . . . 0.0 109.09 176.766 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 38.3 p -130.94 -179.2 5.18 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 120.578 -0.449 . . . . 0.0 111.339 -177.005 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 230' ' ' VAL . . . . . 0.586 ' HB ' ' CB ' ' A' ' 329' ' ' SER . 40.7 t -140.0 140.01 36.19 Favored 'Isoleucine or valine' 0 C--O 1.239 0.528 0 CA-C-O 120.557 0.218 . . . . 0.0 110.772 -178.651 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 32.1 m -99.24 138.92 35.65 Favored 'General case' 0 C--O 1.234 0.277 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.29 176.004 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 127.73 166.23 12.03 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.51 -0.853 . . . . 0.0 111.959 179.202 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 81.3 mt-30 -117.12 102.03 52.89 Favored Pre-proline 0 C--N 1.324 -0.539 0 CA-C-N 116.782 0.291 . . . . 0.0 111.073 -179.557 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 234' ' ' PRO . . . . . 0.412 ' HB2' HD12 ' A' ' 306' ' ' ILE . 6.1 Cg_exo -76.35 126.82 9.36 Favored 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 122.716 2.277 . . . . 0.0 111.155 177.015 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -158.55 141.22 14.44 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.175 -178.739 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 92.8 m-70 -146.72 138.24 24.39 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.495 -177.266 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 237' ' ' LYS . . . . . 0.542 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 6.2 mptt . . . . . 0 C--N 1.323 -0.548 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 252' ' ' GLN . . . . . 0.558 ' HA ' HE21 ' A' ' 252' ' ' GLN . 2.6 mm100 . . . . . 0 N--CA 1.45 -0.434 0 CA-C-O 120.695 0.284 . . . . 0.0 110.878 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -110.28 147.81 17.43 Favored Glycine 0 N--CA 1.447 -0.581 0 C-N-CA 119.842 -1.171 . . . . 0.0 113.019 -176.612 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 70.1 p -118.93 117.73 29.62 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 176.838 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.658 HD13 ' H ' ' A' ' 255' ' ' ILE . 0.2 OUTLIER -128.66 165.64 27.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-O 120.951 0.405 . . . . 0.0 111.128 -176.253 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 40.5 m -99.61 116.87 32.74 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 178.273 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.473 ' HA ' HG13 ' A' ' 230' ' ' VAL . 34.1 m -90.44 144.39 9.22 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.774 0 CA-C-O 121.47 0.653 . . . . 0.0 112.494 -172.378 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 258' ' ' SER . . . . . 0.487 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 40.3 m -90.61 8.48 33.99 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 114.359 -1.291 . . . . 0.0 108.721 170.355 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 259' ' ' ALA . . . . . 0.471 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -91.4 163.69 14.1 Favored 'General case' 0 N--CA 1.449 -0.518 0 CA-C-N 114.994 -1.003 . . . . 0.0 109.453 -179.012 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . 0.457 ' H ' HD13 ' A' ' 228' ' ' LEU . 50.6 m -129.8 149.33 51.59 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 120.762 0.315 . . . . 0.0 111.386 -177.888 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 68.73 37.53 84.53 Favored Glycine 0 N--CA 1.451 -0.355 0 CA-C-N 115.786 -0.643 . . . . 0.0 113.534 176.453 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 262' ' ' LEU . . . . . 0.406 HD11 ' HB3' ' A' ' 259' ' ' ALA . 60.4 mt -92.45 150.74 20.6 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 117.364 0.582 . . . . 0.0 109.835 176.794 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 84.7 mt-30 -144.41 170.26 16.36 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.113 -0.494 . . . . 0.0 109.675 -179.619 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 50.3 t -78.25 141.89 14.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.844 -179.457 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 94.13 -2.07 68.28 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.701 -0.761 . . . . 0.0 113.206 177.288 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 44.8 m-20 -81.04 155.46 26.33 Favored 'General case' 0 CA--C 1.515 -0.386 0 CA-C-O 121.251 0.548 . . . . 0.0 111.202 178.129 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 267' ' ' ALA . . . . . 0.713 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -116.16 146.97 41.86 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.222 -0.899 . . . . 0.0 109.13 178.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 268' ' ' PHE . . . . . 0.671 ' HB3' HD13 ' A' ' 334' ' ' ILE . 6.6 p90 -164.17 162.06 22.55 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 120.4 -0.52 . . . . 0.0 111.93 -174.935 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 269' ' ' THR . . . . . 0.468 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 71.1 p -115.23 147.74 39.98 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 115.016 -0.993 . . . . 0.0 109.137 173.422 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 270' ' ' ILE . . . . . 0.593 HD11 ' HE2' ' A' ' 268' ' ' PHE . 54.1 mt -123.13 138.07 54.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-O 120.61 0.243 . . . . 0.0 110.516 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -63.58 125.2 23.47 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.872 -175.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 103.64 -22.6 35.24 Favored Glycine 0 N--CA 1.449 -0.471 0 CA-C-N 115.73 -0.668 . . . . 0.0 112.207 178.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . 0.657 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 39.5 t -95.11 102.31 13.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-O 120.946 0.403 . . . . 0.0 110.058 178.204 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -110.52 135.76 50.69 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.231 -179.892 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 32.5 p -77.94 156.23 30.38 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.229 0.538 . . . . 0.0 112.078 -177.428 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 32.9 m -113.48 160.3 13.04 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.65 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.478 174.845 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 35.7 m80 -132.19 79.86 1.88 Allowed 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.903 177.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 2.5 tp-100 -53.22 -29.55 32.92 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.585 -0.28 . . . . 0.0 111.296 -176.115 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 50.1 mm -63.6 -48.42 86.88 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.352 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.616 178.914 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 75.2 p -97.81 7.14 46.89 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-O 120.762 0.315 . . . . 0.0 111.5 -177.39 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 52.9 tptt 71.59 50.18 0.27 Allowed 'General case' 0 CA--C 1.536 0.408 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.947 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 2.4 p30 29.62 50.41 0.07 Allowed 'General case' 0 N--CA 1.474 0.741 0 N-CA-C 115.801 1.778 . . . . 0.0 115.801 171.471 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 62.1 p -107.1 88.65 2.78 Favored 'General case' 0 C--N 1.322 -0.612 0 C-N-CA 119.744 -0.782 . . . . 0.0 110.335 167.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 35.5 p -145.62 -70.36 0.27 Allowed 'General case' 0 C--N 1.319 -0.761 0 CA-C-N 115.499 -0.773 . . . . 0.0 111.339 -177.79 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 89.09 32.3 10.86 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.013 -178.526 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 286' ' ' GLN . . . . . 0.4 ' HA ' ' HD3' ' A' ' 287' ' ' PRO . 12.0 mm100 -100.94 127.8 31.24 Favored Pre-proline 0 C--N 1.326 -0.422 0 O-C-N 122.894 -0.18 . . . . 0.0 110.926 -177.244 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 287' ' ' PRO . . . . . 0.468 ' HB2' ' HB ' ' A' ' 269' ' ' THR . 24.2 Cg_exo -58.17 129.84 34.98 Favored 'Trans proline' 0 C--O 1.236 0.406 0 C-N-CA 122.42 2.08 . . . . 0.0 110.734 173.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 40.4 tt0 -72.87 142.06 47.93 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.963 0.411 . . . . 0.0 111.124 -173.773 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 289' ' ' VAL . . . . . 0.431 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 47.7 t -90.6 134.82 28.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 115.465 -0.789 . . . . 0.0 109.931 177.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 290' ' ' PHE . . . . . 0.713 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 45.5 m-85 -111.48 163.06 14.44 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.471 -177.449 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 43.2 mmm-85 -125.25 121.22 33.44 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 173.436 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 47.2 t -66.03 132.16 31.64 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-N 115.597 -0.729 . . . . 0.0 111.591 -175.604 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 293' ' ' LEU . . . . . 0.483 HD11 ' HG3' ' A' ' 252' ' ' GLN . 93.9 mt -93.68 -41.64 9.59 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.906 -0.588 . . . . 0.0 111.562 177.381 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 294' ' ' ALA . . . . . 0.412 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -157.26 142.69 17.3 Favored 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 120.896 -0.322 . . . . 0.0 111.316 -176.601 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 61.2 t -133.92 116.54 23.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 109.238 -0.653 . . . . 0.0 109.238 174.466 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 52.5 p -140.73 92.29 2.49 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.061 -175.741 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 66.84 63.73 3.69 Favored Glycine 0 N--CA 1.453 -0.181 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.222 -179.411 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 76.6 p 51.0 23.21 1.4 Allowed 'General case' 0 N--CA 1.47 0.557 0 C-N-CA 123.614 0.766 . . . . 0.0 112.579 -177.651 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 44.2 m -116.59 113.38 22.64 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 175.361 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . 0.412 ' HA ' ' O ' ' A' ' 294' ' ' ALA . 45.5 t -113.49 130.5 67.4 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.541 -171.325 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 38.3 m -91.16 116.72 29.04 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 108.072 -1.085 . . . . 0.0 108.072 171.484 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 302' ' ' ILE . . . . . 0.535 ' O ' ' HB3' ' A' ' 252' ' ' GLN . 31.0 pt -110.68 137.3 43.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 N-CA-C 112.812 0.671 . . . . 0.0 112.812 -169.047 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 303' ' ' SER . . . . . 0.426 ' HB3' HD11 ' A' ' 293' ' ' LEU . 81.7 p -137.67 153.52 74.15 Favored Pre-proline 0 C--N 1.325 -0.496 0 CA-C-N 114.645 -1.161 . . . . 0.0 108.547 173.889 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 304' ' ' PRO . . . . . 0.53 ' HD2' ' HD1' ' A' ' 290' ' ' PHE . 5.9 Cg_exo -73.67 -173.07 10.83 Favored 'Cis proline' 0 N--CA 1.463 -0.296 0 C-N-CA 124.005 -1.248 . . . . 0.0 112.01 -0.005 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 305' ' ' LYS . . . . . 0.639 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -85.75 170.2 12.69 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 120.873 0.368 . . . . 0.0 110.874 -177.841 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 306' ' ' ILE . . . . . 0.444 HG23 HG21 ' A' ' 322' ' ' VAL . 60.3 mt -112.09 93.6 2.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.59 -176.389 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 307' ' ' LEU . . . . . 0.435 ' HG ' ' HG2' ' A' ' 305' ' ' LYS . 94.4 mt -108.23 104.97 55.58 Favored Pre-proline 0 C--N 1.326 -0.441 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.691 -179.54 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 308' ' ' PRO . . . . . 0.778 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 6.3 Cg_exo -75.96 138.6 20.97 Favored 'Trans proline' 0 N--CA 1.461 -0.422 0 C-N-CA 122.982 2.455 . . . . 0.0 112.467 -177.324 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . 0.471 HG23 ' O ' ' A' ' 322' ' ' VAL . 46.8 t -65.74 -25.59 36.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 121.189 0.518 . . . . 0.0 109.683 174.674 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 310' ' ' GLU . . . . . 0.436 ' HA ' ' OE1' ' A' ' 310' ' ' GLU . 4.8 mm-40 -80.92 33.67 0.33 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.752 -0.658 . . . . 0.0 112.169 177.192 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.417 ' O ' ' HB ' ' A' ' 312' ' ' THR . 21.4 p30 -85.29 -8.08 58.68 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.964 -0.107 . . . . 0.0 111.178 -179.644 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 312' ' ' THR . . . . . 0.417 ' HB ' ' O ' ' A' ' 311' ' ' ASN . 71.1 m 74.91 -46.61 0.6 Allowed 'General case' 0 N--CA 1.471 0.613 0 C-N-CA 123.457 0.703 . . . . 0.0 112.283 178.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 42.8 m-20 -57.47 115.46 2.75 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-O 121.211 0.529 . . . . 0.0 111.116 -179.073 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 23.3 t -61.55 -33.6 57.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.449 -176.379 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -75.79 -22.14 56.68 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 111.752 0.278 . . . . 0.0 111.752 179.626 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 65.5 m -87.12 -20.66 26.76 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 111.777 0.288 . . . . 0.0 111.777 -178.857 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 317' ' ' ARG . . . . . 0.505 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 75.0 mtp180 -56.04 -48.9 95.82 Favored Pre-proline 0 CA--C 1.539 0.525 0 N-CA-C 113.034 0.754 . . . . 0.0 113.034 -179.282 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 318' ' ' PRO . . . . . 0.505 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 52.0 Cg_exo -58.57 -16.18 28.81 Favored 'Trans proline' 0 C--N 1.36 1.137 0 C-N-CA 122.213 1.942 . . . . 0.0 113.988 -176.758 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 8.8 m-85 -106.69 1.28 24.93 Favored 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 121.116 -0.234 . . . . 0.0 111.568 -179.657 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -66.08 139.03 58.15 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.811 0.339 . . . . 0.0 111.02 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 14.8 p-10 -124.07 -9.5 7.66 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.379 -179.466 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 322' ' ' VAL . . . . . 0.471 ' O ' HG23 ' A' ' 309' ' ' VAL . 32.3 m -132.92 163.97 36.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 175.537 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 54.6 m-20 -81.05 -22.16 39.5 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 111.885 0.328 . . . . 0.0 111.885 -177.755 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 324' ' ' ALA . . . . . 0.778 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -171.1 154.66 4.14 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.045 -172.573 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 23.8 pttm -101.31 114.4 65.73 Favored Pre-proline 0 C--N 1.325 -0.488 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 169.314 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -72.57 167.64 26.55 Favored 'Trans proline' 0 C--O 1.235 0.346 0 C-N-CA 122.622 2.215 . . . . 0.0 113.306 -172.47 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -66.62 136.8 56.13 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-N 115.804 -0.634 . . . . 0.0 109.885 175.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 47.1 -155.27 0.05 Allowed 'General case' 0 N--CA 1.471 0.594 0 O-C-N 124.446 1.091 . . . . 0.0 111.19 -173.7 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 329' ' ' SER . . . . . 0.586 ' CB ' ' HB ' ' A' ' 230' ' ' VAL . 53.1 m -98.66 -38.92 8.93 Favored 'General case' 0 C--N 1.322 -0.609 0 C-N-CA 120.548 -0.461 . . . . 0.0 111.024 -177.052 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 330' ' ' ALA . . . . . 0.453 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 79.39 -164.39 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.923 0 N-CA-C 112.869 0.692 . . . . 0.0 112.869 174.34 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -84.49 149.17 26.12 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 115.507 -0.77 . . . . 0.0 112.429 -172.066 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 332' ' ' ILE . . . . . 0.602 HG23 ' CD2' ' A' ' 268' ' ' PHE . 38.3 mt -111.08 145.78 16.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.663 -0.699 . . . . 0.0 111.16 178.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 95.7 m -120.67 97.2 5.44 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 172.693 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 334' ' ' ILE . . . . . 0.671 HD13 ' HB3' ' A' ' 268' ' ' PHE . 40.3 mm -79.18 128.96 38.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 N-CA-C 111.92 0.341 . . . . 0.0 111.92 -175.617 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 335' ' ' LEU . . . . . 0.442 HD23 ' N ' ' A' ' 335' ' ' LEU . 1.5 pt? -152.9 130.74 11.68 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.407 0.622 . . . . 0.0 110.593 174.431 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 23.4 p30 -90.8 5.47 48.24 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.287 -177.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 337' ' ' LYS . . . . . 0.442 ' NZ ' ' HB3' ' A' ' 337' ' ' LYS . 8.0 mtpm? . . . . . 0 C--O 1.245 0.828 0 CA-C-O 118.186 -0.911 . . . . 0.0 110.758 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 42.9 m . . . . . 0 N--CA 1.453 -0.311 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 228' ' ' LEU . . . . . 0.544 ' HB3' ' CB ' ' A' ' 259' ' ' ALA . 87.9 mt -127.1 136.07 51.63 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 172.287 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 40.5 p -122.16 172.17 8.46 Favored 'General case' 0 C--N 1.325 -0.462 0 C-N-CA 119.502 -0.879 . . . . 0.0 110.811 -179.72 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 230' ' ' VAL . . . . . 0.721 HG13 ' HA ' ' A' ' 257' ' ' VAL . 48.3 t -145.82 146.02 19.72 Favored 'Isoleucine or valine' 0 C--O 1.239 0.537 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.328 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 231' ' ' SER . . . . . 0.444 ' HA ' ' OE1' ' A' ' 328' ' ' GLU . 33.3 t -118.79 127.21 53.32 Favored 'General case' 0 N--CA 1.452 -0.328 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.017 -178.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . 0.528 ' O ' ' HD3' ' A' ' 234' ' ' PRO . . . 149.13 160.43 9.13 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.072 179.182 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 14.6 mm-40 -99.34 100.98 11.54 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 116.769 0.285 . . . . 0.0 111.628 -179.069 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 234' ' ' PRO . . . . . 0.528 ' HD3' ' O ' ' A' ' 232' ' ' GLY . 3.2 Cg_endo -84.01 126.44 3.85 Favored 'Trans proline' 0 N--CA 1.455 -0.762 0 C-N-CA 122.711 2.274 . . . . 0.0 111.434 176.352 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 235' ' ' GLU . . . . . 0.445 ' HB3' ' HE2' ' A' ' 237' ' ' LYS . 98.4 mt-10 -126.54 126.79 44.27 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.315 0.578 . . . . 0.0 111.387 -178.7 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 236' ' ' HIS . . . . . 0.523 ' C ' ' HD3' ' A' ' 237' ' ' LYS . 27.8 m80 -139.73 130.3 25.7 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.192 -0.913 . . . . 0.0 109.204 176.358 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 237' ' ' LYS . . . . . 0.621 ' HD3' ' N ' ' A' ' 237' ' ' LYS . 0.1 OUTLIER . . . . . 0 C--N 1.324 -0.54 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.054 -176.126 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 252' ' ' GLN . . . . . 0.556 ' HG3' HD12 ' A' ' 293' ' ' LEU . 2.5 mm100 . . . . . 0 N--CA 1.454 -0.254 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . 0.494 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -97.4 124.08 8.02 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.216 -0.992 . . . . 0.0 111.881 177.553 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 254' ' ' THR . . . . . 0.454 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 76.8 p -115.52 116.13 27.65 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 178.613 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.53 ' N ' HD13 ' A' ' 255' ' ' ILE . 0.2 OUTLIER -135.64 167.13 25.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.628 -175.747 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 86.9 m -92.5 123.34 35.73 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.2 178.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.721 ' HA ' HG13 ' A' ' 230' ' ' VAL . 33.1 m -91.0 144.94 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.66 0 N-CA-C 113.029 0.751 . . . . 0.0 113.029 -173.106 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 258' ' ' SER . . . . . 0.575 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 29.1 m -91.07 10.33 27.22 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 114.113 -1.403 . . . . 0.0 108.866 169.915 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 259' ' ' ALA . . . . . 0.544 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -98.02 176.97 5.57 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.181 -0.918 . . . . 0.0 109.926 -175.19 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 37.2 t -143.77 146.6 33.24 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 110.191 -0.3 . . . . 0.0 110.191 179.067 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 70.98 45.31 51.89 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.996 -0.621 . . . . 0.0 112.906 179.143 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 262' ' ' LEU . . . . . 0.509 HD11 ' HB3' ' A' ' 259' ' ' ALA . 64.0 mt -99.47 144.25 28.79 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 177.101 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 84.2 mt-30 -139.88 160.94 38.78 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 110.287 -0.264 . . . . 0.0 110.287 -178.735 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 264' ' ' VAL . . . . . 0.455 HG22 ' HA ' ' A' ' 294' ' ' ALA . 44.0 t -69.36 136.2 26.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.177 177.527 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 96.03 -1.28 62.93 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.561 -0.828 . . . . 0.0 112.94 178.616 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 266' ' ' ASP . . . . . 0.427 ' O ' ' HA ' ' A' ' 291' ' ' ARG . 65.7 m-20 -78.99 164.21 24.58 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.926 0.394 . . . . 0.0 110.537 177.281 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 267' ' ' ALA . . . . . 0.651 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -123.84 154.38 39.71 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.73 -179.183 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 268' ' ' PHE . . . . . 0.786 ' HB3' HD13 ' A' ' 334' ' ' ILE . 9.4 p90 -164.16 171.19 15.37 Favored 'General case' 0 N--CA 1.449 -0.519 0 C-N-CA 120.297 -0.561 . . . . 0.0 112.217 -179.169 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 69.3 p -129.97 126.11 37.01 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 114.86 -1.064 . . . . 0.0 109.329 175.571 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 270' ' ' ILE . . . . . 0.99 HG12 HG13 ' A' ' 332' ' ' ILE . 60.0 mt -96.74 136.09 28.69 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 116.504 -0.316 . . . . 0.0 110.826 -176.554 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -64.96 128.22 34.86 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.873 -176.395 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 100.98 -23.68 34.72 Favored Glycine 0 N--CA 1.452 -0.26 0 CA-C-N 115.64 -0.709 . . . . 0.0 112.653 177.409 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . 0.726 HG21 ' HG3' ' A' ' 326' ' ' PRO . 31.8 t -102.99 102.33 13.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 120.898 0.38 . . . . 0.0 111.025 179.784 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -113.95 166.35 11.69 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 174.248 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 275' ' ' SER . . . . . 0.486 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 36.5 p -83.72 179.39 7.6 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 112.314 0.487 . . . . 0.0 112.314 -176.443 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 35.7 m -141.46 159.72 22.05 Favored 'Isoleucine or valine' 0 C--O 1.232 0.174 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.743 -177.163 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 80.9 m-70 -118.13 99.58 6.97 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 173.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 10.8 mm100 -73.61 -24.03 59.98 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 111.863 0.32 . . . . 0.0 111.863 -175.206 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 50.7 mm -67.07 -49.27 74.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.764 0.316 . . . . 0.0 111.334 -177.719 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 40.8 p -101.62 -0.14 35.26 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.509 -0.314 . . . . 0.0 111.343 -179.123 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 3.9 tmtp? 60.18 53.6 4.4 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-O 121.903 0.859 . . . . 0.0 109.588 179.725 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 64.8 t0 -117.78 115.91 25.95 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.372 -0.831 . . . . 0.0 109.144 179.08 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 59.2 p -93.96 86.03 4.92 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.918 0.866 . . . . 0.0 111.014 -178.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 284' ' ' THR . . . . . 0.418 ' C ' ' H ' ' A' ' 286' ' ' GLN . 40.0 p -148.63 -88.84 0.08 Allowed 'General case' 0 C--N 1.313 -1.015 0 CA-C-N 114.218 -1.356 . . . . 0.0 109.562 179.282 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 285' ' ' GLY . . . . . 0.507 ' O ' ' HB2' ' A' ' 286' ' ' GLN . . . 68.31 -17.33 0.45 Allowed Glycine 0 C--N 1.333 0.411 0 N-CA-C 114.627 0.611 . . . . 0.0 114.627 173.423 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 286' ' ' GLN . . . . . 0.507 ' HB2' ' O ' ' A' ' 285' ' ' GLY . 72.2 mt-30 76.49 164.45 0.13 Allowed Pre-proline 0 C--O 1.235 0.314 0 C-N-CA 123.519 0.728 . . . . 0.0 110.314 -174.671 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 287' ' ' PRO . . . . . 0.424 ' HD2' ' HB3' ' A' ' 286' ' ' GLN . 78.2 Cg_exo -51.65 128.26 25.58 Favored 'Trans proline' 0 C--N 1.351 0.665 0 C-N-CA 122.641 2.228 . . . . 0.0 112.71 -175.902 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 3.8 tm0? -74.38 135.79 42.45 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 -178.029 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 42.5 t -93.83 121.43 44.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.862 0.363 . . . . 0.0 110.896 -175.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 290' ' ' PHE . . . . . 0.651 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 3.9 m-85 -98.79 160.04 14.54 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.343 -178.517 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 291' ' ' ARG . . . . . 0.432 ' HD2' ' O ' ' A' ' 290' ' ' PHE . 45.2 mmm-85 -131.29 136.97 48.61 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.122 0.487 . . . . 0.0 110.155 175.66 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 46.3 t -83.67 139.86 17.04 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.223 -177.68 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 293' ' ' LEU . . . . . 0.556 HD12 ' HG3' ' A' ' 252' ' ' GLN . 86.6 mt -111.71 -26.4 9.01 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.69 178.914 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 294' ' ' ALA . . . . . 0.486 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -156.35 139.76 15.79 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 120.718 -0.393 . . . . 0.0 111.624 179.496 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 64.8 t -137.52 109.58 6.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 115.825 -0.625 . . . . 0.0 109.521 173.778 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 47.6 t -151.4 116.37 5.23 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.51 -177.892 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 63.2 44.11 97.58 Favored Glycine 0 C--N 1.331 0.282 0 C-N-CA 120.847 -0.692 . . . . 0.0 111.942 -179.202 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 81.0 p 54.76 16.22 1.34 Allowed 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 123.88 0.872 . . . . 0.0 112.332 -175.401 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 35.8 m -101.07 116.06 31.94 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 174.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . 0.486 ' HA ' ' O ' ' A' ' 294' ' ' ALA . 71.8 t -114.64 131.59 66.31 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-O 121.09 0.471 . . . . 0.0 111.867 -172.167 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 51.1 m -93.01 115.99 28.64 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.255 -0.884 . . . . 0.0 108.65 174.056 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 302' ' ' ILE . . . . . 0.494 HG12 ' O ' ' A' ' 253' ' ' GLY . 30.4 pt -110.66 139.68 33.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-O 121.722 0.772 . . . . 0.0 112.771 -170.693 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 303' ' ' SER . . . . . 0.607 ' HA ' ' O ' ' A' ' 304' ' ' PRO . 82.5 p -138.41 169.02 13.74 Favored Pre-proline 0 C--N 1.323 -0.547 0 CA-C-N 114.404 -1.271 . . . . 0.0 107.759 177.082 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 304' ' ' PRO . . . . . 0.607 ' O ' ' HA ' ' A' ' 303' ' ' SER . 9.7 Cg_exo -73.01 -133.29 0.09 OUTLIER 'Cis proline' 0 C--N 1.348 0.516 0 CA-C-N 120.776 1.313 . . . . 0.0 112.527 0.251 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 305' ' ' LYS . . . . . 0.909 ' HD3' ' HG ' ' A' ' 307' ' ' LEU . 0.0 OUTLIER -102.07 145.1 29.8 Favored 'General case' 0 N--CA 1.448 -0.574 0 CA-C-O 121.453 0.644 . . . . 0.0 111.333 177.871 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 306' ' ' ILE . . . . . 0.819 HG23 HG21 ' A' ' 322' ' ' VAL . 2.7 mp -113.04 85.46 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.049 -177.076 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 307' ' ' LEU . . . . . 0.909 ' HG ' ' HD3' ' A' ' 305' ' ' LYS . 55.7 mt -96.77 116.5 66.12 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.704 -174.66 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 308' ' ' PRO . . . . . 0.705 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 68.7 Cg_endo -79.75 140.52 14.73 Favored 'Trans proline' 0 C--O 1.235 0.36 0 C-N-CA 122.95 2.433 . . . . 0.0 113.899 -174.191 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . 0.537 HG22 ' CB ' ' A' ' 320' ' ' ALA . 15.9 t -93.89 -27.92 4.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.821 174.702 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 62.4 mm-40 -82.21 33.49 0.4 Allowed 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.847 -177.73 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.484 ' OD1' ' HB2' ' A' ' 308' ' ' PRO . 5.5 m120 -126.23 168.95 13.38 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.967 177.955 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 27.3 m -80.64 -18.02 49.42 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.898 -176.427 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 50.7 m-20 -57.19 114.67 2.26 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-O 120.989 0.423 . . . . 0.0 111.387 -179.443 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 38.8 t -74.25 -31.44 29.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.579 -179.694 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -70.06 -30.03 67.18 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.428 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 34.0 t -75.76 -28.9 58.63 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.799 -178.767 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 317' ' ' ARG . . . . . 0.769 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 21.7 mmt85 -51.34 -57.38 14.38 Favored Pre-proline 0 CA--C 1.542 0.672 0 N-CA-C 113.882 1.067 . . . . 0.0 113.882 -176.539 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 318' ' ' PRO . . . . . 0.769 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 22.8 Cg_exo -70.79 -21.49 28.63 Favored 'Trans proline' 0 C--N 1.355 0.893 0 C-N-CA 121.958 1.772 . . . . 0.0 113.522 -173.412 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 319' ' ' TYR . . . . . 0.514 ' O ' HD12 ' A' ' 307' ' ' LEU . 0.9 OUTLIER -108.69 2.78 22.11 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.368 0.604 . . . . 0.0 109.598 -175.855 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . 0.677 ' HA ' ' HB2' ' A' ' 307' ' ' LEU . . . -62.36 138.62 58.47 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.318 -178.757 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 321' ' ' ASN . . . . . 0.403 ' O ' ' HA ' ' A' ' 275' ' ' SER . 16.0 p-10 -128.67 -3.46 5.33 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.007 -179.864 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 322' ' ' VAL . . . . . 0.819 HG21 HG23 ' A' ' 306' ' ' ILE . 35.7 m -140.66 166.7 18.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.595 -0.275 . . . . 0.0 110.66 -179.836 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 53.8 m-20 -60.81 -49.23 78.3 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.072 0.463 . . . . 0.0 110.872 179.304 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 324' ' ' ALA . . . . . 0.705 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -157.53 170.65 21.93 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.575 -176.028 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 25.0 pttm -83.1 151.36 63.21 Favored Pre-proline 0 C--N 1.328 -0.359 0 N-CA-C 108.104 -1.072 . . . . 0.0 108.104 170.382 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 326' ' ' PRO . . . . . 0.728 ' HD3' HG21 ' A' ' 306' ' ' ILE . 20.6 Cg_exo -68.02 126.25 14.23 Favored 'Trans proline' 0 N--CA 1.461 -0.405 0 C-N-CA 121.731 1.621 . . . . 0.0 112.886 -174.702 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -83.36 117.3 22.92 Favored 'General case' 0 CA--C 1.511 -0.533 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 167.187 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 328' ' ' GLU . . . . . 0.444 ' OE1' ' HA ' ' A' ' 231' ' ' SER . 31.2 tp10 63.95 168.08 0.16 Allowed 'General case' 0 CA--C 1.539 0.554 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 -165.166 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 329' ' ' SER . . . . . 0.581 ' HB2' ' C ' ' A' ' 230' ' ' VAL . 49.3 m -81.09 -22.19 39.38 Favored 'General case' 0 C--N 1.316 -0.882 0 O-C-N 120.775 -1.203 . . . . 0.0 110.678 -176.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 73.5 -160.09 0.09 Allowed 'General case' 0 N--CA 1.473 0.692 0 O-C-N 123.855 0.722 . . . . 0.0 112.872 170.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 331' ' ' ALA . . . . . 0.433 ' C ' HD12 ' A' ' 332' ' ' ILE . . . -95.51 129.33 42.72 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.254 -0.885 . . . . 0.0 110.041 179.379 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 332' ' ' ILE . . . . . 0.99 HG13 HG12 ' A' ' 270' ' ' ILE . 1.8 mp -111.16 145.49 17.36 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.442 -175.606 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 47.5 m -118.69 97.65 5.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.021 -178.557 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 334' ' ' ILE . . . . . 0.786 HD13 ' HB3' ' A' ' 268' ' ' PHE . 42.7 mm -80.02 136.46 23.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 N-CA-C 112.959 0.726 . . . . 0.0 112.959 -172.675 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 335' ' ' LEU . . . . . 0.473 HD23 ' N ' ' A' ' 335' ' ' LEU . 1.6 pt? -151.21 -173.82 4.62 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 114.69 -1.141 . . . . 0.0 108.737 172.646 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 76.4 m-20 -111.63 -14.05 13.7 Favored 'General case' 0 C--N 1.325 -0.499 0 O-C-N 122.079 -0.388 . . . . 0.0 111.704 -177.135 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 337' ' ' LYS . . . . . 0.544 ' HB2' ' NZ ' ' A' ' 337' ' ' LYS . 9.8 mtmp? . . . . . 0 C--O 1.244 0.792 0 CA-C-O 118.557 -0.735 . . . . 0.0 110.931 -177.163 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 40.8 p . . . . . 0 C--O 1.232 0.147 0 CA-C-O 120.488 0.185 . . . . 0.0 111.118 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 228' ' ' LEU . . . . . 0.413 ' HB3' ' CB ' ' A' ' 259' ' ' ALA . 83.8 mt -104.46 126.15 51.29 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 174.778 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 229' ' ' THR . . . . . 0.561 HG22 ' HA ' ' A' ' 331' ' ' ALA . 68.4 p -129.35 177.94 6.81 Favored 'General case' 0 C--N 1.32 -0.692 0 C-N-CA 120.06 -0.656 . . . . 0.0 111.147 -177.059 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 230' ' ' VAL . . . . . 0.655 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 64.6 t -140.48 142.57 30.72 Favored 'Isoleucine or valine' 0 C--O 1.238 0.474 0 CA-C-O 120.774 0.321 . . . . 0.0 110.309 -179.427 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 43.3 m -109.33 138.17 46.1 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.481 178.627 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 162.39 -170.15 37.9 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.896 -0.669 . . . . 0.0 111.747 -179.728 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 83.6 mt-30 -99.88 116.26 64.86 Favored Pre-proline 0 C--N 1.325 -0.486 0 CA-C-N 116.716 0.258 . . . . 0.0 110.927 179.45 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -69.17 127.6 15.31 Favored 'Trans proline' 0 C--O 1.236 0.412 0 C-N-CA 122.113 1.876 . . . . 0.0 110.971 175.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 235' ' ' GLU . . . . . 0.544 ' O ' ' HB ' ' A' ' 306' ' ' ILE . 0.3 OUTLIER -125.78 -176.92 3.75 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-O 121.661 0.744 . . . . 0.0 111.63 -174.395 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 22.3 p-80 -156.13 133.13 10.54 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 178.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 237' ' ' LYS . . . . . 0.788 ' HD3' ' HA ' ' A' ' 305' ' ' LYS . 8.9 mptt . . . . . 0 C--N 1.32 -0.682 0 C-N-CA 119.439 -0.904 . . . . 0.0 111.69 -172.194 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 252' ' ' GLN . . . . . 0.458 ' CG ' ' HE2' ' A' ' 237' ' ' LYS . 21.6 mt-30 . . . . . 0 N--CA 1.471 0.624 0 CA-C-O 121.382 0.61 . . . . 0.0 111.645 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . 0.537 ' O ' ' HA ' ' A' ' 301' ' ' THR . . . 126.33 -152.22 18.22 Favored Glycine 0 N--CA 1.446 -0.661 0 C-N-CA 119.141 -1.504 . . . . 0.0 113.401 172.812 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 254' ' ' THR . . . . . 0.478 ' HB ' HG22 ' A' ' 299' ' ' THR . 58.4 p -94.21 135.49 35.53 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.13 0.49 . . . . 0.0 111.621 -174.908 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.448 ' O ' ' HA ' ' A' ' 299' ' ' THR . 2.1 pp -132.39 169.07 22.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 115.446 -0.797 . . . . 0.0 111.223 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 83.8 m -105.15 126.25 51.88 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.015 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.432 HG12 HG13 ' A' ' 230' ' ' VAL . 33.5 m -100.81 145.42 11.21 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.643 0 N-CA-C 112.529 0.566 . . . . 0.0 112.529 -174.839 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 258' ' ' SER . . . . . 0.405 ' HB2' ' OG1' ' A' ' 229' ' ' THR . 52.8 m -91.36 7.26 41.89 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 114.694 -1.139 . . . . 0.0 109.132 167.682 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 259' ' ' ALA . . . . . 0.413 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -95.78 170.09 9.56 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-N 115.492 -0.777 . . . . 0.0 110.13 -177.683 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 51.3 p -137.29 153.29 50.34 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.798 0.333 . . . . 0.0 111.45 -178.708 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 72.37 48.79 22.76 Favored Glycine 0 N--CA 1.452 -0.248 0 CA-C-N 115.929 -0.578 . . . . 0.0 112.847 178.342 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 262' ' ' LEU . . . . . 0.422 HD12 HG21 ' A' ' 257' ' ' VAL . 61.7 mt -102.31 144.28 31.01 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.971 0.415 . . . . 0.0 111.08 -178.873 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 72.1 mt-30 -137.78 172.45 12.94 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.69 -0.687 . . . . 0.0 109.547 176.059 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 264' ' ' VAL . . . . . 0.431 HG22 ' HA ' ' A' ' 294' ' ' ALA . 44.5 t -79.04 136.28 24.07 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 174.909 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 95.67 -0.76 63.26 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.5 -0.857 . . . . 0.0 112.586 179.33 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 65.3 m-20 -65.17 152.26 44.05 Favored 'General case' 0 CA--C 1.517 -0.315 0 CA-C-O 121.11 0.481 . . . . 0.0 110.751 178.343 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 267' ' ' ALA . . . . . 0.707 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -124.14 122.76 38.71 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.353 -0.839 . . . . 0.0 109.415 179.544 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 268' ' ' PHE . . . . . 0.414 ' HB3' ' HA ' ' A' ' 334' ' ' ILE . 5.4 p90 -144.56 169.07 18.68 Favored 'General case' 0 C--N 1.319 -0.741 0 C-N-CA 120.016 -0.673 . . . . 0.0 111.784 -172.816 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 269' ' ' THR . . . . . 0.467 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 42.9 p -119.97 148.81 43.08 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.559 -0.746 . . . . 0.0 109.966 176.615 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 270' ' ' ILE . . . . . 0.586 HG12 HD12 ' A' ' 332' ' ' ILE . 58.5 mt -114.09 138.85 42.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 116.559 -0.291 . . . . 0.0 110.668 -177.226 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -67.99 117.04 9.33 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.948 179.082 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 109.4 -22.49 24.49 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.782 -0.723 . . . . 0.0 111.95 -179.14 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . 0.657 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 50.4 t -96.35 101.27 12.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 175.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 274' ' ' ASN . . . . . 0.429 ' HA ' ' HA ' ' A' ' 287' ' ' PRO . 72.5 m-80 -124.44 131.79 53.5 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.494 -177.594 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 54.5 p -64.03 163.99 11.35 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.524 0.678 . . . . 0.0 112.508 -176.488 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 276' ' ' VAL . . . . . 0.866 HG11 HG21 ' A' ' 309' ' ' VAL . 21.5 m -126.81 149.94 32.26 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.623 0 CA-C-N 114.901 -1.045 . . . . 0.0 109.276 176.029 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 58.7 m170 -103.53 120.87 41.71 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 120.756 0.312 . . . . 0.0 110.738 -175.191 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 3.1 mm100 -82.17 -29.2 31.67 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.764 -177.723 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 279' ' ' ILE . . . . . 0.487 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.0 mp -72.12 -52.64 23.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.436 -179.017 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 58.0 p -89.38 -13.06 38.62 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.772 -178.356 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 31.7 mmmt 58.84 45.26 15.64 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.55 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 44.1 t0 -132.8 155.25 49.27 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 110.157 -0.312 . . . . 0.0 110.157 -179.571 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.516 HG22 HG12 ' A' ' 276' ' ' VAL . 59.9 p -107.77 113.38 26.59 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 175.072 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 80.6 p -110.93 6.77 21.38 Favored 'General case' 0 C--N 1.32 -0.699 0 C-N-CA 120.285 -0.566 . . . . 0.0 112.077 -170.318 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 285' ' ' GLY . . . . . 0.4 ' O ' ' HD3' ' A' ' 287' ' ' PRO . . . 66.77 31.6 78.82 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.594 -0.813 . . . . 0.0 113.363 174.414 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 10.6 mm100 -95.89 109.1 44.74 Favored Pre-proline 0 C--N 1.328 -0.338 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 177.817 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 287' ' ' PRO . . . . . 0.467 ' HB2' ' HB ' ' A' ' 269' ' ' THR . 51.5 Cg_exo -58.35 139.34 90.21 Favored 'Trans proline' 0 C--N 1.343 0.288 0 C-N-CA 122.598 2.199 . . . . 0.0 112.888 -176.107 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 40.8 tt0 -77.4 148.37 35.55 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.179 -179.637 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 289' ' ' VAL . . . . . 0.533 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 59.7 t -94.25 137.4 23.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.085 178.063 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 290' ' ' PHE . . . . . 0.707 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 51.7 m-85 -118.34 167.83 11.18 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.758 -176.525 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 37.4 mmt180 -128.66 130.96 47.95 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.77 177.653 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 57.7 t -79.65 139.97 17.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.497 -0.774 . . . . 0.0 111.359 -179.054 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 293' ' ' LEU . . . . . 0.512 ' CD1' ' HB2' ' A' ' 303' ' ' SER . 6.9 mp -102.25 -31.66 10.44 Favored 'General case' 0 C--N 1.334 -0.089 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.844 179.738 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 294' ' ' ALA . . . . . 0.458 ' HB3' ' HB ' ' A' ' 301' ' ' THR . . . -158.55 144.31 16.75 Favored 'General case' 0 N--CA 1.465 0.284 0 C-N-CA 120.664 -0.415 . . . . 0.0 111.763 179.523 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 62.5 t -139.28 112.48 6.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.85 176.085 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 54.2 p -132.67 95.41 3.59 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.368 -0.378 . . . . 0.0 111.114 -178.413 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 65.43 57.78 10.75 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.02 -178.789 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 67.0 p 51.19 22.37 1.31 Allowed 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 123.501 0.72 . . . . 0.0 112.552 -176.174 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 299' ' ' THR . . . . . 0.478 HG22 ' HB ' ' A' ' 254' ' ' THR . 91.7 m -112.29 109.55 19.27 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 174.014 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . 0.467 ' O ' ' HA ' ' A' ' 254' ' ' THR . 47.3 t -107.0 134.1 49.69 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-N 115.704 -0.68 . . . . 0.0 112.02 -168.39 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 301' ' ' THR . . . . . 0.537 ' HA ' ' O ' ' A' ' 253' ' ' GLY . 91.5 m -85.22 114.92 22.68 Favored 'General case' 0 C--O 1.237 0.403 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 169.746 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 302' ' ' ILE . . . . . 0.418 HD13 HG12 ' A' ' 255' ' ' ILE . 30.6 pt -110.7 138.6 38.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 N-CA-C 113.655 0.983 . . . . 0.0 113.655 -167.805 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 303' ' ' SER . . . . . 0.572 ' HB3' ' HA ' ' A' ' 304' ' ' PRO . 68.7 m -153.87 169.39 10.01 Favored Pre-proline 0 C--N 1.323 -0.557 0 CA-C-N 112.859 -1.973 . . . . 0.0 105.89 175.047 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 304' ' ' PRO . . . . . 0.572 ' HA ' ' HB3' ' A' ' 303' ' ' SER . 22.7 Cg_endo -93.38 -119.83 0.0 OUTLIER 'Cis proline' 0 N--CA 1.455 -0.742 0 CA-C-N 121.02 1.4 . . . . 0.0 113.592 0.822 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 305' ' ' LYS . . . . . 0.788 ' HA ' ' HD3' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -98.41 144.29 27.94 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.081 -0.509 . . . . 0.0 112.357 -172.324 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 306' ' ' ILE . . . . . 0.544 ' HB ' ' O ' ' A' ' 235' ' ' GLU . 2.2 mp -104.4 127.35 58.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 170.699 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 307' ' ' LEU . . . . . 0.544 HD13 ' O ' ' A' ' 319' ' ' TYR . 59.0 mt -129.09 98.28 24.17 Favored Pre-proline 0 C--N 1.323 -0.548 0 C-N-CA 120.676 -0.41 . . . . 0.0 110.519 -172.779 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 308' ' ' PRO . . . . . 0.545 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 12.7 Cg_exo -74.17 131.34 15.21 Favored 'Trans proline' 0 C--N 1.343 0.252 0 C-N-CA 122.802 2.335 . . . . 0.0 113.495 -175.19 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . 0.866 HG21 HG11 ' A' ' 276' ' ' VAL . 61.9 t -87.05 -37.57 11.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.563 173.897 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 63.1 mm-40 -81.08 32.69 0.33 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.859 -0.609 . . . . 0.0 111.484 179.814 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.581 HD21 ' HB3' ' A' ' 317' ' ' ARG . 0.0 OUTLIER -85.38 157.05 20.62 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.945 0.403 . . . . 0.0 111.248 179.16 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 36.4 m -92.15 -18.28 23.73 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.839 178.244 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -76.42 121.49 23.13 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.612 -179.746 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 40.7 t -75.76 -20.19 15.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.129 -177.457 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -80.59 -21.96 41.14 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.739 0.304 . . . . 0.0 111.512 178.582 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 36.0 t -96.3 -23.3 16.73 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.559 -0.291 . . . . 0.0 111.456 -176.138 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 317' ' ' ARG . . . . . 0.581 ' HB3' HD21 ' A' ' 311' ' ' ASN . 2.1 ptp180 -62.23 -34.03 14.07 Favored Pre-proline 0 CA--C 1.548 0.901 0 N-CA-C 113.807 1.04 . . . . 0.0 113.807 -178.886 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 318' ' ' PRO . . . . . 0.415 ' CD ' ' N ' ' A' ' 317' ' ' ARG . 26.1 Cg_exo -63.13 -18.14 63.57 Favored 'Trans proline' 0 C--N 1.367 1.521 0 CA-C-N 121.263 1.487 . . . . 0.0 112.113 178.266 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 319' ' ' TYR . . . . . 0.544 ' O ' HD13 ' A' ' 307' ' ' LEU . 48.5 m-85 -103.35 -3.2 25.87 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.028 -177.803 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . 0.723 ' HB1' HG22 ' A' ' 309' ' ' VAL . . . -54.06 144.77 18.49 Favored 'General case' 0 C--N 1.33 -0.246 0 N-CA-C 112.144 0.424 . . . . 0.0 112.144 -178.128 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 321' ' ' ASN . . . . . 0.479 ' O ' HG22 ' A' ' 276' ' ' VAL . 48.9 t30 -148.05 -18.61 0.35 Allowed 'General case' 0 CA--C 1.532 0.278 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.472 -178.281 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 322' ' ' VAL . . . . . 0.532 ' O ' HG23 ' A' ' 309' ' ' VAL . 35.1 m -137.43 160.96 34.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 N-CA-C 110.234 -0.284 . . . . 0.0 110.234 177.654 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 71.8 m-20 -41.9 -69.24 0.14 Allowed 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 112.588 0.588 . . . . 0.0 112.588 -177.364 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 324' ' ' ALA . . . . . 0.545 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -165.7 -176.08 3.74 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.962 0.411 . . . . 0.0 111.496 -175.595 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 325' ' ' LYS . . . . . 0.454 ' HG3' ' HG3' ' A' ' 308' ' ' PRO . 34.4 mtmm -88.02 138.97 30.71 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.592 174.362 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 326' ' ' PRO . . . . . 0.706 ' HB2' ' HB2' ' A' ' 330' ' ' ALA . 43.1 Cg_endo -86.01 167.34 9.57 Favored 'Trans proline' 0 N--CA 1.455 -0.759 0 C-N-CA 122.551 2.167 . . . . 0.0 112.145 178.61 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -70.47 122.98 20.69 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 177.83 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 52.8 mt-10 62.39 -121.04 0.66 Allowed 'General case' 0 N--CA 1.463 0.184 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 -172.328 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 329' ' ' SER . . . . . 0.655 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 33.9 m -111.94 -14.25 13.52 Favored 'General case' 0 C--N 1.322 -0.603 0 C-N-CA 120.535 -0.466 . . . . 0.0 110.118 172.813 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 330' ' ' ALA . . . . . 0.706 ' HB2' ' HB2' ' A' ' 326' ' ' PRO . . . 73.9 -169.19 0.11 Allowed 'General case' 0 N--CA 1.474 0.755 0 O-C-N 124.214 0.946 . . . . 0.0 113.37 172.467 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 331' ' ' ALA . . . . . 0.561 ' HA ' HG22 ' A' ' 229' ' ' THR . . . -80.08 141.54 35.72 Favored 'General case' 0 CA--C 1.517 -0.304 0 CA-C-N 115.101 -0.954 . . . . 0.0 110.611 -179.065 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 332' ' ' ILE . . . . . 0.586 HD12 HG12 ' A' ' 270' ' ' ILE . 16.1 mm -120.68 144.11 30.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.405 -175.503 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 82.3 m -114.04 97.13 6.18 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 175.007 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 334' ' ' ILE . . . . . 0.414 ' HA ' ' HB3' ' A' ' 268' ' ' PHE . 38.5 mm -81.65 125.34 39.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 115.999 -0.546 . . . . 0.0 112.339 -172.045 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 335' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -122.73 163.22 20.56 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.187 170.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 20.9 t-20 -94.04 -14.74 25.5 Favored 'General case' 0 C--N 1.319 -0.76 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 171.659 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 337' ' ' LYS . . . . . 0.65 ' HB2' ' HB3' ' A' ' 267' ' ' ALA . 26.7 tptp . . . . . 0 C--O 1.244 0.799 0 CA-C-N 114.613 -1.176 . . . . 0.0 111.257 174.431 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 26.5 m . . . . . 0 N--CA 1.442 -0.858 0 CA-C-O 121.314 0.578 . . . . 0.0 110.959 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 228' ' ' LEU . . . . . 0.488 ' HB3' ' HA ' ' A' ' 259' ' ' ALA . 55.2 mt -94.08 129.55 40.57 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.598 -178.6 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 229' ' ' THR . . . . . 0.456 ' HA ' ' HA ' ' A' ' 331' ' ' ALA . 60.6 p -126.97 179.53 5.36 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 120.275 -0.57 . . . . 0.0 111.281 -176.18 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 230' ' ' VAL . . . . . 0.756 HG11 HD12 ' A' ' 255' ' ' ILE . 75.3 t -146.39 138.8 19.79 Favored 'Isoleucine or valine' 0 C--O 1.237 0.409 0 CA-C-O 120.735 0.302 . . . . 0.0 110.708 -179.359 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 231' ' ' SER . . . . . 0.425 ' O ' ' HB ' ' A' ' 256' ' ' THR . 49.4 m -137.99 165.37 26.73 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.746 178.686 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 116.12 -108.84 1.89 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 119.913 -1.137 . . . . 0.0 113.995 172.041 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 11.0 mm-40 -62.49 155.36 68.43 Favored Pre-proline 0 C--N 1.328 -0.354 0 N-CA-C 112.761 0.652 . . . . 0.0 112.761 -173.225 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -63.9 175.56 2.98 Favored 'Trans proline' 0 C--N 1.349 0.573 0 C-N-CA 123.611 2.874 . . . . 0.0 112.661 178.161 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 235' ' ' GLU . . . . . 0.425 ' CB ' ' HD2' ' A' ' 325' ' ' LYS . 52.1 mm-40 -92.51 -176.79 4.4 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.695 -176.02 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 37.9 m-70 -113.82 143.75 44.14 Favored 'General case' 0 C--N 1.321 -0.658 0 C-N-CA 119.842 -0.743 . . . . 0.0 112.199 -165.33 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 237' ' ' LYS . . . . . 0.616 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.325 -0.484 0 CA-C-N 115.338 -0.847 . . . . 0.0 109.892 -176.11 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 252' ' ' GLN . . . . . 0.403 ' HA ' HE21 ' A' ' 252' ' ' GLN . 2.6 mm100 . . . . . 0 N--CA 1.467 0.381 0 CA-C-O 120.897 0.38 . . . . 0.0 111.055 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . 0.556 ' O ' ' HA ' ' A' ' 301' ' ' THR . . . 119.05 -153.11 17.03 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 119.25 -1.453 . . . . 0.0 113.752 176.435 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 254' ' ' THR . . . . . 0.562 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 77.8 p -94.78 148.97 21.74 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.219 0.533 . . . . 0.0 112.243 -172.644 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.756 HD12 HG11 ' A' ' 230' ' ' VAL . 22.6 pt -130.65 161.26 40.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.395 -0.82 . . . . 0.0 110.416 177.71 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . 0.425 ' HB ' ' O ' ' A' ' 231' ' ' SER . 93.6 m -94.76 106.19 18.16 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 174.533 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.42 HG12 HG22 ' A' ' 230' ' ' VAL . 34.3 m -93.21 141.46 14.68 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.914 0 C-N-CA 119.565 -0.854 . . . . 0.0 112.329 -174.693 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 53.8 m -93.0 8.91 37.96 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 114.016 -1.447 . . . . 0.0 109.239 169.684 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 259' ' ' ALA . . . . . 0.76 ' HB3' HD11 ' A' ' 262' ' ' LEU . . . -81.17 166.37 20.7 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.861 -177.641 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 42.6 m -124.93 108.26 11.7 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 111.988 0.366 . . . . 0.0 111.988 -174.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 92.71 50.14 2.57 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.617 -0.801 . . . . 0.0 113.429 173.316 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 262' ' ' LEU . . . . . 0.76 HD11 ' HB3' ' A' ' 259' ' ' ALA . 3.2 mp -86.94 143.59 27.32 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.891 0.346 . . . . 0.0 110.319 179.563 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 68.6 mt-30 -131.12 168.84 16.77 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.605 177.876 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 38.6 t -79.22 128.49 38.5 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 C-N-CA 120.8 -0.36 . . . . 0.0 110.338 178.184 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . 0.593 ' H ' ' HB ' ' A' ' 292' ' ' VAL . . . 102.41 8.67 43.2 Favored Glycine 0 N--CA 1.448 -0.532 0 C-N-CA 120.393 -0.908 . . . . 0.0 113.017 177.605 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -76.94 160.93 28.79 Favored 'General case' 0 CA--C 1.515 -0.373 0 CA-C-O 121.047 0.451 . . . . 0.0 110.579 176.424 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 267' ' ' ALA . . . . . 0.647 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -131.68 131.88 43.48 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 177.851 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 268' ' ' PHE . . . . . . . . . . . . . 3.6 p90 -152.33 169.31 22.83 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 119.468 -0.893 . . . . 0.0 111.76 -172.787 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 269' ' ' THR . . . . . 0.739 HG21 ' HB2' ' A' ' 287' ' ' PRO . 71.1 p -119.61 163.05 17.93 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.235 177.477 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 270' ' ' ILE . . . . . 0.593 HG12 HG12 ' A' ' 332' ' ' ILE . 56.7 mt -124.24 140.46 47.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 C-N-CA 120.815 -0.354 . . . . 0.0 111.432 -178.257 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -62.5 113.17 2.8 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.131 179.655 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 103.51 -21.68 38.31 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 121.083 -0.579 . . . . 0.0 112.031 -178.106 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . 0.604 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 51.1 t -101.1 103.77 15.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-O 121.089 0.471 . . . . 0.0 110.77 178.87 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 71.9 m-80 -122.67 156.35 34.52 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.165 -0.471 . . . . 0.0 109.967 179.234 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 53.8 p -71.95 173.83 7.83 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.14 0.495 . . . . 0.0 111.819 -175.842 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 27.1 m -112.02 -178.45 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.674 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 9.9 m-70 -54.51 93.26 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.023 -0.99 . . . . 0.0 110.965 -173.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -81.99 -28.2 32.75 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.981 0.42 . . . . 0.0 109.878 -175.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 279' ' ' ILE . . . . . 0.56 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.6 mp -82.18 -104.31 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.405 0 CA-C-N 116.083 -0.508 . . . . 0.0 109.817 -179.028 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 41.0 p -128.94 76.07 1.69 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.633 0.254 . . . . 0.0 110.676 179.173 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 34.4 mmtp 54.64 31.5 15.32 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.437 -174.559 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 36.3 t70 -87.32 138.44 31.48 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.647 -176.712 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 54.4 p -95.5 120.33 35.57 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.126 -178.593 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 81.5 p -128.93 -45.43 1.28 Allowed 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.276 -171.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 79.62 28.01 52.76 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.701 -0.761 . . . . 0.0 111.967 -178.58 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 25.5 mt-30 -76.05 134.62 71.05 Favored Pre-proline 0 C--N 1.328 -0.366 0 N-CA-C 110.214 -0.291 . . . . 0.0 110.214 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 287' ' ' PRO . . . . . 0.739 ' HB2' HG21 ' A' ' 269' ' ' THR . 26.3 Cg_exo -64.67 134.19 39.85 Favored 'Trans proline' 0 CA--C 1.53 0.308 0 C-N-CA 122.546 2.164 . . . . 0.0 112.098 -177.9 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 69.7 tp60 -76.65 129.14 35.97 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.578 -178.503 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 289' ' ' VAL . . . . . 0.486 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 25.7 t -97.01 137.61 24.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.831 -178.357 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 290' ' ' PHE . . . . . 0.669 ' HD1' ' HD2' ' A' ' 304' ' ' PRO . 55.0 m-85 -115.58 169.43 9.19 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.046 -178.836 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 9.8 tpt180 -131.06 142.56 50.3 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.167 0.508 . . . . 0.0 110.047 -179.154 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . 0.593 ' HB ' ' H ' ' A' ' 265' ' ' GLY . 55.8 t -92.49 130.57 41.4 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.877 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.683 179.693 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 293' ' ' LEU . . . . . 0.564 HD21 ' HB2' ' A' ' 303' ' ' SER . 2.9 mm? -105.71 -24.34 12.54 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.448 -0.342 . . . . 0.0 111.402 -178.355 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 294' ' ' ALA . . . . . . . . . . . . . . . -164.24 145.39 8.43 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.465 0.174 . . . . 0.0 110.982 179.688 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 295' ' ' VAL . . . . . 0.581 HG13 HG22 ' A' ' 300' ' ' VAL . 45.5 t -135.07 138.28 49.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 175.575 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 36.9 t -139.44 87.31 2.18 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 177.922 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 73.41 -128.22 11.31 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.118 -1.039 . . . . 0.0 110.544 -169.483 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 298' ' ' THR . . . . . 0.401 ' O ' HG22 ' A' ' 257' ' ' VAL . 31.1 p -102.35 29.34 5.25 Favored 'General case' 0 C--N 1.315 -0.898 0 O-C-N 122.155 -0.615 . . . . 0.0 110.506 172.63 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 63.5 m -112.07 105.42 13.79 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 174.033 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . 0.707 HG21 HD22 ' A' ' 262' ' ' LEU . 44.3 t -114.24 130.46 68.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 N-CA-C 112.259 0.466 . . . . 0.0 112.259 -168.797 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 301' ' ' THR . . . . . 0.556 ' HA ' ' O ' ' A' ' 253' ' ' GLY . 51.4 m -84.46 113.63 21.34 Favored 'General case' 0 C--O 1.237 0.402 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.219 173.342 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 302' ' ' ILE . . . . . 0.754 HD13 HD13 ' A' ' 255' ' ' ILE . 38.9 pt -116.39 157.13 17.4 Favored 'Isoleucine or valine' 0 C--O 1.24 0.599 0 CA-C-O 121.85 0.833 . . . . 0.0 112.897 -174.602 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 303' ' ' SER . . . . . 0.564 ' HB2' HD21 ' A' ' 293' ' ' LEU . 48.8 m -159.64 163.21 23.58 Favored Pre-proline 0 C--N 1.326 -0.435 0 CA-C-N 113.381 -1.736 . . . . 0.0 106.522 175.012 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 304' ' ' PRO . . . . . 0.669 ' HD2' ' HD1' ' A' ' 290' ' ' PHE . 5.1 Cg_exo -78.63 -134.23 0.14 OUTLIER 'Cis proline' 0 CA--C 1.534 0.518 0 CA-C-N 120.504 1.216 . . . . 0.0 113.047 0.85 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 305' ' ' LYS . . . . . 0.467 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -113.16 156.42 23.25 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.333 0.587 . . . . 0.0 112.375 -176.841 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 306' ' ' ILE . . . . . 0.86 HG23 HG21 ' A' ' 322' ' ' VAL . 2.6 mp -104.34 98.53 6.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.25 -0.886 . . . . 0.0 109.491 179.168 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 307' ' ' LEU . . . . . . . . . . . . . 76.3 mt -107.52 100.19 32.83 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.517 -0.31 . . . . 0.0 111.188 -175.007 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 308' ' ' PRO . . . . . 0.74 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 32.4 Cg_exo -66.94 138.22 47.42 Favored 'Trans proline' 0 N--CA 1.474 0.346 0 C-N-CA 123.622 2.881 . . . . 0.0 114.588 -173.757 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . 0.717 HG22 ' HB1' ' A' ' 320' ' ' ALA . 50.8 t -76.74 -29.9 18.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.051 -0.977 . . . . 0.0 108.771 167.772 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -79.2 30.03 0.22 Allowed 'General case' 0 C--O 1.234 0.289 0 CA-C-N 115.292 -0.867 . . . . 0.0 112.045 179.437 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 74.3 m-80 71.05 154.69 0.14 Allowed 'General case' 0 N--CA 1.469 0.481 0 N-CA-C 113.647 0.98 . . . . 0.0 113.647 173.692 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 312' ' ' THR . . . . . 0.526 ' OG1' ' HG2' ' A' ' 308' ' ' PRO . 44.4 m -168.18 -44.09 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 113.675 -1.602 . . . . 0.0 107.824 173.169 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 39.2 t70 -146.52 167.86 22.64 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 114.246 -1.343 . . . . 0.0 108.59 176.339 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 47.2 t -60.34 -38.26 77.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-O 120.787 0.327 . . . . 0.0 111.104 178.381 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -77.38 -17.83 57.86 Favored 'General case' 0 N--CA 1.463 0.212 0 N-CA-C 111.967 0.358 . . . . 0.0 111.967 -179.844 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 34.7 t -71.51 -25.02 62.08 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.579 -0.282 . . . . 0.0 111.447 -176.765 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 317' ' ' ARG . . . . . 0.768 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 54.2 mtp85 -69.71 -57.96 6.09 Favored Pre-proline 0 CA--C 1.536 0.426 0 N-CA-C 112.257 0.466 . . . . 0.0 112.257 -178.691 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 318' ' ' PRO . . . . . 0.768 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 36.8 Cg_exo -63.69 -35.23 59.27 Favored 'Trans proline' 0 C--N 1.357 0.975 0 C-N-CA 122.051 1.834 . . . . 0.0 112.684 -176.779 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 6.4 m-85 -99.43 32.11 2.9 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.022 -179.23 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . 0.717 ' HB1' HG22 ' A' ' 309' ' ' VAL . . . -55.55 127.68 30.92 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.893 178.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 47.9 t30 -120.99 -28.25 4.82 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.185 -176.654 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 322' ' ' VAL . . . . . 0.86 HG21 HG23 ' A' ' 306' ' ' ILE . 27.2 m -135.42 168.51 22.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.582 -0.281 . . . . 0.0 110.624 179.223 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 65.6 m-20 -52.83 -59.98 3.83 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 121.015 0.436 . . . . 0.0 110.769 176.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 324' ' ' ALA . . . . . 0.74 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -171.79 171.94 5.04 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.427 179.668 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 325' ' ' LYS . . . . . 0.489 ' HB3' ' CG2' ' A' ' 306' ' ' ILE . 21.7 pttp -112.46 117.95 46.27 Favored Pre-proline 0 C--N 1.326 -0.444 0 CA-C-O 121.251 0.548 . . . . 0.0 110.145 172.807 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -72.21 169.33 21.78 Favored 'Trans proline' 0 C--N 1.34 0.103 0 C-N-CA 123.284 2.656 . . . . 0.0 111.884 -177.408 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -63.42 122.27 15.83 Favored 'General case' 0 C--O 1.236 0.372 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 177.607 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 56.0 mt-10 67.79 165.33 0.23 Allowed 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.327 -171.519 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 329' ' ' SER . . . . . 0.681 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 49.0 m -66.65 -14.78 62.89 Favored 'General case' 0 C--N 1.326 -0.423 0 C-N-CA 120.999 -0.28 . . . . 0.0 111.746 -175.673 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 68.17 -162.36 0.2 Allowed 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 113.261 0.837 . . . . 0.0 113.261 171.097 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 331' ' ' ALA . . . . . 0.456 ' HA ' ' HA ' ' A' ' 229' ' ' THR . . . -82.98 150.49 26.35 Favored 'General case' 0 CA--C 1.519 -0.249 0 CA-C-N 115.333 -0.849 . . . . 0.0 111.122 -177.001 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 332' ' ' ILE . . . . . 0.593 HG12 HG12 ' A' ' 270' ' ' ILE . 42.6 mt -122.91 145.23 30.09 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.054 -178.559 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 0.425 ' HB ' ' OG1' ' A' ' 269' ' ' THR . 31.9 m -111.53 106.77 15.73 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 175.238 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 34.9 mm -83.78 121.67 36.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 112.889 0.7 . . . . 0.0 112.889 -170.203 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 335' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -111.62 -168.57 1.33 Allowed 'General case' 0 C--O 1.236 0.394 0 CA-C-N 115.094 -0.957 . . . . 0.0 109.672 171.491 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 74.4 m-80 -116.78 -15.1 10.74 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.806 -0.633 . . . . 0.0 110.989 176.557 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 23.2 pttm . . . . . 0 C--O 1.244 0.779 0 CA-C-O 118.546 -0.74 . . . . 0.0 111.288 -177.619 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 41.1 m . . . . . 0 C--O 1.234 0.264 0 CA-C-O 120.919 0.39 . . . . 0.0 111.525 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 228' ' ' LEU . . . . . 0.442 ' HB3' ' HB2' ' A' ' 259' ' ' ALA . 69.7 mt -89.3 125.12 34.98 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 109.711 -0.478 . . . . 0.0 109.711 177.658 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 58.4 p -124.27 175.35 7.12 Favored 'General case' 0 C--N 1.323 -0.573 0 C-N-CA 119.891 -0.724 . . . . 0.0 110.32 179.12 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 230' ' ' VAL . . . . . 0.669 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 89.0 t -148.63 141.82 18.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-O 120.76 0.314 . . . . 0.0 110.654 -177.614 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 49.0 m -92.38 129.13 38.41 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.905 -0.589 . . . . 0.0 109.619 174.142 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . -86.5 118.52 4.91 Favored Glycine 0 N--CA 1.444 -0.829 0 C-N-CA 120.264 -0.97 . . . . 0.0 113.322 -175.622 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 233' ' ' GLN . . . . . 0.941 ' HB3' ' HD2' ' A' ' 234' ' ' PRO . 75.7 mt-30 -80.2 178.97 2.05 Favored Pre-proline 0 C--N 1.328 -0.358 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 169.641 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 234' ' ' PRO . . . . . 0.941 ' HD2' ' HB3' ' A' ' 233' ' ' GLN . 72.9 Cg_exo -32.22 127.53 0.1 OUTLIER 'Trans proline' 0 C--N 1.366 1.463 0 C-N-CA 123.633 2.888 . . . . 0.0 113.861 -176.782 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 235' ' ' GLU . . . . . 0.701 ' OE1' ' HE3' ' A' ' 325' ' ' LYS . 46.1 mt-10 -95.58 -178.78 4.52 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.589 -175.727 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 236' ' ' HIS . . . . . 0.591 ' C ' ' HD3' ' A' ' 237' ' ' LYS . 91.7 m-70 -135.68 143.55 45.5 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 122.559 1.171 . . . . 0.0 113.549 -166.309 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 237' ' ' LYS . . . . . 0.591 ' HD3' ' C ' ' A' ' 236' ' ' HIS . 0.0 OUTLIER . . . . . 0 C--N 1.314 -0.942 0 CA-C-N 112.531 -2.122 . . . . 0.0 107.729 -179.71 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 252' ' ' GLN . . . . . 0.473 ' HA ' HE21 ' A' ' 252' ' ' GLN . 2.4 mm100 . . . . . 0 N--CA 1.454 -0.231 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . 0.515 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -105.81 122.25 7.06 Favored Glycine 0 N--CA 1.443 -0.883 0 C-N-CA 120.282 -0.961 . . . . 0.0 112.088 177.437 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 254' ' ' THR . . . . . 0.504 ' O ' ' HB2' ' A' ' 233' ' ' GLN . 48.3 p -106.33 116.79 32.54 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 109.16 -0.682 . . . . 0.0 109.16 176.439 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.725 HG22 ' H ' ' A' ' 233' ' ' GLN . 2.1 pp -125.49 165.63 22.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 N-CA-C 112.868 0.692 . . . . 0.0 112.868 -173.074 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 25.7 m -105.98 117.51 34.23 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 178.649 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.508 ' HA ' HG13 ' A' ' 230' ' ' VAL . 33.7 m -90.22 143.0 12.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 C-N-CA 119.71 -0.796 . . . . 0.0 112.757 -171.932 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 258' ' ' SER . . . . . 0.502 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 37.0 m -92.35 9.83 32.41 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 114.076 -1.42 . . . . 0.0 108.791 168.519 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 259' ' ' ALA . . . . . 0.442 ' HB2' ' HB3' ' A' ' 228' ' ' LEU . . . -101.1 168.3 9.68 Favored 'General case' 0 N--CA 1.454 -0.268 0 CA-C-N 115.049 -0.978 . . . . 0.0 109.371 -176.842 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 49.5 m -132.86 163.18 29.69 Favored 'General case' 0 C--N 1.324 -0.529 0 C-N-CA 120.806 -0.358 . . . . 0.0 111.502 -178.487 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 64.29 50.11 61.89 Favored Glycine 0 N--CA 1.452 -0.247 0 CA-C-N 115.729 -0.669 . . . . 0.0 113.128 177.047 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 262' ' ' LEU . . . . . . . . . . . . . 53.4 mt -101.76 159.68 15.12 Favored 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 120.652 -0.419 . . . . 0.0 110.543 179.73 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 73.4 mt-30 -143.35 165.14 28.33 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.988 -0.551 . . . . 0.0 109.812 179.744 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 41.2 t -79.86 134.47 27.49 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 N-CA-C 109.411 -0.588 . . . . 0.0 109.411 173.621 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . 0.512 ' H ' ' HB ' ' A' ' 292' ' ' VAL . . . 95.47 15.81 42.36 Favored Glycine 0 N--CA 1.446 -0.656 0 C-N-CA 120.284 -0.96 . . . . 0.0 112.729 178.918 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 40.7 m-20 -87.82 165.78 15.06 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.956 0.407 . . . . 0.0 110.689 174.784 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 267' ' ' ALA . . . . . 0.737 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -135.8 123.28 22.08 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.541 -0.754 . . . . 0.0 109.503 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 268' ' ' PHE . . . . . 0.42 ' HB2' ' O ' ' A' ' 333' ' ' THR . 5.9 p90 -141.16 175.03 9.97 Favored 'General case' 0 C--N 1.32 -0.704 0 C-N-CA 120.123 -0.631 . . . . 0.0 111.497 -172.554 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 64.3 p -118.32 154.22 32.7 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.748 176.542 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 270' ' ' ILE . . . . . 0.924 HG12 HG13 ' A' ' 332' ' ' ILE . 60.1 mt -124.58 141.28 45.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 120.761 0.315 . . . . 0.0 110.78 -178.068 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -76.03 125.49 29.22 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.903 178.472 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 96.58 -21.83 43.54 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.087 -178.749 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . 0.451 HG23 ' HG3' ' A' ' 326' ' ' PRO . 48.5 t -100.42 103.25 14.54 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 121.059 0.457 . . . . 0.0 110.054 176.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 274' ' ' ASN . . . . . 0.519 ' O ' ' HB ' ' A' ' 322' ' ' VAL . 70.8 m-80 -121.01 137.84 54.45 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 -179.756 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 275' ' ' SER . . . . . 0.666 ' HB3' ' HB2' ' A' ' 288' ' ' GLN . 60.3 p -73.01 174.48 7.8 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.006 0.431 . . . . 0.0 111.511 -175.124 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 276' ' ' VAL . . . . . 0.538 HG11 HG21 ' A' ' 309' ' ' VAL . 33.3 m -110.05 178.69 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.284 -179.421 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 277' ' ' HIS . . . . . 0.78 ' HB2' ' HA ' ' A' ' 281' ' ' LYS . 7.7 p80 -36.84 88.73 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.675 0 O-C-N 124.561 1.163 . . . . 0.0 113.985 -177.271 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 39.7 tt0 -84.64 -36.46 21.96 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.518 -178.173 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 279' ' ' ILE . . . . . 0.782 HG22 HG23 ' A' ' 280' ' ' THR . 2.6 mp -80.94 -84.33 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.305 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.398 -172.788 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . 0.782 HG23 HG22 ' A' ' 279' ' ' ILE . 32.6 p -127.69 45.79 2.67 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 111.597 0.221 . . . . 0.0 111.597 -174.686 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 281' ' ' LYS . . . . . 0.78 ' HA ' ' HB2' ' A' ' 277' ' ' HIS . 3.3 tmtp? 56.68 46.3 20.43 Favored 'General case' 0 CA--C 1.533 0.312 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 -176.792 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 49.2 p-10 -104.75 -162.01 0.86 Allowed 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 114.79 -1.095 . . . . 0.0 110.885 -175.085 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 76.1 p -105.97 124.45 49.59 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 178.749 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 81.2 p -127.28 -75.86 0.57 Allowed 'General case' 0 C--N 1.321 -0.643 0 C-N-CA 120.429 -0.508 . . . . 0.0 111.159 -174.26 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 67.09 31.24 77.22 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.898 -0.668 . . . . 0.0 112.002 -179.306 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 95.2 mm-40 -105.35 145.27 30.47 Favored Pre-proline 0 C--N 1.329 -0.311 0 N-CA-C 110.467 -0.197 . . . . 0.0 110.467 -178.142 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 287' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -55.22 137.5 77.06 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.805 2.336 . . . . 0.0 112.267 -179.813 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 288' ' ' GLN . . . . . 0.666 ' HB2' ' HB3' ' A' ' 275' ' ' SER . 52.0 tt0 -88.37 155.48 19.67 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.895 -176.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 59.0 t -89.84 113.34 25.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.349 178.638 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 290' ' ' PHE . . . . . 0.737 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 54.1 m-85 -100.52 131.12 46.6 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.46 -177.331 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 9.8 tpt180 -106.87 120.53 42.29 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.535 0.683 . . . . 0.0 109.877 178.368 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . 0.512 ' HB ' ' H ' ' A' ' 265' ' ' GLY . 57.6 t -67.66 140.01 19.94 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.954 0 CA-C-N 114.656 -1.157 . . . . 0.0 112.531 -176.198 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 293' ' ' LEU . . . . . 0.571 HD11 ' OG ' ' A' ' 303' ' ' SER . 4.4 mp -104.69 -30.94 9.62 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.739 175.534 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 294' ' ' ALA . . . . . 0.46 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -159.71 144.8 15.37 Favored 'General case' 0 C--N 1.333 -0.126 0 CA-C-O 120.534 0.207 . . . . 0.0 111.532 -176.358 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 70.7 t -138.09 100.23 1.68 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 175.589 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 35.8 m -138.49 113.5 9.27 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.439 -0.346 . . . . 0.0 111.085 -175.457 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 63.17 48.49 79.22 Favored Glycine 0 C--N 1.331 0.252 0 C-N-CA 120.834 -0.698 . . . . 0.0 111.922 -178.716 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 71.3 p 51.08 24.33 1.87 Allowed 'General case' 0 N--CA 1.469 0.5 0 C-N-CA 123.77 0.828 . . . . 0.0 112.229 -174.742 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 299' ' ' THR . . . . . 0.49 ' HA ' ' O ' ' A' ' 255' ' ' ILE . 29.0 m -111.48 111.18 22.02 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 176.304 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 294' ' ' ALA . 44.7 t -111.02 129.08 66.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.587 -172.445 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 93.5 m -90.97 116.08 28.49 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 172.298 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 302' ' ' ILE . . . . . 0.515 HG12 ' O ' ' A' ' 253' ' ' GLY . 29.2 pt -113.26 142.8 24.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 N-CA-C 112.917 0.71 . . . . 0.0 112.917 -171.57 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 303' ' ' SER . . . . . 0.571 ' OG ' HD11 ' A' ' 293' ' ' LEU . 89.5 p -137.71 142.13 35.56 Favored Pre-proline 0 C--N 1.322 -0.599 0 N-CA-C 106.95 -1.5 . . . . 0.0 106.95 169.906 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 304' ' ' PRO . . . . . 0.511 ' HD2' ' HD1' ' A' ' 290' ' ' PHE . 25.2 Cg_exo -66.83 -179.48 13.45 Favored 'Cis proline' 0 C--N 1.331 -0.377 0 CA-C-N 119.913 1.005 . . . . 0.0 112.88 0.868 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 305' ' ' LYS . . . . . 0.563 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -112.87 145.93 39.8 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-O 121.102 0.477 . . . . 0.0 111.543 -179.259 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 306' ' ' ILE . . . . . 0.519 HD12 ' N ' ' A' ' 306' ' ' ILE . 2.2 mp -72.11 106.11 2.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.262 -0.881 . . . . 0.0 111.058 -175.958 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 307' ' ' LEU . . . . . . . . . . . . . 86.7 mt -124.68 108.08 28.82 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.116 -0.493 . . . . 0.0 109.853 178.32 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 308' ' ' PRO . . . . . 0.679 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 23.8 Cg_exo -72.89 136.92 26.0 Favored 'Trans proline' 0 N--CA 1.476 0.452 0 C-N-CA 123.006 2.471 . . . . 0.0 114.423 -170.849 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . 0.539 HG23 ' O ' ' A' ' 322' ' ' VAL . 47.5 t -91.14 -23.53 5.87 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.186 0 CA-C-N 115.283 -0.871 . . . . 0.0 109.549 171.675 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 310' ' ' GLU . . . . . 0.45 ' OE1' ' HB2' ' A' ' 324' ' ' ALA . 50.2 mt-10 -80.9 8.53 8.11 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.182 -179.537 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 22.6 t-20 -74.99 137.36 41.5 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 178.399 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 68.6 m -60.67 -35.98 77.6 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 111.608 0.225 . . . . 0.0 111.608 -174.671 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 39.7 m-20 -61.38 126.76 28.52 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-O 121.167 0.508 . . . . 0.0 111.247 179.89 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 57.9 t -69.86 -28.26 36.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.493 -177.466 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -72.03 -17.92 61.99 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 111.997 0.369 . . . . 0.0 111.997 -179.828 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 35.1 t -76.82 -40.52 47.62 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 121.223 -0.191 . . . . 0.0 111.21 -177.41 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 317' ' ' ARG . . . . . 0.465 ' N ' ' HD2' ' A' ' 318' ' ' PRO . 65.9 mtt85 -54.44 -53.24 61.82 Favored Pre-proline 0 CA--C 1.54 0.584 0 N-CA-C 113.652 0.982 . . . . 0.0 113.652 -176.276 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 318' ' ' PRO . . . . . 0.465 ' HD2' ' N ' ' A' ' 317' ' ' ARG . 9.9 Cg_endo -56.36 -23.93 49.21 Favored 'Trans proline' 0 C--N 1.357 0.989 0 C-N-CA 122.468 2.112 . . . . 0.0 113.282 -176.86 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 53.9 m-85 -115.23 12.38 16.48 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.703 -177.4 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . 0.509 ' HB3' HG22 ' A' ' 309' ' ' VAL . . . -78.1 161.04 27.69 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.35 -178.306 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 29.2 t-20 -122.42 -44.51 2.25 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.734 -175.416 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 322' ' ' VAL . . . . . 0.539 ' O ' HG23 ' A' ' 309' ' ' VAL . 34.7 m -124.95 179.0 3.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.793 -177.884 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 74.9 m-20 -62.3 -60.09 4.07 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.81 -178.736 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 324' ' ' ALA . . . . . 0.679 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -151.27 172.51 15.75 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 112.785 0.661 . . . . 0.0 112.785 -174.27 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 325' ' ' LYS . . . . . 0.701 ' HE3' ' OE1' ' A' ' 235' ' ' GLU . 14.9 ptmt -99.06 126.41 38.29 Favored Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 114.252 -1.34 . . . . 0.0 110.152 170.818 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 326' ' ' PRO . . . . . 0.451 ' HG3' HG23 ' A' ' 273' ' ' VAL . 90.8 Cg_endo -86.21 168.23 9.03 Favored 'Trans proline' 0 N--CA 1.461 -0.403 0 C-N-CA 122.963 2.442 . . . . 0.0 111.857 -179.757 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -69.8 122.71 19.75 Favored 'General case' 0 C--O 1.236 0.385 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 174.448 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 62.2 mm-40 58.22 -140.79 0.75 Allowed 'General case' 0 CA--C 1.528 0.115 0 O-C-N 123.53 0.519 . . . . 0.0 109.647 -172.822 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 329' ' ' SER . . . . . 0.669 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 48.7 m -112.86 -14.12 13.1 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 120.44 -0.504 . . . . 0.0 111.076 176.615 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 67.33 -151.02 0.18 Allowed 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 112.402 0.519 . . . . 0.0 112.402 175.329 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 331' ' ' ALA . . . . . 0.447 ' C ' HD12 ' A' ' 332' ' ' ILE . . . -89.86 127.4 35.99 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.945 -178.293 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 332' ' ' ILE . . . . . 0.924 HG13 HG12 ' A' ' 270' ' ' ILE . 1.7 mp -110.96 140.12 31.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.432 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 0.42 ' O ' ' HB2' ' A' ' 268' ' ' PHE . 50.8 m -103.43 99.0 8.81 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.147 -0.479 . . . . 0.0 109.739 -178.944 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 22.6 mm -84.27 127.67 39.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 N-CA-C 113.934 1.087 . . . . 0.0 113.934 -171.405 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 335' ' ' LEU . . . . . 0.469 HD23 ' N ' ' A' ' 335' ' ' LEU . 1.6 pt? -153.36 -172.85 4.37 Favored 'General case' 0 N--CA 1.447 -0.576 0 CA-C-N 114.024 -1.444 . . . . 0.0 107.65 168.816 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 20.6 t-20 -121.35 -23.92 5.57 Favored 'General case' 0 C--N 1.321 -0.649 0 C-N-CA 120.363 -0.535 . . . . 0.0 110.583 -178.599 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 68.1 mttm . . . . . 0 C--O 1.245 0.818 0 CA-C-O 118.097 -0.954 . . . . 0.0 111.399 179.071 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 54.7 p . . . . . 0 C--O 1.233 0.232 0 CA-C-O 121.349 0.595 . . . . 0.0 110.051 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 228' ' ' LEU . . . . . 0.528 HD13 ' H ' ' A' ' 260' ' ' SER . 91.1 mt -108.52 146.77 32.71 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.116 -0.947 . . . . 0.0 108.871 177.028 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 77.7 p -130.56 179.6 5.84 Favored 'General case' 0 C--N 1.325 -0.477 0 C-N-CA 119.973 -0.691 . . . . 0.0 110.675 -179.013 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 230' ' ' VAL . . . . . 0.88 HG11 HD12 ' A' ' 255' ' ' ILE . 91.3 t -146.51 136.71 17.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 120.91 0.386 . . . . 0.0 110.592 178.902 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 33.7 t -107.04 146.42 31.17 Favored 'General case' 0 N--CA 1.45 -0.465 0 CA-C-N 116.039 -0.528 . . . . 0.0 109.604 176.498 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . 0.478 ' O ' ' HD3' ' A' ' 234' ' ' PRO . . . 124.4 149.18 7.6 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.396 -0.906 . . . . 0.0 111.592 -176.817 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 66.5 mt-30 -98.6 103.82 20.88 Favored Pre-proline 0 C--N 1.323 -0.568 0 CA-C-N 116.72 0.26 . . . . 0.0 111.117 -176.583 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 234' ' ' PRO . . . . . 0.478 ' HD3' ' O ' ' A' ' 232' ' ' GLY . 4.8 Cg_exo -74.96 125.49 9.38 Favored 'Trans proline' 0 N--CA 1.457 -0.626 0 C-N-CA 122.259 1.972 . . . . 0.0 111.077 177.676 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -131.93 141.07 49.22 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.609 -179.14 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 236' ' ' HIS . . . . . 0.492 ' HE1' ' HA ' ' A' ' 252' ' ' GLN . 87.2 m-70 -141.48 149.04 40.41 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.681 -0.69 . . . . 0.0 109.947 178.207 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 237' ' ' LYS . . . . . 0.652 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.32 -0.685 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.498 -175.349 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 252' ' ' GLN . . . . . 0.492 ' HA ' ' HE1' ' A' ' 236' ' ' HIS . 2.7 mm100 . . . . . 0 N--CA 1.449 -0.481 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . 0.47 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -113.76 121.92 5.61 Favored Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.126 -1.035 . . . . 0.0 112.305 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 254' ' ' THR . . . . . 0.451 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 65.7 p -104.16 116.71 32.67 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 177.418 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.88 HD12 HG11 ' A' ' 230' ' ' VAL . 17.0 pt -123.84 147.38 28.27 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.981 -173.93 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 85.6 m -95.71 110.92 22.98 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 174.449 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.471 ' HA ' HG13 ' A' ' 230' ' ' VAL . 34.0 m -89.8 143.14 11.82 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.723 0 C-N-CA 119.93 -0.708 . . . . 0.0 112.833 -168.137 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 258' ' ' SER . . . . . 0.421 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 34.4 t -91.91 7.39 42.29 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 114.454 -1.248 . . . . 0.0 108.667 169.77 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 259' ' ' ALA . . . . . 0.693 ' HB3' HD21 ' A' ' 262' ' ' LEU . . . -88.25 175.08 7.83 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-N 115.473 -0.785 . . . . 0.0 109.243 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . 0.528 ' H ' HD13 ' A' ' 228' ' ' LEU . 32.5 t -134.67 130.19 35.95 Favored 'General case' 0 C--N 1.323 -0.547 0 C-N-CA 120.465 -0.494 . . . . 0.0 111.57 -177.93 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 97.5 16.76 33.29 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.856 -0.688 . . . . 0.0 113.951 174.081 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 262' ' ' LEU . . . . . 0.693 HD21 ' HB3' ' A' ' 259' ' ' ALA . 2.0 mm? -65.7 128.92 37.91 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-N 117.344 0.572 . . . . 0.0 110.859 -178.841 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -128.83 175.39 8.67 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 176.335 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 43.4 t -78.64 131.2 34.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 174.325 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 100.15 9.19 48.92 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.627 -0.797 . . . . 0.0 112.699 -179.557 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -86.12 165.45 16.58 Favored 'General case' 0 CA--C 1.511 -0.521 0 CA-C-O 121.12 0.486 . . . . 0.0 110.147 175.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 267' ' ' ALA . . . . . 0.693 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -140.27 145.68 37.6 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.471 -179.575 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 268' ' ' PHE . . . . . 0.525 ' HB3' HD13 ' A' ' 334' ' ' ILE . 4.6 p90 -159.73 166.04 31.28 Favored 'General case' 0 C--N 1.319 -0.744 0 C-N-CA 120.127 -0.629 . . . . 0.0 111.328 -178.603 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 71.8 p -119.34 126.76 52.19 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.861 -0.608 . . . . 0.0 109.968 177.776 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 270' ' ' ILE . . . . . 0.595 HG12 HD12 ' A' ' 332' ' ' ILE . 46.6 mt -88.89 135.98 24.5 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.912 -177.49 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -65.31 122.16 16.5 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.23 -179.772 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 99.08 -23.86 34.64 Favored Glycine 0 N--CA 1.452 -0.256 0 CA-C-N 115.996 -0.547 . . . . 0.0 112.241 -179.392 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 49.0 t -94.22 108.42 20.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 121.152 0.501 . . . . 0.0 110.37 176.528 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 274' ' ' ASN . . . . . 0.409 ' HB2' ' OD1' ' A' ' 323' ' ' ASP . 63.7 m-80 -123.9 159.99 28.47 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 116.004 -0.544 . . . . 0.0 109.602 -179.398 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 53.1 p -92.04 164.68 13.52 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-O 121.124 0.487 . . . . 0.0 111.327 -179.048 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 276' ' ' VAL . . . . . 0.538 HG11 HG21 ' A' ' 309' ' ' VAL . 30.0 m -125.9 167.46 20.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.544 178.518 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 28.9 m80 -126.0 92.07 3.51 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.595 -0.275 . . . . 0.0 110.72 178.69 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 84.1 mt-30 -72.59 -14.13 61.54 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.769 0.319 . . . . 0.0 111.081 179.184 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 279' ' ' ILE . . . . . 0.513 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.2 mp -77.05 -59.95 2.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 116.539 -0.3 . . . . 0.0 110.319 -178.475 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 51.4 p -85.36 -10.02 56.85 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.454 -179.878 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 31.9 mmmt 58.35 43.81 19.39 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.7 -178.29 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -112.34 154.49 25.64 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.1 -178.357 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 49.8 p -105.96 123.01 47.3 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 176.731 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 284' ' ' THR . . . . . 0.432 ' HB ' ' HG3' ' A' ' 286' ' ' GLN . 82.0 p -124.53 -37.28 2.52 Favored 'General case' 0 C--N 1.317 -0.814 0 C-N-CA 120.487 -0.485 . . . . 0.0 111.508 -172.06 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 70.45 29.49 69.92 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.601 -0.809 . . . . 0.0 111.809 -177.394 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 286' ' ' GLN . . . . . 0.432 ' HG3' ' HB ' ' A' ' 284' ' ' THR . 24.4 mt-30 -76.25 113.87 32.43 Favored Pre-proline 0 C--N 1.33 -0.243 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.826 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 287' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_exo -51.65 126.55 19.97 Favored 'Trans proline' 0 C--O 1.232 0.224 0 C-N-CA 122.42 2.08 . . . . 0.0 111.928 -179.112 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -77.23 130.06 36.74 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 -175.018 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 289' ' ' VAL . . . . . 0.675 HG11 ' HG2' ' A' ' 337' ' ' LYS . 57.6 t -90.01 130.74 38.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.006 -176.108 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 290' ' ' PHE . . . . . 0.693 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 4.6 m-85 -98.79 151.18 21.07 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.05 -178.062 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 291' ' ' ARG . . . . . 0.495 ' HD2' ' C ' ' A' ' 290' ' ' PHE . 1.0 OUTLIER -113.18 130.09 56.32 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 174.172 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 47.9 t -92.49 129.51 42.96 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.231 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.923 -177.625 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 293' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -114.6 -20.7 10.6 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.684 -179.251 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 294' ' ' ALA . . . . . 0.586 ' HB3' ' HB ' ' A' ' 301' ' ' THR . . . -148.92 136.61 20.49 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.641 -0.424 . . . . 0.0 111.914 -179.303 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 295' ' ' VAL . . . . . 0.46 HG11 ' O ' ' A' ' 262' ' ' LEU . 80.4 t -142.7 123.0 10.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.681 -0.691 . . . . 0.0 109.79 175.515 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 36.2 t -154.09 108.66 3.06 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.58 -0.282 . . . . 0.0 110.742 179.158 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 63.57 54.8 29.21 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 121.031 -0.604 . . . . 0.0 112.189 -179.296 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 58.4 p 52.28 21.89 1.82 Allowed 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 123.725 0.81 . . . . 0.0 112.754 -176.764 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 45.8 m -107.64 117.83 35.13 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 173.911 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . 0.451 ' O ' ' HA ' ' A' ' 254' ' ' THR . 48.1 t -117.08 129.96 72.78 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.299 -172.041 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 301' ' ' THR . . . . . 0.586 ' HB ' ' HB3' ' A' ' 294' ' ' ALA . 45.1 m -98.21 116.75 31.09 Favored 'General case' 0 C--O 1.236 0.381 0 N-CA-C 108.744 -0.835 . . . . 0.0 108.744 174.718 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 302' ' ' ILE . . . . . 0.47 HG12 ' O ' ' A' ' 253' ' ' GLY . 29.2 pt -111.81 146.17 17.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 113.373 0.879 . . . . 0.0 113.373 -168.627 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 303' ' ' SER . . . . . 0.526 ' HB3' ' HA ' ' A' ' 304' ' ' PRO . 47.4 m -132.25 166.24 30.15 Favored Pre-proline 0 C--N 1.32 -0.698 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 171.899 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 304' ' ' PRO . . . . . 0.526 ' HA ' ' HB3' ' A' ' 303' ' ' SER . 6.0 Cg_exo -79.67 -142.71 0.24 Allowed 'Cis proline' 0 CA--C 1.531 0.327 0 CA-C-N 120.72 1.293 . . . . 0.0 112.636 0.291 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 305' ' ' LYS . . . . . 0.508 ' C ' HD12 ' A' ' 306' ' ' ILE . 0.0 OUTLIER -97.51 147.6 24.08 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.389 0.614 . . . . 0.0 112.152 178.784 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 306' ' ' ILE . . . . . 1.017 HG23 HG21 ' A' ' 322' ' ' VAL . 1.9 mp -119.83 110.35 28.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 115.043 -0.98 . . . . 0.0 110.131 -176.534 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 307' ' ' LEU . . . . . 0.434 ' HA ' ' HD3' ' A' ' 308' ' ' PRO . 88.6 mt -126.32 115.08 23.48 Favored Pre-proline 0 C--N 1.332 -0.183 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.221 -177.697 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 308' ' ' PRO . . . . . 0.774 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 35.3 Cg_exo -67.31 147.81 78.83 Favored 'Trans proline' 0 N--CA 1.474 0.339 0 C-N-CA 123.762 2.975 . . . . 0.0 114.714 -173.521 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . 0.617 HG22 ' HB1' ' A' ' 320' ' ' ALA . 26.2 t -93.34 -17.81 7.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 114.866 -1.061 . . . . 0.0 108.607 167.654 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 59.4 mm-40 -76.9 -6.71 53.57 Favored 'General case' 0 C--O 1.233 0.199 0 CA-C-N 115.23 -0.895 . . . . 0.0 112.117 -178.157 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 4.1 m120 -85.62 151.47 23.87 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.917 0.389 . . . . 0.0 111.101 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 30.9 m -93.28 -1.16 56.37 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.579 0.704 . . . . 0.0 109.125 175.347 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 313' ' ' ASP . . . . . 0.638 ' O ' ' HG3' ' A' ' 317' ' ' ARG . 59.7 t0 -58.0 117.57 4.47 Favored 'General case' 0 C--N 1.333 -0.116 0 CA-C-N 115.328 -0.851 . . . . 0.0 110.781 -179.292 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 49.0 t -53.54 -33.8 22.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.835 -0.62 . . . . 0.0 112.172 -178.446 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -85.18 -29.81 24.43 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 112.183 0.438 . . . . 0.0 112.183 -178.017 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . 0.559 ' HB3' ' HB3' ' A' ' 313' ' ' ASP . 33.5 t -82.03 -27.74 32.88 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 111.759 0.281 . . . . 0.0 111.759 -175.133 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 317' ' ' ARG . . . . . 0.638 ' HG3' ' O ' ' A' ' 313' ' ' ASP . 49.8 mtp85 -63.98 -52.87 53.24 Favored Pre-proline 0 CA--C 1.539 0.548 0 N-CA-C 112.935 0.717 . . . . 0.0 112.935 -176.478 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 318' ' ' PRO . . . . . 0.604 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 22.1 Cg_exo -67.82 -28.93 35.95 Favored 'Trans proline' 0 C--N 1.357 0.991 0 C-N-CA 121.979 1.786 . . . . 0.0 112.871 -177.005 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 5.1 m-85 -98.42 12.84 33.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.017 -179.005 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . 0.617 ' HB1' HG22 ' A' ' 309' ' ' VAL . . . -59.76 144.27 48.76 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.539 -178.666 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 321' ' ' ASN . . . . . 0.452 ' OD1' HG13 ' A' ' 322' ' ' VAL . 17.5 p30 -142.98 -12.17 0.75 Allowed 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.53 -177.434 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 322' ' ' VAL . . . . . 1.017 HG21 HG23 ' A' ' 306' ' ' ILE . 35.0 m -139.15 178.65 3.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.404 177.658 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 323' ' ' ASP . . . . . 0.409 ' OD1' ' HB2' ' A' ' 274' ' ' ASN . 51.6 m-20 -64.01 -62.58 1.54 Allowed 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.978 176.87 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 324' ' ' ALA . . . . . 0.774 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -162.94 173.75 13.24 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 116.143 -0.481 . . . . 0.0 112.094 -175.44 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 22.0 pttp -119.28 106.97 42.04 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 115.218 -0.901 . . . . 0.0 109.457 172.277 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -86.29 167.52 9.13 Favored 'Trans proline' 0 C--O 1.235 0.367 0 C-N-CA 122.624 2.216 . . . . 0.0 113.507 -172.204 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 327' ' ' ALA . . . . . 0.424 ' O ' ' HB2' ' A' ' 328' ' ' GLU . . . -79.48 132.79 36.44 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 170.155 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 328' ' ' GLU . . . . . 0.424 ' HB2' ' O ' ' A' ' 327' ' ' ALA . 62.1 mm-40 73.27 166.25 0.3 Allowed 'General case' 0 N--CA 1.467 0.387 0 O-C-N 123.566 0.542 . . . . 0.0 109.576 -170.589 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 329' ' ' SER . . . . . 0.686 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 53.9 m -104.44 -10.53 17.64 Favored 'General case' 0 C--N 1.319 -0.731 0 C-N-CA 120.349 -0.54 . . . . 0.0 111.803 -174.265 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 67.62 -161.22 0.22 Allowed 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 113.022 0.749 . . . . 0.0 113.022 172.459 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -75.33 142.72 43.15 Favored 'General case' 0 CA--C 1.518 -0.275 0 CA-C-N 115.117 -0.947 . . . . 0.0 110.475 179.414 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 332' ' ' ILE . . . . . 0.686 HG13 HG23 ' A' ' 230' ' ' VAL . 24.8 mm -120.62 144.46 29.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.753 -175.783 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 33.8 m -111.27 97.63 6.92 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 178.404 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 334' ' ' ILE . . . . . 0.525 HD13 ' HB3' ' A' ' 268' ' ' PHE . 39.5 mm -81.57 131.54 33.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 112.769 0.655 . . . . 0.0 112.769 -173.247 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 335' ' ' LEU . . . . . 0.46 HD23 ' N ' ' A' ' 335' ' ' LEU . 1.7 pt? -152.03 -167.16 2.69 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 114.685 -1.143 . . . . 0.0 108.723 173.118 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 15.9 p-10 -110.88 -25.41 9.87 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 109.635 -0.505 . . . . 0.0 109.635 176.014 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 337' ' ' LYS . . . . . 0.675 ' HG2' HG11 ' A' ' 289' ' ' VAL . 27.1 tptp . . . . . 0 C--O 1.247 0.925 0 O-C-N 124.397 1.061 . . . . 0.0 111.407 177.506 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 61.1 p . . . . . 0 N--CA 1.453 -0.32 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 228' ' ' LEU . . . . . 0.608 HD22 ' H ' ' A' ' 260' ' ' SER . 53.4 mt -111.15 127.1 55.47 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.491 -173.31 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 229' ' ' THR . . . . . 0.527 ' HA ' ' HA ' ' A' ' 331' ' ' ALA . 64.3 p -129.91 -178.83 4.88 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 120.694 -0.402 . . . . 0.0 111.22 -178.822 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 230' ' ' VAL . . . . . 0.744 ' O ' ' HB2' ' A' ' 329' ' ' SER . 34.9 t -134.17 151.59 32.61 Favored 'Isoleucine or valine' 0 C--O 1.24 0.594 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 -179.43 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 41.7 t -126.89 125.37 41.48 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.23 175.383 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 87.61 91.75 1.02 Allowed Glycine 0 CA--C 1.52 0.382 0 C-N-CA 120.888 -0.673 . . . . 0.0 113.97 176.15 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 233' ' ' GLN . . . . . 0.562 ' HG2' ' OG ' ' A' ' 329' ' ' SER . 94.8 mm-40 -97.86 117.01 65.66 Favored Pre-proline 0 CA--C 1.519 -0.242 0 O-C-N 122.821 -0.223 . . . . 0.0 110.623 171.843 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 234' ' ' PRO . . . . . 0.523 ' HD3' HG22 ' A' ' 255' ' ' ILE . 11.8 Cg_exo -67.09 172.93 9.18 Favored 'Trans proline' 0 N--CA 1.462 -0.353 0 C-N-CA 122.685 2.257 . . . . 0.0 111.741 176.565 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 235' ' ' GLU . . . . . 0.416 ' HG3' ' HE2' ' A' ' 237' ' ' LYS . 9.7 pt-20 -96.42 146.91 24.36 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.013 178.058 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 236' ' ' HIS . . . . . 0.629 ' C ' ' HD2' ' A' ' 237' ' ' LYS . 28.6 m80 -126.07 129.78 49.81 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.088 0.471 . . . . 0.0 111.01 -173.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 237' ' ' LYS . . . . . 0.629 ' HD2' ' C ' ' A' ' 236' ' ' HIS . 2.8 mptp? . . . . . 0 C--N 1.323 -0.546 0 CA-C-N 115.441 -0.799 . . . . 0.0 110.0 -179.114 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 252' ' ' GLN . . . . . 0.568 ' HA ' HE21 ' A' ' 252' ' ' GLN . 2.2 mm100 . . . . . 0 N--CA 1.447 -0.591 0 N-CA-C 110.043 -0.354 . . . . 0.0 110.043 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . 0.469 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -154.47 172.58 32.98 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 119.667 -1.254 . . . . 0.0 113.032 -178.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 254' ' ' THR . . . . . 0.549 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 47.0 p -119.38 128.81 54.41 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 177.822 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.523 HG22 ' HD3' ' A' ' 234' ' ' PRO . 26.6 pt -114.66 149.73 16.83 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.357 -175.659 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 40.8 m -98.4 110.47 23.05 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 177.223 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.525 HG21 HD12 ' A' ' 262' ' ' LEU . 35.0 m -92.41 144.99 8.15 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.859 0 CA-C-O 121.631 0.729 . . . . 0.0 112.697 -171.123 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 41.1 m -90.3 7.75 36.83 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 114.046 -1.434 . . . . 0.0 108.41 168.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 259' ' ' ALA . . . . . 0.579 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -91.06 162.04 14.86 Favored 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 115.117 -0.947 . . . . 0.0 110.468 -177.497 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . 0.608 ' H ' HD22 ' A' ' 228' ' ' LEU . 48.7 m -137.82 138.91 39.64 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.122 -0.49 . . . . 0.0 109.814 177.36 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 94.55 34.26 6.4 Favored Glycine 0 N--CA 1.447 -0.586 0 C-N-CA 120.444 -0.884 . . . . 0.0 112.233 -178.42 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 262' ' ' LEU . . . . . 0.525 HD12 HG21 ' A' ' 257' ' ' VAL . 67.5 mt -102.37 143.39 32.18 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 178.361 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 3.0 mm100 -142.78 175.32 9.91 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 178.116 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 264' ' ' VAL . . . . . 0.434 HG22 ' HA ' ' A' ' 294' ' ' ALA . 49.0 t -78.17 132.48 32.37 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.202 177.698 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 103.77 8.24 40.24 Favored Glycine 0 N--CA 1.453 -0.211 0 C-N-CA 120.569 -0.824 . . . . 0.0 112.775 179.406 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -89.05 157.56 18.3 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.915 0.388 . . . . 0.0 110.066 176.838 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 267' ' ' ALA . . . . . 0.605 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -131.23 121.94 25.68 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 178.883 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 268' ' ' PHE . . . . . 0.408 ' HB3' HD13 ' A' ' 334' ' ' ILE . 4.6 p90 -145.14 164.57 30.87 Favored 'General case' 0 C--N 1.32 -0.706 0 C-N-CA 119.4 -0.92 . . . . 0.0 111.988 -173.929 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 75.7 p -117.64 129.6 55.85 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.531 -0.759 . . . . 0.0 109.76 176.191 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 270' ' ' ILE . . . . . . . . . . . . . 66.0 mt -97.54 141.52 15.75 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.766 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 179.838 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 271' ' ' ALA . . . . . 0.47 ' HB3' ' HB1' ' A' ' 330' ' ' ALA . . . -63.98 132.84 51.87 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.032 0.444 . . . . 0.0 111.438 -176.577 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 98.68 -22.35 41.37 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.992 -0.623 . . . . 0.0 112.158 -178.56 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . 0.565 ' O ' ' HA ' ' A' ' 287' ' ' PRO . 45.2 t -77.95 103.44 5.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 120.665 0.269 . . . . 0.0 110.459 178.476 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 274' ' ' ASN . . . . . 0.416 ' O ' ' HB ' ' A' ' 322' ' ' VAL . 3.3 m120 -96.72 136.97 36.51 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 108.79 -0.819 . . . . 0.0 108.79 174.842 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 275' ' ' SER . . . . . 0.404 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 8.1 t -99.48 165.58 11.57 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.773 0.321 . . . . 0.0 110.399 -176.219 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 19.0 m -128.76 155.49 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.014 0 CA-C-N 115.092 -0.958 . . . . 0.0 109.987 167.271 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 277' ' ' HIS . . . . . 0.623 ' HB2' ' HB3' ' A' ' 282' ' ' ASP . 29.3 m80 -100.41 89.74 4.06 Favored 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 108.547 -0.909 . . . . 0.0 108.547 175.148 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 5.3 tm0? -59.78 -47.54 85.3 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.091 -172.139 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 59.2 mt -56.44 -48.15 80.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 N-CA-C 111.942 0.349 . . . . 0.0 111.942 -177.166 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 40.6 p -94.97 -3.71 48.0 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 112.414 0.524 . . . . 0.0 112.414 -176.3 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 4.0 tppp? 59.22 53.2 5.52 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 121.285 0.564 . . . . 0.0 110.256 -178.337 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 282' ' ' ASP . . . . . 0.623 ' HB3' ' HB2' ' A' ' 277' ' ' HIS . 37.2 t70 -120.13 116.37 25.52 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.299 -175.416 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 67.8 p -107.16 118.17 35.99 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.3 178.83 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 67.5 p -129.05 -15.98 4.14 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 112.063 0.394 . . . . 0.0 112.063 -174.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 87.23 -3.09 86.89 Favored Glycine 0 N--CA 1.453 -0.179 0 C-N-CA 120.61 -0.805 . . . . 0.0 112.724 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 286' ' ' GLN . . . . . 0.472 ' HA ' ' HD3' ' A' ' 287' ' ' PRO . 82.9 mt-30 -64.76 137.92 97.3 Favored Pre-proline 0 C--N 1.33 -0.27 0 N-CA-C 110.425 -0.213 . . . . 0.0 110.425 179.006 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 287' ' ' PRO . . . . . 0.565 ' HA ' ' O ' ' A' ' 273' ' ' VAL . 32.8 Cg_exo -62.52 149.37 91.23 Favored 'Trans proline' 0 CA--C 1.529 0.257 0 C-N-CA 122.633 2.222 . . . . 0.0 113.448 -174.558 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 288' ' ' GLN . . . . . 0.553 ' HA ' HE21 ' A' ' 288' ' ' GLN . 1.9 tp-100 -87.06 136.82 32.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.075 176.989 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 289' ' ' VAL . . . . . 0.405 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 38.8 t -94.55 130.15 43.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.901 -0.591 . . . . 0.0 109.645 177.592 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 290' ' ' PHE . . . . . 0.605 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 53.6 m-85 -99.97 165.52 11.5 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.926 0.393 . . . . 0.0 111.772 -175.145 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 30.3 mmt-85 -119.76 127.98 53.32 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 174.075 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 57.7 t -86.6 130.74 36.26 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.886 0 CA-C-O 120.785 0.326 . . . . 0.0 111.583 -175.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 293' ' ' LEU . . . . . 0.511 HD21 ' HB2' ' A' ' 303' ' ' SER . 3.1 mm? -103.58 -34.88 8.5 Favored 'General case' 0 C--N 1.333 -0.112 0 CA-C-N 115.945 -0.571 . . . . 0.0 111.297 178.503 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 294' ' ' ALA . . . . . 0.51 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -154.22 140.1 18.19 Favored 'General case' 0 CA--C 1.518 -0.252 0 C-N-CA 120.648 -0.421 . . . . 0.0 111.593 -179.149 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 96.9 t -135.73 100.09 2.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.705 175.016 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 50.5 m -141.77 118.29 10.92 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.845 -176.33 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 63.93 46.5 91.36 Favored Glycine 0 C--N 1.33 0.236 0 C-N-CA 121.147 -0.549 . . . . 0.0 112.144 -178.018 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 72.2 p 51.0 23.54 1.53 Allowed 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 123.701 0.8 . . . . 0.0 112.221 -175.739 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 299' ' ' THR . . . . . 0.45 ' HA ' ' O ' ' A' ' 255' ' ' ILE . 50.7 m -114.0 118.47 34.22 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 176.609 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . 0.549 ' O ' ' HA ' ' A' ' 254' ' ' THR . 43.6 t -110.18 128.39 66.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.412 -172.515 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 59.3 m -83.97 114.14 21.49 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 108.091 -1.078 . . . . 0.0 108.091 171.568 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 302' ' ' ILE . . . . . 0.469 HG12 ' O ' ' A' ' 253' ' ' GLY . 31.0 pt -111.01 144.76 18.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 N-CA-C 113.279 0.844 . . . . 0.0 113.279 -167.059 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 303' ' ' SER . . . . . 0.511 ' HB2' HD21 ' A' ' 293' ' ' LEU . 50.4 m -149.6 157.7 38.43 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-N 114.041 -1.436 . . . . 0.0 107.409 173.018 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 304' ' ' PRO . . . . . 0.496 ' O ' ' HA ' ' A' ' 303' ' ' SER . 15.7 Cg_exo -69.27 -162.21 1.72 Allowed 'Cis proline' 0 CA--C 1.531 0.34 0 CA-C-N 120.151 1.09 . . . . 0.0 112.811 0.742 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 305' ' ' LYS . . . . . 0.611 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -95.27 142.38 27.75 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.401 0.619 . . . . 0.0 111.964 -178.124 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 306' ' ' ILE . . . . . 0.643 HG23 HG21 ' A' ' 322' ' ' VAL . 2.0 mp -86.35 84.92 2.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.079 -0.964 . . . . 0.0 109.939 -178.397 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 307' ' ' LEU . . . . . . . . . . . . . 96.8 mt -112.38 102.45 54.17 Favored Pre-proline 0 C--N 1.324 -0.501 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.579 -178.757 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 308' ' ' PRO . . . . . 0.684 ' HD2' HD22 ' A' ' 311' ' ' ASN . 12.4 Cg_exo -75.5 150.29 35.86 Favored 'Trans proline' 0 N--CA 1.462 -0.334 0 C-N-CA 122.898 2.399 . . . . 0.0 113.004 -174.398 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 42.5 t -72.26 -27.3 26.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 108.647 -0.872 . . . . 0.0 108.647 170.305 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 54.7 mm-40 -92.21 32.68 1.14 Allowed 'General case' 0 N--CA 1.453 -0.285 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.805 176.3 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.684 HD22 ' HD2' ' A' ' 308' ' ' PRO . 26.0 t-20 -71.98 -31.93 66.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.378 -178.336 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 312' ' ' THR . . . . . 0.5 ' HB ' ' O ' ' A' ' 311' ' ' ASN . 84.9 m 83.34 -25.43 0.14 Allowed 'General case' 0 N--CA 1.469 0.491 0 O-C-N 124.088 0.867 . . . . 0.0 111.116 -178.837 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 65.8 m-20 -81.89 122.9 28.33 Favored 'General case' 0 C--O 1.233 0.216 0 C-N-CA 120.522 -0.471 . . . . 0.0 109.96 172.571 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 38.8 t -59.35 -39.38 78.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 115.188 -0.914 . . . . 0.0 112.229 -173.092 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -66.22 -25.27 66.83 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 112.229 0.455 . . . . 0.0 112.229 -177.332 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 42.4 t -86.54 -12.59 48.32 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 111.773 0.286 . . . . 0.0 111.773 -177.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 317' ' ' ARG . . . . . 0.564 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 51.8 mtp85 -62.8 -50.61 76.78 Favored Pre-proline 0 CA--C 1.538 0.492 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 -178.503 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 318' ' ' PRO . . . . . 0.564 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 39.2 Cg_exo -63.32 -26.05 71.48 Favored 'Trans proline' 0 C--N 1.356 0.936 0 C-N-CA 121.903 1.735 . . . . 0.0 112.788 -177.755 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 6.0 m-85 -93.23 19.99 7.47 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.335 -179.409 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -59.49 131.02 49.68 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 112.31 0.485 . . . . 0.0 112.31 -175.799 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 76.3 m-20 -128.15 -18.38 4.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.507 -0.77 . . . . 0.0 110.255 175.052 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 322' ' ' VAL . . . . . 0.643 HG21 HG23 ' A' ' 306' ' ' ILE . 33.8 m -138.7 176.75 5.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.107 -179.576 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -98.74 -18.97 17.73 Favored 'General case' 0 C--N 1.327 -0.385 0 C-N-CA 121.002 -0.279 . . . . 0.0 111.123 -179.773 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 324' ' ' ALA . . . . . 0.529 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -168.62 156.67 8.1 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.98 -173.117 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 325' ' ' LYS . . . . . 0.401 ' HA ' ' HD3' ' A' ' 326' ' ' PRO . 35.4 mtmm -87.02 120.87 71.71 Favored Pre-proline 0 N--CA 1.453 -0.294 0 N-CA-C 107.618 -1.252 . . . . 0.0 107.618 165.442 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 326' ' ' PRO . . . . . 0.476 ' HG2' HG22 ' A' ' 273' ' ' VAL . 51.1 Cg_exo -61.14 162.81 18.53 Favored 'Trans proline' 0 C--O 1.233 0.274 0 C-N-CA 122.525 2.15 . . . . 0.0 113.612 -171.372 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -73.45 132.35 42.84 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 108.593 -0.891 . . . . 0.0 108.593 170.896 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 9.0 pm0 42.38 -137.46 0.25 Allowed 'General case' 0 N--CA 1.47 0.565 0 O-C-N 124.132 0.895 . . . . 0.0 110.338 -169.757 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 329' ' ' SER . . . . . 0.744 ' HB2' ' O ' ' A' ' 230' ' ' VAL . 38.1 m -113.98 -44.87 3.11 Favored 'General case' 0 C--N 1.322 -0.622 0 C-N-CA 119.797 -0.761 . . . . 0.0 111.604 176.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 330' ' ' ALA . . . . . 0.47 ' HB1' ' HB3' ' A' ' 271' ' ' ALA . . . 78.54 -166.66 0.04 OUTLIER 'General case' 0 N--CA 1.474 0.771 0 O-C-N 123.813 0.696 . . . . 0.0 112.52 176.169 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 331' ' ' ALA . . . . . 0.527 ' HA ' ' HA ' ' A' ' 229' ' ' THR . . . -84.95 157.92 20.67 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.755 -0.657 . . . . 0.0 112.386 -173.764 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 332' ' ' ILE . . . . . 0.479 HD11 ' CG2' ' A' ' 230' ' ' VAL . 29.1 mt -110.0 144.97 17.15 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.232 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.083 -179.223 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 54.4 m -111.45 98.46 7.48 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 172.35 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 334' ' ' ILE . . . . . 0.408 HD13 ' HB3' ' A' ' 268' ' ' PHE . 32.2 mm -84.96 134.79 26.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 N-CA-C 113.247 0.832 . . . . 0.0 113.247 -171.074 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 335' ' ' LEU . . . . . 0.427 HD23 ' N ' ' A' ' 335' ' ' LEU . 1.9 pt? -164.39 -166.16 1.07 Allowed 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 115.074 -0.966 . . . . 0.0 109.62 172.418 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 74.3 m-80 -143.84 21.39 1.8 Allowed 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 175.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 68.2 mttm . . . . . 0 C--O 1.242 0.66 0 CA-C-N 115.196 -0.911 . . . . 0.0 110.84 -174.371 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 51.8 m . . . . . 0 C--O 1.234 0.285 0 CA-C-O 121.051 0.453 . . . . 0.0 111.906 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 228' ' ' LEU . . . . . 0.531 HD13 ' H ' ' A' ' 260' ' ' SER . 88.8 mt -68.77 144.77 54.24 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.317 173.891 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 40.7 p -132.29 179.32 6.18 Favored 'General case' 0 C--N 1.326 -0.441 0 C-N-CA 120.262 -0.575 . . . . 0.0 111.137 -176.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 230' ' ' VAL . . . . . 1.056 HG23 HD11 ' A' ' 332' ' ' ILE . 72.1 t -143.22 145.87 22.15 Favored 'Isoleucine or valine' 0 C--O 1.239 0.532 0 CA-C-O 120.775 0.322 . . . . 0.0 110.373 -179.446 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 46.2 t -131.74 97.58 4.24 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 115.234 -0.894 . . . . 0.0 109.181 173.818 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . -142.15 -157.53 7.19 Favored Glycine 0 N--CA 1.447 -0.6 0 C-N-CA 120.184 -1.008 . . . . 0.0 112.639 -176.008 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 83.5 mt-30 -86.1 159.98 52.95 Favored Pre-proline 0 C--N 1.323 -0.571 0 N-CA-C 110.396 -0.224 . . . . 0.0 110.396 179.775 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo -64.51 174.66 4.15 Favored 'Trans proline' 0 C--N 1.35 0.619 0 C-N-CA 122.875 2.383 . . . . 0.0 111.418 176.357 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 235' ' ' GLU . . . . . 0.538 ' HA ' ' OE1' ' A' ' 235' ' ' GLU . 3.9 mm-40 -91.9 167.54 12.05 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 113.461 0.911 . . . . 0.0 113.461 -174.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 236' ' ' HIS . . . . . 0.519 ' CE1' ' HA2' ' A' ' 253' ' ' GLY . 23.2 m80 -111.63 143.21 42.89 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 113.266 -1.788 . . . . 0.0 111.432 -165.239 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 237' ' ' LYS . . . . . 0.431 ' HD3' ' C ' ' A' ' 236' ' ' HIS . 18.7 mmtp . . . . . 0 C--N 1.317 -0.833 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.793 -173.461 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 252' ' ' GLN . . . . . 0.49 ' HB3' ' O ' ' A' ' 302' ' ' ILE . 3.0 mm100 . . . . . 0 CA--C 1.527 0.095 0 CA-C-O 120.503 0.192 . . . . 0.0 110.729 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . 0.519 ' HA2' ' CE1' ' A' ' 236' ' ' HIS . . . -95.5 152.22 20.29 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.184 177.877 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 52.1 p -129.5 116.96 19.73 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.758 0.314 . . . . 0.0 110.588 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.755 HD12 HG11 ' A' ' 230' ' ' VAL . 18.0 pt -125.94 149.92 31.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 N-CA-C 112.25 0.463 . . . . 0.0 112.25 -175.798 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 91.5 m -98.86 113.35 25.43 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 175.124 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.667 HG21 HD12 ' A' ' 262' ' ' LEU . 34.8 m -90.12 143.26 11.56 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.669 0 N-CA-C 113.38 0.881 . . . . 0.0 113.38 -167.009 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 258' ' ' SER . . . . . 0.433 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 37.4 t -92.73 7.94 41.44 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 113.795 -1.548 . . . . 0.0 108.523 168.163 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 259' ' ' ALA . . . . . 0.522 ' HB3' HD11 ' A' ' 262' ' ' LEU . . . -84.77 165.78 17.51 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-N 115.616 -0.72 . . . . 0.0 109.822 -177.344 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . 0.531 ' H ' HD13 ' A' ' 228' ' ' LEU . 49.4 m -123.47 142.0 51.44 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 120.814 0.34 . . . . 0.0 111.443 -178.005 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 67.3 50.65 43.27 Favored Glycine 0 N--CA 1.452 -0.25 0 CA-C-N 115.812 -0.631 . . . . 0.0 113.58 175.317 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 262' ' ' LEU . . . . . 0.667 HD12 HG21 ' A' ' 257' ' ' VAL . 77.7 mt -99.64 145.83 27.15 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 117.086 0.443 . . . . 0.0 110.842 178.034 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 83.6 mt-30 -142.94 171.75 13.63 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.928 178.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 50.8 t -77.16 133.32 31.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 176.731 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . 0.483 ' O ' ' HE3' ' A' ' 337' ' ' LYS . . . 107.62 -7.83 36.76 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.44 -0.886 . . . . 0.0 112.619 -179.372 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 63.4 m-20 -69.28 155.63 40.09 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-O 121.069 0.462 . . . . 0.0 110.567 178.262 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 267' ' ' ALA . . . . . 0.621 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -130.2 129.69 43.72 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.45 -0.795 . . . . 0.0 108.884 177.442 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 268' ' ' PHE . . . . . . . . . . . . . 3.2 p90 -151.38 175.63 12.06 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 119.97 -0.692 . . . . 0.0 111.466 -175.456 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 269' ' ' THR . . . . . 0.468 HG21 ' HB2' ' A' ' 287' ' ' PRO . 82.7 p -126.14 147.19 49.67 Favored 'General case' 0 C--N 1.32 -0.674 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 176.571 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 270' ' ' ILE . . . . . . . . . . . . . 47.1 mm -103.65 138.26 28.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 N-CA-C 110.236 -0.283 . . . . 0.0 110.236 179.381 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -63.34 135.4 56.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.442 -178.608 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 89.41 -23.19 20.02 Favored Glycine 0 CA--C 1.517 0.198 0 CA-C-N 115.92 -0.582 . . . . 0.0 112.712 179.755 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . 0.473 HG21 ' HG3' ' A' ' 326' ' ' PRO . 42.5 t -86.09 130.24 36.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 120.925 0.393 . . . . 0.0 110.879 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 72.3 m-80 -135.24 142.08 45.91 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.329 179.671 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 65.2 p -84.04 165.81 18.25 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.252 0.549 . . . . 0.0 111.746 -178.279 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 276' ' ' VAL . . . . . 0.428 HG11 HG21 ' A' ' 309' ' ' VAL . 35.4 m -113.64 175.82 2.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 115.315 -0.857 . . . . 0.0 110.668 179.432 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 277' ' ' HIS . . . . . 0.43 ' HB3' ' HA ' ' A' ' 281' ' ' LYS . 5.8 p80 22.04 77.75 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.866 0 O-C-N 124.822 1.326 . . . . 0.0 113.866 179.304 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 278' ' ' GLN . . . . . 0.402 ' HA ' ' NE2' ' A' ' 278' ' ' GLN . 2.7 tp-100 -62.03 -50.52 71.7 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.177 -179.055 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 279' ' ' ILE . . . . . 0.582 ' H ' ' HB3' ' A' ' 282' ' ' ASP . 2.5 mp -104.43 -77.44 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 174.814 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 35.9 p -141.11 92.61 2.5 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 177.477 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 281' ' ' LYS . . . . . 0.43 ' HA ' ' HB3' ' A' ' 277' ' ' HIS . 31.7 mmmt 59.82 26.99 16.23 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.058 -0.973 . . . . 0.0 110.503 -172.6 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 282' ' ' ASP . . . . . 0.582 ' HB3' ' H ' ' A' ' 279' ' ' ILE . 37.3 t70 -81.01 117.38 21.56 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.338 -0.846 . . . . 0.0 109.858 178.605 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 41.1 p -105.52 105.78 15.97 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.991 0.424 . . . . 0.0 110.931 -176.502 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 52.9 p -129.18 -7.58 4.82 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.183 -177.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 67.82 32.6 78.06 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.601 -0.809 . . . . 0.0 113.368 176.249 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 286' ' ' GLN . . . . . 0.415 ' HA ' ' HD3' ' A' ' 287' ' ' PRO . 11.7 mm100 -72.09 135.89 82.32 Favored Pre-proline 0 C--N 1.325 -0.479 0 CA-C-N 117.06 0.43 . . . . 0.0 110.2 179.106 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 287' ' ' PRO . . . . . 0.468 ' HB2' HG21 ' A' ' 269' ' ' THR . 41.0 Cg_exo -57.0 135.0 68.21 Favored 'Trans proline' 0 C--O 1.235 0.333 0 C-N-CA 122.465 2.11 . . . . 0.0 111.958 -178.778 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 2.5 tm0? -75.08 128.93 36.67 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 -177.294 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 46.4 t -94.19 123.83 46.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.935 0.398 . . . . 0.0 110.512 -177.621 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 290' ' ' PHE . . . . . 0.621 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 4.6 m-85 -97.28 168.6 10.32 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.818 -177.214 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 11.9 tpt180 -139.37 121.16 15.41 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 177.355 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 60.7 t -75.61 134.25 29.58 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.913 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.868 -172.824 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 293' ' ' LEU . . . . . 0.621 HD11 ' HB3' ' A' ' 303' ' ' SER . 7.0 mp -104.38 -35.2 8.02 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.628 178.388 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 294' ' ' ALA . . . . . 0.529 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -149.75 137.95 20.51 Favored 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 120.667 -0.413 . . . . 0.0 111.641 -176.545 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 66.5 t -136.03 109.63 9.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.555 174.79 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 50.4 m -151.48 117.02 5.38 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.544 -177.279 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 61.21 46.97 93.4 Favored Glycine 0 C--N 1.33 0.218 0 C-N-CA 120.804 -0.712 . . . . 0.0 111.79 -177.83 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 76.3 p 51.78 19.79 1.01 Allowed 'General case' 0 N--CA 1.471 0.587 0 C-N-CA 123.76 0.824 . . . . 0.0 112.427 -175.169 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 54.3 m -105.22 116.68 32.35 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 176.756 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . 0.529 ' HA ' ' O ' ' A' ' 294' ' ' ALA . 49.0 t -114.21 125.77 71.58 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.288 -172.753 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 53.9 m -87.77 115.76 25.44 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 172.78 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 302' ' ' ILE . . . . . 0.49 ' O ' ' HB3' ' A' ' 252' ' ' GLN . 28.6 pt -110.81 147.81 14.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-O 121.867 0.842 . . . . 0.0 113.156 -169.012 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 303' ' ' SER . . . . . 0.621 ' HB3' HD11 ' A' ' 293' ' ' LEU . 48.2 t -151.23 148.82 23.27 Favored Pre-proline 0 C--N 1.317 -0.812 0 CA-C-N 113.808 -1.542 . . . . 0.0 106.911 174.487 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 304' ' ' PRO . . . . . 0.476 ' C ' ' HA ' ' A' ' 303' ' ' SER . 32.2 Cg_exo -64.31 152.71 74.16 Favored 'Cis proline' 0 C--N 1.332 -0.302 0 C-N-CA 124.252 -1.145 . . . . 0.0 113.299 0.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 305' ' ' LYS . . . . . 0.452 ' HE3' HD11 ' A' ' 307' ' ' LEU . 0.0 OUTLIER -82.04 148.81 28.41 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-N 114.888 -1.051 . . . . 0.0 110.184 173.761 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 306' ' ' ILE . . . . . 1.011 HG21 ' HA ' ' A' ' 325' ' ' LYS . 42.5 mm -84.23 117.85 30.47 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 N-CA-C 113.02 0.748 . . . . 0.0 113.02 -167.626 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 307' ' ' LEU . . . . . 0.452 HD11 ' HE3' ' A' ' 305' ' ' LYS . 82.1 mt -121.46 100.0 44.94 Favored Pre-proline 0 C--N 1.331 -0.199 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.782 177.314 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 308' ' ' PRO . . . . . 0.756 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 16.0 Cg_exo -72.74 134.48 22.06 Favored 'Trans proline' 0 C--O 1.232 0.218 0 C-N-CA 123.19 2.593 . . . . 0.0 113.611 -176.271 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . 0.678 ' HA ' ' HB2' ' A' ' 316' ' ' SER . 46.4 t -72.18 -34.66 50.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.356 0.598 . . . . 0.0 109.409 171.345 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 87.8 mt-10 -77.07 36.27 0.17 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.288 -0.869 . . . . 0.0 111.939 179.777 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.404 ' HB2' ' HB2' ' A' ' 308' ' ' PRO . 20.3 t-20 -122.3 56.71 1.1 Allowed 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 -178.751 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 312' ' ' THR . . . . . 0.568 ' HB ' HG23 ' A' ' 314' ' ' VAL . 30.0 m 60.35 17.43 7.12 Favored 'General case' 0 CA--C 1.539 0.553 0 CA-C-O 121.716 0.77 . . . . 0.0 109.411 -171.762 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 37.1 t70 69.53 -2.58 1.88 Allowed 'General case' 0 CA--C 1.537 0.466 0 CA-C-N 114.728 -1.124 . . . . 0.0 111.233 -177.369 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 314' ' ' VAL . . . . . 0.568 HG23 ' HB ' ' A' ' 312' ' ' THR . 57.6 t -57.44 -45.59 85.67 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 N-CA-C 112.723 0.638 . . . . 0.0 112.723 -177.759 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . 0.53 ' HB3' ' O ' ' A' ' 308' ' ' PRO . . . -74.44 -17.54 60.77 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.021 0.439 . . . . 0.0 110.899 -179.714 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . 0.678 ' HB2' ' HA ' ' A' ' 309' ' ' VAL . 44.3 t -81.36 -18.72 44.64 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.552 177.126 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 317' ' ' ARG . . . . . 0.684 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 37.3 mmm-85 -61.1 -55.84 40.34 Favored Pre-proline 0 CA--C 1.536 0.42 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.635 -176.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 318' ' ' PRO . . . . . 0.684 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 11.8 Cg_exo -71.98 -41.13 2.18 Favored 'Trans proline' 0 C--N 1.357 1.003 0 C-N-CA 121.565 1.51 . . . . 0.0 112.588 -178.516 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER 177.35 96.67 0.01 OUTLIER 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.103 177.653 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . 0.617 ' HB2' ' HA ' ' A' ' 316' ' ' SER . . . -69.68 138.51 53.02 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.077 176.899 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 19.6 p30 -129.23 -27.9 2.41 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.479 -0.328 . . . . 0.0 111.57 176.833 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 322' ' ' VAL . . . . . 0.843 HG21 HG23 ' A' ' 306' ' ' ILE . 35.1 m -138.31 179.49 3.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.703 0.287 . . . . 0.0 110.596 177.758 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 -90.38 -32.72 16.33 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.502 177.776 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 324' ' ' ALA . . . . . 0.756 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -149.2 159.51 44.19 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.638 -0.255 . . . . 0.0 111.478 -175.351 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 325' ' ' LYS . . . . . 1.011 ' HA ' HG21 ' A' ' 306' ' ' ILE . 64.3 pttt -79.94 146.9 64.79 Favored Pre-proline 0 N--CA 1.452 -0.335 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 171.413 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 326' ' ' PRO . . . . . 0.548 ' HD3' HG21 ' A' ' 306' ' ' ILE . 50.6 Cg_exo -57.33 129.81 36.02 Favored 'Trans proline' 0 N--CA 1.462 -0.365 0 C-N-CA 122.253 1.969 . . . . 0.0 111.873 -178.299 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -75.13 121.79 22.61 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 174.285 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER 61.95 -135.95 0.52 Allowed 'General case' 0 C--N 1.332 -0.158 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 -167.474 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 329' ' ' SER . . . . . 0.718 ' HB2' ' O ' ' A' ' 230' ' ' VAL . 50.5 m -113.95 -41.45 3.55 Favored 'General case' 0 C--N 1.32 -0.711 0 C-N-CA 120.16 -0.616 . . . . 0.0 109.871 169.67 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 330' ' ' ALA . . . . . 0.436 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 79.77 -171.04 0.04 OUTLIER 'General case' 0 N--CA 1.479 1.008 0 O-C-N 124.129 0.893 . . . . 0.0 113.394 170.819 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -83.77 157.22 22.17 Favored 'General case' 0 C--O 1.233 0.213 0 CA-C-N 115.176 -0.92 . . . . 0.0 111.107 -176.823 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 332' ' ' ILE . . . . . 1.056 HD11 HG23 ' A' ' 230' ' ' VAL . 1.5 mp -126.37 146.37 32.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.474 -174.854 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 0.417 ' HB ' ' OG1' ' A' ' 269' ' ' THR . 88.6 m -110.66 99.16 8.16 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.998 -0.742 . . . . 0.0 108.998 173.251 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 37.8 mm -81.58 125.7 39.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -171.238 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 335' ' ' LEU . . . . . 0.432 ' HB2' ' O ' ' A' ' 267' ' ' ALA . 8.2 mp -113.07 167.3 10.64 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.074 -0.966 . . . . 0.0 109.958 172.167 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 74.0 m-80 -124.33 6.57 8.4 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 115.315 -0.857 . . . . 0.0 109.271 174.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 337' ' ' LYS . . . . . 0.483 ' HE3' ' O ' ' A' ' 265' ' ' GLY . 21.5 pttp . . . . . 0 C--O 1.244 0.798 0 O-C-N 124.656 1.223 . . . . 0.0 112.565 -179.418 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 29.0 t . . . . . 0 N--CA 1.457 -0.114 0 CA-C-O 121.559 0.695 . . . . 0.0 109.499 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 228' ' ' LEU . . . . . 0.498 HD13 ' H ' ' A' ' 260' ' ' SER . 89.8 mt -99.77 146.79 26.17 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.274 -0.875 . . . . 0.0 109.237 178.533 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 229' ' ' THR . . . . . 0.429 ' HA ' ' HA ' ' A' ' 331' ' ' ALA . 72.5 p -128.93 178.75 6.16 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 119.835 -0.746 . . . . 0.0 111.075 -177.89 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 230' ' ' VAL . . . . . 0.652 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 75.7 t -147.15 127.68 5.39 Favored 'Isoleucine or valine' 0 C--O 1.237 0.434 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.482 -178.918 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 34.1 t -92.53 145.18 24.64 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.012 176.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 115.46 141.64 7.44 Favored Glycine 0 N--CA 1.444 -0.773 0 C-N-CA 120.619 -0.801 . . . . 0.0 111.647 -179.097 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 233' ' ' GLN . . . . . 0.922 ' HG3' ' H ' ' A' ' 328' ' ' GLU . 15.0 mp0 -101.75 103.69 30.16 Favored Pre-proline 0 C--N 1.321 -0.638 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 -177.739 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -85.3 122.47 2.47 Favored 'Trans proline' 0 N--CA 1.45 -1.084 0 C-N-CA 121.485 1.457 . . . . 0.0 111.751 179.64 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 235' ' ' GLU . . . . . 0.479 ' HG2' ' HB3' ' A' ' 325' ' ' LYS . 54.2 mt-10 -154.07 120.05 5.32 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.328 178.787 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 63.3 t-80 -138.64 146.77 42.08 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 174.474 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 237' ' ' LYS . . . . . 0.659 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 5.8 mptt . . . . . 0 C--N 1.326 -0.415 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.765 -169.484 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 4.7 mp0 . . . . . 0 N--CA 1.444 -0.749 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . 0.605 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -80.75 93.08 1.46 Allowed Glycine 0 N--CA 1.446 -0.643 0 C-N-CA 120.312 -0.947 . . . . 0.0 112.23 177.748 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 72.7 p -94.5 116.33 28.66 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.022 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 2.1 pp -136.24 171.53 16.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 N-CA-C 113.012 0.745 . . . . 0.0 113.012 -173.121 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 64.9 m -111.65 117.89 34.15 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 177.505 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.461 ' HB ' ' H ' ' A' ' 259' ' ' ALA . 34.9 m -90.9 144.7 8.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 N-CA-C 113.838 1.051 . . . . 0.0 113.838 -169.101 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 258' ' ' SER . . . . . 0.417 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 39.2 t -92.22 8.42 38.2 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 113.772 -1.558 . . . . 0.0 108.339 166.188 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 259' ' ' ALA . . . . . 0.461 ' H ' ' HB ' ' A' ' 257' ' ' VAL . . . -92.85 166.13 12.57 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.274 -0.876 . . . . 0.0 109.908 -177.52 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . 0.498 ' H ' HD13 ' A' ' 228' ' ' LEU . 32.4 t -139.17 137.09 35.75 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.77 0.319 . . . . 0.0 110.158 178.949 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 97.26 29.4 7.96 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.199 -177.821 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 262' ' ' LEU . . . . . 0.442 HD12 HG21 ' A' ' 257' ' ' VAL . 79.2 mt -101.63 126.78 48.52 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.107 0.479 . . . . 0.0 111.16 -179.617 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 97.0 mm-40 -134.11 -178.92 5.25 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.257 -0.883 . . . . 0.0 108.873 177.359 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 41.0 t -77.81 131.12 35.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 176.653 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 106.41 9.01 32.16 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.305 -0.95 . . . . 0.0 113.195 179.021 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -88.88 163.32 15.68 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.994 0.426 . . . . 0.0 110.31 176.57 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 267' ' ' ALA . . . . . 0.715 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -135.38 146.52 48.42 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.474 -0.784 . . . . 0.0 109.023 177.917 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 268' ' ' PHE . . . . . 0.407 ' HZ ' HG21 ' A' ' 302' ' ' ILE . 2.7 p90 -163.87 175.48 10.38 Favored 'General case' 0 C--N 1.325 -0.489 0 C-N-CA 120.054 -0.658 . . . . 0.0 111.709 -177.841 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 73.9 p -125.41 144.69 50.4 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.471 -0.786 . . . . 0.0 109.131 173.808 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 270' ' ' ILE . . . . . 0.402 ' HB ' ' HB ' ' A' ' 273' ' ' VAL . 58.7 mt -103.14 141.66 18.57 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 C-N-CA 121.127 -0.229 . . . . 0.0 110.968 -176.752 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -67.38 125.79 27.23 Favored 'General case' 0 C--O 1.232 0.133 0 CA-C-O 120.869 0.366 . . . . 0.0 110.947 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 91.82 -22.24 32.23 Favored Glycine 0 N--CA 1.453 -0.189 0 C-N-CA 121.058 -0.591 . . . . 0.0 112.194 -178.262 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . 0.402 ' HB ' ' HB ' ' A' ' 270' ' ' ILE . 48.9 t -94.58 102.55 13.73 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-O 121.33 0.586 . . . . 0.0 110.743 178.346 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 274' ' ' ASN . . . . . 0.687 ' HA ' ' HA ' ' A' ' 287' ' ' PRO . 70.7 m-80 -110.17 150.83 28.08 Favored 'General case' 0 C--N 1.318 -0.801 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 174.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 275' ' ' SER . . . . . 0.488 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 7.6 t -85.35 -169.58 2.71 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 120.301 -0.559 . . . . 0.0 110.092 -174.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 27.3 m -113.27 177.46 1.66 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 CA-C-N 115.612 -0.722 . . . . 0.0 112.054 179.553 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 277' ' ' HIS . . . . . 0.792 ' CG ' ' HA ' ' A' ' 281' ' ' LYS . 3.4 p80 -57.03 119.69 6.73 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 113.893 -1.503 . . . . 0.0 111.838 173.695 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -81.94 -49.52 10.21 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.987 -177.867 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 279' ' ' ILE . . . . . 0.659 ' H ' HD12 ' A' ' 279' ' ' ILE . 2.7 mp -68.18 -93.74 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.401 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.163 -174.759 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . 0.431 HG23 HG22 ' A' ' 279' ' ' ILE . 36.2 p -137.98 68.24 1.4 Allowed 'General case' 0 C--O 1.235 0.307 0 CA-C-O 120.637 0.256 . . . . 0.0 111.393 -174.939 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 281' ' ' LYS . . . . . 0.792 ' HA ' ' CG ' ' A' ' 277' ' ' HIS . 0.0 OUTLIER 56.59 32.33 20.74 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.675 -177.016 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 282' ' ' ASP . . . . . 0.579 ' O ' ' HB3' ' A' ' 277' ' ' HIS . 1.6 m-20 -74.86 -177.03 3.11 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.645 176.134 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 68.9 p -106.57 108.07 19.39 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 120.76 0.314 . . . . 0.0 110.211 178.258 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 74.8 p -117.07 -58.29 2.08 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.681 -175.314 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 64.24 30.85 78.97 Favored Glycine 0 C--O 1.23 -0.124 0 C-N-CA 121.064 -0.589 . . . . 0.0 113.347 174.633 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 286' ' ' GLN . . . . . 0.425 ' HA ' HE21 ' A' ' 286' ' ' GLN . 2.9 mm100 -101.12 129.69 26.58 Favored Pre-proline 0 C--N 1.323 -0.584 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 179.259 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 287' ' ' PRO . . . . . 0.687 ' HA ' ' HA ' ' A' ' 274' ' ' ASN . 48.3 Cg_exo -56.16 138.15 82.02 Favored 'Trans proline' 0 C--N 1.344 0.329 0 C-N-CA 122.563 2.175 . . . . 0.0 112.159 -179.356 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 288' ' ' GLN . . . . . 0.47 ' HA ' HE21 ' A' ' 288' ' ' GLN . 2.2 tp-100 -64.81 139.9 58.81 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.78 -179.069 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 52.8 t -97.42 124.0 50.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 176.205 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 290' ' ' PHE . . . . . 0.715 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 6.2 m-85 -98.87 151.44 20.85 Favored 'General case' 0 C--N 1.323 -0.559 0 C-N-CA 120.884 -0.326 . . . . 0.0 110.876 -174.578 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 37.2 mmt180 -116.97 118.86 33.59 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.691 -0.686 . . . . 0.0 109.34 174.187 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 48.9 t -75.56 127.52 37.05 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.954 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.874 -178.517 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 293' ' ' LEU . . . . . . . . . . . . . 84.8 mt -110.84 -19.48 12.81 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.928 -176.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 294' ' ' ALA . . . . . 0.663 ' HB3' ' HB ' ' A' ' 301' ' ' THR . . . -155.72 138.3 15.05 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 111.85 0.315 . . . . 0.0 111.85 -178.887 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 295' ' ' VAL . . . . . 0.438 HG22 HG13 ' A' ' 300' ' ' VAL . 60.5 t -138.14 132.59 42.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 175.039 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 41.5 t -157.95 110.61 2.38 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.677 -0.238 . . . . 0.0 110.97 -176.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 60.76 46.03 95.29 Favored Glycine 0 C--N 1.33 0.25 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.028 179.798 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 298' ' ' THR . . . . . 0.42 ' O ' HG22 ' A' ' 257' ' ' VAL . 75.6 p 53.91 17.9 1.47 Allowed 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 123.887 0.875 . . . . 0.0 112.647 -175.845 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 52.9 m -102.77 109.55 21.18 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 108.015 -1.106 . . . . 0.0 108.015 171.171 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . 0.438 HG13 HG22 ' A' ' 295' ' ' VAL . 39.9 t -104.56 134.69 45.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.715 -169.124 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 301' ' ' THR . . . . . 0.663 ' HB ' ' HB3' ' A' ' 294' ' ' ALA . 94.3 m -96.99 109.31 22.08 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.352 -0.84 . . . . 0.0 108.997 172.626 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 302' ' ' ILE . . . . . 0.605 HG12 ' O ' ' A' ' 253' ' ' GLY . 30.2 pt -110.66 138.06 40.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-O 121.648 0.737 . . . . 0.0 111.922 -175.37 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 303' ' ' SER . . . . . . . . . . . . . 50.5 m -129.54 150.95 77.1 Favored Pre-proline 0 C--N 1.317 -0.846 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 173.162 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 304' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_exo -68.22 176.54 27.47 Favored 'Cis proline' 0 C--N 1.333 -0.282 0 C-N-CA 124.637 -0.985 . . . . 0.0 112.892 1.015 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 305' ' ' LYS . . . . . 0.888 ' HE2' HD11 ' A' ' 307' ' ' LEU . 0.0 OUTLIER -94.04 166.81 11.96 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.492 178.583 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 306' ' ' ILE . . . . . 0.599 HG22 ' HG2' ' A' ' 325' ' ' LYS . 42.6 mm -87.47 96.3 5.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.366 -174.144 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 307' ' ' LEU . . . . . 0.888 HD11 ' HE2' ' A' ' 305' ' ' LYS . 84.2 mt -106.82 110.32 63.6 Favored Pre-proline 0 C--N 1.33 -0.28 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 175.859 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 308' ' ' PRO . . . . . 0.632 ' HG3' ' HE3' ' A' ' 325' ' ' LYS . 79.1 Cg_endo -82.69 157.8 16.24 Favored 'Trans proline' 0 C--O 1.231 0.143 0 C-N-CA 122.512 2.141 . . . . 0.0 114.364 -172.12 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 39.6 t -81.76 -11.17 12.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 114.958 -1.019 . . . . 0.0 108.467 168.782 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 4.6 mm-40 -70.54 -7.03 40.77 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.19 -0.914 . . . . 0.0 110.219 176.618 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 23.8 t-20 -64.07 118.29 8.3 Favored 'General case' 0 N--CA 1.451 -0.391 0 CA-C-N 115.605 -0.725 . . . . 0.0 109.45 -179.141 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 19.5 m -86.3 -17.19 35.25 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.36 -171.441 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 313' ' ' ASP . . . . . 0.589 ' O ' ' HG3' ' A' ' 317' ' ' ARG . 9.8 t70 -71.83 118.58 14.86 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 178.438 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 314' ' ' VAL . . . . . 0.406 ' HA ' ' CD ' ' A' ' 317' ' ' ARG . 41.2 t -59.08 -36.4 62.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.054 -0.521 . . . . 0.0 112.273 -173.906 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -73.87 -25.36 60.0 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.502 0.191 . . . . 0.0 111.38 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 32.6 t -94.55 -6.22 44.16 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.693 -0.23 . . . . 0.0 111.096 -179.007 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 317' ' ' ARG . . . . . 0.589 ' HG3' ' O ' ' A' ' 313' ' ' ASP . 76.4 mtp180 -59.52 -49.6 91.39 Favored Pre-proline 0 N--CA 1.468 0.464 0 N-CA-C 112.392 0.516 . . . . 0.0 112.392 177.837 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 318' ' ' PRO . . . . . 0.515 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 54.3 Cg_exo -56.5 -24.4 52.86 Favored 'Trans proline' 0 C--N 1.359 1.118 0 C-N-CA 122.477 2.118 . . . . 0.0 112.756 -179.803 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 11.6 m-30 -77.08 -6.19 51.84 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.369 -0.832 . . . . 0.0 111.495 -175.68 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -54.85 130.28 40.51 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-O 120.976 0.417 . . . . 0.0 111.723 -177.662 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 26.7 t-20 -110.71 -37.88 5.31 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.663 -0.699 . . . . 0.0 109.554 179.294 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 322' ' ' VAL . . . . . 0.521 HG21 HG23 ' A' ' 306' ' ' ILE . 34.4 m -130.74 170.28 19.86 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 115.267 -0.879 . . . . 0.0 110.16 179.083 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 73.2 m-20 -62.11 -44.14 97.31 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 112.386 0.513 . . . . 0.0 112.386 -177.782 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 324' ' ' ALA . . . . . 0.509 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -156.56 168.41 27.47 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 112.666 0.617 . . . . 0.0 112.666 -172.493 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 325' ' ' LYS . . . . . 0.632 ' HE3' ' HG3' ' A' ' 308' ' ' PRO . 9.9 mtmp? -102.05 106.45 47.87 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 114.816 -1.084 . . . . 0.0 108.531 167.582 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -80.24 162.51 22.77 Favored 'Trans proline' 0 N--CA 1.459 -0.506 0 C-N-CA 122.018 1.812 . . . . 0.0 112.58 -175.59 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -80.03 122.55 26.88 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 174.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 328' ' ' GLU . . . . . 0.922 ' H ' ' HG3' ' A' ' 233' ' ' GLN . 85.0 tt0 71.89 162.81 0.26 Allowed 'General case' 0 CA--C 1.532 0.251 0 O-C-N 124.093 0.87 . . . . 0.0 109.672 -176.006 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 329' ' ' SER . . . . . 0.652 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 50.6 m -85.34 -14.57 46.02 Favored 'General case' 0 C--N 1.323 -0.554 0 C-N-CA 120.913 -0.315 . . . . 0.0 110.861 -177.375 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 330' ' ' ALA . . . . . 0.48 ' H ' ' HG2' ' A' ' 328' ' ' GLU . . . 63.5 -160.36 0.3 Allowed 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 121.381 0.61 . . . . 0.0 112.611 173.015 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 331' ' ' ALA . . . . . 0.429 ' HA ' ' HA ' ' A' ' 229' ' ' THR . . . -82.03 148.14 28.79 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.292 -0.867 . . . . 0.0 110.131 178.253 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 332' ' ' ILE . . . . . . . . . . . . . 43.4 mt -124.24 144.63 33.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-O 121.169 0.509 . . . . 0.0 111.304 -178.148 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 29.6 m -104.21 97.7 7.62 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.494 -0.775 . . . . 0.0 109.217 179.611 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 36.4 mm -78.55 127.91 38.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 112.858 0.688 . . . . 0.0 112.858 -170.772 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 335' ' ' LEU . . . . . . . . . . . . . 8.2 mp -109.15 176.13 5.2 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 114.871 -1.059 . . . . 0.0 110.122 171.541 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 23.0 p30 -131.61 9.57 4.67 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 115.321 -0.854 . . . . 0.0 109.628 173.526 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 337' ' ' LYS . . . . . 0.536 ' NZ ' ' HB3' ' A' ' 337' ' ' LYS . 8.1 mtpm? . . . . . 0 C--O 1.244 0.794 0 CA-C-O 118.552 -0.737 . . . . 0.0 110.891 178.745 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 65.9 p . . . . . 0 N--CA 1.453 -0.313 0 CA-C-O 121.329 0.585 . . . . 0.0 109.812 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 228' ' ' LEU . . . . . 0.617 HD22 ' HA ' ' A' ' 259' ' ' ALA . 83.4 mt -98.01 126.82 43.6 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-N 115.614 -0.721 . . . . 0.0 109.761 -179.548 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 55.5 p -124.73 179.24 5.07 Favored 'General case' 0 C--N 1.322 -0.625 0 C-N-CA 120.458 -0.497 . . . . 0.0 110.3 -179.611 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 230' ' ' VAL . . . . . 0.712 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 63.5 t -147.63 146.92 17.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 120.602 0.239 . . . . 0.0 110.672 -178.234 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 231' ' ' SER . . . . . 0.528 ' HA ' ' HB3' ' A' ' 328' ' ' GLU . 48.9 m -132.11 96.62 3.94 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 173.386 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . 0.628 ' HA3' HG22 ' A' ' 255' ' ' ILE . . . -122.5 -163.05 11.74 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 119.854 -1.165 . . . . 0.0 113.693 -172.889 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 233' ' ' GLN . . . . . 0.581 ' HB3' ' HD2' ' A' ' 234' ' ' PRO . 94.6 mm-40 -85.49 163.63 43.76 Favored Pre-proline 0 C--N 1.327 -0.397 0 CA-C-N 115.615 -0.293 . . . . 0.0 110.541 -178.833 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 234' ' ' PRO . . . . . 0.581 ' HD2' ' HB3' ' A' ' 233' ' ' GLN . 9.5 Cg_endo -55.37 134.3 63.1 Favored 'Trans proline' 0 C--N 1.35 0.646 0 C-N-CA 122.871 2.38 . . . . 0.0 113.442 -176.51 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 235' ' ' GLU . . . . . 0.564 ' HB2' ' CE ' ' A' ' 325' ' ' LYS . 57.7 mt-10 -97.18 124.79 41.34 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 114.982 -1.008 . . . . 0.0 108.452 177.903 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 236' ' ' HIS . . . . . 0.441 ' HB2' HD21 ' A' ' 307' ' ' LEU . 6.3 p80 -174.1 172.81 3.27 Favored 'General case' 0 CA--C 1.521 -0.152 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 -175.145 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 237' ' ' LYS . . . . . 0.793 ' HB3' ' HG3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER . . . . . 0 CA--C 1.529 0.172 0 CA-C-O 121.546 0.688 . . . . 0.0 110.881 165.649 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 252' ' ' GLN . . . . . 0.604 HE22 HD12 ' A' ' 293' ' ' LEU . 2.5 mm100 . . . . . 0 N--CA 1.471 0.606 0 CA-C-O 122.039 0.923 . . . . 0.0 113.425 . . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -172.11 113.33 0.48 Allowed Glycine 0 N--CA 1.448 -0.555 0 CA-C-N 114.723 -1.126 . . . . 0.0 110.644 178.418 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 74.1 p -95.52 117.47 30.47 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 117.399 0.599 . . . . 0.0 110.771 -175.152 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.628 HG22 ' HA3' ' A' ' 232' ' ' GLY . 22.7 pt -120.81 132.59 69.93 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-O 121.239 0.542 . . . . 0.0 111.97 -175.447 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 60.7 m -88.34 110.55 20.86 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 173.874 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.42 ' HA ' HG13 ' A' ' 230' ' ' VAL . 33.2 m -90.1 143.06 11.98 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.84 0 C-N-CA 119.341 -0.943 . . . . 0.0 112.798 -167.89 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 25.0 m -91.61 9.23 33.09 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 113.852 -1.522 . . . . 0.0 108.301 169.915 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 259' ' ' ALA . . . . . 0.617 ' HA ' HD22 ' A' ' 228' ' ' LEU . . . -100.5 178.19 4.8 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 114.725 -1.125 . . . . 0.0 109.55 -177.314 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 42.0 t -145.03 151.38 38.46 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.782 0.325 . . . . 0.0 110.79 179.113 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 84.52 15.87 67.57 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.982 -0.628 . . . . 0.0 112.876 178.544 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 262' ' ' LEU . . . . . 0.437 ' O ' HG11 ' A' ' 295' ' ' VAL . 63.4 mt -85.38 129.92 34.7 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.678 0.275 . . . . 0.0 110.703 -179.11 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 14.4 mm-40 -139.95 173.04 11.92 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.726 178.93 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 36.1 t -67.63 137.89 23.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 C-N-CA 121.001 -0.279 . . . . 0.0 110.34 -179.852 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 101.93 4.7 51.24 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.541 -0.837 . . . . 0.0 112.962 177.648 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 68.4 m-20 -85.84 137.7 32.58 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.257 0.551 . . . . 0.0 110.143 177.193 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 267' ' ' ALA . . . . . 0.624 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -119.85 122.98 42.52 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.262 -0.881 . . . . 0.0 108.741 178.07 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 268' ' ' PHE . . . . . 0.531 ' HB3' ' HA ' ' A' ' 334' ' ' ILE . 7.8 p90 -142.3 168.31 20.05 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.097 -0.641 . . . . 0.0 112.309 -169.893 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 76.0 p -115.4 162.77 16.68 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 114.859 -1.064 . . . . 0.0 108.486 170.89 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 270' ' ' ILE . . . . . . . . . . . . . 59.5 mt -126.05 141.96 44.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.693 -178.5 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -66.36 112.51 4.06 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.97 179.439 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 272' ' ' GLY . . . . . 0.434 ' HA3' ' HG3' ' A' ' 326' ' ' PRO . . . 104.21 -9.43 50.04 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.642 -0.789 . . . . 0.0 112.467 179.947 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . 0.502 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 58.3 t -102.15 102.95 14.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.884 0.373 . . . . 0.0 110.17 178.796 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 6.9 m120 -126.76 116.38 20.83 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.058 -177.352 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 275' ' ' SER . . . . . 0.478 ' HB3' ' HB2' ' A' ' 288' ' ' GLN . 29.2 p -72.72 161.78 30.32 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 113.24 0.83 . . . . 0.0 113.24 -172.401 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 19.4 m -118.21 178.6 2.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 114.644 -1.162 . . . . 0.0 110.165 178.436 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 85.1 m-70 -112.23 105.08 13.31 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 171.548 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 4.9 mp0 -74.18 -35.88 64.01 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.645 -0.252 . . . . 0.0 111.329 -173.445 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 279' ' ' ILE . . . . . 0.507 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.1 mp -67.9 -55.94 14.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.983 -176.007 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 75.9 p -88.33 -3.81 58.78 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 111.782 0.289 . . . . 0.0 111.782 -177.64 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 28.0 tptp 58.81 53.1 6.04 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 121.441 0.638 . . . . 0.0 110.23 179.391 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -117.03 136.75 52.72 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.605 -176.93 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 66.8 p -107.63 127.53 53.74 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.149 -179.943 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 70.7 p -134.49 -30.75 1.11 Allowed 'General case' 0 C--N 1.321 -0.645 0 CA-C-O 120.774 0.321 . . . . 0.0 111.424 -176.709 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 79.39 32.48 38.25 Favored Glycine 0 N--CA 1.448 -0.536 0 C-N-CA 120.408 -0.901 . . . . 0.0 112.666 178.214 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 71.3 mt-30 -85.0 124.43 72.39 Favored Pre-proline 0 C--N 1.326 -0.415 0 CA-C-N 116.903 0.352 . . . . 0.0 110.489 179.973 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 287' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_exo -59.53 126.0 19.44 Favored 'Trans proline' 0 C--N 1.345 0.395 0 C-N-CA 122.281 1.988 . . . . 0.0 111.285 178.272 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 288' ' ' GLN . . . . . 0.478 ' HB2' ' HB3' ' A' ' 275' ' ' SER . 50.6 tt0 -80.4 150.55 29.76 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.045 0.45 . . . . 0.0 111.589 -175.212 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 289' ' ' VAL . . . . . 0.497 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 50.0 t -99.16 127.35 51.93 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 CA-C-N 115.327 -0.851 . . . . 0.0 110.221 179.278 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 290' ' ' PHE . . . . . 0.624 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 4.0 m-85 -101.2 168.7 9.4 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.562 -0.29 . . . . 0.0 111.025 -176.771 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 21.6 mmt85 -126.49 120.78 30.55 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.264 0.554 . . . . 0.0 110.745 174.418 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 59.5 t -78.24 128.56 38.23 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.829 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.313 176.035 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 293' ' ' LEU . . . . . 0.604 HD12 HE22 ' A' ' 252' ' ' GLN . 83.5 mt -109.0 -30.09 8.25 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 111.986 0.365 . . . . 0.0 111.986 -177.762 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 294' ' ' ALA . . . . . 0.585 ' HB3' ' HB ' ' A' ' 301' ' ' THR . . . -152.44 139.94 19.65 Favored 'General case' 0 C--N 1.329 -0.296 0 C-N-CA 121.171 -0.212 . . . . 0.0 111.334 179.717 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 295' ' ' VAL . . . . . 0.685 HG22 HG13 ' A' ' 300' ' ' VAL . 55.3 t -133.48 128.52 54.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 175.118 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 27.2 m -145.64 97.13 2.93 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.917 -176.316 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 57.45 61.03 7.94 Favored Glycine 0 C--N 1.33 0.224 0 C-N-CA 121.009 -0.615 . . . . 0.0 112.531 178.814 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 81.8 p 56.71 5.4 0.21 Allowed 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 124.395 1.078 . . . . 0.0 113.253 -177.17 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 97.4 m -97.88 106.31 18.6 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 171.623 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . 0.733 HG12 HG23 ' A' ' 302' ' ' ILE . 38.8 t -109.26 120.93 61.48 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.797 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.193 -170.883 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 301' ' ' THR . . . . . 0.585 ' HB ' ' HB3' ' A' ' 294' ' ' ALA . 52.6 m -89.66 105.7 17.98 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 174.526 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 302' ' ' ILE . . . . . 0.733 HG23 HG12 ' A' ' 300' ' ' VAL . 2.4 pp -111.72 179.13 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 121.893 0.854 . . . . 0.0 112.861 -174.898 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 303' ' ' SER . . . . . 0.419 ' HA ' ' O ' ' A' ' 304' ' ' PRO . 67.5 p -160.0 157.47 25.43 Favored Pre-proline 0 C--N 1.314 -0.961 0 CA-C-N 113.668 -1.606 . . . . 0.0 106.678 174.714 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 304' ' ' PRO . . . . . 0.419 ' O ' ' HA ' ' A' ' 303' ' ' SER . 3.8 Cg_exo -78.26 -141.67 0.2 Allowed 'Cis proline' 0 CA--C 1.536 0.605 0 CA-C-N 119.84 0.979 . . . . 0.0 112.993 1.057 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 305' ' ' LYS . . . . . 0.793 ' HG3' ' HB3' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -130.4 171.02 13.42 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.014 -178.545 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 306' ' ' ILE . . . . . 0.415 ' HB ' ' CB ' ' A' ' 235' ' ' GLU . 47.2 mm -132.36 129.35 59.38 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.619 0 C-N-CA 119.242 -0.983 . . . . 0.0 113.57 -164.765 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 307' ' ' LEU . . . . . 0.71 HD13 ' HA ' ' A' ' 316' ' ' SER . 88.0 mt -134.39 125.44 17.75 Favored Pre-proline 0 CA--C 1.514 -0.435 0 CA-C-O 120.883 0.373 . . . . 0.0 111.459 170.287 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 308' ' ' PRO . . . . . 0.991 ' HG2' ' HB2' ' A' ' 311' ' ' ASN . 66.8 Cg_endo -84.24 157.71 13.0 Favored 'Trans proline' 0 N--CA 1.455 -0.782 0 C-N-CA 122.89 2.394 . . . . 0.0 112.711 179.041 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 44.5 t -80.79 -18.93 11.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-O 121.587 0.708 . . . . 0.0 109.126 172.104 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 54.7 mt-10 -94.62 34.91 1.27 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.475 -0.784 . . . . 0.0 111.141 177.613 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.991 ' HB2' ' HG2' ' A' ' 308' ' ' PRO . 19.6 t-20 -103.18 142.09 34.75 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -178.443 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 26.3 m -83.27 -7.46 59.59 Favored 'General case' 0 CA--C 1.54 0.587 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.447 -175.05 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 313' ' ' ASP . . . . . 0.42 ' O ' ' HG3' ' A' ' 317' ' ' ARG . 62.9 m-20 -79.62 140.11 37.23 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.684 0.278 . . . . 0.0 110.821 177.818 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 46.1 t -64.4 -45.63 95.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.655 -177.964 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -75.54 -22.42 57.07 Favored 'General case' 0 N--CA 1.464 0.262 0 N-CA-C 111.999 0.37 . . . . 0.0 111.999 -176.204 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . 0.71 ' HA ' HD13 ' A' ' 307' ' ' LEU . 46.1 t -73.14 -21.52 60.7 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.533 -0.303 . . . . 0.0 111.771 -178.16 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 317' ' ' ARG . . . . . 0.687 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 73.0 mtp180 -74.24 -54.76 3.19 Favored Pre-proline 0 CA--C 1.536 0.434 0 N-CA-C 112.23 0.456 . . . . 0.0 112.23 -176.25 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 318' ' ' PRO . . . . . 0.687 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 16.8 Cg_exo -68.79 -38.66 9.81 Favored 'Trans proline' 0 C--N 1.354 0.848 0 C-N-CA 121.978 1.785 . . . . 0.0 112.268 -178.852 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 319' ' ' TYR . . . . . 0.436 ' O ' HD12 ' A' ' 307' ' ' LEU . 3.2 m-85 -90.11 30.43 1.09 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.089 0.471 . . . . 0.0 110.576 -179.903 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -65.9 159.41 25.6 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.679 -0.692 . . . . 0.0 111.059 179.454 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -142.43 -26.28 0.63 Allowed 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.866 -178.551 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 322' ' ' VAL . . . . . 0.461 HG12 ' HA ' ' A' ' 275' ' ' SER . 33.8 m -132.93 174.13 13.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.402 179.458 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -85.4 -12.76 51.28 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 112.068 0.395 . . . . 0.0 112.068 -179.05 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 324' ' ' ALA . . . . . 0.646 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -178.73 163.42 1.45 Allowed 'General case' 0 N--CA 1.469 0.485 0 CA-C-O 120.737 0.304 . . . . 0.0 111.619 -176.313 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 325' ' ' LYS . . . . . 0.596 ' HD2' ' HD3' ' A' ' 308' ' ' PRO . 6.7 mtpm? -120.56 134.13 24.15 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.731 172.974 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 326' ' ' PRO . . . . . 0.689 ' HB2' ' HB2' ' A' ' 330' ' ' ALA . 3.4 Cg_exo -78.26 167.81 22.6 Favored 'Trans proline' 0 N--CA 1.459 -0.549 0 C-N-CA 122.803 2.335 . . . . 0.0 111.578 177.101 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -65.18 137.15 57.43 Favored 'General case' 0 C--O 1.235 0.334 0 N-CA-C 110.129 -0.323 . . . . 0.0 110.129 177.886 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 328' ' ' GLU . . . . . 0.528 ' HB3' ' HA ' ' A' ' 231' ' ' SER . 55.2 mm-40 59.74 -128.41 1.12 Allowed 'General case' 0 C--O 1.232 0.164 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 -174.163 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 329' ' ' SER . . . . . 0.712 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 42.0 m -111.83 -10.55 14.01 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.548 -0.296 . . . . 0.0 110.204 175.339 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 330' ' ' ALA . . . . . 0.689 ' HB2' ' HB2' ' A' ' 326' ' ' PRO . . . 73.21 -166.39 0.11 Allowed 'General case' 0 N--CA 1.474 0.757 0 N-CA-C 113.56 0.948 . . . . 0.0 113.56 173.824 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -83.16 143.69 30.33 Favored 'General case' 0 CA--C 1.519 -0.223 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.56 -178.852 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 332' ' ' ILE . . . . . . . . . . . . . 23.1 mm -113.32 145.17 19.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.562 -171.875 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 29.7 m -118.98 96.59 5.3 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 174.314 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 334' ' ' ILE . . . . . 0.531 ' HA ' ' HB3' ' A' ' 268' ' ' PHE . 35.7 mm -83.15 130.07 36.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 N-CA-C 112.636 0.606 . . . . 0.0 112.636 -172.968 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 335' ' ' LEU . . . . . 0.449 ' HB2' ' O ' ' A' ' 267' ' ' ALA . 7.3 mp -112.52 160.95 17.3 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.23 -0.896 . . . . 0.0 110.089 171.962 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 72.8 m-80 -112.22 -0.29 15.56 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.261 -0.882 . . . . 0.0 109.209 174.132 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 27.9 mtpp . . . . . 0 C--O 1.245 0.845 0 O-C-N 124.191 0.932 . . . . 0.0 111.2 -178.281 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 43.6 t . . . . . 0 C--O 1.234 0.273 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 228' ' ' LEU . . . . . 0.466 ' HB3' ' CB ' ' A' ' 259' ' ' ALA . 91.7 mt -130.11 125.18 34.49 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 172.461 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 37.6 p -117.87 175.19 5.78 Favored 'General case' 0 C--N 1.32 -0.674 0 C-N-CA 119.483 -0.887 . . . . 0.0 111.214 -177.087 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 230' ' ' VAL . . . . . 0.561 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 60.6 t -148.61 141.44 18.4 Favored 'Isoleucine or valine' 0 C--O 1.24 0.56 0 CA-C-O 120.905 0.383 . . . . 0.0 110.788 -176.448 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 50.0 m -109.98 117.74 34.59 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.907 175.123 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 177.61 169.0 38.1 Favored Glycine 0 N--CA 1.447 -0.578 0 N-CA-C 111.087 -0.805 . . . . 0.0 111.087 -177.903 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 72.2 mt-30 -111.75 101.51 51.43 Favored Pre-proline 0 C--N 1.323 -0.57 0 CA-C-N 117.148 0.474 . . . . 0.0 111.62 -177.86 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_endo -83.62 125.99 3.95 Favored 'Trans proline' 0 N--CA 1.453 -0.864 0 C-N-CA 122.986 2.457 . . . . 0.0 110.331 173.932 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 56.0 mm-40 -120.63 163.55 17.86 Favored 'General case' 0 C--N 1.321 -0.674 0 C-N-CA 120.576 -0.45 . . . . 0.0 111.831 -172.572 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 236' ' ' HIS . . . . . 0.542 ' HB3' ' O ' ' A' ' 306' ' ' ILE . 19.3 p-80 -108.76 145.89 34.43 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.339 172.433 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 237' ' ' LYS . . . . . 0.478 ' H ' HD21 ' A' ' 307' ' ' LEU . 0.0 OUTLIER . . . . . 0 C--N 1.32 -0.679 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.569 178.099 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 53.8 mt-30 . . . . . 0 N--CA 1.471 0.583 0 CA-C-O 121.391 0.615 . . . . 0.0 110.959 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . 0.911 ' O ' ' HA ' ' A' ' 301' ' ' THR . . . 100.35 -23.76 34.62 Favored Glycine 0 N--CA 1.438 -1.203 0 C-N-CA 120.068 -1.063 . . . . 0.0 112.74 -179.248 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 60.0 p -135.81 118.79 16.36 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 118.01 0.905 . . . . 0.0 112.724 -176.676 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.756 HD11 ' HB ' ' A' ' 300' ' ' VAL . 2.1 pp -144.83 170.79 6.75 Favored 'Isoleucine or valine' 0 C--O 1.234 0.283 0 CA-C-O 121.032 0.444 . . . . 0.0 112.001 172.445 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 75.2 m -115.62 114.35 24.79 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.344 177.057 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.446 ' HB ' ' H ' ' A' ' 259' ' ' ALA . 34.9 m -90.86 145.21 7.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 N-CA-C 113.004 0.742 . . . . 0.0 113.004 -173.114 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 258' ' ' SER . . . . . 0.448 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 30.9 m -91.35 8.83 34.22 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 114.077 -1.42 . . . . 0.0 108.502 166.818 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 259' ' ' ALA . . . . . 0.466 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -88.25 175.65 7.58 Favored 'General case' 0 N--CA 1.452 -0.364 0 CA-C-N 115.115 -0.948 . . . . 0.0 109.402 -177.899 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 27.4 p -140.61 117.22 10.88 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 112.356 0.502 . . . . 0.0 112.356 -177.412 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 78.91 50.04 6.12 Favored Glycine 0 N--CA 1.45 -0.392 0 CA-C-N 115.596 -0.729 . . . . 0.0 113.391 175.632 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 262' ' ' LEU . . . . . . . . . . . . . 77.6 mt -85.06 146.53 27.12 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 117.346 0.573 . . . . 0.0 110.268 176.837 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 98.9 mm-40 -123.77 163.25 21.54 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.551 -178.757 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 264' ' ' VAL . . . . . 0.487 HG22 ' HA ' ' A' ' 294' ' ' ALA . 20.2 t -79.48 145.1 9.86 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.215 177.626 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 86.4 10.07 74.67 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.623 -0.799 . . . . 0.0 112.186 177.832 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -88.5 159.59 17.88 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.147 0.499 . . . . 0.0 110.482 177.208 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 267' ' ' ALA . . . . . 0.549 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -121.82 151.48 40.57 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 115.334 -0.848 . . . . 0.0 108.869 178.238 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 268' ' ' PHE . . . . . 0.496 ' HB3' ' HA ' ' A' ' 334' ' ' ILE . 4.1 p90 -164.27 168.75 18.4 Favored 'General case' 0 C--N 1.318 -0.761 0 C-N-CA 119.777 -0.769 . . . . 0.0 111.648 -178.029 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 269' ' ' THR . . . . . 0.497 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 73.3 p -122.85 141.83 51.44 Favored 'General case' 0 N--CA 1.442 -0.848 0 CA-C-N 115.438 -0.801 . . . . 0.0 109.621 177.078 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 270' ' ' ILE . . . . . 0.713 HG12 HG12 ' A' ' 332' ' ' ILE . 61.6 mt -105.49 139.18 27.43 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.57 -178.525 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -61.22 125.86 25.28 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.695 179.512 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 93.51 -22.45 35.31 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.473 -178.811 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . 0.742 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 42.4 t -96.5 114.59 33.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 O-C-N 122.573 -0.369 . . . . 0.0 110.296 177.504 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 274' ' ' ASN . . . . . 0.411 ' HA ' ' HA ' ' A' ' 287' ' ' PRO . 72.3 m-80 -129.2 160.87 31.55 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.304 -179.223 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 68.9 p -86.37 169.61 12.76 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.239 0.542 . . . . 0.0 111.803 -174.883 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 276' ' ' VAL . . . . . 0.41 ' O ' ' HG2' ' A' ' 278' ' ' GLN . 27.3 m -112.03 -178.07 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 115.499 -0.773 . . . . 0.0 111.152 -178.47 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 277' ' ' HIS . . . . . 0.523 ' HB3' ' HA ' ' A' ' 281' ' ' LYS . 5.0 m80 -66.16 80.97 0.08 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.703 -0.681 . . . . 0.0 110.392 -175.33 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 278' ' ' GLN . . . . . 0.467 HE21 ' HA ' ' A' ' 278' ' ' GLN . 2.4 mm100 -80.32 -32.99 37.86 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 111.72 0.267 . . . . 0.0 111.72 -174.418 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 279' ' ' ILE . . . . . 0.548 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.4 mp -69.89 -89.48 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.375 0 CA-C-O 120.831 0.348 . . . . 0.0 110.533 -174.641 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 35.5 p -133.69 60.03 1.72 Allowed 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.076 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 281' ' ' LYS . . . . . 0.523 ' HA ' ' HB3' ' A' ' 277' ' ' HIS . 31.4 mmmt 54.52 41.13 32.14 Favored 'General case' 0 CA--C 1.522 -0.122 0 CA-C-N 115.562 -0.745 . . . . 0.0 109.208 -170.874 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 282' ' ' ASP . . . . . 0.463 ' N ' ' HB3' ' A' ' 277' ' ' HIS . 9.3 t70 -92.33 137.84 32.03 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 114.445 -1.252 . . . . 0.0 110.484 -175.15 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 46.2 p -85.44 105.1 15.82 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.185 -178.387 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 73.1 p -110.72 -41.62 4.24 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.915 -171.804 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 63.64 28.31 72.34 Favored Glycine 0 C--N 1.33 0.24 0 C-N-CA 120.877 -0.677 . . . . 0.0 112.498 177.222 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 84.6 mt-30 -94.5 145.7 30.15 Favored Pre-proline 0 C--N 1.323 -0.547 0 CA-C-O 120.419 0.152 . . . . 0.0 110.647 -176.792 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 287' ' ' PRO . . . . . 0.497 ' HB2' ' HB ' ' A' ' 269' ' ' THR . 27.5 Cg_endo -62.2 143.77 94.75 Favored 'Trans proline' 0 CA--C 1.53 0.31 0 C-N-CA 122.445 2.097 . . . . 0.0 112.029 178.589 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 70.8 tp60 -76.3 128.43 34.86 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.872 0.367 . . . . 0.0 110.945 -177.486 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 289' ' ' VAL . . . . . 0.401 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 45.6 t -93.74 133.18 35.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.059 179.17 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 290' ' ' PHE . . . . . 0.742 ' HZ ' HG11 ' A' ' 273' ' ' VAL . 60.9 m-85 -113.5 168.81 9.44 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.826 -176.996 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 291' ' ' ARG . . . . . 0.452 ' NH1' ' HB2' ' A' ' 267' ' ' ALA . 35.8 mmt180 -126.74 120.38 29.25 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 177.765 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 56.4 t -67.18 125.59 24.96 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.227 -179.755 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 293' ' ' LEU . . . . . 0.656 HD11 ' HB2' ' A' ' 303' ' ' SER . 5.2 mp -85.07 -38.44 19.13 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.841 179.865 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 294' ' ' ALA . . . . . 0.487 ' HA ' HG22 ' A' ' 264' ' ' VAL . . . -167.13 155.48 9.73 Favored 'General case' 0 C--O 1.225 -0.21 0 CA-C-N 116.681 -0.236 . . . . 0.0 110.94 179.059 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 295' ' ' VAL . . . . . 0.672 HG22 HG13 ' A' ' 300' ' ' VAL . 61.7 t -140.49 124.74 18.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 175.384 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 32.4 m -139.73 89.54 2.33 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 120.76 0.314 . . . . 0.0 110.835 -177.189 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . 0.427 ' C ' ' H ' ' A' ' 299' ' ' THR . . . 63.95 65.76 2.87 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.487 179.434 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 81.0 p 63.06 -25.18 0.06 Allowed 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 124.994 1.317 . . . . 0.0 113.683 -178.774 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 299' ' ' THR . . . . . 0.427 ' H ' ' C ' ' A' ' 297' ' ' GLY . 75.3 m -77.43 108.9 10.91 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 174.333 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . 0.756 ' HB ' HD11 ' A' ' 255' ' ' ILE . 48.8 t -106.08 134.42 47.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.025 -173.017 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 301' ' ' THR . . . . . 0.911 ' HA ' ' O ' ' A' ' 253' ' ' GLY . 97.1 m -78.02 105.37 9.19 Favored 'General case' 0 N--CA 1.446 -0.632 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 173.009 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 302' ' ' ILE . . . . . 0.64 HD12 ' O ' ' A' ' 302' ' ' ILE . 2.6 pp -111.24 141.35 26.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 122.179 0.99 . . . . 0.0 113.671 -170.989 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 303' ' ' SER . . . . . 0.656 ' HB2' HD11 ' A' ' 293' ' ' LEU . 57.2 m -167.48 169.55 5.56 Favored Pre-proline 0 C--N 1.317 -0.826 0 N-CA-C 105.342 -2.096 . . . . 0.0 105.342 179.02 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 304' ' ' PRO . . . . . 0.587 ' HA ' ' HB3' ' A' ' 303' ' ' SER . 2.7 Cg_endo -82.65 -157.28 1.35 Allowed 'Cis proline' 0 C--N 1.347 0.458 0 CA-C-N 121.571 1.597 . . . . 0.0 113.473 0.278 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 305' ' ' LYS . . . . . 0.8 ' HD3' ' HG ' ' A' ' 307' ' ' LEU . 0.0 OUTLIER -83.51 163.34 20.51 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.27 -0.877 . . . . 0.0 112.884 -176.069 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 306' ' ' ILE . . . . . 0.542 ' O ' ' HB3' ' A' ' 236' ' ' HIS . 2.7 mp -114.02 94.32 3.06 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.793 -176.761 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 307' ' ' LEU . . . . . 0.8 ' HG ' ' HD3' ' A' ' 305' ' ' LYS . 86.0 mt -108.81 107.24 59.9 Favored Pre-proline 0 C--N 1.327 -0.392 0 C-N-CA 120.81 -0.356 . . . . 0.0 111.606 -177.768 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 308' ' ' PRO . . . . . 0.761 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 23.0 Cg_exo -69.85 145.39 56.5 Favored 'Trans proline' 0 C--N 1.343 0.253 0 C-N-CA 123.505 2.804 . . . . 0.0 113.467 -178.038 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . 0.416 HG23 ' O ' ' A' ' 322' ' ' VAL . 40.3 t -93.69 -25.6 4.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 169.35 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 54.7 mm-40 -79.83 -0.36 34.32 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.113 -0.949 . . . . 0.0 112.144 -177.602 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -80.85 163.34 23.48 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-O 121.004 0.431 . . . . 0.0 111.174 -179.091 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 50.2 m -92.32 -15.87 26.79 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.362 -179.029 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 313' ' ' ASP . . . . . 0.566 ' O ' ' HG3' ' A' ' 317' ' ' ARG . 62.9 t0 -64.26 104.05 0.71 Allowed 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.065 178.93 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 314' ' ' VAL . . . . . 0.432 ' O ' ' HD3' ' A' ' 318' ' ' PRO . 48.5 t -63.63 -30.84 50.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.683 -176.012 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -70.44 -25.17 63.07 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 111.718 0.266 . . . . 0.0 111.718 179.984 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 32.4 t -95.09 -8.28 37.02 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.604 0.24 . . . . 0.0 111.211 -178.115 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 317' ' ' ARG . . . . . 0.566 ' HG3' ' O ' ' A' ' 313' ' ' ASP . 54.4 mtp85 -67.43 -49.96 39.85 Favored Pre-proline 0 CA--C 1.54 0.564 0 N-CA-C 112.938 0.718 . . . . 0.0 112.938 -179.26 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 318' ' ' PRO . . . . . 0.506 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 37.1 Cg_exo -63.41 -31.98 71.95 Favored 'Trans proline' 0 C--N 1.357 1.016 0 C-N-CA 121.951 1.768 . . . . 0.0 112.679 -178.51 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 48.8 m-85 -84.13 -14.95 48.97 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.511 -178.214 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . 0.528 ' HA ' ' CB ' ' A' ' 307' ' ' LEU . . . -49.7 135.29 19.17 Favored 'General case' 0 N--CA 1.464 0.254 0 N-CA-C 112.71 0.633 . . . . 0.0 112.71 -174.097 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 16.1 p-10 -128.38 -10.36 5.18 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.939 178.964 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 322' ' ' VAL . . . . . 0.488 HG21 HG23 ' A' ' 306' ' ' ILE . 33.7 m -132.27 167.29 26.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 N-CA-C 109.986 -0.375 . . . . 0.0 109.986 177.017 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -67.2 -51.89 47.95 Favored 'General case' 0 C--N 1.326 -0.434 0 C-N-CA 121.026 -0.27 . . . . 0.0 111.702 -177.93 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 324' ' ' ALA . . . . . 0.761 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -162.47 -178.04 6.02 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.044 0.449 . . . . 0.0 111.779 -176.388 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 14.5 ptmm? -112.56 132.07 22.37 Favored Pre-proline 0 C--N 1.327 -0.384 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.314 176.949 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -86.15 168.44 9.04 Favored 'Trans proline' 0 N--CA 1.456 -0.71 0 C-N-CA 122.921 2.414 . . . . 0.0 112.412 179.51 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -72.83 123.77 24.05 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.053 -0.522 . . . . 0.0 109.718 175.202 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 66.6 mm-40 65.6 -161.43 0.26 Allowed 'General case' 0 N--CA 1.465 0.307 0 O-C-N 123.574 0.546 . . . . 0.0 110.424 -174.97 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 329' ' ' SER . . . . . 0.561 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 43.0 m -91.16 -13.48 32.88 Favored 'General case' 0 C--N 1.323 -0.578 0 C-N-CA 120.825 -0.35 . . . . 0.0 110.347 178.174 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 64.5 -161.55 0.28 Allowed 'General case' 0 N--CA 1.467 0.425 0 CA-C-N 115.412 -0.813 . . . . 0.0 113.128 171.323 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -86.71 136.72 32.91 Favored 'General case' 0 CA--C 1.517 -0.323 0 CA-C-N 115.09 -0.959 . . . . 0.0 110.577 -179.983 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 332' ' ' ILE . . . . . 0.713 HG12 HG12 ' A' ' 270' ' ' ILE . 45.8 mt -116.12 144.42 23.83 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.847 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.822 -178.735 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 78.1 m -116.26 99.24 7.07 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.156 -178.016 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 334' ' ' ILE . . . . . 0.496 ' HA ' ' HB3' ' A' ' 268' ' ' PHE . 38.3 mm -75.99 131.12 35.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.43 -174.992 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 335' ' ' LEU . . . . . 0.479 HD23 ' HA ' ' A' ' 268' ' ' PHE . 2.0 pt? -148.61 133.68 18.23 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.217 173.68 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 5.6 m120 -78.16 70.93 4.59 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.223 178.406 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 59.4 tttp . . . . . 0 C--O 1.243 0.738 0 CA-C-O 118.315 -0.85 . . . . 0.0 110.713 -174.989 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 54.0 m . . . . . 0 N--CA 1.465 0.322 0 CA-C-O 120.791 0.329 . . . . 0.0 111.304 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 228' ' ' LEU . . . . . 0.568 HD13 ' HB1' ' A' ' 259' ' ' ALA . 85.3 mt -131.5 158.9 39.66 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.982 -0.553 . . . . 0.0 109.845 -177.288 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 229' ' ' THR . . . . . 0.578 ' HA ' ' HA ' ' A' ' 331' ' ' ALA . 37.9 p -132.76 178.87 6.53 Favored 'General case' 0 C--N 1.33 -0.274 0 C-N-CA 120.324 -0.55 . . . . 0.0 111.186 177.851 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 230' ' ' VAL . . . . . 0.597 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 58.7 t -147.47 123.94 2.92 Favored 'Isoleucine or valine' 0 C--O 1.235 0.336 0 CA-C-N 116.654 -0.248 . . . . 0.0 110.921 -179.165 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 49.8 m -109.14 97.68 7.25 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.107 -0.497 . . . . 0.0 109.86 174.446 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . 0.915 ' HA3' ' HB ' ' A' ' 255' ' ' ILE . . . -133.94 -152.14 6.65 Favored Glycine 0 N--CA 1.443 -0.859 0 C-N-CA 119.743 -1.218 . . . . 0.0 113.163 -176.735 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 233' ' ' GLN . . . . . 0.583 ' H ' HG22 ' A' ' 255' ' ' ILE . 11.7 mm100 -72.34 171.45 9.7 Favored Pre-proline 0 C--N 1.324 -0.521 0 CA-C-N 115.2 -0.5 . . . . 0.0 110.988 -179.172 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 234' ' ' PRO . . . . . 0.525 ' HD2' ' HB3' ' A' ' 233' ' ' GLN . 41.7 Cg_exo -56.74 176.29 0.23 Allowed 'Trans proline' 0 C--N 1.356 0.923 0 C-N-CA 123.346 2.697 . . . . 0.0 112.741 177.801 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 235' ' ' GLU . . . . . 0.735 ' HG3' ' HD2' ' A' ' 325' ' ' LYS . 2.6 pm0 -91.38 -176.74 4.64 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.031 0.444 . . . . 0.0 111.102 -174.467 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 236' ' ' HIS . . . . . 0.445 ' CE1' ' HB2' ' A' ' 305' ' ' LYS . 18.9 t-80 -100.87 147.6 25.93 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.509 -0.769 . . . . 0.0 111.702 -171.135 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 237' ' ' LYS . . . . . 0.487 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.327 -0.409 0 CA-C-N 114.735 -1.12 . . . . 0.0 109.914 179.066 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 252' ' ' GLN . . . . . 0.452 ' OE1' ' HA ' ' A' ' 305' ' ' LYS . 2.2 mm100 . . . . . 0 N--CA 1.472 0.659 0 CA-C-O 120.888 0.375 . . . . 0.0 110.566 . . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 101.91 -148.55 17.79 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 119.587 -1.292 . . . . 0.0 113.984 174.778 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 254' ' ' THR . . . . . 0.62 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 71.0 p -101.49 148.66 24.93 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 112.65 0.611 . . . . 0.0 112.65 -171.674 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.915 ' HB ' ' HA3' ' A' ' 232' ' ' GLY . 0.2 OUTLIER -138.01 172.96 13.48 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.243 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.288 173.632 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 58.2 m -100.54 125.81 46.93 Favored 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 109.406 -0.59 . . . . 0.0 109.406 176.729 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.524 ' HA ' HG13 ' A' ' 230' ' ' VAL . 34.0 m -98.73 143.37 13.28 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.828 0 C-N-CA 119.65 -0.82 . . . . 0.0 112.483 -174.541 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 258' ' ' SER . . . . . 0.494 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 38.8 t -91.56 8.48 36.4 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 114.443 -1.253 . . . . 0.0 108.405 169.505 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 259' ' ' ALA . . . . . 0.58 ' HB3' HD11 ' A' ' 262' ' ' LEU . . . -91.32 169.3 10.92 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-N 115.021 -0.99 . . . . 0.0 110.018 -177.442 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . 0.55 ' H ' HD13 ' A' ' 228' ' ' LEU . 37.9 t -136.95 148.57 47.04 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 110.194 -0.298 . . . . 0.0 110.194 -179.751 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 71.27 39.6 61.98 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.977 -0.63 . . . . 0.0 113.083 178.108 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 262' ' ' LEU . . . . . 0.58 HD11 ' HB3' ' A' ' 259' ' ' ALA . 77.6 mt -97.64 142.31 29.6 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.944 0.372 . . . . 0.0 110.395 178.348 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 71.6 mt-30 -143.72 179.96 6.83 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 176.284 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 264' ' ' VAL . . . . . 0.517 HG22 ' HA ' ' A' ' 294' ' ' ALA . 34.0 t -79.31 140.43 16.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 N-CA-C 109.897 -0.408 . . . . 0.0 109.897 176.201 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 93.52 4.72 63.82 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.526 -0.845 . . . . 0.0 112.453 178.797 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -78.89 152.81 30.97 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.083 0.468 . . . . 0.0 110.072 176.578 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 267' ' ' ALA . . . . . 0.709 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -126.96 121.67 32.36 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 178.696 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 268' ' ' PHE . . . . . 0.574 ' CD1' HG21 ' A' ' 332' ' ' ILE . 0.0 OUTLIER -148.04 171.53 15.68 Favored 'General case' 0 C--N 1.318 -0.791 0 C-N-CA 120.218 -0.593 . . . . 0.0 111.026 -172.071 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 269' ' ' THR . . . . . 0.538 ' OG1' ' HB ' ' A' ' 333' ' ' THR . 72.6 p -123.82 156.39 36.23 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 110.2 -0.296 . . . . 0.0 110.2 -179.379 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 270' ' ' ILE . . . . . 0.557 HG12 HG12 ' A' ' 332' ' ' ILE . 60.9 mt -115.02 139.36 41.68 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 120.794 0.33 . . . . 0.0 111.144 -179.332 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -65.82 112.64 3.84 Favored 'General case' 0 C--O 1.231 0.125 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.037 -179.903 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 109.22 -21.85 26.04 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.021 -179.14 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . 0.598 ' O ' ' HA ' ' A' ' 287' ' ' PRO . 47.1 t -93.11 102.67 13.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.885 0.374 . . . . 0.0 110.93 178.722 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 3.8 m120 -103.76 150.98 23.57 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 173.504 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 275' ' ' SER . . . . . 0.445 ' HB2' ' HB2' ' A' ' 288' ' ' GLN . 6.0 t -88.76 -177.96 5.66 Favored 'General case' 0 C--N 1.325 -0.473 0 C-N-CA 120.332 -0.547 . . . . 0.0 110.231 -176.496 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 35.0 m -112.25 -179.01 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.917 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.171 172.887 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 277' ' ' HIS . . . . . 0.425 ' HB3' ' HA ' ' A' ' 281' ' ' LYS . 6.3 p80 -39.74 111.66 0.21 Allowed 'General case' 0 CA--C 1.533 0.298 0 O-C-N 123.972 0.795 . . . . 0.0 112.568 -179.882 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 80.7 mt-30 -80.16 -42.38 23.55 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.475 -176.439 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 279' ' ' ILE . . . . . 0.467 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.7 mp -110.21 -76.16 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.175 177.858 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 21.7 p -142.11 90.78 2.28 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-O 121.124 0.487 . . . . 0.0 111.661 -178.418 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 281' ' ' LYS . . . . . 0.425 ' HA ' ' HB3' ' A' ' 277' ' ' HIS . 74.8 mmtt 61.05 23.98 14.12 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 115.145 -0.934 . . . . 0.0 112.463 175.584 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 11.2 p-10 -86.46 81.64 8.24 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.615 0.721 . . . . 0.0 110.867 176.769 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 37.2 p -102.34 106.9 17.76 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.854 177.753 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 73.1 p -114.67 2.16 14.4 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.835 -0.62 . . . . 0.0 112.174 -170.081 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 71.02 31.29 66.88 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.515 -0.85 . . . . 0.0 112.652 177.859 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 26.2 mt-30 -102.11 142.54 24.79 Favored Pre-proline 0 C--N 1.325 -0.467 0 O-C-N 122.682 -0.305 . . . . 0.0 111.155 179.503 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 287' ' ' PRO . . . . . 0.598 ' HA ' ' O ' ' A' ' 273' ' ' VAL . 39.0 Cg_exo -59.1 136.95 76.46 Favored 'Trans proline' 0 C--N 1.343 0.276 0 C-N-CA 122.988 2.459 . . . . 0.0 112.106 177.89 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 288' ' ' GLN . . . . . 0.445 ' HB2' ' HB2' ' A' ' 275' ' ' SER . 41.5 tt0 -79.52 142.92 35.34 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.827 0.346 . . . . 0.0 111.013 -178.008 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 289' ' ' VAL . . . . . 0.488 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 42.7 t -90.81 126.68 43.54 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.295 179.496 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 290' ' ' PHE . . . . . 0.709 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 33.3 m-85 -110.42 158.76 18.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.677 -0.238 . . . . 0.0 110.583 -176.323 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 291' ' ' ARG . . . . . 0.529 ' HD2' ' C ' ' A' ' 290' ' ' PHE . 9.0 mpt_? -115.88 131.06 57.05 Favored 'General case' 0 CA--C 1.516 -0.357 0 CA-C-O 121.48 0.657 . . . . 0.0 110.74 173.606 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 40.9 t -82.86 140.0 16.97 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 CA-C-N 114.722 -1.126 . . . . 0.0 111.402 -176.354 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 293' ' ' LEU . . . . . 0.448 ' CD2' ' HB2' ' A' ' 303' ' ' SER . 3.3 mm? -103.79 -32.38 9.36 Favored 'General case' 0 C--N 1.334 -0.08 0 N-CA-C 112.353 0.501 . . . . 0.0 112.353 -177.684 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 294' ' ' ALA . . . . . 0.517 ' HA ' HG22 ' A' ' 264' ' ' VAL . . . -157.83 139.27 13.67 Favored 'General case' 0 N--CA 1.464 0.241 0 C-N-CA 120.715 -0.394 . . . . 0.0 111.798 -178.245 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 295' ' ' VAL . . . . . 0.424 HG22 HG22 ' A' ' 300' ' ' VAL . 73.0 t -141.39 111.99 3.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.457 177.612 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 50.2 m -140.38 114.63 9.19 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.584 -0.28 . . . . 0.0 110.707 178.542 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 59.53 54.59 36.44 Favored Glycine 0 C--N 1.33 0.25 0 C-N-CA 121.146 -0.549 . . . . 0.0 112.891 179.172 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 82.8 p 53.08 21.09 1.97 Allowed 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 123.61 0.764 . . . . 0.0 112.302 -177.1 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 58.6 m -111.45 105.89 14.63 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 176.358 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . 0.62 ' O ' ' HA ' ' A' ' 254' ' ' THR . 55.2 t -105.32 131.62 54.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 115.954 -0.567 . . . . 0.0 111.547 -171.881 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 28.5 m -89.1 114.49 25.75 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 108.277 -1.009 . . . . 0.0 108.277 173.454 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 302' ' ' ILE . . . . . 0.538 HD12 ' O ' ' A' ' 302' ' ' ILE . 2.5 pp -110.58 149.07 13.6 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 N-CA-C 113.676 0.991 . . . . 0.0 113.676 -170.558 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 303' ' ' SER . . . . . 0.557 ' HB3' ' HA ' ' A' ' 304' ' ' PRO . 60.3 m -166.21 165.87 9.97 Favored Pre-proline 0 C--N 1.325 -0.487 0 N-CA-C 105.952 -1.87 . . . . 0.0 105.952 -179.724 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 304' ' ' PRO . . . . . 0.557 ' HA ' ' HB3' ' A' ' 303' ' ' SER . 5.8 Cg_exo -79.41 -146.44 0.37 Allowed 'Cis proline' 0 C--N 1.345 0.362 0 CA-C-N 120.996 1.391 . . . . 0.0 113.579 0.64 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 305' ' ' LYS . . . . . 0.682 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -84.11 146.71 27.75 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.478 -0.783 . . . . 0.0 111.739 -176.173 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 306' ' ' ILE . . . . . 0.482 HG23 HG21 ' A' ' 322' ' ' VAL . 2.9 mp -115.26 113.73 44.35 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.199 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.92 179.227 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 307' ' ' LEU . . . . . . . . . . . . . 95.5 mt -133.97 107.37 11.54 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-O 120.563 0.22 . . . . 0.0 111.308 -179.309 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 308' ' ' PRO . . . . . 0.652 ' HG2' ' HB2' ' A' ' 311' ' ' ASN . 45.3 Cg_endo -74.51 148.0 37.03 Favored 'Trans proline' 0 C--O 1.233 0.232 0 C-N-CA 122.796 2.331 . . . . 0.0 113.573 -176.631 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 46.5 t -73.58 -34.26 41.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.059 173.0 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -86.35 34.35 0.63 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.371 -0.832 . . . . 0.0 111.143 178.468 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.652 ' HB2' ' HG2' ' A' ' 308' ' ' PRO . 25.7 t-20 -81.32 -34.2 32.04 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -178.287 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 312' ' ' THR . . . . . 0.401 ' HB ' ' O ' ' A' ' 311' ' ' ASN . 41.8 m 73.91 -11.27 0.98 Allowed 'General case' 0 CA--C 1.539 0.529 0 CA-C-N 115.328 -0.851 . . . . 0.0 111.679 178.662 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 313' ' ' ASP . . . . . 0.477 ' O ' ' HG2' ' A' ' 317' ' ' ARG . 31.1 t70 -79.67 117.42 20.57 Favored 'General case' 0 C--N 1.329 -0.286 0 O-C-N 121.951 -0.468 . . . . 0.0 110.27 175.119 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 26.5 t -59.32 -20.4 18.07 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.473 0 CA-C-N 115.781 -0.645 . . . . 0.0 112.268 -174.706 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -84.89 -38.41 19.45 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 111.949 0.352 . . . . 0.0 111.949 -179.364 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . 0.423 ' OG ' ' HB3' ' A' ' 313' ' ' ASP . 38.3 p -97.93 -28.83 13.64 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 113.511 0.93 . . . . 0.0 113.511 -172.33 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 317' ' ' ARG . . . . . 0.624 ' N ' ' HD2' ' A' ' 318' ' ' PRO . 16.1 ptm180 -66.18 -35.76 11.37 Favored Pre-proline 0 CA--C 1.547 0.86 0 N-CA-C 113.656 0.984 . . . . 0.0 113.656 -176.182 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 318' ' ' PRO . . . . . 0.624 ' HD2' ' N ' ' A' ' 317' ' ' ARG . 12.8 Cg_endo -58.38 -34.13 98.42 Favored 'Trans proline' 0 C--N 1.366 1.468 0 C-N-CA 121.666 1.577 . . . . 0.0 112.512 -179.861 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 51.0 m-85 -101.02 36.8 1.88 Allowed 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.6 -178.085 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -67.86 139.64 56.53 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.485 -178.183 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 321' ' ' ASN . . . . . 0.44 ' OD1' HG13 ' A' ' 322' ' ' VAL . 20.5 p30 -121.78 -14.66 8.07 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.516 178.012 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 322' ' ' VAL . . . . . 0.482 HG21 HG23 ' A' ' 306' ' ' ILE . 34.1 m -133.59 166.74 28.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 115.618 -0.719 . . . . 0.0 109.195 173.458 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 65.0 m-20 -82.7 -27.53 31.16 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 112.164 0.431 . . . . 0.0 112.164 -176.375 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 324' ' ' ALA . . . . . 0.562 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -160.58 158.21 28.66 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.973 0.416 . . . . 0.0 111.716 -175.209 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 325' ' ' LYS . . . . . 0.735 ' HD2' ' HG3' ' A' ' 235' ' ' GLU . 21.5 pttp -114.01 127.26 27.01 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 115.714 -0.676 . . . . 0.0 110.157 177.318 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -86.08 167.84 9.32 Favored 'Trans proline' 0 N--CA 1.457 -0.651 0 C-N-CA 122.814 2.343 . . . . 0.0 112.758 -178.213 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -71.71 124.4 24.69 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.471 178.927 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 61.69 -118.44 0.68 Allowed 'General case' 0 N--CA 1.464 0.239 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.323 -175.578 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 329' ' ' SER . . . . . 0.597 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 32.6 m -112.18 -33.94 6.08 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.59 -0.277 . . . . 0.0 111.309 179.863 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 330' ' ' ALA . . . . . 0.418 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 76.24 -165.99 0.06 Allowed 'General case' 0 N--CA 1.474 0.725 0 O-C-N 123.844 0.715 . . . . 0.0 112.432 177.429 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 331' ' ' ALA . . . . . 0.578 ' HA ' ' HA ' ' A' ' 229' ' ' THR . . . -82.88 153.92 24.87 Favored 'General case' 0 CA--C 1.519 -0.236 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.899 -177.226 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 332' ' ' ILE . . . . . 0.574 HG21 ' CD1' ' A' ' 268' ' ' PHE . 44.4 mt -128.49 144.85 36.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 121.233 0.54 . . . . 0.0 111.762 -177.616 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 0.538 ' HB ' ' OG1' ' A' ' 269' ' ' THR . 94.7 m -108.63 118.75 37.59 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.291 -0.868 . . . . 0.0 109.207 175.23 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 334' ' ' ILE . . . . . 0.491 HG13 HD12 ' A' ' 228' ' ' LEU . 31.9 mm -97.26 132.33 42.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 N-CA-C 113.761 1.023 . . . . 0.0 113.761 -168.025 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 335' ' ' LEU . . . . . 0.467 HD23 ' N ' ' A' ' 335' ' ' LEU . 1.5 pt? -150.78 -162.32 1.53 Allowed 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 113.977 -1.465 . . . . 0.0 108.129 167.993 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 14.9 p-10 -159.34 35.49 0.2 Allowed 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 120.949 0.404 . . . . 0.0 110.212 178.055 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 88.4 tttt . . . . . 0 C--O 1.245 0.83 0 CA-C-N 115.023 -0.99 . . . . 0.0 110.722 -179.433 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 20.3 m . . . . . 0 C--O 1.231 0.131 0 N-CA-C 110.018 -0.364 . . . . 0.0 110.018 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 228' ' ' LEU . . . . . 0.425 HD13 ' HB1' ' A' ' 259' ' ' ALA . 87.7 mt -69.49 136.98 52.17 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.509 176.936 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 61.3 p -125.22 173.99 8.41 Favored 'General case' 0 C--N 1.325 -0.49 0 C-N-CA 119.721 -0.792 . . . . 0.0 110.374 179.766 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 230' ' ' VAL . . . . . 0.916 HG11 HD12 ' A' ' 255' ' ' ILE . 94.5 t -146.06 139.8 20.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-O 120.873 0.368 . . . . 0.0 110.549 -178.801 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 231' ' ' SER . . . . . 0.622 ' HA ' ' OE1' ' A' ' 328' ' ' GLU . 45.8 t -106.04 150.75 25.45 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-N 115.485 -0.779 . . . . 0.0 110.64 178.145 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 79.32 92.67 0.36 Allowed Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.409 178.408 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 233' ' ' GLN . . . . . 0.461 ' O ' ' HG3' ' A' ' 235' ' ' GLU . 82.8 mt-30 -42.74 135.37 2.75 Favored Pre-proline 0 N--CA 1.47 0.531 0 N-CA-C 112.595 0.591 . . . . 0.0 112.595 -177.997 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 234' ' ' PRO . . . . . 0.434 ' HB3' HD11 ' A' ' 302' ' ' ILE . 34.0 Cg_endo -62.97 127.94 21.69 Favored 'Trans proline' 0 C--N 1.349 0.59 0 C-N-CA 122.521 2.147 . . . . 0.0 111.18 175.018 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 235' ' ' GLU . . . . . 0.461 ' HG3' ' O ' ' A' ' 233' ' ' GLN . 49.0 mt-10 -113.64 117.46 31.65 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 112.281 0.475 . . . . 0.0 112.281 -170.419 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 236' ' ' HIS . . . . . 0.54 ' CD2' ' HB2' ' A' ' 305' ' ' LYS . 27.6 t60 -138.32 130.92 29.25 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.507 172.984 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 237' ' ' LYS . . . . . 0.55 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.322 -0.608 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.527 -179.624 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 40.7 mt-30 . . . . . 0 N--CA 1.466 0.351 0 CA-C-O 121.414 0.626 . . . . 0.0 111.515 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . 0.441 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -169.1 105.87 0.23 Allowed Glycine 0 N--CA 1.444 -0.799 0 CA-C-N 115.352 -0.84 . . . . 0.0 111.309 177.391 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 254' ' ' THR . . . . . 0.473 HG22 ' OG1' ' A' ' 301' ' ' THR . 62.8 p -93.47 116.15 28.68 Favored 'General case' 0 C--N 1.324 -0.515 0 C-N-CA 120.579 -0.448 . . . . 0.0 110.006 -177.993 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.916 HD12 HG11 ' A' ' 230' ' ' VAL . 19.0 pt -129.27 157.18 42.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.807 -0.633 . . . . 0.0 112.01 -172.162 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 28.8 m -96.3 109.66 22.12 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 174.606 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.438 ' HA ' HG13 ' A' ' 230' ' ' VAL . 33.6 m -89.94 142.37 13.01 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 C-N-CA 119.429 -0.908 . . . . 0.0 112.235 -173.022 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 258' ' ' SER . . . . . 0.429 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 31.6 m -93.2 9.53 35.68 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 114.377 -1.283 . . . . 0.0 109.44 171.974 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 259' ' ' ALA . . . . . 0.425 ' HB1' HD13 ' A' ' 228' ' ' LEU . . . -80.97 -177.37 6.39 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.189 -175.709 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 50.9 m -125.07 118.92 27.24 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 112.232 0.456 . . . . 0.0 112.232 -175.522 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 59.49 51.35 59.59 Favored Glycine 0 C--N 1.331 0.284 0 CA-C-N 115.656 -0.702 . . . . 0.0 114.127 172.19 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 262' ' ' LEU . . . . . . . . . . . . . 67.9 mt -77.96 160.13 28.39 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 117.453 0.626 . . . . 0.0 110.559 177.753 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 85.7 mt-30 -141.74 167.09 22.96 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.453 179.864 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 44.0 t -78.67 141.47 15.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.496 178.32 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 93.55 1.2 66.36 Favored Glycine 0 N--CA 1.453 -0.229 0 C-N-CA 120.535 -0.84 . . . . 0.0 112.757 177.174 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 266' ' ' ASP . . . . . 0.453 ' HB3' ' CG2' ' A' ' 334' ' ' ILE . 1.3 m-20 -81.09 164.82 22.14 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.032 0.444 . . . . 0.0 110.585 178.243 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 267' ' ' ALA . . . . . 0.54 ' HB1' HG13 ' A' ' 289' ' ' VAL . . . -124.37 146.77 48.65 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.796 -178.086 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 268' ' ' PHE . . . . . 0.721 ' HB3' ' HA ' ' A' ' 334' ' ' ILE . 11.1 p90 -164.09 177.88 8.09 Favored 'General case' 0 C--N 1.322 -0.629 0 C-N-CA 120.152 -0.619 . . . . 0.0 112.405 -176.177 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 43.2 p -134.03 156.55 48.02 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 114.646 -1.161 . . . . 0.0 109.002 173.138 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 270' ' ' ILE . . . . . 0.944 HG12 HG13 ' A' ' 332' ' ' ILE . 77.6 mt -119.15 141.78 37.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-O 120.569 0.223 . . . . 0.0 110.682 -177.524 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -70.16 128.7 37.2 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.768 0.318 . . . . 0.0 110.973 178.112 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 90.56 -23.3 23.12 Favored Glycine 0 N--CA 1.453 -0.172 0 C-N-CA 121.267 -0.492 . . . . 0.0 112.023 -177.822 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . 0.473 ' HB ' ' HB ' ' A' ' 270' ' ' ILE . 57.2 t -94.58 103.23 14.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 175.043 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 274' ' ' ASN . . . . . 0.451 ' HB3' ' O ' ' A' ' 285' ' ' GLY . 8.1 m120 -125.03 129.43 50.27 Favored 'General case' 0 C--N 1.316 -0.865 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 -179.613 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 275' ' ' SER . . . . . 0.571 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 48.8 m -84.18 173.52 10.97 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.751 0.786 . . . . 0.0 112.974 -167.031 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 276' ' ' VAL . . . . . 0.675 HG11 HG21 ' A' ' 309' ' ' VAL . 18.5 m -122.95 166.87 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 CA-C-N 114.676 -1.147 . . . . 0.0 109.327 176.41 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 277' ' ' HIS . . . . . 0.494 ' O ' ' HA ' ' A' ' 281' ' ' LYS . 33.6 m80 -88.16 123.89 33.26 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 177.853 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 10.5 mm100 -80.29 -17.16 52.94 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.086 -176.614 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 46.7 mm -70.31 -65.19 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.736 -179.531 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 64.6 p -108.05 11.58 27.6 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.506 -0.316 . . . . 0.0 111.851 -177.323 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 281' ' ' LYS . . . . . 0.494 ' HA ' ' O ' ' A' ' 277' ' ' HIS . 12.7 mptt 55.41 47.47 21.12 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-O 121.122 0.487 . . . . 0.0 111.192 -177.489 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 282' ' ' ASP . . . . . 0.48 ' HB3' ' HB2' ' A' ' 277' ' ' HIS . 7.3 t70 -79.91 108.96 13.9 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.619 176.971 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.46 HG21 HG11 ' A' ' 309' ' ' VAL . 64.4 p -102.97 98.22 8.22 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.591 -178.142 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 31.1 p -140.55 10.8 2.28 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.613 -0.721 . . . . 0.0 111.763 -177.737 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 285' ' ' GLY . . . . . 0.451 ' O ' ' HB3' ' A' ' 274' ' ' ASN . . . 75.66 33.57 51.49 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.177 -1.011 . . . . 0.0 113.26 175.651 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 286' ' ' GLN . . . . . 0.463 ' O ' ' HB2' ' A' ' 275' ' ' SER . 11.6 mm100 -91.27 111.77 50.52 Favored Pre-proline 0 C--N 1.325 -0.469 0 CA-C-N 117.006 0.403 . . . . 0.0 110.782 -179.636 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 287' ' ' PRO . . . . . 0.408 ' HD2' ' HA ' ' A' ' 286' ' ' GLN . 14.7 Cg_endo -59.59 134.26 56.8 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.916 2.41 . . . . 0.0 113.155 -177.057 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 5.4 tm0? -110.13 152.31 26.18 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 176.806 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 289' ' ' VAL . . . . . 0.54 HG13 ' HB1' ' A' ' 267' ' ' ALA . 53.8 t -68.18 134.03 30.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 CA-C-O 120.924 0.392 . . . . 0.0 111.988 -171.806 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 290' ' ' PHE . . . . . 0.836 ' HA ' ' HD3' ' A' ' 304' ' ' PRO . 4.5 m-85 -97.88 159.48 14.9 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.75 178.051 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 20.3 mmt85 -131.45 125.63 33.0 Favored 'General case' 0 N--CA 1.453 -0.316 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.622 -179.02 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 53.2 t -76.01 135.34 27.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.161 179.318 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 293' ' ' LEU . . . . . 0.589 HD12 HG22 ' A' ' 301' ' ' THR . 85.4 mt -99.49 -43.0 6.69 Favored 'General case' 0 C--N 1.333 -0.13 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.502 179.769 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 294' ' ' ALA . . . . . 0.451 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -154.34 144.23 21.77 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.496 -0.32 . . . . 0.0 111.183 -175.52 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 59.0 t -135.91 113.3 14.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.714 176.87 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 45.6 t -157.33 125.02 5.34 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.55 -177.738 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 61.26 43.7 99.04 Favored Glycine 0 C--N 1.331 0.25 0 C-N-CA 120.987 -0.625 . . . . 0.0 111.773 -177.93 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 67.1 p 50.82 23.02 1.27 Allowed 'General case' 0 N--CA 1.471 0.604 0 C-N-CA 123.709 0.804 . . . . 0.0 112.23 -175.052 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 59.6 m -111.9 116.96 31.48 Favored 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 176.852 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . 0.451 ' HA ' ' O ' ' A' ' 294' ' ' ALA . 61.5 t -113.1 126.67 70.54 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.176 -173.15 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 301' ' ' THR . . . . . 0.589 HG22 HD12 ' A' ' 293' ' ' LEU . 54.5 m -91.24 116.2 28.63 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 173.987 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 302' ' ' ILE . . . . . 0.441 HG12 ' O ' ' A' ' 253' ' ' GLY . 29.5 pt -111.5 158.78 11.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 N-CA-C 113.234 0.828 . . . . 0.0 113.234 -170.013 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 303' ' ' SER . . . . . 0.543 ' HB3' ' HA ' ' A' ' 304' ' ' PRO . 72.1 m -144.47 166.16 19.97 Favored Pre-proline 0 C--N 1.323 -0.584 0 CA-C-N 113.631 -1.622 . . . . 0.0 107.05 172.521 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 304' ' ' PRO . . . . . 0.836 ' HD3' ' HA ' ' A' ' 290' ' ' PHE . 10.5 Cg_exo -72.7 -169.8 6.86 Favored 'Cis proline' 0 C--N 1.346 0.423 0 CA-C-N 120.719 1.293 . . . . 0.0 113.484 0.605 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 305' ' ' LYS . . . . . 0.633 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -78.18 147.73 34.37 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.471 -0.786 . . . . 0.0 111.333 -177.774 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 306' ' ' ILE . . . . . 0.627 HG23 HG21 ' A' ' 322' ' ' VAL . 51.1 mm -114.07 110.71 33.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.718 -174.244 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 307' ' ' LEU . . . . . 0.504 ' HA ' ' HD3' ' A' ' 308' ' ' PRO . 90.7 mt -134.04 123.06 16.66 Favored Pre-proline 0 N--CA 1.465 0.28 0 CA-C-N 116.62 -0.264 . . . . 0.0 111.46 175.776 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 308' ' ' PRO . . . . . 0.723 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 32.7 Cg_exo -67.68 148.92 78.7 Favored 'Trans proline' 0 C--O 1.233 0.236 0 C-N-CA 123.705 2.937 . . . . 0.0 114.284 -176.333 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . 0.675 HG21 HG11 ' A' ' 276' ' ' VAL . 45.2 t -94.14 -13.79 8.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.132 -0.94 . . . . 0.0 109.055 168.988 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 53.1 mt-10 -78.51 35.79 0.24 Allowed 'General case' 0 CA--C 1.533 0.317 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.959 177.225 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.771 ' HA ' ' HD3' ' A' ' 317' ' ' ARG . 15.5 p30 40.74 66.23 0.67 Allowed 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 114.258 1.207 . . . . 0.0 114.258 173.733 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 85.0 m -81.35 -41.55 21.84 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.753 -0.658 . . . . 0.0 109.657 170.118 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 59.0 t0 -137.83 146.05 43.0 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 175.541 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 61.3 t -62.02 -43.36 97.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 O-C-N 123.191 0.307 . . . . 0.0 111.078 178.858 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -69.96 -19.88 63.34 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.005 0.431 . . . . 0.0 111.094 178.58 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 35.0 t -78.74 -15.24 58.69 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.502 179.804 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 317' ' ' ARG . . . . . 0.771 ' HD3' ' HA ' ' A' ' 311' ' ' ASN . 2.4 mmm180 -74.52 -51.87 4.04 Favored Pre-proline 0 CA--C 1.536 0.437 0 N-CA-C 112.883 0.697 . . . . 0.0 112.883 -177.709 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 318' ' ' PRO . . . . . 0.591 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 23.5 Cg_exo -64.95 -18.95 63.69 Favored 'Trans proline' 0 C--N 1.355 0.874 0 C-N-CA 121.844 1.696 . . . . 0.0 112.388 -178.407 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 319' ' ' TYR . . . . . 0.409 ' O ' HD12 ' A' ' 307' ' ' LEU . 3.7 m-85 -113.52 22.08 14.49 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.284 -179.499 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . 0.461 ' HB1' HG22 ' A' ' 309' ' ' VAL . . . -59.68 142.29 53.32 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.226 -177.408 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 50.3 t30 -135.2 -21.57 1.6 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.942 -178.917 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 322' ' ' VAL . . . . . 0.627 HG21 HG23 ' A' ' 306' ' ' ILE . 34.7 m -140.53 172.04 12.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.141 178.658 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 51.1 m-20 -65.94 -44.76 84.09 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.647 -0.251 . . . . 0.0 111.427 179.203 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 324' ' ' ALA . . . . . 0.723 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -174.97 -178.86 1.29 Allowed 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 112.358 0.503 . . . . 0.0 112.358 -177.229 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 36.5 mtmm -108.01 116.72 56.59 Favored Pre-proline 0 N--CA 1.452 -0.364 0 CA-C-N 114.51 -1.223 . . . . 0.0 108.404 168.261 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -71.64 167.09 27.45 Favored 'Trans proline' 0 C--O 1.233 0.236 0 C-N-CA 122.411 2.074 . . . . 0.0 112.22 -177.905 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -67.58 121.58 16.17 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 175.541 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 328' ' ' GLU . . . . . 0.622 ' OE1' ' HA ' ' A' ' 231' ' ' SER . 31.2 tp10 67.53 164.4 0.21 Allowed 'General case' 0 CA--C 1.537 0.45 0 O-C-N 123.986 0.804 . . . . 0.0 109.562 -174.204 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 329' ' ' SER . . . . . 0.486 ' HB2' ' O ' ' A' ' 230' ' ' VAL . 53.5 m -71.21 -29.65 65.41 Favored 'General case' 0 C--N 1.327 -0.403 0 O-C-N 121.65 -0.656 . . . . 0.0 110.875 -177.838 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 330' ' ' ALA . . . . . 0.427 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 74.86 -153.11 0.04 OUTLIER 'General case' 0 N--CA 1.469 0.514 0 O-C-N 123.971 0.794 . . . . 0.0 112.499 173.342 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -87.22 116.61 25.42 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.149 -0.932 . . . . 0.0 111.167 -176.816 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 332' ' ' ILE . . . . . 0.944 HG13 HG12 ' A' ' 270' ' ' ILE . 1.8 mp -107.67 139.92 27.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 177.556 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 61.6 m -129.68 103.89 7.11 Favored 'General case' 0 C--N 1.327 -0.392 0 C-N-CA 120.853 -0.339 . . . . 0.0 111.306 -174.624 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 334' ' ' ILE . . . . . 0.721 ' HA ' ' HB3' ' A' ' 268' ' ' PHE . 3.1 mp -90.73 134.98 27.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.491 -177.161 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 335' ' ' LEU . . . . . 0.711 HD23 ' H ' ' A' ' 335' ' ' LEU . 1.6 pt? -116.73 136.35 53.03 Favored 'General case' 0 N--CA 1.441 -0.897 0 N-CA-C 107.721 -1.215 . . . . 0.0 107.721 166.366 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 15.4 p-10 -75.46 47.56 0.39 Allowed 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.141 0.496 . . . . 0.0 110.822 -177.277 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 337' ' ' LYS . . . . . 0.405 ' HB2' ' NZ ' ' A' ' 337' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.243 0.722 0 CA-C-O 118.364 -0.827 . . . . 0.0 110.603 179.442 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 26.9 m . . . . . 0 N--CA 1.454 -0.268 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 228' ' ' LEU . . . . . . . . . . . . . 72.9 mt -91.54 87.94 6.58 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 -178.836 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 229' ' ' THR . . . . . 0.591 HG22 ' HA ' ' A' ' 331' ' ' ALA . 22.7 p -113.76 173.43 6.43 Favored 'General case' 0 C--N 1.316 -0.865 0 C-N-CA 119.739 -0.784 . . . . 0.0 110.386 -177.953 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 230' ' ' VAL . . . . . 0.557 ' O ' ' HB2' ' A' ' 329' ' ' SER . 78.9 t -142.75 133.12 23.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-O 121.023 0.439 . . . . 0.0 110.785 -176.542 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 39.5 t -108.31 100.28 9.59 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-N 115.339 -0.846 . . . . 0.0 109.482 175.725 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . -173.27 166.77 39.32 Favored Glycine 0 N--CA 1.444 -0.786 0 N-CA-C 111.391 -0.684 . . . . 0.0 111.391 -178.35 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 233' ' ' GLN . . . . . 0.4 ' HA ' ' HD3' ' A' ' 234' ' ' PRO . 12.9 mm-40 -107.49 102.03 42.34 Favored Pre-proline 0 C--N 1.321 -0.659 0 CA-C-N 116.706 0.253 . . . . 0.0 110.72 -179.866 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 234' ' ' PRO . . . . . 0.76 ' HB2' HD12 ' A' ' 306' ' ' ILE . 33.7 Cg_endo -98.11 127.14 0.22 Allowed 'Trans proline' 0 N--CA 1.451 -1.002 0 C-N-CA 123.034 2.489 . . . . 0.0 112.227 -178.479 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -160.28 -177.39 6.22 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.709 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 33.4 t-80 -159.14 132.98 7.47 Favored 'General case' 0 CA--C 1.517 -0.297 0 CA-C-O 121.605 0.716 . . . . 0.0 111.941 176.38 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 237' ' ' LYS . . . . . 0.614 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.322 -0.608 0 CA-C-N 114.67 -1.15 . . . . 0.0 110.012 178.203 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 3.1 mm100 . . . . . 0 N--CA 1.463 0.176 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 253' ' ' GLY . . . . . 0.446 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -128.19 116.06 2.22 Favored Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 118.941 -1.6 . . . . 0.0 113.423 -174.275 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 254' ' ' THR . . . . . 0.467 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 80.9 p -109.41 115.45 29.98 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 170.605 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 255' ' ' ILE . . . . . 0.463 ' O ' ' HA ' ' A' ' 299' ' ' THR . 2.0 pp -131.52 164.85 33.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 N-CA-C 112.733 0.642 . . . . 0.0 112.733 -172.79 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 28.9 m -102.17 118.29 36.59 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 178.789 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 257' ' ' VAL . . . . . 0.422 HG12 HG22 ' A' ' 230' ' ' VAL . 35.0 m -90.4 142.91 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.728 0 C-N-CA 119.768 -0.773 . . . . 0.0 112.762 -172.17 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 32.1 t -91.96 9.56 32.6 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 113.772 -1.558 . . . . 0.0 108.317 168.679 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 259' ' ' ALA . . . . . 0.467 ' HB3' HD11 ' A' ' 262' ' ' LEU . . . -92.19 160.94 14.93 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-N 115.303 -0.862 . . . . 0.0 109.184 179.588 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 34.9 t -118.22 131.06 56.4 Favored 'General case' 0 C--N 1.322 -0.627 0 C-N-CA 120.779 -0.368 . . . . 0.0 111.491 -175.794 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 69.96 51.05 25.71 Favored Glycine 0 N--CA 1.449 -0.445 0 CA-C-N 115.607 -0.724 . . . . 0.0 113.655 173.656 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 262' ' ' LEU . . . . . 0.467 HD11 ' HB3' ' A' ' 259' ' ' ALA . 62.6 mt -91.23 151.55 20.88 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 117.044 0.422 . . . . 0.0 110.161 176.63 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 82.5 mt-30 -137.42 168.22 20.08 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.026 0.441 . . . . 0.0 110.883 -178.427 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 57.6 t -78.23 123.74 35.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.971 176.915 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . 0.452 ' H ' ' HB ' ' A' ' 292' ' ' VAL . . . 114.15 6.98 19.81 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.51 -0.852 . . . . 0.0 112.808 -179.978 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 61.7 m-20 -89.7 166.02 13.84 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.157 0.503 . . . . 0.0 110.611 176.205 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 267' ' ' ALA . . . . . 0.698 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -129.61 153.3 48.21 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.287 -0.87 . . . . 0.0 109.008 177.676 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 268' ' ' PHE . . . . . 0.613 ' HB3' HD13 ' A' ' 334' ' ' ILE . 9.9 p90 -164.0 165.73 22.21 Favored 'General case' 0 C--N 1.32 -0.675 0 C-N-CA 119.701 -0.8 . . . . 0.0 112.498 -176.887 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 269' ' ' THR . . . . . 0.56 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 66.4 p -115.45 149.51 37.94 Favored 'General case' 0 N--CA 1.444 -0.763 0 CA-C-N 114.624 -1.171 . . . . 0.0 109.224 173.302 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 270' ' ' ILE . . . . . 0.999 HG12 HG13 ' A' ' 332' ' ' ILE . 60.5 mt -121.46 131.47 72.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 N-CA-C 110.416 -0.216 . . . . 0.0 110.416 -179.26 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -62.24 132.91 54.26 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.124 -179.499 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 91.47 -21.72 33.94 Favored Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.182 -178.08 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 31.0 t -105.38 104.36 16.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 C-N-CA 122.402 0.281 . . . . 0.0 110.367 -179.483 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 274' ' ' ASN . . . . . 0.529 ' HA ' ' HA ' ' A' ' 287' ' ' PRO . 7.3 m120 -126.11 144.42 50.74 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.509 -0.476 . . . . 0.0 111.408 -175.429 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 275' ' ' SER . . . . . 0.48 ' HB3' ' OE1' ' A' ' 288' ' ' GLN . 29.5 p -63.77 160.98 16.09 Favored 'General case' 0 CA--C 1.515 -0.377 0 CA-C-N 115.826 -0.624 . . . . 0.0 112.494 -179.377 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 276' ' ' VAL . . . . . 0.543 HG21 HG21 ' A' ' 309' ' ' VAL . 33.8 m -119.36 149.94 21.85 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.663 0 CA-C-N 114.916 -1.038 . . . . 0.0 110.618 176.246 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 87.9 m-70 -109.73 71.62 0.77 Allowed 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 173.323 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 -74.42 -9.62 58.77 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.379 -0.828 . . . . 0.0 112.136 -173.459 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 47.1 mm -92.4 -56.6 5.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 120.732 0.301 . . . . 0.0 110.761 -179.676 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 73.0 p -86.48 -14.42 43.2 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.321 -178.716 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 3.1 mmmp? 62.27 48.47 4.8 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.994 -178.231 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 52.6 m-20 -92.28 122.92 35.21 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.285 176.943 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 60.9 p -89.35 102.68 15.35 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.052 0.453 . . . . 0.0 110.054 176.616 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 68.5 p -130.91 -40.22 1.19 Allowed 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.837 -0.619 . . . . 0.0 111.242 -174.972 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 73.07 32.36 60.66 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 120.518 -0.848 . . . . 0.0 112.254 -179.624 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 73.6 mt-30 -76.19 140.41 69.48 Favored Pre-proline 0 C--O 1.223 -0.321 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.603 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 287' ' ' PRO . . . . . 0.56 ' HB2' ' HB ' ' A' ' 269' ' ' THR . 36.2 Cg_endo -69.78 150.57 68.26 Favored 'Trans proline' 0 CA--C 1.529 0.255 0 C-N-CA 122.057 1.838 . . . . 0.0 112.566 -177.163 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 288' ' ' GLN . . . . . 0.48 ' OE1' ' HB3' ' A' ' 275' ' ' SER . 5.5 mm100 -78.34 149.28 33.47 Favored 'General case' 0 CA--C 1.514 -0.422 0 CA-C-O 121.186 0.517 . . . . 0.0 112.2 176.929 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 289' ' ' VAL . . . . . 0.409 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 49.7 t -104.61 112.7 39.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 114.877 -1.056 . . . . 0.0 109.37 175.569 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 290' ' ' PHE . . . . . 0.698 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 53.9 m-85 -98.85 160.23 14.41 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.384 -175.584 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 291' ' ' ARG . . . . . 0.47 ' NH1' ' HB2' ' A' ' 267' ' ' ALA . 32.7 mmt180 -118.02 150.54 39.12 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 178.588 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 292' ' ' VAL . . . . . 0.546 HG13 HG13 ' A' ' 300' ' ' VAL . 52.5 t -100.25 122.92 52.76 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.913 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.57 -177.87 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 293' ' ' LEU . . . . . 0.505 HD21 ' HB3' ' A' ' 303' ' ' SER . 3.4 mm? -104.41 -24.1 13.1 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.465 -0.334 . . . . 0.0 111.674 -177.332 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 294' ' ' ALA . . . . . 0.496 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -154.4 136.59 14.79 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 120.762 -0.375 . . . . 0.0 111.638 179.898 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 58.0 t -135.51 120.1 27.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 175.104 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 31.2 t -157.41 111.69 2.65 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.604 -178.331 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 63.34 50.2 64.43 Favored Glycine 0 C--N 1.33 0.229 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.059 -178.315 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 72.2 p 50.82 23.38 1.4 Allowed 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 123.445 0.698 . . . . 0.0 112.524 -175.576 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 299' ' ' THR . . . . . 0.463 ' HA ' ' O ' ' A' ' 255' ' ' ILE . 40.6 m -111.75 116.87 31.43 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 176.148 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . 0.546 HG13 HG13 ' A' ' 292' ' ' VAL . 59.1 t -113.69 133.91 58.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.619 -172.34 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 43.5 m -96.82 120.61 37.46 Favored 'General case' 0 C--O 1.235 0.32 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 172.548 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 302' ' ' ILE . . . . . 0.446 HG12 ' O ' ' A' ' 253' ' ' GLY . 27.7 pt -111.26 143.72 20.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-O 121.626 0.727 . . . . 0.0 112.811 -169.725 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 303' ' ' SER . . . . . 0.505 ' HB3' HD21 ' A' ' 293' ' ' LEU . 46.8 t -156.29 129.11 4.26 Favored Pre-proline 0 C--N 1.323 -0.578 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 173.24 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 304' ' ' PRO . . . . . 0.653 ' HD2' ' HA ' ' A' ' 290' ' ' PHE . 34.8 Cg_exo -63.0 -176.05 4.24 Favored 'Cis proline' 0 N--CA 1.477 0.505 0 CA-C-N 119.912 1.004 . . . . 0.0 114.324 1.807 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 305' ' ' LYS . . . . . 0.661 ' HE2' HD11 ' A' ' 307' ' ' LEU . 0.0 OUTLIER -136.57 -175.52 4.04 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.938 -176.205 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 306' ' ' ILE . . . . . 0.76 HD12 ' HB2' ' A' ' 234' ' ' PRO . 41.8 mt -94.29 99.97 10.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.946 -173.525 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 307' ' ' LEU . . . . . 0.661 HD11 ' HE2' ' A' ' 305' ' ' LYS . 2.7 mp -114.43 105.55 53.63 Favored Pre-proline 0 C--N 1.33 -0.277 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 175.729 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 308' ' ' PRO . . . . . 0.745 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 24.1 Cg_exo -68.92 127.66 15.61 Favored 'Trans proline' 0 CA--C 1.53 0.286 0 C-N-CA 122.955 2.437 . . . . 0.0 113.394 -176.07 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . 0.659 HG22 ' HB3' ' A' ' 320' ' ' ALA . 76.9 t -84.27 -37.14 12.6 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.088 174.966 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -75.29 -6.65 50.93 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.256 179.243 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.52 ' HB2' ' HB2' ' A' ' 308' ' ' PRO . 69.7 m-80 -136.87 -158.69 0.88 Allowed 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.262 -0.427 . . . . 0.0 109.996 -176.633 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 16.5 m 71.23 -73.16 0.1 Allowed 'General case' 0 C--O 1.234 0.275 0 C-N-CA 123.755 0.822 . . . . 0.0 110.903 177.005 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 51.0 t0 -176.44 159.81 2.0 Allowed 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 177.253 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 61.7 t -64.45 -39.73 86.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-O 120.908 0.385 . . . . 0.0 110.55 176.038 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -72.5 -18.87 61.62 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.637 178.732 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 50.3 m -83.86 -25.86 29.92 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.535 -0.302 . . . . 0.0 111.177 -179.221 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 317' ' ' ARG . . . . . 0.659 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 74.1 mtm180 -49.14 -52.57 46.88 Favored Pre-proline 0 CA--C 1.539 0.52 0 N-CA-C 112.641 0.608 . . . . 0.0 112.641 -178.574 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 318' ' ' PRO . . . . . 0.659 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 51.8 Cg_exo -59.74 -13.97 24.56 Favored 'Trans proline' 0 C--N 1.36 1.14 0 C-N-CA 122.53 2.154 . . . . 0.0 113.833 -177.232 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 44.9 m-85 -110.75 -0.55 17.0 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.99 0.424 . . . . 0.0 110.77 -179.282 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 320' ' ' ALA . . . . . 0.659 ' HB3' HG22 ' A' ' 309' ' ' VAL . . . -90.5 159.85 16.3 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.155 -178.899 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 321' ' ' ASN . . . . . 0.431 ' O ' ' HA ' ' A' ' 275' ' ' SER . 0.1 OUTLIER -130.68 -0.69 4.33 Favored 'General case' 0 N--CA 1.464 0.255 0 N-CA-C 112.75 0.648 . . . . 0.0 112.75 -178.977 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 322' ' ' VAL . . . . . 0.676 HG21 HG23 ' A' ' 306' ' ' ILE . 32.8 m -136.11 162.08 36.71 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.258 0 N-CA-C 110.097 -0.334 . . . . 0.0 110.097 176.988 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 51.6 m-20 -72.92 -39.82 65.97 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 111.731 0.271 . . . . 0.0 111.731 -176.376 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 324' ' ' ALA . . . . . 0.745 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -155.5 174.61 15.02 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 112.149 0.426 . . . . 0.0 112.149 -173.353 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 24.6 pttm -119.12 107.44 41.73 Favored Pre-proline 0 N--CA 1.454 -0.233 0 CA-C-N 115.472 -0.785 . . . . 0.0 110.031 170.923 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 55.0 Cg_endo -74.04 167.82 26.28 Favored 'Trans proline' 0 C--O 1.233 0.232 0 C-N-CA 122.695 2.263 . . . . 0.0 112.562 -176.525 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -71.6 123.81 23.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.875 -179.289 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 54.8 mt-10 66.36 -170.14 0.2 Allowed 'General case' 0 N--CA 1.465 0.32 0 O-C-N 123.674 0.609 . . . . 0.0 111.004 -175.998 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 329' ' ' SER . . . . . 0.557 ' HB2' ' O ' ' A' ' 230' ' ' VAL . 50.9 m -94.29 -27.81 15.93 Favored 'General case' 0 C--N 1.325 -0.467 0 C-N-CA 120.727 -0.389 . . . . 0.0 111.995 -174.458 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 330' ' ' ALA . . . . . 0.477 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 75.62 -151.32 0.03 OUTLIER 'General case' 0 N--CA 1.478 0.95 0 N-CA-C 113.273 0.842 . . . . 0.0 113.273 173.023 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 331' ' ' ALA . . . . . 0.591 ' HA ' HG22 ' A' ' 229' ' ' THR . . . -92.98 120.64 33.49 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 114.741 -1.118 . . . . 0.0 110.818 -177.735 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 332' ' ' ILE . . . . . 0.999 HG13 HG12 ' A' ' 270' ' ' ILE . 1.7 mp -106.54 145.87 13.73 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 115.682 -0.69 . . . . 0.0 111.221 -176.903 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 44.1 m -118.29 95.33 4.83 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.0 -178.077 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 334' ' ' ILE . . . . . 0.613 HD13 ' HB3' ' A' ' 268' ' ' PHE . 39.8 mm -78.34 133.48 30.18 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-O 120.949 0.404 . . . . 0.0 111.35 -176.276 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 335' ' ' LEU . . . . . 0.579 HD13 ' H ' ' A' ' 337' ' ' LYS . 1.8 pp -152.44 -172.65 4.3 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.429 177.875 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -124.96 44.23 2.84 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.776 0.322 . . . . 0.0 110.844 -178.925 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 337' ' ' LYS . . . . . 0.579 ' H ' HD13 ' A' ' 335' ' ' LEU . 60.8 tttm . . . . . 0 C--O 1.245 0.836 0 CA-C-O 118.635 -0.698 . . . . 0.0 110.509 -178.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.86 0 N-CA-C 112.545 -0.222 . . . . 0.0 112.545 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 64.3 p -125.2 168.6 13.23 Favored 'General case' 0 C--N 1.325 -0.473 0 O-C-N 122.704 -0.292 . . . . 0.0 110.631 178.725 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 73.8 p -70.18 161.06 30.96 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.613 178.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 23.3 pt-20 -112.73 29.37 8.01 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-O 121.192 0.52 . . . . 0.0 111.0 178.473 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 38.2 p -89.36 81.76 6.58 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.286 176.642 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 228' ' ' LEU . . . . . . . . . . . . . 73.0 mt -107.62 100.72 10.1 Favored 'General case' 0 N--CA 1.445 -0.692 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 -178.325 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 76.1 p -126.39 172.19 10.36 Favored 'General case' 0 C--N 1.325 -0.459 0 C-N-CA 119.924 -0.71 . . . . 0.0 110.41 -178.621 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . 0.771 HG11 ' HB ' ' A' ' 255' ' ' ILE . 61.5 t -143.96 136.36 23.21 Favored 'Isoleucine or valine' 0 C--O 1.24 0.565 0 CA-C-O 120.779 0.324 . . . . 0.0 110.845 -178.176 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 29.7 m -97.28 160.16 14.5 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.125 177.201 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 92.52 161.58 36.57 Favored Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.462 -0.875 . . . . 0.0 111.177 -177.281 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 233' ' ' GLN . . . . . 0.598 ' HG2' ' HA ' ' A' ' 328' ' ' GLU . 83.4 mt-30 -118.16 102.85 50.38 Favored Pre-proline 0 C--N 1.319 -0.723 0 CA-C-N 117.081 0.44 . . . . 0.0 111.739 -177.354 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 234' ' ' PRO . . . . . 0.414 ' HD3' ' OG ' ' A' ' 329' ' ' SER . 73.9 Cg_endo -75.86 123.75 7.61 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 121.468 1.445 . . . . 0.0 110.444 171.829 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 20.3 pt-20 -166.19 127.1 1.76 Allowed 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.605 -178.584 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 236' ' ' HIS . . . . . 0.479 ' C ' ' HD3' ' A' ' 237' ' ' LYS . 92.1 m-70 -141.04 143.36 34.35 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.219 174.794 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 237' ' ' LYS . . . . . 0.479 ' HD3' ' C ' ' A' ' 236' ' ' HIS . 13.7 mmtm -106.1 159.12 16.31 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.207 -172.62 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 238' ' ' VAL . . . . . . . . . . . . . 51.7 t -67.33 111.73 2.26 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 177.31 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 239' ' ' GLU . . . . . 0.45 ' HB2' ' HB ' ' A' ' 248' ' ' VAL . 53.6 mt-10 -85.87 135.12 33.83 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.56 -176.539 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 240' ' ' ALA . . . . . 0.595 ' O ' ' HA ' ' A' ' 247' ' ' PRO . . . -67.63 -53.29 29.22 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.025 177.75 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 241' ' ' LYS . . . . . 0.53 ' HD2' ' O ' ' A' ' 241' ' ' LYS . 0.0 OUTLIER -146.25 154.58 41.89 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.38 178.024 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 242' ' ' ASP . . . . . 0.481 ' HB3' HG21 ' A' ' 248' ' ' VAL . 2.7 p30 -98.5 -158.02 0.64 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.609 -179.607 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 34.1 t -62.78 -30.5 71.51 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.326 -177.211 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -82.84 -14.27 54.64 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-O 121.191 0.519 . . . . 0.0 109.8 178.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 84.7 26.96 36.56 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.536 -0.84 . . . . 0.0 112.421 177.901 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 246' ' ' MET . . . . . 0.474 ' O ' ' HA ' ' A' ' 241' ' ' LYS . 24.3 ptt? -112.74 152.8 45.05 Favored Pre-proline 0 C--N 1.324 -0.529 0 N-CA-C 110.335 -0.246 . . . . 0.0 110.335 178.895 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 247' ' ' PRO . . . . . 0.595 ' HA ' ' O ' ' A' ' 240' ' ' ALA . 71.0 Cg_exo -53.2 135.89 60.78 Favored 'Trans proline' 0 C--N 1.351 0.67 0 C-N-CA 122.948 2.432 . . . . 0.0 112.537 -177.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.481 HG21 ' HB3' ' A' ' 242' ' ' ASP . 42.1 t -120.1 133.78 65.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 N-CA-C 112.065 0.395 . . . . 0.0 112.065 -174.57 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -103.44 95.27 5.96 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 167.41 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 250' ' ' ASN . . . . . 0.839 HD21 HD21 ' A' ' 307' ' ' LEU . 15.6 p-10 -59.59 154.15 18.23 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.272 -172.122 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . 0.571 ' HG3' ' HG3' ' A' ' 252' ' ' GLN . 22.2 ptt-85 -143.65 -178.97 6.16 Favored 'General case' 0 C--N 1.326 -0.438 0 C-N-CA 120.936 -0.305 . . . . 0.0 111.45 -177.137 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 252' ' ' GLN . . . . . 0.571 ' HG3' ' HG3' ' A' ' 251' ' ' ARG . 25.2 mt-30 62.12 178.19 0.13 Allowed 'General case' 0 N--CA 1.468 0.474 0 N-CA-C 114.13 1.159 . . . . 0.0 114.13 170.86 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 174.72 109.47 0.24 Allowed Glycine 0 N--CA 1.446 -0.648 0 CA-C-N 114.338 -1.301 . . . . 0.0 109.933 -177.145 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 41.5 p -95.44 125.09 39.81 Favored 'General case' 0 C--N 1.324 -0.522 0 O-C-N 122.32 -0.517 . . . . 0.0 111.706 -171.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.771 ' HB ' HG11 ' A' ' 230' ' ' VAL . 20.5 pt -124.37 145.18 31.96 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.901 -176.181 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 31.0 m -99.56 106.05 17.99 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 174.232 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.557 ' HA ' HG13 ' A' ' 230' ' ' VAL . 32.8 m -88.13 141.57 14.13 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.595 0 C-N-CA 119.27 -0.972 . . . . 0.0 113.607 -165.04 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 36.4 m -94.23 10.3 34.57 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 113.404 -1.725 . . . . 0.0 109.275 169.593 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 259' ' ' ALA . . . . . . . . . . . . . . . -126.76 145.58 50.56 Favored 'General case' 0 CA--C 1.518 -0.256 0 N-CA-C 113.037 0.755 . . . . 0.0 113.037 -167.209 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 62.5 m 57.94 -68.51 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.558 0 CA-C-N 113.822 -1.535 . . . . 0.0 114.919 167.354 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 107.49 51.39 0.76 Allowed Glycine 0 N--CA 1.449 -0.466 0 N-CA-C 109.861 -1.296 . . . . 0.0 109.861 -167.408 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 262' ' ' LEU . . . . . 0.409 HD21 HD12 ' A' ' 334' ' ' ILE . 92.4 mt -65.0 163.93 13.71 Favored 'General case' 0 C--O 1.235 0.332 0 N-CA-C 113.709 1.003 . . . . 0.0 113.709 -168.021 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 73.0 mt-30 -135.23 -179.42 5.62 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 113.694 -1.594 . . . . 0.0 108.042 173.425 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 264' ' ' VAL . . . . . 0.43 ' HA ' ' CG1' ' A' ' 292' ' ' VAL . 38.5 t -73.76 127.81 35.84 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 C-N-CA 120.679 -0.408 . . . . 0.0 111.062 -179.79 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . 0.617 ' H ' ' HB ' ' A' ' 292' ' ' VAL . . . 121.49 8.05 7.88 Favored Glycine 0 C--N 1.335 0.486 0 C-N-CA 120.363 -0.922 . . . . 0.0 114.395 175.246 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 65.6 m-20 -90.71 164.93 13.95 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 117.831 0.816 . . . . 0.0 111.517 178.511 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 267' ' ' ALA . . . . . 0.766 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -139.9 126.0 19.84 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.199 -0.909 . . . . 0.0 109.052 174.536 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 268' ' ' PHE . . . . . 0.48 ' HZ ' HG21 ' A' ' 302' ' ' ILE . 4.7 p90 -147.6 166.74 26.47 Favored 'General case' 0 C--N 1.327 -0.413 0 C-N-CA 119.74 -0.784 . . . . 0.0 111.829 -173.353 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 269' ' ' THR . . . . . 0.435 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 44.2 p -117.73 139.82 50.53 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.853 176.09 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 270' ' ' ILE . . . . . 0.546 HG12 HG12 ' A' ' 332' ' ' ILE . 59.6 mt -106.71 144.37 15.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-O 120.668 0.27 . . . . 0.0 110.964 -177.425 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -67.83 119.51 12.64 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.442 -179.827 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 106.04 -22.69 30.91 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 121.098 -0.572 . . . . 0.0 112.386 178.615 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . 0.818 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 36.5 t -87.02 101.44 11.16 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-O 121.046 0.45 . . . . 0.0 110.286 178.756 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 274' ' ' ASN . . . . . 0.526 ' HB3' ' HA2' ' A' ' 285' ' ' GLY . 3.6 m120 -110.01 129.6 55.65 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.272 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 51.0 p -73.01 160.47 32.03 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.588 0.709 . . . . 0.0 112.148 -178.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 276' ' ' VAL . . . . . 0.863 HG21 HG21 ' A' ' 309' ' ' VAL . 22.8 m -127.9 -176.67 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 CA-C-N 114.748 -1.115 . . . . 0.0 110.432 -178.561 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 277' ' ' HIS . . . . . 0.669 ' HB3' ' HA ' ' A' ' 281' ' ' LYS . 0.7 OUTLIER 29.84 51.21 0.08 Allowed 'General case' 0 N--CA 1.473 0.69 0 O-C-N 124.826 1.328 . . . . 0.0 113.624 177.89 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 4.1 tp-100 -74.84 -43.15 56.1 Favored 'General case' 0 N--CA 1.439 -1.018 0 N-CA-C 108.488 -0.931 . . . . 0.0 108.488 171.248 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 279' ' ' ILE . . . . . 0.446 ' O ' ' HB2' ' A' ' 282' ' ' ASP . 26.5 mm -117.32 75.08 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.278 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.269 177.464 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 58.3 p 51.4 81.93 0.07 Allowed 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 123.665 0.786 . . . . 0.0 112.642 -178.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 281' ' ' LYS . . . . . 0.669 ' HA ' ' HB3' ' A' ' 277' ' ' HIS . 1.0 OUTLIER 56.96 27.63 13.47 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-N 115.42 -0.809 . . . . 0.0 112.011 -179.555 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 282' ' ' ASP . . . . . 0.446 ' HB2' ' O ' ' A' ' 279' ' ' ILE . 57.3 t0 -90.1 128.55 36.34 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.947 -0.57 . . . . 0.0 109.677 177.323 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 44.7 p -101.18 114.94 29.36 Favored 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 179.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 76.0 p -116.19 -11.35 11.34 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.649 -0.705 . . . . 0.0 112.145 -167.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 285' ' ' GLY . . . . . 0.526 ' HA2' ' HB3' ' A' ' 274' ' ' ASN . . . 76.83 10.83 85.9 Favored Glycine 0 CA--C 1.517 0.196 0 C-N-CA 120.814 -0.707 . . . . 0.0 113.267 177.249 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 83.2 mt-30 -71.81 131.09 86.14 Favored Pre-proline 0 C--N 1.327 -0.39 0 CA-C-N 116.824 0.312 . . . . 0.0 110.596 179.616 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 287' ' ' PRO . . . . . 0.435 ' HB2' ' HB ' ' A' ' 269' ' ' THR . 15.8 Cg_endo -59.3 131.32 40.3 Favored 'Trans proline' 0 C--N 1.343 0.254 0 C-N-CA 122.699 2.266 . . . . 0.0 112.292 -178.646 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 69.2 tp60 -78.3 132.16 37.35 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.847 -178.528 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 46.9 t -92.13 136.3 24.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.356 179.345 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 290' ' ' PHE . . . . . 0.818 ' HZ ' HG11 ' A' ' 273' ' ' VAL . 55.7 m-85 -117.16 150.67 38.33 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.806 -177.081 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 21.2 mmt85 -108.02 157.69 18.02 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.797 -0.638 . . . . 0.0 109.835 172.252 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . 0.617 ' HB ' ' H ' ' A' ' 265' ' ' GLY . 52.2 t -102.6 128.77 55.07 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.03 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.509 177.406 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 293' ' ' LEU . . . . . 0.659 HD21 ' HB3' ' A' ' 303' ' ' SER . 2.8 mm? -103.99 -37.05 7.53 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.108 -178.578 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 294' ' ' ALA . . . . . . . . . . . . . . . -156.96 141.54 16.75 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.562 -0.29 . . . . 0.0 111.009 -178.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . 0.471 HG22 HG13 ' A' ' 300' ' ' VAL . 46.3 t -131.64 129.01 61.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.052 0.453 . . . . 0.0 110.122 176.176 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 56.5 p -122.3 88.81 3.0 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.793 -0.64 . . . . 0.0 109.897 178.295 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 75.42 -124.3 7.56 Favored Glycine 0 N--CA 1.446 -0.671 0 C-N-CA 119.932 -1.128 . . . . 0.0 110.552 -171.425 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 41.7 p -99.72 26.37 6.3 Favored 'General case' 0 C--N 1.319 -0.745 0 O-C-N 122.142 -0.622 . . . . 0.0 110.87 173.505 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 54.1 m -107.95 106.3 16.49 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 176.009 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . 0.471 HG13 HG22 ' A' ' 295' ' ' VAL . 42.0 t -104.44 124.87 59.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.952 -175.001 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 47.3 m -94.89 109.67 21.64 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 176.149 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 302' ' ' ILE . . . . . 0.566 ' O ' ' HA ' ' A' ' 252' ' ' GLN . 28.8 pt -111.25 160.93 10.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-O 121.459 0.647 . . . . 0.0 112.343 -173.412 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 303' ' ' SER . . . . . 0.659 ' HB3' HD21 ' A' ' 293' ' ' LEU . 34.6 t -167.24 155.9 9.09 Favored Pre-proline 0 C--N 1.32 -0.713 0 N-CA-C 105.964 -1.865 . . . . 0.0 105.964 178.331 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 304' ' ' PRO . . . . . 0.507 ' HA ' ' OG ' ' A' ' 303' ' ' SER . 65.2 Cg_exo -56.46 151.54 27.16 Favored 'Cis proline' 0 N--CA 1.473 0.291 0 CA-C-N 121.23 1.475 . . . . 0.0 114.642 1.715 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 305' ' ' LYS . . . . . 0.613 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -67.34 169.01 9.56 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 114.085 -1.416 . . . . 0.0 111.763 -179.04 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 306' ' ' ILE . . . . . 0.593 HG23 HG21 ' A' ' 322' ' ' VAL . 62.6 mt -108.59 114.09 45.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.85 -178.154 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 307' ' ' LEU . . . . . 0.839 HD21 HD21 ' A' ' 250' ' ' ASN . 94.0 mt -125.94 118.45 23.97 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-N 116.753 -0.203 . . . . 0.0 111.021 -179.72 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 308' ' ' PRO . . . . . 0.741 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 9.9 Cg_exo -74.18 122.31 7.49 Favored 'Trans proline' 0 CA--C 1.534 0.493 0 C-N-CA 123.519 2.813 . . . . 0.0 113.742 -178.557 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . 0.863 HG21 HG21 ' A' ' 276' ' ' VAL . 48.1 t -80.58 -19.44 11.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 121.189 0.518 . . . . 0.0 110.48 176.014 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 59.5 mm-40 -92.77 -5.32 51.42 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.904 0.383 . . . . 0.0 110.834 179.206 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.568 ' HB2' ' HB2' ' A' ' 308' ' ' PRO . 5.5 m120 -132.5 -129.98 0.18 Allowed 'General case' 0 CA--C 1.532 0.285 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.26 -178.531 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 312' ' ' THR . . . . . 0.493 ' OG1' ' HD2' ' A' ' 308' ' ' PRO . 59.6 m 60.84 -78.61 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.281 0 C-N-CA 124.28 1.032 . . . . 0.0 112.121 177.655 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 38.3 t70 -176.68 150.29 0.82 Allowed 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 -177.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 46.7 t -53.18 -37.61 28.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-O 120.748 0.309 . . . . 0.0 111.53 -179.516 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -84.91 -36.3 21.55 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 112.377 0.51 . . . . 0.0 112.377 -178.314 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . 0.523 ' HA ' ' CZ ' ' A' ' 319' ' ' TYR . 67.9 m -93.53 -12.68 29.06 Favored 'General case' 0 C--N 1.327 -0.398 0 N-CA-C 113.364 0.875 . . . . 0.0 113.364 -172.346 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 317' ' ' ARG . . . . . 0.525 ' HG2' ' HD3' ' A' ' 318' ' ' PRO . 33.6 ptt85 -75.44 -34.4 1.59 Allowed Pre-proline 0 CA--C 1.548 0.882 0 N-CA-C 113.171 0.804 . . . . 0.0 113.171 -179.47 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 318' ' ' PRO . . . . . 0.525 ' HD3' ' HG2' ' A' ' 317' ' ' ARG . 33.9 Cg_exo -60.36 -26.79 83.53 Favored 'Trans proline' 0 C--N 1.371 1.718 0 C-N-CA 121.702 1.602 . . . . 0.0 113.17 -177.785 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 319' ' ' TYR . . . . . 0.523 ' CZ ' ' HA ' ' A' ' 316' ' ' SER . 2.7 p90 -106.82 30.0 6.5 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.076 0.465 . . . . 0.0 111.312 177.863 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . 0.706 ' HB3' HG22 ' A' ' 309' ' ' VAL . . . -89.87 162.68 15.34 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.404 -0.817 . . . . 0.0 109.838 173.628 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 321' ' ' ASN . . . . . 0.406 ' OD1' HG13 ' A' ' 322' ' ' VAL . 19.4 p30 -100.71 -19.18 16.16 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 113.788 1.032 . . . . 0.0 113.788 -171.457 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 322' ' ' VAL . . . . . 0.593 HG21 HG23 ' A' ' 306' ' ' ILE . 35.6 m -136.77 161.08 36.78 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.401 0 CA-C-N 118.073 0.397 . . . . 0.0 111.155 -179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 54.5 m-20 -60.91 -41.03 95.34 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 111.849 0.314 . . . . 0.0 111.849 -178.781 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 324' ' ' ALA . . . . . 0.741 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -157.09 166.24 33.82 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.398 -0.364 . . . . 0.0 111.77 -175.346 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 24.5 pttm -106.31 108.93 62.67 Favored Pre-proline 0 C--N 1.327 -0.411 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 169.016 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_exo -65.0 167.24 16.39 Favored 'Trans proline' 0 C--N 1.343 0.244 0 C-N-CA 122.581 2.187 . . . . 0.0 113.107 -170.543 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -62.85 143.53 57.51 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 115.753 -0.658 . . . . 0.0 109.767 175.089 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 328' ' ' GLU . . . . . 0.598 ' HA ' ' HG2' ' A' ' 233' ' ' GLN . 15.6 pt-20 44.86 -135.25 0.65 Allowed 'General case' 0 N--CA 1.468 0.449 0 O-C-N 124.227 0.955 . . . . 0.0 110.941 -174.132 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 329' ' ' SER . . . . . 0.648 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 53.3 m -111.7 -31.63 6.91 Favored 'General case' 0 C--N 1.321 -0.636 0 C-N-CA 120.743 -0.383 . . . . 0.0 110.535 178.317 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 330' ' ' ALA . . . . . 0.432 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 78.6 -167.42 0.04 OUTLIER 'General case' 0 N--CA 1.475 0.824 0 O-C-N 124.111 0.882 . . . . 0.0 112.902 174.634 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -83.85 152.91 24.32 Favored 'General case' 0 CA--C 1.52 -0.182 0 CA-C-N 115.361 -0.836 . . . . 0.0 111.193 -176.179 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 332' ' ' ILE . . . . . 0.582 HD11 HG21 ' A' ' 230' ' ' VAL . 48.7 mt -126.58 145.0 34.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 121.202 0.525 . . . . 0.0 112.034 -176.56 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 87.8 m -111.22 97.57 6.88 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.459 -0.792 . . . . 0.0 109.103 173.486 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 334' ' ' ILE . . . . . 0.409 HD12 HD21 ' A' ' 262' ' ' LEU . 30.2 mm -79.11 132.27 32.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -171.705 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 335' ' ' LEU . . . . . . . . . . . . . 8.4 mp -119.79 151.59 38.57 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.412 -0.813 . . . . 0.0 109.818 170.468 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 75.0 m-80 -110.3 9.95 23.62 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.293 174.193 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 38.8 ttpt . . . . . 0 C--O 1.244 0.788 0 CA-C-O 118.493 -0.765 . . . . 0.0 110.181 179.295 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.776 0 N-CA-C 112.056 -0.418 . . . . 0.0 112.056 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 75.0 p 44.29 42.34 5.12 Favored 'General case' 0 N--CA 1.47 0.547 0 C-N-CA 123.67 0.788 . . . . 0.0 112.509 179.23 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 65.8 p -90.85 -176.2 4.6 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.367 178.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 226' ' ' GLU . . . . . 0.573 ' CD ' ' H ' ' A' ' 226' ' ' GLU . 0.7 OUTLIER -86.46 57.64 4.61 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.323 0.582 . . . . 0.0 110.224 176.252 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 35.7 t -77.54 80.54 4.02 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.237 177.616 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 228' ' ' LEU . . . . . 0.652 HD12 HG13 ' A' ' 334' ' ' ILE . 80.3 mt -103.61 146.9 27.88 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.352 -0.84 . . . . 0.0 109.548 -175.523 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 229' ' ' THR . . . . . 0.593 HG22 ' HA ' ' A' ' 331' ' ' ALA . 40.9 p -126.43 178.77 5.65 Favored 'General case' 0 C--N 1.323 -0.547 0 C-N-CA 119.729 -0.788 . . . . 0.0 111.042 -179.835 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . 0.857 HG11 HD12 ' A' ' 255' ' ' ILE . 58.1 t -146.28 137.15 18.6 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 -179.599 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 70.8 m -111.18 155.41 22.95 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.944 0.402 . . . . 0.0 110.854 178.188 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 86.03 169.63 46.14 Favored Glycine 0 N--CA 1.449 -0.499 0 N-CA-C 110.76 -0.936 . . . . 0.0 110.76 -172.471 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 233' ' ' GLN . . . . . 0.419 ' HA ' ' HD3' ' A' ' 234' ' ' PRO . 86.1 mt-30 -117.54 145.56 36.54 Favored Pre-proline 0 C--N 1.323 -0.572 0 CA-C-N 117.626 0.713 . . . . 0.0 111.482 179.761 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 234' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 233' ' ' GLN . 3.8 Cg_exo -71.94 172.29 14.91 Favored 'Trans proline' 0 N--CA 1.462 -0.374 0 C-N-CA 122.751 2.301 . . . . 0.0 111.55 176.249 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 55.7 mp0 -96.89 151.19 19.92 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.174 0.512 . . . . 0.0 110.911 -179.063 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 236' ' ' HIS . . . . . 0.591 ' CE1' ' HE2' ' A' ' 325' ' ' LYS . 17.1 p-80 -140.48 125.73 18.7 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.33 -0.85 . . . . 0.0 108.9 174.338 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 237' ' ' LYS . . . . . 0.563 ' HD3' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -169.56 140.05 2.16 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 111.76 0.282 . . . . 0.0 111.76 -176.385 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 238' ' ' VAL . . . . . 0.706 HG22 HD21 ' A' ' 250' ' ' ASN . 24.8 t -89.94 111.16 22.8 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.364 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 169.777 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 239' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -116.26 124.76 50.99 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-O 121.074 0.464 . . . . 0.0 111.168 -174.106 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 240' ' ' ALA . . . . . . . . . . . . . . . -66.65 -40.92 88.89 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.568 -177.86 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 241' ' ' LYS . . . . . 0.568 ' HD2' ' O ' ' A' ' 241' ' ' LYS . 0.6 OUTLIER -145.0 149.82 35.81 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.24 178.876 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 54.4 p-10 -102.0 -156.4 0.56 Allowed 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.369 -179.561 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 43.1 t -63.46 -21.34 66.25 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.218 178.046 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -87.25 -15.27 38.63 Favored 'General case' 0 CA--C 1.533 0.322 0 CA-C-O 121.308 0.575 . . . . 0.0 109.718 178.273 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . 0.549 ' HA2' ' HB2' ' A' ' 241' ' ' LYS . . . 72.36 26.66 71.43 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.892 -0.67 . . . . 0.0 112.848 176.586 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 246' ' ' MET . . . . . 0.562 ' O ' HG23 ' A' ' 248' ' ' VAL . 0.0 OUTLIER -111.76 165.95 11.85 Favored Pre-proline 0 C--N 1.325 -0.496 0 N-CA-C 110.326 -0.25 . . . . 0.0 110.326 179.496 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 247' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_exo -58.81 121.09 9.37 Favored 'Trans proline' 0 C--N 1.352 0.725 0 C-N-CA 122.402 2.068 . . . . 0.0 112.172 -176.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.562 HG23 ' O ' ' A' ' 246' ' ' MET . 61.4 t -119.22 152.32 21.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 120.87 0.366 . . . . 0.0 111.73 -174.823 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -120.53 144.46 48.04 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 170.664 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 250' ' ' ASN . . . . . 0.706 HD21 HG22 ' A' ' 238' ' ' VAL . 4.6 m120 -37.66 121.6 0.9 Allowed 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 123.423 0.689 . . . . 0.0 112.253 -175.291 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . 0.564 ' HG3' ' HG3' ' A' ' 252' ' ' GLN . 17.5 ptt-85 -150.31 171.64 16.65 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 120.869 -0.332 . . . . 0.0 111.364 -179.231 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 252' ' ' GLN . . . . . 0.564 ' HG3' ' HG3' ' A' ' 251' ' ' ARG . 26.2 mt-30 61.24 168.97 0.1 Allowed 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 114.894 1.442 . . . . 0.0 114.894 169.737 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . 0.556 ' O ' HG12 ' A' ' 302' ' ' ILE . . . 179.96 110.43 0.28 Allowed Glycine 0 N--CA 1.451 -0.349 0 CA-C-N 113.738 -1.574 . . . . 0.0 110.588 178.581 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 41.6 p -97.12 126.49 42.32 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 117.378 0.589 . . . . 0.0 111.406 -174.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.857 HD12 HG11 ' A' ' 230' ' ' VAL . 12.7 pt -132.18 157.79 43.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.62 -176.406 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 32.7 m -98.98 107.57 20.04 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 175.06 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.567 ' HA ' HG13 ' A' ' 230' ' ' VAL . 29.8 m -89.79 143.31 11.45 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.575 0 C-N-CA 119.556 -0.858 . . . . 0.0 113.012 -168.206 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 258' ' ' SER . . . . . 0.516 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 37.2 m -91.04 9.32 31.3 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 114.023 -1.444 . . . . 0.0 108.893 169.789 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 259' ' ' ALA . . . . . 0.618 ' HB1' HD13 ' A' ' 228' ' ' LEU . . . -84.78 161.56 19.93 Favored 'General case' 0 N--CA 1.448 -0.525 0 CA-C-N 115.119 -0.946 . . . . 0.0 109.502 -177.624 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 34.3 t -126.63 130.77 51.11 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 120.639 0.257 . . . . 0.0 110.61 -178.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 75.87 43.79 21.51 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.963 -0.637 . . . . 0.0 113.328 177.179 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 262' ' ' LEU . . . . . 0.481 HD12 HG21 ' A' ' 257' ' ' VAL . 79.3 mt -89.99 142.92 27.24 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 117.17 0.485 . . . . 0.0 110.478 175.757 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 73.0 mt-30 -133.84 171.43 14.17 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.51 176.845 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 44.0 t -76.58 142.05 14.87 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 N-CA-C 110.195 -0.298 . . . . 0.0 110.195 179.1 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 94.87 -4.9 68.77 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.5 -0.857 . . . . 0.0 113.257 177.255 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 266' ' ' ASP . . . . . 0.506 ' O ' ' HA ' ' A' ' 291' ' ' ARG . 48.7 m-20 -78.88 158.03 28.17 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 117.172 0.486 . . . . 0.0 110.837 178.287 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 267' ' ' ALA . . . . . 0.652 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -122.72 147.67 46.21 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.974 -176.658 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 268' ' ' PHE . . . . . 0.581 ' HA ' ' CD2' ' A' ' 335' ' ' LEU . 3.6 p90 -164.04 173.28 12.73 Favored 'General case' 0 C--N 1.33 -0.259 0 C-N-CA 120.056 -0.657 . . . . 0.0 111.895 -179.872 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 54.1 p -121.58 129.98 53.21 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.345 176.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 270' ' ' ILE . . . . . 0.846 HG12 HG13 ' A' ' 332' ' ' ILE . 62.6 mt -98.35 134.4 37.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.72 -178.839 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -76.07 118.47 18.85 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.828 179.206 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 109.62 -21.44 25.84 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.629 -0.796 . . . . 0.0 111.938 -178.778 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 40.9 t -104.35 102.12 13.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 N-CA-C 109.557 -0.535 . . . . 0.0 109.557 175.293 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 4.1 m120 -104.44 151.57 23.37 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 -179.481 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 275' ' ' SER . . . . . 0.98 ' HB3' ' HB3' ' A' ' 288' ' ' GLN . 23.2 p -88.17 157.53 18.79 Favored 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 112.13 0.419 . . . . 0.0 112.13 -178.079 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 276' ' ' VAL . . . . . 0.536 HG11 HG21 ' A' ' 309' ' ' VAL . 18.8 m -125.98 162.76 28.88 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.605 0 CA-C-N 115.332 -0.849 . . . . 0.0 109.959 172.744 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 277' ' ' HIS . . . . . 0.412 ' HD2' HG21 ' A' ' 284' ' ' THR . 88.8 m-70 -130.04 91.29 3.1 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 175.526 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 4.1 tp-100 -80.64 -23.42 39.71 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.361 -172.112 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 279' ' ' ILE . . . . . 0.505 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.1 mp -64.99 -41.56 92.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 121.069 0.461 . . . . 0.0 109.884 177.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 77.8 p -87.45 -16.44 34.8 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.316 174.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 5.6 tmtm? 59.49 53.65 5.03 Favored 'General case' 0 CA--C 1.531 0.216 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 -176.086 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -110.91 142.26 43.23 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.336 -0.847 . . . . 0.0 109.401 -175.256 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 36.0 p -102.28 106.19 16.96 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 178.295 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 284' ' ' THR . . . . . 0.412 HG21 ' HD2' ' A' ' 277' ' ' HIS . 82.5 p -110.13 -53.47 2.67 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.655 -0.702 . . . . 0.0 111.406 -171.628 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 66.13 31.48 79.41 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 121.001 -0.618 . . . . 0.0 111.966 -179.364 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 286' ' ' GLN . . . . . 0.408 ' HA ' ' HD3' ' A' ' 287' ' ' PRO . 11.2 mm100 -106.11 142.15 24.25 Favored Pre-proline 0 C--N 1.326 -0.451 0 CA-C-N 116.026 -0.087 . . . . 0.0 110.772 -177.311 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 287' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 286' ' ' GLN . 38.6 Cg_exo -59.3 127.82 25.32 Favored 'Trans proline' 0 C--N 1.344 0.295 0 C-N-CA 122.648 2.232 . . . . 0.0 111.671 178.161 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 288' ' ' GLN . . . . . 0.98 ' HB3' ' HB3' ' A' ' 275' ' ' SER . 15.9 pt20 -93.55 159.18 15.34 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.984 -178.163 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 289' ' ' VAL . . . . . 0.482 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 45.6 t -88.53 126.26 41.76 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 CA-C-N 115.446 -0.797 . . . . 0.0 110.002 175.246 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 290' ' ' PHE . . . . . 0.652 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 4.1 m-85 -99.67 169.21 9.43 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 178.762 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 291' ' ' ARG . . . . . 0.506 ' HA ' ' O ' ' A' ' 266' ' ' ASP . 12.5 ttp-105 -144.14 127.47 16.79 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-O 121.808 0.813 . . . . 0.0 110.947 172.417 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . 0.402 HG11 ' CG2' ' A' ' 295' ' ' VAL . 57.5 t -65.84 139.91 20.48 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.979 0 CA-C-N 114.044 -1.434 . . . . 0.0 112.175 -176.347 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 293' ' ' LEU . . . . . 0.513 HD11 ' HB2' ' A' ' 303' ' ' SER . 89.4 mt -105.56 -32.69 8.37 Favored 'General case' 0 CA--C 1.529 0.157 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.193 177.035 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 294' ' ' ALA . . . . . . . . . . . . . . . -158.6 144.94 17.1 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-O 120.463 0.173 . . . . 0.0 111.15 -179.18 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . 0.402 ' CG2' HG11 ' A' ' 292' ' ' VAL . 57.4 t -136.34 126.8 41.33 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 176.836 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 47.0 t -157.54 112.54 2.73 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.897 -178.56 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 57.6 49.76 70.93 Favored Glycine 0 C--N 1.333 0.376 0 C-N-CA 121.148 -0.548 . . . . 0.0 112.469 178.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 298' ' ' THR . . . . . 0.438 ' O ' HG22 ' A' ' 257' ' ' VAL . 66.8 p 55.4 10.3 0.46 Allowed 'General case' 0 N--CA 1.473 0.675 0 C-N-CA 124.201 1.0 . . . . 0.0 112.89 -175.722 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 42.6 m -97.81 106.02 18.26 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 173.351 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . 0.4 HG13 HG22 ' A' ' 295' ' ' VAL . 53.1 t -109.86 127.02 67.03 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.51 -170.494 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 57.3 m -90.54 113.89 25.98 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 172.655 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 302' ' ' ILE . . . . . 0.556 HG12 ' O ' ' A' ' 253' ' ' GLY . 31.0 pt -110.4 174.76 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-O 121.643 0.735 . . . . 0.0 111.727 -173.321 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 303' ' ' SER . . . . . 0.562 ' OG ' ' HA ' ' A' ' 304' ' ' PRO . 31.8 t -163.1 156.67 16.98 Favored Pre-proline 0 C--N 1.317 -0.811 0 N-CA-C 105.759 -1.941 . . . . 0.0 105.759 178.732 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 304' ' ' PRO . . . . . 0.562 ' HA ' ' OG ' ' A' ' 303' ' ' SER . 24.9 Cg_exo -66.33 -179.42 12.34 Favored 'Cis proline' 0 N--CA 1.474 0.339 0 CA-C-N 121.004 1.394 . . . . 0.0 113.906 1.404 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 305' ' ' LYS . . . . . 0.618 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -77.48 160.98 28.29 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.317 -0.856 . . . . 0.0 112.254 -175.264 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 306' ' ' ILE . . . . . 0.526 HD12 ' N ' ' A' ' 306' ' ' ILE . 2.2 mp -94.05 109.91 22.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.18 179.03 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 307' ' ' LEU . . . . . 0.604 HD21 HD22 ' A' ' 250' ' ' ASN . 96.0 mt -141.51 99.39 6.36 Favored Pre-proline 0 CA--C 1.516 -0.361 0 CA-C-O 120.455 0.169 . . . . 0.0 111.052 178.411 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 308' ' ' PRO . . . . . 0.755 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 22.6 Cg_exo -69.43 148.19 66.63 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 123.077 2.518 . . . . 0.0 113.297 -177.354 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . 0.536 HG21 HG11 ' A' ' 276' ' ' VAL . 45.5 t -93.7 -23.98 5.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 170.452 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -76.05 34.37 0.13 Allowed 'General case' 0 CA--C 1.532 0.272 0 CA-C-N 115.375 -0.83 . . . . 0.0 112.726 -177.3 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 77.3 m-20 -99.07 162.87 12.83 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 174.77 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 61.5 m -78.43 -32.81 48.77 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 109.735 -0.469 . . . . 0.0 109.735 176.615 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -65.31 119.57 11.18 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.781 179.699 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 60.1 t -68.39 -35.43 70.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.767 -0.651 . . . . 0.0 111.16 -178.657 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . 0.423 ' O ' ' HD2' ' A' ' 318' ' ' PRO . . . -65.07 -17.9 64.85 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 112.157 0.428 . . . . 0.0 112.157 -178.787 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . 0.593 ' HA ' ' CZ ' ' A' ' 319' ' ' TYR . 52.4 m -78.92 -17.21 55.89 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 111.812 0.301 . . . . 0.0 111.812 -179.313 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 317' ' ' ARG . . . . . 0.427 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 70.0 mtm180 -74.4 -46.88 5.86 Favored Pre-proline 0 CA--C 1.539 0.542 0 N-CA-C 112.928 0.714 . . . . 0.0 112.928 -176.569 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 318' ' ' PRO . . . . . 0.427 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 75.9 Cg_exo -54.85 -38.48 92.32 Favored 'Trans proline' 0 C--N 1.358 1.033 0 C-N-CA 122.126 1.884 . . . . 0.0 113.685 -175.78 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 319' ' ' TYR . . . . . 0.593 ' CZ ' ' HA ' ' A' ' 316' ' ' SER . 2.1 p90 -98.72 7.58 45.92 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 120.76 -0.376 . . . . 0.0 111.937 -178.536 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -60.43 156.02 16.93 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-O 121.122 0.487 . . . . 0.0 111.834 -177.28 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 321' ' ' ASN . . . . . 0.473 ' HB2' ' HE2' ' A' ' 305' ' ' LYS . 46.7 t30 -132.59 -27.61 1.71 Allowed 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.952 -179.04 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 322' ' ' VAL . . . . . 0.485 HG22 ' H ' ' A' ' 307' ' ' LEU . 28.7 m -131.59 166.95 27.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.759 -179.733 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -68.43 -48.05 65.61 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.612 -0.267 . . . . 0.0 111.154 177.832 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 324' ' ' ALA . . . . . 0.755 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -164.63 177.35 8.12 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.988 -0.551 . . . . 0.0 111.59 -176.132 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 325' ' ' LYS . . . . . 0.591 ' HE2' ' CE1' ' A' ' 236' ' ' HIS . 21.9 pttp -118.61 119.52 32.64 Favored Pre-proline 0 C--N 1.325 -0.462 0 CA-C-N 115.346 -0.843 . . . . 0.0 109.692 172.529 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_endo -79.23 169.13 19.4 Favored 'Trans proline' 0 C--O 1.233 0.243 0 C-N-CA 122.962 2.441 . . . . 0.0 112.901 -176.171 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -67.57 129.15 39.02 Favored 'General case' 0 C--O 1.238 0.455 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 175.643 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 57.0 mm-40 65.48 -156.17 0.28 Allowed 'General case' 0 N--CA 1.463 0.216 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 -172.089 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 329' ' ' SER . . . . . 0.661 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 69.3 m -112.5 -12.27 13.5 Favored 'General case' 0 C--N 1.322 -0.606 0 C-N-CA 120.544 -0.462 . . . . 0.0 110.869 176.785 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 70.24 -154.01 0.12 Allowed 'General case' 0 N--CA 1.469 0.502 0 N-CA-C 113.209 0.818 . . . . 0.0 113.209 172.408 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 331' ' ' ALA . . . . . 0.593 ' HA ' HG22 ' A' ' 229' ' ' THR . . . -93.09 137.61 32.28 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.75 -177.801 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 332' ' ' ILE . . . . . 0.846 HG13 HG12 ' A' ' 270' ' ' ILE . 1.9 mp -116.33 144.27 24.41 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.113 -178.685 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 40.8 m -109.87 106.29 15.81 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.609 -0.515 . . . . 0.0 109.609 179.728 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 334' ' ' ILE . . . . . 0.652 HG13 HD12 ' A' ' 228' ' ' LEU . 19.5 mm -81.39 133.55 29.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 N-CA-C 113.755 1.02 . . . . 0.0 113.755 -172.208 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 335' ' ' LEU . . . . . 0.581 ' CD2' ' HA ' ' A' ' 268' ' ' PHE . 1.6 pt? -148.02 -147.62 0.23 Allowed 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 113.61 -1.632 . . . . 0.0 108.344 169.071 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -163.38 -39.97 0.03 OUTLIER 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 108.393 -0.965 . . . . 0.0 108.393 177.801 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 62.4 tttp . . . . . 0 C--O 1.243 0.716 0 CA-C-N 114.55 -1.204 . . . . 0.0 109.5 174.82 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.809 0 N-CA-C 111.966 -0.454 . . . . 0.0 111.966 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 51.0 m -82.87 -24.6 33.15 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.81 0.338 . . . . 0.0 111.038 -177.452 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 66.2 p -106.46 164.69 11.84 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.505 178.098 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 9.0 mp0 -92.73 58.61 3.1 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.021 0.438 . . . . 0.0 109.902 178.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 26.2 t -91.8 -147.75 0.22 Allowed 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.527 -178.139 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 228' ' ' LEU . . . . . 0.525 ' HB3' ' HA ' ' A' ' 259' ' ' ALA . 83.8 mt -108.37 140.79 41.16 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 109.689 -0.486 . . . . 0.0 109.689 179.293 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 70.8 p -124.27 177.12 6.02 Favored 'General case' 0 C--N 1.325 -0.464 0 C-N-CA 119.957 -0.697 . . . . 0.0 110.978 -178.506 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . 0.63 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 61.3 t -146.61 146.84 18.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.014 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 41.3 t -132.08 133.85 44.82 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.822 0.344 . . . . 0.0 110.402 178.755 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 104.21 73.28 0.92 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.41 -0.9 . . . . 0.0 112.929 177.625 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 13.8 mm-40 -66.86 133.0 93.93 Favored Pre-proline 0 C--N 1.33 -0.248 0 CA-C-O 120.84 0.353 . . . . 0.0 111.377 176.546 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 234' ' ' PRO . . . . . 0.58 ' HB2' ' HE1' ' A' ' 236' ' ' HIS . 56.9 Cg_endo -69.97 138.38 37.03 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 122.373 2.049 . . . . 0.0 111.515 176.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -97.88 126.41 43.25 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 121.391 0.615 . . . . 0.0 111.532 -176.261 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 236' ' ' HIS . . . . . 0.58 ' HE1' ' HB2' ' A' ' 234' ' ' PRO . 24.2 m80 -130.41 133.83 46.66 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.404 -0.817 . . . . 0.0 109.562 -178.548 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 237' ' ' LYS . . . . . 0.584 ' HA ' HG21 ' A' ' 312' ' ' THR . 6.8 mptt -120.06 128.02 53.11 Favored 'General case' 0 C--N 1.327 -0.379 0 C-N-CA 120.556 -0.458 . . . . 0.0 110.551 178.923 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 238' ' ' VAL . . . . . 0.777 ' HB ' ' HA ' ' A' ' 316' ' ' SER . 47.4 t -101.9 126.28 55.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.675 178.401 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 239' ' ' GLU . . . . . . . . . . . . . 72.1 mt-10 -126.04 154.78 42.52 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 172.338 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 240' ' ' ALA . . . . . . . . . . . . . . . -57.9 -46.89 84.25 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.728 0.299 . . . . 0.0 111.144 -176.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 241' ' ' LYS . . . . . 0.698 ' HB2' ' HA2' ' A' ' 245' ' ' GLY . 0.0 OUTLIER -145.62 164.48 31.57 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.228 179.089 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 242' ' ' ASP . . . . . 0.476 ' OD1' ' HG2' ' A' ' 246' ' ' MET . 9.4 p-10 -105.28 -158.31 0.65 Allowed 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 109.692 -0.484 . . . . 0.0 109.692 179.12 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 46.6 t -60.18 -36.61 78.0 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.767 175.294 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -87.68 -14.12 40.74 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.632 -0.258 . . . . 0.0 111.652 -179.479 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . 0.698 ' HA2' ' HB2' ' A' ' 241' ' ' LYS . . . 94.42 26.04 14.64 Favored Glycine 0 CA--C 1.519 0.322 0 C-N-CA 120.517 -0.849 . . . . 0.0 114.064 174.335 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 246' ' ' MET . . . . . 0.476 ' HG2' ' OD1' ' A' ' 242' ' ' ASP . 22.8 ptp -113.54 155.96 44.09 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 117.532 0.666 . . . . 0.0 110.596 176.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 247' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_exo -57.6 125.42 18.7 Favored 'Trans proline' 0 C--N 1.35 0.624 0 C-N-CA 122.61 2.207 . . . . 0.0 112.245 -179.331 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 41.5 t -80.38 113.35 19.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.219 -177.197 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 61.5 t0 -122.68 113.93 19.89 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 176.506 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 250' ' ' ASN . . . . . . . . . . . . . 6.5 m120 -75.27 -39.33 59.88 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.567 -0.288 . . . . 0.0 111.191 -177.039 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . 0.906 ' HA ' ' HB3' ' A' ' 305' ' ' LYS . 81.8 mtm180 60.75 -173.97 0.12 Allowed 'General case' 0 N--CA 1.466 0.337 0 N-CA-C 112.362 0.504 . . . . 0.0 112.362 -175.652 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 20.4 mt-30 60.45 178.41 0.1 Allowed 'General case' 0 N--CA 1.468 0.461 0 CA-C-N 114.843 -1.072 . . . . 0.0 112.42 177.02 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . 0.468 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -172.65 95.71 0.11 Allowed Glycine 0 N--CA 1.447 -0.631 0 CA-C-N 115.429 -0.805 . . . . 0.0 111.178 179.099 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 59.9 p -95.39 116.98 29.53 Favored 'General case' 0 C--N 1.323 -0.561 0 O-C-N 122.48 -0.424 . . . . 0.0 110.914 -175.113 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.476 HD12 HG11 ' A' ' 230' ' ' VAL . 21.2 pt -128.78 148.39 33.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.831 -177.618 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 59.8 m -101.27 107.26 18.58 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 174.096 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.691 HG21 HD12 ' A' ' 262' ' ' LEU . 32.8 m -90.73 143.65 10.77 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.728 0 N-CA-C 112.975 0.731 . . . . 0.0 112.975 -168.649 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 35.3 t -91.44 8.04 38.23 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 114.112 -1.404 . . . . 0.0 107.963 167.165 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 259' ' ' ALA . . . . . 0.525 ' HA ' ' HB3' ' A' ' 228' ' ' LEU . . . -85.64 158.12 20.16 Favored 'General case' 0 N--CA 1.448 -0.565 0 CA-C-N 114.926 -1.034 . . . . 0.0 109.626 -178.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 34.1 t -131.94 137.31 47.9 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 116.577 -0.283 . . . . 0.0 110.325 -179.217 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 90.27 39.28 6.07 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.6 -0.809 . . . . 0.0 112.571 -179.437 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 262' ' ' LEU . . . . . 0.691 HD12 HG21 ' A' ' 257' ' ' VAL . 60.2 mt -101.46 139.81 36.6 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.711 0.291 . . . . 0.0 110.877 179.788 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 68.5 mt-30 -142.2 167.72 21.45 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.82 -0.627 . . . . 0.0 109.436 179.298 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 264' ' ' VAL . . . . . 0.418 HG22 ' HA ' ' A' ' 294' ' ' ALA . 48.7 t -70.83 132.87 32.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 C-N-CA 120.772 -0.371 . . . . 0.0 110.161 177.834 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 105.58 8.63 34.72 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.548 -0.834 . . . . 0.0 112.401 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 59.7 m-20 -88.64 162.48 16.31 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.988 0.423 . . . . 0.0 110.861 179.045 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 267' ' ' ALA . . . . . 0.699 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -139.34 123.12 17.57 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.487 -0.779 . . . . 0.0 109.475 179.75 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 268' ' ' PHE . . . . . 0.413 ' HB3' ' HA ' ' A' ' 334' ' ' ILE . 3.5 p90 -142.15 173.66 11.32 Favored 'General case' 0 C--N 1.32 -0.676 0 C-N-CA 120.114 -0.634 . . . . 0.0 111.465 -174.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 269' ' ' THR . . . . . 0.577 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 63.8 p -118.89 132.37 56.1 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.53 178.115 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 270' ' ' ILE . . . . . 0.708 HG12 HG13 ' A' ' 332' ' ' ILE . 50.6 mt -100.61 134.02 41.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.57 179.625 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -72.72 143.47 48.01 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.956 -179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 85.78 -21.55 14.54 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.189 -177.522 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 53.5 t -105.69 102.46 13.9 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-O 120.983 0.42 . . . . 0.0 110.799 -179.593 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 274' ' ' ASN . . . . . 0.407 ' HB2' ' OD1' ' A' ' 323' ' ' ASP . 4.0 m120 -100.72 154.94 18.19 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.22 -0.659 . . . . 0.0 109.22 174.702 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 6.7 t -83.7 179.98 7.46 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.912 0.387 . . . . 0.0 109.96 -177.853 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 276' ' ' VAL . . . . . 0.411 HG22 ' O ' ' A' ' 321' ' ' ASN . 34.2 m -131.92 153.11 38.0 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.712 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.236 172.775 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 26.4 m80 -136.94 137.08 39.17 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.091 179.236 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 8.5 tt0 -67.99 -31.67 71.53 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 120.916 0.389 . . . . 0.0 110.315 177.196 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 72.3 mt -66.54 -50.36 67.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.861 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 71.5 p -85.42 -5.08 59.33 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 111.674 0.25 . . . . 0.0 111.674 -178.615 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 281' ' ' LYS . . . . . 0.512 ' HB3' ' NZ ' ' A' ' 281' ' ' LYS . 0.0 OUTLIER 70.94 52.97 0.27 Allowed 'General case' 0 CA--C 1.535 0.403 0 CA-C-O 121.742 0.782 . . . . 0.0 109.161 179.479 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 56.6 m-20 62.26 10.51 3.87 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 114.732 -1.122 . . . . 0.0 113.95 173.485 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 59.9 p -107.09 107.97 19.22 Favored 'General case' 0 C--N 1.314 -0.956 0 CA-C-O 121.041 0.448 . . . . 0.0 110.589 175.605 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 59.8 p -125.76 -52.37 1.57 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.061 -175.385 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 76.42 10.61 85.58 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.732 -0.747 . . . . 0.0 111.267 -173.363 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 286' ' ' GLN . . . . . 0.42 ' HA ' ' HD3' ' A' ' 287' ' ' PRO . 93.4 mm-40 -111.11 130.42 22.99 Favored Pre-proline 0 C--N 1.326 -0.445 0 N-CA-C 110.322 -0.251 . . . . 0.0 110.322 -177.609 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 287' ' ' PRO . . . . . 0.577 ' HB2' ' HB ' ' A' ' 269' ' ' THR . 27.3 Cg_exo -60.76 142.05 96.63 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.627 2.218 . . . . 0.0 111.696 177.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 4.1 tp60 -68.18 145.05 54.69 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-O 120.877 0.37 . . . . 0.0 110.711 -179.637 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 47.6 t -99.73 121.77 50.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.492 176.631 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 290' ' ' PHE . . . . . 0.699 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 7.3 m-85 -103.31 156.17 17.92 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.028 0.442 . . . . 0.0 111.775 -174.02 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 36.3 mmt180 -122.31 121.18 36.14 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.112 -0.949 . . . . 0.0 109.408 174.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 61.7 t -78.51 135.51 25.84 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.89 -174.476 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 293' ' ' LEU . . . . . 0.401 ' N ' HD12 ' A' ' 293' ' ' LEU . 6.6 mp -106.95 -33.8 7.4 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.674 179.034 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 294' ' ' ALA . . . . . 0.418 ' HA ' HG22 ' A' ' 264' ' ' VAL . . . -155.54 146.7 22.59 Favored 'General case' 0 N--CA 1.463 0.19 0 N-CA-C 111.677 0.251 . . . . 0.0 111.677 -177.365 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . 0.467 HG22 HG13 ' A' ' 300' ' ' VAL . 61.6 t -137.66 126.37 33.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.086 -0.506 . . . . 0.0 109.74 177.169 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 40.3 t -156.69 109.69 2.59 Favored 'General case' 0 C--N 1.326 -0.418 0 C-N-CA 121.139 -0.224 . . . . 0.0 110.944 -177.638 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 59.81 48.57 85.41 Favored Glycine 0 C--N 1.333 0.373 0 C-N-CA 121.077 -0.583 . . . . 0.0 112.488 179.447 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 298' ' ' THR . . . . . 0.422 ' O ' HG22 ' A' ' 257' ' ' VAL . 60.5 p 55.71 10.93 0.58 Allowed 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 124.342 1.057 . . . . 0.0 112.728 -176.361 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 58.3 m -99.92 106.47 18.29 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 173.024 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . 0.574 HG12 HG23 ' A' ' 302' ' ' ILE . 40.2 t -108.9 132.03 58.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.35 -169.519 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 51.6 m -100.87 111.35 23.54 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 175.422 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 302' ' ' ILE . . . . . 0.574 HG23 HG12 ' A' ' 300' ' ' VAL . 27.7 pt -121.64 164.6 18.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-O 121.284 0.564 . . . . 0.0 112.027 -174.262 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 303' ' ' SER . . . . . 0.531 ' HB3' ' HA ' ' A' ' 304' ' ' PRO . 53.1 m -135.29 165.28 37.58 Favored Pre-proline 0 C--N 1.313 -0.984 0 N-CA-C 106.325 -1.732 . . . . 0.0 106.325 168.775 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 304' ' ' PRO . . . . . 0.531 ' HA ' ' HB3' ' A' ' 303' ' ' SER . 17.4 Cg_exo -70.38 176.52 34.05 Favored 'Cis proline' 0 N--CA 1.472 0.243 0 CA-C-N 120.816 1.327 . . . . 0.0 113.71 0.923 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 305' ' ' LYS . . . . . 0.906 ' HB3' ' HA ' ' A' ' 251' ' ' ARG . 0.1 OUTLIER -73.86 152.69 40.15 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 114.986 -1.007 . . . . 0.0 111.284 -178.501 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 306' ' ' ILE . . . . . 0.589 HD11 ' HE2' ' A' ' 290' ' ' PHE . 46.4 mm -94.66 85.29 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.634 -178.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 307' ' ' LEU . . . . . 0.737 ' HG ' ' HG2' ' A' ' 305' ' ' LYS . 66.9 mt -106.12 110.32 63.89 Favored Pre-proline 0 C--N 1.325 -0.462 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 178.109 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 308' ' ' PRO . . . . . 0.481 ' CG ' ' HB2' ' A' ' 311' ' ' ASN . 65.1 Cg_endo -80.9 148.66 17.49 Favored 'Trans proline' 0 N--CA 1.463 -0.275 0 C-N-CA 122.548 2.166 . . . . 0.0 113.609 -172.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . 0.545 HG23 ' O ' ' A' ' 322' ' ' VAL . 47.0 t -87.65 -43.09 15.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.829 175.252 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 65.4 mm-40 -91.51 6.47 45.47 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 112.437 0.532 . . . . 0.0 112.437 -176.287 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.481 ' HB2' ' CG ' ' A' ' 308' ' ' PRO . 5.9 m120 -130.0 173.33 10.82 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 110.231 -0.285 . . . . 0.0 110.231 178.597 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 312' ' ' THR . . . . . 0.584 HG21 ' HA ' ' A' ' 237' ' ' LYS . 23.7 m 60.07 31.03 20.43 Favored 'General case' 0 CA--C 1.539 0.543 0 CA-C-O 121.758 0.79 . . . . 0.0 110.656 176.887 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 44.5 m-20 63.87 -177.71 0.16 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 114.883 -1.053 . . . . 0.0 112.208 177.106 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 314' ' ' VAL . . . . . 0.685 HG13 ' HD2' ' A' ' 317' ' ' ARG . 50.0 t -68.31 -24.66 30.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.426 -176.441 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -60.63 -23.73 64.98 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 111.976 0.362 . . . . 0.0 111.976 -179.859 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . 0.777 ' HA ' ' HB ' ' A' ' 238' ' ' VAL . 31.2 t -86.89 -22.02 25.97 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.31 -177.845 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 317' ' ' ARG . . . . . 0.685 ' HD2' HG13 ' A' ' 314' ' ' VAL . 83.3 mtt-85 -56.6 -53.68 61.8 Favored Pre-proline 0 CA--C 1.541 0.605 0 N-CA-C 113.499 0.926 . . . . 0.0 113.499 -177.525 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 318' ' ' PRO . . . . . 0.613 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 44.1 Cg_exo -61.97 -35.39 77.32 Favored 'Trans proline' 0 C--N 1.356 0.931 0 C-N-CA 122.018 1.812 . . . . 0.0 113.677 -174.587 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 319' ' ' TYR . . . . . 0.666 ' HB2' HG11 ' A' ' 238' ' ' VAL . 7.4 m-85 -105.62 21.67 16.83 Favored 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 121.152 -0.219 . . . . 0.0 111.089 -179.065 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . 0.42 ' CB ' HG22 ' A' ' 309' ' ' VAL . . . -65.79 160.0 24.03 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.096 0.474 . . . . 0.0 111.685 -177.39 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 321' ' ' ASN . . . . . 0.411 ' O ' HG22 ' A' ' 276' ' ' VAL . 20.6 t-20 -123.58 -33.19 3.25 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.85 -0.613 . . . . 0.0 109.956 177.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 322' ' ' VAL . . . . . 0.545 ' O ' HG23 ' A' ' 309' ' ' VAL . 35.4 m -135.42 163.76 34.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.345 177.308 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 323' ' ' ASP . . . . . 0.407 ' OD1' ' HB2' ' A' ' 274' ' ' ASN . 63.6 m-20 -55.89 -41.28 74.21 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 112.684 0.624 . . . . 0.0 112.684 -176.407 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 324' ' ' ALA . . . . . 0.463 ' HA ' ' CB ' ' A' ' 308' ' ' PRO . . . -169.49 167.49 9.82 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 120.876 0.369 . . . . 0.0 111.746 -173.759 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 325' ' ' LYS . . . . . 0.461 ' NZ ' ' HB2' ' A' ' 325' ' ' LYS . 0.0 OUTLIER -108.7 106.25 58.42 Favored Pre-proline 0 C--N 1.325 -0.49 0 CA-C-N 114.968 -1.014 . . . . 0.0 109.26 168.732 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 76.0 Cg_endo -85.21 168.47 10.32 Favored 'Trans proline' 0 C--O 1.234 0.276 0 C-N-CA 122.8 2.333 . . . . 0.0 112.769 -173.472 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -69.6 121.86 17.94 Favored 'General case' 0 C--O 1.235 0.327 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 176.588 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 328' ' ' GLU . . . . . 0.459 ' HA ' ' OE2' ' A' ' 328' ' ' GLU . 43.6 mm-40 64.16 164.24 0.13 Allowed 'General case' 0 C--O 1.234 0.243 0 O-C-N 123.891 0.744 . . . . 0.0 111.417 -175.288 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 329' ' ' SER . . . . . 0.63 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 22.2 m -86.49 -14.49 42.95 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.35 -174.306 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 330' ' ' ALA . . . . . 0.426 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 71.26 -154.43 0.1 Allowed 'General case' 0 N--CA 1.467 0.403 0 CA-C-O 121.332 0.586 . . . . 0.0 112.287 175.532 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -90.04 125.79 35.53 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.147 -0.933 . . . . 0.0 110.168 179.35 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 332' ' ' ILE . . . . . 0.708 HG13 HG12 ' A' ' 270' ' ' ILE . 1.7 mp -106.35 144.72 15.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.31 -178.917 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.402 ' HB ' ' OG1' ' A' ' 269' ' ' THR . 88.5 m -109.97 103.02 11.72 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.069 -0.514 . . . . 0.0 109.711 -178.171 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 334' ' ' ILE . . . . . 0.434 ' C ' HD12 ' A' ' 335' ' ' LEU . 37.9 mm -83.1 129.3 37.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 115.57 -0.741 . . . . 0.0 112.42 -171.209 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 335' ' ' LEU . . . . . 0.434 HD12 ' C ' ' A' ' 334' ' ' ILE . 6.8 mp -123.67 153.04 41.36 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.264 -0.88 . . . . 0.0 109.823 172.644 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 22.9 p30 -110.9 5.02 20.19 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 170.442 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 23.1 tptm . . . . . 0 C--O 1.245 0.82 0 CA-C-N 114.541 -1.209 . . . . 0.0 110.99 -179.412 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.842 0 N-CA-C 112.093 -0.403 . . . . 0.0 112.093 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 46.5 t -84.56 -73.66 0.42 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.784 0.326 . . . . 0.0 110.596 179.397 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 35.1 p -128.82 -88.96 0.52 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.676 178.37 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 41.1 tp10 58.42 82.79 0.13 Allowed 'General case' 0 C--O 1.234 0.268 0 C-N-CA 122.991 0.516 . . . . 0.0 110.749 178.277 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 31.5 t -168.6 -129.83 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 -179.733 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 228' ' ' LEU . . . . . 0.525 ' HB3' ' CB ' ' A' ' 259' ' ' ALA . 85.1 mt -96.46 130.93 43.5 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 109.511 -0.552 . . . . 0.0 109.511 175.728 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 41.3 p -129.63 179.54 5.77 Favored 'General case' 0 C--N 1.325 -0.465 0 C-N-CA 120.296 -0.562 . . . . 0.0 110.986 -178.631 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . 0.806 ' HB ' ' HB3' ' A' ' 329' ' ' SER . 89.5 t -146.18 130.85 11.58 Favored 'Isoleucine or valine' 0 C--O 1.24 0.571 0 CA-C-O 120.601 0.239 . . . . 0.0 111.549 -177.2 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 18.7 m -97.29 97.84 9.49 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.194 -0.912 . . . . 0.0 109.733 172.834 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 163.02 134.74 1.69 Allowed Glycine 0 C--O 1.226 -0.344 0 C-N-CA 120.719 -0.753 . . . . 0.0 111.72 -177.429 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 11.0 mm100 -61.62 144.73 92.44 Favored Pre-proline 0 C--N 1.328 -0.369 0 N-CA-C 112.688 0.625 . . . . 0.0 112.688 -174.516 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -70.7 175.22 9.18 Favored 'Trans proline' 0 C--N 1.348 0.521 0 C-N-CA 123.381 2.721 . . . . 0.0 111.793 175.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 235' ' ' GLU . . . . . 0.506 ' OE1' HD12 ' A' ' 302' ' ' ILE . 87.6 mt-10 -94.3 138.11 32.67 Favored 'General case' 0 C--O 1.211 -0.962 0 C-N-CA 120.833 -0.347 . . . . 0.0 111.688 -176.524 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 236' ' ' HIS . . . . . 0.439 ' HB3' ' O ' ' A' ' 306' ' ' ILE . 25.5 p-80 -169.04 126.82 0.99 Allowed 'General case' 0 C--N 1.307 -1.256 0 CA-C-N 115.097 -0.956 . . . . 0.0 109.366 166.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 237' ' ' LYS . . . . . 0.548 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -138.44 122.37 17.78 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.32 -0.552 . . . . 0.0 110.473 -179.987 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 238' ' ' VAL . . . . . . . . . . . . . 62.0 t -107.35 111.05 34.07 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 C-N-CA 120.484 -0.486 . . . . 0.0 110.023 169.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 239' ' ' GLU . . . . . 0.479 ' O ' ' HA ' ' A' ' 247' ' ' PRO . 54.3 mt-10 -125.82 116.38 21.48 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.01 178.078 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 240' ' ' ALA . . . . . 0.479 ' C ' ' HD2' ' A' ' 241' ' ' LYS . . . -74.83 -51.35 14.22 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.641 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 241' ' ' LYS . . . . . 0.479 ' HD2' ' C ' ' A' ' 240' ' ' ALA . 1.0 OUTLIER -115.83 127.33 54.97 Favored 'General case' 0 CA--C 1.515 -0.384 0 CA-C-O 121.233 0.54 . . . . 0.0 110.696 173.451 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 9.8 p-10 -106.06 -156.45 0.58 Allowed 'General case' 0 C--N 1.315 -0.901 0 CA-C-N 114.912 -1.04 . . . . 0.0 108.665 172.897 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 51.0 m -56.84 -36.04 69.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.51 -0.314 . . . . 0.0 111.047 174.588 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 6.0 m120 -96.74 -14.07 22.26 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.475 -0.329 . . . . 0.0 111.751 -178.488 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 85.61 20.87 55.49 Favored Glycine 0 CA--C 1.519 0.282 0 C-N-CA 120.685 -0.769 . . . . 0.0 113.433 177.201 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 246' ' ' MET . . . . . 0.438 ' HA ' ' HD3' ' A' ' 247' ' ' PRO . 94.6 mmm -114.09 133.03 22.43 Favored Pre-proline 0 C--N 1.326 -0.418 0 CA-C-N 116.964 0.382 . . . . 0.0 110.207 177.156 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 247' ' ' PRO . . . . . 0.479 ' HA ' ' O ' ' A' ' 239' ' ' GLU . 24.4 Cg_exo -64.9 116.68 3.96 Favored 'Trans proline' 0 C--N 1.349 0.573 0 C-N-CA 121.738 1.625 . . . . 0.0 112.175 -177.591 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 46.2 t -147.51 148.93 15.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.674 178.885 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 249' ' ' ASP . . . . . 0.577 ' OD2' HD21 ' A' ' 307' ' ' LEU . 8.5 t70 -89.21 123.96 33.92 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 170.779 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 250' ' ' ASN . . . . . . . . . . . . . 22.1 p30 -80.83 -11.73 59.55 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 112.167 0.432 . . . . 0.0 112.167 -173.369 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . 0.565 ' HB3' ' HD2' ' A' ' 305' ' ' LYS . 36.8 ptt85 44.55 -164.07 0.01 OUTLIER 'General case' 0 N--CA 1.475 0.808 0 C-N-CA 124.592 1.157 . . . . 0.0 113.456 179.368 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 252' ' ' GLN . . . . . 0.487 ' HG3' ' HG3' ' A' ' 251' ' ' ARG . 17.2 mt-30 65.12 132.65 0.02 OUTLIER 'General case' 0 C--O 1.237 0.413 0 C-N-CA 123.995 0.918 . . . . 0.0 112.83 -178.028 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . 0.433 ' O ' ' HA ' ' A' ' 301' ' ' THR . . . -160.86 145.33 10.89 Favored Glycine 0 N--CA 1.449 -0.467 0 CA-C-N 115.007 -0.997 . . . . 0.0 111.94 177.714 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 34.1 p -95.32 117.99 31.28 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.843 0.354 . . . . 0.0 111.13 -179.797 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.611 HD12 HG11 ' A' ' 230' ' ' VAL . 24.7 pt -114.75 142.84 26.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.08 0.467 . . . . 0.0 111.494 -178.724 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 58.1 m -92.49 109.63 21.03 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 176.354 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . . . . . . . . . 33.9 m -90.21 143.78 10.48 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.703 0 C-N-CA 119.646 -0.821 . . . . 0.0 113.004 -168.351 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 258' ' ' SER . . . . . 0.467 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 24.0 t -91.59 9.07 33.7 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 114.051 -1.432 . . . . 0.0 108.192 168.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 259' ' ' ALA . . . . . 0.525 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -99.05 169.8 9.16 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-N 114.774 -1.103 . . . . 0.0 109.484 -178.592 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 33.8 t -142.57 155.28 44.97 Favored 'General case' 0 C--N 1.324 -0.54 0 C-N-CA 120.828 -0.349 . . . . 0.0 110.733 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 74.34 42.8 33.54 Favored Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.47 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 262' ' ' LEU . . . . . . . . . . . . . 64.5 mt -102.39 140.02 37.21 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 110.17 -0.308 . . . . 0.0 110.17 179.37 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 81.5 mt-30 -135.24 169.45 17.44 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.479 -0.328 . . . . 0.0 110.206 179.822 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 45.5 t -77.77 136.26 24.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.594 179.63 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 92.13 7.65 63.81 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.442 -0.885 . . . . 0.0 112.292 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 72.8 m-20 -81.73 160.47 23.63 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.232 0.539 . . . . 0.0 110.133 176.785 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 267' ' ' ALA . . . . . 0.548 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -126.84 145.37 50.67 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 115.332 -0.849 . . . . 0.0 108.822 178.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 268' ' ' PHE . . . . . 0.55 ' HA ' HD23 ' A' ' 335' ' ' LEU . 4.6 p90 -162.53 170.66 18.27 Favored 'General case' 0 C--N 1.32 -0.713 0 C-N-CA 119.971 -0.692 . . . . 0.0 111.452 -177.124 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 269' ' ' THR . . . . . 0.474 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 72.7 p -121.85 150.84 41.35 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.009 178.499 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 270' ' ' ILE . . . . . 0.577 HG12 HG12 ' A' ' 332' ' ' ILE . 54.4 mt -115.51 138.33 46.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 120.864 0.364 . . . . 0.0 111.622 -177.396 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -66.12 117.58 8.64 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 115.571 -0.74 . . . . 0.0 111.062 178.353 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 104.46 -23.05 32.66 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.932 -0.651 . . . . 0.0 112.182 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . 0.876 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 91.0 t -88.36 112.39 23.74 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-O 120.71 0.291 . . . . 0.0 110.491 175.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 72.9 m-80 -129.54 143.58 50.89 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.663 -178.071 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 52.3 p -70.86 164.75 24.68 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.152 0.501 . . . . 0.0 111.699 -177.7 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 29.3 m -112.58 179.48 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-N 115.652 -0.704 . . . . 0.0 112.469 -176.834 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 19.2 p-80 -46.19 106.92 0.09 Allowed 'General case' 0 C--O 1.235 0.304 0 CA-C-N 114.631 -1.168 . . . . 0.0 111.817 176.772 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 278' ' ' GLN . . . . . 0.512 ' H ' ' HB2' ' A' ' 282' ' ' ASP . 8.4 tt0 -83.94 -51.29 7.27 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.19 -176.467 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 279' ' ' ILE . . . . . 0.569 HG22 HG23 ' A' ' 280' ' ' THR . 3.2 mp -105.59 -66.81 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.828 0.347 . . . . 0.0 110.78 -178.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . 0.569 HG23 HG22 ' A' ' 279' ' ' ILE . 21.3 p -139.58 86.46 2.11 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.61 -177.545 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt 59.56 29.57 19.14 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.759 -0.655 . . . . 0.0 112.044 177.108 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 282' ' ' ASP . . . . . 0.512 ' HB2' ' H ' ' A' ' 278' ' ' GLN . 1.7 m-20 -58.05 101.48 0.08 Allowed 'General case' 0 N--CA 1.468 0.43 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.68 -179.535 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 45.1 p -105.88 105.65 15.78 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.159 175.117 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 65.7 p -127.6 -35.0 2.17 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.589 -174.449 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 82.23 26.18 48.97 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.306 -177.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 70.7 mt-30 -79.71 121.13 82.09 Favored Pre-proline 0 C--N 1.329 -0.295 0 O-C-N 122.891 -0.182 . . . . 0.0 110.667 -179.658 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 287' ' ' PRO . . . . . 0.474 ' HB2' ' HB ' ' A' ' 269' ' ' THR . 26.4 Cg_exo -60.33 126.75 20.89 Favored 'Trans proline' 0 C--O 1.234 0.296 0 C-N-CA 122.518 2.145 . . . . 0.0 111.408 177.451 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 4.4 tm0? -74.49 136.54 42.23 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 -175.062 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 289' ' ' VAL . . . . . 0.429 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 44.5 t -86.91 124.54 40.57 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-O 121.038 0.447 . . . . 0.0 111.524 -172.915 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 290' ' ' PHE . . . . . 0.876 ' HZ ' HG11 ' A' ' 273' ' ' VAL . 60.6 m-85 -98.5 168.44 10.19 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.31 -174.694 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 27.8 mmm180 -125.12 148.42 48.57 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.224 -0.898 . . . . 0.0 109.736 178.463 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 47.9 t -100.92 136.75 31.08 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-N 116.607 -0.27 . . . . 0.0 111.098 179.628 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 293' ' ' LEU . . . . . 0.455 ' N ' HD12 ' A' ' 293' ' ' LEU . 5.5 mp -103.95 -39.94 6.4 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.128 -178.868 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 294' ' ' ALA . . . . . . . . . . . . . . . -156.9 139.61 15.09 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.646 0.26 . . . . 0.0 111.473 -178.493 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . 0.519 HG22 HG13 ' A' ' 300' ' ' VAL . 60.6 t -131.21 125.56 57.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-N 116.104 -0.498 . . . . 0.0 109.688 175.842 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 33.9 t -157.29 111.37 2.64 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.583 -0.281 . . . . 0.0 110.758 -178.018 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 60.58 50.82 63.39 Favored Glycine 0 C--N 1.333 0.372 0 C-N-CA 121.087 -0.578 . . . . 0.0 112.615 179.787 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 45.9 p 50.6 23.71 1.42 Allowed 'General case' 0 N--CA 1.47 0.552 0 C-N-CA 123.477 0.711 . . . . 0.0 112.434 -176.395 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 43.7 m -113.21 106.58 14.8 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 108.144 -1.058 . . . . 0.0 108.144 174.072 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . 0.572 HG12 HG23 ' A' ' 302' ' ' ILE . 39.4 t -112.99 131.63 64.06 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 115.944 -0.571 . . . . 0.0 111.557 -168.633 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 301' ' ' THR . . . . . 0.433 ' HA ' ' O ' ' A' ' 253' ' ' GLY . 91.6 m -96.7 110.62 23.03 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 108.725 -0.842 . . . . 0.0 108.725 172.299 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 302' ' ' ILE . . . . . 0.572 HG23 HG12 ' A' ' 300' ' ' VAL . 2.5 pp -111.75 -172.54 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 N-CA-C 112.12 0.415 . . . . 0.0 112.12 -175.134 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 303' ' ' SER . . . . . 0.71 ' OG ' ' HA ' ' A' ' 304' ' ' PRO . 14.8 t 169.95 161.16 0.2 Allowed Pre-proline 0 C--O 1.221 -0.397 0 N-CA-C 106.224 -1.769 . . . . 0.0 106.224 -175.563 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 304' ' ' PRO . . . . . 0.71 ' HA ' ' OG ' ' A' ' 303' ' ' SER . 9.4 Cg_exo -72.94 -172.66 9.87 Favored 'Cis proline' 0 C--N 1.348 0.522 0 CA-C-N 121.384 1.53 . . . . 0.0 113.506 0.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 305' ' ' LYS . . . . . 0.739 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -84.3 176.3 8.82 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 114.751 -1.113 . . . . 0.0 112.644 -175.382 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 306' ' ' ILE . . . . . 0.456 ' HB ' ' O ' ' A' ' 235' ' ' GLU . 50.8 mm -119.46 86.2 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 114.485 -1.234 . . . . 0.0 109.878 -174.017 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 307' ' ' LEU . . . . . 0.577 HD21 ' OD2' ' A' ' 249' ' ' ASP . 83.9 mt -108.84 101.59 44.69 Favored Pre-proline 0 C--N 1.321 -0.633 0 C-N-CA 120.918 -0.313 . . . . 0.0 111.652 -173.618 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 308' ' ' PRO . . . . . 0.774 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 17.9 Cg_exo -69.92 148.44 64.01 Favored 'Trans proline' 0 C--O 1.233 0.232 0 C-N-CA 123.197 2.598 . . . . 0.0 113.336 -177.019 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 44.2 t -93.16 -21.36 6.11 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-N 115.529 -0.76 . . . . 0.0 109.44 173.1 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 53.5 mt-10 -74.62 13.65 0.59 Allowed 'General case' 0 CA--C 1.531 0.223 0 N-CA-C 112.797 0.665 . . . . 0.0 112.797 -178.448 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.406 ' O ' ' HB ' ' A' ' 312' ' ' THR . 77.8 m-20 -82.25 -24.66 34.66 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 120.846 -0.341 . . . . 0.0 110.92 177.468 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 312' ' ' THR . . . . . 0.406 ' HB ' ' O ' ' A' ' 311' ' ' ASN . 58.2 m 72.01 -13.64 0.58 Allowed 'General case' 0 CA--C 1.541 0.634 0 O-C-N 123.743 0.652 . . . . 0.0 112.233 178.159 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -74.13 152.98 39.75 Favored 'General case' 0 C--N 1.331 -0.21 0 O-C-N 121.905 -0.497 . . . . 0.0 110.803 178.347 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 30.8 t -79.35 -19.33 12.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.306 -0.861 . . . . 0.0 111.485 -173.259 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -78.49 -36.88 44.47 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 113.019 0.748 . . . . 0.0 113.019 -174.096 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 16.2 m -88.18 -35.03 17.6 Favored 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -172.657 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 317' ' ' ARG . . . . . 0.424 ' N ' ' CD ' ' A' ' 318' ' ' PRO . 16.9 ptm180 -62.12 -33.05 11.03 Favored Pre-proline 0 CA--C 1.546 0.801 0 N-CA-C 114.516 1.302 . . . . 0.0 114.516 -175.263 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 318' ' ' PRO . . . . . 0.424 ' CD ' ' N ' ' A' ' 317' ' ' ARG . 35.2 Cg_exo -54.86 -38.87 92.26 Favored 'Trans proline' 0 C--N 1.368 1.587 0 C-N-CA 121.587 1.525 . . . . 0.0 112.795 178.874 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 319' ' ' TYR . . . . . 0.575 ' HD1' HD13 ' A' ' 307' ' ' LEU . 2.2 p90 -122.83 32.73 5.63 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 120.504 -0.479 . . . . 0.0 111.83 -179.251 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -63.34 157.15 23.73 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.605 178.171 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 46.2 t30 -128.49 -36.86 1.85 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.068 -0.514 . . . . 0.0 111.49 -177.662 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 322' ' ' VAL . . . . . 0.624 HG11 HG13 ' A' ' 273' ' ' VAL . 34.8 m -131.86 175.62 10.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 120.711 0.291 . . . . 0.0 111.217 -178.847 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 54.7 m-20 -78.62 -44.12 24.71 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.536 -0.302 . . . . 0.0 111.569 -177.272 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 324' ' ' ALA . . . . . 0.774 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -144.55 166.48 25.04 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.458 -175.589 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 325' ' ' LYS . . . . . 0.408 ' HA ' ' HD3' ' A' ' 326' ' ' PRO . 24.1 pttm -115.12 113.89 43.65 Favored Pre-proline 0 C--N 1.327 -0.383 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.729 175.153 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 326' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 325' ' ' LYS . 8.6 Cg_exo -72.92 167.84 26.24 Favored 'Trans proline' 0 C--O 1.233 0.236 0 C-N-CA 122.867 2.378 . . . . 0.0 112.167 -178.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -76.76 128.33 34.44 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 175.084 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 51.0 mt-10 64.96 -167.83 0.21 Allowed 'General case' 0 N--CA 1.466 0.333 0 O-C-N 123.5 0.5 . . . . 0.0 110.463 -176.191 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 329' ' ' SER . . . . . 0.806 ' HB3' ' HB ' ' A' ' 230' ' ' VAL . 42.6 t -90.88 -12.19 36.95 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 177.265 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 63.03 -160.36 0.31 Allowed 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 113.033 0.753 . . . . 0.0 113.033 171.261 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -76.36 127.96 33.9 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 115.182 -0.917 . . . . 0.0 110.676 -178.018 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 332' ' ' ILE . . . . . 0.577 HG12 HG12 ' A' ' 270' ' ' ILE . 50.0 mt -113.61 144.61 20.88 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.962 -177.432 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 95.7 m -115.63 106.09 13.51 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.675 176.824 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 41.2 mm -83.62 138.02 19.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.753 -0.658 . . . . 0.0 112.379 -170.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 335' ' ' LEU . . . . . 0.55 HD23 ' HA ' ' A' ' 268' ' ' PHE . 1.3 pt? -145.16 -159.14 0.96 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 114.978 -1.01 . . . . 0.0 108.814 171.184 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -152.36 48.36 0.76 Allowed 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.837 0.351 . . . . 0.0 111.592 179.709 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 337' ' ' LYS . . . . . 0.464 ' HB2' ' NZ ' ' A' ' 337' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.246 0.911 0 CA-C-O 118.827 -0.606 . . . . 0.0 110.515 178.908 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.952 0 N-CA-C 112.282 -0.327 . . . . 0.0 112.282 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 50.6 m -86.34 68.86 10.36 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.801 0.334 . . . . 0.0 111.164 179.661 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 36.8 p -102.0 -124.69 0.19 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.394 -0.367 . . . . 0.0 110.456 177.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 37.2 tt0 -86.95 37.71 0.77 Allowed 'General case' 0 C--O 1.236 0.365 0 CA-C-O 121.921 0.867 . . . . 0.0 109.698 177.256 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 24.8 m -86.76 -37.17 18.12 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.474 -0.785 . . . . 0.0 109.952 179.196 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 228' ' ' LEU . . . . . 0.546 HD22 ' H ' ' A' ' 260' ' ' SER . 83.7 mt -110.59 113.88 26.85 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 174.678 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 41.6 p -120.71 177.68 4.98 Favored 'General case' 0 C--N 1.32 -0.676 0 C-N-CA 119.926 -0.709 . . . . 0.0 110.617 -177.856 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . 0.738 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 89.7 t -150.88 134.78 8.23 Favored 'Isoleucine or valine' 0 C--O 1.239 0.548 0 CA-C-O 120.826 0.346 . . . . 0.0 110.898 -178.365 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 44.3 t -97.98 153.01 18.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.027 175.674 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . 0.554 ' O ' ' HD3' ' A' ' 234' ' ' PRO . . . 108.42 127.21 5.54 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.449 -0.882 . . . . 0.0 111.489 -178.467 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 233' ' ' GLN . . . . . 0.822 ' HG2' ' H ' ' A' ' 328' ' ' GLU . 64.2 mt-30 -95.27 102.38 9.5 Favored Pre-proline 0 C--N 1.324 -0.507 0 CA-C-N 116.53 0.165 . . . . 0.0 110.56 -177.553 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 234' ' ' PRO . . . . . 0.554 ' HD3' ' O ' ' A' ' 232' ' ' GLY . 74.4 Cg_endo -96.78 125.65 0.26 Allowed 'Trans proline' 0 N--CA 1.45 -1.076 0 C-N-CA 122.294 1.996 . . . . 0.0 112.388 -178.195 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 235' ' ' GLU . . . . . 0.946 ' HA ' ' HE3' ' A' ' 325' ' ' LYS . 24.2 pt-20 -105.72 147.67 28.3 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 173.377 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 236' ' ' HIS . . . . . 0.783 ' HB2' ' H ' ' A' ' 306' ' ' ILE . 39.4 m170 -134.62 130.57 36.64 Favored 'General case' 0 CA--C 1.503 -0.85 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 -178.94 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 237' ' ' LYS . . . . . 0.743 ' HG2' ' HB2' ' A' ' 251' ' ' ARG . 7.5 mmmt -105.24 175.56 5.45 Favored 'General case' 0 C--N 1.315 -0.9 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 -178.815 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 238' ' ' VAL . . . . . 0.992 ' HB ' HG11 ' A' ' 248' ' ' VAL . 43.5 t -48.56 144.82 1.08 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.338 0 O-C-N 123.601 0.563 . . . . 0.0 111.145 -178.072 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 239' ' ' GLU . . . . . 0.671 ' HA ' HD22 ' A' ' 250' ' ' ASN . 7.8 pt-20 -59.85 166.26 2.75 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 115.723 -0.671 . . . . 0.0 112.545 -176.81 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 240' ' ' ALA . . . . . 0.45 ' O ' ' HA ' ' A' ' 247' ' ' PRO . . . -44.05 -44.03 7.18 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-N 115.365 -0.834 . . . . 0.0 113.048 -173.06 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 241' ' ' LYS . . . . . 0.528 ' O ' ' HD3' ' A' ' 241' ' ' LYS . 0.0 OUTLIER -146.26 144.98 30.21 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 120.835 0.35 . . . . 0.0 111.081 178.677 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 57.0 p30 -89.49 -158.38 0.51 Allowed 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.971 -177.366 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 58.6 m -76.99 -15.59 59.59 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.489 -0.323 . . . . 0.0 111.586 -179.112 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 21.1 t-20 -95.81 -15.48 22.49 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.214 0.531 . . . . 0.0 110.164 -179.807 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 94.74 16.61 41.54 Favored Glycine 0 N--CA 1.448 -0.555 0 C-N-CA 120.635 -0.793 . . . . 0.0 111.905 179.495 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 246' ' ' MET . . . . . 0.418 ' HA ' ' HD3' ' A' ' 247' ' ' PRO . 80.7 mtp -83.3 122.2 77.16 Favored Pre-proline 0 C--N 1.326 -0.441 0 CA-C-O 120.604 0.24 . . . . 0.0 110.384 178.75 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 247' ' ' PRO . . . . . 0.45 ' HA ' ' O ' ' A' ' 240' ' ' ALA . 14.0 Cg_exo -69.73 121.15 7.85 Favored 'Trans proline' 0 N--CA 1.461 -0.406 0 C-N-CA 122.583 2.189 . . . . 0.0 112.152 -179.029 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.992 HG11 ' HB ' ' A' ' 238' ' ' VAL . 41.2 t -109.36 146.53 14.74 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 176.615 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -70.83 93.22 0.95 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.068 0.461 . . . . 0.0 110.195 -178.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 250' ' ' ASN . . . . . 0.671 HD22 ' HA ' ' A' ' 239' ' ' GLU . 21.1 t-20 -73.5 133.31 43.59 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.311 -176.807 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . 0.743 ' HB2' ' HG2' ' A' ' 237' ' ' LYS . 27.0 tpt85 -94.67 -98.14 0.16 Allowed 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.815 -178.049 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 252' ' ' GLN . . . . . 0.556 ' HA ' ' CD2' ' A' ' 236' ' ' HIS . 23.4 mt-30 60.5 179.33 0.1 Allowed 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 122.453 0.301 . . . . 0.0 111.2 -178.539 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 157.4 -168.7 34.24 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 119.242 -1.456 . . . . 0.0 113.358 -179.691 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 254' ' ' THR . . . . . 0.563 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 67.2 p -99.53 149.92 22.74 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.911 0.386 . . . . 0.0 111.378 -177.671 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.732 HD12 HG11 ' A' ' 230' ' ' VAL . 18.8 pt -125.32 152.94 32.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.959 178.243 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 39.2 m -96.2 105.65 17.74 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.028 -0.731 . . . . 0.0 109.028 177.126 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.554 ' HA ' HG13 ' A' ' 230' ' ' VAL . 22.7 m -89.93 143.19 11.7 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.681 0 CA-C-O 121.725 0.774 . . . . 0.0 112.73 -169.251 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 258' ' ' SER . . . . . 0.462 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 50.3 m -93.15 8.63 39.34 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 114.219 -1.355 . . . . 0.0 109.129 170.358 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 259' ' ' ALA . . . . . 0.48 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -99.1 174.76 6.17 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.209 -175.098 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . 0.546 ' H ' HD22 ' A' ' 228' ' ' LEU . 64.7 p -141.88 149.88 40.83 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 120.889 0.376 . . . . 0.0 110.981 178.43 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 87.59 32.22 13.91 Favored Glycine 0 N--CA 1.449 -0.446 0 C-N-CA 120.823 -0.704 . . . . 0.0 112.992 179.373 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 262' ' ' LEU . . . . . 0.484 HD12 ' N ' ' A' ' 262' ' ' LEU . 3.2 mp -97.68 135.53 39.34 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-N 116.995 0.398 . . . . 0.0 110.226 178.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -134.04 171.85 13.63 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 177.315 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 38.4 t -78.78 136.65 23.4 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 C-N-CA 120.593 -0.443 . . . . 0.0 109.951 176.658 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 95.61 15.25 44.05 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.538 -0.839 . . . . 0.0 112.141 -179.152 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 266' ' ' ASP . . . . . 0.476 ' HB2' HG21 ' A' ' 292' ' ' VAL . 64.0 m-20 -88.79 166.07 14.27 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.164 0.507 . . . . 0.0 110.779 178.507 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 267' ' ' ALA . . . . . 0.645 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -140.61 122.7 15.68 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.39 -0.823 . . . . 0.0 109.437 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 268' ' ' PHE . . . . . . . . . . . . . 4.6 p90 -142.68 174.11 10.94 Favored 'General case' 0 C--N 1.323 -0.579 0 C-N-CA 119.752 -0.779 . . . . 0.0 111.718 -172.819 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 81.9 p -122.18 148.51 44.85 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.179 177.498 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 270' ' ' ILE . . . . . 0.636 HD12 ' HE1' ' A' ' 290' ' ' PHE . 26.6 mt -113.62 137.53 46.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.212 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -61.47 130.53 46.48 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.343 179.881 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 272' ' ' GLY . . . . . 0.549 ' HA3' ' HG2' ' A' ' 326' ' ' PRO . . . 91.91 -23.12 27.86 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 121.189 -0.529 . . . . 0.0 112.113 -178.878 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . 0.611 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 59.7 t -95.94 103.14 14.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-O 120.96 0.409 . . . . 0.0 110.285 177.222 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 274' ' ' ASN . . . . . 0.621 ' HA ' ' HA ' ' A' ' 287' ' ' PRO . 70.0 m-80 -119.81 149.6 41.8 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.212 -178.306 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 77.7 p -81.45 162.25 23.37 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.387 0.613 . . . . 0.0 111.474 -176.813 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 276' ' ' VAL . . . . . 0.491 HG21 HG21 ' A' ' 309' ' ' VAL . 29.8 m -112.14 -179.27 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.798 0 CA-C-N 114.968 -1.014 . . . . 0.0 110.939 179.63 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 277' ' ' HIS . . . . . 0.547 ' CD2' ' HD2' ' A' ' 281' ' ' LYS . 26.7 p-80 -43.15 115.53 0.77 Allowed 'General case' 0 C--N 1.331 -0.213 0 O-C-N 124.331 1.02 . . . . 0.0 111.732 177.66 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 278' ' ' GLN . . . . . 0.549 ' HB3' HD12 ' A' ' 279' ' ' ILE . 71.2 tp60 -83.57 -38.65 21.38 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.731 -178.059 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 279' ' ' ILE . . . . . 0.94 HG22 HG23 ' A' ' 280' ' ' THR . 2.9 mp -107.25 -80.85 0.32 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.431 0 C-N-CA 120.892 -0.323 . . . . 0.0 111.577 -176.969 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . 0.94 HG23 HG22 ' A' ' 279' ' ' ILE . 35.7 p -127.48 70.74 1.32 Allowed 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 112.787 0.662 . . . . 0.0 112.787 -172.35 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 281' ' ' LYS . . . . . 0.547 ' HD2' ' CD2' ' A' ' 277' ' ' HIS . 14.6 mmmm 53.79 35.45 21.52 Favored 'General case' 0 N--CA 1.47 0.534 0 CA-C-O 121.203 0.525 . . . . 0.0 110.801 178.397 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 52.8 m-20 -69.44 174.04 5.28 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.264 -0.88 . . . . 0.0 111.595 -177.539 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 73.8 p -104.47 109.98 22.07 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.209 178.156 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 67.8 p -116.1 -76.69 0.57 Allowed 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.167 -174.001 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 70.29 7.74 60.85 Favored Glycine 0 C--N 1.329 0.156 0 C-N-CA 121.028 -0.605 . . . . 0.0 113.289 176.577 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 286' ' ' GLN . . . . . 0.434 ' HA ' ' HD3' ' A' ' 287' ' ' PRO . 96.1 mm-40 -93.29 142.43 25.27 Favored Pre-proline 0 C--N 1.324 -0.511 0 N-CA-C 110.314 -0.254 . . . . 0.0 110.314 -179.1 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 287' ' ' PRO . . . . . 0.621 ' HA ' ' HA ' ' A' ' 274' ' ' ASN . 48.2 Cg_exo -56.76 140.78 91.86 Favored 'Trans proline' 0 CA--C 1.529 0.266 0 C-N-CA 122.737 2.291 . . . . 0.0 112.601 -178.549 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 69.5 tp60 -78.22 140.88 38.91 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.006 -178.77 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 289' ' ' VAL . . . . . 0.581 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 42.2 t -92.48 131.25 40.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.706 -179.918 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 290' ' ' PHE . . . . . 0.645 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 8.2 m-30 -106.89 170.31 8.02 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 116.295 -0.412 . . . . 0.0 111.075 -175.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 26.2 mmm180 -118.28 145.02 45.37 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.995 0.426 . . . . 0.0 110.578 176.645 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . 0.476 HG21 ' HB2' ' A' ' 266' ' ' ASP . 59.6 t -101.02 130.42 50.44 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.589 177.716 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 293' ' ' LEU . . . . . 0.914 HD21 ' HB3' ' A' ' 303' ' ' SER . 2.3 mm? -106.1 -29.53 9.83 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.023 -176.504 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 294' ' ' ALA . . . . . 0.449 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -161.89 140.67 9.46 Favored 'General case' 0 C--N 1.331 -0.197 0 C-N-CA 121.013 -0.275 . . . . 0.0 111.442 -178.141 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 58.7 t -135.78 121.08 28.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 176.496 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 62.3 m -150.76 105.61 3.3 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.06 -179.515 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 64.52 57.52 12.66 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.142 179.754 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 298' ' ' THR . . . . . 0.419 ' HB ' HG22 ' A' ' 257' ' ' VAL . 65.5 p 49.42 25.9 1.48 Allowed 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 123.468 0.707 . . . . 0.0 112.448 -176.218 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 299' ' ' THR . . . . . 0.417 ' HA ' ' O ' ' A' ' 255' ' ' ILE . 70.8 m -115.59 111.66 21.0 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 177.166 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . 0.563 ' O ' ' HA ' ' A' ' 254' ' ' THR . 47.4 t -114.4 126.87 72.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.81 -170.817 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 66.3 m -81.55 115.65 20.95 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 172.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 302' ' ' ILE . . . . . 0.466 HD13 HD13 ' A' ' 255' ' ' ILE . 28.3 pt -112.82 148.84 15.54 Favored 'Isoleucine or valine' 0 C--O 1.24 0.594 0 N-CA-C 113.395 0.887 . . . . 0.0 113.395 -171.119 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 303' ' ' SER . . . . . 0.914 ' HB3' HD21 ' A' ' 293' ' ' LEU . 36.1 t -163.59 163.63 16.08 Favored Pre-proline 0 CA--C 1.537 0.458 0 N-CA-C 106.807 -1.553 . . . . 0.0 106.807 -178.314 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 304' ' ' PRO . . . . . 0.743 ' HA ' ' OG ' ' A' ' 303' ' ' SER . 1.0 OUTLIER -83.49 -151.55 0.68 Allowed 'Cis proline' 0 C--N 1.349 0.588 0 CA-C-N 120.752 1.304 . . . . 0.0 112.694 0.565 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 305' ' ' LYS . . . . . 0.572 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -71.52 144.85 49.47 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.346 0.593 . . . . 0.0 111.046 -177.838 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 306' ' ' ILE . . . . . 0.783 ' H ' ' HB2' ' A' ' 236' ' ' HIS . 52.5 mt -108.44 76.64 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-N 115.513 -0.767 . . . . 0.0 109.135 176.6 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 307' ' ' LEU . . . . . 0.674 ' HB2' ' HA ' ' A' ' 320' ' ' ALA . 91.0 mt -98.83 120.23 59.21 Favored Pre-proline 0 C--N 1.322 -0.617 0 CA-C-N 115.505 -0.771 . . . . 0.0 112.261 -172.688 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 308' ' ' PRO . . . . . 0.763 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 15.8 Cg_exo -68.71 147.12 68.86 Favored 'Trans proline' 0 N--CA 1.462 -0.381 0 C-N-CA 123.309 2.673 . . . . 0.0 111.995 175.469 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . 0.558 HG22 ' HB3' ' A' ' 320' ' ' ALA . 35.1 t -93.88 -16.09 7.68 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 N-CA-C 108.018 -1.105 . . . . 0.0 108.018 170.305 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 51.5 mm-40 -96.02 34.06 1.61 Allowed 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 115.218 -0.901 . . . . 0.0 112.422 -177.782 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 25.5 p30 -111.67 -177.18 3.12 Favored 'General case' 0 N--CA 1.464 0.241 0 C-N-CA 120.711 -0.396 . . . . 0.0 110.811 175.523 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 26.2 m -91.07 -20.13 22.4 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.923 -177.334 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 313' ' ' ASP . . . . . 0.546 ' O ' ' HG3' ' A' ' 317' ' ' ARG . 1.3 m-20 -63.58 104.03 0.6 Allowed 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.997 -178.063 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 48.9 t -64.34 -22.95 32.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.119 177.412 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -85.3 -20.87 29.36 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 111.955 0.354 . . . . 0.0 111.955 -179.747 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 67.6 m -94.24 -36.26 12.09 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 112.151 0.426 . . . . 0.0 112.151 -177.162 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 317' ' ' ARG . . . . . 0.546 ' HG3' ' O ' ' A' ' 313' ' ' ASP . 81.5 mtp180 -54.43 -46.88 98.95 Favored Pre-proline 0 CA--C 1.544 0.748 0 N-CA-C 113.228 0.825 . . . . 0.0 113.228 -177.71 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 318' ' ' PRO . . . . . 0.545 ' HD2' ' N ' ' A' ' 317' ' ' ARG . 11.9 Cg_endo -59.45 -38.46 83.41 Favored 'Trans proline' 0 C--N 1.359 1.115 0 C-N-CA 122.075 1.85 . . . . 0.0 112.807 -178.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 38.4 m-85 -97.75 15.34 23.96 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.651 -177.579 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . 0.674 ' HA ' ' HB2' ' A' ' 307' ' ' LEU . . . -82.18 153.51 25.95 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.723 -0.672 . . . . 0.0 111.001 -178.333 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 321' ' ' ASN . . . . . 0.407 HD22 ' H ' ' A' ' 321' ' ' ASN . 0.1 OUTLIER -136.51 -0.18 2.43 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.988 179.756 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 322' ' ' VAL . . . . . 0.447 ' O ' ' HA ' ' A' ' 308' ' ' PRO . 33.1 m -134.21 164.7 33.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 175.574 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -74.63 -33.64 62.61 Favored 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 120.807 -0.357 . . . . 0.0 110.61 -179.385 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 324' ' ' ALA . . . . . 0.763 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -173.22 172.56 3.8 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.402 -0.817 . . . . 0.0 111.282 -175.243 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 325' ' ' LYS . . . . . 0.946 ' HE3' ' HA ' ' A' ' 235' ' ' GLU . 10.7 ptmm? -131.84 106.73 13.99 Favored Pre-proline 0 C--N 1.326 -0.441 0 CA-C-N 115.285 -0.87 . . . . 0.0 110.768 172.616 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 326' ' ' PRO . . . . . 0.549 ' HG2' ' HA3' ' A' ' 272' ' ' GLY . 16.4 Cg_exo -67.39 170.56 13.26 Favored 'Trans proline' 0 C--O 1.233 0.234 0 C-N-CA 123.507 2.804 . . . . 0.0 112.065 178.433 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -58.63 163.85 3.02 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.807 -178.718 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 328' ' ' GLU . . . . . 0.822 ' H ' ' HG2' ' A' ' 233' ' ' GLN . 1.1 pm0 39.26 -153.28 0.01 OUTLIER 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 124.385 1.074 . . . . 0.0 112.748 -175.064 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 329' ' ' SER . . . . . 0.738 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 48.8 m -112.59 -14.33 13.2 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.859 -176.861 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 61.15 -161.51 0.29 Allowed 'General case' 0 N--CA 1.469 0.525 0 N-CA-C 113.5 0.926 . . . . 0.0 113.5 171.38 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -78.04 138.46 38.8 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-N 114.975 -1.011 . . . . 0.0 110.551 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 332' ' ' ILE . . . . . 0.622 HG12 HG12 ' A' ' 270' ' ' ILE . 54.0 mt -122.8 145.14 30.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-O 121.151 0.5 . . . . 0.0 111.473 -176.182 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 89.8 m -106.23 97.44 7.24 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.82 177.437 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 30.5 mm -86.84 117.6 31.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.376 -0.375 . . . . 0.0 112.002 -174.804 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 335' ' ' LEU . . . . . 0.462 HD23 ' N ' ' A' ' 335' ' ' LEU . 1.8 pt? -141.68 134.84 29.2 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.609 -0.723 . . . . 0.0 109.57 173.279 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -106.19 83.29 1.87 Allowed 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -177.768 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 25.4 pttm . . . . . 0 C--O 1.243 0.74 0 CA-C-O 118.578 -0.725 . . . . 0.0 110.158 -179.894 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.769 0 N-CA-C 112.019 -0.432 . . . . 0.0 112.019 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 34.0 t -85.39 -62.03 1.63 Allowed 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 110.318 -0.253 . . . . 0.0 110.318 -178.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 75.1 p 48.28 -140.39 0.64 Allowed 'General case' 0 N--CA 1.466 0.33 0 C-N-CA 123.358 0.663 . . . . 0.0 111.695 179.701 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 35.74 60.25 0.79 Allowed 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 124.101 0.96 . . . . 0.0 112.289 -178.539 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 36.5 t -95.04 121.67 36.9 Favored 'General case' 0 N--CA 1.445 -0.678 0 CA-C-N 115.659 -0.701 . . . . 0.0 110.407 -177.914 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 228' ' ' LEU . . . . . 0.603 ' HB3' ' CB ' ' A' ' 259' ' ' ALA . 84.5 mt -69.42 134.31 48.82 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.383 -0.826 . . . . 0.0 109.477 176.421 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 229' ' ' THR . . . . . 0.617 HG22 ' HA ' ' A' ' 331' ' ' ALA . 41.4 p -131.18 179.38 6.04 Favored 'General case' 0 C--N 1.326 -0.432 0 C-N-CA 119.904 -0.719 . . . . 0.0 112.174 -175.082 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . 0.677 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 53.3 t -122.26 127.81 75.3 Favored 'Isoleucine or valine' 0 C--O 1.238 0.472 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.039 178.482 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 35.7 m -105.86 115.75 30.77 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.317 178.186 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 134.92 170.17 12.11 Favored Glycine 0 N--CA 1.443 -0.851 0 C-N-CA 120.211 -0.995 . . . . 0.0 111.86 -178.499 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 233' ' ' GLN . . . . . 0.427 ' OE1' ' HA ' ' A' ' 327' ' ' ALA . 87.9 mm-40 -113.5 107.96 52.62 Favored Pre-proline 0 C--N 1.321 -0.637 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 -178.473 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 234' ' ' PRO . . . . . 0.652 ' O ' ' HD3' ' A' ' 325' ' ' LYS . 6.3 Cg_exo -74.88 125.74 9.59 Favored 'Trans proline' 0 N--CA 1.454 -0.812 0 C-N-CA 122.072 1.848 . . . . 0.0 111.007 178.073 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 70.0 mm-40 -124.15 149.92 45.73 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.731 178.36 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 78.9 t60 -161.04 130.54 4.81 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-N 115.778 -0.647 . . . . 0.0 110.235 172.39 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 237' ' ' LYS . . . . . 0.6 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -130.39 132.49 45.8 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 114.918 -1.037 . . . . 0.0 108.67 177.166 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 238' ' ' VAL . . . . . 0.576 HG23 HD21 ' A' ' 307' ' ' LEU . 41.4 t -103.63 123.76 57.46 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 C-N-CA 120.115 -0.634 . . . . 0.0 110.767 178.82 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 239' ' ' GLU . . . . . . . . . . . . . 22.7 pt-20 -138.65 143.11 39.08 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 115.649 -0.705 . . . . 0.0 109.442 173.7 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 240' ' ' ALA . . . . . 0.756 ' O ' ' HA ' ' A' ' 247' ' ' PRO . . . -76.62 -91.55 0.03 OUTLIER 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 -178.889 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 241' ' ' LYS . . . . . 0.585 ' O ' ' HD3' ' A' ' 241' ' ' LYS . 0.0 OUTLIER -119.84 144.26 47.45 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.136 175.512 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -101.31 -157.85 0.63 Allowed 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.855 -178.63 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 29.0 p -59.5 -26.38 65.25 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 113.047 0.758 . . . . 0.0 113.047 -177.379 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 48.8 t30 -88.85 -14.61 36.5 Favored 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 120.706 -0.398 . . . . 0.0 110.678 179.389 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . 0.502 ' HA2' ' HE2' ' A' ' 241' ' ' LYS . . . 93.98 3.78 63.64 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.402 -0.904 . . . . 0.0 114.822 170.37 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 246' ' ' MET . . . . . . . . . . . . . 51.8 mtm -95.59 138.35 21.83 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 118.405 1.102 . . . . 0.0 111.258 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 247' ' ' PRO . . . . . 0.756 ' HA ' ' O ' ' A' ' 240' ' ' ALA . 4.7 Cg_exo -76.98 120.32 5.4 Favored 'Trans proline' 0 C--N 1.347 0.479 0 C-N-CA 122.905 2.403 . . . . 0.0 111.389 176.537 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 48.0 t -135.81 109.96 10.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-O 121.035 0.445 . . . . 0.0 110.487 -179.424 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 32.4 t70 -99.53 141.77 31.89 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 174.459 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 250' ' ' ASN . . . . . . . . . . . . . 73.8 m-80 -83.0 37.74 0.56 Allowed 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.812 -0.176 . . . . 0.0 111.356 -178.722 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . 0.803 ' HG3' ' H ' ' A' ' 252' ' ' GLN . 38.1 ptt180 38.08 -108.05 0.06 Allowed 'General case' 0 N--CA 1.473 0.693 0 O-C-N 124.318 1.012 . . . . 0.0 113.038 178.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 252' ' ' GLN . . . . . 0.803 ' H ' ' HG3' ' A' ' 251' ' ' ARG . 2.9 mm100 -127.3 175.21 8.35 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 110.311 -0.255 . . . . 0.0 110.311 -176.88 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -85.3 135.34 13.37 Favored Glycine 0 N--CA 1.448 -0.504 0 C-N-CA 120.317 -0.944 . . . . 0.0 111.848 177.564 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 67.8 p -107.36 118.12 35.89 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.02 0.438 . . . . 0.0 110.162 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.402 ' HB ' ' CG1' ' A' ' 230' ' ' VAL . 24.2 pt -119.39 146.05 24.65 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 116.152 -0.477 . . . . 0.0 111.73 -174.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 92.4 m -97.16 115.81 28.23 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 172.871 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.634 HG21 HD12 ' A' ' 262' ' ' LEU . 32.8 m -92.08 143.19 11.85 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.974 0 C-N-CA 119.388 -0.925 . . . . 0.0 112.697 -170.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 258' ' ' SER . . . . . 0.415 ' HB3' ' OG1' ' A' ' 229' ' ' THR . 23.1 t -90.72 9.92 28.01 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 114.005 -1.452 . . . . 0.0 107.968 169.671 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 259' ' ' ALA . . . . . 0.603 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -93.38 -179.27 5.0 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 114.862 -1.063 . . . . 0.0 110.262 -177.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 32.2 t -152.8 150.92 29.86 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 176.433 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 84.98 22.74 51.84 Favored Glycine 0 N--CA 1.45 -0.406 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.42 -178.649 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 262' ' ' LEU . . . . . 0.634 HD12 HG21 ' A' ' 257' ' ' VAL . 78.6 mt -90.08 140.51 29.58 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.683 0.278 . . . . 0.0 110.439 179.439 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . 0.433 ' HA ' HE21 ' A' ' 263' ' ' GLN . 2.6 mm100 -137.55 168.71 19.12 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.58 -178.28 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 264' ' ' VAL . . . . . 0.496 HG22 ' HA ' ' A' ' 294' ' ' ALA . 45.6 t -74.81 138.58 20.74 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-O 120.743 0.306 . . . . 0.0 110.312 177.645 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 91.37 0.57 73.14 Favored Glycine 0 N--CA 1.449 -0.444 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.685 178.316 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 55.1 m-20 -81.32 165.32 21.49 Favored 'General case' 0 CA--C 1.514 -0.419 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 176.385 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 267' ' ' ALA . . . . . 0.838 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -130.7 148.65 52.51 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 176.869 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 268' ' ' PHE . . . . . 0.633 ' HB3' HD13 ' A' ' 334' ' ' ILE . 3.3 p90 -164.88 168.78 17.32 Favored 'General case' 0 C--N 1.321 -0.649 0 C-N-CA 120.176 -0.61 . . . . 0.0 111.3 -179.216 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 269' ' ' THR . . . . . 0.613 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 63.3 p -113.49 149.5 34.22 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.037 175.55 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 270' ' ' ILE . . . . . . . . . . . . . 59.4 mt -121.53 129.92 75.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 178.186 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -61.29 139.13 58.22 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.242 0.544 . . . . 0.0 112.242 -173.038 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 88.17 -24.95 9.69 Favored Glycine 0 C--O 1.231 -0.074 0 CA-C-N 115.778 -0.646 . . . . 0.0 112.678 179.199 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 38.2 t -97.21 101.49 12.31 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 174.288 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 274' ' ' ASN . . . . . 1.027 ' HA ' ' HA ' ' A' ' 287' ' ' PRO . 3.6 m120 -94.46 169.11 10.44 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.316 -179.084 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 275' ' ' SER . . . . . 0.408 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 8.3 t -104.72 179.79 4.17 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 107.876 -1.157 . . . . 0.0 107.876 171.555 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 32.7 m -126.28 149.15 31.0 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.07 0 C-N-CA 120.472 -0.491 . . . . 0.0 111.196 173.421 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 277' ' ' HIS . . . . . 0.431 ' CD2' ' HB2' ' A' ' 282' ' ' ASP . 90.6 m-70 -78.08 117.2 19.15 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.065 -0.516 . . . . 0.0 109.621 175.169 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 39.4 tt0 -62.91 -35.25 79.44 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.906 -173.137 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 279' ' ' ILE . . . . . 0.642 HG22 HG23 ' A' ' 280' ' ' THR . 60.7 mt -60.09 -69.41 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 112.295 0.48 . . . . 0.0 112.295 -173.57 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . 0.642 HG23 HG22 ' A' ' 279' ' ' ILE . 46.4 p -114.52 17.22 17.45 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 112.424 0.527 . . . . 0.0 112.424 -174.426 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 281' ' ' LYS . . . . . 0.418 ' HE3' HG11 ' A' ' 309' ' ' VAL . 2.8 tmtp? 60.04 53.02 4.79 Favored 'General case' 0 CA--C 1.535 0.397 0 CA-C-O 121.328 0.585 . . . . 0.0 109.527 177.688 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 282' ' ' ASP . . . . . 0.431 ' HB2' ' CD2' ' A' ' 277' ' ' HIS . 58.5 m-20 -94.27 129.98 40.71 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.892 0.377 . . . . 0.0 111.007 -178.804 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 76.1 p -107.2 107.43 18.38 Favored 'General case' 0 C--N 1.321 -0.656 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 173.842 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 47.0 p -118.68 7.27 11.65 Favored 'General case' 0 C--N 1.322 -0.587 0 C-N-CA 120.737 -0.385 . . . . 0.0 111.999 -172.217 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 85.58 26.65 34.91 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.403 -0.903 . . . . 0.0 112.646 176.386 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 286' ' ' GLN . . . . . 0.417 ' HA ' ' HD3' ' A' ' 287' ' ' PRO . 84.7 mt-30 -105.03 117.17 59.28 Favored Pre-proline 0 C--N 1.324 -0.535 0 N-CA-C 110.328 -0.249 . . . . 0.0 110.328 178.616 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 287' ' ' PRO . . . . . 1.027 ' HA ' ' HA ' ' A' ' 274' ' ' ASN . 39.5 Cg_exo -61.7 167.36 10.21 Favored 'Trans proline' 0 C--O 1.233 0.274 0 C-N-CA 123.222 2.615 . . . . 0.0 113.559 -175.67 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 62.9 tp60 -88.05 136.45 32.96 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.278 -0.874 . . . . 0.0 110.564 178.165 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 289' ' ' VAL . . . . . 0.549 HG12 ' HB1' ' A' ' 267' ' ' ALA . 43.8 t -94.47 123.24 46.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.069 -0.514 . . . . 0.0 109.888 177.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 290' ' ' PHE . . . . . 0.838 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 60.1 m-85 -104.07 133.56 48.81 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 112.082 0.401 . . . . 0.0 112.082 -173.396 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 291' ' ' ARG . . . . . 0.635 ' HD2' ' HB2' ' A' ' 267' ' ' ALA . 40.2 mmm-85 -94.91 119.59 33.71 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-O 121.5 0.667 . . . . 0.0 109.414 167.761 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . 0.627 HG11 HG23 ' A' ' 295' ' ' VAL . 54.9 t -71.37 140.91 17.45 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 CA-C-N 114.705 -1.134 . . . . 0.0 112.409 -174.905 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 293' ' ' LEU . . . . . 0.509 ' N ' HD12 ' A' ' 293' ' ' LEU . 3.9 mp -102.34 -30.89 10.79 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.41 175.604 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 294' ' ' ALA . . . . . 0.496 ' HA ' HG22 ' A' ' 264' ' ' VAL . . . -158.02 138.85 13.07 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.55 -0.295 . . . . 0.0 111.558 -177.394 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . 0.627 HG23 HG11 ' A' ' 292' ' ' VAL . 59.4 t -133.84 97.67 2.35 Favored 'Isoleucine or valine' 0 C--O 1.236 0.358 0 CA-C-N 115.851 -0.613 . . . . 0.0 109.378 173.826 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 30.5 m -133.98 114.57 13.38 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.848 -176.064 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 60.96 51.04 61.07 Favored Glycine 0 C--N 1.329 0.179 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.336 -179.515 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 70.4 p 52.32 19.5 1.14 Allowed 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 123.635 0.774 . . . . 0.0 112.654 -176.267 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 32.8 m -109.45 108.95 19.64 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 177.174 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . 0.579 HG12 HG23 ' A' ' 302' ' ' ILE . 43.7 t -112.04 126.96 69.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.54 -170.931 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 301' ' ' THR . . . . . 0.456 ' CG2' ' HB2' ' A' ' 252' ' ' GLN . 69.1 m -98.29 117.92 33.77 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 174.259 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 302' ' ' ILE . . . . . 0.655 ' O ' ' HB3' ' A' ' 252' ' ' GLN . 2.4 pp -116.18 149.82 18.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 N-CA-C 114.116 1.154 . . . . 0.0 114.116 -171.033 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 303' ' ' SER . . . . . 0.51 ' HA ' ' O ' ' A' ' 304' ' ' PRO . 86.1 p -140.64 162.62 48.05 Favored Pre-proline 0 C--O 1.216 -0.682 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 173.185 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 304' ' ' PRO . . . . . 0.51 ' O ' ' HA ' ' A' ' 303' ' ' SER . 17.6 Cg_endo -55.83 174.39 3.55 Favored 'Cis proline' 0 N--CA 1.477 0.554 0 CA-C-N 121.479 1.564 . . . . 0.0 113.825 0.038 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 305' ' ' LYS . . . . . 0.473 ' HD2' ' N ' ' A' ' 305' ' ' LYS . 0.4 OUTLIER -65.3 158.42 26.42 Favored 'General case' 0 CA--C 1.511 -0.553 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.38 179.502 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 306' ' ' ILE . . . . . 0.483 HD11 HD11 ' A' ' 302' ' ' ILE . 43.3 mt -101.62 73.02 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -0.987 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.779 178.453 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 307' ' ' LEU . . . . . 0.576 HD21 HG23 ' A' ' 238' ' ' VAL . 91.7 mt -107.11 112.14 63.2 Favored Pre-proline 0 C--N 1.324 -0.543 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.216 -176.262 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 308' ' ' PRO . . . . . 0.585 ' HA ' ' O ' ' A' ' 322' ' ' VAL . 11.3 Cg_exo -69.79 146.35 59.74 Favored 'Trans proline' 0 N--CA 1.462 -0.324 0 C-N-CA 122.708 2.272 . . . . 0.0 111.034 177.708 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . 0.418 HG11 ' HE3' ' A' ' 281' ' ' LYS . 20.0 t -83.41 -21.32 8.85 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.693 0 CA-C-O 121.282 0.563 . . . . 0.0 110.39 -177.694 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -76.24 -6.95 53.69 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.58 -0.736 . . . . 0.0 112.28 -175.994 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -75.46 153.94 37.31 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.143 0.497 . . . . 0.0 111.749 -177.005 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 53.1 m -96.88 -7.58 33.06 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.835 -0.62 . . . . 0.0 109.402 178.24 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 313' ' ' ASP . . . . . 0.464 ' HB3' ' HB2' ' A' ' 316' ' ' SER . 9.8 t70 -54.25 119.0 4.54 Favored 'General case' 0 C--O 1.232 0.153 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.507 179.868 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 46.7 t -56.57 -49.61 76.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.41 -0.814 . . . . 0.0 112.679 -173.071 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -81.82 -19.73 40.5 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 112.352 0.501 . . . . 0.0 112.352 -174.668 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . 0.464 ' HB2' ' HB3' ' A' ' 313' ' ' ASP . 49.2 m -91.81 -25.26 19.09 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 112.283 0.475 . . . . 0.0 112.283 -175.742 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 317' ' ' ARG . . . . . 0.466 ' CG ' ' HD3' ' A' ' 318' ' ' PRO . 1.6 ptm85 -71.62 -35.79 4.04 Favored Pre-proline 0 CA--C 1.545 0.771 0 N-CA-C 114.293 1.22 . . . . 0.0 114.293 -175.902 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 318' ' ' PRO . . . . . 0.466 ' HD3' ' CG ' ' A' ' 317' ' ' ARG . 24.2 Cg_exo -65.89 -38.92 21.33 Favored 'Trans proline' 0 C--N 1.362 1.268 0 CA-C-N 121.132 1.44 . . . . 0.0 112.476 -177.463 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 3.9 m-85 -95.94 17.37 15.5 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.075 -179.719 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . 0.518 ' HA ' ' HB2' ' A' ' 307' ' ' LEU . . . -64.67 134.34 54.07 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.523 177.805 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 15.2 p-10 -144.11 1.44 1.11 Allowed 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -174.023 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 322' ' ' VAL . . . . . 0.585 ' O ' ' HA ' ' A' ' 308' ' ' PRO . 29.4 m -133.93 161.45 40.92 Favored 'Isoleucine or valine' 0 C--O 1.234 0.266 0 CA-C-O 121.288 0.566 . . . . 0.0 112.262 -177.82 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 323' ' ' ASP . . . . . 0.687 ' HB2' ' HB2' ' A' ' 274' ' ' ASN . 57.2 m-20 -93.24 77.59 4.54 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.865 174.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 324' ' ' ALA . . . . . 0.403 ' HB3' ' O ' ' A' ' 323' ' ' ASP . . . 72.37 163.85 0.28 Allowed 'General case' 0 N--CA 1.471 0.621 0 N-CA-C 113.387 0.884 . . . . 0.0 113.387 175.12 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 325' ' ' LYS . . . . . 0.652 ' HD3' ' O ' ' A' ' 234' ' ' PRO . 9.9 ptpp? -119.15 105.93 43.93 Favored Pre-proline 0 C--N 1.325 -0.459 0 CA-C-N 114.485 -1.234 . . . . 0.0 108.715 166.902 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 326' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 325' ' ' LYS . 3.8 Cg_exo -84.17 167.21 12.43 Favored 'Trans proline' 0 C--O 1.234 0.299 0 C-N-CA 122.657 2.238 . . . . 0.0 112.992 -171.363 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 327' ' ' ALA . . . . . 0.427 ' HA ' ' OE1' ' A' ' 233' ' ' GLN . . . -72.82 134.85 45.07 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 115.605 -0.725 . . . . 0.0 109.689 174.136 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 70.1 mm-40 71.3 111.18 0.06 Allowed 'General case' 0 N--CA 1.464 0.256 0 O-C-N 124.089 0.868 . . . . 0.0 110.432 -173.243 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 329' ' ' SER . . . . . 0.677 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 58.2 m -63.36 -41.28 98.83 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.82 -0.627 . . . . 0.0 111.603 -176.561 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 330' ' ' ALA . . . . . 0.466 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 79.35 -160.66 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.762 0 N-CA-C 112.828 0.677 . . . . 0.0 112.828 174.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 331' ' ' ALA . . . . . 0.617 ' HA ' HG22 ' A' ' 229' ' ' THR . . . -68.43 157.73 35.21 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-N 115.091 -0.958 . . . . 0.0 113.562 -170.405 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 332' ' ' ILE . . . . . 0.507 HD12 ' HB2' ' A' ' 259' ' ' ALA . 17.5 mt -119.16 146.11 24.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.075 -0.966 . . . . 0.0 110.223 179.555 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.518 ' HB ' ' OG1' ' A' ' 269' ' ' THR . 59.5 m -127.18 111.67 14.24 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 175.544 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 334' ' ' ILE . . . . . 0.633 HD13 ' HB3' ' A' ' 268' ' ' PHE . 46.9 mm -83.87 134.93 25.85 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.359 0 N-CA-C 113.295 0.85 . . . . 0.0 113.295 -171.538 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 335' ' ' LEU . . . . . 0.543 ' O ' ' HB3' ' A' ' 267' ' ' ALA . 1.8 pt? -158.45 130.36 6.75 Favored 'General case' 0 C--O 1.222 -0.366 0 CA-C-N 115.083 -0.962 . . . . 0.0 109.906 170.562 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -102.65 2.74 36.34 Favored 'General case' 0 C--N 1.318 -0.801 0 O-C-N 122.011 -0.43 . . . . 0.0 111.144 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 40.1 ttmt . . . . . 0 C--O 1.244 0.773 0 CA-C-O 118.279 -0.867 . . . . 0.0 110.246 -178.388 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.776 0 N-CA-C 112.277 -0.329 . . . . 0.0 112.277 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 33.9 t 65.33 -131.89 0.25 Allowed 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 122.574 0.35 . . . . 0.0 110.073 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 50.1 p -83.15 162.41 21.29 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-O 120.905 0.383 . . . . 0.0 110.653 179.736 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -152.83 86.24 1.25 Allowed 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.197 179.487 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 35.4 m 62.46 77.52 0.33 Allowed 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.015 179.235 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 228' ' ' LEU . . . . . 0.701 ' H ' HD22 ' A' ' 228' ' ' LEU . 1.9 mm? -60.39 150.56 30.49 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.252 -179.665 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 229' ' ' THR . . . . . 0.405 ' HA ' ' HA ' ' A' ' 331' ' ' ALA . 53.6 p -129.96 176.18 8.26 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 119.787 -0.765 . . . . 0.0 111.1 -179.773 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . 0.527 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 64.9 t -148.69 138.87 16.56 Favored 'Isoleucine or valine' 0 C--O 1.238 0.478 0 CA-C-O 120.789 0.328 . . . . 0.0 110.926 -177.128 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 47.1 t -122.72 97.39 5.43 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.419 -0.809 . . . . 0.0 109.101 173.284 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . -126.22 -151.8 7.96 Favored Glycine 0 N--CA 1.445 -0.762 0 C-N-CA 119.951 -1.119 . . . . 0.0 113.102 -175.036 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 233' ' ' GLN . . . . . 0.777 ' H ' HG22 ' A' ' 255' ' ' ILE . 80.3 mt-30 -70.58 169.61 13.53 Favored Pre-proline 0 C--N 1.325 -0.468 0 CA-C-N 115.212 -0.494 . . . . 0.0 110.991 -178.609 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 234' ' ' PRO . . . . . 0.768 ' HD2' ' HB3' ' A' ' 233' ' ' GLN . 18.7 Cg_endo -57.53 175.08 0.43 Allowed 'Trans proline' 0 C--N 1.354 0.833 0 C-N-CA 123.404 2.736 . . . . 0.0 112.833 177.777 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 235' ' ' GLU . . . . . 0.476 ' HB2' ' HD2' ' A' ' 325' ' ' LYS . 25.1 mp0 -91.86 155.18 18.39 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 108.96 -0.756 . . . . 0.0 108.96 -177.052 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 236' ' ' HIS . . . . . 0.618 ' CE1' ' HB3' ' A' ' 251' ' ' ARG . 65.6 m-70 -108.5 148.76 29.76 Favored 'General case' 0 C--N 1.323 -0.581 0 C-N-CA 120.521 -0.472 . . . . 0.0 111.177 -171.511 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 237' ' ' LYS . . . . . 0.44 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -160.23 161.92 33.6 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.5 -0.773 . . . . 0.0 108.957 -178.38 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 238' ' ' VAL . . . . . 0.467 ' HB ' ' HA ' ' A' ' 316' ' ' SER . 45.8 t -103.43 120.82 53.97 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 C-N-CA 120.874 -0.331 . . . . 0.0 110.46 179.728 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 239' ' ' GLU . . . . . 0.469 ' O ' ' HA ' ' A' ' 247' ' ' PRO . 53.7 mt-10 -120.71 154.17 35.95 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.049 176.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 240' ' ' ALA . . . . . . . . . . . . . . . -62.6 -40.02 95.6 Favored 'General case' 0 C--N 1.328 -0.344 0 O-C-N 123.369 0.418 . . . . 0.0 110.944 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 241' ' ' LYS . . . . . 0.595 ' O ' ' HD3' ' A' ' 241' ' ' LYS . 0.0 OUTLIER -149.54 143.29 25.51 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.433 0.635 . . . . 0.0 112.07 178.723 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 242' ' ' ASP . . . . . 0.456 ' HB3' HG22 ' A' ' 248' ' ' VAL . 56.3 p-10 -106.38 -156.56 0.58 Allowed 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.258 179.449 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 47.1 t -58.71 -33.59 70.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.176 178.421 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 51.0 t30 -91.04 -13.83 32.48 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.875 0.369 . . . . 0.0 111.129 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . 0.514 ' HA2' ' HB2' ' A' ' 241' ' ' LYS . . . 95.5 22.14 22.46 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.622 -0.799 . . . . 0.0 112.571 178.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 246' ' ' MET . . . . . . . . . . . . . 83.8 mtp -113.44 151.5 44.49 Favored Pre-proline 0 C--N 1.325 -0.464 0 O-C-N 122.952 -0.146 . . . . 0.0 110.706 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 247' ' ' PRO . . . . . 0.469 ' HA ' ' O ' ' A' ' 239' ' ' GLU . 26.0 Cg_exo -58.9 130.06 34.94 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.277 1.985 . . . . 0.0 111.0 175.352 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.456 HG22 ' HB3' ' A' ' 242' ' ' ASP . 48.5 t -70.21 118.17 14.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-O 121.179 0.514 . . . . 0.0 110.591 -175.077 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 27.2 t70 -79.35 144.21 34.41 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.557 -179.337 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 250' ' ' ASN . . . . . 0.437 HD21 HG22 ' A' ' 238' ' ' VAL . 3.2 m120 -62.27 101.15 0.21 Allowed 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 178.117 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . 0.618 ' HB3' ' CE1' ' A' ' 236' ' ' HIS . 0.6 OUTLIER -67.08 -68.47 0.37 Allowed 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.469 -0.787 . . . . 0.0 112.141 -169.742 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 19.2 mt-30 62.84 178.89 0.14 Allowed 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 -176.769 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . 0.586 ' O ' ' HA ' ' A' ' 301' ' ' THR . . . 133.29 -146.45 18.36 Favored Glycine 0 N--CA 1.445 -0.76 0 C-N-CA 118.576 -1.773 . . . . 0.0 114.223 174.314 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 51.4 p -93.98 130.1 40.21 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.036 -0.582 . . . . 0.0 112.443 -170.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.777 HG22 ' H ' ' A' ' 233' ' ' GLN . 2.3 pp -129.79 163.4 35.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.902 177.432 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 31.3 m -100.47 116.38 32.28 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 -178.51 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.454 ' HA ' HG13 ' A' ' 230' ' ' VAL . 31.8 m -90.78 142.56 12.77 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.573 0 C-N-CA 120.192 -0.603 . . . . 0.0 112.593 -176.098 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 36.8 t -91.94 9.03 34.74 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 114.495 -1.23 . . . . 0.0 108.379 167.575 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 259' ' ' ALA . . . . . 0.537 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -91.07 171.54 9.19 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.138 -0.937 . . . . 0.0 109.748 -178.023 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 34.5 t -143.65 132.02 22.11 Favored 'General case' 0 C--N 1.324 -0.504 0 C-N-CA 120.991 -0.283 . . . . 0.0 110.857 179.508 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 99.24 25.49 9.43 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.682 -0.771 . . . . 0.0 113.083 177.705 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 262' ' ' LEU . . . . . 0.507 HD11 ' CB ' ' A' ' 259' ' ' ALA . 3.4 mp -87.79 146.26 25.71 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 117.034 0.417 . . . . 0.0 110.195 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 83.6 mt-30 -141.04 169.16 18.13 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.105 -0.498 . . . . 0.0 109.768 177.404 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 264' ' ' VAL . . . . . 0.674 HG22 ' HA ' ' A' ' 294' ' ' ALA . 31.8 t -77.86 139.69 18.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 C-N-CA 121.032 -0.267 . . . . 0.0 110.594 -179.677 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 91.71 3.35 68.71 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.13 179.462 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 70.5 m-20 -80.46 166.78 20.89 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.295 0.569 . . . . 0.0 111.039 179.145 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 267' ' ' ALA . . . . . 0.723 ' HB2' ' NH1' ' A' ' 291' ' ' ARG . . . -125.84 144.11 50.79 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 114.802 -1.09 . . . . 0.0 108.551 175.22 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 268' ' ' PHE . . . . . 0.583 ' CD1' HG21 ' A' ' 332' ' ' ILE . 0.0 OUTLIER -163.45 163.82 24.72 Favored 'General case' 0 C--N 1.313 -1.002 0 C-N-CA 120.125 -0.63 . . . . 0.0 110.167 -179.955 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 63.3 p -125.89 137.99 53.77 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 120.822 0.344 . . . . 0.0 110.934 -175.397 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 270' ' ' ILE . . . . . 0.671 HG12 HG12 ' A' ' 332' ' ' ILE . 60.5 mt -95.89 138.63 20.89 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.806 -179.316 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -62.23 125.52 24.18 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.97 179.577 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 94.4 -21.57 41.93 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.125 -178.62 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . 0.461 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 57.0 t -90.73 101.4 12.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.282 0.563 . . . . 0.0 110.106 177.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -115.91 134.32 55.11 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 178.791 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 35.6 p -70.8 152.81 43.36 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.258 0.552 . . . . 0.0 111.97 -179.125 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 276' ' ' VAL . . . . . 0.686 HG11 HG21 ' A' ' 309' ' ' VAL . 33.8 m -114.7 156.07 15.75 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-N 115.221 -0.899 . . . . 0.0 110.157 174.588 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 21.7 m80 -116.6 71.27 0.78 Allowed 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 177.473 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 26.8 mt-30 -70.58 -9.62 57.27 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 112.17 0.433 . . . . 0.0 112.17 -175.239 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 279' ' ' ILE . . . . . 0.49 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.0 mp -67.67 -49.08 73.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 176.024 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 70.1 p -90.93 -12.75 35.11 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.117 0.484 . . . . 0.0 109.925 174.288 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 26.5 tptp 68.28 50.8 0.73 Allowed 'General case' 0 CA--C 1.531 0.237 0 CA-C-N 114.902 -1.045 . . . . 0.0 110.342 -177.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -118.34 142.15 47.8 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.889 177.553 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 62.8 p -107.43 109.93 21.77 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.48 174.745 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 68.0 p -114.33 -12.19 12.45 Favored 'General case' 0 C--N 1.32 -0.691 0 C-N-CA 120.721 -0.392 . . . . 0.0 111.999 -171.429 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 64.16 31.46 80.91 Favored Glycine 0 CA--C 1.518 0.252 0 C-N-CA 120.964 -0.636 . . . . 0.0 113.313 175.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 98.1 mm-40 -89.14 122.46 68.71 Favored Pre-proline 0 C--N 1.327 -0.37 0 CA-C-N 116.941 0.37 . . . . 0.0 110.197 178.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 287' ' ' PRO . . . . . . . . . . . . . 86.1 Cg_exo -48.29 131.08 22.1 Favored 'Trans proline' 0 C--N 1.346 0.42 0 C-N-CA 123.033 2.489 . . . . 0.0 112.989 -177.695 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 67.1 tp60 -70.1 127.28 32.28 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.868 -178.867 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 289' ' ' VAL . . . . . 0.442 HG13 ' HB1' ' A' ' 267' ' ' ALA . 65.7 t -91.73 131.74 38.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 116.042 -0.527 . . . . 0.0 110.578 178.47 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 290' ' ' PHE . . . . . 0.695 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 57.8 m-85 -113.5 154.5 26.96 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.72 -178.272 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 291' ' ' ARG . . . . . 0.723 ' NH1' ' HB2' ' A' ' 267' ' ' ALA . 0.1 OUTLIER -114.5 121.58 43.96 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.15 0.5 . . . . 0.0 110.196 172.812 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . 0.512 HG11 HG23 ' A' ' 295' ' ' VAL . 56.9 t -70.39 136.46 25.99 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-N 115.037 -0.983 . . . . 0.0 111.889 -175.291 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 293' ' ' LEU . . . . . 0.667 HD11 ' HB2' ' A' ' 303' ' ' SER . 5.5 mp -96.22 -35.69 11.19 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.91 -0.587 . . . . 0.0 111.085 179.048 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 294' ' ' ALA . . . . . 0.674 ' HA ' HG22 ' A' ' 264' ' ' VAL . . . -163.63 140.8 7.21 Favored 'General case' 0 C--N 1.332 -0.184 0 C-N-CA 121.058 -0.257 . . . . 0.0 111.641 -179.579 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . 0.512 HG23 HG11 ' A' ' 292' ' ' VAL . 59.9 t -134.77 103.37 4.48 Favored 'Isoleucine or valine' 0 C--O 1.235 0.303 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.784 175.191 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 51.0 m -143.81 114.64 7.73 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.559 -179.013 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 67.05 48.43 59.99 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.901 -0.666 . . . . 0.0 112.276 -178.551 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 77.9 p 51.5 21.53 1.28 Allowed 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 123.608 0.763 . . . . 0.0 112.106 -176.198 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 37.0 m -110.04 105.9 15.2 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 177.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . 0.562 ' HA ' ' O ' ' A' ' 294' ' ' ALA . 48.9 t -108.52 128.09 64.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.4 -172.119 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 301' ' ' THR . . . . . 0.586 ' HA ' ' O ' ' A' ' 253' ' ' GLY . 54.1 m -86.75 115.82 24.44 Favored 'General case' 0 N--CA 1.451 -0.423 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 173.631 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 302' ' ' ILE . . . . . 0.549 HD12 ' O ' ' A' ' 302' ' ' ILE . 2.4 pp -111.74 151.04 13.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 N-CA-C 113.527 0.936 . . . . 0.0 113.527 -171.05 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 303' ' ' SER . . . . . 0.667 ' HB2' HD11 ' A' ' 293' ' ' LEU . 64.9 m -166.99 166.5 8.48 Favored Pre-proline 0 C--N 1.322 -0.595 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 179.326 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 304' ' ' PRO . . . . . 0.586 ' HA ' ' HB3' ' A' ' 303' ' ' SER . 4.3 Cg_exo -77.62 -113.81 0.0 OUTLIER 'Cis proline' 0 C--N 1.347 0.48 0 CA-C-N 120.907 1.36 . . . . 0.0 113.438 0.516 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 305' ' ' LYS . . . . . 0.519 ' HB3' ' HG ' ' A' ' 307' ' ' LEU . 31.2 mmtp -93.04 155.74 17.32 Favored 'General case' 0 CA--C 1.515 -0.385 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.354 -171.473 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 306' ' ' ILE . . . . . 0.456 HD12 ' N ' ' A' ' 306' ' ' ILE . 3.1 mp -131.09 74.18 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.641 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 167.283 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 307' ' ' LEU . . . . . 0.519 ' HG ' ' HB3' ' A' ' 305' ' ' LYS . 73.7 mt -112.67 113.91 50.08 Favored Pre-proline 0 C--N 1.328 -0.366 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.183 -171.092 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 308' ' ' PRO . . . . . 0.743 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 37.8 Cg_exo -66.91 148.62 82.43 Favored 'Trans proline' 0 N--CA 1.472 0.254 0 C-N-CA 123.378 2.719 . . . . 0.0 113.924 -175.137 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . 0.686 HG21 HG11 ' A' ' 276' ' ' VAL . 46.0 t -94.06 -7.92 9.99 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.362 0 CA-C-N 115.421 -0.809 . . . . 0.0 109.303 171.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 310' ' ' GLU . . . . . 0.428 ' HG2' ' O ' ' A' ' 323' ' ' ASP . 65.3 mm-40 -77.17 11.83 1.7 Allowed 'General case' 0 CA--C 1.531 0.248 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.928 179.076 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.519 ' OD1' ' HB2' ' A' ' 308' ' ' PRO . 4.6 m120 -80.41 158.69 25.89 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.888 0.375 . . . . 0.0 110.669 178.472 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 31.5 m -107.74 -13.28 15.06 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.168 0.508 . . . . 0.0 110.494 -176.027 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 11.8 p-10 -87.58 156.25 19.59 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 121.091 0.472 . . . . 0.0 111.172 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 314' ' ' VAL . . . . . 0.411 ' O ' ' HD3' ' A' ' 318' ' ' PRO . 49.1 t -81.79 -24.06 9.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 115.707 -0.678 . . . . 0.0 111.112 -178.295 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -61.9 -42.72 99.42 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 111.913 0.338 . . . . 0.0 111.913 -178.114 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . 0.467 ' HA ' ' HB ' ' A' ' 238' ' ' VAL . 26.3 t -82.1 -10.31 59.24 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.609 -0.268 . . . . 0.0 111.293 -176.431 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 317' ' ' ARG . . . . . 0.638 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 36.8 mmt180 -58.37 -54.5 55.24 Favored Pre-proline 0 N--CA 1.468 0.464 0 N-CA-C 113.554 0.946 . . . . 0.0 113.554 -179.704 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 318' ' ' PRO . . . . . 0.638 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 24.5 Cg_exo -68.21 -19.19 44.81 Favored 'Trans proline' 0 C--N 1.353 0.78 0 C-N-CA 122.017 1.811 . . . . 0.0 113.232 -175.178 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 55.4 m-85 -102.16 -18.37 15.57 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 111.965 0.357 . . . . 0.0 111.965 -174.245 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -55.64 126.49 25.61 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.795 0.331 . . . . 0.0 111.244 -178.666 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 321' ' ' ASN . . . . . 0.411 ' C ' HG22 ' A' ' 276' ' ' VAL . 15.3 p-10 -126.51 -4.94 6.54 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.288 -177.631 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 322' ' ' VAL . . . . . 0.571 ' O ' HG23 ' A' ' 309' ' ' VAL . 29.9 m -136.35 156.43 36.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.637 0.256 . . . . 0.0 110.885 178.511 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 323' ' ' ASP . . . . . 0.428 ' O ' ' HG2' ' A' ' 310' ' ' GLU . 71.9 m-20 -52.93 -50.97 62.93 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.889 -178.065 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 324' ' ' ALA . . . . . 0.743 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -163.05 -179.94 7.07 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.006 0.431 . . . . 0.0 111.135 -177.066 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 325' ' ' LYS . . . . . 0.476 ' HD2' ' HB2' ' A' ' 235' ' ' GLU . 22.0 pttp -105.84 137.43 19.34 Favored Pre-proline 0 C--N 1.325 -0.481 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.122 176.575 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 326' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 325' ' ' LYS . 57.4 Cg_endo -86.35 167.46 9.05 Favored 'Trans proline' 0 N--CA 1.454 -0.809 0 C-N-CA 122.712 2.275 . . . . 0.0 112.306 -179.411 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -75.6 138.34 41.37 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 175.777 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 62.64 -132.42 0.51 Allowed 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 -174.021 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 329' ' ' SER . . . . . 0.527 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 48.6 m -111.49 -17.34 13.1 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 171.185 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 74.47 -173.67 0.13 Allowed 'General case' 0 N--CA 1.474 0.759 0 N-CA-C 113.65 0.981 . . . . 0.0 113.65 170.887 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 331' ' ' ALA . . . . . 0.435 ' HA ' ' O ' ' A' ' 228' ' ' LEU . . . -80.76 146.75 30.84 Favored 'General case' 0 CA--C 1.518 -0.264 0 CA-C-N 114.997 -1.001 . . . . 0.0 111.171 -176.604 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 332' ' ' ILE . . . . . 0.671 HG12 HG12 ' A' ' 270' ' ' ILE . 47.5 mt -128.45 147.18 33.0 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-O 120.956 0.408 . . . . 0.0 111.528 -176.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 88.1 m -116.71 112.96 21.94 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.857 -179.591 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 38.4 mm -79.56 131.87 33.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 113.044 0.757 . . . . 0.0 113.044 -171.482 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 335' ' ' LEU . . . . . . . . . . . . . 9.6 mp -115.92 168.61 9.91 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 114.562 -1.199 . . . . 0.0 109.643 171.5 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -116.82 3.96 12.95 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.473 176.69 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 14.8 ptmm? . . . . . 0 C--O 1.246 0.889 0 CA-C-O 118.611 -0.709 . . . . 0.0 111.687 -176.415 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.848 0 N-CA-C 112.467 -0.253 . . . . 0.0 112.467 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 50.4 m -104.63 -116.04 0.23 Allowed 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 177.734 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 50.3 m -68.32 -42.56 79.2 Favored 'General case' 0 C--O 1.234 0.239 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 175.722 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 226' ' ' GLU . . . . . 0.755 ' HB3' HG23 ' A' ' 333' ' ' THR . 50.8 mm-40 56.53 39.25 29.99 Favored 'General case' 0 C--N 1.333 -0.116 0 CA-C-N 115.053 -0.976 . . . . 0.0 110.954 178.442 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 51.1 m -119.92 49.5 1.39 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.506 -179.236 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 228' ' ' LEU . . . . . 0.471 HD13 ' HB1' ' A' ' 259' ' ' ALA . 89.9 mt -70.28 147.27 49.89 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 175.148 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 63.8 p -126.29 171.65 10.77 Favored 'General case' 0 C--N 1.324 -0.54 0 C-N-CA 119.163 -1.015 . . . . 0.0 111.334 -176.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . 0.893 HG11 HD12 ' A' ' 255' ' ' ILE . 48.0 t -147.1 141.08 20.0 Favored 'Isoleucine or valine' 0 C--O 1.24 0.577 0 CA-C-O 120.657 0.265 . . . . 0.0 110.754 -177.662 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 30.6 t -106.48 148.84 27.7 Favored 'General case' 0 C--O 1.237 0.428 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.985 176.634 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 124.8 157.15 9.61 Favored Glycine 0 N--CA 1.449 -0.486 0 N-CA-C 110.944 -0.862 . . . . 0.0 110.944 -176.712 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 233' ' ' GLN . . . . . 0.54 ' NE2' ' HA ' ' A' ' 328' ' ' GLU . 96.6 mm-40 -110.01 101.48 47.52 Favored Pre-proline 0 C--N 1.324 -0.534 0 CA-C-N 117.419 0.609 . . . . 0.0 111.305 -177.819 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -91.83 126.36 0.92 Allowed 'Trans proline' 0 N--CA 1.448 -1.159 0 C-N-CA 122.806 2.337 . . . . 0.0 111.756 177.605 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 235' ' ' GLU . . . . . 0.594 ' O ' ' HB3' ' A' ' 251' ' ' ARG . 11.0 pt-20 -132.54 149.36 52.33 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.525 -0.307 . . . . 0.0 110.214 177.027 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 236' ' ' HIS . . . . . 0.735 ' CD2' ' HA ' ' A' ' 305' ' ' LYS . 29.3 m80 -136.55 136.11 39.02 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.182 -179.532 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 237' ' ' LYS . . . . . 0.543 ' H ' ' HA ' ' A' ' 250' ' ' ASN . 0.0 OUTLIER -155.16 128.09 8.14 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.024 -179.968 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 238' ' ' VAL . . . . . . . . . . . . . 46.4 t -84.94 147.74 5.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.597 -0.274 . . . . 0.0 110.671 -176.465 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 239' ' ' GLU . . . . . 0.982 ' HA ' ' HB ' ' A' ' 248' ' ' VAL . 7.7 pt-20 -52.85 116.87 2.56 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.869 -0.605 . . . . 0.0 112.499 179.678 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 240' ' ' ALA . . . . . . . . . . . . . . . -81.73 -56.38 4.03 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 174.284 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 241' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -97.98 177.43 5.43 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.195 -0.912 . . . . 0.0 108.996 175.484 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 11.9 p-10 -105.88 -161.47 0.8 Allowed 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 120.852 0.358 . . . . 0.0 110.077 176.379 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 25.1 p -71.5 2.27 5.28 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 112.336 0.495 . . . . 0.0 112.336 178.498 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 49.8 t30 -79.27 -15.14 58.45 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.96 0.41 . . . . 0.0 110.763 178.388 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . 0.42 ' O ' ' HE3' ' A' ' 246' ' ' MET . . . -156.88 -77.68 0.02 OUTLIER Glycine 0 N--CA 1.445 -0.738 0 C-N-CA 120.177 -1.011 . . . . 0.0 112.651 -179.449 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 246' ' ' MET . . . . . 0.6 ' CE ' ' HA ' ' A' ' 246' ' ' MET . 1.6 mmt -112.29 118.06 46.41 Favored Pre-proline 0 C--N 1.326 -0.445 0 CA-C-O 120.967 0.413 . . . . 0.0 111.836 -178.769 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 247' ' ' PRO . . . . . 0.484 ' HD3' ' HA ' ' A' ' 246' ' ' MET . 11.4 Cg_endo -86.64 120.48 1.74 Allowed 'Trans proline' 0 N--CA 1.45 -1.035 0 C-N-CA 123.336 2.69 . . . . 0.0 111.584 174.051 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.982 ' HB ' ' HA ' ' A' ' 239' ' ' GLU . 32.5 t -119.82 120.19 62.54 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 C-N-CA 120.656 -0.418 . . . . 0.0 110.074 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 36.7 t70 -118.31 146.1 44.59 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 116.604 -0.271 . . . . 0.0 110.66 -176.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 250' ' ' ASN . . . . . 0.543 ' HA ' ' H ' ' A' ' 237' ' ' LYS . 73.6 m-80 -61.39 -0.28 0.37 Allowed 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 113.11 0.782 . . . . 0.0 113.11 -176.844 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . 0.594 ' HB3' ' O ' ' A' ' 235' ' ' GLU . 36.0 tpt85 66.31 -93.12 0.03 OUTLIER 'General case' 0 N--CA 1.453 -0.31 0 C-N-CA 123.083 0.553 . . . . 0.0 110.506 179.394 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 21.3 mt-30 59.49 179.08 0.08 Allowed 'General case' 0 N--CA 1.468 0.473 0 CA-C-O 120.951 0.405 . . . . 0.0 110.693 179.223 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 136.0 -160.86 24.75 Favored Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 119.031 -1.557 . . . . 0.0 113.613 176.125 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 254' ' ' THR . . . . . 0.57 ' HB ' HG22 ' A' ' 299' ' ' THR . 66.0 p -94.63 135.73 35.75 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-O 121.331 0.586 . . . . 0.0 111.88 -175.307 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.893 HD12 HG11 ' A' ' 230' ' ' VAL . 14.6 pt -121.77 156.42 26.04 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 CA-C-N 115.535 -0.757 . . . . 0.0 110.179 177.151 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 28.3 m -94.66 111.26 23.04 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 -179.755 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.528 ' HA ' HG13 ' A' ' 230' ' ' VAL . 23.1 m -93.45 144.54 9.28 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.76 0 CA-C-O 121.642 0.734 . . . . 0.0 112.717 -170.213 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 35.4 t -91.19 9.65 30.29 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 114.088 -1.415 . . . . 0.0 108.049 167.857 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 259' ' ' ALA . . . . . 0.471 ' HB1' HD13 ' A' ' 228' ' ' LEU . . . -87.08 163.72 16.85 Favored 'General case' 0 N--CA 1.45 -0.427 0 CA-C-N 115.004 -0.998 . . . . 0.0 109.66 -177.826 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 37.5 t -144.13 143.99 31.37 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-O 120.683 0.278 . . . . 0.0 110.384 -179.726 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 80.94 36.75 21.11 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.649 179.625 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 262' ' ' LEU . . . . . . . . . . . . . 66.4 mt -98.83 150.8 21.51 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.941 0.401 . . . . 0.0 110.432 179.52 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 73.4 mt-30 -142.26 164.73 29.37 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.631 -0.713 . . . . 0.0 109.241 176.29 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 264' ' ' VAL . . . . . 0.514 HG22 ' HA ' ' A' ' 294' ' ' ALA . 39.9 t -74.83 139.28 19.42 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 177.856 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 96.43 -1.91 62.55 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.42 -0.895 . . . . 0.0 113.504 177.737 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 39.7 m-20 -80.09 155.75 27.37 Favored 'General case' 0 CA--C 1.516 -0.353 0 CA-C-N 117.177 0.488 . . . . 0.0 111.053 177.094 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 267' ' ' ALA . . . . . 0.64 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -112.97 152.83 28.93 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.433 -0.803 . . . . 0.0 109.316 178.164 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 268' ' ' PHE . . . . . 0.76 ' HB3' HD13 ' A' ' 334' ' ' ILE . 7.9 p90 -164.84 172.36 13.02 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-O 121.189 0.518 . . . . 0.0 112.156 -175.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 74.4 p -127.84 149.89 50.08 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 114.758 -1.11 . . . . 0.0 108.789 173.131 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 270' ' ' ILE . . . . . 0.641 HG12 HG12 ' A' ' 332' ' ' ILE . 61.1 mt -118.6 136.94 54.18 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.674 0 CA-C-O 120.66 0.267 . . . . 0.0 110.478 -179.194 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -60.41 123.1 16.28 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.936 -0.575 . . . . 0.0 111.766 -176.581 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 100.43 -22.48 39.74 Favored Glycine 0 N--CA 1.451 -0.311 0 CA-C-N 115.915 -0.584 . . . . 0.0 112.223 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . 0.577 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 41.8 t -95.03 109.96 23.18 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 120.803 0.335 . . . . 0.0 110.294 177.818 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 69.6 m-80 -129.48 160.39 33.32 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 179.204 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 35.7 p -85.22 -171.68 3.75 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 111.966 0.358 . . . . 0.0 111.966 -176.359 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 276' ' ' VAL . . . . . 0.472 HG22 ' O ' ' A' ' 321' ' ' ASN . 29.6 m -145.98 173.24 3.36 Favored 'Isoleucine or valine' 0 C--O 1.232 0.176 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.098 178.79 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 39.5 m80 -118.82 127.13 53.24 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.328 -0.396 . . . . 0.0 109.988 171.629 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 83.6 mt-30 -79.32 -23.42 43.5 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 173.891 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 279' ' ' ILE . . . . . 0.565 ' H ' HD12 ' A' ' 279' ' ' ILE . 2.5 mp -63.27 -51.1 75.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.606 -0.725 . . . . 0.0 110.362 179.349 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 70.9 p -100.04 -15.09 18.36 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.022 -0.536 . . . . 0.0 111.799 -176.057 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 34.5 mmtp 65.25 30.13 11.4 Favored 'General case' 0 N--CA 1.467 0.403 0 C-N-CA 123.037 0.535 . . . . 0.0 111.429 -177.186 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 67.0 m-20 -105.83 151.55 24.36 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.072 176.084 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.437 ' HA ' HG12 ' A' ' 276' ' ' VAL . 72.6 p -96.21 92.3 6.32 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.3 0.571 . . . . 0.0 110.412 176.569 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 284' ' ' THR . . . . . 0.415 ' C ' ' H ' ' A' ' 286' ' ' GLN . 47.5 p -141.48 -112.14 0.13 Allowed 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.884 -179.082 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 63.65 -8.62 0.32 Allowed Glycine 0 CA--C 1.522 0.491 0 N-CA-C 114.529 0.572 . . . . 0.0 114.529 174.543 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 286' ' ' GLN . . . . . 0.571 ' HB3' ' HD2' ' A' ' 287' ' ' PRO . 2.0 mp0 67.45 167.72 0.12 Allowed Pre-proline 0 CA--C 1.537 0.453 0 C-N-CA 123.416 0.687 . . . . 0.0 111.045 -177.885 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 287' ' ' PRO . . . . . 0.571 ' HD2' ' HB3' ' A' ' 286' ' ' GLN . 81.3 Cg_exo -47.72 133.66 21.94 Favored 'Trans proline' 0 C--N 1.353 0.8 0 C-N-CA 122.821 2.347 . . . . 0.0 113.77 -172.658 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 71.2 tp60 -69.23 136.61 52.23 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.711 -178.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 48.8 t -94.89 134.13 33.34 Favored 'Isoleucine or valine' 0 C--O 1.236 0.376 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.543 179.586 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 290' ' ' PHE . . . . . 0.64 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 33.4 m-85 -116.81 168.74 9.95 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.443 -176.817 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 42.5 mmm-85 -131.08 125.46 33.23 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 173.819 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . 0.42 HG11 HG23 ' A' ' 295' ' ' VAL . 47.3 t -65.16 134.78 29.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.701 -177.243 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 293' ' ' LEU . . . . . 0.85 HD21 ' HB2' ' A' ' 303' ' ' SER . 2.5 mm? -96.19 -38.72 10.02 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.101 179.397 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 294' ' ' ALA . . . . . 0.514 ' HA ' HG22 ' A' ' 264' ' ' VAL . . . -159.69 142.11 13.58 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 121.088 -0.245 . . . . 0.0 111.452 -178.382 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . 0.437 HG22 HG22 ' A' ' 300' ' ' VAL . 77.8 t -136.16 112.11 12.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.288 -0.415 . . . . 0.0 109.938 175.436 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 37.4 t -150.03 120.42 7.37 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.337 -179.367 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 58.19 51.11 60.39 Favored Glycine 0 C--N 1.33 0.195 0 C-N-CA 121.086 -0.578 . . . . 0.0 112.386 -179.24 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 298' ' ' THR . . . . . 0.505 ' O ' HG22 ' A' ' 257' ' ' VAL . 73.6 p 48.54 27.85 1.57 Allowed 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 123.536 0.734 . . . . 0.0 112.112 -176.526 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 299' ' ' THR . . . . . 0.57 HG22 ' HB ' ' A' ' 254' ' ' THR . 65.3 m -119.66 115.26 23.58 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 176.706 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . 0.483 ' HA ' ' O ' ' A' ' 294' ' ' ALA . 59.7 t -113.79 130.93 67.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.587 -171.69 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 57.0 m -80.62 116.19 20.52 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 172.266 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 302' ' ' ILE . . . . . 0.6 HD12 ' O ' ' A' ' 302' ' ' ILE . 2.5 pp -111.36 140.79 29.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-O 122.264 1.03 . . . . 0.0 113.715 -171.463 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 303' ' ' SER . . . . . 0.85 ' HB2' HD21 ' A' ' 293' ' ' LEU . 49.4 m -165.02 170.98 5.8 Favored Pre-proline 0 C--N 1.325 -0.493 0 N-CA-C 105.829 -1.915 . . . . 0.0 105.829 -178.913 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 304' ' ' PRO . . . . . 0.643 ' HA ' ' HB3' ' A' ' 303' ' ' SER . 5.1 Cg_exo -74.98 -135.57 0.14 OUTLIER 'Cis proline' 0 C--N 1.351 0.664 0 CA-C-N 121.49 1.568 . . . . 0.0 113.578 0.646 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 305' ' ' LYS . . . . . 0.735 ' HA ' ' CD2' ' A' ' 236' ' ' HIS . 0.0 OUTLIER -90.68 144.41 25.77 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.47 -0.786 . . . . 0.0 112.088 -173.303 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 306' ' ' ILE . . . . . 0.635 ' H ' ' CG ' ' A' ' 236' ' ' HIS . 47.3 mm -116.0 86.93 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 114.824 -1.08 . . . . 0.0 108.611 175.121 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 307' ' ' LEU . . . . . 0.524 HD13 ' CD1' ' A' ' 319' ' ' TYR . 58.7 mt -102.29 101.04 17.28 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.196 -173.599 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 308' ' ' PRO . . . . . 0.703 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 32.3 Cg_exo -65.56 134.07 36.87 Favored 'Trans proline' 0 C--N 1.343 0.253 0 C-N-CA 123.14 2.56 . . . . 0.0 113.76 -173.678 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . 0.561 HG23 ' O ' ' A' ' 322' ' ' VAL . 60.4 t -80.59 -28.56 11.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 169.291 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 -79.38 36.03 0.29 Allowed 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 115.279 -0.873 . . . . 0.0 111.186 176.511 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 22.6 p30 -83.7 -175.34 5.77 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.971 0.415 . . . . 0.0 111.137 -176.678 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 85.6 m -123.38 -28.58 3.93 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.407 177.792 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 57.5 m-20 -74.45 132.93 42.36 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.074 -178.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 43.8 t -62.7 -33.05 57.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.982 179.078 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -70.37 -20.45 62.96 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.749 179.752 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . 0.532 ' HA ' ' CZ ' ' A' ' 319' ' ' TYR . 50.4 m -88.25 -7.02 57.44 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 111.936 0.347 . . . . 0.0 111.936 -176.897 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 317' ' ' ARG . . . . . 0.598 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 38.6 mmt180 -63.67 -51.38 66.36 Favored Pre-proline 0 CA--C 1.539 0.528 0 N-CA-C 112.598 0.592 . . . . 0.0 112.598 -179.005 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 318' ' ' PRO . . . . . 0.598 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 26.8 Cg_exo -68.78 -39.55 8.46 Favored 'Trans proline' 0 C--N 1.356 0.964 0 C-N-CA 121.9 1.733 . . . . 0.0 114.441 -172.055 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 319' ' ' TYR . . . . . 0.532 ' CZ ' ' HA ' ' A' ' 316' ' ' SER . 1.8 p90 -88.47 -6.77 57.43 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 113.004 0.742 . . . . 0.0 113.004 -171.598 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -52.99 135.51 36.72 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 111.634 0.235 . . . . 0.0 111.634 -178.799 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 321' ' ' ASN . . . . . 0.472 ' O ' HG22 ' A' ' 276' ' ' VAL . 14.4 p-10 -132.05 -11.25 3.34 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 116.639 -0.255 . . . . 0.0 111.444 -178.187 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 322' ' ' VAL . . . . . 0.561 ' O ' HG23 ' A' ' 309' ' ' VAL . 33.6 m -131.96 166.52 28.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 N-CA-C 110.488 -0.19 . . . . 0.0 110.488 178.855 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -51.84 -66.35 0.4 Allowed 'General case' 0 N--CA 1.465 0.293 0 CA-C-O 121.252 0.548 . . . . 0.0 111.266 178.372 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 324' ' ' ALA . . . . . 0.703 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -167.24 -179.29 4.46 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.584 -177.09 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 325' ' ' LYS . . . . . 0.434 ' HA ' ' HD3' ' A' ' 326' ' ' PRO . 21.5 pttp -109.65 112.34 58.65 Favored Pre-proline 0 N--CA 1.447 -0.624 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 170.342 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 326' ' ' PRO . . . . . 0.434 ' HD3' ' HA ' ' A' ' 325' ' ' LYS . 25.4 Cg_exo -66.49 168.87 15.32 Favored 'Trans proline' 0 C--O 1.234 0.287 0 C-N-CA 122.704 2.269 . . . . 0.0 112.044 -175.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -58.48 146.29 35.82 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 116.009 -0.541 . . . . 0.0 109.787 176.531 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 328' ' ' GLU . . . . . 0.54 ' HA ' ' NE2' ' A' ' 233' ' ' GLN . 16.0 pt-20 48.01 -145.13 0.34 Allowed 'General case' 0 N--CA 1.474 0.759 0 O-C-N 124.09 0.869 . . . . 0.0 110.995 -173.47 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 329' ' ' SER . . . . . 0.663 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 49.2 m -104.66 -19.38 13.98 Favored 'General case' 0 C--N 1.322 -0.602 0 C-N-CA 120.608 -0.437 . . . . 0.0 110.52 -179.448 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 330' ' ' ALA . . . . . 0.414 ' H ' ' HG3' ' A' ' 328' ' ' GLU . . . 73.79 -167.54 0.11 Allowed 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 113.427 0.899 . . . . 0.0 113.427 171.371 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 331' ' ' ALA . . . . . 0.427 ' HA ' ' O ' ' A' ' 228' ' ' LEU . . . -87.26 144.0 27.01 Favored 'General case' 0 C--O 1.232 0.15 0 CA-C-N 115.153 -0.93 . . . . 0.0 111.611 -175.018 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 332' ' ' ILE . . . . . 0.641 HG12 HG12 ' A' ' 270' ' ' ILE . 50.1 mt -120.7 145.33 27.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.74 -178.861 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.755 HG23 ' HB3' ' A' ' 226' ' ' GLU . 61.3 m -130.98 106.07 8.16 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 110.121 -0.326 . . . . 0.0 110.121 178.396 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 334' ' ' ILE . . . . . 0.76 HD13 ' HB3' ' A' ' 268' ' ' PHE . 49.0 mm -78.85 138.12 20.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.022 -0.536 . . . . 0.0 112.191 -174.109 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 335' ' ' LEU . . . . . 0.441 HD23 ' HA ' ' A' ' 268' ' ' PHE . 1.8 pt? -157.55 135.94 11.18 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.289 -0.869 . . . . 0.0 109.327 173.712 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -85.21 2.69 42.67 Favored 'General case' 0 C--N 1.325 -0.499 0 C-N-CA 120.841 -0.344 . . . . 0.0 111.283 -178.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 337' ' ' LYS . . . . . 0.481 ' C ' ' HD3' ' A' ' 337' ' ' LYS . 9.8 tmtt? . . . . . 0 C--O 1.245 0.862 0 CA-C-O 118.056 -0.973 . . . . 0.0 108.381 177.673 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.791 0 N-CA-C 112.226 -0.35 . . . . 0.0 112.226 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 44.4 m -98.23 168.05 10.48 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.505 0.153 . . . . 0.0 110.983 -178.549 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 47.0 m 66.56 -74.93 0.06 Allowed 'General case' 0 N--CA 1.466 0.348 0 O-C-N 123.912 0.757 . . . . 0.0 111.77 177.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 47.6 mt-10 62.5 61.84 1.19 Allowed 'General case' 0 CA--C 1.531 0.25 0 C-N-CA 122.591 0.356 . . . . 0.0 110.659 179.723 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 49.6 m 72.19 -98.34 0.03 OUTLIER 'General case' 0 C--O 1.231 0.083 0 CA-C-N 115.39 -0.823 . . . . 0.0 111.333 -178.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 228' ' ' LEU . . . . . 0.431 HD13 ' HB1' ' A' ' 259' ' ' ALA . 81.9 mt -102.35 142.8 32.98 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.292 -178.182 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 229' ' ' THR . . . . . 0.42 ' OG1' ' HB2' ' A' ' 258' ' ' SER . 35.4 p -120.63 171.37 8.62 Favored 'General case' 0 C--N 1.325 -0.467 0 C-N-CA 119.866 -0.733 . . . . 0.0 110.589 177.372 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . 0.518 ' HA ' ' H ' ' A' ' 258' ' ' SER . 72.4 t -146.69 130.62 10.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 120.916 0.389 . . . . 0.0 110.376 -179.597 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 231' ' ' SER . . . . . 0.508 ' O ' ' HB ' ' A' ' 255' ' ' ILE . 37.4 m -96.02 164.32 12.75 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.821 177.481 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 101.41 142.02 12.38 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.2 -1.0 . . . . 0.0 111.961 -179.283 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 233' ' ' GLN . . . . . 0.425 ' HA ' ' HD2' ' A' ' 234' ' ' PRO . 64.0 mt-30 -100.02 107.81 48.76 Favored Pre-proline 0 C--N 1.322 -0.606 0 O-C-N 123.073 -0.075 . . . . 0.0 111.03 -176.461 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 234' ' ' PRO . . . . . 0.57 ' HB2' HG13 ' A' ' 306' ' ' ILE . 29.0 Cg_endo -61.56 127.62 22.29 Favored 'Trans proline' 0 C--N 1.348 0.511 0 C-N-CA 122.173 1.916 . . . . 0.0 110.718 176.174 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 235' ' ' GLU . . . . . 0.585 ' OE1' ' HE2' ' A' ' 237' ' ' LYS . 0.3 OUTLIER -116.79 -178.34 3.41 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 113.418 0.896 . . . . 0.0 113.418 -170.995 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 55.4 t60 -167.5 135.61 2.47 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 114.632 -1.167 . . . . 0.0 110.915 -173.803 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 237' ' ' LYS . . . . . 0.585 ' HE2' ' OE1' ' A' ' 235' ' ' GLU . 0.0 OUTLIER -168.14 130.81 1.5 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 114.979 -1.009 . . . . 0.0 111.762 173.072 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 238' ' ' VAL . . . . . . . . . . . . . 46.2 t -97.08 112.11 28.41 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-N 115.117 -0.947 . . . . 0.0 108.981 174.125 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 239' ' ' GLU . . . . . 0.851 ' HG3' ' HB ' ' A' ' 248' ' ' VAL . 10.9 pt-20 -115.31 125.84 53.75 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 121.283 0.563 . . . . 0.0 111.414 -175.901 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 240' ' ' ALA . . . . . 0.593 ' O ' ' HA ' ' A' ' 247' ' ' PRO . . . -66.04 -35.68 81.2 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.461 -0.79 . . . . 0.0 111.289 -176.484 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 241' ' ' LYS . . . . . 0.54 ' O ' ' HD3' ' A' ' 241' ' ' LYS . 0.0 OUTLIER -147.98 146.1 28.81 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.117 0.484 . . . . 0.0 111.925 179.711 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 242' ' ' ASP . . . . . 0.54 ' HB3' HG21 ' A' ' 248' ' ' VAL . 12.5 p-10 -98.3 -158.24 0.66 Allowed 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.194 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 56.2 p -69.95 -14.88 62.92 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.412 -0.358 . . . . 0.0 111.62 178.167 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 49.5 t30 -99.21 -13.49 19.7 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.017 0.437 . . . . 0.0 110.352 178.223 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 89.35 23.39 34.41 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.691 -0.766 . . . . 0.0 113.157 175.298 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 246' ' ' MET . . . . . 0.431 ' O ' ' HA ' ' A' ' 241' ' ' LYS . 26.6 mmt -112.61 154.12 44.79 Favored Pre-proline 0 C--N 1.325 -0.475 0 CA-C-N 116.948 0.374 . . . . 0.0 110.487 178.58 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 247' ' ' PRO . . . . . 0.593 ' HA ' ' O ' ' A' ' 240' ' ' ALA . 31.6 Cg_exo -57.09 140.55 92.99 Favored 'Trans proline' 0 C--N 1.348 0.519 0 C-N-CA 122.7 2.267 . . . . 0.0 112.053 178.132 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.851 ' HB ' ' HG3' ' A' ' 239' ' ' GLU . 41.8 t -125.81 126.43 70.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.856 0.36 . . . . 0.0 111.026 -178.248 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 31.1 t70 -89.14 143.92 26.49 Favored 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 175.1 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 250' ' ' ASN . . . . . . . . . . . . . 74.6 m-80 -41.13 124.13 2.18 Favored 'General case' 0 N--CA 1.469 0.498 0 O-C-N 124.007 0.817 . . . . 0.0 112.215 -177.052 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . 0.648 ' HG3' ' H ' ' A' ' 252' ' ' GLN . 16.6 tpp180 -77.36 -178.6 5.25 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 109.522 -0.548 . . . . 0.0 109.522 -177.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 252' ' ' GLN . . . . . 0.648 ' H ' ' HG3' ' A' ' 251' ' ' ARG . 2.8 mm100 -100.2 157.11 16.82 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 178.347 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -85.41 138.5 16.5 Favored Glycine 0 N--CA 1.447 -0.579 0 C-N-CA 120.327 -0.94 . . . . 0.0 112.338 -179.144 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 66.9 p -121.89 116.51 24.53 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 176.728 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.638 HD13 ' H ' ' A' ' 255' ' ' ILE . 0.2 OUTLIER -129.69 158.95 42.18 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 121.038 0.447 . . . . 0.0 111.399 -176.493 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 18.5 m -96.82 116.64 29.5 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 177.681 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.554 HG21 HD12 ' A' ' 262' ' ' LEU . 32.8 m -88.82 143.3 11.46 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.739 0 C-N-CA 119.709 -0.796 . . . . 0.0 112.349 -170.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 258' ' ' SER . . . . . 0.518 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 25.1 m -92.79 9.44 35.17 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 114.341 -1.3 . . . . 0.0 109.33 172.809 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 259' ' ' ALA . . . . . 0.431 ' HB1' HD13 ' A' ' 228' ' ' LEU . . . -83.05 179.9 7.62 Favored 'General case' 0 N--CA 1.452 -0.338 0 CA-C-N 115.417 -0.811 . . . . 0.0 108.942 179.659 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 22.9 t -140.98 127.34 19.82 Favored 'General case' 0 C--N 1.32 -0.693 0 C-N-CA 120.23 -0.588 . . . . 0.0 111.348 -177.484 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 78.8 50.9 5.72 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.891 -0.671 . . . . 0.0 113.276 176.207 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 262' ' ' LEU . . . . . 0.554 HD12 HG21 ' A' ' 257' ' ' VAL . 64.8 mt -95.1 160.13 14.7 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 117.147 0.474 . . . . 0.0 110.559 178.08 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 66.0 mt-30 -142.9 165.23 27.93 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 -179.311 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 27.1 t -79.58 124.14 37.38 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 C-N-CA 120.409 -0.516 . . . . 0.0 109.701 175.531 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . 0.609 ' H ' ' HB ' ' A' ' 292' ' ' VAL . . . 116.0 14.39 7.88 Favored Glycine 0 N--CA 1.449 -0.456 0 C-N-CA 120.316 -0.945 . . . . 0.0 112.835 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 57.1 m-20 -90.51 165.83 13.56 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.186 0.517 . . . . 0.0 111.044 176.346 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 267' ' ' ALA . . . . . 0.585 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -130.59 143.92 51.07 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 175.094 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 268' ' ' PHE . . . . . 0.504 ' HB3' HD13 ' A' ' 334' ' ' ILE . 7.8 p90 -159.5 168.71 25.53 Favored 'General case' 0 C--N 1.323 -0.582 0 C-N-CA 118.958 -1.097 . . . . 0.0 112.644 -173.547 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 269' ' ' THR . . . . . 0.554 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 43.7 p -116.72 144.08 44.87 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.063 -0.971 . . . . 0.0 109.704 175.683 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 270' ' ' ILE . . . . . 0.994 HG12 HG13 ' A' ' 332' ' ' ILE . 57.2 mt -112.0 127.91 68.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 116.563 -0.29 . . . . 0.0 110.469 -178.73 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -65.15 120.04 11.96 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.077 0.465 . . . . 0.0 111.227 -179.478 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 102.7 -23.93 32.37 Favored Glycine 0 N--CA 1.452 -0.28 0 CA-C-N 115.887 -0.597 . . . . 0.0 112.315 179.278 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 39.0 t -96.34 102.48 13.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 174.574 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 274' ' ' ASN . . . . . 0.739 ' HB2' ' HB2' ' A' ' 323' ' ' ASP . 4.2 m120 -91.99 169.63 10.5 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.275 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 8.3 t -109.74 162.48 14.42 Favored 'General case' 0 CA--C 1.507 -0.704 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 178.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 276' ' ' VAL . . . . . 0.405 HG22 ' C ' ' A' ' 321' ' ' ASN . 13.0 m -122.52 178.84 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.067 0 CA-C-N 115.24 -0.891 . . . . 0.0 109.372 166.402 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 22.3 m80 -100.5 133.21 45.27 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 178.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 2.3 mp0 -72.29 -10.22 59.5 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.79 0.329 . . . . 0.0 111.401 -178.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 279' ' ' ILE . . . . . 0.493 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.0 mp -102.43 -57.48 4.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 120.729 0.3 . . . . 0.0 110.946 -178.312 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 60.9 p -101.13 -6.21 24.63 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 112.663 0.616 . . . . 0.0 112.663 -174.226 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 13.9 mmmm 57.54 29.35 16.98 Favored 'General case' 0 N--CA 1.47 0.574 0 N-CA-C 111.591 0.219 . . . . 0.0 111.591 -178.499 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -77.78 139.61 39.36 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.466 -0.334 . . . . 0.0 110.265 -176.489 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 70.3 p -108.2 118.8 37.71 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.862 -0.608 . . . . 0.0 109.806 179.486 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 72.0 p -115.2 -14.36 11.73 Favored 'General case' 0 C--N 1.315 -0.894 0 C-N-CA 120.67 -0.412 . . . . 0.0 111.798 -172.408 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 88.17 5.13 76.94 Favored Glycine 0 N--CA 1.449 -0.435 0 C-N-CA 120.521 -0.847 . . . . 0.0 112.388 179.709 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 286' ' ' GLN . . . . . 0.461 ' HA ' ' HD3' ' A' ' 287' ' ' PRO . 71.0 mt-30 -92.18 138.53 24.37 Favored Pre-proline 0 C--N 1.327 -0.382 0 N-CA-C 110.23 -0.285 . . . . 0.0 110.23 178.677 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 287' ' ' PRO . . . . . 0.635 ' HA ' ' HA ' ' A' ' 274' ' ' ASN . 21.7 Cg_exo -65.58 152.7 81.01 Favored 'Trans proline' 0 C--O 1.233 0.236 0 C-N-CA 122.615 2.21 . . . . 0.0 112.445 -179.031 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 3.9 tp-100 -81.54 150.72 28.08 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.542 177.626 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 62.1 t -94.86 125.04 47.58 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.401 0 CA-C-N 116.096 -0.502 . . . . 0.0 109.657 176.441 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 290' ' ' PHE . . . . . 0.759 ' HD1' ' HD2' ' A' ' 304' ' ' PRO . 69.9 m-85 -106.58 168.42 9.18 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.085 -174.072 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 27.1 tpt180 -132.8 120.89 22.18 Favored 'General case' 0 N--CA 1.448 -0.539 0 CA-C-O 121.222 0.534 . . . . 0.0 109.573 179.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . 0.609 ' HB ' ' H ' ' A' ' 265' ' ' GLY . 57.7 t -65.99 132.42 31.56 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.919 -177.037 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 293' ' ' LEU . . . . . 0.77 HD11 ' HB2' ' A' ' 303' ' ' SER . 88.5 mt -101.42 -44.55 5.59 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.475 178.332 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 294' ' ' ALA . . . . . 0.452 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -150.05 139.11 21.1 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.592 0.234 . . . . 0.0 111.334 -175.123 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 62.0 t -134.11 117.75 26.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.126 176.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 60.6 m -157.01 120.14 4.09 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.471 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 62.32 40.37 98.94 Favored Glycine 0 C--N 1.331 0.305 0 C-N-CA 120.924 -0.655 . . . . 0.0 112.003 -177.539 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 82.1 p 53.35 20.78 2.07 Favored 'General case' 0 N--CA 1.469 0.519 0 C-N-CA 123.939 0.896 . . . . 0.0 112.27 -174.721 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 60.3 m -103.18 107.7 18.62 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 174.493 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . 0.452 ' HA ' ' O ' ' A' ' 294' ' ' ALA . 47.2 t -104.09 128.03 57.81 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.36 -173.247 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 42.0 m -90.48 117.36 29.12 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 172.559 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 302' ' ' ILE . . . . . . . . . . . . . 29.1 pt -110.74 140.74 28.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 N-CA-C 112.83 0.678 . . . . 0.0 112.83 -169.269 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 303' ' ' SER . . . . . 0.77 ' HB2' HD11 ' A' ' 293' ' ' LEU . 48.2 t -130.35 151.39 78.45 Favored Pre-proline 0 C--N 1.323 -0.55 0 CA-C-N 114.104 -1.407 . . . . 0.0 107.207 172.715 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 304' ' ' PRO . . . . . 0.759 ' HD2' ' HD1' ' A' ' 290' ' ' PHE . 34.3 Cg_exo -63.04 179.14 8.44 Favored 'Cis proline' 0 N--CA 1.473 0.308 0 CA-C-N 120.163 1.094 . . . . 0.0 113.09 0.781 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 305' ' ' LYS . . . . . 0.671 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -87.86 148.74 24.5 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.24 177.643 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 306' ' ' ILE . . . . . 0.57 HG13 ' HB2' ' A' ' 234' ' ' PRO . 43.7 mm -65.75 98.66 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.663 -175.075 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 307' ' ' LEU . . . . . 0.721 HD12 HD22 ' A' ' 321' ' ' ASN . 72.6 mt -119.25 95.57 49.39 Favored Pre-proline 0 C--N 1.325 -0.498 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 -179.506 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 308' ' ' PRO . . . . . 0.723 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 6.2 Cg_exo -77.67 169.6 20.58 Favored 'Trans proline' 0 N--CA 1.463 -0.32 0 C-N-CA 123.121 2.547 . . . . 0.0 112.635 -176.8 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . 0.534 HG22 ' HB1' ' A' ' 320' ' ' ALA . 39.2 t -93.56 -30.72 4.41 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-O 121.251 0.548 . . . . 0.0 109.683 177.343 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 42.5 mp0 -86.64 35.68 0.68 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.133 -0.94 . . . . 0.0 112.254 -173.833 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 79.1 m-20 -74.33 158.81 33.33 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.301 0.572 . . . . 0.0 111.845 -178.644 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 28.9 m -90.44 -36.63 14.46 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.129 -0.941 . . . . 0.0 110.22 179.266 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 313' ' ' ASP . . . . . 0.455 ' HB2' ' HB3' ' A' ' 316' ' ' SER . 1.6 m-20 -67.98 133.31 48.86 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.32 179.406 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 39.3 t -60.45 -52.23 63.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.172 -177.768 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -68.46 -17.82 64.28 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.07 -0.514 . . . . 0.0 111.852 -178.234 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . 0.455 ' HB3' ' HB2' ' A' ' 313' ' ' ASP . 39.1 t -84.07 -11.02 57.36 Favored 'General case' 0 C--N 1.323 -0.546 0 C-N-CA 120.973 -0.291 . . . . 0.0 111.357 -178.376 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 317' ' ' ARG . . . . . 0.534 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 81.0 mtm180 -73.65 -49.2 6.46 Favored Pre-proline 0 CA--C 1.536 0.432 0 N-CA-C 112.506 0.558 . . . . 0.0 112.506 -179.082 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 318' ' ' PRO . . . . . 0.534 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 42.3 Cg_exo -61.07 -25.87 81.99 Favored 'Trans proline' 0 C--N 1.361 1.197 0 C-N-CA 122.17 1.914 . . . . 0.0 113.218 -176.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 46.6 m-85 -91.41 27.67 1.9 Allowed 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.473 -0.331 . . . . 0.0 111.313 -177.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . 0.534 ' HB1' HG22 ' A' ' 309' ' ' VAL . . . -77.72 127.55 32.61 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.073 179.297 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 321' ' ' ASN . . . . . 0.721 HD22 HD12 ' A' ' 307' ' ' LEU . 75.5 m-80 -130.47 -9.24 4.13 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 111.859 0.318 . . . . 0.0 111.859 179.216 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 322' ' ' VAL . . . . . 0.508 ' O ' ' HA ' ' A' ' 308' ' ' PRO . 33.1 m -138.5 156.93 30.18 Favored 'Isoleucine or valine' 0 C--O 1.233 0.215 0 CA-C-O 120.944 0.402 . . . . 0.0 111.094 177.691 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 323' ' ' ASP . . . . . 0.739 ' HB2' ' HB2' ' A' ' 274' ' ' ASN . 2.1 m-20 -86.66 86.84 7.35 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.417 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 324' ' ' ALA . . . . . 0.723 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . 77.06 151.0 0.12 Allowed 'General case' 0 N--CA 1.473 0.685 0 CA-C-N 114.66 -1.154 . . . . 0.0 113.791 171.502 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 325' ' ' LYS . . . . . 0.436 ' HA ' ' HD3' ' A' ' 326' ' ' PRO . 55.5 pttt -98.71 105.95 33.88 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 114.435 -1.257 . . . . 0.0 109.287 168.525 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 326' ' ' PRO . . . . . 0.436 ' HD3' ' HA ' ' A' ' 325' ' ' LYS . 5.8 Cg_exo -85.99 169.27 8.99 Favored 'Trans proline' 0 C--O 1.235 0.367 0 C-N-CA 123.483 2.788 . . . . 0.0 113.195 -171.837 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -59.52 127.51 32.41 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.626 177.633 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 24.5 pt-20 44.65 -158.07 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.66 0 O-C-N 124.402 1.064 . . . . 0.0 112.034 -176.363 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 329' ' ' SER . . . . . 0.424 ' O ' ' HB3' ' A' ' 330' ' ' ALA . 54.6 m -102.9 -31.16 10.39 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 112.204 0.446 . . . . 0.0 112.204 -173.643 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 330' ' ' ALA . . . . . 0.424 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 71.95 -152.25 0.08 Allowed 'General case' 0 N--CA 1.471 0.59 0 CA-C-O 121.037 0.446 . . . . 0.0 111.534 178.359 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -85.47 116.34 23.73 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.248 -178.85 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 332' ' ' ILE . . . . . 0.994 HG13 HG12 ' A' ' 270' ' ' ILE . 1.7 mp -101.84 140.85 19.38 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 115.826 -0.624 . . . . 0.0 109.537 176.293 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 73.4 m -110.11 103.32 12.03 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 110.206 -0.294 . . . . 0.0 110.206 -176.624 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 334' ' ' ILE . . . . . 0.504 HD13 ' HB3' ' A' ' 268' ' ' PHE . 34.6 mm -85.89 125.87 40.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 N-CA-C 112.588 0.588 . . . . 0.0 112.588 -174.155 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 335' ' ' LEU . . . . . 0.485 ' N ' HD13 ' A' ' 335' ' ' LEU . 0.0 OUTLIER -139.41 172.43 12.82 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.3 -0.864 . . . . 0.0 109.804 171.259 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 50.9 t30 -136.87 59.11 1.7 Allowed 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 178.552 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 337' ' ' LYS . . . . . 0.431 ' H ' HD23 ' A' ' 335' ' ' LEU . 62.3 tttp . . . . . 0 C--O 1.244 0.768 0 CA-C-O 118.173 -0.918 . . . . 0.0 110.457 -176.106 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.727 0 N-CA-C 112.162 -0.375 . . . . 0.0 112.162 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 61.9 p -91.29 106.55 18.59 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.78 0.324 . . . . 0.0 110.772 179.351 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 71.7 p -110.9 161.4 15.87 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 120.976 0.417 . . . . 0.0 110.701 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 10.3 pm0 -102.98 32.27 3.8 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.9 -176.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 68.3 m 54.49 71.5 0.52 Allowed 'General case' 0 C--O 1.235 0.299 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.854 -178.239 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 228' ' ' LEU . . . . . 0.738 ' O ' ' HA ' ' A' ' 331' ' ' ALA . 5.3 mp -67.91 119.32 12.39 Favored 'General case' 0 N--CA 1.433 -1.316 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.821 179.463 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 229' ' ' THR . . . . . 0.456 ' OG1' ' HB3' ' A' ' 258' ' ' SER . 22.3 p -128.08 178.68 6.04 Favored 'General case' 0 C--N 1.324 -0.533 0 C-N-CA 120.513 -0.475 . . . . 0.0 111.07 178.644 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . 0.965 HG23 HD11 ' A' ' 332' ' ' ILE . 98.3 t -144.82 130.72 14.64 Favored 'Isoleucine or valine' 0 C--O 1.235 0.303 0 CA-C-O 120.578 0.228 . . . . 0.0 111.078 -177.218 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 38.9 t -101.1 112.28 24.71 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 115.538 -0.755 . . . . 0.0 109.484 172.438 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . 0.854 ' H ' ' HG3' ' A' ' 328' ' ' GLU . . . 141.69 125.51 2.08 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.788 -0.72 . . . . 0.0 111.71 -176.319 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 233' ' ' GLN . . . . . 0.824 ' HG2' ' H ' ' A' ' 328' ' ' GLU . 21.8 mt-30 -83.5 123.33 76.75 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-N 116.49 0.145 . . . . 0.0 111.063 -177.12 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -92.71 126.26 0.71 Allowed 'Trans proline' 0 N--CA 1.451 -0.986 0 C-N-CA 122.643 2.228 . . . . 0.0 111.978 177.517 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 235' ' ' GLU . . . . . 0.418 ' HG2' ' HE3' ' A' ' 237' ' ' LYS . 0.7 OUTLIER -157.0 158.36 36.4 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.865 0.364 . . . . 0.0 110.748 177.569 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 236' ' ' HIS . . . . . 0.638 ' HA ' HD21 ' A' ' 250' ' ' ASN . 25.5 m80 -136.07 146.19 46.78 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.322 0.582 . . . . 0.0 111.85 177.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 237' ' ' LYS . . . . . 0.636 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -132.15 129.1 39.38 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 107.664 -1.235 . . . . 0.0 107.664 178.149 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 238' ' ' VAL . . . . . . . . . . . . . 44.5 t -103.78 110.93 31.57 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 C-N-CA 119.908 -0.717 . . . . 0.0 110.819 -179.578 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 239' ' ' GLU . . . . . 0.817 ' HB2' ' HB ' ' A' ' 248' ' ' VAL . 0.6 OUTLIER -65.59 129.54 40.13 Favored 'General case' 0 N--CA 1.448 -0.565 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 174.272 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 240' ' ' ALA . . . . . . . . . . . . . . . -58.68 -38.6 78.56 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-O 120.77 0.319 . . . . 0.0 110.732 -178.563 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 241' ' ' LYS . . . . . 0.883 ' HB2' ' HA2' ' A' ' 245' ' ' GLY . 0.4 OUTLIER -154.96 149.66 26.53 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.665 177.481 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 242' ' ' ASP . . . . . 0.681 ' HB3' HG21 ' A' ' 248' ' ' VAL . 53.7 p-10 -106.12 -156.29 0.57 Allowed 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.816 -0.629 . . . . 0.0 109.619 175.466 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 41.2 t -60.6 -27.96 68.14 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.885 177.75 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 5.7 m120 -93.97 -13.74 26.7 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.57 -0.286 . . . . 0.0 111.576 178.592 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . 0.883 ' HA2' ' HB2' ' A' ' 241' ' ' LYS . . . 87.48 28.23 25.18 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.663 -0.779 . . . . 0.0 113.342 179.089 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 246' ' ' MET . . . . . . . . . . . . . 21.5 ptp -113.68 156.29 43.79 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 117.035 0.418 . . . . 0.0 110.861 178.028 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 247' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_exo -63.13 121.78 9.76 Favored 'Trans proline' 0 C--N 1.349 0.601 0 C-N-CA 122.834 2.356 . . . . 0.0 112.144 -179.827 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.817 ' HB ' ' HB2' ' A' ' 239' ' ' GLU . 41.0 t -101.76 126.5 55.69 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.474 -176.68 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 249' ' ' ASP . . . . . 0.444 ' OD2' ' HD2' ' A' ' 236' ' ' HIS . 60.1 t0 -106.28 140.04 39.85 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 170.417 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 250' ' ' ASN . . . . . 0.638 HD21 ' HA ' ' A' ' 236' ' ' HIS . 21.7 p30 -78.7 48.38 0.8 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.928 0.394 . . . . 0.0 111.646 -177.007 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . 0.494 ' HG3' ' H ' ' A' ' 252' ' ' GLN . 18.2 tpt85 61.39 -135.04 0.6 Allowed 'General case' 0 N--CA 1.452 -0.373 0 CA-C-N 115.569 -0.741 . . . . 0.0 109.258 176.246 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 252' ' ' GLN . . . . . 0.494 ' H ' ' HG3' ' A' ' 251' ' ' ARG . 2.7 mm100 -112.21 169.99 8.48 Favored 'General case' 0 C--N 1.325 -0.491 0 O-C-N 121.91 -0.493 . . . . 0.0 110.219 177.231 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . 0.464 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -87.65 121.07 5.74 Favored Glycine 0 N--CA 1.447 -0.616 0 C-N-CA 120.4 -0.905 . . . . 0.0 111.88 179.269 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 52.3 p -105.1 117.35 33.79 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 178.33 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 2.1 pp -131.46 165.13 32.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -175.121 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 32.6 m -102.53 113.95 27.74 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 179.2 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.622 HG12 HG22 ' A' ' 230' ' ' VAL . 30.6 m -90.61 143.89 10.27 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.718 0 CA-C-O 121.48 0.657 . . . . 0.0 112.589 -174.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 258' ' ' SER . . . . . 0.456 ' HB3' ' OG1' ' A' ' 229' ' ' THR . 25.8 t -92.06 7.31 42.91 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 113.911 -1.495 . . . . 0.0 108.146 167.514 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 259' ' ' ALA . . . . . 0.443 ' H ' ' HB ' ' A' ' 257' ' ' VAL . . . -86.48 172.57 10.24 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 115.128 -0.942 . . . . 0.0 109.713 -178.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 50.2 m -145.65 148.63 33.28 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.833 0.349 . . . . 0.0 111.043 -179.328 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 81.14 15.9 75.81 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.992 -0.623 . . . . 0.0 113.184 178.236 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 262' ' ' LEU . . . . . 0.406 HD12 HG21 ' A' ' 257' ' ' VAL . 70.7 mt -76.31 145.73 39.36 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.971 0.385 . . . . 0.0 110.351 179.234 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 85.0 mt-30 -140.8 164.75 29.39 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.092 -0.504 . . . . 0.0 109.911 -179.126 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 45.7 t -76.24 122.87 31.34 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.257 177.489 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 113.43 -3.07 25.02 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.44 -0.886 . . . . 0.0 112.795 179.085 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 266' ' ' ASP . . . . . 0.479 ' HA ' ' OD1' ' A' ' 336' ' ' ASN . 58.6 m-20 -81.58 151.76 27.53 Favored 'General case' 0 CA--C 1.513 -0.475 0 CA-C-O 120.82 0.343 . . . . 0.0 110.296 177.074 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 267' ' ' ALA . . . . . 0.606 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -114.47 149.35 36.46 Favored 'General case' 0 N--CA 1.443 -0.806 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 173.792 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 268' ' ' PHE . . . . . 0.687 ' HB3' HD13 ' A' ' 334' ' ' ILE . 4.1 p90 -163.95 172.36 14.03 Favored 'General case' 0 C--N 1.318 -0.782 0 C-N-CA 119.632 -0.827 . . . . 0.0 111.699 -177.13 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 74.9 p -118.12 127.36 53.7 Favored 'General case' 0 N--CA 1.443 -0.801 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.337 177.688 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 270' ' ' ILE . . . . . 0.533 HG23 ' O ' ' A' ' 329' ' ' SER . 25.8 mm -95.23 129.92 44.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 CA-C-N 115.3 -0.863 . . . . 0.0 110.454 -178.27 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 271' ' ' ALA . . . . . 0.596 ' HB3' ' HB3' ' A' ' 330' ' ' ALA . . . -66.47 129.57 40.3 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 121.007 0.432 . . . . 0.0 111.133 -178.518 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 92.98 -22.87 31.94 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 121.032 -0.604 . . . . 0.0 112.065 -178.036 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . 0.498 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 45.8 t -101.14 117.79 46.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 121.195 0.521 . . . . 0.0 110.294 176.491 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -130.67 142.19 50.43 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.701 -178.556 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 4.8 t -81.87 172.45 13.3 Favored 'General case' 0 CA--C 1.512 -0.518 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 -177.047 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 29.9 m -130.5 178.43 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.835 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.713 173.29 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 86.2 m-70 -109.68 86.39 2.29 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 173.715 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 278' ' ' GLN . . . . . 0.424 ' HB3' ' O ' ' A' ' 320' ' ' ALA . 23.7 pt20 -72.35 -14.85 61.83 Favored 'General case' 0 N--CA 1.464 0.261 0 N-CA-C 111.964 0.357 . . . . 0.0 111.964 -173.45 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 279' ' ' ILE . . . . . 0.538 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.4 mp -73.15 -52.11 23.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 121.126 0.489 . . . . 0.0 110.038 -179.538 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 42.9 p -97.95 -3.14 38.98 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.505 -178.799 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 64.85 54.57 1.31 Allowed 'General case' 0 N--CA 1.466 0.35 0 CA-C-O 121.547 0.689 . . . . 0.0 110.012 178.466 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 58.9 m-20 -115.43 130.78 57.0 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 121.033 0.444 . . . . 0.0 110.817 177.824 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 65.7 p -106.32 117.8 34.97 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.246 176.906 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 70.4 p -123.44 -23.19 4.87 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.809 -171.602 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 75.19 31.73 56.97 Favored Glycine 0 N--CA 1.453 -0.186 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.817 177.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 3.0 mm100 -89.77 131.27 40.11 Favored Pre-proline 0 C--N 1.327 -0.375 0 N-CA-C 110.359 -0.237 . . . . 0.0 110.359 179.7 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 287' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_exo -50.21 128.22 22.05 Favored 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 122.78 2.32 . . . . 0.0 112.546 -178.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 50.1 tt0 -74.56 148.03 41.22 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.668 -176.381 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 52.7 t -94.48 117.97 39.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.459 -0.791 . . . . 0.0 109.639 175.384 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 290' ' ' PHE . . . . . 0.744 ' HA ' ' HD3' ' A' ' 304' ' ' PRO . 5.0 m-85 -99.06 170.13 8.92 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.014 0.435 . . . . 0.0 111.604 -175.799 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 21.1 tpp180 -140.03 123.74 17.33 Favored 'General case' 0 N--CA 1.446 -0.668 0 CA-C-N 115.533 -0.758 . . . . 0.0 109.358 177.011 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 44.0 t -81.42 136.62 22.74 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.591 -176.211 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 293' ' ' LEU . . . . . 0.465 HD22 ' N ' ' A' ' 293' ' ' LEU . 2.2 mm? -108.0 -30.51 8.41 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.164 178.299 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 294' ' ' ALA . . . . . . . . . . . . . . . -156.12 136.92 13.43 Favored 'General case' 0 C--N 1.331 -0.201 0 C-N-CA 121.06 -0.256 . . . . 0.0 111.603 -177.508 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 60.6 t -132.49 117.86 33.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.034 -0.53 . . . . 0.0 109.641 175.063 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 34.9 t -157.52 119.52 3.75 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.519 -177.404 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 58.85 44.24 96.11 Favored Glycine 0 C--N 1.333 0.383 0 C-N-CA 121.163 -0.541 . . . . 0.0 112.318 -179.029 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 51.4 p 50.51 24.06 1.49 Allowed 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 123.703 0.801 . . . . 0.0 112.583 -175.343 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 41.0 m -111.12 112.78 24.82 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 108.388 -0.968 . . . . 0.0 108.388 173.61 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 39.0 t -111.91 132.29 60.93 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.731 -169.216 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 88.0 m -91.92 109.35 20.69 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 172.554 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 302' ' ' ILE . . . . . 0.464 HG12 ' O ' ' A' ' 253' ' ' GLY . 29.1 pt -111.33 150.87 13.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 N-CA-C 113.099 0.777 . . . . 0.0 113.099 -170.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 303' ' ' SER . . . . . 0.543 ' HB2' ' HA ' ' A' ' 304' ' ' PRO . 85.8 p -135.06 166.39 29.51 Favored Pre-proline 0 C--N 1.322 -0.597 0 N-CA-C 106.52 -1.659 . . . . 0.0 106.52 170.063 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 304' ' ' PRO . . . . . 0.744 ' HD3' ' HA ' ' A' ' 290' ' ' PHE . 14.7 Cg_exo -70.45 -167.58 4.14 Favored 'Cis proline' 0 CA--C 1.53 0.28 0 CA-C-N 120.75 1.303 . . . . 0.0 113.282 0.57 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 305' ' ' LYS . . . . . 0.607 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -81.31 162.84 23.3 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.736 179.803 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 306' ' ' ILE . . . . . 0.445 HG23 HG21 ' A' ' 322' ' ' VAL . 43.5 mm -111.55 84.3 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-O 120.831 0.348 . . . . 0.0 110.525 -177.373 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 307' ' ' LEU . . . . . . . . . . . . . 85.0 mt -108.35 103.49 50.91 Favored Pre-proline 0 C--N 1.327 -0.371 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 179.434 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 308' ' ' PRO . . . . . 0.807 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 13.5 Cg_exo -76.94 156.09 34.36 Favored 'Trans proline' 0 N--CA 1.465 -0.184 0 C-N-CA 122.611 2.207 . . . . 0.0 113.848 -171.472 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 46.7 t -78.89 -16.22 13.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 N-CA-C 108.18 -1.044 . . . . 0.0 108.18 168.069 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 67.0 mm-40 -83.61 7.05 18.54 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 114.805 -1.088 . . . . 0.0 110.885 175.033 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -68.74 128.24 35.94 Favored 'General case' 0 C--O 1.233 0.232 0 CA-C-O 120.764 0.316 . . . . 0.0 110.167 -176.59 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 61.7 m -75.89 -34.3 59.97 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.562 -175.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 313' ' ' ASP . . . . . 0.598 ' O ' ' HG3' ' A' ' 317' ' ' ARG . 28.0 t70 -68.85 114.32 7.06 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.976 0.417 . . . . 0.0 110.491 177.584 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 314' ' ' VAL . . . . . 0.667 ' HA ' ' HD3' ' A' ' 317' ' ' ARG . 41.5 t -63.86 -20.23 26.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.634 -0.712 . . . . 0.0 111.652 -175.836 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -75.09 -34.13 61.71 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.545 0.212 . . . . 0.0 111.468 178.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . 0.419 ' HA ' ' CE1' ' A' ' 319' ' ' TYR . 34.2 t -89.4 -6.78 56.27 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.619 0.247 . . . . 0.0 111.359 -177.158 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 317' ' ' ARG . . . . . 0.667 ' HD3' ' HA ' ' A' ' 314' ' ' VAL . 56.8 mtp85 -69.68 -47.03 25.35 Favored Pre-proline 0 CA--C 1.541 0.609 0 N-CA-C 113.302 0.852 . . . . 0.0 113.302 -179.495 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 318' ' ' PRO . . . . . 0.454 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 87.2 Cg_exo -52.2 -38.49 71.67 Favored 'Trans proline' 0 C--N 1.361 1.224 0 C-N-CA 122.444 2.096 . . . . 0.0 113.796 -174.536 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 319' ' ' TYR . . . . . 0.419 ' CE1' ' HA ' ' A' ' 316' ' ' SER . 1.5 p90 -109.17 39.13 2.12 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 112.077 0.399 . . . . 0.0 112.077 -178.35 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . 0.424 ' O ' ' HB3' ' A' ' 278' ' ' GLN . . . -71.99 135.66 46.48 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.896 174.219 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 16.0 p-10 -119.01 -2.41 10.8 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 120.82 -0.352 . . . . 0.0 111.485 -176.703 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 322' ' ' VAL . . . . . 0.445 HG21 HG23 ' A' ' 306' ' ' ILE . 30.8 m -135.11 163.17 36.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 N-CA-C 110.34 -0.244 . . . . 0.0 110.34 175.112 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 56.7 m-20 -72.37 -38.18 68.6 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 111.657 0.243 . . . . 0.0 111.657 -178.677 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 324' ' ' ALA . . . . . 0.807 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -159.84 162.29 34.67 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.694 -171.867 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 325' ' ' LYS . . . . . 0.465 ' HA ' ' HD3' ' A' ' 326' ' ' PRO . 54.2 pttt -105.21 106.41 55.64 Favored Pre-proline 0 C--N 1.324 -0.501 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.279 169.424 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 326' ' ' PRO . . . . . 0.465 ' HD3' ' HA ' ' A' ' 325' ' ' LYS . 5.9 Cg_exo -86.49 166.83 9.03 Favored 'Trans proline' 0 C--O 1.233 0.256 0 C-N-CA 122.946 2.431 . . . . 0.0 113.566 -170.4 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 327' ' ' ALA . . . . . 0.513 ' HA ' ' HG2' ' A' ' 233' ' ' GLN . . . -81.69 122.02 27.11 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.235 -0.893 . . . . 0.0 109.444 172.032 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 328' ' ' GLU . . . . . 0.854 ' HG3' ' H ' ' A' ' 232' ' ' GLY . 53.6 mp0 60.48 175.42 0.1 Allowed 'General case' 0 N--CA 1.465 0.323 0 O-C-N 123.608 0.568 . . . . 0.0 111.084 -173.666 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 329' ' ' SER . . . . . 0.738 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 37.7 m -106.47 -15.46 14.8 Favored 'General case' 0 C--N 1.324 -0.532 0 C-N-CA 120.33 -0.548 . . . . 0.0 111.085 -177.347 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 330' ' ' ALA . . . . . 0.596 ' HB3' ' HB3' ' A' ' 271' ' ' ALA . . . 62.95 -152.8 0.34 Allowed 'General case' 0 N--CA 1.465 0.312 0 CA-C-O 120.852 0.358 . . . . 0.0 111.857 175.094 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 331' ' ' ALA . . . . . 0.738 ' HA ' ' O ' ' A' ' 228' ' ' LEU . . . -68.5 139.78 55.67 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.56 -0.745 . . . . 0.0 112.203 -175.153 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 332' ' ' ILE . . . . . 0.965 HD11 HG23 ' A' ' 230' ' ' VAL . 2.2 mp -111.7 144.59 19.23 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.279 179.379 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 84.8 m -121.07 105.71 10.88 Favored 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 175.522 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 334' ' ' ILE . . . . . 0.687 HD13 ' HB3' ' A' ' 268' ' ' PHE . 39.8 mm -79.95 127.73 39.07 Favored 'Isoleucine or valine' 0 C--O 1.235 0.3 0 N-CA-C 112.432 0.53 . . . . 0.0 112.432 -175.831 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 335' ' ' LEU . . . . . 0.562 HD23 ' HA ' ' A' ' 268' ' ' PHE . 1.8 pt? -148.91 132.46 16.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.58 174.036 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 336' ' ' ASN . . . . . 0.479 ' OD1' ' HA ' ' A' ' 266' ' ' ASP . 72.3 m-80 -109.0 77.38 1.06 Allowed 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.386 176.454 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 22.0 pttp . . . . . 0 C--O 1.243 0.743 0 O-C-N 124.589 1.18 . . . . 0.0 112.179 -179.078 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.784 0 N-CA-C 112.221 -0.351 . . . . 0.0 112.221 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 41.5 m -72.23 127.42 32.5 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.67 0.271 . . . . 0.0 110.451 179.789 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . 0.436 ' O ' ' HA ' ' A' ' 333' ' ' THR . 48.3 p -110.98 -118.58 0.29 Allowed 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.617 -179.653 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 226' ' ' GLU . . . . . 0.517 ' HA ' ' O ' ' A' ' 332' ' ' ILE . 42.1 mt-10 -122.35 31.61 6.08 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.182 0.515 . . . . 0.0 110.004 178.399 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 39.6 t -75.62 -30.92 59.68 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.565 -177.659 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 228' ' ' LEU . . . . . 0.602 ' HB3' ' CB ' ' A' ' 259' ' ' ALA . 80.9 mt -82.26 138.95 34.48 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.884 178.61 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 229' ' ' THR . . . . . 0.412 HG22 ' HA ' ' A' ' 331' ' ' ALA . 70.8 p -126.63 178.25 6.02 Favored 'General case' 0 C--N 1.325 -0.478 0 C-N-CA 120.104 -0.638 . . . . 0.0 110.752 -179.043 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . 0.56 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 84.1 t -143.42 150.21 17.64 Favored 'Isoleucine or valine' 0 C--O 1.239 0.544 0 N-CA-C 110.356 -0.239 . . . . 0.0 110.356 -178.574 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 33.1 t -126.08 129.1 48.44 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.298 178.597 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 110.2 109.95 3.23 Favored Glycine 0 C--O 1.228 -0.277 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.852 178.258 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 233' ' ' GLN . . . . . 0.58 ' HG3' ' O ' ' A' ' 326' ' ' PRO . 14.3 mm-40 -111.43 101.41 50.66 Favored Pre-proline 0 C--N 1.324 -0.505 0 O-C-N 122.807 -0.231 . . . . 0.0 111.135 178.989 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 234' ' ' PRO . . . . . 0.478 ' O ' ' HE2' ' A' ' 325' ' ' LYS . 7.0 Cg_exo -70.25 126.13 12.64 Favored 'Trans proline' 0 N--CA 1.459 -0.513 0 C-N-CA 122.247 1.964 . . . . 0.0 110.855 176.202 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 235' ' ' GLU . . . . . 0.408 ' HA ' ' CD ' ' A' ' 325' ' ' LYS . 13.0 pt-20 -97.41 124.42 41.59 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 121.634 0.731 . . . . 0.0 111.502 -177.639 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 236' ' ' HIS . . . . . 0.701 ' HB3' HD22 ' A' ' 250' ' ' ASN . 26.1 m80 -122.2 147.51 46.09 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.49 179.745 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 237' ' ' LYS . . . . . 0.455 ' H ' ' HD2' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -145.63 158.5 43.84 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 115.137 -0.938 . . . . 0.0 109.214 -178.912 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 238' ' ' VAL . . . . . 0.44 HG22 ' OD1' ' A' ' 250' ' ' ASN . 30.0 t -100.73 111.67 31.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 C-N-CA 120.306 -0.558 . . . . 0.0 111.097 -174.686 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 239' ' ' GLU . . . . . 0.868 ' HG2' HG21 ' A' ' 248' ' ' VAL . 8.3 pm0 -105.42 167.71 9.57 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.969 -0.56 . . . . 0.0 109.989 174.335 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 240' ' ' ALA . . . . . . . . . . . . . . . -73.52 -60.49 2.22 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.872 0.368 . . . . 0.0 111.02 -178.229 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 241' ' ' LYS . . . . . 0.693 ' HB2' ' HA2' ' A' ' 245' ' ' GLY . 0.0 OUTLIER -121.98 147.37 46.14 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.435 179.842 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -100.78 -160.0 0.77 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.128 -0.487 . . . . 0.0 109.801 -179.122 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 37.8 t -59.54 -30.15 68.41 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.267 178.546 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 5.8 m120 -98.72 1.49 46.16 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 111.836 0.31 . . . . 0.0 111.836 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . 0.693 ' HA2' ' HB2' ' A' ' 241' ' ' LYS . . . 69.0 38.99 85.27 Favored Glycine 0 N--CA 1.455 -0.092 0 C-N-CA 120.621 -0.799 . . . . 0.0 113.006 177.054 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 246' ' ' MET . . . . . . . . . . . . . 24.9 mmt -112.19 157.58 39.46 Favored Pre-proline 0 C--N 1.323 -0.565 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 178.021 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 247' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_exo -59.09 119.69 7.09 Favored 'Trans proline' 0 C--N 1.348 0.535 0 C-N-CA 121.803 1.669 . . . . 0.0 110.516 177.065 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.868 HG21 ' HG2' ' A' ' 239' ' ' GLU . 59.7 t -79.66 113.41 18.99 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 N-CA-C 112.562 0.579 . . . . 0.0 112.562 -170.805 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -108.8 115.87 30.91 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 114.64 -1.164 . . . . 0.0 108.08 169.357 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 250' ' ' ASN . . . . . 0.701 HD22 ' HB3' ' A' ' 236' ' ' HIS . 6.7 m120 -57.38 138.28 55.13 Favored 'General case' 0 C--N 1.321 -0.665 0 N-CA-C 112.547 0.573 . . . . 0.0 112.547 -170.115 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -80.19 -177.04 5.89 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.188 -0.914 . . . . 0.0 111.123 173.44 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 252' ' ' GLN . . . . . 0.481 ' HA ' HE21 ' A' ' 252' ' ' GLN . 3.0 mm100 -94.88 172.23 8.28 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.561 -176.786 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -106.23 138.52 14.4 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.186 -1.007 . . . . 0.0 112.942 -176.166 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 254' ' ' THR . . . . . 0.493 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 75.6 p -111.0 117.98 34.81 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 176.595 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.695 HD13 ' H ' ' A' ' 255' ' ' ILE . 0.2 OUTLIER -123.09 163.91 21.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 120.733 0.302 . . . . 0.0 111.269 -176.058 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 85.7 m -100.93 112.61 25.09 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 172.327 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.611 HG21 HD12 ' A' ' 262' ' ' LEU . 35.2 m -90.01 144.97 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.783 0 CA-C-O 121.663 0.744 . . . . 0.0 112.663 -169.764 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 258' ' ' SER . . . . . 0.511 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 23.2 m -90.31 7.7 37.1 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 114.376 -1.284 . . . . 0.0 108.637 171.283 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 259' ' ' ALA . . . . . 0.602 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -96.19 159.53 14.91 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-N 114.89 -1.05 . . . . 0.0 110.162 -177.509 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . 0.476 ' H ' HD22 ' A' ' 228' ' ' LEU . 45.8 p -127.97 154.14 45.93 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.362 -179.129 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 73.83 20.25 79.75 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 121.113 -0.565 . . . . 0.0 113.377 178.117 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 262' ' ' LEU . . . . . 0.611 HD12 HG21 ' A' ' 257' ' ' VAL . 77.5 mt -78.32 142.82 37.47 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 117.11 0.455 . . . . 0.0 110.606 179.347 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 81.6 mt-30 -141.3 174.5 10.48 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.975 -0.557 . . . . 0.0 109.866 -179.894 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 44.1 t -78.72 132.95 31.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 N-CA-C 110.098 -0.334 . . . . 0.0 110.098 176.332 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 102.89 4.4 48.42 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.378 -0.915 . . . . 0.0 112.61 179.071 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -86.05 153.8 21.87 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.871 0.367 . . . . 0.0 110.185 177.181 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 267' ' ' ALA . . . . . 0.546 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -125.08 142.48 51.46 Favored 'General case' 0 C--N 1.322 -0.592 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 177.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 268' ' ' PHE . . . . . 0.461 ' HB3' HD13 ' A' ' 334' ' ' ILE . 3.8 p90 -160.13 169.85 22.46 Favored 'General case' 0 C--N 1.323 -0.562 0 C-N-CA 120.097 -0.641 . . . . 0.0 111.572 -176.929 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 269' ' ' THR . . . . . 0.427 ' HB ' ' HB3' ' A' ' 287' ' ' PRO . 67.4 p -119.08 145.88 45.55 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.526 175.872 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 270' ' ' ILE . . . . . 0.729 HG12 HD12 ' A' ' 332' ' ' ILE . 57.9 mt -111.51 131.97 61.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.696 -177.265 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -66.08 120.13 12.62 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.372 -178.531 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 272' ' ' GLY . . . . . 0.533 ' HA3' ' HG3' ' A' ' 326' ' ' PRO . . . 101.3 -22.32 39.52 Favored Glycine 0 C--O 1.23 -0.1 0 C-N-CA 120.971 -0.633 . . . . 0.0 112.102 -179.673 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 52.2 t -103.16 102.68 13.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 176.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 7.1 m120 -119.62 156.66 29.98 Favored 'General case' 0 C--N 1.323 -0.583 0 C-N-CA 120.1 -0.64 . . . . 0.0 111.235 -173.9 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 59.0 p -75.8 166.81 22.98 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.301 0.572 . . . . 0.0 112.41 -173.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 34.3 m -123.96 153.66 30.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 114.909 -1.041 . . . . 0.0 109.851 174.261 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 53.1 m170 -110.35 91.51 3.68 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 179.345 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 16.9 pt20 -79.44 -11.36 59.91 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.92 -0.582 . . . . 0.0 112.435 -172.077 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 279' ' ' ILE . . . . . 0.484 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.2 mp -76.42 -55.92 9.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-O 120.935 0.398 . . . . 0.0 109.962 179.003 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 45.6 p -96.12 -1.4 48.65 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.618 -178.865 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 281' ' ' LYS . . . . . 0.418 ' HB3' ' NZ ' ' A' ' 281' ' ' LYS . 3.8 mmmp? 52.74 52.37 14.13 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.06 -177.793 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 52.1 t0 -111.64 146.92 36.59 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.04 -177.464 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 36.4 p -107.1 110.6 22.75 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.938 0.399 . . . . 0.0 110.391 176.576 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 78.3 p -119.05 -26.45 5.96 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.702 -176.755 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 71.35 31.92 65.56 Favored Glycine 0 N--CA 1.449 -0.46 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.925 176.711 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 95.2 mm-40 -82.72 133.18 49.66 Favored Pre-proline 0 C--N 1.325 -0.49 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 179.232 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 287' ' ' PRO . . . . . 0.427 ' HB3' ' HB ' ' A' ' 269' ' ' THR . 82.2 Cg_exo -49.47 133.26 31.18 Favored 'Trans proline' 0 C--N 1.345 0.379 0 C-N-CA 122.902 2.402 . . . . 0.0 112.851 -177.453 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 3.3 tm0? -83.65 134.89 34.76 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 -176.804 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 40.3 t -98.39 125.23 51.77 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-O 120.986 0.422 . . . . 0.0 110.776 -176.0 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 290' ' ' PHE . . . . . 0.546 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 6.0 m-85 -98.29 165.65 11.77 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.138 0.495 . . . . 0.0 112.181 -173.782 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 40.2 mmt-85 -129.46 120.35 25.31 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 114.889 -1.051 . . . . 0.0 108.763 174.014 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 58.3 t -77.98 135.78 25.5 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.913 0 CA-C-N 116.306 -0.406 . . . . 0.0 112.059 -174.844 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 293' ' ' LEU . . . . . . . . . . . . . 72.2 mt -102.49 -37.81 7.83 Favored 'General case' 0 N--CA 1.462 0.152 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.674 177.382 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 294' ' ' ALA . . . . . . . . . . . . . . . -151.51 139.91 20.48 Favored 'General case' 0 C--N 1.328 -0.339 0 C-N-CA 120.999 -0.28 . . . . 0.0 111.55 -175.139 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 58.0 t -137.71 110.21 7.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.987 -0.551 . . . . 0.0 109.614 175.339 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 58.9 p -139.85 104.06 4.79 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.163 -175.672 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 61.16 56.79 21.8 Favored Glycine 0 C--N 1.331 0.266 0 C-N-CA 120.979 -0.629 . . . . 0.0 112.406 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 66.4 p 53.21 17.24 0.95 Allowed 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 123.98 0.912 . . . . 0.0 112.519 -176.12 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 89.5 m -105.54 108.1 19.44 Favored 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 174.115 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . 0.493 ' O ' ' HA ' ' A' ' 254' ' ' THR . 45.2 t -111.05 135.04 51.43 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.35 -172.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 60.4 m -99.85 114.02 26.93 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 173.129 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 302' ' ' ILE . . . . . . . . . . . . . 27.2 pt -110.66 137.11 44.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 N-CA-C 113.094 0.775 . . . . 0.0 113.094 -168.801 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 303' ' ' SER . . . . . . . . . . . . . 50.3 m -119.49 157.59 51.28 Favored Pre-proline 0 C--N 1.32 -0.716 0 CA-C-N 114.029 -1.441 . . . . 0.0 107.641 170.569 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 304' ' ' PRO . . . . . 0.525 ' HD3' ' HA ' ' A' ' 290' ' ' PHE . 2.7 Cg_exo -75.23 -172.48 10.88 Favored 'Cis proline' 0 N--CA 1.462 -0.335 0 C-N-CA 124.368 -1.097 . . . . 0.0 111.716 -0.077 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 305' ' ' LYS . . . . . 0.449 ' HD2' ' O ' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -80.89 145.35 31.36 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.271 0.558 . . . . 0.0 111.804 179.462 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 306' ' ' ILE . . . . . 0.731 HG23 HG21 ' A' ' 322' ' ' VAL . 2.9 mp -99.86 100.5 10.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.41 -172.783 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 307' ' ' LEU . . . . . 0.468 ' HA ' ' HD3' ' A' ' 308' ' ' PRO . 82.9 mt -117.14 119.74 34.49 Favored Pre-proline 0 CA--C 1.516 -0.363 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.413 179.766 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 308' ' ' PRO . . . . . 0.792 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 7.1 Cg_exo -80.19 139.66 13.45 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 123.183 2.589 . . . . 0.0 113.406 -176.065 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . 0.474 HG22 ' HB3' ' A' ' 320' ' ' ALA . 45.3 t -82.04 -30.16 9.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 167.284 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 310' ' ' GLU . . . . . 0.405 ' HB2' ' HB2' ' A' ' 324' ' ' ALA . 89.1 mt-10 -84.73 25.79 0.88 Allowed 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 115.006 -0.997 . . . . 0.0 111.169 177.553 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.711 ' HB2' ' HB2' ' A' ' 308' ' ' PRO . 24.5 t-20 -87.74 141.63 28.45 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 179.638 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 38.0 m -60.3 -28.53 68.18 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.198 -178.019 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 32.7 t70 -79.14 113.46 17.28 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.001 0.429 . . . . 0.0 110.195 177.107 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 314' ' ' VAL . . . . . 0.477 ' O ' ' HD3' ' A' ' 318' ' ' PRO . 40.4 t -69.04 -19.86 24.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.965 -177.543 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -75.03 -17.89 60.42 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 112.218 0.451 . . . . 0.0 112.218 -179.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 59.4 m -96.7 -22.03 17.24 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 112.43 0.53 . . . . 0.0 112.43 -176.394 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 317' ' ' ARG . . . . . 0.415 ' N ' ' CD ' ' A' ' 318' ' ' PRO . 15.9 ptp180 -74.5 -31.65 1.25 Allowed Pre-proline 0 CA--C 1.549 0.92 0 N-CA-C 114.901 1.445 . . . . 0.0 114.901 -175.584 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 318' ' ' PRO . . . . . 0.477 ' HD3' ' O ' ' A' ' 314' ' ' VAL . 33.6 Cg_exo -62.09 -39.09 51.92 Favored 'Trans proline' 0 C--N 1.365 1.412 0 CA-C-N 121.486 1.566 . . . . 0.0 112.68 -178.009 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 54.7 m-85 -112.02 41.33 1.98 Allowed 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.543 -179.731 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . 0.474 ' HB3' HG22 ' A' ' 309' ' ' VAL . . . -78.63 159.87 27.84 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.967 179.699 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 47.2 t30 -111.83 -25.29 9.53 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.76 -178.744 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 322' ' ' VAL . . . . . 0.731 HG21 HG23 ' A' ' 306' ' ' ILE . 33.0 m -134.46 172.68 15.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.766 179.878 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 53.1 m-20 -67.15 -49.69 63.89 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.557 176.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 324' ' ' ALA . . . . . 0.792 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -173.08 179.64 2.2 Favored 'General case' 0 CA--C 1.518 -0.281 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.555 -177.166 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 325' ' ' LYS . . . . . 0.478 ' HE2' ' O ' ' A' ' 234' ' ' PRO . 8.7 ptpp? -126.83 106.96 22.61 Favored Pre-proline 0 C--N 1.326 -0.414 0 CA-C-N 115.324 -0.853 . . . . 0.0 109.805 171.525 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 326' ' ' PRO . . . . . 0.58 ' O ' ' HG3' ' A' ' 233' ' ' GLN . 67.1 Cg_endo -78.92 167.14 22.52 Favored 'Trans proline' 0 C--N 1.34 0.124 0 C-N-CA 122.535 2.156 . . . . 0.0 112.49 -175.878 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -63.03 129.63 41.18 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.122 176.81 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 47.1 mt-10 73.01 142.72 0.06 Allowed 'General case' 0 N--CA 1.469 0.493 0 O-C-N 123.977 0.798 . . . . 0.0 110.561 -174.564 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 329' ' ' SER . . . . . 0.56 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 17.6 m -77.31 -22.29 52.17 Favored 'General case' 0 C--N 1.323 -0.55 0 C-N-CA 120.865 -0.334 . . . . 0.0 111.383 -174.652 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 330' ' ' ALA . . . . . 0.445 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 74.15 -162.6 0.08 Allowed 'General case' 0 N--CA 1.47 0.546 0 O-C-N 123.716 0.635 . . . . 0.0 112.686 174.251 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 331' ' ' ALA . . . . . 0.412 ' HA ' HG22 ' A' ' 229' ' ' THR . . . -81.34 145.93 30.61 Favored 'General case' 0 CA--C 1.517 -0.29 0 CA-C-N 115.318 -0.856 . . . . 0.0 110.943 -178.042 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 332' ' ' ILE . . . . . 0.729 HD12 HG12 ' A' ' 270' ' ' ILE . 29.4 mm -115.47 144.55 22.81 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.245 -177.304 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.436 ' HA ' ' O ' ' A' ' 225' ' ' THR . 75.5 m -109.05 96.65 6.46 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 110.094 -0.336 . . . . 0.0 110.094 179.118 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 334' ' ' ILE . . . . . 0.461 HD13 ' HB3' ' A' ' 268' ' ' PHE . 45.7 mm -81.71 130.61 35.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 N-CA-C 111.912 0.338 . . . . 0.0 111.912 -175.329 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 335' ' ' LEU . . . . . 0.431 HD23 ' N ' ' A' ' 335' ' ' LEU . 1.9 pt? -156.58 132.43 9.62 Favored 'General case' 0 C--O 1.234 0.244 0 CA-C-O 121.388 0.613 . . . . 0.0 110.982 174.671 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 76.1 m-20 -94.69 52.63 1.53 Allowed 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.451 176.713 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 55.8 tptt . . . . . 0 C--O 1.246 0.897 0 CA-C-O 118.124 -0.941 . . . . 0.0 109.525 -179.807 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.861 0 N-CA-C 112.154 -0.378 . . . . 0.0 112.154 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 44.1 m -78.55 112.84 16.03 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.592 0.196 . . . . 0.0 111.186 -178.407 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . 0.711 HG22 ' H ' ' A' ' 227' ' ' SER . 78.9 m 67.4 -78.13 0.04 OUTLIER 'General case' 0 N--CA 1.468 0.435 0 O-C-N 123.777 0.673 . . . . 0.0 111.812 176.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 54.1 mt-10 56.42 30.51 17.13 Favored 'General case' 0 C--N 1.333 -0.137 0 C-N-CA 122.973 0.509 . . . . 0.0 112.124 -178.384 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 227' ' ' SER . . . . . 0.711 ' H ' HG22 ' A' ' 225' ' ' THR . 48.3 m -96.04 -27.86 14.9 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.629 174.323 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 228' ' ' LEU . . . . . 0.471 ' HB3' ' CB ' ' A' ' 259' ' ' ALA . 90.5 mt -128.12 141.3 51.53 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.289 -0.869 . . . . 0.0 109.09 176.766 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 38.3 p -130.94 -179.2 5.18 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 120.578 -0.449 . . . . 0.0 111.339 -177.005 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . 0.586 ' HB ' ' CB ' ' A' ' 329' ' ' SER . 40.7 t -140.0 140.01 36.19 Favored 'Isoleucine or valine' 0 C--O 1.239 0.528 0 CA-C-O 120.557 0.218 . . . . 0.0 110.772 -178.651 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 32.1 m -99.24 138.92 35.65 Favored 'General case' 0 C--O 1.234 0.277 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.29 176.004 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 127.73 166.23 12.03 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.51 -0.853 . . . . 0.0 111.959 179.202 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 81.3 mt-30 -117.12 102.03 52.89 Favored Pre-proline 0 C--N 1.324 -0.539 0 CA-C-N 116.782 0.291 . . . . 0.0 111.073 -179.557 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 234' ' ' PRO . . . . . 0.412 ' HB2' HD12 ' A' ' 306' ' ' ILE . 6.1 Cg_exo -76.35 126.82 9.36 Favored 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 122.716 2.277 . . . . 0.0 111.155 177.015 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -158.55 141.22 14.44 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.175 -178.739 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 92.8 m-70 -146.72 138.24 24.39 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.495 -177.266 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 237' ' ' LYS . . . . . 0.542 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 6.2 mptt -121.61 135.79 54.98 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 -179.856 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 238' ' ' VAL . . . . . 0.517 HG22 HD13 ' A' ' 307' ' ' LEU . 42.5 t -73.82 111.03 8.37 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 C-N-CA 120.541 -0.464 . . . . 0.0 109.85 179.831 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 239' ' ' GLU . . . . . 0.598 ' HG3' ' HB ' ' A' ' 248' ' ' VAL . 9.6 pt-20 -102.59 140.86 36.31 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.329 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 240' ' ' ALA . . . . . 0.501 ' O ' ' HA ' ' A' ' 247' ' ' PRO . . . -75.47 -86.93 0.04 OUTLIER 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.209 -173.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 241' ' ' LYS . . . . . 0.491 ' HD2' ' N ' ' A' ' 241' ' ' LYS . 11.7 mptt -107.4 128.95 54.93 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.864 0.364 . . . . 0.0 110.5 -179.392 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 242' ' ' ASP . . . . . 0.439 ' HB3' HG21 ' A' ' 248' ' ' VAL . 2.9 p30 -76.07 -167.38 0.73 Allowed 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.28 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 46.8 t -60.63 -27.88 68.12 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.868 -176.841 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -90.45 -7.82 52.09 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.278 0.561 . . . . 0.0 109.666 179.789 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . 0.464 ' HA2' ' HB3' ' A' ' 241' ' ' LYS . . . 87.07 32.17 15.14 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.861 176.488 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 246' ' ' MET . . . . . 0.466 ' O ' ' HA ' ' A' ' 241' ' ' LYS . 64.5 mtt -113.12 148.14 38.83 Favored Pre-proline 0 C--N 1.325 -0.494 0 O-C-N 122.785 -0.244 . . . . 0.0 110.862 -179.473 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 247' ' ' PRO . . . . . 0.501 ' HA ' ' O ' ' A' ' 240' ' ' ALA . 24.5 Cg_exo -60.88 131.47 37.45 Favored 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 122.654 2.236 . . . . 0.0 111.359 176.898 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.598 ' HB ' ' HG3' ' A' ' 239' ' ' GLU . 31.7 t -114.09 129.08 70.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 N-CA-C 112.769 0.655 . . . . 0.0 112.769 -171.393 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -102.14 100.4 10.62 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 106.325 -1.731 . . . . 0.0 106.325 163.448 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 250' ' ' ASN . . . . . 0.949 HD21 HD21 ' A' ' 307' ' ' LEU . 20.4 p30 -49.07 152.27 1.14 Allowed 'General case' 0 N--CA 1.469 0.486 0 N-CA-C 113.789 1.033 . . . . 0.0 113.789 -165.503 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . 0.571 ' CD ' ' H ' ' A' ' 251' ' ' ARG . 0.3 OUTLIER -68.52 -177.49 0.95 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 114.375 -1.284 . . . . 0.0 112.004 -174.582 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 252' ' ' GLN . . . . . 0.558 ' HA ' HE21 ' A' ' 252' ' ' GLN . 2.6 mm100 -98.33 174.64 6.39 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.878 -177.393 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -110.28 147.81 17.43 Favored Glycine 0 N--CA 1.447 -0.581 0 C-N-CA 119.842 -1.171 . . . . 0.0 113.019 -176.612 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 70.1 p -118.93 117.73 29.62 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 176.838 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.658 HD13 ' H ' ' A' ' 255' ' ' ILE . 0.2 OUTLIER -128.66 165.64 27.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-O 120.951 0.405 . . . . 0.0 111.128 -176.253 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 40.5 m -99.61 116.87 32.74 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 178.273 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.473 ' HA ' HG13 ' A' ' 230' ' ' VAL . 34.1 m -90.44 144.39 9.22 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.774 0 CA-C-O 121.47 0.653 . . . . 0.0 112.494 -172.378 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 258' ' ' SER . . . . . 0.487 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 40.3 m -90.61 8.48 33.99 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 114.359 -1.291 . . . . 0.0 108.721 170.355 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 259' ' ' ALA . . . . . 0.471 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -91.4 163.69 14.1 Favored 'General case' 0 N--CA 1.449 -0.518 0 CA-C-N 114.994 -1.003 . . . . 0.0 109.453 -179.012 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . 0.457 ' H ' HD13 ' A' ' 228' ' ' LEU . 50.6 m -129.8 149.33 51.59 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 120.762 0.315 . . . . 0.0 111.386 -177.888 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 68.73 37.53 84.53 Favored Glycine 0 N--CA 1.451 -0.355 0 CA-C-N 115.786 -0.643 . . . . 0.0 113.534 176.453 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 262' ' ' LEU . . . . . 0.406 HD11 ' HB3' ' A' ' 259' ' ' ALA . 60.4 mt -92.45 150.74 20.6 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 117.364 0.582 . . . . 0.0 109.835 176.794 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 84.7 mt-30 -144.41 170.26 16.36 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.113 -0.494 . . . . 0.0 109.675 -179.619 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 50.3 t -78.25 141.89 14.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.844 -179.457 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 94.13 -2.07 68.28 Favored Glycine 0 N--CA 1.448 -0.503 0 C-N-CA 120.701 -0.761 . . . . 0.0 113.206 177.288 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 44.8 m-20 -81.04 155.46 26.33 Favored 'General case' 0 CA--C 1.515 -0.386 0 CA-C-O 121.251 0.548 . . . . 0.0 111.202 178.129 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 267' ' ' ALA . . . . . 0.713 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -116.16 146.97 41.86 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.222 -0.899 . . . . 0.0 109.13 178.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 268' ' ' PHE . . . . . 0.671 ' HB3' HD13 ' A' ' 334' ' ' ILE . 6.6 p90 -164.17 162.06 22.55 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 120.4 -0.52 . . . . 0.0 111.93 -174.935 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 269' ' ' THR . . . . . 0.468 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 71.1 p -115.23 147.74 39.98 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 115.016 -0.993 . . . . 0.0 109.137 173.422 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 270' ' ' ILE . . . . . 0.593 HD11 ' HE2' ' A' ' 268' ' ' PHE . 54.1 mt -123.13 138.07 54.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-O 120.61 0.243 . . . . 0.0 110.516 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -63.58 125.2 23.47 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.677 -0.692 . . . . 0.0 111.872 -175.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 103.64 -22.6 35.24 Favored Glycine 0 N--CA 1.449 -0.471 0 CA-C-N 115.73 -0.668 . . . . 0.0 112.207 178.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . 0.657 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 39.5 t -95.11 102.31 13.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-O 120.946 0.403 . . . . 0.0 110.058 178.204 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -110.52 135.76 50.69 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.231 -179.892 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 32.5 p -77.94 156.23 30.38 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.229 0.538 . . . . 0.0 112.078 -177.428 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 32.9 m -113.48 160.3 13.04 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.65 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.478 174.845 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 35.7 m80 -132.19 79.86 1.88 Allowed 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.903 177.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 2.5 tp-100 -53.22 -29.55 32.92 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.585 -0.28 . . . . 0.0 111.296 -176.115 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 50.1 mm -63.6 -48.42 86.88 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.352 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.616 178.914 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 75.2 p -97.81 7.14 46.89 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-O 120.762 0.315 . . . . 0.0 111.5 -177.39 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 52.9 tptt 71.59 50.18 0.27 Allowed 'General case' 0 CA--C 1.536 0.408 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.947 179.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 2.4 p30 29.62 50.41 0.07 Allowed 'General case' 0 N--CA 1.474 0.741 0 N-CA-C 115.801 1.778 . . . . 0.0 115.801 171.471 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 62.1 p -107.1 88.65 2.78 Favored 'General case' 0 C--N 1.322 -0.612 0 C-N-CA 119.744 -0.782 . . . . 0.0 110.335 167.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 35.5 p -145.62 -70.36 0.27 Allowed 'General case' 0 C--N 1.319 -0.761 0 CA-C-N 115.499 -0.773 . . . . 0.0 111.339 -177.79 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 89.09 32.3 10.86 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.82 -0.705 . . . . 0.0 112.013 -178.526 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 286' ' ' GLN . . . . . 0.4 ' HA ' ' HD3' ' A' ' 287' ' ' PRO . 12.0 mm100 -100.94 127.8 31.24 Favored Pre-proline 0 C--N 1.326 -0.422 0 O-C-N 122.894 -0.18 . . . . 0.0 110.926 -177.244 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 287' ' ' PRO . . . . . 0.468 ' HB2' ' HB ' ' A' ' 269' ' ' THR . 24.2 Cg_exo -58.17 129.84 34.98 Favored 'Trans proline' 0 C--O 1.236 0.406 0 C-N-CA 122.42 2.08 . . . . 0.0 110.734 173.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 40.4 tt0 -72.87 142.06 47.93 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.963 0.411 . . . . 0.0 111.124 -173.773 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 289' ' ' VAL . . . . . 0.431 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 47.7 t -90.6 134.82 28.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 115.465 -0.789 . . . . 0.0 109.931 177.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 290' ' ' PHE . . . . . 0.713 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 45.5 m-85 -111.48 163.06 14.44 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.471 -177.449 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 43.2 mmm-85 -125.25 121.22 33.44 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 173.436 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 47.2 t -66.03 132.16 31.64 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-N 115.597 -0.729 . . . . 0.0 111.591 -175.604 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 293' ' ' LEU . . . . . 0.483 HD11 ' HG3' ' A' ' 252' ' ' GLN . 93.9 mt -93.68 -41.64 9.59 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.906 -0.588 . . . . 0.0 111.562 177.381 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 294' ' ' ALA . . . . . 0.412 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -157.26 142.69 17.3 Favored 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 120.896 -0.322 . . . . 0.0 111.316 -176.601 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 61.2 t -133.92 116.54 23.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 109.238 -0.653 . . . . 0.0 109.238 174.466 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 52.5 p -140.73 92.29 2.49 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.061 -175.741 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 66.84 63.73 3.69 Favored Glycine 0 N--CA 1.453 -0.181 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.222 -179.411 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 76.6 p 51.0 23.21 1.4 Allowed 'General case' 0 N--CA 1.47 0.557 0 C-N-CA 123.614 0.766 . . . . 0.0 112.579 -177.651 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 44.2 m -116.59 113.38 22.64 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 175.361 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . 0.412 ' HA ' ' O ' ' A' ' 294' ' ' ALA . 45.5 t -113.49 130.5 67.4 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.541 -171.325 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 38.3 m -91.16 116.72 29.04 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 108.072 -1.085 . . . . 0.0 108.072 171.484 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 302' ' ' ILE . . . . . 0.535 ' O ' ' HB3' ' A' ' 252' ' ' GLN . 31.0 pt -110.68 137.3 43.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 N-CA-C 112.812 0.671 . . . . 0.0 112.812 -169.047 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 303' ' ' SER . . . . . 0.426 ' HB3' HD11 ' A' ' 293' ' ' LEU . 81.7 p -137.67 153.52 74.15 Favored Pre-proline 0 C--N 1.325 -0.496 0 CA-C-N 114.645 -1.161 . . . . 0.0 108.547 173.889 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 304' ' ' PRO . . . . . 0.53 ' HD2' ' HD1' ' A' ' 290' ' ' PHE . 5.9 Cg_exo -73.67 -173.07 10.83 Favored 'Cis proline' 0 N--CA 1.463 -0.296 0 C-N-CA 124.005 -1.248 . . . . 0.0 112.01 -0.005 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 305' ' ' LYS . . . . . 0.639 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -85.75 170.2 12.69 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 120.873 0.368 . . . . 0.0 110.874 -177.841 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 306' ' ' ILE . . . . . 0.444 HG23 HG21 ' A' ' 322' ' ' VAL . 60.3 mt -112.09 93.6 2.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.59 -176.389 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 307' ' ' LEU . . . . . 0.949 HD21 HD21 ' A' ' 250' ' ' ASN . 94.4 mt -108.23 104.97 55.58 Favored Pre-proline 0 C--N 1.326 -0.441 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.691 -179.54 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 308' ' ' PRO . . . . . 0.778 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 6.3 Cg_exo -75.96 138.6 20.97 Favored 'Trans proline' 0 N--CA 1.461 -0.422 0 C-N-CA 122.982 2.455 . . . . 0.0 112.467 -177.324 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . 0.471 HG23 ' O ' ' A' ' 322' ' ' VAL . 46.8 t -65.74 -25.59 36.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 121.189 0.518 . . . . 0.0 109.683 174.674 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 310' ' ' GLU . . . . . 0.436 ' HA ' ' OE1' ' A' ' 310' ' ' GLU . 4.8 mm-40 -80.92 33.67 0.33 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.752 -0.658 . . . . 0.0 112.169 177.192 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.417 ' O ' ' HB ' ' A' ' 312' ' ' THR . 21.4 p30 -85.29 -8.08 58.68 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.964 -0.107 . . . . 0.0 111.178 -179.644 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 312' ' ' THR . . . . . 0.417 ' HB ' ' O ' ' A' ' 311' ' ' ASN . 71.1 m 74.91 -46.61 0.6 Allowed 'General case' 0 N--CA 1.471 0.613 0 C-N-CA 123.457 0.703 . . . . 0.0 112.283 178.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 42.8 m-20 -57.47 115.46 2.75 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-O 121.211 0.529 . . . . 0.0 111.116 -179.073 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 23.3 t -61.55 -33.6 57.9 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.449 -176.379 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -75.79 -22.14 56.68 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 111.752 0.278 . . . . 0.0 111.752 179.626 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 65.5 m -87.12 -20.66 26.76 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 111.777 0.288 . . . . 0.0 111.777 -178.857 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 317' ' ' ARG . . . . . 0.505 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 75.0 mtp180 -56.04 -48.9 95.82 Favored Pre-proline 0 CA--C 1.539 0.525 0 N-CA-C 113.034 0.754 . . . . 0.0 113.034 -179.282 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 318' ' ' PRO . . . . . 0.505 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 52.0 Cg_exo -58.57 -16.18 28.81 Favored 'Trans proline' 0 C--N 1.36 1.137 0 C-N-CA 122.213 1.942 . . . . 0.0 113.988 -176.758 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 8.8 m-85 -106.69 1.28 24.93 Favored 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 121.116 -0.234 . . . . 0.0 111.568 -179.657 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -66.08 139.03 58.15 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.811 0.339 . . . . 0.0 111.02 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 14.8 p-10 -124.07 -9.5 7.66 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.379 -179.466 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 322' ' ' VAL . . . . . 0.471 ' O ' HG23 ' A' ' 309' ' ' VAL . 32.3 m -132.92 163.97 36.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 175.537 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 54.6 m-20 -81.05 -22.16 39.5 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 111.885 0.328 . . . . 0.0 111.885 -177.755 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 324' ' ' ALA . . . . . 0.778 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -171.1 154.66 4.14 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.045 -172.573 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 23.8 pttm -101.31 114.4 65.73 Favored Pre-proline 0 C--N 1.325 -0.488 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 169.314 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -72.57 167.64 26.55 Favored 'Trans proline' 0 C--O 1.235 0.346 0 C-N-CA 122.622 2.215 . . . . 0.0 113.306 -172.47 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -66.62 136.8 56.13 Favored 'General case' 0 C--O 1.237 0.422 0 CA-C-N 115.804 -0.634 . . . . 0.0 109.885 175.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 47.1 -155.27 0.05 Allowed 'General case' 0 N--CA 1.471 0.594 0 O-C-N 124.446 1.091 . . . . 0.0 111.19 -173.7 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 329' ' ' SER . . . . . 0.586 ' CB ' ' HB ' ' A' ' 230' ' ' VAL . 53.1 m -98.66 -38.92 8.93 Favored 'General case' 0 C--N 1.322 -0.609 0 C-N-CA 120.548 -0.461 . . . . 0.0 111.024 -177.052 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 330' ' ' ALA . . . . . 0.453 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 79.39 -164.39 0.03 OUTLIER 'General case' 0 N--CA 1.477 0.923 0 N-CA-C 112.869 0.692 . . . . 0.0 112.869 174.34 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -84.49 149.17 26.12 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 115.507 -0.77 . . . . 0.0 112.429 -172.066 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 332' ' ' ILE . . . . . 0.602 HG23 ' CD2' ' A' ' 268' ' ' PHE . 38.3 mt -111.08 145.78 16.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.663 -0.699 . . . . 0.0 111.16 178.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 95.7 m -120.67 97.2 5.44 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 172.693 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 334' ' ' ILE . . . . . 0.671 HD13 ' HB3' ' A' ' 268' ' ' PHE . 40.3 mm -79.18 128.96 38.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 N-CA-C 111.92 0.341 . . . . 0.0 111.92 -175.617 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 335' ' ' LEU . . . . . 0.442 HD23 ' N ' ' A' ' 335' ' ' LEU . 1.5 pt? -152.9 130.74 11.68 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.407 0.622 . . . . 0.0 110.593 174.431 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 23.4 p30 -90.8 5.47 48.24 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.287 -177.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 337' ' ' LYS . . . . . 0.442 ' NZ ' ' HB3' ' A' ' 337' ' ' LYS . 8.0 mtpm? . . . . . 0 C--O 1.245 0.828 0 CA-C-O 118.186 -0.911 . . . . 0.0 110.758 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.807 0 N-CA-C 112.081 -0.408 . . . . 0.0 112.081 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 50.2 m -79.15 124.53 28.42 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 110.407 -0.22 . . . . 0.0 110.407 179.71 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 46.5 m 66.59 -90.03 0.03 OUTLIER 'General case' 0 CA--C 1.533 0.312 0 O-C-N 123.612 0.57 . . . . 0.0 110.326 -177.44 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 4.5 tm-20 62.79 98.54 0.03 OUTLIER 'General case' 0 C--N 1.34 0.177 0 CA-C-O 121.655 0.741 . . . . 0.0 110.027 179.698 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 42.9 m -117.46 -62.65 1.54 Allowed 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.44 -0.8 . . . . 0.0 109.409 178.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 228' ' ' LEU . . . . . 0.544 ' HB3' ' CB ' ' A' ' 259' ' ' ALA . 87.9 mt -127.1 136.07 51.63 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 172.287 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 40.5 p -122.16 172.17 8.46 Favored 'General case' 0 C--N 1.325 -0.462 0 C-N-CA 119.502 -0.879 . . . . 0.0 110.811 -179.72 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . 0.721 HG13 ' HA ' ' A' ' 257' ' ' VAL . 48.3 t -145.82 146.02 19.72 Favored 'Isoleucine or valine' 0 C--O 1.239 0.537 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.328 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 231' ' ' SER . . . . . 0.444 ' HA ' ' OE1' ' A' ' 328' ' ' GLU . 33.3 t -118.79 127.21 53.32 Favored 'General case' 0 N--CA 1.452 -0.328 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.017 -178.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . 0.528 ' O ' ' HD3' ' A' ' 234' ' ' PRO . . . 149.13 160.43 9.13 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.072 179.182 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 14.6 mm-40 -99.34 100.98 11.54 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-N 116.769 0.285 . . . . 0.0 111.628 -179.069 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 234' ' ' PRO . . . . . 0.528 ' HD3' ' O ' ' A' ' 232' ' ' GLY . 3.2 Cg_endo -84.01 126.44 3.85 Favored 'Trans proline' 0 N--CA 1.455 -0.762 0 C-N-CA 122.711 2.274 . . . . 0.0 111.434 176.352 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 235' ' ' GLU . . . . . 0.445 ' HB3' ' HE2' ' A' ' 237' ' ' LYS . 98.4 mt-10 -126.54 126.79 44.27 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.315 0.578 . . . . 0.0 111.387 -178.7 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 236' ' ' HIS . . . . . 0.523 ' C ' ' HD3' ' A' ' 237' ' ' LYS . 27.8 m80 -139.73 130.3 25.7 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.192 -0.913 . . . . 0.0 109.204 176.358 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 237' ' ' LYS . . . . . 0.621 ' HD3' ' N ' ' A' ' 237' ' ' LYS . 0.1 OUTLIER -167.39 174.35 8.07 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.054 -176.126 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 238' ' ' VAL . . . . . . . . . . . . . 44.7 t -101.4 110.78 29.12 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 N-CA-C 109.303 -0.629 . . . . 0.0 109.303 176.321 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 239' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -110.4 152.09 26.69 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.604 -179.411 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 240' ' ' ALA . . . . . 0.589 ' O ' ' HA ' ' A' ' 247' ' ' PRO . . . -93.5 -61.23 1.6 Allowed 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.241 -176.377 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 241' ' ' LYS . . . . . . . . . . . . . 11.7 mmmm -98.2 127.58 44.22 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.86 -0.336 . . . . 0.0 110.397 -173.899 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 55.2 p-10 -95.25 -156.94 0.54 Allowed 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 110.033 -0.358 . . . . 0.0 110.033 174.849 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 38.4 t -66.79 -25.52 66.51 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.762 0.315 . . . . 0.0 111.294 -179.779 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 6.0 m120 -98.54 -14.21 20.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.735 0.302 . . . . 0.0 111.189 -179.534 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 93.04 22.5 27.54 Favored Glycine 0 N--CA 1.449 -0.49 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.476 -179.589 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 246' ' ' MET . . . . . . . . . . . . . 66.5 mtm -113.34 154.0 45.45 Favored Pre-proline 0 C--N 1.326 -0.425 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 177.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 247' ' ' PRO . . . . . 0.589 ' HA ' ' O ' ' A' ' 240' ' ' ALA . 3.4 Cg_exo -74.49 119.14 5.62 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.109 1.873 . . . . 0.0 111.787 -179.9 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 59.2 t -145.06 138.14 21.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.567 -178.093 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 64.0 t0 -73.04 121.12 19.63 Favored 'General case' 0 C--N 1.329 -0.322 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 174.191 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 250' ' ' ASN . . . . . . . . . . . . . 19.7 p30 -64.66 162.35 15.92 Favored 'General case' 0 C--O 1.234 0.242 0 CA-C-O 121.275 0.559 . . . . 0.0 112.484 -174.633 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 15.6 ptm180 -69.03 -177.06 0.96 Allowed 'General case' 0 C--O 1.235 0.291 0 CA-C-N 114.852 -1.067 . . . . 0.0 112.379 -172.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 252' ' ' GLN . . . . . 0.556 ' HG3' HD12 ' A' ' 293' ' ' LEU . 2.5 mm100 -80.29 176.19 9.98 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.312 -0.858 . . . . 0.0 109.844 177.894 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . 0.494 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -97.4 124.08 8.02 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.216 -0.992 . . . . 0.0 111.881 177.553 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 254' ' ' THR . . . . . 0.454 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 76.8 p -115.52 116.13 27.65 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 178.613 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.53 ' N ' HD13 ' A' ' 255' ' ' ILE . 0.2 OUTLIER -135.64 167.13 25.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.628 -175.747 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 86.9 m -92.5 123.34 35.73 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.2 178.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.721 ' HA ' HG13 ' A' ' 230' ' ' VAL . 33.1 m -91.0 144.94 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.66 0 N-CA-C 113.029 0.751 . . . . 0.0 113.029 -173.106 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 258' ' ' SER . . . . . 0.575 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 29.1 m -91.07 10.33 27.22 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 114.113 -1.403 . . . . 0.0 108.866 169.915 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 259' ' ' ALA . . . . . 0.544 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -98.02 176.97 5.57 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.181 -0.918 . . . . 0.0 109.926 -175.19 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 37.2 t -143.77 146.6 33.24 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 110.191 -0.3 . . . . 0.0 110.191 179.067 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 70.98 45.31 51.89 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.996 -0.621 . . . . 0.0 112.906 179.143 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 262' ' ' LEU . . . . . 0.509 HD11 ' HB3' ' A' ' 259' ' ' ALA . 64.0 mt -99.47 144.25 28.79 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 177.101 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 84.2 mt-30 -139.88 160.94 38.78 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 110.287 -0.264 . . . . 0.0 110.287 -178.735 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 264' ' ' VAL . . . . . 0.455 HG22 ' HA ' ' A' ' 294' ' ' ALA . 44.0 t -69.36 136.2 26.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.177 177.527 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 96.03 -1.28 62.93 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 120.561 -0.828 . . . . 0.0 112.94 178.616 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 266' ' ' ASP . . . . . 0.427 ' O ' ' HA ' ' A' ' 291' ' ' ARG . 65.7 m-20 -78.99 164.21 24.58 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.926 0.394 . . . . 0.0 110.537 177.281 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 267' ' ' ALA . . . . . 0.651 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -123.84 154.38 39.71 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.73 -179.183 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 268' ' ' PHE . . . . . 0.786 ' HB3' HD13 ' A' ' 334' ' ' ILE . 9.4 p90 -164.16 171.19 15.37 Favored 'General case' 0 N--CA 1.449 -0.519 0 C-N-CA 120.297 -0.561 . . . . 0.0 112.217 -179.169 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 69.3 p -129.97 126.11 37.01 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 114.86 -1.064 . . . . 0.0 109.329 175.571 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 270' ' ' ILE . . . . . 0.99 HG12 HG13 ' A' ' 332' ' ' ILE . 60.0 mt -96.74 136.09 28.69 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 116.504 -0.316 . . . . 0.0 110.826 -176.554 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -64.96 128.22 34.86 Favored 'General case' 0 C--N 1.332 -0.156 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.873 -176.395 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 100.98 -23.68 34.72 Favored Glycine 0 N--CA 1.452 -0.26 0 CA-C-N 115.64 -0.709 . . . . 0.0 112.653 177.409 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . 0.726 HG21 ' HG3' ' A' ' 326' ' ' PRO . 31.8 t -102.99 102.33 13.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 120.898 0.38 . . . . 0.0 111.025 179.784 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -113.95 166.35 11.69 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 174.248 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 275' ' ' SER . . . . . 0.486 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 36.5 p -83.72 179.39 7.6 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 112.314 0.487 . . . . 0.0 112.314 -176.443 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 35.7 m -141.46 159.72 22.05 Favored 'Isoleucine or valine' 0 C--O 1.232 0.174 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.743 -177.163 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 80.9 m-70 -118.13 99.58 6.97 Favored 'General case' 0 C--N 1.327 -0.41 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 173.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 10.8 mm100 -73.61 -24.03 59.98 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 111.863 0.32 . . . . 0.0 111.863 -175.206 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 50.7 mm -67.07 -49.27 74.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.764 0.316 . . . . 0.0 111.334 -177.719 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 40.8 p -101.62 -0.14 35.26 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.509 -0.314 . . . . 0.0 111.343 -179.123 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 3.9 tmtp? 60.18 53.6 4.4 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-O 121.903 0.859 . . . . 0.0 109.588 179.725 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 64.8 t0 -117.78 115.91 25.95 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.372 -0.831 . . . . 0.0 109.144 179.08 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 59.2 p -93.96 86.03 4.92 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.918 0.866 . . . . 0.0 111.014 -178.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 284' ' ' THR . . . . . 0.418 ' C ' ' H ' ' A' ' 286' ' ' GLN . 40.0 p -148.63 -88.84 0.08 Allowed 'General case' 0 C--N 1.313 -1.015 0 CA-C-N 114.218 -1.356 . . . . 0.0 109.562 179.282 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 285' ' ' GLY . . . . . 0.507 ' O ' ' HB2' ' A' ' 286' ' ' GLN . . . 68.31 -17.33 0.45 Allowed Glycine 0 C--N 1.333 0.411 0 N-CA-C 114.627 0.611 . . . . 0.0 114.627 173.423 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 286' ' ' GLN . . . . . 0.507 ' HB2' ' O ' ' A' ' 285' ' ' GLY . 72.2 mt-30 76.49 164.45 0.13 Allowed Pre-proline 0 C--O 1.235 0.314 0 C-N-CA 123.519 0.728 . . . . 0.0 110.314 -174.671 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 287' ' ' PRO . . . . . 0.424 ' HD2' ' HB3' ' A' ' 286' ' ' GLN . 78.2 Cg_exo -51.65 128.26 25.58 Favored 'Trans proline' 0 C--N 1.351 0.665 0 C-N-CA 122.641 2.228 . . . . 0.0 112.71 -175.902 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 3.8 tm0? -74.38 135.79 42.45 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 -178.029 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 42.5 t -93.83 121.43 44.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.862 0.363 . . . . 0.0 110.896 -175.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 290' ' ' PHE . . . . . 0.651 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 3.9 m-85 -98.79 160.04 14.54 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.343 -178.517 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 291' ' ' ARG . . . . . 0.432 ' HD2' ' O ' ' A' ' 290' ' ' PHE . 45.2 mmm-85 -131.29 136.97 48.61 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.122 0.487 . . . . 0.0 110.155 175.66 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 46.3 t -83.67 139.86 17.04 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.68 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.223 -177.68 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 293' ' ' LEU . . . . . 0.556 HD12 ' HG3' ' A' ' 252' ' ' GLN . 86.6 mt -111.71 -26.4 9.01 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.69 178.914 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 294' ' ' ALA . . . . . 0.486 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -156.35 139.76 15.79 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 120.718 -0.393 . . . . 0.0 111.624 179.496 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 64.8 t -137.52 109.58 6.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 115.825 -0.625 . . . . 0.0 109.521 173.778 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 47.6 t -151.4 116.37 5.23 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.51 -177.892 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 63.2 44.11 97.58 Favored Glycine 0 C--N 1.331 0.282 0 C-N-CA 120.847 -0.692 . . . . 0.0 111.942 -179.202 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 81.0 p 54.76 16.22 1.34 Allowed 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 123.88 0.872 . . . . 0.0 112.332 -175.401 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 35.8 m -101.07 116.06 31.94 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 174.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . 0.486 ' HA ' ' O ' ' A' ' 294' ' ' ALA . 71.8 t -114.64 131.59 66.31 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-O 121.09 0.471 . . . . 0.0 111.867 -172.167 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 51.1 m -93.01 115.99 28.64 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.255 -0.884 . . . . 0.0 108.65 174.056 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 302' ' ' ILE . . . . . 0.494 HG12 ' O ' ' A' ' 253' ' ' GLY . 30.4 pt -110.66 139.68 33.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-O 121.722 0.772 . . . . 0.0 112.771 -170.693 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 303' ' ' SER . . . . . 0.607 ' HA ' ' O ' ' A' ' 304' ' ' PRO . 82.5 p -138.41 169.02 13.74 Favored Pre-proline 0 C--N 1.323 -0.547 0 CA-C-N 114.404 -1.271 . . . . 0.0 107.759 177.082 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 304' ' ' PRO . . . . . 0.607 ' O ' ' HA ' ' A' ' 303' ' ' SER . 9.7 Cg_exo -73.01 -133.29 0.09 OUTLIER 'Cis proline' 0 C--N 1.348 0.516 0 CA-C-N 120.776 1.313 . . . . 0.0 112.527 0.251 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 305' ' ' LYS . . . . . 0.909 ' HD3' ' HG ' ' A' ' 307' ' ' LEU . 0.0 OUTLIER -102.07 145.1 29.8 Favored 'General case' 0 N--CA 1.448 -0.574 0 CA-C-O 121.453 0.644 . . . . 0.0 111.333 177.871 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 306' ' ' ILE . . . . . 0.819 HG23 HG21 ' A' ' 322' ' ' VAL . 2.7 mp -113.04 85.46 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.049 -177.076 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 307' ' ' LEU . . . . . 0.909 ' HG ' ' HD3' ' A' ' 305' ' ' LYS . 55.7 mt -96.77 116.5 66.12 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.704 -174.66 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 308' ' ' PRO . . . . . 0.705 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 68.7 Cg_endo -79.75 140.52 14.73 Favored 'Trans proline' 0 C--O 1.235 0.36 0 C-N-CA 122.95 2.433 . . . . 0.0 113.899 -174.191 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . 0.537 HG22 ' CB ' ' A' ' 320' ' ' ALA . 15.9 t -93.89 -27.92 4.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.821 174.702 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 62.4 mm-40 -82.21 33.49 0.4 Allowed 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.847 -177.73 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.484 ' OD1' ' HB2' ' A' ' 308' ' ' PRO . 5.5 m120 -126.23 168.95 13.38 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.967 177.955 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 27.3 m -80.64 -18.02 49.42 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.898 -176.427 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 50.7 m-20 -57.19 114.67 2.26 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-O 120.989 0.423 . . . . 0.0 111.387 -179.443 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 38.8 t -74.25 -31.44 29.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.579 -179.694 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -70.06 -30.03 67.18 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.428 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 34.0 t -75.76 -28.9 58.63 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.799 -178.767 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 317' ' ' ARG . . . . . 0.769 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 21.7 mmt85 -51.34 -57.38 14.38 Favored Pre-proline 0 CA--C 1.542 0.672 0 N-CA-C 113.882 1.067 . . . . 0.0 113.882 -176.539 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 318' ' ' PRO . . . . . 0.769 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 22.8 Cg_exo -70.79 -21.49 28.63 Favored 'Trans proline' 0 C--N 1.355 0.893 0 C-N-CA 121.958 1.772 . . . . 0.0 113.522 -173.412 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 319' ' ' TYR . . . . . 0.514 ' O ' HD12 ' A' ' 307' ' ' LEU . 0.9 OUTLIER -108.69 2.78 22.11 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 121.368 0.604 . . . . 0.0 109.598 -175.855 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . 0.677 ' HA ' ' HB2' ' A' ' 307' ' ' LEU . . . -62.36 138.62 58.47 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.318 -178.757 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 321' ' ' ASN . . . . . 0.403 ' O ' ' HA ' ' A' ' 275' ' ' SER . 16.0 p-10 -128.67 -3.46 5.33 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.007 -179.864 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 322' ' ' VAL . . . . . 0.819 HG21 HG23 ' A' ' 306' ' ' ILE . 35.7 m -140.66 166.7 18.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.595 -0.275 . . . . 0.0 110.66 -179.836 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 53.8 m-20 -60.81 -49.23 78.3 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.072 0.463 . . . . 0.0 110.872 179.304 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 324' ' ' ALA . . . . . 0.705 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -157.53 170.65 21.93 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.575 -176.028 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 25.0 pttm -83.1 151.36 63.21 Favored Pre-proline 0 C--N 1.328 -0.359 0 N-CA-C 108.104 -1.072 . . . . 0.0 108.104 170.382 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 326' ' ' PRO . . . . . 0.728 ' HD3' HG21 ' A' ' 306' ' ' ILE . 20.6 Cg_exo -68.02 126.25 14.23 Favored 'Trans proline' 0 N--CA 1.461 -0.405 0 C-N-CA 121.731 1.621 . . . . 0.0 112.886 -174.702 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -83.36 117.3 22.92 Favored 'General case' 0 CA--C 1.511 -0.533 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 167.187 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 328' ' ' GLU . . . . . 0.444 ' OE1' ' HA ' ' A' ' 231' ' ' SER . 31.2 tp10 63.95 168.08 0.16 Allowed 'General case' 0 CA--C 1.539 0.554 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 -165.166 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 329' ' ' SER . . . . . 0.581 ' HB2' ' C ' ' A' ' 230' ' ' VAL . 49.3 m -81.09 -22.19 39.38 Favored 'General case' 0 C--N 1.316 -0.882 0 O-C-N 120.775 -1.203 . . . . 0.0 110.678 -176.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 73.5 -160.09 0.09 Allowed 'General case' 0 N--CA 1.473 0.692 0 O-C-N 123.855 0.722 . . . . 0.0 112.872 170.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 331' ' ' ALA . . . . . 0.433 ' C ' HD12 ' A' ' 332' ' ' ILE . . . -95.51 129.33 42.72 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.254 -0.885 . . . . 0.0 110.041 179.379 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 332' ' ' ILE . . . . . 0.99 HG13 HG12 ' A' ' 270' ' ' ILE . 1.8 mp -111.16 145.49 17.36 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.442 -175.606 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 47.5 m -118.69 97.65 5.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.021 -178.557 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 334' ' ' ILE . . . . . 0.786 HD13 ' HB3' ' A' ' 268' ' ' PHE . 42.7 mm -80.02 136.46 23.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 N-CA-C 112.959 0.726 . . . . 0.0 112.959 -172.675 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 335' ' ' LEU . . . . . 0.473 HD23 ' N ' ' A' ' 335' ' ' LEU . 1.6 pt? -151.21 -173.82 4.62 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 114.69 -1.141 . . . . 0.0 108.737 172.646 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 76.4 m-20 -111.63 -14.05 13.7 Favored 'General case' 0 C--N 1.325 -0.499 0 O-C-N 122.079 -0.388 . . . . 0.0 111.704 -177.135 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 337' ' ' LYS . . . . . 0.544 ' HB2' ' NZ ' ' A' ' 337' ' ' LYS . 9.8 mtmp? . . . . . 0 C--O 1.244 0.792 0 CA-C-O 118.557 -0.735 . . . . 0.0 110.931 -177.163 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.809 0 N-CA-C 111.859 -0.496 . . . . 0.0 111.859 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 69.7 m -79.61 77.06 6.23 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.105 0.479 . . . . 0.0 111.143 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 41.0 p -124.89 162.27 24.77 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.22 177.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 4.9 mm-40 -92.63 52.36 1.87 Allowed 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.53 -0.304 . . . . 0.0 110.396 -179.773 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 40.8 p -76.11 -74.18 0.24 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.564 -0.289 . . . . 0.0 111.118 -177.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 228' ' ' LEU . . . . . 0.413 ' HB3' ' CB ' ' A' ' 259' ' ' ALA . 83.8 mt -104.46 126.15 51.29 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 174.778 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 229' ' ' THR . . . . . 0.561 HG22 ' HA ' ' A' ' 331' ' ' ALA . 68.4 p -129.35 177.94 6.81 Favored 'General case' 0 C--N 1.32 -0.692 0 C-N-CA 120.06 -0.656 . . . . 0.0 111.147 -177.059 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . 0.655 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 64.6 t -140.48 142.57 30.72 Favored 'Isoleucine or valine' 0 C--O 1.238 0.474 0 CA-C-O 120.774 0.321 . . . . 0.0 110.309 -179.427 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 43.3 m -109.33 138.17 46.1 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.481 178.627 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 162.39 -170.15 37.9 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.896 -0.669 . . . . 0.0 111.747 -179.728 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 83.6 mt-30 -99.88 116.26 64.86 Favored Pre-proline 0 C--N 1.325 -0.486 0 CA-C-N 116.716 0.258 . . . . 0.0 110.927 179.45 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -69.17 127.6 15.31 Favored 'Trans proline' 0 C--O 1.236 0.412 0 C-N-CA 122.113 1.876 . . . . 0.0 110.971 175.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 235' ' ' GLU . . . . . 0.679 ' HG3' ' HB3' ' A' ' 251' ' ' ARG . 0.3 OUTLIER -125.78 -176.92 3.75 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-O 121.661 0.744 . . . . 0.0 111.63 -174.395 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 236' ' ' HIS . . . . . . . . . . . . . 22.3 p-80 -156.13 133.13 10.54 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 178.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 237' ' ' LYS . . . . . 0.788 ' HD3' ' HA ' ' A' ' 305' ' ' LYS . 8.9 mptt -104.96 125.51 51.03 Favored 'General case' 0 C--N 1.32 -0.682 0 C-N-CA 119.439 -0.904 . . . . 0.0 111.69 -172.194 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 238' ' ' VAL . . . . . 0.656 ' HB ' HG11 ' A' ' 248' ' ' VAL . 48.1 t -104.08 155.2 5.84 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-N 114.504 -1.225 . . . . 0.0 108.049 171.404 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 239' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -66.71 174.77 2.69 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 117.641 0.2 . . . . 0.0 111.449 -179.53 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 240' ' ' ALA . . . . . . . . . . . . . . . -14.58 -67.03 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.959 0 O-C-N 124.814 1.321 . . . . 0.0 114.371 -176.078 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 241' ' ' LYS . . . . . 0.584 ' H ' ' HD3' ' A' ' 241' ' ' LYS . 0.0 OUTLIER -138.96 165.2 27.72 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 178.093 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 57.8 p30 -91.29 -158.32 0.55 Allowed 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.837 179.479 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 28.5 p -75.52 -7.56 54.49 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 112.324 0.49 . . . . 0.0 112.324 -178.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 244' ' ' ASN . . . . . 0.42 ' HB2' ' HG3' ' A' ' 246' ' ' MET . 4.3 m120 -111.63 -13.12 13.82 Favored 'General case' 0 C--N 1.327 -0.397 0 O-C-N 122.267 -0.271 . . . . 0.0 110.966 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 83.82 25.64 44.9 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.737 -0.744 . . . . 0.0 111.589 -175.926 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 246' ' ' MET . . . . . 0.42 ' HG3' ' HB2' ' A' ' 244' ' ' ASN . 82.2 mtp -88.19 141.25 30.88 Favored Pre-proline 0 C--N 1.327 -0.4 0 CA-C-N 115.831 -0.185 . . . . 0.0 110.764 -178.887 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 247' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_exo -55.58 121.01 9.18 Favored 'Trans proline' 0 C--N 1.346 0.408 0 C-N-CA 122.836 2.357 . . . . 0.0 112.092 178.694 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.656 HG11 ' HB ' ' A' ' 238' ' ' VAL . 61.1 t -84.5 139.79 17.03 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.086 -178.214 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -92.7 100.25 12.79 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 177.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 250' ' ' ASN . . . . . . . . . . . . . 5.7 m120 -86.66 -21.83 26.49 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.578 -179.518 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . 0.679 ' HB3' ' HG3' ' A' ' 235' ' ' GLU . 2.3 tpm_? 57.62 -108.61 0.43 Allowed 'General case' 0 CA--C 1.535 0.366 0 CA-C-N 115.49 -0.777 . . . . 0.0 111.4 177.395 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 252' ' ' GLN . . . . . 0.458 ' CG ' ' HE2' ' A' ' 237' ' ' LYS . 21.6 mt-30 61.68 170.95 0.12 Allowed 'General case' 0 N--CA 1.471 0.624 0 CA-C-O 121.382 0.61 . . . . 0.0 111.645 -178.272 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . 0.537 ' O ' ' HA ' ' A' ' 301' ' ' THR . . . 126.33 -152.22 18.22 Favored Glycine 0 N--CA 1.446 -0.661 0 C-N-CA 119.141 -1.504 . . . . 0.0 113.401 172.812 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 254' ' ' THR . . . . . 0.478 ' HB ' HG22 ' A' ' 299' ' ' THR . 58.4 p -94.21 135.49 35.53 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.13 0.49 . . . . 0.0 111.621 -174.908 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.448 ' O ' ' HA ' ' A' ' 299' ' ' THR . 2.1 pp -132.39 169.07 22.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 115.446 -0.797 . . . . 0.0 111.223 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 83.8 m -105.15 126.25 51.88 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.015 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.432 HG12 HG13 ' A' ' 230' ' ' VAL . 33.5 m -100.81 145.42 11.21 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.643 0 N-CA-C 112.529 0.566 . . . . 0.0 112.529 -174.839 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 258' ' ' SER . . . . . 0.405 ' HB2' ' OG1' ' A' ' 229' ' ' THR . 52.8 m -91.36 7.26 41.89 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 114.694 -1.139 . . . . 0.0 109.132 167.682 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 259' ' ' ALA . . . . . 0.413 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -95.78 170.09 9.56 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-N 115.492 -0.777 . . . . 0.0 110.13 -177.683 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 51.3 p -137.29 153.29 50.34 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.798 0.333 . . . . 0.0 111.45 -178.708 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 72.37 48.79 22.76 Favored Glycine 0 N--CA 1.452 -0.248 0 CA-C-N 115.929 -0.578 . . . . 0.0 112.847 178.342 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 262' ' ' LEU . . . . . 0.422 HD12 HG21 ' A' ' 257' ' ' VAL . 61.7 mt -102.31 144.28 31.01 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.971 0.415 . . . . 0.0 111.08 -178.873 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 72.1 mt-30 -137.78 172.45 12.94 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.69 -0.687 . . . . 0.0 109.547 176.059 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 264' ' ' VAL . . . . . 0.431 HG22 ' HA ' ' A' ' 294' ' ' ALA . 44.5 t -79.04 136.28 24.07 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 174.909 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 95.67 -0.76 63.26 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.5 -0.857 . . . . 0.0 112.586 179.33 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 65.3 m-20 -65.17 152.26 44.05 Favored 'General case' 0 CA--C 1.517 -0.315 0 CA-C-O 121.11 0.481 . . . . 0.0 110.751 178.343 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 267' ' ' ALA . . . . . 0.707 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -124.14 122.76 38.71 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.353 -0.839 . . . . 0.0 109.415 179.544 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 268' ' ' PHE . . . . . 0.414 ' HB3' ' HA ' ' A' ' 334' ' ' ILE . 5.4 p90 -144.56 169.07 18.68 Favored 'General case' 0 C--N 1.319 -0.741 0 C-N-CA 120.016 -0.673 . . . . 0.0 111.784 -172.816 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 269' ' ' THR . . . . . 0.467 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 42.9 p -119.97 148.81 43.08 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.559 -0.746 . . . . 0.0 109.966 176.615 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 270' ' ' ILE . . . . . 0.586 HG12 HD12 ' A' ' 332' ' ' ILE . 58.5 mt -114.09 138.85 42.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 116.559 -0.291 . . . . 0.0 110.668 -177.226 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -67.99 117.04 9.33 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.948 179.082 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 109.4 -22.49 24.49 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.782 -0.723 . . . . 0.0 111.95 -179.14 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . 0.657 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 50.4 t -96.35 101.27 12.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 175.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 274' ' ' ASN . . . . . 0.429 ' HA ' ' HA ' ' A' ' 287' ' ' PRO . 72.5 m-80 -124.44 131.79 53.5 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.494 -177.594 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 54.5 p -64.03 163.99 11.35 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.524 0.678 . . . . 0.0 112.508 -176.488 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 276' ' ' VAL . . . . . 0.866 HG11 HG21 ' A' ' 309' ' ' VAL . 21.5 m -126.81 149.94 32.26 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.623 0 CA-C-N 114.901 -1.045 . . . . 0.0 109.276 176.029 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 58.7 m170 -103.53 120.87 41.71 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 120.756 0.312 . . . . 0.0 110.738 -175.191 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 3.1 mm100 -82.17 -29.2 31.67 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.764 -177.723 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 279' ' ' ILE . . . . . 0.487 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.0 mp -72.12 -52.64 23.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.436 -179.017 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 58.0 p -89.38 -13.06 38.62 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.772 -178.356 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 31.7 mmmt 58.84 45.26 15.64 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.55 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 44.1 t0 -132.8 155.25 49.27 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 110.157 -0.312 . . . . 0.0 110.157 -179.571 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.516 HG22 HG12 ' A' ' 276' ' ' VAL . 59.9 p -107.77 113.38 26.59 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 175.072 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 80.6 p -110.93 6.77 21.38 Favored 'General case' 0 C--N 1.32 -0.699 0 C-N-CA 120.285 -0.566 . . . . 0.0 112.077 -170.318 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 285' ' ' GLY . . . . . 0.4 ' O ' ' HD3' ' A' ' 287' ' ' PRO . . . 66.77 31.6 78.82 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.594 -0.813 . . . . 0.0 113.363 174.414 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 10.6 mm100 -95.89 109.1 44.74 Favored Pre-proline 0 C--N 1.328 -0.338 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 177.817 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 287' ' ' PRO . . . . . 0.467 ' HB2' ' HB ' ' A' ' 269' ' ' THR . 51.5 Cg_exo -58.35 139.34 90.21 Favored 'Trans proline' 0 C--N 1.343 0.288 0 C-N-CA 122.598 2.199 . . . . 0.0 112.888 -176.107 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 40.8 tt0 -77.4 148.37 35.55 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.179 -179.637 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 289' ' ' VAL . . . . . 0.533 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 59.7 t -94.25 137.4 23.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.085 178.063 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 290' ' ' PHE . . . . . 0.707 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 51.7 m-85 -118.34 167.83 11.18 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.758 -176.525 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 37.4 mmt180 -128.66 130.96 47.95 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.77 177.653 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 57.7 t -79.65 139.97 17.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.497 -0.774 . . . . 0.0 111.359 -179.054 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 293' ' ' LEU . . . . . 0.512 ' CD1' ' HB2' ' A' ' 303' ' ' SER . 6.9 mp -102.25 -31.66 10.44 Favored 'General case' 0 C--N 1.334 -0.089 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.844 179.738 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 294' ' ' ALA . . . . . 0.458 ' HB3' ' HB ' ' A' ' 301' ' ' THR . . . -158.55 144.31 16.75 Favored 'General case' 0 N--CA 1.465 0.284 0 C-N-CA 120.664 -0.415 . . . . 0.0 111.763 179.523 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 62.5 t -139.28 112.48 6.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.85 176.085 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 54.2 p -132.67 95.41 3.59 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.368 -0.378 . . . . 0.0 111.114 -178.413 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 65.43 57.78 10.75 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.02 -178.789 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 67.0 p 51.19 22.37 1.31 Allowed 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 123.501 0.72 . . . . 0.0 112.552 -176.174 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 299' ' ' THR . . . . . 0.478 HG22 ' HB ' ' A' ' 254' ' ' THR . 91.7 m -112.29 109.55 19.27 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 174.014 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . 0.467 ' O ' ' HA ' ' A' ' 254' ' ' THR . 47.3 t -107.0 134.1 49.69 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-N 115.704 -0.68 . . . . 0.0 112.02 -168.39 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 301' ' ' THR . . . . . 0.537 ' HA ' ' O ' ' A' ' 253' ' ' GLY . 91.5 m -85.22 114.92 22.68 Favored 'General case' 0 C--O 1.237 0.403 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 169.746 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 302' ' ' ILE . . . . . 0.418 HD13 HG12 ' A' ' 255' ' ' ILE . 30.6 pt -110.7 138.6 38.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 N-CA-C 113.655 0.983 . . . . 0.0 113.655 -167.805 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 303' ' ' SER . . . . . 0.572 ' HB3' ' HA ' ' A' ' 304' ' ' PRO . 68.7 m -153.87 169.39 10.01 Favored Pre-proline 0 C--N 1.323 -0.557 0 CA-C-N 112.859 -1.973 . . . . 0.0 105.89 175.047 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 304' ' ' PRO . . . . . 0.572 ' HA ' ' HB3' ' A' ' 303' ' ' SER . 22.7 Cg_endo -93.38 -119.83 0.0 OUTLIER 'Cis proline' 0 N--CA 1.455 -0.742 0 CA-C-N 121.02 1.4 . . . . 0.0 113.592 0.822 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 305' ' ' LYS . . . . . 0.788 ' HA ' ' HD3' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -98.41 144.29 27.94 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.081 -0.509 . . . . 0.0 112.357 -172.324 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 306' ' ' ILE . . . . . 0.544 ' HB ' ' O ' ' A' ' 235' ' ' GLU . 2.2 mp -104.4 127.35 58.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 170.699 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 307' ' ' LEU . . . . . 0.544 HD13 ' O ' ' A' ' 319' ' ' TYR . 59.0 mt -129.09 98.28 24.17 Favored Pre-proline 0 C--N 1.323 -0.548 0 C-N-CA 120.676 -0.41 . . . . 0.0 110.519 -172.779 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 308' ' ' PRO . . . . . 0.545 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 12.7 Cg_exo -74.17 131.34 15.21 Favored 'Trans proline' 0 C--N 1.343 0.252 0 C-N-CA 122.802 2.335 . . . . 0.0 113.495 -175.19 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . 0.866 HG21 HG11 ' A' ' 276' ' ' VAL . 61.9 t -87.05 -37.57 11.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.563 173.897 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 63.1 mm-40 -81.08 32.69 0.33 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.859 -0.609 . . . . 0.0 111.484 179.814 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.581 HD21 ' HB3' ' A' ' 317' ' ' ARG . 0.0 OUTLIER -85.38 157.05 20.62 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.945 0.403 . . . . 0.0 111.248 179.16 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 36.4 m -92.15 -18.28 23.73 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.839 178.244 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -76.42 121.49 23.13 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.612 -179.746 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 40.7 t -75.76 -20.19 15.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.129 -177.457 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -80.59 -21.96 41.14 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.739 0.304 . . . . 0.0 111.512 178.582 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 36.0 t -96.3 -23.3 16.73 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.559 -0.291 . . . . 0.0 111.456 -176.138 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 317' ' ' ARG . . . . . 0.581 ' HB3' HD21 ' A' ' 311' ' ' ASN . 2.1 ptp180 -62.23 -34.03 14.07 Favored Pre-proline 0 CA--C 1.548 0.901 0 N-CA-C 113.807 1.04 . . . . 0.0 113.807 -178.886 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 318' ' ' PRO . . . . . 0.415 ' CD ' ' N ' ' A' ' 317' ' ' ARG . 26.1 Cg_exo -63.13 -18.14 63.57 Favored 'Trans proline' 0 C--N 1.367 1.521 0 CA-C-N 121.263 1.487 . . . . 0.0 112.113 178.266 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 319' ' ' TYR . . . . . 0.544 ' O ' HD13 ' A' ' 307' ' ' LEU . 48.5 m-85 -103.35 -3.2 25.87 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.028 -177.803 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . 0.723 ' HB1' HG22 ' A' ' 309' ' ' VAL . . . -54.06 144.77 18.49 Favored 'General case' 0 C--N 1.33 -0.246 0 N-CA-C 112.144 0.424 . . . . 0.0 112.144 -178.128 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 321' ' ' ASN . . . . . 0.479 ' O ' HG22 ' A' ' 276' ' ' VAL . 48.9 t30 -148.05 -18.61 0.35 Allowed 'General case' 0 CA--C 1.532 0.278 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.472 -178.281 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 322' ' ' VAL . . . . . 0.532 ' O ' HG23 ' A' ' 309' ' ' VAL . 35.1 m -137.43 160.96 34.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 N-CA-C 110.234 -0.284 . . . . 0.0 110.234 177.654 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 71.8 m-20 -41.9 -69.24 0.14 Allowed 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 112.588 0.588 . . . . 0.0 112.588 -177.364 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 324' ' ' ALA . . . . . 0.545 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -165.7 -176.08 3.74 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.962 0.411 . . . . 0.0 111.496 -175.595 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 325' ' ' LYS . . . . . 0.454 ' HG3' ' HG3' ' A' ' 308' ' ' PRO . 34.4 mtmm -88.02 138.97 30.71 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.592 174.362 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 326' ' ' PRO . . . . . 0.706 ' HB2' ' HB2' ' A' ' 330' ' ' ALA . 43.1 Cg_endo -86.01 167.34 9.57 Favored 'Trans proline' 0 N--CA 1.455 -0.759 0 C-N-CA 122.551 2.167 . . . . 0.0 112.145 178.61 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -70.47 122.98 20.69 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 177.83 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 52.8 mt-10 62.39 -121.04 0.66 Allowed 'General case' 0 N--CA 1.463 0.184 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 -172.328 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 329' ' ' SER . . . . . 0.655 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 33.9 m -111.94 -14.25 13.52 Favored 'General case' 0 C--N 1.322 -0.603 0 C-N-CA 120.535 -0.466 . . . . 0.0 110.118 172.813 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 330' ' ' ALA . . . . . 0.706 ' HB2' ' HB2' ' A' ' 326' ' ' PRO . . . 73.9 -169.19 0.11 Allowed 'General case' 0 N--CA 1.474 0.755 0 O-C-N 124.214 0.946 . . . . 0.0 113.37 172.467 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 331' ' ' ALA . . . . . 0.561 ' HA ' HG22 ' A' ' 229' ' ' THR . . . -80.08 141.54 35.72 Favored 'General case' 0 CA--C 1.517 -0.304 0 CA-C-N 115.101 -0.954 . . . . 0.0 110.611 -179.065 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 332' ' ' ILE . . . . . 0.586 HD12 HG12 ' A' ' 270' ' ' ILE . 16.1 mm -120.68 144.11 30.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.405 -175.503 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 82.3 m -114.04 97.13 6.18 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 175.007 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 334' ' ' ILE . . . . . 0.414 ' HA ' ' HB3' ' A' ' 268' ' ' PHE . 38.5 mm -81.65 125.34 39.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 115.999 -0.546 . . . . 0.0 112.339 -172.045 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 335' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -122.73 163.22 20.56 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.187 170.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 20.9 t-20 -94.04 -14.74 25.5 Favored 'General case' 0 C--N 1.319 -0.76 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 171.659 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 337' ' ' LYS . . . . . 0.65 ' HB2' ' HB3' ' A' ' 267' ' ' ALA . 26.7 tptp . . . . . 0 C--O 1.244 0.799 0 CA-C-N 114.613 -1.176 . . . . 0.0 111.257 174.431 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.81 0 N-CA-C 111.738 -0.545 . . . . 0.0 111.738 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 35.7 t -86.83 155.04 20.44 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 177.406 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 47.6 p -82.69 160.8 22.32 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.121 0.486 . . . . 0.0 111.189 -178.62 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -98.42 62.99 1.48 Allowed 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 121.651 0.739 . . . . 0.0 109.809 174.909 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 26.5 m -78.92 -155.09 0.08 Allowed 'General case' 0 N--CA 1.442 -0.858 0 CA-C-N 115.122 -0.945 . . . . 0.0 110.959 -175.917 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 228' ' ' LEU . . . . . 0.488 ' HB3' ' HA ' ' A' ' 259' ' ' ALA . 55.2 mt -94.08 129.55 40.57 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.598 -178.6 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 229' ' ' THR . . . . . 0.456 ' HA ' ' HA ' ' A' ' 331' ' ' ALA . 60.6 p -126.97 179.53 5.36 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 120.275 -0.57 . . . . 0.0 111.281 -176.18 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . 0.756 HG11 HD12 ' A' ' 255' ' ' ILE . 75.3 t -146.39 138.8 19.79 Favored 'Isoleucine or valine' 0 C--O 1.237 0.409 0 CA-C-O 120.735 0.302 . . . . 0.0 110.708 -179.359 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 231' ' ' SER . . . . . 0.425 ' O ' ' HB ' ' A' ' 256' ' ' THR . 49.4 m -137.99 165.37 26.73 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.746 178.686 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 116.12 -108.84 1.89 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 119.913 -1.137 . . . . 0.0 113.995 172.041 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 11.0 mm-40 -62.49 155.36 68.43 Favored Pre-proline 0 C--N 1.328 -0.354 0 N-CA-C 112.761 0.652 . . . . 0.0 112.761 -173.225 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -63.9 175.56 2.98 Favored 'Trans proline' 0 C--N 1.349 0.573 0 C-N-CA 123.611 2.874 . . . . 0.0 112.661 178.161 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 235' ' ' GLU . . . . . 0.425 ' CB ' ' HD2' ' A' ' 325' ' ' LYS . 52.1 mm-40 -92.51 -176.79 4.4 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.695 -176.02 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 236' ' ' HIS . . . . . 0.501 ' HA ' ' HB3' ' A' ' 251' ' ' ARG . 37.9 m-70 -113.82 143.75 44.14 Favored 'General case' 0 C--N 1.321 -0.658 0 C-N-CA 119.842 -0.743 . . . . 0.0 112.199 -165.33 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 237' ' ' LYS . . . . . 0.616 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -126.2 176.21 7.23 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.338 -0.847 . . . . 0.0 109.892 -176.11 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 238' ' ' VAL . . . . . 0.78 ' HB ' HG11 ' A' ' 248' ' ' VAL . 28.6 t -50.45 155.29 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 O-C-N 123.67 0.606 . . . . 0.0 111.439 -176.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 239' ' ' GLU . . . . . . . . . . . . . 52.0 mt-10 -61.96 173.7 1.02 Allowed 'General case' 0 CA--C 1.53 0.185 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.73 -179.287 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 240' ' ' ALA . . . . . 0.626 ' O ' ' HA ' ' A' ' 247' ' ' PRO . . . -46.21 -59.59 2.81 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 115.527 -0.761 . . . . 0.0 112.029 -177.132 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 241' ' ' LYS . . . . . 0.537 ' HD2' ' C ' ' A' ' 240' ' ' ALA . 0.9 OUTLIER -115.76 130.34 56.81 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.957 0.408 . . . . 0.0 110.666 177.045 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 242' ' ' ASP . . . . . 0.469 ' HB2' ' CE2' ' A' ' 319' ' ' TYR . 2.8 p30 -86.59 -163.86 0.97 Allowed 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.514 -0.766 . . . . 0.0 111.155 -178.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 24.3 m -63.66 -29.64 70.85 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 112.077 0.399 . . . . 0.0 112.077 -175.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 75.8 m-20 -92.85 -2.51 55.82 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.813 0.339 . . . . 0.0 110.938 -178.719 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 82.59 26.29 47.13 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.827 -0.701 . . . . 0.0 112.599 179.676 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 246' ' ' MET . . . . . 0.43 ' HA ' ' HD3' ' A' ' 247' ' ' PRO . 82.0 mtp -101.2 149.04 35.95 Favored Pre-proline 0 C--N 1.325 -0.473 0 CA-C-O 120.566 0.222 . . . . 0.0 110.637 179.319 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 247' ' ' PRO . . . . . 0.626 ' HA ' ' O ' ' A' ' 240' ' ' ALA . 2.9 Cg_exo -79.06 128.89 8.58 Favored 'Trans proline' 0 C--O 1.234 0.314 0 C-N-CA 122.853 2.369 . . . . 0.0 113.08 -175.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.78 HG11 ' HB ' ' A' ' 238' ' ' VAL . 21.7 t -122.32 159.54 25.38 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 175.603 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 249' ' ' ASP . . . . . 0.555 ' O ' ' HB2' ' A' ' 237' ' ' LYS . 64.2 t0 -72.14 89.57 1.16 Allowed 'General case' 0 C--O 1.233 0.234 0 CA-C-O 121.14 0.495 . . . . 0.0 109.87 179.362 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 250' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -77.49 90.89 3.88 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.418 -179.413 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . 0.501 ' HB3' ' HA ' ' A' ' 236' ' ' HIS . 29.1 tpt180 -78.65 -95.3 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.015 -175.523 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 252' ' ' GLN . . . . . 0.403 ' HA ' HE21 ' A' ' 252' ' ' GLN . 2.6 mm100 60.1 177.9 0.09 Allowed 'General case' 0 N--CA 1.467 0.381 0 C-N-CA 123.133 0.573 . . . . 0.0 111.055 -177.851 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . 0.556 ' O ' ' HA ' ' A' ' 301' ' ' THR . . . 119.05 -153.11 17.03 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 119.25 -1.453 . . . . 0.0 113.752 176.435 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 254' ' ' THR . . . . . 0.562 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 77.8 p -94.78 148.97 21.74 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.219 0.533 . . . . 0.0 112.243 -172.644 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.756 HD12 HG11 ' A' ' 230' ' ' VAL . 22.6 pt -130.65 161.26 40.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.395 -0.82 . . . . 0.0 110.416 177.71 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . 0.425 ' HB ' ' O ' ' A' ' 231' ' ' SER . 93.6 m -94.76 106.19 18.16 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 174.533 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.42 HG12 HG22 ' A' ' 230' ' ' VAL . 34.3 m -93.21 141.46 14.68 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.914 0 C-N-CA 119.565 -0.854 . . . . 0.0 112.329 -174.693 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 53.8 m -93.0 8.91 37.96 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 114.016 -1.447 . . . . 0.0 109.239 169.684 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 259' ' ' ALA . . . . . 0.76 ' HB3' HD11 ' A' ' 262' ' ' LEU . . . -81.17 166.37 20.7 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.861 -177.641 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 42.6 m -124.93 108.26 11.7 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 111.988 0.366 . . . . 0.0 111.988 -174.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 92.71 50.14 2.57 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.617 -0.801 . . . . 0.0 113.429 173.316 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 262' ' ' LEU . . . . . 0.76 HD11 ' HB3' ' A' ' 259' ' ' ALA . 3.2 mp -86.94 143.59 27.32 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.891 0.346 . . . . 0.0 110.319 179.563 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 68.6 mt-30 -131.12 168.84 16.77 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.605 177.876 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 38.6 t -79.22 128.49 38.5 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 C-N-CA 120.8 -0.36 . . . . 0.0 110.338 178.184 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . 0.593 ' H ' ' HB ' ' A' ' 292' ' ' VAL . . . 102.41 8.67 43.2 Favored Glycine 0 N--CA 1.448 -0.532 0 C-N-CA 120.393 -0.908 . . . . 0.0 113.017 177.605 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -76.94 160.93 28.79 Favored 'General case' 0 CA--C 1.515 -0.373 0 CA-C-O 121.047 0.451 . . . . 0.0 110.579 176.424 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 267' ' ' ALA . . . . . 0.647 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -131.68 131.88 43.48 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 177.851 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 268' ' ' PHE . . . . . . . . . . . . . 3.6 p90 -152.33 169.31 22.83 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 119.468 -0.893 . . . . 0.0 111.76 -172.787 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 269' ' ' THR . . . . . 0.739 HG21 ' HB2' ' A' ' 287' ' ' PRO . 71.1 p -119.61 163.05 17.93 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.235 177.477 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 270' ' ' ILE . . . . . 0.593 HG12 HG12 ' A' ' 332' ' ' ILE . 56.7 mt -124.24 140.46 47.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 C-N-CA 120.815 -0.354 . . . . 0.0 111.432 -178.257 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -62.5 113.17 2.8 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.131 179.655 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 103.51 -21.68 38.31 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 121.083 -0.579 . . . . 0.0 112.031 -178.106 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . 0.604 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 51.1 t -101.1 103.77 15.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-O 121.089 0.471 . . . . 0.0 110.77 178.87 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 71.9 m-80 -122.67 156.35 34.52 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.165 -0.471 . . . . 0.0 109.967 179.234 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 53.8 p -71.95 173.83 7.83 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.14 0.495 . . . . 0.0 111.819 -175.842 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 27.1 m -112.02 -178.45 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.674 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 9.9 m-70 -54.51 93.26 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.023 -0.99 . . . . 0.0 110.965 -173.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -81.99 -28.2 32.75 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.981 0.42 . . . . 0.0 109.878 -175.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 279' ' ' ILE . . . . . 0.56 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.6 mp -82.18 -104.31 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.405 0 CA-C-N 116.083 -0.508 . . . . 0.0 109.817 -179.028 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 41.0 p -128.94 76.07 1.69 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.633 0.254 . . . . 0.0 110.676 179.173 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 34.4 mmtp 54.64 31.5 15.32 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.437 -174.559 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 36.3 t70 -87.32 138.44 31.48 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.647 -176.712 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 54.4 p -95.5 120.33 35.57 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.126 -178.593 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 81.5 p -128.93 -45.43 1.28 Allowed 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.276 -171.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 79.62 28.01 52.76 Favored Glycine 0 N--CA 1.448 -0.558 0 C-N-CA 120.701 -0.761 . . . . 0.0 111.967 -178.58 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 25.5 mt-30 -76.05 134.62 71.05 Favored Pre-proline 0 C--N 1.328 -0.366 0 N-CA-C 110.214 -0.291 . . . . 0.0 110.214 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 287' ' ' PRO . . . . . 0.739 ' HB2' HG21 ' A' ' 269' ' ' THR . 26.3 Cg_exo -64.67 134.19 39.85 Favored 'Trans proline' 0 CA--C 1.53 0.308 0 C-N-CA 122.546 2.164 . . . . 0.0 112.098 -177.9 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 69.7 tp60 -76.65 129.14 35.97 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.578 -178.503 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 289' ' ' VAL . . . . . 0.486 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 25.7 t -97.01 137.61 24.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.831 -178.357 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 290' ' ' PHE . . . . . 0.669 ' HD1' ' HD2' ' A' ' 304' ' ' PRO . 55.0 m-85 -115.58 169.43 9.19 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.046 -178.836 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 9.8 tpt180 -131.06 142.56 50.3 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.167 0.508 . . . . 0.0 110.047 -179.154 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . 0.593 ' HB ' ' H ' ' A' ' 265' ' ' GLY . 55.8 t -92.49 130.57 41.4 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.877 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.683 179.693 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 293' ' ' LEU . . . . . 0.564 HD21 ' HB2' ' A' ' 303' ' ' SER . 2.9 mm? -105.71 -24.34 12.54 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.448 -0.342 . . . . 0.0 111.402 -178.355 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 294' ' ' ALA . . . . . . . . . . . . . . . -164.24 145.39 8.43 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.465 0.174 . . . . 0.0 110.982 179.688 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . 0.581 HG13 HG22 ' A' ' 300' ' ' VAL . 45.5 t -135.07 138.28 49.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 175.575 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 36.9 t -139.44 87.31 2.18 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 177.922 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 73.41 -128.22 11.31 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.118 -1.039 . . . . 0.0 110.544 -169.483 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 298' ' ' THR . . . . . 0.401 ' O ' HG22 ' A' ' 257' ' ' VAL . 31.1 p -102.35 29.34 5.25 Favored 'General case' 0 C--N 1.315 -0.898 0 O-C-N 122.155 -0.615 . . . . 0.0 110.506 172.63 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 63.5 m -112.07 105.42 13.79 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 174.033 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . 0.707 HG21 HD22 ' A' ' 262' ' ' LEU . 44.3 t -114.24 130.46 68.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 N-CA-C 112.259 0.466 . . . . 0.0 112.259 -168.797 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 301' ' ' THR . . . . . 0.556 ' HA ' ' O ' ' A' ' 253' ' ' GLY . 51.4 m -84.46 113.63 21.34 Favored 'General case' 0 C--O 1.237 0.402 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.219 173.342 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 302' ' ' ILE . . . . . 0.754 HD13 HD13 ' A' ' 255' ' ' ILE . 38.9 pt -116.39 157.13 17.4 Favored 'Isoleucine or valine' 0 C--O 1.24 0.599 0 CA-C-O 121.85 0.833 . . . . 0.0 112.897 -174.602 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 303' ' ' SER . . . . . 0.564 ' HB2' HD21 ' A' ' 293' ' ' LEU . 48.8 m -159.64 163.21 23.58 Favored Pre-proline 0 C--N 1.326 -0.435 0 CA-C-N 113.381 -1.736 . . . . 0.0 106.522 175.012 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 304' ' ' PRO . . . . . 0.669 ' HD2' ' HD1' ' A' ' 290' ' ' PHE . 5.1 Cg_exo -78.63 -134.23 0.14 OUTLIER 'Cis proline' 0 CA--C 1.534 0.518 0 CA-C-N 120.504 1.216 . . . . 0.0 113.047 0.85 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 305' ' ' LYS . . . . . 0.467 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -113.16 156.42 23.25 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.333 0.587 . . . . 0.0 112.375 -176.841 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 306' ' ' ILE . . . . . 0.86 HG23 HG21 ' A' ' 322' ' ' VAL . 2.6 mp -104.34 98.53 6.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.25 -0.886 . . . . 0.0 109.491 179.168 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 307' ' ' LEU . . . . . . . . . . . . . 76.3 mt -107.52 100.19 32.83 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.517 -0.31 . . . . 0.0 111.188 -175.007 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 308' ' ' PRO . . . . . 0.74 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 32.4 Cg_exo -66.94 138.22 47.42 Favored 'Trans proline' 0 N--CA 1.474 0.346 0 C-N-CA 123.622 2.881 . . . . 0.0 114.588 -173.757 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . 0.717 HG22 ' HB1' ' A' ' 320' ' ' ALA . 50.8 t -76.74 -29.9 18.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.051 -0.977 . . . . 0.0 108.771 167.772 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -79.2 30.03 0.22 Allowed 'General case' 0 C--O 1.234 0.289 0 CA-C-N 115.292 -0.867 . . . . 0.0 112.045 179.437 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 74.3 m-80 71.05 154.69 0.14 Allowed 'General case' 0 N--CA 1.469 0.481 0 N-CA-C 113.647 0.98 . . . . 0.0 113.647 173.692 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 312' ' ' THR . . . . . 0.526 ' OG1' ' HG2' ' A' ' 308' ' ' PRO . 44.4 m -168.18 -44.09 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 113.675 -1.602 . . . . 0.0 107.824 173.169 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 39.2 t70 -146.52 167.86 22.64 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 114.246 -1.343 . . . . 0.0 108.59 176.339 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 47.2 t -60.34 -38.26 77.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-O 120.787 0.327 . . . . 0.0 111.104 178.381 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -77.38 -17.83 57.86 Favored 'General case' 0 N--CA 1.463 0.212 0 N-CA-C 111.967 0.358 . . . . 0.0 111.967 -179.844 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 34.7 t -71.51 -25.02 62.08 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.579 -0.282 . . . . 0.0 111.447 -176.765 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 317' ' ' ARG . . . . . 0.768 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 54.2 mtp85 -69.71 -57.96 6.09 Favored Pre-proline 0 CA--C 1.536 0.426 0 N-CA-C 112.257 0.466 . . . . 0.0 112.257 -178.691 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 318' ' ' PRO . . . . . 0.768 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 36.8 Cg_exo -63.69 -35.23 59.27 Favored 'Trans proline' 0 C--N 1.357 0.975 0 C-N-CA 122.051 1.834 . . . . 0.0 112.684 -176.779 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 319' ' ' TYR . . . . . 0.469 ' CE2' ' HB2' ' A' ' 242' ' ' ASP . 6.4 m-85 -99.43 32.11 2.9 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.022 -179.23 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . 0.717 ' HB1' HG22 ' A' ' 309' ' ' VAL . . . -55.55 127.68 30.92 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.893 178.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 47.9 t30 -120.99 -28.25 4.82 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.185 -176.654 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 322' ' ' VAL . . . . . 0.86 HG21 HG23 ' A' ' 306' ' ' ILE . 27.2 m -135.42 168.51 22.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.582 -0.281 . . . . 0.0 110.624 179.223 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 65.6 m-20 -52.83 -59.98 3.83 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 121.015 0.436 . . . . 0.0 110.769 176.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 324' ' ' ALA . . . . . 0.74 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -171.79 171.94 5.04 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.427 179.668 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 325' ' ' LYS . . . . . 0.489 ' HB3' ' CG2' ' A' ' 306' ' ' ILE . 21.7 pttp -112.46 117.95 46.27 Favored Pre-proline 0 C--N 1.326 -0.444 0 CA-C-O 121.251 0.548 . . . . 0.0 110.145 172.807 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -72.21 169.33 21.78 Favored 'Trans proline' 0 C--N 1.34 0.103 0 C-N-CA 123.284 2.656 . . . . 0.0 111.884 -177.408 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -63.42 122.27 15.83 Favored 'General case' 0 C--O 1.236 0.372 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 177.607 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 56.0 mt-10 67.79 165.33 0.23 Allowed 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.327 -171.519 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 329' ' ' SER . . . . . 0.681 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 49.0 m -66.65 -14.78 62.89 Favored 'General case' 0 C--N 1.326 -0.423 0 C-N-CA 120.999 -0.28 . . . . 0.0 111.746 -175.673 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 68.17 -162.36 0.2 Allowed 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 113.261 0.837 . . . . 0.0 113.261 171.097 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 331' ' ' ALA . . . . . 0.456 ' HA ' ' HA ' ' A' ' 229' ' ' THR . . . -82.98 150.49 26.35 Favored 'General case' 0 CA--C 1.519 -0.249 0 CA-C-N 115.333 -0.849 . . . . 0.0 111.122 -177.001 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 332' ' ' ILE . . . . . 0.593 HG12 HG12 ' A' ' 270' ' ' ILE . 42.6 mt -122.91 145.23 30.09 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.054 -178.559 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.425 ' HB ' ' OG1' ' A' ' 269' ' ' THR . 31.9 m -111.53 106.77 15.73 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 175.238 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 34.9 mm -83.78 121.67 36.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 112.889 0.7 . . . . 0.0 112.889 -170.203 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 335' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -111.62 -168.57 1.33 Allowed 'General case' 0 C--O 1.236 0.394 0 CA-C-N 115.094 -0.957 . . . . 0.0 109.672 171.491 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 74.4 m-80 -116.78 -15.1 10.74 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.806 -0.633 . . . . 0.0 110.989 176.557 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 23.2 pttm . . . . . 0 C--O 1.244 0.779 0 CA-C-O 118.546 -0.74 . . . . 0.0 111.288 -177.619 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.868 0 N-CA-C 112.161 -0.376 . . . . 0.0 112.161 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 224' ' ' SER . . . . . 0.532 ' HB3' ' HB1' ' A' ' 331' ' ' ALA . 75.2 p -151.68 -156.93 0.76 Allowed 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 29.1 p -84.44 -85.43 0.13 Allowed 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.749 0.309 . . . . 0.0 110.257 174.81 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 54.3 mt-10 -113.67 62.39 0.65 Allowed 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.761 176.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 41.1 m 55.48 47.83 20.2 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-N 115.782 -0.644 . . . . 0.0 111.525 178.779 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 228' ' ' LEU . . . . . 0.442 ' HB3' ' HB2' ' A' ' 259' ' ' ALA . 69.7 mt -89.3 125.12 34.98 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 109.711 -0.478 . . . . 0.0 109.711 177.658 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 58.4 p -124.27 175.35 7.12 Favored 'General case' 0 C--N 1.323 -0.573 0 C-N-CA 119.891 -0.724 . . . . 0.0 110.32 179.12 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . 0.669 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 89.0 t -148.63 141.82 18.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-O 120.76 0.314 . . . . 0.0 110.654 -177.614 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 49.0 m -92.38 129.13 38.41 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.905 -0.589 . . . . 0.0 109.619 174.142 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . -86.5 118.52 4.91 Favored Glycine 0 N--CA 1.444 -0.829 0 C-N-CA 120.264 -0.97 . . . . 0.0 113.322 -175.622 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 233' ' ' GLN . . . . . 0.941 ' HB3' ' HD2' ' A' ' 234' ' ' PRO . 75.7 mt-30 -80.2 178.97 2.05 Favored Pre-proline 0 C--N 1.328 -0.358 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 169.641 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 234' ' ' PRO . . . . . 0.941 ' HD2' ' HB3' ' A' ' 233' ' ' GLN . 72.9 Cg_exo -32.22 127.53 0.1 OUTLIER 'Trans proline' 0 C--N 1.366 1.463 0 C-N-CA 123.633 2.888 . . . . 0.0 113.861 -176.782 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 235' ' ' GLU . . . . . 0.701 ' OE1' ' HE3' ' A' ' 325' ' ' LYS . 46.1 mt-10 -95.58 -178.78 4.52 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.589 -175.727 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 236' ' ' HIS . . . . . 0.591 ' C ' ' HD3' ' A' ' 237' ' ' LYS . 91.7 m-70 -135.68 143.55 45.5 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 122.559 1.171 . . . . 0.0 113.549 -166.309 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 237' ' ' LYS . . . . . 0.591 ' HD3' ' C ' ' A' ' 236' ' ' HIS . 0.0 OUTLIER -156.76 127.55 6.73 Favored 'General case' 0 C--N 1.314 -0.942 0 CA-C-N 112.531 -2.122 . . . . 0.0 107.729 -179.71 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 238' ' ' VAL . . . . . . . . . . . . . 46.8 t -79.09 111.76 16.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 C-N-CA 120.125 -0.63 . . . . 0.0 110.625 -174.27 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 239' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -119.15 171.5 8.24 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.484 -179.062 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 240' ' ' ALA . . . . . 0.402 ' O ' ' HA ' ' A' ' 247' ' ' PRO . . . -80.82 -59.41 2.68 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.861 0.362 . . . . 0.0 110.751 -179.435 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 241' ' ' LYS . . . . . 0.6 ' H ' ' HD3' ' A' ' 241' ' ' LYS . 0.0 OUTLIER -138.32 159.26 42.5 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.837 178.149 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 242' ' ' ASP . . . . . 0.422 ' OD1' ' HG2' ' A' ' 246' ' ' MET . 11.7 p-10 -97.55 -159.34 0.73 Allowed 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 178.156 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 52.9 m -67.62 -27.04 66.55 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.616 -0.265 . . . . 0.0 111.033 177.602 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 23.3 t-20 -83.98 -15.97 45.78 Favored 'General case' 0 CA--C 1.531 0.234 0 CA-C-O 120.999 0.428 . . . . 0.0 110.093 178.893 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 85.58 26.3 36.08 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.692 -0.766 . . . . 0.0 113.376 173.664 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 246' ' ' MET . . . . . 0.436 ' O ' ' HA ' ' A' ' 241' ' ' LYS . 26.8 ptt? -106.72 157.36 35.36 Favored Pre-proline 0 C--N 1.324 -0.505 0 CA-C-N 117.011 0.405 . . . . 0.0 110.078 177.445 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 247' ' ' PRO . . . . . 0.402 ' HA ' ' O ' ' A' ' 240' ' ' ALA . 22.0 Cg_exo -63.44 120.83 8.4 Favored 'Trans proline' 0 C--N 1.347 0.458 0 C-N-CA 122.272 1.981 . . . . 0.0 111.033 177.641 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 45.2 t -99.33 111.09 28.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 120.848 0.356 . . . . 0.0 111.849 -173.492 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -100.37 124.22 45.58 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 170.856 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 250' ' ' ASN . . . . . 0.702 HD21 ' HG3' ' A' ' 305' ' ' LYS . 14.1 p-10 -76.15 -13.16 60.2 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.04 -0.527 . . . . 0.0 112.022 -174.222 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . 0.609 ' HG2' ' H ' ' A' ' 252' ' ' GLN . 63.1 ttt-85 58.17 -127.76 1.52 Allowed 'General case' 0 CA--C 1.539 0.553 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 176.621 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 252' ' ' GLN . . . . . 0.609 ' H ' ' HG2' ' A' ' 251' ' ' ARG . 2.4 mm100 -115.03 176.73 4.93 Favored 'General case' 0 C--N 1.33 -0.258 0 O-C-N 121.981 -0.449 . . . . 0.0 110.068 178.325 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . 0.515 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -105.81 122.25 7.06 Favored Glycine 0 N--CA 1.443 -0.883 0 C-N-CA 120.282 -0.961 . . . . 0.0 112.088 177.437 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 254' ' ' THR . . . . . 0.504 ' O ' ' HB2' ' A' ' 233' ' ' GLN . 48.3 p -106.33 116.79 32.54 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 109.16 -0.682 . . . . 0.0 109.16 176.439 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.725 HG22 ' H ' ' A' ' 233' ' ' GLN . 2.1 pp -125.49 165.63 22.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 N-CA-C 112.868 0.692 . . . . 0.0 112.868 -173.074 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 25.7 m -105.98 117.51 34.23 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 178.649 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.508 ' HA ' HG13 ' A' ' 230' ' ' VAL . 33.7 m -90.22 143.0 12.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 C-N-CA 119.71 -0.796 . . . . 0.0 112.757 -171.932 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 258' ' ' SER . . . . . 0.502 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 37.0 m -92.35 9.83 32.41 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 114.076 -1.42 . . . . 0.0 108.791 168.519 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 259' ' ' ALA . . . . . 0.442 ' HB2' ' HB3' ' A' ' 228' ' ' LEU . . . -101.1 168.3 9.68 Favored 'General case' 0 N--CA 1.454 -0.268 0 CA-C-N 115.049 -0.978 . . . . 0.0 109.371 -176.842 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 49.5 m -132.86 163.18 29.69 Favored 'General case' 0 C--N 1.324 -0.529 0 C-N-CA 120.806 -0.358 . . . . 0.0 111.502 -178.487 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 64.29 50.11 61.89 Favored Glycine 0 N--CA 1.452 -0.247 0 CA-C-N 115.729 -0.669 . . . . 0.0 113.128 177.047 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 262' ' ' LEU . . . . . . . . . . . . . 53.4 mt -101.76 159.68 15.12 Favored 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 120.652 -0.419 . . . . 0.0 110.543 179.73 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 73.4 mt-30 -143.35 165.14 28.33 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.988 -0.551 . . . . 0.0 109.812 179.744 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 41.2 t -79.86 134.47 27.49 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 N-CA-C 109.411 -0.588 . . . . 0.0 109.411 173.621 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . 0.512 ' H ' ' HB ' ' A' ' 292' ' ' VAL . . . 95.47 15.81 42.36 Favored Glycine 0 N--CA 1.446 -0.656 0 C-N-CA 120.284 -0.96 . . . . 0.0 112.729 178.918 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 40.7 m-20 -87.82 165.78 15.06 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.956 0.407 . . . . 0.0 110.689 174.784 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 267' ' ' ALA . . . . . 0.737 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -135.8 123.28 22.08 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.541 -0.754 . . . . 0.0 109.503 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 268' ' ' PHE . . . . . 0.42 ' HB2' ' O ' ' A' ' 333' ' ' THR . 5.9 p90 -141.16 175.03 9.97 Favored 'General case' 0 C--N 1.32 -0.704 0 C-N-CA 120.123 -0.631 . . . . 0.0 111.497 -172.554 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 64.3 p -118.32 154.22 32.7 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.748 176.542 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 270' ' ' ILE . . . . . 0.924 HG12 HG13 ' A' ' 332' ' ' ILE . 60.1 mt -124.58 141.28 45.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 120.761 0.315 . . . . 0.0 110.78 -178.068 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -76.03 125.49 29.22 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.903 178.472 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 96.58 -21.83 43.54 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.087 -178.749 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . 0.451 HG23 ' HG3' ' A' ' 326' ' ' PRO . 48.5 t -100.42 103.25 14.54 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 CA-C-O 121.059 0.457 . . . . 0.0 110.054 176.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 274' ' ' ASN . . . . . 0.519 ' O ' ' HB ' ' A' ' 322' ' ' VAL . 70.8 m-80 -121.01 137.84 54.45 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 -179.756 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 275' ' ' SER . . . . . 0.666 ' HB3' ' HB2' ' A' ' 288' ' ' GLN . 60.3 p -73.01 174.48 7.8 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.006 0.431 . . . . 0.0 111.511 -175.124 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 276' ' ' VAL . . . . . 0.538 HG11 HG21 ' A' ' 309' ' ' VAL . 33.3 m -110.05 178.69 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.284 -179.421 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 277' ' ' HIS . . . . . 0.78 ' HB2' ' HA ' ' A' ' 281' ' ' LYS . 7.7 p80 -36.84 88.73 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.675 0 O-C-N 124.561 1.163 . . . . 0.0 113.985 -177.271 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 39.7 tt0 -84.64 -36.46 21.96 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.721 -0.672 . . . . 0.0 111.518 -178.173 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 279' ' ' ILE . . . . . 0.782 HG22 HG23 ' A' ' 280' ' ' THR . 2.6 mp -80.94 -84.33 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.305 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.398 -172.788 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . 0.782 HG23 HG22 ' A' ' 279' ' ' ILE . 32.6 p -127.69 45.79 2.67 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 111.597 0.221 . . . . 0.0 111.597 -174.686 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 281' ' ' LYS . . . . . 0.78 ' HA ' ' HB2' ' A' ' 277' ' ' HIS . 3.3 tmtp? 56.68 46.3 20.43 Favored 'General case' 0 CA--C 1.533 0.312 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 -176.792 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 49.2 p-10 -104.75 -162.01 0.86 Allowed 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 114.79 -1.095 . . . . 0.0 110.885 -175.085 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 76.1 p -105.97 124.45 49.59 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 178.749 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 81.2 p -127.28 -75.86 0.57 Allowed 'General case' 0 C--N 1.321 -0.643 0 C-N-CA 120.429 -0.508 . . . . 0.0 111.159 -174.26 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 67.09 31.24 77.22 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.898 -0.668 . . . . 0.0 112.002 -179.306 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 95.2 mm-40 -105.35 145.27 30.47 Favored Pre-proline 0 C--N 1.329 -0.311 0 N-CA-C 110.467 -0.197 . . . . 0.0 110.467 -178.142 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 287' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -55.22 137.5 77.06 Favored 'Trans proline' 0 C--N 1.346 0.413 0 C-N-CA 122.805 2.336 . . . . 0.0 112.267 -179.813 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 288' ' ' GLN . . . . . 0.666 ' HB2' ' HB3' ' A' ' 275' ' ' SER . 52.0 tt0 -88.37 155.48 19.67 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.895 -176.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 59.0 t -89.84 113.34 25.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.349 178.638 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 290' ' ' PHE . . . . . 0.737 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 54.1 m-85 -100.52 131.12 46.6 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.46 -177.331 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 9.8 tpt180 -106.87 120.53 42.29 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.535 0.683 . . . . 0.0 109.877 178.368 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . 0.512 ' HB ' ' H ' ' A' ' 265' ' ' GLY . 57.6 t -67.66 140.01 19.94 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.954 0 CA-C-N 114.656 -1.157 . . . . 0.0 112.531 -176.198 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 293' ' ' LEU . . . . . 0.571 HD11 ' OG ' ' A' ' 303' ' ' SER . 4.4 mp -104.69 -30.94 9.62 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.739 175.534 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 294' ' ' ALA . . . . . 0.46 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -159.71 144.8 15.37 Favored 'General case' 0 C--N 1.333 -0.126 0 CA-C-O 120.534 0.207 . . . . 0.0 111.532 -176.358 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 70.7 t -138.09 100.23 1.68 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 175.589 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 35.8 m -138.49 113.5 9.27 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.439 -0.346 . . . . 0.0 111.085 -175.457 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 63.17 48.49 79.22 Favored Glycine 0 C--N 1.331 0.252 0 C-N-CA 120.834 -0.698 . . . . 0.0 111.922 -178.716 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 71.3 p 51.08 24.33 1.87 Allowed 'General case' 0 N--CA 1.469 0.5 0 C-N-CA 123.77 0.828 . . . . 0.0 112.229 -174.742 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 299' ' ' THR . . . . . 0.49 ' HA ' ' O ' ' A' ' 255' ' ' ILE . 29.0 m -111.48 111.18 22.02 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 176.304 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 294' ' ' ALA . 44.7 t -111.02 129.08 66.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.587 -172.445 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 93.5 m -90.97 116.08 28.49 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 172.298 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 302' ' ' ILE . . . . . 0.515 HG12 ' O ' ' A' ' 253' ' ' GLY . 29.2 pt -113.26 142.8 24.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 N-CA-C 112.917 0.71 . . . . 0.0 112.917 -171.57 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 303' ' ' SER . . . . . 0.571 ' OG ' HD11 ' A' ' 293' ' ' LEU . 89.5 p -137.71 142.13 35.56 Favored Pre-proline 0 C--N 1.322 -0.599 0 N-CA-C 106.95 -1.5 . . . . 0.0 106.95 169.906 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 304' ' ' PRO . . . . . 0.511 ' HD2' ' HD1' ' A' ' 290' ' ' PHE . 25.2 Cg_exo -66.83 -179.48 13.45 Favored 'Cis proline' 0 C--N 1.331 -0.377 0 CA-C-N 119.913 1.005 . . . . 0.0 112.88 0.868 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 305' ' ' LYS . . . . . 0.702 ' HG3' HD21 ' A' ' 250' ' ' ASN . 0.0 OUTLIER -112.87 145.93 39.8 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-O 121.102 0.477 . . . . 0.0 111.543 -179.259 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 306' ' ' ILE . . . . . 0.519 HD12 ' N ' ' A' ' 306' ' ' ILE . 2.2 mp -72.11 106.11 2.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 115.262 -0.881 . . . . 0.0 111.058 -175.958 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 307' ' ' LEU . . . . . 0.628 HD21 ' ND2' ' A' ' 250' ' ' ASN . 86.7 mt -124.68 108.08 28.82 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.116 -0.493 . . . . 0.0 109.853 178.32 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 308' ' ' PRO . . . . . 0.679 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 23.8 Cg_exo -72.89 136.92 26.0 Favored 'Trans proline' 0 N--CA 1.476 0.452 0 C-N-CA 123.006 2.471 . . . . 0.0 114.423 -170.849 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . 0.539 HG23 ' O ' ' A' ' 322' ' ' VAL . 47.5 t -91.14 -23.53 5.87 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.186 0 CA-C-N 115.283 -0.871 . . . . 0.0 109.549 171.675 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 310' ' ' GLU . . . . . 0.45 ' OE1' ' HB2' ' A' ' 324' ' ' ALA . 50.2 mt-10 -80.9 8.53 8.11 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.182 -179.537 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 22.6 t-20 -74.99 137.36 41.5 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 178.399 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 68.6 m -60.67 -35.98 77.6 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 111.608 0.225 . . . . 0.0 111.608 -174.671 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 39.7 m-20 -61.38 126.76 28.52 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-O 121.167 0.508 . . . . 0.0 111.247 179.89 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 57.9 t -69.86 -28.26 36.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.493 -177.466 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -72.03 -17.92 61.99 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 111.997 0.369 . . . . 0.0 111.997 -179.828 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 35.1 t -76.82 -40.52 47.62 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 121.223 -0.191 . . . . 0.0 111.21 -177.41 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 317' ' ' ARG . . . . . 0.465 ' N ' ' HD2' ' A' ' 318' ' ' PRO . 65.9 mtt85 -54.44 -53.24 61.82 Favored Pre-proline 0 CA--C 1.54 0.584 0 N-CA-C 113.652 0.982 . . . . 0.0 113.652 -176.276 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 318' ' ' PRO . . . . . 0.465 ' HD2' ' N ' ' A' ' 317' ' ' ARG . 9.9 Cg_endo -56.36 -23.93 49.21 Favored 'Trans proline' 0 C--N 1.357 0.989 0 C-N-CA 122.468 2.112 . . . . 0.0 113.282 -176.86 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 53.9 m-85 -115.23 12.38 16.48 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.703 -177.4 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . 0.509 ' HB3' HG22 ' A' ' 309' ' ' VAL . . . -78.1 161.04 27.69 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.35 -178.306 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 29.2 t-20 -122.42 -44.51 2.25 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.734 -175.416 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 322' ' ' VAL . . . . . 0.539 ' O ' HG23 ' A' ' 309' ' ' VAL . 34.7 m -124.95 179.0 3.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.793 -177.884 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 74.9 m-20 -62.3 -60.09 4.07 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.81 -178.736 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 324' ' ' ALA . . . . . 0.679 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -151.27 172.51 15.75 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 112.785 0.661 . . . . 0.0 112.785 -174.27 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 325' ' ' LYS . . . . . 0.701 ' HE3' ' OE1' ' A' ' 235' ' ' GLU . 14.9 ptmt -99.06 126.41 38.29 Favored Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 114.252 -1.34 . . . . 0.0 110.152 170.818 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 326' ' ' PRO . . . . . 0.451 ' HG3' HG23 ' A' ' 273' ' ' VAL . 90.8 Cg_endo -86.21 168.23 9.03 Favored 'Trans proline' 0 N--CA 1.461 -0.403 0 C-N-CA 122.963 2.442 . . . . 0.0 111.857 -179.757 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -69.8 122.71 19.75 Favored 'General case' 0 C--O 1.236 0.385 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 174.448 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 62.2 mm-40 58.22 -140.79 0.75 Allowed 'General case' 0 CA--C 1.528 0.115 0 O-C-N 123.53 0.519 . . . . 0.0 109.647 -172.822 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 329' ' ' SER . . . . . 0.669 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 48.7 m -112.86 -14.12 13.1 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 120.44 -0.504 . . . . 0.0 111.076 176.615 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 67.33 -151.02 0.18 Allowed 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 112.402 0.519 . . . . 0.0 112.402 175.329 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 331' ' ' ALA . . . . . 0.532 ' HB1' ' HB3' ' A' ' 224' ' ' SER . . . -89.86 127.4 35.99 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.945 -178.293 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 332' ' ' ILE . . . . . 0.924 HG13 HG12 ' A' ' 270' ' ' ILE . 1.7 mp -110.96 140.12 31.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.432 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.426 ' OG1' ' HA ' ' A' ' 224' ' ' SER . 50.8 m -103.43 99.0 8.81 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.147 -0.479 . . . . 0.0 109.739 -178.944 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 22.6 mm -84.27 127.67 39.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 N-CA-C 113.934 1.087 . . . . 0.0 113.934 -171.405 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 335' ' ' LEU . . . . . 0.469 HD23 ' N ' ' A' ' 335' ' ' LEU . 1.6 pt? -153.36 -172.85 4.37 Favored 'General case' 0 N--CA 1.447 -0.576 0 CA-C-N 114.024 -1.444 . . . . 0.0 107.65 168.816 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 20.6 t-20 -121.35 -23.92 5.57 Favored 'General case' 0 C--N 1.321 -0.649 0 C-N-CA 120.363 -0.535 . . . . 0.0 110.583 -178.599 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 68.1 mttm . . . . . 0 C--O 1.245 0.818 0 CA-C-O 118.097 -0.954 . . . . 0.0 111.399 179.071 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.81 0 N-CA-C 112.268 -0.333 . . . . 0.0 112.268 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 49.5 m -66.25 -32.52 73.99 Favored 'General case' 0 C--O 1.234 0.267 0 CA-C-O 120.39 0.138 . . . . 0.0 111.106 -179.866 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 44.8 m 70.4 -79.93 0.04 OUTLIER 'General case' 0 CA--C 1.534 0.333 0 O-C-N 123.68 0.613 . . . . 0.0 110.158 -178.416 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 226' ' ' GLU . . . . . 0.41 ' O ' ' HG2' ' A' ' 226' ' ' GLU . 37.9 tt0 56.61 34.49 24.54 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-O 121.812 0.815 . . . . 0.0 110.824 175.081 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 54.7 p -128.84 7.0 5.57 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.051 177.686 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 228' ' ' LEU . . . . . 0.528 HD13 ' H ' ' A' ' 260' ' ' SER . 91.1 mt -108.52 146.77 32.71 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.116 -0.947 . . . . 0.0 108.871 177.028 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 77.7 p -130.56 179.6 5.84 Favored 'General case' 0 C--N 1.325 -0.477 0 C-N-CA 119.973 -0.691 . . . . 0.0 110.675 -179.013 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . 0.88 HG11 HD12 ' A' ' 255' ' ' ILE . 91.3 t -146.51 136.71 17.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 120.91 0.386 . . . . 0.0 110.592 178.902 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 33.7 t -107.04 146.42 31.17 Favored 'General case' 0 N--CA 1.45 -0.465 0 CA-C-N 116.039 -0.528 . . . . 0.0 109.604 176.498 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . 0.478 ' O ' ' HD3' ' A' ' 234' ' ' PRO . . . 124.4 149.18 7.6 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.396 -0.906 . . . . 0.0 111.592 -176.817 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 66.5 mt-30 -98.6 103.82 20.88 Favored Pre-proline 0 C--N 1.323 -0.568 0 CA-C-N 116.72 0.26 . . . . 0.0 111.117 -176.583 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 234' ' ' PRO . . . . . 0.478 ' HD3' ' O ' ' A' ' 232' ' ' GLY . 4.8 Cg_exo -74.96 125.49 9.38 Favored 'Trans proline' 0 N--CA 1.457 -0.626 0 C-N-CA 122.259 1.972 . . . . 0.0 111.077 177.676 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -131.93 141.07 49.22 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.609 -179.14 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 236' ' ' HIS . . . . . 0.492 ' HE1' ' HA ' ' A' ' 252' ' ' GLN . 87.2 m-70 -141.48 149.04 40.41 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.681 -0.69 . . . . 0.0 109.947 178.207 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 237' ' ' LYS . . . . . 0.652 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -117.31 178.29 4.43 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.498 -175.349 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 238' ' ' VAL . . . . . 0.716 ' HB ' HG11 ' A' ' 248' ' ' VAL . 41.4 t -50.45 154.56 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.566 0 O-C-N 123.622 0.577 . . . . 0.0 111.31 -177.361 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 239' ' ' GLU . . . . . 0.646 ' O ' ' HB ' ' A' ' 248' ' ' VAL . 5.5 mm-40 -47.64 159.08 0.17 Allowed 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 113.032 0.752 . . . . 0.0 113.032 -177.137 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 240' ' ' ALA . . . . . . . . . . . . . . . -47.97 -35.41 10.78 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 115.259 -0.882 . . . . 0.0 112.009 179.069 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 241' ' ' LYS . . . . . 0.587 ' O ' ' HD3' ' A' ' 241' ' ' LYS . 0.0 OUTLIER -134.68 147.44 50.11 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.784 175.83 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -95.84 -175.88 3.55 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.835 179.647 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 44.0 m -67.57 -16.25 64.09 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.166 -0.47 . . . . 0.0 112.027 -175.574 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 5.7 m120 -90.34 -12.88 36.37 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-O 121.01 0.434 . . . . 0.0 110.329 176.869 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 89.82 17.74 53.26 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 121.006 -0.616 . . . . 0.0 112.288 -179.667 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 246' ' ' MET . . . . . 0.421 ' HA ' ' HD3' ' A' ' 247' ' ' PRO . 60.9 mtt -91.26 143.87 28.96 Favored Pre-proline 0 C--N 1.326 -0.442 0 CA-C-O 120.478 0.18 . . . . 0.0 110.621 -178.534 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 247' ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' ' 246' ' ' MET . 25.7 Cg_exo -65.81 125.87 15.0 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 122.885 2.39 . . . . 0.0 112.753 -177.18 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.716 HG11 ' HB ' ' A' ' 238' ' ' VAL . 31.7 t -120.1 144.43 28.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.009 178.825 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 8.1 t70 -88.45 112.32 22.81 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.068 178.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 250' ' ' ASN . . . . . . . . . . . . . 26.0 t-20 -99.69 -52.23 3.52 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.844 -176.343 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 98.4 mtt180 68.36 173.79 0.28 Allowed 'General case' 0 N--CA 1.472 0.668 0 N-CA-C 114.104 1.149 . . . . 0.0 114.104 179.832 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 252' ' ' GLN . . . . . 0.492 ' HA ' ' HE1' ' A' ' 236' ' ' HIS . 2.7 mm100 -117.34 177.55 4.69 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 114.312 -1.313 . . . . 0.0 109.341 179.931 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . 0.47 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -113.76 121.92 5.61 Favored Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.126 -1.035 . . . . 0.0 112.305 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 254' ' ' THR . . . . . 0.451 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 65.7 p -104.16 116.71 32.67 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 177.418 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.88 HD12 HG11 ' A' ' 230' ' ' VAL . 17.0 pt -123.84 147.38 28.27 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 116.092 -0.504 . . . . 0.0 111.981 -173.93 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 85.6 m -95.71 110.92 22.98 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 174.449 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.471 ' HA ' HG13 ' A' ' 230' ' ' VAL . 34.0 m -89.8 143.14 11.82 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.723 0 C-N-CA 119.93 -0.708 . . . . 0.0 112.833 -168.137 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 258' ' ' SER . . . . . 0.421 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 34.4 t -91.91 7.39 42.29 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 114.454 -1.248 . . . . 0.0 108.667 169.77 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 259' ' ' ALA . . . . . 0.693 ' HB3' HD21 ' A' ' 262' ' ' LEU . . . -88.25 175.08 7.83 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-N 115.473 -0.785 . . . . 0.0 109.243 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . 0.528 ' H ' HD13 ' A' ' 228' ' ' LEU . 32.5 t -134.67 130.19 35.95 Favored 'General case' 0 C--N 1.323 -0.547 0 C-N-CA 120.465 -0.494 . . . . 0.0 111.57 -177.93 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 97.5 16.76 33.29 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.856 -0.688 . . . . 0.0 113.951 174.081 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 262' ' ' LEU . . . . . 0.693 HD21 ' HB3' ' A' ' 259' ' ' ALA . 2.0 mm? -65.7 128.92 37.91 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-N 117.344 0.572 . . . . 0.0 110.859 -178.841 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -128.83 175.39 8.67 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 176.335 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 43.4 t -78.64 131.2 34.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 174.325 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 100.15 9.19 48.92 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.627 -0.797 . . . . 0.0 112.699 -179.557 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -86.12 165.45 16.58 Favored 'General case' 0 CA--C 1.511 -0.521 0 CA-C-O 121.12 0.486 . . . . 0.0 110.147 175.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 267' ' ' ALA . . . . . 0.693 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -140.27 145.68 37.6 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.471 -179.575 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 268' ' ' PHE . . . . . 0.525 ' HB3' HD13 ' A' ' 334' ' ' ILE . 4.6 p90 -159.73 166.04 31.28 Favored 'General case' 0 C--N 1.319 -0.744 0 C-N-CA 120.127 -0.629 . . . . 0.0 111.328 -178.603 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 71.8 p -119.34 126.76 52.19 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.861 -0.608 . . . . 0.0 109.968 177.776 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 270' ' ' ILE . . . . . 0.595 HG12 HD12 ' A' ' 332' ' ' ILE . 46.6 mt -88.89 135.98 24.5 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.912 -177.49 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -65.31 122.16 16.5 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.002 -0.545 . . . . 0.0 111.23 -179.772 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 99.08 -23.86 34.64 Favored Glycine 0 N--CA 1.452 -0.256 0 CA-C-N 115.996 -0.547 . . . . 0.0 112.241 -179.392 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 49.0 t -94.22 108.42 20.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 121.152 0.501 . . . . 0.0 110.37 176.528 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 274' ' ' ASN . . . . . 0.409 ' HB2' ' OD1' ' A' ' 323' ' ' ASP . 63.7 m-80 -123.9 159.99 28.47 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 116.004 -0.544 . . . . 0.0 109.602 -179.398 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 53.1 p -92.04 164.68 13.52 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-O 121.124 0.487 . . . . 0.0 111.327 -179.048 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 276' ' ' VAL . . . . . 0.538 HG11 HG21 ' A' ' 309' ' ' VAL . 30.0 m -125.9 167.46 20.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.544 178.518 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 28.9 m80 -126.0 92.07 3.51 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.595 -0.275 . . . . 0.0 110.72 178.69 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 84.1 mt-30 -72.59 -14.13 61.54 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.769 0.319 . . . . 0.0 111.081 179.184 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 279' ' ' ILE . . . . . 0.513 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.2 mp -77.05 -59.95 2.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 116.539 -0.3 . . . . 0.0 110.319 -178.475 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 51.4 p -85.36 -10.02 56.85 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.454 -179.878 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 31.9 mmmt 58.35 43.81 19.39 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.7 -178.29 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -112.34 154.49 25.64 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.1 -178.357 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 49.8 p -105.96 123.01 47.3 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 176.731 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 284' ' ' THR . . . . . 0.432 ' HB ' ' HG3' ' A' ' 286' ' ' GLN . 82.0 p -124.53 -37.28 2.52 Favored 'General case' 0 C--N 1.317 -0.814 0 C-N-CA 120.487 -0.485 . . . . 0.0 111.508 -172.06 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 70.45 29.49 69.92 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.601 -0.809 . . . . 0.0 111.809 -177.394 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 286' ' ' GLN . . . . . 0.432 ' HG3' ' HB ' ' A' ' 284' ' ' THR . 24.4 mt-30 -76.25 113.87 32.43 Favored Pre-proline 0 C--N 1.33 -0.243 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.826 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 287' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_exo -51.65 126.55 19.97 Favored 'Trans proline' 0 C--O 1.232 0.224 0 C-N-CA 122.42 2.08 . . . . 0.0 111.928 -179.112 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -77.23 130.06 36.74 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 -175.018 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 289' ' ' VAL . . . . . 0.675 HG11 ' HG2' ' A' ' 337' ' ' LYS . 57.6 t -90.01 130.74 38.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.006 -176.108 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 290' ' ' PHE . . . . . 0.693 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 4.6 m-85 -98.79 151.18 21.07 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.05 -178.062 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 291' ' ' ARG . . . . . 0.495 ' HD2' ' C ' ' A' ' 290' ' ' PHE . 1.0 OUTLIER -113.18 130.09 56.32 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 174.172 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 47.9 t -92.49 129.51 42.96 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.231 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.923 -177.625 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 293' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -114.6 -20.7 10.6 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.684 -179.251 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 294' ' ' ALA . . . . . 0.586 ' HB3' ' HB ' ' A' ' 301' ' ' THR . . . -148.92 136.61 20.49 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.641 -0.424 . . . . 0.0 111.914 -179.303 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . 0.46 HG11 ' O ' ' A' ' 262' ' ' LEU . 80.4 t -142.7 123.0 10.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.681 -0.691 . . . . 0.0 109.79 175.515 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 36.2 t -154.09 108.66 3.06 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.58 -0.282 . . . . 0.0 110.742 179.158 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 63.57 54.8 29.21 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 121.031 -0.604 . . . . 0.0 112.189 -179.296 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 58.4 p 52.28 21.89 1.82 Allowed 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 123.725 0.81 . . . . 0.0 112.754 -176.764 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 45.8 m -107.64 117.83 35.13 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 173.911 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . 0.451 ' O ' ' HA ' ' A' ' 254' ' ' THR . 48.1 t -117.08 129.96 72.78 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.299 -172.041 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 301' ' ' THR . . . . . 0.586 ' HB ' ' HB3' ' A' ' 294' ' ' ALA . 45.1 m -98.21 116.75 31.09 Favored 'General case' 0 C--O 1.236 0.381 0 N-CA-C 108.744 -0.835 . . . . 0.0 108.744 174.718 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 302' ' ' ILE . . . . . 0.47 HG12 ' O ' ' A' ' 253' ' ' GLY . 29.2 pt -111.81 146.17 17.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 113.373 0.879 . . . . 0.0 113.373 -168.627 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 303' ' ' SER . . . . . 0.526 ' HB3' ' HA ' ' A' ' 304' ' ' PRO . 47.4 m -132.25 166.24 30.15 Favored Pre-proline 0 C--N 1.32 -0.698 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 171.899 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 304' ' ' PRO . . . . . 0.526 ' HA ' ' HB3' ' A' ' 303' ' ' SER . 6.0 Cg_exo -79.67 -142.71 0.24 Allowed 'Cis proline' 0 CA--C 1.531 0.327 0 CA-C-N 120.72 1.293 . . . . 0.0 112.636 0.291 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 305' ' ' LYS . . . . . 0.508 ' C ' HD12 ' A' ' 306' ' ' ILE . 0.0 OUTLIER -97.51 147.6 24.08 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.389 0.614 . . . . 0.0 112.152 178.784 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 306' ' ' ILE . . . . . 1.017 HG23 HG21 ' A' ' 322' ' ' VAL . 1.9 mp -119.83 110.35 28.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 115.043 -0.98 . . . . 0.0 110.131 -176.534 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 307' ' ' LEU . . . . . 0.434 ' HA ' ' HD3' ' A' ' 308' ' ' PRO . 88.6 mt -126.32 115.08 23.48 Favored Pre-proline 0 C--N 1.332 -0.183 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.221 -177.697 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 308' ' ' PRO . . . . . 0.774 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 35.3 Cg_exo -67.31 147.81 78.83 Favored 'Trans proline' 0 N--CA 1.474 0.339 0 C-N-CA 123.762 2.975 . . . . 0.0 114.714 -173.521 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . 0.617 HG22 ' HB1' ' A' ' 320' ' ' ALA . 26.2 t -93.34 -17.81 7.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 114.866 -1.061 . . . . 0.0 108.607 167.654 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 59.4 mm-40 -76.9 -6.71 53.57 Favored 'General case' 0 C--O 1.233 0.199 0 CA-C-N 115.23 -0.895 . . . . 0.0 112.117 -178.157 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 4.1 m120 -85.62 151.47 23.87 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.917 0.389 . . . . 0.0 111.101 179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 30.9 m -93.28 -1.16 56.37 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.579 0.704 . . . . 0.0 109.125 175.347 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 313' ' ' ASP . . . . . 0.638 ' O ' ' HG3' ' A' ' 317' ' ' ARG . 59.7 t0 -58.0 117.57 4.47 Favored 'General case' 0 C--N 1.333 -0.116 0 CA-C-N 115.328 -0.851 . . . . 0.0 110.781 -179.292 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 49.0 t -53.54 -33.8 22.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.835 -0.62 . . . . 0.0 112.172 -178.446 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -85.18 -29.81 24.43 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 112.183 0.438 . . . . 0.0 112.183 -178.017 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . 0.559 ' HB3' ' HB3' ' A' ' 313' ' ' ASP . 33.5 t -82.03 -27.74 32.88 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 111.759 0.281 . . . . 0.0 111.759 -175.133 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 317' ' ' ARG . . . . . 0.638 ' HG3' ' O ' ' A' ' 313' ' ' ASP . 49.8 mtp85 -63.98 -52.87 53.24 Favored Pre-proline 0 CA--C 1.539 0.548 0 N-CA-C 112.935 0.717 . . . . 0.0 112.935 -176.478 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 318' ' ' PRO . . . . . 0.604 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 22.1 Cg_exo -67.82 -28.93 35.95 Favored 'Trans proline' 0 C--N 1.357 0.991 0 C-N-CA 121.979 1.786 . . . . 0.0 112.871 -177.005 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 5.1 m-85 -98.42 12.84 33.7 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.017 -179.005 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . 0.617 ' HB1' HG22 ' A' ' 309' ' ' VAL . . . -59.76 144.27 48.76 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.539 -178.666 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 321' ' ' ASN . . . . . 0.452 ' OD1' HG13 ' A' ' 322' ' ' VAL . 17.5 p30 -142.98 -12.17 0.75 Allowed 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.53 -177.434 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 322' ' ' VAL . . . . . 1.017 HG21 HG23 ' A' ' 306' ' ' ILE . 35.0 m -139.15 178.65 3.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.404 177.658 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 323' ' ' ASP . . . . . 0.409 ' OD1' ' HB2' ' A' ' 274' ' ' ASN . 51.6 m-20 -64.01 -62.58 1.54 Allowed 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.978 176.87 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 324' ' ' ALA . . . . . 0.774 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -162.94 173.75 13.24 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 116.143 -0.481 . . . . 0.0 112.094 -175.44 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 22.0 pttp -119.28 106.97 42.04 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 115.218 -0.901 . . . . 0.0 109.457 172.277 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -86.29 167.52 9.13 Favored 'Trans proline' 0 C--O 1.235 0.367 0 C-N-CA 122.624 2.216 . . . . 0.0 113.507 -172.204 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 327' ' ' ALA . . . . . 0.424 ' O ' ' HB2' ' A' ' 328' ' ' GLU . . . -79.48 132.79 36.44 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 170.155 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 328' ' ' GLU . . . . . 0.424 ' HB2' ' O ' ' A' ' 327' ' ' ALA . 62.1 mm-40 73.27 166.25 0.3 Allowed 'General case' 0 N--CA 1.467 0.387 0 O-C-N 123.566 0.542 . . . . 0.0 109.576 -170.589 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 329' ' ' SER . . . . . 0.686 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 53.9 m -104.44 -10.53 17.64 Favored 'General case' 0 C--N 1.319 -0.731 0 C-N-CA 120.349 -0.54 . . . . 0.0 111.803 -174.265 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 67.62 -161.22 0.22 Allowed 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 113.022 0.749 . . . . 0.0 113.022 172.459 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -75.33 142.72 43.15 Favored 'General case' 0 CA--C 1.518 -0.275 0 CA-C-N 115.117 -0.947 . . . . 0.0 110.475 179.414 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 332' ' ' ILE . . . . . 0.686 HG13 HG23 ' A' ' 230' ' ' VAL . 24.8 mm -120.62 144.46 29.42 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.753 -175.783 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 33.8 m -111.27 97.63 6.92 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 178.404 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 334' ' ' ILE . . . . . 0.525 HD13 ' HB3' ' A' ' 268' ' ' PHE . 39.5 mm -81.57 131.54 33.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 112.769 0.655 . . . . 0.0 112.769 -173.247 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 335' ' ' LEU . . . . . 0.46 HD23 ' N ' ' A' ' 335' ' ' LEU . 1.7 pt? -152.03 -167.16 2.69 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 114.685 -1.143 . . . . 0.0 108.723 173.118 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 15.9 p-10 -110.88 -25.41 9.87 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 109.635 -0.505 . . . . 0.0 109.635 176.014 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 337' ' ' LYS . . . . . 0.675 ' HG2' HG11 ' A' ' 289' ' ' VAL . 27.1 tptp . . . . . 0 C--O 1.247 0.925 0 O-C-N 124.397 1.061 . . . . 0.0 111.407 177.506 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.953 0 N-CA-C 112.131 -0.387 . . . . 0.0 112.131 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 23.3 t 59.72 -141.71 0.61 Allowed 'General case' 0 CA--C 1.533 0.293 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 -179.291 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 60.9 m -112.09 -75.58 0.61 Allowed 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 178.708 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 47.91 66.81 0.95 Allowed 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.646 -0.707 . . . . 0.0 111.033 178.855 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 61.1 p -88.71 98.16 11.54 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.552 177.054 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 228' ' ' LEU . . . . . 0.608 HD22 ' H ' ' A' ' 260' ' ' SER . 53.4 mt -111.15 127.1 55.47 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.491 -173.31 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 229' ' ' THR . . . . . 0.527 ' HA ' ' HA ' ' A' ' 331' ' ' ALA . 64.3 p -129.91 -178.83 4.88 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 120.694 -0.402 . . . . 0.0 111.22 -178.822 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . 0.744 ' O ' ' HB2' ' A' ' 329' ' ' SER . 34.9 t -134.17 151.59 32.61 Favored 'Isoleucine or valine' 0 C--O 1.24 0.594 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 -179.43 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 41.7 t -126.89 125.37 41.48 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.23 175.383 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 87.61 91.75 1.02 Allowed Glycine 0 CA--C 1.52 0.382 0 C-N-CA 120.888 -0.673 . . . . 0.0 113.97 176.15 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 233' ' ' GLN . . . . . 0.562 ' HG2' ' OG ' ' A' ' 329' ' ' SER . 94.8 mm-40 -97.86 117.01 65.66 Favored Pre-proline 0 CA--C 1.519 -0.242 0 O-C-N 122.821 -0.223 . . . . 0.0 110.623 171.843 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 234' ' ' PRO . . . . . 0.523 ' HD3' HG22 ' A' ' 255' ' ' ILE . 11.8 Cg_exo -67.09 172.93 9.18 Favored 'Trans proline' 0 N--CA 1.462 -0.353 0 C-N-CA 122.685 2.257 . . . . 0.0 111.741 176.565 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 235' ' ' GLU . . . . . 0.416 ' HG3' ' HE2' ' A' ' 237' ' ' LYS . 9.7 pt-20 -96.42 146.91 24.36 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.013 178.058 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 236' ' ' HIS . . . . . 0.629 ' C ' ' HD2' ' A' ' 237' ' ' LYS . 28.6 m80 -126.07 129.78 49.81 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.088 0.471 . . . . 0.0 111.01 -173.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 237' ' ' LYS . . . . . 0.629 ' HD2' ' C ' ' A' ' 236' ' ' HIS . 2.8 mptp? -118.11 177.48 4.78 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.441 -0.799 . . . . 0.0 110.0 -179.114 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 238' ' ' VAL . . . . . 0.893 ' HB ' HG11 ' A' ' 248' ' ' VAL . 52.2 t -48.68 131.35 6.18 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.224 0 O-C-N 123.817 0.698 . . . . 0.0 110.797 -179.446 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 239' ' ' GLU . . . . . 1.021 ' HA ' ' HB3' ' A' ' 251' ' ' ARG . 0.8 OUTLIER -56.16 158.59 3.94 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 113.713 1.005 . . . . 0.0 113.713 -172.811 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 240' ' ' ALA . . . . . 0.57 ' H ' ' HD3' ' A' ' 251' ' ' ARG . . . -26.21 -71.45 0.03 OUTLIER 'General case' 0 N--CA 1.471 0.624 0 CA-C-N 113.826 -1.534 . . . . 0.0 114.274 -172.559 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 241' ' ' LYS . . . . . 0.574 ' O ' ' HD3' ' A' ' 241' ' ' LYS . 0.0 OUTLIER -151.13 145.49 25.49 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.079 0.466 . . . . 0.0 111.681 -176.34 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 12.7 p-10 -103.29 -158.09 0.65 Allowed 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.747 -177.319 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 43.6 t -67.32 -30.99 70.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.733 177.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 5.7 m120 -83.83 -13.56 53.42 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.837 0.351 . . . . 0.0 110.488 177.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 70.34 47.76 41.77 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 121.124 -0.56 . . . . 0.0 113.022 176.575 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 246' ' ' MET . . . . . 0.438 ' HA ' ' HD3' ' A' ' 247' ' ' PRO . 25.0 mmt -99.14 121.46 55.44 Favored Pre-proline 0 C--N 1.326 -0.438 0 CA-C-N 116.794 0.297 . . . . 0.0 110.517 179.085 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 247' ' ' PRO . . . . . 0.438 ' HD3' ' HA ' ' A' ' 246' ' ' MET . 12.0 Cg_exo -72.71 121.88 7.75 Favored 'Trans proline' 0 C--N 1.343 0.286 0 C-N-CA 122.907 2.405 . . . . 0.0 112.116 -178.068 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.893 HG11 ' HB ' ' A' ' 238' ' ' VAL . 21.5 t -123.24 160.57 26.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 116.374 -0.376 . . . . 0.0 110.005 -178.601 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 249' ' ' ASP . . . . . 0.443 ' HB3' ' HG2' ' A' ' 237' ' ' LYS . 51.7 t0 -52.51 147.51 8.22 Favored 'General case' 0 N--CA 1.469 0.503 0 C-N-CA 123.152 0.581 . . . . 0.0 110.189 178.658 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 250' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -34.9 142.46 0.05 Allowed 'General case' 0 N--CA 1.475 0.796 0 N-CA-C 115.176 1.547 . . . . 0.0 115.176 -169.461 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . 1.021 ' HB3' ' HA ' ' A' ' 239' ' ' GLU . 27.5 ptt180 -89.59 -59.27 2.25 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 114.207 -1.36 . . . . 0.0 111.668 178.445 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 252' ' ' GLN . . . . . 0.568 ' HA ' HE21 ' A' ' 252' ' ' GLN . 2.2 mm100 -97.61 178.39 5.19 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.043 -174.349 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . 0.469 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -154.47 172.58 32.98 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 119.667 -1.254 . . . . 0.0 113.032 -178.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 254' ' ' THR . . . . . 0.549 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 47.0 p -119.38 128.81 54.41 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 177.822 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.523 HG22 ' HD3' ' A' ' 234' ' ' PRO . 26.6 pt -114.66 149.73 16.83 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.357 -175.659 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 40.8 m -98.4 110.47 23.05 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 177.223 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.525 HG21 HD12 ' A' ' 262' ' ' LEU . 35.0 m -92.41 144.99 8.15 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.859 0 CA-C-O 121.631 0.729 . . . . 0.0 112.697 -171.123 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 41.1 m -90.3 7.75 36.83 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 114.046 -1.434 . . . . 0.0 108.41 168.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 259' ' ' ALA . . . . . 0.579 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -91.06 162.04 14.86 Favored 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 115.117 -0.947 . . . . 0.0 110.468 -177.497 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . 0.608 ' H ' HD22 ' A' ' 228' ' ' LEU . 48.7 m -137.82 138.91 39.64 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.122 -0.49 . . . . 0.0 109.814 177.36 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 94.55 34.26 6.4 Favored Glycine 0 N--CA 1.447 -0.586 0 C-N-CA 120.444 -0.884 . . . . 0.0 112.233 -178.42 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 262' ' ' LEU . . . . . 0.525 HD12 HG21 ' A' ' 257' ' ' VAL . 67.5 mt -102.37 143.39 32.18 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 178.361 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 3.0 mm100 -142.78 175.32 9.91 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 178.116 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 264' ' ' VAL . . . . . 0.434 HG22 ' HA ' ' A' ' 294' ' ' ALA . 49.0 t -78.17 132.48 32.37 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.202 177.698 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 103.77 8.24 40.24 Favored Glycine 0 N--CA 1.453 -0.211 0 C-N-CA 120.569 -0.824 . . . . 0.0 112.775 179.406 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -89.05 157.56 18.3 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.915 0.388 . . . . 0.0 110.066 176.838 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 267' ' ' ALA . . . . . 0.605 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -131.23 121.94 25.68 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 178.883 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 268' ' ' PHE . . . . . 0.408 ' HB3' HD13 ' A' ' 334' ' ' ILE . 4.6 p90 -145.14 164.57 30.87 Favored 'General case' 0 C--N 1.32 -0.706 0 C-N-CA 119.4 -0.92 . . . . 0.0 111.988 -173.929 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 75.7 p -117.64 129.6 55.85 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.531 -0.759 . . . . 0.0 109.76 176.191 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 270' ' ' ILE . . . . . . . . . . . . . 66.0 mt -97.54 141.52 15.75 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.766 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 179.838 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 271' ' ' ALA . . . . . 0.47 ' HB3' ' HB1' ' A' ' 330' ' ' ALA . . . -63.98 132.84 51.87 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.032 0.444 . . . . 0.0 111.438 -176.577 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 98.68 -22.35 41.37 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.992 -0.623 . . . . 0.0 112.158 -178.56 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . 0.565 ' O ' ' HA ' ' A' ' 287' ' ' PRO . 45.2 t -77.95 103.44 5.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 120.665 0.269 . . . . 0.0 110.459 178.476 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 274' ' ' ASN . . . . . 0.416 ' O ' ' HB ' ' A' ' 322' ' ' VAL . 3.3 m120 -96.72 136.97 36.51 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 108.79 -0.819 . . . . 0.0 108.79 174.842 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 275' ' ' SER . . . . . 0.404 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 8.1 t -99.48 165.58 11.57 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.773 0.321 . . . . 0.0 110.399 -176.219 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 19.0 m -128.76 155.49 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.014 0 CA-C-N 115.092 -0.958 . . . . 0.0 109.987 167.271 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 277' ' ' HIS . . . . . 0.623 ' HB2' ' HB3' ' A' ' 282' ' ' ASP . 29.3 m80 -100.41 89.74 4.06 Favored 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 108.547 -0.909 . . . . 0.0 108.547 175.148 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 5.3 tm0? -59.78 -47.54 85.3 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.091 -172.139 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 59.2 mt -56.44 -48.15 80.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 N-CA-C 111.942 0.349 . . . . 0.0 111.942 -177.166 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 40.6 p -94.97 -3.71 48.0 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 112.414 0.524 . . . . 0.0 112.414 -176.3 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 4.0 tppp? 59.22 53.2 5.52 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 121.285 0.564 . . . . 0.0 110.256 -178.337 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 282' ' ' ASP . . . . . 0.623 ' HB3' ' HB2' ' A' ' 277' ' ' HIS . 37.2 t70 -120.13 116.37 25.52 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.299 -175.416 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 67.8 p -107.16 118.17 35.99 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.3 178.83 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 67.5 p -129.05 -15.98 4.14 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 112.063 0.394 . . . . 0.0 112.063 -174.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 87.23 -3.09 86.89 Favored Glycine 0 N--CA 1.453 -0.179 0 C-N-CA 120.61 -0.805 . . . . 0.0 112.724 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 286' ' ' GLN . . . . . 0.472 ' HA ' ' HD3' ' A' ' 287' ' ' PRO . 82.9 mt-30 -64.76 137.92 97.3 Favored Pre-proline 0 C--N 1.33 -0.27 0 N-CA-C 110.425 -0.213 . . . . 0.0 110.425 179.006 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 287' ' ' PRO . . . . . 0.565 ' HA ' ' O ' ' A' ' 273' ' ' VAL . 32.8 Cg_exo -62.52 149.37 91.23 Favored 'Trans proline' 0 CA--C 1.529 0.257 0 C-N-CA 122.633 2.222 . . . . 0.0 113.448 -174.558 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 288' ' ' GLN . . . . . 0.553 ' HA ' HE21 ' A' ' 288' ' ' GLN . 1.9 tp-100 -87.06 136.82 32.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.075 176.989 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 289' ' ' VAL . . . . . 0.405 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 38.8 t -94.55 130.15 43.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.901 -0.591 . . . . 0.0 109.645 177.592 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 290' ' ' PHE . . . . . 0.605 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 53.6 m-85 -99.97 165.52 11.5 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.926 0.393 . . . . 0.0 111.772 -175.145 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 30.3 mmt-85 -119.76 127.98 53.32 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 174.075 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 57.7 t -86.6 130.74 36.26 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.886 0 CA-C-O 120.785 0.326 . . . . 0.0 111.583 -175.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 293' ' ' LEU . . . . . 0.511 HD21 ' HB2' ' A' ' 303' ' ' SER . 3.1 mm? -103.58 -34.88 8.5 Favored 'General case' 0 C--N 1.333 -0.112 0 CA-C-N 115.945 -0.571 . . . . 0.0 111.297 178.503 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 294' ' ' ALA . . . . . 0.51 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -154.22 140.1 18.19 Favored 'General case' 0 CA--C 1.518 -0.252 0 C-N-CA 120.648 -0.421 . . . . 0.0 111.593 -179.149 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 96.9 t -135.73 100.09 2.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.705 175.016 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 50.5 m -141.77 118.29 10.92 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.845 -176.33 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 63.93 46.5 91.36 Favored Glycine 0 C--N 1.33 0.236 0 C-N-CA 121.147 -0.549 . . . . 0.0 112.144 -178.018 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 72.2 p 51.0 23.54 1.53 Allowed 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 123.701 0.8 . . . . 0.0 112.221 -175.739 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 299' ' ' THR . . . . . 0.45 ' HA ' ' O ' ' A' ' 255' ' ' ILE . 50.7 m -114.0 118.47 34.22 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 176.609 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . 0.549 ' O ' ' HA ' ' A' ' 254' ' ' THR . 43.6 t -110.18 128.39 66.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.412 -172.515 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 59.3 m -83.97 114.14 21.49 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 108.091 -1.078 . . . . 0.0 108.091 171.568 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 302' ' ' ILE . . . . . 0.469 HG12 ' O ' ' A' ' 253' ' ' GLY . 31.0 pt -111.01 144.76 18.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 N-CA-C 113.279 0.844 . . . . 0.0 113.279 -167.059 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 303' ' ' SER . . . . . 0.511 ' HB2' HD21 ' A' ' 293' ' ' LEU . 50.4 m -149.6 157.7 38.43 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-N 114.041 -1.436 . . . . 0.0 107.409 173.018 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 304' ' ' PRO . . . . . 0.496 ' O ' ' HA ' ' A' ' 303' ' ' SER . 15.7 Cg_exo -69.27 -162.21 1.72 Allowed 'Cis proline' 0 CA--C 1.531 0.34 0 CA-C-N 120.151 1.09 . . . . 0.0 112.811 0.742 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 305' ' ' LYS . . . . . 0.611 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -95.27 142.38 27.75 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.401 0.619 . . . . 0.0 111.964 -178.124 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 306' ' ' ILE . . . . . 0.643 HG23 HG21 ' A' ' 322' ' ' VAL . 2.0 mp -86.35 84.92 2.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.079 -0.964 . . . . 0.0 109.939 -178.397 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 307' ' ' LEU . . . . . . . . . . . . . 96.8 mt -112.38 102.45 54.17 Favored Pre-proline 0 C--N 1.324 -0.501 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.579 -178.757 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 308' ' ' PRO . . . . . 0.684 ' HD2' HD22 ' A' ' 311' ' ' ASN . 12.4 Cg_exo -75.5 150.29 35.86 Favored 'Trans proline' 0 N--CA 1.462 -0.334 0 C-N-CA 122.898 2.399 . . . . 0.0 113.004 -174.398 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 42.5 t -72.26 -27.3 26.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 108.647 -0.872 . . . . 0.0 108.647 170.305 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 54.7 mm-40 -92.21 32.68 1.14 Allowed 'General case' 0 N--CA 1.453 -0.285 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.805 176.3 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.684 HD22 ' HD2' ' A' ' 308' ' ' PRO . 26.0 t-20 -71.98 -31.93 66.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.378 -178.336 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 312' ' ' THR . . . . . 0.5 ' HB ' ' O ' ' A' ' 311' ' ' ASN . 84.9 m 83.34 -25.43 0.14 Allowed 'General case' 0 N--CA 1.469 0.491 0 O-C-N 124.088 0.867 . . . . 0.0 111.116 -178.837 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 65.8 m-20 -81.89 122.9 28.33 Favored 'General case' 0 C--O 1.233 0.216 0 C-N-CA 120.522 -0.471 . . . . 0.0 109.96 172.571 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 38.8 t -59.35 -39.38 78.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 115.188 -0.914 . . . . 0.0 112.229 -173.092 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -66.22 -25.27 66.83 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 112.229 0.455 . . . . 0.0 112.229 -177.332 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 42.4 t -86.54 -12.59 48.32 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 111.773 0.286 . . . . 0.0 111.773 -177.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 317' ' ' ARG . . . . . 0.564 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 51.8 mtp85 -62.8 -50.61 76.78 Favored Pre-proline 0 CA--C 1.538 0.492 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 -178.503 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 318' ' ' PRO . . . . . 0.564 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 39.2 Cg_exo -63.32 -26.05 71.48 Favored 'Trans proline' 0 C--N 1.356 0.936 0 C-N-CA 121.903 1.735 . . . . 0.0 112.788 -177.755 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 6.0 m-85 -93.23 19.99 7.47 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.335 -179.409 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -59.49 131.02 49.68 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 112.31 0.485 . . . . 0.0 112.31 -175.799 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 76.3 m-20 -128.15 -18.38 4.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.507 -0.77 . . . . 0.0 110.255 175.052 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 322' ' ' VAL . . . . . 0.643 HG21 HG23 ' A' ' 306' ' ' ILE . 33.8 m -138.7 176.75 5.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.107 -179.576 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -98.74 -18.97 17.73 Favored 'General case' 0 C--N 1.327 -0.385 0 C-N-CA 121.002 -0.279 . . . . 0.0 111.123 -179.773 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 324' ' ' ALA . . . . . 0.529 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -168.62 156.67 8.1 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.98 -173.117 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 325' ' ' LYS . . . . . 0.401 ' HA ' ' HD3' ' A' ' 326' ' ' PRO . 35.4 mtmm -87.02 120.87 71.71 Favored Pre-proline 0 N--CA 1.453 -0.294 0 N-CA-C 107.618 -1.252 . . . . 0.0 107.618 165.442 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 326' ' ' PRO . . . . . 0.476 ' HG2' HG22 ' A' ' 273' ' ' VAL . 51.1 Cg_exo -61.14 162.81 18.53 Favored 'Trans proline' 0 C--O 1.233 0.274 0 C-N-CA 122.525 2.15 . . . . 0.0 113.612 -171.372 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -73.45 132.35 42.84 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 108.593 -0.891 . . . . 0.0 108.593 170.896 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 9.0 pm0 42.38 -137.46 0.25 Allowed 'General case' 0 N--CA 1.47 0.565 0 O-C-N 124.132 0.895 . . . . 0.0 110.338 -169.757 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 329' ' ' SER . . . . . 0.744 ' HB2' ' O ' ' A' ' 230' ' ' VAL . 38.1 m -113.98 -44.87 3.11 Favored 'General case' 0 C--N 1.322 -0.622 0 C-N-CA 119.797 -0.761 . . . . 0.0 111.604 176.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 330' ' ' ALA . . . . . 0.47 ' HB1' ' HB3' ' A' ' 271' ' ' ALA . . . 78.54 -166.66 0.04 OUTLIER 'General case' 0 N--CA 1.474 0.771 0 O-C-N 123.813 0.696 . . . . 0.0 112.52 176.169 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 331' ' ' ALA . . . . . 0.527 ' HA ' ' HA ' ' A' ' 229' ' ' THR . . . -84.95 157.92 20.67 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.755 -0.657 . . . . 0.0 112.386 -173.764 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 332' ' ' ILE . . . . . 0.479 HD11 ' CG2' ' A' ' 230' ' ' VAL . 29.1 mt -110.0 144.97 17.15 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.232 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.083 -179.223 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 54.4 m -111.45 98.46 7.48 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 172.35 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 334' ' ' ILE . . . . . 0.408 HD13 ' HB3' ' A' ' 268' ' ' PHE . 32.2 mm -84.96 134.79 26.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 N-CA-C 113.247 0.832 . . . . 0.0 113.247 -171.074 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 335' ' ' LEU . . . . . 0.427 HD23 ' N ' ' A' ' 335' ' ' LEU . 1.9 pt? -164.39 -166.16 1.07 Allowed 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 115.074 -0.966 . . . . 0.0 109.62 172.418 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 74.3 m-80 -143.84 21.39 1.8 Allowed 'General case' 0 C--N 1.324 -0.525 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 175.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 68.2 mttm . . . . . 0 C--O 1.242 0.66 0 CA-C-N 115.196 -0.911 . . . . 0.0 110.84 -174.371 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.914 0 N-CA-C 112.429 -0.268 . . . . 0.0 112.429 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 50.6 p -78.68 125.78 29.83 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.595 0.236 . . . . 0.0 111.048 178.784 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 84.8 m -71.66 -59.21 2.88 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.413 179.545 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 34.6 69.32 0.16 Allowed 'General case' 0 N--CA 1.471 0.609 0 O-C-N 124.356 1.035 . . . . 0.0 113.088 -179.309 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 51.8 m 60.25 90.53 0.06 Allowed 'General case' 0 C--O 1.234 0.285 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.906 176.838 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 228' ' ' LEU . . . . . 0.531 HD13 ' H ' ' A' ' 260' ' ' SER . 88.8 mt -68.77 144.77 54.24 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.317 173.891 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 40.7 p -132.29 179.32 6.18 Favored 'General case' 0 C--N 1.326 -0.441 0 C-N-CA 120.262 -0.575 . . . . 0.0 111.137 -176.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . 1.056 HG23 HD11 ' A' ' 332' ' ' ILE . 72.1 t -143.22 145.87 22.15 Favored 'Isoleucine or valine' 0 C--O 1.239 0.532 0 CA-C-O 120.775 0.322 . . . . 0.0 110.373 -179.446 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 46.2 t -131.74 97.58 4.24 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 115.234 -0.894 . . . . 0.0 109.181 173.818 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . -142.15 -157.53 7.19 Favored Glycine 0 N--CA 1.447 -0.6 0 C-N-CA 120.184 -1.008 . . . . 0.0 112.639 -176.008 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 83.5 mt-30 -86.1 159.98 52.95 Favored Pre-proline 0 C--N 1.323 -0.571 0 N-CA-C 110.396 -0.224 . . . . 0.0 110.396 179.775 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo -64.51 174.66 4.15 Favored 'Trans proline' 0 C--N 1.35 0.619 0 C-N-CA 122.875 2.383 . . . . 0.0 111.418 176.357 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 235' ' ' GLU . . . . . 0.538 ' HA ' ' OE1' ' A' ' 235' ' ' GLU . 3.9 mm-40 -91.9 167.54 12.05 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 113.461 0.911 . . . . 0.0 113.461 -174.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 236' ' ' HIS . . . . . 0.582 ' HB3' ' ND2' ' A' ' 250' ' ' ASN . 23.2 m80 -111.63 143.21 42.89 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 113.266 -1.788 . . . . 0.0 111.432 -165.239 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 237' ' ' LYS . . . . . 0.431 ' HD3' ' C ' ' A' ' 236' ' ' HIS . 18.7 mmtp -112.64 148.84 33.77 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.793 -173.461 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 238' ' ' VAL . . . . . 0.643 HG23 HD21 ' A' ' 307' ' ' LEU . 65.3 t -91.8 115.28 30.49 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-O 121.06 0.457 . . . . 0.0 110.738 178.022 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 239' ' ' GLU . . . . . . . . . . . . . 9.9 pt-20 -94.37 116.69 29.1 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.408 -0.815 . . . . 0.0 109.123 174.581 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 240' ' ' ALA . . . . . 0.522 ' O ' ' HA ' ' A' ' 247' ' ' PRO . . . -47.73 -51.86 20.57 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 115.671 -0.695 . . . . 0.0 112.698 -169.967 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 241' ' ' LYS . . . . . 0.813 ' HB2' ' HA2' ' A' ' 245' ' ' GLY . 0.1 OUTLIER -113.59 144.17 43.33 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-O 120.82 0.343 . . . . 0.0 111.773 -179.167 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 10.8 p-10 -93.24 -157.46 0.54 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.298 -178.016 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 48.0 p -60.68 -29.18 69.15 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.589 177.327 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 6.2 m120 -97.89 2.04 48.75 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.369 -179.583 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . 0.813 ' HA2' ' HB2' ' A' ' 241' ' ' LYS . . . 71.64 31.09 65.55 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.891 -0.671 . . . . 0.0 113.272 177.253 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 246' ' ' MET . . . . . . . . . . . . . 24.1 mmt -110.25 152.46 43.21 Favored Pre-proline 0 C--N 1.325 -0.479 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 178.473 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 247' ' ' PRO . . . . . 0.522 ' HA ' ' O ' ' A' ' 240' ' ' ALA . 23.4 Cg_exo -65.51 120.79 8.04 Favored 'Trans proline' 0 C--N 1.345 0.378 0 C-N-CA 122.226 1.951 . . . . 0.0 111.879 -178.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 62.2 t -133.66 134.29 56.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.591 -178.787 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 37.4 t70 -89.82 117.8 28.93 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 174.757 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 250' ' ' ASN . . . . . 0.582 ' ND2' ' HB3' ' A' ' 236' ' ' HIS . 49.5 t30 -65.31 159.9 22.89 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.155 -174.51 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 37.7 ptt180 -66.76 -172.98 0.2 Allowed 'General case' 0 CA--C 1.533 0.303 0 N-CA-C 113.012 0.745 . . . . 0.0 113.012 -175.782 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 252' ' ' GLN . . . . . 0.49 ' HB3' ' O ' ' A' ' 302' ' ' ILE . 3.0 mm100 -96.61 177.96 5.49 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.222 -0.899 . . . . 0.0 110.729 -177.233 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . 0.519 ' HA2' ' CE1' ' A' ' 236' ' ' HIS . . . -95.5 152.22 20.29 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.184 177.877 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 52.1 p -129.5 116.96 19.73 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.758 0.314 . . . . 0.0 110.588 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.755 HD12 HG11 ' A' ' 230' ' ' VAL . 18.0 pt -125.94 149.92 31.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 N-CA-C 112.25 0.463 . . . . 0.0 112.25 -175.798 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 91.5 m -98.86 113.35 25.43 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 175.124 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.667 HG21 HD12 ' A' ' 262' ' ' LEU . 34.8 m -90.12 143.26 11.56 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.669 0 N-CA-C 113.38 0.881 . . . . 0.0 113.38 -167.009 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 258' ' ' SER . . . . . 0.433 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 37.4 t -92.73 7.94 41.44 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 113.795 -1.548 . . . . 0.0 108.523 168.163 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 259' ' ' ALA . . . . . 0.522 ' HB3' HD11 ' A' ' 262' ' ' LEU . . . -84.77 165.78 17.51 Favored 'General case' 0 N--CA 1.452 -0.363 0 CA-C-N 115.616 -0.72 . . . . 0.0 109.822 -177.344 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . 0.531 ' H ' HD13 ' A' ' 228' ' ' LEU . 49.4 m -123.47 142.0 51.44 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 120.814 0.34 . . . . 0.0 111.443 -178.005 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 67.3 50.65 43.27 Favored Glycine 0 N--CA 1.452 -0.25 0 CA-C-N 115.812 -0.631 . . . . 0.0 113.58 175.317 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 262' ' ' LEU . . . . . 0.667 HD12 HG21 ' A' ' 257' ' ' VAL . 77.7 mt -99.64 145.83 27.15 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 117.086 0.443 . . . . 0.0 110.842 178.034 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 83.6 mt-30 -142.94 171.75 13.63 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.928 178.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 50.8 t -77.16 133.32 31.03 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 176.731 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . 0.483 ' O ' ' HE3' ' A' ' 337' ' ' LYS . . . 107.62 -7.83 36.76 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.44 -0.886 . . . . 0.0 112.619 -179.372 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 63.4 m-20 -69.28 155.63 40.09 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-O 121.069 0.462 . . . . 0.0 110.567 178.262 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 267' ' ' ALA . . . . . 0.621 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -130.2 129.69 43.72 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 115.45 -0.795 . . . . 0.0 108.884 177.442 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 268' ' ' PHE . . . . . . . . . . . . . 3.2 p90 -151.38 175.63 12.06 Favored 'General case' 0 C--N 1.322 -0.607 0 C-N-CA 119.97 -0.692 . . . . 0.0 111.466 -175.456 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 269' ' ' THR . . . . . 0.468 HG21 ' HB2' ' A' ' 287' ' ' PRO . 82.7 p -126.14 147.19 49.67 Favored 'General case' 0 C--N 1.32 -0.674 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 176.571 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 270' ' ' ILE . . . . . . . . . . . . . 47.1 mm -103.65 138.26 28.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 N-CA-C 110.236 -0.283 . . . . 0.0 110.236 179.381 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -63.34 135.4 56.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.442 -178.608 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 89.41 -23.19 20.02 Favored Glycine 0 CA--C 1.517 0.198 0 CA-C-N 115.92 -0.582 . . . . 0.0 112.712 179.755 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . 0.473 HG21 ' HG3' ' A' ' 326' ' ' PRO . 42.5 t -86.09 130.24 36.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-O 120.925 0.393 . . . . 0.0 110.879 179.939 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 72.3 m-80 -135.24 142.08 45.91 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.329 179.671 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 65.2 p -84.04 165.81 18.25 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.252 0.549 . . . . 0.0 111.746 -178.279 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 276' ' ' VAL . . . . . 0.428 HG11 HG21 ' A' ' 309' ' ' VAL . 35.4 m -113.64 175.82 2.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 115.315 -0.857 . . . . 0.0 110.668 179.432 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 277' ' ' HIS . . . . . 0.43 ' HB3' ' HA ' ' A' ' 281' ' ' LYS . 5.8 p80 22.04 77.75 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.866 0 O-C-N 124.822 1.326 . . . . 0.0 113.866 179.304 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 278' ' ' GLN . . . . . 0.402 ' HA ' ' NE2' ' A' ' 278' ' ' GLN . 2.7 tp-100 -62.03 -50.52 71.7 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.177 -179.055 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 279' ' ' ILE . . . . . 0.582 ' H ' ' HB3' ' A' ' 282' ' ' ASP . 2.5 mp -104.43 -77.44 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 174.814 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 35.9 p -141.11 92.61 2.5 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 177.477 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 281' ' ' LYS . . . . . 0.43 ' HA ' ' HB3' ' A' ' 277' ' ' HIS . 31.7 mmmt 59.82 26.99 16.23 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.058 -0.973 . . . . 0.0 110.503 -172.6 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 282' ' ' ASP . . . . . 0.582 ' HB3' ' H ' ' A' ' 279' ' ' ILE . 37.3 t70 -81.01 117.38 21.56 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.338 -0.846 . . . . 0.0 109.858 178.605 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 41.1 p -105.52 105.78 15.97 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.991 0.424 . . . . 0.0 110.931 -176.502 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 52.9 p -129.18 -7.58 4.82 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.183 -177.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 67.82 32.6 78.06 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.601 -0.809 . . . . 0.0 113.368 176.249 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 286' ' ' GLN . . . . . 0.415 ' HA ' ' HD3' ' A' ' 287' ' ' PRO . 11.7 mm100 -72.09 135.89 82.32 Favored Pre-proline 0 C--N 1.325 -0.479 0 CA-C-N 117.06 0.43 . . . . 0.0 110.2 179.106 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 287' ' ' PRO . . . . . 0.468 ' HB2' HG21 ' A' ' 269' ' ' THR . 41.0 Cg_exo -57.0 135.0 68.21 Favored 'Trans proline' 0 C--O 1.235 0.333 0 C-N-CA 122.465 2.11 . . . . 0.0 111.958 -178.778 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 2.5 tm0? -75.08 128.93 36.67 Favored 'General case' 0 C--N 1.326 -0.451 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 -177.294 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 46.4 t -94.19 123.83 46.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 120.935 0.398 . . . . 0.0 110.512 -177.621 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 290' ' ' PHE . . . . . 0.621 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 4.6 m-85 -97.28 168.6 10.32 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.818 -177.214 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 11.9 tpt180 -139.37 121.16 15.41 Favored 'General case' 0 C--N 1.318 -0.792 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 177.355 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 60.7 t -75.61 134.25 29.58 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.913 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.868 -172.824 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 293' ' ' LEU . . . . . 0.621 HD11 ' HB3' ' A' ' 303' ' ' SER . 7.0 mp -104.38 -35.2 8.02 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.628 178.388 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 294' ' ' ALA . . . . . 0.529 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -149.75 137.95 20.51 Favored 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 120.667 -0.413 . . . . 0.0 111.641 -176.545 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 66.5 t -136.03 109.63 9.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.555 174.79 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 50.4 m -151.48 117.02 5.38 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.544 -177.279 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 61.21 46.97 93.4 Favored Glycine 0 C--N 1.33 0.218 0 C-N-CA 120.804 -0.712 . . . . 0.0 111.79 -177.83 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 76.3 p 51.78 19.79 1.01 Allowed 'General case' 0 N--CA 1.471 0.587 0 C-N-CA 123.76 0.824 . . . . 0.0 112.427 -175.169 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 54.3 m -105.22 116.68 32.35 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 176.756 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . 0.529 ' HA ' ' O ' ' A' ' 294' ' ' ALA . 49.0 t -114.21 125.77 71.58 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.288 -172.753 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 53.9 m -87.77 115.76 25.44 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 172.78 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 302' ' ' ILE . . . . . 0.49 ' O ' ' HB3' ' A' ' 252' ' ' GLN . 28.6 pt -110.81 147.81 14.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-O 121.867 0.842 . . . . 0.0 113.156 -169.012 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 303' ' ' SER . . . . . 0.621 ' HB3' HD11 ' A' ' 293' ' ' LEU . 48.2 t -151.23 148.82 23.27 Favored Pre-proline 0 C--N 1.317 -0.812 0 CA-C-N 113.808 -1.542 . . . . 0.0 106.911 174.487 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 304' ' ' PRO . . . . . 0.476 ' C ' ' HA ' ' A' ' 303' ' ' SER . 32.2 Cg_exo -64.31 152.71 74.16 Favored 'Cis proline' 0 C--N 1.332 -0.302 0 C-N-CA 124.252 -1.145 . . . . 0.0 113.299 0.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 305' ' ' LYS . . . . . 0.452 ' HE3' HD11 ' A' ' 307' ' ' LEU . 0.0 OUTLIER -82.04 148.81 28.41 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-N 114.888 -1.051 . . . . 0.0 110.184 173.761 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 306' ' ' ILE . . . . . 1.011 HG21 ' HA ' ' A' ' 325' ' ' LYS . 42.5 mm -84.23 117.85 30.47 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 N-CA-C 113.02 0.748 . . . . 0.0 113.02 -167.626 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 307' ' ' LEU . . . . . 0.643 HD21 HG23 ' A' ' 238' ' ' VAL . 82.1 mt -121.46 100.0 44.94 Favored Pre-proline 0 C--N 1.331 -0.199 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.782 177.314 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 308' ' ' PRO . . . . . 0.756 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 16.0 Cg_exo -72.74 134.48 22.06 Favored 'Trans proline' 0 C--O 1.232 0.218 0 C-N-CA 123.19 2.593 . . . . 0.0 113.611 -176.271 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . 0.678 ' HA ' ' HB2' ' A' ' 316' ' ' SER . 46.4 t -72.18 -34.66 50.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.356 0.598 . . . . 0.0 109.409 171.345 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 87.8 mt-10 -77.07 36.27 0.17 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.288 -0.869 . . . . 0.0 111.939 179.777 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.404 ' HB2' ' HB2' ' A' ' 308' ' ' PRO . 20.3 t-20 -122.3 56.71 1.1 Allowed 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 -178.751 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 312' ' ' THR . . . . . 0.568 ' HB ' HG23 ' A' ' 314' ' ' VAL . 30.0 m 60.35 17.43 7.12 Favored 'General case' 0 CA--C 1.539 0.553 0 CA-C-O 121.716 0.77 . . . . 0.0 109.411 -171.762 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 37.1 t70 69.53 -2.58 1.88 Allowed 'General case' 0 CA--C 1.537 0.466 0 CA-C-N 114.728 -1.124 . . . . 0.0 111.233 -177.369 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 314' ' ' VAL . . . . . 0.568 HG23 ' HB ' ' A' ' 312' ' ' THR . 57.6 t -57.44 -45.59 85.67 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 N-CA-C 112.723 0.638 . . . . 0.0 112.723 -177.759 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . 0.53 ' HB3' ' O ' ' A' ' 308' ' ' PRO . . . -74.44 -17.54 60.77 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.021 0.439 . . . . 0.0 110.899 -179.714 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . 0.678 ' HB2' ' HA ' ' A' ' 309' ' ' VAL . 44.3 t -81.36 -18.72 44.64 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.552 177.126 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 317' ' ' ARG . . . . . 0.684 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 37.3 mmm-85 -61.1 -55.84 40.34 Favored Pre-proline 0 CA--C 1.536 0.42 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.635 -176.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 318' ' ' PRO . . . . . 0.684 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 11.8 Cg_exo -71.98 -41.13 2.18 Favored 'Trans proline' 0 C--N 1.357 1.003 0 C-N-CA 121.565 1.51 . . . . 0.0 112.588 -178.516 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER 177.35 96.67 0.01 OUTLIER 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.103 177.653 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . 0.617 ' HB2' ' HA ' ' A' ' 316' ' ' SER . . . -69.68 138.51 53.02 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.077 176.899 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 19.6 p30 -129.23 -27.9 2.41 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.479 -0.328 . . . . 0.0 111.57 176.833 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 322' ' ' VAL . . . . . 0.843 HG21 HG23 ' A' ' 306' ' ' ILE . 35.1 m -138.31 179.49 3.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.703 0.287 . . . . 0.0 110.596 177.758 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 -90.38 -32.72 16.33 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.502 177.776 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 324' ' ' ALA . . . . . 0.756 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -149.2 159.51 44.19 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.638 -0.255 . . . . 0.0 111.478 -175.351 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 325' ' ' LYS . . . . . 1.011 ' HA ' HG21 ' A' ' 306' ' ' ILE . 64.3 pttt -79.94 146.9 64.79 Favored Pre-proline 0 N--CA 1.452 -0.335 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 171.413 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 326' ' ' PRO . . . . . 0.548 ' HD3' HG21 ' A' ' 306' ' ' ILE . 50.6 Cg_exo -57.33 129.81 36.02 Favored 'Trans proline' 0 N--CA 1.462 -0.365 0 C-N-CA 122.253 1.969 . . . . 0.0 111.873 -178.299 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -75.13 121.79 22.61 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 174.285 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER 61.95 -135.95 0.52 Allowed 'General case' 0 C--N 1.332 -0.158 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 -167.474 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 329' ' ' SER . . . . . 0.718 ' HB2' ' O ' ' A' ' 230' ' ' VAL . 50.5 m -113.95 -41.45 3.55 Favored 'General case' 0 C--N 1.32 -0.711 0 C-N-CA 120.16 -0.616 . . . . 0.0 109.871 169.67 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 330' ' ' ALA . . . . . 0.436 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 79.77 -171.04 0.04 OUTLIER 'General case' 0 N--CA 1.479 1.008 0 O-C-N 124.129 0.893 . . . . 0.0 113.394 170.819 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -83.77 157.22 22.17 Favored 'General case' 0 C--O 1.233 0.213 0 CA-C-N 115.176 -0.92 . . . . 0.0 111.107 -176.823 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 332' ' ' ILE . . . . . 1.056 HD11 HG23 ' A' ' 230' ' ' VAL . 1.5 mp -126.37 146.37 32.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.474 -174.854 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.417 ' HB ' ' OG1' ' A' ' 269' ' ' THR . 88.6 m -110.66 99.16 8.16 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.998 -0.742 . . . . 0.0 108.998 173.251 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 37.8 mm -81.58 125.7 39.69 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -171.238 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 335' ' ' LEU . . . . . 0.432 ' HB2' ' O ' ' A' ' 267' ' ' ALA . 8.2 mp -113.07 167.3 10.64 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.074 -0.966 . . . . 0.0 109.958 172.167 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 74.0 m-80 -124.33 6.57 8.4 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 115.315 -0.857 . . . . 0.0 109.271 174.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 337' ' ' LYS . . . . . 0.483 ' HE3' ' O ' ' A' ' 265' ' ' GLY . 21.5 pttp . . . . . 0 C--O 1.244 0.798 0 O-C-N 124.656 1.223 . . . . 0.0 112.565 -179.418 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.833 0 N-CA-C 112.198 -0.361 . . . . 0.0 112.198 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 49.4 m 59.93 71.86 0.55 Allowed 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 121.003 0.43 . . . . 0.0 111.031 -178.021 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 88.8 m -69.14 -49.16 59.47 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.711 -179.238 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 86.7 tt0 53.23 45.83 27.76 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-O 121.588 0.709 . . . . 0.0 110.427 179.378 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 29.0 t -147.81 24.94 1.06 Allowed 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.559 0.695 . . . . 0.0 109.499 179.749 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 228' ' ' LEU . . . . . 0.498 HD13 ' H ' ' A' ' 260' ' ' SER . 89.8 mt -99.77 146.79 26.17 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.274 -0.875 . . . . 0.0 109.237 178.533 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 229' ' ' THR . . . . . 0.429 ' HA ' ' HA ' ' A' ' 331' ' ' ALA . 72.5 p -128.93 178.75 6.16 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 119.835 -0.746 . . . . 0.0 111.075 -177.89 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . 0.652 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 75.7 t -147.15 127.68 5.39 Favored 'Isoleucine or valine' 0 C--O 1.237 0.434 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.482 -178.918 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 34.1 t -92.53 145.18 24.64 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.012 176.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 115.46 141.64 7.44 Favored Glycine 0 N--CA 1.444 -0.773 0 C-N-CA 120.619 -0.801 . . . . 0.0 111.647 -179.097 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 233' ' ' GLN . . . . . 0.922 ' HG3' ' H ' ' A' ' 328' ' ' GLU . 15.0 mp0 -101.75 103.69 30.16 Favored Pre-proline 0 C--N 1.321 -0.638 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 -177.739 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -85.3 122.47 2.47 Favored 'Trans proline' 0 N--CA 1.45 -1.084 0 C-N-CA 121.485 1.457 . . . . 0.0 111.751 179.64 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 235' ' ' GLU . . . . . 0.479 ' HG2' ' HB3' ' A' ' 325' ' ' LYS . 54.2 mt-10 -154.07 120.05 5.32 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.328 178.787 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 236' ' ' HIS . . . . . 0.462 ' NE2' ' HB2' ' A' ' 250' ' ' ASN . 63.3 t-80 -138.64 146.77 42.08 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 174.474 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 237' ' ' LYS . . . . . 0.659 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 5.8 mptt -122.34 135.66 54.76 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.765 -169.484 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 238' ' ' VAL . . . . . 0.915 HG22 ' HB2' ' A' ' 249' ' ' ASP . 46.7 t -70.78 124.5 27.15 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 115.661 -0.7 . . . . 0.0 109.706 175.765 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 239' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 -85.4 154.28 21.95 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.772 0.32 . . . . 0.0 110.347 179.477 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 240' ' ' ALA . . . . . . . . . . . . . . . -65.32 -32.13 73.62 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.352 -179.005 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 241' ' ' LYS . . . . . 0.69 ' O ' ' HD3' ' A' ' 241' ' ' LYS . 0.0 OUTLIER -141.32 144.88 34.84 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 121.256 0.55 . . . . 0.0 111.823 -179.899 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 54.6 p-10 -106.97 -156.5 0.58 Allowed 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.081 174.18 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 32.7 p -68.29 -9.25 46.24 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 112.018 0.377 . . . . 0.0 112.018 176.594 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 5.5 m120 -111.18 -10.07 14.31 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.705 0.288 . . . . 0.0 111.253 176.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . 0.48 ' HA2' ' HB2' ' A' ' 241' ' ' LYS . . . 93.01 15.88 50.15 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.723 -0.751 . . . . 0.0 113.571 177.432 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 246' ' ' MET . . . . . . . . . . . . . 26.1 ptt? -113.09 151.19 43.98 Favored Pre-proline 0 C--N 1.324 -0.516 0 CA-C-N 117.121 0.46 . . . . 0.0 110.248 177.592 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 247' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_exo -68.84 118.19 5.51 Favored 'Trans proline' 0 C--N 1.346 0.418 0 C-N-CA 121.856 1.704 . . . . 0.0 111.592 -178.253 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 43.9 t -145.24 143.61 22.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.142 -177.152 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 249' ' ' ASP . . . . . 0.915 ' HB2' HG22 ' A' ' 238' ' ' VAL . 9.0 t70 -89.29 140.64 29.29 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 109.454 -0.572 . . . . 0.0 109.454 175.055 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 250' ' ' ASN . . . . . 0.462 ' HB2' ' NE2' ' A' ' 236' ' ' HIS . 67.4 m-80 -87.91 -64.99 1.06 Allowed 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 112.495 0.554 . . . . 0.0 112.495 -172.406 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . 0.441 ' HB2' ' CD2' ' A' ' 236' ' ' HIS . 68.6 mtp180 -113.61 158.77 20.4 Favored 'General case' 0 CA--C 1.511 -0.525 0 N-CA-C 114.322 1.23 . . . . 0.0 114.322 -171.82 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 4.7 mp0 -91.73 178.0 6.04 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 113.249 -1.796 . . . . 0.0 109.265 179.099 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . 0.605 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -80.75 93.08 1.46 Allowed Glycine 0 N--CA 1.446 -0.643 0 C-N-CA 120.312 -0.947 . . . . 0.0 112.23 177.748 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 72.7 p -94.5 116.33 28.66 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.022 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . . . . . . . . . 2.1 pp -136.24 171.53 16.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 N-CA-C 113.012 0.745 . . . . 0.0 113.012 -173.121 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 64.9 m -111.65 117.89 34.15 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 177.505 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.461 ' HB ' ' H ' ' A' ' 259' ' ' ALA . 34.9 m -90.9 144.7 8.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 N-CA-C 113.838 1.051 . . . . 0.0 113.838 -169.101 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 258' ' ' SER . . . . . 0.417 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 39.2 t -92.22 8.42 38.2 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 113.772 -1.558 . . . . 0.0 108.339 166.188 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 259' ' ' ALA . . . . . 0.461 ' H ' ' HB ' ' A' ' 257' ' ' VAL . . . -92.85 166.13 12.57 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.274 -0.876 . . . . 0.0 109.908 -177.52 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . 0.498 ' H ' HD13 ' A' ' 228' ' ' LEU . 32.4 t -139.17 137.09 35.75 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.77 0.319 . . . . 0.0 110.158 178.949 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 97.26 29.4 7.96 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 120.904 -0.665 . . . . 0.0 112.199 -177.821 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 262' ' ' LEU . . . . . 0.442 HD12 HG21 ' A' ' 257' ' ' VAL . 79.2 mt -101.63 126.78 48.52 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.107 0.479 . . . . 0.0 111.16 -179.617 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 97.0 mm-40 -134.11 -178.92 5.25 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.257 -0.883 . . . . 0.0 108.873 177.359 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 41.0 t -77.81 131.12 35.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 176.653 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 106.41 9.01 32.16 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.305 -0.95 . . . . 0.0 113.195 179.021 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -88.88 163.32 15.68 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.994 0.426 . . . . 0.0 110.31 176.57 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 267' ' ' ALA . . . . . 0.715 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -135.38 146.52 48.42 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.474 -0.784 . . . . 0.0 109.023 177.917 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 268' ' ' PHE . . . . . 0.407 ' HZ ' HG21 ' A' ' 302' ' ' ILE . 2.7 p90 -163.87 175.48 10.38 Favored 'General case' 0 C--N 1.325 -0.489 0 C-N-CA 120.054 -0.658 . . . . 0.0 111.709 -177.841 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 73.9 p -125.41 144.69 50.4 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.471 -0.786 . . . . 0.0 109.131 173.808 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 270' ' ' ILE . . . . . 0.402 ' HB ' ' HB ' ' A' ' 273' ' ' VAL . 58.7 mt -103.14 141.66 18.57 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 C-N-CA 121.127 -0.229 . . . . 0.0 110.968 -176.752 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -67.38 125.79 27.23 Favored 'General case' 0 C--O 1.232 0.133 0 CA-C-O 120.869 0.366 . . . . 0.0 110.947 179.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 91.82 -22.24 32.23 Favored Glycine 0 N--CA 1.453 -0.189 0 C-N-CA 121.058 -0.591 . . . . 0.0 112.194 -178.262 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . 0.402 ' HB ' ' HB ' ' A' ' 270' ' ' ILE . 48.9 t -94.58 102.55 13.73 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-O 121.33 0.586 . . . . 0.0 110.743 178.346 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 274' ' ' ASN . . . . . 0.687 ' HA ' ' HA ' ' A' ' 287' ' ' PRO . 70.7 m-80 -110.17 150.83 28.08 Favored 'General case' 0 C--N 1.318 -0.801 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 174.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 275' ' ' SER . . . . . 0.488 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 7.6 t -85.35 -169.58 2.71 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 120.301 -0.559 . . . . 0.0 110.092 -174.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 27.3 m -113.27 177.46 1.66 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 CA-C-N 115.612 -0.722 . . . . 0.0 112.054 179.553 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 277' ' ' HIS . . . . . 0.792 ' CG ' ' HA ' ' A' ' 281' ' ' LYS . 3.4 p80 -57.03 119.69 6.73 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 113.893 -1.503 . . . . 0.0 111.838 173.695 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -81.94 -49.52 10.21 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.987 -177.867 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 279' ' ' ILE . . . . . 0.659 ' H ' HD12 ' A' ' 279' ' ' ILE . 2.7 mp -68.18 -93.74 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.401 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.163 -174.759 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . 0.431 HG23 HG22 ' A' ' 279' ' ' ILE . 36.2 p -137.98 68.24 1.4 Allowed 'General case' 0 C--O 1.235 0.307 0 CA-C-O 120.637 0.256 . . . . 0.0 111.393 -174.939 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 281' ' ' LYS . . . . . 0.792 ' HA ' ' CG ' ' A' ' 277' ' ' HIS . 0.0 OUTLIER 56.59 32.33 20.74 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.675 -177.016 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 282' ' ' ASP . . . . . 0.579 ' O ' ' HB3' ' A' ' 277' ' ' HIS . 1.6 m-20 -74.86 -177.03 3.11 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.645 176.134 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 68.9 p -106.57 108.07 19.39 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 120.76 0.314 . . . . 0.0 110.211 178.258 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 74.8 p -117.07 -58.29 2.08 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.681 -175.314 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 64.24 30.85 78.97 Favored Glycine 0 C--O 1.23 -0.124 0 C-N-CA 121.064 -0.589 . . . . 0.0 113.347 174.633 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 286' ' ' GLN . . . . . 0.425 ' HA ' HE21 ' A' ' 286' ' ' GLN . 2.9 mm100 -101.12 129.69 26.58 Favored Pre-proline 0 C--N 1.323 -0.584 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 179.259 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 287' ' ' PRO . . . . . 0.687 ' HA ' ' HA ' ' A' ' 274' ' ' ASN . 48.3 Cg_exo -56.16 138.15 82.02 Favored 'Trans proline' 0 C--N 1.344 0.329 0 C-N-CA 122.563 2.175 . . . . 0.0 112.159 -179.356 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 288' ' ' GLN . . . . . 0.47 ' HA ' HE21 ' A' ' 288' ' ' GLN . 2.2 tp-100 -64.81 139.9 58.81 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.78 -179.069 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 289' ' ' VAL . . . . . . . . . . . . . 52.8 t -97.42 124.0 50.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 176.205 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 290' ' ' PHE . . . . . 0.715 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 6.2 m-85 -98.87 151.44 20.85 Favored 'General case' 0 C--N 1.323 -0.559 0 C-N-CA 120.884 -0.326 . . . . 0.0 110.876 -174.578 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 37.2 mmt180 -116.97 118.86 33.59 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.691 -0.686 . . . . 0.0 109.34 174.187 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 48.9 t -75.56 127.52 37.05 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.954 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.874 -178.517 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 293' ' ' LEU . . . . . . . . . . . . . 84.8 mt -110.84 -19.48 12.81 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.928 -176.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 294' ' ' ALA . . . . . 0.663 ' HB3' ' HB ' ' A' ' 301' ' ' THR . . . -155.72 138.3 15.05 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 111.85 0.315 . . . . 0.0 111.85 -178.887 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . 0.438 HG22 HG13 ' A' ' 300' ' ' VAL . 60.5 t -138.14 132.59 42.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 175.039 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 41.5 t -157.95 110.61 2.38 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.677 -0.238 . . . . 0.0 110.97 -176.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 60.76 46.03 95.29 Favored Glycine 0 C--N 1.33 0.25 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.028 179.798 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 298' ' ' THR . . . . . 0.42 ' O ' HG22 ' A' ' 257' ' ' VAL . 75.6 p 53.91 17.9 1.47 Allowed 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 123.887 0.875 . . . . 0.0 112.647 -175.845 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 52.9 m -102.77 109.55 21.18 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 108.015 -1.106 . . . . 0.0 108.015 171.171 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . 0.438 HG13 HG22 ' A' ' 295' ' ' VAL . 39.9 t -104.56 134.69 45.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.715 -169.124 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 301' ' ' THR . . . . . 0.663 ' HB ' ' HB3' ' A' ' 294' ' ' ALA . 94.3 m -96.99 109.31 22.08 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.352 -0.84 . . . . 0.0 108.997 172.626 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 302' ' ' ILE . . . . . 0.605 HG12 ' O ' ' A' ' 253' ' ' GLY . 30.2 pt -110.66 138.06 40.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-O 121.648 0.737 . . . . 0.0 111.922 -175.37 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 303' ' ' SER . . . . . . . . . . . . . 50.5 m -129.54 150.95 77.1 Favored Pre-proline 0 C--N 1.317 -0.846 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 173.162 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 304' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_exo -68.22 176.54 27.47 Favored 'Cis proline' 0 C--N 1.333 -0.282 0 C-N-CA 124.637 -0.985 . . . . 0.0 112.892 1.015 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 305' ' ' LYS . . . . . 0.888 ' HE2' HD11 ' A' ' 307' ' ' LEU . 0.0 OUTLIER -94.04 166.81 11.96 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.492 178.583 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 306' ' ' ILE . . . . . 0.599 HG22 ' HG2' ' A' ' 325' ' ' LYS . 42.6 mm -87.47 96.3 5.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.366 -174.144 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 307' ' ' LEU . . . . . 0.888 HD11 ' HE2' ' A' ' 305' ' ' LYS . 84.2 mt -106.82 110.32 63.6 Favored Pre-proline 0 C--N 1.33 -0.28 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 175.859 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 308' ' ' PRO . . . . . 0.632 ' HG3' ' HE3' ' A' ' 325' ' ' LYS . 79.1 Cg_endo -82.69 157.8 16.24 Favored 'Trans proline' 0 C--O 1.231 0.143 0 C-N-CA 122.512 2.141 . . . . 0.0 114.364 -172.12 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 39.6 t -81.76 -11.17 12.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 114.958 -1.019 . . . . 0.0 108.467 168.782 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 4.6 mm-40 -70.54 -7.03 40.77 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.19 -0.914 . . . . 0.0 110.219 176.618 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 23.8 t-20 -64.07 118.29 8.3 Favored 'General case' 0 N--CA 1.451 -0.391 0 CA-C-N 115.605 -0.725 . . . . 0.0 109.45 -179.141 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 19.5 m -86.3 -17.19 35.25 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.36 -171.441 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 313' ' ' ASP . . . . . 0.589 ' O ' ' HG3' ' A' ' 317' ' ' ARG . 9.8 t70 -71.83 118.58 14.86 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 178.438 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 314' ' ' VAL . . . . . 0.406 ' HA ' ' CD ' ' A' ' 317' ' ' ARG . 41.2 t -59.08 -36.4 62.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 116.054 -0.521 . . . . 0.0 112.273 -173.906 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -73.87 -25.36 60.0 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.502 0.191 . . . . 0.0 111.38 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 32.6 t -94.55 -6.22 44.16 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.693 -0.23 . . . . 0.0 111.096 -179.007 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 317' ' ' ARG . . . . . 0.589 ' HG3' ' O ' ' A' ' 313' ' ' ASP . 76.4 mtp180 -59.52 -49.6 91.39 Favored Pre-proline 0 N--CA 1.468 0.464 0 N-CA-C 112.392 0.516 . . . . 0.0 112.392 177.837 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 318' ' ' PRO . . . . . 0.515 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 54.3 Cg_exo -56.5 -24.4 52.86 Favored 'Trans proline' 0 C--N 1.359 1.118 0 C-N-CA 122.477 2.118 . . . . 0.0 112.756 -179.803 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 11.6 m-30 -77.08 -6.19 51.84 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.369 -0.832 . . . . 0.0 111.495 -175.68 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -54.85 130.28 40.51 Favored 'General case' 0 C--O 1.233 0.219 0 CA-C-O 120.976 0.417 . . . . 0.0 111.723 -177.662 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 26.7 t-20 -110.71 -37.88 5.31 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.663 -0.699 . . . . 0.0 109.554 179.294 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 322' ' ' VAL . . . . . 0.521 HG21 HG23 ' A' ' 306' ' ' ILE . 34.4 m -130.74 170.28 19.86 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 115.267 -0.879 . . . . 0.0 110.16 179.083 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 73.2 m-20 -62.11 -44.14 97.31 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 112.386 0.513 . . . . 0.0 112.386 -177.782 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 324' ' ' ALA . . . . . 0.509 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -156.56 168.41 27.47 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 112.666 0.617 . . . . 0.0 112.666 -172.493 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 325' ' ' LYS . . . . . 0.632 ' HE3' ' HG3' ' A' ' 308' ' ' PRO . 9.9 mtmp? -102.05 106.45 47.87 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 114.816 -1.084 . . . . 0.0 108.531 167.582 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -80.24 162.51 22.77 Favored 'Trans proline' 0 N--CA 1.459 -0.506 0 C-N-CA 122.018 1.812 . . . . 0.0 112.58 -175.59 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -80.03 122.55 26.88 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 174.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 328' ' ' GLU . . . . . 0.922 ' H ' ' HG3' ' A' ' 233' ' ' GLN . 85.0 tt0 71.89 162.81 0.26 Allowed 'General case' 0 CA--C 1.532 0.251 0 O-C-N 124.093 0.87 . . . . 0.0 109.672 -176.006 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 329' ' ' SER . . . . . 0.652 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 50.6 m -85.34 -14.57 46.02 Favored 'General case' 0 C--N 1.323 -0.554 0 C-N-CA 120.913 -0.315 . . . . 0.0 110.861 -177.375 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 330' ' ' ALA . . . . . 0.48 ' H ' ' HG2' ' A' ' 328' ' ' GLU . . . 63.5 -160.36 0.3 Allowed 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 121.381 0.61 . . . . 0.0 112.611 173.015 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 331' ' ' ALA . . . . . 0.429 ' HA ' ' HA ' ' A' ' 229' ' ' THR . . . -82.03 148.14 28.79 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.292 -0.867 . . . . 0.0 110.131 178.253 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 332' ' ' ILE . . . . . . . . . . . . . 43.4 mt -124.24 144.63 33.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-O 121.169 0.509 . . . . 0.0 111.304 -178.148 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 29.6 m -104.21 97.7 7.62 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.494 -0.775 . . . . 0.0 109.217 179.611 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 334' ' ' ILE . . . . . . . . . . . . . 36.4 mm -78.55 127.91 38.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 112.858 0.688 . . . . 0.0 112.858 -170.772 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 335' ' ' LEU . . . . . . . . . . . . . 8.2 mp -109.15 176.13 5.2 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 114.871 -1.059 . . . . 0.0 110.122 171.541 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 23.0 p30 -131.61 9.57 4.67 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 115.321 -0.854 . . . . 0.0 109.628 173.526 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 337' ' ' LYS . . . . . 0.536 ' NZ ' ' HB3' ' A' ' 337' ' ' LYS . 8.1 mtpm? . . . . . 0 C--O 1.244 0.794 0 CA-C-O 118.552 -0.737 . . . . 0.0 110.891 178.745 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.895 0 N-CA-C 111.948 -0.461 . . . . 0.0 111.948 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 55.4 p -93.18 -36.9 12.38 Favored 'General case' 0 C--N 1.326 -0.423 0 O-C-N 122.712 -0.287 . . . . 0.0 110.985 179.795 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 41.9 m 73.62 -57.46 0.62 Allowed 'General case' 0 N--CA 1.467 0.424 0 O-C-N 123.921 0.763 . . . . 0.0 110.791 -179.478 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 4.7 mm-40 57.05 34.27 24.65 Favored 'General case' 0 N--CA 1.465 0.302 0 C-N-CA 123.364 0.665 . . . . 0.0 112.41 176.88 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 65.9 p -141.3 21.31 2.23 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.699 -0.682 . . . . 0.0 109.812 173.387 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 228' ' ' LEU . . . . . 0.617 HD22 ' HA ' ' A' ' 259' ' ' ALA . 83.4 mt -98.01 126.82 43.6 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-N 115.614 -0.721 . . . . 0.0 109.761 -179.548 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 55.5 p -124.73 179.24 5.07 Favored 'General case' 0 C--N 1.322 -0.625 0 C-N-CA 120.458 -0.497 . . . . 0.0 110.3 -179.611 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . 0.712 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 63.5 t -147.63 146.92 17.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 120.602 0.239 . . . . 0.0 110.672 -178.234 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 231' ' ' SER . . . . . 0.528 ' HA ' ' HB3' ' A' ' 328' ' ' GLU . 48.9 m -132.11 96.62 3.94 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 173.386 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . 0.628 ' HA3' HG22 ' A' ' 255' ' ' ILE . . . -122.5 -163.05 11.74 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 119.854 -1.165 . . . . 0.0 113.693 -172.889 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 233' ' ' GLN . . . . . 0.581 ' HB3' ' HD2' ' A' ' 234' ' ' PRO . 94.6 mm-40 -85.49 163.63 43.76 Favored Pre-proline 0 C--N 1.327 -0.397 0 CA-C-N 115.615 -0.293 . . . . 0.0 110.541 -178.833 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 234' ' ' PRO . . . . . 0.581 ' HD2' ' HB3' ' A' ' 233' ' ' GLN . 9.5 Cg_endo -55.37 134.3 63.1 Favored 'Trans proline' 0 C--N 1.35 0.646 0 C-N-CA 122.871 2.38 . . . . 0.0 113.442 -176.51 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 235' ' ' GLU . . . . . 0.564 ' HB2' ' CE ' ' A' ' 325' ' ' LYS . 57.7 mt-10 -97.18 124.79 41.34 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 114.982 -1.008 . . . . 0.0 108.452 177.903 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 236' ' ' HIS . . . . . 0.441 ' HB2' HD21 ' A' ' 307' ' ' LEU . 6.3 p80 -174.1 172.81 3.27 Favored 'General case' 0 CA--C 1.521 -0.152 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 -175.145 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 237' ' ' LYS . . . . . 0.793 ' HB3' ' HG3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -161.41 125.25 3.32 Favored 'General case' 0 CA--C 1.529 0.172 0 CA-C-O 121.546 0.688 . . . . 0.0 110.881 165.649 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 238' ' ' VAL . . . . . 0.696 ' HB ' HG11 ' A' ' 248' ' ' VAL . 40.9 t -108.85 156.49 9.44 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.81 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 172.266 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 239' ' ' GLU . . . . . . . . . . . . . 16.4 pt-20 -54.57 152.22 7.07 Favored 'General case' 0 C--O 1.235 0.32 0 N-CA-C 111.582 0.216 . . . . 0.0 111.582 -177.863 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 240' ' ' ALA . . . . . 0.438 ' O ' ' HA ' ' A' ' 247' ' ' PRO . . . -33.24 -55.15 0.41 Allowed 'General case' 0 N--CA 1.471 0.61 0 N-CA-C 113.729 1.011 . . . . 0.0 113.729 -175.284 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 241' ' ' LYS . . . . . 0.56 ' HD2' ' O ' ' A' ' 241' ' ' LYS . 0.0 OUTLIER -135.05 150.68 50.32 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.763 0.316 . . . . 0.0 111.472 -179.294 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -96.37 -158.2 0.64 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.477 -177.77 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 65.0 m -60.23 -33.02 71.68 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.233 -0.439 . . . . 0.0 112.111 -177.936 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 50.7 t30 -87.87 -13.35 42.27 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 121.038 0.447 . . . . 0.0 110.387 179.247 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . 0.526 ' HA2' ' HB2' ' A' ' 241' ' ' LYS . . . 84.56 24.57 45.99 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.546 -0.835 . . . . 0.0 113.206 176.011 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 246' ' ' MET . . . . . 0.426 ' HA ' ' HD3' ' A' ' 247' ' ' PRO . 19.4 ptp -92.44 141.15 24.44 Favored Pre-proline 0 C--N 1.327 -0.411 0 CA-C-N 117.007 0.403 . . . . 0.0 110.173 176.042 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 247' ' ' PRO . . . . . 0.438 ' HA ' ' O ' ' A' ' 240' ' ' ALA . 20.0 Cg_exo -66.73 121.87 9.16 Favored 'Trans proline' 0 C--N 1.344 0.307 0 C-N-CA 122.547 2.165 . . . . 0.0 112.484 -176.95 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.696 HG11 ' HB ' ' A' ' 238' ' ' VAL . 47.7 t -91.51 140.73 15.57 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 176.188 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -78.0 89.97 4.17 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.231 0.538 . . . . 0.0 110.363 -178.328 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 250' ' ' ASN . . . . . 0.705 ' HB2' ' HB2' ' A' ' 237' ' ' LYS . 22.1 p30 -100.31 9.75 42.23 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.791 -177.067 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . . . . . . . . . 82.9 mtm180 -113.61 161.87 16.91 Favored 'General case' 0 CA--C 1.509 -0.613 0 N-CA-C 113.151 0.796 . . . . 0.0 113.151 -177.712 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 252' ' ' GLN . . . . . 0.604 HE22 HD12 ' A' ' 293' ' ' LEU . 2.5 mm100 55.58 179.74 0.04 OUTLIER 'General case' 0 N--CA 1.471 0.606 0 CA-C-N 113.616 -1.629 . . . . 0.0 113.425 170.65 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . -172.11 113.33 0.48 Allowed Glycine 0 N--CA 1.448 -0.555 0 CA-C-N 114.723 -1.126 . . . . 0.0 110.644 178.418 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 74.1 p -95.52 117.47 30.47 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 117.399 0.599 . . . . 0.0 110.771 -175.152 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.628 HG22 ' HA3' ' A' ' 232' ' ' GLY . 22.7 pt -120.81 132.59 69.93 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-O 121.239 0.542 . . . . 0.0 111.97 -175.447 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 60.7 m -88.34 110.55 20.86 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 173.874 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.42 ' HA ' HG13 ' A' ' 230' ' ' VAL . 33.2 m -90.1 143.06 11.98 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.84 0 C-N-CA 119.341 -0.943 . . . . 0.0 112.798 -167.89 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 25.0 m -91.61 9.23 33.09 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 113.852 -1.522 . . . . 0.0 108.301 169.915 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 259' ' ' ALA . . . . . 0.617 ' HA ' HD22 ' A' ' 228' ' ' LEU . . . -100.5 178.19 4.8 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 114.725 -1.125 . . . . 0.0 109.55 -177.314 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 42.0 t -145.03 151.38 38.46 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.782 0.325 . . . . 0.0 110.79 179.113 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 84.52 15.87 67.57 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.982 -0.628 . . . . 0.0 112.876 178.544 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 262' ' ' LEU . . . . . 0.437 ' O ' HG11 ' A' ' 295' ' ' VAL . 63.4 mt -85.38 129.92 34.7 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.678 0.275 . . . . 0.0 110.703 -179.11 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 14.4 mm-40 -139.95 173.04 11.92 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.726 178.93 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 36.1 t -67.63 137.89 23.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 C-N-CA 121.001 -0.279 . . . . 0.0 110.34 -179.852 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 101.93 4.7 51.24 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.541 -0.837 . . . . 0.0 112.962 177.648 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 68.4 m-20 -85.84 137.7 32.58 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.257 0.551 . . . . 0.0 110.143 177.193 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 267' ' ' ALA . . . . . 0.624 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -119.85 122.98 42.52 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.262 -0.881 . . . . 0.0 108.741 178.07 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 268' ' ' PHE . . . . . 0.531 ' HB3' ' HA ' ' A' ' 334' ' ' ILE . 7.8 p90 -142.3 168.31 20.05 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.097 -0.641 . . . . 0.0 112.309 -169.893 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 76.0 p -115.4 162.77 16.68 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 114.859 -1.064 . . . . 0.0 108.486 170.89 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 270' ' ' ILE . . . . . . . . . . . . . 59.5 mt -126.05 141.96 44.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.693 -178.5 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -66.36 112.51 4.06 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.97 179.439 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 272' ' ' GLY . . . . . 0.434 ' HA3' ' HG3' ' A' ' 326' ' ' PRO . . . 104.21 -9.43 50.04 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.642 -0.789 . . . . 0.0 112.467 179.947 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . 0.502 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 58.3 t -102.15 102.95 14.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.884 0.373 . . . . 0.0 110.17 178.796 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 6.9 m120 -126.76 116.38 20.83 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.058 -177.352 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 275' ' ' SER . . . . . 0.478 ' HB3' ' HB2' ' A' ' 288' ' ' GLN . 29.2 p -72.72 161.78 30.32 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 113.24 0.83 . . . . 0.0 113.24 -172.401 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 19.4 m -118.21 178.6 2.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 114.644 -1.162 . . . . 0.0 110.165 178.436 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 85.1 m-70 -112.23 105.08 13.31 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 171.548 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 4.9 mp0 -74.18 -35.88 64.01 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.645 -0.252 . . . . 0.0 111.329 -173.445 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 279' ' ' ILE . . . . . 0.507 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.1 mp -67.9 -55.94 14.84 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.983 -176.007 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 75.9 p -88.33 -3.81 58.78 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 111.782 0.289 . . . . 0.0 111.782 -177.64 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 28.0 tptp 58.81 53.1 6.04 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 121.441 0.638 . . . . 0.0 110.23 179.391 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -117.03 136.75 52.72 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.605 -176.93 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 66.8 p -107.63 127.53 53.74 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.149 -179.943 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 70.7 p -134.49 -30.75 1.11 Allowed 'General case' 0 C--N 1.321 -0.645 0 CA-C-O 120.774 0.321 . . . . 0.0 111.424 -176.709 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 79.39 32.48 38.25 Favored Glycine 0 N--CA 1.448 -0.536 0 C-N-CA 120.408 -0.901 . . . . 0.0 112.666 178.214 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 71.3 mt-30 -85.0 124.43 72.39 Favored Pre-proline 0 C--N 1.326 -0.415 0 CA-C-N 116.903 0.352 . . . . 0.0 110.489 179.973 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 287' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_exo -59.53 126.0 19.44 Favored 'Trans proline' 0 C--N 1.345 0.395 0 C-N-CA 122.281 1.988 . . . . 0.0 111.285 178.272 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 288' ' ' GLN . . . . . 0.478 ' HB2' ' HB3' ' A' ' 275' ' ' SER . 50.6 tt0 -80.4 150.55 29.76 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.045 0.45 . . . . 0.0 111.589 -175.212 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 289' ' ' VAL . . . . . 0.497 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 50.0 t -99.16 127.35 51.93 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 CA-C-N 115.327 -0.851 . . . . 0.0 110.221 179.278 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 290' ' ' PHE . . . . . 0.624 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 4.0 m-85 -101.2 168.7 9.4 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.562 -0.29 . . . . 0.0 111.025 -176.771 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 21.6 mmt85 -126.49 120.78 30.55 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.264 0.554 . . . . 0.0 110.745 174.418 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 59.5 t -78.24 128.56 38.23 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.829 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.313 176.035 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 293' ' ' LEU . . . . . 0.604 HD12 HE22 ' A' ' 252' ' ' GLN . 83.5 mt -109.0 -30.09 8.25 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 111.986 0.365 . . . . 0.0 111.986 -177.762 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 294' ' ' ALA . . . . . 0.585 ' HB3' ' HB ' ' A' ' 301' ' ' THR . . . -152.44 139.94 19.65 Favored 'General case' 0 C--N 1.329 -0.296 0 C-N-CA 121.171 -0.212 . . . . 0.0 111.334 179.717 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . 0.685 HG22 HG13 ' A' ' 300' ' ' VAL . 55.3 t -133.48 128.52 54.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 175.118 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 27.2 m -145.64 97.13 2.93 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.917 -176.316 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 57.45 61.03 7.94 Favored Glycine 0 C--N 1.33 0.224 0 C-N-CA 121.009 -0.615 . . . . 0.0 112.531 178.814 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 81.8 p 56.71 5.4 0.21 Allowed 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 124.395 1.078 . . . . 0.0 113.253 -177.17 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 97.4 m -97.88 106.31 18.6 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 171.623 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . 0.733 HG12 HG23 ' A' ' 302' ' ' ILE . 38.8 t -109.26 120.93 61.48 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.797 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.193 -170.883 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 301' ' ' THR . . . . . 0.585 ' HB ' ' HB3' ' A' ' 294' ' ' ALA . 52.6 m -89.66 105.7 17.98 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 174.526 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 302' ' ' ILE . . . . . 0.733 HG23 HG12 ' A' ' 300' ' ' VAL . 2.4 pp -111.72 179.13 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 121.893 0.854 . . . . 0.0 112.861 -174.898 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 303' ' ' SER . . . . . 0.419 ' HA ' ' O ' ' A' ' 304' ' ' PRO . 67.5 p -160.0 157.47 25.43 Favored Pre-proline 0 C--N 1.314 -0.961 0 CA-C-N 113.668 -1.606 . . . . 0.0 106.678 174.714 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 304' ' ' PRO . . . . . 0.419 ' O ' ' HA ' ' A' ' 303' ' ' SER . 3.8 Cg_exo -78.26 -141.67 0.2 Allowed 'Cis proline' 0 CA--C 1.536 0.605 0 CA-C-N 119.84 0.979 . . . . 0.0 112.993 1.057 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 305' ' ' LYS . . . . . 0.793 ' HG3' ' HB3' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -130.4 171.02 13.42 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.014 -178.545 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 306' ' ' ILE . . . . . 0.415 ' HB ' ' CB ' ' A' ' 235' ' ' GLU . 47.2 mm -132.36 129.35 59.38 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.619 0 C-N-CA 119.242 -0.983 . . . . 0.0 113.57 -164.765 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 307' ' ' LEU . . . . . 0.71 HD13 ' HA ' ' A' ' 316' ' ' SER . 88.0 mt -134.39 125.44 17.75 Favored Pre-proline 0 CA--C 1.514 -0.435 0 CA-C-O 120.883 0.373 . . . . 0.0 111.459 170.287 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 308' ' ' PRO . . . . . 0.991 ' HG2' ' HB2' ' A' ' 311' ' ' ASN . 66.8 Cg_endo -84.24 157.71 13.0 Favored 'Trans proline' 0 N--CA 1.455 -0.782 0 C-N-CA 122.89 2.394 . . . . 0.0 112.711 179.041 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 44.5 t -80.79 -18.93 11.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-O 121.587 0.708 . . . . 0.0 109.126 172.104 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 54.7 mt-10 -94.62 34.91 1.27 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.475 -0.784 . . . . 0.0 111.141 177.613 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.991 ' HB2' ' HG2' ' A' ' 308' ' ' PRO . 19.6 t-20 -103.18 142.09 34.75 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 -178.443 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 26.3 m -83.27 -7.46 59.59 Favored 'General case' 0 CA--C 1.54 0.587 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.447 -175.05 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 313' ' ' ASP . . . . . 0.42 ' O ' ' HG3' ' A' ' 317' ' ' ARG . 62.9 m-20 -79.62 140.11 37.23 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.684 0.278 . . . . 0.0 110.821 177.818 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 46.1 t -64.4 -45.63 95.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.655 -177.964 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -75.54 -22.42 57.07 Favored 'General case' 0 N--CA 1.464 0.262 0 N-CA-C 111.999 0.37 . . . . 0.0 111.999 -176.204 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . 0.71 ' HA ' HD13 ' A' ' 307' ' ' LEU . 46.1 t -73.14 -21.52 60.7 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.533 -0.303 . . . . 0.0 111.771 -178.16 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 317' ' ' ARG . . . . . 0.687 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 73.0 mtp180 -74.24 -54.76 3.19 Favored Pre-proline 0 CA--C 1.536 0.434 0 N-CA-C 112.23 0.456 . . . . 0.0 112.23 -176.25 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 318' ' ' PRO . . . . . 0.687 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 16.8 Cg_exo -68.79 -38.66 9.81 Favored 'Trans proline' 0 C--N 1.354 0.848 0 C-N-CA 121.978 1.785 . . . . 0.0 112.268 -178.852 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 319' ' ' TYR . . . . . 0.436 ' O ' HD12 ' A' ' 307' ' ' LEU . 3.2 m-85 -90.11 30.43 1.09 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.089 0.471 . . . . 0.0 110.576 -179.903 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -65.9 159.41 25.6 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.679 -0.692 . . . . 0.0 111.059 179.454 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -142.43 -26.28 0.63 Allowed 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.866 -178.551 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 322' ' ' VAL . . . . . 0.461 HG12 ' HA ' ' A' ' 275' ' ' SER . 33.8 m -132.93 174.13 13.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.402 179.458 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -85.4 -12.76 51.28 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 112.068 0.395 . . . . 0.0 112.068 -179.05 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 324' ' ' ALA . . . . . 0.646 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -178.73 163.42 1.45 Allowed 'General case' 0 N--CA 1.469 0.485 0 CA-C-O 120.737 0.304 . . . . 0.0 111.619 -176.313 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 325' ' ' LYS . . . . . 0.596 ' HD2' ' HD3' ' A' ' 308' ' ' PRO . 6.7 mtpm? -120.56 134.13 24.15 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-N 115.889 -0.596 . . . . 0.0 109.731 172.974 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 326' ' ' PRO . . . . . 0.689 ' HB2' ' HB2' ' A' ' 330' ' ' ALA . 3.4 Cg_exo -78.26 167.81 22.6 Favored 'Trans proline' 0 N--CA 1.459 -0.549 0 C-N-CA 122.803 2.335 . . . . 0.0 111.578 177.101 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -65.18 137.15 57.43 Favored 'General case' 0 C--O 1.235 0.334 0 N-CA-C 110.129 -0.323 . . . . 0.0 110.129 177.886 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 328' ' ' GLU . . . . . 0.528 ' HB3' ' HA ' ' A' ' 231' ' ' SER . 55.2 mm-40 59.74 -128.41 1.12 Allowed 'General case' 0 C--O 1.232 0.164 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 -174.163 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 329' ' ' SER . . . . . 0.712 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 42.0 m -111.83 -10.55 14.01 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 116.548 -0.296 . . . . 0.0 110.204 175.339 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 330' ' ' ALA . . . . . 0.689 ' HB2' ' HB2' ' A' ' 326' ' ' PRO . . . 73.21 -166.39 0.11 Allowed 'General case' 0 N--CA 1.474 0.757 0 N-CA-C 113.56 0.948 . . . . 0.0 113.56 173.824 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -83.16 143.69 30.33 Favored 'General case' 0 CA--C 1.519 -0.223 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.56 -178.852 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 332' ' ' ILE . . . . . . . . . . . . . 23.1 mm -113.32 145.17 19.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.562 -171.875 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 29.7 m -118.98 96.59 5.3 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 174.314 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 334' ' ' ILE . . . . . 0.531 ' HA ' ' HB3' ' A' ' 268' ' ' PHE . 35.7 mm -83.15 130.07 36.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 N-CA-C 112.636 0.606 . . . . 0.0 112.636 -172.968 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 335' ' ' LEU . . . . . 0.449 ' HB2' ' O ' ' A' ' 267' ' ' ALA . 7.3 mp -112.52 160.95 17.3 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.23 -0.896 . . . . 0.0 110.089 171.962 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 72.8 m-80 -112.22 -0.29 15.56 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.261 -0.882 . . . . 0.0 109.209 174.132 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 27.9 mtpp . . . . . 0 C--O 1.245 0.845 0 O-C-N 124.191 0.932 . . . . 0.0 111.2 -178.281 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.872 0 N-CA-C 112.044 -0.423 . . . . 0.0 112.044 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 32.0 t 60.75 81.75 0.18 Allowed 'General case' 0 C--O 1.234 0.239 0 C-N-CA 122.864 0.466 . . . . 0.0 111.075 -179.863 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 34.5 p -77.05 -94.13 0.03 OUTLIER 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.375 176.673 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 17.2 tp10 -123.82 75.15 1.33 Allowed 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 173.607 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 43.6 t 65.56 -98.36 0.06 Allowed 'General case' 0 C--O 1.234 0.273 0 CA-C-N 115.374 -0.83 . . . . 0.0 109.426 -171.183 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 228' ' ' LEU . . . . . 0.466 ' HB3' ' CB ' ' A' ' 259' ' ' ALA . 91.7 mt -130.11 125.18 34.49 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 172.461 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 37.6 p -117.87 175.19 5.78 Favored 'General case' 0 C--N 1.32 -0.674 0 C-N-CA 119.483 -0.887 . . . . 0.0 111.214 -177.087 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . 0.561 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 60.6 t -148.61 141.44 18.4 Favored 'Isoleucine or valine' 0 C--O 1.24 0.56 0 CA-C-O 120.905 0.383 . . . . 0.0 110.788 -176.448 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 50.0 m -109.98 117.74 34.59 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.907 175.123 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 177.61 169.0 38.1 Favored Glycine 0 N--CA 1.447 -0.578 0 N-CA-C 111.087 -0.805 . . . . 0.0 111.087 -177.903 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 233' ' ' GLN . . . . . . . . . . . . . 72.2 mt-30 -111.75 101.51 51.43 Favored Pre-proline 0 C--N 1.323 -0.57 0 CA-C-N 117.148 0.474 . . . . 0.0 111.62 -177.86 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 234' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_endo -83.62 125.99 3.95 Favored 'Trans proline' 0 N--CA 1.453 -0.864 0 C-N-CA 122.986 2.457 . . . . 0.0 110.331 173.932 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 56.0 mm-40 -120.63 163.55 17.86 Favored 'General case' 0 C--N 1.321 -0.674 0 C-N-CA 120.576 -0.45 . . . . 0.0 111.831 -172.572 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 236' ' ' HIS . . . . . 0.542 ' HB3' ' O ' ' A' ' 306' ' ' ILE . 19.3 p-80 -108.76 145.89 34.43 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.339 172.433 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 237' ' ' LYS . . . . . 0.566 ' HG3' ' H ' ' A' ' 250' ' ' ASN . 0.0 OUTLIER -166.98 173.99 8.81 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.569 178.099 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 238' ' ' VAL . . . . . 0.573 HG21 ' SD ' ' A' ' 246' ' ' MET . 95.8 t -70.27 147.87 11.31 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-N 115.451 -0.795 . . . . 0.0 110.396 172.63 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 239' ' ' GLU . . . . . 0.565 ' HA ' ' HB2' ' A' ' 249' ' ' ASP . 14.8 pt-20 -68.32 176.5 2.76 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.958 178.111 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 240' ' ' ALA . . . . . 0.82 ' HA ' HG13 ' A' ' 248' ' ' VAL . . . -29.19 -59.13 0.14 Allowed 'General case' 0 N--CA 1.473 0.691 0 O-C-N 124.318 1.011 . . . . 0.0 113.29 -177.647 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 241' ' ' LYS . . . . . 0.597 ' HD2' ' O ' ' A' ' 241' ' ' LYS . 0.1 OUTLIER -158.47 148.53 19.81 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-O 121.175 0.512 . . . . 0.0 111.78 177.647 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 242' ' ' ASP . . . . . 0.58 ' OD1' ' HG2' ' A' ' 246' ' ' MET . 13.1 p-10 -105.92 -157.89 0.63 Allowed 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 177.239 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 48.4 t -65.79 -33.05 74.96 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.748 0.308 . . . . 0.0 110.493 175.162 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 43.9 t30 -86.63 -15.61 39.18 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.564 -179.852 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 72.03 44.82 44.28 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.519 -0.848 . . . . 0.0 112.805 178.004 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 246' ' ' MET . . . . . 0.665 ' HB2' ' HD2' ' A' ' 247' ' ' PRO . 25.1 ptm -77.26 170.04 18.22 Favored Pre-proline 0 CA--C 1.533 0.321 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 177.539 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 247' ' ' PRO . . . . . 0.665 ' HD2' ' HB2' ' A' ' 246' ' ' MET . 51.7 Cg_exo -42.81 142.96 1.89 Allowed 'Trans proline' 0 C--N 1.36 1.143 0 C-N-CA 123.304 2.67 . . . . 0.0 114.677 -172.322 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.82 HG13 ' HA ' ' A' ' 240' ' ' ALA . 57.5 t -68.02 152.81 9.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 114.55 -1.205 . . . . 0.0 111.065 -177.978 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 249' ' ' ASP . . . . . 0.565 ' HB2' ' HA ' ' A' ' 239' ' ' GLU . 9.8 t0 -49.9 115.02 1.22 Allowed 'General case' 0 CA--C 1.528 0.125 0 O-C-N 123.96 0.788 . . . . 0.0 109.367 179.109 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 250' ' ' ASN . . . . . 0.566 ' H ' ' HG3' ' A' ' 237' ' ' LYS . 19.9 p30 -93.57 166.4 12.26 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 113.762 1.023 . . . . 0.0 113.762 -164.086 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . 0.454 ' HG2' ' OD1' ' A' ' 250' ' ' ASN . 18.7 ptp180 43.86 -145.4 0.1 Allowed 'General case' 0 N--CA 1.475 0.788 0 CA-C-N 113.789 -1.551 . . . . 0.0 113.301 -179.316 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 53.8 mt-30 69.18 160.57 0.19 Allowed 'General case' 0 N--CA 1.471 0.583 0 CA-C-O 121.391 0.615 . . . . 0.0 110.959 -173.018 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . 0.911 ' O ' ' HA ' ' A' ' 301' ' ' THR . . . 100.35 -23.76 34.62 Favored Glycine 0 N--CA 1.438 -1.203 0 C-N-CA 120.068 -1.063 . . . . 0.0 112.74 -179.248 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 254' ' ' THR . . . . . . . . . . . . . 60.0 p -135.81 118.79 16.36 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 118.01 0.905 . . . . 0.0 112.724 -176.676 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.756 HD11 ' HB ' ' A' ' 300' ' ' VAL . 2.1 pp -144.83 170.79 6.75 Favored 'Isoleucine or valine' 0 C--O 1.234 0.283 0 CA-C-O 121.032 0.444 . . . . 0.0 112.001 172.445 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 75.2 m -115.62 114.35 24.79 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.344 177.057 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.446 ' HB ' ' H ' ' A' ' 259' ' ' ALA . 34.9 m -90.86 145.21 7.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 N-CA-C 113.004 0.742 . . . . 0.0 113.004 -173.114 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 258' ' ' SER . . . . . 0.448 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 30.9 m -91.35 8.83 34.22 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 114.077 -1.42 . . . . 0.0 108.502 166.818 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 259' ' ' ALA . . . . . 0.466 ' CB ' ' HB3' ' A' ' 228' ' ' LEU . . . -88.25 175.65 7.58 Favored 'General case' 0 N--CA 1.452 -0.364 0 CA-C-N 115.115 -0.948 . . . . 0.0 109.402 -177.899 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 27.4 p -140.61 117.22 10.88 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 112.356 0.502 . . . . 0.0 112.356 -177.412 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 78.91 50.04 6.12 Favored Glycine 0 N--CA 1.45 -0.392 0 CA-C-N 115.596 -0.729 . . . . 0.0 113.391 175.632 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 262' ' ' LEU . . . . . . . . . . . . . 77.6 mt -85.06 146.53 27.12 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 117.346 0.573 . . . . 0.0 110.268 176.837 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 98.9 mm-40 -123.77 163.25 21.54 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.551 -178.757 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 264' ' ' VAL . . . . . 0.487 HG22 ' HA ' ' A' ' 294' ' ' ALA . 20.2 t -79.48 145.1 9.86 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.215 177.626 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 86.4 10.07 74.67 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.623 -0.799 . . . . 0.0 112.186 177.832 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -88.5 159.59 17.88 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.147 0.499 . . . . 0.0 110.482 177.208 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 267' ' ' ALA . . . . . 0.549 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -121.82 151.48 40.57 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 115.334 -0.848 . . . . 0.0 108.869 178.238 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 268' ' ' PHE . . . . . 0.496 ' HB3' ' HA ' ' A' ' 334' ' ' ILE . 4.1 p90 -164.27 168.75 18.4 Favored 'General case' 0 C--N 1.318 -0.761 0 C-N-CA 119.777 -0.769 . . . . 0.0 111.648 -178.029 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 269' ' ' THR . . . . . 0.497 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 73.3 p -122.85 141.83 51.44 Favored 'General case' 0 N--CA 1.442 -0.848 0 CA-C-N 115.438 -0.801 . . . . 0.0 109.621 177.078 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 270' ' ' ILE . . . . . 0.713 HG12 HG12 ' A' ' 332' ' ' ILE . 61.6 mt -105.49 139.18 27.43 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.57 -178.525 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -61.22 125.86 25.28 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.695 179.512 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 93.51 -22.45 35.31 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.473 -178.811 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . 0.742 HG11 ' HZ ' ' A' ' 290' ' ' PHE . 42.4 t -96.5 114.59 33.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 O-C-N 122.573 -0.369 . . . . 0.0 110.296 177.504 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 274' ' ' ASN . . . . . 0.411 ' HA ' ' HA ' ' A' ' 287' ' ' PRO . 72.3 m-80 -129.2 160.87 31.55 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.304 -179.223 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 275' ' ' SER . . . . . . . . . . . . . 68.9 p -86.37 169.61 12.76 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.239 0.542 . . . . 0.0 111.803 -174.883 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 276' ' ' VAL . . . . . 0.41 ' O ' ' HG2' ' A' ' 278' ' ' GLN . 27.3 m -112.03 -178.07 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 115.499 -0.773 . . . . 0.0 111.152 -178.47 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 277' ' ' HIS . . . . . 0.523 ' HB3' ' HA ' ' A' ' 281' ' ' LYS . 5.0 m80 -66.16 80.97 0.08 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.703 -0.681 . . . . 0.0 110.392 -175.33 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 278' ' ' GLN . . . . . 0.467 HE21 ' HA ' ' A' ' 278' ' ' GLN . 2.4 mm100 -80.32 -32.99 37.86 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 111.72 0.267 . . . . 0.0 111.72 -174.418 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 279' ' ' ILE . . . . . 0.548 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.4 mp -69.89 -89.48 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.375 0 CA-C-O 120.831 0.348 . . . . 0.0 110.533 -174.641 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 35.5 p -133.69 60.03 1.72 Allowed 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.076 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 281' ' ' LYS . . . . . 0.523 ' HA ' ' HB3' ' A' ' 277' ' ' HIS . 31.4 mmmt 54.52 41.13 32.14 Favored 'General case' 0 CA--C 1.522 -0.122 0 CA-C-N 115.562 -0.745 . . . . 0.0 109.208 -170.874 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 282' ' ' ASP . . . . . 0.463 ' N ' ' HB3' ' A' ' 277' ' ' HIS . 9.3 t70 -92.33 137.84 32.03 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 114.445 -1.252 . . . . 0.0 110.484 -175.15 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 46.2 p -85.44 105.1 15.82 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.185 -178.387 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 73.1 p -110.72 -41.62 4.24 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.915 -171.804 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 63.64 28.31 72.34 Favored Glycine 0 C--N 1.33 0.24 0 C-N-CA 120.877 -0.677 . . . . 0.0 112.498 177.222 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 84.6 mt-30 -94.5 145.7 30.15 Favored Pre-proline 0 C--N 1.323 -0.547 0 CA-C-O 120.419 0.152 . . . . 0.0 110.647 -176.792 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 287' ' ' PRO . . . . . 0.497 ' HB2' ' HB ' ' A' ' 269' ' ' THR . 27.5 Cg_endo -62.2 143.77 94.75 Favored 'Trans proline' 0 CA--C 1.53 0.31 0 C-N-CA 122.445 2.097 . . . . 0.0 112.029 178.589 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 70.8 tp60 -76.3 128.43 34.86 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.872 0.367 . . . . 0.0 110.945 -177.486 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 289' ' ' VAL . . . . . 0.401 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 45.6 t -93.74 133.18 35.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.059 179.17 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 290' ' ' PHE . . . . . 0.742 ' HZ ' HG11 ' A' ' 273' ' ' VAL . 60.9 m-85 -113.5 168.81 9.44 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.826 -176.996 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 291' ' ' ARG . . . . . 0.452 ' NH1' ' HB2' ' A' ' 267' ' ' ALA . 35.8 mmt180 -126.74 120.38 29.25 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 177.765 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 56.4 t -67.18 125.59 24.96 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.227 -179.755 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 293' ' ' LEU . . . . . 0.656 HD11 ' HB2' ' A' ' 303' ' ' SER . 5.2 mp -85.07 -38.44 19.13 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.841 179.865 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 294' ' ' ALA . . . . . 0.487 ' HA ' HG22 ' A' ' 264' ' ' VAL . . . -167.13 155.48 9.73 Favored 'General case' 0 C--O 1.225 -0.21 0 CA-C-N 116.681 -0.236 . . . . 0.0 110.94 179.059 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . 0.672 HG22 HG13 ' A' ' 300' ' ' VAL . 61.7 t -140.49 124.74 18.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 175.384 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 32.4 m -139.73 89.54 2.33 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 120.76 0.314 . . . . 0.0 110.835 -177.189 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . 0.427 ' C ' ' H ' ' A' ' 299' ' ' THR . . . 63.95 65.76 2.87 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.487 179.434 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 81.0 p 63.06 -25.18 0.06 Allowed 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 124.994 1.317 . . . . 0.0 113.683 -178.774 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 299' ' ' THR . . . . . 0.427 ' H ' ' C ' ' A' ' 297' ' ' GLY . 75.3 m -77.43 108.9 10.91 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 174.333 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . 0.756 ' HB ' HD11 ' A' ' 255' ' ' ILE . 48.8 t -106.08 134.42 47.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.025 -173.017 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 301' ' ' THR . . . . . 0.911 ' HA ' ' O ' ' A' ' 253' ' ' GLY . 97.1 m -78.02 105.37 9.19 Favored 'General case' 0 N--CA 1.446 -0.632 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 173.009 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 302' ' ' ILE . . . . . 0.64 HD12 ' O ' ' A' ' 302' ' ' ILE . 2.6 pp -111.24 141.35 26.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 CA-C-O 122.179 0.99 . . . . 0.0 113.671 -170.989 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 303' ' ' SER . . . . . 0.656 ' HB2' HD11 ' A' ' 293' ' ' LEU . 57.2 m -167.48 169.55 5.56 Favored Pre-proline 0 C--N 1.317 -0.826 0 N-CA-C 105.342 -2.096 . . . . 0.0 105.342 179.02 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 304' ' ' PRO . . . . . 0.587 ' HA ' ' HB3' ' A' ' 303' ' ' SER . 2.7 Cg_endo -82.65 -157.28 1.35 Allowed 'Cis proline' 0 C--N 1.347 0.458 0 CA-C-N 121.571 1.597 . . . . 0.0 113.473 0.278 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 305' ' ' LYS . . . . . 0.8 ' HD3' ' HG ' ' A' ' 307' ' ' LEU . 0.0 OUTLIER -83.51 163.34 20.51 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.27 -0.877 . . . . 0.0 112.884 -176.069 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 306' ' ' ILE . . . . . 0.542 ' O ' ' HB3' ' A' ' 236' ' ' HIS . 2.7 mp -114.02 94.32 3.06 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.793 -176.761 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 307' ' ' LEU . . . . . 0.8 ' HG ' ' HD3' ' A' ' 305' ' ' LYS . 86.0 mt -108.81 107.24 59.9 Favored Pre-proline 0 C--N 1.327 -0.392 0 C-N-CA 120.81 -0.356 . . . . 0.0 111.606 -177.768 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 308' ' ' PRO . . . . . 0.761 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 23.0 Cg_exo -69.85 145.39 56.5 Favored 'Trans proline' 0 C--N 1.343 0.253 0 C-N-CA 123.505 2.804 . . . . 0.0 113.467 -178.038 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . 0.416 HG23 ' O ' ' A' ' 322' ' ' VAL . 40.3 t -93.69 -25.6 4.8 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 169.35 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 54.7 mm-40 -79.83 -0.36 34.32 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.113 -0.949 . . . . 0.0 112.144 -177.602 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -80.85 163.34 23.48 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-O 121.004 0.431 . . . . 0.0 111.174 -179.091 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 50.2 m -92.32 -15.87 26.79 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.362 -179.029 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 313' ' ' ASP . . . . . 0.566 ' O ' ' HG3' ' A' ' 317' ' ' ARG . 62.9 t0 -64.26 104.05 0.71 Allowed 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.065 178.93 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 314' ' ' VAL . . . . . 0.432 ' O ' ' HD3' ' A' ' 318' ' ' PRO . 48.5 t -63.63 -30.84 50.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.024 -0.535 . . . . 0.0 111.683 -176.012 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -70.44 -25.17 63.07 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 111.718 0.266 . . . . 0.0 111.718 179.984 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 32.4 t -95.09 -8.28 37.02 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.604 0.24 . . . . 0.0 111.211 -178.115 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 317' ' ' ARG . . . . . 0.566 ' HG3' ' O ' ' A' ' 313' ' ' ASP . 54.4 mtp85 -67.43 -49.96 39.85 Favored Pre-proline 0 CA--C 1.54 0.564 0 N-CA-C 112.938 0.718 . . . . 0.0 112.938 -179.26 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 318' ' ' PRO . . . . . 0.506 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 37.1 Cg_exo -63.41 -31.98 71.95 Favored 'Trans proline' 0 C--N 1.357 1.016 0 C-N-CA 121.951 1.768 . . . . 0.0 112.679 -178.51 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 48.8 m-85 -84.13 -14.95 48.97 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.511 -178.214 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . 0.528 ' HA ' ' CB ' ' A' ' 307' ' ' LEU . . . -49.7 135.29 19.17 Favored 'General case' 0 N--CA 1.464 0.254 0 N-CA-C 112.71 0.633 . . . . 0.0 112.71 -174.097 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 16.1 p-10 -128.38 -10.36 5.18 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.939 178.964 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 322' ' ' VAL . . . . . 0.488 HG21 HG23 ' A' ' 306' ' ' ILE . 33.7 m -132.27 167.29 26.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 N-CA-C 109.986 -0.375 . . . . 0.0 109.986 177.017 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -67.2 -51.89 47.95 Favored 'General case' 0 C--N 1.326 -0.434 0 C-N-CA 121.026 -0.27 . . . . 0.0 111.702 -177.93 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 324' ' ' ALA . . . . . 0.761 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -162.47 -178.04 6.02 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.044 0.449 . . . . 0.0 111.779 -176.388 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 14.5 ptmm? -112.56 132.07 22.37 Favored Pre-proline 0 C--N 1.327 -0.384 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.314 176.949 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -86.15 168.44 9.04 Favored 'Trans proline' 0 N--CA 1.456 -0.71 0 C-N-CA 122.921 2.414 . . . . 0.0 112.412 179.51 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -72.83 123.77 24.05 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.053 -0.522 . . . . 0.0 109.718 175.202 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 66.6 mm-40 65.6 -161.43 0.26 Allowed 'General case' 0 N--CA 1.465 0.307 0 O-C-N 123.574 0.546 . . . . 0.0 110.424 -174.97 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 329' ' ' SER . . . . . 0.561 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 43.0 m -91.16 -13.48 32.88 Favored 'General case' 0 C--N 1.323 -0.578 0 C-N-CA 120.825 -0.35 . . . . 0.0 110.347 178.174 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 330' ' ' ALA . . . . . . . . . . . . . . . 64.5 -161.55 0.28 Allowed 'General case' 0 N--CA 1.467 0.425 0 CA-C-N 115.412 -0.813 . . . . 0.0 113.128 171.323 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 331' ' ' ALA . . . . . . . . . . . . . . . -86.71 136.72 32.91 Favored 'General case' 0 CA--C 1.517 -0.323 0 CA-C-N 115.09 -0.959 . . . . 0.0 110.577 -179.983 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 332' ' ' ILE . . . . . 0.713 HG12 HG12 ' A' ' 270' ' ' ILE . 45.8 mt -116.12 144.42 23.83 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.847 0 CA-C-N 115.76 -0.654 . . . . 0.0 110.822 -178.735 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 78.1 m -116.26 99.24 7.07 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.156 -178.016 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 334' ' ' ILE . . . . . 0.496 ' HA ' ' HB3' ' A' ' 268' ' ' PHE . 38.3 mm -75.99 131.12 35.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.43 -174.992 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 335' ' ' LEU . . . . . 0.479 HD23 ' HA ' ' A' ' 268' ' ' PHE . 2.0 pt? -148.61 133.68 18.23 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.217 173.68 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 5.6 m120 -78.16 70.93 4.59 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.223 178.406 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 59.4 tttp . . . . . 0 C--O 1.243 0.738 0 CA-C-O 118.315 -0.85 . . . . 0.0 110.713 -174.989 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.731 0 N-CA-C 111.851 -0.5 . . . . 0.0 111.851 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 51.7 p -73.36 -38.93 65.55 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.413 0.149 . . . . 0.0 111.081 179.69 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 51.2 m 62.93 -84.96 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.366 0 O-C-N 123.719 0.637 . . . . 0.0 111.294 177.954 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 226' ' ' GLU . . . . . 0.406 ' O ' ' HB2' ' A' ' 227' ' ' SER . 5.2 tp10 -124.71 78.91 1.72 Allowed 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 175.096 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 227' ' ' SER . . . . . 0.406 ' HB2' ' O ' ' A' ' 226' ' ' GLU . 54.0 m 74.2 -77.89 0.05 Allowed 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 115.243 -0.889 . . . . 0.0 111.304 -175.877 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 228' ' ' LEU . . . . . 0.568 HD13 ' HB1' ' A' ' 259' ' ' ALA . 85.3 mt -131.5 158.9 39.66 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.982 -0.553 . . . . 0.0 109.845 -177.288 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 229' ' ' THR . . . . . 0.578 ' HA ' ' HA ' ' A' ' 331' ' ' ALA . 37.9 p -132.76 178.87 6.53 Favored 'General case' 0 C--N 1.33 -0.274 0 C-N-CA 120.324 -0.55 . . . . 0.0 111.186 177.851 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . 0.597 ' HB ' ' HB2' ' A' ' 329' ' ' SER . 58.7 t -147.47 123.94 2.92 Favored 'Isoleucine or valine' 0 C--O 1.235 0.336 0 CA-C-N 116.654 -0.248 . . . . 0.0 110.921 -179.165 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 49.8 m -109.14 97.68 7.25 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.107 -0.497 . . . . 0.0 109.86 174.446 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . 0.915 ' HA3' ' HB ' ' A' ' 255' ' ' ILE . . . -133.94 -152.14 6.65 Favored Glycine 0 N--CA 1.443 -0.859 0 C-N-CA 119.743 -1.218 . . . . 0.0 113.163 -176.735 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 233' ' ' GLN . . . . . 0.583 ' H ' HG22 ' A' ' 255' ' ' ILE . 11.7 mm100 -72.34 171.45 9.7 Favored Pre-proline 0 C--N 1.324 -0.521 0 CA-C-N 115.2 -0.5 . . . . 0.0 110.988 -179.172 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 234' ' ' PRO . . . . . 0.525 ' HD2' ' HB3' ' A' ' 233' ' ' GLN . 41.7 Cg_exo -56.74 176.29 0.23 Allowed 'Trans proline' 0 C--N 1.356 0.923 0 C-N-CA 123.346 2.697 . . . . 0.0 112.741 177.801 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 235' ' ' GLU . . . . . 0.735 ' HG3' ' HD2' ' A' ' 325' ' ' LYS . 2.6 pm0 -91.38 -176.74 4.64 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.031 0.444 . . . . 0.0 111.102 -174.467 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 236' ' ' HIS . . . . . 0.445 ' CE1' ' HB2' ' A' ' 305' ' ' LYS . 18.9 t-80 -100.87 147.6 25.93 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.509 -0.769 . . . . 0.0 111.702 -171.135 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 237' ' ' LYS . . . . . 0.487 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -166.68 147.87 6.15 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 114.735 -1.12 . . . . 0.0 109.914 179.066 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 238' ' ' VAL . . . . . 0.568 HG23 HD21 ' A' ' 307' ' ' LEU . 56.8 t -99.53 111.95 30.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 174.073 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 239' ' ' GLU . . . . . 0.442 ' O ' ' HA ' ' A' ' 247' ' ' PRO . 91.4 mt-10 -92.55 144.56 25.22 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.953 -173.165 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 240' ' ' ALA . . . . . . . . . . . . . . . -63.29 -39.03 93.43 Favored 'General case' 0 CA--C 1.522 -0.111 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.808 179.486 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 241' ' ' LYS . . . . . 0.659 ' O ' ' HD3' ' A' ' 241' ' ' LYS . 0.1 OUTLIER -141.89 139.9 32.7 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.061 176.763 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 242' ' ' ASP . . . . . 0.441 ' CG ' ' H ' ' A' ' 244' ' ' ASN . 9.5 p-10 -105.95 -156.55 0.58 Allowed 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 -179.519 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 48.8 m -63.48 -19.55 64.83 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.192 175.208 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 244' ' ' ASN . . . . . 0.441 ' H ' ' CG ' ' A' ' 242' ' ' ASP . 5.3 m120 -104.65 -6.04 20.82 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.838 0.351 . . . . 0.0 111.06 177.716 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . 0.608 ' HA2' ' HB2' ' A' ' 241' ' ' LYS . . . 85.09 19.09 59.75 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.712 -0.756 . . . . 0.0 113.675 175.583 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 246' ' ' MET . . . . . 0.431 ' O ' HG23 ' A' ' 248' ' ' VAL . 83.4 mtp -113.28 157.74 40.23 Favored Pre-proline 0 C--N 1.326 -0.451 0 CA-C-N 117.12 0.46 . . . . 0.0 110.676 178.51 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 247' ' ' PRO . . . . . 0.442 ' HA ' ' O ' ' A' ' 239' ' ' GLU . 12.1 Cg_exo -68.29 120.6 7.56 Favored 'Trans proline' 0 C--N 1.348 0.524 0 C-N-CA 122.34 2.027 . . . . 0.0 111.055 177.123 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.431 HG23 ' O ' ' A' ' 246' ' ' MET . 62.6 t -129.89 137.56 56.3 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.475 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -173.951 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -79.87 101.66 8.68 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 107.842 -1.17 . . . . 0.0 107.842 170.35 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 250' ' ' ASN . . . . . 0.47 HD22 ' HD3' ' A' ' 237' ' ' LYS . 44.4 t30 -98.95 147.45 24.98 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.464 -0.789 . . . . 0.0 112.925 -165.933 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . 0.41 ' HD3' ' HA ' ' A' ' 251' ' ' ARG . 19.7 tpp180 93.15 -125.32 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 125.616 1.566 . . . . 0.0 111.241 173.332 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 252' ' ' GLN . . . . . 0.452 ' OE1' ' HA ' ' A' ' 305' ' ' LYS . 2.2 mm100 63.31 179.29 0.15 Allowed 'General case' 0 N--CA 1.472 0.659 0 CA-C-O 120.888 0.375 . . . . 0.0 110.566 -173.331 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . . . . . . . . . . . 101.91 -148.55 17.79 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 119.587 -1.292 . . . . 0.0 113.984 174.778 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 254' ' ' THR . . . . . 0.62 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 71.0 p -101.49 148.66 24.93 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 112.65 0.611 . . . . 0.0 112.65 -171.674 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.915 ' HB ' ' HA3' ' A' ' 232' ' ' GLY . 0.2 OUTLIER -138.01 172.96 13.48 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.243 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.288 173.632 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 58.2 m -100.54 125.81 46.93 Favored 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 109.406 -0.59 . . . . 0.0 109.406 176.729 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.524 ' HA ' HG13 ' A' ' 230' ' ' VAL . 34.0 m -98.73 143.37 13.28 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.828 0 C-N-CA 119.65 -0.82 . . . . 0.0 112.483 -174.541 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 258' ' ' SER . . . . . 0.494 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 38.8 t -91.56 8.48 36.4 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 114.443 -1.253 . . . . 0.0 108.405 169.505 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 259' ' ' ALA . . . . . 0.58 ' HB3' HD11 ' A' ' 262' ' ' LEU . . . -91.32 169.3 10.92 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-N 115.021 -0.99 . . . . 0.0 110.018 -177.442 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . 0.55 ' H ' HD13 ' A' ' 228' ' ' LEU . 37.9 t -136.95 148.57 47.04 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 110.194 -0.298 . . . . 0.0 110.194 -179.751 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 71.27 39.6 61.98 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.977 -0.63 . . . . 0.0 113.083 178.108 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 262' ' ' LEU . . . . . 0.58 HD11 ' HB3' ' A' ' 259' ' ' ALA . 77.6 mt -97.64 142.31 29.6 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.944 0.372 . . . . 0.0 110.395 178.348 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 71.6 mt-30 -143.72 179.96 6.83 Favored 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 176.284 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 264' ' ' VAL . . . . . 0.517 HG22 ' HA ' ' A' ' 294' ' ' ALA . 34.0 t -79.31 140.43 16.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 N-CA-C 109.897 -0.408 . . . . 0.0 109.897 176.201 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 93.52 4.72 63.82 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.526 -0.845 . . . . 0.0 112.453 178.797 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -78.89 152.81 30.97 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.083 0.468 . . . . 0.0 110.072 176.578 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 267' ' ' ALA . . . . . 0.709 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -126.96 121.67 32.36 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 178.696 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 268' ' ' PHE . . . . . 0.574 ' CD1' HG21 ' A' ' 332' ' ' ILE . 0.0 OUTLIER -148.04 171.53 15.68 Favored 'General case' 0 C--N 1.318 -0.791 0 C-N-CA 120.218 -0.593 . . . . 0.0 111.026 -172.071 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 269' ' ' THR . . . . . 0.538 ' OG1' ' HB ' ' A' ' 333' ' ' THR . 72.6 p -123.82 156.39 36.23 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 110.2 -0.296 . . . . 0.0 110.2 -179.379 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 270' ' ' ILE . . . . . 0.557 HG12 HG12 ' A' ' 332' ' ' ILE . 60.9 mt -115.02 139.36 41.68 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-O 120.794 0.33 . . . . 0.0 111.144 -179.332 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -65.82 112.64 3.84 Favored 'General case' 0 C--O 1.231 0.125 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.037 -179.903 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 109.22 -21.85 26.04 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.021 -179.14 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . 0.598 ' O ' ' HA ' ' A' ' 287' ' ' PRO . 47.1 t -93.11 102.67 13.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.885 0.374 . . . . 0.0 110.93 178.722 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 274' ' ' ASN . . . . . . . . . . . . . 3.8 m120 -103.76 150.98 23.57 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 173.504 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 275' ' ' SER . . . . . 0.445 ' HB2' ' HB2' ' A' ' 288' ' ' GLN . 6.0 t -88.76 -177.96 5.66 Favored 'General case' 0 C--N 1.325 -0.473 0 C-N-CA 120.332 -0.547 . . . . 0.0 110.231 -176.496 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 276' ' ' VAL . . . . . . . . . . . . . 35.0 m -112.25 -179.01 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.917 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.171 172.887 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 277' ' ' HIS . . . . . 0.425 ' HB3' ' HA ' ' A' ' 281' ' ' LYS . 6.3 p80 -39.74 111.66 0.21 Allowed 'General case' 0 CA--C 1.533 0.298 0 O-C-N 123.972 0.795 . . . . 0.0 112.568 -179.882 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 80.7 mt-30 -80.16 -42.38 23.55 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.475 -176.439 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 279' ' ' ILE . . . . . 0.467 HD12 ' N ' ' A' ' 279' ' ' ILE . 2.7 mp -110.21 -76.16 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.175 177.858 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 21.7 p -142.11 90.78 2.28 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-O 121.124 0.487 . . . . 0.0 111.661 -178.418 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 281' ' ' LYS . . . . . 0.425 ' HA ' ' HB3' ' A' ' 277' ' ' HIS . 74.8 mmtt 61.05 23.98 14.12 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 115.145 -0.934 . . . . 0.0 112.463 175.584 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 11.2 p-10 -86.46 81.64 8.24 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.615 0.721 . . . . 0.0 110.867 176.769 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 37.2 p -102.34 106.9 17.76 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.854 177.753 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 73.1 p -114.67 2.16 14.4 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.835 -0.62 . . . . 0.0 112.174 -170.081 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 71.02 31.29 66.88 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.515 -0.85 . . . . 0.0 112.652 177.859 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 26.2 mt-30 -102.11 142.54 24.79 Favored Pre-proline 0 C--N 1.325 -0.467 0 O-C-N 122.682 -0.305 . . . . 0.0 111.155 179.503 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 287' ' ' PRO . . . . . 0.598 ' HA ' ' O ' ' A' ' 273' ' ' VAL . 39.0 Cg_exo -59.1 136.95 76.46 Favored 'Trans proline' 0 C--N 1.343 0.276 0 C-N-CA 122.988 2.459 . . . . 0.0 112.106 177.89 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 288' ' ' GLN . . . . . 0.445 ' HB2' ' HB2' ' A' ' 275' ' ' SER . 41.5 tt0 -79.52 142.92 35.34 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.827 0.346 . . . . 0.0 111.013 -178.008 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 289' ' ' VAL . . . . . 0.488 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 42.7 t -90.81 126.68 43.54 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.295 179.496 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 290' ' ' PHE . . . . . 0.709 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 33.3 m-85 -110.42 158.76 18.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.677 -0.238 . . . . 0.0 110.583 -176.323 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 291' ' ' ARG . . . . . 0.529 ' HD2' ' C ' ' A' ' 290' ' ' PHE . 9.0 mpt_? -115.88 131.06 57.05 Favored 'General case' 0 CA--C 1.516 -0.357 0 CA-C-O 121.48 0.657 . . . . 0.0 110.74 173.606 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 40.9 t -82.86 140.0 16.97 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 CA-C-N 114.722 -1.126 . . . . 0.0 111.402 -176.354 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 293' ' ' LEU . . . . . 0.448 ' CD2' ' HB2' ' A' ' 303' ' ' SER . 3.3 mm? -103.79 -32.38 9.36 Favored 'General case' 0 C--N 1.334 -0.08 0 N-CA-C 112.353 0.501 . . . . 0.0 112.353 -177.684 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 294' ' ' ALA . . . . . 0.517 ' HA ' HG22 ' A' ' 264' ' ' VAL . . . -157.83 139.27 13.67 Favored 'General case' 0 N--CA 1.464 0.241 0 C-N-CA 120.715 -0.394 . . . . 0.0 111.798 -178.245 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . 0.424 HG22 HG22 ' A' ' 300' ' ' VAL . 73.0 t -141.39 111.99 3.31 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.457 177.612 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 50.2 m -140.38 114.63 9.19 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.584 -0.28 . . . . 0.0 110.707 178.542 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 59.53 54.59 36.44 Favored Glycine 0 C--N 1.33 0.25 0 C-N-CA 121.146 -0.549 . . . . 0.0 112.891 179.172 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 82.8 p 53.08 21.09 1.97 Allowed 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 123.61 0.764 . . . . 0.0 112.302 -177.1 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 58.6 m -111.45 105.89 14.63 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 176.358 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . 0.62 ' O ' ' HA ' ' A' ' 254' ' ' THR . 55.2 t -105.32 131.62 54.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 115.954 -0.567 . . . . 0.0 111.547 -171.881 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 28.5 m -89.1 114.49 25.75 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 108.277 -1.009 . . . . 0.0 108.277 173.454 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 302' ' ' ILE . . . . . 0.538 HD12 ' O ' ' A' ' 302' ' ' ILE . 2.5 pp -110.58 149.07 13.6 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 N-CA-C 113.676 0.991 . . . . 0.0 113.676 -170.558 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 303' ' ' SER . . . . . 0.557 ' HB3' ' HA ' ' A' ' 304' ' ' PRO . 60.3 m -166.21 165.87 9.97 Favored Pre-proline 0 C--N 1.325 -0.487 0 N-CA-C 105.952 -1.87 . . . . 0.0 105.952 -179.724 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 304' ' ' PRO . . . . . 0.557 ' HA ' ' HB3' ' A' ' 303' ' ' SER . 5.8 Cg_exo -79.41 -146.44 0.37 Allowed 'Cis proline' 0 C--N 1.345 0.362 0 CA-C-N 120.996 1.391 . . . . 0.0 113.579 0.64 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 305' ' ' LYS . . . . . 0.682 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -84.11 146.71 27.75 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.478 -0.783 . . . . 0.0 111.739 -176.173 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 306' ' ' ILE . . . . . 0.482 HG23 HG21 ' A' ' 322' ' ' VAL . 2.9 mp -115.26 113.73 44.35 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.199 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.92 179.227 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 307' ' ' LEU . . . . . 0.568 HD21 HG23 ' A' ' 238' ' ' VAL . 95.5 mt -133.97 107.37 11.54 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-O 120.563 0.22 . . . . 0.0 111.308 -179.309 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 308' ' ' PRO . . . . . 0.652 ' HG2' ' HB2' ' A' ' 311' ' ' ASN . 45.3 Cg_endo -74.51 148.0 37.03 Favored 'Trans proline' 0 C--O 1.233 0.232 0 C-N-CA 122.796 2.331 . . . . 0.0 113.573 -176.631 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 46.5 t -73.58 -34.26 41.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.059 173.0 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -86.35 34.35 0.63 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.371 -0.832 . . . . 0.0 111.143 178.468 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.652 ' HB2' ' HG2' ' A' ' 308' ' ' PRO . 25.7 t-20 -81.32 -34.2 32.04 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.836 -0.431 . . . . 0.0 109.836 -178.287 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 312' ' ' THR . . . . . 0.401 ' HB ' ' O ' ' A' ' 311' ' ' ASN . 41.8 m 73.91 -11.27 0.98 Allowed 'General case' 0 CA--C 1.539 0.529 0 CA-C-N 115.328 -0.851 . . . . 0.0 111.679 178.662 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 313' ' ' ASP . . . . . 0.477 ' O ' ' HG2' ' A' ' 317' ' ' ARG . 31.1 t70 -79.67 117.42 20.57 Favored 'General case' 0 C--N 1.329 -0.286 0 O-C-N 121.951 -0.468 . . . . 0.0 110.27 175.119 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 26.5 t -59.32 -20.4 18.07 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.473 0 CA-C-N 115.781 -0.645 . . . . 0.0 112.268 -174.706 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -84.89 -38.41 19.45 Favored 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 111.949 0.352 . . . . 0.0 111.949 -179.364 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . 0.423 ' OG ' ' HB3' ' A' ' 313' ' ' ASP . 38.3 p -97.93 -28.83 13.64 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 113.511 0.93 . . . . 0.0 113.511 -172.33 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 317' ' ' ARG . . . . . 0.624 ' N ' ' HD2' ' A' ' 318' ' ' PRO . 16.1 ptm180 -66.18 -35.76 11.37 Favored Pre-proline 0 CA--C 1.547 0.86 0 N-CA-C 113.656 0.984 . . . . 0.0 113.656 -176.182 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 318' ' ' PRO . . . . . 0.624 ' HD2' ' N ' ' A' ' 317' ' ' ARG . 12.8 Cg_endo -58.38 -34.13 98.42 Favored 'Trans proline' 0 C--N 1.366 1.468 0 C-N-CA 121.666 1.577 . . . . 0.0 112.512 -179.861 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 51.0 m-85 -101.02 36.8 1.88 Allowed 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.6 -178.085 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . . . . . . . . . . . -67.86 139.64 56.53 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.485 -178.183 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 321' ' ' ASN . . . . . 0.44 ' OD1' HG13 ' A' ' 322' ' ' VAL . 20.5 p30 -121.78 -14.66 8.07 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.516 178.012 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 322' ' ' VAL . . . . . 0.482 HG21 HG23 ' A' ' 306' ' ' ILE . 34.1 m -133.59 166.74 28.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 115.618 -0.719 . . . . 0.0 109.195 173.458 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 65.0 m-20 -82.7 -27.53 31.16 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 112.164 0.431 . . . . 0.0 112.164 -176.375 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 324' ' ' ALA . . . . . 0.562 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -160.58 158.21 28.66 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.973 0.416 . . . . 0.0 111.716 -175.209 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 325' ' ' LYS . . . . . 0.735 ' HD2' ' HG3' ' A' ' 235' ' ' GLU . 21.5 pttp -114.01 127.26 27.01 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 115.714 -0.676 . . . . 0.0 110.157 177.318 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -86.08 167.84 9.32 Favored 'Trans proline' 0 N--CA 1.457 -0.651 0 C-N-CA 122.814 2.343 . . . . 0.0 112.758 -178.213 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -71.71 124.4 24.69 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.471 178.927 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 61.69 -118.44 0.68 Allowed 'General case' 0 N--CA 1.464 0.239 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.323 -175.578 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 329' ' ' SER . . . . . 0.597 ' HB2' ' HB ' ' A' ' 230' ' ' VAL . 32.6 m -112.18 -33.94 6.08 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.59 -0.277 . . . . 0.0 111.309 179.863 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 330' ' ' ALA . . . . . 0.418 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 76.24 -165.99 0.06 Allowed 'General case' 0 N--CA 1.474 0.725 0 O-C-N 123.844 0.715 . . . . 0.0 112.432 177.429 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 331' ' ' ALA . . . . . 0.578 ' HA ' ' HA ' ' A' ' 229' ' ' THR . . . -82.88 153.92 24.87 Favored 'General case' 0 CA--C 1.519 -0.236 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.899 -177.226 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 332' ' ' ILE . . . . . 0.574 HG21 ' CD1' ' A' ' 268' ' ' PHE . 44.4 mt -128.49 144.85 36.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-O 121.233 0.54 . . . . 0.0 111.762 -177.616 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.538 ' HB ' ' OG1' ' A' ' 269' ' ' THR . 94.7 m -108.63 118.75 37.59 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.291 -0.868 . . . . 0.0 109.207 175.23 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 334' ' ' ILE . . . . . 0.491 HG13 HD12 ' A' ' 228' ' ' LEU . 31.9 mm -97.26 132.33 42.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 N-CA-C 113.761 1.023 . . . . 0.0 113.761 -168.025 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 335' ' ' LEU . . . . . 0.467 HD23 ' N ' ' A' ' 335' ' ' LEU . 1.5 pt? -150.78 -162.32 1.53 Allowed 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 113.977 -1.465 . . . . 0.0 108.129 167.993 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 14.9 p-10 -159.34 35.49 0.2 Allowed 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 120.949 0.404 . . . . 0.0 110.212 178.055 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 337' ' ' LYS . . . . . . . . . . . . . 88.4 tttt . . . . . 0 C--O 1.245 0.83 0 CA-C-N 115.023 -0.99 . . . . 0.0 110.722 -179.433 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.485 1.903 0 N-CA-C 112.283 -0.327 . . . . 0.0 112.283 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 42.8 m -93.42 63.09 3.48 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 120.916 0.389 . . . . 0.0 110.688 -179.951 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 41.8 p -100.05 -124.03 0.16 Allowed 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 116.462 -0.335 . . . . 0.0 110.5 179.505 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 226' ' ' GLU . . . . . 0.465 ' HB2' ' HB1' ' A' ' 331' ' ' ALA . 24.4 pt-20 40.24 41.68 1.04 Allowed 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 123.993 0.917 . . . . 0.0 112.961 178.904 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 20.3 m -86.99 -34.83 19.13 Favored 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 110.018 -0.364 . . . . 0.0 110.018 177.71 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 228' ' ' LEU . . . . . 0.425 HD13 ' HB1' ' A' ' 259' ' ' ALA . 87.7 mt -69.49 136.98 52.17 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.509 176.936 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 229' ' ' THR . . . . . . . . . . . . . 61.3 p -125.22 173.99 8.41 Favored 'General case' 0 C--N 1.325 -0.49 0 C-N-CA 119.721 -0.792 . . . . 0.0 110.374 179.766 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . 0.916 HG11 HD12 ' A' ' 255' ' ' ILE . 94.5 t -146.06 139.8 20.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-O 120.873 0.368 . . . . 0.0 110.549 -178.801 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 231' ' ' SER . . . . . 0.622 ' HA ' ' OE1' ' A' ' 328' ' ' GLU . 45.8 t -106.04 150.75 25.45 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-N 115.485 -0.779 . . . . 0.0 110.64 178.145 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . 79.32 92.67 0.36 Allowed Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.409 178.408 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 233' ' ' GLN . . . . . 0.461 ' O ' ' HG3' ' A' ' 235' ' ' GLU . 82.8 mt-30 -42.74 135.37 2.75 Favored Pre-proline 0 N--CA 1.47 0.531 0 N-CA-C 112.595 0.591 . . . . 0.0 112.595 -177.997 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 234' ' ' PRO . . . . . 0.434 ' HB3' HD11 ' A' ' 302' ' ' ILE . 34.0 Cg_endo -62.97 127.94 21.69 Favored 'Trans proline' 0 C--N 1.349 0.59 0 C-N-CA 122.521 2.147 . . . . 0.0 111.18 175.018 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 235' ' ' GLU . . . . . 0.461 ' HG3' ' O ' ' A' ' 233' ' ' GLN . 49.0 mt-10 -113.64 117.46 31.65 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 112.281 0.475 . . . . 0.0 112.281 -170.419 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 236' ' ' HIS . . . . . 0.694 ' ND1' ' HA ' ' A' ' 251' ' ' ARG . 27.6 t60 -138.32 130.92 29.25 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.507 172.984 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 237' ' ' LYS . . . . . 0.55 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -126.71 157.65 38.51 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.527 -179.624 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 238' ' ' VAL . . . . . . . . . . . . . 41.9 t -97.5 117.16 41.72 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 171.948 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 239' ' ' GLU . . . . . 0.426 ' O ' ' HA ' ' A' ' 247' ' ' PRO . 46.3 mm-40 -84.54 121.25 27.34 Favored 'General case' 0 C--N 1.322 -0.602 0 C-N-CA 121.032 -0.267 . . . . 0.0 110.659 -177.663 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 240' ' ' ALA . . . . . . . . . . . . . . . -68.21 -38.94 82.47 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.19 0.519 . . . . 0.0 109.941 175.441 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 241' ' ' LYS . . . . . 0.759 ' HB2' ' HA2' ' A' ' 245' ' ' GLY . 0.0 OUTLIER -153.14 140.88 20.02 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.006 176.421 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 242' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -95.92 -156.99 0.55 Allowed 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.492 178.733 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 61.9 p -67.01 -20.14 65.82 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.547 0.213 . . . . 0.0 111.137 176.656 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 244' ' ' ASN . . . . . . . . . . . . . 50.3 t30 -98.78 -14.17 19.83 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.892 0.377 . . . . 0.0 110.664 177.966 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . 0.759 ' HA2' ' HB2' ' A' ' 241' ' ' LYS . . . 95.14 25.92 13.41 Favored Glycine 0 CA--C 1.518 0.266 0 C-N-CA 120.57 -0.824 . . . . 0.0 113.292 175.949 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 246' ' ' MET . . . . . 0.41 ' O ' HG23 ' A' ' 248' ' ' VAL . 49.0 mtm -111.6 150.12 41.72 Favored Pre-proline 0 C--N 1.322 -0.628 0 O-C-N 122.722 -0.281 . . . . 0.0 110.418 -179.648 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 247' ' ' PRO . . . . . 0.426 ' HA ' ' O ' ' A' ' 239' ' ' GLU . 6.7 Cg_exo -70.23 120.34 7.08 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.209 1.939 . . . . 0.0 110.697 174.939 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . 0.41 HG23 ' O ' ' A' ' 246' ' ' MET . 47.5 t -124.24 143.2 38.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-O 121.049 0.452 . . . . 0.0 111.615 -174.139 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 249' ' ' ASP . . . . . 0.438 ' OD1' ' HB3' ' A' ' 251' ' ' ARG . 9.0 t70 -85.43 90.76 8.03 Favored 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 173.847 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 250' ' ' ASN . . . . . . . . . . . . . 49.1 t30 -84.96 69.69 10.82 Favored 'General case' 0 N--CA 1.464 0.231 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 -175.996 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . 0.694 ' HA ' ' ND1' ' A' ' 236' ' ' HIS . 14.0 ptp180 -75.71 -146.51 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.327 -0.851 . . . . 0.0 113.239 -170.107 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 252' ' ' GLN . . . . . 0.417 ' H ' ' HB2' ' A' ' 251' ' ' ARG . 40.7 mt-30 66.34 178.69 0.21 Allowed 'General case' 0 N--CA 1.466 0.351 0 C-N-CA 123.842 0.857 . . . . 0.0 111.515 -178.958 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . 0.441 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -169.1 105.87 0.23 Allowed Glycine 0 N--CA 1.444 -0.799 0 CA-C-N 115.352 -0.84 . . . . 0.0 111.309 177.391 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 254' ' ' THR . . . . . 0.473 HG22 ' OG1' ' A' ' 301' ' ' THR . 62.8 p -93.47 116.15 28.68 Favored 'General case' 0 C--N 1.324 -0.515 0 C-N-CA 120.579 -0.448 . . . . 0.0 110.006 -177.993 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.916 HD12 HG11 ' A' ' 230' ' ' VAL . 19.0 pt -129.27 157.18 42.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.807 -0.633 . . . . 0.0 112.01 -172.162 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 28.8 m -96.3 109.66 22.12 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 174.606 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.438 ' HA ' HG13 ' A' ' 230' ' ' VAL . 33.6 m -89.94 142.37 13.01 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 C-N-CA 119.429 -0.908 . . . . 0.0 112.235 -173.022 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 258' ' ' SER . . . . . 0.429 ' H ' ' HA ' ' A' ' 230' ' ' VAL . 31.6 m -93.2 9.53 35.68 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 114.377 -1.283 . . . . 0.0 109.44 171.974 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 259' ' ' ALA . . . . . 0.425 ' HB1' HD13 ' A' ' 228' ' ' LEU . . . -80.97 -177.37 6.39 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.189 -175.709 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 50.9 m -125.07 118.92 27.24 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 112.232 0.456 . . . . 0.0 112.232 -175.522 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 59.49 51.35 59.59 Favored Glycine 0 C--N 1.331 0.284 0 CA-C-N 115.656 -0.702 . . . . 0.0 114.127 172.19 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 262' ' ' LEU . . . . . . . . . . . . . 67.9 mt -77.96 160.13 28.39 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 117.453 0.626 . . . . 0.0 110.559 177.753 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 85.7 mt-30 -141.74 167.09 22.96 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.453 179.864 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 44.0 t -78.67 141.47 15.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.496 178.32 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 93.55 1.2 66.36 Favored Glycine 0 N--CA 1.453 -0.229 0 C-N-CA 120.535 -0.84 . . . . 0.0 112.757 177.174 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 266' ' ' ASP . . . . . 0.453 ' HB3' ' CG2' ' A' ' 334' ' ' ILE . 1.3 m-20 -81.09 164.82 22.14 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 121.032 0.444 . . . . 0.0 110.585 178.243 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 267' ' ' ALA . . . . . 0.54 ' HB1' HG13 ' A' ' 289' ' ' VAL . . . -124.37 146.77 48.65 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.796 -178.086 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 268' ' ' PHE . . . . . 0.721 ' HB3' ' HA ' ' A' ' 334' ' ' ILE . 11.1 p90 -164.09 177.88 8.09 Favored 'General case' 0 C--N 1.322 -0.629 0 C-N-CA 120.152 -0.619 . . . . 0.0 112.405 -176.177 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 269' ' ' THR . . . . . . . . . . . . . 43.2 p -134.03 156.55 48.02 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 114.646 -1.161 . . . . 0.0 109.002 173.138 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 270' ' ' ILE . . . . . 0.944 HG12 HG13 ' A' ' 332' ' ' ILE . 77.6 mt -119.15 141.78 37.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-O 120.569 0.223 . . . . 0.0 110.682 -177.524 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -70.16 128.7 37.2 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.768 0.318 . . . . 0.0 110.973 178.112 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 90.56 -23.3 23.12 Favored Glycine 0 N--CA 1.453 -0.172 0 C-N-CA 121.267 -0.492 . . . . 0.0 112.023 -177.822 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . 0.473 ' HB ' ' HB ' ' A' ' 270' ' ' ILE . 57.2 t -94.58 103.23 14.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 175.043 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 274' ' ' ASN . . . . . 0.451 ' HB3' ' O ' ' A' ' 285' ' ' GLY . 8.1 m120 -125.03 129.43 50.27 Favored 'General case' 0 C--N 1.316 -0.865 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 -179.613 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 275' ' ' SER . . . . . 0.571 ' HA ' ' HA ' ' A' ' 322' ' ' VAL . 48.8 m -84.18 173.52 10.97 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.751 0.786 . . . . 0.0 112.974 -167.031 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 276' ' ' VAL . . . . . 0.675 HG11 HG21 ' A' ' 309' ' ' VAL . 18.5 m -122.95 166.87 17.23 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.514 0 CA-C-N 114.676 -1.147 . . . . 0.0 109.327 176.41 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 277' ' ' HIS . . . . . 0.494 ' O ' ' HA ' ' A' ' 281' ' ' LYS . 33.6 m80 -88.16 123.89 33.26 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 177.853 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 10.5 mm100 -80.29 -17.16 52.94 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.086 -176.614 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 46.7 mm -70.31 -65.19 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.736 -179.531 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 64.6 p -108.05 11.58 27.6 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.506 -0.316 . . . . 0.0 111.851 -177.323 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 281' ' ' LYS . . . . . 0.494 ' HA ' ' O ' ' A' ' 277' ' ' HIS . 12.7 mptt 55.41 47.47 21.12 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-O 121.122 0.487 . . . . 0.0 111.192 -177.489 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 282' ' ' ASP . . . . . 0.48 ' HB3' ' HB2' ' A' ' 277' ' ' HIS . 7.3 t70 -79.91 108.96 13.9 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.619 176.971 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.46 HG21 HG11 ' A' ' 309' ' ' VAL . 64.4 p -102.97 98.22 8.22 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.591 -178.142 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 31.1 p -140.55 10.8 2.28 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.613 -0.721 . . . . 0.0 111.763 -177.737 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 285' ' ' GLY . . . . . 0.451 ' O ' ' HB3' ' A' ' 274' ' ' ASN . . . 75.66 33.57 51.49 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.177 -1.011 . . . . 0.0 113.26 175.651 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 286' ' ' GLN . . . . . 0.463 ' O ' ' HB2' ' A' ' 275' ' ' SER . 11.6 mm100 -91.27 111.77 50.52 Favored Pre-proline 0 C--N 1.325 -0.469 0 CA-C-N 117.006 0.403 . . . . 0.0 110.782 -179.636 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 287' ' ' PRO . . . . . 0.408 ' HD2' ' HA ' ' A' ' 286' ' ' GLN . 14.7 Cg_endo -59.59 134.26 56.8 Favored 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.916 2.41 . . . . 0.0 113.155 -177.057 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 288' ' ' GLN . . . . . . . . . . . . . 5.4 tm0? -110.13 152.31 26.18 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 176.806 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 289' ' ' VAL . . . . . 0.54 HG13 ' HB1' ' A' ' 267' ' ' ALA . 53.8 t -68.18 134.03 30.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 CA-C-O 120.924 0.392 . . . . 0.0 111.988 -171.806 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 290' ' ' PHE . . . . . 0.836 ' HA ' ' HD3' ' A' ' 304' ' ' PRO . 4.5 m-85 -97.88 159.48 14.9 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.75 178.051 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 291' ' ' ARG . . . . . . . . . . . . . 20.3 mmt85 -131.45 125.63 33.0 Favored 'General case' 0 N--CA 1.453 -0.316 0 CA-C-N 115.923 -0.581 . . . . 0.0 110.622 -179.02 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . . . . . . . . . 53.2 t -76.01 135.34 27.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.161 179.318 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 293' ' ' LEU . . . . . 0.589 HD12 HG22 ' A' ' 301' ' ' THR . 85.4 mt -99.49 -43.0 6.69 Favored 'General case' 0 C--N 1.333 -0.13 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.502 179.769 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 294' ' ' ALA . . . . . 0.451 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -154.34 144.23 21.77 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.496 -0.32 . . . . 0.0 111.183 -175.52 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 59.0 t -135.91 113.3 14.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.714 176.87 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 45.6 t -157.33 125.02 5.34 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.55 -177.738 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 61.26 43.7 99.04 Favored Glycine 0 C--N 1.331 0.25 0 C-N-CA 120.987 -0.625 . . . . 0.0 111.773 -177.93 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 67.1 p 50.82 23.02 1.27 Allowed 'General case' 0 N--CA 1.471 0.604 0 C-N-CA 123.709 0.804 . . . . 0.0 112.23 -175.052 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 299' ' ' THR . . . . . . . . . . . . . 59.6 m -111.9 116.96 31.48 Favored 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 176.852 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . 0.451 ' HA ' ' O ' ' A' ' 294' ' ' ALA . 61.5 t -113.1 126.67 70.54 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.176 -173.15 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 301' ' ' THR . . . . . 0.589 HG22 HD12 ' A' ' 293' ' ' LEU . 54.5 m -91.24 116.2 28.63 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 173.987 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 302' ' ' ILE . . . . . 0.441 HG12 ' O ' ' A' ' 253' ' ' GLY . 29.5 pt -111.5 158.78 11.85 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 N-CA-C 113.234 0.828 . . . . 0.0 113.234 -170.013 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 303' ' ' SER . . . . . 0.543 ' HB3' ' HA ' ' A' ' 304' ' ' PRO . 72.1 m -144.47 166.16 19.97 Favored Pre-proline 0 C--N 1.323 -0.584 0 CA-C-N 113.631 -1.622 . . . . 0.0 107.05 172.521 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 304' ' ' PRO . . . . . 0.836 ' HD3' ' HA ' ' A' ' 290' ' ' PHE . 10.5 Cg_exo -72.7 -169.8 6.86 Favored 'Cis proline' 0 C--N 1.346 0.423 0 CA-C-N 120.719 1.293 . . . . 0.0 113.484 0.605 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 305' ' ' LYS . . . . . 0.633 ' H ' ' HD3' ' A' ' 305' ' ' LYS . 0.0 OUTLIER -78.18 147.73 34.37 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.471 -0.786 . . . . 0.0 111.333 -177.774 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 306' ' ' ILE . . . . . 0.627 HG23 HG21 ' A' ' 322' ' ' VAL . 51.1 mm -114.07 110.71 33.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.718 -174.244 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 307' ' ' LEU . . . . . 0.504 ' HA ' ' HD3' ' A' ' 308' ' ' PRO . 90.7 mt -134.04 123.06 16.66 Favored Pre-proline 0 N--CA 1.465 0.28 0 CA-C-N 116.62 -0.264 . . . . 0.0 111.46 175.776 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 308' ' ' PRO . . . . . 0.723 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 32.7 Cg_exo -67.68 148.92 78.7 Favored 'Trans proline' 0 C--O 1.233 0.236 0 C-N-CA 123.705 2.937 . . . . 0.0 114.284 -176.333 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . 0.675 HG21 HG11 ' A' ' 276' ' ' VAL . 45.2 t -94.14 -13.79 8.32 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.132 -0.94 . . . . 0.0 109.055 168.988 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 53.1 mt-10 -78.51 35.79 0.24 Allowed 'General case' 0 CA--C 1.533 0.317 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.959 177.225 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.771 ' HA ' ' HD3' ' A' ' 317' ' ' ARG . 15.5 p30 40.74 66.23 0.67 Allowed 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 114.258 1.207 . . . . 0.0 114.258 173.733 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 85.0 m -81.35 -41.55 21.84 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.753 -0.658 . . . . 0.0 109.657 170.118 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 59.0 t0 -137.83 146.05 43.0 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 175.541 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 61.3 t -62.02 -43.36 97.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 O-C-N 123.191 0.307 . . . . 0.0 111.078 178.858 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -69.96 -19.88 63.34 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.005 0.431 . . . . 0.0 111.094 178.58 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 35.0 t -78.74 -15.24 58.69 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.502 179.804 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 317' ' ' ARG . . . . . 0.771 ' HD3' ' HA ' ' A' ' 311' ' ' ASN . 2.4 mmm180 -74.52 -51.87 4.04 Favored Pre-proline 0 CA--C 1.536 0.437 0 N-CA-C 112.883 0.697 . . . . 0.0 112.883 -177.709 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 318' ' ' PRO . . . . . 0.591 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 23.5 Cg_exo -64.95 -18.95 63.69 Favored 'Trans proline' 0 C--N 1.355 0.874 0 C-N-CA 121.844 1.696 . . . . 0.0 112.388 -178.407 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 319' ' ' TYR . . . . . 0.409 ' O ' HD12 ' A' ' 307' ' ' LEU . 3.7 m-85 -113.52 22.08 14.49 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.284 -179.499 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . 0.461 ' HB1' HG22 ' A' ' 309' ' ' VAL . . . -59.68 142.29 53.32 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.226 -177.408 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 321' ' ' ASN . . . . . . . . . . . . . 50.3 t30 -135.2 -21.57 1.6 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.942 -178.917 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 322' ' ' VAL . . . . . 0.627 HG21 HG23 ' A' ' 306' ' ' ILE . 34.7 m -140.53 172.04 12.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.141 178.658 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 51.1 m-20 -65.94 -44.76 84.09 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.647 -0.251 . . . . 0.0 111.427 179.203 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 324' ' ' ALA . . . . . 0.723 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -174.97 -178.86 1.29 Allowed 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 112.358 0.503 . . . . 0.0 112.358 -177.229 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 36.5 mtmm -108.01 116.72 56.59 Favored Pre-proline 0 N--CA 1.452 -0.364 0 CA-C-N 114.51 -1.223 . . . . 0.0 108.404 168.261 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -71.64 167.09 27.45 Favored 'Trans proline' 0 C--O 1.233 0.236 0 C-N-CA 122.411 2.074 . . . . 0.0 112.22 -177.905 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -67.58 121.58 16.17 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 175.541 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 328' ' ' GLU . . . . . 0.622 ' OE1' ' HA ' ' A' ' 231' ' ' SER . 31.2 tp10 67.53 164.4 0.21 Allowed 'General case' 0 CA--C 1.537 0.45 0 O-C-N 123.986 0.804 . . . . 0.0 109.562 -174.204 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 329' ' ' SER . . . . . 0.486 ' HB2' ' O ' ' A' ' 230' ' ' VAL . 53.5 m -71.21 -29.65 65.41 Favored 'General case' 0 C--N 1.327 -0.403 0 O-C-N 121.65 -0.656 . . . . 0.0 110.875 -177.838 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 330' ' ' ALA . . . . . 0.427 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 74.86 -153.11 0.04 OUTLIER 'General case' 0 N--CA 1.469 0.514 0 O-C-N 123.971 0.794 . . . . 0.0 112.499 173.342 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 331' ' ' ALA . . . . . 0.465 ' HB1' ' HB2' ' A' ' 226' ' ' GLU . . . -87.22 116.61 25.42 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.149 -0.932 . . . . 0.0 111.167 -176.816 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 332' ' ' ILE . . . . . 0.944 HG13 HG12 ' A' ' 270' ' ' ILE . 1.8 mp -107.67 139.92 27.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 177.556 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 61.6 m -129.68 103.89 7.11 Favored 'General case' 0 C--N 1.327 -0.392 0 C-N-CA 120.853 -0.339 . . . . 0.0 111.306 -174.624 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 334' ' ' ILE . . . . . 0.721 ' HA ' ' HB3' ' A' ' 268' ' ' PHE . 3.1 mp -90.73 134.98 27.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.491 -177.161 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 335' ' ' LEU . . . . . 0.711 HD23 ' H ' ' A' ' 335' ' ' LEU . 1.6 pt? -116.73 136.35 53.03 Favored 'General case' 0 N--CA 1.441 -0.897 0 N-CA-C 107.721 -1.215 . . . . 0.0 107.721 166.366 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 15.4 p-10 -75.46 47.56 0.39 Allowed 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.141 0.496 . . . . 0.0 110.822 -177.277 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 337' ' ' LYS . . . . . 0.405 ' HB2' ' NZ ' ' A' ' 337' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--O 1.243 0.722 0 CA-C-O 118.364 -0.827 . . . . 0.0 110.603 179.442 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 223' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.714 0 N-CA-C 112.238 -0.345 . . . . 0.0 112.238 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 224' ' ' SER . . . . . . . . . . . . . 33.6 p -132.84 46.5 2.61 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.88 0.371 . . . . 0.0 111.359 179.923 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 225' ' ' THR . . . . . . . . . . . . . 68.9 p -85.96 177.53 7.57 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.394 177.971 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 226' ' ' GLU . . . . . . . . . . . . . 5.3 tp10 -118.55 38.55 3.71 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.896 0.855 . . . . 0.0 109.4 177.665 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 227' ' ' SER . . . . . . . . . . . . . 26.9 m -129.59 117.7 20.84 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.368 -0.833 . . . . 0.0 109.532 178.065 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 228' ' ' LEU . . . . . . . . . . . . . 72.9 mt -91.54 87.94 6.58 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 -178.836 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 229' ' ' THR . . . . . 0.591 HG22 ' HA ' ' A' ' 331' ' ' ALA . 22.7 p -113.76 173.43 6.43 Favored 'General case' 0 C--N 1.316 -0.865 0 C-N-CA 119.739 -0.784 . . . . 0.0 110.386 -177.953 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 230' ' ' VAL . . . . . 0.557 ' O ' ' HB2' ' A' ' 329' ' ' SER . 78.9 t -142.75 133.12 23.1 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-O 121.023 0.439 . . . . 0.0 110.785 -176.542 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 231' ' ' SER . . . . . . . . . . . . . 39.5 t -108.31 100.28 9.59 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-N 115.339 -0.846 . . . . 0.0 109.482 175.725 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 232' ' ' GLY . . . . . . . . . . . . . . . -173.27 166.77 39.32 Favored Glycine 0 N--CA 1.444 -0.786 0 N-CA-C 111.391 -0.684 . . . . 0.0 111.391 -178.35 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 233' ' ' GLN . . . . . 0.4 ' HA ' ' HD3' ' A' ' 234' ' ' PRO . 12.9 mm-40 -107.49 102.03 42.34 Favored Pre-proline 0 C--N 1.321 -0.659 0 CA-C-N 116.706 0.253 . . . . 0.0 110.72 -179.866 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 234' ' ' PRO . . . . . 0.76 ' HB2' HD12 ' A' ' 306' ' ' ILE . 33.7 Cg_endo -98.11 127.14 0.22 Allowed 'Trans proline' 0 N--CA 1.451 -1.002 0 C-N-CA 123.034 2.489 . . . . 0.0 112.227 -178.479 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 235' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -160.28 -177.39 6.22 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.709 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 236' ' ' HIS . . . . . 0.977 ' HA ' ' HG2' ' A' ' 251' ' ' ARG . 33.4 t-80 -159.14 132.98 7.47 Favored 'General case' 0 CA--C 1.517 -0.297 0 CA-C-O 121.605 0.716 . . . . 0.0 111.941 176.38 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 237' ' ' LYS . . . . . 0.614 ' HD2' ' N ' ' A' ' 237' ' ' LYS . 0.0 OUTLIER -114.61 134.65 54.89 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 114.67 -1.15 . . . . 0.0 110.012 178.203 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 238' ' ' VAL . . . . . 0.411 HG22 ' HE1' ' A' ' 236' ' ' HIS . 41.2 t -103.96 112.21 36.62 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 177.423 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 239' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -90.75 147.24 23.37 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 120.724 -0.39 . . . . 0.0 110.408 177.481 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 240' ' ' ALA . . . . . 0.474 ' C ' ' HD2' ' A' ' 241' ' ' LYS . . . -76.48 -68.74 0.56 Allowed 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.235 -176.654 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 241' ' ' LYS . . . . . 0.474 ' HD2' ' C ' ' A' ' 240' ' ' ALA . 3.5 mptp? -112.69 129.01 56.55 Favored 'General case' 0 CA--C 1.514 -0.416 0 CA-C-O 120.956 0.408 . . . . 0.0 110.886 -179.51 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 242' ' ' ASP . . . . . 0.414 ' CG ' ' H ' ' A' ' 244' ' ' ASN . 7.3 p-10 -96.23 -157.65 0.6 Allowed 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.549 -0.75 . . . . 0.0 109.048 174.52 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 243' ' ' SER . . . . . . . . . . . . . 34.9 t -62.55 -29.9 70.91 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.859 0.361 . . . . 0.0 110.798 175.848 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 244' ' ' ASN . . . . . 0.414 ' H ' ' CG ' ' A' ' 242' ' ' ASP . 22.4 t-20 -94.73 -15.22 24.04 Favored 'General case' 0 CA--C 1.532 0.254 0 CA-C-O 121.035 0.445 . . . . 0.0 110.387 179.235 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 245' ' ' GLY . . . . . . . . . . . . . . . 92.13 20.0 37.44 Favored Glycine 0 CA--C 1.517 0.209 0 C-N-CA 120.751 -0.737 . . . . 0.0 113.01 175.607 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 246' ' ' MET . . . . . . . . . . . . . 26.5 ptt? -113.67 160.3 32.39 Favored Pre-proline 0 C--N 1.324 -0.514 0 N-CA-C 110.235 -0.283 . . . . 0.0 110.235 179.05 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 247' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -72.74 120.5 6.72 Favored 'Trans proline' 0 C--N 1.347 0.455 0 C-N-CA 121.993 1.795 . . . . 0.0 110.548 175.276 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 248' ' ' VAL . . . . . . . . . . . . . 62.7 t -115.46 131.11 68.77 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 121.214 0.53 . . . . 0.0 112.111 -173.645 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 249' ' ' ASP . . . . . . . . . . . . . 61.3 t0 -87.82 87.71 7.44 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.008 -0.997 . . . . 0.0 108.688 172.232 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 250' ' ' ASN . . . . . . . . . . . . . 21.6 p30 -101.62 -14.24 17.5 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.881 -0.6 . . . . 0.0 112.456 -173.417 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 251' ' ' ARG . . . . . 0.977 ' HG2' ' HA ' ' A' ' 236' ' ' HIS . 2.7 tpm_? -75.04 -84.34 0.05 Allowed 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 111.92 0.341 . . . . 0.0 111.92 -168.957 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 252' ' ' GLN . . . . . . . . . . . . . 3.1 mm100 61.79 179.22 0.12 Allowed 'General case' 0 C--N 1.344 0.345 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 -173.373 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 253' ' ' GLY . . . . . 0.446 ' O ' HG12 ' A' ' 302' ' ' ILE . . . -128.19 116.06 2.22 Favored Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 118.941 -1.6 . . . . 0.0 113.423 -174.275 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 254' ' ' THR . . . . . 0.467 ' HA ' ' O ' ' A' ' 300' ' ' VAL . 80.9 p -109.41 115.45 29.98 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 170.605 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 255' ' ' ILE . . . . . 0.463 ' O ' ' HA ' ' A' ' 299' ' ' THR . 2.0 pp -131.52 164.85 33.32 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 N-CA-C 112.733 0.642 . . . . 0.0 112.733 -172.79 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 256' ' ' THR . . . . . . . . . . . . . 28.9 m -102.17 118.29 36.59 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 178.789 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 257' ' ' VAL . . . . . 0.422 HG12 HG22 ' A' ' 230' ' ' VAL . 35.0 m -90.4 142.91 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.728 0 C-N-CA 119.768 -0.773 . . . . 0.0 112.762 -172.17 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 258' ' ' SER . . . . . . . . . . . . . 32.1 t -91.96 9.56 32.6 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 113.772 -1.558 . . . . 0.0 108.317 168.679 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 259' ' ' ALA . . . . . 0.467 ' HB3' HD11 ' A' ' 262' ' ' LEU . . . -92.19 160.94 14.93 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-N 115.303 -0.862 . . . . 0.0 109.184 179.588 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 260' ' ' SER . . . . . . . . . . . . . 34.9 t -118.22 131.06 56.4 Favored 'General case' 0 C--N 1.322 -0.627 0 C-N-CA 120.779 -0.368 . . . . 0.0 111.491 -175.794 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 261' ' ' GLY . . . . . . . . . . . . . . . 69.96 51.05 25.71 Favored Glycine 0 N--CA 1.449 -0.445 0 CA-C-N 115.607 -0.724 . . . . 0.0 113.655 173.656 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 262' ' ' LEU . . . . . 0.467 HD11 ' HB3' ' A' ' 259' ' ' ALA . 62.6 mt -91.23 151.55 20.88 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 117.044 0.422 . . . . 0.0 110.161 176.63 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 263' ' ' GLN . . . . . . . . . . . . . 82.5 mt-30 -137.42 168.22 20.08 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.026 0.441 . . . . 0.0 110.883 -178.427 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 264' ' ' VAL . . . . . . . . . . . . . 57.6 t -78.23 123.74 35.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.971 176.915 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . 0.452 ' H ' ' HB ' ' A' ' 292' ' ' VAL . . . 114.15 6.98 19.81 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.51 -0.852 . . . . 0.0 112.808 -179.978 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 266' ' ' ASP . . . . . . . . . . . . . 61.7 m-20 -89.7 166.02 13.84 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.157 0.503 . . . . 0.0 110.611 176.205 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 267' ' ' ALA . . . . . 0.698 ' HA ' ' O ' ' A' ' 290' ' ' PHE . . . -129.61 153.3 48.21 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.287 -0.87 . . . . 0.0 109.008 177.676 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 268' ' ' PHE . . . . . 0.613 ' HB3' HD13 ' A' ' 334' ' ' ILE . 9.9 p90 -164.0 165.73 22.21 Favored 'General case' 0 C--N 1.32 -0.675 0 C-N-CA 119.701 -0.8 . . . . 0.0 112.498 -176.887 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 269' ' ' THR . . . . . 0.56 ' HB ' ' HB2' ' A' ' 287' ' ' PRO . 66.4 p -115.45 149.51 37.94 Favored 'General case' 0 N--CA 1.444 -0.763 0 CA-C-N 114.624 -1.171 . . . . 0.0 109.224 173.302 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 270' ' ' ILE . . . . . 0.999 HG12 HG13 ' A' ' 332' ' ' ILE . 60.5 mt -121.46 131.47 72.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 N-CA-C 110.416 -0.216 . . . . 0.0 110.416 -179.26 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 271' ' ' ALA . . . . . . . . . . . . . . . -62.24 132.91 54.26 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.124 -179.499 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 272' ' ' GLY . . . . . . . . . . . . . . . 91.47 -21.72 33.94 Favored Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.182 -178.08 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 273' ' ' VAL . . . . . . . . . . . . . 31.0 t -105.38 104.36 16.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 C-N-CA 122.402 0.281 . . . . 0.0 110.367 -179.483 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 274' ' ' ASN . . . . . 0.529 ' HA ' ' HA ' ' A' ' 287' ' ' PRO . 7.3 m120 -126.11 144.42 50.74 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.509 -0.476 . . . . 0.0 111.408 -175.429 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 275' ' ' SER . . . . . 0.48 ' HB3' ' OE1' ' A' ' 288' ' ' GLN . 29.5 p -63.77 160.98 16.09 Favored 'General case' 0 CA--C 1.515 -0.377 0 CA-C-N 115.826 -0.624 . . . . 0.0 112.494 -179.377 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 276' ' ' VAL . . . . . 0.543 HG21 HG21 ' A' ' 309' ' ' VAL . 33.8 m -119.36 149.94 21.85 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.663 0 CA-C-N 114.916 -1.038 . . . . 0.0 110.618 176.246 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 277' ' ' HIS . . . . . . . . . . . . . 87.9 m-70 -109.73 71.62 0.77 Allowed 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 173.323 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 278' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 -74.42 -9.62 58.77 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.379 -0.828 . . . . 0.0 112.136 -173.459 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 279' ' ' ILE . . . . . . . . . . . . . 47.1 mm -92.4 -56.6 5.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 120.732 0.301 . . . . 0.0 110.761 -179.676 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 280' ' ' THR . . . . . . . . . . . . . 73.0 p -86.48 -14.42 43.2 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.321 -178.716 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 281' ' ' LYS . . . . . . . . . . . . . 3.1 mmmp? 62.27 48.47 4.8 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.994 -178.231 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 282' ' ' ASP . . . . . . . . . . . . . 52.6 m-20 -92.28 122.92 35.21 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.285 176.943 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 60.9 p -89.35 102.68 15.35 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.052 0.453 . . . . 0.0 110.054 176.616 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 284' ' ' THR . . . . . . . . . . . . . 68.5 p -130.91 -40.22 1.19 Allowed 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.837 -0.619 . . . . 0.0 111.242 -174.972 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 285' ' ' GLY . . . . . . . . . . . . . . . 73.07 32.36 60.66 Favored Glycine 0 N--CA 1.448 -0.543 0 C-N-CA 120.518 -0.848 . . . . 0.0 112.254 -179.624 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 286' ' ' GLN . . . . . . . . . . . . . 73.6 mt-30 -76.19 140.41 69.48 Favored Pre-proline 0 C--O 1.223 -0.321 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.603 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 287' ' ' PRO . . . . . 0.56 ' HB2' ' HB ' ' A' ' 269' ' ' THR . 36.2 Cg_endo -69.78 150.57 68.26 Favored 'Trans proline' 0 CA--C 1.529 0.255 0 C-N-CA 122.057 1.838 . . . . 0.0 112.566 -177.163 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 288' ' ' GLN . . . . . 0.48 ' OE1' ' HB3' ' A' ' 275' ' ' SER . 5.5 mm100 -78.34 149.28 33.47 Favored 'General case' 0 CA--C 1.514 -0.422 0 CA-C-O 121.186 0.517 . . . . 0.0 112.2 176.929 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 289' ' ' VAL . . . . . 0.409 ' CG1' ' HB1' ' A' ' 267' ' ' ALA . 49.7 t -104.61 112.7 39.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 114.877 -1.056 . . . . 0.0 109.37 175.569 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 290' ' ' PHE . . . . . 0.698 ' O ' ' HA ' ' A' ' 267' ' ' ALA . 53.9 m-85 -98.85 160.23 14.41 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.384 -175.584 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 291' ' ' ARG . . . . . 0.47 ' NH1' ' HB2' ' A' ' 267' ' ' ALA . 32.7 mmt180 -118.02 150.54 39.12 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 178.588 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 292' ' ' VAL . . . . . 0.546 HG13 HG13 ' A' ' 300' ' ' VAL . 52.5 t -100.25 122.92 52.76 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.913 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.57 -177.87 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 293' ' ' LEU . . . . . 0.505 HD21 ' HB3' ' A' ' 303' ' ' SER . 3.4 mm? -104.41 -24.1 13.1 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.465 -0.334 . . . . 0.0 111.674 -177.332 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 294' ' ' ALA . . . . . 0.496 ' O ' ' HA ' ' A' ' 300' ' ' VAL . . . -154.4 136.59 14.79 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 120.762 -0.375 . . . . 0.0 111.638 179.898 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 295' ' ' VAL . . . . . . . . . . . . . 58.0 t -135.51 120.1 27.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 175.104 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 296' ' ' SER . . . . . . . . . . . . . 31.2 t -157.41 111.69 2.65 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.604 -178.331 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 63.34 50.2 64.43 Favored Glycine 0 C--N 1.33 0.229 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.059 -178.315 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 298' ' ' THR . . . . . . . . . . . . . 72.2 p 50.82 23.38 1.4 Allowed 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 123.445 0.698 . . . . 0.0 112.524 -175.576 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 299' ' ' THR . . . . . 0.463 ' HA ' ' O ' ' A' ' 255' ' ' ILE . 40.6 m -111.75 116.87 31.43 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 176.148 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . 0.546 HG13 HG13 ' A' ' 292' ' ' VAL . 59.1 t -113.69 133.91 58.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.603 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.619 -172.34 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 301' ' ' THR . . . . . . . . . . . . . 43.5 m -96.82 120.61 37.46 Favored 'General case' 0 C--O 1.235 0.32 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 172.548 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 302' ' ' ILE . . . . . 0.446 HG12 ' O ' ' A' ' 253' ' ' GLY . 27.7 pt -111.26 143.72 20.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-O 121.626 0.727 . . . . 0.0 112.811 -169.725 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 303' ' ' SER . . . . . 0.505 ' HB3' HD21 ' A' ' 293' ' ' LEU . 46.8 t -156.29 129.11 4.26 Favored Pre-proline 0 C--N 1.323 -0.578 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 173.24 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 304' ' ' PRO . . . . . 0.653 ' HD2' ' HA ' ' A' ' 290' ' ' PHE . 34.8 Cg_exo -63.0 -176.05 4.24 Favored 'Cis proline' 0 N--CA 1.477 0.505 0 CA-C-N 119.912 1.004 . . . . 0.0 114.324 1.807 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 305' ' ' LYS . . . . . 0.661 ' HE2' HD11 ' A' ' 307' ' ' LEU . 0.0 OUTLIER -136.57 -175.52 4.04 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.938 -176.205 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 306' ' ' ILE . . . . . 0.76 HD12 ' HB2' ' A' ' 234' ' ' PRO . 41.8 mt -94.29 99.97 10.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.946 -173.525 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 307' ' ' LEU . . . . . 0.661 HD11 ' HE2' ' A' ' 305' ' ' LYS . 2.7 mp -114.43 105.55 53.63 Favored Pre-proline 0 C--N 1.33 -0.277 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 175.729 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 308' ' ' PRO . . . . . 0.745 ' HB3' ' HA ' ' A' ' 324' ' ' ALA . 24.1 Cg_exo -68.92 127.66 15.61 Favored 'Trans proline' 0 CA--C 1.53 0.286 0 C-N-CA 122.955 2.437 . . . . 0.0 113.394 -176.07 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . 0.659 HG22 ' HB3' ' A' ' 320' ' ' ALA . 76.9 t -84.27 -37.14 12.6 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.088 174.966 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 310' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -75.29 -6.65 50.93 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.256 179.243 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.52 ' HB2' ' HB2' ' A' ' 308' ' ' PRO . 69.7 m-80 -136.87 -158.69 0.88 Allowed 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.262 -0.427 . . . . 0.0 109.996 -176.633 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 312' ' ' THR . . . . . . . . . . . . . 16.5 m 71.23 -73.16 0.1 Allowed 'General case' 0 C--O 1.234 0.275 0 C-N-CA 123.755 0.822 . . . . 0.0 110.903 177.005 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 313' ' ' ASP . . . . . . . . . . . . . 51.0 t0 -176.44 159.81 2.0 Allowed 'General case' 0 C--N 1.328 -0.358 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 177.253 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 314' ' ' VAL . . . . . . . . . . . . . 61.7 t -64.45 -39.73 86.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-O 120.908 0.385 . . . . 0.0 110.55 176.038 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 315' ' ' ALA . . . . . . . . . . . . . . . -72.5 -18.87 61.62 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.637 178.732 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 50.3 m -83.86 -25.86 29.92 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.535 -0.302 . . . . 0.0 111.177 -179.221 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 317' ' ' ARG . . . . . 0.659 ' HB2' ' HD3' ' A' ' 318' ' ' PRO . 74.1 mtm180 -49.14 -52.57 46.88 Favored Pre-proline 0 CA--C 1.539 0.52 0 N-CA-C 112.641 0.608 . . . . 0.0 112.641 -178.574 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 318' ' ' PRO . . . . . 0.659 ' HD3' ' HB2' ' A' ' 317' ' ' ARG . 51.8 Cg_exo -59.74 -13.97 24.56 Favored 'Trans proline' 0 C--N 1.36 1.14 0 C-N-CA 122.53 2.154 . . . . 0.0 113.833 -177.232 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 44.9 m-85 -110.75 -0.55 17.0 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.99 0.424 . . . . 0.0 110.77 -179.282 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 320' ' ' ALA . . . . . 0.659 ' HB3' HG22 ' A' ' 309' ' ' VAL . . . -90.5 159.85 16.3 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.155 -178.899 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 321' ' ' ASN . . . . . 0.431 ' O ' ' HA ' ' A' ' 275' ' ' SER . 0.1 OUTLIER -130.68 -0.69 4.33 Favored 'General case' 0 N--CA 1.464 0.255 0 N-CA-C 112.75 0.648 . . . . 0.0 112.75 -178.977 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 322' ' ' VAL . . . . . 0.676 HG21 HG23 ' A' ' 306' ' ' ILE . 32.8 m -136.11 162.08 36.71 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.258 0 N-CA-C 110.097 -0.334 . . . . 0.0 110.097 176.988 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 323' ' ' ASP . . . . . . . . . . . . . 51.6 m-20 -72.92 -39.82 65.97 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 111.731 0.271 . . . . 0.0 111.731 -176.376 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 324' ' ' ALA . . . . . 0.745 ' HA ' ' HB3' ' A' ' 308' ' ' PRO . . . -155.5 174.61 15.02 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 112.149 0.426 . . . . 0.0 112.149 -173.353 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 325' ' ' LYS . . . . . . . . . . . . . 24.6 pttm -119.12 107.44 41.73 Favored Pre-proline 0 N--CA 1.454 -0.233 0 CA-C-N 115.472 -0.785 . . . . 0.0 110.031 170.923 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 326' ' ' PRO . . . . . . . . . . . . . 55.0 Cg_endo -74.04 167.82 26.28 Favored 'Trans proline' 0 C--O 1.233 0.232 0 C-N-CA 122.695 2.263 . . . . 0.0 112.562 -176.525 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 327' ' ' ALA . . . . . . . . . . . . . . . -71.6 123.81 23.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.875 -179.289 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 328' ' ' GLU . . . . . . . . . . . . . 54.8 mt-10 66.36 -170.14 0.2 Allowed 'General case' 0 N--CA 1.465 0.32 0 O-C-N 123.674 0.609 . . . . 0.0 111.004 -175.998 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 329' ' ' SER . . . . . 0.557 ' HB2' ' O ' ' A' ' 230' ' ' VAL . 50.9 m -94.29 -27.81 15.93 Favored 'General case' 0 C--N 1.325 -0.467 0 C-N-CA 120.727 -0.389 . . . . 0.0 111.995 -174.458 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 330' ' ' ALA . . . . . 0.477 ' HB3' ' O ' ' A' ' 329' ' ' SER . . . 75.62 -151.32 0.03 OUTLIER 'General case' 0 N--CA 1.478 0.95 0 N-CA-C 113.273 0.842 . . . . 0.0 113.273 173.023 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 331' ' ' ALA . . . . . 0.591 ' HA ' HG22 ' A' ' 229' ' ' THR . . . -92.98 120.64 33.49 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 114.741 -1.118 . . . . 0.0 110.818 -177.735 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 332' ' ' ILE . . . . . 0.999 HG13 HG12 ' A' ' 270' ' ' ILE . 1.7 mp -106.54 145.87 13.73 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 115.682 -0.69 . . . . 0.0 111.221 -176.903 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 44.1 m -118.29 95.33 4.83 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.0 -178.077 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 334' ' ' ILE . . . . . 0.613 HD13 ' HB3' ' A' ' 268' ' ' PHE . 39.8 mm -78.34 133.48 30.18 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-O 120.949 0.404 . . . . 0.0 111.35 -176.276 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 335' ' ' LEU . . . . . 0.579 HD13 ' H ' ' A' ' 337' ' ' LYS . 1.8 pp -152.44 -172.65 4.3 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.429 177.875 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 336' ' ' ASN . . . . . . . . . . . . . 6.3 m120 -124.96 44.23 2.84 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.776 0.322 . . . . 0.0 110.844 -178.925 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 337' ' ' LYS . . . . . 0.579 ' H ' HD13 ' A' ' 335' ' ' LEU . 60.8 tttm . . . . . 0 C--O 1.245 0.836 0 CA-C-O 118.635 -0.698 . . . . 0.0 110.509 -178.943 . . . . . . . . 1 1 . 1 stop_ save_